[{"id":"keith-stewart","kind":"person","name":"A. Keith Stewart","aka":[],"tldr":"Keith Stewart is a myeloma researcher who leads Canada's largest cancer centre.","summary":"A. Keith Stewart is Director of the Princess Margaret Cancer Centre and Vice President, Cancer, at University Health Network, having previously worked at the Mayo Clinic Comprehensive Cancer Center in Arizona. He is a multiple myeloma researcher known for leading the ASPIRE trial of carfilzomib in relapsed disease and for myeloma genomics studies. His selected paper reports the combination of carfilzomib, lenalidomide and dexamethasone for relapsed multiple myeloma. He now combines academic leadership of Canada's largest cancer centre with continued work in myeloma and cancer genomics.","asOf":"2026-09-08","links":[{"label":"Princess Margaret","url":"https://www.uhn.ca/PrincessMargaret"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Stewart%20AK%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":["carfilzomib","lenalidomide"],"companies":[],"institutions":["princess-margaret","mayo-clinic-arizona"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Princess Margaret Cancer Centre; Vice President, Cancer, University Health Network","institutionId":"princess-margaret","specialisms":["Multiple myeloma","Cancer genomics","Academic leadership"],"profiles":[{"label":"Princess Margaret","url":"https://www.uhn.ca/PrincessMargaret"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Stewart%20AK%5BAuthor%5D"}],"papers":[{"title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","journal":"New England Journal of Medicine","year":2015,"url":"https://doi.org/10.1056/NEJMoa1411321","doi":"10.1056/NEJMoa1411321"}]},{"id":"murray-brunt","kind":"person","name":"A. Murray Brunt","aka":[],"tldr":"Led FAST-Forward, which cut breast radiotherapy from three weeks to one with no loss of effectiveness.","summary":"Murray Brunt (Keele University) was chief investigator of FAST-Forward, the UK trial of 4,000 women showing that 26 Gy in five fractions over one week is non-inferior to 40 Gy in 15 fractions for local recurrence and normal tissue effects after breast conservation, a result adopted rapidly during the COVID-19 pandemic and now standard in many countries. He also led the FAST trial of five-fraction schedules over five weeks.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Brunt%20AM%5BAuthor%5D%20FAST-Forward"}],"tags":["radiotherapy","breast","hypofractionation"],"related":[],"cancers":["breast-hr-positive"],"sections":[],"technologies":["imrt-igrt"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Clinical Oncology, Keele University; Consultant, University Hospitals of North Midlands","specialisms":["Breast radiotherapy","Hypofractionation","Radiotherapy trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Brunt%20AM%5BAuthor%5D%20FAST-Forward"}],"papers":[{"title":"Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial","journal":"Lancet","year":2020,"doi":"10.1016/S0140-6736(20)30932-6"},{"title":"Ten-year results of FAST: a randomized controlled trial of 5-fraction whole-breast radiotherapy for early breast cancer","journal":"JCO","year":2020,"doi":"10.1200/JCO.19.02750"}]},{"id":"oliver-sartor","kind":"person","name":"A. Oliver Sartor","aka":[],"tldr":"Led VISION, the trial that made lutetium-PSMA the first radioligand therapy for prostate cancer.","summary":"Oliver Sartor was co-principal investigator of VISION, which showed 177Lu-PSMA-617 improves survival in PSMA-positive metastatic castration-resistant prostate cancer and led to Pluvicto's approval, and was a lead investigator of PSMAfore, which moved the therapy before chemotherapy. He also co-led ALSYMPCA (radium-223). He directs the radiopharmaceutical trials programme at Mayo Clinic.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Oliver_Sartor","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sartor%20O%5BAuthor%5D%20PSMA%20lutetium"}],"tags":["prostate","radioligand","trialist"],"related":[],"cancers":["prostate"],"sections":[],"technologies":["radioligand-therapy","psma-pet"],"targets":["psma"],"drugs":["pluvicto"],"companies":[],"institutions":["mayo-clinic"],"pathways":[],"terms":[],"trials":["vision","psmafore","alsympca"],"people":[],"bottlenecks":[],"keyPapers":["paper-vision-nejm-2021"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology and Urology, Mayo Clinic","institutionId":"mayo-clinic","specialisms":["Prostate cancer","Radioligand therapy","PSMA-targeted therapy","Radium-223"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sartor%20O%5BAuthor%5D%20PSMA%20lutetium"}],"papers":[{"title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer (VISION)","journal":"NEJM","year":2021,"doi":"10.1056/NEJMoa2107322"},{"title":"Alpha emitter radium-223 and survival in metastatic prostate cancer (ALSYMPCA)","journal":"NEJM","year":2013,"doi":"10.1056/NEJMoa1213755"}]},{"id":"aaron-ciechanover","kind":"person","name":"Aaron Ciechanover","aka":[],"tldr":"Shared the 2004 Nobel Prize in Chemistry for discovering how cells label proteins for destruction. That labelling system is what proteasome inhibitors block and what every protein degrader hijacks.","summary":"Aaron Ciechanover, with Avram Hershko at the Technion and Irwin Rose at the Fox Chase Cancer Center, discovered ubiquitin-mediated protein degradation: the cell tags a protein with a chain of ubiquitin molecules and the proteasome then destroys it. The three shared the 2004 Nobel Prize in Chemistry, one third each, \"for the discovery of ubiquitin-mediated protein degradation\". The clinical consequences are direct. Blocking the proteasome kills myeloma cells, which is what bortezomib and carfilzomib do. Redirecting the tagging machinery at a protein of choice is what PROTACs and molecular glues do, and it is how drugs are now being made against targets long called undruggable. Ciechanover continues to publish from the Rappaport-Technion Integrated Cancer Center on the ubiquitin-proteasome system in cancer and on degrader technology in myeloma and lymphoma.","asOf":"2026-09-25","wikipedia":"https://en.wikipedia.org/wiki/Aaron_Ciechanover","links":[{"label":"Technion","url":"https://www.technion.ac.il/en/"},{"label":"Nobel Prize in Chemistry 2004","url":"https://api.nobelprize.org/2.1/nobelPrize/che/2004"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ciechanover%20A%5BAuthor%5D"}],"tags":["scientist","nobel-laureate","cancer-biology"],"related":[],"cancers":["multiple-myeloma"],"sections":["drug-discovery","targeted-therapy"],"technologies":["protac-degrader","molecular-glue-platforms"],"targets":[],"drugs":["bortezomib","carfilzomib"],"companies":[],"institutions":["technion","rambam"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Distinguished Research Professor, Rappaport-Technion Integrated Cancer Center and Rappaport Faculty of Medicine, Technion","institutionId":"technion","specialisms":["Ubiquitin-proteasome system","Protein degradation","Targeted protein degradation","Cancer biochemistry"],"profiles":[{"label":"Technion","url":"https://www.technion.ac.il/en/"},{"label":"Nobel Prize in Chemistry 2004","url":"https://api.nobelprize.org/2.1/nobelPrize/che/2004"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ciechanover%20A%5BAuthor%5D"}],"papers":[{"title":"The landscape of the ubiquitin-proteasome system in cancer","year":2026,"note":"Rappaport Faculty of Medicine, Technion; indexed on Europe PMC"},{"title":"Proteolysis targeting chimeric-based technology in myeloma and lymphoma","year":2026,"note":"Department of Cell Biology and Cancer Science, Rappaport Faculty of Medicine, Technion; indexed on Europe PMC"}]},{"id":"aaron-schimmer","kind":"person","name":"Aaron D. Schimmer","aka":[],"tldr":"Leukaemia researcher who found that AML stem cells depend on mitochondrial proteases and metabolism.","summary":"Aaron D. Schimmer is Research Director and Senior Scientist at the Princess Margaret Cancer Centre, with an affiliation at the Ontario Institute for Cancer Research. He is a leukaemia researcher who found that acute myeloid leukaemia stem cells depend on mitochondrial proteases such as ClpP and on oxidative phosphorylation. That work led him into drug repurposing, including trials of the antibiotic tigecycline, and his selected paper describes inhibiting mitochondrial translation as a therapeutic strategy in AML. He now directs the research programme at Princess Margaret while continuing to study mitochondrial metabolism in leukaemia.","asOf":"2026-09-08","links":[{"label":"UHN profile","url":"https://www.uhnresearch.ca/researcher/aaron-d-schimmer"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schimmer%20AD%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["aml"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["princess-margaret","oicr"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["cancer-cell"],"dependsOn":[],"notes":[],"role":"Research Director, Princess Margaret Cancer Centre; Senior Scientist","institutionId":"princess-margaret","specialisms":["AML","Mitochondrial metabolism","Drug repurposing"],"profiles":[{"label":"UHN profile","url":"https://www.uhnresearch.ca/researcher/aaron-d-schimmer"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schimmer%20AD%5BAuthor%5D"}],"papers":[{"title":"Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia","journal":"Cancer Cell","year":2011,"url":"https://doi.org/10.1016/j.ccr.2011.10.015","doi":"10.1016/j.ccr.2011.10.015"}]},{"id":"abhay-soi","kind":"person","name":"Abhay Soi","aka":[],"tldr":"Business leader who leads Max Healthcare, the Indian private hospital group whose network includes the Max Institute of Cancer Care.","summary":"Abhay Soi leads Max Healthcare Institute as Chairman and Managing Director, according to the company's Wikipedia article. Max Healthcare is one of India's largest private hospital groups and operates the Max Institute of Cancer Care across its hospitals. The article records that he became chairman after his company Radiant Life Care acquired a large stake in Max Healthcare and that he later became the group's sole promoter after KKR sold its holding. The group's own leadership pages could not be read at the time of checking.","asOf":"2026-09-10","links":[{"label":"Source: Wikipedia article on Max Healthcare (leadership infobox)","url":"https://en.wikipedia.org/wiki/Max_Healthcare"}],"tags":["leadership","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["max-healthcare"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chairman and Managing Director, Max Healthcare Institute","institutionId":"max-healthcare","specialisms":["Healthcare business leadership","Hospital group management"],"profiles":[{"label":"Wikipedia: Max Healthcare","url":"https://en.wikipedia.org/wiki/Max_Healthcare"}],"papers":[]},{"id":"adda-bounedjar","kind":"person","name":"Adda Bounedjar","aka":[],"tldr":"Adda Bounedjar represents Anti-Cancer Center of Blida in the Organisation of European Cancer Institutes, which lists the organisation among its members in Algeria.","summary":"Adda Bounedjar is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Anti-Cancer Center of Blida, its associate member in Algeria. OnCo records the name from the OECI membership list so that the organisation's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the organisation's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Anti-Cancer Center of Blida website","url":"https://ehs-clccblida.dz"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["blida-anti-cancer-center"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Anti-Cancer Center of Blida to the Organisation of European Cancer Institutes","institutionId":"blida-anti-cancer-center","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Anti-Cancer Center of Blida website","url":"https://ehs-clccblida.dz"}],"papers":[{"title":"A review of the international early recommendations for departments organization and cancer management priorities during the global COVID-19 pandemic: applicability in low- and middle-income countries","journal":"Eur J Cancer","year":2020,"url":"https://doi.org/10.1016/j.ejca.2020.05.015","doi":"10.1016/j.ejca.2020.05.015","note":"Europe PMC author record matched by affiliation"},{"title":"Neoadjuvant endocrine therapy with or without palbociclib in low-risk patients: a phase III randomized double-blind SAFIA trial","journal":"J Cancer Res Clin Oncol","year":2023,"url":"https://doi.org/10.1007/s00432-023-04588-3","doi":"10.1007/s00432-023-04588-3","note":"Europe PMC author record matched by affiliation"},{"title":"Africa Guidelines for Hepatocellular Carcinoma Buildup Process","journal":"JCO Glob Oncol","year":2023,"url":"https://doi.org/10.1200/go.23.00159","doi":"10.1200/go.23.00159","note":"Europe PMC author record matched by affiliation"}]},{"id":"aditya-bardia","kind":"person","name":"Aditya Bardia","aka":[],"tldr":"Led ASCENT, the trial that made sacituzumab govitecan the first ADC for triple-negative breast cancer, and the EMERALD trial of elacestrant.","summary":"Aditya Bardia was principal investigator of ASCENT, which showed sacituzumab govitecan nearly doubles survival in pretreated metastatic TNBC, and of EMERALD, which won elacestrant the first oral SERD approval for ESR1-mutant disease. He is a lead investigator on the TROPION-Breast programme and ctDNA-guided studies. His work has defined the TROP2 ADC class in breast cancer.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bardia%20A%5BAuthor%5D%20sacituzumab%20OR%20elacestrant"}],"tags":["breast","adc","trialist"],"related":[],"cancers":["tnbc","breast-hr-positive"],"sections":[],"technologies":["adc","endocrine-therapy","liquid-biopsy"],"targets":["trop2","estrogen-receptor"],"drugs":["sacituzumab-govitecan","datopotamab-deruxtecan","elacestrant"],"companies":[],"institutions":["ucla-jonsson"],"pathways":[],"terms":[],"trials":["ascent","tropion-breast01","emerald"],"people":[],"bottlenecks":[],"keyPapers":["paper-ascent-nejm-2021","paper-tropion-breast01-jco-2024"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medicine and Director of Translational Research Integration, UCLA Jonsson Comprehensive Cancer Center","institutionId":"ucla-jonsson","specialisms":["Antibody-drug conjugates","Triple-negative breast cancer","Oral SERDs","Circulating tumour DNA"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bardia%20A%5BAuthor%5D%20sacituzumab%20OR%20elacestrant"}],"papers":[{"title":"Sacituzumab govitecan in metastatic triple-negative breast cancer (ASCENT)","journal":"NEJM","year":2021,"doi":"10.1056/NEJMoa2028485"},{"title":"Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, HER2-negative advanced breast cancer (EMERALD)","journal":"JCO","year":2022,"doi":"10.1200/JCO.22.00338"},{"title":"TROPION-Breast01: datopotamab deruxtecan versus chemotherapy in pretreated hormone-receptor-positive breast cancer, and why a PFS win did not translate to survival","journal":"Journal of Clinical Oncology","year":2024,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=TROPION-Breast01+datopotamab+deruxtecan+Bardia"}],"orcid":"0000-0003-4885-1157"},{"id":"adria-comella-carnice","kind":"person","name":"Adrià Comella Carnicé","aka":[],"tldr":"Adrià Comella Carnicé represents Hospital de la Santa Creu i Sant Pau in the Organisation of European Cancer Institutes, which lists the centre among its members in Spain.","summary":"Adrià Comella Carnicé is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Hospital de la Santa Creu i Sant Pau, its member in Spain. Hospital de Sant Pau is a Barcelona university hospital, famous for its modernista buildings, whose cancer campus with the Puigvert Foundation is an associate member of the Organisation of European Cancer Institutes. OnCo records the name from the OECI membership list so that the centre's page has a named contact point; the person's exact title, appointment date and biography are not yet recorded and should be checked on the institution's own pages before being relied on.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Hospital de la Santa Creu i Sant Pau website","url":"https://www.santpau.cat/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["hospital-de-sant-pau"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Hospital de la Santa Creu i Sant Pau to the Organisation of European Cancer Institutes","institutionId":"hospital-de-sant-pau","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Hospital de la Santa Creu i Sant Pau website","url":"https://www.santpau.cat/"}],"papers":[{"title":"Turning the Crisis Into an Opportunity: Digital Health Strategies Deployed During the COVID-19 Outbreak","journal":"JMIR Public Health and Surveillance","year":2020,"url":"https://doi.org/10.2196/19106","doi":"10.2196/19106","note":"OpenAlex author record matched by institution"},{"title":"Clinical Validation of Digital Healthcare Solutions: State of the Art, Challenges and Opportunities","journal":"Healthcare","year":2024,"url":"https://doi.org/10.3390/healthcare12111057","doi":"10.3390/healthcare12111057","note":"OpenAlex author record matched by institution"},{"title":"Development and validation of a population-based risk stratification model for severe COVID-19 in the general population","journal":"Scientific Reports","year":2022,"url":"https://doi.org/10.1038/s41598-022-07138-y","doi":"10.1038/s41598-022-07138-y","note":"OpenAlex author record matched by institution"}]},{"id":"adrian-ochsenbein","kind":"person","name":"Adrian Ochsenbein","aka":[],"tldr":"Bern medical oncology chief whose lab targets leukaemia stem cells and CD70 signalling.","summary":"Adrian Ochsenbein is Chief Physician of Medical Oncology at Inselspital, Bern University Hospital, and a Director of the University Cancer Center Inselspital. His translational research investigates leukaemia stem cells and immune regulation, leading to the clinical development of the anti-CD70 antibody cusatuzumab in acute myeloid leukaemia. He combines a large clinical department with a laboratory programme in tumour immunology.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.tumorzentrum.insel.ch/de/ueber-uns/organisation"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ochsenbein+AF%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","leukaemia","immunotherapy"],"related":[],"cancers":["aml","cml"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["inselspital-bern"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director UCI; Chief Physician, Medical Oncology","institutionId":"inselspital-bern","specialisms":["Medical oncology","Leukaemia stem cells","Tumour immunology"],"profiles":[{"label":"Institution profile","url":"https://www.tumorzentrum.insel.ch/de/ueber-uns/organisation"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ochsenbein+AF%5BAuthor%5D"}],"papers":[{"title":"Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents","journal":"Nature Medicine","year":2020,"url":"https://doi.org/10.1038/s41591-020-0910-8","doi":"10.1038/s41591-020-0910-8"}]},{"id":"adrian-krainer","kind":"person","name":"Adrian R. Krainer","aka":[],"tldr":"Adrian Krainer invented the antisense drug nusinersen and studies how splicing errors drive cancer.","summary":"Adrian R. Krainer is St. Giles Foundation Professor at Cold Spring Harbor Laboratory and an RNA biologist who studies how splicing works and how it goes wrong. He is best known for the splice-switching antisense oligonucleotide work that produced nusinersen for spinal muscular atrophy, recognised with a Breakthrough Prize. His selected paper shows antisense correction of SMN2 splicing in the central nervous system in a mouse model of the disease. His laboratory now applies oligonucleotide therapeutics to the splicing factors that are mutated in leukaemia and solid tumours, asking whether splicing errors in cancer can be corrected the same way.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Krainer%20AR%5BAuthor%5D"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["antisense-sirna"],"targets":[],"drugs":[],"companies":[],"institutions":["cold-spring-harbor"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["genes-and-development"],"dependsOn":[],"notes":[],"role":"St. Giles Foundation Professor","institutionId":"cold-spring-harbor","specialisms":["RNA splicing","Antisense oligonucleotides","Splicing in cancer"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Krainer%20AR%5BAuthor%5D"}],"papers":[{"title":"Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model","journal":"Genes & Development","year":2010,"url":"https://doi.org/10.1101/gad.1941310","doi":"10.1101/gad.1941310"}],"orcid":"0000-0001-9024-9501"},{"id":"aimery-de-gramont","kind":"person","name":"Aimery de Gramont","aka":[],"tldr":"Invented the FOLFOX regimen that anchors colorectal chemotherapy and founded the GERCOR and ARCAD trial groups.","summary":"Aimery de Gramont (Paris) designed the infusional fluorouracil and oxaliplatin regimen known as FOLFOX, showed its benefit in the pivotal 2000 trial, and co-led MOSAIC and the IDEA collaboration on adjuvant duration. He founded the GERCOR cooperative group and the ARCAD database of pooled colorectal trials, which has reshaped endpoints and trial design in the disease.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=de%20Gramont%20A%5BAuthor%5D%20oxaliplatin%20colorectal"}],"tags":["colorectal","chemotherapy","cooperative-group"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":["cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Head of Medical Oncology, Institut Hospitalier Franco-Britannique; Founder, GERCOR and ARCAD","specialisms":["Colorectal cancer","Chemotherapy regimens","Adjuvant therapy","Meta-analysis"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=de%20Gramont%20A%5BAuthor%5D%20oxaliplatin%20colorectal"}],"papers":[{"title":"Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer","journal":"JCO","year":2000,"doi":"10.1200/JCO.2000.18.16.2938"},{"title":"Duration of adjuvant chemotherapy for stage III colon cancer (IDEA)","journal":"NEJM","year":2018,"doi":"10.1056/NEJMoa1713709"}]},{"id":"ajai-chari","kind":"person","name":"Ajai Chari","aka":[],"tldr":"Led the pivotal talquetamab trial, establishing GPRC5D as the second bispecific target in myeloma.","summary":"Ajai Chari was principal investigator and first author of MonumenTAL-1, the trial that established the GPRC5DxCD3 bispecific talquetamab in relapsed myeloma and validated a target beyond BCMA. He has led studies of subcutaneous daratumumab, selinexor and real-world outcomes in myeloma and directs the myeloma programme at UCSF after many years at Mount Sinai.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chari%20A%5BAuthor%5D%20talquetamab"}],"tags":["myeloma","bispecific","gprc5d"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":["bispecific-antibody","t-cell-engager"],"targets":["gprc5d","cd3","cd38"],"drugs":[],"companies":[],"institutions":["ucsf"],"pathways":[],"terms":[],"trials":["monumental-1"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director of the Multiple Myeloma Program, UCSF Helen Diller Family Comprehensive Cancer Center","institutionId":"ucsf","specialisms":["Multiple myeloma","Bispecific antibodies","GPRC5D-targeted therapy","Real-world outcomes"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chari%20A%5BAuthor%5D%20talquetamab"}],"papers":[{"title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma (MonumenTAL-1)","journal":"NEJM","year":2022,"doi":"10.1056/NEJMoa2204591"},{"title":"Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA)","journal":"Lancet Haematology","year":2020,"doi":"10.1016/S2352-3026(20)30070-3"}]},{"id":"kapoor-akhil","kind":"person","name":"Akhil Kapoor","aka":[],"tldr":"First author of METRO PLUS, the Varanasi trial that doubled survival in advanced head and neck cancer by adding cheap oral metronomic drugs to standard chemotherapy.","summary":"Akhil Kapoor is a medical oncologist at Tata Memorial Centre's Varanasi hospitals and first author of METRO PLUS (JCO Global Oncology 2026), a randomised trial of 238 patients with advanced unresectable head and neck cancer in which paclitaxel-carboplatin plus oral metronomic chemotherapy gave a median overall survival of 10 months against 5 months with chemotherapy alone (hazard ratio 0.54). His work continues the Tata Memorial tradition of trials designed for the drugs and budgets available to most of the world's patients.","asOf":"2026-09-10","links":[{"label":"Tata Memorial Centre","url":"https://tmc.gov.in"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kapoor%20A%5BAuthor%5D%20Varanasi%20head%20and%20neck%20metronomic"}],"tags":[],"related":[],"cancers":["head-and-neck"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["paclitaxel","carboplatin","methotrexate"],"companies":[],"institutions":["homi-bhabha-cancer-hospital-varanasi","tata-memorial"],"pathways":[],"terms":[],"trials":["metro-plus-varanasi"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Medical oncologist, Homi Bhabha Cancer Hospital and MPMMCC, Varanasi (Tata Memorial Centre)","institutionId":"homi-bhabha-cancer-hospital-varanasi","specialisms":["Head and neck cancer","Metronomic chemotherapy","Pragmatic trials","Global oncology"],"profiles":[{"label":"Tata Memorial Centre","url":"https://tmc.gov.in"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kapoor%20A%5BAuthor%5D%20Varanasi%20head%20and%20neck%20metronomic"}],"papers":[{"title":"Integrating metronomic therapy with standard chemotherapy in advanced unresectable head and neck cancer: a randomized trial addressing global cancer care equity (METRO PLUS)","journal":"JCO Global Oncology","year":2026,"doi":"10.1200/GO-25-00721"}],"orcid":"0000-0001-6006-2631"},{"id":"akifumi-takaori","kind":"person","name":"Akifumi Takaori","aka":[],"tldr":"Hematologist who directs Kyoto University Hospital, one of Japan's leading academic medical centres.","summary":"Akifumi Takaori (Takaori-Kondo) is Director of Kyoto University Hospital and a professor of hematology and oncology at Kyoto University. His research has addressed leukemia biology, hematopoietic stem cell transplantation and the molecular pathogenesis of blood cancers. He leads the hospital's clinical, research and educational missions.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.kuhp.kyoto-u.ac.jp/english/outline/greeting.html"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Takaori-Kondo+A%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","hematology","leukemia"],"related":[],"cancers":["aml","multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["kyoto-university-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director of Kyoto University Hospital","institutionId":"kyoto-university-hospital","specialisms":["Hematology","Leukemia","Hematopoietic stem cell transplantation"],"profiles":[{"label":"Institution profile","url":"https://www.kuhp.kyoto-u.ac.jp/english/outline/greeting.html"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Takaori-Kondo+A%5BAuthor%5D"}],"papers":[{"title":"Antiviral defense by APOBEC3 Family Proteins","journal":"Uirusu","year":2005,"url":"https://doi.org/10.2222/jsv.55.267","doi":"10.2222/jsv.55.267","note":"OpenAlex author record matched by institution"},{"title":"Clinical Impacts of Germline DDX41 Mutations on Myeloid Neoplasms","journal":"Blood","year":2020,"url":"https://doi.org/10.1182/blood-2020-140174","doi":"10.1182/blood-2020-140174","note":"OpenAlex author record matched by institution"},{"title":"High-resolution Computed Tomography Findings of Diffuse Pulmonary Involvement by Mycosis Fungoides","journal":"Journal of Thoracic Imaging","year":2007,"url":"https://doi.org/10.1097/rti.0b013e3180592af8","doi":"10.1097/rti.0b013e3180592af8","note":"OpenAlex author record matched by institution"}]},{"id":"alan-ashworth","kind":"person","name":"Alan Ashworth","aka":[],"tldr":"Co-discovered that BRCA-deficient cancers die when PARP is blocked, the idea behind an entire drug class.","summary":"Alan Ashworth is President of the UCSF Helen Diller Family Comprehensive Cancer Center and a molecular biologist specialising in DNA repair, synthetic lethality, BRCA and PARP inhibitors. He co-identified BRCA2 and, with colleagues at the Institute of Cancer Research, showed that BRCA-deficient cells die when PARP is blocked, the synthetic lethality behind olaparib and the PARP inhibitor class. His papers include the Nature report on targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy and a review of synthetic lethal therapies beyond PARP inhibitors, with relevance to ovarian cancer and triple-negative breast cancer. He now leads UCSF's cancer centre.","asOf":"2026-09-08","links":[{"label":"UCSF profile","url":"https://profiles.ucsf.edu/search/?searchtype=people&searchfor=Alan%20Ashworth"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ashworth%20A%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Alan%20Ashworth"}],"tags":[],"related":[],"cancers":["ovarian","tnbc"],"sections":[],"technologies":["parp-inhibitor","synthetic-lethality-approaches"],"targets":["brca","parp"],"drugs":["olaparib"],"companies":[],"institutions":["ucsf"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nature-reviews-clinical-oncology"],"dependsOn":[],"notes":[],"role":"President, UCSF Helen Diller Family Comprehensive Cancer Center","institutionId":"ucsf","specialisms":["DNA repair","Synthetic lethality","BRCA","PARP inhibitors"],"profiles":[{"label":"UCSF profile","url":"https://profiles.ucsf.edu/search/?searchtype=people&searchfor=Alan%20Ashworth"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ashworth%20A%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Alan%20Ashworth"}],"papers":[{"title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","journal":"Nature","year":2005,"url":"https://doi.org/10.1038/nature03445","doi":"10.1038/nature03445"},{"title":"Synthetic lethal therapies for cancer: what's next after PARP inhibitors?","journal":"Nature Reviews Clinical Oncology","year":2018,"url":"https://doi.org/10.1038/s41571-018-0055-6","doi":"10.1038/s41571-018-0055-6"}]},{"id":"alan-dandrea","kind":"person","name":"Alan D. D'Andrea","aka":[],"tldr":"Mapped the Fanconi anaemia/BRCA DNA repair pathway and how tumours become resistant to PARP inhibitors.","summary":"Alan D'Andrea's laboratory defined the Fanconi anaemia pathway and its convergence with BRCA1/2 in homologous recombination, and has led the field's understanding of PARP inhibitor resistance mechanisms including restoration of replication fork protection and loss of 53BP1. He directs women's cancers and DNA repair research at Dana-Farber and has translated these findings into trials of ATR and DNA-PK inhibitor combinations.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=D'Andrea%20AD%5BAuthor%5D%20Fanconi%20PARP"}],"tags":["dna-repair","parp","resistance"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":["parp-inhibitor","synthetic-lethality-approaches"],"targets":["parp","brca","atr"],"drugs":[],"companies":[],"institutions":["dana-farber"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nature-reviews-cancer"],"dependsOn":[],"notes":[],"role":"Director, Susan F. Smith Center for Women's Cancers and Center for DNA Damage and Repair, Dana-Farber Cancer Institute","institutionId":"dana-farber","specialisms":["DNA damage response","Fanconi anaemia pathway","PARP inhibitor resistance","Ovarian cancer"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=D'Andrea%20AD%5BAuthor%5D%20Fanconi%20PARP"}],"papers":[{"title":"The Fanconi anaemia/BRCA pathway","journal":"Nature Reviews Cancer","year":2003,"doi":"10.1038/nrc970"},{"title":"Mechanisms and consequences of cancer genome instability: lessons from genome sequencing studies","journal":"Annual Review of Pathology","year":2016}],"orcid":"0000-0001-6168-6294"},{"id":"alan-venook","kind":"person","name":"Alan P. Venook","aka":[],"tldr":"GI oncologist who led CALGB/SWOG 80405 and helped show that tumour side matters in colorectal cancer.","summary":"Alan Venook is Shorenstein Associate Director for Program Development at the UCSF Helen Diller Family Comprehensive Cancer Center and a long-time investigator with the Alliance for Clinical Trials in Oncology. A medical oncologist in colorectal and liver cancer, he chaired CALGB/SWOG 80405, the first-line trial of cetuximab versus bevacizumab with chemotherapy in KRAS wild-type metastatic colorectal cancer, whose analyses established primary tumour sidedness as a treatment factor. His papers report that trial in JAMA and a pooled analysis of primary tumour side in RAS wild-type disease treated with EGFR directed antibodies across six randomised trials. His work spans colorectal cancer, hepatocellular carcinoma and cooperative group trials aimed at EGFR and VEGF.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Alan_Venook","links":[{"label":"UCSF profile","url":"https://profiles.ucsf.edu/search/?searchtype=people&searchfor=Alan%20P.%20Venook"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Venook%20AP%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Alan%20P.%20Venook"}],"tags":[],"related":[],"cancers":["colorectal","hcc"],"sections":[],"technologies":[],"targets":["egfr","vegf"],"drugs":[],"companies":["alliance-oncology"],"institutions":["ucsf"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["annals-of-oncology"],"dependsOn":[],"notes":[],"role":"Shorenstein Associate Director for Program Development, UCSF Helen Diller Family Comprehensive Cancer Center","institutionId":"ucsf","specialisms":["Colorectal cancer","Liver cancer","Cooperative group trials"],"profiles":[{"label":"UCSF profile","url":"https://profiles.ucsf.edu/search/?searchtype=people&searchfor=Alan%20P.%20Venook"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Venook%20AP%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Alan%20P.%20Venook"}],"papers":[{"title":"Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial","journal":"JAMA","year":2017,"url":"https://doi.org/10.1001/jama.2017.7105","doi":"10.1001/jama.2017.7105"},{"title":"Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials","journal":"Annals of Oncology","year":2017,"url":"https://doi.org/10.1093/annonc/mdx175","doi":"10.1093/annonc/mdx175"}]},{"id":"alastair-greystoke","kind":"person","name":"Alastair Greystoke","aka":[],"tldr":"The Newcastle oncologist who led the NHS England pilot that put a blood test for lung cancer mutations into the diagnostic pathway, and who co-leads the CONCORDE radiotherapy platform.","summary":"Alastair Greystoke is Professor of Precision Oncology at Newcastle University and a consultant at the Northern Centre for Cancer Care, one of four consultants running the Sir Bobby Robson Early Clinical Trials Centre at the Freeman Hospital. He joined Newcastle in 2014 after eight years in Manchester and The Christie, leads systemic therapy research for non-small-cell lung cancer in the north east across a phase 1 to phase 4 portfolio, and leads the pharmacodynamic biomarker team at the Newcastle University Cancer Centre.\n\nHe is clinical director for cancer for the North East and Yorkshire Genomic Medicine Service and led the NHS England pilot that assessed the cost-effectiveness of cell-free DNA testing in advanced lung cancer, the work that lies behind the National Cancer Plan's statement that a circulating tumour DNA test returns a result on average 16 days faster than a tissue biopsy and was added to the National Genomic Test Directory in May 2025. He is joint chief investigator of CONCORDE, the Bayesian adaptive platform testing DNA damage response inhibitors alongside radical radiotherapy.","asOf":"2026-09-25","links":[{"label":"Newcastle University staff page","url":"https://www.ncl.ac.uk/medical-sciences/people/profile/alastairgreystoke.html"}],"tags":["lung","trialist","uk","genomics"],"related":["corinne-faivre-finn","gary-middleton"],"cancers":["nsclc","lung-cancer"],"sections":["diagnostics","targeted-therapy"],"technologies":["liquid-biopsy"],"targets":[],"drugs":[],"companies":[],"institutions":["newcastle-cancer-centre"],"pathways":[],"terms":[],"trials":["national-lung-matrix-trial"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Precision Oncology, Newcastle University; Consultant Medical Oncologist, Northern Centre for Cancer Care; Clinical Director for Cancer, North East and Yorkshire Genomic Medicine Service","institutionId":"newcastle-cancer-centre","specialisms":["Early-phase lung cancer drug development","Circulating tumour DNA in the diagnostic pathway","Pharmacodynamic biomarkers"],"profiles":[{"label":"Newcastle University staff page","url":"https://www.ncl.ac.uk/medical-sciences/people/profile/alastairgreystoke.html"}],"papers":[{"title":"The National Lung Matrix Trial of personalized therapy in lung cancer","journal":"Nature","year":2020,"doi":"10.1038/s41586-020-2481-8"}]},{"id":"albert-koong","kind":"person","name":"Albert C. Koong","aka":[],"tldr":"Albert Koong is a radiation oncologist leading MD Anderson's radiation department, with a focus on pancreatic cancer and SBRT.","summary":"Albert Koong is Chair of the Department of Radiation Oncology at MD Anderson Cancer Center. A radiation oncologist and physician-scientist, his research covers stereotactic body radiotherapy for pancreatic ductal adenocarcinoma and the tumour hypoxia and unfolded-protein-response biology that shapes radiation response. His papers include a phase I study of stereotactic radiosurgery in locally advanced pancreatic cancer and a phase II study of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in the same setting. He now leads the radiation department at MD Anderson, working across SBRT and modern image-guided external beam techniques.","asOf":"2026-09-08","links":[{"label":"MD Anderson faculty","url":"https://faculty.mdanderson.org/search?q=Albert%20C.%20Koong"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Koong%20AC%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Albert%20C.%20Koong"}],"tags":[],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":["sbrt","imrt-igrt"],"targets":[],"drugs":[],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["ijrobp"],"dependsOn":[],"notes":[],"role":"Chair, Department of Radiation Oncology, MD Anderson","institutionId":"md-anderson","specialisms":["Radiation oncology","Pancreatic cancer","Stereotactic radiotherapy"],"profiles":[{"label":"MD Anderson faculty","url":"https://faculty.mdanderson.org/search?q=Albert%20C.%20Koong"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Koong%20AC%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Albert%20C.%20Koong"}],"papers":[{"title":"Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer","journal":"International Journal of Radiation Oncology, Biology, Physics","year":2004,"url":"https://doi.org/10.1016/j.ijrobp.2003.11.004","doi":"10.1016/j.ijrobp.2003.11.004"},{"title":"Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer","journal":"International Journal of Radiation Oncology, Biology, Physics","year":2005,"url":"https://doi.org/10.1016/j.ijrobp.2005.07.002","doi":"10.1016/j.ijrobp.2005.07.002"}]},{"id":"albert-lasker","kind":"person","name":"Albert Lasker","aka":[],"tldr":"The man who invented modern advertising put his fortune and his methods behind medical research, founding the Lasker Foundation with his wife Mary in 1942; after his death in 1952 she carried the campaign for cancer research into law.","summary":"Albert Davis Lasker (1880-1952) built Lord & Thomas into the largest advertising agency of its day and is credited with inventing much of modern advertising. In 1942 he and his wife Mary Woodard Lasker founded the Lasker Foundation, whose stated mission is to improve health by accelerating support for medical research through recognition of research excellence, advocacy, and education; its Lasker Awards became the most watched prize in American medicine. The Laskers applied advertising's tools to research funding: they remade the American Society for the Control of Cancer into the American Cancer Society with a research budget, and lobbied Congress for the National Institutes of Health. Albert died of cancer in 1952; Mary Lasker's campaign culminated in the National Cancer Act of 1971.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Albert_Lasker","links":[{"label":"Lasker Foundation: about","url":"https://laskerfoundation.org/about/"}],"tags":["hero","donor"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["lasker-foundation"],"pathways":[],"terms":[],"trials":[],"people":["mary-lasker"],"bottlenecks":["b-funding-allocation","b-knowledge-diffusion"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Advertising pioneer who co-founded the Lasker Foundation with Mary Lasker in 1942","specialisms":["Medical research advocacy","Foundation building"],"profiles":[],"papers":[]},{"id":"albert-salazar-soler","kind":"person","name":"Albert Salazar Soler","aka":[],"tldr":"Albert Salazar Soler represents Vall d'Hebron University Hospital / VHIO in the Organisation of European Cancer Institutes, which lists the centre among its members in Spain.","summary":"Albert Salazar Soler is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Vall d'Hebron University Hospital / VHIO, its member in Spain. Vall d'Hebron is Spain's leading cancer research hospital and a global leader in phase 1 and breast cancer ADC trials. OnCo records the name from the OECI membership list so that the centre's page has a named contact point; the person's exact title, appointment date and biography are not yet recorded and should be checked on the institution's own pages before being relied on.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Vall d'Hebron University Hospital / VHIO website","url":"https://www.vallhebron.com/es"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["vall-dhebron"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Vall d'Hebron University Hospital / VHIO to the Organisation of European Cancer Institutes","institutionId":"vall-dhebron","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Vall d'Hebron University Hospital / VHIO website","url":"https://www.vallhebron.com/es"}],"papers":[]},{"id":"alberto-bardelli","kind":"person","name":"Alberto Bardelli","aka":[],"tldr":"Used ctDNA to show how colorectal cancers evolve resistance to EGFR antibodies and how that resistance can fade.","summary":"Alberto Bardelli led the 2012 Nature study showing that KRAS mutations emerge in the blood of colorectal cancer patients months before radiological progression on cetuximab or panitumumab, one of the first demonstrations of liquid biopsy for tracking resistance, and later showed these clones decay when anti-EGFR therapy is stopped, the basis for rechallenge strategies. His laboratory also showed that mismatch repair inactivation increases immunotherapy sensitivity.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Alberto_Bardelli","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bardelli%20A%5BAuthor%5D%20colorectal%20ctDNA"}],"tags":["ctdna","colorectal","resistance"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":["liquid-biopsy"],"targets":["egfr","kras"],"drugs":[],"companies":[],"institutions":["candiolo","airc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Scientific Director, IFOM ETS - The AIRC Institute of Molecular Oncology; Professor, University of Turin","institutionId":"candiolo","specialisms":["Colorectal cancer genomics","Liquid biopsy","Acquired resistance","Tumour evolution"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bardelli%20A%5BAuthor%5D%20colorectal%20ctDNA"}],"papers":[{"title":"Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer","journal":"Nature","year":2012,"doi":"10.1038/nature11156"},{"title":"Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth","journal":"Nature","year":2017,"doi":"10.1038/nature24673"}],"orcid":"0000-0003-1647-5070"},{"id":"alberto-gabizon","kind":"person","name":"Alberto Gabizon","aka":[],"tldr":"The clinician half of the partnership that turned a liposome chemistry idea into Doxil, and the person who did the trials that showed it behaved differently in patients from free doxorubicin.","summary":"Alberto Gabizon worked with Yechezkel Barenholz at the Hebrew University on pegylated liposomal doxorubicin and then took it into patients, establishing the pharmacokinetics that distinguish it from free doxorubicin: a long circulation half-life, accumulation in tumour tissue, and a toxicity profile in which hand-foot syndrome and mucositis replace alopecia and cardiac damage. The product was approved by the FDA in 1995 and remains standard in relapsed ovarian cancer, used as a single agent or with carboplatin, trabectedin or bevacizumab, and as the comparator arm in modern trials including MIRASOL. He continues to work at Shaare Zedek Medical Center on nanomedicine pharmacology and combination strategies.","asOf":"2026-09-25","links":[{"label":"Shaare Zedek Medical Center","url":"https://www.szmc.org.il/eng/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gabizon%20A%5BAuthor%5D%20liposomal%20doxorubicin"},{"label":"Europe PMC author and affiliation search","url":"https://europepmc.org/search?query=AUTH%3A%22Gabizon%20A%22%20AND%20liposomal"}],"tags":["clinician-scientist","drug-delivery"],"related":[],"cancers":["ovarian","kaposi-sarcoma"],"sections":["drug-discovery","chemotherapy"],"technologies":[],"targets":[],"drugs":["pegylated-liposomal-doxorubicin","doxorubicin"],"companies":[],"institutions":["shaare-zedek","hebrew-university-of-jerusalem"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Oncologist, Shaare Zedek Medical Center; professor, Hebrew University-Hadassah Medical School","institutionId":"shaare-zedek","specialisms":["Liposomal drug delivery","Pharmacokinetics of nanomedicines","Ovarian and breast cancer","Early-phase trials"],"profiles":[{"label":"Shaare Zedek Medical Center","url":"https://www.szmc.org.il/eng/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gabizon%20A%5BAuthor%5D%20liposomal%20doxorubicin"},{"label":"Europe PMC author and affiliation search","url":"https://europepmc.org/search?query=AUTH%3A%22Gabizon%20A%22%20AND%20liposomal"}],"papers":[{"title":"Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes","journal":"Cancer Research","year":1994,"url":"https://pubmed.ncbi.nlm.nih.gov/8313389/","note":"PMID 8313389. Plasma clearance 0.1 litres per hour for the liposomal form against 45 for free doxorubicin, and a volume of distribution of 4 litres against 254."},{"title":"Doxil, the first FDA-approved nano-drug: lessons learned","journal":"Journal of Controlled Release","year":2012,"doi":"10.1016/j.jconrel.2012.03.020","note":"Barenholz Y; the retrospective covering the joint programme"}]},{"id":"aleix-prat","kind":"person","name":"Aleix Prat","aka":[],"tldr":"Translational oncologist who built genomic tests (HER2DX) to decide which HER2-positive patients can skip chemotherapy.","summary":"Aleix Prat developed the HER2DX genomic assay and led PAM50-based analyses across breast cancer trials, and is a principal investigator of PHERGain, which uses PET response to omit chemotherapy in HER2-positive early disease. He directs medical oncology at Hospital Clínic and the SOLTI cooperative group, focusing on biology-guided de-escalation.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Prat%20A%5BAuthor%5D%20breast%20PAM50%20HER2DX"}],"tags":["breast","genomics","de-escalation"],"related":[],"cancers":["breast-her2-positive","breast-hr-positive"],"sections":[],"technologies":["rna-seq","fdg-pet"],"targets":[],"drugs":[],"companies":["solti"],"institutions":["hospital-clinic-barcelona"],"pathways":[],"terms":[],"trials":["phergain"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["the-breast"],"dependsOn":[],"notes":[],"role":"Head of Medical Oncology, Hospital Clínic de Barcelona; Scientific Director, SOLTI","institutionId":"hospital-clinic-barcelona","specialisms":["Breast cancer genomics","HER2-positive de-escalation","PAM50 and HER2DX","Neoadjuvant trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Prat%20A%5BAuthor%5D%20breast%20PAM50%20HER2DX"}],"papers":[{"title":"Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain)","journal":"Lancet Oncology","year":2021,"doi":"10.1016/S1470-2045(21)00122-4"},{"title":"Clinical implications of the intrinsic molecular subtypes of breast cancer","journal":"The Breast","year":2015,"doi":"10.1016/j.breast.2015.07.008"}],"orcid":"0000-0003-2377-540X"},{"id":"aleksandar-sekulic","kind":"person","name":"Aleksandar Sekulic","aka":[],"tldr":"Mayo Clinic dermatologist who led ERIVANCE, the trial that established vismodegib, the first Hedgehog pathway inhibitor, for advanced basal cell carcinoma.","summary":"Aleksandar Sekulic is a dermatologist and physician-scientist at Mayo Clinic in Arizona. He was first author of the 2012 New England Journal of Medicine report of ERIVANCE BCC, the phase 2 trial in which the Hedgehog pathway inhibitor vismodegib produced responses in most patients with locally advanced and in a third of those with metastatic basal cell carcinoma, the basis of the drug's approval.","asOf":"2026-09-18","links":[],"tags":["skin","targeted-therapy","trialist"],"related":[],"cancers":["locally-advanced-bcc","skin-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["mayo-clinic-arizona"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-erivance-vismodegib-sekulic-nejm-2012"],"journals":[],"dependsOn":[],"notes":[],"role":"Dermatologist, Mayo Clinic Comprehensive Cancer Center in Arizona","institutionId":"mayo-clinic-arizona","specialisms":["Basal cell carcinoma","Hedgehog pathway inhibitors","Skin cancer"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sekulic%5BAuthor%5D"}],"papers":[{"title":"ERIVANCE BCC: efficacy and safety of vismodegib in advanced basal cell carcinoma","journal":"New England Journal of Medicine","year":2012,"url":"https://doi.org/10.1056/NEJMoa1113713","doi":"10.1056/NEJMoa1113713"}]},{"id":"alessandro-delle-donne","kind":"person","name":"Alessandro Delle Donne","aka":[],"tldr":"Health manager who leads the IRCCS Istituto Tumori Giovanni Paolo II in Bari, first as Direttore Generale and, since 2025, as Commissario Straordinario.","summary":"Alessandro Delle Donne leads the IRCCS Istituto Tumori Giovanni Paolo II in Bari, the Puglia region's research cancer institute. Regional news reports in March and July 2024 describe him as Direttore Generale, appointing Vito Campanile as health director and a new head of medical oncology, and a November 2025 report names him Commissario Straordinario of the institute, receiving an award for artificial intelligence in healthcare in Arezzo together with scientific director Raffaella Massafra. In that report he described AI applied to diagnostic pathways and research as one of the most important challenges for the healthcare of the future. The institute's own website and the Regione Puglia health portal could not be reached.","asOf":"2026-09-10","links":[{"label":"Source: Borderline24 report, Commissario Straordinario (November 2025)","url":"https://www.borderline24.com/2025/11/28/listituto-tumori-giovanni-paolo-ii-di-bari-conquista-arezzo-con-lia-in-sanita/"},{"label":"Source: Borderline24 report naming him Direttore Generale (March 2024)","url":"https://www.borderline24.com/2024/03/26/istituto-tumori-bari-e-vito-campanile-il-nuovo-direttore-sanitario/"}],"tags":["leadership","hospital-management","research-institute"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["istituto-tumori-bari"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["critical-reviews-in-oncology-hematology"],"dependsOn":[],"notes":[],"role":"Commissario Straordinario (Extraordinary Commissioner), IRCCS Istituto Tumori Giovanni Paolo II, Bari","institutionId":"istituto-tumori-bari","specialisms":["Health service management","Cancer centre management"],"profiles":[{"label":"Borderline24 report naming him Commissario Straordinario (November 2025)","url":"https://www.borderline24.com/2025/11/28/listituto-tumori-giovanni-paolo-ii-di-bari-conquista-arezzo-con-lia-in-sanita/"}],"papers":[{"title":"Standardized and simplified reporting of next-generation sequencing results in advanced non-small-cell lung cancer: Practical indications from an Italian multidisciplinary group","journal":"Critical Reviews in Oncology/Hematology","year":2023,"url":"https://doi.org/10.1016/j.critrevonc.2023.104217","doi":"10.1016/j.critrevonc.2023.104217","note":"OpenAlex author record matched by institution"},{"title":"Chronic treatment of COPD: state of the art and real-world analysis of healthcare costs based on medication adherence data","journal":"Recenti Progressi in Medicina","year":2022,"url":"https://doi.org/10.1701/3761.37486","doi":"10.1701/3761.37486","note":"OpenAlex author record matched by institution"},{"title":"Analysis of the Introduction in Clinical Practice of New Oral Anticoagulants in Local Health Agency BT: Translation of the Clinical Trial Data to a Local Health Care Area","journal":"Pharmaceutics","year":2021,"url":"https://doi.org/10.3390/pharmaceutics13020252","doi":"10.3390/pharmaceutics13020252","note":"OpenAlex author record matched by institution"}]},{"id":"alessandro-gronchi","kind":"person","name":"Alessandro Gronchi","aka":[],"tldr":"Sarcoma surgeon who led the ISG-STS 1001 trial of histology-tailored neoadjuvant chemotherapy.","summary":"Alessandro Gronchi is Chair of the Sarcoma Service at the Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, a surgeon whose specialisms are sarcoma surgery, retroperitoneal sarcoma and neoadjuvant chemotherapy. He is known for chairing ISG-STS 1001, the randomised trial that compared histology-tailored neoadjuvant chemotherapy with standard chemotherapy in high-risk soft-tissue sarcoma, and STRASS, which tested preoperative radiotherapy. His Lancet Oncology paper on ISG-STS 1001 set out how tailoring chemotherapy to sarcoma histotype compares with a standard regimen. He continues to lead the sarcoma surgical programme at INT Milan, with his publications listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gronchi%20A%5BAuthor%5D%20sarcoma"}],"tags":[],"related":[],"cancers":["sarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["int-milan"],"pathways":[],"terms":[],"trials":["isg-sts-1001"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chair, Sarcoma Service, Fondazione IRCCS Istituto Nazionale dei Tumori","institutionId":"int-milan","specialisms":["Sarcoma surgery","Retroperitoneal sarcoma","Neoadjuvant chemotherapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gronchi%20A%5BAuthor%5D%20sarcoma"}],"papers":[{"title":"Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001)","journal":"Lancet Oncology","year":2017,"doi":"10.1016/S1470-2045(17)30334-0"}],"orcid":"0000-0002-4703-3534"},{"id":"alessandro-venturi","kind":"person","name":"Alessandro Venturi","aka":[],"tldr":"Alessandro Venturi represents Fondazione IRCCS Policlinico San Matteo in the Organisation of European Cancer Institutes, which lists the centre among its members in Italy.","summary":"Alessandro Venturi is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Fondazione IRCCS Policlinico San Matteo, its member in Italy. The Policlinico San Matteo in Pavia, founded in 1449, is one of Italy's oldest and largest teaching hospitals and an associate member of the Organisation of European Cancer Institutes. OnCo records the name from the OECI membership list so that the centre's page has a named contact point; the person's exact title, appointment date and biography are not yet recorded and should be checked on the institution's own pages before being relied on.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Fondazione IRCCS Policlinico San Matteo website","url":"http://www.sanmatteo.org/site/home.html"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["policlinico-san-matteo"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Fondazione IRCCS Policlinico San Matteo to the Organisation of European Cancer Institutes","institutionId":"policlinico-san-matteo","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Fondazione IRCCS Policlinico San Matteo website","url":"http://www.sanmatteo.org/site/home.html"}],"papers":[]},{"id":"alex-herrera","kind":"person","name":"Alex F. Herrera","aka":[],"tldr":"Led the SWOG S1826 trial that made nivolumab part of first-line Hodgkin lymphoma treatment.","summary":"Alex Herrera is Chief of the Division of Lymphoma at City of Hope and SWOG Executive Officer for Leukemia, Lymphoma and Myeloma. A haematologist-oncologist specialising in Hodgkin lymphoma and immunotherapy, he was study chair of SWOG S1826, which compared nivolumab-AVD with brentuximab-AVD and led to the 2026 approval of nivolumab in untreated advanced Hodgkin lymphoma. His papers report nivolumab plus AVD in advanced-stage classic Hodgkin lymphoma in the New England Journal of Medicine and interim results of brentuximab vedotin combined with nivolumab in relapsed or refractory Hodgkin lymphoma in Blood. He also works on diffuse large B-cell lymphoma and oversees SWOG's haematologic committees.","asOf":"2026-09-08","links":[{"label":"City of Hope research faculty","url":"https://www.cityofhope.org/research/find-a-researcher"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Herrera%20AF%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Alex%20F.%20Herrera"}],"tags":[],"related":[],"cancers":["hodgkin-lymphoma","dlbcl"],"sections":[],"technologies":[],"targets":[],"drugs":["nivolumab","brentuximab-vedotin"],"companies":["swog"],"institutions":["city-of-hope"],"pathways":[],"terms":[],"trials":["swog-s1826"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["blood"],"dependsOn":[],"notes":[],"role":"Chief, Division of Lymphoma, City of Hope; SWOG Executive Officer, Leukemia/Lymphoma/Myeloma","institutionId":"city-of-hope","specialisms":["Hodgkin lymphoma","Immunotherapy","Cooperative group trials"],"profiles":[{"label":"City of Hope research faculty","url":"https://www.cityofhope.org/research/find-a-researcher"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Herrera%20AF%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Alex%20F.%20Herrera"}],"papers":[{"title":"Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma","journal":"New England Journal of Medicine","year":2024,"url":"https://doi.org/10.1056/NEJMoa2405888","doi":"10.1056/NEJMoa2405888"},{"title":"Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma","journal":"Blood","year":2018,"url":"https://doi.org/10.1182/blood-2017-10-811224","doi":"10.1182/blood-2017-10-811224"}]},{"id":"alexander-drilon","kind":"person","name":"Alexander Drilon","aka":[],"tldr":"Led the trials of larotrectinib, entrectinib, repotrectinib and selpercatinib that turned rare gene fusions into treatable targets.","summary":"Alexander Drilon is Chief of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center, where he specialises in oncogene-driven lung cancer and phase 1 trials. He is known for leading the trials of larotrectinib, entrectinib, repotrectinib and selpercatinib that turned rare NTRK, ROS1 and RET gene fusions into treatable targets, including as lead author on the pivotal larotrectinib and repotrectinib studies and as a leader of the LIBRETTO RET programme. His selected papers cover larotrectinib in TRK fusion-positive cancers in adults and children, and repotrectinib in ROS1 fusion-positive non-small-cell lung cancer. He now runs the early drug development programme at MSK, with a focus on small-molecule kinase inhibitors in lung and thyroid cancer.","asOf":"2026-09-08","links":[{"label":"MSK profile","url":"https://www.mskcc.org/cancer-care/doctors/alexander-drilon"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Drilon%20A%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["nsclc","thyroid"],"sections":[],"technologies":["kinase-inhibitors"],"targets":["ntrk","ros1","ret"],"drugs":["repotrectinib","selpercatinib"],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief, Early Drug Development Service","institutionId":"mskcc","specialisms":["Oncogene-driven lung cancer","NTRK, ROS1, RET fusions","Phase 1 trials"],"profiles":[{"label":"MSK profile","url":"https://www.mskcc.org/cancer-care/doctors/alexander-drilon"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Drilon%20A%5BAuthor%5D"}],"papers":[{"title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","journal":"New England Journal of Medicine","year":2018,"url":"https://doi.org/10.1056/NEJMoa1714448","doi":"10.1056/NEJMoa1714448"},{"title":"Repotrectinib in ROS1 fusion-positive non-small-cell lung cancer","journal":"New England Journal of Medicine","year":2024,"url":"https://doi.org/10.1056/NEJMoa2302299","doi":"10.1056/NEJMoa2302299"}]},{"id":"alexander-perl","kind":"person","name":"Alexander E. Perl","aka":[],"tldr":"Led ADMIRAL, which made gilteritinib the standard for relapsed FLT3-mutant AML.","summary":"Alexander Perl was principal investigator of ADMIRAL, which showed the FLT3 inhibitor gilteritinib doubles survival versus salvage chemotherapy in relapsed or refractory FLT3-mutant AML, the first randomised trial to establish single-agent targeted therapy in the disease. He led the earlier phase 1/2 gilteritinib study and studies of resistance to FLT3 inhibition. He leads AML clinical research at Penn.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Perl%20AE%5BAuthor%5D%20gilteritinib"}],"tags":["aml","flt3","targeted-therapy"],"related":[],"cancers":["aml"],"sections":[],"technologies":["kinase-inhibitors"],"targets":["flt3"],"drugs":[],"companies":[],"institutions":["penn-abramson"],"pathways":[],"terms":[],"trials":["admiral"],"people":[],"bottlenecks":[],"keyPapers":["paper-admiral-gilteritinib-flt3-nejm-2019"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medicine, Abramson Cancer Center, University of Pennsylvania","institutionId":"penn-abramson","specialisms":["Acute myeloid leukaemia","FLT3 inhibitors","Relapsed AML","Resistance mechanisms"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Perl%20AE%5BAuthor%5D%20gilteritinib"}],"papers":[{"title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML (ADMIRAL)","journal":"NEJM","year":2019,"doi":"10.1056/NEJMoa1902688"},{"title":"Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study","journal":"Lancet Oncology","year":2017,"doi":"10.1016/S1470-2045(17)30416-3"}]},{"id":"alexander-eggermont","kind":"person","name":"Alexander Eggermont","aka":[],"tldr":"Surgical oncologist who led the EORTC adjuvant ipilimumab and pembrolizumab trials in melanoma.","summary":"Alexander Eggermont is Chief Scientific Officer of the Princess Máxima Center and Professor at Utrecht, and a former President of the EORTC and Director General of Gustave Roussy. A surgical oncologist by training, he specialises in melanoma and adjuvant immunotherapy. He led the EORTC trials that tested adjuvant checkpoint blockade in stage III melanoma: EORTC 18071 of adjuvant ipilimumab and KEYNOTE-054 of adjuvant pembrolizumab, the latter reported in the New England Journal of Medicine as a placebo-controlled trial of pembrolizumab after resection. His work helped establish immunotherapy after surgery in melanoma, and his publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Eggermont%20AM%5BAuthor%5D%20adjuvant%20melanoma"}],"tags":[],"related":[],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab","ipilimumab"],"companies":["curie-nki-eortc"],"institutions":["gustave-roussy"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Scientific Officer, Princess Máxima Center; Professor, Utrecht; former EORTC President","institutionId":"curie-nki-eortc","specialisms":["Melanoma","Adjuvant immunotherapy","Surgical oncology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Eggermont%20AM%5BAuthor%5D%20adjuvant%20melanoma"}],"papers":[{"title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (KEYNOTE-054)","journal":"NEJM","year":2018,"doi":"10.1056/NEJMoa1802357"}]},{"id":"alexander-stratigos","kind":"person","name":"Alexander J. Stratigos","aka":[],"tldr":"Athens dermatologist who led the trial showing that cemiplimab works in advanced basal cell carcinoma after Hedgehog inhibitors have failed, and who co-authors the European skin cancer guidelines.","summary":"Alexander Stratigos is professor of dermatology at the University of Athens and works at Andreas Sygros Hospital. He was first author of the 2021 Lancet Oncology report of the phase 2 trial in which the PD-1 antibody cemiplimab produced durable responses in locally advanced basal cell carcinoma after progression on or intolerance of Hedgehog pathway inhibitors, leading to its approval in that setting. He leads the European guideline groups for basal and squamous-cell skin cancer.","asOf":"2026-09-18","links":[],"tags":["skin","immunotherapy","guidelines"],"related":[],"cancers":["locally-advanced-bcc","advanced-cutaneous-scc","skin-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["nkua-athens"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-cemiplimab-bcc-stratigos-lancet-oncol-2021"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Dermatology, National and Kapodistrian University of Athens, Andreas Sygros Hospital","institutionId":"nkua-athens","specialisms":["Basal cell carcinoma","Cutaneous squamous-cell carcinoma","Skin cancer guidelines"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Stratigos%5BAuthor%5D"}],"papers":[{"title":"Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy","journal":"The Lancet Oncology","year":2021,"url":"https://doi.org/10.1016/S1470-2045(21)00126-1","doi":"10.1016/S1470-2045(21)00126-1"}]},{"id":"alex-scott","kind":"person","name":"Alexandra \"Alex\" Scott","aka":[],"tldr":"Diagnosed with neuroblastoma before her first birthday, she set up a lemonade stand at four to raise money for her hospital. By her death at eight in 2004 it had raised $1 million; the foundation in her name has raised hundreds of millions since.","summary":"Alex Scott (1996-2004) of Wynnewood, Pennsylvania, was diagnosed with neuroblastoma shortly before her first birthday. In 2000, aged four, after a stem cell transplant, she told her parents she wanted to hold a lemonade stand to give the money to her doctors so they could help other children. The stand became an annual event copied across the country, and by the time she died on 1 August 2004, aged eight, it had raised $1 million. Her parents, Liz and Jay Scott, formalised Alex's Lemonade Stand Foundation in 2005. It has since raised well over $250 million and become one of the largest private funders of childhood cancer research in the United States, supporting early-career investigators, clinical trials and the Childhood Cancer Data Lab.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Alex%27s_Lemonade_Stand_Foundation","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Alex%27s_Lemonade_Stand_Foundation"},{"label":"Alex's Lemonade Stand Foundation","url":"https://www.alexslemonade.org/"}],"tags":["hero","patient"],"related":["alexs-lemonade-stand"],"cancers":["neuroblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["alsf"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-rare-cancers","b-funding-allocation"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Child with neuroblastoma who started Alex's Lemonade Stand","specialisms":["Neuroblastoma","Childhood cancer","Research fundraising"],"profiles":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Alex%27s_Lemonade_Stand_Foundation"},{"label":"Alex's Lemonade Stand Foundation","url":"https://www.alexslemonade.org/"}],"papers":[]},{"id":"alexandre-chan","kind":"person","name":"Alexandre Chan","aka":[],"tldr":"Oncology pharmacist-scientist at UC Irvine and President of MASCC, the multinational society for supportive care in cancer, known for research on cancer-related cognitive impairment.","summary":"Alexandre Chan is President of the Multinational Association of Supportive Care in Cancer (MASCC) and a professor of clinical pharmacy at the University of California, Irvine. His research addresses supportive care and survivorship, including cancer-related cognitive impairment, chemotherapy toxicities and symptom management. He has held leadership roles in international oncology pharmacy organisations.","asOf":"2026-09-10","links":[{"label":"Society page","url":"https://mascc.org/about-mascc/leadership/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chan+A%5BAuthor%5D+supportive+care+cancer"}],"tags":["leadership","clinician-scientist","supportive care","survivorship"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["mascc"],"pathways":[],"terms":["palliative-treatment","late-effects"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President","institutionId":"mascc","specialisms":["Supportive care in cancer","Oncology pharmacy","Cancer-related cognitive impairment"],"profiles":[{"label":"Society page","url":"https://mascc.org/about-mascc/leadership/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chan+A%5BAuthor%5D+supportive+care+cancer"}],"papers":[{"title":"Association of proinflammatory cytokines and chemotherapy-associated cognitive impairment in breast cancer patients: a multi-centered, prospective, cohort study","journal":"Annals of Oncology","year":2015,"doi":"10.1093/annonc/mdv206"}],"orcid":"0000-0003-4391-4219"},{"id":"alexis-cortot","kind":"person","name":"Alexis Cortot","aka":[],"tldr":"Lille pulmonologist and thoracic oncologist who presides over the IFCT, France's academic lung cancer trials group.","summary":"Alexis Cortot is President of the Intergroupe Francophone de Cancérologie Thoracique (IFCT), elected at the June 2025 general assembly. He is a pulmonologist at Lille University Hospital whose research covers targeted therapy and immunotherapy for non-small cell lung cancer. The IFCT runs multicentre academic trials in thoracic oncology across France and francophone countries.","asOf":"2026-09-10","links":[{"label":"Society page","url":"https://www.ifct.fr/a-propos-de-l-ifct/conseil-d-administration"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cortot+AB%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","lung cancer","clinical trials"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["ifct"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President","institutionId":"ifct","specialisms":["Thoracic oncology","Lung cancer","Pulmonology"],"profiles":[{"label":"Society page","url":"https://www.ifct.fr/a-propos-de-l-ifct/conseil-d-administration"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cortot+AB%5BAuthor%5D"}],"papers":[{"title":"First-Line Afatinib plus Cetuximab for EGFR -Mutant Non–Small Cell Lung Cancer: Results from the Randomized Phase II IFCT-1503 ACE-Lung Study","journal":"Clinical Cancer Research","year":2021,"doi":"10.1158/1078-0432.ccr-20-4604"},{"title":"Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non–small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study","journal":"European Journal of Cancer","year":2020,"doi":"10.1016/j.ejca.2020.02.022"},{"title":"Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non–Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the IFCT-1703 R2D2 Trial","journal":"Journal of Clinical Oncology","year":2022,"doi":"10.1200/jco.21.01455"}],"orcid":"0000-0003-0098-2238"},{"id":"alfred-sloan","kind":"person","name":"Alfred P. Sloan Jr.","aka":[],"tldr":"In the 1940s the General Motors chairman joined engineer Charles Kettering to establish the Sloan Kettering Institute, dedicated in 1948, which gave Memorial Hospital a research arm and its modern name.","summary":"Alfred P. Sloan Jr. (1875-1966) ran General Motors for decades and, through the Alfred P. Sloan Foundation, became one of the largest funders of American science. Memorial Sloan Kettering's history records that in the 1940s two General Motors executives, Alfred P. Sloan and Charles F. Kettering, joined forces to establish the Sloan Kettering Institute, which was formally dedicated in 1948. The idea was to apply the organised research methods of industry to cancer: a laboratory institute beside a hospital, so that findings could move to patients and patients' problems back to the bench. The Institute became the basic-science arm of what is now Memorial Sloan Kettering Cancer Center, the largest private cancer centre in the world, and the model of hospital plus research institute was copied widely.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Alfred_P._Sloan","links":[{"label":"MSK: history and milestones","url":"https://www.mskcc.org/about/history-milestones"}],"tags":["hero","donor"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":[],"people":["charles-kettering"],"bottlenecks":["b-funding-allocation","b-translational-valley"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"General Motors chairman who, with Charles Kettering, established the Sloan Kettering Institute","specialisms":["Cancer research institute founding","Industrial philanthropy"],"profiles":[],"papers":[]},{"id":"alfredo-addeo","kind":"person","name":"Alfredo Addeo","aka":[],"tldr":"Thoracic oncologist who heads the Oncology Division at Geneva University Hospitals.","summary":"Alfredo Addeo is Head of the Oncology Division at Geneva University Hospitals (HUG). A medical oncologist specialising in thoracic oncology and immunotherapy, he has published widely on immune checkpoint inhibitors, biomarkers of response and the design of clinical trials in non-small-cell lung cancer, small-cell lung cancer and mesothelioma. His papers include the SAKK 19/17 safety analysis of first-line durvalumab in PD-L1 positive advanced non-small-cell lung cancer in patients with a performance status of 2, a Swiss cohort study of immune checkpoint inhibitors in relapsed small-cell lung cancer, and a French-language review on whether to treat elderly patients with metastatic non-small-cell lung cancer with immunotherapy. He leads the division's clinical and research work in Geneva.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.hug.ch/en/oncology"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Addeo+A%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","lung cancer","immunotherapy"],"related":[],"cancers":["nsclc","sclc","mesothelioma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["hug-geneva"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["cancer-immunology-immunotherapy"],"dependsOn":[],"notes":[],"role":"Head of Division, Oncology","institutionId":"hug-geneva","specialisms":["Thoracic oncology","Immunotherapy","Medical oncology"],"profiles":[{"label":"Institution profile","url":"https://www.hug.ch/en/oncology"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Addeo+A%5BAuthor%5D"}],"papers":[{"title":"SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2","journal":"Cancer Immunology, Immunotherapy","year":2020,"doi":"10.1007/s00262-020-02757-8"},{"title":"Cancer du poumon non à petites cellules métastatique du sujet âgé et immunothérapie. Traiter ou s’abstenir?","journal":"Revue Médicale Suisse","year":2025,"doi":"10.53738/revmed.2025.21.918.47231"},{"title":"Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohort","journal":"Cancer Immunology, Immunotherapy","year":2020,"doi":"10.1007/s00262-020-02565-0"}]},{"id":"ali-taher","kind":"person","name":"Ali Taher","aka":[],"tldr":"Physician who directs the Naef K. Basile Cancer Institute, the multidisciplinary cancer centre of the American University of Beirut Medical Center in Lebanon.","summary":"Ali Taher (MD, PhD, FRCP) is Director of the Naef K. Basile Cancer Institute (NKBCI) at the American University of Beirut Medical Center. In his director's message he describes the institute as 'an exciting and growing institute with leading clinicians, educators, and scientists working together to improve patient care', with the aim of reducing the burden of cancer in Lebanon and the region. NKBCI operates as a multidisciplinary cancer centre within AUBMC, with radiation oncology, pathology, laboratory and clinical research units, holds JCI, Magnet, CAP and JACIE accreditations, and runs basic, translational, clinical and population research alongside community outreach on prevention and early detection.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Ali_T._Taher","links":[{"label":"Source: NKBCI institute page naming the director","url":"https://sites.aub.edu.lb/aubmcacc/nkbci/"}],"tags":["leadership","clinician-scientist","comprehensive-cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["aubmc-basile-cancer-institute"],"pathways":[],"terms":["radiotherapy","early-detection-term"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Naef K. Basile Cancer Institute, American University of Beirut Medical Center","institutionId":"aubmc-basile-cancer-institute","specialisms":["Haematology","Oncology","Cancer centre management"],"profiles":[{"label":"NKBCI director's message","url":"https://sites.aub.edu.lb/aubmcacc/aboutus/nkbci-dean-message/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Taher+A%5BAuthor%5D+AND+Beirut"}],"papers":[{"title":"Hepatocellular carcinoma as an emerging morbidity in the thalassemia syndromes: A comprehensive review","journal":"Cancer","year":2016,"doi":"10.1002/cncr.30462"}]},{"id":"alice-yu","kind":"person","name":"Alice L. Yu","aka":[],"tldr":"Led the trial proving that an anti-GD2 antibody improves survival in high-risk neuroblastoma.","summary":"Alice Yu is Professor of Pediatrics at UC San Diego and an immunotherapy investigator with the Children's Oncology Group (COG). A paediatric oncologist specialising in neuroblastoma and anti-GD2 antibodies, she was study chair of COG ANBL0032, the randomised trial of ch14.18 (dinutuximab) with GM-CSF and IL-2 that established anti-GD2 immunotherapy in high-risk neuroblastoma. Her papers report the anti-GD2 antibody with GM-CSF, interleukin-2 and isotretinoin for neuroblastoma in the New England Journal of Medicine and the long-term follow-up of that phase III study in Clinical Cancer Research. Her work made a monoclonal antibody against GD2 part of paediatric immunotherapy.","asOf":"2026-09-08","links":[{"label":"Children's Oncology Group","url":"https://childrensoncologygroup.org"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Yu%20AL%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Alice%20L.%20Yu"}],"tags":[],"related":[],"cancers":["neuroblastoma"],"sections":[],"technologies":["monoclonal-antibody"],"targets":["gd2"],"drugs":["dinutuximab"],"companies":["childrens-oncology-group"],"institutions":[],"pathways":[],"terms":[],"trials":["anbl0032"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Pediatrics, UC San Diego; Children's Oncology Group immunotherapy investigator","institutionId":"childrens-oncology-group","specialisms":["Neuroblastoma","Anti-GD2 antibodies","Paediatric immunotherapy"],"profiles":[{"label":"Children's Oncology Group","url":"https://childrensoncologygroup.org"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Yu%20AL%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Alice%20L.%20Yu"}],"papers":[{"title":"Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma","journal":"New England Journal of Medicine","year":2010,"url":"https://doi.org/10.1056/NEJMoa0911123","doi":"10.1056/NEJMoa0911123"},{"title":"Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032","journal":"Clinical Cancer Research","year":2021,"url":"https://doi.org/10.1158/1078-0432.CCR-20-3909","doi":"10.1158/1078-0432.CCR-20-3909"}]},{"id":"alice-chen","kind":"person","name":"Alice P. Chen","aka":[],"tldr":"NCI oncologist who led the trial that showed atezolizumab produces lasting responses in alveolar soft part sarcoma, the first approved treatment for this rare cancer.","summary":"Alice Chen leads early clinical trials at the National Cancer Institute's Division of Cancer Treatment and Diagnosis and co-led the NCI-MATCH precision medicine trial. She was first author of the 2023 New England Journal of Medicine report of the phase 2 trial in which the PD-L1 antibody atezolizumab produced durable responses in about a quarter of patients with advanced alveolar soft part sarcoma, the basis of the drug's approval for the disease.","asOf":"2026-09-18","links":[],"tags":["sarcoma","rare-cancers","immunotherapy","trialist"],"related":[],"cancers":["alveolar-soft-part-sarcoma","sarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["nci"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-atezolizumab-alveolar-soft-part-sarcoma-chen-nejm-2023"],"journals":[],"dependsOn":[],"notes":[],"role":"Medical oncologist, Division of Cancer Treatment and Diagnosis, National Cancer Institute","institutionId":"nci","specialisms":["Early-phase trials","Rare cancers","Precision oncology trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chen%5BAuthor%5D"}],"papers":[{"title":"Atezolizumab for advanced alveolar soft part sarcoma","journal":"New England Journal of Medicine","year":2023,"url":"https://doi.org/10.1056/NEJMoa2303383","doi":"10.1056/NEJMoa2303383"}]},{"id":"alice-shaw","kind":"person","name":"Alice T. Shaw","aka":[],"tldr":"Lung cancer doctor whose trials at Massachusetts General Hospital showed that crizotinib works in ROS1-rearranged lung cancer and defined how ALK-positive tumours become resistant to targeted drugs.","summary":"Alice Shaw led the clinical development of ALK and ROS1 inhibitors while at Massachusetts General Hospital. She was first author of the 2014 New England Journal of Medicine report showing crizotinib's activity in ROS1-rearranged non-small-cell lung cancer, which led to its approval for that indication, and led trials of ceritinib, alectinib and lorlatinib and studies of ALK resistance mutations. In 2019 she moved to Novartis to lead translational clinical oncology.","asOf":"2026-09-18","links":[],"tags":["lung","targeted-therapy","trialist"],"related":[],"cancers":["ros1-positive-nsclc","nsclc","lung-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-shaw-crizotinib-ros1-nejm-2014"],"journals":[],"dependsOn":[],"notes":[],"role":"Thoracic oncologist and drug developer","specialisms":["ALK-positive lung cancer","ROS1-positive lung cancer","Kinase inhibitor resistance"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Shaw%5BAuthor%5D"}],"papers":[{"title":"Crizotinib in ROS1-rearranged non-small-cell lung cancer","journal":"New England Journal of Medicine","year":2014,"url":"https://doi.org/10.1056/NEJMoa1406766","doi":"10.1056/NEJMoa1406766"}]},{"id":"alicia-jackson","kind":"person","name":"Alicia Jackson","aka":[],"tldr":"Materials scientist and biotechnology founder who directs ARPA-H, the United States agency that funds high-risk, high-reward health research programmes.","summary":"Alicia Jackson is Director of the Advanced Research Projects Agency for Health (ARPA-H), the United States government agency that funds high-risk, high-reward biomedical research. She holds a PhD in materials science from MIT and previously served as a Program Manager and Deputy Director of DARPA's Biological Technologies Office, where she guided an investment portfolio across biodefence, novel medicine development and biomanufacturing. She founded and led Evernow, a company focused on women's health during menopause, and co-founded or advised several biotechnology start-ups.","asOf":"2026-09-10","links":[{"label":"Source: ARPA-H Our People page","url":"https://arpa-h.gov/about/people"}],"tags":["leadership","government","research-funding"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["arpa-h"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director of the Advanced Research Projects Agency for Health","institutionId":"arpa-h","specialisms":["Biomedical research funding","Biotechnology","Women's health"],"profiles":[{"label":"Institution profile","url":"https://arpa-h.gov/about/people/alicia-jackson"}],"papers":[]},{"id":"alinta-hegmane","kind":"person","name":"Alinta Hegmane","aka":[],"tldr":"Alinta Hegmane represents Riga East University Hospital / Oncology Centre of Latvia in the Organisation of European Cancer Institutes, which lists the centre among its members in Latvia.","summary":"Alinta Hegmane is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Riga East University Hospital / Oncology Centre of Latvia, its full member in Latvia. OnCo records the name from the OECI membership list so that the centre's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the institution's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Riga East University Hospital / Oncology Centre of Latvia website","url":"https://www.aslimnica.lv"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["riga-east-university-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Riga East University Hospital / Oncology Centre of Latvia to the Organisation of European Cancer Institutes","institutionId":"riga-east-university-hospital","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Riga East University Hospital / Oncology Centre of Latvia website","url":"https://www.aslimnica.lv"}],"papers":[{"title":"European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer","journal":"Annals of Oncology","year":2021,"url":"https://doi.org/10.1016/j.annonc.2021.11.013","doi":"10.1016/j.annonc.2021.11.013","note":"OpenAlex author record matched by institution"},{"title":"Prognostic relevance of carbonic anhydrase IX expression is distinct in various subtypes of breast cancer and its silencing suppresses self-renewal capacity of breast cancer cells","journal":"Cancer Chemotherapy and Pharmacology","year":2014,"url":"https://doi.org/10.1007/s00280-014-2635-1","doi":"10.1007/s00280-014-2635-1","note":"OpenAlex author record matched by institution"},{"title":"Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer","journal":"Cancers","year":2022,"url":"https://doi.org/10.3390/cancers14071598","doi":"10.3390/cancers14071598","note":"OpenAlex author record matched by institution"}]},{"id":"alon-chen","kind":"person","name":"Alon Chen","aka":[],"tldr":"Neuroscientist who has been President of the Weizmann Institute of Science since 2019, leading one of the world's foremost basic research institutes, including its cancer research programmes.","summary":"Alon Chen is President of the Weizmann Institute of Science in Rehovot, Israel, a position he has held since 2019. A neurobiologist, his own laboratory studies the neurobiology of stress and its links to psychiatric disorders. As President he oversees the institute's research across the life sciences, including its cancer research and immunotherapy programmes.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chen+A%5BAuthor%5D+Weizmann+stress"}],"tags":["leadership","basic science"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["weizmann"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President","institutionId":"weizmann","specialisms":["Neuroscience","Stress biology","Research leadership"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chen+A%5BAuthor%5D+Weizmann+stress"}],"papers":[],"orcid":"0000-0003-3625-8233"},{"id":"alvaro-bonet-pla","kind":"person","name":"Álvaro Bonet Pla","aka":[],"tldr":"Álvaro Bonet Pla represents INCLIVA Biomedical Research Institute / Hospital Clínico Universitario de Valencia in the Organisation of European Cancer Institutes, which lists the centre among its members in Spain.","summary":"Álvaro Bonet Pla is listed by the Organisation of European Cancer Institutes (OECI) as the representative of INCLIVA Biomedical Research Institute / Hospital Clínico Universitario de Valencia, its full member in Spain. OnCo records the name from the OECI membership list so that the centre's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the institution's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"INCLIVA Biomedical Research Institute / Hospital Clínico Universitario de Valencia website","url":"https://www.incliva.es/en/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["incliva-valencia"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of INCLIVA Biomedical Research Institute / Hospital Clínico Universitario de Valencia to the Organisation of European Cancer Institutes","institutionId":"incliva-valencia","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"INCLIVA Biomedical Research Institute / Hospital Clínico Universitario de Valencia website","url":"https://www.incliva.es/en/"}],"papers":[{"title":"Dabigatrón versus acenocumarol para la prevención del ictus en la fibrilación atrial: análisis de impacto presupuestario en un departamento sanitario","journal":"Revista Española de Salud Pública","year":2013,"url":"https://doi.org/10.4321/s1135-57272013000400004","doi":"10.4321/s1135-57272013000400004","note":"OpenAlex author record matched by institution"},{"title":"Estrategias para un control eficaz de la hipertensión arterial en España. Documento de consenso","journal":"Revista Española de Geriatría y Gerontología","year":2006,"url":"https://doi.org/10.1016/s0211-139x(06)72977-8","doi":"10.1016/s0211-139x(06)72977-8","note":"OpenAlex author record matched by institution"},{"title":"Tratamiento combinado con antagonistas del calcio e inhibidores de la enzima de conversión de angiotensina (IECA) como terapia inicial preferible a diuréticos e IECA en hipertensos de riesgo alto","journal":"FMC - Formación Médica Continuada en Atención Primaria","year":2009,"url":"https://doi.org/10.1016/s1134-2072(09)71973-5","doi":"10.1016/s1134-2072(09)71973-5","note":"OpenAlex author record matched by institution"}]},{"id":"amanda-fader","kind":"person","name":"Amanda Nickles Fader","aka":[],"tldr":"Baltimore gynaecologic oncologist who led the trial showing that adding trastuzumab to chemotherapy helps women with HER2-positive uterine serous carcinoma, an aggressive form of endometrial cancer.","summary":"Amanda Nickles Fader is a gynaecologic oncologist at Johns Hopkins. She was first author of the 2018 Journal of Clinical Oncology report of the randomised phase 2 trial in which adding trastuzumab to carboplatin and paclitaxel lengthened progression-free survival in advanced or recurrent HER2/neu-positive uterine serous carcinoma, a result that entered guidelines. Her research also covers minimally invasive surgery and rare gynaecological cancers.","asOf":"2026-09-18","links":[],"tags":["endometrial","gynaecological","trialist"],"related":[],"cancers":["endometrial-p53-abnormal","endometrial"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["johns-hopkins"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-fader-trastuzumab-uterine-serous-jco-2018"],"journals":[],"dependsOn":[],"notes":[],"role":"Gynaecologic oncologist, Johns Hopkins","institutionId":"johns-hopkins","specialisms":["Uterine serous carcinoma","HER2-directed therapy","Minimally invasive gynaecologic surgery"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fader%5BAuthor%5D"}],"papers":[{"title":"Carboplatin-paclitaxel with or without trastuzumab in HER2-positive advanced or recurrent uterine serous carcinoma","journal":"Journal of Clinical Oncology","year":2018,"url":"https://doi.org/10.1200/JCO.2017.76.5966","doi":"10.1200/JCO.2017.76.5966"}]},{"id":"amanda-pritchard","kind":"person","name":"Amanda Pritchard","aka":[],"tldr":"Former head of NHS England who returned to lead Guy's and St Thomas' NHS Foundation Trust as Chief Executive in September 2025.","summary":"Amanda Pritchard DBE is Chief Executive of Guy's and St Thomas' NHS Foundation Trust, the London trust whose services include the Guy's Cancer centre, a role she took up in September 2025. She previously spent nearly four years as Chief Executive of NHS England, the first woman to lead the health service, after two years as its Chief Operating Officer, and before that had already led Guy's and St Thomas' as Chief Executive. She began her NHS career as a graduate trainee in 1997 and received a damehood in 2026. The trust's executive team includes Professor Ian Abbs as Chief Medical Officer and Sarah Clarke as Chief Executive of the Cancer Surgery Clinical Group.","asOf":"2026-09-10","links":[{"label":"Source: Guy's and St Thomas' executive directors page","url":"https://www.guysandstthomas.nhs.uk/about-us/our-board/executive-directors"}],"tags":["leadership","hospital-management","nhs"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["guys-st-thomas"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive of Guy's and St Thomas' NHS Foundation Trust","institutionId":"guys-st-thomas","specialisms":["Health service leadership","NHS management","Hospital operations"],"profiles":[{"label":"Institution profile","url":"https://www.guysandstthomas.nhs.uk/about-us/our-board/executive-directors"}],"papers":[]},{"id":"amar-gajjar","kind":"person","name":"Amar Gajjar","aka":[],"tldr":"Led the St. Jude medulloblastoma trials that introduced molecular subgroups into risk-adapted treatment.","summary":"Amar Gajjar led SJMB96 and SJMB03, the St. Jude medulloblastoma trials that established risk-adapted craniospinal radiotherapy with dose-intensive chemotherapy and showed how WNT, SHH and group 3/4 subgroups predict outcome, and SJMB12, the first trial to assign treatment by molecular subgroup. He co-chairs the Children's Oncology Group CNS committee and directs neuro-oncology at St. Jude.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gajjar%20A%5BAuthor%5D%20medulloblastoma"}],"tags":["paediatric","medulloblastoma","st-jude"],"related":[],"cancers":["medulloblastoma"],"sections":[],"technologies":["methylation-profiling","proton-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":["st-jude"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chair, Department of Pediatric Medicine, St. Jude Children's Research Hospital","institutionId":"st-jude","specialisms":["Medulloblastoma","Paediatric neuro-oncology","Risk-adapted therapy","Molecular stratification"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gajjar%20A%5BAuthor%5D%20medulloblastoma"}],"papers":[{"title":"Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96)","journal":"Lancet Oncology","year":2006,"doi":"10.1016/S1470-2045(06)70867-1"},{"title":"Outcomes by clinical and molecular features in children with medulloblastoma treated with risk-adapted therapy: results of an international phase III trial (SJMB03)","journal":"JCO","year":2021,"doi":"10.1200/JCO.20.01372"}],"orcid":"0000-0001-5019-0699"},{"id":"amar-kishan","kind":"person","name":"Amar U. Kishan","aka":[],"tldr":"Radiation oncologist who showed MRI-guided prostate radiotherapy causes fewer side effects.","summary":"Amar Kishan is Professor and Vice Chair of Clinical and Translational Research in Radiation Oncology at UCLA, part of the UCLA Jonsson Comprehensive Cancer Center. A radiation oncologist specialising in prostate radiotherapy, MR-guided radiotherapy and hypofractionation, he led MIRAGE, the randomised trial of MRI-guided versus CT-guided stereotactic body radiotherapy for prostate cancer, which showed fewer side effects with MRI guidance. His papers report the MIRAGE trial in JAMA Oncology and an individual patient data meta-analysis of androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer in Lancet Oncology. His record also links to the ArteraAI Prostate test.","asOf":"2026-09-08","links":[{"label":"UCLA profile","url":"https://www.uclahealth.org/providers?q=Amar%20U.%20Kishan"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kishan%20AU%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Amar%20U.%20Kishan"}],"tags":[],"related":[],"cancers":["prostate"],"sections":[],"technologies":["mr-linac","sbrt"],"targets":[],"drugs":["artera-ai-prostate"],"companies":[],"institutions":["ucla-jonsson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["jama-oncology"],"dependsOn":[],"notes":[],"role":"Professor and Vice Chair of Clinical and Translational Research, Radiation Oncology, UCLA","institutionId":"ucla-jonsson","specialisms":["Prostate radiotherapy","MR-guided radiotherapy","Hypofractionation"],"profiles":[{"label":"UCLA profile","url":"https://www.uclahealth.org/providers?q=Amar%20U.%20Kishan"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kishan%20AU%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Amar%20U.%20Kishan"}],"papers":[{"title":"Magnetic Resonance Imaging-Guided vs Computed Tomography-Guided Stereotactic Body Radiotherapy for Prostate Cancer: The MIRAGE Randomized Clinical Trial","journal":"JAMA Oncology","year":2023,"url":"https://doi.org/10.1001/jamaoncol.2022.6558","doi":"10.1001/jamaoncol.2022.6558"},{"title":"Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis","journal":"Lancet Oncology","year":2022,"url":"https://doi.org/10.1016/S1470-2045(21)00705-1","doi":"10.1016/S1470-2045(21)00705-1"}]},{"id":"amer-zeidan","kind":"person","name":"Amer M. Zeidan","aka":[],"tldr":"Yale haematologist who led VERONA, the trial that asked whether adding venetoclax to azacitidine helps people with higher-risk myelodysplastic syndromes, and found it did not lengthen survival.","summary":"Amer Zeidan leads the myelodysplastic syndromes programme at Yale Cancer Center. He was the lead investigator of VERONA, the phase 3 trial of venetoclax plus azacitidine against azacitidine alone in newly diagnosed higher-risk MDS, and presented its results in 2024: the combination did not improve overall survival. He publishes widely on MDS treatment patterns, health outcomes and trial endpoints.","asOf":"2026-09-18","links":[],"tags":["mds","trialist"],"related":[],"cancers":["mds-higher-risk","mds"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["yale-cancer-center"],"pathways":[],"terms":[],"trials":["verona"],"people":[],"bottlenecks":[],"keyPapers":["paper-amer-zeidan-n-engl-j-med-2020","paper-amer-zeidan-j-clin-oncol-2021","paper-commands-luspatercept-mds-lancet-2023"],"journals":[],"dependsOn":[],"notes":[],"role":"Haematologist, Yale Cancer Center","institutionId":"yale-cancer-center","specialisms":["Myelodysplastic syndromes","Acute myeloid leukaemia","Trial design and outcomes research"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Zeidan%5BAuthor%5D"}],"papers":[{"title":"Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes","journal":"New England Journal of Medicine","year":2020,"url":"https://doi.org/10.1056/nejmoa1908892","doi":"10.1056/nejmoa1908892","note":"Europe PMC author record matched by affiliation (Yale Cancer Center / Smilow Cancer Hospital); 420 citations on Europe PMC."},{"title":"Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia","journal":"Journal of Clinical Oncology","year":2021,"url":"https://doi.org/10.1200/jco.20.01632","doi":"10.1200/jco.20.01632","note":"Europe PMC author record matched by affiliation (Yale Cancer Center / Smilow Cancer Hospital); 150 citations on Europe PMC."},{"title":"COMMANDS: luspatercept versus epoetin alfa as first treatment for anaemia in lower-risk MDS needing transfusions","journal":"The Lancet","year":2023,"url":"https://doi.org/10.1016/S0140-6736(23)00874-7","doi":"10.1016/S0140-6736(23)00874-7","note":"Europe PMC author record matched by affiliation (Yale Cancer Center / Smilow Cancer Hospital); 140 citations on Europe PMC."}],"orcid":"0000-0001-7017-8160"},{"id":"amit-oza","kind":"person","name":"Amit M. Oza","aka":[],"tldr":"Amit Oza is a gynaecologic oncologist who led early olaparib and niraparib studies in ovarian cancer.","summary":"Amit M. Oza is Head of the Division of Medical Oncology and Hematology and Director of the Cancer Clinical Research Unit at the Princess Margaret Cancer Centre. He is a gynaecologic oncologist known for leading early olaparib and niraparib studies that established PARP inhibition in BRCA-mutant and platinum-sensitive ovarian cancer. His selected paper reports a randomised phase 2 trial of olaparib combined with chemotherapy in recurrent platinum-sensitive ovarian cancer. He now heads medical oncology at Princess Margaret and continues to lead gynaecologic trials in ovarian and endometrial cancer.","asOf":"2026-09-08","links":[{"label":"UHN profile","url":"https://www.uhnresearch.ca/researcher/amit-m-oza"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Oza%20AM%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["ovarian","endometrial"],"sections":[],"technologies":[],"targets":["parp"],"drugs":["olaparib","niraparib"],"companies":[],"institutions":["princess-margaret"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Head, Division of Medical Oncology and Hematology; Director, Cancer Clinical Research Unit","institutionId":"princess-margaret","specialisms":["Ovarian cancer","PARP inhibitors","Gynaecologic trials"],"profiles":[{"label":"UHN profile","url":"https://www.uhnresearch.ca/researcher/amit-m-oza"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Oza%20AM%5BAuthor%5D"}],"papers":[{"title":"Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial","journal":"Lancet Oncology","year":2015,"url":"https://doi.org/10.1016/S1470-2045(14)71135-0","doi":"10.1016/S1470-2045(14)71135-0"},{"title":"SOLO-1: two years of olaparib maintenance after first-line chemotherapy for BRCA-mutated ovarian cancer","journal":"New England Journal of Medicine","year":2018,"url":"https://doi.org/10.1056/NEJMoa1810858","doi":"10.1056/NEJMoa1810858"}]},{"id":"amod-sarnaik","kind":"person","name":"Amod A. Sarnaik","aka":[],"tldr":"Amod Sarnaik led the pivotal lifileucel trial that produced the first approved TIL therapy.","summary":"Amod A. Sarnaik is a Surgical Oncologist in Cutaneous Oncology and a Senior Member at Moffitt Cancer Center, specialising in melanoma surgery and cellular immunotherapy. He is known as principal investigator of C-144-01, the pivotal trial of lifileucel that produced the first approved tumour-infiltrating lymphocyte therapy, with accelerated approval in advanced melanoma in 2024. His selected paper reports lifileucel, a tumour-infiltrating lymphocyte therapy, in metastatic melanoma. He continues to combine melanoma surgery with the development of TIL therapy at Moffitt.","asOf":"2026-09-08","links":[{"label":"Moffitt profile","url":"https://www.moffitt.org/providers/amod-sarnaik/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sarnaik%20AA%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["melanoma"],"sections":[],"technologies":["til-therapy"],"targets":[],"drugs":["lifileucel"],"companies":[],"institutions":["moffitt"],"pathways":[],"terms":[],"trials":["c-144-01"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Surgical Oncologist, Cutaneous Oncology; Senior Member","institutionId":"moffitt","specialisms":["Melanoma surgery","TIL therapy","Cellular immunotherapy"],"profiles":[{"label":"Moffitt profile","url":"https://www.moffitt.org/providers/amod-sarnaik/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sarnaik%20AA%5BAuthor%5D"}],"papers":[{"title":"Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma","journal":"Journal of Clinical Oncology","year":2021,"url":"https://doi.org/10.1200/JCO.21.00612","doi":"10.1200/JCO.21.00612"},{"title":"C-144-01: lifileucel, tumour-infiltrating lymphocytes grown from a patient's own tumour, in melanoma after checkpoint inhibitors have failed","journal":"Journal of Clinical Oncology","year":2021,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=C-144-01%20lifileucel%20tumor-infiltrating%20lymphocyte%20melanoma%20Sarnaik%20JCO%202021"}],"orcid":"0000-0002-2337-5898"},{"id":"ana-oaknin","kind":"person","name":"Ana Oaknin","aka":[],"tldr":"Barcelona oncologist who led GARNET, the trial that brought dostarlimab to mismatch repair-deficient endometrial cancer, and who has led many trials of new drugs for gynaecological cancers.","summary":"Ana Oaknin leads the gynaecological cancer programme at the Vall d'Hebron Institute of Oncology. She was first author of the 2020 JAMA Oncology report of the GARNET trial cohort in which the PD-1 antibody dostarlimab produced durable responses in recurrent or advanced mismatch repair-deficient endometrial cancer, the basis of its first approval, and has been a lead investigator on trials of tisotumab vedotin and other new agents in cervical and ovarian cancer.","asOf":"2026-09-18","links":[],"tags":["endometrial","gynaecological","immunotherapy","trialist"],"related":[],"cancers":["endometrial-mmr-deficient","endometrial","cervical"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["vall-dhebron"],"pathways":[],"terms":[],"trials":["garnet"],"people":[],"bottlenecks":[],"keyPapers":["paper-garnet-dostarlimab-oaknin-jama-oncol-2020"],"journals":[],"dependsOn":[],"notes":[],"role":"Head of the Gynaecological Cancer Programme, Vall d'Hebron Institute of Oncology, Barcelona","institutionId":"vall-dhebron","specialisms":["Endometrial cancer","Cervical cancer","Immunotherapy and antibody-drug conjugates"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Oaknin%5BAuthor%5D"}],"papers":[{"title":"GARNET: dostarlimab in mismatch repair-deficient recurrent or advanced endometrial cancer","journal":"JAMA Oncology","year":2020,"url":"https://doi.org/10.1001/jamaoncol.2020.4515","doi":"10.1001/jamaoncol.2020.4515"}]},{"id":"ananya-choudhury","kind":"person","name":"Ananya Choudhury","aka":[],"tldr":"Ananya Choudhury is a clinical oncologist developing biomarker-guided radiotherapy for bladder cancer.","summary":"Ananya Choudhury is Professor of Clinical Oncology at the University of Manchester and a consultant at The Christie NHS Foundation Trust. Her specialisms are bladder cancer radiotherapy, hypoxia biomarkers and radiobiology, using modern image-guided external beam techniques. She is known for developing biomarker-guided radiotherapy for bladder cancer, including hypoxia signatures that select patients for radiosensitisation. Her papers include an individual patient data meta-analysis of hypofractionated radiotherapy in the BC2001 and BCON trials, a phase II study of hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer, and a study of pre-treatment lymphocytopaenia as an adverse prognostic marker. Her publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Choudhury%20A%5BAuthor%5D%20bladder%20radiotherapy%20hypoxia"}],"tags":[],"related":[],"cancers":["urothelial"],"sections":[],"technologies":["imrt-igrt"],"targets":[],"drugs":[],"companies":[],"institutions":["the-christie"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Clinical Oncology, University of Manchester; Consultant, The Christie","institutionId":"the-christie","specialisms":["Bladder cancer radiotherapy","Hypoxia biomarkers","Radiobiology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Choudhury%20A%5BAuthor%5D%20bladder%20radiotherapy%20hypoxia"}],"papers":[{"title":"Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials","journal":"The Lancet Oncology","year":2021,"doi":"10.1016/s1470-2045(20)30607-0"},{"title":"Phase II Study of Conformal Hypofractionated Radiotherapy With Concurrent Gemcitabine in Muscle-Invasive Bladder Cancer","journal":"Journal of Clinical Oncology","year":2011,"doi":"10.1200/jco.2010.31.5721"},{"title":"Pre-treatment lymphocytopaenia is an adverse prognostic biomarker in muscle-invasive and advanced bladder cancer","journal":"Annals of Oncology","year":2016,"doi":"10.1093/annonc/mdv546"}]},{"id":"ander-urruticoechea","kind":"person","name":"Ander Urruticoechea","aka":[],"tldr":"Medical oncologist from Gipuzkoa who became President of GEICAM, Spain's academic breast cancer research group, in 2025 on the retirement of its founder Miguel Martín.","summary":"Ander Urruticoechea is President of GEICAM (Grupo Español de Investigación en Cáncer de Mama), the Spanish academic breast cancer research group. He took over the presidency in 2025 following the retirement of Miguel Martín, who had led the group for some 30 years after founding it with other oncologists. He is a medical oncologist at the Unidad de Oncología de Guipúzcoa (Osakidetza, the Basque health service) and a researcher at the Biogipuzkoa Health Research Institute. In a May 2025 interview he set out the challenge of sustaining academic breast cancer research without public funding and said he favours shared rather than single-person models of leadership.","asOf":"2026-09-10","links":[{"label":"Source: iSanidad interview naming him GEICAM president (May 2025)","url":"https://isanidad.com/330649/el-dr-urruticoechea-tomas-las-riendas-de-geicam-con-el-reto-de-sostener-la-investigacion-academica-en-cancer-de-mama-sin-apoyo-publico/"}],"tags":["leadership","professional-society","clinician-scientist"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["geicam"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["miguel-martin"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Presidente (President) of GEICAM, the Spanish Breast Cancer Group","institutionId":"geicam","specialisms":["Medical oncology","Breast cancer","Academic clinical research"],"profiles":[{"label":"iSanidad interview on taking over the GEICAM presidency (May 2025)","url":"https://isanidad.com/330649/el-dr-urruticoechea-tomas-las-riendas-de-geicam-con-el-reto-de-sostener-la-investigacion-academica-en-cancer-de-mama-sin-apoyo-publico/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Urruticoechea+A%5BAuthor%5D"}],"papers":[{"title":"Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based Therapy","journal":"Journal of Clinical Oncology","year":2017,"doi":"10.1200/jco.2016.70.6267"},{"title":"Proliferation Marker Ki-67 in Early Breast Cancer","journal":"Journal of Clinical Oncology","year":2005,"doi":"10.1200/jco.2005.07.501"},{"title":"A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study","journal":"Oncotarget","year":2017,"doi":"10.18632/oncotarget.17113"}]},{"id":"ilbawi-andre","kind":"person","name":"André Ilbawi","aka":[],"tldr":"The WHO's lead on cancer control, steering the cervical cancer elimination and global breast and childhood cancer initiatives.","summary":"André Ilbawi is a surgical oncologist and the Technical Lead for Cancer Control at the World Health Organization, working with the International Agency for Research on Cancer. He steers the WHO's cervical cancer elimination strategy, the Global Breast Cancer Initiative and the Global Initiative for Childhood Cancer, with a focus on cancer control policy, global health and access to medicines. His publications include a global analysis of national cancer control plans, a review of the growing burden, rising costs and unequal access in global cancer control, and a modelling study of the mortality impact of meeting the WHO cervical cancer elimination targets in low-income and lower-middle-income countries. His work connects HPV vaccination, screening and treatment into national programmes.","asOf":"2026-09-08","links":[{"label":"WHO cancer","url":"https://www.who.int/health-topics/cancer"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ilbawi%20AM%5BAuthor%5D%20WHO%20cancer"}],"tags":[],"related":[],"cancers":["cervical","breast-hr-positive"],"sections":[],"technologies":["hpv-vaccine"],"targets":[],"drugs":[],"companies":[],"institutions":["iarc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Technical Lead for Cancer Control, World Health Organization","specialisms":["Cancer control policy","Global health","Surgical oncology","Access to medicines"],"profiles":[{"label":"WHO cancer","url":"https://www.who.int/health-topics/cancer"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ilbawi%20AM%5BAuthor%5D%20WHO%20cancer"}],"papers":[{"title":"National cancer control plans: a global analysis","journal":"The Lancet Oncology","year":2018,"doi":"10.1016/s1470-2045(18)30681-8"},{"title":"Global cancer control: responding to the growing burden, rising costs and inequalities in access","journal":"ESMO Open","year":2018,"doi":"10.1136/esmoopen-2017-000285"},{"title":"Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries","journal":"The Lancet","year":2020,"doi":"10.1016/s0140-6736(20)30157-4"}]},{"id":"andrea-agnelli","kind":"person","name":"Andrea Agnelli","aka":[],"tldr":"Andrea Agnelli represents Istituto di Candiolo IRCCS (FPO) in the Organisation of European Cancer Institutes, which lists the centre among its members in Italy.","summary":"Andrea Agnelli is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Istituto di Candiolo IRCCS (FPO), its member in Italy. Piedmont's cancer institute near Turin, a world reference for colorectal cancer genomics, patient-derived xenografts and MET biology. OnCo records the name from the OECI membership list so that the centre's page has a named contact point; the person's exact title, appointment date and biography are not yet recorded and should be checked on the institution's own pages before being relied on.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Istituto di Candiolo IRCCS (FPO) website","url":"https://inoc.it/it/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["candiolo"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Istituto di Candiolo IRCCS (FPO) to the Organisation of European Cancer Institutes","institutionId":"candiolo","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Istituto di Candiolo IRCCS (FPO) website","url":"https://inoc.it/it/"}],"papers":[]},{"id":"andrea-cercek","kind":"person","name":"Andrea Cercek","aka":[],"tldr":"Led the study in which every patient with mismatch-repair-deficient rectal cancer had a complete response to dostarlimab, without surgery or radiation.","summary":"Medical oncologist whose 2022 NEJM study of neoadjuvant dostarlimab in dMMR locally advanced rectal cancer produced a 100% clinical complete response rate, later extended to over 100 patients across dMMR solid tumours and now the basis of the AZUR-1 registrational programme. Co-directs MSK's young-onset colorectal cancer centre.","asOf":"2026-09-08","links":[{"label":"MSK profile","url":"https://www.mskcc.org/cancer-care/doctors/andrea-cercek"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cercek%20A%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["colorectal"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["pd1"],"drugs":["dostarlimab"],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":["azur-1"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Section Head, Colorectal Cancer; Co-Director, Center for Young Onset Colorectal and GI Cancers","institutionId":"mskcc","specialisms":["Colorectal cancer","Rectal cancer organ preservation","dMMR immunotherapy","Young-onset GI cancer"],"profiles":[{"label":"MSK profile","url":"https://www.mskcc.org/cancer-care/doctors/andrea-cercek"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cercek%20A%5BAuthor%5D"}],"papers":[{"title":"PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer","journal":"New England Journal of Medicine","year":2022,"url":"https://doi.org/10.1056/NEJMoa2201445","doi":"10.1056/NEJMoa2201445"},{"title":"Nonoperative management of mismatch repair-deficient tumors","journal":"New England Journal of Medicine","year":2025}]},{"id":"andrea-decensi","kind":"person","name":"Andrea DeCensi","aka":[],"tldr":"Italian oncologist who led TAM-01, the trial that showed a low dose of tamoxifen halves recurrence after non-invasive breast cancer with fewer side effects than the standard dose.","summary":"Andrea DeCensi is a medical oncologist at Galliera Hospital in Genoa who has spent his career on breast cancer prevention. He was first author of the 2019 Journal of Clinical Oncology report of TAM-01, an Italian trial in which tamoxifen at 5 mg a day for three years reduced recurrence and new breast cancers after ductal carcinoma in situ and other non-invasive lesions, with a toxicity profile little different from placebo. Low-dose tamoxifen is now an option in guidelines for risk reduction.","asOf":"2026-09-18","links":[],"tags":["breast","prevention","trialist"],"related":[],"cancers":["ductal-carcinoma-in-situ","breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ospedali-galliera"],"pathways":[],"terms":[],"trials":["tam-01"],"people":[],"bottlenecks":[],"keyPapers":["paper-andrea-decensi-cancer-prev-res-phila-2014","paper-andrea-decensi-diabetologia-2017","paper-andrea-decensi-j-clin-oncol-2019"],"journals":[],"dependsOn":[],"notes":[],"role":"Medical oncologist, E.O. Ospedali Galliera, Genoa","institutionId":"ospedali-galliera","specialisms":["Breast cancer prevention","Low-dose tamoxifen","Chemoprevention trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=DeCensi%5BAuthor%5D"}],"papers":[{"title":"Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders","journal":"Cancer prevention research","year":2014,"url":"https://doi.org/10.1158/1940-6207.capr-13-0424","doi":"10.1158/1940-6207.capr-13-0424","note":"Europe PMC author record matched by affiliation (E.O. Ospedali Galliera); 325 citations on Europe PMC."},{"title":"Repurposing metformin for the prevention of cancer and cancer recurrence","journal":"Diabetologia","year":2017,"url":"https://doi.org/10.1007/s00125-017-4372-6","doi":"10.1007/s00125-017-4372-6","note":"Europe PMC author record matched by affiliation (E.O. Ospedali Galliera); 232 citations on Europe PMC."},{"title":"Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update","journal":"Journal of Clinical Oncology","year":2019,"url":"https://doi.org/10.1200/jco.19.01472","doi":"10.1200/jco.19.01472","note":"Europe PMC author record matched by affiliation (E.O. Ospedali Galliera); 169 citations on Europe PMC."}]},{"id":"andrea-necchi","kind":"person","name":"Andrea Necchi","aka":[],"tldr":"Led PURE-01, the first neoadjuvant pembrolizumab trial in bladder cancer, and now leads bladder-preserving immunotherapy studies.","summary":"Andrea Necchi led PURE-01, which showed neoadjuvant pembrolizumab alone produces pathological complete responses in more than a third of muscle-invasive bladder cancers and defined biomarkers of response, and is a lead investigator of the KEYNOTE-057 and SunRISe programmes in non-muscle-invasive disease. He heads GU oncology at San Raffaele and studies bladder-sparing strategies.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Necchi%20A%5BAuthor%5D%20bladder%20pembrolizumab"}],"tags":["urothelial","neoadjuvant","italy"],"related":[],"cancers":["urothelial"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["pd1"],"drugs":["pembrolizumab"],"companies":[],"institutions":["san-raffaele"],"pathways":[],"terms":[],"trials":["sunrise-1"],"people":[],"bottlenecks":[],"keyPapers":["paper-sunrise-1-jco-2025"],"journals":["european-urology"],"dependsOn":[],"notes":[],"role":"Head of Genitourinary Medical Oncology, IRCCS San Raffaele Hospital; Professor, Vita-Salute San Raffaele University","institutionId":"san-raffaele","specialisms":["Urothelial cancer","Neoadjuvant immunotherapy","Bladder preservation","Non-muscle-invasive disease"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Necchi%20A%5BAuthor%5D%20bladder%20pembrolizumab"}],"papers":[{"title":"Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01)","journal":"JCO","year":2018,"doi":"10.1200/JCO.18.01148"},{"title":"Updated results of PURE-01 with preliminary activity of neoadjuvant pembrolizumab in patients with muscle-invasive bladder carcinoma with variant histologies","journal":"European Urology","year":2020,"doi":"10.1016/j.eururo.2019.10.026"},{"title":"SunRISe-1: TAR-200, a gemcitabine-releasing device placed in the bladder, for BCG-unresponsive non-muscle-invasive bladder cancer","journal":"Journal of Clinical Oncology","year":2025,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=SunRISe-1+TAR-200+BCG-unresponsive"}],"orcid":"0000-0002-3007-2756"},{"id":"andrea-sartore-bianchi","kind":"person","name":"Andrea Sartore-Bianchi","aka":[],"tldr":"Milan oncologist who was lead author of HERACLES, the first trial to show that HER2-targeted drugs work in HER2-amplified colorectal cancer.","summary":"Andrea Sartore-Bianchi is a medical oncologist at the Niguarda Cancer Center in Milan. He was first author of the 2016 Lancet Oncology report of HERACLES, the phase 2 trial in which trastuzumab plus lapatinib produced responses in about a third of patients with heavily pretreated HER2-amplified, KRAS wild-type metastatic colorectal cancer, establishing HER2 as a target in the disease. His research covers resistance to anti-EGFR antibodies and molecular selection for therapy.","asOf":"2026-09-18","links":[],"tags":["colorectal","targeted-therapy","trialist"],"related":[],"cancers":["her2-amplified-colorectal","colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["niguarda-cancer-center"],"pathways":[],"terms":[],"trials":["heracles"],"people":[],"bottlenecks":[],"keyPapers":["paper-sartore-bianchi-heracles-trastuzumab-lapatinib-lancet-oncol-2016"],"journals":[],"dependsOn":[],"notes":[],"role":"Medical oncologist, Niguarda Cancer Center and University of Milan","institutionId":"niguarda-cancer-center","specialisms":["HER2-amplified colorectal cancer","Precision oncology","Anti-EGFR therapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sartore-Bianchi%5BAuthor%5D"}],"papers":[{"title":"HERACLES: trastuzumab and lapatinib in HER2-amplified, KRAS wild-type metastatic colorectal cancer","journal":"The Lancet Oncology","year":2016,"url":"https://doi.org/10.1016/S1470-2045(16)00150-9","doi":"10.1016/S1470-2045(16)00150-9"}],"orcid":"0000-0003-0780-0409"},{"id":"andrea-seale","kind":"person","name":"Andrea Seale","aka":[],"tldr":"Chief executive of the Canadian Cancer Society, the national charity that funds cancer research, advocates on policy and runs support services across Canada.","summary":"Andrea Seale is Chief Executive Officer of the Canadian Cancer Society, the national cancer charity that funds research, delivers cancer support and prevention programmes, and advocates on public policy. She leads an executive team that includes Catalina Lopez-Correa as Executive Vice President of Research, Sandra Krueckl as Executive Vice President of Mission Services, and Riaz Kara as Executive Vice President of Advocacy and Policy.","asOf":"2026-09-10","links":[{"label":"Source: Canadian Cancer Society Our People page","url":"https://cancer.ca/en/about-us/our-people"}],"tags":["leadership","charity","advocacy"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["canadian-cancer-society"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive Officer, Canadian Cancer Society","institutionId":"canadian-cancer-society","specialisms":["Charity leadership","Cancer advocacy","Support programmes and fundraising"],"profiles":[{"label":"Institution profile","url":"https://cancer.ca/en/about-us/our-people"}],"papers":[]},{"id":"andrea-sironi","kind":"person","name":"Andrea Sironi","aka":[],"tldr":"President of Fondazione AIRC, the Italian charitable foundation that raises funds from the public to finance cancer research across the country.","summary":"Andrea Sironi is President of Fondazione AIRC per la ricerca sul cancro, the Italian foundation that raises funds from the public to finance cancer research, as listed on the foundation's governing bodies page. The Consiglio di amministrazione that he presides over is the governing body with ordinary and extraordinary administrative powers, approving budgets and three-year plans and appointing the consigliere delegato and scientific director. Daniele Finocchiaro serves as Consigliere delegato and Anna Mondino as Scientific Director.","asOf":"2026-09-10","links":[{"label":"Source: AIRC governing bodies page","url":"https://www.airc.it/fondazione/chi-siamo/i-nostri-organi-di-governo"}],"tags":["leadership","funding","charity"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["airc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President of Fondazione AIRC per la ricerca sul cancro","institutionId":"airc","specialisms":["Charity governance","Cancer research funding","Economics"],"profiles":[{"label":"Institution profile","url":"https://www.airc.it/fondazione/chi-siamo/i-nostri-organi-di-governo"}],"papers":[]},{"id":"andreas-du-bois","kind":"person","name":"Andreas du Bois","aka":[],"tldr":"Surgeon who chairs the German AGO group and led DESKTOP III, proving secondary surgery can extend survival in selected relapsed ovarian cancer.","summary":"Andreas du Bois (Kliniken Essen-Mitte) chairs the AGO ovarian cancer study group, whose trials established carboplatin-paclitaxel as standard and defined the prognostic value of complete cytoreduction. He was principal investigator of DESKTOP III, which showed secondary cytoreductive surgery improves overall survival in AGO-score-positive platinum-sensitive relapse, and of the TRUST trial of primary versus interval surgery.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=du%20Bois%20A%5BAuthor%5D%20ovarian%20DESKTOP"}],"tags":["ovarian","surgery","cooperative-group"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["kliniken-essen-mitte"],"pathways":[],"terms":[],"trials":["desktop-iii"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["cancer-wiley"],"dependsOn":[],"notes":[],"role":"Director of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte; Chair, AGO Study Group","institutionId":"kliniken-essen-mitte","specialisms":["Ovarian cancer surgery","Cooperative-group trials","Cytoreductive surgery","Chemotherapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=du%20Bois%20A%5BAuthor%5D%20ovarian%20DESKTOP"}],"papers":[{"title":"Randomized trial of cytoreductive surgery for relapsed ovarian cancer (DESKTOP III)","journal":"NEJM","year":2021,"doi":"10.1056/NEJMoa2103294"},{"title":"Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials","journal":"Cancer","year":2009,"doi":"10.1002/cncr.24149"}],"orcid":"0000-0002-8477-506X"},{"id":"andreas-engert","kind":"person","name":"Andreas Engert","aka":[],"tldr":"Led the GHSG for two decades, running the HD10 to HD18 trials that cure over 90% of Hodgkin lymphoma with less treatment.","summary":"Andreas Engert chaired the German Hodgkin Study Group from 2007 to 2020, leading HD10 (two cycles of ABVD plus 20 Gy for early favourable disease), HD15 (six cycles of escalated BEACOPP with PET-guided radiotherapy omission) and HD18, which together defined modern risk- and PET-adapted Hodgkin lymphoma therapy with cure rates above 90%. He was president of the European Hematology Association.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Engert%20A%5BAuthor%5D%20Hodgkin"}],"tags":["hodgkin","ghsg","de-escalation"],"related":[],"cancers":["hodgkin-lymphoma"],"sections":[],"technologies":["fdg-pet","cytotoxic-chemotherapy"],"targets":[],"drugs":[],"companies":["ghsg"],"institutions":["uniklinik-koeln"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Internal Medicine, Hematology and Oncology, University Hospital Cologne; former Chair, German Hodgkin Study Group","institutionId":"uniklinik-koeln","specialisms":["Hodgkin lymphoma","Treatment de-escalation","Cooperative-group trials","Late effects"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Engert%20A%5BAuthor%5D%20Hodgkin"}],"papers":[{"title":"Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma (HD10)","journal":"NEJM","year":2010,"doi":"10.1056/NEJMoa1000067"},{"title":"Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial","journal":"Lancet","year":2012,"doi":"10.1016/S0140-6736(11)61940-5"}]},{"id":"andreas-trumpp","kind":"person","name":"Andreas Trumpp","aka":[],"tldr":"Andreas Trumpp is a stem cell biologist studying how dormant cancer cells seed metastases and resist therapy.","summary":"Andreas Trumpp is Head of Stem Cells and Cancer at the German Cancer Research Center (DKFZ) and Managing Director of HI-STEM in Heidelberg. A stem cell biologist, his specialisms are cancer stem cells, metastasis and circulating tumour cells. His group identified metastasis-initiating cells among the circulating tumour cells of breast cancer patients, reported in Nature Biotechnology as a population able to seed metastases in a xenograft assay. He studies how dormant cancer cells seed metastases and resist therapy, alongside dormancy in haematopoietic and leukaemic stem cells. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Trumpp%20A%5BAuthor%5D%20metastasis%20stem%20cells"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["dkfz"],"pathways":["emt"],"terms":["ctdna"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nature-biotechnology"],"dependsOn":[],"notes":[],"role":"Head of Stem Cells and Cancer, DKFZ; Managing Director, HI-STEM","institutionId":"dkfz","specialisms":["Cancer stem cells","Metastasis","Circulating tumour cells"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Trumpp%20A%5BAuthor%5D%20metastasis%20stem%20cells"}],"papers":[{"title":"Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay","journal":"Nature Biotechnology","year":2013,"doi":"10.1038/nbt.2576"}],"orcid":"0000-0002-6212-3466"},{"id":"andreas-von-deimling","kind":"person","name":"Andreas von Deimling","aka":[],"tldr":"Co-created the DNA methylation classifier that changed how brain tumours are diagnosed worldwide.","summary":"Andreas von Deimling is Head of Neuropathology at Heidelberg University Hospital and the German Cancer Research Center (DKFZ). His specialisms are neuropathology, brain tumour classification and DNA methylation profiling, with a research interest in IDH1 and IDH2 in glioma and glioblastoma. With Stefan Pfister and David Capper he developed the Heidelberg DNA methylation-based classifier for central nervous system tumours, published in Nature and now embedded in the WHO classification. The classifier changed how brain tumours are diagnosed worldwide, and his publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=von%20Deimling%20A%5BAuthor%5D%20methylation%20classifier"}],"tags":[],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":["methylation-profiling"],"targets":["idh"],"drugs":[],"companies":[],"institutions":["heidelberg-nct","dkfz"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Head of Neuropathology, Heidelberg University Hospital and DKFZ","institutionId":"heidelberg-nct","specialisms":["Neuropathology","Brain tumour classification","DNA methylation profiling"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=von%20Deimling%20A%5BAuthor%5D%20methylation%20classifier"}],"papers":[{"title":"DNA methylation-based classification of central nervous system tumours","journal":"Nature","year":2018,"doi":"10.1038/nature26000"}]},{"id":"andres-cervantes","kind":"person","name":"Andrés Cervantes","aka":[],"tldr":"Andrés Cervantes is a gastrointestinal oncologist and was ESMO President for 2023-2024.","summary":"Andrés Cervantes is Professor of Medicine at the University of Valencia and Head of Medical Oncology at the INCLIVA Biomedical Research Institute and Hospital Clínico Universitario de Valencia, and served as President of the European Society for Medical Oncology (ESMO) for 2023-2024. A gastrointestinal oncologist specialising in colorectal cancer, he is best known for guideline work. He led the ESMO Clinical Practice Guidelines on metastatic colorectal cancer in Annals of Oncology, in their 2014 and 2023 editions, and co-authored the 2012 ESMO consensus guidelines on a personalised approach to colon and rectal cancer. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cervantes%20A%5BAuthor%5D%20colorectal"}],"tags":[],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["esmo","incliva-valencia"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medicine, University of Valencia; Head of Medical Oncology, INCLIVA; ESMO President 2023-2024","institutionId":"esmo","specialisms":["Gastrointestinal oncology","Colorectal cancer","Guidelines"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cervantes%20A%5BAuthor%5D%20colorectal"}],"papers":[{"title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","journal":"Annals of Oncology","year":2023,"doi":"10.1016/j.annonc.2022.10.003"},{"title":"ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making","journal":"Annals of Oncology","year":2012,"doi":"10.1093/annonc/mds236"},{"title":"Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","journal":"Annals of Oncology","year":2014,"doi":"10.1093/annonc/mdu260"}]},{"id":"andres-ferreri","kind":"person","name":"Andrés J. M. Ferreri","aka":[],"tldr":"Led the IELSG trials that made MATRix induction and consolidation the standard for primary CNS lymphoma.","summary":"Andrés Ferreri led IELSG20, which established high-dose methotrexate plus cytarabine for primary CNS lymphoma, and IELSG32, which showed the MATRix regimen (adding rituximab and thiotepa) followed by autologous transplant or whole-brain radiotherapy produces durable remissions in most fit patients. He coordinates the International Extranodal Lymphoma Study Group and leads trials of novel agents in CNS and ocular lymphomas.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ferreri%20AJM%5BAuthor%5D%20CNS%20lymphoma"}],"tags":["lymphoma","cns-lymphoma","ielsg"],"related":[],"cancers":["primary-cns-lymphoma"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":[],"companies":["ielsg"],"institutions":["san-raffaele"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Head of the Lymphoma Unit, IRCCS San Raffaele Scientific Institute, Milan","institutionId":"san-raffaele","specialisms":["Primary CNS lymphoma","Extranodal lymphomas","High-dose methotrexate regimens","Cooperative-group trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ferreri%20AJM%5BAuthor%5D%20CNS%20lymphoma"}],"papers":[{"title":"Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial","journal":"Lancet Haematology","year":2016,"doi":"10.1016/S2352-3026(16)00036-3"},{"title":"High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma (IELSG20)","journal":"Lancet","year":2009,"doi":"10.1016/S0140-6736(09)61416-1"}]},{"id":"andrew-lassman","kind":"person","name":"Andrew B. Lassman","aka":[],"tldr":"New York neuro-oncologist who led INTELLANCE-1, the trial that tested the EGFR-directed antibody-drug conjugate depatuxizumab mafodotin in newly diagnosed glioblastoma and found it did not extend survival.","summary":"Andrew Lassman is chief of neuro-oncology at Columbia University Irving Medical Center. He was the lead investigator and first author of the 2023 Neuro-Oncology report of INTELLANCE-1, the phase 3 trial of depatuxizumab mafodotin added to radiotherapy and temozolomide in EGFR-amplified newly diagnosed glioblastoma, which showed no overall survival benefit despite earlier promise. He leads several cooperative-group glioma trials.","asOf":"2026-09-18","links":[],"tags":["brain","trialist"],"related":[],"cancers":["glioblastoma","brain-tumours"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["columbia-hicc"],"pathways":[],"terms":[],"trials":["intellance-1"],"people":[],"bottlenecks":[],"keyPapers":["paper-andrew-lassman-neuro-oncol-2020","paper-andrew-lassman-j-clin-oncol-2022","paper-andrew-lassman-j-clin-oncol-2023"],"journals":[],"dependsOn":[],"notes":[],"role":"Chief of Neuro-Oncology, Columbia University Irving Medical Center","institutionId":"columbia-hicc","specialisms":["Glioblastoma","Antibody-drug conjugates","Neuro-oncology trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lassman%5BAuthor%5D"}],"papers":[{"title":"Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions","journal":"Neuro-Oncology","year":2020,"url":"https://doi.org/10.1093/neuonc/noaa106","doi":"10.1093/neuonc/noaa106","note":"Europe PMC author record matched by affiliation (Herbert Irving Comprehensive Cancer Center, Columbia University); 999 citations on Europe PMC."},{"title":"Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline","journal":"Journal of Clinical Oncology","year":2022,"url":"https://doi.org/10.1200/jco.21.02314","doi":"10.1200/jco.21.02314","note":"Europe PMC author record matched by affiliation (Herbert Irving Comprehensive Cancer Center, Columbia University); 691 citations on Europe PMC."},{"title":"RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults","journal":"Journal of Clinical Oncology","year":2023,"url":"https://doi.org/10.1200/jco.23.01059","doi":"10.1200/jco.23.01059","note":"Europe PMC author record matched by affiliation (Herbert Irving Comprehensive Cancer Center, Columbia University); 389 citations on Europe PMC."}],"orcid":"0000-0001-7386-9928"},{"id":"andrew-biankin","kind":"person","name":"Andrew Biankin","aka":[],"tldr":"The Glasgow surgeon-scientist who mapped the genomic subtypes of pancreatic cancer and built Precision-Panc, the UK programme that profiled tumours to route patients into the PRIMUS trials.","summary":"Andrew Biankin holds the Regius Chair of Surgery at the University of Glasgow, is a Cancer Research UK Clinician Scientist and Wellcome Trust Senior Investigator, a Fellow of the Royal Society of Edinburgh and of the Academy of Medical Sciences, and Executive Director of ICGC-ARGO, the International Cancer Genome Consortium's Accelerating Research in Genomic Oncology programme. His university page says he has authored over 160 articles including seminal works on cancer genomics and precision medicine, and that his work now focuses on implementing precision oncology in health systems. He leads the Precision-Panc programme, whose master protocol (ISRCTN14879538, sponsored by NHS Greater Glasgow and Clyde) took extra tissue at diagnostic biopsy from patients at 27 UK sites to match them to the PRIMUS trials, and co-authored the STARPAC2 protocol.","asOf":"2026-09-24","links":[{"label":"University of Glasgow staff page","url":"https://www.gla.ac.uk/schools/cancersciences/staff/andrewbiankin/"},{"label":"ORCID","url":"https://orcid.org/0000-0002-0362-5597"}],"tags":["pancreatic","genomics","uk","surgeon"],"related":["paula-ghaneh"],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":["kras"],"drugs":[],"companies":[],"institutions":["wolfson-wohl-cancer-research-centre","glasgow-royal-infirmary"],"pathways":[],"terms":["genomic-profiling"],"trials":["precision-panc"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Regius Professor of Surgery, University of Glasgow; Executive Director, ICGC-ARGO","institutionId":"wolfson-wohl-cancer-research-centre","specialisms":["Pancreatic cancer genomics","Precision oncology","Molecular subtyping","Therapeutic development"],"profiles":[{"label":"University of Glasgow staff page","url":"https://www.gla.ac.uk/schools/cancersciences/staff/andrewbiankin/"},{"label":"ORCID","url":"https://orcid.org/0000-0002-0362-5597"}],"papers":[{"title":"Molecular subtyping and precision medicine for pancreatic cancer","journal":"Journal of Clinical Medicine","year":2021,"doi":"10.3390/jcm10010149"},{"title":"Study protocol: multi-centre, randomised controlled clinical trial exploring stromal targeting in locally advanced pancreatic cancer; STARPAC2","journal":"BMC Cancer","year":2025,"doi":"10.1186/s12885-024-13333-z","note":"Precision-Panc team"}],"orcid":"0000-0002-0362-5597"},{"id":"andrew-wei","kind":"person","name":"Andrew H. Wei","aka":[],"tldr":"Australian haematologist who led VIALE-C and QUAZAR AML-001, advancing venetoclax and oral azacitidine maintenance in AML.","summary":"Andrew Wei was principal investigator of VIALE-C (venetoclax plus low-dose cytarabine) and first author of QUAZAR AML-001, which showed oral azacitidine maintenance improves survival after remission in older AML patients, the first maintenance therapy approved in AML. He leads the Australasian Leukaemia and Lymphoma Group AML programme and the venetoclax-based intensive chemotherapy trials.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wei%20AH%5BAuthor%5D%20venetoclax%20azacitidine"}],"tags":["aml","venetoclax","australia"],"related":[],"cancers":["aml"],"sections":[],"technologies":["mrd-testing"],"targets":["bcl2"],"drugs":["venetoclax"],"companies":[],"institutions":["peter-mac","wehi"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["blood"],"dependsOn":[],"notes":[],"role":"Consultant Haematologist, Peter MacCallum Cancer Centre and Royal Melbourne Hospital; Professor, University of Melbourne","institutionId":"peter-mac","specialisms":["Acute myeloid leukaemia","Venetoclax","Measurable residual disease","Maintenance therapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wei%20AH%5BAuthor%5D%20venetoclax%20azacitidine"}],"papers":[{"title":"Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission (QUAZAR AML-001)","journal":"NEJM","year":2020,"doi":"10.1056/NEJMoa2004444"},{"title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial (VIALE-C)","journal":"Blood","year":2020,"doi":"10.1182/blood.2020004856"}],"orcid":"0000-0002-7514-3298"},{"id":"andrew-aguirre","kind":"person","name":"Andrew J. Aguirre","aka":[],"tldr":"Uses organoids and functional genomics to find what pancreatic cancers depend on beyond KRAS.","summary":"Andrew J. Aguirre is an Institute Member at the Broad Institute of MIT and Harvard and a physician at Dana-Farber, working on pancreatic ductal adenocarcinoma and KRAS biology. He is known for leading real-time genomic profiling of advanced pancreatic cancer to enable precision medicine, the subject of his selected paper. His laboratory uses patient-derived organoids and functional genomics to find what pancreatic cancers depend on beyond KRAS. He now studies RAS-pathway dependencies and resistance to KRAS and RAS inhibitors.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Aguirre%20AJ%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":["organoids","kras-inhibitors"],"targets":["kras"],"drugs":[],"companies":[],"institutions":["broad-institute"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Institute Member, Broad; Physician, Dana-Farber","institutionId":"broad-institute","specialisms":["Pancreatic cancer","KRAS biology","Organoids"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Aguirre%20AJ%5BAuthor%5D"}],"papers":[{"title":"Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine","journal":"Cancer Discovery","year":2018,"url":"https://doi.org/10.1158/2159-8290.CD-18-0275","doi":"10.1158/2159-8290.CD-18-0275"}],"orcid":"0000-0002-0701-6203"},{"id":"andrew-armstrong","kind":"person","name":"Andrew J. Armstrong","aka":[],"tldr":"Led ARCHES, which established enzalutamide with hormone therapy for metastatic hormone-sensitive prostate cancer.","summary":"Andrew Armstrong was principal investigator of ARCHES, the trial showing enzalutamide plus androgen deprivation improves radiographic progression-free and overall survival in metastatic hormone-sensitive prostate cancer, and led the PROPHECY study validating AR-V7 in circulating tumour cells as a marker of resistance to AR inhibitors. He directs prostate cancer research at Duke.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Armstrong%20AJ%5BAuthor%5D%20enzalutamide%20ARCHES"}],"tags":["prostate","trialist"],"related":[],"cancers":["prostate"],"sections":[],"technologies":["androgen-deprivation","liquid-biopsy"],"targets":["androgen-receptor"],"drugs":[],"companies":[],"institutions":["duke-cancer-institute"],"pathways":[],"terms":[],"trials":["arches"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medicine, Surgery, and Pharmacology and Cancer Biology, Duke Cancer Institute","institutionId":"duke-cancer-institute","specialisms":["Prostate cancer","Androgen receptor inhibitors","Biomarkers of resistance","Circulating tumour cells"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Armstrong%20AJ%5BAuthor%5D%20enzalutamide%20ARCHES"}],"papers":[{"title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","journal":"JCO","year":2019,"doi":"10.1200/JCO.19.00799"},{"title":"Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the PROPHECY study","journal":"JCO","year":2019,"doi":"10.1200/JCO.18.01731"}],"orcid":"0000-0001-7012-1754"},{"id":"andrew-wagner","kind":"person","name":"Andrew J. Wagner","aka":[],"tldr":"Boston sarcoma doctor who first showed that mTOR inhibitors shrink perivascular epithelioid cell tumours and then led AMPECT, the trial that made nab-sirolimus the first approved treatment for these rare cancers.","summary":"Andrew Wagner is a medical oncologist in the sarcoma centre at Dana-Farber Cancer Institute. He was first author of the 2010 Journal of Clinical Oncology report showing responses to sirolimus in malignant perivascular epithelioid cell tumours, linking their TSC1/TSC2 loss to mTOR dependence, and of the 2021 Journal of Clinical Oncology report of AMPECT, the phase 2 trial in which nab-sirolimus produced durable responses in advanced malignant PEComa, the basis of the first approval for the disease.","asOf":"2026-09-18","links":[],"tags":["sarcoma","rare-cancers","targeted-therapy","trialist"],"related":[],"cancers":["pecoma","sarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["dana-farber"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-ampect-nab-sirolimus-pecoma-wagner-jco-2021","paper-wagner-sirolimus-pecoma-jco-2010"],"journals":[],"dependsOn":[],"notes":[],"role":"Sarcoma medical oncologist, Dana-Farber Cancer Institute","institutionId":"dana-farber","specialisms":["PEComa","mTOR inhibitors","Rare sarcomas"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wagner%5BAuthor%5D"}],"papers":[{"title":"AMPECT: nab-sirolimus for malignant perivascular epithelioid cell tumours","journal":"Journal of Clinical Oncology","year":2021,"url":"https://doi.org/10.1200/JCO.21.01728","doi":"10.1200/JCO.21.01728"},{"title":"Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumours","journal":"Journal of Clinical Oncology","year":2010,"url":"https://doi.org/10.1200/JCO.2009.25.2981","doi":"10.1200/JCO.2009.25.2981"}]},{"id":"andrew-little","kind":"person","name":"Andrew Little","aka":[],"tldr":"Chief Executive of Movember, the global men's health charity that funds prostate cancer, testicular cancer and mental health programmes.","summary":"Andrew Little is Chief Executive Officer of Movember, the global men's health charity best known for its annual moustache campaign and its funding of prostate cancer, testicular cancer and mental health work. He heads the Global Leadership Team, which is responsible for executing the strategies set by Movember's Board of Directors. The leadership team also includes the Director of the Movember Institute of Men's Health.","asOf":"2026-09-10","links":[{"label":"Source: Movember governance page","url":"https://au.movember.com/about-us/governance"}],"tags":["leadership","charity","mens-health"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["movember"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive Officer, Movember","institutionId":"movember","specialisms":["Charity leadership","Men's health","Prostate and testicular cancer funding"],"profiles":[{"label":"Movember leadership and governance","url":"https://au.movember.com/about-us/governance"}],"papers":[]},{"id":"andrew-mesecar","kind":"person","name":"Andrew Mesecar","aka":[],"tldr":"Structural biologist who directs the Purdue Institute for Cancer Research, an NCI-designated basic science cancer centre in West Lafayette, Indiana.","summary":"Andrew Mesecar is the Robert W. Miller Director of the Purdue Institute for Cancer Research (PICR), one of only seven NCI-designated basic science cancer centres in the United States. He is Distinguished Professor of Biochemistry, Walther Professor of Cancer Structural Biology and Assistant Vice President for Research at Purdue University, and a member of the institute's Targets, Structures and Drugs programme. The institute's directory lists him at the head of a senior leadership team that includes deputy director Andrea Kasinski, associate directors Deborah Knapp and Dorothy Teegarden and senior managing director Douglas Cuttell. PICR describes its mission as promoting basic discovery, transdisciplinary collaboration and an improved drug discovery pipeline.","asOf":"2026-09-10","links":[{"label":"Source: Purdue Institute for Cancer Research directory (senior leadership)","url":"https://cancer.research.purdue.edu/directory/"}],"tags":["leadership","research-institute"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["purdue-cancer-research"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["molecular-cancer-research"],"dependsOn":[],"notes":[],"role":"Robert W. Miller Director, Purdue Institute for Cancer Research","institutionId":"purdue-cancer-research","specialisms":["Structural biology","Biochemistry","Drug discovery"],"profiles":[{"label":"PICR directory profile","url":"https://cancer.research.purdue.edu/directory/andrew-mesecar/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mesecar+AD%5BAuthor%5D"}],"papers":[{"title":"Structural Basis for Tumor Pyruvate Kinase M2 Allosteric Regulation and Catalysis ,","journal":"Biochemistry","year":2005,"doi":"10.1021/bi0474923"},{"title":"Steady-state kinetic studies reveal that the anti-cancer target Ubiquitin-Specific Protease 17 (USP17) is a highly efficient deubiquitinating enzyme","journal":"Archives of Biochemistry and Biophysics","year":2016,"doi":"10.1016/j.abb.2016.10.008"},{"title":"Cholesterol Sulfonation Enzyme, SULT2B1b, Modulates AR and Cell Growth Properties in Prostate Cancer","journal":"Molecular Cancer Research","year":2016,"doi":"10.1158/1541-7786.mcr-16-0137"}],"orcid":"0000-0002-1241-2577"},{"id":"andrew-tutt","kind":"person","name":"Andrew Tutt","aka":[],"tldr":"Led OlympiA, the trial that showed a year of olaparib after surgery improves survival in BRCA-mutated breast cancer.","summary":"Andrew Tutt is Director of the Breast Cancer Now Toby Robins Research Centre at The Institute of Cancer Research and a consultant clinical oncologist at The Royal Marsden and Guy's. His specialisms are triple-negative breast cancer, BRCA and DNA repair, PARP inhibitors and platinum chemotherapy. His work on BRCA-deficient breast cancer runs from the first clinical proof-of-concept for a PARP inhibitor, through the TNT trial of carboplatin in BRCA1/2-mutated and triple-negative subgroups reported in Nature Medicine, to OlympiA, the adjuvant olaparib trial in BRCA-mutated breast cancer published in the New England Journal of Medicine. This body of work defined DNA-repair-targeted therapy in breast cancer. His ICR profile and PubMed listing are linked.","asOf":"2026-09-08","links":[{"label":"ICR profile","url":"https://www.icr.ac.uk/research-and-discoveries/our-research/researchers/professor-andrew-tutt"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tutt%20A%5BAuthor%5D%20olaparib%20breast"}],"tags":[],"related":[],"cancers":["tnbc"],"sections":[],"technologies":["parp-inhibitor","platinum"],"targets":["brca","parp"],"drugs":["olaparib","carboplatin"],"companies":[],"institutions":["royal-marsden","icr-london","breast-cancer-now"],"pathways":[],"terms":[],"trials":["olympia","tnt"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Breast Cancer Now Toby Robins Research Centre, ICR; Consultant Clinical Oncologist, Royal Marsden and Guy's","institutionId":"royal-marsden","specialisms":["Triple-negative breast cancer","BRCA and DNA repair","PARP inhibitors","Platinum chemotherapy"],"profiles":[{"label":"ICR profile","url":"https://www.icr.ac.uk/research-and-discoveries/our-research/researchers/professor-andrew-tutt"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tutt%20A%5BAuthor%5D%20olaparib%20breast"}],"papers":[{"title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer (OlympiA)","journal":"NEJM","year":2021,"doi":"10.1056/NEJMoa2105215"},{"title":"Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial","journal":"Nature Medicine","year":2018,"doi":"10.1038/s41591-018-0009-7"}]},{"id":"andrew-wardley","kind":"person","name":"Andrew Wardley","aka":[],"tldr":"Andrew Wardley is a breast oncologist involved in the PERSEPHONE trial of shorter trastuzumab.","summary":"Andrew Wardley is a consultant medical oncologist at The Christie NHS Foundation Trust and Honorary Professor at the University of Manchester. He specialises in breast cancer, HER2-positive disease and adjuvant trials. He contributed to PERSEPHONE, the trial that compared six months with twelve months of adjuvant trastuzumab. His papers include the monarcHER phase 2 trial of abemaciclib plus trastuzumab with or without fulvestrant in hormone receptor-positive, HER2-positive advanced breast cancer, the PERUSE study of first-line pertuzumab with trastuzumab and a taxane, and a study of enzalutamide with trastuzumab in HER2-positive, androgen receptor-positive disease. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wardley%20A%5BAuthor%5D%20breast%20trastuzumab"}],"tags":[],"related":[],"cancers":["breast-her2-positive"],"sections":[],"technologies":[],"targets":[],"drugs":["trastuzumab"],"companies":[],"institutions":["the-christie"],"pathways":[],"terms":[],"trials":["persephone"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["breast-cancer-research-and-treatment"],"dependsOn":[],"notes":[],"role":"Consultant Medical Oncologist, The Christie; Honorary Professor, University of Manchester","institutionId":"the-christie","specialisms":["Breast cancer","HER2-positive disease","Adjuvant trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wardley%20A%5BAuthor%5D%20breast%20trastuzumab"}],"papers":[{"title":"The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer","journal":"Breast Cancer Research and Treatment","year":2021,"doi":"10.1007/s10549-021-06109-7"},{"title":"Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial","journal":"The Lancet Oncology","year":2020,"doi":"10.1016/s1470-2045(20)30112-1"},{"title":"Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)","journal":"Annals of Oncology","year":2019,"doi":"10.1093/annonc/mdz061"},{"title":"monarchE: two years of abemaciclib after surgery in high-risk, hormone-receptor-positive early breast cancer","journal":"Journal of Clinical Oncology","year":2020,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=monarchE+abemaciclib+adjuvant+Johnston+2020"}],"orcid":"0000-0002-9639-0888"},{"id":"andrew-zhu","kind":"person","name":"Andrew X. Zhu","aka":[],"tldr":"Oncologist who led REACH-2, the first positive biomarker-selected trial in liver cancer, which established ramucirumab for patients with a high alpha-fetoprotein level.","summary":"Andrew Zhu led the liver cancer programme at Massachusetts General Hospital for many years. He was first author of the 2019 Lancet Oncology report of REACH-2, which showed that ramucirumab lengthened survival compared with placebo in previously treated hepatocellular carcinoma with alpha-fetoprotein of 400 ng/mL or more, the first positive phase 3 trial in liver cancer to select patients by a biomarker. He has also led trials of ivosidenib in IDH1-mutant cholangiocarcinoma.","asOf":"2026-09-18","links":[],"tags":["hcc","biliary","trialist"],"related":[],"cancers":["hcc-advanced","hcc","intrahepatic-cholangiocarcinoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["reach-2"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Hepatobiliary medical oncologist and trial lead","specialisms":["Hepatocellular carcinoma","Biliary tract cancer","Biomarker-selected trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Zhu%5BAuthor%5D"}],"papers":[]},{"id":"andrzej-kawecki","kind":"person","name":"Andrzej Kawecki","aka":[],"tldr":"Radiation oncologist specialising in head and neck cancer who oversees clinical affairs at Poland's National Research Institute of Oncology.","summary":"Andrzej Kawecki is Deputy Director for Clinical Affairs at the Maria Skłodowska-Curie National Research Institute of Oncology in Warsaw. A professor of medical sciences and radiation oncologist, his clinical and research work centres on head and neck cancers. His role is listed on the institute's management page.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://nio.gov.pl/dyrekcja-instytutu"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kawecki+A%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","head and neck cancer","radiotherapy"],"related":[],"cancers":["head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["nio-warsaw"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Deputy Director for Clinical Affairs","institutionId":"nio-warsaw","specialisms":["Radiation oncology","Head and neck cancer"],"profiles":[{"label":"Institution profile","url":"https://nio.gov.pl/dyrekcja-instytutu"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kawecki+A%5BAuthor%5D"}],"papers":[{"title":"Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer","journal":"New England Journal of Medicine","year":2008,"doi":"10.1056/nejmoa0802656"},{"title":"Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651","journal":"Journal of Clinical Oncology","year":2023,"doi":"10.1200/jco.22.00332"},{"title":"Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study","journal":"Annals of Oncology","year":2011,"doi":"10.1093/annonc/mdq588"}],"orcid":"0000-0003-4653-6655"},{"id":"ane-gerda-eriksson","kind":"person","name":"Ane Gerda Eriksson","aka":[],"tldr":"Oslo gynaecological oncology surgeon at the Norwegian Radium Hospital and President-Elect of ESGO.","summary":"Ane Gerda Eriksson is President-Elect of the European Society of Gynaecological Oncology and a gynaecological oncology surgeon at the Norwegian Radium Hospital, Oslo University Hospital. Her clinical and research work centres on surgical management of endometrial and ovarian cancer, including sentinel lymph node approaches. She is active in ESGO guideline and education activities.","asOf":"2026-09-10","links":[{"label":"Society page","url":"https://www.esgo.org/about/council/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Eriksson+AG%5BAuthor%5D+gynecologic"}],"tags":["leadership","clinician-scientist","gynaecological oncology"],"related":[],"cancers":["endometrial","ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["esgo"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["international-journal-of-gynecological-cancer"],"dependsOn":[],"notes":[],"role":"President-Elect","institutionId":"esgo","specialisms":["Gynaecological oncology","Endometrial cancer","Surgical oncology"],"profiles":[{"label":"Society page","url":"https://www.esgo.org/about/council/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Eriksson+AG%5BAuthor%5D+gynecologic"}],"papers":[{"title":"Self-reported lower extremity lymphedema and quality of life after surgical staging of endometrial carcinoma: A population based cross-sectional study","journal":"Gynecologic Oncology","year":2023,"doi":"10.1016/j.ygyno.2023.05.070"},{"title":"Update on Sentinel Lymph Node Biopsy in Surgical Staging of Endometrial Carcinoma","journal":"Journal of Clinical Medicine","year":2021,"doi":"10.3390/jcm10143094"},{"title":"Effect of substantial lymphovascular space invasion on location of first disease recurrence in surgical stage I endometrioid endometrial adenocarcinoma","journal":"International Journal of Gynecological Cancer","year":2025,"doi":"10.1016/j.ijgc.2025.101651"}],"orcid":"0000-0002-4913-1218"},{"id":"angela-demichele","kind":"person","name":"Angela DeMichele","aka":[],"tldr":"Angela DeMichele led the first palbociclib clinical trial and co-leads the I-SPY 2 adaptive platform.","summary":"Angela DeMichele is Co-Leader of the Breast Cancer Research Program and the Alan and Jill Miller Professor in Breast Cancer Excellence at the Abramson Cancer Center, University of Pennsylvania. She is a medical oncologist known for conducting the first palbociclib clinical trial in breast cancer and for co-leading the I-SPY 2 adaptive platform trial. Her selected paper reports the phase 2 activity, safety and predictive biomarkers of the CDK4/6 inhibitor palbociclib in Rb-positive advanced breast cancer. She now studies disseminated tumour cell dormancy as a target for preventing late recurrence in hormone receptor-positive and triple-negative breast cancer.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=DeMichele%20A%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["breast-hr-positive","tnbc"],"sections":[],"technologies":[],"targets":["cdk4-6"],"drugs":["palbociclib"],"companies":[],"institutions":["penn-abramson"],"pathways":[],"terms":["basket-umbrella-platform"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Co-Leader, Breast Cancer Research Program; Alan and Jill Miller Professor in Breast Cancer Excellence","institutionId":"penn-abramson","specialisms":["Breast cancer","CDK4/6 inhibitors","I-SPY 2 platform trial","Dormancy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=DeMichele%20A%5BAuthor%5D"}],"papers":[{"title":"CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment","journal":"Clinical Cancer Research","year":2015,"url":"https://doi.org/10.1158/1078-0432.CCR-14-2258","doi":"10.1158/1078-0432.CCR-14-2258"}],"orcid":"0000-0003-1297-4251"},{"id":"angela-lamarca","kind":"person","name":"Angela Lamarca","aka":[],"tldr":"Oncologist who was lead author of ABC-06, the first randomised trial to show that second-line chemotherapy helps people with advanced bile duct cancer.","summary":"Angela Lamarca trained and worked at The Christie in Manchester before moving to Madrid. She was first author of the 2021 Lancet Oncology report of ABC-06, the UK trial that showed FOLFOX plus active symptom control lengthened survival compared with symptom control alone after gemcitabine and cisplatin in advanced biliary tract cancer, establishing a second-line standard. She also works on neuroendocrine tumours.","asOf":"2026-09-18","links":[],"tags":["biliary","trialist"],"related":[],"cancers":["cholangiocarcinoma","biliary-tract-cancer","neuroendocrine"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["abc-06"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Medical oncologist, biliary tract and neuroendocrine cancers","specialisms":["Biliary tract cancer","Neuroendocrine tumours","Second-line chemotherapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lamarca%5BAuthor%5D"}],"papers":[]},{"id":"angelika-eggert","kind":"person","name":"Angelika Eggert","aka":[],"tldr":"Angelika Eggert is a paediatric oncologist and neuroblastoma researcher.","summary":"Angelika Eggert is Director of the Department of Pediatric Oncology and Hematology at Charité Universitätsmedizin Berlin. A paediatric oncologist, her specialisms are neuroblastoma, paediatric oncology and tumour biology. She studies neuroblastoma biology, including Trk receptor signalling and risk-adapted therapy. Her papers include a Nature Communications study of spatial and temporal intratumour heterogeneity and its consequences for treatment decisions based on a single biopsy, a study showing neuroblastoma cells depend on HDAC11 for mitotic progression, and the randomised GPOH trial NB2004-HR, which tested extended induction chemotherapy in high-risk neuroblastoma. Her publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Eggert%20A%5BAuthor%5D%20neuroblastoma"}],"tags":[],"related":[],"cancers":["neuroblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["charite"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Department of Pediatric Oncology and Hematology, Charité","institutionId":"charite","specialisms":["Neuroblastoma","Paediatric oncology","Tumour biology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Eggert%20A%5BAuthor%5D%20neuroblastoma"}],"papers":[{"title":"Spatial and temporal intratumour heterogeneity has potential consequences for single biopsy-based neuroblastoma treatment decisions","journal":"Nature Communications","year":2021,"doi":"10.1038/s41467-021-26870-z"},{"title":"Neuroblastoma cells depend on HDAC11 for mitotic cell cycle progression and survival","journal":"Cell Death & Disease","year":2017,"doi":"10.1038/cddis.2017.49"},{"title":"Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial NB2004-HR","journal":"Annals of Oncology","year":2020,"doi":"10.1016/j.annonc.2019.11.011"}],"orcid":"0000-0003-3476-8184"},{"id":"angelina-jolie","kind":"person","name":"Angelina Jolie","aka":[],"tldr":"Her 2013 New York Times essay about carrying a BRCA1 mutation and choosing preventive mastectomy roughly doubled referrals for hereditary cancer testing in several countries: the \"Angelina Jolie effect\".","summary":"Angelina Jolie's mother, Marcheline Bertrand, died of ovarian cancer in 2007 at 56. In May 2013 Jolie wrote in The New York Times that she carried a BRCA1 mutation, that her doctors estimated a high lifetime risk of breast and ovarian cancer, and that she had chosen a preventive double mastectomy. In 2015 she wrote a second essay about removing her ovaries and fallopian tubes. Published studies in the UK, US, Canada and Australia recorded a sharp and sustained rise in referrals for genetic counselling and BRCA testing after the first essay, with no fall in the proportion of tests that were appropriate. Her essays are the clearest documented example of a single public disclosure changing uptake of a preventive medical service.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Angelina_Jolie","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Angelina_Jolie"},{"label":"My Medical Choice (NYT, 2013)","url":"https://www.nytimes.com/2013/05/14/opinion/my-medical-choice.html"}],"tags":["public-figure","patient","advocate"],"related":[],"cancers":["ovarian","tnbc"],"sections":[],"technologies":["germline-testing","chemoprevention","risk-reducing-salpingectomy"],"targets":["brca"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["hereditary-cancer-syndromes","germline-vs-somatic"],"trials":[],"people":["mary-claire-king","judy-garber","susan-domchek"],"bottlenecks":["b-hereditary-risk","b-prevention-adoption"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Patient whose public account of BRCA1 testing and risk-reducing surgery changed testing uptake","specialisms":["Hereditary breast and ovarian cancer","BRCA1","Risk-reducing surgery"],"profiles":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Angelina_Jolie"},{"label":"My Medical Choice (NYT, 2013)","url":"https://www.nytimes.com/2013/05/14/opinion/my-medical-choice.html"}],"papers":[]},{"id":"angelita-habr-gama","kind":"person","name":"Angelita Habr-Gama","aka":[],"tldr":"Brazilian surgeon who first showed that rectal cancers that vanish after chemoradiation can be watched rather than removed.","summary":"Angelita Habr-Gama (University of São Paulo) published the 2004 series demonstrating that patients with a clinical complete response to chemoradiation for distal rectal cancer could safely avoid surgery, founding the watch-and-wait approach now tested in OPRA and adopted worldwide. She has led the International Watch & Wait Database and continues to refine response assessment and salvage strategies.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Habr-Gama%20A%5BAuthor%5D%20rectal%20watch%20and%20wait"}],"tags":["colorectal","surgery","organ-preservation","latin-america"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["organ-preservation","chemoradiation","complete-response"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Surgery, University of São Paulo; Angelita & Joaquim Gama Institute","specialisms":["Rectal cancer","Watch-and-wait","Colorectal surgery"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Habr-Gama%20A%5BAuthor%5D%20rectal%20watch%20and%20wait"}],"papers":[{"title":"Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results","journal":"Annals of Surgery","year":2004,"doi":"10.1097/01.sla.0000141194.27992.32"},{"title":"Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD)","journal":"Lancet","year":2018,"doi":"10.1016/S0140-6736(18)31078-X"}]},{"id":"dcruz-anil","kind":"person","name":"Anil K. D'Cruz","aka":[],"tldr":"Led the Tata Memorial trial that settled a decades-old question, showing that removing neck lymph nodes at the first operation for early oral cancer saves lives.","summary":"Anil D'Cruz is a head and neck surgeon who directed Tata Memorial Hospital before moving to Apollo Hospitals, and has served as President of the Union for International Cancer Control. He was principal investigator of the randomised trial of elective versus therapeutic neck dissection in node-negative oral cancer (596 enrolled, 500 analysed), which found 3-year overall survival of 80.0% with elective dissection against 67.5% with watchful waiting (hazard ratio 0.64) and changed guidelines worldwide. His work spans oral cancer surgery, thyroid cancer and cancer control policy for low- and middle-income countries.","asOf":"2026-09-10","links":[{"label":"Apollo Hospitals","url":"https://www.apollohospitals.com"},{"label":"Union for International Cancer Control","url":"https://www.uicc.org"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=D'Cruz%20AK%5BAuthor%5D%20Tata%20Memorial%20head%20and%20neck"}],"tags":[],"related":[],"cancers":["head-and-neck"],"sections":[],"technologies":["sentinel-node"],"targets":[],"drugs":[],"companies":[],"institutions":["apollo-hospitals","tata-memorial"],"pathways":[],"terms":[],"trials":["elective-neck-dissection-tmh"],"people":[],"bottlenecks":[],"keyPapers":["paper-dcruz-elective-neck-dissection-nejm-2015"],"journals":[],"dependsOn":[],"notes":[],"role":"Head and neck surgical oncologist; former Director, Tata Memorial Hospital; Director of Oncology, Apollo Hospitals","institutionId":"apollo-hospitals","specialisms":["Head and neck surgery","Oral cancer","Neck dissection","Global cancer control"],"profiles":[{"label":"Apollo Hospitals","url":"https://www.apollohospitals.com"},{"label":"Union for International Cancer Control","url":"https://www.uicc.org"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=D'Cruz%20AK%5BAuthor%5D%20Tata%20Memorial%20head%20and%20neck"}],"papers":[{"title":"Elective versus therapeutic neck dissection in node-negative oral cancer","journal":"New England Journal of Medicine","year":2015,"doi":"10.1056/NEJMoa1506007"}]},{"id":"anirban-maitra","kind":"person","name":"Anirban Maitra","aka":[],"tldr":"Anirban Maitra is a pancreatic cancer pathologist working on catching the disease early and understanding its precursors.","summary":"Anirban Maitra is Scientific Director of the Sheikh Ahmed Center for Pancreatic Cancer Research at MD Anderson Cancer Center. A pathologist and pancreatic cancer researcher, he leads early-detection efforts including the pancreatic cancer risk and cyst programmes, and studies the biology of pancreatic precursor lesions and KRAS-driven tumorigenesis. His papers include a Gastroenterology review of the opportunities and challenges in early detection of pancreatic cancer and a Modern Pathology analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. His work connects pancreatic ductal adenocarcinoma pathology to multi-cancer early detection and liquid biopsy.","asOf":"2026-09-08","links":[{"label":"MD Anderson faculty","url":"https://faculty.mdanderson.org/search?q=Anirban%20Maitra"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Maitra%20A%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Anirban%20Maitra"}],"tags":[],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":["mced","liquid-biopsy"],"targets":["kras"],"drugs":[],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Scientific Director, Sheikh Ahmed Center for Pancreatic Cancer Research, MD Anderson","institutionId":"md-anderson","specialisms":["Pancreatic cancer","Early detection","Cancer pathology"],"profiles":[{"label":"MD Anderson faculty","url":"https://faculty.mdanderson.org/search?q=Anirban%20Maitra"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Maitra%20A%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Anirban%20Maitra"}],"papers":[{"title":"Early Detection of Pancreatic Cancer: Opportunities and Challenges","journal":"Gastroenterology","year":2019,"url":"https://doi.org/10.1053/j.gastro.2019.01.259","doi":"10.1053/j.gastro.2019.01.259"},{"title":"Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray","journal":"Modern Pathology","year":2003,"url":"https://doi.org/10.1097/01.MP.0000086072.56290.FB","doi":"10.1097/01.MP.0000086072.56290.FB"}]},{"id":"ankita-mishra-bundela","kind":"person","name":"Ankita Mishra Bundela","aka":[],"tldr":"Indian Administrative Service officer who, as Joint Secretary for PMSSY, heads the health ministry division that builds the new AIIMS hospitals and upgrades government medical colleges.","summary":"Ankita Mishra Bundela, IAS, is Joint Secretary in charge of the Pradhan Mantri Swasthya Suraksha Yojana (PMSSY) at India's Ministry of Health and Family Welfare, the central scheme under which the new All India Institutes of Medical Sciences are established and existing government medical colleges are upgraded. The PMSSY division's contact page lists her at the head of the administration of the scheme, above deputy secretaries Aditya Kumar Mamgain and Arvind Thakur and joint directors covering the PMSSY sections. Search listings record her visiting AIIMS Bathinda in January 2025 in this capacity.","asOf":"2026-09-10","links":[{"label":"Source: PMSSY division contact page, Ministry of Health and Family Welfare","url":"https://pmssy.mohfw.gov.in/index4.php?lang=1&level=0&linkid=1&lid=1"}],"tags":["leadership","government"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["aiims-network"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Joint Secretary (PMSSY), Ministry of Health and Family Welfare, Government of India","institutionId":"aiims-network","specialisms":["Public administration","Health infrastructure policy","Tertiary care planning"],"profiles":[{"label":"PMSSY contact page listing division officers","url":"https://pmssy.mohfw.gov.in/index4.php?lang=1&level=0&linkid=1&lid=1"}],"papers":[]},{"id":"ann-partridge","kind":"person","name":"Ann H. Partridge","aka":[],"tldr":"Ann Partridge led the POSITIVE trial showing women can safely pause hormone therapy to have a baby.","summary":"Ann H. Partridge is Vice Chair of Medical Oncology and Director of the Program for Young Adults with Breast Cancer at Dana-Farber Brigham Cancer Center. She is known for leading the POSITIVE trial, which showed that women can safely pause endocrine therapy to have a baby, and for the Young Women's Breast Cancer Study. Her selected paper reports interrupting endocrine therapy to attempt pregnancy after breast cancer. She now directs Dana-Farber's adult survivorship and young women's breast cancer programmes, with a focus on fertility and life after cancer.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Ann_Partridge","links":[{"label":"Dana-Farber profile","url":"https://www.dana-farber.org/find-a-doctor/ann-h-partridge"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Partridge%20AH%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["breast-hr-positive"],"sections":[],"technologies":["endocrine-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":["dana-farber"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Vice Chair of Medical Oncology; Director, Program for Young Adults with Breast Cancer","institutionId":"dana-farber","specialisms":["Young women's breast cancer","Survivorship","Fertility after cancer"],"profiles":[{"label":"Dana-Farber profile","url":"https://www.dana-farber.org/find-a-doctor/ann-h-partridge"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Partridge%20AH%5BAuthor%5D"}],"papers":[{"title":"Interrupting endocrine therapy to attempt pregnancy after breast cancer","journal":"New England Journal of Medicine","year":2023,"url":"https://doi.org/10.1056/NEJMoa2212856","doi":"10.1056/NEJMoa2212856"}],"orcid":"0000-0002-4722-4824"},{"id":"ann-lurie","kind":"person","name":"Ann Lurie","aka":["Robert H. Lurie"],"tldr":"After her husband Robert was diagnosed with advanced colon cancer in 1987 at 46, she turned the family's fortune to Northwestern's cancer centre, which carries his name, and to the children's hospital that carries both.","summary":"Ann Lurie (1944-2024) trained as a nurse and married the Chicago real-estate investor Robert H. Lurie, who, as Northwestern's cancer centre records, was diagnosed with advanced colon cancer in 1987 at the age of 46; he died in 1990. What Robert and Ann did following his diagnosis, the centre says, has been transformative: the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, an NCI-designated comprehensive centre where more than 18,000 people a year receive a new cancer diagnosis, bears his name, as does the Robert H. Lurie Medical Research Center, and the Ann & Robert H. Lurie Children's Hospital of Chicago bears both. Amounts for the gifts are not stated on the centre's page and are not repeated here. She later funded health and education work in Kenya and Ethiopia.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Ann_Lurie","links":[{"label":"Lurie Cancer Center: about","url":"https://www.cancer.northwestern.edu/about/index.html"}],"tags":["hero","donor","carer"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["northwestern-lurie"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-funding-allocation"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Nurse and philanthropist behind Northwestern's Robert H. Lurie Comprehensive Cancer Center","specialisms":["Cancer centre building","Paediatric hospital building"],"profiles":[],"papers":[]},{"id":"ann-lii-cheng","kind":"person","name":"Ann-Lii Cheng","aka":[],"tldr":"Taiwanese oncologist who led the Asia-Pacific sorafenib trial and co-led IMbrave150, the immunotherapy standard for liver cancer.","summary":"Ann-Lii Cheng led the Asia-Pacific trial that confirmed sorafenib's benefit in hepatitis B-driven hepatocellular carcinoma and was co-principal investigator of IMbrave150, which established atezolizumab plus bevacizumab as first-line therapy. He has led or co-led most major HCC systemic therapy trials in Asia, including REFLECT (lenvatinib) and the adjuvant IMbrave050 study.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cheng%20AL%5BAuthor%5D%20hepatocellular"}],"tags":["hcc","immunotherapy","asia"],"related":[],"cancers":["hcc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["pdl1","vegf"],"drugs":["atezolizumab"],"companies":[],"institutions":["ntuh"],"pathways":[],"terms":[],"trials":["imbrave150","reflect","imbrave050"],"people":[],"bottlenecks":[],"keyPapers":["paper-imbrave150-nejm-2020"],"journals":[],"dependsOn":[],"notes":[],"role":"Distinguished Professor and Director, National Taiwan University Cancer Center","institutionId":"ntuh","specialisms":["Hepatocellular carcinoma","Immunotherapy","Asia-Pacific trials","Targeted therapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cheng%20AL%5BAuthor%5D%20hepatocellular"}],"papers":[{"title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","journal":"Lancet Oncology","year":2009,"doi":"10.1016/S1470-2045(08)70285-7"},{"title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","journal":"Journal of Hepatology","year":2022,"doi":"10.1016/j.jhep.2021.11.030"},{"title":"IMbrave150: atezolizumab plus bevacizumab replaces sorafenib as first treatment for advanced liver cancer","journal":"New England Journal of Medicine","year":2020,"url":"https://doi.org/10.1056/NEJMoa1915745","doi":"10.1056/NEJMoa1915745"}],"orcid":"0000-0002-9152-6512"},{"id":"anna-fagotti","kind":"person","name":"Anna Fagotti","aka":[],"tldr":"Surgeon who developed the laparoscopic score for predicting whether ovarian cancer can be fully removed.","summary":"Anna Fagotti is Director of the Gynecologic Oncology Unit at Policlinico Universitario A. Gemelli in Rome and Professor at the Università Cattolica. Her specialisms are ovarian cancer surgery, laparoscopic assessment and cytoreductive surgery. She devised the Fagotti laparoscopic predictive index, a score used to judge whether advanced ovarian cancer can be completely removed at surgery. Her papers include the SCORPION randomised trial of primary debulking surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer, the INTERNATIONAL MISSION study of minimally invasive surgery after neoadjuvant chemotherapy, and the ESGO-ESMO-ESP consensus recommendations on ovarian cancer. Her publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fagotti%20A%5BAuthor%5D%20ovarian%20laparoscopy"}],"tags":[],"related":[],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["gemelli"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["international-journal-of-gynecological-cancer"],"dependsOn":[],"notes":[],"role":"Director, Gynecologic Oncology Unit, Gemelli; Professor, Università Cattolica","institutionId":"gemelli","specialisms":["Ovarian cancer surgery","Laparoscopic assessment","Cytoreductive surgery"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fagotti%20A%5BAuthor%5D%20ovarian%20laparoscopy"}],"papers":[{"title":"Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850)","journal":"International Journal of Gynecological Cancer","year":2020,"doi":"10.1136/ijgc-2020-001640"},{"title":"The INTERNATIONAL MISSION study: minimally invasive surgery in ovarian neoplasms after neoadjuvant chemotherapy","journal":"International Journal of Gynecological Cancer","year":2019,"doi":"10.1136/ijgc-2018-000012"},{"title":"ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease","journal":"Annals of Oncology","year":2024,"doi":"10.1016/j.annonc.2023.11.015"}],"orcid":"0000-0001-5579-335X"},{"id":"anna-nowak","kind":"person","name":"Anna K. Nowak","aka":[],"tldr":"Australian oncologist who led DREAM and DREAM3R, testing durvalumab with chemotherapy in mesothelioma.","summary":"Anna Nowak (University of Western Australia) led the DREAM phase 2 trial, the first to show durvalumab can be combined with first-line platinum-pemetrexed in mesothelioma, and is co-principal investigator of the international DREAM3R phase 3 trial with PrE0506. Her laboratory work on chemotherapy-induced immune modulation underpins the chemo-immunotherapy approach in the disease.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Nowak%20AK%5BAuthor%5D%20mesothelioma%20durvalumab"}],"tags":["mesothelioma","immunotherapy","australia"],"related":[],"cancers":["mesothelioma"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["pdl1"],"drugs":["durvalumab"],"companies":[],"institutions":["university-of-western-australia"],"pathways":[],"terms":[],"trials":["dream3r"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["clinical-lung-cancer"],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology and Dean of Medicine, University of Western Australia","institutionId":"university-of-western-australia","specialisms":["Mesothelioma","Immunotherapy","Chemo-immunotherapy combinations","Tumour immunology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Nowak%20AK%5BAuthor%5D%20mesothelioma%20durvalumab"}],"papers":[{"title":"Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in","journal":"Lancet Oncology","year":2020,"doi":"10.1016/S1470-2045(20)30462-9"},{"title":"Chemotherapy with or without durvalumab in mesothelioma (DREAM3R): rationale and design","journal":"Clinical Lung Cancer","year":2021}],"orcid":"0000-0002-9317-9526"},{"id":"anna-sapino","kind":"person","name":"Anna Sapino","aka":[],"tldr":"Pathologist and Scientific Director of the Candiolo Cancer Institute (INOC), Piedmont's oncology IRCCS and an OECI-certified Comprehensive Cancer Centre.","summary":"Anna Sapino is Scientific Director of the Istituto Nazionale Oncologico Candiolo (Istituto di Candiolo IRCCS), the only oncological IRCCS in Piedmont. She is a professor of anatomic pathology at the University of Turin with a long research record in breast cancer pathology and biomarkers. She oversees the institute's research programmes and its clinical research and innovation division.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://inoc.it/it/direzione-scientifica/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sapino+A%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","pathology","breast cancer"],"related":[],"cancers":["breast-hr-positive","breast-her2-positive"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["candiolo"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["seminars-in-cancer-biology"],"dependsOn":[],"notes":[],"role":"Scientific Director","institutionId":"candiolo","specialisms":["Anatomic pathology","Breast cancer","Molecular pathology"],"profiles":[{"label":"Institution profile","url":"https://inoc.it/it/direzione-scientifica/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sapino+A%5BAuthor%5D"}],"papers":[{"title":"Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond","journal":"Seminars in Cancer Biology","year":2021,"doi":"10.1016/j.semcancer.2020.02.016"},{"title":"Genotyping tumour DNA in cerebrospinal fluid and plasma of a HER2-positive breast cancer patient with brain metastases","journal":"ESMO Open","year":2017,"doi":"10.1136/esmoopen-2017-000253"},{"title":"Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies","journal":"ESMO Open","year":2022,"doi":"10.1016/j.esmoop.2022.100459"}]},{"id":"anne-armstrong","kind":"person","name":"Anne Armstrong","aka":[],"tldr":"Medical oncologist who co-chairs the breast disease group at The Christie, the Manchester cancer centre that is a site of the PHOENIX, PARTNER and ASCENT-05 trials for triple-negative disease.","summary":"Anne Armstrong is a consultant in medical oncology and honorary senior lecturer at The Christie NHS Foundation Trust in Manchester, where her consultant page lists breast cancer as her specialty and names her co-chair of the trust's Breast Disease Group. The Christie's breast clinical oncology team provides radiotherapy, systemic anti-cancer treatment and specialised surgery for the region, and the trust is a UK site of the PHOENIX window-of-opportunity trial in residual triple-negative disease, of PARTNER and of ASCENT-05. Her name appears as investigator on The Christie's news pages about breast trials.","asOf":"2026-09-24","links":[{"label":"The Christie consultant page","url":"https://www.christie.nhs.uk/your-treatment-and-care/find-your-consultant/armstrong-anne"},{"label":"The Christie breast clinical oncology team","url":"https://www.christie.nhs.uk/your-treatment-and-care/services/clinical-oncology/meet-the-clinical-oncology-teams/breast"}],"tags":["breast","uk"],"related":[],"cancers":["tnbc","breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["the-christie"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Consultant in Medical Oncology and Honorary Senior Lecturer, The Christie; Co-Chair of the Breast Disease Group","institutionId":"the-christie","specialisms":["Breast cancer","Triple-negative breast cancer","Immunotherapy window trials","Early-phase trials"],"profiles":[{"label":"The Christie consultant page","url":"https://www.christie.nhs.uk/your-treatment-and-care/find-your-consultant/armstrong-anne"},{"label":"The Christie breast clinical oncology team","url":"https://www.christie.nhs.uk/your-treatment-and-care/services/clinical-oncology/meet-the-clinical-oncology-teams/breast"}],"papers":[]},{"id":"anne-chiang","kind":"person","name":"Anne C. Chiang","aka":[],"tldr":"Anne Chiang is a thoracic oncologist overseeing SWOG's breast and lung trial portfolios.","summary":"Anne Chiang is SWOG Executive Officer for Breast and Lung and Associate Professor at Yale School of Medicine. A medical oncologist focused on small-cell and non-small-cell lung cancer, her work includes NCCN guideline authorship and quality-of-care research. Her papers include the NCCN Clinical Practice Guidelines in Oncology for small cell lung cancer, and her record links to IMpower133, a trial in small-cell lung cancer. She now oversees the breast and lung trial portfolios of the SWOG Cancer Research Network, bringing a thoracic oncologist's perspective to cooperative group trials.","asOf":"2026-09-08","links":[{"label":"SWOG leadership","url":"https://www.swog.org/about/leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chiang%20AC%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Anne%20C.%20Chiang"}],"tags":[],"related":[],"cancers":["sclc","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["swog"],"institutions":[],"pathways":[],"terms":[],"trials":["impower133"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["jnccn"],"dependsOn":[],"notes":[],"role":"SWOG Executive Officer, Breast and Lung; Associate Professor, Yale School of Medicine","institutionId":"swog","specialisms":["Lung cancer","Small-cell lung cancer","Cooperative group trials"],"profiles":[{"label":"SWOG leadership","url":"https://www.swog.org/about/leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chiang%20AC%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Anne%20C.%20Chiang"}],"papers":[{"title":"Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology","journal":"Journal of the National Comprehensive Cancer Network","year":2021,"url":"https://doi.org/10.6004/jnccn.2021.0058","doi":"10.6004/jnccn.2021.0058"}],"orcid":"0000-0002-2111-4694"},{"id":"anne-coyle","kind":"person","name":"Anne Coyle","aka":[],"tldr":"Anne Coyle represents Beaumont RCSI Cancer Centre in the Organisation of European Cancer Institutes, which lists the centre among its members in Ireland.","summary":"Anne Coyle is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Beaumont RCSI Cancer Centre, its member in Ireland. Beaumont Hospital's designated cancer centre with the Royal College of Surgeons in Ireland, home of Ireland's national neurosurgery centre and accredited by OECI as a Cancer Centre. OnCo records the name from the OECI membership list so that the centre's page has a named contact point; the person's exact title, appointment date and biography are not yet recorded and should be checked on the institution's own pages before being relied on.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Beaumont RCSI Cancer Centre website","url":"https://beaumontrcsicancercentre.ie/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["beaumont-rcsi-cancer-centre"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Beaumont RCSI Cancer Centre to the Organisation of European Cancer Institutes","institutionId":"beaumont-rcsi-cancer-centre","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Beaumont RCSI Cancer Centre website","url":"https://beaumontrcsicancercentre.ie/"}],"papers":[]},{"id":"annette-walker","kind":"person","name":"Annette Walker","aka":[],"tldr":"Health system executive who leads City of Hope Orange County and oversaw the opening of Orange County's first cancer specialty hospital in Irvine.","summary":"Annette Walker is President of City of Hope Orange County, the Orange County arm of the City of Hope cancer research and treatment organisation. She led development of its comprehensive cancer campus and regional network in Irvine, a project of about one billion dollars whose cancer specialty hospital opened in December 2025. She was previously president of strategy at Providence St. Joseph Health, where she helped merge two large health organisations.","asOf":"2026-09-10","links":[{"label":"Source: Orange County Business Journal OC500 profile (Nov 2025)","url":"https://www.ocbj.com/oc-500/2025/oc500-2025-annette-walker/"}],"tags":["leadership","hospital","cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["city-of-hope"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President of City of Hope Orange County","institutionId":"city-of-hope-orange-county","specialisms":["Health system leadership","Cancer campus development","Healthcare strategy"],"profiles":[{"label":"Orange County Business Journal OC500 2025 profile","url":"https://www.ocbj.com/oc-500/2025/oc500-2025-annette-walker/"}],"papers":[]},{"id":"annika-auranen","kind":"person","name":"Annika Auranen","aka":[],"tldr":"Chief physician who directs Tays Cancer Centre in Tampere and the FICAN Mid regional cancer centre for central Finland.","summary":"Annika Auranen is Director and chief physician of Tays Cancer Centre (Tays Syöpäkeskus) at Tampere University Hospital, and of Sisä-Suomen syöpäkeskus FICAN Mid, the regional cancer centre for central Finland. The centre operates as part of the Wellbeing Services County of Pirkanmaa and Tampere University, combining cancer treatment and research. The centre's contacts page lists her as Director alongside special advisor Merja Helenius.","asOf":"2026-09-10","links":[{"label":"Source: Tays Cancer Centre contacts page naming the Director","url":"https://www.tayscancercentre.fi/contacts/"}],"tags":["leadership","clinician-scientist","comprehensive-cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["fican"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["gynecologic-oncology"],"dependsOn":[],"notes":[],"role":"Director and Chief Physician, Tays Cancer Centre","institutionId":"tays-cancer-centre","specialisms":["Oncology","Cancer centre management","Regional cancer networks"],"profiles":[{"label":"Tays Cancer Centre contacts page","url":"https://www.tayscancercentre.fi/contacts/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Auranen+A%5BAuthor%5D"}],"papers":[{"title":"Combined ASRGL1 and p53 immunohistochemistry as an independent predictor of survival in endometrioid endometrial carcinoma","journal":"Gynecologic Oncology","year":2018,"doi":"10.1016/j.ygyno.2018.02.016"},{"title":"Expression of the miR-200 family in tumor tissue, plasma and urine of epithelial ovarian cancer patients in comparison to benign counterparts","journal":"BMC Research Notes","year":2020,"doi":"10.1186/s13104-020-05155-6"},{"title":"ALDH1A1‐related stemness in high‐grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR‐PI3K/aurora kinase inhibitors","journal":"The Journal of Pathology","year":2019,"doi":"10.1002/path.5356"}],"orcid":"0000-0002-9678-4684"},{"id":"anthony-nichols","kind":"person","name":"Anthony C. Nichols","aka":[],"tldr":"Canadian surgeon who led ORATOR, the first randomised trial to compare robotic surgery with radiotherapy for early throat cancer, which found swallowing was slightly better after radiotherapy.","summary":"Anthony Nichols is a head and neck surgeon at Western University and London Health Sciences Centre in London, Ontario. He was first author of the 2019 Lancet Oncology report of ORATOR, the phase 2 trial that randomised patients with early oropharyngeal cancer to radiotherapy or transoral robotic surgery and found swallowing-related quality of life was modestly better after radiotherapy at one year. He also led ORATOR2 in HPV-positive disease.","asOf":"2026-09-18","links":[],"tags":["head-and-neck","surgery","trialist"],"related":[],"cancers":["hpv-positive-oropharyngeal-cancer","oropharyngeal-cancer","head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["lhsc-verspeeten"],"pathways":[],"terms":[],"trials":["orator"],"people":[],"bottlenecks":[],"keyPapers":["paper-anthony-nichols-lancet-oncol-2019","paper-anthony-nichols-nat-genet-2017","paper-anthony-nichols-nat-genet-2014"],"journals":[],"dependsOn":[],"notes":[],"role":"Head and neck surgeon, Western University and London Health Sciences Centre, Ontario","institutionId":"lhsc-verspeeten","specialisms":["Oropharyngeal cancer","Transoral robotic surgery","Randomised surgical trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Nichols%5BAuthor%5D"}],"papers":[{"title":"Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial","journal":"The Lancet Oncology","year":2019,"url":"https://doi.org/10.1016/s1470-2045(19)30410-3","doi":"10.1016/s1470-2045(19)30410-3","note":"Europe PMC author record matched by affiliation (Verspeeten Family Cancer Centre, London Health Sciences Centre); 335 citations on Europe PMC."},{"title":"Impaired H3K36 methylation defines a subset of head and neck squamous cell carcinomas","journal":"Nature Genetics","year":2017,"url":"https://doi.org/10.1038/ng.3757","doi":"10.1038/ng.3757","note":"Europe PMC author record matched by affiliation (Verspeeten Family Cancer Centre, London Health Sciences Centre); 225 citations on Europe PMC."},{"title":"Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands","journal":"Nature Genetics","year":2014,"url":"https://doi.org/10.1038/ng.3096","doi":"10.1038/ng.3096","note":"Europe PMC author record matched by affiliation (Verspeeten Family Cancer Centre, London Health Sciences Centre); 164 citations on Europe PMC."}],"orcid":"0000-0002-0760-980X"},{"id":"anthony-goncalves","kind":"person","name":"Anthony Gonçalves","aka":[],"tldr":"Anthony Gonçalves is a medical oncologist leading breast and ovarian cancer research at Institut Paoli-Calmettes.","summary":"Anthony Gonçalves is Head of Medical Oncology at Institut Paoli-Calmettes in Marseille, part of the UNICANCER network of French cancer centres. His specialisms are breast cancer, ovarian cancer and translational research, and he leads UNICANCER breast and gynaecological trials alongside translational genomics programmes. His papers include the UCBG 12-1 phase II trial of abiraterone acetate plus prednisone in androgen receptor-positive triple-negative breast cancer, the New England Journal of Medicine report of talazoparib in advanced breast cancer with a germline BRCA mutation, and the BAYPAN phase III trial of gemcitabine with sorafenib in advanced pancreatic cancer. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Goncalves%20A%5BAuthor%5D%20breast%20cancer"}],"tags":[],"related":[],"cancers":["breast-hr-positive","ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["unicancer"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Head of Medical Oncology, Institut Paoli-Calmettes, Marseille","institutionId":"unicancer","specialisms":["Breast cancer","Ovarian cancer","Translational research"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Goncalves%20A%5BAuthor%5D%20breast%20cancer"}],"papers":[{"title":"A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)","journal":"Annals of Oncology","year":2016,"doi":"10.1093/annonc/mdw067"},{"title":"Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation","journal":"New England Journal of Medicine","year":2018,"doi":"10.1056/nejmoa1802905"},{"title":"BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer","journal":"Annals of Oncology","year":2012,"doi":"10.1093/annonc/mds135"}]},{"id":"anthony-zietman","kind":"person","name":"Anthony L. Zietman","aka":[],"tldr":"Led the proton dose-escalation trial in prostate cancer and the comparative-effectiveness debate over proton therapy.","summary":"Anthony Zietman led PROG 95-09, the randomised trial showing high-dose proton-boosted radiotherapy improves biochemical control in localised prostate cancer, and co-leads the PARTIQoL trial comparing protons with IMRT. He has championed evidence-based adoption of proton therapy, led bladder-preserving trimodality therapy at MGH, and edited the International Journal of Radiation Oncology, Biology, Physics.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Zietman%20AL%5BAuthor%5D%20prostate%20proton"}],"tags":["radiotherapy","proton","prostate"],"related":[],"cancers":["prostate","urothelial"],"sections":[],"technologies":["proton-therapy","imrt-igrt"],"targets":[],"drugs":[],"companies":[],"institutions":["mgh","astro"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["ijrobp"],"dependsOn":[],"notes":[],"role":"Jenot and William Shipley Professor of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School","institutionId":"mgh","specialisms":["Prostate radiotherapy","Proton therapy","Dose escalation","Bladder preservation"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Zietman%20AL%5BAuthor%5D%20prostate%20proton"}],"papers":[{"title":"Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09","journal":"JCO","year":2010,"doi":"10.1200/JCO.2009.25.8475"},{"title":"Particle therapy at the 'tipping point': an introduction to the Red Journal's special edition","journal":"International Journal of Radiation Oncology, Biology, Physics","year":2016}]},{"id":"anthony-lawler","kind":"person","name":"Anthony Lawler","aka":[],"tldr":"Head of Australia's medicines and medical devices regulator, the body that approves cancer drugs for the Australian market.","summary":"Professor Anthony (Tony) Lawler heads the Therapeutic Goods Administration, Australia's regulator of medicines and medical devices, as Deputy Secretary of the Health Products Regulation Group within the federal Department of Health. He took up the role in June 2023, succeeding Professor John Skerritt, and in October 2025 was elected Chair of the International Coalition of Medicines Regulatory Authorities. The TGA website timed out during checks, so the role is recorded from Wikipedia.","asOf":"2026-09-10","links":[{"label":"Source: Wikipedia, Therapeutic Goods Administration","url":"https://en.wikipedia.org/wiki/Therapeutic_Goods_Administration"}],"tags":["leadership","regulation","australia"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["tga"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Head of the Therapeutic Goods Administration and Deputy Secretary, Health Products Regulation Group (since 2023)","institutionId":"tga","specialisms":["Medicines regulation","Health products policy","International regulatory cooperation"],"profiles":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Anthony_Lawler"}],"papers":[]},{"id":"anthony-letai","kind":"person","name":"Anthony Letai","aka":[],"tldr":"Invented BH3 profiling, the functional test behind venetoclax's success, before becoming NCI director.","summary":"Anthony Letai is Director of the National Cancer Institute, having previously worked as a haematologist-scientist at Dana-Farber. He is known for inventing BH3 profiling, a functional test that measures mitochondrial apoptotic priming and predicts response to BCL-2 inhibitors such as venetoclax in acute myeloid leukaemia and chronic lymphocytic leukaemia. His selected paper shows that pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Appointed NCI director in 2025, he brought to the role a career in functional precision medicine and ex vivo drug testing.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Anthony_Letai","links":[{"label":"NCI leadership","url":"https://www.cancer.gov/about-nci/leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Letai%20A%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["aml","cll"],"sections":[],"technologies":["bh3-profiling","functional-drug-testing"],"targets":["bcl2"],"drugs":["venetoclax"],"companies":[],"institutions":["nci"],"pathways":["apoptosis-bcl2"],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, National Cancer Institute","institutionId":"nci","specialisms":["Apoptosis","BH3 profiling","Functional precision medicine","Leukaemia"],"profiles":[{"label":"NCI leadership","url":"https://www.cancer.gov/about-nci/leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Letai%20A%5BAuthor%5D"}],"papers":[{"title":"Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy","journal":"Science","year":2011,"url":"https://doi.org/10.1126/science.1206727","doi":"10.1126/science.1206727"}]},{"id":"anthony-may","kind":"person","name":"Anthony May","aka":[],"tldr":"Former county council chief executive who has led Nottingham University Hospitals NHS Trust, which runs the Nottingham cancer centre at City Hospital, since September 2022.","summary":"Anthony May OBE DL is Chief Executive of Nottingham University Hospitals NHS Trust, the trust that runs Queen's Medical Centre, City Hospital (home of the Nottingham cancer centre), Ropewalk House and the National Rehabilitation Centre. He joined the trust as Chief Executive on 1 September 2022. He was previously Chief Executive of Nottinghamshire County Council from April 2015 to August 2022, responsible for a budget of about 1.1 billion pounds and around 18,000 staff, chaired the Midlands Engine Operating Board for five years and led the Association of County Council Chief Executives for more than two years.","asOf":"2026-09-10","links":[{"label":"Source: Nottingham University Hospitals board page","url":"https://www.nuh.nhs.uk/meet-the-board"}],"tags":["leadership","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["nottingham-cancer-centre"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive, Nottingham University Hospitals NHS Trust","institutionId":"nottingham-cancer-centre","specialisms":["Public sector leadership","Hospital management","Health and local government"],"profiles":[{"label":"NUH Meet the Board","url":"https://www.nuh.nhs.uk/meet-the-board"}],"papers":[]},{"id":"anthony-chan","kind":"person","name":"Anthony T. C. Chan","aka":[],"tldr":"Leading nasopharyngeal carcinoma researcher who directs the Hong Kong Cancer Institute at CUHK.","summary":"Anthony Chan is Li Shu Fan Medical Foundation Professor of Clinical Oncology at The Chinese University of Hong Kong, Director of the Hong Kong Cancer Institute and a Pro-Vice-Chancellor of the university. His research has shaped the treatment of nasopharyngeal carcinoma, including trials of concurrent chemoradiotherapy and studies of plasma Epstein-Barr virus DNA as a biomarker.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.clo.cuhk.edu.hk/staff/university-staff/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chan+AT%5BAuthor%5D+nasopharyngeal"}],"tags":["leadership","clinician-scientist","nasopharyngeal cancer","head and neck cancer"],"related":[],"cancers":["nasopharyngeal","head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["prince-of-wales-hospital-cuhk"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Li Shu Fan Medical Foundation Professor of Clinical Oncology; Director, Hong Kong Cancer Institute","institutionId":"prince-of-wales-hospital-cuhk","specialisms":["Nasopharyngeal carcinoma","Head and neck cancer","EBV-related cancers"],"profiles":[{"label":"Institution profile","url":"https://www.clo.cuhk.edu.hk/staff/university-staff/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chan+AT%5BAuthor%5D+nasopharyngeal"}],"papers":[{"title":"Concurrent Chemotherapy-Radiotherapy Compared With Radiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma: Progression-Free Survival Analysis of a Phase III Randomized Trial","journal":"Journal of Clinical Oncology","year":2002,"doi":"10.1200/jco.2002.08.149"},{"title":"Phase II Study of Neoadjuvant Carboplatin and Paclitaxel Followed by Radiotherapy and Concurrent Cisplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma: Therapeutic Monitoring With Plasma Epstein-Barr Virus DNA","journal":"Journal of Clinical Oncology","year":2004,"doi":"10.1200/jco.2004.05.178"},{"title":"A phase II study of concurrent cetuximab–cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma","journal":"Annals of Oncology","year":2012,"doi":"10.1093/annonc/mdr401"}]},{"id":"anthony-damico","kind":"person","name":"Anthony V. D'Amico","aka":[],"tldr":"Created the low, intermediate and high-risk classification that every prostate cancer decision starts from.","summary":"Anthony D'Amico developed the 1998 risk stratification of localised prostate cancer by PSA, Gleason score and stage that remains the backbone of guidelines and trial eligibility, and led the randomised trial showing six months of androgen deprivation with radiotherapy improves survival in intermediate and high-risk disease. He continues to publish on PSA kinetics and on tailoring hormone therapy duration.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=D'Amico%20AV%5BAuthor%5D%20prostate%20risk"}],"tags":["prostate","radiotherapy","risk-stratification"],"related":[],"cancers":["prostate"],"sections":[],"technologies":["imrt-igrt","androgen-deprivation"],"targets":[],"drugs":[],"companies":[],"institutions":["dana-farber"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Radiation Oncology, Brigham and Women's Hospital and Dana-Farber Cancer Institute","institutionId":"dana-farber","specialisms":["Prostate radiotherapy","Risk stratification","Androgen deprivation with radiotherapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=D'Amico%20AV%5BAuthor%5D%20prostate%20risk"}],"papers":[{"title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer","journal":"JAMA","year":1998,"doi":"10.1001/jama.280.11.969"},{"title":"Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial","journal":"JAMA","year":2008,"doi":"10.1001/jama.299.3.289"}]},{"id":"antoine-italiano","kind":"person","name":"Antoine Italiano","aka":[],"tldr":"Bordeaux oncologist who led CABONE, the trial that showed cabozantinib shrinks or stabilises osteosarcoma and Ewing sarcoma after standard treatment has failed.","summary":"Antoine Italiano leads early-phase trials and the sarcoma unit at Institut Bergonié in Bordeaux. He was first author of the 2020 Lancet Oncology report of CABONE, the French Sarcoma Group phase 2 trial in which cabozantinib produced responses and prolonged disease control in advanced Ewing sarcoma and osteosarcoma. He also leads the PROFILER and other molecular profiling programmes in France.","asOf":"2026-09-18","links":[],"tags":["sarcoma","early-phase","trialist"],"related":[],"cancers":["osteosarcoma","ewing-sarcoma","sarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["institut-bergonie"],"pathways":[],"terms":[],"trials":["cabone"],"people":[],"bottlenecks":[],"keyPapers":["paper-antoine-italiano-nature-2020","paper-antoine-italiano-nat-cancer-2021","paper-antoine-italiano-j-clin-oncol-2022"],"journals":[],"dependsOn":[],"notes":[],"role":"Head of Early-Phase Trials and Sarcoma Unit, Institut Bergonié, Bordeaux","institutionId":"institut-bergonie","specialisms":["Sarcoma","Early-phase trials","Precision oncology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Italiano%5BAuthor%5D"}],"papers":[{"title":"B cells are associated with survival and immunotherapy response in sarcoma","journal":"Nature","year":2020,"url":"https://doi.org/10.1038/s41586-019-1906-8","doi":"10.1038/s41586-019-1906-8","note":"Europe PMC author record matched by affiliation (Institut Bergonié); 1668 citations on Europe PMC."},{"title":"Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression","journal":"Nature Cancer","year":2021,"url":"https://doi.org/10.1038/s43018-021-00232-6","doi":"10.1038/s43018-021-00232-6","note":"Europe PMC author record matched by affiliation (Institut Bergonié); 501 citations on Europe PMC."},{"title":"Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study","journal":"Journal of Clinical Oncology","year":2022,"url":"https://doi.org/10.1200/jco.21.01874","doi":"10.1200/jco.21.01874","note":"Europe PMC author record matched by affiliation (Institut Bergonié); 412 citations on Europe PMC."}]},{"id":"anton-benet-catala","kind":"person","name":"Anton Benet Català","aka":[],"tldr":"Anton Benet Català represents Hospital Universitari Sant Joan de Reus in the Organisation of European Cancer Institutes, which lists the centre among its members in Spain.","summary":"Anton Benet Català is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Hospital Universitari Sant Joan de Reus, its member in Spain. Hospital Universitari Sant Joan de Reus hosts the Southern Catalonia Oncology Institute and is a full member of the Organisation of European Cancer Institutes. OnCo records the name from the OECI membership list so that the centre's page has a named contact point; the person's exact title, appointment date and biography are not yet recorded and should be checked on the institution's own pages before being relied on.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Hospital Universitari Sant Joan de Reus website","url":"https://www.salutsantjoan.cat/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["hospital-sant-joan-de-reus"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Hospital Universitari Sant Joan de Reus to the Organisation of European Cancer Institutes","institutionId":"hospital-sant-joan-de-reus","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Hospital Universitari Sant Joan de Reus website","url":"https://www.salutsantjoan.cat/"}],"papers":[]},{"id":"antoni-ribas","kind":"person","name":"Antoni Ribas","aka":[],"tldr":"Melanoma immunotherapy leader behind pembrolizumab's first trials and the science of why immunotherapy fails.","summary":"Antoni Ribas is Professor of Medicine and Director of the Tumor Immunology Program at the UCLA Jonsson Comprehensive Cancer Center, and a past president of the American Association for Cancer Research (AACR). A medical oncologist specialising in melanoma, he led the earliest pembrolizumab studies in melanoma, including KEYNOTE-001, and defined mechanisms of resistance to checkpoint blockade such as JAK1/2 and B2M loss. His papers include a New England Journal of Medicine report on mutations associated with acquired resistance to PD-1 blockade in melanoma and a Science review of cancer immunotherapy using checkpoint blockade. He is a founder of cell-therapy and TCR companies and works on PD-1, BRAF and TCR-T cell therapy.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Antoni_Ribas_(professor)","links":[{"label":"UCLA profile","url":"https://www.uclahealth.org/providers?q=Antoni%20Ribas"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ribas%20A%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Antoni%20Ribas"}],"tags":[],"related":[],"cancers":["melanoma"],"sections":[],"technologies":["checkpoint-inhibitor","tcr-t"],"targets":["pd1","braf"],"drugs":["pembrolizumab"],"companies":[],"institutions":["ucla-jonsson","aacr"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medicine; Director, Tumor Immunology Program, UCLA Jonsson Comprehensive Cancer Center","institutionId":"ucla-jonsson","specialisms":["Melanoma","Immunotherapy","Resistance to checkpoint blockade"],"profiles":[{"label":"UCLA profile","url":"https://www.uclahealth.org/providers?q=Antoni%20Ribas"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ribas%20A%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Antoni%20Ribas"}],"papers":[{"title":"Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma","journal":"New England Journal of Medicine","year":2016,"url":"https://doi.org/10.1056/NEJMoa1604958","doi":"10.1056/NEJMoa1604958"},{"title":"Cancer immunotherapy using checkpoint blockade","journal":"Science","year":2018,"url":"https://doi.org/10.1126/science.aar4060","doi":"10.1126/science.aar4060"},{"title":"Tumeh 2014: PD-1 blockade works by releasing T cells already present at the tumour edge","journal":"Nature","year":2014,"url":"https://doi.org/10.1038/nature13954","doi":"10.1038/nature13954"}]},{"id":"antonio-cuneo","kind":"person","name":"Antonio Cuneo","aka":[],"tldr":"Ferrara haematologist and CLL expert who chairs GIMEMA's Scientific Committee.","summary":"Antonio Cuneo chairs the Scientific Committee of Fondazione GIMEMA, guiding the group's trial portfolio in adult haematological malignancies. A professor of haematology at the University of Ferrara, his research centres on chronic lymphocytic leukaemia and the cytogenetics of lymphoid and myeloid neoplasms. His role is listed on GIMEMA's organisational chart.","asOf":"2026-09-10","links":[{"label":"Society page","url":"https://www.gimema.it/organigramma/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cuneo+A%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","leukaemia"],"related":[],"cancers":["cll"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["gimema"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["cancer-medicine","haematologica"],"dependsOn":[],"notes":[],"role":"President of the Scientific Committee","institutionId":"gimema","specialisms":["Haematology","Chronic lymphocytic leukaemia","Cytogenetics"],"profiles":[{"label":"Society page","url":"https://www.gimema.it/organigramma/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cuneo+A%5BAuthor%5D"}],"papers":[{"title":"Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study","journal":"Haematologica","year":2018,"doi":"10.3324/haematol.2018.189837"},{"title":"Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real‐world setting. A GIMEMA‐ERIC and US study","journal":"Cancer Medicine","year":2020,"doi":"10.1002/cam4.3470"}],"orcid":"0000-0003-2001-1308"},{"id":"antonio-gonzalez-martin","kind":"person","name":"Antonio González-Martín","aka":[],"tldr":"Gynaecological medical oncologist directing the Cancer Center Clínica Universidad de Navarra; led the PRIMA trial of niraparib maintenance in ovarian cancer.","summary":"Antonio González-Martín is Director of the Cancer Center Clínica Universidad de Navarra (CCUN) and Co-Director of its Department of Medical Oncology. He is a leading gynaecological oncologist who served as principal investigator of the PRIMA/ENGOT-OV26 trial establishing niraparib first-line maintenance in advanced ovarian cancer, and has been president of the Spanish Ovarian Cancer Research Group (GEICO).","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://cancercenter.cun.es/cancer-center/organigrama"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gonzalez-Martin+A%5BAuthor%5D+ovarian"}],"tags":["leadership","clinician-scientist","ovarian cancer","gynaecological oncology"],"related":[],"cancers":["ovarian","endometrial","cervical"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cun-navarra"],"pathways":[],"terms":[],"trials":["prima","beatcc"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Cancer Center Clínica Universidad de Navarra","institutionId":"cun-navarra","specialisms":["Medical oncology","Ovarian cancer","Gynaecological oncology"],"profiles":[{"label":"Institution profile","url":"https://cancercenter.cun.es/cancer-center/organigrama"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gonzalez-Martin+A%5BAuthor%5D+ovarian"}],"papers":[{"title":"Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer","journal":"New England Journal of Medicine","year":2019,"doi":"10.1056/nejmoa1910962"},{"title":"Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","journal":"Annals of Oncology","year":2023,"doi":"10.1016/j.annonc.2023.07.011"},{"title":"Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer","journal":"New England Journal of Medicine","year":2016,"doi":"10.1056/nejmoa1611310"}]},{"id":"antonio-llombart-bosch","kind":"person","name":"Antonio Llombart Bosch","aka":[],"tldr":"Physician who presides over the board of trustees of the Fundación Instituto Valenciano de Oncología (IVO), the private non profit cancer centre in Valencia.","summary":"Antonio Llombart Bosch is Presidente del Patronato of the Fundación Instituto Valenciano de Oncología (IVO), a private non profit foundation created in 1976 that runs a dedicated cancer hospital in Valencia. The foundation's board page lists him alongside vice president Tomás Trénor y Puig, Marqués del Turia, secretary Jaime Olleros Izard and treasurer Santiago Bauzá Anglada. The IVO publishes its management structure only as a 2026 organisation chart image, so the executive team below the board could not be read from the site.","asOf":"2026-09-10","links":[{"label":"Source: IVO 'El patronato' page","url":"https://www.ivo.es/la-fundacion/el-patronato/"}],"tags":["leadership","philanthropy","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ivo-valencia"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Presidente del Patronato (Chair of the Board of Trustees), Fundación Instituto Valenciano de Oncología","institutionId":"ivo-valencia","specialisms":["Oncology","Foundation governance"],"profiles":[{"label":"IVO board of trustees page","url":"https://www.ivo.es/la-fundacion/el-patronato/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Llombart-Bosch+A%5BAuthor%5D"}],"papers":[{"title":"Histological heterogeneity of Ewing’s sarcoma/PNET: an immunohistochemical analysis of 415 genetically confirmed cases with clinical support","journal":"Virchows Archiv","year":2009,"doi":"10.1007/s00428-009-0842-7"},{"title":"Solitary, multiple, benign, atypical, or malignant: the “Granular Cell Tumor” puzzle","journal":"Virchows Archiv","year":2015,"doi":"10.1007/s00428-015-1877-6"},{"title":"Immunohistochemical analysis and prognostic significance of PD-L1, PD-1, and CD8+ tumor-infiltrating lymphocytes in Ewing’s sarcoma family of tumors (ESFT)","journal":"Virchows Archiv","year":2018,"doi":"10.1007/s00428-018-2316-2"}]},{"id":"antonio-rosato","kind":"person","name":"Antonio Rosato","aka":[],"tldr":"Immunologist and Scientific Director of the Istituto Oncologico Veneto, leading its translational cancer research.","summary":"Antonio Rosato is Scientific Director (Direttore Scientifico) of the Istituto Oncologico Veneto IRCCS and a professor of immunology at the University of Padua. His research focuses on tumour immunology and adoptive cell therapies, and he oversees the institute's research strategy, clinical trials and IRCCS scientific programmes.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rosato+A%5BAuthor%5D+Padova"}],"tags":["leadership","clinician-scientist","immunotherapy"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["iov-veneto"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["journal-of-experimental-and-clinical-cancer-research"],"dependsOn":[],"notes":[],"role":"Scientific Director","institutionId":"iov-veneto","specialisms":["Tumour immunology","Cancer immunotherapy","Translational research"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rosato+A%5BAuthor%5D+Padova"}],"papers":[{"title":"Anti-PSMA CAR-Engineered NK-92 Cells: An Off-the-Shelf Cell Therapy for Prostate Cancer","journal":"Cells","year":2020,"doi":"10.3390/cells9061382"},{"title":"The immune cell landscape of metastatic uveal melanoma correlates with overall survival","journal":"Journal of Experimental & Clinical Cancer Research","year":2021,"doi":"10.1186/s13046-021-01947-1"},{"title":"The immune microenvironment of HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma: a multiparametric quantitative and spatial analysis unveils a rationale to target treatment-naïve tumors with immune checkpoint inhibitors","journal":"Journal of Experimental & Clinical Cancer Research","year":2022,"doi":"10.1186/s13046-022-02481-4"}],"orcid":"0000-0002-5263-8386"},{"id":"arjun-balar","kind":"person","name":"Arjun V. Balar","aka":[],"tldr":"Led KEYNOTE-052 and IMvigor210 cohort 1, establishing first-line immunotherapy for cisplatin-ineligible bladder cancer.","summary":"Arjun Balar led KEYNOTE-052 and the cisplatin-ineligible cohort of IMvigor210, the studies that gave pembrolizumab and atezolizumab their first-line approvals in urothelial cancer for patients who cannot receive cisplatin, and KEYNOTE-057 in BCG-unresponsive non-muscle-invasive disease. He continues to lead combination and bladder-preservation trials at NYU.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Balar%20AV%5BAuthor%5D%20urothelial%20pembrolizumab"}],"tags":["urothelial","immunotherapy"],"related":[],"cancers":["urothelial"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["pd1","pdl1"],"drugs":["pembrolizumab","atezolizumab"],"companies":[],"institutions":["nyu-perlmutter"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medicine and Director, Genitourinary Medical Oncology Program, NYU Langone Perlmutter Cancer Center","institutionId":"nyu-perlmutter","specialisms":["Urothelial cancer","First-line immunotherapy","Non-muscle-invasive bladder cancer","Combination therapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Balar%20AV%5BAuthor%5D%20urothelial%20pembrolizumab"}],"papers":[{"title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052)","journal":"Lancet Oncology","year":2017,"doi":"10.1016/S1470-2045(17)30616-2"},{"title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057)","journal":"Lancet Oncology","year":2021,"doi":"10.1016/S1470-2045(21)00147-9"}]},{"id":"armando-giuliano","kind":"person","name":"Armando E. Giuliano","aka":[],"tldr":"Brought sentinel node biopsy to breast cancer and led ACOSOG Z0011, which ended routine axillary dissection for many women.","summary":"Armando Giuliano performed the first sentinel lymph node biopsies for breast cancer in the early 1990s and then led ACOSOG Z0011, the trial showing women with one or two positive sentinel nodes treated with breast conservation and radiotherapy do not need completion axillary dissection. The ten-year results changed practice worldwide and spared hundreds of thousands of women lymphoedema. He continues to lead surgical trials at Cedars-Sinai.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Armando_E._Giuliano","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Giuliano%20AE%5BAuthor%5D%20sentinel%20Z0011"}],"tags":["breast","surgery","de-escalation"],"related":[],"cancers":["breast-hr-positive"],"sections":[],"technologies":["sentinel-node"],"targets":[],"drugs":[],"companies":[],"institutions":["cedars-sinai-cancer"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Executive Vice Chair of Surgery, Cedars-Sinai Medical Center","institutionId":"cedars-sinai-cancer","specialisms":["Breast surgical oncology","Sentinel lymph node biopsy","Axillary de-escalation"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Giuliano%20AE%5BAuthor%5D%20sentinel%20Z0011"}],"papers":[{"title":"Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis (ACOSOG Z0011)","journal":"JAMA","year":2017,"doi":"10.1001/jama.2017.11470"},{"title":"Lymphatic mapping and sentinel lymphadenectomy for breast cancer","journal":"Annals of Surgery","year":1994,"doi":"10.1097/00000658-199409000-00015"}],"orcid":"0000-0002-5421-945X"},{"id":"armando-santoro","kind":"person","name":"Armando Santoro","aka":[],"tldr":"Veteran Italian medical oncologist who leads oncology and haematology at Humanitas and has co-authored major trials in lymphoma, liver cancer and novel targeted drugs.","summary":"Armando Santoro heads the Medical Oncology and Hematology Unit at IRCCS Humanitas Research Hospital and is Full Professor of Medical Oncology at Humanitas University. Trained in oncology and haematology in Genoa and formerly at Italy's National Cancer Institute in Milan, he joined Humanitas in 1997. His clinical research spans lymphomas, hepatocellular carcinoma and early-phase development of biological and targeted therapies.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.humanitas.it/medici/armando-santoro/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Santoro+A%5BAuthor%5D+AND+Humanitas"}],"tags":["clinician-scientist","leadership","lymphoma","drug development"],"related":[],"cancers":["hodgkin-lymphoma","dlbcl","hcc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["humanitas"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Head of the Medical Oncology and Hematology Unit; Full Professor of Medical Oncology, Humanitas University","institutionId":"humanitas","specialisms":["Medical oncology","Lymphoma","Hepatocellular carcinoma","Drug development"],"profiles":[{"label":"Institution profile","url":"https://www.humanitas.it/medici/armando-santoro/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Santoro+A%5BAuthor%5D+AND+Humanitas"}],"papers":[{"title":"Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma","journal":"New England Journal of Medicine","year":2022,"url":"https://doi.org/10.1056/NEJMoa2116596","doi":"10.1056/NEJMoa2116596"},{"title":"Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation","journal":"New England Journal of Medicine","year":2023,"url":"https://doi.org/10.1056/NEJMoa2303810","doi":"10.1056/NEJMoa2303810"}],"orcid":"0000-0003-1709-9492"},{"id":"arnaud-mejean","kind":"person","name":"Arnaud Méjean","aka":[],"tldr":"Surgeon who led CARMENA, the trial that showed most metastatic kidney cancer patients do not benefit from removing the kidney.","summary":"Arnaud Méjean (Paris) was principal investigator of CARMENA, which showed sunitinib alone was non-inferior to cytoreductive nephrectomy followed by sunitinib in intermediate and poor-risk metastatic renal cell carcinoma, ending routine upfront nephrectomy in the targeted therapy era. His work redefined the role of surgery in advanced kidney cancer and is being revisited in the immunotherapy era.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mejean%20A%5BAuthor%5D%20CARMENA"}],"tags":["rcc","surgery"],"related":[],"cancers":["rcc"],"sections":[],"technologies":["robotic-surgery"],"targets":[],"drugs":[],"companies":[],"institutions":["carpem-aphp-centre"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["european-urology"],"dependsOn":[],"notes":[],"role":"Head of Urology, Hôpital Européen Georges-Pompidou; Professor, Université Paris Cité","institutionId":"carpem-aphp-centre","specialisms":["Urological surgery","Cytoreductive nephrectomy","Renal cell carcinoma"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mejean%20A%5BAuthor%5D%20CARMENA"}],"papers":[{"title":"Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma (CARMENA)","journal":"NEJM","year":2018,"doi":"10.1056/NEJMoa1803675"},{"title":"Cytoreductive nephrectomy in metastatic renal cancer: update on the CARMENA trial","journal":"European Urology","year":2021}]},{"id":"arthur-violante-sapia","kind":"person","name":"Arthur Violante Sapia","aka":[],"tldr":"Executive Director of ICESP, the São Paulo state cancer institute of the Hospital das Clínicas that treats public-system patients across four units.","summary":"Dr Arthur Violante Sapia is Diretor Executivo of the Instituto do Câncer do Estado de São Paulo Octavio Frias de Oliveira (ICESP), the cancer institute inaugurated in May 2008 as a unit of the Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo and managed by the Fundação Faculdade de Medicina as a social health organisation. ICESP serves the public SUS system exclusively and, as of February 2026, operated four units with 520 beds, about 5,900 staff and contractors and more than 40,000 active patients. Its leadership page lists Professor William Carlos Nahas as President of the Conselho Diretor, Denise Barbosa Henriques Kerr as deputy executive director and Professor Maria Del Pilar Estevez Diz as Director of the clinical staff.","asOf":"2026-09-10","links":[{"label":"Source: ICESP Conselho Diretor e Diretorias page","url":"https://icesp.org.br/conselho-diretor-e-diretorias/"},{"label":"Source: ICESP institutional overview","url":"https://icesp.org.br/o-icesp/"}],"tags":["leadership","hospital-management","comprehensive-cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["icesp"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Diretor Executivo (Executive Director), Instituto do Câncer do Estado de São Paulo (ICESP)","institutionId":"icesp","specialisms":["Hospital management","Public oncology services"],"profiles":[{"label":"ICESP board and directorates page","url":"https://icesp.org.br/conselho-diretor-e-diretorias/"}],"papers":[]},{"id":"arto-mannermaa","kind":"person","name":"Arto Mannermaa","aka":[],"tldr":"Arto Mannermaa represents Kuopio University Hospital Cancer Center in the Organisation of European Cancer Institutes, which lists the centre among its members in Finland.","summary":"Arto Mannermaa is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Kuopio University Hospital Cancer Center, its full member in Finland. OnCo records the name from the OECI membership list so that the centre's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the institution's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Kuopio University Hospital Cancer Center website","url":"https://www.pshyvinvointialue.fi"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["kuopio-university-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Kuopio University Hospital Cancer Center to the Organisation of European Cancer Institutes","institutionId":"kuopio-university-hospital","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Kuopio University Hospital Cancer Center website","url":"https://www.pshyvinvointialue.fi"}],"papers":[{"title":"FinnGen provides genetic insights from a well-phenotyped isolated population","journal":"Nature","year":2023,"url":"https://doi.org/10.1038/s41586-022-05473-8","doi":"10.1038/s41586-022-05473-8","note":"Europe PMC author record matched by affiliation"},{"title":"New insights into the genetic etiology of Alzheimer's disease and related dementias","journal":"Nat Genet","year":2022,"url":"https://doi.org/10.1038/s41588-022-01024-z","doi":"10.1038/s41588-022-01024-z","note":"Europe PMC author record matched by affiliation"},{"title":"Genome-wide association study identifies novel breast cancer susceptibility loci","journal":"Nature","year":2007,"url":"https://doi.org/10.1038/nature05887","doi":"10.1038/nature05887","note":"Europe PMC author record matched by affiliation"}]},{"id":"katz-artur","kind":"person","name":"Artur Katz","aka":[],"tldr":"Artur Katz is a senior São Paulo oncologist and long-time leader of the Sírio-Libanês oncology centre.","summary":"Artur Katz is a medical oncologist at the Oncology Center of Hospital Sírio-Libanês in São Paulo, where he has long led the oncology centre. He specialises in breast cancer, medical oncology and clinical trials, taking part in Brazilian and international breast cancer studies and cooperative groups. His publications include a review of survival endpoints across recent randomised trials in advanced breast cancer and a report of real-world outcomes for patients with HR-positive, HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors at a Brazilian reference centre. He remains one of the senior figures in Brazilian breast oncology.","asOf":"2026-09-08","links":[{"label":"Hospital Sírio-Libanês","url":"https://www.hospitalsiriolibanes.org.br"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Katz%20A%5BAuthor%5D%20Sirio-Libanes%20oncology"}],"tags":[],"related":[],"cancers":["breast-hr-positive"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["sirio-libanes"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["cancer-treatment-and-research-communications"],"dependsOn":[],"notes":[],"role":"Medical oncologist; Oncology Center, Hospital Sírio-Libanês","institutionId":"sirio-libanes","specialisms":["Breast cancer","Medical oncology","Clinical trials"],"profiles":[{"label":"Hospital Sírio-Libanês","url":"https://www.hospitalsiriolibanes.org.br"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Katz%20A%5BAuthor%5D%20Sirio-Libanes%20oncology"}],"papers":[{"title":"Overall Survival and Post-Progression Survival in Advanced Breast Cancer: A Review of Recent Randomized Clinical Trials","journal":"Journal of Clinical Oncology","year":2010,"doi":"10.1200/jco.2009.25.5414"},{"title":"Real-world treatment outcomes in HR+ HER2- metastatic breast cancer patients treated with CDK4/6 inhibitors: Results from a reference center in Brazil","journal":"Cancer Treatment and Research Communications","year":2023,"doi":"10.1016/j.ctarc.2023.100683"}]},{"id":"arul-chinnaiyan","kind":"person","name":"Arul M. Chinnaiyan","aka":[],"tldr":"Discovered the TMPRSS2-ERG fusion in prostate cancer and built one of the first clinical sequencing programmes.","summary":"Arul M. Chinnaiyan is Director of the Michigan Center for Translational Pathology, S.P. Hicks Professor of Pathology and an HHMI Investigator at the University of Michigan Rogel Cancer Center. He is a pathologist-scientist known for discovering the TMPRSS2-ERG gene fusion in prostate cancer in 2005 and for building one of the first clinical sequencing programmes, MI-ONCOSEQ. His selected papers report recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer, and integrative clinical genomics of advanced prostate cancer. He continues to work on comprehensive genomic profiling, long non-coding RNA and urine-based prostate cancer diagnostics.","asOf":"2026-09-08","links":[{"label":"Michigan profile","url":"https://www.pathology.med.umich.edu/faculty/arul"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chinnaiyan%20AM%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["prostate"],"sections":[],"technologies":["cgp","rna-seq"],"targets":[],"drugs":[],"companies":[],"institutions":["michigan-rogel"],"pathways":[],"terms":["gene-fusion"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Michigan Center for Translational Pathology; S.P. Hicks Professor of Pathology; HHMI Investigator","institutionId":"michigan-rogel","specialisms":["Prostate cancer genomics","Gene fusions","Precision oncology sequencing","Long non-coding RNA"],"profiles":[{"label":"Michigan profile","url":"https://www.pathology.med.umich.edu/faculty/arul"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chinnaiyan%20AM%5BAuthor%5D"}],"papers":[{"title":"Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer","journal":"Science","year":2005,"url":"https://doi.org/10.1126/science.1117679","doi":"10.1126/science.1117679"},{"title":"Integrative clinical genomics of advanced prostate cancer","journal":"Cell","year":2015,"url":"https://doi.org/10.1016/j.cell.2015.05.001","doi":"10.1016/j.cell.2015.05.001"}],"orcid":"0000-0001-9282-3415"},{"id":"asem-mansour","kind":"person","name":"Asem Mansour","aka":[],"tldr":"Radiologist who leads the King Hussein Cancer Center in Amman, the leading comprehensive cancer centre in Jordan and the region.","summary":"Asem Mansour is CEO and Director General of the King Hussein Cancer Center (KHCC) in Amman, Jordan. A diagnostic radiologist, he has overseen the centre's expansion into a Joint Commission-accredited comprehensive cancer centre treating adults and children from Jordan and neighbouring countries, and its growing clinical research and training activities.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mansour+A%5BAuthor%5D+King+Hussein+Cancer+Center"}],"tags":["leadership","cancer centre management","global oncology"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["khcc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["hematology-oncology-and-stem-cell-therapy"],"dependsOn":[],"notes":[],"role":"CEO and Director General","institutionId":"khcc","specialisms":["Radiology","Cancer centre leadership","Oncology services in the Middle East"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mansour+A%5BAuthor%5D+King+Hussein+Cancer+Center"}],"papers":[{"title":"Oncology Medical Training and Practice: Managing Jordan’s Brain Drain Through Brain Train—The King Hussein Cancer Center Experience","journal":"JCO Global Oncology","year":2020,"doi":"10.1200/go.20.00141"},{"title":"Cancer care in Jordan","journal":"Hematology/Oncology and Stem Cell Therapy","year":2015,"doi":"10.1016/j.hemonc.2015.02.001"},{"title":"Burden of Cancer Among Syrian Refugees in Jordan","journal":"Journal of Global Oncology","year":2018,"doi":"10.1200/jgo.18.00132"}]},{"id":"ash-alizadeh","kind":"person","name":"Ash A. Alizadeh","aka":[],"tldr":"Co-invented the CAPP-Seq method for reading tumour DNA in blood and used it to track lymphoma and lung cancer.","summary":"Ash Alizadeh is Professor of Medicine (Oncology) at Stanford University, within the Stanford Cancer Institute. An oncologist and computational biologist, he co-developed CAPP-Seq and phased variant enrichment for ultrasensitive circulating tumour DNA detection, applied to minimal residual disease in lymphoma and lung cancer, and led early work on tumour cell-of-origin classification in diffuse large B-cell lymphoma. His papers include a Nature Medicine report of an ultrasensitive method for quantitating circulating tumour DNA with broad patient coverage and the Nature paper identifying distinct types of diffuse large B-cell lymphoma by gene expression profiling. He continues to work on liquid biopsy and molecular residual disease testing.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Ash_Alizadeh","links":[{"label":"Stanford profile","url":"https://profiles.stanford.edu/search?q=Ash%20A.%20Alizadeh"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Alizadeh%20AA%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Ash%20A.%20Alizadeh"}],"tags":[],"related":[],"cancers":["dlbcl","nsclc"],"sections":[],"technologies":["liquid-biopsy","mrd-testing"],"targets":[],"drugs":[],"companies":[],"institutions":["stanford"],"pathways":[],"terms":["ctdna","mrd"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medicine (Oncology), Stanford University","institutionId":"stanford","specialisms":["Circulating tumour DNA","Lymphoma","Computational oncology"],"profiles":[{"label":"Stanford profile","url":"https://profiles.stanford.edu/search?q=Ash%20A.%20Alizadeh"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Alizadeh%20AA%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Ash%20A.%20Alizadeh"}],"papers":[{"title":"An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage","journal":"Nature Medicine","year":2014,"url":"https://doi.org/10.1038/nm.3519","doi":"10.1038/nm.3519"},{"title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","journal":"Nature","year":2000,"url":"https://doi.org/10.1038/35000501","doi":"10.1038/35000501"}],"orcid":"0000-0002-5153-5625"},{"id":"ashish-kamat","kind":"person","name":"Ashish M. Kamat","aka":[],"tldr":"Urologist who set the definitions for BCG-unresponsive bladder cancer and leads the International Bladder Cancer Group.","summary":"Ashish Kamat led the consensus that defined BCG-unresponsive non-muscle-invasive bladder cancer and the trial endpoints now used by regulators, and has led studies of BCG dosing, intravesical therapy and urinary biomarkers. He is president of the International Bladder Cancer Group and a senior author of the Lancet seminar on bladder cancer. His work shapes the entire non-muscle-invasive trial landscape.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kamat%20AM%5BAuthor%5D%20bladder%20BCG"}],"tags":["urothelial","surgery","bcg"],"related":[],"cancers":["urothelial"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Urology and Cancer Biology, MD Anderson Cancer Center","institutionId":"md-anderson","specialisms":["Non-muscle-invasive bladder cancer","BCG immunotherapy","Urologic oncology","Trial design standards"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kamat%20AM%5BAuthor%5D%20bladder%20BCG"}],"papers":[{"title":"Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group","journal":"JCO","year":2016,"doi":"10.1200/JCO.2015.64.4070"},{"title":"Bladder cancer","journal":"Lancet","year":2016,"doi":"10.1016/S0140-6736(16)30512-8"}],"orcid":"0000-0003-3546-9928"},{"id":"ashley-ball-gamble","kind":"person","name":"Ashley Ball-Gamble","aka":[],"tldr":"Chief executive of CCLG, the UK charity and professional body that unites the children's and young people's cancer community.","summary":"Ashley Ball-Gamble is Chief Executive Officer of the Children's Cancer and Leukaemia Group (CCLG), a registered charity founded nearly 50 years ago that brings together professionals working in children's and young people's cancer to drive collective action and research. The executive team also includes Claire Shinfield (Director of Engagement) and Chief Nurses Jeanette Hawkins and Jo Stark. The charity's Chair is Dr Sara Stoneham, a consultant paediatric and teenage and young adult oncologist at University College London Hospital, and David Oxnam chairs the Board of Trustees.","asOf":"2026-09-10","links":[{"label":"Source: CCLG executive members page","url":"https://www.cclg.org.uk/about-us/our-team/our-executive-members"}],"tags":["leadership","paediatric-oncology","charity"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["cclg"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive Officer of the Children's Cancer and Leukaemia Group","institutionId":"cclg","specialisms":["Childhood cancer","Charity leadership","Professional membership organisations"],"profiles":[{"label":"Institution executive members page","url":"https://www.cclg.org.uk/about-us/our-team/our-executive-members"}],"papers":[{"title":"The Childhood Cancer Diagnosis (CCD) Study: a UK observational study to describe referral pathways and quantify diagnostic intervals in children and young people with cancer","journal":"BMJ Open","year":2022,"doi":"10.1136/bmjopen-2021-058744"},{"title":"Clinical presentation of bone tumours in children and young people: a systematic review and meta-analysis","journal":"Archives of Disease in Childhood","year":2025,"doi":"10.1136/archdischild-2024-327879"},{"title":"Research priorities for children’s cancer: a James Lind Alliance Priority Setting Partnership in the UK","journal":"BMJ Open","year":2023,"doi":"10.1136/bmjopen-2023-077387"}]},{"id":"ashya-king","kind":"person","name":"Ashya King","aka":[],"tldr":"In 2014 his parents took him from a British hospital to seek proton beam therapy for a brain tumour abroad, were arrested, then vindicated. The case sped the building of NHS proton centres.","summary":"Ashya King was five when he had surgery for medulloblastoma at Southampton General Hospital in 2014. His parents, Brett and Naghemeh King, disagreed with the plan for conventional radiotherapy and, in August 2014, took him out of the hospital to seek proton beam therapy, which the NHS was not then providing in the UK for his tumour type. A European arrest warrant led to their detention in Spain and a court fight; the warrant was withdrawn amid public outcry, and the NHS agreed to fund treatment at the Proton Therapy Center in Prague. His family later said he was cancer-free. The case brought the debate about parental choice and evidence into the open, and the first NHS high-energy proton centres opened at The Christie in Manchester in 2018 and at University College Hospital, London, in 2021. Because Ashya is a private individual, this record covers the public case only.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Ashya_King_case","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Ashya_King_case"}],"tags":["hero","patient"],"related":[],"cancers":["medulloblastoma"],"sections":[],"technologies":["proton-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":["the-christie"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-patient-voice","b-knowledge-diffusion","b-surgery-radiation-innovation"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Child whose family's fight for proton therapy changed access in Britain","specialisms":["Medulloblastoma","Proton therapy","Patient and family choice"],"profiles":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Ashya_King_case"}],"papers":[]},{"id":"assia-konsoulova","kind":"person","name":"Assia Konsoulova","aka":[],"tldr":"Assia Konsoulova represents Bulgarian Joint Cancer Network (BJCN) in the Organisation of European Cancer Institutes, which lists the organisation among its members in Bulgaria.","summary":"Assia Konsoulova is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Bulgarian Joint Cancer Network (BJCN), its associate member in Bulgaria. OnCo records the name from the OECI membership list so that the organisation's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the organisation's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Bulgarian Joint Cancer Network (BJCN) website","url":"https://bjcn.bg/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["bjcn"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Bulgarian Joint Cancer Network (BJCN) to the Organisation of European Cancer Institutes","institutionId":"bjcn","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Bulgarian Joint Cancer Network (BJCN) website","url":"https://bjcn.bg/"}],"papers":[{"title":"Teenagers and young adults with cancer in Europe: from national programmes to a European integrated coordinated project","journal":"Eur J Cancer Care (Engl)","year":2016,"url":"https://doi.org/10.1111/ecc.12365","doi":"10.1111/ecc.12365","note":"Europe PMC author record matched by affiliation"},{"title":"Small cell lung cancer and neuroendocrine tumours","journal":"Breathe (Sheff)","year":2024,"url":"https://doi.org/10.1183/20734735.0004-2024","doi":"10.1183/20734735.0004-2024","note":"Europe PMC author record matched by affiliation"},{"title":"ERS statement on harmonised standards for lung cancer registration and lung cancer services in Europe","journal":"Eur Respir J","year":2018,"url":"https://doi.org/10.1183/13993003.00610-2018","doi":"10.1183/13993003.00610-2018","note":"Europe PMC author record matched by affiliation"}]},{"id":"astrid-beiglbock","kind":"person","name":"Astrid Beiglböck","aka":[],"tldr":"Executive Director of the Tumour Centre at University Hospital Basel, coordinating the hospital's organ-specific cancer centres.","summary":"Astrid Beiglböck leads the medical centres of Universitätsspital Basel and is Executive Director (Geschäftsführerin) of its Tumour Centre. The Tumour Centre brings together the hospital's organ-specific tumour centres, clinics and specialised nursing under a joint management committee to deliver interdisciplinary cancer care. Her role is listed on the Tumour Centre's web page.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.unispital-basel.ch/en/tumorzentrum"}],"tags":["leadership","cancer centre management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["usb-basel"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Head of Medical Centres and Executive Director, Tumour Centre","institutionId":"usb-basel","specialisms":["Cancer centre management","Interdisciplinary oncology"],"profiles":[{"label":"Institution profile","url":"https://www.unispital-basel.ch/en/tumorzentrum"}],"papers":[]},{"id":"ate-van-der-zee","kind":"person","name":"Ate van der Zee","aka":[],"tldr":"Professor who chairs the executive board of University Medical Center Groningen, the academic hospital in the northern Netherlands that houses the UMCG Comprehensive Cancer Center.","summary":"Professor Ate van der Zee leads University Medical Center Groningen (UMCG) as voorzitter of its Raad van Bestuur, the executive board of the academic hospital of the University of Groningen. UMCG is one of the eight Dutch university medical centres and includes the UMCG Comprehensive Cancer Center, which brings together its cancer care and cancer research. The Dutch Wikipedia article on UMCG names him as board chair; it does not name a separate head for the cancer centre.","asOf":"2026-09-10","links":[{"label":"Source: Dutch Wikipedia article on UMCG naming the board chair","url":"https://nl.wikipedia.org/wiki/Universitair_Medisch_Centrum_Groningen"}],"tags":["leadership","hospital-management","comprehensive-cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["umcg-groningen"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["jco","gynecologic-oncology","international-journal-of-gynecological-cancer"],"dependsOn":[],"notes":[],"role":"Chair of the Executive Board (voorzitter Raad van Bestuur), University Medical Center Groningen","institutionId":"umcg-groningen","specialisms":["Academic hospital governance","Hospital management"],"profiles":[{"label":"Wikipedia: Universitair Medisch Centrum Groningen (Dutch)","url":"https://nl.wikipedia.org/wiki/Universitair_Medisch_Centrum_Groningen"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=van+der+Zee+AGJ%5BAuthor%5D"}],"papers":[{"title":"Sentinel Node Dissection Is Safe in the Treatment of Early-Stage Vulvar Cancer","journal":"Journal of Clinical Oncology","year":2008,"doi":"10.1200/jco.2007.14.0566"},{"title":"Sentinel nodes in vulvar cancer: Long-term follow-up of the GROningen INternational Study on Sentinel nodes in Vulvar cancer (GROINSS-V) I","journal":"Gynecologic Oncology","year":2016,"doi":"10.1016/j.ygyno.2015.09.077"},{"title":"European Society of Gynaecological Oncology Guidelines for the Management of Patients with Vulvar Cancer - Update 2023","journal":"International Journal of Gynecological Cancer","year":2023,"doi":"10.1136/ijgc-2023-004486"}]},{"id":"atiporn-ingsathit","kind":"person","name":"Atiporn Ingsathit","aka":[],"tldr":"Physician who directs Ramathibodi Hospital, the university hospital of the Faculty of Medicine Ramathibodi Hospital at Mahidol University in Bangkok.","summary":"Professor Atiporn Ingsathit, MD, PhD, is Director of Ramathibodi Hospital, the teaching hospital of the Faculty of Medicine Ramathibodi Hospital, Mahidol University, in Bangkok. She serves on the faculty's administrative team under Dean Clinical Professor Artit Ungkanont. Her research includes a single-centre, population-controlled retrospective cohort study of the incidence of new malignancies after kidney transplantation in Thai adult recipients at the highest-volume kidney transplant centre in Thailand, published in Transplant International. She combines hospital leadership with clinical and academic medicine.","asOf":"2026-09-10","links":[{"label":"Source: Ramathibodi administrative team page","url":"https://www.rama.mahidol.ac.th/en/aboutus/administrative-team"}],"tags":["leadership","clinician-scientist","university-hospital"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ramathibodi-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director of Ramathibodi Hospital","institutionId":"ramathibodi-hospital","specialisms":["Hospital leadership","Clinical medicine","Academic medicine"],"profiles":[{"label":"Ramathibodi administrative team","url":"https://www.rama.mahidol.ac.th/en/aboutus/administrative-team"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ingsathit+A%5BAuthor%5D"}],"papers":[{"title":"Incidence of De Novo Post-Transplant Malignancies in Thai Adult Kidney Transplant Recipients: A Single-Center, Population-Controlled, Retrospective Cohort Study at the Highest Volume Kidney Transplant Center in Thailand","journal":"Transplant International","year":2024,"doi":"10.3389/ti.2024.11614"}]},{"id":"audre-lorde","kind":"person","name":"Audre Lorde","aka":[],"tldr":"After a mastectomy in 1978 she wrote The Cancer Journals, refusing a prosthesis and the expectation that women hide their cancer. The book became a founding text of patient writing.","summary":"Audre Lorde (1934-1992), poet and essayist, had a mastectomy for breast cancer in 1978. The Cancer Journals (1980) drew on her diaries to examine fear, mortality, the pressure to wear a prosthesis and look as if nothing had happened, and the particular experience of a Black lesbian woman in the medical system. She declined a prosthesis and argued that visible survivors mattered to one another. She was diagnosed with liver cancer in 1984 and wrote about it in A Burst of Light (1988), including her choice of care in Europe. She died in St Croix on 17 November 1992 at 58. Her work is taught in medical humanities and remains a reference for patient voice and for health disparities.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Audre_Lorde","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Audre_Lorde"},{"label":"Poetry Foundation","url":"https://www.poetryfoundation.org/poets/audre-lorde"}],"tags":["hero","patient","advocate"],"related":[],"cancers":["hcc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["cancer-health-disparities"],"trials":[],"people":[],"bottlenecks":["b-patient-voice","b-trial-diversity"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Poet whose Cancer Journals reframed illness, prosthesis and silence","specialisms":["Breast cancer","Patient narrative","Health equity"],"profiles":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Audre_Lorde"},{"label":"Poetry Foundation","url":"https://www.poetryfoundation.org/poets/audre-lorde"}],"papers":[]},{"id":"audrius-simaitis","kind":"person","name":"Audrius Šimaitis","aka":[],"tldr":"Audrius Šimaitis represents Klaipėda University Hospital in the Organisation of European Cancer Institutes, which lists the centre among its members in Lithuania.","summary":"Audrius Šimaitis is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Klaipėda University Hospital, its member in Lithuania. Klaipėda University Hospital is the main hospital of western Lithuania and a full member of the Organisation of European Cancer Institutes. OnCo records the name from the OECI membership list so that the centre's page has a named contact point; the person's exact title, appointment date and biography are not yet recorded and should be checked on the institution's own pages before being relied on.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Klaipėda University Hospital website","url":"https://www.kul.lt/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["klaipeda-university-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Klaipėda University Hospital to the Organisation of European Cancer Institutes","institutionId":"klaipeda-university-hospital","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Klaipėda University Hospital website","url":"https://www.kul.lt/"}],"papers":[]},{"id":"aurelien-marabelle","kind":"person","name":"Aurélien Marabelle","aka":[],"tldr":"Aurélien Marabelle is the immunotherapy investigator behind the tumour-agnostic pembrolizumab data in MSI-high cancers.","summary":"Aurélien Marabelle is Clinical Director of the Cancer Immunotherapy Program (DITEP) at Gustave Roussy. His specialisms are immuno-oncology, early-phase immunotherapy, MSI-high tumours and intratumoural therapy, with a focus on PD-1 and immune checkpoint inhibitors. He was lead author of the KEYNOTE-158 analysis in the Journal of Clinical Oncology, which reported the efficacy of pembrolizumab in non-colorectal cancers with high microsatellite instability or mismatch repair deficiency and supported the drug's tumour-agnostic approvals. He now leads early-phase immunotherapy trials at DITEP and works on delivering immunotherapy directly into tumours. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Marabelle%20A%5BAuthor%5D%20pembrolizumab"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["pd1"],"drugs":["pembrolizumab"],"companies":[],"institutions":["gustave-roussy"],"pathways":[],"terms":["msi","tmb"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Clinical Director, Cancer Immunotherapy Program (DITEP), Gustave Roussy","institutionId":"gustave-roussy","specialisms":["Immuno-oncology","Early-phase immunotherapy","MSI-high tumours","Intratumoural therapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Marabelle%20A%5BAuthor%5D%20pembrolizumab"}],"papers":[{"title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer (KEYNOTE-158)","journal":"JCO","year":2020,"doi":"10.1200/JCO.19.02105"}],"orcid":"0000-0002-5816-3019"},{"id":"avram-hershko","kind":"person","name":"Avram Hershko","aka":[],"tldr":"Shared the 2004 Nobel Prize in Chemistry for the discovery of ubiquitin-mediated protein degradation, and still works on how the machinery that destroys proteins controls cell division.","summary":"Avram Hershko, with his then doctoral student Aaron Ciechanover and with Irwin Rose, showed in the late 1970s and early 1980s that cells destroy proteins in an energy-dependent, highly selective way by tagging them with ubiquitin. The three shared the 2004 Nobel Prize in Chemistry, one third each. Hershko's later work, still published from the Department of Biochemistry at the Technion's Rappaport Faculty of Medicine, is on the anaphase-promoting complex and the mitotic checkpoint: how the ubiquitylation of Cdc20 is controlled, how the mitotic checkpoint complex is disassembled, and therefore how a cell decides it is safe to divide. That is the biology every mitotic checkpoint and APC/C-directed drug programme rests on.","asOf":"2026-09-25","wikipedia":"https://en.wikipedia.org/wiki/Avram_Hershko","links":[{"label":"Technion","url":"https://www.technion.ac.il/en/"},{"label":"Nobel Prize in Chemistry 2004","url":"https://api.nobelprize.org/2.1/nobelPrize/che/2004"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hershko%20A%5BAuthor%5D%20ubiquitin"}],"tags":["scientist","nobel-laureate","cancer-biology"],"related":[],"cancers":[],"sections":["drug-discovery"],"technologies":["protac-degrader"],"targets":[],"drugs":["bortezomib"],"companies":[],"institutions":["technion"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Distinguished Professor, Department of Biochemistry, Rappaport Faculty of Medicine, Technion","institutionId":"technion","specialisms":["Ubiquitin-proteasome system","Cell cycle regulation","Anaphase-promoting complex","Biochemistry"],"profiles":[{"label":"Technion","url":"https://www.technion.ac.il/en/"},{"label":"Nobel Prize in Chemistry 2004","url":"https://api.nobelprize.org/2.1/nobelPrize/che/2004"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hershko%20A%5BAuthor%5D%20ubiquitin"}],"papers":[{"title":"Mechanisms of ubiquitylation of the mitotic regulatory protein Cdc20","year":2026,"note":"Department of Biochemistry, Rappaport Faculty of Medicine, Technion; indexed on Europe PMC"},{"title":"Role of ubiquitin-protein ligase UBR5 in the disassembly of mitotic checkpoint complexes","year":2022,"note":"Department of Biochemistry, Rappaport Faculty of Medicine, Technion; indexed on Europe PMC"}]},{"id":"axel-behrens","kind":"person","name":"Axel Behrens","aka":[],"tldr":"Cancer biologist who directs the Cancer Research UK Convergence Science Centre, the joint Institute of Cancer Research and Imperial College London programme bringing engineering and physical sciences into cancer research.","summary":"Axel Behrens is Director of the Cancer Research UK Convergence Science Centre, which Cancer Research UK lists among its funded research centres with The Institute of Cancer Research and Imperial College London as partner institutions. The centre exists to bring together cancer biologists and clinicians with engineers, physical scientists and data scientists. The centre's own website and the ICR pages could not be fetched, so this record relies on the Cancer Research UK centres listing.","asOf":"2026-09-10","links":[{"label":"Source: Cancer Research UK research centres page listing the centre Director","url":"https://www.cancerresearchuk.org/funding-for-researchers/our-research-infrastructure/our-centres"}],"tags":["leadership","clinician-scientist","research-institute"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cruk","icr-london"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Cancer Research UK Convergence Science Centre","institutionId":"cruk-convergence-science-centre","specialisms":["Cancer biology","Convergence science","Research centre leadership"],"profiles":[{"label":"Cancer Research UK: our centres (names the Director)","url":"https://www.cancerresearchuk.org/funding-for-researchers/our-research-infrastructure/our-centres"},{"label":"CRUK Convergence Science Centre website","url":"https://www.convergencesciencecentre.ac.uk/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Behrens+A%5BAuthor%5D+AND+cancer"}],"papers":[{"title":"YAP1 and TAZ Control Pancreatic Cancer Initiation in Mice by Direct Up-regulation of JAK–STAT3 Signaling","journal":"Gastroenterology","year":2016,"doi":"10.1053/j.gastro.2016.05.006"}],"orcid":"0000-0002-1557-1143"},{"id":"ajaikumar-b-s","kind":"person","name":"B. S. Ajaikumar","aka":[],"tldr":"A US-trained oncologist who returned to Bengaluru and built HCG into India's largest specialist cancer hospital chain.","summary":"B. S. Ajaikumar founded HealthCare Global Enterprises in Bengaluru and grew it into a network of comprehensive cancer centres across India and Africa, bringing technologies such as robotic radiosurgery, hospital cyclotrons and molecular diagnostics into Indian private practice early. He remains executive chairman and a frequent commentator on the economics and organisation of cancer care in India.","asOf":"2026-09-10","links":[{"label":"HCG","url":"https://hcgoncology.com"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ajaikumar%20BS%5BAuthor%5D%20HCG"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["sbrt","cgp"],"targets":[],"drugs":[],"companies":[],"institutions":["hcg"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Executive Chairman and founder, HealthCare Global Enterprises (HCG); radiation and medical oncologist","institutionId":"hcg","specialisms":["Radiation oncology","Cancer hospital networks","Precision oncology","Private-sector cancer care"],"profiles":[{"label":"HCG","url":"https://hcgoncology.com"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ajaikumar%20BS%5BAuthor%5D%20HCG"}],"papers":[{"title":"Landscape of clinically actionable mutations in breast cancer ‘A cohort study’","journal":"Translational Oncology","year":2021,"doi":"10.1016/j.tranon.2020.100877"},{"title":"Role of yoga in cancer patients: Expectations, benefits, and risks: A review","journal":"Indian Journal of Palliative Care","year":2017,"doi":"10.4103/ijpc.ijpc_107_17"},{"title":"The role of radiation therapy in the treatment of small cell undifferentiated bronchogenic cancer","journal":"International Journal of Radiation Oncology*Biology*Physics","year":1979,"doi":"10.1016/0360-3016(79)90603-5"}]},{"id":"barbara-bradfield","kind":"person","name":"Barbara Bradfield","aka":[],"tldr":"In 1992 she was the first patient with recurrent HER2-positive breast cancer to be treated with the antibody that became Herceptin, in Dennis Slamon's trial at UCLA. She became its first long-term survivor.","summary":"Barbara Bradfield had HER2-positive breast cancer that had recurred and spread when, in 1992, Dennis Slamon at UCLA asked her to join the first clinical trial of the humanised anti-HER2 antibody, later trastuzumab. She initially declined further treatment, then agreed; her disease responded and did not return. Her case, told in Robert Bazell's book Her-2 and dramatised in the 2008 film Living Proof, gave the programme evidence at a moment when its future inside Genentech was uncertain. Trastuzumab was approved by the FDA in 1998 for metastatic HER2-positive disease and, after the adjuvant trials of 2005, for early disease, changing a subtype once regarded as among the worst into one of the more treatable. She remained a public voice for the trial participants whose consent made the drug possible.","asOf":"2026-09-09","links":[{"label":"Living Proof (2008 film)","url":"https://en.wikipedia.org/wiki/Living_Proof_(2008_film)"},{"label":"Dennis Slamon (Wikipedia)","url":"https://en.wikipedia.org/wiki/Dennis_Slamon"}],"tags":["hero","patient"],"related":[],"cancers":["breast-her2-positive"],"sections":[],"technologies":["monoclonal-antibody"],"targets":["her2"],"drugs":["trastuzumab"],"companies":[],"institutions":["ucla-jonsson"],"pathways":[],"terms":[],"trials":["hera-b31-n9831"],"people":["dennis-slamon"],"bottlenecks":["b-trial-enrolment","b-translational-valley"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"First long-term survivor of the trastuzumab trials","specialisms":["HER2-positive breast cancer","Clinical trial participation"],"profiles":[{"label":"Living Proof (2008 film)","url":"https://en.wikipedia.org/wiki/Living_Proof_(2008_film)"},{"label":"Dennis Slamon (Wikipedia)","url":"https://en.wikipedia.org/wiki/Dennis_Slamon"}],"papers":[]},{"id":"barbara-burtness","kind":"person","name":"Barbara Burtness","aka":[],"tldr":"Led KEYNOTE-048, which made pembrolizumab first-line therapy for recurrent or metastatic head and neck cancer.","summary":"Barbara Burtness (Yale Cancer Center) was principal investigator of KEYNOTE-048, which showed pembrolizumab alone or with chemotherapy improves survival over the EXTREME regimen in recurrent or metastatic head and neck squamous cell carcinoma, establishing PD-1 blockade first line. She chaired the ECOG-ACRIN head and neck committee for many years and led the early cetuximab trials in the disease.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Barbara_Burtness","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Burtness%20B%5BAuthor%5D%20head%20neck%20pembrolizumab"}],"tags":["head-and-neck","immunotherapy","ecog-acrin"],"related":[],"cancers":["head-and-neck"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["pd1","egfr"],"drugs":["pembrolizumab"],"companies":[],"institutions":["yale-cancer-center"],"pathways":[],"terms":[],"trials":["keynote-048"],"people":[],"bottlenecks":[],"keyPapers":["paper-keynote-048-lancet-2019"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medicine and Co-Leader, Developmental Therapeutics, Yale Cancer Center","institutionId":"yale-cancer-center","specialisms":["Head and neck cancer","Immunotherapy","Cooperative-group trials","HPV-associated cancer"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Burtness%20B%5BAuthor%5D%20head%20neck%20pembrolizumab"}],"papers":[{"title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048)","journal":"Lancet","year":2019,"doi":"10.1016/S0140-6736(19)32591-7"},{"title":"Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study","journal":"JCO","year":2005,"doi":"10.1200/JCO.2005.02.147"},{"title":"KEYNOTE-048: pembrolizumab, alone or with chemotherapy, as first treatment for recurrent or metastatic head and neck cancer","journal":"The Lancet","year":2019,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=KEYNOTE-048+pembrolizumab+head+and+neck+Burtness+Lancet+2019"}],"orcid":"0000-0003-4660-1859"},{"id":"barbara-eichhorst","kind":"person","name":"Barbara Eichhorst","aka":[],"tldr":"Led CLL13 (GAIA), showing venetoclax-based fixed-duration therapy beats chemoimmunotherapy in fit CLL patients.","summary":"Barbara Eichhorst was principal investigator of CLL13/GAIA, the trial showing venetoclax plus obinutuzumab, with or without ibrutinib, achieves higher MRD-negativity and longer progression-free survival than FCR or BR in fit patients with untreated CLL, extending fixed-duration therapy to the fit population. She led CLL10 (FCR versus BR) and chairs the ESMO CLL guidelines.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Eichhorst%20B%5BAuthor%5D%20chronic%20lymphocytic%20leukemia"}],"tags":["cll","venetoclax","guidelines"],"related":[],"cancers":["cll"],"sections":[],"technologies":["mrd-testing"],"targets":["bcl2","cd20"],"drugs":["venetoclax"],"companies":[],"institutions":["uniklinik-koeln"],"pathways":[],"terms":[],"trials":["cll13-gaia"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medicine and Head of the CLL Outpatient Clinic, University Hospital Cologne; Secretary, German CLL Study Group","institutionId":"uniklinik-koeln","specialisms":["Chronic lymphocytic leukaemia","Time-limited combinations","Chemoimmunotherapy","Guidelines"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Eichhorst%20B%5BAuthor%5D%20chronic%20lymphocytic%20leukemia"}],"papers":[{"title":"First-line venetoclax combinations in chronic lymphocytic leukemia (CLL13/GAIA)","journal":"NEJM","year":2023,"doi":"10.1056/NEJMoa2213093"},{"title":"First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10)","journal":"Lancet Oncology","year":2016,"doi":"10.1016/S1470-2045(16)30051-1"}]},{"id":"barbara-jereczek-fossa","kind":"person","name":"Barbara Jereczek-Fossa","aka":[],"tldr":"Milan radiation oncologist leading ESTRO, Europe's radiotherapy and oncology society.","summary":"Barbara Jereczek-Fossa is President of the European Society for Radiotherapy and Oncology (ESTRO). She is a radiation oncologist at the European Institute of Oncology and the University of Milan, where her research covers hypofractionated and stereotactic radiotherapy, particularly for prostate and other genitourinary cancers. As ESTRO President she leads the society's scientific, educational and policy activities across Europe.","asOf":"2026-09-10","links":[{"label":"Society page","url":"https://www.estro.org/About/ESTRO-Organisation-Structure/Board"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Jereczek-Fossa+BA%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","radiotherapy","prostate cancer"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["estro"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President","institutionId":"estro","specialisms":["Radiation oncology","Prostate cancer radiotherapy","Stereotactic radiotherapy"],"profiles":[{"label":"Society page","url":"https://www.estro.org/About/ESTRO-Organisation-Structure/Board"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Jereczek-Fossa+BA%5BAuthor%5D"}],"papers":[{"title":"National societies' needs as assessed by the ESTRO National Societies Committee survey: A European perspective","journal":"Radiotherapy and Oncology","year":2020,"doi":"10.1016/j.radonc.2020.08.001"},{"title":"Establishing a benchmark of diversity, equity, inclusion and workforce engagement in radiation oncology in Europe – An ESTRO collaborative project","journal":"Radiotherapy and Oncology","year":2022,"doi":"10.1016/j.radonc.2022.04.011"},{"title":"The European Prostate Cancer Centres of Excellence: A Novel Proposal from the European Association of Urology Prostate Cancer Centre Consensus Meeting","journal":"European Urology","year":2019,"doi":"10.1016/j.eururo.2019.01.033"}]},{"id":"bas-raaymakers","kind":"person","name":"Bas W. Raaymakers","aka":[],"tldr":"Physicist who invented the MR-linac, letting radiotherapy see and adapt to the tumour in real time.","summary":"Bas Raaymakers conceived and led the development of the integrated MRI and linear accelerator at UMC Utrecht in collaboration with Elekta and Philips, treating the first patients on a high-field MR-linac in 2017 and enabling daily adaptive radiotherapy with soft-tissue visibility. He leads the MR-Linac Consortium's physics programme and works on real-time tumour tracking.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Raaymakers%20BW%5BAuthor%5D%20MR-linac"}],"tags":["radiotherapy","mr-linac","physics"],"related":[],"cancers":[],"sections":[],"technologies":["mr-linac","imrt-igrt"],"targets":[],"drugs":[],"companies":[],"institutions":["umc-utrecht"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Experimental Clinical Physics, UMC Utrecht","institutionId":"umc-utrecht","specialisms":["MR-guided radiotherapy","MR-linac development","Medical physics","Adaptive radiotherapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Raaymakers%20BW%5BAuthor%5D%20MR-linac"}],"papers":[{"title":"First patients treated with a 1.5 T MRI-Linac: clinical proof of concept of a high-precision, high-field MRI guided radiotherapy treatment","journal":"Physics in Medicine and Biology","year":2017,"doi":"10.1088/1361-6560/aa9517"},{"title":"Integrating a 1.5 T MRI scanner with a 6 MV accelerator: proof of concept","journal":"Physics in Medicine and Biology","year":2009,"doi":"10.1088/0031-9155/54/12/N01"}],"orcid":"0000-0002-8036-6808"},{"id":"bayli-divita-dean","kind":"person","name":"Bayli DiVita Dean","aka":[],"tldr":"Bayli DiVita Dean is the scientist and science communicator who runs patient connections at Future of Cancer Care Today; a thirty-minute call with her team is the service's entry point.","summary":"Bayli DiVita Dean developed her expertise in cancer immunotherapy research at the University of Florida and in translating complex science into accessible language at the American Brain Tumor Association before joining FCCT, where she leads patient connections and the calls that patients and families say shift how they think about what is possible.","asOf":"2026-09-10","links":[{"label":"FCCT","url":"https://sijbrandijfoundation.org/fcct"}],"tags":["patient-first"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["future-of-cancer-care-today"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Patient Connections, Future of Cancer Care Today","specialisms":["Cancer immunotherapy","Science communication"],"profiles":[{"label":"FCCT","url":"https://sijbrandijfoundation.org/fcct"}],"papers":[]},{"id":"beata-halassy","kind":"person","name":"Beata Halassy","aka":[],"tldr":"Beata Halassy is a Croatian virologist who grows and characterises viruses, and is the senior author of a 2024 case report of self-experimental oncolytic virotherapy.","summary":"Beata Halassy works at the Centre for Research and Knowledge Transfer in Biotechnology at the University of Zagreb and at the Centre of Excellence for Virus Immunology and Vaccines. Her published work spans virus production and purification, vaccine and antivenom manufacturing and quality, and immunology, with more than seventy works listed on her ORCID record, including studies of snake antivenom pharmacokinetics, virus-like particle vaccine candidates, and the purification of vesicular stomatitis virus.\n\nIn 2024 she was the senior and corresponding author of a case report in Vaccines describing self-experimental neoadjuvant oncolytic virotherapy in recurrent breast cancer, using an Edmonston-Zagreb measles vaccine strain and a vesicular stomatitis virus Indiana strain prepared in her own laboratory. The report is the patient's own published account: she is both an author and the subject, and the paper's ethics statement explains how the case was handled. It became the starting point for a wider argument about whether journals should publish self-experimentation, taken up by bioethicists in the Journal of Medical Ethics in 2026. The case report's own conclusion states that self-medicating with oncolytic viruses should not be a first approach to a diagnosed cancer. She disclosed becoming a consultant to Vyriad in 2021 and a European patent application covering the subject matter.","asOf":"2026-09-25","links":[{"label":"ORCID","url":"https://orcid.org/0000-0001-7370-0997"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Halassy%20B%5BAuthor%5D"},{"label":"University of Zagreb","url":"https://www.unizg.hr/"}],"tags":["virology","oncolytic-virus","croatia"],"related":[],"cancers":["tnbc"],"sections":[],"technologies":["oncolytic-virus"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["dubravko-forcic"],"bottlenecks":[],"keyPapers":["paper-halassy-self-experiment-ovt-vaccines-2024","paper-pugh-self-experimentation-publication-jme-2026"],"journals":[],"dependsOn":[],"notes":[],"role":"Virologist, Centre for Research and Knowledge Transfer in Biotechnology, University of Zagreb; Centre of Excellence for Virus Immunology and Vaccines, Zagreb","specialisms":["Virology","Vaccine and antivenom production","Oncolytic virotherapy","Bioprocess development"],"profiles":[{"label":"ORCID","url":"https://orcid.org/0000-0001-7370-0997"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Halassy%20B%5BAuthor%5D"},{"label":"University of Zagreb","url":"https://www.unizg.hr/"}],"papers":[{"title":"An unconventional case study of neoadjuvant oncolytic virotherapy for recurrent breast cancer","journal":"Vaccines","year":2024,"doi":"10.3390/vaccines12090958"},{"title":"Native elution immunoaffinity chromatography for the efficient purification of vesicular stomatitis virus","journal":"Journal of Chromatography A","year":2026,"doi":"10.1016/j.chroma.2026.467294"},{"title":"Production- and purification-relevant properties of human and murine cytomegalovirus","journal":"Viruses","year":2021,"doi":"10.3390/v13122481"}],"orcid":"0000-0001-7370-0997"},{"id":"beata-jagielska","kind":"person","name":"Beata Jagielska","aka":[],"tldr":"Clinical oncologist who directs Poland's national cancer institute, the Maria Skłodowska-Curie National Research Institute of Oncology in Warsaw.","summary":"Beata Jagielska is Director of the Maria Skłodowska-Curie National Research Institute of Oncology (NIO-PIB) in Warsaw, Poland's national cancer research institute and largest oncology hospital. A specialist in internal medicine, chemotherapy and clinical oncology, she has been associated with the institute for three decades. Her appointment is listed on the institute's management page.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://nio.gov.pl/dyrekcja-instytutu"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Jagielska+B%5BAuthor%5D"}],"tags":["leadership","clinical oncology"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["nio-warsaw"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["journal-of-cancer-research-and-clinical-oncology"],"dependsOn":[],"notes":[],"role":"Director","institutionId":"nio-warsaw","specialisms":["Clinical oncology","Chemotherapy","Internal medicine"],"profiles":[{"label":"Institution profile","url":"https://nio.gov.pl/dyrekcja-instytutu"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Jagielska+B%5BAuthor%5D"}],"papers":[{"title":"Cardio-oncology: the Polish National Oncology Network model","journal":"European Heart Journal","year":2026,"doi":"10.1093/eurheartj/ehag077"},{"title":"The impact of changing the funding model for genetic diagnostics and improved access to personalized medicine in oncology","journal":"Expert Review of Pharmacoeconomics & Outcomes Research","year":2022,"doi":"10.1080/14737167.2023.2140139"},{"title":"Advanced adenoid cystic carcinoma (ACC) is featured by SWI/SNF chromatin remodeling complex aberrations","journal":"Journal of Cancer Research and Clinical Oncology","year":2018,"doi":"10.1007/s00432-018-2783-5"}]},{"id":"beatriz-castelo","kind":"person","name":"Beatriz Castelo","aka":[],"tldr":"Beatriz Castelo is a medical oncologist in the head and neck programme at La Paz.","summary":"Beatriz Castelo is a medical oncologist at Hospital Universitario La Paz in Madrid, where she treats and researches head and neck squamous cell carcinoma within the medical oncology department. Her specialisms are head and neck cancer and medical oncology. Her papers include the first Spanish Society for Head and Neck Cancer expert consensus on multidisciplinary management of head and neck cancer, developed using Delphi methodology, a Clinical Cancer Research study using whole-exome sequencing to find CYP3A4 variants that predict paclitaxel dose-limiting neuropathy, and a qualitative journey-map study of breast cancer patient experiences. Her publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Castelo%20B%5BAuthor%5D%20head%20and%20neck"}],"tags":[],"related":[],"cancers":["head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["la-paz"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["oral-oncology"],"dependsOn":[],"notes":[],"role":"Medical Oncologist, Hospital Universitario La Paz","institutionId":"la-paz","specialisms":["Head and neck cancer","Medical oncology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Castelo%20B%5BAuthor%5D%20head%20and%20neck"}],"papers":[{"title":"Multidisciplinary management of head and neck cancer: First expert consensus using Delphi methodology from the Spanish Society for Head and Neck Cancer (part 1)","journal":"Oral Oncology","year":2017,"doi":"10.1016/j.oraloncology.2017.04.004"},{"title":"Whole-Exome Sequencing Reveals Defective CYP3A4 Variants Predictive of Paclitaxel Dose-Limiting Neuropathy","journal":"Clinical Cancer Research","year":2015,"doi":"10.1158/1078-0432.ccr-14-1758"},{"title":"Breast cancer patient experiences through a journey map: A qualitative study","journal":"PLOS ONE","year":2021,"doi":"10.1371/journal.pone.0257680"}]},{"id":"behnam-badie","kind":"person","name":"Behnam Badie","aka":[],"tldr":"Neurosurgeon who delivers CAR-T cells directly into the brain in City of Hope's glioma trials.","summary":"Behnam Badie is Chief of the Division of Neurosurgery at City of Hope. A neurosurgeon-scientist specialising in neurosurgical oncology and glioma, he co-leads City of Hope's brain tumour CAR-T programme and is responsible for intracranial and intraventricular delivery of CAR-T cells in the IL13Rα2 trials. His papers include a Clinical Cancer Research report on the bioactivity and safety of IL13Rα2-redirected CAR CD8+ T cells in recurrent glioblastoma and the New England Journal of Medicine case of regression of glioblastoma after CAR T-cell therapy. His work also covers fluorescence-guided surgery for glioma and glioblastoma.","asOf":"2026-09-08","links":[{"label":"City of Hope research faculty","url":"https://www.cityofhope.org/research/find-a-researcher"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Badie%20B%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Behnam%20Badie"}],"tags":[],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":["car-t","fluorescence-guided-surgery"],"targets":[],"drugs":[],"companies":[],"institutions":["city-of-hope"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief, Division of Neurosurgery, City of Hope","institutionId":"city-of-hope","specialisms":["Neurosurgical oncology","Glioma","CAR-T delivery"],"profiles":[{"label":"City of Hope research faculty","url":"https://www.cityofhope.org/research/find-a-researcher"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Badie%20B%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Behnam%20Badie"}],"papers":[{"title":"Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma","journal":"Clinical Cancer Research","year":2015,"url":"https://doi.org/10.1158/1078-0432.CCR-15-0428","doi":"10.1158/1078-0432.CCR-15-0428"},{"title":"Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy","journal":"New England Journal of Medicine","year":2016,"url":"https://doi.org/10.1056/NEJMoa1610497","doi":"10.1056/NEJMoa1610497"}]},{"id":"ben-o-sullivan","kind":"person","name":"Ben O'Sullivan","aka":[],"tldr":"Ben O'Sullivan represents University Hospital Waterford in the Organisation of European Cancer Institutes, which lists the centre among its members in Ireland.","summary":"Ben O'Sullivan is listed by the Organisation of European Cancer Institutes (OECI) as the representative of University Hospital Waterford, its member in Ireland. University Hospital Waterford is the regional hospital for the south-east of Ireland, run by the Health Service Executive, with a cancer centre providing surgery, medical oncology and radiotherapy, and a full member of the Organisation of European Cancer Institutes. OnCo records the name from the OECI membership list so that the centre's page has a named contact point; the person's exact title, appointment date and biography are not yet recorded and should be checked on the institution's own pages before being relied on.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"University Hospital Waterford website","url":"https://www2.hse.ie/services/hospitals/university-hospital-waterford/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["university-hospital-waterford"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of University Hospital Waterford to the Organisation of European Cancer Institutes","institutionId":"university-hospital-waterford","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"University Hospital Waterford website","url":"https://www2.hse.ie/services/hospitals/university-hospital-waterford/"}],"papers":[]},{"id":"benjamin-besse","kind":"person","name":"Benjamin Besse","aka":[],"tldr":"Benjamin Besse is a lung cancer trialist central to the Dato-DXd and HER3-DXd lung programmes.","summary":"Benjamin Besse is Head of Clinical Research at Gustave Roussy and a thoracic oncologist. His specialisms are thoracic oncology, antibody-drug conjugates in lung cancer and oncogene-driven non-small-cell lung cancer. He is a principal investigator in the TROPION-Lung and HERTHENA-Lung programmes, which test datopotamab deruxtecan and patritumab deruxtecan in lung cancer, and in trials of targeted therapy for oncogene-driven disease. His Journal of Clinical Oncology paper on TROPION-Lung01 compared datopotamab deruxtecan with docetaxel in previously treated advanced or metastatic non-small-cell lung cancer. He is linked to the TROPION-Lung01 and HERTHENA-Lung02 trials, and his publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Besse%20B%5BAuthor%5D%20lung%20deruxtecan"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["datopotamab-deruxtecan","patritumab-deruxtecan"],"companies":[],"institutions":["gustave-roussy"],"pathways":[],"terms":[],"trials":["tropion-lung01","herthena-lung02"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Head of Clinical Research, Gustave Roussy; thoracic oncologist","institutionId":"gustave-roussy","specialisms":["Thoracic oncology","ADCs in lung cancer","Oncogene-driven NSCLC"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Besse%20B%5BAuthor%5D%20lung%20deruxtecan"}],"papers":[{"title":"Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer (TROPION-Lung01)","journal":"JCO","year":2025,"doi":"10.1200/JCO-24-01544"},{"title":"MARIPOSA: amivantamab plus lazertinib versus osimertinib as first treatment for EGFR-mutated lung cancer","journal":"New England Journal of Medicine","year":2024,"url":"https://doi.org/10.1056/NEJMoa2403614","doi":"10.1056/NEJMoa2403614"}],"orcid":"0000-0001-5090-8189"},{"id":"benjamin-kasenda","kind":"person","name":"Benjamin Kasenda","aka":[],"tldr":"Basel haematologist-oncologist who co-led phase 2 trials of high-dose chemotherapy and autologous transplant in primary CNS lymphoma.","summary":"Benjamin Kasenda is a senior physician in internal medicine and haematology/oncology at Universitätsspital Basel, working within the Tumour Centre with a focus on gastrointestinal tumours and lymphoma. He has co-authored prospective phase 2 trials in the Lancet Haematology evaluating high-dose chemotherapy with autologous stem-cell transplantation for primary CNS lymphoma, including in older patients.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.unispital-basel.ch/en/tumorzentrum"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kasenda+B%5BAuthor%5D"}],"tags":["clinician-scientist","lymphoma","haematology"],"related":[],"cancers":["primary-cns-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["usb-basel"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Senior Physician, Medical Oncology and Haematology (Tumour Centre)","institutionId":"usb-basel","specialisms":["Primary CNS lymphoma","Gastrointestinal tumours","Haematology-oncology","Clinical trials"],"profiles":[{"label":"Institution profile","url":"https://www.unispital-basel.ch/en/tumorzentrum"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kasenda+B%5BAuthor%5D"}],"papers":[{"title":"High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial","journal":"Lancet Haematology","year":2016,"url":"https://doi.org/10.1016/S2352-3026(16)30050-3","doi":"10.1016/S2352-3026(16)30050-3"},{"title":"High-dose chemotherapy and autologous haematopoietic stem-cell transplantation in older, fit patients with primary diffuse large B-cell CNS lymphoma (MARTA): a single-arm, phase 2 trial","journal":"Lancet Haematology","year":2024,"url":"https://doi.org/10.1016/S2352-3026(23)00371-X","doi":"10.1016/S2352-3026(23)00371-X"}],"orcid":"0000-0003-0110-8585"},{"id":"benjamin-kile","kind":"person","name":"Benjamin Kile","aka":[],"tldr":"Blood cell molecular biologist who has led Sydney's Garvan Institute of Medical Research since 2023, sharpening its focus on genomics, immunology and cancer.","summary":"Benjamin Kile is Executive Director of the Garvan Institute of Medical Research in Sydney, home of the Kinghorn Cancer Centre run jointly with St Vincent's Hospital, a role he took up in April 2023. Previously Dean of Biomedical Sciences at Monash University, his research on platelet and blood cell biology and cell death has been widely published, and he has refined Garvan's strategy around genomics, immunology and cancer.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kile+BT%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","genomics","haematology"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["garvan-institute"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["science","cell"],"dependsOn":[],"notes":[],"role":"Executive Director","institutionId":"garvan-institute","specialisms":["Blood cell biology","Molecular biology","Research leadership"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kile+BT%5BAuthor%5D"}],"papers":[{"title":"BAK/BAX macropores facilitate mitochondrial herniation and mtDNA efflux during apoptosis","journal":"Science","year":2018,"url":"https://doi.org/10.1126/science.aao6047","doi":"10.1126/science.aao6047","note":"Europe PMC author record matched by affiliation"},{"title":"Apoptotic caspases suppress mtDNA-induced STING-mediated type I IFN production","journal":"Cell","year":2014,"url":"https://doi.org/10.1016/j.cell.2014.11.036","doi":"10.1016/j.cell.2014.11.036","note":"Europe PMC author record matched by affiliation"},{"title":"Programmed anuclear cell death delimits platelet life span","journal":"Cell","year":2007,"url":"https://doi.org/10.1016/j.cell.2007.01.037","doi":"10.1016/j.cell.2007.01.037","note":"Europe PMC author record matched by affiliation"}],"orcid":"0000-0002-8836-8947"},{"id":"benjamin-ebert","kind":"person","name":"Benjamin L. Ebert","aka":[],"tldr":"Discovered how lenalidomide works, launching the field of molecular-glue degraders, and defined clonal haematopoiesis before leading Dana-Farber.","summary":"Benjamin L. Ebert is President and Chief Executive Officer of Dana-Farber Brigham Cancer Center and a haematologist-scientist working on myeloid malignancies and multiple myeloma. He is known for discovering how lenalidomide works, showing that it induces degradation of IKZF1, IKZF3 and CK1 alpha through cereblon, which launched the field of molecular glue degraders. He also defined clonal haematopoiesis of indeterminate potential. His selected papers cover clonal haematopoiesis and blood cancer risk inferred from blood DNA sequence, and lenalidomide's selective degradation of IKZF1 and IKZF3 in myeloma cells. He has led Dana-Farber since 2024 and received the Sjöberg Prize the same year.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Benjamin_L._Ebert","links":[{"label":"Dana-Farber leadership","url":"https://www.dana-farber.org/about/leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ebert%20BL%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["aml","multiple-myeloma"],"sections":[],"technologies":["protac-degrader"],"targets":[],"drugs":["lenalidomide"],"companies":[],"institutions":["dana-farber"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President and Chief Executive Officer","institutionId":"dana-farber","specialisms":["Myeloid malignancies","Clonal haematopoiesis","Molecular glue degraders","Lenalidomide mechanism"],"profiles":[{"label":"Dana-Farber leadership","url":"https://www.dana-farber.org/about/leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ebert%20BL%5BAuthor%5D"}],"papers":[{"title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","journal":"New England Journal of Medicine","year":2014,"url":"https://doi.org/10.1056/NEJMoa1408617","doi":"10.1056/NEJMoa1408617"},{"title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","journal":"Science","year":2014,"url":"https://doi.org/10.1126/science.1244851","doi":"10.1126/science.1244851"}],"orcid":"0000-0003-0197-5451"},{"id":"solomon-benjamin","kind":"person","name":"Benjamin Solomon","aka":[],"tldr":"Principal investigator of CROWN, where lorlatinib produced the longest disease control ever recorded for a targeted lung cancer pill.","summary":"Benjamin Solomon is Professor of Medical Oncology and Head of Lung Medical Oncology at the Peter MacCallum Cancer Centre in Melbourne. He led the PROFILE 1014 and CROWN trials, which established crizotinib and then lorlatinib as treatments for ALK-positive non-small-cell lung cancer, and CROWN produced the longest disease control recorded for a targeted lung cancer pill. His publications include the five-year outcomes of lorlatinib against crizotinib in advanced ALK-positive disease. He directs thoracic medical oncology and lung cancer research at Peter Mac, with interests in ALK inhibitors, targeted therapy and clinical trials.","asOf":"2026-09-08","links":[{"label":"Peter MacCallum Cancer Centre","url":"https://www.petermac.org"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Solomon%20BJ%5BAuthor%5D%20ALK%20lung%20cancer"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":["alk"],"drugs":["lorlatinib"],"companies":[],"institutions":["peter-mac"],"pathways":[],"terms":[],"trials":["crown"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology; Head, Lung Medical Oncology, Peter Mac","institutionId":"peter-mac","specialisms":["Lung cancer","ALK inhibitors","Targeted therapy","Clinical trials"],"profiles":[{"label":"Peter MacCallum Cancer Centre","url":"https://www.petermac.org"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Solomon%20BJ%5BAuthor%5D%20ALK%20lung%20cancer"}],"papers":[{"title":"Lorlatinib versus crizotinib in patients with advanced ALK-positive NSCLC: 5-year outcomes from CROWN","journal":"Journal of Clinical Oncology","year":2024,"doi":"10.1200/JCO.24.00581"},{"title":"CROWN: lorlatinib versus crizotinib as first treatment for ALK-positive lung cancer","journal":"New England Journal of Medicine","year":2020,"url":"https://doi.org/10.1056/NEJMoa2027187","doi":"10.1056/NEJMoa2027187"}],"orcid":"0000-0003-3059-5730"},{"id":"bernard-fisher","kind":"person","name":"Bernard Fisher","aka":[],"tldr":"He argued that breast cancer is a systemic disease from early on, then proved in randomised trials that lumpectomy with radiation equals mastectomy and that tamoxifen after surgery, and even before cancer, saves lives.","summary":"Bernard Fisher (1918-2019) was a surgeon at the University of Pittsburgh who chaired the National Surgical Adjuvant Breast and Bowel Project from 1967 to 1994. Against the Halsted doctrine that breast cancer spread in orderly fashion and demanded ever more radical surgery, he proposed that it was systemic early and could only be controlled with systemic treatment, and he insisted on randomised trials to test it. NSABP B-04 and B-06, reported in 1985 with twenty-year follow-up in 2002, showed that lumpectomy with radiotherapy gave the same survival as mastectomy; B-14 established adjuvant tamoxifen; and the P-1 trial in 1998 showed tamoxifen could prevent breast cancer in women at high risk. In 1994 a data fraud by a Montreal investigator led to his removal; the findings were confirmed and he was later vindicated and honoured with the Lasker Award and the American Association for Cancer Research's lifetime award.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Bernard_Fisher_(scientist)","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Bernard_Fisher_(scientist)"},{"label":"NRG Oncology (NSABP legacy)","url":"https://www.nrgoncology.org/"}],"tags":["hero","pioneer"],"related":[],"cancers":["breast-hr-positive"],"sections":["surgery","hormonal"],"technologies":["endocrine-therapy","chemoprevention"],"targets":[],"drugs":["tamoxifen"],"companies":["nrg-oncology"],"institutions":[],"pathways":[],"terms":["neoadjuvant-adjuvant"],"trials":[],"people":["rose-kushner"],"bottlenecks":["b-surgery-radiation-innovation","b-trial-design","b-toxicity-qol"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Surgeon whose NSABP trials ended the radical mastectomy and established adjuvant therapy","specialisms":["Breast surgery","Clinical trials","Adjuvant therapy","Chemoprevention"],"profiles":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Bernard_Fisher_(scientist)"},{"label":"NRG Oncology (NSABP legacy)","url":"https://www.nrgoncology.org/"}],"papers":[{"title":"Twenty-Year Follow-up of a Randomized Trial Comparing Total Mastectomy, Lumpectomy, and Lumpectomy plus Irradiation for the Treatment of Invasive Breast Cancer","journal":"New England Journal of Medicine","year":2002,"doi":"10.1056/nejmoa022152"},{"title":"Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17.","journal":"Journal of Clinical Oncology","year":1998,"doi":"10.1200/jco.1998.16.2.441"},{"title":"Tamoxifen, Radiation Therapy, or Both for Prevention of Ipsilateral Breast Tumor Recurrence After Lumpectomy in Women With Invasive Breast Cancers of One Centimeter or Less","journal":"Journal of Clinical Oncology","year":2002,"doi":"10.1200/jco.2002.11.101"}]},{"id":"bernardo-rubinstein","kind":"person","name":"Bernardo Rubinstein","aka":[],"tldr":"President of the Instituto Alexander Fleming, a private specialist cancer hospital in Buenos Aires that opened in 1994.","summary":"Bernardo Rubinstein is Presidente of the Instituto Alexander Fleming, a private oncology specialty hospital in Buenos Aires, Argentina, that opened on 14 March 1994 and positions itself as a leading cancer treatment centre in Latin America with a multidisciplinary team affiliated to the University of Buenos Aires. He heads the institute's Directorio, which also includes executive director Alejandra Rubinstein, academic director Reinaldo Chacón, medical director Federico A. Coló and general manager Antonio Goitisolo. The institute offers prevention, diagnosis and treatment services across surgery, medical oncology, haematology, radiotherapy and diagnostic imaging.","asOf":"2026-09-10","links":[{"label":"Source: Instituto Alexander Fleming institutional page (Directorio)","url":"https://alexanderfleming.org/quienes-somos/"}],"tags":["leadership","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["instituto-alexander-fleming"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Presidente (President) of the Instituto Alexander Fleming","institutionId":"instituto-alexander-fleming","specialisms":["Healthcare governance","Private hospital management"],"profiles":[{"label":"Instituto Alexander Fleming, Quiénes somos","url":"https://alexanderfleming.org/quienes-somos/"}],"papers":[]},{"id":"bert-vogelstein","kind":"person","name":"Bert Vogelstein","aka":[],"tldr":"Bert Vogelstein is the most-cited scientist in cancer genetics: he mapped how colorectal cancer develops and founded the field of cancer genome sequencing and blood-based detection.","summary":"Bert Vogelstein is Clayton Professor of Oncology, Co-Director of the Ludwig Center and an HHMI Investigator at Johns Hopkins Hospital and the Sidney Kimmel Comprehensive Cancer Center. He is the most-cited scientist in cancer genetics, having mapped with Kenneth Kinzler how colorectal cancer develops through the adenoma-carcinoma sequence, discovered the tumour-suppressor role of p53 and sequenced the first cancer genomes. His selected papers survey cancer genome landscapes and describe detection and localisation of surgically resectable cancers with a multi-analyte blood test. That test, CancerSEEK, is the basis of multi-cancer early detection, and his laboratory continues to work on liquid biopsy and blood-based screening.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Bert_Vogelstein","links":[{"label":"Ludwig Center","url":"https://www.hopkinsmedicine.org/kimmel-cancer-center/research/ludwig-center"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Vogelstein%20B%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["colorectal","pancreatic"],"sections":[],"technologies":["mced","liquid-biopsy","wes-wgs"],"targets":["tp53","kras"],"drugs":[],"companies":[],"institutions":["johns-hopkins"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Clayton Professor of Oncology; Co-Director, Ludwig Center; HHMI Investigator","institutionId":"johns-hopkins","specialisms":["Cancer genetics","Colorectal tumorigenesis","Liquid biopsy","Early detection"],"profiles":[{"label":"Ludwig Center","url":"https://www.hopkinsmedicine.org/kimmel-cancer-center/research/ludwig-center"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Vogelstein%20B%5BAuthor%5D"}],"papers":[{"title":"Cancer genome landscapes","journal":"Science","year":2013,"url":"https://doi.org/10.1126/science.1235122","doi":"10.1126/science.1235122"},{"title":"Detection and localization of surgically resectable cancers with a multi-analyte blood test","journal":"Science","year":2018,"url":"https://doi.org/10.1126/science.aar3247","doi":"10.1126/science.aar3247"},{"title":"DETECT-A: a blood test plus PET-CT found treatable cancers in 10,000 women with no symptoms","journal":"Science","year":2020,"url":"https://doi.org/10.1126/science.abb9601","doi":"10.1126/science.abb9601"},{"title":"DYNAMIC: a blood test safely halved chemotherapy use after surgery for stage II colon cancer","journal":"New England Journal of Medicine","year":2022,"url":"https://doi.org/10.1056/NEJMoa2200075","doi":"10.1056/NEJMoa2200075"},{"title":"El-Deiry 1993: WAF1, the gene through which p53 stops cell division","journal":"Cell","year":1993,"url":"https://doi.org/10.1016/0092-8674(93)90500-P","doi":"10.1016/0092-8674(93)90500-P"},{"title":"Hollstein 1991: p53 mutations in human cancers","journal":"Science","year":1991,"url":"https://doi.org/10.1126/science.1905840","doi":"10.1126/science.1905840"},{"title":"Vogelstein, Lane and Levine 2000: surfing the p53 network","journal":"Nature","year":2000,"url":"https://doi.org/10.1038/35042675","doi":"10.1038/35042675"}]},{"id":"berta-cerda-alvarez","kind":"person","name":"Berta Cerda Álvarez","aka":[],"tldr":"Physician who directs Chile's Instituto Nacional del Cáncer, the country's public national cancer institute.","summary":"Dra. Berta Cerda Álvarez is Directora of the Instituto Nacional del Cáncer (INC), Chile's public national cancer institute. An institute news article of 29 July 2025 reports that she led its participatory public accountability report (Cuenta Pública Participativa) for 2024, which recorded more than 65,000 in-person consultations, 3,412 surgeries and 28,000 chemotherapy cycles, resolution of 86.9 percent of GES health guarantees, 17 clinical studies and the handover of the site for a new institute building, with institutional reaccreditation and robotic surgery among the goals set for 2025. The institute's website was unreachable at the time of this check, so the article was read from an archived copy.","asOf":"2026-09-10","links":[{"label":"Source: INC article on the 2024 Cuenta Pública led by the Directora (July 2025, archived copy)","url":"https://web.archive.org/web/20250805173531/http://www.incancer.cl/en-cuenta-publica-2024-se-refuerza-el-compromiso-con-la-salud-oncologica-de-excelencia/"}],"tags":["leadership","hospital-management","government"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["inc-chile"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Directora, Instituto Nacional del Cáncer (Chile)","institutionId":"inc-chile","specialisms":["Oncology","Public hospital management"],"profiles":[{"label":"INC news article naming the Directora (archived copy)","url":"https://web.archive.org/web/20250805173531/http://www.incancer.cl/en-cuenta-publica-2024-se-refuerza-el-compromiso-con-la-salud-oncologica-de-excelencia/"}],"papers":[]},{"id":"bertine-lahuis","kind":"person","name":"Bertine Lahuis","aka":[],"tldr":"Chair of the executive board of Radboud university medical centre in Nijmegen, the academic hospital that houses the Radboudumc Centre for Oncology.","summary":"Bertine Lahuis chairs the Raad van Bestuur (Executive Board) of Radboudumc, the university medical centre of Radboud University in Nijmegen, which includes the Radboudumc Centre for Oncology. As of 1 April 2025 the board comprises Lahuis as chair, Jan Smit as dean and vice-chair, Lot Winkel-Rüter as chief financial officer and Frédérique van Berkestijn as chief operating officer. Board members are appointed for fixed terms by the Supervisory Board of the Radboud University Medical Center Foundation. The board page does not give individual appointment dates.","asOf":"2026-09-10","links":[{"label":"Source: Radboudumc executive board page","url":"https://www.radboudumc.nl/over-het-radboudumc/organisatie/raad-van-bestuur"}],"tags":["leadership","hospital-management","comprehensive-cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["radboudumc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chair of the Executive Board (voorzitter Raad van Bestuur), Radboudumc, Nijmegen","institutionId":"radboudumc","specialisms":["Hospital governance","Academic medicine","Psychiatry"],"profiles":[{"label":"Radboudumc Raad van Bestuur page","url":"https://www.radboudumc.nl/over-het-radboudumc/organisatie/raad-van-bestuur"}],"papers":[]},{"id":"beth-devine","kind":"person","name":"Beth Devine","aka":[],"tldr":"Pharmacist-health economist serving as 2026-2027 President of ISPOR, the global society for health economics and outcomes research.","summary":"Beth Devine, PhD, PharmD, MBA, is President of ISPOR for the 2026-2027 term. Her academic work at the University of Washington focuses on comparative effectiveness research, health technology assessment and the use of real-world evidence in decision making, all of which shape how new oncology therapies are evaluated for value and reimbursement.","asOf":"2026-09-10","links":[{"label":"Society page","url":"https://www.ispor.org/about/board-of-directors"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Devine+EB%5BAuthor%5D"}],"tags":["leadership","health economics","health technology assessment"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ispor"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["journal-of-geriatric-oncology"],"dependsOn":[],"notes":[],"role":"President (2026-2027)","institutionId":"ispor","specialisms":["Health economics and outcomes research","Comparative effectiveness","Health technology assessment"],"profiles":[{"label":"Society page","url":"https://www.ispor.org/about/board-of-directors"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Devine+EB%5BAuthor%5D"}],"papers":[{"title":"Use of geriatric assessment in cancer clinical trials: A systematic review","journal":"Journal of Geriatric Oncology","year":2022,"doi":"10.1016/j.jgo.2022.04.014"}]},{"id":"betty-ford","kind":"person","name":"Betty Ford","aka":[],"tldr":"Weeks after becoming First Lady in 1974 she had a mastectomy and, unusually for the time, said so publicly. Clinics recorded a surge of women coming for breast examinations.","summary":"Betty Ford (1918-2011) was diagnosed with breast cancer in September 1974, a few weeks after her husband Gerald Ford became President. She had a radical mastectomy and chose to discuss the diagnosis and operation openly at a time when breast cancer was rarely mentioned in public. In the following weeks women across the United States sought breast examinations and mammograms in large numbers; among those diagnosed as a result was Happy Rockefeller, wife of the Vice President. Ford went on to speak with equal candour about her treatment for alcohol and prescription drug dependence, founding the Betty Ford Center in 1982. Her disclosure is often credited as the start of open public conversation about breast cancer in America.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Betty_Ford","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Betty_Ford"},{"label":"Gerald R. Ford Presidential Foundation","url":"https://www.geraldrfordfoundation.org/"}],"tags":["public-figure","patient","advocate"],"related":[],"cancers":[],"sections":[],"technologies":["mammography"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-early-detection","b-patient-voice"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"First Lady who spoke openly about her mastectomy in 1974","specialisms":["Breast cancer","Public disclosure","Early detection"],"profiles":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Betty_Ford"},{"label":"Gerald R. Ford Presidential Foundation","url":"https://www.geraldrfordfoundation.org/"}],"papers":[]},{"id":"biju-george","kind":"person","name":"Biju George","aka":[],"tldr":"Physician who serves as Director of Christian Medical College, Vellore, the not-for-profit teaching hospital and medical school in Tamil Nadu, India.","summary":"Dr Biju George is Director of Christian Medical College (CMC), Vellore, a not-for-profit Christian teaching hospital and medical college in Tamil Nadu. The college's administration page lists him as Director alongside Dr Solomon Sathishkumar (Principal), Dr Rajesh I (Medical Superintendent), Mrs Alice Sony (Nursing Superintendent) and seven Associate Directors. The page functions as a directory and gives no appointment date or biography.","asOf":"2026-09-10","links":[{"label":"Source: CMC Vellore administration page","url":"https://www.cmch-vellore.edu/administration/"}],"tags":["leadership","clinician-scientist","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cmc-vellore"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["leukemia","blood-advances"],"dependsOn":[],"notes":[],"role":"Director, Christian Medical College, Vellore","institutionId":"cmc-vellore","specialisms":["Academic medicine","Hospital management","Medical education"],"profiles":[{"label":"CMC Vellore administration page","url":"https://www.cmch-vellore.edu/administration/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=George+B%5BAuthor%5D+AND+Vellore"}],"papers":[{"title":"Treatment of children with newly diagnosed acute promyelocytic leukemia with arsenic trioxide: a single center experience","journal":"Leukemia","year":2004,"doi":"10.1038/sj.leu.2403480"},{"title":"Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors","journal":"Blood Advances","year":2021,"doi":"10.1182/bloodadvances.2020003654"},{"title":"Acute myeloid leukaemia: challenges and real world data from India","journal":"British Journal of Haematology","year":2015,"doi":"10.1111/bjh.13406"}],"orcid":"0000-0002-9847-9501"},{"id":"bill-gates","kind":"person","name":"Bill Gates","aka":["Bill and Melinda Gates","Gates Foundation"],"tldr":"The Gates Foundation has committed $4.1 billion to Gavi, the vaccine alliance it helped found in 2000, whose HPV programme had fully immunised nearly 60 million girls against cervical cancer by the end of 2024.","summary":"Bill Gates and Melinda French Gates founded the Gates Foundation, which Gavi records as a founding partner with total commitments of US$4.1 billion to date: a US$750 million commitment to the Vaccine Fund in 2000, more than US$1 billion over 2011-2015, US$1.55 billion for 2016-2020 and US$1.6 billion for the 2021-2025 strategic period. Gavi's HPV vaccine programme, which began in 2014, is the route by which most girls in the world's poorest countries are protected against the virus that causes cervical cancer: by the end of 2024, 42 countries had launched national HPV programmes with Gavi support, fully immunising more than 59.8 million girls, with a target of over 86 million girls by the end of 2025 and more than 1.4 million future cervical cancer deaths averted; in December 2022 the Gavi Board approved a revitalisation of the programme with more than US$600 million through 2025 after the WHO endorsed single-dose schedules. Cervical cancer is the first cancer the world has a credible plan to eliminate, and this money is much of the plan.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Bill_Gates","links":[{"label":"Gavi: Gates Foundation donor profile","url":"https://www.gavi.org/investing-gavi/funding/donor-profiles/bill-melinda-gates-foundation"},{"label":"Gavi: human papillomavirus vaccine support","url":"https://www.gavi.org/types-support/vaccine-support/human-papillomavirus"}],"tags":["hero","donor"],"related":[],"cancers":["cervical"],"sections":[],"technologies":["hpv-vaccine"],"targets":[],"drugs":[],"companies":[],"institutions":["gates-foundation","who"],"pathways":[],"terms":[],"trials":[],"people":["harald-zur-hausen","ian-frazer"],"bottlenecks":["b-global-access","b-prevention-adoption"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Co-founder of the Gates Foundation, Gavi's founding partner and the largest private funder of HPV vaccine access","specialisms":["Vaccine access","Cervical cancer prevention","Global health"],"profiles":[],"papers":[]},{"id":"bill-greenhalf","kind":"person","name":"Bill Greenhalf","aka":[],"tldr":"Liverpool molecular scientist behind the EUROPAC registry's laboratory work and the biomarker analyses of the ESPAC trial samples.","summary":"Bill Greenhalf is a Reader in Molecular and Clinical Cancer Medicine at the University of Liverpool (Institute of Systems, Molecular and Integrative Biology). He works on the molecular side of the EUROPAC registry of familial pancreatic cancer and hereditary pancreatitis and on biomarker studies from the ESPAC trials, including the ESPAC-3 analysis of tumour hENT1 expression and survival from gemcitabine (Journal of the National Cancer Institute 2014) and the Liverpool Experimental Cancer Medicine Centre biomarker discovery programme (ISRCTN74588872).","asOf":"2026-09-24","links":[{"label":"University of Liverpool staff page","url":"https://www.liverpool.ac.uk/people/william-greenhalf"}],"tags":["pancreatic","uk","biomarkers"],"related":["chris-halloran"],"cancers":["pancreatic"],"sections":["early-detection"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["liverpool-hpb-centre"],"pathways":[],"terms":[],"trials":["europac","espac-3"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Reader, Molecular and Clinical Cancer Medicine, University of Liverpool","institutionId":"liverpool-hpb-centre","specialisms":["Familial pancreatic cancer","Hereditary pancreatitis","Biomarkers","Molecular pathology of ESPAC samples"],"profiles":[{"label":"University of Liverpool staff page","url":"https://www.liverpool.ac.uk/people/william-greenhalf"}],"papers":[{"title":"Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial","journal":"Journal of the National Cancer Institute","year":2014,"doi":"10.1093/jnci/djt347"},{"title":"European Registry of Hereditary Pancreatic Diseases (EUROPAC): protocol for primary and secondary screening in individuals at high risk of pancreatic cancer","journal":"BMJ Open","year":2025,"doi":"10.1136/bmjopen-2025-100027"}]},{"id":"billy-starr","kind":"person","name":"Billy Starr","aka":[],"tldr":"After his mother died of melanoma he organised a bike ride across Massachusetts in 1980 with 36 riders; the Pan-Mass Challenge has since raised $1.125 billion for Dana-Farber and passes on every rider-raised dollar.","summary":"Billy Starr organised the first Pan-Mass Challenge in 1980, after his mother's death from melanoma and a long hike on the Appalachian Trail, with just 36 riders and 10 volunteers. The PMC's own account records that it now involves more than 6,800 riders and 3,500 volunteers, that since 1980 it has raised $1.125 billion for Dana-Farber Cancer Institute, that 100 percent of all rider-raised funds go directly to cancer research and treatment at Dana-Farber and the Jimmy Fund, and that it provides 67 percent of the Jimmy Fund's annual revenue. It is the largest athletic fundraiser for a single institution in the United States and the template for hundreds of charity rides. Starr still leads the organisation and rides each year.","asOf":"2026-09-10","links":[{"label":"Pan-Mass Challenge: about","url":"https://www.pmc.org/about"}],"tags":["hero","donor"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["pan-mass-challenge","dana-farber","jimmy-fund"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-funding-allocation"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Founder of the Pan-Mass Challenge, which has raised $1.125 billion for Dana-Farber","specialisms":["Cancer fundraising","Endurance events","Melanoma"],"profiles":[],"papers":[]},{"id":"xu-binghe","kind":"person","name":"Binghe Xu","aka":[],"tldr":"Principal investigator of OptiTROP-Breast01, the Chinese trial that got the TROP2 ADC sacituzumab tirumotecan approved before any Western approval.","summary":"Binghe Xu is Professor of Medical Oncology and Director of the Department of Medical Oncology at the Cancer Hospital of the Chinese Academy of Medical Sciences in Beijing. He was principal investigator of OptiTROP-Breast01, the Chinese trial that secured approval for the TROP2 antibody-drug conjugate sacituzumab tirumotecan before any Western approval, and has led Chinese breast cancer trials of pyrotinib, dalpiciclib and other antibody-drug conjugates in pretreated triple-negative and HR-positive disease. His publications include the PHOEBE trial comparing pyrotinib plus capecitabine with lapatinib plus capecitabine in HER2-positive metastatic breast cancer. Several of his trials produced first approvals in China for drugs from Sichuan Kelun-Biotech and Jiangsu Hengrui Pharmaceuticals.","asOf":"2026-09-08","links":[{"label":"Cancer Hospital, CAMS","url":"https://www.cicams.ac.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Xu%20B%5BAuthor%5D%20Chinese%20Academy%20of%20Medical%20Sciences%20breast%20cancer"}],"tags":[],"related":[],"cancers":["tnbc","breast-hr-positive","breast-her2-positive"],"sections":[],"technologies":[],"targets":["trop2","her2"],"drugs":["sacituzumab-tirumotecan","pyrotinib"],"companies":["kelun-biotech","hengrui"],"institutions":["cams-cancer-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology; Director, Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences","institutionId":"cams-cancer-hospital","specialisms":["Breast cancer","Antibody-drug conjugates","TROP2","Clinical trials"],"profiles":[{"label":"Cancer Hospital, CAMS","url":"https://www.cicams.ac.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Xu%20B%5BAuthor%5D%20Chinese%20Academy%20of%20Medical%20Sciences%20breast%20cancer"}],"papers":[{"title":"Pyrotinib plus capecitabine versus lapatinib plus capecitabine for HER2-positive metastatic breast cancer (PHOEBE)","journal":"Lancet Oncology","year":2021,"doi":"10.1016/S1470-2045(20)30702-6"},{"title":"DESTINY-Breast03: trastuzumab deruxtecan beats T-DM1 as second-line treatment of HER2-positive metastatic breast cancer","journal":"New England Journal of Medicine","year":2022,"url":"https://doi.org/10.1056/NEJMoa2115022","doi":"10.1056/NEJMoa2115022"},{"title":"DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group","journal":"New England Journal of Medicine","year":2022,"url":"https://doi.org/10.1056/NEJMoa2203690","doi":"10.1056/NEJMoa2203690"},{"title":"NATALEE: three years of ribociclib after surgery in a broad population of hormone-receptor-positive early breast cancer","journal":"New England Journal of Medicine","year":2024,"url":"https://doi.org/10.1056/NEJMoa2305488","doi":"10.1056/NEJMoa2305488"},{"title":"TROPION-Breast01: datopotamab deruxtecan versus chemotherapy in pretreated hormone-receptor-positive breast cancer, and why a PFS win did not translate to survival","journal":"Journal of Clinical Oncology","year":2024,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=TROPION-Breast01+datopotamab+deruxtecan+Bardia"}]},{"id":"bjorn-atle-bjornbeth","kind":"person","name":"Bjørn Atle Bjørnbeth","aka":[],"tldr":"Bjørn Atle Bjørnbeth represents Oslo University Hospital, The Norwegian Radium Hospital in the Organisation of European Cancer Institutes, which lists the centre among its members in Norway.","summary":"Bjørn Atle Bjørnbeth is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Oslo University Hospital, The Norwegian Radium Hospital, its full member in Norway. OnCo records the name from the OECI membership list so that the centre's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the institution's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Oslo University Hospital, The Norwegian Radium Hospital website","url":"https://www.ous-research.no/institute/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oslo-radium-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Oslo University Hospital, The Norwegian Radium Hospital to the Organisation of European Cancer Institutes","institutionId":"oslo-radium-hospital","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Oslo University Hospital, The Norwegian Radium Hospital website","url":"https://www.ous-research.no/institute/"}],"papers":[{"title":"Laparoscopic Versus Open Resection for Colorectal Liver Metastases: The OSLO-COMET Randomized Controlled Trial","journal":"Ann Surg","year":2018,"url":"https://doi.org/10.1097/sla.0000000000002353","doi":"10.1097/sla.0000000000002353","note":"Europe PMC author record matched by affiliation"},{"title":"Survival Following Liver Transplantation for Patients With Nonresectable Liver-only Colorectal Metastases","journal":"Ann Surg","year":2020,"url":"https://doi.org/10.1097/sla.0000000000003404","doi":"10.1097/sla.0000000000003404","note":"Europe PMC author record matched by affiliation"},{"title":"ALPPS Improves Resectability Compared With Conventional Two-stage Hepatectomy in Patients With Advanced Colorectal Liver Metastasis: Results From a Scandinavian Multicenter Randomized Controlled Trial (LIGRO Trial)","journal":"Ann Surg","year":2018,"url":"https://doi.org/10.1097/sla.0000000000002511","doi":"10.1097/sla.0000000000002511","note":"Europe PMC author record matched by affiliation"}]},{"id":"bob-li","kind":"person","name":"Bob T. Li","aka":[],"tldr":"Ran the trials that made trastuzumab deruxtecan the first HER2-directed drug for lung cancer.","summary":"Bob T. Li is a Medical Oncologist in Thoracic Oncology and Physician Ambassador to China and Asia-Pacific at Memorial Sloan Kettering Cancer Center. He is known for leading DESTINY-Lung01, the trial that established trastuzumab deruxtecan as the first HER2-directed drug for HER2-mutant non-small-cell lung cancer, and for early studies of HER2-directed therapy in lung cancer. His selected paper reports trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. He continues to work on antibody-drug conjugates and early drug development while leading MSK's partnerships across the Asia-Pacific region.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Li%20BT%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["adc"],"targets":["her2"],"drugs":["trastuzumab-deruxtecan"],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Physician Ambassador to China and Asia-Pacific; Medical Oncologist, Thoracic Oncology","institutionId":"mskcc","specialisms":["HER2-mutant lung cancer","Antibody-drug conjugates","Early drug development"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Li%20BT%5BAuthor%5D"}],"papers":[{"title":"Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer","journal":"New England Journal of Medicine","year":2022,"url":"https://doi.org/10.1056/NEJMoa2112431","doi":"10.1056/NEJMoa2112431"}],"orcid":"0000-0001-6661-8733"},{"id":"boris-pasche","kind":"person","name":"Boris C. Pasche","aka":[],"tldr":"Oncologist who leads the Barbara Ann Karmanos Cancer Institute in Detroit as President and CEO and chairs the Department of Oncology at Wayne State University.","summary":"Boris C. Pasche (MD, PhD, FACP) leads the Barbara Ann Karmanos Cancer Institute in Detroit as President and Chief Executive Officer, according to the institute's English Wikipedia article, which describes the institute as being 'under the direction of President and CEO Boris C. Pasche'. Karmanos is a National Cancer Institute designated comprehensive cancer centre, and its academic partner is Wayne State University School of Medicine, whose Department of Oncology page lists him as Chair. The Karmanos website itself could not be fetched when checked.","asOf":"2026-09-10","links":[{"label":"Source: Wikipedia article on the institute (names President and CEO)","url":"https://en.wikipedia.org/wiki/Barbara_Ann_Karmanos_Cancer_Institute"},{"label":"Source: Wayne State Department of Oncology page (Chair)","url":"https://oncology.med.wayne.edu/"}],"tags":["leadership","clinician-scientist","comprehensive-cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["karmanos"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["clinical-cancer-research","jama"],"dependsOn":[],"notes":[],"role":"President and Chief Executive Officer, Barbara Ann Karmanos Cancer Institute","institutionId":"karmanos","specialisms":["Medical oncology","Cancer genetics","Cancer centre leadership"],"profiles":[{"label":"Wayne State University Department of Oncology","url":"https://oncology.med.wayne.edu/"},{"label":"Wikipedia: Barbara Ann Karmanos Cancer Institute","url":"https://en.wikipedia.org/wiki/Barbara_Ann_Karmanos_Cancer_Institute"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Pasche+B%5BAuthor%5D"}],"papers":[{"title":"TGFβ in Pancreas and Colorectal Cancer: Opportunities to Overcome Therapeutic Resistance","journal":"Clinical Cancer Research","year":2024,"doi":"10.1158/1078-0432.ccr-24-0468"},{"title":"TGF-β signaling alterations and susceptibility to colorectal cancer","journal":"Human Molecular Genetics","year":2007,"doi":"10.1093/hmg/ddl486"},{"title":"One Step Forward Toward Identification of the Genetic Signature of Glioblastomas","journal":"JAMA","year":2009,"doi":"10.1001/jama.2009.1023"}]},{"id":"boubou-hallberg","kind":"person","name":"Boubou Hallberg","aka":[],"tldr":"Hospital Director and CEO of Sahlgrenska University Hospital in Gothenburg, one of northern Europe's largest university hospitals.","summary":"Boubou Hallberg is Hospital Director and Chief Executive Officer of Sahlgrenska University Hospital in Gothenburg, Sweden. The hospital, together with the University of Gothenburg's Sahlgrenska Center for Cancer Research, forms a major Nordic cancer care and research environment. Hallberg is a paediatrician by training and leads the hospital's executive management team.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.sahlgrenska.se/en/about-us/about-the-hospital/"}],"tags":["leadership","hospital management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["sahlgrenska"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Hospital Director, Chief Executive Officer","institutionId":"sahlgrenska","specialisms":["Hospital management","Paediatrics"],"profiles":[{"label":"Institution profile","url":"https://www.sahlgrenska.se/en/about-us/about-the-hospital/"}],"papers":[]},{"id":"bradley-cairns","kind":"person","name":"Bradley Cairns","aka":[],"tldr":"Epigenetics researcher who became CEO of Huntsman Cancer Institute at the University of Utah in September 2025.","summary":"Bradley Cairns is Chief Executive Officer of Huntsman Cancer Institute at the University of Utah, an NCI-designated comprehensive cancer centre, succeeding Mary Beckerle in September 2025. A professor of oncological sciences and long-time Huntsman investigator, his laboratory studies chromatin remodelling and epigenetic regulation in development, the germline and cancer.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cairns+BR%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","epigenetics"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["huntsman"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nature"],"dependsOn":[],"notes":[],"role":"Chief Executive Officer","institutionId":"huntsman","specialisms":["Chromatin and epigenetics","Germline biology","Cancer research leadership"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cairns+BR%5BAuthor%5D"}],"papers":[{"title":"The biology of chromatin remodeling complexes","journal":"Annual Review of Biochemistry","year":2009,"url":"https://doi.org/10.1146/annurev.biochem.77.062706.153223","doi":"10.1146/annurev.biochem.77.062706.153223","note":"Europe PMC author record matched by affiliation"},{"title":"Mechanisms of action and regulation of ATP-dependent chromatin-remodelling complexes","journal":"Nature Reviews Molecular Cell Biology","year":2017,"url":"https://doi.org/10.1038/nrm.2017.26","doi":"10.1038/nrm.2017.26","note":"Europe PMC author record matched by affiliation"},{"title":"Distinctive chromatin in human sperm packages genes for embryo development","journal":"Nature","year":2009,"url":"https://doi.org/10.1038/nature08162","doi":"10.1038/nature08162","note":"Europe PMC author record matched by affiliation"}],"orcid":"0000-0002-9864-8811"},{"id":"bradley-bernstein","kind":"person","name":"Bradley E. Bernstein","aka":[],"tldr":"Bradley Bernstein mapped the chromatin landscapes that let cancer cells switch identities and resist drugs.","summary":"Bradley E. Bernstein is an Institute Member at the Broad Institute of MIT and Harvard and Chair of Cancer Biology at Dana-Farber. He is an epigenomicist known for defining bivalent chromatin domains and for using single-cell approaches to show how glioma and other tumours exploit epigenetic plasticity to switch identities and resist drugs. His selected paper uses single-cell RNA sequencing to reveal intratumoural heterogeneity in primary glioblastoma. His laboratory continues to map chromatin landscapes in cancer, with relevance to epigenetic drugs and single-cell and spatial profiling.","asOf":"2026-09-08","links":[{"label":"Broad bio","url":"https://www.broadinstitute.org/bios/bradley-e-bernstein"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bernstein%20BE%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":["single-cell-spatial","epigenetic-drugs"],"targets":[],"drugs":[],"companies":[],"institutions":["broad-institute"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Institute Member, Broad; Chair, Cancer Biology, Dana-Farber","institutionId":"broad-institute","specialisms":["Epigenomics","Chromatin","Glioma"],"profiles":[{"label":"Broad bio","url":"https://www.broadinstitute.org/bios/bradley-e-bernstein"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bernstein%20BE%5BAuthor%5D"}],"papers":[{"title":"Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma","journal":"Science","year":2014,"url":"https://doi.org/10.1126/science.1254257","doi":"10.1126/science.1254257"}]},{"id":"bradley-monk","kind":"person","name":"Bradley J. Monk","aka":[],"tldr":"Gynaecologic oncologist who co-led KEYNOTE-826, innovaTV 301 and KEYNOTE-A18, the trials that rebuilt cervical cancer treatment.","summary":"Bradley Monk (GOG Partners) was a lead investigator of GOG 240, which established bevacizumab in advanced cervical cancer, and co-led KEYNOTE-826, innovaTV 301 (tisotumab vedotin) and KEYNOTE-A18, together the three practice-changing cervical cancer trials of the past five years. He co-leads the GOG Partners industry-collaboration programme and has led ovarian PARP inhibitor trials including ATHENA.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Bradley_J._Monk","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Monk%20BJ%5BAuthor%5D%20cervical"}],"tags":["cervical","ovarian","cooperative-group"],"related":[],"cancers":["cervical","ovarian"],"sections":[],"technologies":["checkpoint-inhibitor","adc"],"targets":["pd1","tissue-factor","vegf"],"drugs":["pembrolizumab","tisotumab-vedotin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["keynote-826","innovatv-301","keynote-a18","athena-mono"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Gynecologic Oncologist, Florida Cancer Specialists; Professor, University of Arizona and Creighton University; Co-Director, GOG Partners","specialisms":["Cervical cancer","Ovarian cancer","Antibody-drug conjugates","Cooperative-group trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Monk%20BJ%5BAuthor%5D%20cervical"}],"papers":[{"title":"Improved survival with bevacizumab in advanced cervical cancer (GOG 240)","journal":"NEJM","year":2014,"doi":"10.1056/NEJMoa1309748"},{"title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826)","journal":"NEJM","year":2021,"doi":"10.1056/NEJMoa2112435"}]},{"id":"brahim-lakhal","kind":"person","name":"Brahim Lakhal","aka":[],"tldr":"Professor appointed by royal decree in 2026 as Director General of the Rabat-Salé-Kénitra territorial health group, which runs the Institut National d'Oncologie in Rabat.","summary":"Professor Brahim Lakhal is Directeur Général of the Groupement Sanitaire Territorial (GST) de la région Rabat-Salé-Kénitra, the territorial health group that succeeded the CHU Ibn Sina and manages the region's hospital establishments, including the Institut National d'Oncologie Sidi Mohamed Ben Abdellah, the Hôpital Ibn Sina and the Hôpital des Spécialités in Rabat. The GST website reports that he was appointed by King Mohammed VI by royal decree dated 9 April 2026, on the proposal of the Head of Government and the initiative of the Minister of Health, with the announcement published on 9 September 2026. The site does not name a separate director for the Institut National d'Oncologie, a 187-bed tertiary oncology institute founded in 1985.","asOf":"2026-09-10","links":[{"label":"Source: GST RSK news item on the appointment of the Directeur Général","url":"https://www.gst-rsk.ma/actualites/nomination-du-professeur-brahim-lakhal-directeur-general-du-groupement-sanitaire-territorial-gst-de-la-region-rabat-sale-kenitra/"},{"label":"Source: Wikipedia (French), Institut national d'oncologie Sidi Mohamed ben Abdellah","url":"https://fr.wikipedia.org/wiki/Institut_national_d%27oncologie_Sidi_Mohamed_ben_Abdellah"}],"tags":["leadership","hospital-management","government"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["institut-national-oncologie-rabat"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Directeur Général, Groupement Sanitaire Territorial Rabat-Salé-Kénitra (parent body of the Institut National d'Oncologie)","institutionId":"institut-national-oncologie-rabat","specialisms":["Health system management","Hospital governance"],"profiles":[{"label":"GST Rabat-Salé-Kénitra appointment announcement","url":"https://www.gst-rsk.ma/actualites/nomination-du-professeur-brahim-lakhal-directeur-general-du-groupement-sanitaire-territorial-gst-de-la-region-rabat-sale-kenitra/"}],"papers":[]},{"id":"brandi-williams-broome","kind":"person","name":"Brandi Williams Broome","aka":[],"tldr":"Nonprofit executive who leads The V Foundation, a charity that raises money to fund cancer research across the United States.","summary":"Brandi Williams Broome is Chief Executive Officer of The V Foundation for Cancer Research, a charity headquartered in Cary, North Carolina, that funds cancer research through grant programmes and fundraising events. She brings more than 20 years of nonprofit leadership experience, including over a decade in senior executive roles at the American Heart Association and the American Diabetes Association, where she built high-performing fundraising teams and national corporate partnerships. She is a graduate of the University of Tennessee.","asOf":"2026-09-10","links":[{"label":"Source: V Foundation leadership page","url":"https://www.v.org/about/leadership/"}],"tags":["leadership","research-funding","charity"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["v-foundation"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive Officer, The V Foundation for Cancer Research","institutionId":"v-foundation","specialisms":["Nonprofit leadership","Fundraising","Research funding"],"profiles":[{"label":"V Foundation leadership profile","url":"https://www.v.org/leadership-team/brandi-williams-broome/"}],"papers":[]},{"id":"brandon-wainwright","kind":"person","name":"Brandon Wainwright","aka":[],"tldr":"Geneticist known for work on the genetic drivers of childhood brain cancer who became Director and CEO of QIMR Berghofer, a leading Australian medical research institute, in 2026.","summary":"Professor Brandon Wainwright AM is Director and CEO of QIMR Berghofer Medical Research Institute in Brisbane, an Australian medical research institute with major cancer research programmes, a role he took up in 2026. He was previously Professor at The University of Queensland, led its Institute for Molecular Bioscience until 2019 and was Co-Director of the Children's Brain Cancer Centre. His research addresses genetic pathways in medulloblastoma and other cancers, including the role of Hedgehog signalling.","asOf":"2026-09-10","links":[{"label":"Source: QIMR Berghofer directors page","url":"https://www.qimrb.edu.au/about/governance/directors"}],"tags":["leadership","clinician-scientist","genetics","paediatric-oncology"],"related":[],"cancers":["medulloblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["qimr-berghofer"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director and CEO of QIMR Berghofer Medical Research Institute","institutionId":"qimr-berghofer","specialisms":["Cancer genetics","Medulloblastoma","Hedgehog signalling","Research leadership"],"profiles":[{"label":"QIMR Berghofer directors page","url":"https://www.qimrb.edu.au/about/governance/directors"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wainwright+BJ%5BAuthor%5D"}],"papers":[{"title":"Familial melanoma and p16 — a hung jury","journal":"Nature Genetics","year":1994,"doi":"10.1038/ng0994-3"},{"title":"Efficient detection and monitoring of pediatric brain malignancies with liquid biopsy based on patient-specific somatic mutation screening","journal":"Neuro-Oncology","year":2023,"doi":"10.1093/neuonc/noad032"},{"title":"Hedgehog pathway inhibitor saridegib (IPI-926) increases lifespan in a mouse medulloblastoma model","journal":"Proceedings of the National Academy of Sciences","year":2012,"doi":"10.1073/pnas.1114718109"}]},{"id":"brasil-silva-neto","kind":"person","name":"Brasil Silva Neto","aka":[],"tldr":"Urologist who has served as President of Hospital de Clínicas de Porto Alegre, a leading Brazilian university hospital, since 2024.","summary":"Brasil Silva Neto is President (Presidente) of Hospital de Clínicas de Porto Alegre (HCPA), the university hospital of the Universidade Federal do Rio Grande do Sul and one of Brazil's foremost academic medical centres, in office since 2024. A professor of urology, his clinical and research interests include prostate and other urological cancers.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Silva+Neto+B%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","urology","prostate cancer"],"related":[],"cancers":["prostate","urothelial"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["hcpa-porto-alegre"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["clinical-and-translational-oncology"],"dependsOn":[],"notes":[],"role":"President","institutionId":"hcpa-porto-alegre","specialisms":["Urology","Uro-oncology","Hospital leadership"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Silva+Neto+B%5BAuthor%5D"}],"papers":[{"title":"The impact of 5-alpha-reductase inhibitors on mortality in a prostate cancer chemoprevention setting: a meta-analysis","journal":"World Journal of Urology","year":2020,"doi":"10.1007/s00345-020-03202-2"},{"title":"Urinary microRNAs expression in prostate cancer diagnosis: a systematic review","journal":"Clinical and Translational Oncology","year":2020,"doi":"10.1007/s12094-020-02349-z"},{"title":"Androgen receptor isoforms expression in benign prostatic hyperplasia and primary prostate cancer","journal":"PLOS ONE","year":2018,"doi":"10.1371/journal.pone.0200613"}]},{"id":"breda-duggan","kind":"person","name":"Breda Duggan","aka":[],"tldr":"Breda Duggan represents Mid-Western Cancer Centre, University Hospital Limerick in the Organisation of European Cancer Institutes, which lists the organisation among its members in Ireland.","summary":"Breda Duggan is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Mid-Western Cancer Centre, University Hospital Limerick, its full member in Ireland. OnCo records the name from the OECI membership list so that the organisation's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the organisation's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Mid-Western Cancer Centre, University Hospital Limerick website","url":"https://www2.hse.ie/services/hospitals/university-hospital-limerick/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["mid-western-cancer-centre"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Mid-Western Cancer Centre, University Hospital Limerick to the Organisation of European Cancer Institutes","institutionId":"mid-western-cancer-centre","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Mid-Western Cancer Centre, University Hospital Limerick website","url":"https://www2.hse.ie/services/hospitals/university-hospital-limerick/"}],"papers":[]},{"id":"brenda-hubley","kind":"person","name":"Brenda Hubley","aka":[],"tldr":"Radiation therapist turned health executive who leads Cancer Care Alberta, the provincial cancer programme for Alberta, Canada.","summary":"Brenda Hubley is Chair and Managing Director of Cancer Care Alberta, the organisation responsible for cancer services across the province of Alberta. She has a clinical background as a radiation therapist and more than 30 years in health care, with senior leadership roles in cancer programmes at large academic centres and in rural and community settings. She previously served as Chief Program Officer for Cancer Care Alberta within Alberta Health Services.","asOf":"2026-09-10","links":[{"label":"Source: Cancer Care Alberta homepage","url":"https://www.cancercarealberta.ca/"}],"tags":["leadership","health-system","radiation-therapy"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cancer-care-alberta"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chair and Managing Director, Cancer Care Alberta","institutionId":"cancer-care-alberta","specialisms":["Radiation therapy","Cancer programme leadership","Health services management"],"profiles":[{"label":"Institution profile","url":"https://www.cancercarealberta.ca/"}],"papers":[]},{"id":"brendan-brown","kind":"person","name":"Brendan Brown","aka":[],"tldr":"Chief Executive of Leeds Teaching Hospitals NHS Trust, the NHS trust that runs the Leeds Cancer Centre at St James's University Hospital.","summary":"Brendan Brown is Chief Executive of Leeds Teaching Hospitals NHS Trust, which operates the Leeds Cancer Centre at St James's University Hospital, one of the largest cancer centres in the UK. He leads the Trust's board of executive directors alongside the Chief Medical Officer, Chief Nurse and Chief Operating Officer. The Trust website does not name a separate clinical director for the cancer centre.","asOf":"2026-09-10","links":[{"label":"Source: Leeds Teaching Hospitals Trust Board members page","url":"https://www.leedsth.nhs.uk/about/board/directors/"}],"tags":["leadership","nhs","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["leeds-cancer-centre"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive, Leeds Teaching Hospitals NHS Trust","institutionId":"leeds-cancer-centre","specialisms":["Hospital management","NHS leadership","Cancer services"],"profiles":[{"label":"Trust Board members","url":"https://www.leedsth.nhs.uk/about/board/directors/"}],"papers":[]},{"id":"brian-druker","kind":"person","name":"Brian Druker","aka":[],"tldr":"He pushed a shelved kinase inhibitor through the laboratory and into a 1998 trial when few believed a targeted pill could work. Imatinib made chronic myeloid leukaemia a disease people live with, and became the model for targeted therapy.","summary":"Brian Druker trained at Dana-Farber, where he developed the antibody used to measure tyrosine phosphorylation, and moved to Oregon Health & Science University in 1993 to find a treatment for chronic myeloid leukaemia, whose BCR-ABL kinase had been defined by Janet Rowley's translocation and Owen Witte's biochemistry. He persuaded Ciba-Geigy, later Novartis, to let him test their compounds, showed that STI571 killed CML cells while sparing normal ones, and argued the company into a phase 1 trial that opened in June 1998 with Bud Romine as its first patient. Nearly all patients at effective doses achieved normal blood counts, and the FDA approved imatinib in May 2001. Ten-year survival in chronic-phase CML is now above 80 percent, and the drug established the template of matching an inhibitor to a driver mutation. He directs the OHSU Knight Cancer Institute and received the Lasker Award in 2009.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Brian_Druker","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Brian_Druker"},{"label":"OHSU Knight Cancer Institute","url":"https://www.ohsu.edu/knight-cancer-institute"}],"tags":["hero","pioneer"],"related":[],"cancers":["cml"],"sections":["targeted-therapy"],"technologies":["kinase-inhibitors"],"targets":["bcr-abl"],"drugs":["imatinib"],"companies":[],"institutions":["ohsu-knight"],"pathways":[],"terms":["oncogene-addiction"],"trials":[],"people":["bud-romine","janet-rowley","charles-sawyers","owen-witte"],"bottlenecks":["b-translational-valley","b-incentive-misalignment"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Physician-scientist who brought imatinib to patients with chronic myeloid leukaemia","institutionId":"ohsu-knight","specialisms":["Chronic myeloid leukaemia","Kinase inhibitors","Targeted therapy"],"profiles":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Brian_Druker"},{"label":"OHSU Knight Cancer Institute","url":"https://www.ohsu.edu/knight-cancer-institute"}],"papers":[{"title":"Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia","journal":"New England Journal of Medicine","year":2006,"doi":"10.1056/nejmoa062867"},{"title":"Functional genomic landscape of acute myeloid leukaemia","journal":"Nature","year":2018,"doi":"10.1038/s41586-018-0623-z"},{"title":"Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia","journal":"New England Journal of Medicine","year":2017,"doi":"10.1056/nejmoa1609324"}]},{"id":"brian-huntly","kind":"person","name":"Brian Huntly","aka":[],"tldr":"Cambridge haematologist and EHA President Elect whose laboratory studies how epigenetic regulators drive leukaemia and how they can be targeted.","summary":"Brian Huntly is President Elect of the European Hematology Association and Professor of Leukaemia Stem Cell Biology at the University of Cambridge. His group investigates the transcriptional and epigenetic mechanisms that initiate and maintain acute myeloid leukaemia. He combines clinical haematology practice with laboratory research on novel leukaemia therapies.","asOf":"2026-09-10","links":[{"label":"Society page","url":"https://ehaweb.org/about-eha/organization/eha-board"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Huntly+BJ%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","haematology","leukaemia"],"related":[],"cancers":["aml"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["eha"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President Elect","institutionId":"eha","specialisms":["Acute myeloid leukaemia","Leukaemia stem cells","Epigenetics"],"profiles":[{"label":"Society page","url":"https://ehaweb.org/about-eha/organization/eha-board"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Huntly+BJ%5BAuthor%5D"}],"papers":[{"title":"Leukaemia stem cells and the evolution of cancer-stem-cell research","journal":"Nature Reviews Cancer","year":2005,"doi":"10.1038/nrc1592"},{"title":"Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance","journal":"Blood","year":2016,"doi":"10.1182/blood-2015-07-604496"},{"title":"Targeting Epigenetic Readers in Cancer","journal":"New England Journal of Medicine","year":2012,"doi":"10.1056/nejmra1112635"}],"orcid":"0000-0003-0312-161X"},{"id":"brian-rini","kind":"person","name":"Brian I. Rini","aka":[],"tldr":"Led KEYNOTE-426, which made pembrolizumab plus axitinib a first-line standard for kidney cancer.","summary":"Brian Rini was principal investigator of KEYNOTE-426, the trial showing pembrolizumab plus axitinib improves survival over sunitinib in first-line advanced renal cell carcinoma, and of IMmotion151 (atezolizumab plus bevacizumab). He has led studies of active surveillance in metastatic RCC and of biomarkers of immunotherapy response. He directs clinical trials at Vanderbilt-Ingram.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rini%20BI%5BAuthor%5D%20renal%20pembrolizumab%20axitinib"}],"tags":["rcc","immunotherapy","trialist"],"related":[],"cancers":["rcc"],"sections":[],"technologies":["checkpoint-inhibitor","antiangiogenic"],"targets":["pd1","vegf"],"drugs":["pembrolizumab"],"companies":[],"institutions":["vanderbilt-ingram"],"pathways":[],"terms":[],"trials":["keynote-426"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief of Clinical Trials, Vanderbilt-Ingram Cancer Center; Ingram Professor of Cancer Research","institutionId":"vanderbilt-ingram","specialisms":["Renal cell carcinoma","Immunotherapy combinations","Antiangiogenic therapy","Trial design"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rini%20BI%5BAuthor%5D%20renal%20pembrolizumab%20axitinib"}],"papers":[{"title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma (KEYNOTE-426)","journal":"NEJM","year":2019,"doi":"10.1056/NEJMoa1816714"},{"title":"Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial","journal":"Lancet Oncology","year":2016,"doi":"10.1016/S1470-2045(16)30196-6"}],"orcid":"0000-0002-2212-080X"},{"id":"brigitte-widemann","kind":"person","name":"Brigitte C. Widemann","aka":[],"tldr":"Led the selumetinib trials that gave children with neurofibromatosis their first approved drug.","summary":"Brigitte C. Widemann is Chief of the Pediatric Oncology Branch and Special Advisor to the NCI Director for Childhood Cancer at the National Cancer Institute. She is a paediatric oncologist known for the neurofibromatosis type 1 plexiform neurofibroma studies that led to selumetinib's approval, the first approved drug for children with the condition. Her selected paper reports selumetinib in children with inoperable plexiform neurofibromas. She now leads NCI's paediatric oncology branch and its rare tumour initiatives, with interests spanning neuroblastoma and sarcomas.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Brigitte_C._Widemann","links":[{"label":"NCI CCR profile","url":"https://ccr.cancer.gov/staff-directory/brigitte-c-widemann"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Widemann%20BC%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["neuroblastoma","sarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["nci"],"pathways":["ras-mapk"],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief, Pediatric Oncology Branch; Special Advisor to the NCI Director for Childhood Cancer","institutionId":"nci","specialisms":["Paediatric oncology","Neurofibromatosis","MEK inhibitors"],"profiles":[{"label":"NCI CCR profile","url":"https://ccr.cancer.gov/staff-directory/brigitte-c-widemann"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Widemann%20BC%5BAuthor%5D"}],"papers":[{"title":"Selumetinib in children with inoperable plexiform neurofibromas","journal":"New England Journal of Medicine","year":2020,"url":"https://doi.org/10.1056/NEJMoa1912735","doi":"10.1056/NEJMoa1912735"}]},{"id":"bruce-levine","kind":"person","name":"Bruce L. Levine","aka":[],"tldr":"Built the manufacturing that turned CAR-T from a lab idea into a product given to thousands of patients.","summary":"Bruce L. Levine is the Barbara and Edward Netter Professor in Cancer Gene Therapy and Founding Director of the Clinical Cell and Vaccine Production Facility at the Abramson Cancer Center, University of Pennsylvania. He is known for building the manufacturing that turned CAR-T from a laboratory idea into a product given to thousands of patients, including co-developing the CTL019 manufacturing process. His selected paper reviews global manufacturing of CAR T cell therapy. He is a past president of the International Society for Cell & Gene Therapy and continues to work on cell therapy manufacturing and in vivo CAR-T.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Levine%20BL%5BAuthor%5D"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["car-t","in-vivo-car-t"],"targets":[],"drugs":[],"companies":[],"institutions":["penn-abramson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Barbara and Edward Netter Professor in Cancer Gene Therapy; Founding Director, Clinical Cell and Vaccine Production Facility","institutionId":"penn-abramson","specialisms":["Cell therapy manufacturing","CAR-T","Translational immunotherapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Levine%20BL%5BAuthor%5D"}],"papers":[{"title":"Global manufacturing of CAR T cell therapy","journal":"Molecular Therapy Methods & Clinical Development","year":2017,"url":"https://doi.org/10.1016/j.omtm.2016.12.006","doi":"10.1016/j.omtm.2016.12.006"},{"title":"ELIANA: the global trial that made tisagenlecleucel the first approved CAR-T therapy for children and young adults with relapsed ALL","journal":"New England Journal of Medicine","year":2018,"url":"https://doi.org/10.1056/NEJMoa1709866","doi":"10.1056/NEJMoa1709866"},{"title":"Maude 2014: CD19 CAR-T cells produce complete remission in 27 of 30 children and adults with relapsed ALL","journal":"New England Journal of Medicine","year":2014,"url":"https://doi.org/10.1056/NEJMoa1407222","doi":"10.1056/NEJMoa1407222"}],"orcid":"0000-0001-6971-8465"},{"id":"bruce-stillman","kind":"person","name":"Bruce W. Stillman","aka":[],"tldr":"Bruce Stillman discovered how DNA replication starts, the process cancer cells push into overdrive.","summary":"Bruce W. Stillman is President and Chief Executive Officer of Cold Spring Harbor Laboratory, which he has led since 1994. He is a molecular biologist known for discovering how DNA replication starts, identifying the origin recognition complex and the mechanisms of chromatin assembly during replication. His selected paper describes ATP-dependent recognition of eukaryotic origins of DNA replication by a multiprotein complex. His research on DNA replication, chromatin and genome stability bears on the process that cancer cells push into overdrive.","asOf":"2026-09-08","links":[{"label":"CSHL leadership","url":"https://www.cshl.edu/about-us/leadership/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Stillman%20B%5BAuthor%5D"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cold-spring-harbor"],"pathways":["p53-cell-cycle"],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President and Chief Executive Officer","institutionId":"cold-spring-harbor","specialisms":["DNA replication","Chromatin","Genome stability"],"profiles":[{"label":"CSHL leadership","url":"https://www.cshl.edu/about-us/leadership/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Stillman%20B%5BAuthor%5D"}],"papers":[{"title":"ATP-dependent recognition of eukaryotic origins of DNA replication by a multiprotein complex","journal":"Nature","year":1992,"url":"https://doi.org/10.1038/357128a0","doi":"10.1038/357128a0"}],"orcid":"0000-0002-9453-4091"},{"id":"bruno-sangro","kind":"person","name":"Bruno Sangro","aka":[],"tldr":"Hepatologist at Clínica Universidad de Navarra and a leading international investigator in liver cancer systemic therapy and radioembolisation.","summary":"Bruno Sangro leads translational research on the Executive Committee of the Cancer Center Clínica Universidad de Navarra and directs the Liver Unit at the clinic. He has been a principal investigator in major hepatocellular carcinoma trials, including immunotherapy combinations, and has contributed to EASL and ESMO guidelines for liver cancer.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://cancercenter.cun.es/cancer-center/organigrama"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sangro+B%5BAuthor%5D"}],"tags":["clinician-scientist","liver cancer","immunotherapy"],"related":[],"cancers":["hcc","cholangiocarcinoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cun-navarra"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Translational Research lead, Executive Committee","institutionId":"cun-navarra","specialisms":["Hepatocellular carcinoma","Hepatology","Liver cancer immunotherapy"],"profiles":[{"label":"Institution profile","url":"https://cancercenter.cun.es/cancer-center/organigrama"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sangro+B%5BAuthor%5D"}],"papers":[{"title":"Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","journal":"Annals of Oncology","year":2024,"doi":"10.1016/j.annonc.2024.02.005"},{"title":"Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study","journal":"The Lancet","year":2025,"doi":"10.1016/s0140-6736(24)02551-0"},{"title":"Immunotherapy of Hepatocellular Carcinoma: Facts and Hopes","journal":"Clinical Cancer Research","year":2018,"doi":"10.1158/1078-0432.ccr-17-0289"}],"orcid":"0000-0002-4177-6417"},{"id":"bryan-haugen","kind":"person","name":"Bryan R. Haugen","aka":[],"tldr":"Colorado endocrinologist who chaired the 2015 American Thyroid Association guidelines, the reference for how thyroid nodules and differentiated thyroid cancer are diagnosed and treated.","summary":"Bryan Haugen heads the division of endocrinology, metabolism and diabetes at the University of Colorado and directs its thyroid tumour programme. He chaired the task force that produced the 2015 American Thyroid Association management guidelines for adults with thyroid nodules and differentiated thyroid cancer, which introduced more conservative surgery and radioiodine use for low-risk disease. His research covers thyroid cancer biology and redifferentiation therapy.","asOf":"2026-09-18","links":[],"tags":["thyroid","guidelines"],"related":[],"cancers":["papillary-thyroid-cancer","follicular-thyroid-cancer","thyroid"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["colorado-cancer-center"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-ata-2015-thyroid-nodules-dtc-haugen-thyroid-2016"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medicine and Head of Endocrinology, University of Colorado","institutionId":"colorado-cancer-center","specialisms":["Differentiated thyroid cancer","Thyroid nodules","Clinical guidelines"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Haugen%5BAuthor%5D"}],"papers":[{"title":"2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer","journal":"Thyroid","year":2016,"url":"https://doi.org/10.1089/thy.2015.0020","doi":"10.1089/thy.2015.0020"}]},{"id":"bud-romine","kind":"person","name":"Bud Romine","aka":[],"tldr":"A retired railway engineer from Oregon with chronic myeloid leukaemia, he was the first person to take the drug that became Gleevec, in June 1998, after reading about Brian Druker's research in a newspaper.","summary":"Bud Romine, from Tillamook, Oregon, had chronic myeloid leukaemia when he read a 1996 newspaper account of Brian Druker's laboratory work at Oregon Health & Science University on a compound that switched off the BCR-ABL kinase. He wrote to Druker asking to be treated and, in June 1998, became the first patient dosed in the phase 1 trial of STI571, later imatinib. The trial went on to show that nearly every patient at effective doses achieved a normal blood count, a result without precedent in cancer drug development, and the FDA approved imatinib in May 2001 in under three months of review. His letter and his willingness to be first are part of the documented history of the drug at OHSU and in accounts such as Jessica Wapner's The Philadelphia Chromosome.","asOf":"2026-09-09","links":[{"label":"OHSU Knight Cancer Institute","url":"https://www.ohsu.edu/knight-cancer-institute"},{"label":"Imatinib (Wikipedia)","url":"https://en.wikipedia.org/wiki/Imatinib"}],"tags":["hero","patient"],"related":[],"cancers":["cml"],"sections":[],"technologies":["kinase-inhibitors"],"targets":["bcr-abl"],"drugs":["imatinib"],"companies":[],"institutions":[],"pathways":[],"terms":["oncogene-addiction"],"trials":[],"people":["brian-druker","janet-rowley"],"bottlenecks":["b-trial-enrolment"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"First patient in the imatinib (STI571) phase 1 trial","specialisms":["Chronic myeloid leukaemia","Clinical trial participation"],"profiles":[{"label":"OHSU Knight Cancer Institute","url":"https://www.ohsu.edu/knight-cancer-institute"},{"label":"Imatinib (Wikipedia)","url":"https://en.wikipedia.org/wiki/Imatinib"}],"papers":[]},{"id":"cho-byoung-chul","kind":"person","name":"Byoung Chul Cho","aka":[],"tldr":"Co-led MARIPOSA, the trial where amivantamab plus lazertinib beat osimertinib, and a leading figure in Asian lung cancer drug development.","summary":"Byoung Chul Cho is Professor in the Division of Medical Oncology and Director of the Yonsei Lung Cancer Center at Severance Hospital, Yonsei University, in Seoul. He co-led MARIPOSA, the trial in which amivantamab plus lazertinib beat osimertinib in previously untreated EGFR-mutated advanced non-small-cell lung cancer, and was a principal investigator for lazertinib from its phase 1 study onwards. He has also led numerous EGFR, MET and immunotherapy trials, and his publications include the MARIPOSA report on amivantamab plus lazertinib. He is a leading figure in Asian lung cancer drug development, with interests in EGFR-mutant disease and bispecific antibodies.","asOf":"2026-09-08","links":[{"label":"Yonsei Cancer Center","url":"https://sev.severance.healthcare"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cho%20BC%5BAuthor%5D%20Yonsei%20lung%20cancer"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":["egfr","met"],"drugs":["amivantamab","lazertinib"],"companies":[],"institutions":["severance"],"pathways":[],"terms":[],"trials":["mariposa"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor, Division of Medical Oncology; Director, Yonsei Lung Cancer Center","institutionId":"severance","specialisms":["Lung cancer","EGFR-mutant NSCLC","Bispecific antibodies","Drug development"],"profiles":[{"label":"Yonsei Cancer Center","url":"https://sev.severance.healthcare"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cho%20BC%5BAuthor%5D%20Yonsei%20lung%20cancer"}],"papers":[{"title":"Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC (MARIPOSA)","journal":"NEJM","year":2024,"doi":"10.1056/NEJMoa2403614"},{"title":"ADRIATIC: durvalumab after chemoradiotherapy for limited-stage small-cell lung cancer","journal":"New England Journal of Medicine","year":2024,"url":"https://doi.org/10.1056/NEJMoa2404873","doi":"10.1056/NEJMoa2404873"},{"title":"DeLLphi-301: tarlatamab, a DLL3-targeting T-cell engager, in previously treated small-cell lung cancer","journal":"New England Journal of Medicine","year":2023,"url":"https://doi.org/10.1056/NEJMoa2307980","doi":"10.1056/NEJMoa2307980"},{"title":"FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer","journal":"New England Journal of Medicine","year":2018,"url":"https://doi.org/10.1056/NEJMoa1713137","doi":"10.1056/NEJMoa1713137"},{"title":"PACIFIC: a year of durvalumab after chemoradiotherapy for stage III lung cancer","journal":"New England Journal of Medicine","year":2017,"url":"https://doi.org/10.1056/NEJMoa1709937","doi":"10.1056/NEJMoa1709937"}]},{"id":"ola-landgren","kind":"person","name":"C. Ola Landgren","aka":[],"tldr":"Showed that MGUS precedes essentially all myeloma and leads MRD-driven trials aiming for cure without transplant.","summary":"Ola Landgren led the prospective studies showing that monoclonal gammopathy of undetermined significance precedes virtually every case of multiple myeloma, defining the disease's precursor states, and now leads MRD-driven trials such as MANHATTAN and the daratumumab-KRd studies that achieve MRD negativity in most patients without transplant. He co-leads the international effort that made MRD an FDA-accepted endpoint.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Landgren%20O%5BAuthor%5D%20myeloma%20MRD%20OR%20MGUS"}],"tags":["myeloma","mrd","precursor"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":["mrd-testing"],"targets":["cd38"],"drugs":[],"companies":[],"institutions":["sylvester-miami"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-jaiswal-chip-nejm-2014"],"journals":["jama-oncology","blood"],"dependsOn":[],"notes":[],"role":"Chief of Myeloma and Director of the Sylvester Myeloma Institute, Sylvester Comprehensive Cancer Center, University of Miami","institutionId":"sylvester-miami","specialisms":["Multiple myeloma","Minimal residual disease","Precursor conditions (MGUS)","Quadruplet therapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Landgren%20O%5BAuthor%5D%20myeloma%20MRD%20OR%20MGUS"}],"papers":[{"title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study","journal":"Blood","year":2009,"doi":"10.1182/blood-2008-12-194241"},{"title":"Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma: the MANHATTAN nonrandomized clinical trial","journal":"JAMA Oncology","year":2021,"doi":"10.1001/jamaoncol.2021.0611"},{"title":"Jaiswal: clonal haematopoiesis, the pre-leukaemic clones in most people over 70","journal":"New England Journal of Medicine","year":2014,"url":"https://doi.org/10.1056/NEJMoa1408617","doi":"10.1056/NEJMoa1408617"}]},{"id":"pramesh-c-s","kind":"person","name":"C. S. Pramesh","aka":[],"tldr":"The surgeon who built the National Cancer Grid into a network of hundreds of Indian cancer centres and used its buying power to cut cancer drug prices by a median of 82%.","summary":"C. S. Pramesh is a thoracic surgeon and Director of Tata Memorial Hospital in Mumbai. He has been the convener of the National Cancer Grid since its formation and is first author of the papers describing it, of India's Choosing Wisely list for cancer care, and of the Bulletin of the World Health Organization report on the Grid's pooled procurement pilot, which pooled demand for 40 anticancer drugs from 23 centres and cut costs by about 13.2 billion rupees. He co-founded the CReDO research methods workshops that have trained more than 250 oncologists, and writes on the ethics and pragmatism of trials in low- and middle-income countries.","asOf":"2026-09-10","links":[{"label":"Tata Memorial Centre","url":"https://tmc.gov.in"},{"label":"National Cancer Grid","url":"https://www.ncgindia.org"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Pramesh%20CS%5BAuthor%5D%20National%20Cancer%20Grid"}],"tags":[],"related":[],"cancers":["esophageal","nsclc"],"sections":[],"technologies":["global-oncology-access"],"targets":[],"drugs":[],"companies":[],"institutions":["tata-memorial","national-cancer-grid"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-drug-pricing","b-global-access"],"keyPapers":["paper-pramesh-ncg-pooled-procurement-2023"],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Tata Memorial Hospital; thoracic surgical oncologist; convener, National Cancer Grid","institutionId":"tata-memorial","specialisms":["Thoracic surgical oncology","Oesophageal and lung cancer surgery","Health systems and cancer policy","Pooled procurement","Clinical research methods"],"profiles":[{"label":"Tata Memorial Centre","url":"https://tmc.gov.in"},{"label":"National Cancer Grid","url":"https://www.ncgindia.org"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Pramesh%20CS%5BAuthor%5D%20National%20Cancer%20Grid"}],"papers":[{"title":"A National Cancer Grid pooled procurement initiative, India","journal":"Bulletin of the World Health Organization","year":2023,"doi":"10.2471/BLT.23.289714"},{"title":"The National Cancer Grid of India","journal":"Indian Journal of Medical and Paediatric Oncology","year":2014,"doi":"10.4103/0971-5851.142040"},{"title":"Choosing Wisely for cancer care in India","journal":"Indian Journal of Surgical Oncology","year":2020,"doi":"10.1007/s13193-020-01051-4"}]},{"id":"caetano-reis-e-sousa","kind":"person","name":"Caetano Reis e Sousa","aka":[],"tldr":"Immunologist who works out how dendritic cells detect dying tumour cells and start an anti-cancer response.","summary":"Caetano Reis e Sousa is Principal Group Leader of the Immunobiology Laboratory at The Francis Crick Institute in London. His specialisms are innate immunity, dendritic cells and cross-presentation. He studies the receptors dendritic cells use to sense dead cells and viruses, including DNGR-1 and other C-type lectins, and how those signals let dendritic cells prime T cells. His Current Opinion in Immunology paper reviewed how myeloid C-type lectin receptors sense cell death. This work explains how the immune system detects dying tumour cells and underpins cancer vaccination and immunotherapy. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Reis%20e%20Sousa%20C%5BAuthor%5D%20dendritic"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["francis-crick"],"pathways":["pd1-checkpoint"],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Principal Group Leader, Immunobiology Laboratory, Francis Crick Institute","institutionId":"francis-crick","specialisms":["Innate immunity","Dendritic cells","Cross-presentation"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Reis%20e%20Sousa%20C%5BAuthor%5D%20dendritic"}],"papers":[{"title":"Sensing of cell death by myeloid C-type lectin receptors","journal":"Current Opinion in Immunology","year":2012}]},{"id":"zhou-caicun","kind":"person","name":"Caicun Zhou","aka":["caicun-zhou"],"tldr":"Principal investigator of HARMONi-2, the trial where ivonescimab beat pembrolizumab head-to-head, and of the first EGFR-TKI phase 3 in Chinese patients.","summary":"Caicun Zhou is Professor of Medical Oncology at Shanghai Pulmonary Hospital, Tongji University, and a leader of the Chinese Thoracic Oncology Group. He led OPTIMAL, one of the first trials to prove that an EGFR tyrosine kinase inhibitor, erlotinib, beats chemotherapy in EGFR-mutant non-small-cell lung cancer, and it was the first EGFR-TKI phase 3 in Chinese patients. Two decades later he was principal investigator of HARMONi-2, in which the Akeso bispecific antibody ivonescimab, which targets PD-1 and VEGF, beat pembrolizumab head-to-head in first-line PD-L1-positive non-small-cell lung cancer. His publications include the HARMONi-2 and OPTIMAL trial reports, and his interests span EGFR inhibitors, immunotherapy and bispecific antibodies. He is President of the International Association for the Study of Lung Cancer for the 2025 to 2027 term and one of the most prolific lung cancer clinical investigators in China.","asOf":"2026-09-08","links":[{"label":"Shanghai Pulmonary Hospital","url":"https://www.shsfkyy.com"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Zhou%20C%5BAuthor%5D%20Shanghai%20Pulmonary%20Hospital%20ivonescimab"},{"label":"IASLC board","url":"https://www.iaslc.org/learn-about-us/board-directors"}],"tags":["leadership","clinician-scientist","lung cancer"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":[],"targets":["pd1","vegf","egfr"],"drugs":["ivonescimab"],"companies":["ctong","akeso"],"institutions":["shanghai-pulmonary-hospital","iaslc"],"pathways":[],"terms":[],"trials":["harmoni-2"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University; President, IASLC (2025-2027)","institutionId":"shanghai-pulmonary-hospital","specialisms":["Lung cancer","EGFR inhibitors","Immunotherapy","Bispecific antibodies","Targeted therapy"],"profiles":[{"label":"Shanghai Pulmonary Hospital","url":"https://www.shsfkyy.com"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Zhou%20C%5BAuthor%5D%20Shanghai%20Pulmonary%20Hospital%20ivonescimab"},{"label":"IASLC board","url":"https://www.iaslc.org/learn-about-us/board-directors"}],"papers":[{"title":"Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2)","journal":"Lancet","year":2025,"doi":"10.1016/S0140-6736(24)02722-3"},{"title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL)","journal":"Lancet Oncology","year":2011,"doi":"10.1016/S1470-2045(11)70184-X"},{"title":"Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial","journal":"The Lancet Respiratory Medicine","year":2021,"doi":"10.1016/s2213-2600(20)30365-9"},{"title":"Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)","journal":"Annals of Oncology","year":2015,"doi":"10.1093/annonc/mdv276"},{"title":"FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer","journal":"New England Journal of Medicine","year":2018,"url":"https://doi.org/10.1056/NEJMoa1713137","doi":"10.1056/NEJMoa1713137"},{"title":"HARMONi-2: ivonescimab, a PD-1 x VEGF bispecific, beats pembrolizumab head-to-head in PD-L1-positive lung cancer","journal":"The Lancet","year":2025,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=HARMONi-2+ivonescimab+pembrolizumab+Lancet"}]},{"id":"candace-johnson","kind":"person","name":"Candace S. Johnson","aka":[],"tldr":"Candace Johnson is a pharmacologist who has led America's oldest cancer centre since 2015.","summary":"Candace S. Johnson is President and Chief Executive Officer of Roswell Park Comprehensive Cancer Center, America's oldest cancer centre, a post she has held since 2015. She is a cancer pharmacologist and long-time Roswell Park scientist whose research studied calcitriol and how vitamin D can potentiate chemotherapy. Her selected paper reviews vitamin D and cancer. She now combines academic leadership of the centre with her background in cancer pharmacology.","asOf":"2026-09-08","links":[{"label":"Roswell Park profile","url":"https://www.roswellpark.org/candace-johnson"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Johnson%20CS%5BAuthor%5D"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["roswell-park"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President and Chief Executive Officer","institutionId":"roswell-park","specialisms":["Cancer pharmacology","Vitamin D and calcitriol","Academic leadership"],"profiles":[{"label":"Roswell Park profile","url":"https://www.roswellpark.org/candace-johnson"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Johnson%20CS%5BAuthor%5D"}],"papers":[{"title":"Vitamin D and cancer","journal":"Journal of Steroid Biochemistry and Molecular Biology","year":2010}],"orcid":"0000-0002-1211-4692"},{"id":"carien-creutzberg","kind":"person","name":"Carien L. Creutzberg","aka":[],"tldr":"Led the PORTEC trials that defined who needs radiotherapy for endometrial cancer and brought molecular classification into treatment decisions.","summary":"Carien Creutzberg led PORTEC-1, -2 and -3, the Dutch trials that established vaginal brachytherapy over external beam radiotherapy for intermediate-risk endometrial cancer and tested chemoradiotherapy for high-risk disease, and pioneered the integration of the TCGA molecular classification (POLE, MMRd, p53abn, NSMP) into the PORTEC-4a trial and ESGO-ESTRO-ESP guidelines. She co-leads the RAINBO platform of molecularly directed adjuvant trials.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Creutzberg%20CL%5BAuthor%5D%20PORTEC"}],"tags":["endometrial","radiotherapy","molecular-classification"],"related":[],"cancers":["endometrial"],"sections":[],"technologies":["brachytherapy","imrt-igrt"],"targets":[],"drugs":[],"companies":[],"institutions":["lumc-leiden"],"pathways":[],"terms":[],"trials":["portec-3"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Radiation Oncology, Leiden University Medical Center","institutionId":"lumc-leiden","specialisms":["Endometrial cancer","Radiotherapy","Molecular classification","Cooperative-group trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Creutzberg%20CL%5BAuthor%5D%20PORTEC"}],"papers":[{"title":"Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial","journal":"Lancet Oncology","year":2018,"doi":"10.1016/S1470-2045(18)30079-2"},{"title":"Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2)","journal":"Lancet","year":2010,"doi":"10.1016/S0140-6736(09)62163-2"}],"orcid":"0000-0002-7008-4321"},{"id":"carl-june","kind":"person","name":"Carl H. June","aka":[],"tldr":"Developed the CD19 CAR-T therapy that became the first approved gene-modified cell therapy for cancer.","summary":"Carl H. June is the Richard W. Vague Professor in Immunotherapy and Director of the Center for Cellular Immunotherapies at the Abramson Cancer Center, University of Pennsylvania. He is known for developing the CD19 CAR-T therapy that became the first approved gene-modified cell therapy for cancer, leading the CTL019 programme that included Emily Whitehead's treatment in 2012 and culminated in the approval of tisagenlecleucel in 2017. His selected papers report chimeric antigen receptor-modified T cells in chronic lymphoid leukaemia and CAR T cells producing sustained remissions in leukaemia. His centre developed the 4-1BB CAR design now used widely, and he continues to work on gene-modified T cells for leukaemia and lymphoma.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Carl_H._June","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=June%20CH%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["all-leukemia","cll","dlbcl"],"sections":[],"technologies":["car-t"],"targets":["cd19"],"drugs":["tisagenlecleucel"],"companies":[],"institutions":["penn-abramson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Richard W. Vague Professor in Immunotherapy; Director, Center for Cellular Immunotherapies","institutionId":"penn-abramson","specialisms":["CAR-T cell therapy","Gene-modified T cells","Cellular immunotherapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=June%20CH%5BAuthor%5D"}],"papers":[{"title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","journal":"New England Journal of Medicine","year":2011,"url":"https://doi.org/10.1056/NEJMoa1103849","doi":"10.1056/NEJMoa1103849"},{"title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","journal":"New England Journal of Medicine","year":2014,"url":"https://doi.org/10.1056/NEJMoa1407222","doi":"10.1056/NEJMoa1407222"},{"title":"ELIANA: the global trial that made tisagenlecleucel the first approved CAR-T therapy for children and young adults with relapsed ALL","journal":"New England Journal of Medicine","year":2018,"url":"https://doi.org/10.1056/NEJMoa1709866","doi":"10.1056/NEJMoa1709866"}],"orcid":"0000-0003-0241-3557"},{"id":"carl-james","kind":"person","name":"Carl James","aka":[],"tldr":"Chief executive of the Welsh health trust that runs Velindre Cancer Centre, the specialist cancer hospital for south east Wales.","summary":"Carl James is Chief Executive of Velindre University NHS Trust, the NHS Wales trust established in 1994 as a specialist provider of cancer services, whose Velindre Cancer Centre in Cardiff delivers radiotherapy including stereotactic techniques. He is quoted in that role in an August 2026 trust announcement welcoming Dr Sarah Green as Executive Director of Workforce and Organisational Development. The trust's chair is Sara Moseley.","asOf":"2026-09-10","links":[{"label":"Source: Velindre trust announcement, 12 August 2026","url":"https://velindre.nhs.wales/news/latest-news/velindre-university-nhs-trust-appoints-new-executive-director-of-workforce-and-organisational-development/"}],"tags":["leadership","hospital-management","nhs","wales"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["velindre-cardiff"],"pathways":[],"terms":["radiotherapy","sbrt-term"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive, Velindre University NHS Trust","institutionId":"velindre-cardiff","specialisms":["NHS leadership","Cancer services","Health system management"],"profiles":[{"label":"Velindre University NHS Trust news (quoted as Chief Executive)","url":"https://velindre.nhs.wales/news/latest-news/velindre-university-nhs-trust-appoints-new-executive-director-of-workforce-and-organisational-development/"}],"papers":[]},{"id":"carla-goncalo","kind":"person","name":"Carla Gonçalo","aka":[],"tldr":"Health manager who chairs the board of IPO Lisboa, the Portuguese Oncology Institute in Lisbon, since the board took office in 2025.","summary":"Carla Gonçalo is Presidente do Conselho de Administração of the Instituto Português de Oncologia de Lisboa Francisco Gentil (IPO Lisboa), the public oncology hospital that serves as the cancer reference centre for the Lisbon region. She is a health manager who previously sat on the management council of the Executive Directorate of Portugal's National Health Service (SNS) and earlier served as vice-president of the Central Administration of the Health System (ACSS). The current board was appointed by Resolução do Conselho de Ministros n.º 60/2025, published on 18 March 2025, for a three-year term.","asOf":"2026-09-10","links":[{"label":"Source: IPO Lisboa news, new administration","url":"https://www.ipolisboa.min-saude.pt/noticias/ipo-lisboa-tem-nova-administracao/"}],"tags":["leadership","health-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ipo-lisboa"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Presidente do Conselho de Administração (Chair of the Board of Directors) of IPO Lisboa","institutionId":"ipo-lisboa","specialisms":["Health services management","Hospital governance","Public health administration"],"profiles":[{"label":"Institution news: new board announced","url":"https://www.ipolisboa.min-saude.pt/noticias/ipo-lisboa-tem-nova-administracao/"},{"label":"Institution governance page","url":"https://www.ipolisboa.min-saude.pt/ipo/governacao/"}],"papers":[]},{"id":"carla-van-gils","kind":"person","name":"Carla van Gils","aka":[],"tldr":"Cancer epidemiologist who co-leads KWF, the Dutch Cancer Society, the Netherlands' largest charitable funder of cancer research.","summary":"Carla van Gils is one of the two bestuurders (executive directors) of KWF Kankerbestrijding, the Dutch Cancer Society, a donor-funded foundation established in 1949 that finances cancer research at universities and institutes across the Netherlands; she leads the organisation jointly with Dorine Manson under a supervisory board chaired by Wiebe Draijer. She is Professor of Clinical Epidemiology of Cancer at UMC Utrecht, where she previously coordinated the cancer research programme of the Julius Center, and joined the KWF executive on 1 June 2021.","asOf":"2026-09-10","links":[{"label":"Source: KWF organisation page","url":"https://www.kwf.nl/over-ons/onze-organisatie"}],"tags":["leadership","clinician-scientist","epidemiology","research-funding"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["kwf"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["jama","radiology","jnci"],"dependsOn":[],"notes":[],"role":"Bestuurder (Executive Director) of KWF Kankerbestrijding, jointly with Dorine Manson","institutionId":"kwf","specialisms":["Clinical epidemiology of cancer","Cancer research funding","Research programme leadership"],"profiles":[{"label":"Institution organisation page","url":"https://www.kwf.nl/over-ons/onze-organisatie"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=van+Gils+CH%5BAuthor%5D"}],"papers":[{"title":"Consumption of Vegetables and Fruits and Risk of Breast Cancer","journal":"JAMA","year":2005,"doi":"10.1001/jama.293.2.183"},{"title":"MR Imaging as an Additional Screening Modality for the Detection of Breast Cancer in Women Aged 50–75 Years with Extremely Dense Breasts: The DENSE Trial Study Design","journal":"Radiology","year":2015,"doi":"10.1148/radiol.2015141827"},{"title":"Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis","journal":"JNCI: Journal of the National Cancer Institute","year":2018,"doi":"10.1093/jnci/djx273"}],"orcid":"0000-0003-0817-7567"},{"id":"carlo-cimbri","kind":"person","name":"Carlo Cimbri","aka":[],"tldr":"Carlo Cimbri represents IEO (European Institute of Oncology) in the Organisation of European Cancer Institutes, which lists the centre among its members in Italy.","summary":"Carlo Cimbri is listed by the Organisation of European Cancer Institutes (OECI) as the representative of IEO (European Institute of Oncology), its member in Italy. Founded by Umberto Veronesi, pioneer of breast-conserving surgery and sentinel node biopsy. OnCo records the name from the OECI membership list so that the centre's page has a named contact point; the person's exact title, appointment date and biography are not yet recorded and should be checked on the institution's own pages before being relied on.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"IEO (European Institute of Oncology) website","url":"http://www.ieo.it/en"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ieo-milan"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of IEO (European Institute of Oncology) to the Organisation of European Cancer Institutes","institutionId":"ieo-milan","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"IEO (European Institute of Oncology) website","url":"http://www.ieo.it/en"}],"papers":[]},{"id":"barrios-carlos","kind":"person","name":"Carlos Barrios","aka":[],"tldr":"Carlos Barrios is the most visible Latin American voice in global breast cancer trials and a founder of the region's cooperative group LACOG.","summary":"Carlos Barrios is a medical oncologist and Director of the Oncology Research Center at Hospital São Lucas PUCRS, a co-founder of the Latin American Cooperative Oncology Group (LACOG), and a collaborator with Hospital Israelita Albert Einstein and other major São Paulo centres. He has served on the steering committees of numerous global breast cancer trials and is the most visible Latin American voice in that field, having built LACOG to expand trial access across the region. His publications include analyses of trastuzumab emtansine in HER2-positive advanced breast cancer from the KAMILLA safety trial and a qualitative study of barriers to multidisciplinary breast cancer care in five Latin American countries. His interests are breast cancer, Latin American trials and global oncology.","asOf":"2026-09-08","links":[{"label":"LACOG","url":"https://lacog.org.br"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Barrios%20CH%5BAuthor%5D%20breast%20cancer%20Latin%20America"}],"tags":[],"related":[],"cancers":["breast-hr-positive","breast-her2-positive"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["einstein-sao-paulo"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Medical oncologist; Director, Oncology Research Center, Hospital São Lucas PUCRS; Latin American Cooperative Oncology Group","specialisms":["Breast cancer","Clinical trials in Latin America","Global oncology"],"profiles":[{"label":"LACOG","url":"https://lacog.org.br"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Barrios%20CH%5BAuthor%5D%20breast%20cancer%20Latin%20America"}],"papers":[{"title":"Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial☆","journal":"Annals of Oncology","year":2020,"doi":"10.1016/j.annonc.2020.06.020"},{"title":"Final results of the global and Asia cohorts of KAMILLA, a phase IIIB safety trial of trastuzumab emtansine in patients with HER2-positive advanced breast cancer","journal":"ESMO Open","year":2022,"doi":"10.1016/j.esmoop.2022.100561"},{"title":"Barriers and facilitators to provide multidisciplinary care for breast cancer patients in five Latin American countries: A descriptive-interpretative qualitative study","journal":"The Lancet Regional Health - Americas","year":2022,"doi":"10.1016/j.lana.2022.100254"},{"title":"DESTINY-Breast06: trastuzumab deruxtecan before any chemotherapy in hormone-receptor-positive, HER2-low or ultralow breast cancer","journal":"New England Journal of Medicine","year":2024,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DESTINY-Breast06+trastuzumab+deruxtecan+HER2-low+chemotherapy-naive"},{"title":"NATALEE: three years of ribociclib after surgery in a broad population of hormone-receptor-positive early breast cancer","journal":"New England Journal of Medicine","year":2024,"url":"https://doi.org/10.1056/NEJMoa2305488","doi":"10.1056/NEJMoa2305488"},{"title":"TROPION-Breast01: datopotamab deruxtecan versus chemotherapy in pretreated hormone-receptor-positive breast cancer, and why a PFS win did not translate to survival","journal":"Journal of Clinical Oncology","year":2024,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=TROPION-Breast01+datopotamab+deruxtecan+Bardia"}]},{"id":"carlos-caldas","kind":"person","name":"Carlos Caldas","aka":[],"tldr":"Led METABRIC, which used 2,000 tumours to define ten genomic subtypes of breast cancer and their long-term outcomes.","summary":"Carlos Caldas led METABRIC, the integrated genomic and transcriptomic analysis of 2,000 breast cancers that defined ten integrative clusters with distinct 20-year outcomes, and the follow-up showing that late relapse risk differs sharply between them. His group built a large breast cancer PDX biobank for functional testing and studies the evolution of metastatic breast cancer. He led the Cambridge Breast Cancer Research Unit.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Carlos_Caldas","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Caldas%20C%5BAuthor%5D%20breast%20genomic%20METABRIC"}],"tags":["genomics","breast","classification"],"related":[],"cancers":["breast-hr-positive","tnbc","breast-her2-positive"],"sections":[],"technologies":["wes-wgs","rna-seq","pdx-models"],"targets":[],"drugs":[],"companies":[],"institutions":["cruk-cambridge-centre"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Cancer Medicine, University of Cambridge; Senior Group Leader, CRUK Cambridge Institute","institutionId":"cruk-cambridge-centre","specialisms":["Breast cancer genomics","Integrative clusters","Patient-derived xenografts","Functional genomics"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Caldas%20C%5BAuthor%5D%20breast%20genomic%20METABRIC"}],"papers":[{"title":"The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups (METABRIC)","journal":"Nature","year":2012,"doi":"10.1038/nature10983"},{"title":"Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups","journal":"Nature","year":2019,"doi":"10.1038/s41586-019-1007-8"}],"orcid":"0000-0003-3547-1489"},{"id":"carlos-mingo-rodriguez","kind":"person","name":"Carlos Mingo Rodriguez","aka":[],"tldr":"Carlos Mingo Rodriguez represents Hospital Universitario Ramón y Cajal in the Organisation of European Cancer Institutes, which lists the centre among its full members in Spain.","summary":"Carlos Mingo Rodriguez is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Hospital Universitario Ramón y Cajal, its full member in Spain. OnCo records the name from the OECI membership list so that the centre's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the institution's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Hospital Universitario Ramón y Cajal website","url":"https://www.comunidad.madrid/hospital/ramonycajal/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ramon-y-cajal"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Hospital Universitario Ramón y Cajal to the Organisation of European Cancer Institutes","institutionId":"ramon-y-cajal","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Hospital Universitario Ramón y Cajal website","url":"https://www.comunidad.madrid/hospital/ramonycajal/"}],"papers":[]},{"id":"carmen-martinez-de-pancorbo-gonzalez","kind":"person","name":"Carmen Martínez de Pancorbo González","aka":[],"tldr":"Carmen Martínez de Pancorbo González represents Hospital Universitario 12 de Octubre in the Organisation of European Cancer Institutes, which lists the centre among its members in Spain.","summary":"Carmen Martínez de Pancorbo González is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Hospital Universitario 12 de Octubre, its full member in Spain. OnCo records the name from the OECI membership list so that the centre's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the institution's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Hospital Universitario 12 de Octubre website","url":"https://www.comunidad.madrid/hospital/12octubre/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["12-de-octubre"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Hospital Universitario 12 de Octubre to the Organisation of European Cancer Institutes","institutionId":"12-de-octubre","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Hospital Universitario 12 de Octubre website","url":"https://www.comunidad.madrid/hospital/12octubre/"}],"papers":[]},{"id":"carolina-samuelsson","kind":"person","name":"Carolina Samuelsson","aka":[],"tldr":"Physician and hospital director of Skåne University Hospital, the university hospital serving southern Sweden and home to Lund's cancer services.","summary":"Carolina Samuelsson is Hospital Director (sjukhusdirektör) of Skåne University Hospital in Lund and Malmö, one of Sweden's largest university hospitals and the clinical partner of Lund University's cancer research. A specialist in anaesthesiology and intensive care by training, she is responsible for the hospital's overall operations, including its comprehensive cancer care.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Samuelsson+C%5BAuthor%5D"}],"tags":["leadership","hospital management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["lund-skane"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Hospital Director","institutionId":"lund-skane","specialisms":["Hospital leadership","Anaesthesiology and intensive care","Health system management"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Samuelsson+C%5BAuthor%5D"}],"papers":[{"title":"Gender differences in outcome and use of resources do exist in Swedish intensive care, but to no advantage for women of premenopausal age","journal":"Critical Care","year":2015,"url":"https://doi.org/10.1186/s13054-015-0873-1","doi":"10.1186/s13054-015-0873-1","note":"OpenAlex author record matched by institution"},{"title":"Cerebral Glutamine and Glutamate Levels in Relation to Compromised Energy Metabolism: A Microdialysis Study in Subarachnoid Hemorrhage Patients","journal":"Journal of Cerebral Blood Flow & Metabolism","year":2007,"url":"https://doi.org/10.1038/sj.jcbfm.9600433","doi":"10.1038/sj.jcbfm.9600433","note":"OpenAlex author record matched by institution"}]},{"id":"carolina-wiesner","kind":"person","name":"Carolina Wiesner","aka":[],"tldr":"Carolina Wiesner represents Instituto Nacional de Cancerología (Colombia) in the Organisation of European Cancer Institutes, which lists the centre among its members in Colombia.","summary":"Carolina Wiesner is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Instituto Nacional de Cancerología (Colombia), its associate member in Colombia. OnCo records the name from the OECI membership list so that the centre's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the institution's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Instituto Nacional de Cancerología (Colombia) website","url":"https://www.cancer.gov.co"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["inc-colombia"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Instituto Nacional de Cancerología (Colombia) to the Organisation of European Cancer Institutes","institutionId":"inc-colombia","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Instituto Nacional de Cancerología (Colombia) website","url":"https://www.cancer.gov.co"}],"papers":[{"title":"Performance of standardised colposcopy to detect cervical precancer and cancer for triage of women testing positive for human papillomavirus: results from the ESTAMPA multicentric screening study","journal":"The Lancet Global Health","year":2023,"url":"https://doi.org/10.1016/s2214-109x(22)00545-9","doi":"10.1016/s2214-109x(22)00545-9","note":"OpenAlex author record matched by institution"},{"title":"Access to cancer care in Colombia, a middle-income country with universal health coverage","journal":"Journal of Cancer Policy","year":2018,"url":"https://doi.org/10.1016/j.jcpo.2018.01.003","doi":"10.1016/j.jcpo.2018.01.003","note":"OpenAlex author record matched by institution"},{"title":"Distribution of human papillomavirus genotypes by severity of cervical lesions in HPV screened positive women from the ESTAMPA study in Latin America","journal":"PLoS ONE","year":2022,"url":"https://doi.org/10.1371/journal.pone.0272205","doi":"10.1371/journal.pone.0272205","note":"OpenAlex author record matched by institution"}]},{"id":"caroline-dive","kind":"person","name":"Caroline Dive","aka":[],"tldr":"Built small-cell lung cancer models from circulating tumour cells and leads the Manchester institute.","summary":"Caroline Dive is Director of the Cancer Research UK Manchester Institute and Professor of Cancer Pharmacology, working with The Christie NHS Foundation Trust and Cancer Research UK. Her specialisms are liquid biopsy, circulating tumour cells and small-cell lung cancer models. She pioneered explant models of small-cell lung cancer grown from patients' circulating tumour cells, reported in Nature Medicine as a study of the tumorigenicity and genetic profiles of those cells. She now leads the Manchester institute and its biomarker centre, working across circulating tumour DNA and patient-derived xenografts. Her publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dive%20C%5BAuthor%5D%20circulating%20tumour%20cells%20small%20cell"}],"tags":[],"related":[],"cancers":["sclc"],"sections":[],"technologies":["liquid-biopsy","pdx-models"],"targets":[],"drugs":[],"companies":[],"institutions":["the-christie","cruk"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Cancer Research UK Manchester Institute; Professor of Cancer Pharmacology","institutionId":"the-christie","specialisms":["Liquid biopsy","Circulating tumour cells","Small-cell lung cancer models"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dive%20C%5BAuthor%5D%20circulating%20tumour%20cells%20small%20cell"}],"papers":[{"title":"Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer","journal":"Nature Medicine","year":2014,"doi":"10.1038/nm.3600"}],"orcid":"0000-0002-1726-8850"},{"id":"caroline-moore","kind":"person","name":"Caroline Moore","aka":[],"tldr":"The UCL urologist who has spent her career on the two questions that decide whether a man with prostate cancer is harmed by being diagnosed: who needs a biopsy, and who needs treating at all.","summary":"Caroline Moore is Professor of Urology at University College London and an honorary consultant urologist at University College London Hospitals, where she heads urology in the Department of Targeted Intervention. Her work sits on the diagnostic half of the overdiagnosis problem: she was a senior investigator on PRECISION, the randomised comparison that showed MRI with targeted biopsy finds more clinically significant cancer and less clinically insignificant cancer than a standard twelve-core transrectal biopsy, and that 28 percent of men in the MRI arm had a non-suspicious scan and no biopsy at all.\n\nShe leads UCL work on active surveillance and on focal therapy, and on the patient-reported outcomes of both, which is where the argument about screening will eventually be settled: a programme that detects cancers it then does not have to treat radically is a different proposition from the one the UK National Screening Committee modelled.","asOf":"2026-09-25","links":[{"label":"UCL profiles","url":"https://profiles.ucl.ac.uk/4911-caroline-moore"}],"tags":["prostate","uk","diagnostics"],"related":["mark-emberton","hashim-ahmed"],"cancers":["prostate","prostate-low-risk","prostate-intermediate-risk"],"sections":["diagnostics","surgery"],"technologies":["mri"],"targets":[],"drugs":[],"companies":[],"institutions":["uclh"],"pathways":[],"terms":[],"trials":["promis"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Urology and Head of Urology, Department of Targeted Intervention, University College London; Honorary Consultant Urologist, University College London Hospitals","institutionId":"uclh","specialisms":["MRI-guided diagnosis of prostate cancer","Active surveillance","Focal therapy"],"profiles":[{"label":"UCL profiles","url":"https://profiles.ucl.ac.uk/4911-caroline-moore"}],"papers":[{"title":"MRI-targeted or standard biopsy for prostate-cancer diagnosis","journal":"New England Journal of Medicine","year":2018,"doi":"10.1056/NEJMoa1801993"}]},{"id":"caroline-robert","kind":"person","name":"Caroline Robert","aka":[],"tldr":"Led KEYNOTE-006 and COMBI-v, the trials that made pembrolizumab and dabrafenib-trametinib standards in melanoma.","summary":"Caroline Robert was principal investigator of KEYNOTE-006, which showed pembrolizumab beats ipilimumab in advanced melanoma and established PD-1 monotherapy, of CheckMate 066 (nivolumab versus chemotherapy) and of COMBI-v (dabrafenib plus trametinib versus vemurafenib). She has led long-term follow-up analyses defining durable remission after stopping immunotherapy and heads dermato-oncology at Gustave Roussy.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Robert%20C%5BAuthor%5D%20melanoma%20pembrolizumab"}],"tags":["melanoma","immunotherapy","trialist"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":["checkpoint-inhibitor","kinase-inhibitors"],"targets":["pd1","braf"],"drugs":["pembrolizumab","nivolumab","ipilimumab"],"companies":[],"institutions":["gustave-roussy"],"pathways":[],"terms":[],"trials":["keynote-006"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Head of Dermatology Unit, Gustave Roussy; Professor, Paris-Saclay University","institutionId":"gustave-roussy","specialisms":["Melanoma","Immunotherapy","BRAF/MEK targeted therapy","Dermato-oncology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Robert%20C%5BAuthor%5D%20melanoma%20pembrolizumab"}],"papers":[{"title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006)","journal":"NEJM","year":2015,"doi":"10.1056/NEJMoa1503093"},{"title":"Improved overall survival in melanoma with combined dabrafenib and trametinib (COMBI-v)","journal":"NEJM","year":2015,"doi":"10.1056/NEJMoa1412690"},{"title":"Nivolumab in previously untreated melanoma without BRAF mutation (CheckMate 066)","journal":"NEJM","year":2015,"doi":"10.1056/NEJMoa1412082"}],"orcid":"0000-0002-9493-0238"},{"id":"caron-jacobson","kind":"person","name":"Caron A. Jacobson","aka":[],"tldr":"Boston lymphoma doctor who led ZUMA-5, the trial that brought the CAR-T therapy axicabtagene ciloleucel to relapsed follicular lymphoma.","summary":"Caron Jacobson leads the immune effector cell therapy programme at Dana-Farber Cancer Institute. She was first author of the 2022 Lancet Oncology report of ZUMA-5, the phase 2 trial in which axicabtagene ciloleucel produced high and durable response rates in relapsed or refractory indolent non-Hodgkin lymphoma, the basis for its approval in follicular lymphoma. She also investigates CAR-T therapy in large B-cell lymphoma.","asOf":"2026-09-18","links":[],"tags":["lymphoma","car-t","cell-therapy","trialist"],"related":[],"cancers":["follicular-lymphoma","marginal-zone-lymphoma","non-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["dana-farber"],"pathways":[],"terms":[],"trials":["zuma-5"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Lymphoma specialist and medical director of immune effector cell therapy, Dana-Farber Cancer Institute","institutionId":"dana-farber","specialisms":["CAR-T cell therapy","Follicular lymphoma","Large B-cell lymphoma"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Jacobson%5BAuthor%5D"}],"papers":[]},{"id":"carsten-bokemeyer","kind":"person","name":"Carsten Bokemeyer","aka":[],"tldr":"Medical oncologist known for germ cell tumour research and anti-EGFR trials in colorectal cancer.","summary":"Carsten Bokemeyer is Director of the Department of Oncology, Hematology and BMT at Universitätsklinikum Hamburg-Eppendorf. A medical oncologist, his specialisms are testicular cancer, colorectal cancer and medical oncology. He led the OPUS trial of cetuximab with FOLFOX in colorectal cancer and has a long record in germ cell tumour research. His papers include a study of early tumour shrinkage as a predictor of long-term outcome in cetuximab-treated metastatic colorectal cancer, a European Urology report establishing serum microRNA miR-371a-3p as a biomarker for germ cell tumours, and a review of catumaxomab, a trifunctional anti-EpCAM antibody used for malignant ascites. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bokemeyer%20C%5BAuthor%5D%20cetuximab%20colorectal"}],"tags":[],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":["cetuximab"],"companies":[],"institutions":["uke-hamburg"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Department of Oncology, Hematology and BMT, UKE Hamburg","institutionId":"uke-hamburg","specialisms":["Testicular cancer","Colorectal cancer","Medical oncology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bokemeyer%20C%5BAuthor%5D%20cetuximab%20colorectal"}],"papers":[{"title":"Catumaxomab – trifunctional anti-EpCAM antibody used to treat malignant ascites","journal":"Expert Opinion on Biological Therapy","year":2010,"doi":"10.1517/14712598.2010.504706"},{"title":"Serum Levels of MicroRNA miR-371a-3p: A Sensitive and Specific New Biomarker for Germ Cell Tumours","journal":"European Urology","year":2017,"doi":"10.1016/j.eururo.2016.07.029"},{"title":"Use of Early Tumor Shrinkage to Predict Long-Term Outcome in Metastatic Colorectal Cancer Treated With Cetuximab","journal":"Journal of Clinical Oncology","year":2013,"doi":"10.1200/jco.2012.42.8532"}]},{"id":"carsten-denkert","kind":"person","name":"Carsten Denkert","aka":[],"tldr":"Pathologist who established tumour-infiltrating lymphocytes as a biomarker in breast cancer.","summary":"Carsten Denkert is Director of the Institute of Pathology at Philipps University Marburg and pathology lead for the German Breast Group (GBG). His specialisms are breast pathology, tumour-infiltrating lymphocytes and predictive biomarkers, using histopathology and immunohistochemistry. He is known for establishing tumour-infiltrating lymphocytes as a biomarker in breast cancer through analyses of GBG neoadjuvant trials, showing that stromal lymphocytes predict response to chemotherapy in triple-negative and HER2-positive disease. His Lancet Oncology paper pooled patients treated with neoadjuvant therapy to relate tumour-infiltrating lymphocytes to prognosis across breast cancer subtypes. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Denkert%20C%5BAuthor%5D%20tumor-infiltrating%20lymphocytes%20breast"}],"tags":[],"related":[],"cancers":["tnbc"],"sections":[],"technologies":["histopathology-ihc"],"targets":[],"drugs":[],"companies":["gbg"],"institutions":[],"pathways":[],"terms":["tils"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Institute of Pathology, Philipps University Marburg; GBG pathology lead","institutionId":"gbg","specialisms":["Breast pathology","Tumour-infiltrating lymphocytes","Predictive biomarkers"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Denkert%20C%5BAuthor%5D%20tumor-infiltrating%20lymphocytes%20breast"}],"papers":[{"title":"Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy","journal":"Lancet Oncology","year":2018,"doi":"10.1016/S1470-2045(17)30904-X"},{"title":"KEYNOTE-522: adding pembrolizumab before and after surgery in early triple-negative breast cancer","journal":"New England Journal of Medicine","year":2022,"url":"https://doi.org/10.1056/NEJMoa2112651","doi":"10.1056/NEJMoa2112651"}],"orcid":"0000-0002-2249-0982"},{"id":"cary-adams","kind":"person","name":"Cary Adams","aka":[],"tldr":"Long-serving chief executive of the Union for International Cancer Control, the world's largest international cancer membership organisation.","summary":"Dr Cary Adams has been Chief Executive Officer of the Union for International Cancer Control since 2009. UICC is the largest international cancer organisation, with more than 1,150 member organisations in over 170 countries. He came to the role from international business management in banking, has served two terms as Chair of the NCD Alliance board, and holds honorary doctorates from the University for Business and International Studies Geneva and the University of Bath. The current UICC President is Ulrika Årehed Kågström (2024 to 2026).","asOf":"2026-09-10","links":[{"label":"Source: UICC team page","url":"https://www.uicc.org/who-we-are/our-team"}],"tags":["leadership","global-health","advocacy"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["uicc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["lancet-oncology"],"dependsOn":[],"notes":[],"role":"Chief Executive Officer, Union for International Cancer Control (since 2009)","institutionId":"uicc","specialisms":["Global cancer control","Non-communicable disease advocacy","Nonprofit leadership"],"profiles":[{"label":"UICC biography","url":"https://www.uicc.org/mr-cary-adams-ceo"}],"papers":[{"title":"C/Can 2025: City Cancer Challenge, a new initiative to improve cancer care in cities","journal":"The Lancet Oncology","year":2017,"doi":"10.1016/s1470-2045(17)30083-9"},{"title":"The World Cancer Declaration: from resolution to action","journal":"The Lancet Oncology","year":2011,"doi":"10.1016/s1470-2045(11)70298-4"},{"title":"A deliverable national cancer control plan for the UK: lessons from abroad and the need for discipline at home","journal":"The Lancet Oncology","year":2025,"doi":"10.1016/s1470-2045(25)00650-3"}]},{"id":"catherine-wu","kind":"person","name":"Catherine J. Wu","aka":[],"tldr":"Led the first personalised neoantigen peptide vaccine trial in melanoma and mapped how CLL evolves under treatment.","summary":"Catherine Wu led the 2017 Nature trial of NeoVax, a personalised neoantigen peptide vaccine that induced durable T-cell responses in melanoma patients, published alongside Şahin's mRNA work as the founding evidence for individualised cancer vaccines. Her laboratory also defined the clonal evolution of chronic lymphocytic leukaemia and its driver mutations. She directs transplantation and cellular therapies at Dana-Farber.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wu%20CJ%5BAuthor%5D%20neoantigen%20vaccine"}],"tags":["vaccine","neoantigen","genomics"],"related":[],"cancers":["melanoma","cll","glioblastoma"],"sections":[],"technologies":["neoantigen-mrna-vaccine","wes-wgs"],"targets":[],"drugs":[],"companies":[],"institutions":["dana-farber","broad-institute"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief, Division of Stem Cell Transplantation and Cellular Therapies, Dana-Farber Cancer Institute; Professor, Harvard Medical School","institutionId":"dana-farber","specialisms":["Neoantigen vaccines","Cancer genomics","CLL evolution","Tumour immunology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wu%20CJ%5BAuthor%5D%20neoantigen%20vaccine"}],"papers":[{"title":"An immunogenic personal neoantigen vaccine for patients with melanoma","journal":"Nature","year":2017,"doi":"10.1038/nature22991"},{"title":"Evolution and impact of subclonal mutations in chronic lymphocytic leukemia","journal":"Cell","year":2013,"doi":"10.1016/j.cell.2013.01.019"}]},{"id":"catherine-thieblemont","kind":"person","name":"Catherine Thieblemont","aka":[],"tldr":"Led EPCORE NHL-1, the trial that established the subcutaneous bispecific epcoritamab for relapsed large B-cell lymphoma.","summary":"Catherine Thieblemont (Hôpital Saint-Louis, Paris) was principal investigator of EPCORE NHL-1, the pivotal trial showing the subcutaneous CD3xCD20 bispecific epcoritamab produces deep, durable responses in relapsed or refractory large B-cell lymphoma, leading to its approval. She has led LYSA trials in marginal zone and elderly DLBCL and co-chairs the EPCORE programme moving bispecifics into earlier lines.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Thieblemont%20C%5BAuthor%5D%20epcoritamab"}],"tags":["lymphoma","bispecific","lysa"],"related":[],"cancers":["dlbcl"],"sections":[],"technologies":["bispecific-antibody","t-cell-engager"],"targets":["cd20","cd3"],"drugs":[],"companies":[],"institutions":["aphp-nord-cancer-institute"],"pathways":[],"terms":[],"trials":["epcore-nhl-1","epcore-dlbcl-1"],"people":[],"bottlenecks":[],"keyPapers":["paper-epcore-nhl-1-epcoritamab-jco-2023"],"journals":[],"dependsOn":[],"notes":[],"role":"Head of Hemato-Oncology, Hôpital Saint-Louis, Paris; Professor, Université Paris Cité","institutionId":"aphp-nord-cancer-institute","specialisms":["Aggressive lymphoma","Bispecific antibodies","Marginal zone lymphoma","Cooperative-group trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Thieblemont%20C%5BAuthor%5D%20epcoritamab"}],"papers":[{"title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I/II trial (EPCORE NHL-1)","journal":"JCO","year":2023,"doi":"10.1200/JCO.22.01725"},{"title":"Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (REMARC)","journal":"JCO","year":2017,"doi":"10.1200/JCO.2017.72.6984"},{"title":"EPCORE NHL-1: epcoritamab, a subcutaneous CD20 x CD3 bispecific, in relapsed large B-cell lymphoma including after CAR-T","journal":"Journal of Clinical Oncology","year":2023,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=EPCORE%20NHL-1%20epcoritamab%20large%20B-cell%20lymphoma%20Thieblemont%20JCO%202023"}]},{"id":"cathryn-cox","kind":"person","name":"Cathryn Cox","aka":[],"tldr":"Chief Executive of Sydney Children's Hospitals Network, Australia's largest paediatric health service and home to the Kids Cancer Centre and Cancer Centre for Children.","summary":"Cathryn Cox PSM has been Chief Executive of the Sydney Children's Hospitals Network since August 2020. The Network operates The Children's Hospital at Westmead and Sydney Children's Hospital, Randwick, whose paediatric oncology services work closely with the co-located Children's Cancer Institute. Her role is executive leadership of the health service rather than clinical research.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.schn.health.nsw.gov.au/about/our-people/leadership-group"}],"tags":["leadership","paediatric oncology"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["sydney-childrens-hospitals-network"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive","institutionId":"sydney-childrens-hospitals-network","specialisms":["Paediatric health service leadership","Health system management"],"profiles":[{"label":"Institution profile","url":"https://www.schn.health.nsw.gov.au/about/our-people/leadership-group"}],"papers":[]},{"id":"cesar-adolfo-gomez-derch","kind":"person","name":"César Adolfo Gómez Derch","aka":[],"tldr":"César Adolfo Gómez Derch represents Hospital Clínico San Carlos in the Organisation of European Cancer Institutes, which lists the centre among its full members in Spain.","summary":"César Adolfo Gómez Derch is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Hospital Clínico San Carlos, its full member in Spain. OnCo records the name from the OECI membership list so that the centre's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the institution's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Hospital Clínico San Carlos website","url":"https://www.comunidad.madrid/hospital/clinicosancarlos"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["clinico-san-carlos"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Hospital Clínico San Carlos to the Organisation of European Cancer Institutes","institutionId":"clinico-san-carlos","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Hospital Clínico San Carlos website","url":"https://www.comunidad.madrid/hospital/clinicosancarlos"}],"papers":[]},{"id":"cesar-gregorio-munoz-sanchez-miguel","kind":"person","name":"César Gregorio Muñoz Sánchez-Miguel","aka":[],"tldr":"César Gregorio Muñoz Sánchez-Miguel represents Centro Integral Oncológico Clara Campal (HM CIOCC) in the Organisation of European Cancer Institutes, which lists the centre among its members in Spain.","summary":"César Gregorio Muñoz Sánchez-Miguel is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Centro Integral Oncológico Clara Campal (HM CIOCC), its member in Spain. Centro Integral Oncológico Clara Campal is the private comprehensive cancer centre of the HM Hospitales group at HM Sanchinarro in Madrid, with a large early-phase trials unit, and a full member of the Organisation of European Cancer Institutes. OnCo records the name from the OECI membership list so that the centre's page has a named contact point; the person's exact title, appointment date and biography are not yet recorded and should be checked on the institution's own pages before being relied on.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Centro Integral Oncológico Clara Campal (HM CIOCC) website","url":"https://www.hmciocc.com/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["clara-campal-oncology-centre"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Centro Integral Oncológico Clara Campal (HM CIOCC) to the Organisation of European Cancer Institutes","institutionId":"clara-campal-oncology-centre","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Centro Integral Oncológico Clara Campal (HM CIOCC) website","url":"https://www.hmciocc.com/"}],"papers":[]},{"id":"chadwick-boseman","kind":"person","name":"Chadwick Boseman","aka":[],"tldr":"He made Black Panther and other films while being treated for colon cancer, which he kept private. His death at 43 in 2020 forced attention on rising colorectal cancer in young adults and its heavier toll on Black Americans.","summary":"Chadwick Boseman (1976-2020) was diagnosed with stage III colon cancer in 2016 and continued to work through surgery and chemotherapy, filming Black Panther, Marshall, Da 5 Bloods and Ma Rainey's Black Bottom without disclosing his illness. He died on 28 August 2020 at 43. The announcement prompted a wave of public discussion about colorectal cancer in people under 50, whose incidence has been rising for decades, and about the higher incidence and mortality among Black Americans. In May 2021 the US Preventive Services Task Force lowered the recommended starting age for colorectal screening from 50 to 45, a change that had been under review and that advocates linked to the awareness his death created.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Chadwick_Boseman","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Chadwick_Boseman"},{"label":"Colorectal Cancer Alliance","url":"https://colorectalcancer.org/"}],"tags":["public-figure","patient"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":["colorectal-screening"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["cancer-health-disparities","aya-oncology"],"trials":[],"people":[],"bottlenecks":["b-early-detection","b-trial-diversity"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Actor whose death brought early-onset colorectal cancer into public view","specialisms":["Early-onset colorectal cancer","Cancer disparities","Public awareness"],"profiles":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Chadwick_Boseman"},{"label":"Colorectal Cancer Alliance","url":"https://colorectalcancer.org/"}],"papers":[]},{"id":"chak-sing-lau","kind":"person","name":"Chak-sing Lau","aka":[],"tldr":"Rheumatologist who is Dean of Medicine at the University of Hong Kong, the academic partner of Queen Mary Hospital, and formerly chief of the hospital's Department of Medicine.","summary":"Professor Chak-sing Lau, BBS, JP, is the forty-first Dean of Medicine at The University of Hong Kong, whose LKS Faculty of Medicine is the teaching and research partner of Queen Mary Hospital, and is also interim Vice-President and Pro-Vice-Chancellor (Health). He holds the Daniel CK Yu Professorship in Rheumatology and Clinical Immunology and previously served as Chairperson of the Department of Medicine, Chief of Service in Medicine at Queen Mary Hospital and President of the Hong Kong Academy of Medicine. He is regarded as a pioneer of rheumatology in Hong Kong and founded the Hong Kong Arthritis and Rheumatism Foundation in 2001.","asOf":"2026-09-10","links":[{"label":"Source: HKUMed leadership page","url":"https://www.med.hku.hk/en/about-hkumed/leadership"}],"tags":["leadership","clinician-scientist","academic-medicine"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["queen-mary-hospital-hku"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["lancet","nejm"],"dependsOn":[],"notes":[],"role":"Dean of Medicine, LKS Faculty of Medicine, The University of Hong Kong","institutionId":"queen-mary-hospital-hku","specialisms":["Rheumatology","Clinical immunology","Academic medicine"],"profiles":[{"label":"HKUMed Dean's Corner","url":"https://www.med.hku.hk/en/about-hkumed/leadership/professor-lau-chak-sing"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lau+CS%5BAuthor%5D"}],"papers":[{"title":"Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial","journal":"The Lancet","year":2020,"url":"https://doi.org/10.1016/s0140-6736(20)31042-4","doi":"10.1016/s0140-6736(20)31042-4","note":"Europe PMC author record matched by affiliation"},{"title":"Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis","journal":"New England Journal of Medicine","year":2000,"url":"https://doi.org/10.1056/nejm200010193431604","doi":"10.1056/nejm200010193431604","note":"Europe PMC author record matched by affiliation"},{"title":"Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)","journal":"Annals of the Rheumatic Diseases","year":2016,"url":"https://doi.org/10.1136/annrheumdis-2015-207726","doi":"10.1136/annrheumdis-2015-207726","note":"Europe PMC author record matched by affiliation"}],"orcid":"0000-0001-6698-8355"},{"id":"qi-changsong","kind":"person","name":"Changsong Qi","aka":[],"tldr":"First author of the CT041 trials that showed a CAR-T can shrink gastric and pancreatic tumours.","summary":"Changsong Qi is Associate Professor of Gastrointestinal Oncology at Peking University Cancer Hospital in Beijing. He was first author of the CT041 trials, which showed that a CAR-T cell therapy directed at Claudin 18.2, now named satricabtagene autoleucel, can shrink gastric and pancreatic tumours. Working with Lin Shen, he led the clinical conduct of the phase 1 and phase 2 studies, and his publications include the interim results of Claudin 18.2-specific CAR T cells in gastrointestinal cancers. He continues to work on immunotherapy and early-phase trials for gastric cancer.","asOf":"2026-09-08","links":[{"label":"Peking University Cancer Hospital","url":"https://www.bjcancer.org"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Qi%20C%5BAuthor%5D%20claudin18.2%20CAR%20T"}],"tags":[],"related":[],"cancers":["gastric"],"sections":[],"technologies":["car-t"],"targets":["cldn18-2"],"drugs":["satricabtagene-autoleucel"],"companies":[],"institutions":["pku-cancer-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Associate Professor of GI Oncology, Peking University Cancer Hospital","institutionId":"pku-cancer-hospital","specialisms":["Gastric cancer","CAR-T","Claudin 18.2","Early-phase trials"],"profiles":[{"label":"Peking University Cancer Hospital","url":"https://www.bjcancer.org"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Qi%20C%5BAuthor%5D%20claudin18.2%20CAR%20T"}],"papers":[{"title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results","journal":"Nature Medicine","year":2022,"doi":"10.1038/s41591-022-01800-8"}]},{"id":"charles-simone","kind":"person","name":"Charles B. Simone II","aka":[],"tldr":"The radiation oncologist who is chief medical officer of the New York Proton Center, the proton therapy centre founded by Memorial Sloan Kettering, Montefiore and Mount Sinai.","summary":"Charles Simone is Chief Medical Officer of the New York Proton Center, which its leadership page lists alongside Chief Executive Officer Christopher Panczner and Director of Medical Physics Haibo Lin. The centre was created through a partnership of three academic medical centres, Memorial Sloan Kettering Cancer Center, Montefiore and Mount Sinai, and describes itself as the first and only proton therapy centre in New York. His research concerns proton therapy for lung and other thoracic cancers and the comparative evidence for particle therapy. His publications are listed on PubMed.","asOf":"2026-09-17","links":[{"label":"New York Proton Center: leadership","url":"https://www.nyproton.com/about/leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Simone+CB%5BAuthor%5D+proton"}],"tags":["leadership"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["proton-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":["new-york-proton-center"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Medical Officer, New York Proton Center","institutionId":"new-york-proton-center","specialisms":["Radiation oncology","Proton therapy","Thoracic oncology"],"profiles":[{"label":"New York Proton Center: leadership","url":"https://www.nyproton.com/about/leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Simone+CB%5BAuthor%5D+proton"}],"papers":[{"title":"Proton FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases: The FAST-01 Nonrandomized Trial","journal":"JAMA Oncology","year":2023,"url":"https://doi.org/10.1001/jamaoncol.2022.5843","doi":"10.1001/jamaoncol.2022.5843","note":"Europe PMC author record matched by affiliation"},{"title":"Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline","journal":"Journal of Clinical Oncology","year":2022,"url":"https://doi.org/10.1200/JCO.21.02528","doi":"10.1200/JCO.21.02528","note":"Europe PMC author record matched by affiliation"},{"title":"Spatially fractionated radiation therapy: History, present and the future","journal":"Clinical and Translational Radiation Oncology","year":2020,"url":"https://doi.org/10.1016/j.ctro.2019.10.004","doi":"10.1016/j.ctro.2019.10.004","note":"Europe PMC author record matched by affiliation"}]},{"id":"charles-coutant","kind":"person","name":"Charles Coutant","aka":[],"tldr":"Charles Coutant represents Centre Georges-François Leclerc in the Organisation of European Cancer Institutes, which lists the centre among its members in France.","summary":"Charles Coutant is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Centre Georges-François Leclerc, its full member in France. OnCo records the name from the OECI membership list so that the centre's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the institution's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Centre Georges-François Leclerc website","url":"https://www.cgfl.fr"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["centre-georges-francois-leclerc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Centre Georges-François Leclerc to the Organisation of European Cancer Institutes","institutionId":"centre-georges-francois-leclerc","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Centre Georges-François Leclerc website","url":"https://www.cgfl.fr"}],"papers":[{"title":"Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk","journal":"J Clin Oncol","year":2020,"url":"https://doi.org/10.1200/jco.19.01758","doi":"10.1200/jco.19.01758","note":"Europe PMC author record matched by affiliation"},{"title":"Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas","journal":"Br J Cancer","year":2013,"url":"https://doi.org/10.1038/bjc.2012.557","doi":"10.1038/bjc.2012.557","note":"Europe PMC author record matched by affiliation"},{"title":"Clinical nomogram to predict bone-only metastasis in patients with early breast carcinoma","journal":"Br J Cancer","year":2015,"url":"https://doi.org/10.1038/bjc.2015.308","doi":"10.1038/bjc.2015.308","note":"Europe PMC author record matched by affiliation"}]},{"id":"charles-blanke","kind":"person","name":"Charles D. Blanke","aka":[],"tldr":"Charles Blanke is a GI oncologist who chaired SWOG for a decade and led early imatinib trials in GIST.","summary":"Charles Blanke is Chief Medical Officer of the SWOG Cancer Research Network and Professor at Oregon Health & Science University. A gastrointestinal medical oncologist, he served as SWOG group chair from 2013 to 2025 before becoming chief medical officer. He led pivotal imatinib dose trials in gastrointestinal stromal tumour, reported in the Journal of Clinical Oncology as the phase III intergroup trial S0033 of imatinib at two dose levels in KIT-expressing GIST and the long-term results of a randomised phase II trial of standard versus higher-dose imatinib. His work spans sarcomas including GIST, colorectal cancer and clinical trial leadership.","asOf":"2026-09-08","links":[{"label":"SWOG leadership","url":"https://www.swog.org/about/leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Blanke%20CD%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Charles%20D.%20Blanke"}],"tags":[],"related":[],"cancers":["sarcoma","colorectal"],"sections":[],"technologies":[],"targets":["kit"],"drugs":["imatinib"],"companies":["swog"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Medical Officer, SWOG Cancer Research Network; Professor, Oregon Health & Science University","institutionId":"swog","specialisms":["Gastrointestinal oncology","GIST","Clinical trial leadership"],"profiles":[{"label":"SWOG leadership","url":"https://www.swog.org/about/leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Blanke%20CD%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Charles%20D.%20Blanke"}],"papers":[{"title":"Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033","journal":"Journal of Clinical Oncology","year":2008,"url":"https://doi.org/10.1200/JCO.2007.13.4452","doi":"10.1200/JCO.2007.13.4452"},{"title":"Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT","journal":"Journal of Clinical Oncology","year":2008,"url":"https://doi.org/10.1200/JCO.2007.13.4403","doi":"10.1200/JCO.2007.13.4403"}]},{"id":"charles-geyer","kind":"person","name":"Charles E. Geyer Jr.","aka":[],"tldr":"Breast trialist who co-led OlympiA, showing adjuvant olaparib improves survival in BRCA carriers.","summary":"Charles Geyer Jr. is a breast cancer trial leader with NRG Oncology and Professor of Medicine at the University of Pittsburgh. A medical oncologist and long-time NSABP/NRG leader, he co-chaired OlympiA, the trial of adjuvant olaparib in germline BRCA carriers, led NSABP B-31 analyses of adjuvant trastuzumab, and led the KATHERINE trial of trastuzumab emtansine for residual disease. His papers report the overall survival analysis of the OlympiA phase III trial in Annals of Oncology and trastuzumab emtansine for residual invasive HER2-positive breast cancer in the New England Journal of Medicine. His work covers triple-negative, HR-positive and HER2-positive breast cancer, PARP inhibitors and HER2.","asOf":"2026-09-08","links":[{"label":"NRG Oncology","url":"https://www.nrgoncology.org"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Geyer%20CE%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Charles%20E.%20Geyer%20Jr."}],"tags":[],"related":[],"cancers":["tnbc","breast-hr-positive","breast-her2-positive"],"sections":[],"technologies":[],"targets":["brca","parp","her2"],"drugs":["olaparib","trastuzumab-emtansine"],"companies":["nrg-oncology"],"institutions":[],"pathways":[],"terms":[],"trials":["olympia","katherine","hera-b31-n9831"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["annals-of-oncology"],"dependsOn":[],"notes":[],"role":"Breast cancer trial leader, NRG Oncology; Professor of Medicine, University of Pittsburgh","institutionId":"nrg-oncology","specialisms":["Breast cancer","Adjuvant therapy","PARP inhibitors"],"profiles":[{"label":"NRG Oncology","url":"https://www.nrgoncology.org"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Geyer%20CE%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Charles%20E.%20Geyer%20Jr."}],"papers":[{"title":"Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer","journal":"Annals of Oncology","year":2022,"url":"https://doi.org/10.1016/j.annonc.2022.09.159","doi":"10.1016/j.annonc.2022.09.159"},{"title":"Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer","journal":"New England Journal of Medicine","year":2019,"url":"https://doi.org/10.1056/NEJMoa1814017","doi":"10.1056/NEJMoa1814017"},{"title":"OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer","journal":"New England Journal of Medicine","year":2021,"url":"https://doi.org/10.1056/NEJMoa2105215","doi":"10.1056/NEJMoa2105215"}]},{"id":"charles-kettering","kind":"person","name":"Charles F. Kettering","aka":[],"tldr":"The inventor of the electric car starter and head of General Motors research joined Alfred Sloan in the 1940s to establish the Sloan Kettering Institute for cancer research.","summary":"Charles F. Kettering (1876-1958) held more than a hundred patents, including the electric starter and leaded petrol, and ran General Motors' research laboratories for 27 years. Memorial Sloan Kettering's history records that in the 1940s he and Alfred P. Sloan joined forces to establish the Sloan Kettering Institute, dedicated in 1948 next to Memorial Hospital in New York. Kettering brought the conviction that cancer, like an engineering problem, would yield to organised, well-funded research; Sloan brought the money and the corporate model. The Institute they founded is now the research arm of Memorial Sloan Kettering Cancer Center, whose scientists' work includes the biology behind checkpoint immunotherapy and CD19 CAR-T cells.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Charles_F._Kettering","links":[{"label":"MSK: history and milestones","url":"https://www.mskcc.org/about/history-milestones"}],"tags":["hero","donor"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":[],"people":["alfred-sloan"],"bottlenecks":["b-funding-allocation","b-translational-valley"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Inventor and General Motors research chief who co-founded the Sloan Kettering Institute","specialisms":["Cancer research institute founding","Industrial research methods"],"profiles":[],"papers":[]},{"id":"charles-sawyers","kind":"person","name":"Charles L. Sawyers","aka":[],"tldr":"Co-developed imatinib's successor dasatinib and the prostate drug enzalutamide, and explained how cancers resist targeted drugs.","summary":"Physician-scientist who characterised BCR-ABL resistance mutations, co-developed dasatinib, and with Michael Jung co-invented enzalutamide and apalutamide. His laboratory studies androgen receptor signalling and lineage plasticity in castration-resistant prostate cancer. Lasker Award 2009, Breakthrough Prize 2013.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Charles_Sawyers","links":[{"label":"MSK lab","url":"https://www.mskcc.org/research-areas/labs/charles-sawyers"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sawyers%20CL%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":["androgen-receptor","bcr-abl"],"drugs":["enzalutamide","apalutamide","dasatinib"],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chair, Human Oncology and Pathogenesis Program; HHMI Investigator","institutionId":"mskcc","specialisms":["Prostate cancer","Kinase inhibitor resistance","Androgen receptor biology","Lineage plasticity"],"profiles":[{"label":"MSK lab","url":"https://www.mskcc.org/research-areas/labs/charles-sawyers"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sawyers%20CL%5BAuthor%5D"}],"papers":[{"title":"Development of a second-generation antiandrogen for treatment of advanced prostate cancer","journal":"Science","year":2009,"url":"https://doi.org/10.1126/science.1168175","doi":"10.1126/science.1168175"},{"title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","journal":"Science","year":2001,"url":"https://doi.org/10.1126/science.1062538","doi":"10.1126/science.1062538"}],"orcid":"0000-0003-4955-6475"},{"id":"charles-perou","kind":"person","name":"Charles M. Perou","aka":[],"tldr":"Defined the molecular subtypes of breast cancer (luminal, HER2-enriched, basal-like) that clinicians now use every day.","summary":"Charles Perou led the 2000 Nature paper that used expression profiling to divide breast cancer into intrinsic subtypes, the classification that introduced basal-like disease and underpins triple-negative research. He developed the PAM50 assay that became Prosigna and co-led the TCGA breast cancer analysis. His lab continues to map breast tumour heterogeneity and immune microenvironments.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Perou%20CM%5BAuthor%5D%20breast%20subtypes"}],"tags":["breast","genomics","classification"],"related":[],"cancers":["tnbc","breast-hr-positive","breast-her2-positive"],"sections":[],"technologies":["rna-seq","companion-diagnostic"],"targets":[],"drugs":[],"companies":[],"institutions":["unc-lineberger"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-tcga-pancancer-atlas-cell-2018"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Genetics and Pathology, UNC Lineberger Comprehensive Cancer Center","institutionId":"unc-lineberger","specialisms":["Breast cancer genomics","Intrinsic subtypes","PAM50","Tumour classification"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Perou%20CM%5BAuthor%5D%20breast%20subtypes"}],"papers":[{"title":"Molecular portraits of human breast tumours","journal":"Nature","year":2000,"doi":"10.1038/35021093"},{"title":"Supervised risk predictor of breast cancer based on intrinsic subtypes (PAM50)","journal":"JCO","year":2009,"doi":"10.1200/JCO.2008.18.1370"},{"title":"Comprehensive molecular portraits of human breast tumours","journal":"Nature","year":2012,"doi":"10.1038/nature11412"},{"title":"TCGA Pan-Cancer Atlas: 10,000 tumours across 33 cancer types, classified by molecular features","journal":"Cell","year":2018,"url":"https://doi.org/10.1016/j.cell.2018.03.022","doi":"10.1016/j.cell.2018.03.022"}]},{"id":"charles-rudin","kind":"person","name":"Charles M. Rudin","aka":[],"tldr":"Defined the molecular subtypes of small-cell lung cancer and led early trials of DLL3-targeted therapy.","summary":"Charles Rudin led the consensus that split small-cell lung cancer into ASCL1, NEUROD1, POU2F3 and inflamed subtypes, giving the disease its first biology-based classification. He was a lead investigator of the rovalpituzumab tesirine and tarlatamab DLL3 programmes and of KEYNOTE-604. His laboratory studies SCLC plasticity and lineage transformation of EGFR-mutant lung cancer.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rudin%20CM%5BAuthor%5D%20small%20cell%20lung"}],"tags":["sclc","biology","dll3"],"related":[],"cancers":["sclc"],"sections":[],"technologies":[],"targets":["dll3"],"drugs":["tarlatamab"],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":["dellphi-304"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nature-reviews-cancer"],"dependsOn":[],"notes":[],"role":"Chief, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center","institutionId":"mskcc","specialisms":["Small-cell lung cancer","SCLC molecular subtypes","DLL3","Neuroendocrine carcinoma biology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rudin%20CM%5BAuthor%5D%20small%20cell%20lung"}],"papers":[{"title":"Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data","journal":"Nature Reviews Cancer","year":2019,"doi":"10.1038/s41568-019-0133-9"},{"title":"Small-cell lung cancer","journal":"Nature Reviews Disease Primers","year":2021,"doi":"10.1038/s41572-020-00235-0"}],"orcid":"0000-0001-5204-3465"},{"id":"charles-swanton","kind":"person","name":"Charles Swanton","aka":[],"tldr":"Leads TRACERx, the study that follows lung cancers as they evolve, and showed how air pollution can trigger lung cancer without new mutations.","summary":"Charles Swanton is Deputy Clinical Director of The Francis Crick Institute and Chief Clinician of Cancer Research UK, and is involved in Cancer Grand Challenges. His specialisms are tumour evolution, lung cancer, circulating tumour DNA, and air pollution and cancer. He leads TRACERx, the programme that sequenced lung cancers over time to map clonal evolution, circulating tumour DNA dynamics and metastasis, using whole-exome and whole-genome sequencing and liquid biopsy. His Nature papers describe the evolution of non-small-cell lung cancer metastases in TRACERx and show how air pollutants promote lung adenocarcinoma through inflammation acting on pre-existing mutations rather than new ones. His Crick profile and PubMed listing are linked.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Charles_Swanton","links":[{"label":"Crick profile","url":"https://www.crick.ac.uk/research/find-a-researcher/charles-swanton"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Swanton%20C%5BAuthor%5D%20TRACERx"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["liquid-biopsy","wes-wgs"],"targets":[],"drugs":[],"companies":[],"institutions":["francis-crick","cruk","cancer-grand-challenges"],"pathways":[],"terms":["ctdna"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Deputy Clinical Director, Francis Crick Institute; Chief Clinician, Cancer Research UK","institutionId":"francis-crick","specialisms":["Tumour evolution","Lung cancer","Circulating tumour DNA","Air pollution and cancer"],"profiles":[{"label":"Crick profile","url":"https://www.crick.ac.uk/research/find-a-researcher/charles-swanton"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Swanton%20C%5BAuthor%5D%20TRACERx"}],"papers":[{"title":"The evolution of non-small cell lung cancer metastases in TRACERx","journal":"Nature","year":2023,"doi":"10.1038/s41586-023-05729-x"},{"title":"Lung adenocarcinoma promotion by air pollutants","journal":"Nature","year":2023,"doi":"10.1038/s41586-023-05874-3"},{"title":"Gerlinger: a single biopsy misses most of the mutations in a kidney tumour","journal":"New England Journal of Medicine","year":2012,"url":"https://doi.org/10.1056/NEJMoa1113205","doi":"10.1056/NEJMoa1113205"},{"title":"TRACERx 421: the full-cohort picture of how lung cancer evolves and which subclones drive relapse","journal":"Nature","year":2023,"url":"https://doi.org/10.1038/s41586-023-05783-5","doi":"10.1038/s41586-023-05783-5"},{"title":"TRACERx first 100: tracking how lung cancers evolve, and how chromosomal chaos predicts relapse","journal":"New England Journal of Medicine","year":2017,"url":"https://doi.org/10.1056/NEJMoa1616288","doi":"10.1056/NEJMoa1616288"}],"orcid":"0000-0002-4299-3018"},{"id":"charlie-gourley","kind":"person","name":"Charlie Gourley","aka":[],"tldr":"Edinburgh medical oncologist and ovarian cancer researcher who is Clinical Director of the CRUK Scotland Centre.","summary":"Prof. Charlie Gourley is Clinical Director of the CRUK Scotland Centre, the joint Edinburgh-Glasgow Cancer Research UK centre, and Professor of Medical Oncology at the University of Edinburgh. His research focuses on the molecular subtypes of ovarian cancer and on PARP inhibitor and platinum response, and he has led translational work within international ovarian cancer trials.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.crukscotlandcentre.ac.uk/about-us/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gourley+C%5BAuthor%5D+ovarian"}],"tags":["leadership","clinician-scientist","ovarian cancer"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["edinburgh-cancer-centre"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Clinical Director, CRUK Scotland Centre","institutionId":"edinburgh-cancer-centre","specialisms":["Ovarian cancer","Medical oncology","Gynaecological cancer genomics"],"profiles":[{"label":"Institution profile","url":"https://www.crukscotlandcentre.ac.uk/about-us/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gourley+C%5BAuthor%5D+ovarian"}],"papers":[{"title":"Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial","journal":"The Lancet","year":2022,"doi":"10.1016/s0140-6736(21)02175-9"},{"title":"Increased Incidence of Visceral Metastases in Scottish Patients With BRCA1/2-Defective Ovarian Cancer: An Extension of the Ovarian BRCAness Phenotype","journal":"Journal of Clinical Oncology","year":2010,"doi":"10.1200/jco.2009.25.1082"},{"title":"Epithelial ovarian cancer","journal":"The Lancet","year":2019,"doi":"10.1016/s0140-6736(18)32552-2"}]},{"id":"charlotte-coles","kind":"person","name":"Charlotte E. Coles","aka":[],"tldr":"Led IMPORT LOW, which showed partial-breast radiotherapy is as effective as whole-breast treatment with fewer side effects.","summary":"Charlotte Coles was chief investigator of IMPORT LOW, the UK trial showing partial-breast radiotherapy after breast conservation matches whole-breast radiotherapy for local control with less breast hardening, and co-led IMPORT HIGH and the PRIMETIME study of radiotherapy omission. She chaired the Lancet Breast Cancer Commission and is a leader in ESTRO. Her work drives the shift to shorter, more targeted breast radiotherapy.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Charlotte_Coles","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Coles%20CE%5BAuthor%5D%20breast%20radiotherapy%20IMPORT"}],"tags":["radiotherapy","breast","de-escalation"],"related":[],"cancers":["breast-hr-positive"],"sections":[],"technologies":["imrt-igrt"],"targets":[],"drugs":[],"companies":[],"institutions":["cruk-cambridge-centre","estro"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Breast Cancer Clinical Oncology, University of Cambridge; Consultant, Addenbrooke's Hospital","institutionId":"cruk-cambridge-centre","specialisms":["Breast radiotherapy","Partial breast irradiation","Hypofractionation","Radiotherapy de-escalation"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Coles%20CE%5BAuthor%5D%20breast%20radiotherapy%20IMPORT"}],"papers":[{"title":"Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial","journal":"Lancet","year":2017,"doi":"10.1016/S0140-6736(17)31145-5"},{"title":"The Lancet Breast Cancer Commission","journal":"Lancet","year":2024,"doi":"10.1016/S0140-6736(24)00747-5"}],"orcid":"0000-0003-4473-8552"},{"id":"charu-aggarwal","kind":"person","name":"Charu Aggarwal","aka":[],"tldr":"Showed that adding blood-based sequencing to tissue testing finds more targetable lung cancer mutations.","summary":"Charu Aggarwal is the Leslye M. Heisler Professor for Lung Cancer Excellence and Section Chief of Thoracic and Head & Neck Medical Oncology at the Abramson Cancer Center, University of Pennsylvania. She is a thoracic oncologist known for plasma next-generation sequencing studies showing that adding blood-based testing to tissue testing finds more targetable lung cancer mutations, work that changed how metastatic lung cancer is genotyped. Her selected paper reports the clinical implications of plasma-based genotyping for delivering personalised therapy in metastatic non-small-cell lung cancer. She now leads immunotherapy and head and neck cancer trials at Penn.","asOf":"2026-09-08","links":[{"label":"Penn profile","url":"https://www.pennmedicine.org/providers/profile/charu-aggarwal"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Aggarwal%20C%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["nsclc","head-and-neck"],"sections":[],"technologies":["liquid-biopsy","cgp"],"targets":[],"drugs":[],"companies":[],"institutions":["penn-abramson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["jama-oncology"],"dependsOn":[],"notes":[],"role":"Leslye M. Heisler Professor for Lung Cancer Excellence; Section Chief, Thoracic and Head & Neck Medical Oncology","institutionId":"penn-abramson","specialisms":["Lung cancer","Liquid biopsy","Immunotherapy"],"profiles":[{"label":"Penn profile","url":"https://www.pennmedicine.org/providers/profile/charu-aggarwal"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Aggarwal%20C%5BAuthor%5D"}],"papers":[{"title":"Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer","journal":"JAMA Oncology","year":2019,"url":"https://doi.org/10.1001/jamaoncol.2018.4305","doi":"10.1001/jamaoncol.2018.4305"}]},{"id":"chee-cheng-ean","kind":"person","name":"Chee Cheng Ean","aka":[],"tldr":"Medical oncologist who leads Singapore's National University Cancer Institute (NCIS), the country's public cancer centre for adults and children.","summary":"Chee Cheng Ean is Executive Director of the National University Cancer Institute, Singapore (NCIS), part of the National University Health System. A senior consultant medical oncologist, she oversees NCIS's clinical services, research and education across its haematology-oncology, radiation oncology and surgical oncology departments.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.ncis.com.sg/about-ncis/at-the-helm"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chee+CE%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","medical oncology","gastrointestinal cancer"],"related":[],"cancers":["colorectal","gastric"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["nuh-ncis"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Executive Director","institutionId":"nuh-ncis","specialisms":["Medical oncology","Gastrointestinal cancers","Cancer service leadership"],"profiles":[{"label":"Institution profile","url":"https://www.ncis.com.sg/about-ncis/at-the-helm"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chee+CE%5BAuthor%5D"}],"papers":[{"title":"Negative Predictive Biomarkers in Colorectal Cancer: PRESSING Ahead","journal":"Journal of Clinical Oncology","year":2019,"doi":"10.1200/jco.19.01977"},{"title":"Making sense of adjuvant chemotherapy in colorectal cancer","journal":"Journal of Gastrointestinal Oncology","year":2019,"doi":"10.21037/jgo.2019.06.03"},{"title":"State-of-the-Art Management of Colorectal Cancer: Treatment Advances and Innovation","journal":"American Society of Clinical Oncology Educational Book","year":2024,"doi":"10.1200/edbk_438466"}]},{"id":"chen-chien-tzung","kind":"person","name":"Chen Chien-Tzung","aka":[],"tldr":"Plastic and reconstructive surgeon who leads Linkou Chang Gung Memorial Hospital, the flagship medical centre of Taiwan's Chang Gung hospital system.","summary":"Chen Chien-Tzung (陳建宗) leads Linkou Chang Gung Memorial Hospital as its superintendent (院長), according to the hospital's Chinese-language Wikipedia article, which lists him in the infobox. Linkou Chang Gung is the largest branch of the Chang Gung Medical Foundation founded by Wang Yung-ching, whose hospitals also include Keelung, Taipei, Taoyuan, Yunlin, Chiayi and Kaohsiung. PubMed lists Chien-Tzung Chen as an author in the Department of Plastic and Reconstructive Surgery at Linkou Chang Gung Memorial Hospital and Chang Gung University in 2025 and 2026 publications. The hospital's own English pages are script-rendered and did not expose a leadership listing when checked, so this record uses conservative wording and no start date.","asOf":"2026-09-10","links":[{"label":"Source: Chinese Wikipedia article on Linkou Chang Gung Memorial Hospital (infobox)","url":"https://zh.wikipedia.org/wiki/林口長庚紀念醫院"}],"tags":["leadership","hospital-management","clinician-scientist"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["chang-gung-memorial-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Superintendent of Linkou Chang Gung Memorial Hospital","institutionId":"chang-gung-memorial-hospital","specialisms":["Plastic and reconstructive surgery","Hospital management"],"profiles":[{"label":"Wikipedia (Chinese): 林口長庚紀念醫院","url":"https://zh.wikipedia.org/wiki/林口長庚紀念醫院"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chen+CT%5BAuthor%5D+AND+Chang+Gung+AND+plastic"}],"papers":[{"title":"Free Functioning Muscle Transfer for Lower Extremity Posttraumatic Composite Structure and Functional Defect","journal":"Plastic & Reconstructive Surgery","year":2007,"url":"https://doi.org/10.1097/01.prs.0000260595.85557.41","doi":"10.1097/01.prs.0000260595.85557.41","note":"OpenAlex author record matched by institution"},{"title":"Frontal Sinus Fractures: A Treatment Algorithm and Assessment of Outcomes Based on 78 Clinical Cases","journal":"Plastic & Reconstructive Surgery","year":2006,"url":"https://doi.org/10.1097/01.prs.0000227738.42077.2d","doi":"10.1097/01.prs.0000227738.42077.2d","note":"OpenAlex author record matched by institution"},{"title":"Patient Benefit From Endoscopically Assisted Fixation of Condylar Neck Fractures—A Randomized Controlled Trial","journal":"Journal of Oral and Maxillofacial Surgery","year":2008,"url":"https://doi.org/10.1016/j.joms.2008.09.019","doi":"10.1016/j.joms.2008.09.019","note":"OpenAlex author record matched by institution"}]},{"id":"chen-wei-ming","kind":"person","name":"Chen Wei-ming","aka":[],"tldr":"Superintendent who has led Taipei Veterans General Hospital, one of Taiwan's largest medical centres, since January 2022.","summary":"Chen Wei-ming (陳威明) has been Superintendent of Taipei Veterans General Hospital since 16 January 2022. The hospital, founded in 1958 and run directly by the Veterans Affairs Council, is a designated medical centre with about 2,900 beds and hosts one of Taiwan's largest cancer services. The hospital's own site blocked automated access, so his role is recorded from the Chinese Wikipedia article for the hospital.","asOf":"2026-09-10","links":[{"label":"Source: Chinese Wikipedia, Taipei Veterans General Hospital","url":"https://zh.wikipedia.org/wiki/臺北榮民總醫院"}],"tags":["leadership","hospital-management","taiwan"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["taipei-veterans-general-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Superintendent of Taipei Veterans General Hospital","institutionId":"taipei-veterans-general-hospital","specialisms":["Hospital leadership","Medical centre governance","Veterans healthcare"],"profiles":[{"label":"Wikipedia (hospital article, leadership)","url":"https://zh.wikipedia.org/wiki/臺北榮民總醫院"}],"papers":[]},{"id":"cheryl-willman","kind":"person","name":"Cheryl L. Willman","aka":[],"tldr":"Cheryl Willman is a leukaemia genomics pioneer who leads Mayo Clinic's cancer centre across its three sites.","summary":"Cheryl Willman is Executive Director of the Mayo Clinic Comprehensive Cancer Center, including its Florida site, and previously directed the University of New Mexico Comprehensive Cancer Center. A haematopathologist, her genomic studies defined high-risk subtypes of acute lymphoblastic leukaemia, including work in Hispanic and Native American children. Her papers include a Blood study identifying novel cluster groups in paediatric high-risk B-precursor acute lymphoblastic leukaemia by gene expression profiling and a Nature Genetics study of ancestry and pharmacogenomics of relapse in the disease. She has led the Mayo Clinic cancer centre since 2021 and works on leukaemia genomics, health disparities and expression profiling.","asOf":"2026-09-08","links":[{"label":"Mayo Clinic research faculty","url":"https://www.mayo.edu/research/faculty"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Willman%20CL%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Cheryl%20L.%20Willman"}],"tags":[],"related":[],"cancers":["all-leukemia","aml"],"sections":[],"technologies":["rna-seq","cgp"],"targets":[],"drugs":[],"companies":[],"institutions":["mayo-clinic","mayo-clinic-florida","unm-cancer-center"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["blood","nature-genetics"],"dependsOn":[],"notes":[],"role":"Executive Director, Mayo Clinic Comprehensive Cancer Center","institutionId":"mayo-clinic","specialisms":["Leukaemia genomics","Cancer center leadership","Health disparities"],"profiles":[{"label":"Mayo Clinic research faculty","url":"https://www.mayo.edu/research/faculty"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Willman%20CL%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Cheryl%20L.%20Willman"}],"papers":[{"title":"Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome","journal":"Blood","year":2010,"url":"https://doi.org/10.1182/blood-2009-08-239681","doi":"10.1182/blood-2009-08-239681"},{"title":"Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia","journal":"Nature Genetics","year":2011,"url":"https://doi.org/10.1038/ng.763","doi":"10.1038/ng.763"}]},{"id":"chiara-gibertoni","kind":"person","name":"Chiara Gibertoni","aka":[],"tldr":"General Director of the IRCCS Policlinico Sant'Orsola in Bologna, one of Italy's largest university hospitals.","summary":"Chiara Gibertoni is Direttore Generale of the IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola. The hospital is a research-designated (IRCCS) university medical centre affiliated with the University of Bologna, with major haematology and medical oncology programmes. Her role is recorded in the public record for the institution.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.aosp.bo.it"}],"tags":["leadership","hospital management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["sant-orsola-bologna"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"General Director (Direttore Generale)","institutionId":"sant-orsola-bologna","specialisms":["Hospital management","Health administration"],"profiles":[{"label":"Institution profile","url":"https://www.aosp.bo.it"}],"papers":[]},{"id":"ching-hon-pui","kind":"person","name":"Ching-Hon Pui","aka":[],"tldr":"Led the St. Jude Total Therapy studies that cure over 90% of children with leukaemia without cranial radiation.","summary":"Ching-Hon Pui has led the St. Jude Total Therapy studies for three decades, showing in Total XV that cranial irradiation can be omitted for all children with acute lymphoblastic leukaemia when MRD-guided intensification is used, and pushing five-year survival above 90%. He has worked to bring these protocols to China and other middle-income countries and has authored the definitive reviews of childhood ALL.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Pui%20CH%5BAuthor%5D%20acute%20lymphoblastic%20leukemia"}],"tags":["paediatric","all","st-jude"],"related":[],"cancers":["all-leukemia"],"sections":[],"technologies":["mrd-testing"],"targets":[],"drugs":[],"companies":[],"institutions":["st-jude"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chair, Department of Oncology, St. Jude Children's Research Hospital","institutionId":"st-jude","specialisms":["Paediatric acute lymphoblastic leukaemia","Risk-adapted therapy","Pharmacogenomics","Global paediatric oncology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Pui%20CH%5BAuthor%5D%20acute%20lymphoblastic%20leukemia"}],"papers":[{"title":"Treating childhood acute lymphoblastic leukemia without cranial irradiation (Total Therapy XV)","journal":"NEJM","year":2009,"doi":"10.1056/NEJMoa0900386"},{"title":"Childhood acute lymphoblastic leukemia: progress through collaboration","journal":"JCO","year":2015,"doi":"10.1200/JCO.2014.59.1636"}],"orcid":"0000-0003-0303-5658"},{"id":"chong-jen-yu","kind":"person","name":"Chong-Jen Yu","aka":[],"tldr":"Pulmonologist appointed Superintendent of National Taiwan University Hospital in August 2025, leading Taiwan's flagship academic medical centre.","summary":"Chong-Jen Yu (余忠仁) has served as Superintendent of National Taiwan University Hospital since August 2025, the 17th superintendent in the hospital's National Taiwan University era. A professor of internal medicine and specialist in pulmonary and critical care medicine, he previously led NTUH's Hsin-Chu branch. As Superintendent he oversees the hospital's clinical services, including its cancer centre.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Yu+CJ%5BAuthor%5D+National+Taiwan+University+Hospital"}],"tags":["leadership","pulmonology"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ntuh"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nejm","pnas","lancet"],"dependsOn":[],"notes":[],"role":"Superintendent","institutionId":"ntuh","specialisms":["Pulmonology","Critical care medicine","Hospital leadership"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Yu+CJ%5BAuthor%5D+National+Taiwan+University+Hospital"}],"papers":[{"title":"Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer","journal":"New England Journal of Medicine","year":2020,"url":"https://doi.org/10.1056/NEJMoa2027071","doi":"10.1056/NEJMoa2027071","note":"Europe PMC author record matched by affiliation"},{"title":"MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib","journal":"Proceedings of the National Academy of Sciences","year":2007,"url":"https://doi.org/10.1073/pnas.0710370104","doi":"10.1073/pnas.0710370104","note":"Europe PMC author record matched by affiliation"},{"title":"First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study","journal":"Lancet","year":2017,"url":"https://doi.org/10.1016/S0140-6736(17)30123-X","doi":"10.1016/S0140-6736(17)30123-X","note":"Europe PMC author record matched by affiliation"}],"orcid":"0000-0001-5664-9392"},{"id":"chris-parker","kind":"person","name":"Chris C. Parker","aka":[],"tldr":"London radiation oncologist who led ALSYMPCA, the trial that showed radium-223 lengthens survival in prostate cancer that has spread to bone, and RADICALS-RT, which showed radiotherapy after prostatectomy can safely wait until the PSA rises.","summary":"Chris Parker is a clinical oncologist at The Royal Marsden and The Institute of Cancer Research. He was first author of the 2013 New England Journal of Medicine report of ALSYMPCA, in which the alpha-emitter radium-223 improved overall survival in castration-resistant prostate cancer with bone metastases, and of the 2020 Lancet report of RADICALS-RT, which found that early salvage radiotherapy on PSA rise was as good as adjuvant radiotherapy after prostatectomy, with less toxicity.","asOf":"2026-09-18","links":[],"tags":["prostate","radiotherapy","trialist"],"related":[],"cancers":["prostate-mcrpc","prostate-bcr","prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["royal-marsden"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-radicals-rt-lancet-2020","paper-alsympca-radium-223-nejm-2013"],"journals":[],"dependsOn":[],"notes":[],"role":"Clinical oncologist, The Royal Marsden and The Institute of Cancer Research","institutionId":"royal-marsden","specialisms":["Prostate radiotherapy","Radium-223","Post-prostatectomy radiotherapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Parker%5BAuthor%5D"}],"papers":[{"title":"ALSYMPCA: alpha emitter radium-223 and survival in metastatic prostate cancer with bone metastases","journal":"New England Journal of Medicine","year":2013,"url":"https://doi.org/10.1056/NEJMoa1213755","doi":"10.1056/NEJMoa1213755"},{"title":"RADICALS-RT: timing of radiotherapy after radical prostatectomy","journal":"The Lancet","year":2020,"url":"https://doi.org/10.1016/S0140-6736(20)31553-1","doi":"10.1016/S0140-6736(20)31553-1"}]},{"id":"chris-decker","kind":"person","name":"Chris Decker","aka":[],"tldr":"Leads CDISC, the non-profit that sets the clinical trial data standards required by FDA and PMDA, including oncology-specific therapeutic area guides.","summary":"Chris Decker is President and Chief Executive Officer of the Clinical Data Interchange Standards Consortium (CDISC). CDISC develops global standards such as SDTM, ADaM and CDASH that structure clinical trial data for regulatory submission, along with therapeutic-area user guides for cancers including breast, prostate and lung. He previously held senior roles in clinical data science and standards implementation in industry.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.cdisc.org/leadership-team"}],"tags":["leadership","data standards","regulation"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cdisc"],"pathways":[],"terms":["bla-nda"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President and Chief Executive Officer","institutionId":"cdisc","specialisms":["Clinical data standards","Clinical trial data interoperability","Regulatory submissions"],"profiles":[{"label":"Institution profile","url":"https://www.cdisc.org/leadership-team"}],"papers":[]},{"id":"chris-halloran","kind":"person","name":"Chris Halloran","aka":[],"tldr":"Liverpool pancreatic surgeon who leads EUROPAC, the UK registry and surveillance programme for families with inherited pancreatic cancer risk and hereditary pancreatitis.","summary":"Chris Halloran is Professor of Pancreatic Surgery at the University of Liverpool. His university page records a Liverpool medical degree (1994), FRCS (Eng) in 1998, research with Eithne Costello and John Neoptolemos on combination chemo-gene therapy for pancreatic cancer, recognition as a surgical trials methodologist, the European Pancreatic Club Gold Medal (2016) and an honorary FRCSEd (2024). He is clinical lead of EUROPAC, the European registry of familial pancreatic cancer and hereditary pancreatitis (ISRCTN62546421, sponsored by the University of Liverpool), whose scientific arm Europac-PLUS and surveillance arm Europac-PRIME study secondary screening; the 2026 European Journal of Cancer outcomes paper reports 893 individuals under UK surveillance since 2000. He was a co-author of ESPAC5.","asOf":"2026-09-24","links":[{"label":"University of Liverpool staff page","url":"https://www.liverpool.ac.uk/people/christopher-halloran"}],"tags":["pancreatic","surgeon","uk","surveillance"],"related":["bill-greenhalf","paula-ghaneh"],"cancers":["pancreatic"],"sections":["early-detection","surgery"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["liverpool-hpb-centre"],"pathways":[],"terms":[],"trials":["europac","espac-5"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Pancreatic Surgery, University of Liverpool; Clinical Lead, EUROPAC","institutionId":"liverpool-hpb-centre","specialisms":["Pancreatic surgery","Familial pancreatic cancer surveillance","Surgical trial methodology","Acute pancreatitis"],"profiles":[{"label":"University of Liverpool staff page","url":"https://www.liverpool.ac.uk/people/christopher-halloran"}],"papers":[{"title":"Risk-stratified surveillance for individuals in the UK at high risk of developing pancreatic cancer: outcomes from the European Registry of Hereditary Pancreatic Diseases (EUROPAC)","journal":"European Journal of Cancer","year":2026,"doi":"10.1016/j.ejca.2026.116592"},{"title":"European Registry of Hereditary Pancreatic Diseases (EUROPAC): protocol for primary and secondary screening in individuals at high risk of pancreatic cancer","journal":"BMJ Open","year":2025,"doi":"10.1136/bmjopen-2025-100027"},{"title":"Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5)","journal":"Lancet Gastroenterology and Hepatology","year":2023,"doi":"10.1016/S2468-1253(22)00348-X"}]},{"id":"chris-hillis","kind":"person","name":"Chris Hillis","aka":[],"tldr":"Blood cancer specialist who leads the Juravinski Cancer Centre, one of Ontario's largest integrated cancer programmes, as Vice President of Oncology.","summary":"Chris Hillis is Vice President, Oncology and Site Executive for the Juravinski Hospital and Cancer Centre at Hamilton Health Sciences, leading one of Ontario's largest integrated cancer programmes, and serves as Regional Vice President for the Hamilton Niagara Haldimand Brant Regional Cancer Program with Ontario Health. He is a malignant haematologist focused on chronic lymphocytic leukaemia and myeloproliferative neoplasms and an Associate Professor at McMaster University. He previously served as Chief of Oncology and Associate Chief Medical Information Officer, holds an MSc in quality improvement and patient safety, and leads a CIHR-funded research programme on making clinical trial outcomes more meaningful to patients with haematological malignancies.","asOf":"2026-09-10","links":[{"label":"Source: Hamilton Health Sciences senior leadership team","url":"https://www.hamiltonhealthsciences.ca/about-us/our-organization/senior-leadership-team/"}],"tags":["leadership","clinician-scientist","haematology"],"related":[],"cancers":["cll"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["juravinski"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["leukemia-and-lymphoma"],"dependsOn":[],"notes":[],"role":"Vice President, Oncology and Site Executive, Juravinski Hospital and Cancer Centre, Hamilton Health Sciences","institutionId":"juravinski","specialisms":["Malignant haematology","Chronic lymphocytic leukaemia","Myeloproliferative neoplasms","Quality improvement"],"profiles":[{"label":"Institution senior leadership page","url":"https://www.hamiltonhealthsciences.ca/about-us/our-organization/senior-leadership-team/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hillis+C%5BAuthor%5D+AND+hematology"}],"papers":[{"title":"Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a meta-analysis","journal":"Leukemia & Lymphoma","year":2015,"doi":"10.3109/10428194.2015.1091929"},{"title":"A pneumococcal pneumonia and influenza vaccination quality improvement program for women receiving chemotherapy for gynecologic cancers at a major tertiary cancer Centre","journal":"Gynecologic Oncology","year":2021,"doi":"10.1016/j.ygyno.2021.01.014"},{"title":"Gender and BCR‐ABL transcript type are correlated with molecular response to imatinib treatment in patients with chronic myeloid leukemia","journal":"European Journal of Haematology","year":2015,"doi":"10.1111/ejh.12597"}]},{"id":"christian-blank","kind":"person","name":"Christian Blank","aka":[],"tldr":"Led NADINA, which showed giving immunotherapy before melanoma surgery beats giving it after.","summary":"Christian Blank is a medical oncologist and group leader at the Netherlands Cancer Institute (NKI-AvL) and Professor at Leiden University. His specialisms are melanoma, neoadjuvant immunotherapy and immune biomarkers. He pioneered checkpoint blockade before melanoma surgery through the OpACIN and PRADO studies and the phase 3 NADINA trial, which established response-directed neoadjuvant nivolumab plus ipilimumab. His New England Journal of Medicine paper on NADINA reported neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma, showing that immunotherapy given before surgery beats giving it after. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Blank%20CU%5BAuthor%5D%20neoadjuvant%20melanoma"}],"tags":[],"related":[],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":["nivolumab","ipilimumab"],"companies":[],"institutions":["nki"],"pathways":[],"terms":["neoadjuvant-adjuvant"],"trials":["nadina"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Medical Oncologist and Group Leader, Netherlands Cancer Institute; Professor, Leiden University","institutionId":"nki","specialisms":["Melanoma","Neoadjuvant immunotherapy","Immune biomarkers"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Blank%20CU%5BAuthor%5D%20neoadjuvant%20melanoma"}],"papers":[{"title":"Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma (NADINA)","journal":"NEJM","year":2024,"doi":"10.1056/NEJMoa2402604"}]},{"id":"christian-brandts","kind":"person","name":"Christian Brandts","aka":[],"tldr":"Haematologist-oncologist who is Managing Director of the University Cancer Center Frankfurt.","summary":"Christian Brandts is Director of the University Cancer Center Frankfurt (UCT), the comprehensive cancer centre of Universitätsmedizin Frankfurt, Georg-Speyer-Haus and Krankenhaus Nordwest. A professor of haematology and medical oncology, his research has focused on signalling in acute myeloid leukaemia and on structures for precision oncology and molecular tumour boards.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.uct-frankfurt.de/ueber-uns/direktorium/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Brandts+CH%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","haematology","precision oncology"],"related":[],"cancers":["aml"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["uct-frankfurt"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, UCT Frankfurt (Geschäftsführender Direktor)","institutionId":"uct-frankfurt","specialisms":["Haematology and medical oncology","Leukaemia","Cancer centre management"],"profiles":[{"label":"Institution profile","url":"https://www.uct-frankfurt.de/ueber-uns/direktorium/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Brandts+CH%5BAuthor%5D"}],"papers":[{"title":"Metabolic Rewiring Is Essential for AML Cell Survival to Overcome Autophagy Inhibition by Loss of ATG3","journal":"Cancers","year":2021,"doi":"10.3390/cancers13236142"},{"title":"Colonization with multidrug resistant organisms determines the clinical course of patients with acute myeloid leukemia undergoing intensive induction chemotherapy","journal":"PLOS ONE","year":2019,"doi":"10.1371/journal.pone.0210991"},{"title":"Translatome proteomics identifies autophagy as a resistance mechanism to on-target FLT3 inhibitors in acute myeloid leukemia","journal":"Leukemia","year":2022,"doi":"10.1038/s41375-022-01678-y"}],"orcid":"0000-0003-1732-2535"},{"id":"christian-capitini","kind":"person","name":"Christian Capitini","aka":[],"tldr":"Physician who directs the University of Wisconsin Carbone Cancer Center, the NCI-designated comprehensive cancer centre in Madison.","summary":"Christian Capitini, MD, is Director of the University of Wisconsin Carbone Cancer Center (UWCCC), listed at the head of the centre's leadership page. UW Carbone is a matrix cancer centre within the UW School of Medicine and Public Health, drawing its members from 38 departments and nine schools and colleges at the University of Wisconsin-Madison. The leadership page gives his name and title only; it did not include further biographical detail.","asOf":"2026-09-10","links":[{"label":"Source: UW Carbone Cancer Center leadership page","url":"https://cancer.wisc.edu/uwccc-leadership/"}],"tags":["leadership","clinician-scientist","comprehensive-cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["uw-carbone"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, University of Wisconsin Carbone Cancer Center","institutionId":"uw-carbone","specialisms":["Oncology","Academic cancer centre leadership"],"profiles":[{"label":"UW Carbone Cancer Center leadership page","url":"https://cancer.wisc.edu/uwccc-leadership/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Capitini+CM%5BAuthor%5D"}],"papers":[{"title":"Stromal remodeling regulates dendritic cell abundance and activity in the tumor microenvironment","journal":"Cell Reports","year":2022,"doi":"10.1016/j.celrep.2022.111201"}],"orcid":"0000-0002-2276-6731"},{"id":"christian-sauvr","kind":"person","name":"Christian Sauvr","aka":[],"tldr":"Hospital chief executive who leads Sygehus Lillebælt, the Region of Southern Denmark hospital group whose Vejle site is a specialist cancer hospital.","summary":"Christian Sauvr leads Sygehus Lillebælt (Lillebaelt Hospital) as administrerende sygehusdirektør, the chief executive of the hospital group in the Region of Southern Denmark that runs Vejle Sygehus and Kolding Sygehus. The Danish Wikipedia article on Sygehus Lillebælt names him as head of the hospital management from 1 July 2020. Vejle Sygehus houses the group's oncology department and has repeatedly been recognised as Denmark's best mid-sized hospital, with particular recognition for its breast and lung cancer treatment. The hospital website did not expose a management page to the fetch, so the role is recorded from Wikipedia.","asOf":"2026-09-10","links":[{"label":"Source: Danish Wikipedia article on Sygehus Lillebælt naming the chief executive","url":"https://da.wikipedia.org/wiki/Sygehus_Lilleb%C3%A6lt"}],"tags":["leadership","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["vejle-cancer-centre"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive (administrerende sygehusdirektør), Sygehus Lillebælt (Lillebaelt Hospital)","institutionId":"vejle-cancer-centre","specialisms":["Hospital management","Regional health services"],"profiles":[{"label":"Wikipedia: Sygehus Lillebælt (Danish)","url":"https://da.wikipedia.org/wiki/Sygehus_Lilleb%C3%A6lt"}],"papers":[]},{"id":"christian-singer","kind":"person","name":"Christian Singer","aka":[],"tldr":"Gynaecological oncologist at the Medical University of Vienna and ABCSG Vice-President, known for work on breast cancer and hereditary cancer risk.","summary":"Christian Singer is Vice-President of the Austrian Breast & Colorectal Cancer Study Group and heads the breast health centre at the Medical University of Vienna's Department of Obstetrics and Gynaecology. His research covers breast cancer treatment, BRCA-associated hereditary breast and ovarian cancer, and translational biomarker studies within ABCSG trials.","asOf":"2026-09-10","links":[{"label":"Society page","url":"https://www.abcsg.org/en/about-us/board/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Singer+CF%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","breast cancer","hereditary cancer"],"related":[],"cancers":["breast-hr-positive","ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["abcsg"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["journal-of-experimental-and-clinical-cancer-research"],"dependsOn":[],"notes":[],"role":"Vice-President","institutionId":"abcsg","specialisms":["Breast cancer","Gynaecological oncology","Hereditary cancer"],"profiles":[{"label":"Society page","url":"https://www.abcsg.org/en/about-us/board/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Singer+CF%5BAuthor%5D"}],"papers":[{"title":"Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34)","journal":"European Journal of Cancer","year":2020,"doi":"10.1016/j.ejca.2020.03.018"},{"title":"Neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in women with early HER2-positive breast cancer: the randomized phase 2 ABCSG-52/ATHENE trial","journal":"Nature Cancer","year":2025,"doi":"10.1038/s43018-024-00890-2"},{"title":"Differential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patients","journal":"Journal of Experimental & Clinical Cancer Research","year":2023,"doi":"10.1186/s13046-023-02876-x"}]},{"id":"christiane-pott","kind":"person","name":"Christiane Pott","aka":[],"tldr":"Kiel professor of medicine who serves as President of the German Lymphoma Alliance, the umbrella body for German lymphoma study groups, alongside co-president Georg Lenz.","summary":"Christiane Pott is President (Praesidentin) of the German Lymphoma Alliance, the alliance that brings together German lymphoma study groups and centres, as listed on the organisation's contacts page. She is based at UKSH Campus Kiel. The alliance lists Georg Lenz of Universitaetsklinikum Muenster as its other President.","asOf":"2026-09-10","links":[{"label":"Source: German Lymphoma Alliance contacts page","url":"https://www.german-lymphoma-alliance.de/website-ansprechpartner.html"}],"tags":["leadership","clinician-scientist","haematology","cooperative-group"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["german-lymphoma-alliance"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["blood","nejm"],"dependsOn":[],"notes":[],"role":"President (Praesidentin) of the German Lymphoma Alliance","institutionId":"german-lymphoma-alliance","specialisms":["Lymphoma","Haematology","Clinical trials"],"profiles":[{"label":"Institution profile","url":"https://www.german-lymphoma-alliance.de/website-ansprechpartner.html"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Pott+C%5BAuthor%5D+lymphoma"}],"papers":[{"title":"Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study","journal":"Blood","year":2010,"doi":"10.1182/blood-2009-06-230250"},{"title":"Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma","journal":"New England Journal of Medicine","year":2018,"doi":"10.1056/nejmoa1715519"},{"title":"Minimal residual disease in mantle cell lymphoma: insights into biology and impact on treatment","journal":"Hematology","year":2016,"doi":"10.1182/asheducation-2016.1.437"}]},{"id":"christina-curtis","kind":"person","name":"Christina Curtis","aka":[],"tldr":"Showed that colorectal cancers grow as a 'Big Bang' and that metastasis can be seeded years before diagnosis.","summary":"Christina Curtis developed the Big Bang model showing that colorectal tumours acquire their intratumour heterogeneity early and grow without stringent selection, and used computational modelling of paired primary-metastasis genomes to show that metastatic seeding often occurs years before the primary tumour is detected. She co-led METABRIC and her laboratory now studies how germline immunogenetics shapes somatic tumour evolution.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Curtis%20C%5BAuthor%5D%20tumor%20evolution"}],"tags":["tumour-evolution","computational","genomics"],"related":[],"cancers":["colorectal","breast-hr-positive"],"sections":[],"technologies":["wes-wgs"],"targets":[],"drugs":[],"companies":[],"institutions":["stanford"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-gerlinger-intratumour-heterogeneity-nejm-2012"],"journals":["nature-genetics"],"dependsOn":[],"notes":[],"role":"Professor of Medicine, Genetics and Biomedical Data Science, Stanford University","institutionId":"stanford","specialisms":["Tumour evolution","Computational cancer biology","Metastasis timing","Breast cancer genomics"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Curtis%20C%5BAuthor%5D%20tumor%20evolution"}],"papers":[{"title":"A Big Bang model of human colorectal tumor growth","journal":"Nature Genetics","year":2015,"doi":"10.1038/ng.3214"},{"title":"Quantitative evidence for early metastatic seeding in colorectal cancer","journal":"Nature Genetics","year":2019,"doi":"10.1038/s41588-019-0423-x"},{"title":"Gerlinger: a single biopsy misses most of the mutations in a kidney tumour","journal":"New England Journal of Medicine","year":2012,"url":"https://doi.org/10.1056/NEJMoa1113205","doi":"10.1056/NEJMoa1113205"}],"orcid":"0000-0003-0166-3802"},{"id":"christine-brown","kind":"person","name":"Christine E. Brown","aka":[],"tldr":"Engineered the IL13Rα2 CAR-T cells that produced a complete response in glioblastoma when infused into the brain.","summary":"Christine Brown is Deputy Director of the T Cell Therapeutics Research Laboratories at City of Hope. An immunologist leading CAR-T development for brain tumours, she engineered the IL13Rα2 CAR-T cells that produced a complete response in glioblastoma when infused into the brain. Her papers include the 2016 New England Journal of Medicine case of regression of glioblastoma after intraventricular CAR T-cell therapy and a Nature Medicine phase 1 trial of locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma. Her work established locoregional delivery and continues on armoured and next-generation CAR designs for glioma and glioblastoma.","asOf":"2026-09-08","links":[{"label":"City of Hope research faculty","url":"https://www.cityofhope.org/research/find-a-researcher"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Brown%20CE%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Christine%20E.%20Brown"}],"tags":[],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":["car-t","armored-car"],"targets":[],"drugs":[],"companies":[],"institutions":["city-of-hope"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Deputy Director, T Cell Therapeutics Research Laboratories, City of Hope","institutionId":"city-of-hope","specialisms":["CAR-T cell therapy","Glioblastoma","Regional delivery"],"profiles":[{"label":"City of Hope research faculty","url":"https://www.cityofhope.org/research/find-a-researcher"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Brown%20CE%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Christine%20E.%20Brown"}],"papers":[{"title":"Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy","journal":"New England Journal of Medicine","year":2016,"url":"https://doi.org/10.1056/NEJMoa1610497","doi":"10.1056/NEJMoa1610497"},{"title":"Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial","journal":"Nature Medicine","year":2024,"url":"https://doi.org/10.1038/s41591-024-02875-1","doi":"10.1038/s41591-024-02875-1"}],"orcid":"0000-0003-4915-8207"},{"id":"christine-chung","kind":"person","name":"Christine H. Chung","aka":[],"tldr":"Head and neck oncologist who helped define the genomic subtypes of HPV-positive and HPV-negative disease.","summary":"Christine H. Chung is Chair of the Department of Head and Neck-Endocrine Oncology at Moffitt Cancer Center. She is a head and neck oncologist known for helping define the genomic subtypes of HPV-positive and HPV-negative disease, including as a co-author of The Cancer Genome Atlas analyses of head and neck cancer. Her selected paper reports the comprehensive genomic characterisation of head and neck squamous cell carcinomas. She now leads head and neck oncology at Moffitt and runs immunotherapy and treatment de-escalation trials.","asOf":"2026-09-08","links":[{"label":"Moffitt profile","url":"https://www.moffitt.org/providers/christine-chung/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chung%20CH%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["moffitt"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chair, Department of Head and Neck-Endocrine Oncology","institutionId":"moffitt","specialisms":["Head and neck cancer","HPV-associated cancer","Genomics"],"profiles":[{"label":"Moffitt profile","url":"https://www.moffitt.org/providers/christine-chung/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chung%20CH%5BAuthor%5D"}],"papers":[{"title":"Comprehensive genomic characterization of head and neck squamous cell carcinomas","journal":"Nature","year":2015,"url":"https://doi.org/10.1038/nature14129","doi":"10.1038/nature14129"}]},{"id":"christof-von-kalle","kind":"person","name":"Christof von Kalle","aka":[],"tldr":"Gene therapy pioneer who developed methods to track vector integration in treated patients.","summary":"Christof von Kalle is Director of the Clinical Study Center at the Berlin Institute of Health at Charité Universitätsmedizin Berlin. His specialisms are gene therapy, cell therapy safety and translational research, with links to CAR-T and in vivo CAR-T technologies. He is a gene therapy pioneer who developed integration-site analysis to track vector integration in treated patients, methods that revealed insertional mutagenesis in early gene therapy trials. He led translational oncology at NCT Heidelberg before moving to Berlin. His recent papers apply deep learning to histology, including a review of gastrointestinal cancer classification and studies predicting lymph node status from tumour histology in colorectal and prostate cancer. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=von%20Kalle%20C%5BAuthor%5D%20gene%20therapy%20integration"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["car-t","in-vivo-car-t"],"targets":[],"drugs":[],"companies":[],"institutions":["charite"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Clinical Study Center, Berlin Institute of Health at Charité","institutionId":"charite","specialisms":["Gene therapy","Cell therapy safety","Translational research"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=von%20Kalle%20C%5BAuthor%5D%20gene%20therapy%20integration"}],"papers":[{"title":"Gastrointestinal cancer classification and prognostication from histology using deep learning: Systematic review","journal":"European Journal of Cancer","year":2021,"doi":"10.1016/j.ejca.2021.07.012"},{"title":"Deep learning can predict lymph node status directly from histology in colorectal cancer","journal":"European Journal of Cancer","year":2021,"doi":"10.1016/j.ejca.2021.08.039"},{"title":"Deep learning approach to predict lymph node metastasis directly from primary tumour histology in prostate cancer","journal":"BJU International","year":2021,"doi":"10.1111/bju.15386"}]},{"id":"christophe-le-tourneau","kind":"person","name":"Christophe Le Tourneau","aka":[],"tldr":"Led SHIVA, the first randomised trial of genomics-matched therapy, and heads Institut Curie's early trials unit.","summary":"Christophe Le Tourneau is Head of Early Phase Trials (D3i) at Institut Curie, Professor at Paris-Saclay and part of the UNICANCER network. His specialisms are early-phase trials, head and neck cancer and precision medicine methodology, with a focus on comprehensive genomic profiling. He led SHIVA, the first randomised trial of molecularly targeted therapy chosen by tumour molecular profiling versus conventional therapy in advanced cancer, reported in Lancet Oncology. He now directs early-phase trials at Institut Curie with a particular interest in head and neck squamous cell carcinoma. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Le%20Tourneau%20C%5BAuthor%5D%20SHIVA"}],"tags":[],"related":[],"cancers":["head-and-neck"],"sections":[],"technologies":["cgp"],"targets":[],"drugs":[],"companies":["unicancer"],"institutions":["institut-curie"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Head of Early Phase Trials (D3i), Institut Curie; Professor, Paris-Saclay","institutionId":"unicancer","specialisms":["Early-phase trials","Head and neck cancer","Precision medicine methodology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Le%20Tourneau%20C%5BAuthor%5D%20SHIVA"}],"papers":[{"title":"Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA)","journal":"Lancet Oncology","year":2015,"doi":"10.1016/S1470-2045(15)00188-6"}],"orcid":"0000-0001-9772-4686"},{"id":"christophe-tournigand","kind":"person","name":"Christophe Tournigand","aka":[],"tldr":"Christophe Tournigand represents AP-HP Henri-Mondor University Hospitals Cancer Institute in the Organisation of European Cancer Institutes, which lists the centre among its full members in France.","summary":"Christophe Tournigand is listed by the Organisation of European Cancer Institutes (OECI) as the representative of AP-HP Henri-Mondor University Hospitals Cancer Institute, its full member in France. OnCo records the name from the OECI membership list so that the centre's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the institution's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"AP-HP Henri-Mondor University Hospitals Cancer Institute website","url":"https://iuc-hopitaux-u-mondor.aphp.fr/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["henri-mondor"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of AP-HP Henri-Mondor University Hospitals Cancer Institute to the Organisation of European Cancer Institutes","institutionId":"henri-mondor","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"AP-HP Henri-Mondor University Hospitals Cancer Institute website","url":"https://iuc-hopitaux-u-mondor.aphp.fr/"}],"papers":[{"title":"Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study","journal":"J Clin Oncol","year":2015,"url":"https://doi.org/10.1200/jco.2015.63.4238","doi":"10.1200/jco.2015.63.4238","note":"Europe PMC author record matched by affiliation"},{"title":"Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study","journal":"J Clin Oncol","year":2023,"url":"https://doi.org/10.1200/jco.22.00686","doi":"10.1200/jco.22.00686","note":"Europe PMC author record matched by affiliation"}]},{"id":"christopher-sweeney","kind":"person","name":"Christopher J. Sweeney","aka":[],"tldr":"Led CHAARTED, which showed adding docetaxel to hormone therapy extends survival in newly metastatic prostate cancer.","summary":"Christopher Sweeney (University of Adelaide; formerly Dana-Farber) was principal investigator of CHAARTED, the ECOG trial showing early docetaxel with androgen deprivation adds more than a year of survival in high-volume metastatic hormone-sensitive prostate cancer, and co-led ENZAMET (enzalutamide) with ANZUP. His work established treatment intensification at diagnosis as the standard approach. He now directs an immunogenomics institute in South Australia.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sweeney%20CJ%5BAuthor%5D%20prostate%20docetaxel"}],"tags":["prostate","trialist","ecog-acrin"],"related":[],"cancers":["prostate"],"sections":[],"technologies":["androgen-deprivation","cytotoxic-chemotherapy"],"targets":["androgen-receptor"],"drugs":[],"companies":[],"institutions":["saigenci-adelaide"],"pathways":[],"terms":[],"trials":["chaarted"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, South Australian Immunogenomics Cancer Institute; Professor, University of Adelaide","institutionId":"saigenci-adelaide","specialisms":["Metastatic hormone-sensitive prostate cancer","Docetaxel and androgen receptor inhibitors","Cooperative-group trials","Immunogenomics"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sweeney%20CJ%5BAuthor%5D%20prostate%20docetaxel"}],"papers":[{"title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer (CHAARTED)","journal":"NEJM","year":2015,"doi":"10.1056/NEJMoa1503747"},{"title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer (ENZAMET)","journal":"NEJM","year":2019,"doi":"10.1056/NEJMoa1903835"}],"orcid":"0000-0002-0398-6018"},{"id":"chris-lord","kind":"person","name":"Christopher Lord","aka":[],"tldr":"Co-discovered the synthetic lethality between PARP inhibition and BRCA loss that underlies PARP inhibitor therapy.","summary":"Christopher Lord is Professor of Cancer Genomics and Deputy Director of the Breast Cancer Now Research Centre at The Institute of Cancer Research. His specialisms are synthetic lethality, PARP inhibitors, DNA repair and drug resistance, with a focus on PARP and BRCA1/BRCA2. With Alan Ashworth he showed that BRCA-deficient cells are exquisitely sensitive to PARP inhibition, reported in Nature as a strategy for targeting the DNA repair defect in BRCA mutant cells, the discovery that underlies PARP inhibitor therapy. He has since mapped resistance mechanisms and new synthetic-lethal targets, and his Science review covered PARP inhibitors and synthetic lethality in the clinic. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lord%20CJ%5BAuthor%5D%20PARP%20synthetic%20lethality"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["parp-inhibitor","synthetic-lethality-approaches"],"targets":["parp","brca"],"drugs":[],"companies":[],"institutions":["icr-london"],"pathways":[],"terms":["synthetic-lethality"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Cancer Genomics; Deputy Director, Breast Cancer Now Research Centre, ICR","institutionId":"icr-london","specialisms":["Synthetic lethality","PARP inhibitors","DNA repair","Drug resistance"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lord%20CJ%5BAuthor%5D%20PARP%20synthetic%20lethality"}],"papers":[{"title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","journal":"Nature","year":2005,"doi":"10.1038/nature03445"},{"title":"PARP inhibitors: synthetic lethality in the clinic","journal":"Science","year":2017,"doi":"10.1126/science.aam7344"}]},{"id":"christopher-booth","kind":"person","name":"Christopher M. Booth","aka":[],"tldr":"Oncologist who co-led CHALLENGE and founded Common Sense Oncology to refocus trials on outcomes that matter to patients.","summary":"Christopher Booth (Queen's University, Canada) was co-principal investigator of the CHALLENGE trial showing exercise improves survival after colon cancer, and founded Common Sense Oncology, an international movement arguing that trials should measure overall survival and quality of life, avoid weak surrogate endpoints and address affordability. His health services research examines the real-world value of new cancer drugs.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Booth%20CM%5BAuthor%5D%20oncology"}],"tags":["evidence","policy","exercise"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":["exercise-oncology"],"targets":[],"drugs":[],"companies":[],"institutions":["queens-university-kingston"],"pathways":[],"terms":[],"trials":["challenge"],"people":[],"bottlenecks":[],"keyPapers":["paper-challenge-exercise-nejm-2025","paper-prasad-surrogate-endpoints-jama-im-2015"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Oncology and Public Health Sciences, Queen's University; Medical Oncologist, Kingston Health Sciences Centre","institutionId":"queens-university-kingston","specialisms":["Cancer policy and evidence","Common Sense Oncology","Health services research","Exercise oncology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Booth%20CM%5BAuthor%5D%20oncology"}],"papers":[{"title":"Structured exercise after adjuvant chemotherapy for colon cancer (CHALLENGE)","journal":"NEJM","year":2025},{"title":"Common Sense Oncology: outcomes that matter","journal":"Lancet Oncology","year":2023,"doi":"10.1016/S1470-2045(23)00319-4"},{"title":"CHALLENGE: a structured exercise programme after chemotherapy improves survival in colon cancer","journal":"New England Journal of Medicine","year":2025,"url":"https://doi.org/10.1056/NEJMoa2502760","doi":"10.1056/NEJMoa2502760"},{"title":"Prasad: most surrogate endpoints in cancer trials correlate poorly with survival","journal":"JAMA Internal Medicine","year":2015,"url":"https://doi.org/10.1001/jamainternmed.2015.2829","doi":"10.1001/jamainternmed.2015.2829"}],"orcid":"0000-0002-1505-0575"},{"id":"christopher-flowers","kind":"person","name":"Christopher R. Flowers","aka":[],"tldr":"Christopher Flowers is a lymphoma specialist who leads MD Anderson's entire medical oncology division.","summary":"Christopher Flowers is Division Head of Cancer Medicine and Chair of Lymphoma and Myeloma at MD Anderson Cancer Center. A haematologist-oncologist, he focuses on lymphoma epidemiology, outcomes and disparities, and on trials of novel agents in diffuse large B-cell lymphoma and follicular lymphoma. His papers include a Journal of Clinical Oncology report on polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma and a review in CA: a Cancer Journal for Clinicians on improving outcomes for patients with the disease. He heads the Division of Cancer Medicine, the largest medical oncology group in the world, with work on CD20 and CD19 directed therapy.","asOf":"2026-09-08","links":[{"label":"MD Anderson faculty","url":"https://faculty.mdanderson.org/search?q=Christopher%20R.%20Flowers"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Flowers%20CR%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Christopher%20R.%20Flowers"}],"tags":[],"related":[],"cancers":["dlbcl"],"sections":[],"technologies":[],"targets":["cd20","cd19"],"drugs":[],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["ca-cancer-journal"],"dependsOn":[],"notes":[],"role":"Division Head, Cancer Medicine; Chair, Lymphoma and Myeloma, MD Anderson","institutionId":"md-anderson","specialisms":["Lymphoma","Health outcomes","Clinical trials"],"profiles":[{"label":"MD Anderson faculty","url":"https://faculty.mdanderson.org/search?q=Christopher%20R.%20Flowers"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Flowers%20CR%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Christopher%20R.%20Flowers"}],"papers":[{"title":"Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma","journal":"Journal of Clinical Oncology","year":2020,"url":"https://doi.org/10.1200/JCO.19.00172","doi":"10.1200/JCO.19.00172"},{"title":"Improving outcomes for patients with diffuse large B-cell lymphoma","journal":"CA: a Cancer Journal for Clinicians","year":2010,"url":"https://doi.org/10.3322/caac.20087","doi":"10.3322/caac.20087"}],"orcid":"0000-0002-9524-3990"},{"id":"christopher-vakoc","kind":"person","name":"Christopher R. Vakoc","aka":[],"tldr":"Found that leukaemias depend on the chromatin reader BRD4, launching BET inhibitors, and mapped transcriptional addictions in sarcoma.","summary":"Christopher R. Vakoc is Professor at the Cold Spring Harbor Laboratory Cancer Center, where he studies transcriptional dependencies in cancer. He is known for finding through an RNA interference screen that acute myeloid leukaemia depends on the chromatin reader BRD4, work that launched BET inhibitors, and for developing CRISPR domain-scanning to find druggable protein domains. His selected paper reports the RNAi screen identifying Brd4 as a therapeutic target in AML. His laboratory now maps transcriptional addictions in Ewing sarcoma and rhabdomyosarcoma using CRISPR functional genomics.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Vakoc%20CR%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["aml","sarcoma"],"sections":[],"technologies":["epigenetic-drugs","crispr-screens"],"targets":[],"drugs":[],"companies":[],"institutions":["cold-spring-harbor"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor, CSHL Cancer Center","institutionId":"cold-spring-harbor","specialisms":["Transcriptional dependencies","BET and chromatin regulators","CRISPR domain screens"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Vakoc%20CR%5BAuthor%5D"}],"papers":[{"title":"RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia","journal":"Nature","year":2011,"url":"https://doi.org/10.1038/nature10334","doi":"10.1038/nature10334"}],"orcid":"0000-0002-1158-7180"},{"id":"christos-fasianos","kind":"person","name":"Christos Fasianos","aka":[],"tldr":"President of the governing board of Saint Savvas, the public anticancer oncology hospital in Athens.","summary":"Christos Fasianos (Χρήστος Φασιανός) is President of the Board of Directors (Πρόεδρος Διοικητικού Συμβουλίου) of the Saint Savvas Anticancer Oncology Hospital of Athens (Γενικό Αντικαρκινικό Ογκολογικό Νοσοκομείο Αθηνών 'Ο Άγιος Σάββας'), a public specialist cancer hospital in Athens. The hospital's governing bodies page lists him as President and Georgia Pontiki (Γεωργία Ποντίκη) as Vice President, together with regular and alternate board members. The page gives no appointment date or biography.","asOf":"2026-09-10","links":[{"label":"Source: Saint Savvas hospital governing bodies (Organa Dioikisis) page","url":"https://agsavvas-hosp.gr/organa-dioikisis/"}],"tags":["leadership","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["saint-savvas-athens"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President of the Board of Directors, Saint Savvas Anticancer Oncology Hospital of Athens","institutionId":"saint-savvas-athens","specialisms":["Hospital governance","Public hospital administration"],"profiles":[{"label":"Saint Savvas governing bodies page","url":"https://agsavvas-hosp.gr/organa-dioikisis/"}],"papers":[]},{"id":"christos-karapetis","kind":"person","name":"Christos Karapetis","aka":[],"tldr":"Australian medical oncologist whose landmark NEJM analysis showed KRAS mutation predicts lack of benefit from cetuximab in colorectal cancer.","summary":"Christos (Chris) Karapetis is a Professor of medical oncology at Flinders University and Flinders Medical Centre in Adelaide and serves on the Board of Directors of the Australasian Gastro-Intestinal Trials Group. He was first author of the 2008 New England Journal of Medicine analysis of the CO.17 trial establishing KRAS mutation status as a predictive biomarker for cetuximab in advanced colorectal cancer, and has led numerous AGITG trials.","asOf":"2026-09-10","links":[{"label":"Society page","url":"https://gicancer.org.au/about-us/board-of-directors/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Karapetis+CS%5BAuthor%5D"}],"tags":["clinician-scientist","colorectal cancer","clinical trials"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["agitg"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Board Director","institutionId":"agitg","specialisms":["Medical oncology","Colorectal cancer","Biomarkers","Clinical trials"],"profiles":[{"label":"Society page","url":"https://gicancer.org.au/about-us/board-of-directors/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Karapetis+CS%5BAuthor%5D"}],"papers":[{"title":"K-ras mutations and benefit from cetuximab in advanced colorectal cancer","journal":"New England Journal of Medicine","year":2008,"url":"https://doi.org/10.1056/NEJMoa0804385","doi":"10.1056/NEJMoa0804385"}]},{"id":"claire-harrison","kind":"person","name":"Claire Harrison","aka":[],"tldr":"Led COMFORT-II, which established ruxolitinib as the first drug for myelofibrosis, and most UK MPN trials since.","summary":"Claire Harrison was principal investigator of COMFORT-II, the European trial showing the JAK inhibitor ruxolitinib shrinks spleens and improves symptoms compared with best available therapy in myelofibrosis, which with COMFORT-I made ruxolitinib the first approved MPN therapy. She has led the MAJIC, PT-1 and RESPONSE trials in polycythaemia vera and essential thrombocythaemia and chairs the UK MPN research network.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Harrison%20CN%5BAuthor%5D%20myelofibrosis%20ruxolitinib"}],"tags":["mpn","jak-inhibitor","uk"],"related":[],"cancers":["myeloproliferative-neoplasms"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":[],"companies":[],"institutions":["guys-st-thomas"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-comfort-1-ruxolitinib-myelofibrosis-nejm-2012","paper-momentum-momelotinib-lancet-2023"],"journals":["blood"],"dependsOn":[],"notes":[],"role":"Professor of Myeloproliferative Neoplasms and Clinical Director of Haematology, Guy's and St Thomas' NHS Foundation Trust","institutionId":"guys-st-thomas","specialisms":["Myeloproliferative neoplasms","Myelofibrosis","JAK inhibitors","Clinical trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Harrison%20CN%5BAuthor%5D%20myelofibrosis%20ruxolitinib"}],"papers":[{"title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis (COMFORT-II)","journal":"NEJM","year":2012,"doi":"10.1056/NEJMoa1110556"},{"title":"Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide (MAJIC-ET)","journal":"Blood","year":2017,"doi":"10.1182/blood-2017-05-785790"},{"title":"COMFORT-I: ruxolitinib, the first JAK inhibitor, versus placebo for myelofibrosis","journal":"New England Journal of Medicine","year":2012,"url":"https://doi.org/10.1056/NEJMoa1110557","doi":"10.1056/NEJMoa1110557"},{"title":"MOMENTUM: momelotinib versus danazol for myelofibrosis patients with anaemia after a prior JAK inhibitor","journal":"The Lancet","year":2023,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=MOMENTUM%20momelotinib%20danazol%20myelofibrosis%20anaemia%20Verstovsek%20Lancet%202023"}]},{"id":"claudio-cracco","kind":"person","name":"Claudio Cracco","aka":[],"tldr":"Chief executive who runs IRCCS Ospedale Sacro Cuore Don Calabria, the research hospital of the Don Calabria religious institute at Negrar near Verona.","summary":"Claudio Cracco is Amministratore Delegato of IRCCS Ospedale Sacro Cuore Don Calabria at Negrar di Valpolicella near Verona, a private not-for-profit research hospital (IRCCS) run by the Opera Don Calabria. The hospital's leadership page lists him alongside the President, Fratel Gedovar Nazzari, and the Direttore Sanitario, Fabrizio Nicolis. No appointment date is given on the page.","asOf":"2026-09-10","links":[{"label":"Source: IRCCS Sacro Cuore Don Calabria 'La direzione' page","url":"https://www.sacrocuore.it/la-direzione/"}],"tags":["leadership","hospital-management","research-institute"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["sacro-cuore-don-calabria"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Amministratore Delegato (Chief Executive), IRCCS Ospedale Sacro Cuore Don Calabria","institutionId":"sacro-cuore-don-calabria","specialisms":["Hospital management","Not-for-profit healthcare governance"],"profiles":[{"label":"Sacro Cuore Don Calabria leadership page (La direzione)","url":"https://www.sacrocuore.it/la-direzione/"}],"papers":[]},{"id":"claudio-lombardo","kind":"person","name":"Claudio Lombardo","aka":[],"tldr":"Long-serving General Manager of the OECI, running the day-to-day operations of Europe's cancer institute network.","summary":"Claudio Lombardo is the General Manager of the Organisation of European Cancer Institutes and a co-opted member of its board. He manages the organisation's secretariat and programmes, including the accreditation and designation scheme for comprehensive cancer centres. His work sits at the interface of cancer centre management and European health policy.","asOf":"2026-09-10","links":[{"label":"Society page","url":"https://www.oeci.eu/Governance.aspx"}],"tags":["leadership","cancer policy","accreditation"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["jco-oncology-practice","european-journal-of-cancer"],"dependsOn":[],"notes":[],"role":"OECI General Manager","institutionId":"oeci","specialisms":["Cancer centre networks","Health policy","Accreditation and designation"],"profiles":[{"label":"Society page","url":"https://www.oeci.eu/Governance.aspx"}],"papers":[{"title":"Pioneering Quality Assessment in European Cancer Centers: A Data Analysis of the Organization for European Cancer Institutes Accreditation and Designation Program","journal":"Journal of Oncology Practice","year":2014,"doi":"10.1200/jop.2013.001331"},{"title":"Policy statement on multidisciplinary cancer care","journal":"European Journal of Cancer","year":2014,"doi":"10.1016/j.ejca.2013.11.012"},{"title":"Use of information and communication technologies (ICTs) in cancer multidisciplinary team meetings: an explorative study based on EU healthcare professionals","journal":"BMJ Open","year":2022,"doi":"10.1136/bmjopen-2021-051181"}],"orcid":"0000-0001-7554-449X"},{"id":"claus-belka","kind":"person","name":"Claus Belka","aka":[],"tldr":"Claus Belka is a radiation oncologist leading MR-guided adaptive radiotherapy research in Munich.","summary":"Claus Belka is Director of the Department of Radiation Oncology at LMU Klinikum München. His specialisms are radiation oncology, MR-guided radiotherapy and radiobiology, and his department was an early adopter of MR-linac technology for adaptive treatment. He leads research into MR-guided adaptive radiotherapy, modern image-guided external beam techniques, radiobiology and combinations of radiotherapy with immunotherapy. His work sits at the point where imaging, physics and radiation biology meet in the clinic. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Belka%20C%5BAuthor%5D%20MR-guided%20radiotherapy"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["mr-linac","imrt-igrt"],"targets":[],"drugs":[],"companies":[],"institutions":["lmu-munich"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Department of Radiation Oncology, LMU Munich","institutionId":"lmu-munich","specialisms":["Radiation oncology","MR-guided radiotherapy","Radiobiology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Belka%20C%5BAuthor%5D%20MR-guided%20radiotherapy"}],"papers":[{"title":"ESTRO-ACROP recommendations on the clinical implementation of hybrid MR-linac systems in radiation oncology","journal":"Radiotherapy and Oncology","year":2021,"doi":"10.1016/j.radonc.2021.03.025"},{"title":"Radiation induced CNS toxicity – molecular and cellular mechanisms","journal":"British Journal of Cancer","year":2001,"doi":"10.1054/bjoc.2001.2100"},{"title":"Differential role of caspase-8 and BID activation during radiation- and CD95-induced apoptosis","journal":"Oncogene","year":2000,"doi":"10.1038/sj.onc.1203401"}]},{"id":"clemens-kratochwil","kind":"person","name":"Clemens Kratochwil","aka":[],"tldr":"Clemens Kratochwil reported the first patients treated with actinium-225 PSMA therapy.","summary":"Clemens Kratochwil is a nuclear medicine physician at Heidelberg University Hospital, working within the NCT and DKFZ network. His specialisms are targeted alpha therapy, PSMA radioligands and dosimetry in prostate cancer. He reported the first patients treated with actinium-225 PSMA therapy, published in the Journal of Nuclear Medicine as 225Ac-PSMA-617 for PSMA-targeted alpha-radiation therapy of metastatic castration-resistant prostate cancer. That first clinical experience launched the alpha-emitter era in prostate cancer, and he continues to work on actinium-225 PSMA agents and their dosimetry. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kratochwil%20C%5BAuthor%5D%20225Ac%20PSMA"}],"tags":[],"related":[],"cancers":["prostate"],"sections":[],"technologies":["targeted-alpha-therapy"],"targets":["psma"],"drugs":["ac225-psma"],"companies":[],"institutions":["heidelberg-nct"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["journal-of-nuclear-medicine"],"dependsOn":[],"notes":[],"role":"Nuclear medicine physician, Heidelberg University Hospital","institutionId":"heidelberg-nct","specialisms":["Targeted alpha therapy","PSMA radioligands","Dosimetry"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kratochwil%20C%5BAuthor%5D%20225Ac%20PSMA"}],"papers":[{"title":"225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer","journal":"Journal of Nuclear Medicine","year":2016,"doi":"10.2967/jnumed.116.178673"}],"orcid":"0000-0003-1334-8260"},{"id":"clifford-hudis","kind":"person","name":"Clifford A. Hudis","aka":[],"tldr":"Clifford Hudis is a breast oncologist who has run ASCO since 2016.","summary":"Clifford Hudis is Chief Executive Officer of the American Society of Clinical Oncology (ASCO), a role he has held since 2016, and was formerly Chief of the Breast Medicine Service at Memorial Sloan Kettering Cancer Center. A breast oncologist, he served as ASCO president in 2013 to 2014 and now oversees the society's meetings, journals, guidelines and CancerLinQ. His papers include a New England Journal of Medicine review of trastuzumab's mechanism of action and clinical use and the STEEP proposal for standardised efficacy end point definitions in adjuvant breast cancer trials. His work spans HR-positive and HER2-positive breast cancer, professional society leadership and health policy.","asOf":"2026-09-08","links":[{"label":"ASCO leadership","url":"https://www.asco.org/about-asco/asco-leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hudis%20CA%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Clifford%20A.%20Hudis"}],"tags":[],"related":[],"cancers":["breast-hr-positive","breast-her2-positive"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["asco","mskcc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive Officer, American Society of Clinical Oncology","institutionId":"asco","specialisms":["Breast cancer","Professional society leadership","Health policy"],"profiles":[{"label":"ASCO leadership","url":"https://www.asco.org/about-asco/asco-leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hudis%20CA%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Clifford%20A.%20Hudis"}],"papers":[{"title":"Trastuzumab--mechanism of action and use in clinical practice","journal":"New England Journal of Medicine","year":2007,"url":"https://doi.org/10.1056/NEJMra043186","doi":"10.1056/NEJMra043186"},{"title":"Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system","journal":"Journal of Clinical Oncology","year":2007,"url":"https://doi.org/10.1200/JCO.2006.10.3523","doi":"10.1200/JCO.2006.10.3523"}]},{"id":"constance-lehman","kind":"person","name":"Constance D. Lehman","aka":[],"tldr":"Breast radiologist who co-developed the Mirai AI model that predicts breast cancer risk from a mammogram.","summary":"Constance Lehman co-led with Regina Barzilay the development and validation of Mirai, a deep-learning model that predicts five-year breast cancer risk from mammograms more accurately than clinical risk models across diverse populations, and led the ACRIN studies establishing MRI screening of the contralateral breast. She has led national breast imaging quality initiatives and now works on AI-driven personalised screening.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lehman%20CD%5BAuthor%5D%20mammography%20deep%20learning"}],"tags":["screening","ai","breast"],"related":[],"cancers":["breast-hr-positive"],"sections":[],"technologies":["radiology-ai-screening","mammography","mri"],"targets":[],"drugs":[],"companies":[],"institutions":["mgh"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["science-translational-medicine"],"dependsOn":[],"notes":[],"role":"Professor of Radiology, Harvard Medical School; Co-Director, Breast Imaging Research Center, Massachusetts General Hospital","institutionId":"mgh","specialisms":["Breast imaging","AI risk prediction","Screening MRI","Radiology outcomes"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lehman%20CD%5BAuthor%5D%20mammography%20deep%20learning"}],"papers":[{"title":"Toward robust mammography-based models for breast cancer risk","journal":"Science Translational Medicine","year":2021,"doi":"10.1126/scitranslmed.aba4373"},{"title":"MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer (ACRIN 6667)","journal":"NEJM","year":2007,"doi":"10.1056/NEJMoa065447"}]},{"id":"constantine-tam","kind":"person","name":"Constantine S. Tam","aka":[],"tldr":"Led the zanubrutinib SEQUOIA trial and the first ibrutinib-venetoclax study in mantle cell lymphoma.","summary":"Constantine Tam (Alfred Health, Melbourne) was principal investigator of SEQUOIA, which established zanubrutinib over bendamustine-rituximab in untreated CLL, and led the AIM study, the first trial to combine ibrutinib and venetoclax in mantle cell lymphoma, which produced unexpectedly high complete remission rates. He led the first-in-human zanubrutinib trial and leads lymphoma at Alfred Health.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tam%20CS%5BAuthor%5D%20zanubrutinib%20OR%20ibrutinib%20venetoclax"}],"tags":["cll","btk","australia"],"related":[],"cancers":["cll","mantle-cell-lymphoma"],"sections":[],"technologies":["kinase-inhibitors"],"targets":["bcl2"],"drugs":["venetoclax"],"companies":[],"institutions":["alfred-health-monash"],"pathways":[],"terms":[],"trials":["sequoia"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Head of Lymphoma Service, Alfred Health; Professor of Haematology, Monash University","institutionId":"alfred-health-monash","specialisms":["Chronic lymphocytic leukaemia","Mantle cell lymphoma","BTK inhibitors","Venetoclax combinations"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tam%20CS%5BAuthor%5D%20zanubrutinib%20OR%20ibrutinib%20venetoclax"}],"papers":[{"title":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA)","journal":"Lancet Oncology","year":2022,"doi":"10.1016/S1470-2045(22)00293-5"},{"title":"Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma (AIM)","journal":"NEJM","year":2018,"doi":"10.1056/NEJMoa1715519"}],"orcid":"0000-0002-9759-5017"},{"id":"corinne-faivre-finn","kind":"person","name":"Corinne Faivre-Finn","aka":[],"tldr":"Led CONVERT, which set the radiotherapy schedule for limited-stage small-cell lung cancer.","summary":"Corinne Faivre-Finn was chief investigator of CONVERT, the international trial that compared twice-daily and once-daily thoracic radiotherapy in limited-stage SCLC and confirmed twice-daily 45 Gy as the standard. She co-leads studies of radiotherapy-immunotherapy combinations in the PACIFIC and ADRIATIC era and the Christie's thoracic radiotherapy research group.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Faivre-Finn%20C%5BAuthor%5D%20small-cell%20radiotherapy"}],"tags":["radiotherapy","sclc"],"related":[],"cancers":["sclc","nsclc"],"sections":[],"technologies":["imrt-igrt"],"targets":[],"drugs":[],"companies":[],"institutions":["the-christie"],"pathways":[],"terms":[],"trials":["convert","adriatic"],"people":[],"bottlenecks":[],"keyPapers":["paper-adriatic-nejm-2024"],"journals":["journal-of-thoracic-oncology"],"dependsOn":[],"notes":[],"role":"Professor of Thoracic Radiation Oncology, University of Manchester and The Christie","institutionId":"the-christie","specialisms":["Small-cell lung cancer radiotherapy","Thoracic radiotherapy","Radiotherapy-immunotherapy combinations","Real-world data"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Faivre-Finn%20C%5BAuthor%5D%20small-cell%20radiotherapy"}],"papers":[{"title":"Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT)","journal":"Lancet Oncology","year":2017,"doi":"10.1016/S1470-2045(17)30318-2"},{"title":"Four-year survival with durvalumab after chemoradiotherapy in stage III NSCLC: an update from the PACIFIC trial","journal":"Journal of Thoracic Oncology","year":2021,"doi":"10.1016/j.jtho.2020.12.015"},{"title":"ADRIATIC: durvalumab after chemoradiotherapy for limited-stage small-cell lung cancer","journal":"New England Journal of Medicine","year":2024,"url":"https://doi.org/10.1056/NEJMoa2404873","doi":"10.1056/NEJMoa2404873"}],"orcid":"0000-0001-5617-9781"},{"id":"cornelis-van-de-velde","kind":"person","name":"Cornelis J. H. van de Velde","aka":[],"tldr":"Surgeon who led the Dutch TME trial, proving standardised rectal surgery with radiotherapy cuts local recurrence.","summary":"Cornelis van de Velde led the Dutch TME trial, which showed that total mesorectal excision taught through a national quality programme combined with short-course preoperative radiotherapy reduces local recurrence in rectal cancer, and the Dutch D1-D2 gastric cancer trial that clarified the role of extended lymphadenectomy. He founded the EURECCA registry programme and has been president of ESSO and ECCO.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=van%20de%20Velde%20CJ%5BAuthor%5D%20rectal%20TME"}],"tags":["surgery","colorectal","quality"],"related":[],"cancers":["colorectal","gastric"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["lumc-leiden","esso"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Emeritus Professor of Surgical Oncology, Leiden University Medical Center","institutionId":"lumc-leiden","specialisms":["Colorectal surgery","Total mesorectal excision","Gastric cancer surgery","Surgical quality"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=van%20de%20Velde%20CJ%5BAuthor%5D%20rectal%20TME"}],"papers":[{"title":"Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer (Dutch TME trial)","journal":"NEJM","year":2001,"doi":"10.1056/NEJM200108303450901"},{"title":"Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial","journal":"Lancet Oncology","year":2010,"doi":"10.1016/S1470-2045(10)70070-X"}]},{"id":"costas-lyssiotis","kind":"person","name":"Costas A. Lyssiotis","aka":[],"tldr":"Costas Lyssiotis shows how pancreatic tumours feed off their surrounding cells and how to cut the supply.","summary":"Costas A. Lyssiotis is Maisel Research Professor of Oncology at the University of Michigan Rogel Cancer Center, working on cancer metabolism in pancreatic cancer. He is known for showing how pancreatic tumours feed off their surrounding cells, describing the exchange of alanine between pancreatic stellate cells and cancer cells. His selected paper reports that pancreatic stellate cells support tumour metabolism through autophagic alanine secretion. He now studies tumour-stroma metabolic crosstalk and metabolic dependencies that could be exploited with drugs.","asOf":"2026-09-08","links":[{"label":"Michigan profile","url":"https://www.rogelcancercenter.org/costas-lyssiotis-phd"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lyssiotis%20CA%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["michigan-rogel"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Maisel Research Professor of Oncology","institutionId":"michigan-rogel","specialisms":["Cancer metabolism","Pancreatic cancer","Tumour-stroma metabolic crosstalk"],"profiles":[{"label":"Michigan profile","url":"https://www.rogelcancercenter.org/costas-lyssiotis-phd"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lyssiotis%20CA%5BAuthor%5D"}],"papers":[{"title":"Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion","journal":"Nature","year":2016,"url":"https://doi.org/10.1038/nature19084","doi":"10.1038/nature19084"}],"orcid":"0000-0001-9309-6141"},{"id":"courtney-dinardo","kind":"person","name":"Courtney D. DiNardo","aka":[],"tldr":"Led VIALE-A, which made venetoclax plus azacitidine the standard for older patients with acute myeloid leukaemia.","summary":"Courtney DiNardo was principal investigator of VIALE-A, which showed venetoclax plus azacitidine improves survival and doubles remission rates in older adults with AML unfit for intensive chemotherapy, replacing hypomethylating agents alone and reshaping AML treatment globally. She led the first-in-human ivosidenib trial and co-led AGILE (ivosidenib plus azacitidine in IDH1-mutant AML). Her work continues on venetoclax-based triplets and measurable residual disease.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=DiNardo%20CD%5BAuthor%5D%20venetoclax%20azacitidine"}],"tags":["aml","venetoclax","trialist"],"related":[],"cancers":["aml"],"sections":[],"technologies":[],"targets":["bcl2","idh"],"drugs":["venetoclax"],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":["viale-a","agile"],"people":[],"bottlenecks":[],"keyPapers":["paper-viale-a-venetoclax-azacitidine-nejm-2020","paper-agile-ivosidenib-azacitidine-nejm-2022"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Leukemia, MD Anderson Cancer Center","institutionId":"md-anderson","specialisms":["Acute myeloid leukaemia","Venetoclax combinations","IDH inhibitors","Older patients"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=DiNardo%20CD%5BAuthor%5D%20venetoclax%20azacitidine"}],"papers":[{"title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia (VIALE-A)","journal":"NEJM","year":2020,"doi":"10.1056/NEJMoa2012971"},{"title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","journal":"NEJM","year":2018,"doi":"10.1056/NEJMoa1716984"},{"title":"AGILE: ivosidenib plus azacitidine for newly diagnosed IDH1-mutated AML in patients unfit for intensive chemotherapy","journal":"New England Journal of Medicine","year":2022,"url":"https://doi.org/10.1056/NEJMoa2117344","doi":"10.1056/NEJMoa2117344"}],"orcid":"0000-0001-9003-0390"},{"id":"cristian-ayala-munita","kind":"person","name":"Cristián Ayala Munita","aka":[],"tldr":"General Manager of Fundación Arturo López Pérez, the Chilean non-profit cancer foundation that runs an oncology institute in Santiago.","summary":"Cristián Ayala Munita is General Manager (Gerente General) of Fundación Arturo López Pérez (FALP), a Chilean non-profit foundation dedicated to cancer care that operates an oncology institute in Santiago. He leads the administrative side of the organisation, while Dr Ricardo Morales Insunza serves as Medical Director and Rolando Medeiros Soux presides over the board of directors. Other senior posts listed by the foundation include the manager of the Instituto Oncológico, Marcos Simpson Álvarez, and the Scientific Director, Dr Christian Caglevic Medina.","asOf":"2026-09-10","links":[{"label":"Source: FALP administration page","url":"https://www.falp.org/fundacion/administracion-falp/"}],"tags":["leadership","hospital-management","latin-america"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["falp-chile"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"General Manager (Gerente General) of Fundación Arturo López Pérez","institutionId":"falp-chile","specialisms":["Hospital management","Cancer care delivery","Non-profit healthcare"],"profiles":[{"label":"Institution profile","url":"https://www.falp.org/fundacion/administracion-falp/"}],"papers":[]},{"id":"cristina-marchesi","kind":"person","name":"Cristina Marchesi","aka":[],"tldr":"Physician and health service manager who has been General Director of the Romagna cancer institute IRST in Meldola since July 2025.","summary":"Cristina Marchesi is Direttrice Generale of the IRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' (IRST), the national reference cancer institute for care, research and training based in Meldola with sites in Forlì, Cesena and Ravenna, part of the Emilia-Romagna regional health service. A physician who qualified in 1985 and specialised in hygiene and preventive medicine, she was General Director of the AUSL-IRCCS of Reggio Emilia from 2020 to January 2025 and has been vice-president of FIASO, the Italian federation of health authorities, since July 2023. She took up the IRST post on 1 July 2025, succeeding Lorenzo Maffioli, and leads the institute alongside President Luca Zambianchi, Medical Director Martina Rosticci and Scientific Director Nicola Normanno.","asOf":"2026-09-10","links":[{"label":"Source: IRST Direzione Generale page","url":"https://www.irst.emr.it/it/listituto/organizzazione/direzioni/direzione-generale"}],"tags":["leadership","health-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["irst-meldola"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Direttrice Generale (General Director) of IRST 'Dino Amadori' IRCCS","institutionId":"irst-meldola","specialisms":["Healthcare management","Public health and preventive medicine","Hospital and community care integration"],"profiles":[{"label":"Institution profile","url":"https://www.irst.emr.it/it/persone/professionisti/marchesi-cristina"}],"papers":[]},{"id":"cristina-saura","kind":"person","name":"Cristina Saura","aka":[],"tldr":"Spanish breast oncologist leading DESTINY-Breast09, which moved trastuzumab deruxtecan into first-line HER2-positive disease.","summary":"Cristina Saura led NALA (neratinib plus capecitabine) and is a principal investigator of DESTINY-Breast09, the trial showing trastuzumab deruxtecan plus pertuzumab outperforms the CLEOPATRA regimen first line. She heads breast cancer at Vall d'Hebron, is active in the SOLTI cooperative group, and works on ctDNA and brain-metastasis strategies in HER2-positive disease.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Saura%20C%5BAuthor%5D%20breast%20HER2"}],"tags":["breast","her2","adc"],"related":[],"cancers":["breast-her2-positive"],"sections":[],"technologies":["adc"],"targets":["her2"],"drugs":["trastuzumab-deruxtecan"],"companies":["solti"],"institutions":["vall-dhebron"],"pathways":[],"terms":[],"trials":["destiny-breast09"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Head of the Breast Cancer Unit, Vall d'Hebron University Hospital and VHIO","institutionId":"vall-dhebron","specialisms":["HER2-positive breast cancer","Antibody-drug conjugates","Tyrosine kinase inhibitors","Brain metastases"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Saura%20C%5BAuthor%5D%20breast%20HER2"}],"papers":[{"title":"Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with two or more HER2-directed regimens (NALA)","journal":"JCO","year":2020,"doi":"10.1200/JCO.20.00147"},{"title":"Trastuzumab deruxtecan plus pertuzumab for first-line HER2-positive advanced breast cancer (DESTINY-Breast09)","journal":"NEJM","year":2025}]},{"id":"crystal-mackall","kind":"person","name":"Crystal L. Mackall","aka":[],"tldr":"Crystal Mackall is a cell therapy pioneer whose team brought GD2 CAR-T to children with brain tumours that had no treatment.","summary":"Crystal Mackall is Director of the Stanford Center for Cancer Cell Therapy and Ernest and Amelia Gallo Family Professor at Stanford, within the Stanford Cancer Institute. A paediatric oncologist and immunologist, she leads Stanford's cancer cell therapy programme, whose GD2 CAR-T trial in H3K27M diffuse midline glioma produced the first meaningful responses in that disease. Her papers include the Nature report of GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas and a Nature study showing that c-Jun overexpression in CAR T cells induces exhaustion resistance. She studies CAR-T exhaustion and enhancement across glioma, neuroblastoma and sarcomas.","asOf":"2026-09-08","links":[{"label":"Stanford profile","url":"https://profiles.stanford.edu/search?q=Crystal%20L.%20Mackall"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mackall%20CL%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Crystal%20L.%20Mackall"}],"tags":[],"related":[],"cancers":["glioblastoma","neuroblastoma","sarcoma"],"sections":[],"technologies":["car-t","armored-car"],"targets":["gd2"],"drugs":[],"companies":[],"institutions":["stanford"],"pathways":[],"terms":["h3k27m"],"trials":["gd2-cart01"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Stanford Center for Cancer Cell Therapy; Ernest and Amelia Gallo Family Professor","institutionId":"stanford","specialisms":["CAR-T cell therapy","Paediatric oncology","Immunotherapy"],"profiles":[{"label":"Stanford profile","url":"https://profiles.stanford.edu/search?q=Crystal%20L.%20Mackall"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mackall%20CL%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Crystal%20L.%20Mackall"}],"papers":[{"title":"GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas","journal":"Nature","year":2022,"url":"https://doi.org/10.1038/s41586-022-04489-4","doi":"10.1038/s41586-022-04489-4"},{"title":"c-Jun overexpression in CAR T cells induces exhaustion resistance","journal":"Nature","year":2019,"url":"https://doi.org/10.1038/s41586-019-1805-z","doi":"10.1038/s41586-019-1805-z"}]},{"id":"ross-camidge","kind":"person","name":"D. Ross Camidge","aka":[],"tldr":"Led the crizotinib and brigatinib trials that defined ALK-targeted lung cancer therapy.","summary":"Ross Camidge led the first crizotinib expansion cohort in ALK-positive lung cancer and was principal investigator of the ALTA and ALTA-1L brigatinib trials, and senior author on ALEX (alectinib). He has championed CNS-specific endpoints and ctDNA monitoring in oncogene-driven disease. He directs thoracic oncology research at the University of Colorado.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Camidge%20DR%5BAuthor%5D%20ALK%20lung"}],"tags":["lung","alk","targeted-therapy"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["kinase-inhibitors"],"targets":["alk"],"drugs":["lorlatinib"],"companies":[],"institutions":["colorado-cancer-center"],"pathways":[],"terms":[],"trials":["crown"],"people":[],"bottlenecks":[],"keyPapers":["paper-shaw-crown-lorlatinib-crizotinib-nejm-2020"],"journals":[],"dependsOn":[],"notes":[],"role":"Joyce Zeff Chair in Lung Cancer Research, University of Colorado Cancer Center","institutionId":"colorado-cancer-center","specialisms":["ALK-positive lung cancer","Oncogene-driven NSCLC","Brain metastases","Trial design"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Camidge%20DR%5BAuthor%5D%20ALK%20lung"}],"papers":[{"title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer (ALEX)","journal":"NEJM","year":2017,"doi":"10.1056/NEJMoa1704795"},{"title":"Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer (ALTA-1L)","journal":"NEJM","year":2018,"doi":"10.1056/NEJMoa1810171"},{"title":"CROWN: lorlatinib versus crizotinib as first treatment for ALK-positive lung cancer","journal":"New England Journal of Medicine","year":2020,"url":"https://doi.org/10.1056/NEJMoa2027187","doi":"10.1056/NEJMoa2027187"}]},{"id":"d-wade-clapp","kind":"person","name":"D. Wade Clapp","aka":[],"tldr":"Paediatric haematologist-oncologist and National Academy of Medicine member who is Interim Director of the IU Simon Comprehensive Cancer Center in Indianapolis.","summary":"D. Wade Clapp is Interim Director of the Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana's NCI-designated comprehensive cancer centre, and is listed first on the centre's Executive Committee; his centre biography records the interim directorship as of June 2026. He is Associate Dean for Cancer Research, Distinguished Professor and H.H. Gregg Professor of Oncology at Indiana University School of Medicine, with professorships in Pediatrics, Microbiology and Immunology, Biochemistry and Molecular Biology, and Medical and Molecular Genetics. His laboratory studies the molecular basis of genetic conditions that predispose to cancer, in particular neurofibromatosis type 1 and Fanconi anaemia, and his translational work contributed to the first drugs for plexiform neurofibromas to reach the clinic, including selumetinib. He was elected to the National Academy of Medicine in 2020.","asOf":"2026-09-10","links":[{"label":"Source: IU Simon Cancer Center Executive Committee page","url":"https://cancer.iu.edu/about/leadership/executive-committee.html"},{"label":"Source: IU Simon Cancer Center member biography","url":"https://cancer.iu.edu/about/members/bio/1600/index.html"}],"tags":["leadership","clinician-scientist","comprehensive-cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["selumetinib"],"companies":[],"institutions":["iu-simon"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Interim Director, Indiana University Melvin and Bren Simon Comprehensive Cancer Center","institutionId":"iu-simon","specialisms":["Paediatric haematology and oncology","Neurofibromatosis type 1","Fanconi anaemia","Cancer predisposition genetics"],"profiles":[{"label":"IU Simon Cancer Center biography","url":"https://cancer.iu.edu/about/members/bio/1600/index.html"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Clapp+DW%5BAuthor%5D"}],"papers":[{"title":"Fanconi anaemia and cancer: an intricate relationship","journal":"Nature Reviews Cancer","year":2018,"doi":"10.1038/nrc.2017.116"},{"title":"Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial","journal":"The Lancet Oncology","year":2012,"doi":"10.1016/s1470-2045(12)70414-x"},{"title":"Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma","journal":"Journal of Clinical Oncology","year":2019,"doi":"10.1200/jco.19.01367"}]},{"id":"lee-dae-ho","kind":"person","name":"Dae Ho Lee","aka":[],"tldr":"Dae Ho Lee is a thoracic oncologist behind Korean participation in the EGFR, ALK, and MET inhibitor trials that shaped lung cancer care.","summary":"Dae Ho Lee is Professor of Medical Oncology and a thoracic oncologist at Asan Medical Center in Seoul. He has led and co-led non-small-cell lung cancer trials including third-generation EGFR inhibitor studies with osimertinib and lazertinib and MET-directed therapies, and was an investigator in MARIPOSA, the trial of amivantamab plus lazertinib in previously untreated EGFR-mutated disease. His publications include the MARIPOSA report, and he contributes to Korean lung cancer treatment guidelines. His work has anchored Korean participation in the EGFR, ALK and MET inhibitor trials that shaped lung cancer care.","asOf":"2026-09-08","links":[{"label":"Asan Medical Center","url":"https://eng.amc.seoul.kr"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lee%20DH%5BAuthor%5D%20Asan%20lung%20cancer"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":["egfr","met"],"drugs":["amivantamab","lazertinib","osimertinib"],"companies":[],"institutions":["asan-medical-center"],"pathways":[],"terms":[],"trials":["mariposa"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology; thoracic oncology","institutionId":"asan-medical-center","specialisms":["Lung cancer","EGFR and ALK inhibitors","Clinical trials"],"profiles":[{"label":"Asan Medical Center","url":"https://eng.amc.seoul.kr"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lee%20DH%5BAuthor%5D%20Asan%20lung%20cancer"}],"papers":[{"title":"Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC (MARIPOSA)","journal":"NEJM","year":2024,"doi":"10.1056/NEJMoa2403614"}]},{"id":"dale-bramley","kind":"person","name":"Dale Bramley","aka":[],"tldr":"Public health physician who is Chief Executive of Health New Zealand Te Whatu Ora, the national body that runs Auckland City Hospital and its Te Pūriri o Te Ora cancer and blood service.","summary":"Dale Bramley is Chief Executive of Health New Zealand Te Whatu Ora, the single national organisation that since 2022 has run New Zealand's public hospitals, including Auckland City Hospital and its Te Pūriri o Te Ora Cancer and Blood Service. Health New Zealand's executive team page describes him as a public health medicine specialist and former chief executive of Waitematā District Health Board; Wikipedia records that he was appointed Chief Executive on 25 June 2025, succeeding Margie Apa. Auckland City Hospital no longer publishes a separate leadership page, its former adhb.health.nz site redirecting to a Health New Zealand services directory.","asOf":"2026-09-10","links":[{"label":"Source: Health New Zealand 'Our executive team' page","url":"https://www.healthnz.govt.nz/about-us/who-we-are/our-executive-team"},{"label":"Source: Wikipedia article on Te Whatu Ora (appointment date)","url":"https://en.wikipedia.org/wiki/Te_Whatu_Ora"}],"tags":["leadership","government","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["auckland-city-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive, Health New Zealand Te Whatu Ora (parent body of Auckland City Hospital)","institutionId":"auckland-city-hospital","specialisms":["Public health medicine","Health system leadership"],"profiles":[{"label":"Health New Zealand executive team","url":"https://www.healthnz.govt.nz/about-us/who-we-are/our-executive-team"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bramley+D%5BAuthor%5D+AND+New+Zealand"}],"papers":[]},{"id":"cicely-saunders","kind":"person","name":"Dame Cicely Saunders","aka":[],"tldr":"Nurse, social worker and doctor who opened St Christopher's Hospice in 1967 and established that pain in advanced cancer could be prevented with regular oral morphine and attention to the whole person.","summary":"Cicely Saunders (1918-2005) trained first as a nurse and then as a medical social worker before, at the suggestion of a surgeon, qualifying as a doctor in 1957 so that she would be listened to. Working at St Joseph's Hospice in Hackney, she showed that giving oral opioids by the clock rather than on demand kept patients with advanced cancer free of pain and alert, and she described total pain as physical, emotional, social and spiritual. In 1967 she opened St Christopher's Hospice in south London, the first to combine care, teaching and research, and it became the model for hospices and palliative care services worldwide. She was made a Dame in 1979 and received the Order of Merit in 1989. Palliative medicine became a recognised specialty in Britain in 1987 largely on the foundations she laid.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Cicely_Saunders","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Cicely_Saunders"},{"label":"St Christopher's Hospice","url":"https://www.stchristophers.org.uk/"},{"label":"Cicely Saunders International","url":"https://cicelysaundersinternational.org/"}],"tags":["hero","advocate","pioneer"],"related":[],"cancers":[],"sections":["supportive-care"],"technologies":["hospice-end-of-life","palliative-care","pain-management"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-palliative","b-toxicity-qol"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Founder of the modern hospice movement","specialisms":["Palliative care","Hospice","Cancer pain"],"profiles":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Cicely_Saunders"},{"label":"St Christopher's Hospice","url":"https://www.stchristophers.org.uk/"},{"label":"Cicely Saunders International","url":"https://cicelysaundersinternational.org/"}],"papers":[{"title":"The Evolution of Palliative Care","journal":"Journal of the Royal Society of Medicine","year":2001,"doi":"10.1177/014107680109400904"}]},{"id":"deborah-james","kind":"person","name":"Dame Deborah James","aka":[],"tldr":"Diagnosed with bowel cancer at 35, she spent five years telling people to check their poo, co-hosted the BBC's You, Me and the Big C, and raised over £11 million for Cancer Research UK in the weeks before her death in 2022.","summary":"Deborah James (1981-2022) was a deputy headteacher when she was diagnosed with stage IV bowel cancer in December 2016 at 35, having had symptoms dismissed. Writing as Bowelbabe, she used plain language and humour to describe treatment and symptoms, co-hosted the BBC podcast You, Me and the Big C from 2018, and pushed the message that bowel cancer is not an old person's disease. In May 2022, moving to hospice care at home, she launched the Bowelbabe Fund for Cancer Research UK with a target of £250,000; it passed £11 million within weeks. She was made a Dame by Prince William at her parents' home. She died on 28 June 2022 at 40. Bowel Cancer UK and NHS England reported sustained increases in symptom searches and referrals during and after her campaign.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Deborah_James_(journalist)","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Deborah_James_(journalist)"},{"label":"Bowelbabe Fund for Cancer Research UK","url":"https://bowelbabe.org/"},{"label":"Cancer Research UK","url":"https://www.cancerresearchuk.org/"}],"tags":["hero","patient","advocate"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":["colorectal-screening","hospice-end-of-life"],"targets":[],"drugs":[],"companies":[],"institutions":["cruk","bowelbabe-fund"],"pathways":[],"terms":["aya-oncology","fit-test"],"trials":[],"people":[],"bottlenecks":["b-patient-voice","b-early-detection","b-funding-allocation"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"\"Bowelbabe\": patient, broadcaster and fundraiser for bowel cancer research","specialisms":["Colorectal cancer","Early-onset bowel cancer","Cancer fundraising"],"profiles":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Deborah_James_(journalist)"},{"label":"Bowelbabe Fund for Cancer Research UK","url":"https://bowelbabe.org/"},{"label":"Cancer Research UK","url":"https://www.cancerresearchuk.org/"}],"papers":[]},{"id":"dan-theodorescu","kind":"person","name":"Dan Theodorescu","aka":[],"tldr":"Professor of urology and of cellular and molecular medicine who directs the University of Arizona Cancer Center, the NCI-designated cancer centre in Tucson.","summary":"Dan Theodorescu, MD, PhD, is Director of the University of Arizona Cancer Center and holds the Nancy C. and Craig M. Berge Endowed Chair for the Director of the Cancer Center. He is Professor of Urology and of Cellular and Molecular Medicine at the University of Arizona and also leads the centre's Developmental Therapeutics Program. The University of Arizona Cancer Center is the NCI-designated cancer centre headquartered in Tucson.","asOf":"2026-09-10","links":[{"label":"Source: University of Arizona Cancer Center leadership page","url":"https://cancercenter.arizona.edu/message-director/leadership"}],"tags":["leadership","clinician-scientist","comprehensive-cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["arizona-cancer-center"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nature-reviews-cancer","lancet-oncology","nature"],"dependsOn":[],"notes":[],"role":"Director, University of Arizona Cancer Center","institutionId":"arizona-cancer-center","specialisms":["Urology","Cellular and molecular medicine","Developmental therapeutics"],"profiles":[{"label":"University of Arizona Cancer Center leadership page","url":"https://cancercenter.arizona.edu/message-director/leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Theodorescu+D%5BAuthor%5D"}],"papers":[{"title":"Advances in bladder cancer biology and therapy","journal":"Nature Reviews Cancer","year":2020,"doi":"10.1038/s41568-020-00313-1"},{"title":"Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis","journal":"The Lancet Oncology","year":2006,"doi":"10.1016/s1470-2045(06)70584-8"},{"title":"Y chromosome loss in cancer drives growth by evasion of adaptive immunity","journal":"Nature","year":2023,"doi":"10.1038/s41586-023-06234-x"}],"orcid":"0000-0002-8708-8206"},{"id":"daniel-haber","kind":"person","name":"Daniel A. Haber","aka":[],"tldr":"Co-discovered EGFR mutations in lung cancer and pioneered circulating tumour cell technology.","summary":"Daniel A. Haber is Director of the Mass General Cancer Center at Massachusetts General Hospital and an HHMI Investigator. He is known for co-discovering the EGFR mutations that predict response to gefitinib in non-small-cell lung cancer, and for pioneering circulating tumour cell technology through the CTC-Chip. His selected papers report the activating EGFR mutations underlying gefitinib responsiveness in lung cancer, and the isolation of rare circulating tumour cells by microchip technology. He now directs the cancer centre and continues to work on liquid biopsy and circulating tumour cell biology.","asOf":"2026-09-08","links":[{"label":"MGH Cancer Center","url":"https://www.massgeneral.org/cancer-center"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Haber%20DA%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["liquid-biopsy"],"targets":["egfr"],"drugs":[],"companies":[],"institutions":["mgh"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Mass General Cancer Center; HHMI Investigator","institutionId":"mgh","specialisms":["Circulating tumour cells","EGFR mutations","Cancer genetics"],"profiles":[{"label":"MGH Cancer Center","url":"https://www.massgeneral.org/cancer-center"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Haber%20DA%5BAuthor%5D"}],"papers":[{"title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","journal":"New England Journal of Medicine","year":2004,"url":"https://doi.org/10.1056/NEJMoa040938","doi":"10.1056/NEJMoa040938"},{"title":"Isolation of rare circulating tumour cells in cancer patients by microchip technology","journal":"Nature","year":2007,"url":"https://doi.org/10.1038/nature06385","doi":"10.1038/nature06385"}]},{"id":"daniel-von-hoff","kind":"person","name":"Daniel D. Von Hoff","aka":[],"tldr":"Led the MPACT trial of nab-paclitaxel plus gemcitabine and has run more first-in-human cancer trials than almost anyone.","summary":"Daniel Von Hoff (TGen and HonorHealth, Phoenix) was principal investigator of MPACT, which established gemcitabine plus nab-paclitaxel as a first-line standard in metastatic pancreatic cancer, and has led the early clinical development of many approved drugs including gemcitabine, irinotecan and vismodegib. He founded one of the largest phase 1 programmes in the United States and was a founding editor of Molecular Cancer Therapeutics.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Daniel_Von_Hoff","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Von%20Hoff%20DD%5BAuthor%5D%20pancreatic"}],"tags":["pancreatic","early-phase","drug-development"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":[],"companies":[],"institutions":["tgen"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Distinguished Professor, Translational Genomics Research Institute (TGen); Physician-in-Chief, HonorHealth Research Institute","institutionId":"tgen","specialisms":["Pancreatic cancer","Early drug development","Phase 1 trials","Precision oncology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Von%20Hoff%20DD%5BAuthor%5D%20pancreatic"}],"papers":[{"title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine (MPACT)","journal":"NEJM","year":2013,"doi":"10.1056/NEJMoa1304369"},{"title":"Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial","journal":"JCO","year":2011,"doi":"10.1200/JCO.2011.36.5742"}]},{"id":"daniel-spratt","kind":"person","name":"Daniel E. Spratt","aka":[],"tldr":"Radiation oncologist who built AI models from trial slides to decide which prostate cancer patients need hormone therapy.","summary":"Daniel Spratt led the development and validation of the ArteraAI multimodal AI prostate test using digitised pathology and clinical data from NRG/RTOG trials, the first AI biomarker to enter NCCN prostate guidelines. He has led analyses of the Decipher genomic classifier and chairs NRG GU trials of biomarker-guided treatment intensification and de-intensification.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Spratt%20DE%5BAuthor%5D%20prostate%20artificial%20intelligence"}],"tags":["prostate","ai","radiotherapy"],"related":[],"cancers":["prostate"],"sections":[],"technologies":["digital-pathology-ai","imrt-igrt"],"targets":[],"drugs":["artera-ai-prostate"],"companies":[],"institutions":["case-ccc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nejm-evidence"],"dependsOn":[],"notes":[],"role":"Chair of Radiation Oncology, University Hospitals Seidman Cancer Center and Case Western Reserve University","institutionId":"case-ccc","specialisms":["Prostate radiotherapy","AI biomarkers","Genomic classifiers","Cooperative-group trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Spratt%20DE%5BAuthor%5D%20prostate%20artificial%20intelligence"}],"papers":[{"title":"Artificial intelligence predictive model for hormone therapy use in prostate cancer","journal":"NEJM Evidence","year":2023},{"title":"Individual patient-level meta-analysis of the performance of the Decipher genomic classifier in high-risk men after prostatectomy to predict development of metastatic disease","journal":"JCO","year":2017,"doi":"10.1200/JCO.2016.70.2811"}],"orcid":"0000-0002-5973-4741"},{"id":"daniel-ludwig","kind":"person","name":"Daniel K. Ludwig","aka":[],"tldr":"In 1971 he put nearly all of his international holdings into a cancer research institute that carries his name reluctantly; it has since spent more than $1.8 billion of its own money on cancer science.","summary":"Daniel K. Ludwig (1897-1992) built one of the world's largest shipping and industrial fortunes and, in 1971, launched the Ludwig Institute for Cancer Research, endowing it with nearly all of his international holdings; the Institute records that he had to be persuaded strongly to allow his name to be used. Because the Institute funds and runs its own laboratories from its endowment, its scientists could pursue long programmes in tumour immunology, tumour antigens and cancer genomics without grant cycles. Ludwig Cancer Research states that it has invested more than $1.8 billion of its own resources in cancer research and holds an endowment of $1.5 billion, and that Ludwig Centers and professorships created in 2006 at six leading US institutions each receive more than $2 million a year in perpetuity. Few single gifts have funded as much basic cancer biology for as long.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Daniel_K._Ludwig","links":[{"label":"Ludwig Cancer Research: about","url":"https://www.ludwigcancerresearch.org/about/"}],"tags":["hero","donor"],"related":[],"cancers":[],"sections":[],"technologies":["immunotherapy","cgp"],"targets":[],"drugs":[],"companies":[],"institutions":["ludwig-cancer-research","mskcc","mit-koch","stanford","uchicago-cancer","johns-hopkins"],"pathways":[],"terms":[],"trials":[],"people":["james-allison"],"bottlenecks":["b-funding-allocation","b-translational-valley"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Shipping magnate who endowed the Ludwig Institute for Cancer Research in 1971","specialisms":["Cancer research endowment","Institute building","Cancer immunology"],"profiles":[],"papers":[]},{"id":"daniel-aebersold","kind":"person","name":"Daniel M. Aebersold","aka":[],"tldr":"Radiation oncologist who chairs the directorate of the University Cancer Center Inselspital in Bern.","summary":"Daniel M. Aebersold is Chair of the Directorate of the University Cancer Center Inselspital (UCI) and Chief Physician of Radiation Oncology at Inselspital, Bern University Hospital. His research covers radiotherapy for head and neck and prostate cancers, including trials of hypofractionation and combined-modality treatment. He leads the multidisciplinary governance of the cancer centre.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.tumorzentrum.insel.ch/de/ueber-uns/organisation"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Aebersold+DM%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","radiotherapy","head and neck cancer"],"related":[],"cancers":["head-and-neck","prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["inselspital-bern"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["international-journal-of-cancer"],"dependsOn":[],"notes":[],"role":"Chair of the UCI Directorate; Chief Physician, Radiation Oncology","institutionId":"inselspital-bern","specialisms":["Radiation oncology","Head and neck cancer","Prostate cancer radiotherapy"],"profiles":[{"label":"Institution profile","url":"https://www.tumorzentrum.insel.ch/de/ueber-uns/organisation"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Aebersold+DM%5BAuthor%5D"}],"papers":[{"title":"Acute Toxicity and Quality of Life After Dose-Intensified Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: First Results of the Randomized Trial SAKK 09/10","journal":"Journal of Clinical Oncology","year":2015,"doi":"10.1200/jco.2015.63.3529"},{"title":"Validation of the Decipher genomic classifier in patients receiving salvage radiotherapy without hormone therapy after radical prostatectomy – an ancillary study of the SAKK 09/10 randomized clinical trial","journal":"Annals of Oncology","year":2022,"doi":"10.1016/j.annonc.2022.05.007"},{"title":"Involvement of the hepatocyte growth factor/scatter factor receptor c-met and of Bcl-xL in the resistance of oropharyngeal cancer to ionizing radiation","journal":"International Journal of Cancer","year":2001,"doi":"10.1002/1097-0215(20010220)96:1<41::aid-ijc5>3.0.co;2-f"}],"orcid":"0000-0002-9493-3834"},{"id":"daniel-palmer","kind":"person","name":"Daniel Palmer","aka":[],"tldr":"Liverpool medical oncologist, second author of ESPAC-4 and co-lead of ESPAC5, who directs the Liverpool Experimental Cancer Medicine Centre and leads the national GIRFT review of pancreatic cancer services.","summary":"Daniel Palmer is Professor in Molecular and Clinical Cancer Medicine at the University of Liverpool. GIRFT's workstream page says he has been the North West Cancer Research chair and honorary consultant in medical oncology at Liverpool since 2011, sits on the UK National Cancer Research Network upper GI group and its hepatobiliary and pancreatic subgroups, directs the Cancer Research UK and NIHR Liverpool Experimental Cancer Medicine Centre with a portfolio of early-phase trials for pancreatic cancer, and is joint clinical lead of the GIRFT pancreatic cancer review whose national report was published in November 2025. He was second author of ESPAC-4 and co-led ESPAC5.","asOf":"2026-09-24","links":[{"label":"University of Liverpool staff page","url":"https://www.liverpool.ac.uk/people/daniel-palmer"},{"label":"GIRFT pancreatic cancer workstream (clinical lead biography)","url":"https://gettingitrightfirsttime.co.uk/medical_specialties/pancreatic-cancer/"}],"tags":["pancreatic","trialist","uk","girft"],"related":["paula-ghaneh"],"cancers":["pancreatic","hcc","biliary-tract-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["gemcitabine","capecitabine"],"companies":[],"institutions":["liverpool-hpb-centre","clatterbridge"],"pathways":[],"terms":[],"trials":["espac-4","espac-5"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology, University of Liverpool; Director, CRUK and NIHR Liverpool Experimental Cancer Medicine Centre; GIRFT joint clinical lead for pancreatic cancer","institutionId":"liverpool-hpb-centre","specialisms":["Pancreatic and hepatobiliary oncology","Early-phase trials","Adjuvant chemotherapy"],"profiles":[{"label":"University of Liverpool staff page","url":"https://www.liverpool.ac.uk/people/daniel-palmer"},{"label":"GIRFT pancreatic cancer workstream (clinical lead biography)","url":"https://gettingitrightfirsttime.co.uk/medical_specialties/pancreatic-cancer/"}],"papers":[{"title":"Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4)","journal":"Lancet","year":2017,"doi":"10.1016/S0140-6736(16)32409-6"},{"title":"Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5)","journal":"Lancet Gastroenterology and Hepatology","year":2023,"doi":"10.1016/S2468-1253(22)00348-X"}]},{"id":"daniel-serin","kind":"person","name":"Daniel Serin","aka":[],"tldr":"Daniel Serin represents Institut Sainte Catherine in the Organisation of European Cancer Institutes, which lists the organisation among its members in France.","summary":"Daniel Serin is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Institut Sainte Catherine, its associate member in France. OnCo records the name from the OECI membership list so that the organisation's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the organisation's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Institut Sainte Catherine website","url":"https://www.icap84.org/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["institut-sainte-catherine"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Institut Sainte Catherine to the Organisation of European Cancer Institutes","institutionId":"institut-sainte-catherine","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Institut Sainte Catherine website","url":"https://www.icap84.org/"}],"papers":[{"title":"Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review","journal":"Breast Cancer Res Treat","year":2012,"url":"https://doi.org/10.1007/s10549-011-1837-z","doi":"10.1007/s10549-011-1837-z","note":"Europe PMC author record matched by affiliation"},{"title":"Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study","journal":"Oncologist","year":2010,"url":"https://doi.org/10.1634/theoncologist.2009-0029","doi":"10.1634/theoncologist.2009-0029","note":"Europe PMC author record matched by affiliation"}],"orcid":"0000-0002-9343-4793"},{"id":"daniel-staub","kind":"person","name":"Daniel Staub","aka":[],"tldr":"Daniel Staub represents University Hospital Basel / Tumour Centre in the Organisation of European Cancer Institutes, which lists the centre among its members in Switzerland.","summary":"Daniel Staub is listed by the Organisation of European Cancer Institutes (OECI) as the representative of University Hospital Basel / Tumour Centre, its associate member in Switzerland. OnCo records the name from the OECI membership list so that the centre's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the institution's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"University Hospital Basel / Tumour Centre website","url":"https://www.unispital-basel.ch/en/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["usb-basel"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of University Hospital Basel / Tumour Centre to the Organisation of European Cancer Institutes","institutionId":"usb-basel","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"University Hospital Basel / Tumour Centre website","url":"https://www.unispital-basel.ch/en/"}],"papers":[{"title":"2024 ESC Guidelines for the management of peripheral arterial and aortic diseases","journal":"European Heart Journal","year":2024,"url":"https://doi.org/10.1093/eurheartj/ehae179","doi":"10.1093/eurheartj/ehae179","note":"OpenAlex author record matched by institution"},{"title":"Vasa Vasorum and Plaque Neovascularization on Contrast-Enhanced Carotid Ultrasound Imaging Correlates With Cardiovascular Disease and Past Cardiovascular Events","journal":"Stroke","year":2009,"url":"https://doi.org/10.1161/strokeaha.109.560342","doi":"10.1161/strokeaha.109.560342","note":"OpenAlex author record matched by institution"},{"title":"Carotid Plaque-RADS","journal":"JACC. Cardiovascular imaging","year":2023,"url":"https://doi.org/10.1016/j.jcmg.2023.09.005","doi":"10.1016/j.jcmg.2023.09.005","note":"OpenAlex author record matched by institution"}],"orcid":"0000-0001-5956-2698"},{"id":"daniele-piacentini","kind":"person","name":"Daniele Piacentini","aka":[],"tldr":"Daniele Piacentini represents Policlinico Universitario A. Gemelli in the Organisation of European Cancer Institutes, which lists the centre among its members in Italy.","summary":"Daniele Piacentini is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Policlinico Universitario A. Gemelli, its full member in Italy. OnCo records the name from the OECI membership list so that the centre's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the institution's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Policlinico Universitario A. Gemelli website","url":"https://www.policlinicogemelli.it"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["gemelli"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Policlinico Universitario A. Gemelli to the Organisation of European Cancer Institutes","institutionId":"gemelli","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Policlinico Universitario A. Gemelli website","url":"https://www.policlinicogemelli.it"}],"papers":[]},{"id":"danny-rischin","kind":"person","name":"Danny Rischin","aka":[],"tldr":"Melbourne oncologist who led C-POST, the trial that showed cemiplimab after surgery and radiotherapy cuts recurrence in high-risk cutaneous squamous-cell carcinoma.","summary":"Danny Rischin directs medical oncology at the Peter MacCallum Cancer Centre and chairs head and neck trials for the Trans-Tasman Radiation Oncology Group. He was first author of the 2025 New England Journal of Medicine report of C-POST, in which adjuvant cemiplimab improved disease-free survival compared with placebo after surgery and radiotherapy for high-risk cutaneous squamous-cell carcinoma, and led the cemiplimab phase 2 programme in advanced disease.","asOf":"2026-09-18","links":[],"tags":["skin","head-and-neck","immunotherapy","trialist"],"related":[],"cancers":["advanced-cutaneous-scc","head-and-neck","skin-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["peter-mac"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-c-post-adjuvant-cemiplimab-nejm-2025"],"journals":[],"dependsOn":[],"notes":[],"role":"Medical oncologist and Director of Medical Oncology, Peter MacCallum Cancer Centre","institutionId":"peter-mac","specialisms":["Head and neck cancer","Cutaneous squamous-cell carcinoma","Chemoradiotherapy trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rischin%5BAuthor%5D"}],"papers":[{"title":"C-POST: adjuvant cemiplimab versus placebo in high-risk cutaneous squamous cell carcinoma","journal":"New England Journal of Medicine","year":2025,"url":"https://doi.org/10.1056/NEJMoa2502449","doi":"10.1056/NEJMoa2502449"}],"orcid":"0000-0002-3368-0386"},{"id":"dario-altieri","kind":"person","name":"Dario C. Altieri","aka":[],"tldr":"Cancer biologist who has been President and CEO of The Wistar Institute in Philadelphia since 2015 and directs its NCI-designated Ellen and Ronald Caplan Cancer Center.","summary":"Dario C. Altieri (MD) is President and Chief Executive Officer of The Wistar Institute in Philadelphia, Director of its Ellen and Ronald Caplan Cancer Center and the Robert and Penny Fox Distinguished Professor in the Genome Regulation and Cell Signaling Program. He joined Wistar in September 2010 as Cancer Center Director and its first Chief Scientific Officer and was appointed President and CEO in 2015. Born in Milan and trained at the University of Milan School of Medicine, he previously held positions at Scripps Clinic and Research Foundation, Yale University School of Medicine and the University of Massachusetts Medical School, where he was founding chair of Cancer Biology. His laboratory studies how cancer cells exploit cellular plasticity and mitochondrial reprogramming, including the survivin pathway and the mitochondria-targeted drug Gamitrinib, which has entered clinical trials.","asOf":"2026-09-10","links":[{"label":"Source: The Wistar Institute leadership page","url":"https://www.wistar.org/about/leadership/"},{"label":"Source: Wistar scientist profile","url":"https://www.wistar.org/our-scientists/dario-c-altieri/"}],"tags":["leadership","clinician-scientist","research-institute"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["wistar"],"pathways":[],"terms":["signalling-pathway","targeted-therapy-term"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President and Chief Executive Officer, The Wistar Institute; Director, Ellen and Ronald Caplan Cancer Center","institutionId":"wistar","specialisms":["Cancer biology","Mitochondrial signalling","Survivin and cell death"],"profiles":[{"label":"Wistar leadership page","url":"https://www.wistar.org/about/leadership/"},{"label":"Wistar scientist profile","url":"https://www.wistar.org/our-scientists/dario-c-altieri/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Altieri+DC%5BAuthor%5D"}],"papers":[{"title":"PI3K therapy reprograms mitochondrial trafficking to fuel tumor cell invasion","journal":"Proceedings of the National Academy of Sciences","year":2015,"doi":"10.1073/pnas.1500722112"},{"title":"Mitochondrial dynamics and metastasis","journal":"Cellular and Molecular Life Sciences","year":2019,"doi":"10.1007/s00018-018-2961-2"},{"title":"Mitochondrial Akt Regulation of Hypoxic Tumor Reprogramming","journal":"Cancer Cell","year":2016,"doi":"10.1016/j.ccell.2016.07.004"}],"orcid":"0000-0002-0617-3469"},{"id":"darren-hargrave","kind":"person","name":"Darren R. Hargrave","aka":[],"tldr":"London paediatric neuro-oncologist who led the trial showing that dabrafenib and trametinib work in children with BRAF V600-mutant high-grade glioma.","summary":"Darren Hargrave is a paediatric neuro-oncologist at Great Ormond Street Hospital and a leader of European paediatric drug-development consortia. He was first author of the 2023 Journal of Clinical Oncology report of the phase 2 trial in which dabrafenib plus trametinib produced responses in relapsed or refractory BRAF V600-mutant paediatric high-grade glioma, and a senior investigator on the trial that established the same combination for paediatric low-grade glioma.","asOf":"2026-09-18","links":[],"tags":["paediatric","brain","targeted-therapy","trialist"],"related":[],"cancers":["paediatric-high-grade-glioma","childhood-cancers"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["great-ormond-street"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-hargrave-dabrafenib-trametinib-paediatric-hgg-jco-2023"],"journals":[],"dependsOn":[],"notes":[],"role":"Paediatric neuro-oncologist, Great Ormond Street Hospital and UCL Great Ormond Street Institute of Child Health","institutionId":"great-ormond-street","specialisms":["Paediatric glioma","BRAF-directed therapy","Paediatric drug development"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hargrave%5BAuthor%5D"}],"papers":[{"title":"Dabrafenib plus trametinib in relapsed or refractory BRAF V600-mutant paediatric high-grade glioma","journal":"Journal of Clinical Oncology","year":2023,"url":"https://doi.org/10.1200/JCO.23.00558","doi":"10.1200/JCO.23.00558"}],"orcid":"0000-0001-8219-9807"},{"id":"david-palma","kind":"person","name":"David A. Palma","aka":[],"tldr":"Led SABR-COMET, the trial that showed treating a few metastases with high-dose radiation can prolong survival.","summary":"David Palma (London, Ontario) was principal investigator of SABR-COMET, the randomised phase 2 trial showing stereotactic ablative radiotherapy to all sites of oligometastatic disease improves overall survival, which launched the oligometastatic treatment paradigm and the SABR-COMET-3 and -10 phase 3 trials. He also studies treatment de-escalation in head and neck cancer and hosts a widely used teaching channel.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Palma%20DA%5BAuthor%5D%20SABR-COMET"}],"tags":["radiotherapy","oligometastatic","sbrt"],"related":[],"cancers":[],"sections":[],"technologies":["sbrt"],"targets":[],"drugs":[],"companies":[],"institutions":["lhsc-verspeeten"],"pathways":[],"terms":["oligometastatic","sbrt-term","radiotherapy","de-escalation"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Radiation Oncologist, London Health Sciences Centre; Professor, Western University","institutionId":"lhsc-verspeeten","specialisms":["Oligometastatic disease","Stereotactic radiotherapy","Pragmatic trial design"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Palma%20DA%5BAuthor%5D%20SABR-COMET"}],"papers":[{"title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET)","journal":"Lancet","year":2019,"doi":"10.1016/S0140-6736(18)32487-5"},{"title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial","journal":"JCO","year":2020,"doi":"10.1200/JCO.20.00818"}],"orcid":"0000-0002-9542-0627"},{"id":"david-tuveson","kind":"person","name":"David A. Tuveson","aka":[],"tldr":"Built the pancreatic cancer organoid models now used to test drugs against a patient's own tumour.","summary":"David A. Tuveson is Director of the Cold Spring Harbor Laboratory Cancer Center and Roy J. Zuckerberg Professor, specialising in pancreatic ductal adenocarcinoma. He is known for building the first pancreatic ductal organoid models, now used to test drugs against a patient's own tumour, and the mouse models that defined stromal biology in the disease. His selected papers describe organoid models of human and mouse ductal pancreatic cancer and organoid profiling that identifies common responders to chemotherapy. His laboratory drives organoid pharmacotyping trials and functional ex vivo drug testing, and he is a Lustgarten Foundation leader.","asOf":"2026-09-08","links":[{"label":"CSHL profile","url":"https://www.cshl.edu/research/faculty-staff/david-tuveson/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tuveson%20DA%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":["organoids","pdac-organoid-pharmacotyping","functional-drug-testing"],"targets":[],"drugs":[],"companies":[],"institutions":["cold-spring-harbor"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, CSHL Cancer Center; Roy J. Zuckerberg Professor","institutionId":"cold-spring-harbor","specialisms":["Pancreatic cancer","Organoids","Tumour stroma"],"profiles":[{"label":"CSHL profile","url":"https://www.cshl.edu/research/faculty-staff/david-tuveson/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tuveson%20DA%5BAuthor%5D"}],"papers":[{"title":"Organoid models of human and mouse ductal pancreatic cancer","journal":"Cell","year":2015,"url":"https://doi.org/10.1016/j.cell.2014.12.021","doi":"10.1016/j.cell.2014.12.021"},{"title":"Organoid profiling identifies common responders to chemotherapy in pancreatic cancer","journal":"Cancer Discovery","year":2018,"url":"https://doi.org/10.1158/2159-8290.CD-18-0349","doi":"10.1158/2159-8290.CD-18-0349"}],"orcid":"0000-0002-8017-2712"},{"id":"david-solit","kind":"person","name":"David B. Solit","aka":[],"tldr":"Built MSK-IMPACT, the first FDA-authorised tumour sequencing panel, and the clinical genomics programme behind OncoKB and cBioPortal.","summary":"David B. Solit is Director of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology at Memorial Sloan Kettering Cancer Center. He is known for building MSK-IMPACT, the first FDA-authorised tumour sequencing panel, and the clinical genomics programme behind OncoKB and cBioPortal. His selected paper reports the mutational landscape of metastatic cancer revealed by prospective clinical sequencing of 10,000 patients. His centre has sequenced tens of thousands of tumours to define actionable alterations, and he continues to study exceptional responders and bladder cancer genomics.","asOf":"2026-09-08","links":[{"label":"MSK lab","url":"https://www.mskcc.org/research-areas/labs/david-solit"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Solit%20DB%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["urothelial"],"sections":[],"technologies":["cgp"],"targets":[],"drugs":[],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Marie-Josée and Henry R. Kravis Center for Molecular Oncology","institutionId":"mskcc","specialisms":["Cancer genomics","MSK-IMPACT","Exceptional responders","Bladder cancer"],"profiles":[{"label":"MSK lab","url":"https://www.mskcc.org/research-areas/labs/david-solit"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Solit%20DB%5BAuthor%5D"}],"papers":[{"title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","journal":"Nature Medicine","year":2017,"url":"https://doi.org/10.1038/nm.4333","doi":"10.1038/nm.4333"}]},{"id":"david-baker","kind":"person","name":"David Baker","aka":[],"tldr":"Nobel laureate biochemist who founded and directs the Institute for Protein Design, which builds new proteins for medicine including cancer therapeutics.","summary":"David Baker is Founder and Director of the Institute for Protein Design at the University of Washington, founded in 2012 with the mission of creating new proteins that address challenges across medicine, technology and sustainability. He is a Howard Hughes Medical Institute Investigator and the Henrietta and Aubrey Davis Endowed Professor in Biochemistry. His group developed the Rosetta and RoseTTAFold methods for protein structure prediction and design, and he received half of the 2024 Nobel Prize in Chemistry for computational protein design. Neil King serves as the institute's Deputy Director.","asOf":"2026-09-10","links":[{"label":"Source: Institute for Protein Design faculty and staff page","url":"https://www.ipd.uw.edu/people/faculty_and_staff/"}],"tags":["leadership","clinician-scientist","protein-design","drug-discovery"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["hhmi"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Founder and Director of the Institute for Protein Design","institutionId":"institute-for-protein-design","specialisms":["Computational protein design","Structural biology","Biochemistry"],"profiles":[{"label":"IPD faculty and staff","url":"https://www.ipd.uw.edu/people/faculty_and_staff/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Baker+D%5BAuthor%5D+AND+protein+design"}],"papers":[],"papersExpected":true},{"id":"david-baldwin","kind":"person","name":"David Baldwin","aka":[],"tldr":"The Nottingham chest physician who chairs the UK clinical expert group for lung cancer and advises the National Screening Committee: the person whose job it is to turn the screening evidence into an NHS service.","summary":"David Baldwin is a consultant respiratory physician at Nottingham University Hospitals and an honorary professor of medicine at the University of Nottingham, sub-specialising in lung cancer, mesothelioma and interventional procedures. His public page lists him as Lead Clinician for Lung Cancer at NHS England, chair of the UK Clinical Expert Group for Lung Cancer and Mesothelioma, and an adviser to the UK National Screening Committee at the Department of Health and Social Care, with research grants totalling more than 35 million pounds and more than 240 papers.\n\nHe was the lead respiratory physician on the UK Lung Cancer Screening trial and leads the recruitment work package of the European 4-in-the-Lung-Run project. He has previously been honorary secretary of the British Thoracic Society, clinical lead on the NICE lung cancer guideline development group, chair of the lung cancer quality standards group, clinical director of the East Midlands Cancer Alliance and chair of the National Cancer Research Institute's screening, prevention and early diagnosis group. The Clinical Expert Group he chairs wrote the commissioning guidance for the whole lung cancer pathway that the National Lung Cancer Audit cites.","asOf":"2026-09-25","links":[{"label":"University of Nottingham staff page","url":"https://www.nottingham.ac.uk/medicine/people/david.baldwin"}],"tags":["lung","screening","uk","policy"],"related":["john-field","matthew-callister"],"cancers":["nsclc","lung-cancer"],"sections":["early-detection"],"technologies":["low-dose-ct-screening"],"targets":[],"drugs":[],"companies":[],"institutions":["nottingham-cancer-centre"],"pathways":[],"terms":[],"trials":["ukls"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Consultant Respiratory Physician, Nottingham University Hospitals NHS Trust; Honorary Professor of Medicine, University of Nottingham; Lead Clinician for Lung Cancer, NHS England","institutionId":"nottingham-cancer-centre","specialisms":["Lung cancer pathways and policy","CT screening","Lung cancer epidemiology"],"profiles":[{"label":"University of Nottingham staff page","url":"https://www.nottingham.ac.uk/medicine/people/david.baldwin"}],"papers":[{"title":"The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer","journal":"Health Technology Assessment","year":2016,"doi":"10.3310/hta20400"}]},{"id":"david-cameron","kind":"person","name":"David Cameron","aka":[],"tldr":"David Cameron is a breast oncologist who chairs the Breast International Group.","summary":"David Cameron is Professor of Oncology at the University of Edinburgh and Chair of the Breast International Group (BIG). His specialisms are breast cancer, adjuvant trials and trial governance. He chairs the network behind HERA, APHINITY and OlympiA and was a senior investigator on the long-term follow-up of HERA, published in The Lancet as the final analysis of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer. His other papers include BEATRICE, a phase 3 trial of adjuvant bevacizumab-containing therapy in triple-negative breast cancer, and updated results from MONALEESA-2 on first-line ribociclib plus letrozole in hormone receptor-positive advanced disease. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cameron%20D%5BAuthor%5D%20HERA%20trastuzumab"}],"tags":[],"related":[],"cancers":["breast-her2-positive"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["big"],"institutions":[],"pathways":[],"terms":[],"trials":["hera-b31-n9831","aphinity"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Oncology, University of Edinburgh; Chair, Breast International Group","institutionId":"big","specialisms":["Breast cancer","Adjuvant trials","Trial governance"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cameron%20D%5BAuthor%5D%20HERA%20trastuzumab"}],"papers":[{"title":"11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial","journal":"The Lancet","year":2017,"doi":"10.1016/s0140-6736(16)32616-2"},{"title":"Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial","journal":"The Lancet Oncology","year":2013,"doi":"10.1016/s1470-2045(13)70335-8"},{"title":"Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer","journal":"Annals of Oncology","year":2018,"doi":"10.1093/annonc/mdy155"},{"title":"DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group","journal":"New England Journal of Medicine","year":2022,"url":"https://doi.org/10.1056/NEJMoa2203690","doi":"10.1056/NEJMoa2203690"}]},{"id":"david-cunningham","kind":"person","name":"David Cunningham","aka":[],"tldr":"Gastrointestinal oncologist who led landmark trials of perioperative chemotherapy in gastric and oesophageal cancer.","summary":"David Cunningham is a consultant medical oncologist and Director of Clinical Research at The Royal Marsden. His specialisms are gastrointestinal oncology, oesophago-gastric cancer and colorectal cancer. He led the MAGIC trial of perioperative chemotherapy in gastric cancer, reported in the New England Journal of Medicine as perioperative chemotherapy versus surgery alone for resectable gastro-oesophageal cancer, and the REAL-2 trial. He has directed clinical research at the Royal Marsden across gastric and gastro-oesophageal junction, oesophageal and colorectal cancers. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cunningham%20D%5BAuthor%5D%20gastric%20perioperative"}],"tags":[],"related":[],"cancers":["gastric","esophageal","colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["royal-marsden"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Consultant Medical Oncologist and Director of Clinical Research, Royal Marsden","institutionId":"royal-marsden","specialisms":["Gastrointestinal oncology","Oesophago-gastric cancer","Colorectal cancer"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cunningham%20D%5BAuthor%5D%20gastric%20perioperative"}],"papers":[{"title":"Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer (MAGIC)","journal":"NEJM","year":2006,"doi":"10.1056/NEJMoa055531"},{"title":"CodeBreaK 300: sotorasib plus panitumumab in chemotherapy-refractory KRAS G12C colorectal cancer","journal":"New England Journal of Medicine","year":2023,"url":"https://doi.org/10.1056/NEJMoa2308795","doi":"10.1056/NEJMoa2308795"}],"orcid":"0000-0001-5158-1069"},{"id":"david-dearnaley","kind":"person","name":"David Dearnaley","aka":[],"tldr":"British radiation oncologist who led CHHiP, the trial that showed prostate cancer can be treated in 20 radiotherapy sessions rather than 37 with the same results, changing practice worldwide.","summary":"David Dearnaley led prostate radiotherapy research at The Institute of Cancer Research and The Royal Marsden for three decades. He was first author of the 2016 Lancet Oncology report of CHHiP, the UK trial in which 60 Gy in 20 fractions was non-inferior to 74 Gy in 37 fractions for localised prostate cancer, making moderate hypofractionation the standard. His earlier trials established dose escalation with conformal radiotherapy.","asOf":"2026-09-18","links":[],"tags":["prostate","radiotherapy","trialist"],"related":[],"cancers":["prostate-intermediate-risk","prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["icr-london"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-chhip-lancet-oncol-2016"],"journals":[],"dependsOn":[],"notes":[],"role":"Emeritus Professor of Uro-Oncology, The Institute of Cancer Research and The Royal Marsden","institutionId":"icr-london","specialisms":["Prostate radiotherapy","Hypofractionation","Radiotherapy technique"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dearnaley%5BAuthor%5D"}],"papers":[{"title":"CHHiP: conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer","journal":"The Lancet Oncology","year":2016,"url":"https://doi.org/10.1016/S1470-2045(16)30102-4","doi":"10.1016/S1470-2045(16)30102-4"}]},{"id":"david-fennelly","kind":"person","name":"David Fennelly","aka":[],"tldr":"Medical oncologist who is Clinical Director for Cancer Services at St Vincent's University Hospital and its UCD Cancer Centre in Dublin, Ireland's largest cancer care provider.","summary":"Dr David Fennelly is Clinical Director for Cancer Services at St Vincent's University Hospital (SVUH) and St Vincent's UCD Cancer Centre in Dublin, and HSE Cancer Lead for the Dublin and South East health region. The hospital describes him as having nearly 30 years of experience in medical oncology, and in July 2026 he set out a vision for a nationally coordinated cancer network to an Oireachtas committee shaping Ireland's next National Cancer Strategy. On 24 June 2026 St Vincent's UCD Cancer Centre was designated an OECI Cancer Centre by the Organisation of European Cancer Institutes; the hospital describes the centre as Ireland's largest cancer care provider with six national specialty designations, and its Chief Executive Officer is Pauline McGrath.","asOf":"2026-09-10","links":[{"label":"Source: SVUH news article on OECI Cancer Centre designation (June 2026)","url":"https://www.stvincents.ie/st-vincents-ucd-cancer-centre-awarded-european-recognition-for-excellence-in-cancer-care/"},{"label":"Source: SVUH news article on Dr Fennelly's Oireachtas evidence (July 2026)","url":"https://www.stvincents.ie/st-vincents-cancer-expert-helps-shape-irelands-next-national-cancer-strategy-dr-david-fennelly-outlines-vision-for-a-nationally-coordinated-cancer-network-before-oireachtas-committee/"}],"tags":["leadership","clinician-scientist","comprehensive-cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Clinical Director for Cancer Services, St Vincent's University Hospital and St Vincent's UCD Cancer Centre","institutionId":"st-vincents-ucd-cancer-centre","specialisms":["Medical oncology","Cancer services leadership","National cancer strategy"],"profiles":[{"label":"SVUH article on OECI designation naming the cancer services leadership","url":"https://www.stvincents.ie/st-vincents-ucd-cancer-centre-awarded-european-recognition-for-excellence-in-cancer-care/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fennelly+D%5BAuthor%5D"}],"papers":[{"title":"Immunotherapy in surgical oncology","journal":"British Journal of Surgery","year":2022,"doi":"10.1093/bjs/znac385"},{"title":"Characterising the prognostic potential of HLA-DR during colorectal cancer development","journal":"Cancer Immunology, Immunotherapy","year":2020,"doi":"10.1007/s00262-020-02571-2"},{"title":"Late cardiac effects of chemotherapy in breast cancer survivors treated with adjuvant doxorubicin: 10-year follow-up","journal":"Breast Cancer Research and Treatment","year":2016,"doi":"10.1007/s10549-016-3781-4"}]},{"id":"david-koch","kind":"person","name":"David H. Koch","aka":[],"tldr":"Treated for prostate cancer from 1992, he gave MIT $100 million in 2007 to build an institute that puts engineers and cancer biologists under one roof, and MSK $150 million in 2015 for a new outpatient cancer building.","summary":"David H. Koch (1940-2019), the industrialist and MIT alumnus, was diagnosed with prostate cancer in 1992 and became one of the largest individual donors to cancer research in the United States. MIT records that on 9 October 2007 it launched a major cancer initiative supported by his $100 million gift, which became the David H. Koch Institute for Integrative Cancer Research, deliberately mixing engineers with cancer biologists to work on drug delivery, nanomedicine, imaging and immunology. In 2015 Memorial Sloan Kettering announced a record $150 million gift from him for the David H. Koch Center for Cancer Care, a 23-storey outpatient building on the East River. He also funded the David H. Koch Cancer Research Building at Johns Hopkins, a genitourinary cancer research centre at MD Anderson and the Prostate Cancer Foundation, on whose board he sat. He died of prostate cancer in 2019.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/David_Koch","links":[{"label":"MIT Koch Institute: history","url":"https://ki.mit.edu/about/history"},{"label":"MSK press release: $150 million gift (2015)","url":"https://www.mskcc.org/press-releases/msk-receives-gift-150-million-david-koch-patient-facility"}],"tags":["hero","donor","patient"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["mit-koch","mskcc","johns-hopkins","md-anderson","pcf"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-funding-allocation","b-translational-valley"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Prostate cancer patient whose gifts built the MIT Koch Institute and the MSK Koch Center for Cancer Care","specialisms":["Cancer research buildings","Engineering and cancer biology","Prostate cancer"],"profiles":[],"papers":[]},{"id":"david-porter","kind":"person","name":"David L. Porter","aka":[],"tldr":"Treated the first adult CLL patients with CAR-T and reported a decade of durable remissions.","summary":"David L. Porter is the Jodi Fisher Horowitz Professor in Leukemia Care Excellence and Director of Cell Therapy and Transplant at the Abramson Cancer Center, University of Pennsylvania. He is known for treating the first adult patients with chronic lymphocytic leukaemia using CAR-T cells, leading the clinical side of Penn's first CTL019 studies. His selected paper reports decade-long leukaemia remissions with persistence of CD4-positive CAR T cells in long-term responders. He now leads cell therapy and stem cell transplant at Penn, spanning CAR-T for leukaemia and allogeneic transplantation.","asOf":"2026-09-08","links":[{"label":"Penn profile","url":"https://www.pennmedicine.org/providers/profile/david-porter"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Porter%20DL%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["cll","all-leukemia"],"sections":[],"technologies":["car-t","allogeneic-hsct"],"targets":["cd19"],"drugs":["tisagenlecleucel"],"companies":[],"institutions":["penn-abramson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Jodi Fisher Horowitz Professor in Leukemia Care Excellence; Director, Cell Therapy and Transplant","institutionId":"penn-abramson","specialisms":["CAR-T","Chronic lymphocytic leukaemia","Stem cell transplant"],"profiles":[{"label":"Penn profile","url":"https://www.pennmedicine.org/providers/profile/david-porter"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Porter%20DL%5BAuthor%5D"}],"papers":[{"title":"Decade-long leukaemia remissions with persistence of CD4+ CAR T cells","journal":"Nature","year":2022,"url":"https://doi.org/10.1038/s41586-021-04390-6","doi":"10.1038/s41586-021-04390-6"},{"title":"Maude 2014: CD19 CAR-T cells produce complete remission in 27 of 30 children and adults with relapsed ALL","journal":"New England Journal of Medicine","year":2014,"url":"https://doi.org/10.1056/NEJMoa1407222","doi":"10.1056/NEJMoa1407222"}]},{"id":"david-gershenson","kind":"person","name":"David M. Gershenson","aka":[],"tldr":"Houston gynaecologic oncologist who defined low-grade serous ovarian cancer as a distinct disease and led GOG 281, the trial that showed the MEK inhibitor trametinib works better than standard treatments for it.","summary":"David Gershenson is a gynaecologic oncologist at MD Anderson Cancer Center whose work established low-grade serous carcinoma of the ovary as a separate, relatively chemotherapy-resistant disease. He was first author of the 2017 Journal of Clinical Oncology study of hormonal maintenance therapy after primary treatment and of the 2022 Lancet report of GOG 281/LOGS, in which trametinib lengthened progression-free survival compared with standard-of-care options in recurrent low-grade serous carcinoma. He has also led studies of rare ovarian germ cell and sex cord-stromal tumours.","asOf":"2026-09-18","links":[],"tags":["ovarian","gynaecological","trialist"],"related":[],"cancers":["low-grade-serous-ovarian-cancer","ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-gog-281-trametinib-lgsoc-gershenson-lancet-2022","paper-gershenson-hormonal-maintenance-lgsoc-jco-2017"],"journals":[],"dependsOn":[],"notes":[],"role":"Gynaecologic oncologist, MD Anderson Cancer Center","institutionId":"md-anderson","specialisms":["Low-grade serous ovarian cancer","Rare ovarian tumours","Hormonal and MEK-directed therapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gershenson%5BAuthor%5D"}],"papers":[{"title":"GOG 281/LOGS: trametinib versus standard of care in recurrent low-grade serous ovarian cancer","journal":"The Lancet","year":2022,"url":"https://doi.org/10.1016/S0140-6736(21)02175-9","doi":"10.1016/S0140-6736(21)02175-9"},{"title":"Hormonal maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum","journal":"Journal of Clinical Oncology","year":2017,"url":"https://doi.org/10.1200/JCO.2016.71.0632","doi":"10.1200/JCO.2016.71.0632"}],"orcid":"0000-0001-9712-2140"},{"id":"david-planchard","kind":"person","name":"David Planchard","aka":[],"tldr":"Gustave Roussy thoracic oncologist on the IFCT board, widely published on BRAF- and EGFR-targeted therapy in lung cancer.","summary":"David Planchard is a medical oncologist at Gustave Roussy (Villejuif) and a member of the IFCT board. He has led or co-led pivotal trials of targeted agents in oncogene-driven non-small cell lung cancer, including BRAF V600E-mutant disease, and contributes to ESMO clinical practice guidelines for metastatic NSCLC.","asOf":"2026-09-10","links":[{"label":"Society page","url":"https://www.ifct.fr/a-propos-de-l-ifct/conseil-d-administration"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Planchard+D%5BAuthor%5D"}],"tags":["clinician-scientist","lung cancer","targeted therapy"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["ifct"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Board member (Conseil d'Administration)","institutionId":"ifct","specialisms":["Thoracic oncology","Lung cancer","Targeted therapy"],"profiles":[{"label":"Society page","url":"https://www.ifct.fr/a-propos-de-l-ifct/conseil-d-administration"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Planchard+D%5BAuthor%5D"}],"papers":[{"title":"Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial","journal":"The Lancet Oncology","year":2016,"doi":"10.1016/s1470-2045(16)30146-2"},{"title":"Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC","journal":"New England Journal of Medicine","year":2023,"doi":"10.1056/nejmoa2306434"},{"title":"Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial","journal":"The Lancet Oncology","year":2016,"doi":"10.1016/s1470-2045(16)00077-2"}]},{"id":"david-probert","kind":"person","name":"David Probert","aka":[],"tldr":"Chief Executive of University College London Hospitals NHS Foundation Trust, which runs the UCH Macmillan Cancer Centre.","summary":"David Probert is Chief Executive of University College London Hospitals NHS Foundation Trust (UCLH). The trust operates the UCH Macmillan Cancer Centre and the UK's first NHS proton beam therapy centre in London, and partners closely with the UCL Cancer Institute. He is responsible for the trust's clinical services, research partnerships and strategy.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.uclh.nhs.uk/about-us/who-we-are/our-board"}],"tags":["leadership","hospital management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["uclh"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive","institutionId":"uclh","specialisms":["Hospital management","NHS leadership"],"profiles":[{"label":"Institution profile","url":"https://www.uclh.nhs.uk/about-us/who-we-are/our-board"}],"papers":[],"orcid":"0000-0002-8235-2215"},{"id":"david-sebag-montefiore","kind":"person","name":"David Sebag-Montefiore","aka":[],"tldr":"The Leeds clinical oncologist who led CR07, the trial that made short-course radiotherapy before surgery the standard for rectal cancer, and who now works on preserving the rectum instead of removing it.","summary":"David Sebag-Montefiore is an academic clinical oncologist at the University of Leeds and an honorary clinical oncologist at Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust. He leads the Leeds Radiotherapy Research Group and is a clinical director of the Leeds Clinical Trials Research Unit; he was awarded the Audrey and Stanley Burton Chair of Clinical Oncology in 2012. He was first author of MRC CR07, which showed that short-course preoperative radiotherapy cut local recurrence by 61 percent against surgery with selective postoperative chemoradiotherapy, and is second author of the STAR-TREC 12-month results, the first randomised comparison of two radiotherapy schedules for organ preservation in rectal cancer.","asOf":"2026-09-24","links":[{"label":"University of Leeds staff page","url":"https://medicinehealth.leeds.ac.uk/medicine/staff/745/professor-david-sebag-montefiore"}],"tags":["colorectal","trialist","uk","radiotherapy"],"related":["matt-seymour","dion-morton"],"cancers":["colorectal","rectal-cancer"],"sections":["radiation"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["leeds-cancer-centre"],"pathways":[],"terms":["radiotherapy"],"trials":["cr07","star-trec"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Clinical Oncology (Audrey and Stanley Burton Chair), University of Leeds; Clinical Director, Leeds Clinical Trials Research Unit","institutionId":"leeds-cancer-centre","specialisms":["Rectal cancer radiotherapy","Organ preservation","Randomised radiotherapy trials"],"profiles":[{"label":"University of Leeds staff page","url":"https://medicinehealth.leeds.ac.uk/medicine/staff/745/professor-david-sebag-montefiore"}],"papers":[{"title":"Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial","journal":"Lancet","year":2009,"doi":"10.1016/S0140-6736(09)60484-0"},{"title":"Chemoradiotherapy versus short-course radiotherapy for response-adapted organ preservation in early-stage and intermediate-stage rectal cancer (STAR-TREC): 12-month results","journal":"Lancet Oncology","year":2026,"doi":"10.1016/S1470-2045(26)00228-7"}]},{"id":"davide-fornaciari","kind":"person","name":"Davide Fornaciari","aka":[],"tldr":"Director general who leads the Azienda USL-IRCCS di Reggio Emilia, the health authority that runs the Arcispedale Santa Maria Nuova and its oncology research institute.","summary":"Davide Fornaciari leads the Azienda USL-IRCCS di Reggio Emilia as Direttore Generale, according to the Italian Wikipedia article on the Arcispedale Santa Maria Nuova, the hospital at the heart of the authority and an IRCCS (research hospital) in advanced technologies and care models in oncology. The article cites a May 2025 announcement from the Municipality of Reggio Emilia referring to him as the newly appointed Direttore Generale of the AUSL. The authority's own website could not be reached when checked.","asOf":"2026-09-10","links":[{"label":"Source: Italian Wikipedia article naming the Direttore Generale","url":"https://it.wikipedia.org/wiki/Arcispedale_Santa_Maria_Nuova"}],"tags":["leadership","hospital-management","research-institute"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ausl-irccs-reggio-emilia"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Direttore Generale, Azienda USL-IRCCS di Reggio Emilia","institutionId":"ausl-irccs-reggio-emilia","specialisms":["Public health administration","Hospital management"],"profiles":[{"label":"Wikipedia (Italian): Arcispedale Santa Maria Nuova","url":"https://it.wikipedia.org/wiki/Arcispedale_Santa_Maria_Nuova"}],"papers":[]},{"id":"dawn-hershman","kind":"person","name":"Dawn L. Hershman","aka":[],"tldr":"Breast oncologist who co-leads SWOG and studies adherence, toxicity, and how care is actually delivered.","summary":"Dawn Hershman is Group Co-Chair of the SWOG Cancer Research Network and Professor of Medicine and Epidemiology at Columbia University. A breast medical oncologist and health outcomes researcher, she co-chairs SWOG with Primo Lara and has led its cancer care delivery research and trials on chemotherapy-induced neuropathy and endocrine therapy adherence. Her papers include a JAMA randomised trial of acupuncture for aromatase inhibitor related joint pain in early-stage breast cancer and a Journal of Clinical Oncology cohort study of early discontinuation and nonadherence to adjuvant hormonal therapy. Her work spans triple-negative and HR-positive breast cancer, care delivery and survivorship.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Dawn_L._Hershman","links":[{"label":"SWOG leadership","url":"https://www.swog.org/about/leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hershman%20DL%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Dawn%20L.%20Hershman"}],"tags":[],"related":[],"cancers":["tnbc","breast-hr-positive"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["swog"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Group Co-Chair, SWOG Cancer Research Network; Professor of Medicine and Epidemiology, Columbia University","institutionId":"swog","specialisms":["Breast cancer","Cancer care delivery","Survivorship"],"profiles":[{"label":"SWOG leadership","url":"https://www.swog.org/about/leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hershman%20DL%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Dawn%20L.%20Hershman"}],"papers":[{"title":"Effect of Acupuncture vs Sham Acupuncture or Waitlist Control on Joint Pain Related to Aromatase Inhibitors Among Women With Early-Stage Breast Cancer: A Randomized Clinical Trial","journal":"JAMA","year":2018,"url":"https://doi.org/10.1001/jama.2018.8907","doi":"10.1001/jama.2018.8907"},{"title":"Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients","journal":"Journal of Clinical Oncology","year":2010,"url":"https://doi.org/10.1200/JCO.2009.25.9655","doi":"10.1200/JCO.2009.25.9655"}]},{"id":"dean-fennell","kind":"person","name":"Dean A. Fennell","aka":[],"tldr":"Led CONFIRM and MARS 2, which showed nivolumab helps relapsed mesothelioma and that radical surgery does not.","summary":"Dean Fennell (University of Leicester) was chief investigator of CONFIRM, the first placebo-controlled trial to show a survival benefit for a checkpoint inhibitor (nivolumab) in relapsed mesothelioma, and of MARS 2, which showed extended pleurectomy decortication worsens survival and quality of life compared with chemotherapy alone, ending routine radical surgery. He leads the MEDUSA mesothelioma evolution programme.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fennell%20DA%5BAuthor%5D%20mesothelioma"}],"tags":["mesothelioma","immunotherapy","surgery","uk"],"related":[],"cancers":["mesothelioma"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["pd1"],"drugs":["nivolumab"],"companies":[],"institutions":["leicester-cancer-research-centre"],"pathways":[],"terms":[],"trials":["mars-2"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Thoracic Medical Oncology, University of Leicester","institutionId":"leicester-cancer-research-centre","specialisms":["Mesothelioma","Immunotherapy","Surgical trials","Tumour evolution"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fennell%20DA%5BAuthor%5D%20mesothelioma"}],"papers":[{"title":"Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM)","journal":"Lancet Oncology","year":2021,"doi":"10.1016/S1470-2045(21)00471-X"},{"title":"Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2)","journal":"Lancet Respiratory Medicine","year":2024}],"orcid":"0000-0001-7373-1312"},{"id":"dean-bajorin","kind":"person","name":"Dean F. Bajorin","aka":[],"tldr":"Led CheckMate 274, which established adjuvant nivolumab after bladder cancer surgery.","summary":"Dean Bajorin was principal investigator of CheckMate 274, the trial showing adjuvant nivolumab improves disease-free survival in muscle-invasive urothelial cancer after radical surgery, the first adjuvant immunotherapy approval in the disease. He developed the Bajorin prognostic model for metastatic urothelial cancer and led decades of chemotherapy trials at MSKCC.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bajorin%20DF%5BAuthor%5D%20urothelial%20nivolumab"}],"tags":["urothelial","adjuvant","immunotherapy"],"related":[],"cancers":["urothelial"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["pd1"],"drugs":["nivolumab"],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":["checkmate-274"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Attending Physician, Genitourinary Oncology, Memorial Sloan Kettering Cancer Center","institutionId":"mskcc","specialisms":["Urothelial cancer","Adjuvant immunotherapy","Chemotherapy","Prognostic models"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bajorin%20DF%5BAuthor%5D%20urothelial%20nivolumab"}],"papers":[{"title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma (CheckMate 274)","journal":"NEJM","year":2021,"doi":"10.1056/NEJMoa2034442"},{"title":"Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy","journal":"JCO","year":1999,"doi":"10.1200/JCO.1999.17.10.3173"}],"orcid":"0000-0003-4001-7088"},{"id":"dearbhaile-collins","kind":"person","name":"Dearbhaile Collins","aka":[],"tldr":"Medical oncologist who leads cancer services at Cork University Hospital as Clinical Director, with a focus on gynaecological and thoracic cancers and early-phase trials.","summary":"Dr Dearbhaile Collins is Clinical Director of Cancer Services and Consultant Medical Oncologist at Cork University Hospital (CUH), the largest hospital in the HSE South West region and the Cork academic cancer centre linked to University College Cork. CUH's leadership page lists her as Clinical Director (Oncology) on the Executive Management Board under chief executive Jennifer Kearney. Her CUH profile records a medical degree from University College Dublin, a PhD in translational oncology from the National University of Ireland, a Masters in Medical Ethics and Law from the University of Manchester, and a fellowship at the Drug Development Unit of the Royal Marsden Hospital and Institute of Cancer Research under Johann de Bono. She is President of the Irish Society of Gynaecological Oncology and co-chair of Cancer Trials Ireland's gynaecological cancer trials group.","asOf":"2026-09-10","links":[{"label":"Source: CUH consultant profile (archived copy, October 2025; live site under maintenance)","url":"https://web.archive.org/web/20251018210106/https://www.cuh.hse.ie/our-services/our-consultants-a-z/dr-dearbhaile-collins/"},{"label":"Source: CUH leadership team page (archived copy, January 2026)","url":"https://web.archive.org/web/20260101015106/https://cuh.hse.ie/about-us/our-structure/leadership-team/"}],"tags":["leadership","clinician-scientist","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["royal-marsden","icr-london"],"pathways":[],"terms":[],"trials":[],"people":["johann-de-bono"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Clinical Director of Cancer Services and Consultant Medical Oncologist, Cork University Hospital","institutionId":"cork-university-hospital","specialisms":["Medical oncology","Gynaecological cancers","Thoracic cancers","Early-phase clinical trials"],"profiles":[{"label":"CUH consultant profile","url":"https://www.cuh.hse.ie/our-services/our-consultants-a-z/dr-dearbhaile-collins/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Collins+DC%5BAuthor%5D+AND+Cork"}],"papers":[{"title":"Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial","journal":"The Lancet Oncology","year":2019,"doi":"10.1016/s1470-2045(18)30859-3"},{"title":"Exploiting somatic alterations as therapeutic targets in advanced and metastatic cervical cancer","journal":"Cancer Treatment Reviews","year":2021,"doi":"10.1016/j.ctrv.2021.102225"},{"title":"A Rare Thyroid Metastasis from Uveal Melanoma and Response to Immunotherapy Agents","journal":"Case Reports in Oncological Medicine","year":2016,"doi":"10.1155/2016/6564094"}],"orcid":"0000-0002-5156-0142"},{"id":"deb-bulych","kind":"person","name":"Deb Bulych","aka":[],"tldr":"Long-serving cancer care leader who is President and CEO of the Saskatchewan Cancer Agency, the provincial cancer body for Saskatchewan, Canada.","summary":"Deb Bulych is President and Chief Executive Officer of the Saskatchewan Cancer Agency, the provincial agency responsible for cancer prevention, screening, treatment and research in Saskatchewan. She has been with the agency for 30 years in roles including clinical oncology social work, Director of Social Work, Director of Supportive Care, Director of Nursing and Vice President of Care Services, and has led programmes such as new patient navigation, fatigue management, pain and symptom management and patient-reported outcomes. She holds a Master of Health Studies and chairs the Canadian Models of Care Advisory Committee under the Canadian Partnership Against Cancer.","asOf":"2026-09-10","links":[{"label":"Source: Saskatchewan Cancer Agency executive leadership team page","url":"https://www.saskcancer.ca/about-us/who-we-are/executive-leadership-team"}],"tags":["leadership","hospital-management","government"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["saskatchewan-cancer-agency"],"pathways":[],"terms":["qol-pro","palliative-treatment"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President and Chief Executive Officer, Saskatchewan Cancer Agency","institutionId":"saskatchewan-cancer-agency","specialisms":["Cancer system leadership","Supportive care","Person-centred care"],"profiles":[{"label":"Saskatchewan Cancer Agency executive leadership team","url":"https://www.saskcancer.ca/about-us/who-we-are/executive-leadership-team"}],"papers":[]},{"id":"deb-schrag","kind":"person","name":"Deborah Schrag","aka":[],"tldr":"Led PATHFINDER, the first prospective study of a multi-cancer blood test in practice, and the PROSPECT rectal cancer trial.","summary":"Deborah Schrag was principal investigator of PATHFINDER, the first prospective study to return Galleri multi-cancer early detection results to participants and their doctors, which showed a cancer signal in about 1% of people and a positive predictive value near 40%, and of PROSPECT, the Alliance trial showing FOLFOX can replace pelvic radiotherapy for many rectal cancers. She chairs medicine at MSKCC and leads pragmatic outcomes research.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Deborah_Schrag","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schrag%20D%5BAuthor%5D%20PATHFINDER%20OR%20PROSPECT"}],"tags":["early-detection","mced","colorectal"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":["mced"],"targets":[],"drugs":["galleri"],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":["pathfinder-2","nhs-galleri"],"people":[],"bottlenecks":[],"keyPapers":["paper-pathfinder-lancet-2023"],"journals":[],"dependsOn":[],"notes":[],"role":"Chair, Department of Medicine, Memorial Sloan Kettering Cancer Center","institutionId":"mskcc","specialisms":["Multi-cancer early detection","Colorectal cancer","Health services research","Pragmatic trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schrag%20D%5BAuthor%5D%20PATHFINDER%20OR%20PROSPECT"}],"papers":[{"title":"Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study","journal":"Lancet","year":2023,"doi":"10.1016/S0140-6736(23)01700-2"},{"title":"Preoperative treatment of locally advanced rectal cancer (PROSPECT)","journal":"NEJM","year":2023,"doi":"10.1056/NEJMoa2303269"}],"orcid":"0000-0002-4334-5717"},{"id":"deborah-bruner","kind":"person","name":"Deborah Watkins Bruner","aka":[],"tldr":"Nurse scientist who put patient-reported outcomes into cooperative group radiation trials.","summary":"Deborah Watkins Bruner is Senior Vice President for Research at Emory University and Vice Chair of NRG Oncology. A nurse scientist specialising in patient-reported outcomes and radiation oncology nursing, she pioneered integrating patient-reported outcomes and quality of life measures into NRG and RTOG trials, notably in prostate and head and neck cancer. Her papers include a Journal of Clinical Oncology analysis of the issues in integrating patient-reported outcomes into National Cancer Institute network trials and a JAMA Oncology phase 3 comparison of quality of life with hypofractionated versus conventional radiotherapy in low-risk prostate cancer. She continues to shape trial design in cooperative group research.","asOf":"2026-09-08","links":[{"label":"NRG Oncology","url":"https://www.nrgoncology.org"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bruner%20DW%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Deborah%20Watkins%20Bruner"}],"tags":[],"related":[],"cancers":["prostate","head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["nrg-oncology"],"institutions":[],"pathways":[],"terms":["real-world-evidence"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["jama-oncology"],"dependsOn":[],"notes":[],"role":"Senior Vice President for Research, Emory University; NRG Oncology Vice Chair","institutionId":"nrg-oncology","specialisms":["Patient-reported outcomes","Radiation oncology nursing","Trial design"],"profiles":[{"label":"NRG Oncology","url":"https://www.nrgoncology.org"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bruner%20DW%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Deborah%20Watkins%20Bruner"}],"papers":[{"title":"Issues and challenges with integrating patient-reported outcomes in clinical trials supported by the National Cancer Institute-sponsored clinical trials networks","journal":"Journal of Clinical Oncology","year":2007,"url":"https://doi.org/10.1200/JCO.2007.11.3324","doi":"10.1200/JCO.2007.11.3324"},{"title":"Quality of Life in Patients With Low-Risk Prostate Cancer Treated With Hypofractionated vs Conventional Radiotherapy: A Phase 3 Randomized Clinical Trial","journal":"JAMA Oncology","year":2019,"url":"https://doi.org/10.1001/jamaoncol.2018.6752","doi":"10.1001/jamaoncol.2018.6752"}],"orcid":"0000-0002-5770-9948"},{"id":"debra-black","kind":"person","name":"Debra Black","aka":[],"tldr":"Her 2007 melanoma diagnosis led her and her husband Leon to found the Melanoma Research Alliance, now the largest private funder of melanoma research.","summary":"Debra Black, a Broadway producer, was diagnosed with melanoma in 2007. MRA's own account begins there: melanoma touched the lives of Debra and Leon Black, and they founded the Melanoma Research Alliance that year. She has chaired its board since. The Alliance has invested more than $200 million through over 500 grant awards, its funded researchers have contributed to 20 new FDA-approved melanoma treatments, and the Blacks cover all operating costs so that 100% of every donation goes to research. Her role as a patient-founder shaped the Alliance's priorities: young investigators, team science across institutions, and an annual retreat where unpublished results are shared so that promising ideas reach patients faster.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Debra_Black","links":[{"label":"Melanoma Research Alliance: overview","url":"https://www.curemelanoma.org/mra-overview/mra-overview"}],"tags":["hero","donor","patient"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["mra"],"pathways":[],"terms":[],"trials":[],"people":["leon-black"],"bottlenecks":["b-funding-allocation","b-patient-voice"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Melanoma patient who co-founded the Melanoma Research Alliance","specialisms":["Melanoma research funding","Patient-founded foundations"],"profiles":[],"papers":[]},{"id":"debu-tripathy","kind":"person","name":"Debu Tripathy","aka":[],"tldr":"Leads one of the largest breast medical oncology departments, and led the ribociclib trial in premenopausal women.","summary":"Debu Tripathy is Chair of the Department of Breast Medical Oncology at MD Anderson Cancer Center and editor-in-chief of the journal Cancer. A breast medical oncologist specialising in endocrine therapy and clinical trials, he was principal investigator of MONALEESA-7, the phase 3 trial of ribociclib plus endocrine therapy in premenopausal women with hormone-receptor-positive advanced breast cancer, and is a leader in HER2-directed and antibody-drug conjugate trials. His papers report the MONALEESA-7 trial in Lancet Oncology and its overall survival analysis in the New England Journal of Medicine. He leads one of the largest breast medical oncology departments, working on CDK4/6 and the oestrogen receptor.","asOf":"2026-09-08","links":[{"label":"MD Anderson faculty","url":"https://faculty.mdanderson.org/search?q=Debu%20Tripathy"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tripathy%20D%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Debu%20Tripathy"}],"tags":[],"related":[],"cancers":["breast-hr-positive","breast-her2-positive","tnbc"],"sections":[],"technologies":[],"targets":["cdk4-6","estrogen-receptor"],"drugs":["ribociclib"],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chair, Department of Breast Medical Oncology, MD Anderson","institutionId":"md-anderson","specialisms":["Breast cancer","Endocrine therapy","Clinical trials"],"profiles":[{"label":"MD Anderson faculty","url":"https://faculty.mdanderson.org/search?q=Debu%20Tripathy"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tripathy%20D%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Debu%20Tripathy"}],"papers":[{"title":"Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial","journal":"Lancet Oncology","year":2018,"url":"https://doi.org/10.1016/S1470-2045(18)30292-4","doi":"10.1016/S1470-2045(18)30292-4"},{"title":"Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer","journal":"New England Journal of Medicine","year":2019,"url":"https://doi.org/10.1056/nejmoa1903765","doi":"10.1056/nejmoa1903765"}]},{"id":"declan-murphy","kind":"person","name":"Declan G. Murphy","aka":[],"tldr":"Urologist who co-led proPSMA, the trial that showed PSMA PET should replace CT and bone scan for staging prostate cancer.","summary":"Declan Murphy was co-principal investigator of proPSMA, the randomised trial showing PSMA PET-CT is 27% more accurate than conventional imaging for staging high-risk prostate cancer, the evidence behind PSMA PET's adoption in guidelines. He directs GU oncology at Peter Mac, leads robotic surgery, and chairs the ANZUP theranostics and surgical sub-committees.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Murphy%20DG%5BAuthor%5D%20PSMA%20prostate"}],"tags":["prostate","imaging","surgery"],"related":[],"cancers":["prostate"],"sections":[],"technologies":["psma-pet","robotic-surgery"],"targets":["psma"],"drugs":[],"companies":["anzup"],"institutions":["peter-mac"],"pathways":[],"terms":[],"trials":["propsma"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["european-urology"],"dependsOn":[],"notes":[],"role":"Director of Genitourinary Oncology, Peter MacCallum Cancer Centre","institutionId":"peter-mac","specialisms":["Urological surgery","PSMA PET","Robotic prostatectomy","Prostate cancer staging"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Murphy%20DG%5BAuthor%5D%20PSMA%20prostate"}],"papers":[{"title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA)","journal":"Lancet","year":2020,"doi":"10.1016/S0140-6736(20)30314-7"},{"title":"Prostate-specific membrane antigen positron emission tomography (PSMA-PET) for local staging of prostate cancer: a systematic review and meta-analysis","journal":"European Urology","year":2020}],"orcid":"0000-0002-7500-5899"},{"id":"delia-nicoara","kind":"person","name":"Delia Nicoară","aka":[],"tldr":"Delia Nicoară represents Cancer Free Future Association (CFFA) in the Organisation of European Cancer Institutes, which lists the organisation among its members in Romania.","summary":"Delia Nicoară is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Cancer Free Future Association (CFFA), its associate member in Romania. OnCo records the name from the OECI membership list so that the organisation's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the organisation's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Cancer Free Future Association (CFFA) website","url":"https://www.cancerfreefuture.eu/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cancer-free-future-association"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Cancer Free Future Association (CFFA) to the Organisation of European Cancer Institutes","institutionId":"cancer-free-future-association","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Cancer Free Future Association (CFFA) website","url":"https://www.cancerfreefuture.eu/"}],"papers":[]},{"id":"denis-lacombe","kind":"person","name":"Denis Lacombe","aka":[],"tldr":"Denis Lacombe leads Europe's academic cancer trials organisation.","summary":"Denis Lacombe is Chief Executive Officer of the EORTC, Europe's academic cancer trials organisation. His specialisms are clinical trial methodology, academic research infrastructure and health policy. He has championed treatment-optimisation trials and pragmatic academic research alongside regulatory studies. His papers include a Nature Reviews Clinical Oncology piece on a European perspective for effective cancer drug development, an EORTC Brain Tumor Group phase II trial of sagopilone in recurrent glioblastoma, and the joint final report of EORTC 26951 and RTOG 9402 on procarbazine, lomustine and vincristine chemotherapy for anaplastic oligodendroglial tumours. His EORTC profile is linked.","asOf":"2026-09-08","links":[{"label":"EORTC","url":"https://www.eortc.org/"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["curie-nki-eortc"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive Officer, EORTC","institutionId":"curie-nki-eortc","specialisms":["Clinical trial methodology","Academic research infrastructure","Health policy"],"profiles":[{"label":"EORTC","url":"https://www.eortc.org/"}],"papers":[{"title":"European perspective for effective cancer drug development","journal":"Nature Reviews Clinical Oncology","year":2014,"doi":"10.1038/nrclinonc.2014.98"},{"title":"Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group","journal":"Annals of Oncology","year":2011,"doi":"10.1093/annonc/mdq729"},{"title":"Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors","journal":"Journal of Clinical Oncology","year":2022,"doi":"10.1200/jco.21.02543"},{"title":"Stupp 2005: temozolomide added to radiotherapy for newly diagnosed glioblastoma","journal":"New England Journal of Medicine","year":2005,"url":"https://doi.org/10.1056/NEJMoa043330","doi":"10.1056/NEJMoa043330"}],"orcid":"0009-0008-9094-393X"},{"id":"denise-galloway","kind":"person","name":"Denise A. Galloway","aka":[],"tldr":"Virologist whose HPV research underpinned the vaccines that are eliminating cervical cancer.","summary":"Denise Galloway is Director of the Pathogen-Associated Malignancies Integrated Research Center at Fred Hutchinson Cancer Center. A molecular virologist specialising in HPV and viral oncology, she characterised how HPV oncoproteins transform cells and led early serologic and vaccine work that underpinned the vaccines now reducing cervical cancer. She received the Lasker-DeBakey Award in 2017 with Douglas Lowy and John Schiller for HPV vaccine contributions. Her papers include a review of the shared and distinct pathways of human papillomavirus pathogenesis and a comparison of capsid antibody responses to HPV types 16, 18 and 6 after incident infection, with relevance to cervical and head and neck cancer prevention.","asOf":"2026-09-08","links":[{"label":"Fred Hutch faculty directory","url":"https://www.fredhutch.org/en/faculty-lab-directory.html?q=Denise%20A.%20Galloway"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Galloway%20DA%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Denise%20A.%20Galloway"}],"tags":[],"related":[],"cancers":["cervical","head-and-neck"],"sections":[],"technologies":["hpv-vaccine"],"targets":[],"drugs":[],"companies":[],"institutions":["fred-hutch"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Pathogen-Associated Malignancies Integrated Research Center, Fred Hutchinson Cancer Center","institutionId":"fred-hutch","specialisms":["HPV","Viral oncology","Cancer prevention"],"profiles":[{"label":"Fred Hutch faculty directory","url":"https://www.fredhutch.org/en/faculty-lab-directory.html?q=Denise%20A.%20Galloway"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Galloway%20DA%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Denise%20A.%20Galloway"}],"papers":[{"title":"Human papillomaviruses: shared and distinct pathways for pathogenesis","journal":"Current Opinion in Virology","year":2015,"url":"https://doi.org/10.1016/j.coviro.2015.09.001","doi":"10.1016/j.coviro.2015.09.001"},{"title":"Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection","journal":"Journal of Infectious Diseases","year":2000,"url":"https://doi.org/10.1086/315498","doi":"10.1086/315498"}],"orcid":"0000-0002-6713-6127"},{"id":"denise-aberle","kind":"person","name":"Denise R. Aberle","aka":[],"tldr":"Principal investigator of the National Lung Screening Trial, which first proved CT screening saves lives.","summary":"Denise Aberle was national principal investigator of the ACRIN arm of the National Lung Screening Trial, whose 2011 result of a 20% reduction in lung cancer mortality with low-dose CT led to the first lung screening recommendations and Medicare coverage in the United States. She continues to work on quantitative imaging and AI for nodule assessment.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Denise_Aberle","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Aberle%20DR%5BAuthor%5D%20lung%20screening"}],"tags":["screening","lung","radiology"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["ct","radiology-ai-screening"],"targets":[],"drugs":[],"companies":[],"institutions":["ucla-jonsson"],"pathways":[],"terms":[],"trials":["nlst-nelson"],"people":[],"bottlenecks":[],"keyPapers":["paper-nlst-nejm-2011"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Radiology and Bioengineering, UCLA","institutionId":"ucla-jonsson","specialisms":["Thoracic radiology","Lung cancer screening","Imaging trials","Quantitative imaging"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Aberle%20DR%5BAuthor%5D%20lung%20screening"}],"papers":[{"title":"Reduced lung-cancer mortality with low-dose computed tomographic screening (NLST)","journal":"NEJM","year":2011,"doi":"10.1056/NEJMoa1102873"},{"title":"Results of the two incidence screenings in the National Lung Screening Trial","journal":"NEJM","year":2013,"doi":"10.1056/NEJMoa1208962"}]},{"id":"denise-soares-dos-santos","kind":"person","name":"Denise Soares dos Santos","aka":[],"tldr":"Chief executive of BP, the philanthropic Beneficência Portuguesa hospital group in São Paulo whose services include a large oncology programme.","summary":"Denise Soares dos Santos is Chief Executive Officer (CEO) of BP - A Beneficência Portuguesa de São Paulo, one of Brazil's largest philanthropic hospital institutions, founded in 1859. BP's corporate governance page lists her at the head of the Diretoria Executiva, alongside executive directors for technology, finance and operations, people and customer experience, business and expansion, and medical and technical development (Veridiana Camargo de Arruda Penteado), with Regina Stella Lelis as executive director of Hospital BP, BP Mirante and the diagnostic units. The Conselho de Administração is chaired by Josué Dimas de Melo Pimenta.","asOf":"2026-09-10","links":[{"label":"Source: BP 'Governança corporativa' page","url":"https://www.bp.org.br/institucional/governanca-corporativa/"}],"tags":["leadership","hospital-management","philanthropy"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["bp-beneficencia-portuguesa"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive Officer, BP - A Beneficência Portuguesa de São Paulo","institutionId":"bp-beneficencia-portuguesa","specialisms":["Hospital management","Philanthropic healthcare"],"profiles":[{"label":"BP corporate governance page (Portuguese)","url":"https://www.bp.org.br/institucional/governanca-corporativa/"}],"papers":[]},{"id":"dennis-slamon","kind":"person","name":"Dennis J. Slamon","aka":[],"tldr":"Linked HER2 amplification to aggressive breast cancer and drove trastuzumab and later palbociclib to approval.","summary":"Dennis Slamon is Director of Clinical/Translational Research at the UCLA Jonsson Comprehensive Cancer Center and Chief of its Division of Hematology-Oncology. A medical oncologist specialising in breast cancer, his 1987 Science paper tied HER2 amplification to shorter survival and he led the clinical development of trastuzumab, later leading palbociclib development and the NATALEE adjuvant ribociclib trial. His papers include the Science report correlating relapse and survival with amplification of the HER-2/neu oncogene and the New England Journal of Medicine trial of chemotherapy plus a monoclonal antibody against HER2 in metastatic breast cancer. His work spans HER2-positive and HR-positive breast cancer and CDK4/6 inhibitors.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Dennis_Slamon","links":[{"label":"UCLA profile","url":"https://www.uclahealth.org/providers?q=Dennis%20J.%20Slamon"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Slamon%20DJ%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Dennis%20J.%20Slamon"}],"tags":[],"related":[],"cancers":["breast-her2-positive","breast-hr-positive"],"sections":[],"technologies":[],"targets":["her2","cdk4-6"],"drugs":["trastuzumab","palbociclib","ribociclib"],"companies":[],"institutions":["ucla-jonsson"],"pathways":[],"terms":[],"trials":["natalee"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Clinical/Translational Research, UCLA Jonsson Comprehensive Cancer Center; Chief, Division of Hematology-Oncology","institutionId":"ucla-jonsson","specialisms":["Breast cancer","HER2","CDK4/6 inhibitors"],"profiles":[{"label":"UCLA profile","url":"https://www.uclahealth.org/providers?q=Dennis%20J.%20Slamon"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Slamon%20DJ%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Dennis%20J.%20Slamon"}],"papers":[{"title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene","journal":"Science","year":1987,"url":"https://doi.org/10.1126/science.3798106","doi":"10.1126/science.3798106"},{"title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","journal":"New England Journal of Medicine","year":2001,"url":"https://doi.org/10.1056/NEJM200103153441101","doi":"10.1056/NEJM200103153441101"},{"title":"NATALEE: three years of ribociclib after surgery in a broad population of hormone-receptor-positive early breast cancer","journal":"New England Journal of Medicine","year":2024,"url":"https://doi.org/10.1056/NEJMoa2305488","doi":"10.1056/NEJMoa2305488"},{"title":"Slamon 1989: HER2/neu in human breast and ovarian cancer","journal":"Science","year":1989,"url":"https://doi.org/10.1126/science.2470152","doi":"10.1126/science.2470152"}]},{"id":"derrick-haslem","kind":"person","name":"Derrick S. Haslem","aka":[],"tldr":"Medical oncologist who leads the oncology clinical programme across Intermountain Health's cancer centres in Utah and neighbouring states.","summary":"Derrick S. Haslem is Senior Medical Director of the Oncology Clinical Program at Intermountain Health, the not-for-profit health system whose cancer centres span Utah and surrounding states. He is a board-certified medical oncologist with expertise in targeted therapy, genomics and breast cancer, and completed his haematology and oncology fellowship at Huntsman Cancer Hospital, University of Utah, in 2009. He practises at Intermountain cancer centres in St George, Murray and Logan and has expanded rural access to cancer care through tele-oncology services in Utah, Idaho and Wyoming.","asOf":"2026-09-10","links":[{"label":"Source: Intermountain Health provider profile","url":"https://doctors.intermountainhealth.org/provider/derrick-s-haslem/2556921"}],"tags":["leadership","clinician-scientist","medical-oncology","tele-oncology"],"related":[],"cancers":["breast-hr-positive","breast-her2-positive","tnbc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["intermountain-cancer"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["oncotarget"],"dependsOn":[],"notes":[],"role":"Senior Medical Director of the Oncology Clinical Program, Intermountain Health","institutionId":"intermountain-cancer","specialisms":["Medical oncology","Breast cancer","Cancer genomics and targeted therapy","Tele-oncology"],"profiles":[{"label":"Institution profile","url":"https://doctors.intermountainhealth.org/provider/derrick-s-haslem/2556921"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Haslem+DS%5BAuthor%5D"}],"papers":[{"title":"Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study","journal":"Journal of Clinical Oncology","year":2021,"doi":"10.1200/jco.20.02923"},{"title":"Precision oncology in advanced cancer patients improves overall survival with lower weekly healthcare costs","journal":"Oncotarget","year":2018,"doi":"10.18632/oncotarget.24384"},{"title":"A Retrospective Analysis of Precision Medicine Outcomes in Patients With Advanced Cancer Reveals Improved Progression-Free Survival Without Increased Health Care Costs","journal":"Journal of Oncology Practice","year":2017,"doi":"10.1200/jop.2016.011486"}],"orcid":"0009-0000-4469-2086"},{"id":"shetty-devi","kind":"person","name":"Devi Shetty","aka":[],"tldr":"The cardiac surgeon who showed that high-volume hospitals can cut the price of complex care by an order of magnitude, a model now applied to cancer at Narayana Health's Bengaluru campus.","summary":"Devi Shetty founded Narayana Hrudayalaya in 2001 at Bommasandra outside Bengaluru and built it into Narayana Health, a listed group of 24 hospitals whose economics of scale bring the price of a coronary bypass to a small fraction of US charges. With Kiran Mazumdar-Shaw he established the Mazumdar-Shaw Medical Centre (2009), the group's cancer and multispecialty campus. He has been an influential voice for universal health insurance in India, and holds the Padma Shri (2004) and Padma Bhushan (2012).","asOf":"2026-09-10","links":[{"label":"Narayana Health","url":"https://www.narayanahealth.org"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Devi_Shetty"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["global-oncology-access"],"targets":[],"drugs":[],"companies":[],"institutions":["narayana-health"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-global-access","b-drug-pricing"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chairman and founder, Narayana Health; cardiac surgeon","institutionId":"narayana-health","specialisms":["Low-cost hospital models","Cardiac surgery","Health financing","Hospital operations"],"profiles":[{"label":"Narayana Health","url":"https://www.narayanahealth.org"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Devi_Shetty"}],"papers":[],"orcid":"0000-0001-9767-034X"},{"id":"dharmendra-singh-gangwar","kind":"person","name":"Dharmendra Singh Gangwar","aka":[],"tldr":"Former Indian Administrative Service secretary and physician who is Chief Executive Officer of the Rajiv Gandhi Cancer Institute and Research Centre in Delhi.","summary":"Dharmendra Singh Gangwar is Chief Executive Officer of the Rajiv Gandhi Cancer Institute and Research Centre (RGCIRC), a not-for-profit specialist cancer hospital in Rohini, Delhi, with a second site at Niti Bagh. He holds an MBBS from King George's Medical College, Lucknow, and is a former member of the Indian Administrative Service and Secretary to the Government of India, with more than 35 years in public health, governance and institutional development. As Additional Secretary and Financial Advisor in the Ministry of Health and Family Welfare he oversaw a health budget of more than 82,000 crore rupees during the COVID-19 pandemic, and he also serves as President of AIIMS Rewari. The institute's Chairman is Ashok Kumar Agarwal and its Medical Director is Sudhir Rawal.","asOf":"2026-09-10","links":[{"label":"Source: RGCIRC Office of CEO page","url":"https://www.rgcirc.org/office-of-ceo/"},{"label":"RGCIRC Office of Chairman page","url":"https://www.rgcirc.org/office-of-chairman/"}],"tags":["leadership","hospital-management","philanthropy"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["rgci"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive Officer, Rajiv Gandhi Cancer Institute and Research Centre, Delhi","institutionId":"rgci","specialisms":["Public health administration","Health financing","Hospital governance"],"profiles":[{"label":"RGCIRC Office of CEO","url":"https://www.rgcirc.org/office-of-ceo/"}],"papers":[]},{"id":"diane-simeone","kind":"person","name":"Diane M. Simeone","aka":[],"tldr":"Pancreatic cancer surgeon-scientist who directs UC San Diego Moores Cancer Center, an NCI-designated comprehensive cancer center.","summary":"Diane M. Simeone, MD, is Director of UC San Diego Moores Cancer Center and Professor of Surgery and Pharmacology. She is a surgical oncologist and pancreatic cancer researcher whose work spans pancreatic cancer stem cells, early detection in high-risk individuals and the Precision Promise adaptive platform trial. She previously directed the Pancreatic Cancer Center at NYU Langone.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://moorescancercenter.ucsd.edu/about/leadership/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Simeone+DM%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","pancreatic cancer","surgical oncology"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ucsd-moores"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["international-journal-of-cancer"],"dependsOn":[],"notes":[],"role":"Director, Moores Cancer Center; Koman Family Presidential Director's Chair","institutionId":"ucsd-moores","specialisms":["Pancreatic cancer","Surgical oncology","Cancer early detection"],"profiles":[{"label":"Institution profile","url":"https://moorescancercenter.ucsd.edu/about/leadership/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Simeone+DM%5BAuthor%5D"}],"papers":[{"title":"Validation of a Serum-Based Biomarker Signature for Detection of Early-Stage Pancreatic Ductal Adenocarcinoma","journal":"Gastroenterology","year":2026,"doi":"10.1053/j.gastro.2025.08.034"},{"title":"A High Performing Biomarker Signature for Detecting Early-Stage Pancreatic Ductal Adenocarcinoma in High-Risk Individuals","journal":"Cancers","year":2025,"doi":"10.3390/cancers17111866"},{"title":"Pancreatic Cancer Early Detection Biomarkers for High‐Risk Individuals: Insights From the PRECEDE Consortium","journal":"International Journal of Cancer","year":2026,"doi":"10.1002/ijc.70592"}],"orcid":"0000-0001-5142-3087"},{"id":"didier-peiffert","kind":"person","name":"Didier Peiffert","aka":[],"tldr":"Didier Peiffert represents Institut de Cancérologie de Lorraine in the Organisation of European Cancer Institutes, which lists the centre among its members in France.","summary":"Didier Peiffert is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Institut de Cancérologie de Lorraine, its member in France. The Institut de Cancérologie de Lorraine, formerly the Centre Alexis Vautrin, is the Unicancer comprehensive cancer centre for Lorraine near Nancy and a full member of the Organisation of European Cancer Institutes. OnCo records the name from the OECI membership list so that the centre's page has a named contact point; the person's exact title, appointment date and biography are not yet recorded and should be checked on the institution's own pages before being relied on.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Institut de Cancérologie de Lorraine website","url":"https://www.icl-lorraine.fr/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["institut-de-cancerologie-de-lorraine"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Institut de Cancérologie de Lorraine to the Organisation of European Cancer Institutes","institutionId":"institut-de-cancerologie-de-lorraine","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Institut de Cancérologie de Lorraine website","url":"https://www.icl-lorraine.fr/"}],"papers":[]},{"id":"diep-bao-tuan","kind":"person","name":"Diệp Bảo Tuấn","aka":[],"tldr":"Physician who directs Ho Chi Minh City Oncology Hospital, the main public cancer hospital serving southern Vietnam.","summary":"Diệp Bảo Tuấn (TS.BS, doctor of medicine) is Director of Ho Chi Minh City Oncology Hospital (Bệnh viện Ung Bướu TP.HCM), a public specialist cancer hospital operating on two sites in Ho Chi Minh City. The hospital's own announcement of a deputy director appointment in January 2025 names him as Giám đốc Bệnh viện, and its 2026 notices continue to publish a quarterly public reception schedule for the Director. The hospital website did not give further biographical detail.","asOf":"2026-09-10","links":[{"label":"Source: hospital announcement naming the Director (January 2025)","url":"https://benhvienungbuou.vn/le-cong-bo-va-trao-quyet-dinh-dieu-dong-bo-nhiem-pho-giam-doc-benh-vien-ung-buou-tp-hcm/"}],"tags":["leadership","clinician-scientist","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["hcmc-oncology-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director (Giám đốc), Ho Chi Minh City Oncology Hospital","institutionId":"hcmc-oncology-hospital","specialisms":["Oncology","Hospital management"],"profiles":[{"label":"Hospital leadership page","url":"https://benhvienungbuou.vn/ban-giam-doc-qua-cac-thoi-ky/"}],"papers":[]},{"id":"ye-dingwei","kind":"person","name":"Dingwei Ye","aka":[],"tldr":"Dingwei Ye is China's leading uro-oncologist, whose department runs the Chinese arms of major prostate and bladder cancer trials.","summary":"Dingwei Ye is Professor and Chair of the Department of Urology at Fudan University Shanghai Cancer Center. He is China's leading uro-oncologist, and his department runs the Chinese arms of major prostate and bladder cancer trials, including studies of androgen receptor pathway inhibitors such as enzalutamide, PARP inhibitors, and the antibody-drug conjugates enfortumab vedotin and disitamab vedotin in urothelial cancer. His publications include trials of abiraterone plus prednisone and of apalutamide in metastatic castration-sensitive prostate cancer, including the LATITUDE study. His interests span prostate, bladder and kidney cancer and urologic surgery.","asOf":"2026-09-08","links":[{"label":"Fudan University Shanghai Cancer Center","url":"https://www.shca.org.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ye%20D%5BAuthor%5D%20Fudan%20prostate%20urology"}],"tags":[],"related":[],"cancers":["prostate","urothelial","rcc"],"sections":[],"technologies":[],"targets":[],"drugs":["disitamab-vedotin","enzalutamide"],"companies":[],"institutions":["fuscc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor and Chair, Department of Urology, Fudan University Shanghai Cancer Center","institutionId":"fuscc","specialisms":["Prostate cancer","Bladder cancer","Kidney cancer","Urologic surgery"],"profiles":[{"label":"Fudan University Shanghai Cancer Center","url":"https://www.shca.org.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ye%20D%5BAuthor%5D%20Fudan%20prostate%20urology"}],"papers":[{"title":"Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer","journal":"New England Journal of Medicine","year":2017,"doi":"10.1056/nejmoa1704174"},{"title":"Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer","journal":"New England Journal of Medicine","year":2019,"doi":"10.1056/nejmoa1903307"},{"title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","journal":"The Lancet Oncology","year":2019,"doi":"10.1016/s1470-2045(19)30082-8"}]},{"id":"dion-morton","kind":"person","name":"Dion Morton","aka":[],"tldr":"The Birmingham surgeon who chairs FOxTROT and runs the surgical trials programme that tests how bowel cancer operations are done, not just which drugs come with them.","summary":"Dion Morton is Barling Professor of Surgery at the University of Birmingham, appointed Professor of Surgery in 2006 and to the Barling Chair in 2015, and is surgery section head in the Department of Cancer and Genomic Sciences. His university page lists him on the trial management groups of ISAAC, CReST, TREC, FOxTROT (as chair), ROSSINI, ARISTOTLE and DREAMs. He is first author of the mature FOxTROT results; the Birmingham Clinical Trials Unit sponsors STAR-TREC and the ROSSINI surgical site infection trials.","asOf":"2026-09-24","links":[{"label":"University of Birmingham staff page","url":"https://www.birmingham.ac.uk/staff/profiles/applied-health/morton-dion"}],"tags":["colorectal","surgeon","uk","trialist"],"related":["matt-seymour"],"cancers":["colorectal","rectal-cancer"],"sections":["surgery"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["birmingham-cancer-centre"],"pathways":[],"terms":[],"trials":["foxtrot","star-trec"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Barling Professor of Surgery, University of Birmingham","institutionId":"birmingham-cancer-centre","specialisms":["Colorectal surgery","Surgical trials","Neoadjuvant treatment of colon cancer"],"profiles":[{"label":"University of Birmingham staff page","url":"https://www.birmingham.ac.uk/staff/profiles/applied-health/morton-dion"}],"papers":[{"title":"Preoperative chemotherapy for operable colon cancer: mature results of an international randomized controlled trial (FOxTROT)","journal":"Journal of Clinical Oncology","year":2023,"doi":"10.1200/JCO.22.00046"}]},{"id":"dirk-schadendorf","kind":"person","name":"Dirk Schadendorf","aka":[],"tldr":"Melanoma expert who directs the West German Cancer Center at University Hospital Essen.","summary":"Dirk Schadendorf is Director of the West German Cancer Center (WTZ) and Director of the Department of Dermatology at University Hospital Essen. He is one of Europe's most prolific melanoma investigators, having led or co-led pivotal trials of immune checkpoint inhibitors and BRAF/MEK-targeted therapy in adjuvant and metastatic settings. Under his leadership the WTZ is a designated German comprehensive cancer centre and part of the NCT West network.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://wtz-essen.de/direktorium-wtz-essen/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schadendorf+D%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","melanoma","immunotherapy"],"related":[],"cancers":["melanoma","cutaneous-scc","merkel-cell-carcinoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["essen-wtz"],"pathways":[],"terms":[],"trials":["checkmate-067"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director WTZ Essen; Director, Department of Dermatology","institutionId":"essen-wtz","specialisms":["Melanoma","Skin cancer","Immunotherapy and targeted therapy"],"profiles":[{"label":"Institution profile","url":"https://wtz-essen.de/direktorium-wtz-essen/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schadendorf+D%5BAuthor%5D"}],"papers":[{"title":"Melanoma","journal":"Lancet","year":2018,"url":"https://doi.org/10.1016/S0140-6736(18)31559-9","doi":"10.1016/S0140-6736(18)31559-9"},{"title":"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716)","journal":"Lancet","year":2022,"url":"https://doi.org/10.1016/S0140-6736(22)00562-1","doi":"10.1016/S0140-6736(22)00562-1"},{"title":"Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma (IMMUNED)","journal":"Lancet","year":2020,"url":"https://doi.org/10.1016/S0140-6736(20)30417-7","doi":"10.1016/S0140-6736(20)30417-7"}]},{"id":"diwani-msemo","kind":"person","name":"Diwani Msemo","aka":[],"tldr":"Executive Director of the Ocean Road Cancer Institute, Tanzania's national cancer hospital in Dar es Salaam.","summary":"Dr Diwani Msemo leads the Ocean Road Cancer Institute (ORCI), Tanzania's national specialised cancer institute in Dar es Salaam. In August 2026 he announced that ORCI would begin offering major cancer surgery in October, ending the need to refer patients to other national hospitals for operations before returning for radiotherapy or chemotherapy. He also reported the installation of a PET scanner at ORCI, described as the first in East and Central Africa.","asOf":"2026-09-10","links":[{"label":"Source: Daily News Tanzania, ORCI set to begin major cancer surgery (August 2026)","url":"https://dailynews.co.tz/orci-set-to-begin-major-cancer-surgery/"}],"tags":["leadership","clinician-scientist","africa","global-oncology"],"related":[],"cancers":[],"sections":[],"technologies":["pet"],"targets":[],"drugs":[],"companies":[],"institutions":["ocean-road-cancer-institute"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Executive Director, Ocean Road Cancer Institute","institutionId":"ocean-road-cancer-institute","specialisms":["Cancer services in Tanzania","Radiotherapy access","Health system leadership"],"profiles":[{"label":"Daily News (Tanzania) report","url":"https://dailynews.co.tz/orci-set-to-begin-major-cancer-surgery/"}],"papers":[{"title":"Changing Patterns of lung, liver, and head and neck non-AIDS-defining cancers relative to HIV status in Tanzania between 2002-2014","journal":"Infectious Agents and Cancer","year":2016,"doi":"10.1186/s13027-016-0106-5"},{"title":"Impact of Initiating Screening Programs on Referral and Management of Cervical Cancer in Tanzania","journal":"Journal of Global Oncology","year":2019,"doi":"10.1200/jgo.18.00052"}],"orcid":"0009-0008-5856-1894"},{"id":"oh-do-youn","kind":"person","name":"Do-Youn Oh","aka":[],"tldr":"Principal investigator of TOPAZ-1, the trial that added immunotherapy to first-line chemotherapy for bile duct cancer.","summary":"Do-Youn Oh is Professor of Internal Medicine at Seoul National University Hospital, specialising in gastrointestinal and hepatobiliary oncology. She was principal investigator of TOPAZ-1, the trial that added the immunotherapy durvalumab to first-line gemcitabine plus cisplatin for advanced biliary tract cancer, the first phase 3 in more than a decade to improve outcomes in that disease. Her publications include the TOPAZ-1 report on durvalumab plus gemcitabine and cisplatin. She runs pancreatic and biliary clinical trials at Seoul National University Hospital, with interests in immunotherapy for biliary tract cancer and pancreatic cancer.","asOf":"2026-09-08","links":[{"label":"Seoul National University Hospital","url":"https://www.snuh.org"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Oh%20DY%5BAuthor%5D%20biliary%20tract%20cancer%20Seoul%20National%20University"}],"tags":[],"related":[],"cancers":["cholangiocarcinoma","pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":["durvalumab","gemcitabine-cisplatin"],"companies":[],"institutions":["snuh"],"pathways":[],"terms":[],"trials":["topaz-1"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nejm-evidence"],"dependsOn":[],"notes":[],"role":"Professor of Internal Medicine; gastrointestinal and hepatobiliary oncology","institutionId":"snuh","specialisms":["Biliary tract cancer","Pancreatic cancer","Immunotherapy","Clinical trials"],"profiles":[{"label":"Seoul National University Hospital","url":"https://www.snuh.org"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Oh%20DY%5BAuthor%5D%20biliary%20tract%20cancer%20Seoul%20National%20University"}],"papers":[{"title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1)","journal":"NEJM Evidence","year":2022,"doi":"10.1056/EVIDoa2200015"},{"title":"NETTER-2: lutetium-177 dotatate as first treatment for higher-grade gastroenteropancreatic neuroendocrine tumours","journal":"The Lancet","year":2024,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NETTER-2+lutetium+dotatate+first-line+Singh+Lancet"}],"orcid":"0000-0003-1663-9901"},{"id":"domenica-lorusso","kind":"person","name":"Domenica Lorusso","aka":[],"tldr":"Led KEYNOTE-A18, which showed adding pembrolizumab to chemoradiotherapy improves survival in locally advanced cervical cancer.","summary":"Domenica Lorusso was principal investigator of KEYNOTE-A18, the ENGOT trial showing pembrolizumab with chemoradiotherapy improves progression-free and overall survival in high-risk locally advanced cervical cancer, the first systemic addition to chemoradiation to do so in two decades. She has led the MITO group's ovarian and endometrial trials and co-led studies of trastuzumab deruxtecan in gynaecological cancers.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lorusso%20D%5BAuthor%5D%20cervical%20pembrolizumab"}],"tags":["cervical","immunotherapy","italy"],"related":[],"cancers":["cervical","endometrial","ovarian"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["pd1"],"drugs":["pembrolizumab","trastuzumab-deruxtecan"],"companies":[],"institutions":["humanitas"],"pathways":[],"terms":[],"trials":["keynote-a18"],"people":[],"bottlenecks":[],"keyPapers":["paper-keynote-a18-pfs-lancet-2024","paper-keynote-a18-os-lancet-2024"],"journals":[],"dependsOn":[],"notes":[],"role":"Director of Gynaecological Oncology, Humanitas San Pio X and Humanitas University, Milan","institutionId":"humanitas","specialisms":["Cervical cancer","Endometrial cancer","Ovarian cancer","Immunotherapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lorusso%20D%5BAuthor%5D%20cervical%20pembrolizumab"}],"papers":[{"title":"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18)","journal":"Lancet","year":2024,"doi":"10.1016/S0140-6736(24)00317-9"},{"title":"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results","journal":"Lancet","year":2024,"doi":"10.1016/S0140-6736(24)01808-7"}],"orcid":"0000-0003-0981-0598"},{"id":"dominique-bazy","kind":"person","name":"Dominique Bazy","aka":[],"tldr":"President of Fondation ARC, the French charitable foundation that funds cancer research, whose board mandate was renewed in June 2026.","summary":"Dominique Bazy is President of the Board of Fondation ARC pour la recherche sur le cancer, the French foundation dedicated to funding cancer research, with his mandate renewed on 26 June 2026 according to the foundation's governance page. He also heads Barber Hauler Capital Advisers. The board comprises twelve volunteer members, including Alain Chevallier as Treasurer and Professor Eric Solary of Gustave Roussy, alongside institutional partners such as the Institut National du Cancer.","asOf":"2026-09-10","links":[{"label":"Source: Fondation ARC board page","url":"https://www.fondation-arc.org/la-fondation/notre-fonctionnement/notre-gouvernance/le-conseil-dadministration/"}],"tags":["leadership","funding","charity"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["fondation-arc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President of Fondation ARC pour la recherche sur le cancer","institutionId":"fondation-arc","specialisms":["Charity governance","Cancer research funding","Finance"],"profiles":[{"label":"Institution profile","url":"https://www.fondation-arc.org/la-fondation/notre-fonctionnement/notre-gouvernance/le-conseil-dadministration/"}],"papers":[]},{"id":"donald-pinkel","kind":"person","name":"Donald Pinkel","aka":[],"tldr":"As the founding director of St. Jude Children's Research Hospital in 1962 he designed Total Therapy, combining drugs with treatment of the brain and spinal fluid, and raised childhood leukaemia cure rates from near zero to about half within a decade.","summary":"Donald Pinkel (1926-2022) became the first medical director of St. Jude Children's Research Hospital in Memphis when it opened in 1962, at a time when acute lymphoblastic leukaemia killed almost every child within a year. His Total Therapy studies treated children with combination chemotherapy for remission, added prophylactic treatment of the central nervous system, first with cranial irradiation and intrathecal methotrexate, because that was where the disease hid and relapsed, and continued treatment for two to three years. By 1971 he reported that around half of children were long-term survivors, and the design he set out remains the skeleton of every ALL protocol today, with cure rates now above 90 percent. He insisted from the start that St. Jude treat Black and white children on the same wards. He received the Lasker Award in 1972 and later led paediatric oncology in Milwaukee and Texas.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Donald_Pinkel","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Donald_Pinkel"},{"label":"St. Jude Children's Research Hospital","url":"https://www.stjude.org/"}],"tags":["hero","pioneer"],"related":[],"cancers":["all-leukemia"],"sections":["chemotherapy"],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["methotrexate","vincristine"],"companies":[],"institutions":[],"pathways":[],"terms":["cancer-health-disparities"],"trials":[],"people":["emil-freireich","emil-frei"],"bottlenecks":["b-rare-cancers","b-survivorship"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"First director of St. Jude; devised Total Therapy for childhood leukaemia","specialisms":["Paediatric oncology","Acute lymphoblastic leukaemia","Protocol design"],"profiles":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Donald_Pinkel"},{"label":"St. Jude Children's Research Hospital","url":"https://www.stjude.org/"}],"papers":[{"title":"Treatment of Acute Lymphoblastic Leukemia -- 30 Years' Experience at St. Jude Children's Research Hospital","journal":"New England Journal of Medicine","year":1993,"doi":"10.1056/nejm199310283291801"},{"title":"ACTINOMYCIN D IN CHILDHOOD CANCER","journal":"Pediatrics","year":1959,"doi":"10.1542/peds.23.2.342"}]},{"id":"kim-dong-wan","kind":"person","name":"Dong-Wan Kim","aka":[],"tldr":"Dong-Wan Kim is a thoracic oncologist central to the ALK and ROS1 inhibitor trials, from crizotinib to brigatinib and beyond.","summary":"Dong-Wan Kim is Professor of Internal Medicine and a thoracic oncologist at Seoul National University Hospital. He has been an investigator on the PROFILE and ALTA trials and on later ALK and ROS1 inhibitor studies, including lorlatinib and repotrectinib, as well as EGFR studies, helping to establish targeted therapy for fusion-driven lung cancer. His publications include the ALTA-1L trial comparing brigatinib with crizotinib in ALK-positive non-small-cell lung cancer. He remains central to the development of ALK and ROS1 inhibitors, from crizotinib to brigatinib and beyond.","asOf":"2026-09-08","links":[{"label":"Seoul National University Hospital","url":"https://www.snuh.org"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kim%20DW%5BAuthor%5D%20Seoul%20National%20University%20ALK%20lung"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":["alk","ros1"],"drugs":["lorlatinib","repotrectinib"],"companies":[],"institutions":["snuh"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Internal Medicine; thoracic oncology","institutionId":"snuh","specialisms":["Lung cancer","ALK and ROS1 fusions","Targeted therapy"],"profiles":[{"label":"Seoul National University Hospital","url":"https://www.snuh.org"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kim%20DW%5BAuthor%5D%20Seoul%20National%20University%20ALK%20lung"}],"papers":[{"title":"Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer (ALTA-1L)","journal":"NEJM","year":2018,"doi":"10.1056/NEJMoa1810171"},{"title":"CROWN: lorlatinib versus crizotinib as first treatment for ALK-positive lung cancer","journal":"New England Journal of Medicine","year":2020,"url":"https://doi.org/10.1056/NEJMoa2027187","doi":"10.1056/NEJMoa2027187"}]},{"id":"tu-dongsheng","kind":"person","name":"Dongsheng Tu","aka":[],"tldr":"Dongsheng Tu is the statistician behind decades of CCTG trials, including the erlotinib and cetuximab studies that changed lung and colorectal cancer care.","summary":"Dongsheng Tu is Senior Biostatistician at the Canadian Cancer Trials Group and Professor at Queen's University. He has been the statistician behind decades of CCTG trials, including BR.21, which tested erlotinib in non-small-cell lung cancer, and CO.17, which tested cetuximab in colorectal cancer, both of which changed care in those diseases. His publications include the CO.17 report on cetuximab for the treatment of colorectal cancer. He continues to contribute methodology for adaptive and biomarker-driven trials, with interests in biostatistics, clinical trial design and survival analysis.","asOf":"2026-09-08","links":[{"label":"Canadian Cancer Trials Group","url":"https://www.ctg.queensu.ca"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tu%20D%5BAuthor%5D%20Canadian%20Cancer%20Trials%20Group"}],"tags":[],"related":[],"cancers":["colorectal","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["cetuximab"],"companies":["cctg"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Senior Biostatistician, Canadian Cancer Trials Group; Professor, Queen's University","institutionId":"cctg","specialisms":["Biostatistics","Clinical trial design","Survival analysis"],"profiles":[{"label":"Canadian Cancer Trials Group","url":"https://www.ctg.queensu.ca"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tu%20D%5BAuthor%5D%20Canadian%20Cancer%20Trials%20Group"}],"papers":[{"title":"Cetuximab for the treatment of colorectal cancer (CO.17)","journal":"NEJM","year":2007,"doi":"10.1056/NEJMoa071834"}]},{"id":"donna-mckay","kind":"person","name":"Donna McKay","aka":[],"tldr":"President and CEO of the Breast Cancer Research Foundation, the largest private funder of breast cancer research worldwide.","summary":"Donna McKay is President and Chief Executive Officer of the Breast Cancer Research Foundation (BCRF), a US non-profit that funds breast cancer research internationally. She leads the foundation's strategy, operations and fundraising. BCRF supports hundreds of investigators across prevention, diagnosis, treatment, metastasis and survivorship research.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.bcrf.org/team"}],"tags":["leadership","breast cancer","research funding"],"related":[],"cancers":["breast-hr-positive","breast-her2-positive","tnbc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["bcrf"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President & CEO","institutionId":"bcrf","specialisms":["Non-profit leadership","Breast cancer research funding"],"profiles":[{"label":"Institution profile","url":"https://www.bcrf.org/team"}],"papers":[]},{"id":"dorraya-el-ashry","kind":"person","name":"Dorraya El-Ashry","aka":[],"tldr":"Breast cancer biologist and Chief Scientific Officer of the Breast Cancer Research Foundation, directing its global research grant portfolio.","summary":"Dorraya El-Ashry is Chief Scientific Officer of the Breast Cancer Research Foundation, where she oversees the foundation's scientific strategy and research programmes. A cancer biologist, her own research focused on oestrogen receptor signalling and the role of the tumour microenvironment and circulating tumour cells in breast cancer progression. She previously held faculty positions at the University of Miami and the University of Minnesota.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.bcrf.org/team"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=El-Ashry+D%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","breast cancer"],"related":[],"cancers":["breast-hr-positive","tnbc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["bcrf"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["breast-cancer-research-and-treatment"],"dependsOn":[],"notes":[],"role":"Chief Scientific Officer","institutionId":"bcrf","specialisms":["Breast cancer biology","Tumour microenvironment","Research strategy"],"profiles":[{"label":"Institution profile","url":"https://www.bcrf.org/team"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=El-Ashry+D%5BAuthor%5D"}],"papers":[{"title":"Activation of Mitogen-Activated Protein Kinase in Estrogen Receptor α–Positive Breast Cancer Cells In vitro Induces an In vivo Molecular Phenotype of Estrogen Receptor α–Negative Human Breast Tumors","journal":"Cancer Research","year":2006,"doi":"10.1158/0008-5472.can-05-4363"},{"title":"Identification of Cancer-Associated Fibroblasts in Circulating Blood from Patients with Metastatic Breast Cancer","journal":"Cancer Research","year":2015,"doi":"10.1158/0008-5472.can-15-1633"},{"title":"Paget’s disease of the nipple in a Her2-positive breast cancer xenograft model","journal":"Breast Cancer Research and Treatment","year":2019,"doi":"10.1007/s10549-019-05490-8"}]},{"id":"douglas-levine","kind":"person","name":"Douglas A. Levine","aka":[],"tldr":"Surgeon-scientist who led the TCGA endometrial cancer study that created today's four molecular subtypes.","summary":"Douglas Levine led the TCGA integrated genomic characterisation of endometrial carcinoma, which defined the POLE ultramutated, microsatellite-unstable, copy-number-low and copy-number-high (p53-abnormal) subtypes now embedded in international guidelines and trials. He also co-led the TCGA ovarian cancer analysis and directs gynaecologic oncology at NYU Langone, where his laboratory studies the origins of high-grade serous cancer.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Levine%20DA%5BAuthor%5D%20endometrial%20genomic"}],"tags":["endometrial","genomics","surgery"],"related":[],"cancers":["endometrial","ovarian"],"sections":[],"technologies":["wes-wgs"],"targets":[],"drugs":[],"companies":[],"institutions":["nyu-perlmutter"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-tcga-pancancer-atlas-cell-2018"],"journals":[],"dependsOn":[],"notes":[],"role":"Director of Gynecologic Oncology, NYU Langone Perlmutter Cancer Center","institutionId":"nyu-perlmutter","specialisms":["Gynaecologic oncology surgery","Endometrial cancer genomics","Ovarian cancer genomics","Translational research"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Levine%20DA%5BAuthor%5D%20endometrial%20genomic"}],"papers":[{"title":"Integrated genomic characterization of endometrial carcinoma","journal":"Nature","year":2013,"doi":"10.1038/nature12113"},{"title":"Integrated genomic analyses of ovarian carcinoma","journal":"Nature","year":2011,"doi":"10.1038/nature10166"},{"title":"TCGA Pan-Cancer Atlas: 10,000 tumours across 33 cancer types, classified by molecular features","journal":"Cell","year":2018,"url":"https://doi.org/10.1016/j.cell.2018.03.022","doi":"10.1016/j.cell.2018.03.022"}],"orcid":"0000-0003-1038-8232"},{"id":"douglas-lowy","kind":"person","name":"Douglas R. Lowy","aka":[],"tldr":"Co-developed the HPV vaccine technology that is eliminating cervical cancer in vaccinated populations.","summary":"Douglas R. Lowy is Principal Deputy Director of the National Cancer Institute, where he has also served as acting director. He is known for co-developing with John Schiller the virus-like particle technology underlying all licensed HPV vaccines, work recognised with the Lasker Award in 2017. His selected paper shows that the papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. His work on HPV biology and vaccine development is the basis for the prevention of cervical cancer and HPV-related head and neck cancer in vaccinated populations.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Douglas_R._Lowy","links":[{"label":"NCI leadership","url":"https://www.cancer.gov/about-nci/leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lowy%20DR%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["cervical","head-and-neck"],"sections":[],"technologies":["hpv-vaccine"],"targets":[],"drugs":["gardasil-9"],"companies":[],"institutions":["nci"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Principal Deputy Director, National Cancer Institute","institutionId":"nci","specialisms":["HPV biology","Vaccine development","Cancer prevention"],"profiles":[{"label":"NCI leadership","url":"https://www.cancer.gov/about-nci/leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lowy%20DR%5BAuthor%5D"}],"papers":[{"title":"Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic","journal":"PNAS","year":1992,"url":"https://doi.org/10.1073/pnas.89.24.12180","doi":"10.1073/pnas.89.24.12180"}]},{"id":"douglas-hawkins","kind":"person","name":"Douglas S. Hawkins","aka":[],"tldr":"Paediatric oncologist who chairs the world's largest childhood cancer research organisation.","summary":"Douglas Hawkins is Group Chair of the Children's Oncology Group (COG) and Professor of Pediatrics at Seattle Children's and the University of Washington, with ties to Fred Hutchinson Cancer Center. A paediatric oncologist specialising in bone and soft-tissue sarcomas, he led COG Ewing sarcoma trials and has chaired the Children's Oncology Group since 2020. His papers include a Journal of Clinical Oncology review of current management and collaborative future approaches in Ewing sarcoma and a COG report that adding vincristine and irinotecan to standard chemotherapy did not improve outcome in intermediate-risk rhabdomyosarcoma. His record links to the Euro Ewing 2012 trial.","asOf":"2026-09-08","links":[{"label":"Children's Oncology Group","url":"https://childrensoncologygroup.org"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hawkins%20DS%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Douglas%20S.%20Hawkins"}],"tags":[],"related":[],"cancers":["sarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["childrens-oncology-group"],"institutions":["fred-hutch"],"pathways":[],"terms":[],"trials":["euro-ewing-2012"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Group Chair, Children's Oncology Group; Professor of Pediatrics, Seattle Children's and University of Washington","institutionId":"childrens-oncology-group","specialisms":["Paediatric sarcoma","Ewing sarcoma","Cooperative group trials"],"profiles":[{"label":"Children's Oncology Group","url":"https://childrensoncologygroup.org"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hawkins%20DS%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Douglas%20S.%20Hawkins"}],"papers":[{"title":"Ewing Sarcoma: Current Management and Future Approaches Through Collaboration","journal":"Journal of Clinical Oncology","year":2015,"url":"https://doi.org/10.1200/JCO.2014.59.5256","doi":"10.1200/JCO.2014.59.5256"},{"title":"Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group","journal":"Journal of Clinical Oncology","year":2018,"url":"https://doi.org/10.1200/JCO.2018.77.9694","doi":"10.1200/JCO.2018.77.9694"}]},{"id":"drew-pardoll","kind":"person","name":"Drew M. Pardoll","aka":[],"tldr":"Immunologist who helped define the PD-1 pathway's role in cancer and built one of the largest immunotherapy institutes.","summary":"Drew M. Pardoll is Director of the Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins Hospital and the Sidney Kimmel Comprehensive Cancer Center. He is a tumour immunologist who helped define the role of the PD-1 pathway in cancer, co-discovering PD-L2 and contributing to the clinical development of PD-1 blockade. His selected paper reviews the blockade of immune checkpoints in cancer immunotherapy. He now directs one of the largest immunotherapy institutes, with continued interests in immune checkpoint inhibitors and cancer vaccines.","asOf":"2026-09-08","links":[{"label":"Bloomberg~Kimmel Institute","url":"https://www.hopkinsmedicine.org/kimmel-cancer-center/research/bloomberg-kimmel-institute-cancer-immunotherapy"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Pardoll%20DM%5BAuthor%5D"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["pd1","pdl1"],"drugs":[],"companies":[],"institutions":["johns-hopkins"],"pathways":["pd1-checkpoint"],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nature-reviews-cancer"],"dependsOn":[],"notes":[],"role":"Director, Bloomberg~Kimmel Institute for Cancer Immunotherapy","institutionId":"johns-hopkins","specialisms":["Tumour immunology","PD-1 pathway","Cancer vaccines"],"profiles":[{"label":"Bloomberg~Kimmel Institute","url":"https://www.hopkinsmedicine.org/kimmel-cancer-center/research/bloomberg-kimmel-institute-cancer-immunotherapy"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Pardoll%20DM%5BAuthor%5D"}],"papers":[{"title":"The blockade of immune checkpoints in cancer immunotherapy","journal":"Nature Reviews Cancer","year":2012,"url":"https://doi.org/10.1038/nrc3239","doi":"10.1038/nrc3239"},{"title":"Iwai and Honjo: tumours use PD-L1 to escape T cells, and blocking it restores attack","journal":"PNAS","year":2002,"url":"https://doi.org/10.1073/pnas.192461099","doi":"10.1073/pnas.192461099"},{"title":"Le 2015: PD-1 blockade works in tumours with mismatch-repair deficiency, whatever the organ","journal":"New England Journal of Medicine","year":2015,"url":"https://doi.org/10.1056/NEJMoa1500596","doi":"10.1056/NEJMoa1500596"},{"title":"Topalian 2012: the first large trial of a PD-1 antibody shows durable responses across melanoma, lung and kidney cancer","journal":"New England Journal of Medicine","year":2012,"url":"https://doi.org/10.1056/NEJMoa1200690","doi":"10.1056/NEJMoa1200690"}],"orcid":"0000-0001-6215-1013"},{"id":"drew-weissman","kind":"person","name":"Drew Weissman","aka":[],"tldr":"Drew Weissman is the Nobel laureate whose modified-mRNA discovery underlies mRNA vaccines and now in vivo CAR-T.","summary":"Drew Weissman is the Roberts Family Professor in Vaccine Research and Director of the Penn Institute for RNA Innovation at the Abramson Cancer Center, University of Pennsylvania. He is the Nobel laureate who, with Katalin Karikó, discovered that nucleoside modification lets messenger RNA evade innate immune sensing, the finding behind mRNA vaccines, recognised with the Nobel Prize in 2023. His selected paper reports the suppression of RNA recognition by Toll-like receptors through nucleoside modification. His laboratory now works on targeted lipid nanoparticles, including in vivo T-cell engineering that seeded the company Capstan, with relevance to personalised mRNA cancer vaccines and in vivo CAR-T.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Weissman%20D%5BAuthor%5D"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["neoantigen-mrna-vaccine","in-vivo-car-t"],"targets":[],"drugs":[],"companies":[],"institutions":["penn-abramson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Roberts Family Professor in Vaccine Research; Director, Penn Institute for RNA Innovation","institutionId":"penn-abramson","specialisms":["mRNA therapeutics","Lipid nanoparticles","In vivo cell engineering"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Weissman%20D%5BAuthor%5D"}],"papers":[{"title":"Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA","journal":"Immunity","year":2005,"url":"https://doi.org/10.1016/j.immuni.2005.06.008","doi":"10.1016/j.immuni.2005.06.008"}],"orcid":"0000-0002-1501-6510"},{"id":"dubravko-forcic","kind":"person","name":"Dubravko Forcic","aka":[],"tldr":"Dubravko Forcic is a Croatian virologist who works on vaccine virus strains and was joint first author of the 2024 self-experimental oncolytic virotherapy case report.","summary":"Dubravko Forcic works at the Centre for Research and Knowledge Transfer in Biotechnology at the University of Zagreb and at the Centre of Excellence for Virus Immunology and Vaccines. His published work concerns the vaccine virus strains made in Croatia, including the determination of the coding and non-coding nucleotide sequences of the Edmonston-Zagreb measles master seed and working seed lot, the strain used in paediatric vaccines for decades and the strain used in the 2024 case report.\n\nHe was joint first author, with the radiologist Karmen Mrsic, of the Vaccines case report describing self-experimental neoadjuvant oncolytic virotherapy in recurrent breast cancer, and shares its conceptualisation with Beata Halassy. Neither virus used in that protocol had been engineered for tumour selectivity; both were grown as clarified cell-culture supernatants in MRC-5 and Vero cells.","asOf":"2026-09-25","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Forcic%20D%5BAuthor%5D"},{"label":"University of Zagreb","url":"https://www.unizg.hr/"}],"tags":["virology","oncolytic-virus","croatia"],"related":[],"cancers":[],"sections":[],"technologies":["oncolytic-virus"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["beata-halassy"],"bottlenecks":[],"keyPapers":["paper-halassy-self-experiment-ovt-vaccines-2024"],"journals":[],"dependsOn":[],"notes":[],"role":"Virologist, Centre for Research and Knowledge Transfer in Biotechnology, University of Zagreb; Centre of Excellence for Virus Immunology and Vaccines, Zagreb","specialisms":["Virology","Measles and mumps vaccine strains","Virus genome sequencing","Oncolytic virotherapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Forcic%20D%5BAuthor%5D"},{"label":"University of Zagreb","url":"https://www.unizg.hr/"}],"papers":[{"title":"An unconventional case study of neoadjuvant oncolytic virotherapy for recurrent breast cancer","journal":"Vaccines","year":2024,"doi":"10.3390/vaccines12090958"},{"title":"Determination of the coding and non-coding nucleotide sequences of genuine Edmonston-Zagreb master seed and current working seed lot","journal":"Vaccine","year":2005,"doi":"10.1016/j.vaccine.2004.08.021"}]},{"id":"dung-le","kind":"person","name":"Dung T. Le","aka":[],"tldr":"First author of the studies that showed mismatch-repair-deficient tumours respond to PD-1 blockade regardless of origin.","summary":"Dung T. Le is Professor of Oncology and Co-Director of GI Cancer Immunotherapy at Johns Hopkins Hospital and the Sidney Kimmel Comprehensive Cancer Center. She is known as first author of the studies showing that mismatch-repair-deficient tumours respond to PD-1 blockade regardless of where they arise, leading the KEYNOTE-016 study and its extension that established pembrolizumab's tissue-agnostic activity. Her selected paper reports PD-1 blockade in tumours with mismatch-repair deficiency. She also works on GVAX and pancreatic cancer vaccines in colorectal and pancreatic cancer.","asOf":"2026-09-08","links":[{"label":"Hopkins profile","url":"https://www.hopkinsmedicine.org/profiles/details/dung-le"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Le%20DT%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["colorectal","pancreatic"],"sections":[],"technologies":[],"targets":["pd1"],"drugs":["pembrolizumab"],"companies":[],"institutions":["johns-hopkins"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Oncology; Co-Director, GI Cancer Immunotherapy","institutionId":"johns-hopkins","specialisms":["MSI-high cancers","Pancreatic cancer immunotherapy","Cancer vaccines"],"profiles":[{"label":"Hopkins profile","url":"https://www.hopkinsmedicine.org/profiles/details/dung-le"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Le%20DT%5BAuthor%5D"}],"papers":[{"title":"PD-1 blockade in tumors with mismatch-repair deficiency","journal":"New England Journal of Medicine","year":2015,"url":"https://doi.org/10.1056/NEJMoa1500596","doi":"10.1056/NEJMoa1500596"},{"title":"KEYNOTE-177: pembrolizumab instead of chemotherapy as first treatment for mismatch-repair-deficient metastatic colorectal cancer","journal":"New England Journal of Medicine","year":2020,"url":"https://doi.org/10.1056/NEJMoa2017699","doi":"10.1056/NEJMoa2017699"},{"title":"Le 2017: mismatch-repair deficiency predicts response to PD-1 blockade across twelve tumour types, leading to the first tissue-agnostic drug approval","journal":"Science","year":2017,"url":"https://doi.org/10.1126/science.aan6733","doi":"10.1126/science.aan6733"}],"orcid":"0000-0002-2110-7697"},{"id":"shelley-hwang","kind":"person","name":"E. Shelley Hwang","aka":[],"tldr":"Duke surgeon who led COMET, the trial testing whether women with low-risk DCIS can safely be monitored instead of having surgery straight away.","summary":"Shelley Hwang is a breast surgeon at Duke Cancer Institute whose research asks whether ductal carcinoma in situ is overtreated. She led the COMET trial, which randomised women with low-risk DCIS to guideline-concordant care or active monitoring with endocrine therapy, and was first author of its 2024 JAMA report showing that the rate of invasive cancer at two years was not worse with monitoring. She also leads laboratory work on the biology of DCIS progression.","asOf":"2026-09-18","links":[],"tags":["breast","surgery","de-escalation","trialist"],"related":[],"cancers":["ductal-carcinoma-in-situ","breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["duke-cancer-institute"],"pathways":[],"terms":[],"trials":["comet-dcis"],"people":[],"bottlenecks":[],"keyPapers":["paper-shelley-hwang-cancer-cell-2014","paper-asco-neoadjuvant-therapy-breast-guideline-jco-2021","paper-shelley-hwang-cancer-cell-2019"],"journals":[],"dependsOn":[],"notes":[],"role":"Breast surgical oncologist, Duke Cancer Institute","institutionId":"duke-cancer-institute","specialisms":["Ductal carcinoma in situ","Active monitoring","Surgical de-escalation"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hwang%5BAuthor%5D"}],"papers":[{"title":"Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells","journal":"Cancer Cell","year":2014,"url":"https://doi.org/10.1016/j.ccell.2014.09.006","doi":"10.1016/j.ccell.2014.09.006","note":"Europe PMC author record matched by affiliation (Duke Cancer Institute); 857 citations on Europe PMC."},{"title":"Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline","journal":"Journal of Clinical Oncology","year":2021,"url":"https://doi.org/10.1200/jco.20.03399","doi":"10.1200/jco.20.03399","note":"Europe PMC author record matched by affiliation (Duke Cancer Institute); 840 citations on Europe PMC."},{"title":"Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets","journal":"Cancer Cell","year":2019,"url":"https://doi.org/10.1016/j.ccell.2019.02.009","doi":"10.1016/j.ccell.2019.02.009","note":"Europe PMC author record matched by affiliation (Duke Cancer Institute); 818 citations on Europe PMC."}]},{"id":"ebrahim-delpassand","kind":"person","name":"Ebrahim S. Delpassand","aka":[],"tldr":"The nuclear medicine physician who founded and leads Excel Diagnostics in Houston, a radiopharmaceutical therapy centre that also runs early trials of new radioligands.","summary":"Ebrahim Delpassand is Chief Executive Officer and medical director of Excel Diagnostics and Nuclear Oncology Center in Houston, which its site describes as a Radiopharmaceutical Therapy Center of Excellence designated by the Society of Nuclear Medicine and Molecular Imaging, offering PET-CT and other imaging, radionuclide therapy and clinical trials. He has been an investigator on early trials of somatostatin and PSMA radioligands. His publications are listed on PubMed.","asOf":"2026-09-17","links":[{"label":"Excel Diagnostics","url":"https://www.exceldiagnostics.com/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Delpassand+ES%5BAuthor%5D"}],"tags":["leadership"],"related":[],"cancers":[],"sections":[],"technologies":["radioligand-therapy","psma-pet"],"targets":[],"drugs":[],"companies":[],"institutions":["excel-diagnostics-nuclear-oncology"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive Officer and Medical Director, Excel Diagnostics and Nuclear Oncology Center","institutionId":"excel-diagnostics-nuclear-oncology","specialisms":["Nuclear medicine","Radiopharmaceutical therapy","Molecular imaging","Radiopharmaceutical trials"],"profiles":[{"label":"Excel Diagnostics","url":"https://www.exceldiagnostics.com/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Delpassand+ES%5BAuthor%5D"}],"papers":[],"papersExpected":true},{"id":"eileen-oreilly","kind":"person","name":"Eileen M. O'Reilly","aka":[],"tldr":"Leading pancreatic cancer trialist, including the maintenance PARP-inhibitor and germline-BRCA studies.","summary":"Eileen M. O'Reilly holds the Winthrop Rockefeller Chair in Medical Oncology and is Section Head of Hepatopancreaticobiliary and Neuroendocrine Cancers at Memorial Sloan Kettering Cancer Center. She is a leading pancreatic cancer trialist, known for the maintenance PARP-inhibitor and germline BRCA studies in the disease. Her selected paper reports a randomised phase 2 trial of gemcitabine and cisplatin with or without veliparib in pancreatic adenocarcinoma with a germline BRCA or PALB2 mutation. She directs pancreatic and hepatobiliary cancer research at MSK and leads trials in BRCA-mutant pancreatic cancer and NCI cooperative group gastrointestinal studies.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=O'Reilly%20EM%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["pancreatic","cholangiocarcinoma"],"sections":[],"technologies":[],"targets":["brca","parp"],"drugs":["olaparib"],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Winthrop Rockefeller Chair in Medical Oncology; Section Head, Hepatopancreaticobiliary and Neuroendocrine Cancers","institutionId":"mskcc","specialisms":["Pancreatic cancer","Biliary cancer","BRCA-associated pancreatic cancer"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=O'Reilly%20EM%5BAuthor%5D"}],"papers":[{"title":"Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA/PALB2 mutation","journal":"Journal of Clinical Oncology","year":2020,"url":"https://doi.org/10.1200/JCO.19.02931","doi":"10.1200/JCO.19.02931"}],"orcid":"0000-0002-8076-9199"},{"id":"einar-gustafson","kind":"person","name":"Einar \"Jimmy\" Gustafson","aka":[],"tldr":"A 12-year-old lymphoma patient of Sidney Farber whose 1948 radio broadcast launched the Jimmy Fund, which has funded Dana-Farber for more than 75 years.","summary":"Einar Gustafson (1936-2001), a farm boy from New Sweden, Maine, was being treated for lymphoma by Sidney Farber at Children's Hospital Boston when, on 22 May 1948, he was interviewed on the national radio show Truth or Consequences under the pseudonym Jimmy while members of the Boston Braves gathered at his bedside. Listeners sent in more than $200,000 for a television set and for Farber's Children's Cancer Research Foundation, and the Jimmy Fund was born. His identity was kept private for fifty years; he survived his cancer, drove a truck, raised a family, and was reintroduced to the public in 1998. The Jimmy Fund remains the principal charitable arm of Dana-Farber Cancer Institute and the official charity of the Boston Red Sox.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Einar_Gustafson","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Einar_Gustafson"},{"label":"The Jimmy Fund","url":"https://www.jimmyfund.org/"}],"tags":["hero","patient"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["dana-farber"],"pathways":[],"terms":[],"trials":[],"people":["sidney-farber"],"bottlenecks":["b-funding-allocation","b-rare-cancers"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"The boy behind the Jimmy Fund","specialisms":["Paediatric lymphoma","Cancer fundraising","Childhood cancer"],"profiles":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Einar_Gustafson"},{"label":"The Jimmy Fund","url":"https://www.jimmyfund.org/"}],"papers":[]},{"id":"eitan-friedman","kind":"person","name":"Eitan Friedman","aka":[],"tldr":"Mapped which inherited cancer variants recur in which Israeli communities, and showed that outside the Ashkenazi founder panel there is no shortcut: you have to sequence.","summary":"Eitan Friedman's oncogenetics work at Sheba Medical Center's Meirav clinic is the systematic survey of what inherited cancer risk looks like across Israel's communities. With Laitman and colleagues he genotyped high-risk Ashkenazi, Balkan, North African, Yemenite and Asian (Iraqi and Iranian) Jews and found community-specific recurring variants: BRCA1 Tyr978X in 23 of 892 people of Iraqi and Iranian origin, BRCA1 c.981delAT in 7 of 264 of North African origin, BRCA1 A1708E in 8 of 282 of Balkan origin. The same group's study of 250 ethnically diverse high-risk Israeli families, screened after the common Jewish founders were excluded, found 19 different pathogenic BRCA1/2 variants and concluded that there are no predominant recurring variants across these populations, which is the argument for sequencing rather than a founder panel outside the Ashkenazi population. His recent work covers hormone therapy after oophorectomy, prostate screening in male carriers and breast surveillance in young carriers.","asOf":"2026-09-25","links":[{"label":"Sheba Medical Center","url":"https://www.shebaonline.org"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Friedman%20E%5BAuthor%5D%20BRCA%20Sheba"}],"tags":["clinician-scientist","genetics"],"related":[],"cancers":["breast-hr-positive","ovarian"],"sections":["prevention","diagnostics"],"technologies":["germline-testing"],"targets":["brca"],"drugs":[],"companies":[],"institutions":["sheba","tel-aviv-university"],"pathways":[],"terms":["founder-variant"],"trials":[],"people":[],"bottlenecks":["b-hereditary-risk"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Oncogeneticist, Meirav High Risk Clinic, Sheba Medical Center; professor, Gray Faculty of Medical and Health Sciences, Tel Aviv University","institutionId":"sheba","specialisms":["Cancer genetics","BRCA founder variants","Non-Ashkenazi Jewish and Arab cancer genetics","High-risk surveillance"],"profiles":[{"label":"Sheba Medical Center","url":"https://www.shebaonline.org"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Friedman%20E%5BAuthor%5D%20BRCA%20Sheba"}],"papers":[{"title":"Germline mutations in BRCA1 and BRCA2 genes in ethnically diverse high risk families in Israel","journal":"Breast Cancer Research and Treatment","year":2011,"doi":"10.1007/s10549-010-1217-0"},{"title":"Recurring founder mutations in BRCA1 and BRCA2 in ethnically diverse Jewish populations","journal":"Breast Cancer Research and Treatment","year":2012,"doi":"10.1007/s10549-012-2006-8"}]},{"id":"eleftherios-mamounas","kind":"person","name":"Eleftherios P. Mamounas","aka":[],"tldr":"Surgeon who chairs the NRG Oncology breast committee and co-led the KATHERINE and B-42 trials.","summary":"Eleftherios Mamounas (Orlando Health) chairs the NRG Oncology Breast Committee and was NSABP protocol chair for B-42 (extended letrozole) and co-chair of KATHERINE, which established adjuvant T-DM1 for residual disease after neoadjuvant therapy. He has led work using the 21-gene assay to predict locoregional recurrence and radiotherapy benefit. His current trials test omission of surgery and radiotherapy after excellent neoadjuvant response.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mamounas%20EP%5BAuthor%5D%20breast%20NSABP"}],"tags":["breast","surgery","nrg-oncology"],"related":[],"cancers":["breast-her2-positive","breast-hr-positive"],"sections":[],"technologies":[],"targets":[],"drugs":["trastuzumab-emtansine"],"companies":[],"institutions":["orlando-health-cancer-institute"],"pathways":[],"terms":[],"trials":["katherine"],"people":[],"bottlenecks":[],"keyPapers":["paper-katherine-nejm-2019"],"journals":[],"dependsOn":[],"notes":[],"role":"Medical Director, Comprehensive Breast Program, Orlando Health Cancer Institute; Chair, NRG Oncology Breast Committee","institutionId":"orlando-health-cancer-institute","specialisms":["Breast surgical oncology","Adjuvant and neoadjuvant trials","Genomic risk assays","Cooperative-group leadership"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mamounas%20EP%5BAuthor%5D%20breast%20NSABP"}],"papers":[{"title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer (KATHERINE)","journal":"NEJM","year":2019,"doi":"10.1056/NEJMoa1814017"},{"title":"Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42)","journal":"Lancet Oncology","year":2019,"doi":"10.1016/S1470-2045(18)30621-1"}]},{"id":"elena-elez","kind":"person","name":"Elena Élez","aka":[],"tldr":"Elena Élez is a colorectal cancer investigator who led the BREAKWATER trial's clinical programme.","summary":"Elena Élez is Head of the Gastrointestinal and Endocrine Tumours Group at the Vall d'Hebron Institute of Oncology (VHIO) in Barcelona. Her specialisms are colorectal cancer, BRAF- and KRAS-mutant disease and precision oncology. She was a principal investigator of BREAKWATER, the trial of encorafenib in BRAF-mutant colorectal cancer, and of trials of KRAS G12C inhibitors in colorectal cancer. Her papers include the updated results and subgroup analyses of the BEACON study establishing encorafenib plus cetuximab in previously treated BRAF V600E-mutant metastatic colorectal cancer, a review of prognosis and treatment in BRAF mutant colorectal cancer, and a phase Ib dose-escalation study of encorafenib and cetuximab with or without alpelisib. Her publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Elez%20E%5BAuthor%5D%20colorectal%20BRAF"}],"tags":[],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":["braf","kras"],"drugs":["encorafenib"],"companies":[],"institutions":["vall-dhebron"],"pathways":[],"terms":[],"trials":["breakwater"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Head, Gastrointestinal and Endocrine Tumours Group, VHIO","institutionId":"vall-dhebron","specialisms":["Colorectal cancer","BRAF and KRAS-mutant disease","Precision oncology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Elez%20E%5BAuthor%5D%20colorectal%20BRAF"}],"papers":[{"title":"Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study","journal":"Journal of Clinical Oncology","year":2021,"doi":"10.1200/jco.20.02088"},{"title":"BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives","journal":"Annals of Oncology","year":2017,"doi":"10.1093/annonc/mdx401"},{"title":"A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF -Mutant Colorectal Cancer","journal":"Cancer Discovery","year":2017,"doi":"10.1158/2159-8290.cd-16-0795"},{"title":"BREAKWATER: encorafenib plus cetuximab with chemotherapy as first treatment for BRAF V600E-mutated colorectal cancer","journal":"New England Journal of Medicine","year":2025,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BREAKWATER+encorafenib+cetuximab+mFOLFOX6+colorectal"},{"title":"KEYNOTE-177: pembrolizumab instead of chemotherapy as first treatment for mismatch-repair-deficient metastatic colorectal cancer","journal":"New England Journal of Medicine","year":2020,"url":"https://doi.org/10.1056/NEJMoa2017699","doi":"10.1056/NEJMoa2017699"}]},{"id":"elena-garralda","kind":"person","name":"Elena Garralda","aka":[],"tldr":"Elena Garralda leads one of Europe's largest phase 1 units.","summary":"Elena Garralda is Director of the Early Drug Development Unit (UITM) at the Vall d'Hebron Institute of Oncology (VHIO) in Barcelona, one of Europe's largest phase 1 units. Her specialisms are phase 1 trials, immuno-oncology and novel modalities, including bispecific antibodies and antibody-drug conjugates. She runs first-in-human trials of ADCs, bispecifics, cell therapies and immunotherapies. Her papers include the Nature Medicine phase 1 trial of OMO-103, a MYC-targeting agent, in solid tumours, a study of the cytokine agent NIZ985 alone and with an anti-PD-1 agent in advanced solid tumours or lymphoma, and the ARROW phase 1/2 study of pralsetinib in RET fusion-positive non-small-cell lung cancer. Her publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Garralda%20E%5BAuthor%5D%20phase%20I"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["bispecific-antibody","adc"],"targets":[],"drugs":[],"companies":[],"institutions":["vall-dhebron"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Early Drug Development Unit (UITM), VHIO","institutionId":"vall-dhebron","specialisms":["Phase 1 trials","Immuno-oncology","Novel modalities"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Garralda%20E%5BAuthor%5D%20phase%20I"}],"papers":[{"title":"MYC targeting by OMO-103 in solid tumors: a phase 1 trial","journal":"Nature Medicine","year":2024,"doi":"10.1038/s41591-024-02805-1"},{"title":"Phase I/Ib study evaluating safety, efficacy, pharmacokinetics and pharmacodynamics of NIZ985 monotherapy and in combination with an anti-PD-1 agent in patients with advanced solid tumors or lymphoma","journal":"European Journal of Cancer","year":2026,"doi":"10.1016/j.ejca.2026.116899"},{"title":"Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study","journal":"The Lancet Oncology","year":2021,"doi":"10.1016/s1470-2045(21)00247-3"}],"orcid":"0000-0002-4412-7842"},{"id":"eli-broad","kind":"person","name":"Eli Broad","aka":["Eli and Edythe Broad"],"tldr":"Eli and Edythe Broad gave $100 million in 2004 to start the Broad Institute and kept giving until their total passed $700 million in 2013; the genomics it produced underpins much of precision oncology.","summary":"Eli Broad (1933-2021) and Edythe Broad founded the Broad Institute of MIT and Harvard with a $100 million gift in 2004, followed by a second $100 million in 2005 ('Broads' Dollars Doubled', in the Institute's words), an endowment gift in 2008 that made it permanent, and a further $100 million in 2013 which, the Institute stated, brought their total contributions to $700 million, making them the second largest donors ever to a university, hospital or research institute for biomedical research. The Institute is not a cancer centre, but its cancer programme produced the Cancer Cell Line Encyclopedia, the Dependency Map and much of The Cancer Genome Atlas, and its sequencing and analysis tools are used in nearly every tumour genomics study. The Broads' gifts are the clearest case of disease-agnostic science philanthropy paying off for cancer.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Eli_Broad","links":[{"label":"Broad Institute: next decade launched with new $100M gift (2013, archived)","url":"https://web.archive.org/web/2014/https://www.broadinstitute.org/news/5346"},{"label":"Broad Institute","url":"https://www.broadinstitute.org/"}],"tags":["hero","donor"],"related":[],"cancers":[],"sections":[],"technologies":["cgp"],"targets":[],"drugs":[],"companies":[],"institutions":["broad-institute"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-funding-allocation","b-data-silos","b-undruggable-targets"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"With Edythe Broad, founder of the Broad Institute of MIT and Harvard","specialisms":["Genomics","Institute building","Cancer genomics"],"profiles":[],"papers":[]},{"id":"eli-sprecher","kind":"person","name":"Eli Sprecher","aka":[],"tldr":"Dermatologist and geneticist who has been chief executive of Tel Aviv Sourasky Medical Center, a major Israeli academic hospital, since 2024.","summary":"Professor Eli Sprecher is CEO of Tel Aviv Sourasky Medical Center (Ichilov), a major academic medical centre in Tel Aviv, having succeeded Ronni Gamzu in 2024. He previously headed the hospital's Dermatology Division (2008 to 2024) and served as Deputy CEO for patient safety and for research and development. His research addresses the genetic basis of skin diseases, including the mechanisms of fingerprint formation.","asOf":"2026-09-10","links":[{"label":"Source: Sourasky Executive Leadership page","url":"https://www.tasmc.org.il/en/aboutl/management/"}],"tags":["leadership","clinician-scientist","dermatology","genetics"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["tel-aviv-sourasky"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"CEO, Tel Aviv Sourasky Medical Center (Ichilov)","institutionId":"tel-aviv-sourasky","specialisms":["Dermatology","Genetics of skin disease","Hospital leadership"],"profiles":[{"label":"Executive Leadership page","url":"https://www.tasmc.org.il/en/aboutl/management/"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Eli_Sprecher"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sprecher+E%5BAuthor%5D"}],"papers":[{"title":"Genetic Determinants of Susceptibility to UV Light-Associated Skin Cancer","journal":"Exogenous Dermatology","year":2004,"doi":"10.1159/000091899"}]},{"id":"eliane-piaggio","kind":"person","name":"Eliane Piaggio","aka":[],"tldr":"Eliane Piaggio is an immunologist studying regulatory T cells and immune profiling to guide immunotherapy.","summary":"Eliane Piaggio is Team Leader for Translational Immunotherapy at Institut Curie in Paris. An immunologist, her specialisms are tumour immunology, regulatory T cells and immunotherapy biomarkers. Her group characterises intratumoural regulatory T cells and the immune signatures that predict response to immunotherapy. Her papers include a study showing that PI3K pathway inhibition increases the immune infiltrate in muscle-invasive bladder cancer, a Nature Communications report that CD8+ T cell responsiveness to anti-PD-1 in melanoma is epigenetically regulated by Suv39h1, and a review of humanised mouse models for evaluating cancer immunotherapeutics. Her publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Piaggio%20E%5BAuthor%5D%20regulatory%20T%20cells%20tumor"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["institut-curie"],"pathways":["pd1-checkpoint"],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["oncoimmunology"],"dependsOn":[],"notes":[],"role":"Team Leader, Translational Immunotherapy, Institut Curie","institutionId":"institut-curie","specialisms":["Tumour immunology","Regulatory T cells","Immunotherapy biomarkers"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Piaggio%20E%5BAuthor%5D%20regulatory%20T%20cells%20tumor"}],"papers":[{"title":"Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer","journal":"OncoImmunology","year":2019,"doi":"10.1080/2162402x.2019.1581556"},{"title":"CD8+T cell responsiveness to anti-PD-1 is epigenetically regulated by Suv39h1 in melanomas","journal":"Nature Communications","year":2022,"doi":"10.1038/s41467-022-31504-z"},{"title":"Humanized Mouse Models to Evaluate Cancer Immunotherapeutics","journal":"Annual Review of Cancer Biology","year":2021,"doi":"10.1146/annurev-cancerbio-050520-100526"}]},{"id":"elias-jabbour","kind":"person","name":"Elias Jabbour","aka":[],"tldr":"Leukaemia specialist who built chemotherapy-light regimens combining inotuzumab, blinatumomab and ponatinib for adult ALL.","summary":"Elias Jabbour led the MD Anderson regimens combining low-intensity chemotherapy with inotuzumab ozogamicin and blinatumomab in older adults with ALL, and the chemotherapy-free ponatinib plus blinatumomab regimen for Philadelphia-positive ALL, which produce complete molecular remissions in most patients and challenge the need for transplant. He was senior author of INO-VATE and leads adult ALL research at MD Anderson.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Jabbour%20E%5BAuthor%5D%20acute%20lymphoblastic%20leukemia%20blinatumomab"}],"tags":["all","immunotherapy","chemo-free"],"related":[],"cancers":["all-leukemia"],"sections":[],"technologies":["t-cell-engager","adc"],"targets":["cd19","cd3"],"drugs":["blinatumomab"],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":["ino-vate"],"people":[],"bottlenecks":[],"keyPapers":["paper-ino-vate-inotuzumab-all-nejm-2016"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Leukemia, MD Anderson Cancer Center","institutionId":"md-anderson","specialisms":["Adult acute lymphoblastic leukaemia","Antibody and bispecific therapy","Chemotherapy-free regimens","Philadelphia-positive ALL"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Jabbour%20E%5BAuthor%5D%20acute%20lymphoblastic%20leukemia%20blinatumomab"}],"papers":[{"title":"Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial","journal":"Lancet Haematology","year":2023,"doi":"10.1016/S2352-3026(22)00319-2"},{"title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia (INO-VATE)","journal":"NEJM","year":2016,"doi":"10.1056/NEJMoa1509277"}],"orcid":"0000-0003-4465-6119"},{"id":"eliezer-van-allen","kind":"person","name":"Eliezer M. Van Allen","aka":[],"tldr":"Computational oncologist who built open tools for interpreting tumour genomes and predicting response.","summary":"Eliezer M. Van Allen is Chief of the Division of Population Sciences at Dana-Farber Brigham Cancer Center and an Associate Member of the Broad Institute. He is a computational oncologist known for building open tools that interpret tumour genomes and predict response to treatment. His selected paper reports the genomic correlates of response to CTLA-4 blockade in metastatic melanoma. His laboratory, spanning Dana-Farber and the Broad, now studies genomic determinants of therapeutic response and resistance in melanoma and prostate cancer, and builds open clinical interpretation and decision-support tools.","asOf":"2026-09-08","links":[{"label":"Van Allen lab","url":"https://vanallenlab.dana-farber.org"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Van%20Allen%20EM%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["melanoma","prostate"],"sections":[],"technologies":["cgp","ai-trial-matching"],"targets":[],"drugs":[],"companies":[],"institutions":["dana-farber"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief, Division of Population Sciences; Associate Member, Broad Institute","institutionId":"dana-farber","specialisms":["Computational oncology","Cancer genomics","Precision medicine","AI in oncology"],"profiles":[{"label":"Van Allen lab","url":"https://vanallenlab.dana-farber.org"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Van%20Allen%20EM%5BAuthor%5D"}],"papers":[{"title":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma","journal":"Science","year":2015,"url":"https://doi.org/10.1126/science.aad0095","doi":"10.1126/science.aad0095"}],"orcid":"0000-0002-0201-4444"},{"id":"weiderpass-elisabete","kind":"person","name":"Elisabete Weiderpass","aka":[],"tldr":"Leads the WHO's cancer research agency, which classifies carcinogens and publishes the world's cancer statistics.","summary":"Elisabete Weiderpass is Director of the International Agency for Research on Cancer, the WHO's cancer research agency. A cancer epidemiologist, she has directed IARC since 2019, overseeing the Monographs programme that classifies carcinogens, the GLOBOCAN statistics that report the world's cancer burden, its cohort studies and the WHO Classification of Tumours. Her publications include a review asking whether early-onset cancer is an emerging global epidemic, a worldwide analysis of cervical cancer incidence and mortality, and a description of the Global Breast Cancer Initiative. Her interests span cancer epidemiology, prevention and research leadership.","asOf":"2026-09-08","links":[{"label":"IARC","url":"https://www.iarc.who.int"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Weiderpass%20E%5BAuthor%5D"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["chemoprevention"],"targets":[],"drugs":[],"companies":[],"institutions":["iarc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["lancet-global-health"],"dependsOn":[],"notes":[],"role":"Director, International Agency for Research on Cancer (WHO)","institutionId":"iarc","specialisms":["Cancer epidemiology","Global cancer burden","Prevention","Research leadership"],"profiles":[{"label":"IARC","url":"https://www.iarc.who.int"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Weiderpass%20E%5BAuthor%5D"}],"papers":[{"title":"Is early-onset cancer an emerging global epidemic? Current evidence and future implications","journal":"Nature Reviews Clinical Oncology","year":2022,"doi":"10.1038/s41571-022-00672-8"},{"title":"Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis","journal":"The Lancet Global Health","year":2020,"doi":"10.1016/s2214-109x(19)30482-6"},{"title":"The Global Breast Cancer Initiative: a strategic collaboration to strengthen health care for non-communicable diseases","journal":"The Lancet Oncology","year":2021,"doi":"10.1016/s1470-2045(21)00071-1"}]},{"id":"elisabeth-kubler-ross","kind":"person","name":"Elisabeth Kübler-Ross","aka":[],"tldr":"Her 1969 book On Death and Dying, based on interviews with terminally ill patients in a Chicago hospital, made it acceptable for doctors to talk with patients about dying and helped launch the American hospice movement.","summary":"Elisabeth Kübler-Ross (1926-2004), a Swiss-born psychiatrist, began interviewing dying patients in front of medical students and clergy at the University of Chicago's Billings Hospital in the mid-1960s, at a time when many physicians did not tell patients they had cancer. On Death and Dying (1969) reported what the patients said and proposed the five stages of grief, a framework that is now debated but that gave a vocabulary to the experience. The book, a 1969 Life magazine feature and her lectures shifted medical culture towards disclosure and towards care for the dying, and she was an early champion of hospice in the United States, testifying to the Senate in 1972. She later became controversial for her interest in the afterlife, but her early work remains a foundation of psycho-oncology and palliative care.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Elisabeth_K%C3%BCbler-Ross","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Elisabeth_K%C3%BCbler-Ross"},{"label":"Elisabeth Kübler-Ross Foundation","url":"https://www.ekrfoundation.org/"}],"tags":["hero","pioneer","advocate"],"related":[],"cancers":[],"sections":["supportive-care"],"technologies":["hospice-end-of-life","psycho-oncology"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-palliative","b-patient-voice"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Psychiatrist who made the dying patient's experience a subject of medicine","specialisms":["Psychiatry","Death and dying","Hospice care"],"profiles":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Elisabeth_K%C3%BCbler-Ross"},{"label":"Elisabeth Kübler-Ross Foundation","url":"https://www.ekrfoundation.org/"}],"papers":[{"title":"A Letter from Dr. Elisabeth Kubler-Ross","journal":"Journal of Palliative Care","year":1988,"doi":"10.1177/082585978800400402"}]},{"id":"elisabeth-schorb","kind":"person","name":"Elisabeth Schorb","aka":[],"tldr":"Internal medicine oncologist who directs the Comprehensive Cancer Center Freiburg and heads its clinical trials unit.","summary":"PD Dr Elisabeth Schorb is Direktorin und Sprecherin of the Tumorzentrum Freiburg - CCCF, the certified oncology centre of excellence of the University Medical Center Freiburg. She is a senior physician in the Department of Internal Medicine I and heads its clinical trials centre and early clinical trials unit. The CCCF executive board she leads includes Justus Duyster (medical oncology), Stefan Fichtner-Feigl (surgical oncology), Melanie Börries (data-driven medicine), Michael Quante (prevention and patient participation) and Andreas Rimner (scientific director since 2025).","asOf":"2026-09-10","links":[{"label":"Source: CCCF leadership page","url":"https://www.uniklinik-freiburg.de/cccf/ueber-uns/leitung.html"}],"tags":["leadership","clinician-scientist","cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ccc-freiburg"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["lancet-haematology","blood-advances"],"dependsOn":[],"notes":[],"role":"Director and Spokesperson of the Tumorzentrum Freiburg - CCCF","institutionId":"ccc-freiburg","specialisms":["Haematology and oncology","Clinical trials","Cancer centre leadership"],"profiles":[{"label":"Institution leadership page","url":"https://www.uniklinik-freiburg.de/cccf/ueber-uns/leitung.html"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schorb+E%5BAuthor%5D"}],"papers":[{"title":"High-dose chemotherapy and autologous haematopoietic stem-cell transplantation in older, fit patients with primary diffuse large B-cell CNS lymphoma (MARTA): a single-arm, phase 2 trial","journal":"The Lancet Haematology","year":2024,"doi":"10.1016/s2352-3026(23)00371-x"},{"title":"High-dose chemotherapy and autologous stem cell transplant in elderly patients with primary CNS lymphoma: a pilot study","journal":"Blood Advances","year":2020,"doi":"10.1182/bloodadvances.2020002064"},{"title":"Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B‐cell lymphoma of the central nervous system – an international study of feasibility and efficacy in routine clinical practice","journal":"British Journal of Haematology","year":2020,"doi":"10.1111/bjh.16451"}],"orcid":"0000-0003-0948-2125"},{"id":"elisabetta-zanon","kind":"person","name":"Elisabetta Zanon","aka":[],"tldr":"Chief Executive Officer of the European Cancer Organisation, coordinating Europe's oncology community on cancer policy.","summary":"Elisabetta Zanon is Chief Executive Officer of the European Cancer Organisation, the Brussels-based federation of oncology professional societies and patient organisations. She leads the organisation's engagement with EU institutions on cancer policy, including implementation of Europe's Beating Cancer Plan.","asOf":"2026-09-10","links":[{"label":"Society page","url":"https://www.europeancancer.org/resource/team.html"}],"tags":["leadership","cancer policy","advocacy"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ecco"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive Officer","institutionId":"ecco","specialisms":["Cancer policy","EU health policy","Advocacy"],"profiles":[{"label":"Society page","url":"https://www.europeancancer.org/resource/team.html"}],"papers":[]},{"id":"elizabeth-mittendorf","kind":"person","name":"Elizabeth A. Mittendorf","aka":[],"tldr":"Surgeon-scientist who led IMpassion031 and studies of surgery de-escalation after neoadjuvant immunotherapy.","summary":"Elizabeth Mittendorf led IMpassion031, showing neoadjuvant atezolizumab plus chemotherapy raises pathological complete response in TNBC regardless of PD-L1 status, and ran the early HER2 peptide vaccine trials. As a breast surgeon she leads Alliance trials asking whether axillary surgery and radiotherapy can be omitted after excellent neoadjuvant response. She directs breast immuno-oncology at Dana-Farber.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mittendorf%20EA%5BAuthor%5D%20breast%20immunotherapy"}],"tags":["tnbc","surgery","immunotherapy"],"related":[],"cancers":["tnbc"],"sections":[],"technologies":["checkpoint-inhibitor","sentinel-node"],"targets":[],"drugs":["atezolizumab"],"companies":[],"institutions":["dana-farber"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["cancer-immunology-research"],"dependsOn":[],"notes":[],"role":"Director, Breast Immuno-Oncology Program, Dana-Farber Brigham Cancer Center","institutionId":"dana-farber","specialisms":["Breast surgical oncology","Immunotherapy","Neoadjuvant trials","Tumour immunology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mittendorf%20EA%5BAuthor%5D%20breast%20immunotherapy"}],"papers":[{"title":"Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031)","journal":"Lancet","year":2020,"doi":"10.1016/S0140-6736(20)31953-X"},{"title":"PD-L1 expression in triple-negative breast cancer","journal":"Cancer Immunology Research","year":2014,"doi":"10.1158/2326-6066.CIR-13-0127"}]},{"id":"elizabeth-jaffee","kind":"person","name":"Elizabeth M. Jaffee","aka":[],"tldr":"Pancreatic cancer immunologist who developed the GVAX vaccine and led national cancer policy panels.","summary":"Elizabeth M. Jaffee is Deputy Director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and Co-Director of the Skip Viragh Center for Pancreas Cancer. She is a pancreatic cancer immunologist known for developing the GVAX pancreas vaccine and for studies of how to convert immunologically cold pancreatic tumours into ones the immune system can see. Her selected paper shows that immunotherapy converts non-immunogenic pancreatic tumours into immunogenic foci of immune regulation. A former AACR president and chair of the NCI's National Cancer Advisory Board, she continues to work on cancer vaccines and checkpoint inhibitors in pancreatic cancer.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Elizabeth_Jaffee","links":[{"label":"Hopkins profile","url":"https://www.hopkinsmedicine.org/profiles/details/elizabeth-jaffee"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Jaffee%20EM%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":["shared-antigen-vaccine","checkpoint-inhibitor"],"targets":[],"drugs":[],"companies":[],"institutions":["johns-hopkins"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["cancer-immunology-research"],"dependsOn":[],"notes":[],"role":"Deputy Director, Sidney Kimmel Comprehensive Cancer Center; Co-Director, Skip Viragh Center for Pancreas Cancer","institutionId":"johns-hopkins","specialisms":["Pancreatic cancer","Cancer vaccines","Tumour immunology"],"profiles":[{"label":"Hopkins profile","url":"https://www.hopkinsmedicine.org/profiles/details/elizabeth-jaffee"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Jaffee%20EM%5BAuthor%5D"}],"papers":[{"title":"Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation","journal":"Cancer Immunology Research","year":2014,"url":"https://doi.org/10.1158/2326-6066.CIR-14-0027","doi":"10.1158/2326-6066.CIR-14-0027"}]},{"id":"ellen-copson","kind":"person","name":"Ellen Copson","aka":[],"tldr":"First author of POSH, the UK prospective cohort of young-onset breast cancer that showed germline BRCA carriers did no worse than non-carriers, and the ones with triple-negative disease did better in the first two years.","summary":"Ellen Copson qualified from the United Medical and Dental Schools of Guy's and St Thomas' in 1996, trained in medical oncology in Southampton from 2001 and has been a consultant medical oncologist treating breast cancer at University Hospital Southampton since 2009, returning to academic medicine in 2012; the University of Southampton lists her as Professor Ellen Copson. Her consultant page describes a particular interest in familial breast cancer and its diagnosis and management. She was first author of POSH (Lancet Oncology 2018), the prospective cohort of 2,733 women diagnosed with breast cancer at 40 or under across 127 UK hospitals, which found no difference in overall survival between germline BRCA carriers and non-carriers, and a survival advantage for carriers with triple-negative disease in the first two years, evidence that informs the timing of risk-reducing surgery after a triple-negative diagnosis.","asOf":"2026-09-24","links":[{"label":"University Hospital Southampton consultant page","url":"https://www.uhs.nhs.uk/for-patients/find-your-consultant/dr-ellen-copson"},{"label":"University of Southampton profile","url":"https://www.southampton.ac.uk/people/5x2clr/professor-ellen-copson"}],"tags":["breast","oncogenetics","uk"],"related":["jean-abraham"],"cancers":["tnbc","breast-cancer"],"sections":[],"technologies":[],"targets":["brca"],"drugs":[],"companies":[],"institutions":["southampton-cancer"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology, University of Southampton; Consultant Medical Oncologist (breast), University Hospital Southampton","institutionId":"southampton-cancer","specialisms":["Early and metastatic breast cancer","Familial and young-onset breast cancer","Oncogenetics","Host factors and treatment response"],"profiles":[{"label":"University Hospital Southampton consultant page","url":"https://www.uhs.nhs.uk/for-patients/find-your-consultant/dr-ellen-copson"},{"label":"University of Southampton profile","url":"https://www.southampton.ac.uk/people/5x2clr/professor-ellen-copson"}],"papers":[{"title":"Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study","journal":"Lancet Oncology","year":2018,"doi":"10.1016/s1470-2045(17)30891-4"}]},{"id":"ellen-stovall","kind":"person","name":"Ellen L. Stovall","aka":[],"tldr":"Led the survivorship movement's organisation for sixteen years and co-edited the Institute of Medicine report that defined what survivorship care is.","summary":"Ellen Stovall led the National Coalition for Cancer Survivorship as chief executive from 1992 to 2008, the period in which the organisation moved to Washington, founded the Cancer Leadership Council, held the first national congress on cancer survivorship in 1995, and published Imperatives for Quality Cancer Care, the document the coalition's history credits with prompting the National Cancer Institute's director to establish the Office of Cancer Survivorship in 1996.\n\nThe coalition held one of two consumer seats on the Institute of Medicine's National Cancer Policy Board from 1996; its history records that Stovall served as vice-chair of the Institute of Medicine's Committee on Survivorship and co-edited its report on adult cancer survivorship. She was one of three editors, with Maria Hewitt and Sheldon Greenfield, of \"From Cancer Patient to Cancer Survivor: Lost in Transition\" in 2006. That report defined survivorship care as prevention, surveillance, intervention and coordination, and its second recommendation created the survivorship care plan.\n\nShe wrote and spoke as a person who had had cancer as well as an advocate; her remarks to the NCI and American Cancer Society survivorship symposium in June 2002 were published in Cancer in 2005. Oncology Times published \"Remembering Cancer Advocate Ellen Stovall\" in February 2016. ASCO's Ellen L. Stovall Award and Lecture for Advancement of Cancer Survivorship Care carries her name.","asOf":"2026-10-02","links":[{"label":"National Coalition for Cancer Survivorship (now Cancer Nation): Our History","url":"https://canceradvocacy.org/about/our-history/"},{"label":"Institute of Medicine and National Research Council, From Cancer Patient to Cancer Survivor: Lost in Transition (National Academies Press 2006)","url":"https://doi.org/10.17226/11468"},{"label":"Eastman, Remembering cancer advocate Ellen Stovall (Oncology Times 2016;38:18)","url":"https://doi.org/10.1097/01.COT.0000480908.36011.cf"}],"tags":["survivorship","history","advocacy"],"related":["rejuv-history-survivorship-movement","rejuv-history-lost-in-transition","rejuv-history-seasons-of-survival","survivorship-care-plan","rejuvenation-roadmap"],"cancers":[],"sections":["rejuvenation","supportive-care"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Cancer survivor and advocate; chief executive of the National Coalition for Cancer Survivorship from 1992 to 2008","specialisms":["Cancer survivorship","Quality of cancer care","Patient advocacy","Health policy"],"profiles":[{"label":"National Coalition for Cancer Survivorship: Our History","url":"https://canceradvocacy.org/about/our-history/"}],"papers":[{"title":"From Cancer Patient to Cancer Survivor: Lost in Transition (co-editor, with Maria Hewitt and Sheldon Greenfield)","journal":"National Academies Press","year":2006,"url":"https://doi.org/10.17226/11468","doi":"10.17226/11468"},{"title":"Remarks of Ellen Stovall, NCI/ACS Survivorship Symposium June 2002","journal":"Cancer","year":2005,"url":"https://doi.org/10.1002/cncr.21243","doi":"10.1002/cncr.21243"}]},{"id":"emer-cooke","kind":"person","name":"Emer Cooke","aka":[],"tldr":"Executive Director of the European Medicines Agency since November 2020, overseeing EU approval of cancer medicines.","summary":"Emer Cooke has been Executive Director of the European Medicines Agency since 16 November 2020. A pharmacist by training, she previously led regulation of medicines and health technologies at the World Health Organization and held earlier roles at the EMA and the European Commission. She heads the agency responsible for the scientific evaluation and supervision of medicines, including oncology products, across the European Union.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.ema.europa.eu/en/about-us/who-we-are/executive-director"}],"tags":["leadership","regulation","drug approval"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["who"],"pathways":[],"terms":["regulatory-agencies"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Executive Director","institutionId":"ema","specialisms":["Medicines regulation","Regulatory science","Public health policy"],"profiles":[{"label":"Institution profile","url":"https://www.ema.europa.eu/en/about-us/who-we-are/executive-director"}],"papers":[{"title":"Real-World Evidence in EU Medicines Regulation: Enabling Use and Establishing Value","journal":"Clin Pharmacol Ther","year":2022,"url":"https://doi.org/10.1002/cpt.2479","doi":"10.1002/cpt.2479","note":"Europe PMC author record matched by affiliation"},{"title":"The European Medicines Agency's EU conditional marketing authorisations for COVID-19 vaccines","journal":"Lancet","year":2021,"url":"https://doi.org/10.1016/s0140-6736(21)00085-4","doi":"10.1016/s0140-6736(21)00085-4","note":"Europe PMC author record matched by affiliation"},{"title":"Clinical Evidence 2030","journal":"Clin Pharmacol Ther","year":2025,"url":"https://doi.org/10.1002/cpt.3596","doi":"10.1002/cpt.3596","note":"Europe PMC author record matched by affiliation"}]},{"id":"emil-frei","kind":"person","name":"Emil \"Tom\" Frei III","aka":[],"tldr":"With Emil Freireich he showed that combinations of drugs could cure childhood leukaemia, then extended the idea to Hodgkin lymphoma and to adjuvant treatment after surgery.","summary":"Emil Frei III (1924-2013) arrived at the National Cancer Institute in 1955 and, with Emil Freireich, ran the first randomised trials in leukaemia and the VAMP combination that produced the first cures of childhood acute lymphoblastic leukaemia. He argued from bacterial resistance to tuberculosis that cancers should be attacked with several drugs at once, a principle applied at the NCI in the MOPP regimen that made advanced Hodgkin lymphoma curable. He moved to MD Anderson in 1965 and in 1972 became director and physician-in-chief of the Sidney Farber Cancer Center in Boston, later Dana-Farber, where he led work on adjuvant chemotherapy for osteosarcoma and breast cancer and high-dose therapy. He received the Lasker Award in 1972 with Freireich, Pinkel and others for the cure of childhood leukaemia.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Emil_Frei","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Emil_Frei"},{"label":"Dana-Farber Cancer Institute","url":"https://www.dana-farber.org/"}],"tags":["hero","pioneer"],"related":[],"cancers":["all-leukemia","hodgkin-lymphoma","osteosarcoma"],"sections":["chemotherapy"],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":[],"companies":[],"institutions":["nci","md-anderson","dana-farber"],"pathways":[],"terms":["neoadjuvant-adjuvant"],"trials":[],"people":["emil-freireich","sidney-farber"],"bottlenecks":["b-combination-space"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Pioneer of combination chemotherapy; long-time physician-in-chief of Dana-Farber","specialisms":["Combination chemotherapy","Acute leukaemia","Hodgkin lymphoma","Adjuvant chemotherapy"],"profiles":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Emil_Frei"},{"label":"Dana-Farber Cancer Institute","url":"https://www.dana-farber.org/"}],"papers":[{"title":"The National Cancer Chemotherapy Program","journal":"Science","year":1982,"doi":"10.1126/science.7046055"},{"title":"Bone marrow autotransplantation for solid tumors--prospects.","journal":"Journal of Clinical Oncology","year":1989,"doi":"10.1200/jco.1989.7.4.515"},{"title":"Tumor necrosis factor: still a promising agent.","journal":"Journal of Clinical Oncology","year":1989,"doi":"10.1200/jco.1989.7.3.291"}]},{"id":"emil-freireich","kind":"person","name":"Emil J Freireich","aka":[],"tldr":"At the NCI in the early 1960s he and Emil Frei gave children four drugs at once, VAMP, against fierce opposition, and turned a leukaemia almost no child survived into a curable one. He also worked out platelet transfusion.","summary":"Emil J Freireich (1927-2021) joined the National Cancer Institute in 1955 and, with Emil Frei and James Holland, took on childhood acute lymphoblastic leukaemia when single drugs produced only brief remissions. He established that bleeding deaths were caused by low platelets and that fresh platelet transfusions prevented them, making intensive chemotherapy survivable. In 1961-62 he and Frei devised VAMP, giving vincristine, amethopterin (methotrexate), 6-mercaptopurine and prednisone together in full doses, a regimen colleagues thought reckless; it produced long remissions and the first cures. He moved to MD Anderson in 1965, where he built the Department of Developmental Therapeutics and trained a generation of leukaemia physicians, and he continued to see patients into his nineties.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Emil_J._Freireich","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Emil_J._Freireich"},{"label":"MD Anderson","url":"https://www.mdanderson.org/"}],"tags":["hero","pioneer"],"related":[],"cancers":["all-leukemia","aml"],"sections":["chemotherapy"],"technologies":["cytotoxic-chemotherapy","transfusion-support"],"targets":[],"drugs":["vincristine","methotrexate"],"companies":[],"institutions":["nci","md-anderson"],"pathways":[],"terms":[],"trials":[],"people":["emil-frei","donald-pinkel"],"bottlenecks":["b-combination-space","b-toxicity-qol"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Pioneer of combination chemotherapy and the cure of childhood leukaemia","specialisms":["Acute lymphoblastic leukaemia","Combination chemotherapy","Supportive care"],"profiles":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Emil_J._Freireich"},{"label":"MD Anderson","url":"https://www.mdanderson.org/"}],"papers":[{"title":"Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia","journal":"Blood","year":2016,"doi":"10.1182/blood-2015-09-667675"},{"title":"The Leukemias: A Half-Century of Discovery","journal":"Journal of Clinical Oncology","year":2014,"doi":"10.1200/jco.2014.57.1034"},{"title":"Toward the potential cure of leukemias in the next decade","journal":"Cancer","year":2018,"doi":"10.1002/cncr.31669"}]},{"id":"emile-voest","kind":"person","name":"Emile Voest","aka":[],"tldr":"Led the DRUP trial giving off-label targeted drugs by genomic match, and developed organoid-based testing.","summary":"Emile Voest is a medical oncologist and group leader at the Netherlands Cancer Institute (NKI-AvL). His specialisms are precision oncology, organoids and off-label drug access trials, and he works with patient-derived organoids, whole-genome sequencing and functional ex vivo drug testing. He founded the Dutch DRUP trial, which gives off-label targeted drugs by genomic match, and the Hartwig Medical Foundation whole-genome sequencing programme. His Nature paper on the Drug Rediscovery protocol described how this approach expands the use of existing anticancer drugs. He also developed patient-derived organoid co-cultures to test how tumours respond to immunotherapy. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Voest%20EE%5BAuthor%5D%20DRUP"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["organoids","wes-wgs","functional-drug-testing"],"targets":[],"drugs":[],"companies":[],"institutions":["nki"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Medical Oncologist and Group Leader, Netherlands Cancer Institute","institutionId":"nki","specialisms":["Precision oncology","Organoids","Off-label drug access trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Voest%20EE%5BAuthor%5D%20DRUP"}],"papers":[{"title":"The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs","journal":"Nature","year":2019,"doi":"10.1038/s41586-019-1600-x"},{"title":"NICHE-2: a month of nivolumab and ipilimumab before surgery clears mismatch-repair-deficient colon cancer in most patients","journal":"New England Journal of Medicine","year":2024,"url":"https://doi.org/10.1056/NEJMoa2400634","doi":"10.1056/NEJMoa2400634"}]},{"id":"emily-bergsland","kind":"person","name":"Emily K. Bergsland","aka":[],"tldr":"Neuroendocrine tumour specialist who helps design the trials that set treatment for these rare cancers.","summary":"Emily Bergsland is Professor of Medicine and Associate Director for Education at the UCSF Helen Diller Family Comprehensive Cancer Center. A medical oncologist focused on gastroenteropancreatic neuroendocrine tumours, she chaired the Alliance A021202 trial of pazopanib versus placebo in progressive carcinoid tumours and co-authors national neuroendocrine tumour treatment guidelines. Her papers include NCCN guidance on the management of advanced gastroenteropancreatic neuroendocrine tumours, a review of systemic therapies for advanced gastrointestinal carcinoid tumours and the A021202 trial report. Her record links to lutetium-177 dotatate, somatostatin receptor 2 and VEGF-directed therapy, and she leads UCSF's cancer education programmes.","asOf":"2026-09-08","links":[{"label":"UCSF profile","url":"https://profiles.ucsf.edu/search/?searchtype=people&searchfor=Emily%20K.%20Bergsland"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bergsland%20EK%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Emily%20K.%20Bergsland"}],"tags":[],"related":[],"cancers":["neuroendocrine"],"sections":[],"technologies":["radioligand-therapy"],"targets":["sstr2","vegf"],"drugs":["lutathera"],"companies":[],"institutions":["ucsf"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["jnccn","hematology-oncology-clinics-of-north-america"],"dependsOn":[],"notes":[],"role":"Professor of Medicine; Associate Director for Education, UCSF Helen Diller Family Comprehensive Cancer Center","institutionId":"ucsf","specialisms":["Neuroendocrine tumours","Gastrointestinal oncology","Clinical trials"],"profiles":[{"label":"UCSF profile","url":"https://profiles.ucsf.edu/search/?searchtype=people&searchfor=Emily%20K.%20Bergsland"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bergsland%20EK%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Emily%20K.%20Bergsland"}],"papers":[{"title":"Management of Advanced Gastroenteropancreatic Neuroendocrine Tumors","journal":"Journal of the National Comprehensive Cancer Network","year":2025,"url":"https://doi.org/10.6004/jnccn.2025.5012","doi":"10.6004/jnccn.2025.5012"},{"title":"Systemic Therapies for Advanced Gastrointestinal Carcinoid Tumors","journal":"Hematology/Oncology Clinics of North America","year":2016,"url":"https://doi.org/10.1016/j.hoc.2015.09.002","doi":"10.1016/j.hoc.2015.09.002"},{"title":"Prospective randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (Alliance A021202)","journal":"Journal of Clinical Oncology (ASCO Annual Meeting abstract)","year":2019,"url":"https://doi.org/10.1200/JCO.2019.37.15_suppl.4005","doi":"10.1200/JCO.2019.37.15_suppl.4005"}]},{"id":"emily-whitehead","kind":"person","name":"Emily Whitehead","aka":[],"tldr":"The first child treated with CAR-T cells, in 2012. Her recovery from relapsed leukaemia turned an experimental idea into an approved therapy.","summary":"Emily Whitehead was diagnosed with acute lymphoblastic leukaemia in 2010 at the age of five and relapsed twice on standard chemotherapy. In April 2012, at six, she became the first child in the world to receive CD19-directed CAR-T cells (CTL019, later tisagenlecleucel), developed at the University of Pennsylvania and given at Children's Hospital of Philadelphia. She developed severe cytokine release syndrome, which was controlled with the IL-6 blocker tocilizumab, a rescue that became standard practice for CAR-T toxicity. She has been in remission since May 2012. In August 2017 the FDA approved tisagenlecleucel, the first gene-modified cell therapy for any disease, for children and young adults with relapsed or refractory ALL. Her parents founded the Emily Whitehead Foundation to support paediatric cancer immunotherapy research.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Emily_Whitehead","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Emily_Whitehead"},{"label":"Emily Whitehead Foundation","url":"https://emilywhiteheadfoundation.org/"}],"tags":["hero","patient"],"related":[],"cancers":["all-leukemia"],"sections":["cell-therapy"],"technologies":["car-t"],"targets":["cd19"],"drugs":["tisagenlecleucel"],"companies":[],"institutions":["penn-abramson"],"pathways":[],"terms":["crs"],"trials":["eliana"],"people":["carl-june","bruce-levine","david-porter"],"bottlenecks":["b-trial-enrolment","b-rare-cancers"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Patient whose case launched CAR-T for children","specialisms":["Acute lymphoblastic leukaemia","CAR-T cell therapy","Paediatric oncology"],"profiles":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Emily_Whitehead"},{"label":"Emily Whitehead Foundation","url":"https://emilywhiteheadfoundation.org/"}],"papers":[]},{"id":"emma-browne","kind":"person","name":"Emma Browne","aka":[],"tldr":"Emma Browne represents Irish Cancer Society in the Organisation of European Cancer Institutes, which lists the centre among its members in Ireland.","summary":"Emma Browne is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Irish Cancer Society, its member in Ireland. Ireland's national cancer charity, funding research and Cancer Trials Ireland and providing night nursing, support lines and Daffodil Centres in hospitals. OnCo records the name from the OECI membership list so that the centre's page has a named contact point; the person's exact title, appointment date and biography are not yet recorded and should be checked on the institution's own pages before being relied on.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Irish Cancer Society website","url":"https://www.cancer.ie/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["irish-cancer-society"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Irish Cancer Society to the Organisation of European Cancer Institutes","institutionId":"irish-cancer-society","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Irish Cancer Society website","url":"https://www.cancer.ie/"}],"papers":[]},{"id":"emmanuel-barranger","kind":"person","name":"Emmanuel Barranger","aka":[],"tldr":"Professor who runs the Centre Antoine Lacassagne, the regional cancer centre in Nice, as its Directeur Général.","summary":"Professor Emmanuel Barranger is Directeur Général of the Centre Antoine Lacassagne in Nice, one of the French Centres de Lutte Contre le Cancer created by the ordinance of 1 October 1945 and part of the Unicancer network. The centre's organisation page states he was appointed for five years by ministerial decree of the Minister of Health. He leads the establishment together with Deputy Director General Guillaume Girard, alongside a medical conference chaired by Professor Alexandre Bozec.","asOf":"2026-09-10","links":[{"label":"Source: Centre Antoine Lacassagne organisation page","url":"https://www.centreantoinelacassagne.org/organisation-du-centre/"}],"tags":["leadership","clinician-scientist","cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["centre-antoine-lacassagne"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["bulletin-du-cancer","clinical-breast-cancer"],"dependsOn":[],"notes":[],"role":"Directeur Général of the Centre Antoine Lacassagne","institutionId":"centre-antoine-lacassagne","specialisms":["Cancer centre leadership","Comprehensive cancer care","Hospital governance"],"profiles":[{"label":"Institution organisation page","url":"https://www.centreantoinelacassagne.org/organisation-du-centre/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Barranger+E%5BAuthor%5D"}],"papers":[{"title":"Effect of Neoadjuvant Chemotherapy on the Surgical Treatment of Patients With Locally Advanced Breast Cancer Requiring Initial Mastectomy","journal":"Clinical Breast Cancer","year":2015,"doi":"10.1016/j.clbc.2015.03.001"},{"title":"Impact de la pandémie de COVID-19 sur les prises en charge pour cancer du sein et gynécologique","journal":"Bulletin du Cancer","year":2021,"doi":"10.1016/j.bulcan.2020.10.013"},{"title":"Clinicopathological characterization of a real-world multicenter cohort of endometrioid ovarian carcinoma: Analysis of the French national ESME-Unicancer database","journal":"Gynecologic Oncology","year":2021,"doi":"10.1016/j.ygyno.2021.07.019"}]},{"id":"eniarti","kind":"person","name":"Eniarti","aka":[],"tldr":"Physician who leads Dharmais Cancer Hospital in Jakarta, Indonesia's national cancer centre, as its president director.","summary":"Dr Eniarti, M.Sc., Sp.KJ., M.M.R., QHIA, is Direktur Utama of Rumah Sakit Kanker Dharmais, the national cancer centre in Jakarta. In June 2026 she announced a collaboration with AstraZeneca Indonesia to introduce next-generation sequencing for precision diagnostics, describing it as part of the hospital's effort to strengthen cancer care capacity. Her credentials indicate specialist training in psychiatry and hospital management.","asOf":"2026-09-10","links":[{"label":"Source: Antara news report quoting the Direktur Utama (June 2026)","url":"https://www.antaranews.com/berita/5594340/rs-kanker-dharmais-terapkan-ngs-untuk-dukung-diagnostik-presisi"}],"tags":["leadership","hospital","indonesia"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["astrazeneca"],"institutions":["dharmais-cancer-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Direktur Utama of RS Kanker Dharmais","institutionId":"dharmais-cancer-hospital","specialisms":["Hospital leadership","Psychiatry","Cancer service development"],"profiles":[{"label":"Antara news report (June 2026)","url":"https://www.antaranews.com/berita/5594340/rs-kanker-dharmais-terapkan-ngs-untuk-dukung-diagnostik-presisi"}],"papers":[]},{"id":"enrique-espinosa","kind":"person","name":"Enrique Espinosa","aka":[],"tldr":"Enrique Espinosa is a medical oncologist working on melanoma and gene-expression biomarkers.","summary":"Enrique Espinosa is a medical oncologist at Hospital Universitario La Paz and Professor at the Universidad Autónoma de Madrid. His specialisms are melanoma, breast cancer and gene expression signatures, and his research covers melanoma treatment and prognostic gene-expression signatures in breast cancer and melanoma. He works within the Spanish Multidisciplinary Melanoma Group (GEM). His papers include the GEM-1402 phase II trial of nivolumab plus ipilimumab in treatment-naive metastatic uveal melanoma, a Nature Medicine phase 2 study of clinical and molecular response to tebentafusp in previously treated metastatic uveal melanoma, and a GEM review of predictive factors of response to immunotherapy. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Espinosa%20E%5BAuthor%5D%20melanoma%20gene%20expression"}],"tags":[],"related":[],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["la-paz"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Medical Oncologist, Hospital Universitario La Paz; Professor, Universidad Autónoma de Madrid","institutionId":"la-paz","specialisms":["Melanoma","Breast cancer","Gene expression signatures"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Espinosa%20E%5BAuthor%5D%20melanoma%20gene%20expression"}],"papers":[{"title":"Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402)","journal":"Journal of Clinical Oncology","year":2021,"doi":"10.1200/jco.20.00550"},{"title":"Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial","journal":"Nature Medicine","year":2022,"doi":"10.1038/s41591-022-02015-7"},{"title":"Predictive factors of response to immunotherapy—a review from the Spanish Melanoma Group (GEM)","journal":"Annals of Translational Medicine","year":2017,"doi":"10.21037/atm.2017.08.10"}]},{"id":"enriqueta-felip","kind":"person","name":"Enriqueta Felip","aka":[],"tldr":"Thoracic oncologist who led IMpower010, establishing adjuvant atezolizumab in lung cancer.","summary":"Enriqueta Felip is Head of the Thoracic Cancers Unit at Vall d'Hebron University Hospital in Barcelona and Professor at the Autonomous University of Barcelona. Her specialisms are lung cancer, targeted therapy and perioperative immunotherapy. She was principal investigator of IMpower010, reported in The Lancet, which tested adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer and established adjuvant immunotherapy in this setting. She is also a leader in trials of EGFR-, ALK- and KRAS-targeted therapy, including osimertinib. Her publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Felip%20E%5BAuthor%5D%20lung%20atezolizumab"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":["egfr","alk"],"drugs":["atezolizumab","osimertinib"],"companies":[],"institutions":["vall-dhebron"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Head of Thoracic Cancers Unit, Vall d'Hebron; Professor, Autonomous University of Barcelona","institutionId":"vall-dhebron","specialisms":["Lung cancer","Targeted therapy","Perioperative immunotherapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Felip%20E%5BAuthor%5D%20lung%20atezolizumab"}],"papers":[{"title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010)","journal":"Lancet","year":2021,"doi":"10.1016/S0140-6736(21)02098-5"},{"title":"CheckMate 816: three cycles of nivolumab plus chemotherapy before lung cancer surgery","journal":"New England Journal of Medicine","year":2022,"url":"https://doi.org/10.1056/NEJMoa2202170","doi":"10.1056/NEJMoa2202170"},{"title":"CROWN: lorlatinib versus crizotinib as first treatment for ALK-positive lung cancer","journal":"New England Journal of Medicine","year":2020,"url":"https://doi.org/10.1056/NEJMoa2027187","doi":"10.1056/NEJMoa2027187"},{"title":"DeLLphi-301: tarlatamab, a DLL3-targeting T-cell engager, in previously treated small-cell lung cancer","journal":"New England Journal of Medicine","year":2023,"url":"https://doi.org/10.1056/NEJMoa2307980","doi":"10.1056/NEJMoa2307980"},{"title":"KEYNOTE-189: pembrolizumab plus chemotherapy as first treatment for non-squamous lung cancer without a driver mutation","journal":"New England Journal of Medicine","year":2018,"url":"https://doi.org/10.1056/NEJMoa1801005","doi":"10.1056/NEJMoa1801005"},{"title":"MARIPOSA: amivantamab plus lazertinib versus osimertinib as first treatment for EGFR-mutated lung cancer","journal":"New England Journal of Medicine","year":2024,"url":"https://doi.org/10.1056/NEJMoa2403614","doi":"10.1056/NEJMoa2403614"}],"orcid":"0000-0002-7620-0098"},{"id":"ephrat-levy-lahad","kind":"person","name":"Ephrat Levy-Lahad","aka":[],"tldr":"Produced the evidence that made Israel the first country to offer BRCA testing to a whole population group, by measuring cancer risk in carriers found through healthy men rather than through cancer clinics.","summary":"Ephrat Levy-Lahad directs the Medical Genetics Institute at Shaare Zedek Medical Center. With Mary-Claire King she designed the study that answered the objection to population BRCA screening: that risk estimates from families referred to cancer clinics cannot be applied to people found at random. Gabai-Kapara and colleagues genotyped 8,195 healthy Ashkenazi Israeli men, found 2.17 percent carrying one of the three founder variants, then enrolled their female relatives. Cumulative risk of breast or ovarian cancer by age 80 was 0.83 for BRCA1 carriers and 0.76 for BRCA2 carriers, and 51 percent of the 167 carrier families had little or no relevant cancer history, so family-history criteria would have missed them. Israel made founder testing available to every woman of Ashkenazi origin in January 2020. Levy-Lahad's group has since published on how the programme performs in practice, comparing carriers found by population screening with those found through oncogenetics clinics, and on long-read sequencing in the diagnostic laboratory.","asOf":"2026-09-25","links":[{"label":"Shaare Zedek Medical Center, Medical Genetics Institute","url":"https://www.szmc.org.il/eng/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Levy-Lahad%20E%5BAuthor%5D%20BRCA"}],"tags":["clinician-scientist","genetics","prevention"],"related":[],"cancers":["breast-hr-positive","ovarian"],"sections":["prevention","diagnostics"],"technologies":["germline-testing"],"targets":["brca"],"drugs":[],"companies":[],"institutions":["shaare-zedek","hebrew-university-of-jerusalem"],"pathways":[],"terms":["founder-variant"],"trials":[],"people":[],"bottlenecks":["b-hereditary-risk"],"keyPapers":["paper-gabai-kapara-population-brca-screening-pnas-2014"],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Medical Genetics Institute, Shaare Zedek Medical Center; professor, Hebrew University-Hadassah Medical School","institutionId":"shaare-zedek","specialisms":["Cancer genetics","BRCA1 and BRCA2","Population genetic screening","Genetic counselling"],"profiles":[{"label":"Shaare Zedek Medical Center, Medical Genetics Institute","url":"https://www.szmc.org.il/eng/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Levy-Lahad%20E%5BAuthor%5D%20BRCA"}],"papers":[{"title":"Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2","journal":"Proceedings of the National Academy of Sciences","year":2014,"doi":"10.1073/pnas.1415979111"},{"title":"Comparative analysis of BRCA pathogenic variant detection in a real-world setting: population screening versus oncogenetic clinics","journal":"JCO Precision Oncology","year":2026,"doi":"10.1200/po-25-01023"}],"orcid":"0000-0003-0917-8863"},{"id":"erez-barenboim","kind":"person","name":"Erez Barenboim","aka":[],"tldr":"Internal medicine physician and former air force chief medical officer who directs Rabin Medical Center in Petah Tikva, the Clalit hospital whose Beilinson campus houses the Davidoff Cancer Center.","summary":"Erez Barenboim (ארז ברנבוים) directs Rabin Medical Center in Petah Tikva, the Clalit Health Services hospital whose Beilinson campus includes the Davidoff Cancer Center. Hebrew Wikipedia describes him as an internal medicine physician with a master's degree in health systems management who previously directed a hospital in the Assuta network, served as deputy director of Meir Medical Center and was chief medical officer of the Israeli Air Force. The hospital's own website could not be reached to confirm who currently heads the Davidoff Cancer Center itself, so this record points at the director of the parent hospital.","asOf":"2026-09-10","links":[{"label":"Source: Hebrew Wikipedia article on Erez Barenboim","url":"https://he.wikipedia.org/wiki/ארז_ברנבוים"},{"label":"Source: Hebrew Wikipedia article on Rabin Medical Center (director field)","url":"https://he.wikipedia.org/wiki/מרכז_רפואי_רבין"}],"tags":["leadership","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["rabin-davidoff-center"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director of Rabin Medical Center, the Clalit hospital that houses the Davidoff Cancer Center","institutionId":"rabin-davidoff-center","specialisms":["Internal medicine","Hospital management","Health systems management"],"profiles":[{"label":"Wikipedia (Hebrew)","url":"https://he.wikipedia.org/wiki/ארז_ברנבוים"}],"papers":[{"title":"Brief posturographic test as an indicator of fatigue","journal":"Psychiatry Clin Neurosci","year":2006,"url":"https://doi.org/10.1111/j.1440-1819.2006.01511.x","doi":"10.1111/j.1440-1819.2006.01511.x","note":"Europe PMC author record matched by affiliation"}]},{"id":"eric-klein","kind":"person","name":"Eric A. Klein","aka":[],"tldr":"Urologist who led the CCGA study validating the Galleri methylation-based multi-cancer detection test.","summary":"Eric Klein led the Circulating Cell-free Genome Atlas (CCGA) study that developed and clinically validated the Galleri cell-free DNA methylation test for detecting more than 50 cancer types and predicting tissue of origin, the basis for the PATHFINDER and NHS-Galleri trials. As a urologist he led the SELECT prevention trial and the development of the Oncotype DX prostate score.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Klein%20EA%5BAuthor%5D%20multi-cancer%20early%20detection"}],"tags":["early-detection","mced","prostate"],"related":[],"cancers":["prostate"],"sections":[],"technologies":["mced","methylation-profiling"],"targets":[],"drugs":["galleri"],"companies":[],"institutions":["cleveland-clinic"],"pathways":[],"terms":[],"trials":["nhs-galleri","pathfinder-2"],"people":[],"bottlenecks":[],"keyPapers":["paper-pathfinder-lancet-2023"],"journals":["annals-of-oncology"],"dependsOn":[],"notes":[],"role":"Emeritus Professor and Chairman, Glickman Urological and Kidney Institute, Cleveland Clinic; Distinguished Scientist, GRAIL","institutionId":"cleveland-clinic","specialisms":["Multi-cancer early detection","Prostate cancer","Genomic classifiers","Urologic oncology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Klein%20EA%5BAuthor%5D%20multi-cancer%20early%20detection"}],"papers":[{"title":"Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set (CCGA)","journal":"Annals of Oncology","year":2021,"doi":"10.1016/j.annonc.2021.05.806"},{"title":"Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)","journal":"JAMA","year":2011,"doi":"10.1001/jama.2011.1437"},{"title":"PATHFINDER: the first prospective test of a multi-cancer blood test in people without symptoms","journal":"The Lancet","year":2023,"url":"https://doi.org/10.1016/S0140-6736(23)01700-2","doi":"10.1016/S0140-6736(23)01700-2"}]},{"id":"eric-haura","kind":"person","name":"Eric B. Haura","aka":[],"tldr":"Eric Haura is a lung cancer physician-scientist who maps drug-target signalling with proteomics.","summary":"Eric B. Haura is Associate Center Director for Clinical Science and Director of the Lung Cancer Center of Excellence at Moffitt Cancer Center. He is a lung cancer physician-scientist known for mapping drug-target signalling with proteomics, using phosphoproteomics and protein-interaction mapping to understand why kinase inhibitors work and then fail. His selected paper reports proteomic and phosphoproteomic analyses of EGFR-mutant lung cancer. He now directs Moffitt's lung cancer centre and continues to study signalling networks in non-small-cell lung cancer.","asOf":"2026-09-08","links":[{"label":"Moffitt profile","url":"https://www.moffitt.org/providers/eric-haura/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Haura%20EB%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["proteomics"],"targets":[],"drugs":[],"companies":[],"institutions":["moffitt"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["molecular-cancer-therapeutics"],"dependsOn":[],"notes":[],"role":"Associate Center Director for Clinical Science; Director, Lung Cancer Center of Excellence","institutionId":"moffitt","specialisms":["Lung cancer","Proteomics","Signalling networks"],"profiles":[{"label":"Moffitt profile","url":"https://www.moffitt.org/providers/eric-haura/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Haura%20EB%5BAuthor%5D"}],"papers":[{"title":"Proteomic and phosphoproteomic analyses of EGFR-mutant lung cancer","journal":"Molecular Cancer Therapeutics","year":2016}]},{"id":"eric-felix-lartigau","kind":"person","name":"Eric Felix Lartigau","aka":[],"tldr":"Eric Felix Lartigau represents Centre Oscar Lambret in the Organisation of European Cancer Institutes, which lists the centre among its members in France.","summary":"Eric Felix Lartigau is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Centre Oscar Lambret, its full member in France. OnCo records the name from the OECI membership list so that the centre's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the institution's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Centre Oscar Lambret website","url":"https://www.centreoscarlambret.fr"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["centre-oscar-lambret"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Centre Oscar Lambret to the Organisation of European Cancer Institutes","institutionId":"centre-oscar-lambret","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Centre Oscar Lambret website","url":"https://www.centreoscarlambret.fr"}],"papers":[{"title":"Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group","journal":"Radiother Oncol","year":2021,"url":"https://doi.org/10.1016/j.radonc.2021.01.013","doi":"10.1016/j.radonc.2021.01.013","note":"Europe PMC author record matched by affiliation"},{"title":"ESTRO ACROP consensus guideline on implementation and practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer","journal":"Radiother Oncol","year":2017,"url":"https://doi.org/10.1016/j.radonc.2017.05.012","doi":"10.1016/j.radonc.2017.05.012","note":"Europe PMC author record matched by affiliation"},{"title":"Multi institutional phase II study of concomitant stereotactic reirradiation and cetuximab for recurrent head and neck cancer","journal":"Radiother Oncol","year":2013,"url":"https://doi.org/10.1016/j.radonc.2013.08.012","doi":"10.1016/j.radonc.2013.08.012","note":"Europe PMC author record matched by affiliation"}]},{"id":"eric-small","kind":"person","name":"Eric J. Small","aka":[],"tldr":"Prostate cancer trialist who helped bring abiraterone and sipuleucel-T to patients, and led ASCO in 2025-26.","summary":"Eric Small is Deputy Director and Chief Scientific Officer of the UCSF Helen Diller Family Comprehensive Cancer Center and served as President of the American Society of Clinical Oncology (ASCO) for the 2025 to 2026 term. A medical oncologist specialising in prostate and genitourinary cancer, his trials underpinned approvals in castration-resistant prostate cancer, including the phase 3 sipuleucel-T and abiraterone studies. His papers include the placebo-controlled phase III trial of sipuleucel-T in metastatic asymptomatic hormone refractory prostate cancer and an Annals of Oncology report on apalutamide in non-metastatic castration-resistant prostate cancer. His work centres on the androgen receptor and clinical trials.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Eric._J._Small","links":[{"label":"UCSF profile","url":"https://profiles.ucsf.edu/search/?searchtype=people&searchfor=Eric%20J.%20Small"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Small%20EJ%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Eric%20J.%20Small"}],"tags":[],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":["androgen-receptor"],"drugs":[],"companies":[],"institutions":["ucsf","asco"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["annals-of-oncology"],"dependsOn":[],"notes":[],"role":"Deputy Director and Chief Scientific Officer, UCSF Helen Diller Family Comprehensive Cancer Center; ASCO President 2025-2026","institutionId":"ucsf","specialisms":["Prostate cancer","Genitourinary oncology","Clinical trials"],"profiles":[{"label":"UCSF profile","url":"https://profiles.ucsf.edu/search/?searchtype=people&searchfor=Eric%20J.%20Small"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Small%20EJ%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Eric%20J.%20Small"}],"papers":[{"title":"Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer","journal":"Journal of Clinical Oncology","year":2006,"url":"https://doi.org/10.1200/JCO.2005.04.5252","doi":"10.1200/JCO.2005.04.5252"},{"title":"Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer","journal":"Annals of Oncology","year":2019,"url":"https://doi.org/10.1093/annonc/mdz397","doi":"10.1093/annonc/mdz397"}]},{"id":"eric-jonasch","kind":"person","name":"Eric Jonasch","aka":[],"tldr":"Houston oncologist who led the trial that established belzutifan, the first drug for the tumours of von Hippel-Lindau disease, including kidney cancers, pancreatic tumours and haemangioblastomas.","summary":"Eric Jonasch is a genitourinary medical oncologist at MD Anderson Cancer Center and directs its von Hippel-Lindau clinical centre. He was first author of the 2021 New England Journal of Medicine report of the phase 2 trial in which the HIF-2α inhibitor belzutifan shrank renal cell carcinomas and also pancreatic lesions and central nervous system haemangioblastomas in patients with VHL disease, leading to the first approval of a drug for the syndrome.","asOf":"2026-09-18","links":[],"tags":["kidney","targeted-therapy","trialist"],"related":[],"cancers":["spinal-cord-tumours","clear-cell-rcc","rcc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-belzutifan-vhl-jonasch-nejm-2021"],"journals":[],"dependsOn":[],"notes":[],"role":"Genitourinary medical oncologist, MD Anderson Cancer Center","institutionId":"md-anderson","specialisms":["Kidney cancer","Von Hippel-Lindau disease","HIF-2α inhibitors"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Jonasch%5BAuthor%5D"}],"papers":[{"title":"Belzutifan for renal cell carcinoma and other tumours in von Hippel-Lindau disease","journal":"New England Journal of Medicine","year":2021,"url":"https://doi.org/10.1056/NEJMoa2103425","doi":"10.1056/NEJMoa2103425"}]},{"id":"eric-winer","kind":"person","name":"Eric P. Winer","aka":[],"tldr":"Breast cancer specialist who leads Yale Cancer Center and Smilow Cancer Hospital, and who previously ran breast oncology at Dana-Farber for more than two decades.","summary":"Medical oncologist appointed Director of Yale Cancer Center and Physician-in-Chief of Smilow Cancer Hospital on 1 February 2022, after leading the breast oncology programme at Dana-Farber Cancer Institute, where he was Chief of the Division of Breast Oncology and Chief Clinical Strategy Officer. His research has focused on the treatment of breast cancer, in particular HER2-positive disease, de-escalation of therapy for lower-risk patients and the design of adjuvant and neoadjuvant trials through the Alliance cooperative group and Translational Breast Cancer Research Consortium. He served as President of the American Society of Clinical Oncology for 2022-2023.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Eric_Winer","links":[{"label":"Yale Cancer Center leadership","url":"https://medicine.yale.edu/cancer/about/people/"},{"label":"Yale School of Medicine profile","url":"https://medicine.yale.edu/profile/eric-winer/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Winer%20EP%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["breast-her2-positive","tnbc"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab"],"companies":[],"institutions":["yale-cancer-center","yale-school-of-medicine","dana-farber"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Yale Cancer Center; President and Physician-in-Chief, Smilow Cancer Hospital; Deputy Dean for Cancer Research, Yale School of Medicine","institutionId":"yale-cancer-center","specialisms":["Breast cancer","HER2-positive breast cancer","Clinical trial design","Academic leadership"],"profiles":[{"label":"Yale Cancer Center leadership","url":"https://medicine.yale.edu/cancer/about/people/"},{"label":"Yale School of Medicine profile","url":"https://medicine.yale.edu/profile/eric-winer/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Winer%20EP%5BAuthor%5D"}],"papers":[{"title":"Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer","journal":"New England Journal of Medicine","year":2015,"url":"https://doi.org/10.1056/NEJMoa1406281","doi":"10.1056/NEJMoa1406281"},{"title":"Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial","journal":"Lancet Oncology","year":2021,"url":"https://doi.org/10.1016/S1470-2045(20)30754-3","doi":"10.1016/S1470-2045(20)30754-3"}],"orcid":"0000-0002-8819-1723"},{"id":"eric-fearon","kind":"person","name":"Eric R. Fearon","aka":[],"tldr":"Co-author of the Fearon-Vogelstein model of how colorectal cancer develops step by step.","summary":"Eric R. Fearon is Director of the Rogel Cancer Center and Emanuel N. Maisel Professor of Oncology at the University of Michigan. He is a molecular geneticist known as co-author of the Fearon-Vogelstein model describing how colorectal cancer develops step by step, and for cloning the DCC gene. His selected paper sets out a genetic model for colorectal tumorigenesis. He now directs the Rogel Cancer Center while continuing to study Wnt and APC signalling and tumour suppressor genes in colorectal cancer.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Eric_Fearon","links":[{"label":"Rogel Cancer Center","url":"https://www.rogelcancercenter.org"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fearon%20ER%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["michigan-rogel"],"pathways":["wnt"],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Rogel Cancer Center; Emanuel N. Maisel Professor of Oncology","institutionId":"michigan-rogel","specialisms":["Colorectal cancer genetics","Wnt/APC signalling","Tumour suppressor genes"],"profiles":[{"label":"Rogel Cancer Center","url":"https://www.rogelcancercenter.org"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fearon%20ER%5BAuthor%5D"}],"papers":[{"title":"A genetic model for colorectal tumorigenesis","journal":"Cell","year":1990,"url":"https://doi.org/10.1016/0092-8674(90)90186-I","doi":"10.1016/0092-8674(90)90186-I"}],"orcid":"0000-0003-2867-3971"},{"id":"eric-van-cutsem","kind":"person","name":"Eric Van Cutsem","aka":[],"tldr":"Led CRYSTAL, which established cetuximab in RAS wild-type colorectal cancer, and has shaped ESMO's GI guidelines for two decades.","summary":"Eric Van Cutsem was principal investigator of CRYSTAL, showing cetuximab plus FOLFIRI improves survival in KRAS wild-type metastatic colorectal cancer, the result that made RAS testing mandatory. He has led trials across colorectal, gastric, pancreatic and biliary cancers, chaired ESMO's GI guideline committees and the World GI Congress. His current work includes HER2- and KRAS-directed therapy in GI cancers.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Van%20Cutsem%20E%5BAuthor%5D%20colorectal%20cetuximab"}],"tags":["colorectal","guidelines","esmo"],"related":[],"cancers":["colorectal","gastric","pancreatic"],"sections":[],"technologies":["monoclonal-antibody"],"targets":["egfr","kras"],"drugs":[],"companies":[],"institutions":["uz-leuven","esmo"],"pathways":[],"terms":[],"trials":["crystal-fire3"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["annals-of-oncology"],"dependsOn":[],"notes":[],"role":"Professor of Medicine and Head of Digestive Oncology, University Hospitals Leuven","institutionId":"uz-leuven","specialisms":["Colorectal cancer","Gastro-oesophageal cancer","Anti-EGFR therapy","Guidelines"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Van%20Cutsem%20E%5BAuthor%5D%20colorectal%20cetuximab"}],"papers":[{"title":"Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer (CRYSTAL)","journal":"NEJM","year":2009,"doi":"10.1056/NEJMoa0805019"},{"title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer","journal":"Annals of Oncology","year":2016,"doi":"10.1093/annonc/mdw235"}]},{"id":"erik-wexler","kind":"person","name":"Erik G. Wexler","aka":[],"tldr":"Chief executive of Providence, one of the largest not-for-profit health systems in the United States, which runs a network of hospitals and cancer programmes across the western states.","summary":"Erik G. Wexler is President and CEO of Providence, a not-for-profit Catholic health system operating hospitals, clinics and cancer services across the western United States. Providence is one of the largest not-for-profit health systems in the country and runs a network of hospitals and cancer programmes across the western states. He also serves as an ex-officio member of the Providence Board of Directors. His expertise is in health system leadership, not-for-profit healthcare and hospital operations, and the Providence leadership page is the public record of his role.","asOf":"2026-09-10","links":[{"label":"Source: Providence leadership page","url":"https://www.providence.org/about/leadership"}],"tags":["leadership","health-system"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["providence-health"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President and CEO of Providence","institutionId":"providence-health","specialisms":["Health system leadership","Not-for-profit healthcare","Hospital operations"],"profiles":[{"label":"Providence leadership page","url":"https://www.providence.org/about/leadership"}],"papers":[]},{"id":"erik-johnsson","kind":"person","name":"Erik Johnsson","aka":[],"tldr":"Erik Johnsson represents Sahlgrenska University Hospital / Sahlgrenska Center for Cancer Research in the Organisation of European Cancer Institutes, which lists the centre among its members in Sweden.","summary":"Erik Johnsson is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Sahlgrenska University Hospital / Sahlgrenska Center for Cancer Research, its full member in Sweden. OnCo records the name from the OECI membership list so that the centre's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the institution's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Sahlgrenska University Hospital / Sahlgrenska Center for Cancer Research website","url":"https://www.sahlgrenska.se/en/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["sahlgrenska"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Sahlgrenska University Hospital / Sahlgrenska Center for Cancer Research to the Organisation of European Cancer Institutes","institutionId":"sahlgrenska","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Sahlgrenska University Hospital / Sahlgrenska Center for Cancer Research website","url":"https://www.sahlgrenska.se/en/"}],"papers":[]},{"id":"erik-sahai","kind":"person","name":"Erik Sahai","aka":[],"tldr":"Cell biologist studying how the tumour's surroundings help cancer cells invade and resist drugs.","summary":"Erik Sahai is Principal Group Leader of the Tumour Cell Biology Laboratory at The Francis Crick Institute in London. His specialisms are the tumour microenvironment, cancer cell invasion, and drug resistance and plasticity, with an interest in the fibroblast marker FAP. He uses intravital imaging and computational models to study how fibroblasts interact with tumour cells, how cancer cells invade, and the non-genetic plasticity that lets them survive targeted therapy. His Nature Reviews Cancer paper set out a framework for understanding cancer-associated fibroblasts. His work explains how a tumour's surroundings help it spread and resist drugs. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sahai%20E%5BAuthor%5D%20tumour%20microenvironment"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["fap"],"drugs":[],"companies":[],"institutions":["francis-crick"],"pathways":["emt"],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nature-reviews-cancer"],"dependsOn":[],"notes":[],"role":"Principal Group Leader, Tumour Cell Biology Laboratory, Francis Crick Institute","institutionId":"francis-crick","specialisms":["Tumour microenvironment","Cancer cell invasion","Drug resistance and plasticity"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sahai%20E%5BAuthor%5D%20tumour%20microenvironment"}],"papers":[{"title":"A framework for advancing our understanding of cancer-associated fibroblasts","journal":"Nature Reviews Cancer","year":2020,"doi":"10.1038/s41568-019-0238-1"}],"orcid":"0000-0002-3932-5086"},{"id":"erin-oshea","kind":"person","name":"Erin K. O'Shea","aka":[],"tldr":"Systems biologist who has led the Howard Hughes Medical Institute, a major funder of US biomedical and cancer research, since 2016.","summary":"Erin K. O'Shea is President of the Howard Hughes Medical Institute (HHMI), the largest private funder of academic biomedical research in the United States, whose investigators include many leading cancer biologists. Previously HHMI's Chief Scientific Officer and a Harvard professor, her research addressed signalling and gene regulatory networks in yeast and cyanobacteria.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=O%27Shea+EK%5BAuthor%5D"}],"tags":["leadership","research funding","systems biology"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["hhmi"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nature","science"],"dependsOn":[],"notes":[],"role":"President","institutionId":"hhmi","specialisms":["Systems biology","Gene regulation","Research funding leadership"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=O%27Shea+EK%5BAuthor%5D"}],"papers":[{"title":"Global analysis of protein localization in budding yeast","journal":"Nature","year":2003,"url":"https://doi.org/10.1038/nature02026","doi":"10.1038/nature02026","note":"Europe PMC author record matched by affiliation"},{"title":"Global analysis of protein expression in yeast","journal":"Nature","year":2003,"url":"https://doi.org/10.1038/nature02046","doi":"10.1038/nature02046","note":"Europe PMC author record matched by affiliation"},{"title":"Noise in gene expression: origins, consequences, and control","journal":"Science","year":2005,"url":"https://doi.org/10.1126/science.1105891","doi":"10.1126/science.1105891","note":"Europe PMC author record matched by affiliation"}],"orcid":"0000-0002-2649-1018"},{"id":"ernst-j-kuipers","kind":"person","name":"Ernst J. Kuipers","aka":[],"tldr":"Ernst J. Kuipers represents Netherlands Comprehensive Cancer Organisation (IKNL) in the Organisation of European Cancer Institutes, which lists the centre among its members in The Netherlands.","summary":"Ernst J. Kuipers is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Netherlands Comprehensive Cancer Organisation (IKNL), its member in The Netherlands. IKNL is the Dutch national cancer organisation that runs the Netherlands Cancer Registry and supports quality of care and research across the country, and a full member of the Organisation of European Cancer Institutes. OnCo records the name from the OECI membership list so that the centre's page has a named contact point; the person's exact title, appointment date and biography are not yet recorded and should be checked on the institution's own pages before being relied on.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Netherlands Comprehensive Cancer Organisation (IKNL) website","url":"http://www.iknl.nl/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["iknl"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Netherlands Comprehensive Cancer Organisation (IKNL) to the Organisation of European Cancer Institutes","institutionId":"iknl","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Netherlands Comprehensive Cancer Organisation (IKNL) website","url":"http://www.iknl.nl/"}],"papers":[{"title":"The impact of the temporary suspension of national cancer screening programmes due to the COVID-19 epidemic on the diagnosis of breast and colorectal cancer in the Netherlands","journal":"J Hematol Oncol","year":2020,"url":"https://doi.org/10.1186/s13045-020-00984-1","doi":"10.1186/s13045-020-00984-1","note":"Europe PMC author record matched by affiliation"},{"title":"Prospective Dutch colorectal cancer cohort: an infrastructure for long-term observational, prognostic, predictive and (randomized) intervention research","journal":"Acta Oncol","year":2016,"url":"https://doi.org/10.1080/0284186x.2016.1189094","doi":"10.1080/0284186x.2016.1189094","note":"Europe PMC author record matched by affiliation"},{"title":"Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing","journal":"Gastroenterology","year":2017,"url":"https://doi.org/10.1053/j.gastro.2017.05.004","doi":"10.1053/j.gastro.2017.05.004","note":"Europe PMC author record matched by affiliation"}]},{"id":"esteban-langlois","kind":"person","name":"Esteban Langlois","aka":[],"tldr":"Physician who serves as Director Médico of Hospital Italiano de Buenos Aires, one of Argentina's leading non-profit university hospitals.","summary":"Esteban Langlois is Director Médico of the Hospital Italiano de Buenos Aires, a non-profit university hospital founded in 1853 and run by the Sociedad Italiana de Beneficencia en Buenos Aires. A September 2025 report on the hospital being ranked among the five best in Latin America quotes him in that role, thanking the whole hospital team for the commitment that made the recognition possible. The hospital's own website is script-rendered and its authorities page could not be read, so no appointment date is given.","asOf":"2026-09-10","links":[{"label":"Source: Consenso Salud news report naming the Director Médico (September 2025)","url":"https://consensosalud.com.ar/el-hospital-italiano-entre-los-mejores-5-de-america-latina/"}],"tags":["leadership","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["hospital-italiano-buenos-aires"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director Médico (Medical Director), Hospital Italiano de Buenos Aires","institutionId":"hospital-italiano-buenos-aires","specialisms":["Hospital management","Academic medicine"],"profiles":[{"label":"Consenso Salud report quoting the Director Médico (September 2025)","url":"https://consensosalud.com.ar/el-hospital-italiano-entre-los-mejores-5-de-america-latina/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Langlois+E%5BAuthor%5D+AND+Buenos+Aires"}],"papers":[{"title":"Mortality in an elderly type 2 diabetic patients’ cohort who attended a self-management educational workshop","journal":"Primary care diabetes","year":2011,"url":"https://doi.org/10.1016/j.pcd.2011.03.002","doi":"10.1016/j.pcd.2011.03.002","note":"OpenAlex author record matched by institution"},{"title":"Prevención de eventos cardiovasculares en hipertensos mayores de 65 años bajo el cuidado de un programa de control: Estudio de cohorte","journal":"Anales de Medicina Interna","year":2005,"url":"https://doi.org/10.4321/s0212-71992005000400003","doi":"10.4321/s0212-71992005000400003","note":"OpenAlex author record matched by institution"}]},{"id":"ethan-basch","kind":"person","name":"Ethan Basch","aka":[],"tldr":"Proved that letting patients report symptoms electronically during chemotherapy improves quality of life and survival.","summary":"Ethan Basch led the randomised trial showing that systematic electronic patient-reported symptom monitoring during chemotherapy improves quality of life, reduces emergency visits and extends overall survival, and the national PRO-TECT trial confirming it in community practices. He developed the PRO-CTCAE toxicity instrument with the NCI and has shaped FDA and ASCO policy on patient-reported outcomes.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Basch%20E%5BAuthor%5D%20patient-reported%20outcomes"}],"tags":["supportive-care","patient-reported-outcomes","outcomes"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["unc-lineberger"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-basch-epro-survival-jama-2017"],"journals":[],"dependsOn":[],"notes":[],"role":"Chief of Medical Oncology and Physician-in-Chief, UNC Lineberger Comprehensive Cancer Center","institutionId":"unc-lineberger","specialisms":["Patient-reported outcomes","Symptom monitoring","Health outcomes research","Trial methodology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Basch%20E%5BAuthor%5D%20patient-reported%20outcomes"}],"papers":[{"title":"Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment","journal":"JAMA","year":2017,"doi":"10.1001/jama.2017.7156"},{"title":"Effect of electronic symptom monitoring on patient-reported outcomes among patients with metastatic cancer: a randomized clinical trial (PRO-TECT)","journal":"JAMA","year":2022,"doi":"10.1001/jama.2022.9265"}]},{"id":"eunice-wang","kind":"person","name":"Eunice S. Wang","aka":[],"tldr":"Eunice Wang is an AML trialist who helped bring FLT3 and menin inhibitors to patients.","summary":"Eunice S. Wang is Chief of the Leukemia Service at Roswell Park Comprehensive Cancer Center. She is an acute myeloid leukaemia trialist known for helping bring FLT3 inhibitors and menin inhibitors to patients, as an investigator on gilteritinib, quizartinib and revumenib studies. Her selected paper reviews crenolanib for FLT3-mutated AML. She leads leukaemia clinical research at Roswell Park and serves on the NCCN acute myeloid leukaemia guideline panel.","asOf":"2026-09-08","links":[{"label":"Roswell Park profile","url":"https://www.roswellpark.org/eunice-wang"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wang%20ES%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["aml"],"sections":[],"technologies":[],"targets":["flt3","menin"],"drugs":["gilteritinib","revumenib"],"companies":[],"institutions":["roswell-park"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["blood-advances"],"dependsOn":[],"notes":[],"role":"Chief, Leukemia Service","institutionId":"roswell-park","specialisms":["Acute myeloid leukaemia","FLT3 inhibitors","Novel leukaemia agents"],"profiles":[{"label":"Roswell Park profile","url":"https://www.roswellpark.org/eunice-wang"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wang%20ES%5BAuthor%5D"}],"papers":[{"title":"Crenolanib for FLT3-mutated AML","journal":"Blood Advances","year":2021}]},{"id":"eva-ciruelos","kind":"person","name":"Eva Ciruelos","aka":[],"tldr":"Madrid breast oncologist and Vice President of the SOLTI breast cancer research group.","summary":"Eva Ciruelos is Vice President of SOLTI Cancer Research Group and a medical oncologist leading the breast cancer unit at Hospital Universitario 12 de Octubre in Madrid. She has been an investigator on numerous SOLTI and international breast cancer trials spanning HER2-positive, hormone receptor-positive and triple-negative disease. Her role is listed on SOLTI's board page.","asOf":"2026-09-10","links":[{"label":"Society page","url":"https://www.gruposolti.org/junta-directiva/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ciruelos+E%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","breast cancer"],"related":[],"cancers":["breast-hr-positive","breast-her2-positive"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["solti"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Vice President (Vicepresidenta)","institutionId":"solti","specialisms":["Breast cancer","Medical oncology","Clinical trials"],"profiles":[{"label":"Society page","url":"https://www.gruposolti.org/junta-directiva/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ciruelos+E%5BAuthor%5D"}],"papers":[{"title":"Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial","journal":"Clinical Cancer Research","year":2020,"doi":"10.1158/1078-0432.ccr-20-0844"},{"title":"Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study","journal":"Annals of Oncology","year":2023,"doi":"10.1016/j.annonc.2023.05.004"},{"title":"Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial","journal":"The Lancet Oncology","year":2020,"doi":"10.1016/s1470-2045(19)30786-7"}],"orcid":"0000-0002-2796-1042"},{"id":"evandro-de-azambuja","kind":"person","name":"Evandro de Azambuja","aka":[],"tldr":"Evandro de Azambuja is a breast oncologist who studies heart safety of HER2-targeted therapy in BIG trials.","summary":"Evandro de Azambuja is Head of the Medical Support Team at Institut Jules Bordet in Brussels and a medical oncologist working with the Breast International Group (BIG). His specialisms are breast cancer, cardio-oncology and adjuvant HER2 therapy. He works on adjuvant HER2 trials and the cardiac safety of trastuzumab-based therapy. His papers include the NeoALTTO phase 3 trial of lapatinib with trastuzumab in HER2-positive early breast cancer and its link between pathological complete response and outcomes, the New England Journal of Medicine report of adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer, and an analysis of trastuzumab-associated cardiac events at long-term follow-up in the HERA trial. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=de%20Azambuja%20E%5BAuthor%5D%20cardiotoxicity%20trastuzumab"}],"tags":[],"related":[],"cancers":["breast-her2-positive"],"sections":[],"technologies":["cardio-oncology"],"targets":[],"drugs":[],"companies":["big"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Head of Medical Support Team, Institut Jules Bordet; Medical Oncologist","institutionId":"big","specialisms":["Breast cancer","Cardio-oncology","Adjuvant HER2 therapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=de%20Azambuja%20E%5BAuthor%5D%20cardiotoxicity%20trastuzumab"}],"papers":[{"title":"Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response","journal":"The Lancet Oncology","year":2014,"doi":"10.1016/s1470-2045(14)70320-1"},{"title":"Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer","journal":"New England Journal of Medicine","year":2017,"doi":"10.1056/nejmoa1703643"},{"title":"Trastuzumab-Associated Cardiac Events at 8 Years of Median Follow-Up in the Herceptin Adjuvant Trial (BIG 1-01)","journal":"Journal of Clinical Oncology","year":2014,"doi":"10.1200/jco.2013.53.9288"},{"title":"OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer","journal":"New England Journal of Medicine","year":2021,"url":"https://doi.org/10.1056/NEJMoa2105215","doi":"10.1056/NEJMoa2105215"}],"orcid":"0000-0001-9501-4509"},{"id":"evanthia-galanis","kind":"person","name":"Evanthia Galanis","aka":[],"tldr":"Evanthia Galanis is a brain tumour specialist who chairs one of the largest US clinical trial networks.","summary":"Evanthia Galanis is Group Chair of the Alliance for Clinical Trials in Oncology and Professor of Oncology at Mayo Clinic. A medical oncologist specialising in neuro-oncology, her research centres on glioblastoma and oncolytic measles virus therapy, and she became group chair of the Alliance in 2023, succeeding Monica Bertagnolli. Her papers include a Cancer Research study of an oncolytic measles virus expressing the sodium iodide symporter for drug-resistant ovarian cancer and a Journal of Clinical Oncology phase II trial of vorinostat in recurrent glioblastoma. She now leads one of the largest US clinical trial networks while continuing work on oncolytic viruses in glioma and ovarian cancer.","asOf":"2026-09-08","links":[{"label":"Mayo Clinic research faculty","url":"https://www.mayo.edu/research/faculty"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Galanis%20E%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Evanthia%20Galanis"}],"tags":[],"related":[],"cancers":["glioblastoma","ovarian"],"sections":[],"technologies":["oncolytic-virus"],"targets":[],"drugs":[],"companies":["alliance-oncology"],"institutions":["mayo-clinic"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["cancer-research"],"dependsOn":[],"notes":[],"role":"Group Chair, Alliance for Clinical Trials in Oncology; Professor of Oncology, Mayo Clinic","institutionId":"mayo-clinic","specialisms":["Neuro-oncology","Oncolytic viruses","Cooperative group trials"],"profiles":[{"label":"Mayo Clinic research faculty","url":"https://www.mayo.edu/research/faculty"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Galanis%20E%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Evanthia%20Galanis"}],"papers":[{"title":"Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer","journal":"Cancer Research","year":2015,"url":"https://doi.org/10.1158/0008-5472.CAN-14-2533","doi":"10.1158/0008-5472.CAN-14-2533"},{"title":"Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study","journal":"Journal of Clinical Oncology","year":2009,"url":"https://doi.org/10.1200/JCO.2008.19.0694","doi":"10.1200/JCO.2008.19.0694"}]},{"id":"evelyn-lauder","kind":"person","name":"Evelyn Lauder","aka":[],"tldr":"A breast cancer survivor and Estée Lauder executive who co-created the pink ribbon in 1992 and founded the Breast Cancer Research Foundation in 1993, now one of the largest private funders of breast cancer research.","summary":"Evelyn Lauder (1936-2011) came to New York as a child refugee from Vienna and became a senior executive at the Estée Lauder Companies. After her own treatment for breast cancer, she worked with Alexandra Penney of Self magazine in 1992 to create and distribute the pink ribbon at Estée Lauder counters, launching the Breast Cancer Awareness Campaign that has since collected millions of signatures for research funding. In 1993 she founded the Breast Cancer Research Foundation with a model of low overhead and rapid, investigator-driven grants; it has become one of the largest private funders of breast cancer research in the world, supporting many of the investigators behind current therapy. She helped create the Evelyn H. Lauder Breast Center at Memorial Sloan Kettering. She died of ovarian cancer in November 2011.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Evelyn_Lauder","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Evelyn_Lauder"},{"label":"Breast Cancer Research Foundation","url":"https://www.bcrf.org/"}],"tags":["hero","advocate","patient"],"related":["src-bcrf"],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-funding-allocation"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Co-creator of the pink ribbon and founder of the Breast Cancer Research Foundation","specialisms":["Breast cancer research funding","Cancer awareness"],"profiles":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Evelyn_Lauder"},{"label":"Breast Cancer Research Foundation","url":"https://www.bcrf.org/"}],"papers":[]},{"id":"everett-vokes","kind":"person","name":"Everett E. Vokes","aka":[],"tldr":"Head and neck cancer leader who established organ-preserving chemoradiation and led ASCO in 2021-22.","summary":"Everett Vokes is Chair of Medicine at the University of Chicago and served as President of the American Society of Clinical Oncology (ASCO) for 2021 to 2022. A medical oncologist specialising in head and neck and lung cancer, his trials of induction chemotherapy and chemoradiotherapy shaped head and neck cancer treatment and established organ-preserving chemoradiation. His papers include a New England Journal of Medicine review of head and neck cancer and a Journal of Clinical Oncology report on weekly carboplatin and paclitaxel followed by concomitant chemoradiotherapy as curative, organ-preserving therapy for advanced head and neck cancer. His record links to the RTOG 0129 HPV analysis and modern image-guided radiotherapy.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Everett_E._Vokes","links":[{"label":"ASCO leadership","url":"https://www.asco.org/about-asco/asco-leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Vokes%20EE%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Everett%20E.%20Vokes"}],"tags":[],"related":[],"cancers":["head-and-neck","nsclc"],"sections":[],"technologies":["imrt-igrt"],"targets":[],"drugs":[],"companies":[],"institutions":["asco"],"pathways":[],"terms":[],"trials":["rtog-0129"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"ASCO President 2021-2022; Chair of Medicine, University of Chicago","institutionId":"asco","specialisms":["Head and neck cancer","Lung cancer","Chemoradiation"],"profiles":[{"label":"ASCO leadership","url":"https://www.asco.org/about-asco/asco-leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Vokes%20EE%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Everett%20E.%20Vokes"}],"papers":[{"title":"Head and neck cancer","journal":"New England Journal of Medicine","year":1993,"url":"https://doi.org/10.1056/NEJM199301213280306","doi":"10.1056/NEJM199301213280306"},{"title":"Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer","journal":"Journal of Clinical Oncology","year":2003,"url":"https://doi.org/10.1200/JCO.2003.06.006","doi":"10.1200/JCO.2003.06.006"},{"title":"CheckMate 816: three cycles of nivolumab plus chemotherapy before lung cancer surgery","journal":"New England Journal of Medicine","year":2022,"url":"https://doi.org/10.1056/NEJMoa2202170","doi":"10.1056/NEJMoa2202170"}],"orcid":"0000-0002-8645-8068"},{"id":"ewan-birney","kind":"person","name":"Ewan Birney","aka":[],"tldr":"Computational biologist who directs EMBL-EBI, home of the open genomic and cancer data resources used worldwide.","summary":"Ewan Birney is Director of EMBL's European Bioinformatics Institute (EMBL-EBI) near Cambridge, UK. He is a computational biologist who played leading roles in the ENCODE project and the Ensembl genome browser, and has co-led the Global Alliance for Genomics and Health. EMBL-EBI hosts open resources, including the European Genome-phenome Archive and Open Targets, that underpin cancer genomics research.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.ebi.ac.uk/about/leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Birney+E%5BAuthor%5D"}],"tags":["leadership","genomics","bioinformatics"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["embl-ebi"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director of EMBL-EBI","institutionId":"embl-ebi","specialisms":["Genomics","Bioinformatics","Functional genomics"],"profiles":[{"label":"Institution profile","url":"https://www.ebi.ac.uk/about/leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Birney+E%5BAuthor%5D"}],"papers":[{"title":"Velvet: algorithms for de novo short read assembly using de Bruijn graphs","journal":"Genome Research","year":2008,"url":"https://doi.org/10.1101/gr.074492.107","doi":"10.1101/gr.074492.107","note":"Europe PMC author record matched by affiliation"},{"title":"AlphaFold Protein Structure Database: massively expanding the structural coverage of protein-sequence space with high-accuracy models","journal":"Nucleic Acids Research","year":2022,"url":"https://doi.org/10.1093/nar/gkab1061","doi":"10.1093/nar/gkab1061","note":"Europe PMC author record matched by affiliation"},{"title":"Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt","journal":"Nature Protocols","year":2009,"url":"https://doi.org/10.1038/nprot.2009.97","doi":"10.1038/nprot.2009.97","note":"Europe PMC author record matched by affiliation"}],"orcid":"0000-0001-8314-8497"},{"id":"eytan-stein","kind":"person","name":"Eytan M. Stein","aka":[],"tldr":"Led the enasidenib and revumenib trials that brought IDH2 and menin inhibitors to acute leukaemia.","summary":"Eytan Stein led the first-in-human trial of the IDH2 inhibitor enasidenib, which won approval for relapsed IDH2-mutant AML, and was a lead investigator of AUGMENT-101, the trial establishing the menin inhibitor revumenib for KMT2A-rearranged and NPM1-mutant acute leukaemia. He heads the leukaemia service at MSKCC and directs early-phase leukaemia drug development.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Stein%20EM%5BAuthor%5D%20enasidenib%20OR%20revumenib"}],"tags":["aml","menin","idh","early-phase"],"related":[],"cancers":["aml","all-leukemia"],"sections":[],"technologies":[],"targets":["idh","menin"],"drugs":["revumenib"],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":["augment-101"],"people":[],"bottlenecks":[],"keyPapers":["paper-augment-101-revumenib-menin-nature-2023"],"journals":["blood"],"dependsOn":[],"notes":[],"role":"Chief, Leukemia Service, Memorial Sloan Kettering Cancer Center","institutionId":"mskcc","specialisms":["Acute myeloid leukaemia","IDH inhibitors","Menin inhibitors","Early drug development"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Stein%20EM%5BAuthor%5D%20enasidenib%20OR%20revumenib"}],"papers":[{"title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","journal":"Blood","year":2017,"doi":"10.1182/blood-2017-04-779405"},{"title":"The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia","journal":"Nature","year":2023,"doi":"10.1038/s41586-023-05812-3"},{"title":"AUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation","journal":"Nature","year":2023,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=AUGMENT-101%20revumenib%20menin%20inhibitor%20KMT2A%20NPM1%20Issa%20Nature%202023"}]},{"id":"ezra-cohen","kind":"person","name":"Ezra E. W. Cohen","aka":[],"tldr":"Led KEYNOTE-040, which showed pembrolizumab improves survival in previously treated head and neck cancer.","summary":"Ezra Cohen was principal investigator of KEYNOTE-040, the randomised trial showing pembrolizumab improves overall survival over standard chemotherapy in platinum-refractory head and neck squamous cell carcinoma, and led the SITC consensus on immunotherapy in the disease. He has also led targeted therapy trials in thyroid cancer and chairs the head and neck section of major cooperative groups.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cohen%20EEW%5BAuthor%5D%20head%20neck%20pembrolizumab"}],"tags":["head-and-neck","immunotherapy"],"related":[],"cancers":["head-and-neck","thyroid"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["pd1"],"drugs":["pembrolizumab"],"companies":[],"institutions":["ucsd-moores"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["jitc"],"dependsOn":[],"notes":[],"role":"Professor of Medicine and Chief of Hematology-Oncology, UC San Diego Moores Cancer Center","institutionId":"ucsd-moores","specialisms":["Head and neck cancer","Immunotherapy","Thyroid cancer","Precision oncology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cohen%20EEW%5BAuthor%5D%20head%20neck%20pembrolizumab"}],"papers":[{"title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040)","journal":"Lancet","year":2019,"doi":"10.1016/S0140-6736(18)31999-8"},{"title":"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)","journal":"Journal for ImmunoTherapy of Cancer","year":2019,"doi":"10.1186/s40425-019-0662-5"}],"orcid":"0000-0002-9872-6242"},{"id":"f-stephen-hodi","kind":"person","name":"F. Stephen Hodi","aka":[],"tldr":"First author of the 2010 ipilimumab trial that proved immunotherapy could extend survival in melanoma.","summary":"F. Stephen Hodi is Director of the Melanoma Center and the Center for Immuno-Oncology at Dana-Farber Brigham Cancer Center. He is known as first author of the 2010 phase 3 ipilimumab trial that opened the checkpoint-inhibitor era in melanoma, and later for the long-term follow-up of nivolumab plus ipilimumab in CheckMate 067. His selected papers report ipilimumab in metastatic melanoma and the long-term results of nivolumab with or without ipilimumab in advanced melanoma. He now directs Dana-Farber's immuno-oncology centre and continues to work on CTLA-4 and PD-1 blockade.","asOf":"2026-09-08","links":[{"label":"Dana-Farber profile","url":"https://www.dana-farber.org/find-a-doctor/f-stephen-hodi"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hodi%20FS%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["melanoma"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["ctla4","pd1"],"drugs":["ipilimumab","nivolumab"],"companies":[],"institutions":["dana-farber"],"pathways":[],"terms":[],"trials":["checkmate-067"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Melanoma Center and Center for Immuno-Oncology","institutionId":"dana-farber","specialisms":["Melanoma","Checkpoint inhibitors","Immuno-oncology"],"profiles":[{"label":"Dana-Farber profile","url":"https://www.dana-farber.org/find-a-doctor/f-stephen-hodi"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hodi%20FS%5BAuthor%5D"}],"papers":[{"title":"Improved survival with ipilimumab in patients with metastatic melanoma","journal":"New England Journal of Medicine","year":2010,"url":"https://doi.org/10.1056/NEJMoa1003466","doi":"10.1056/NEJMoa1003466"},{"title":"Long-term survival with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma (CheckMate 067)","journal":"New England Journal of Medicine","year":2025,"url":"https://doi.org/10.1056/NEJMoa2407417","doi":"10.1056/NEJMoa2407417"},{"title":"CheckMate 067 at ten years: half of melanoma patients treated with nivolumab plus ipilimumab were alive a decade later","journal":"New England Journal of Medicine","year":2025,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CheckMate%20067%2010-year%20nivolumab%20ipilimumab%20melanoma%20Wolchok%20NEJM%202025"},{"title":"Topalian 2012: the first large trial of a PD-1 antibody shows durable responses across melanoma, lung and kidney cancer","journal":"New England Journal of Medicine","year":2012,"url":"https://doi.org/10.1056/NEJMoa1200690","doi":"10.1056/NEJMoa1200690"}]},{"id":"fabrice-andre","kind":"person","name":"Fabrice André","aka":[],"tldr":"Breast cancer geneticist who led SOLAR-1 and the SAFIR precision-medicine trials; ESMO President 2025-2026.","summary":"Fabrice André is Director of Research at Gustave Roussy and Professor of Medical Oncology at Paris-Saclay, and served as President of the European Society for Medical Oncology (ESMO) for 2025-2026. His specialisms are breast cancer, precision oncology and genomics-driven trials, using comprehensive genomic profiling. He leads the breast cancer genomics programme at Gustave Roussy and was principal investigator of SOLAR-1, the trial of alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer reported in the New England Journal of Medicine. He also led the SAFIR01 and SAFIR02 genomics-guided trials, with the Nature paper on SAFIR02-BREAST testing genomics to select treatment for metastatic breast cancer. His Gustave Roussy profile and PubMed listing are linked.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Fabrice_Andr%C3%A9","links":[{"label":"Gustave Roussy","url":"https://www.gustaveroussy.fr/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Andre%20F%5BAuthor%5D%20breast%20alpelisib"}],"tags":[],"related":[],"cancers":["breast-hr-positive"],"sections":[],"technologies":["cgp"],"targets":["pik3ca"],"drugs":["alpelisib"],"companies":[],"institutions":["gustave-roussy","esmo"],"pathways":[],"terms":[],"trials":["solar-1"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director of Research, Gustave Roussy; Professor of Medical Oncology, Paris-Saclay","institutionId":"gustave-roussy","specialisms":["Breast cancer","Precision oncology","Genomics-driven trials","ESMO leadership"],"profiles":[{"label":"Gustave Roussy","url":"https://www.gustaveroussy.fr/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Andre%20F%5BAuthor%5D%20breast%20alpelisib"}],"papers":[{"title":"Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer","journal":"NEJM","year":2019,"doi":"10.1056/NEJMoa1813904"},{"title":"Genomics to select treatment for patients with metastatic breast cancer (SAFIR02-BREAST)","journal":"Nature","year":2022,"doi":"10.1038/s41586-022-05068-3"}]},{"id":"fabrice-barlesi","kind":"person","name":"Fabrice Barlesi","aka":[],"tldr":"Fabrice Barlesi runs Europe's largest cancer centre and is a leading lung cancer trialist.","summary":"Fabrice Barlesi is Director General of Gustave Roussy and a thoracic oncologist, having previously led thoracic oncology in Marseille. His specialisms are thoracic oncology, immunotherapy, precision medicine and cancer centre leadership. He runs Europe's largest cancer centre and is a leading lung cancer trialist whose research covers immune checkpoint inhibitors and targeted therapy in non-small-cell lung cancer. He was the founding coordinator of several French national lung cancer trial programmes, and his Lancet paper on Biomarkers France reported a nationwide programme of routine molecular profiling for patients with advanced non-small-cell lung cancer. His Gustave Roussy profile and PubMed listing are linked.","asOf":"2026-09-08","links":[{"label":"Gustave Roussy","url":"https://www.gustaveroussy.fr/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Barlesi%20F%5BAuthor%5D%20lung"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":[],"companies":[],"institutions":["gustave-roussy"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director General, Gustave Roussy; thoracic oncologist","institutionId":"gustave-roussy","specialisms":["Thoracic oncology","Immunotherapy","Precision medicine","Cancer centre leadership"],"profiles":[{"label":"Gustave Roussy","url":"https://www.gustaveroussy.fr/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Barlesi%20F%5BAuthor%5D%20lung"}],"papers":[{"title":"Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme (Biomarkers France)","journal":"Lancet","year":2016,"doi":"10.1016/S0140-6736(16)00004-0"}]},{"id":"faisal-mahmood","kind":"person","name":"Faisal Mahmood","aka":[],"tldr":"Built UNI and CONCH, the pathology foundation models that let AI read whole-slide images across cancer types.","summary":"Faisal Mahmood's laboratory developed CLAM for weakly supervised whole-slide learning, TOAD for predicting tumour origin, and the UNI and CONCH foundation models trained on more than 100 million pathology images, which set the benchmark for general-purpose computational pathology. His group also builds multimodal models integrating histology with genomics for prognosis and is a leading academic voice on AI in pathology.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mahmood%20F%5BAuthor%5D%20computational%20pathology"}],"tags":["ai","pathology","foundation-models"],"related":[],"cancers":[],"sections":[],"technologies":["pathology-foundation-model","digital-pathology-ai"],"targets":[],"drugs":[],"companies":[],"institutions":["broad-institute"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-alphafold2-jumper-nature-2021"],"journals":[],"dependsOn":[],"notes":[],"role":"Associate Professor of Pathology, Harvard Medical School and Brigham and Women's Hospital; Associate Member, Broad Institute","institutionId":"broad-institute","specialisms":["Computational pathology","Pathology foundation models","Multimodal AI","Weakly supervised learning"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mahmood%20F%5BAuthor%5D%20computational%20pathology"}],"papers":[{"title":"Towards a general-purpose foundation model for computational pathology (UNI)","journal":"Nature Medicine","year":2024,"doi":"10.1038/s41591-024-02857-3"},{"title":"AI-based pathology predicts origins for cancers of unknown primary","journal":"Nature","year":2021,"doi":"10.1038/s41586-021-03512-4"},{"title":"Data-efficient and weakly supervised computational pathology on whole-slide images","journal":"Nature Biomedical Engineering","year":2021,"doi":"10.1038/s41551-020-00682-4"},{"title":"AlphaFold 2: predicting protein structures to near-experimental accuracy","journal":"Nature","year":2021,"url":"https://doi.org/10.1038/s41586-021-03819-2","doi":"10.1038/s41586-021-03819-2"}],"orcid":"0000-0001-7587-1562"},{"id":"faisal-sultan","kind":"person","name":"Faisal Sultan","aka":[],"tldr":"Physician who is Chief Executive Officer of Shaukat Khanum Memorial Cancer Hospital and Research Centre, Pakistan's philanthropic cancer hospital network.","summary":"Dr Faisal Sultan is Chief Executive Officer of Shaukat Khanum Memorial Cancer Hospital and Research Centre (SKMCH&RC), heading a senior management team that includes Chief Medical Officer Dr M. Aasim Yusuf and medical directors for the Lahore and Peshawar hospitals. The hospitals are run by the Shaukat Khanum Memorial Trust, whose Board of Governors is chaired by Dr Nausherwan Khan Burki and whose founder is Imran Khan. The Lahore hospital opened on 29 December 1994 and the Peshawar hospital on 29 December 2015, with a Karachi hospital under development; the institution reports that about 75 percent of its patients receive financially supported treatment.","asOf":"2026-09-10","links":[{"label":"Source: SKMCH&RC leadership page (Board of Governors and senior management)","url":"https://shaukatkhanum.org.pk/about-us/our-leadership/"},{"label":"Source: SKMCH&RC about us page","url":"https://shaukatkhanum.org.pk/about-us/"}],"tags":["leadership","hospital-management","philanthropy"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["shaukat-khanum"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive Officer, Shaukat Khanum Memorial Cancer Hospital and Research Centre","institutionId":"shaukat-khanum","specialisms":["Infectious diseases","Hospital management","Cancer care access"],"profiles":[{"label":"SKMCH&RC leadership page","url":"https://shaukatkhanum.org.pk/about-us/our-leadership/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sultan+F%5BAuthor%5D+AND+Shaukat+Khanum"}],"papers":[{"title":"Epidemiology of cancers in Lahore, Pakistan, 2010–2012: a cross-sectional study","journal":"BMJ Open","year":2016,"doi":"10.1136/bmjopen-2016-011828"},{"title":"Cancer care in times of conflict: cross border care in Pakistan of patients from Afghanistan","journal":"ecancermedicalscience","year":2020,"doi":"10.3332/ecancer.2020.1018"},{"title":"Hepatocellular Carcinoma in Pakistan: National Trends and Global Perspective","journal":"Gastroenterology Research and Practice","year":2016,"doi":"10.1155/2016/5942306"}],"orcid":"0000-0002-2618-988X"},{"id":"fan-daiming","kind":"person","name":"Fan Daiming","aka":[],"tldr":"Academician who presides over the China Anti-Cancer Association, China's national oncology society with branches in every province and around 260,000 individual members.","summary":"Fan Daiming (樊代明), an academician (院士), is President (理事长) of the China Anti-Cancer Association (CACA), the national first-level oncology society registered with the Ministry of Civil Affairs and supervised by the China Association for Science and Technology. CACA's 'About the Association' page lists him as current president, with Hao Xishan as honorary president, Zhao Yong as secretary general and vice presidents including He Jie, Fan Jia, Shen Hongbing and Cheng Xiangdong. The association was founded on 28 April 1984 by Jin Xianzhai, has its secretariat in Tianjin, and its earlier presidents were Wu Huanxing, Zhang Tianze, Xu Guangwei and Hao Xishan. CACA publishes the CACA guidelines and the English-language journal Holistic Integrative Oncology.","asOf":"2026-09-10","links":[{"label":"Source: China Anti-Cancer Association 'About the Association' page listing current leaders","url":"http://www.caca.org.cn/gyxh/index.shtml"}],"tags":["leadership","professional-society"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["caca"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["cancer-letters","international-journal-of-cancer","journal-of-experimental-and-clinical-cancer-research"],"dependsOn":[],"notes":[],"role":"President (理事长) of the China Anti-Cancer Association","institutionId":"caca","specialisms":["Integrative oncology","Professional society leadership","Cancer control policy"],"profiles":[{"label":"CACA: About the Association (current leadership)","url":"http://www.caca.org.cn/gyxh/index.shtml"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fan+D%5BAuthor%5D+AND+integrative+oncology"}],"papers":[{"title":"Multi-drug resistance in cancer chemotherapeutics: Mechanisms and lab approaches","journal":"Cancer Letters","year":2014,"doi":"10.1016/j.canlet.2014.03.013"},{"title":"miR‐15b and miR‐16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells","journal":"International Journal of Cancer","year":2008,"doi":"10.1002/ijc.23501"},{"title":"Tunicamycin specifically aggravates ER stress and overcomes chemoresistance in multidrug-resistant gastric cancer cells by inhibiting N-glycosylation","journal":"Journal of Experimental & Clinical Cancer Research","year":2018,"doi":"10.1186/s13046-018-0935-8"}]},{"id":"zhang-fangliang","kind":"person","name":"Fangliang (Frank) Zhang","aka":["Frank Zhang","张方亮"],"tldr":"Frank Zhang founded GenScript and its cell therapy spin-out Legend Biotech, whose Nanjing team invented the myeloma CAR-T that became Carvykti.","summary":"Zhang founded GenScript in New Jersey in 2002 and moved it to Nanjing; Legend Biotech, spun out in 2014, developed the llama-derived BCMA CAR-T LCAR-B38M (LEGEND-2), partnered it with Janssen in 2017 and listed on Nasdaq in 2020; ciltacabtagene autoleucel was approved by the FDA in 2022 and the NMPA in 2024. He stepped back from executive roles in 2021.","asOf":"2026-09-10","links":[{"label":"Legend Biotech","url":"https://www.legendbiotech.com/"}],"tags":["china"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["ciltacabtagene-autoleucel"],"companies":["legend-biotech"],"institutions":[],"pathways":[],"terms":[],"trials":["legend-2","cartitude-1"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Founder and former Chairman, Legend Biotech; former Chairman, GenScript Biotech","specialisms":["Cell therapy","Biotech leadership","Gene synthesis"],"profiles":[{"label":"Legend Biotech","url":"https://www.legendbiotech.com/"}],"papers":[]},{"id":"farhat-abbas","kind":"person","name":"Farhat Abbas","aka":[],"tldr":"Urological surgeon who is Chief Executive Officer of the Aga Khan University Hospital and Health System in Pakistan, based at the Karachi teaching hospital.","summary":"Farhat Abbas (MD, FCPS, FRCS, FRCSEd, FEBU, FACS) is Chief Executive Officer of The Aga Khan University Hospital and Health System, Pakistan, and also Special Advisor to the President and Husein Cumber Professor of Surgery (Urology) at Aga Khan University. In his welcome message he describes a relationship with AKU spanning more than 40 years, training as a surgeon and serving in multiple roles across the university and its health services. The hospital's page notes that in 2024 nearly 1.5 million patients received financial support through its Patient Welfare and Zakat programmes, and that it is accredited by Joint Commission International and the College of American Pathologists.","asOf":"2026-09-10","links":[{"label":"Source: AKUH Pakistan CEO welcome page","url":"https://hospitals.aku.edu/pakistan/AboutUs/Pages/welcome-by-ceo-akuh-pakistan.aspx"}],"tags":["leadership","clinician-scientist","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["aku-karachi"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["world-journal-of-surgical-oncology"],"dependsOn":[],"notes":[],"role":"Chief Executive Officer, The Aga Khan University Hospital and Health System, Pakistan","institutionId":"aku-karachi","specialisms":["Urology","Surgery","Hospital management"],"profiles":[{"label":"Welcome by CEO, AKUH Pakistan","url":"https://hospitals.aku.edu/pakistan/AboutUs/Pages/welcome-by-ceo-akuh-pakistan.aspx"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Abbas+F%5BAuthor%5D+AND+Aga+Khan"}],"papers":[{"title":"Granular cell tumors of the urinary bladder","journal":"World Journal of Surgical Oncology","year":2007,"doi":"10.1186/1477-7819-5-33"},{"title":"Incidental Prostate Cancer: The Importance of Complete Prostatic Removal at Cystoprostatectomy for Bladder Cancer","journal":"Urologia Internationalis","year":2000,"doi":"10.1159/000030486"}]},{"id":"ma-fei","kind":"person","name":"Fei Ma","aka":[],"tldr":"A breast oncologist who led Chinese pyrotinib and ADC trials and studies of ctDNA in HER2-positive disease.","summary":"Fei Ma is Professor of Medical Oncology at the Cancer Hospital of the Chinese Academy of Medical Sciences in Beijing. She has led Chinese trials of pyrotinib and of HER2-directed antibody-drug conjugates, and studies circulating tumour DNA and resistance in HER2-positive breast cancer. Her publications include the phase 1 study and biomarker analysis of pyrotinib, a randomised phase 2 comparison of pyrotinib or lapatinib with capecitabine in pretreated HER2-positive metastatic breast cancer, and the PHILA phase 3 trial of pyrotinib added to trastuzumab and docetaxel as first-line treatment. Her interests are HER2, antibody-drug conjugates and liquid biopsy.","asOf":"2026-09-08","links":[{"label":"Cancer Hospital, CAMS","url":"https://www.cicams.ac.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ma%20F%5BAuthor%5D%20Chinese%20Academy%20of%20Medical%20Sciences%20pyrotinib"}],"tags":[],"related":[],"cancers":["breast-her2-positive"],"sections":[],"technologies":["liquid-biopsy"],"targets":["her2"],"drugs":["pyrotinib"],"companies":[],"institutions":["cams-cancer-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology; Cancer Hospital, Chinese Academy of Medical Sciences","institutionId":"cams-cancer-hospital","specialisms":["Breast cancer","HER2","Antibody-drug conjugates","Circulating tumour DNA"],"profiles":[{"label":"Cancer Hospital, CAMS","url":"https://www.cicams.ac.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ma%20F%5BAuthor%5D%20Chinese%20Academy%20of%20Medical%20Sciences%20pyrotinib"}],"papers":[{"title":"Pyrotinib or Lapatinib Combined With Capecitabine in HER2–Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study","journal":"Journal of Clinical Oncology","year":2019,"doi":"10.1200/jco.19.00108"},{"title":"Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial","journal":"BMJ","year":2023,"doi":"10.1136/bmj-2023-076065"},{"title":"Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer","journal":"Journal of Clinical Oncology","year":2017,"doi":"10.1200/jco.2016.69.6179"}]},{"id":"wang-feng-sysucc","kind":"person","name":"Feng Wang","aka":[],"tldr":"A GI oncologist whose work on immunotherapy biomarkers and Chinese gastric cancer trials feeds global guidelines.","summary":"Feng Wang is Professor of Medical Oncology at Sun Yat-sen University Cancer Center in Guangzhou. He leads gastrointestinal immunotherapy research at the centre, including biomarker analyses of response to PD-1 antibodies and Chinese trials of first-line immunochemotherapy in gastric cancer, and his work feeds global guidelines. His publications include a phase Ib/II study of toripalimab in chemo-refractory gastric cancer with tumour mutational burden as a biomarker, an evaluation of POLE and POLD1 mutations as biomarkers for immunotherapy across cancer types, and the Chinese Society of Clinical Oncology guidelines for gastric cancer. His interests are gastric cancer, colorectal cancer and immunotherapy biomarkers.","asOf":"2026-09-08","links":[{"label":"Sun Yat-sen University Cancer Center","url":"https://www.sysucc.org.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wang%20F%5BAuthor%5D%20Sun%20Yat-sen%20gastric%20cancer%20immunotherapy"}],"tags":[],"related":[],"cancers":["gastric","colorectal"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":[],"companies":[],"institutions":["sysucc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["cancer-communications"],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology, Sun Yat-sen University Cancer Center","institutionId":"sysucc","specialisms":["Gastric cancer","Colorectal cancer","Immunotherapy biomarkers"],"profiles":[{"label":"Sun Yat-sen University Cancer Center","url":"https://www.sysucc.org.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wang%20F%5BAuthor%5D%20Sun%20Yat-sen%20gastric%20cancer%20immunotherapy"}],"papers":[{"title":"Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432","journal":"Annals of Oncology","year":2019,"doi":"10.1093/annonc/mdz197"},{"title":"Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types","journal":"JAMA Oncology","year":2019,"doi":"10.1001/jamaoncol.2019.2963"},{"title":"The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021","journal":"Cancer Communications","year":2021,"doi":"10.1002/cac2.12193"}]},{"id":"feng-zhang","kind":"person","name":"Feng Zhang","aka":[],"tldr":"Pioneer of CRISPR-Cas9 genome editing in human cells, the tool behind cancer dependency screens and edited cell therapies.","summary":"Feng Zhang is a Core Institute Member of the Broad Institute of MIT and Harvard and the James and Patricia Poitras Professor of Neuroscience at MIT. He is a pioneer of CRISPR-Cas9 genome editing in human cells, having adapted the system for mammalian genome editing in 2013 and later discovered the Cas12 and Cas13 systems. His selected paper reports multiplex genome engineering using CRISPR/Cas systems. His tools underpin genome-wide cancer dependency screens and next-generation engineered and off-the-shelf cell therapies, and his laboratory continues to work on molecular tools and delivery.","asOf":"2026-09-08","links":[{"label":"Broad bio","url":"https://www.broadinstitute.org/bios/feng-zhang"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Zhang%20F%5BAuthor%5D"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["crispr-screens","allogeneic-cell-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":["broad-institute"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Core Institute Member, Broad; James and Patricia Poitras Professor of Neuroscience, MIT","institutionId":"broad-institute","specialisms":["CRISPR genome editing","Molecular tools","Delivery"],"profiles":[{"label":"Broad bio","url":"https://www.broadinstitute.org/bios/feng-zhang"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Zhang%20F%5BAuthor%5D"}],"papers":[{"title":"Multiplex genome engineering using CRISPR/Cas systems","journal":"Science","year":2013,"url":"https://doi.org/10.1126/science.1231143","doi":"10.1126/science.1231143"}]},{"id":"ferdinandos-skoulidis","kind":"person","name":"Ferdinandos Skoulidis","aka":[],"tldr":"Led CodeBreaK 100, the trial that made sotorasib the first approved KRAS inhibitor, and showed STK11/KEAP1 co-mutations blunt immunotherapy.","summary":"Ferdinandos Skoulidis was lead author of the phase 2 CodeBreaK 100 report that won sotorasib accelerated approval for KRAS G12C-mutant NSCLC, closing forty years of KRAS being undruggable. His earlier work showed that STK11 and KEAP1 co-mutations define an immunotherapy-resistant subgroup of KRAS-mutant lung cancer. He continues to lead KRAS combination trials at MD Anderson.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Skoulidis%20F%5BAuthor%5D%20KRAS"}],"tags":["lung","kras","targeted-therapy"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["kras-inhibitors"],"targets":["kras"],"drugs":["sotorasib","adagrasib"],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":["codebreak-200"],"people":[],"bottlenecks":[],"keyPapers":["paper-codebreak-200-lancet-2023","paper-ostrem-kras-g12c-nature-2013"],"journals":[],"dependsOn":[],"notes":[],"role":"Associate Professor of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center","institutionId":"md-anderson","specialisms":["KRAS-mutant lung cancer","Co-mutations and immunotherapy resistance","Targeted therapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Skoulidis%20F%5BAuthor%5D%20KRAS"}],"papers":[{"title":"Sotorasib for lung cancers with KRAS p.G12C mutation (CodeBreaK 100)","journal":"NEJM","year":2021,"doi":"10.1056/NEJMoa2103695"},{"title":"STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma","journal":"Cancer Discovery","year":2018,"doi":"10.1158/2159-8290.CD-18-0099"},{"title":"CodeBreaK 200: sotorasib versus docetaxel in KRAS G12C-mutated lung cancer, a modest win for the first KRAS drug","journal":"The Lancet","year":2023,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CodeBreaK+200+sotorasib+docetaxel+de+Langen+Lancet"},{"title":"Ostrem and Shokat: the hidden pocket that made KRAS G12C druggable","journal":"Nature","year":2013,"url":"https://doi.org/10.1038/nature12796","doi":"10.1038/nature12796"}]},{"id":"fernando-pelaez","kind":"person","name":"Fernando Peláez","aka":[],"tldr":"Biologist and long-time CNIO director of biotechnology programmes who became Acting Scientific Director of Spain's national cancer research centre in 2025.","summary":"Fernando Peláez is Acting Scientific Director of the Centro Nacional de Investigaciones Oncológicas (CNIO) in Madrid, following the 2025 departure of María Blasco. A biologist with a background in natural-products drug discovery, he previously directed CNIO's Biotechnology Programme. In September 2025 the CNIO Board of Trustees proposed Raúl Rabadán as the centre's next Scientific Director, with Peláez holding the acting role in the interim.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.cnio.es/en/about-the-cnio/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Pelaez+F%5BAuthor%5D+CNIO"}],"tags":["leadership","drug discovery","basic science"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cnio"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nature","pnas","science"],"dependsOn":[],"notes":[],"role":"Acting Scientific Director","institutionId":"cnio","specialisms":["Drug discovery","Microbiology","Research management"],"profiles":[{"label":"Institution profile","url":"https://www.cnio.es/en/about-the-cnio/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Pelaez+F%5BAuthor%5D+CNIO"}],"papers":[{"title":"Platensimycin is a selective FabF inhibitor with potent antibiotic properties","journal":"Nature","year":2006,"url":"https://doi.org/10.1038/nature04784","doi":"10.1038/nature04784","note":"Europe PMC author record matched by affiliation (Merck Sharp & Dohme research centre, Madrid, before CNIO)"},{"title":"Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties","journal":"Proceedings of the National Academy of Sciences","year":2007,"url":"https://doi.org/10.1073/pnas.0700746104","doi":"10.1073/pnas.0700746104","note":"Europe PMC author record matched by affiliation (Merck Sharp & Dohme research centre, Madrid, before CNIO)"},{"title":"Discovery of a small molecule insulin mimetic with antidiabetic activity in mice","journal":"Science","year":1999,"url":"https://doi.org/10.1126/science.284.5416.974","doi":"10.1126/science.284.5416.974","note":"Europe PMC author record matched by affiliation (Merck Sharp & Dohme research centre, Madrid, before CNIO)"}]},{"id":"filippo-de-braud","kind":"person","name":"Filippo de Braud","aka":[],"tldr":"Filippo de Braud heads medical oncology and the phase 1 programme at Italy's national cancer institute.","summary":"Filippo de Braud is Director of Medical Oncology and Hematology at the Fondazione IRCCS Istituto Nazionale dei Tumori in Milan and Professor at the University of Milan. His specialisms are medical oncology, early-phase trials and gastrointestinal cancers, and he heads the phase 1 programme at Italy's national cancer institute. His papers include the combined phase I results of the pan-TRK, ROS1 and ALK inhibitor entrectinib from the ALKA-372-001 and STARTRK-1 trials, a Cancer Discovery study showing a fasting-mimicking diet is safe and reshapes metabolism and antitumour immunity in patients with cancer, and the CheckMate 032 trial of nivolumab alone or with ipilimumab in recurrent small-cell lung cancer. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=de%20Braud%20F%5BAuthor%5D%20phase%20I"}],"tags":[],"related":[],"cancers":["sclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["int-milan"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Medical Oncology and Hematology, INT Milan; Professor, University of Milan","institutionId":"int-milan","specialisms":["Medical oncology","Early-phase trials","Gastrointestinal cancers"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=de%20Braud%20F%5BAuthor%5D%20phase%20I"}],"papers":[{"title":"Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)","journal":"Cancer Discovery","year":2017,"doi":"10.1158/2159-8290.cd-16-1237"},{"title":"Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer","journal":"Cancer Discovery","year":2021,"doi":"10.1158/2159-8290.cd-21-0030"},{"title":"Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial","journal":"The Lancet Oncology","year":2016,"doi":"10.1016/s1470-2045(16)30098-5"}],"orcid":"0000-0003-0103-730X"},{"id":"fiona-blackhall","kind":"person","name":"Fiona Blackhall","aka":[],"tldr":"Fiona Blackhall is a thoracic oncologist leading small-cell lung cancer trials and biomarker research at The Christie.","summary":"Fiona Blackhall is Professor of Thoracic Oncology at the University of Manchester and a consultant at The Christie NHS Foundation Trust. Her specialisms are lung cancer, small-cell lung cancer and biomarker-driven trials. She leads thoracic oncology research in Manchester with trials in small-cell and non-small-cell lung cancer and studies of blood-based biomarkers. Her papers include an analysis of the prognostic value of circulating tumour cells in limited-stage small-cell lung cancer within the CONVERT radiotherapy trial, the randomised ERCC1 biomarker trial comparing platinum and non-platinum therapy in advanced non-small-cell lung cancer, and a review of liquid biopsy as a route to improved care in small-cell lung cancer. Her publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Blackhall%20F%5BAuthor%5D%20small%20cell%20lung"}],"tags":[],"related":[],"cancers":["sclc","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["the-christie"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Thoracic Oncology, University of Manchester; Consultant, The Christie","institutionId":"the-christie","specialisms":["Lung cancer","Small-cell lung cancer","Biomarker-driven trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Blackhall%20F%5BAuthor%5D%20small%20cell%20lung"}],"papers":[{"title":"Prognostic value of circulating tumour cells in limited-stage small-cell lung cancer: analysis of the concurrent once-daily versus twice-daily radiotherapy (CONVERT) randomised controlled trial","journal":"Annals of Oncology","year":2019,"doi":"10.1093/annonc/mdz122"},{"title":"Randomized Prospective Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum Therapy in Advanced Non–Small-Cell Lung Cancer: ERCC1 Trial (ET)","journal":"Journal of Clinical Oncology","year":2017,"doi":"10.1200/jco.2016.68.1841"},{"title":"Liquid Biopsy in Small Cell Lung Cancer—A Route to Improved Clinical Care?","journal":"Cells","year":2020,"doi":"10.3390/cells9122586"},{"title":"DeLLphi-301: tarlatamab, a DLL3-targeting T-cell engager, in previously treated small-cell lung cancer","journal":"New England Journal of Medicine","year":2023,"url":"https://doi.org/10.1056/NEJMoa2307980","doi":"10.1056/NEJMoa2307980"}],"orcid":"0000-0001-8716-3395"},{"id":"fitzhugh-mullan","kind":"person","name":"Fitzhugh Mullan","aka":[],"tldr":"Wrote the 1985 essay that gave cancer survivorship its name and its first framework, then co-founded the organisation that changed what people treated for cancer are called.","summary":"Fitzhugh Mullan was a physician who had been treated for cancer; the Institute of Medicine's 2006 survivorship report describes him as \"a physician and cancer survivor\". In July 1985 the New England Journal of Medicine published his essay \"Seasons of survival: reflections of a physician with cancer\", which divided survival into acute, extended and permanent seasons and argued that the time after treatment was unmapped territory with hazards of its own. The Institute of Medicine's 2006 survivorship report opens by quoting his challenge: \"The challenge in overcoming cancer is not only to find therapies that will prevent or arrest the disease quickly, but also to map the middle ground of survivorship and minimize its medical and social hazards\".\n\nThe following year he was a co-founder of the National Coalition for Cancer Survivorship, formed by twenty-three people in Albuquerque, New Mexico in October 1986, and served as its founding president. The organisation's purpose was to replace the words \"cancer victim\" with \"cancer survivor\" and to define a survivor as someone living with cancer from diagnosis for the balance of life, which is the definition the National Cancer Institute uses today and credits to the coalition.\n\nHis later writing was largely in health policy rather than in oncology, and Health Affairs maintains a reading list of it. He died; The Lancet published an obituary in its issue of January 2020 and Health Affairs a final conversation with him in February 2020. OnCo has not read the 1985 essay itself, which is paywalled and carries no abstract in Europe PMC, and takes the quotation above from the Institute of Medicine report that reproduces it.","asOf":"2026-10-02","links":[{"label":"Mullan, Seasons of survival: reflections of a physician with cancer (New England Journal of Medicine 1985;313:270-273)","url":"https://doi.org/10.1056/NEJM198507253130421"},{"label":"National Coalition for Cancer Survivorship (now Cancer Nation): Our History","url":"https://canceradvocacy.org/about/our-history/"},{"label":"From Cancer Patient to Cancer Survivor: Lost in Transition, executive summary (National Academies Press reader)","url":"https://nap.nationalacademies.org/read/11468/chapter/2"}],"tags":["survivorship","history","advocacy"],"related":["rejuv-history-seasons-of-survival","rejuv-history-survivorship-movement","rejuv-history-lost-in-transition","rejuv-mind-the-word-survivor","rejuvenation-roadmap"],"cancers":[],"sections":["rejuvenation","supportive-care"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Physician and writer; founding president of the National Coalition for Cancer Survivorship","specialisms":["Cancer survivorship","Health policy","Patient advocacy"],"profiles":[{"label":"Europe PMC: Mullan 1985, Seasons of survival","url":"https://europepmc.org/article/MED/4010738"}],"papers":[{"title":"Seasons of survival: reflections of a physician with cancer","journal":"New England Journal of Medicine","year":1985,"url":"https://doi.org/10.1056/NEJM198507253130421","doi":"10.1056/NEJM198507253130421"},{"title":"Fitzhugh Mullan (obituary)","journal":"The Lancet","year":2020,"url":"https://doi.org/10.1016/S0140-6736(20)30104-5","doi":"10.1016/S0140-6736(20)30104-5","note":"Written by Geoff Watts; cited here as the source for the fact of his death."},{"title":"Legacies and lessons: a final conversation with Fitzhugh Mullan","journal":"Health Affairs","year":2020,"url":"https://doi.org/10.1377/hlthaff.2019.01715","doi":"10.1377/hlthaff.2019.01715"}]},{"id":"flavio-tomasich","kind":"person","name":"Flávio Daniel Saavedra Tomasich","aka":[],"tldr":"Abdominal cancer surgeon who chairs the governing board of the Liga Paranaense de Combate ao Câncer, the body that runs Hospital Erasto Gaertner in Curitiba.","summary":"Flávio Daniel Saavedra Tomasich is Presidente of the Conselho de Administração of the Liga Paranaense de Combate ao Câncer, which runs Hospital Erasto Gaertner, a specialist cancer hospital in Curitiba, Paraná. The hospital's governance page describes him as a member of the clinical staff in the abdominal surgery service and states that the Liga is governed by a 19 member board serving four year terms, with Claudiane Ligia Minari as vice president and José Clemente Linhares as clinical director. Day to day management sits with an executive board of Fernando Cesar de Oliveira (administrative), Enio Fabrício Ostrovski Ponczek (financial) and Maria Rachel de Castro (care).","asOf":"2026-09-10","links":[{"label":"Source: Hospital Erasto Gaertner 'Conselho de Administração' page","url":"https://erastogaertner.com.br/pagina/conselho-de-administracao"},{"label":"Source: Hospital Erasto Gaertner 'Diretoria e Gerências' page","url":"https://erastogaertner.com.br/pagina/diretoria-e-gerencias"}],"tags":["leadership","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["erasto-gaertner"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Presidente do Conselho de Administração, Liga Paranaense de Combate ao Câncer (Hospital Erasto Gaertner)","institutionId":"erasto-gaertner","specialisms":["Abdominal surgical oncology","Hospital governance"],"profiles":[{"label":"Hospital Erasto Gaertner board page","url":"https://erastogaertner.com.br/pagina/conselho-de-administracao"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tomasich+F%5BAuthor%5D"}],"papers":[{"title":"Leiomiossarcoma primário de adrenal","journal":"Arquivos Brasileiros de Endocrinologia & Metabologia","year":2008,"doi":"10.1590/s0004-27302008000900017"},{"title":"Metástases intestinais de melanoma","journal":"Revista do Colégio Brasileiro de Cirurgiões","year":2003,"doi":"10.1590/s0100-69912003000200003"}],"orcid":"0000-0001-7219-0374"},{"id":"florence-duffaud","kind":"person","name":"Florence Duffaud","aka":[],"tldr":"Marseille oncologist who led REGOBONE, the trial that showed regorafenib delays progression in metastatic osteosarcoma and other bone sarcomas.","summary":"Florence Duffaud is a medical oncologist at Hôpital de la Timone in Marseille and a leader of the French Sarcoma Group. She was first author of the 2019 Lancet Oncology report of the osteosarcoma cohort of REGOBONE, the randomised phase 2 trial in which regorafenib improved progression-free survival compared with placebo in metastatic osteosarcoma after chemotherapy; other cohorts studied Ewing sarcoma, chondrosarcoma and chordoma.","asOf":"2026-09-18","links":[],"tags":["sarcoma","trialist"],"related":[],"cancers":["osteosarcoma","ewing-sarcoma","chondrosarcoma","sarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ap-hm-timone"],"pathways":[],"terms":[],"trials":["regobone"],"people":[],"bottlenecks":[],"keyPapers":["paper-florence-duffaud-ann-oncol-2017","paper-florence-duffaud-lancet-oncol-2020","paper-florence-duffaud-lancet-oncol-2019"],"journals":[],"dependsOn":[],"notes":[],"role":"Medical oncologist, Hôpital de la Timone, Aix-Marseille University","institutionId":"ap-hm-timone","specialisms":["Bone sarcoma","Gastrointestinal stromal tumour","Kinase inhibitors in sarcoma"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Duffaud%5BAuthor%5D"}],"papers":[{"title":"Improved survival using specialized multidisciplinary board in sarcoma patients","journal":"Annals of Oncology","year":2017,"url":"https://doi.org/10.1093/annonc/mdx484","doi":"10.1093/annonc/mdx484","note":"Europe PMC author record matched by affiliation (Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille); 274 citations on Europe PMC."},{"title":"Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial","journal":"The Lancet Oncology","year":2020,"url":"https://doi.org/10.1016/s1470-2045(19)30825-3","doi":"10.1016/s1470-2045(19)30825-3","note":"Europe PMC author record matched by affiliation (Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille); 267 citations on Europe PMC."},{"title":"Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study","journal":"The Lancet Oncology","year":2019,"url":"https://doi.org/10.1016/s1470-2045(18)30742-3","doi":"10.1016/s1470-2045(18)30742-3","note":"Europe PMC author record matched by affiliation (Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille); 266 citations on Europe PMC."}],"orcid":"0000-0002-2057-3557"},{"id":"florian-lordick","kind":"person","name":"Florian Lordick","aka":[],"tldr":"German GI oncologist who leads ESMO's gastric cancer guidelines and pivotal perioperative trials.","summary":"Florian Lordick (University Cancer Center Leipzig) led the MUNICON trials of PET-guided treatment and is a principal investigator on trials of perioperative immunotherapy and HER2-directed therapy in gastro-oesophageal cancer. He chairs the ESMO gastric cancer guideline group and has served on the ESMO executive board. His work focuses on tailoring perioperative therapy and on nutrition in GI cancer.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lordick%20F%5BAuthor%5D%20gastric"}],"tags":["gastric","guidelines","esmo"],"related":[],"cancers":["gastric","esophageal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["university-hospital-leipzig"],"pathways":[],"terms":[],"trials":["matterhorn"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["annals-of-oncology"],"dependsOn":[],"notes":[],"role":"Director, University Cancer Center Leipzig; Professor of Oncology, University of Leipzig","institutionId":"university-hospital-leipzig","specialisms":["Gastro-oesophageal cancer","Perioperative therapy","Guidelines","Supportive care"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lordick%20F%5BAuthor%5D%20gastric"}],"papers":[{"title":"Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","journal":"Annals of Oncology","year":2022,"doi":"10.1016/j.annonc.2022.07.004"},{"title":"PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial","journal":"Lancet Oncology","year":2007,"doi":"10.1016/S1470-2045(07)70244-9"}],"orcid":"0000-0001-8591-9339"},{"id":"florian-greten","kind":"person","name":"Florian R. Greten","aka":[],"tldr":"Tumour biologist known for linking inflammation to cancer, directing the Georg-Speyer-Haus within UCT Frankfurt.","summary":"Florian R. Greten directs the Georg-Speyer-Haus, the Institute for Tumor Biology and Experimental Therapy in Frankfurt, and sits on the directorate of the University Cancer Center Frankfurt. His laboratory studies how inflammation and the tumour microenvironment drive colorectal and other gastrointestinal cancers, including landmark work on NF-kB signalling in colitis-associated cancer.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.uct-frankfurt.de/ueber-uns/direktorium/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Greten+FR%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","cancer biology","colorectal cancer"],"related":[],"cancers":["colorectal","gastric"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["uct-frankfurt"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Georg-Speyer-Haus (Institute for Tumor Biology and Experimental Therapy)","institutionId":"uct-frankfurt","specialisms":["Tumour biology","Inflammation and cancer","Colorectal cancer","Tumour microenvironment"],"profiles":[{"label":"Institution profile","url":"https://www.uct-frankfurt.de/ueber-uns/direktorium/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Greten+FR%5BAuthor%5D"}],"papers":[{"title":"Inflammation and Cancer: Triggers, Mechanisms, and Consequences","journal":"Immunity","year":2019,"url":"https://doi.org/10.1016/j.immuni.2019.06.025","doi":"10.1016/j.immuni.2019.06.025"},{"title":"Grivennikov, Greten and Karin 2010: immunity, inflammation and cancer","journal":"Cell","year":2010,"url":"https://doi.org/10.1016/j.cell.2010.01.025","doi":"10.1016/j.cell.2010.01.025"}],"orcid":"0000-0002-3928-6080"},{"id":"florian-roser","kind":"person","name":"Florian Roser","aka":[],"tldr":"Neurosurgeon specialising in brain and skull base tumours, serving as Chief Medical Officer of Cleveland Clinic Abu Dhabi.","summary":"Florian Roser is Chief Medical Officer of Cleveland Clinic Abu Dhabi. A neurosurgeon specialising in skull base and brain tumours, including meningiomas and gliomas, he has a research record that includes reports on the transition from meningeal melanocytoma to primary cerebral melanoma, a malignant triton tumour diagnosed twelve years after radiosurgery for a vestibular schwannoma, and the surgical management of olfactory groove meningiomas. In his current role he oversees clinical quality and medical staff across the hospital's institutes, including its Cancer Institute. His clinical interests sit within neuro-oncology and neurosurgery.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.clevelandclinicabudhabi.ae/en/about-us/leadership-team"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Roser+F%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","neuro-oncology","neurosurgery"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cleveland-clinic-abu-dhabi"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Medical Officer","institutionId":"cleveland-clinic-abu-dhabi","specialisms":["Neurosurgery","Skull base and brain tumours","Clinical leadership"],"profiles":[{"label":"Institution profile","url":"https://www.clevelandclinicabudhabi.ae/en/about-us/leadership-team"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Roser+F%5BAuthor%5D"}],"papers":[{"title":"Transition from meningeal melanocytoma to primary cerebral melanoma","journal":"Journal of Neurosurgery","year":2004,"doi":"10.3171/jns.2004.101.3.0528"},{"title":"Malignant triton tumor diagnosed twelve years after radiosurgically treated vestibular schwannoma","journal":"Clinical Neurology and Neurosurgery","year":2019,"doi":"10.1016/j.clineuro.2019.05.015"},{"title":"OLFACTORY GROOVE MENINGIOMAS","journal":"Neurosurgery","year":2007,"doi":"10.1227/01.neu.0000255453.20602.80"}],"orcid":"0000-0002-7854-6789"},{"id":"fran-visco","kind":"person","name":"Fran Visco","aka":[],"tldr":"A lawyer treated for breast cancer in 1987 who built the National Breast Cancer Coalition and won the Department of Defense breast cancer programme, the first to put trained patient advocates on scientific review panels.","summary":"Fran Visco was diagnosed with breast cancer in 1987 at 39 and became the founding president of the National Breast Cancer Coalition in 1991, which she still leads. In 1992 the coalition delivered 600,000 signatures to Washington and secured a $210 million appropriation for breast cancer research through the Department of Defense, creating the Congressionally Directed Medical Research Programs, which have since funded billions of dollars of peer-reviewed research and which pioneered the inclusion of trained consumer advocates as voting members of scientific review panels. Her Project LEAD course has trained thousands of advocates in the science and statistics needed to sit at that table. She served on the National Cancer Advisory Board and on the President's Cancer Panel, and the coalition's Artemis Project sets deadlines for a preventive vaccine.","asOf":"2026-09-09","links":[{"label":"National Breast Cancer Coalition","url":"https://www.stopbreastcancer.org/"},{"label":"National Breast Cancer Coalition (Wikipedia)","url":"https://en.wikipedia.org/wiki/National_Breast_Cancer_Coalition"}],"tags":["hero","advocate","patient"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["nci"],"pathways":[],"terms":[],"trials":[],"people":["susan-love"],"bottlenecks":["b-patient-voice","b-funding-allocation","b-trial-design"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Founding president of the National Breast Cancer Coalition","specialisms":["Breast cancer advocacy","Research policy","Patient participation in peer review"],"profiles":[{"label":"National Breast Cancer Coalition","url":"https://www.stopbreastcancer.org/"},{"label":"National Breast Cancer Coalition (Wikipedia)","url":"https://en.wikipedia.org/wiki/National_Breast_Cancer_Coalition"}],"papers":[]},{"id":"francesco-de-lorenzo","kind":"person","name":"Francesco De Lorenzo","aka":[],"tldr":"Francesco De Lorenzo represents FAVO, Italian Federation of Voluntary Associations in Oncology in the Organisation of European Cancer Institutes, which lists the organisation among its members in Italy.","summary":"Francesco De Lorenzo is listed by the Organisation of European Cancer Institutes (OECI) as the representative of FAVO, Italian Federation of Voluntary Associations in Oncology, its associate member in Italy. OnCo records the name from the OECI membership list so that the organisation's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the organisation's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"FAVO, Italian Federation of Voluntary Associations in Oncology website","url":"https://www.favo.it/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["favo"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of FAVO, Italian Federation of Voluntary Associations in Oncology to the Organisation of European Cancer Institutes","institutionId":"favo","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"FAVO, Italian Federation of Voluntary Associations in Oncology website","url":"https://www.favo.it/"}],"papers":[]},{"id":"francesco-lo-coco","kind":"person","name":"Francesco Lo-Coco","aka":[],"tldr":"Italian haematologist who led APL0406, the trial that showed acute promyelocytic leukaemia can be cured with all-trans retinoic acid and arsenic trioxide alone, without chemotherapy.","summary":"Francesco Lo-Coco was professor of haematology at the University of Rome Tor Vergata and a leading investigator of the Italian GIMEMA group. He was first author of the 2013 New England Journal of Medicine report of APL0406, the Italian-German trial that showed all-trans retinoic acid plus arsenic trioxide was at least as effective as ATRA plus chemotherapy in low- and intermediate-risk acute promyelocytic leukaemia, with far fewer haematological complications. The chemotherapy-free regimen became the standard of care. He died in 2019.","asOf":"2026-09-18","links":[],"tags":["leukaemia","trialist"],"related":[],"cancers":["apl","aml"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["apl0406"],"people":[],"bottlenecks":[],"keyPapers":["paper-apl0406-lo-coco-nejm-2013"],"journals":[],"dependsOn":[],"notes":[],"role":"Haematologist, University of Rome Tor Vergata (died 2019)","specialisms":["Acute promyelocytic leukaemia","Arsenic trioxide","Molecular monitoring"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lo-Coco%5BAuthor%5D"}],"papers":[{"title":"APL0406: retinoic acid plus arsenic trioxide without chemotherapy for low- and intermediate-risk acute promyelocytic leukaemia","journal":"New England Journal of Medicine","year":2013,"url":"https://doi.org/10.1056/NEJMoa1300874","doi":"10.1056/NEJMoa1300874"}]},{"id":"francisca-vazquez","kind":"person","name":"Francisca Vazquez","aka":[],"tldr":"Francisca Vazquez leads DepMap, the public map of which genes each cancer cell line cannot live without.","summary":"Francisca Vazquez is Director of the Cancer Dependency Map at the Broad Institute of MIT and Harvard. She leads DepMap, the public map of which genes each cancer cell line cannot live without, integrating genome-wide CRISPR and drug screens across more than 1,000 cell lines to reveal synthetic-lethal targets. Her selected paper defines a cancer dependency map. She continues to direct this functional genomics resource, which the field uses to find new cancer dependencies.","asOf":"2026-09-08","links":[{"label":"DepMap","url":"https://depmap.org"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Vazquez%20F%5BAuthor%5D"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["crispr-screens","synthetic-lethality-approaches"],"targets":[],"drugs":[],"companies":[],"institutions":["broad-institute"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Cancer Dependency Map (DepMap)","institutionId":"broad-institute","specialisms":["Functional genomics","CRISPR screens","Cancer dependencies"],"profiles":[{"label":"DepMap","url":"https://depmap.org"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Vazquez%20F%5BAuthor%5D"}],"papers":[{"title":"Defining a cancer dependency map","journal":"Cell","year":2017,"url":"https://doi.org/10.1016/j.cell.2017.06.010","doi":"10.1016/j.cell.2017.06.010"}]},{"id":"francisco-berrospi-espinoza","kind":"person","name":"Francisco Berrospi Espinoza","aka":[],"tldr":"Cancer surgeon who heads Peru's national cancer institute, INEN, after more than two decades as an abdominal surgeon there.","summary":"Francisco Berrospi Espinoza is Jefe Institucional of the Instituto Nacional de Enfermedades Neoplásicas (INEN), Peru's national cancer institute in Lima. He trained in medicine at the Universidad Nacional de Trujillo, specialised in general and oncological surgery at the Universidad Peruana Cayetano Heredia and holds a master's degree in health services management from ESAN. He has been an attending surgeon in INEN's Abdominal Surgery Department since 2000 and previously directed the institute's surgery department; his clinical focus is gastrointestinal and hepato-pancreato-biliary cancer surgery. He was designated Jefe Institucional by Resolución Suprema 016-2022-SA in August 2022.","asOf":"2026-09-10","links":[{"label":"Source: INEN Jefatura Institucional page","url":"https://portal.inen.sld.pe/jefatura-institucional/"}],"tags":["leadership","clinician-scientist","surgical-oncology"],"related":[],"cancers":["gastric","hcc","pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["inen-peru"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Jefe Institucional (Institutional Head) of INEN","institutionId":"inen-peru","specialisms":["Surgical oncology","Hepato-pancreato-biliary surgery","Gastrointestinal cancer surgery"],"profiles":[{"label":"Institution profile","url":"https://portal.inen.sld.pe/jefatura-institucional/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Berrospi+F%5BAuthor%5D"}],"papers":[{"title":"Risk factors associated with recurrence of pancreatic solid pseudopapillary neoplasms: a single institution experience","journal":"HPB","year":2021,"doi":"10.1016/j.hpb.2020.11.577"}]},{"id":"franck-morschhauser","kind":"person","name":"Franck Morschhauser","aka":[],"tldr":"Lille haematologist and President of LYSA, the French-Belgian lymphoma cooperative group, who led the RELEVANCE trial of chemotherapy-free therapy in follicular lymphoma.","summary":"Franck Morschhauser is President of LYSA, the Lymphoma Study Association, and Professor of Haematology at Lille University Hospital, France. He was first author of the RELEVANCE trial comparing rituximab plus lenalidomide with rituximab-chemotherapy in untreated follicular lymphoma. His research spans novel immunotherapies and targeted agents across indolent and aggressive B-cell lymphomas.","asOf":"2026-09-10","links":[{"label":"Society page","url":"https://experts-recherche-lymphome.org/lysa_redirect/en/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Morschhauser+F%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","lymphoma","haematology"],"related":[],"cancers":["follicular-lymphoma","dlbcl"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["lysa"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President","institutionId":"lysa","specialisms":["Lymphoma","Follicular lymphoma","Immunotherapy"],"profiles":[{"label":"Society page","url":"https://experts-recherche-lymphome.org/lysa_redirect/en/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Morschhauser+F%5BAuthor%5D"}],"papers":[{"title":"Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma","journal":"New England Journal of Medicine","year":2018,"url":"https://doi.org/10.1056/NEJMoa1805104","doi":"10.1056/NEJMoa1805104"}]},{"id":"franco-cavalli","kind":"person","name":"Franco Cavalli","aka":[],"tldr":"Swiss oncologist who presides over the board of the international study group that runs clinical trials in lymphomas arising outside the lymph nodes.","summary":"Franco Cavalli, of Bellinzona, Switzerland, is President of the Board of the International Extranodal Lymphoma Study Group (IELSG), a not-for-profit association founded in 1998 that brings together medical oncologists, haematologists, imaging specialists, pathologists, biologists and biostatisticians to conduct clinical and translational studies in extranodal lymphomas. The board he chairs includes representatives of national lymphoma cooperative groups from Europe, North America, Australia and China; Emanuele Zucca serves as IELSG Scientific and Medical Director.","asOf":"2026-09-10","links":[{"label":"Source: IELSG Board of Directors page","url":"https://ielsg.org/site/about-us/board-of-directors/"}],"tags":["leadership","clinician-scientist","lymphoma","clinical-trials"],"related":[],"cancers":["dlbcl"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["ielsg"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["hematology-oncology-clinics-of-north-america"],"dependsOn":[],"notes":[],"role":"President of the Board, International Extranodal Lymphoma Study Group","institutionId":"ielsg","specialisms":["Medical oncology","Lymphoma","International clinical trials"],"profiles":[{"label":"IELSG Board of Directors","url":"https://ielsg.org/site/about-us/board-of-directors/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cavalli+F%5BAuthor%5D+AND+lymphoma"}],"papers":[{"title":"Management of non-Hodgkin lymphomas arising at extranodal sites","journal":"Therapeutische Umschau","year":2010,"doi":"10.1024/0040-5930/a000088"},{"title":"Emerging Role of Infectious Etiologies in the Pathogenesis of Marginal Zone B-cell Lymphomas","journal":"Clinical Cancer Research","year":2014,"doi":"10.1158/1078-0432.ccr-14-0496"},{"title":"Marginal Zone Lymphomas","journal":"Hematology/Oncology Clinics of North America","year":2008,"doi":"10.1016/j.hoc.2008.07.011"}]},{"id":"francois-clement-bidard","kind":"person","name":"François-Clément Bidard","aka":[],"tldr":"Led PADA-1, the first trial to switch endocrine therapy on a rising ESR1 mutation in blood.","summary":"François-Clément Bidard is Head of Medical Oncology at Institut Curie and Professor at UVSQ Paris-Saclay. His specialisms are breast cancer, circulating tumour DNA, endocrine therapy and circulating tumour cells, with a focus on the oestrogen receptor in HR-positive, HER2-negative disease. He led PADA-1, the first trial to switch endocrine therapy on a rising ESR1 mutation detected in blood, reported in Lancet Oncology as a switch to fulvestrant and palbociclib during aromatase inhibitor therapy. He also led EMERALD, the Journal of Clinical Oncology trial of elacestrant versus standard endocrine therapy in advanced breast cancer. He pioneered ctDNA-guided treatment switching, and his publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bidard%20FC%5BAuthor%5D%20ESR1%20ctDNA"}],"tags":[],"related":[],"cancers":["breast-hr-positive"],"sections":[],"technologies":["liquid-biopsy"],"targets":["estrogen-receptor"],"drugs":["elacestrant","fulvestrant"],"companies":[],"institutions":["institut-curie"],"pathways":[],"terms":[],"trials":["emerald"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Head of Medical Oncology, Institut Curie; Professor, UVSQ Paris-Saclay","institutionId":"institut-curie","specialisms":["Breast cancer","Circulating tumour DNA","Endocrine therapy","Circulating tumour cells"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bidard%20FC%5BAuthor%5D%20ESR1%20ctDNA"}],"papers":[{"title":"Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1)","journal":"Lancet Oncology","year":2022,"doi":"10.1016/S1470-2045(22)00555-1"},{"title":"Elacestrant versus standard endocrine therapy for estrogen receptor-positive, HER2-negative advanced breast cancer (EMERALD)","journal":"JCO","year":2022,"doi":"10.1200/JCO.22.00338"}],"orcid":"0000-0001-5932-8949"},{"id":"frank-mccormick","kind":"person","name":"Frank McCormick","aka":[],"tldr":"RAS biologist who founded Onyx Pharmaceuticals and led the NCI's national effort to drug RAS.","summary":"Frank McCormick is Professor at the UCSF Helen Diller Family Comprehensive Cancer Center and former Scientific Lead of the RAS Initiative at the National Cancer Institute (NIH). A molecular biologist who has worked on RAS signalling for four decades, he founded Onyx Pharmaceuticals, the company behind the origins of sorafenib and carfilzomib, and served as scientific lead of the NCI RAS Initiative at Frederick National Laboratory. His papers include a Clinical Cancer Research review of KRAS as a therapeutic target and a Cancer Cell commentary on covalent KRAS inhibitors entering the clinic. His work on KRAS and RAS inhibitors bears on pancreatic ductal adenocarcinoma, colorectal cancer and non-small-cell lung cancer.","asOf":"2026-09-08","links":[{"label":"UCSF profile","url":"https://profiles.ucsf.edu/search/?searchtype=people&searchfor=Frank%20McCormick"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=McCormick%20F%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Frank%20McCormick"}],"tags":[],"related":[],"cancers":["pancreatic","colorectal","nsclc"],"sections":[],"technologies":["kras-inhibitors"],"targets":["kras"],"drugs":[],"companies":[],"institutions":["ucsf","nci"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["cancer-cell"],"dependsOn":[],"notes":[],"role":"Professor, UCSF Helen Diller Family Comprehensive Cancer Center; former Scientific Lead, NCI RAS Initiative","institutionId":"ucsf","specialisms":["RAS biology","Signal transduction","Drug discovery"],"profiles":[{"label":"UCSF profile","url":"https://profiles.ucsf.edu/search/?searchtype=people&searchfor=Frank%20McCormick"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=McCormick%20F%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Frank%20McCormick"}],"papers":[{"title":"KRAS as a Therapeutic Target","journal":"Clinical Cancer Research","year":2015,"url":"https://doi.org/10.1158/1078-0432.CCR-14-2662","doi":"10.1158/1078-0432.CCR-14-2662"},{"title":"Sticking it to KRAS: Covalent Inhibitors Enter the Clinic","journal":"Cancer Cell","year":2020,"url":"https://doi.org/10.1016/j.ccell.2019.12.009","doi":"10.1016/j.ccell.2019.12.009"}],"orcid":"0000-0002-6619-7120"},{"id":"frank-vermassen","kind":"person","name":"Frank Vermassen","aka":[],"tldr":"Frank Vermassen represents Ghent University Hospital / Cancer Research Institute Ghent in the Organisation of European Cancer Institutes, which lists the centre among its members in Belgium.","summary":"Frank Vermassen is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Ghent University Hospital / Cancer Research Institute Ghent, its full member in Belgium. OnCo records the name from the OECI membership list so that the centre's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the institution's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Ghent University Hospital / Cancer Research Institute Ghent website","url":"https://www.uzgent.be/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["uz-gent"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Ghent University Hospital / Cancer Research Institute Ghent to the Organisation of European Cancer Institutes","institutionId":"uz-gent","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Ghent University Hospital / Cancer Research Institute Ghent website","url":"https://www.uzgent.be/"}],"papers":[{"title":"Editor's Choice – European Society for Vascular Surgery (ESVS) 2019 Clinical Practice Guidelines on the Management of Abdominal Aorto-iliac Artery Aneurysms","journal":"European Journal of Vascular and Endovascular Surgery","year":2018,"url":"https://doi.org/10.1016/j.ejvs.2018.09.020","doi":"10.1016/j.ejvs.2018.09.020","note":"OpenAlex author record matched by institution"},{"title":"Global vascular guidelines on the management of chronic limb-threatening ischemia","journal":"Journal of Vascular Surgery","year":2019,"url":"https://doi.org/10.1016/j.jvs.2019.02.016","doi":"10.1016/j.jvs.2019.02.016","note":"OpenAlex author record matched by institution"}]},{"id":"fred-saad","kind":"person","name":"Fred Saad","aka":[],"tldr":"Montreal urologist who led the zoledronic acid trials in prostate cancer bone metastases and was lead author of ARANOTE, which established darolutamide plus hormone therapy for metastatic hormone-sensitive disease.","summary":"Fred Saad is chief of urology at the Centre hospitalier de l'Université de Montréal and a leading investigator in advanced prostate cancer. He led the trials that established zoledronic acid for bone metastases from castration-resistant prostate cancer and was first author of the 2024 Journal of Clinical Oncology report of ARANOTE, in which darolutamide plus androgen deprivation therapy improved radiographic progression-free survival in metastatic hormone-sensitive prostate cancer.","asOf":"2026-09-18","links":[],"tags":["prostate","trialist"],"related":[],"cancers":["prostate-mhspc","prostate-mcrpc","prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["chum"],"pathways":[],"terms":[],"trials":["aranote"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor and Chief of Urology, Centre hospitalier de l'Université de Montréal","institutionId":"chum","specialisms":["Advanced prostate cancer","Bone-targeted therapy","Androgen receptor inhibitors"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Saad%5BAuthor%5D"}],"papers":[{"title":"ARASENS: darolutamide added to androgen deprivation and docetaxel in metastatic hormone-sensitive prostate cancer","journal":"New England Journal of Medicine","year":2022,"url":"https://doi.org/10.1056/NEJMoa2119115","doi":"10.1056/NEJMoa2119115"}]},{"id":"bray-freddie","kind":"person","name":"Freddie Bray","aka":[],"tldr":"Freddie Bray runs GLOBOCAN, the source of the world's cancer incidence and mortality figures.","summary":"Freddie Bray is Head of the Cancer Surveillance Branch at the International Agency for Research on Cancer. He runs GLOBOCAN and the Global Cancer Observatory, the source of the world's cancer incidence and mortality figures, coordinates cancer registries worldwide and publishes the Global Cancer Statistics series. His publications include the GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. His interests are cancer surveillance, global cancer statistics, registries and projections of the future cancer burden.","asOf":"2026-09-08","links":[{"label":"IARC","url":"https://www.iarc.who.int"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bray%20F%5BAuthor%5D%20global%20cancer%20statistics"}],"tags":["statistics"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["iarc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["ca-cancer-journal"],"dependsOn":[],"notes":[],"role":"Head, Cancer Surveillance Branch, IARC","institutionId":"iarc","specialisms":["Cancer surveillance","Global cancer statistics","Registries","Projections"],"profiles":[{"label":"IARC","url":"https://www.iarc.who.int"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bray%20F%5BAuthor%5D%20global%20cancer%20statistics"}],"papers":[{"title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","journal":"CA: A Cancer Journal for Clinicians","year":2024,"doi":"10.3322/caac.21834"},{"title":"Bray 2018: GLOBOCAN 2018, worldwide incidence and mortality for 36 cancers","journal":"CA: A Cancer Journal for Clinicians","year":2018,"url":"https://doi.org/10.3322/caac.21492","doi":"10.3322/caac.21492"},{"title":"Jemal 2011: Global cancer statistics (GLOBOCAN 2008)","journal":"CA: A Cancer Journal for Clinicians","year":2011,"url":"https://doi.org/10.3322/caac.20107","doi":"10.3322/caac.20107"},{"title":"Parkin 2005: Global cancer statistics, 2002","journal":"CA: A Cancer Journal for Clinicians","year":2005,"url":"https://doi.org/10.3322/canjclin.55.2.74","doi":"10.3322/canjclin.55.2.74"},{"title":"Sung 2021: GLOBOCAN 2020, the year breast cancer overtook lung cancer as the most diagnosed cancer","journal":"CA: A Cancer Journal for Clinicians","year":2021,"url":"https://doi.org/10.3322/caac.21660","doi":"10.3322/caac.21660"},{"title":"Torre 2015: Global cancer statistics, 2012","journal":"CA: A Cancer Journal for Clinicians","year":2015,"url":"https://doi.org/10.3322/caac.21262","doi":"10.3322/caac.21262"}]},{"id":"freddie-hamdy","kind":"person","name":"Freddie C. Hamdy","aka":[],"tldr":"Led ProtecT, the trial that showed monitoring, surgery and radiotherapy give equally low prostate cancer death rates at 15 years.","summary":"Freddie Hamdy was chief investigator of ProtecT, the UK randomised trial of active monitoring, prostatectomy and radiotherapy for PSA-detected localised prostate cancer, whose 10- and 15-year results showed very low and similar mortality across arms and made active surveillance a mainstream choice. He also co-led the CAP screening trial. He leads urological research in Oxford.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hamdy%20FC%5BAuthor%5D%20ProtecT"}],"tags":["prostate","surgery","active-surveillance"],"related":[],"cancers":["prostate"],"sections":[],"technologies":["robotic-surgery"],"targets":[],"drugs":[],"companies":[],"institutions":["oxford-cancer"],"pathways":[],"terms":[],"trials":["protect"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Nuffield Professor of Surgery, University of Oxford","institutionId":"oxford-cancer","specialisms":["Prostate cancer","Active surveillance","Urological surgery","Screening"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hamdy%20FC%5BAuthor%5D%20ProtecT"}],"papers":[{"title":"10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer (ProtecT)","journal":"NEJM","year":2016,"doi":"10.1056/NEJMoa1606220"},{"title":"Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer","journal":"NEJM","year":2023,"doi":"10.1056/NEJMoa2214122"}],"orcid":"0000-0003-2627-2154"},{"id":"frederick-locke","kind":"person","name":"Frederick L. Locke","aka":[],"tldr":"Led the ZUMA-7 trial that put CAR-T ahead of transplant in relapsed large B-cell lymphoma.","summary":"Frederick L. Locke is Chair of the Department of Blood and Marrow Transplant and Cellular Immunotherapy at Moffitt Cancer Center. He is known for leading the ZUMA-7 trial, which put CAR-T ahead of transplant in relapsed large B-cell lymphoma, and was principal investigator of ZUMA-1 and ZUMA-7 with axicabtagene ciloleucel. His selected paper reports axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. He is also a leader in CAR-T real-world outcomes and in managing the toxicity of cellular therapy.","asOf":"2026-09-08","links":[{"label":"Moffitt profile","url":"https://www.moffitt.org/providers/frederick-locke/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Locke%20FL%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["dlbcl"],"sections":[],"technologies":["car-t"],"targets":["cd19"],"drugs":["axicabtagene-ciloleucel"],"companies":[],"institutions":["moffitt"],"pathways":[],"terms":[],"trials":["zuma-7"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chair, Department of Blood and Marrow Transplant and Cellular Immunotherapy","institutionId":"moffitt","specialisms":["CAR-T therapy","Lymphoma","Cellular therapy toxicity"],"profiles":[{"label":"Moffitt profile","url":"https://www.moffitt.org/providers/frederick-locke/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Locke%20FL%5BAuthor%5D"}],"papers":[{"title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","journal":"New England Journal of Medicine","year":2022,"url":"https://doi.org/10.1056/NEJMoa2116133","doi":"10.1056/NEJMoa2116133"},{"title":"ZUMA-1: axicabtagene ciloleucel for refractory large B-cell lymphoma, the first CAR-T approved for lymphoma","journal":"New England Journal of Medicine","year":2017,"url":"https://doi.org/10.1056/NEJMoa1707447","doi":"10.1056/NEJMoa1707447"}]},{"id":"frederik-giesel","kind":"person","name":"Frederik Giesel","aka":[],"tldr":"Frederik Giesel co-developed FAPI PET imaging and now leads nuclear medicine in Düsseldorf.","summary":"Frederik Giesel is Director of Nuclear Medicine at University Hospital Düsseldorf, having previously worked at Heidelberg University Hospital within the NCT and DKFZ network. His specialisms are molecular imaging, FAPI PET and PSMA theranostics. He co-led the first-in-human FAPI PET studies in Heidelberg, and his Journal of Nuclear Medicine paper reported the biodistribution and preliminary dosimetry of two DOTA-containing FAP-targeting agents imaged with 68Ga-FAPI PET/CT. He continues to develop FAP-targeted imaging and therapy in Düsseldorf. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Giesel%20FL%5BAuthor%5D%20FAPI"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["fapi-pet"],"targets":["fap"],"drugs":[],"companies":[],"institutions":["heidelberg-nct"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["journal-of-nuclear-medicine"],"dependsOn":[],"notes":[],"role":"Director of Nuclear Medicine, University Hospital Düsseldorf; formerly Heidelberg","institutionId":"heidelberg-nct","specialisms":["Molecular imaging","FAPI PET","PSMA theranostics"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Giesel%20FL%5BAuthor%5D%20FAPI"}],"papers":[{"title":"68Ga-FAPI PET/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents","journal":"Journal of Nuclear Medicine","year":2019,"doi":"10.2967/jnumed.118.215913"}]},{"id":"frederique-penault-llorca","kind":"person","name":"Frédérique Penault-Llorca","aka":[],"tldr":"Professor who directs Centre Jean Perrin, the comprehensive cancer centre for the Auvergne region in Clermont-Ferrand, now in her second five-year term.","summary":"Professeure Frédérique Penault-Llorca is Directrice Générale of Centre Jean Perrin, the Centre de Lutte Contre le Cancer in Clermont-Ferrand. The centre's organisation page states that she is serving her second five-year term, appointed by ministerial decree, and is supported by Raphaël Zint, Directeur Général Adjoint, and an executive team of twelve members including several physicians. The centre describes this physician and manager partnership as a distinctive feature of French cancer centres.","asOf":"2026-09-10","links":[{"label":"Source: Centre Jean Perrin organisation page","url":"https://www.cjp.fr/nous-connaitre/notre-organisation"}],"tags":["leadership","clinician-scientist","comprehensive-cancer-centre"],"related":[],"cancers":["breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["centre-jean-perrin"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Directrice Générale (Director General), Centre Jean Perrin","institutionId":"centre-jean-perrin","specialisms":["Pathology","Breast cancer biomarkers","Cancer centre management"],"profiles":[{"label":"Centre Jean Perrin organisation page","url":"https://www.cjp.fr/nous-connaitre/notre-organisation"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Penault-Llorca+F%5BAuthor%5D"}],"papers":[{"title":"Ki67 Expression and Docetaxel Efficacy in Patients With Estrogen Receptor–Positive Breast Cancer","journal":"Journal of Clinical Oncology","year":2009,"doi":"10.1200/jco.2008.18.2808"},{"title":"HER2-Low Breast Cancer: Pathological and Clinical Landscape","journal":"Journal of Clinical Oncology","year":2020,"doi":"10.1200/jco.19.02488"},{"title":"Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","journal":"Annals of Oncology","year":2019,"doi":"10.1093/annonc/mdz173"}]},{"id":"funda-meric-bernstam","kind":"person","name":"Funda Meric-Bernstam","aka":[],"tldr":"Funda Meric-Bernstam runs the world's largest phase 1 programme and led the tumour-agnostic HER2 ADC study.","summary":"Funda Meric-Bernstam is Chair of Investigational Cancer Therapeutics at MD Anderson Cancer Center, where she runs the world's largest phase 1 programme. A surgical oncologist turned early-drug-development leader, she directs MD Anderson's Institute for Personalized Cancer Therapy and chaired DESTINY-PanTumor02, the trial that led to the tumour-agnostic approval of trastuzumab deruxtecan for HER2 IHC 3+ solid tumours. Her papers report the primary results of the DESTINY-PanTumor02 phase II trial of trastuzumab deruxtecan in HER2-expressing solid tumours and the feasibility of large-scale genomic testing to enrol patients onto genomically matched trials. Her work spans precision oncology, comprehensive genomic profiling and companion diagnostics.","asOf":"2026-09-08","links":[{"label":"MD Anderson faculty","url":"https://faculty.mdanderson.org/search?q=Funda%20Meric-Bernstam"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Meric-Bernstam%20F%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Funda%20Meric-Bernstam"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["cgp","companion-diagnostic"],"targets":["her2"],"drugs":["trastuzumab-deruxtecan"],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":["destiny-pantumor02"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chair, Investigational Cancer Therapeutics, MD Anderson","institutionId":"md-anderson","specialisms":["Phase 1 trials","Precision oncology","HER2"],"profiles":[{"label":"MD Anderson faculty","url":"https://faculty.mdanderson.org/search?q=Funda%20Meric-Bernstam"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Meric-Bernstam%20F%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Funda%20Meric-Bernstam"}],"papers":[{"title":"Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial","journal":"Journal of Clinical Oncology","year":2024,"url":"https://doi.org/10.1200/JCO.23.02005","doi":"10.1200/JCO.23.02005"},{"title":"Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials","journal":"Journal of Clinical Oncology","year":2015,"url":"https://doi.org/10.1200/JCO.2014.60.4165","doi":"10.1200/JCO.2014.60.4165"}]},{"id":"gabriel-hortobagyi","kind":"person","name":"Gabriel N. Hortobagyi","aka":[],"tldr":"Breast oncologist who led MONALEESA-2, the first CDK4/6 trial to show an overall survival gain in first-line HR-positive disease.","summary":"Gabriel Hortobagyi has run breast cancer trials at MD Anderson for four decades and was principal investigator of MONALEESA-2, which showed ribociclib plus letrozole improves progression-free and then overall survival in postmenopausal HR-positive advanced breast cancer. He has chaired ASCO and helped write the AJCC staging system for breast cancer. His work continues on endocrine resistance and adjuvant CDK4/6 inhibition.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hortobagyi%20GN%5BAuthor%5D%20ribociclib"}],"tags":["breast","trialist"],"related":[],"cancers":["breast-hr-positive"],"sections":[],"technologies":["cdk46-inhibitor"],"targets":["cdk4-6"],"drugs":["ribociclib"],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":["monaleesa-2","natalee"],"people":[],"bottlenecks":[],"keyPapers":["paper-natalee-nejm-2024"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Breast Medical Oncology, MD Anderson Cancer Center","institutionId":"md-anderson","specialisms":["Breast cancer","CDK4/6 inhibitors","Endocrine therapy","Neoadjuvant therapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hortobagyi%20GN%5BAuthor%5D%20ribociclib"}],"papers":[{"title":"Ribociclib as first-line therapy for HR-positive, advanced breast cancer (MONALEESA-2)","journal":"NEJM","year":2016,"doi":"10.1056/NEJMoa1609709"},{"title":"Overall survival with ribociclib plus letrozole in advanced breast cancer","journal":"NEJM","year":2022,"doi":"10.1056/NEJMoa2114663"},{"title":"NATALEE: three years of ribociclib after surgery in a broad population of hormone-receptor-positive early breast cancer","journal":"New England Journal of Medicine","year":2024,"url":"https://doi.org/10.1056/NEJMoa2305488","doi":"10.1056/NEJMoa2305488"}],"orcid":"0000-0002-4873-4412"},{"id":"gad-getz","kind":"person","name":"Gad Getz","aka":[],"tldr":"Wrote the algorithms (MuTect, MutSig, ABSOLUTE) that most cancer genome studies use to find mutations.","summary":"Gad Getz is Director of Cancer Genome Computational Analysis and an Institute Member at the Broad Institute of MIT and Harvard. He is a computational biologist who wrote the algorithms MuTect, MutSig and ABSOLUTE that most cancer genome studies use to find mutations, and who led analysis for The Cancer Genome Atlas and PanCancer projects. His selected paper addresses mutational heterogeneity in cancer and the search for new cancer-associated genes. His group continues to define significantly mutated genes, mutational signatures and clonal architecture across cancers from whole-exome and whole-genome sequencing.","asOf":"2026-09-08","links":[{"label":"Broad bio","url":"https://www.broadinstitute.org/bios/gad-getz"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Getz%20G%5BAuthor%5D"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["wes-wgs"],"targets":[],"drugs":[],"companies":[],"institutions":["broad-institute"],"pathways":[],"terms":["mutational-signature"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Cancer Genome Computational Analysis; Institute Member","institutionId":"broad-institute","specialisms":["Cancer genome analysis","Mutational signatures","Tumour heterogeneity"],"profiles":[{"label":"Broad bio","url":"https://www.broadinstitute.org/bios/gad-getz"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Getz%20G%5BAuthor%5D"}],"papers":[{"title":"Mutational heterogeneity in cancer and the search for new cancer-associated genes","journal":"Nature","year":2013,"url":"https://doi.org/10.1038/nature12213","doi":"10.1038/nature12213"},{"title":"TCGA Pan-Cancer Atlas: 10,000 tumours across 33 cancer types, classified by molecular features","journal":"Cell","year":2018,"url":"https://doi.org/10.1016/j.cell.2018.03.022","doi":"10.1016/j.cell.2018.03.022"}],"orcid":"0000-0002-0936-0753"},{"id":"gal-markel","kind":"person","name":"Gal Markel","aka":[],"tldr":"A tumour immunologist who helped build Israel's melanoma cell therapy programme at Sheba and now runs the melanoma centre at Davidoff, publishing what checkpoint drugs do outside the clean conditions of a trial.","summary":"Gal Markel was part of the group at Sheba's Ella Lemelbaum Institute that established tumour-infiltrating lymphocyte therapy in Israel, and now directs the Skin Cancer and Melanoma Center at the Davidoff Cancer Center, Rabin Medical Center, with an appointment in clinical microbiology and immunology at Tel Aviv University. His recent published work is largely real-world: outcomes of dual checkpoint blockade with nivolumab and ipilimumab outside trial populations, PD-1 inhibitors in cutaneous squamous cell carcinoma in organ transplant recipients, and body-composition measurements from routine computed tomography as a predictor of survival on immunotherapy. He was also an investigator on the adjuvant vibostolimab and pembrolizumab melanoma trial.","asOf":"2026-09-25","links":[{"label":"Davidoff Cancer Center, Rabin Medical Center","url":"https://hospitals.clalit.co.il/rabin"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Markel%20G%5BAuthor%5D%20melanoma"}],"tags":["clinician-scientist","immunotherapy"],"related":[],"cancers":["melanoma"],"sections":["immunotherapy"],"technologies":["til-therapy","checkpoint-inhibitor"],"targets":[],"drugs":[],"companies":[],"institutions":["rabin-davidoff-center","sheba","tel-aviv-university"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Skin Cancer and Melanoma Center, Davidoff Cancer Center, Rabin Medical Center; Gray Faculty of Medical and Health Sciences, Tel Aviv University","institutionId":"rabin-davidoff-center","specialisms":["Melanoma","Tumour immunology","Checkpoint inhibitors","Real-world outcomes"],"profiles":[{"label":"Davidoff Cancer Center, Rabin Medical Center","url":"https://hospitals.clalit.co.il/rabin"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Markel%20G%5BAuthor%5D%20melanoma"}],"papers":[{"title":"Dual checkpoint blockade beyond clinical trials: real-world experience with nivolumab and ipilimumab","year":2026,"note":"Skin Cancer and Melanoma Center, Davidoff Cancer Center, Rabin Medical Center; indexed on Europe PMC"},{"title":"Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis","journal":"Clinical Cancer Research","year":2013,"doi":"10.1158/1078-0432.ccr-13-0380"}]},{"id":"gary-lyman","kind":"person","name":"Gary H. Lyman","aka":[],"tldr":"Gary Lyman is an oncologist and health economist behind guidelines on growth factors, thrombosis, and biosimilars in cancer care.","summary":"Gary Lyman is Professor in the Public Health Sciences and Clinical Research Divisions at Fred Hutchinson Cancer Center. A medical oncologist and epidemiologist specialising in supportive care, health economics and comparative effectiveness, he chaired ASCO guidelines on neutropenia, venous thromboembolism and biosimilars in cancer care. His papers include the ASCO clinical practice guideline update on venous thromboembolism prophylaxis and treatment in patients with cancer and the ASCO guideline update on the use of white blood cell growth factors. He directs comparative effectiveness research at Fred Hutch, with links to cardio-oncology and geriatric assessment.","asOf":"2026-09-08","links":[{"label":"Fred Hutch faculty directory","url":"https://www.fredhutch.org/en/faculty-lab-directory.html?q=Gary%20H.%20Lyman"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lyman%20GH%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Gary%20H.%20Lyman"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["cardio-oncology","geriatric-assessment"],"targets":[],"drugs":[],"companies":[],"institutions":["fred-hutch"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor, Public Health Sciences and Clinical Research Divisions, Fred Hutchinson Cancer Center","institutionId":"fred-hutch","specialisms":["Supportive care","Health economics","Comparative effectiveness"],"profiles":[{"label":"Fred Hutch faculty directory","url":"https://www.fredhutch.org/en/faculty-lab-directory.html?q=Gary%20H.%20Lyman"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lyman%20GH%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Gary%20H.%20Lyman"}],"papers":[{"title":"Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update","journal":"Journal of Clinical Oncology","year":2020,"url":"https://doi.org/10.1200/JCO.19.01461","doi":"10.1200/JCO.19.01461"},{"title":"Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update","journal":"Journal of Clinical Oncology","year":2015,"url":"https://doi.org/10.1200/JCO.2015.62.3488","doi":"10.1200/JCO.2015.62.3488"}],"orcid":"0000-0002-0823-8086"},{"id":"gary-middleton","kind":"person","name":"Gary Middleton","aka":[],"tldr":"The Birmingham oncologist who ran the National Lung Matrix Trial, the largest umbrella trial in lung cancer, and published the honest answer: most drug-biomarker pairs did not work.","summary":"Gary Middleton is Professor of Medical Oncology in the Department of Immunology and Immunotherapy at the University of Birmingham, an honorary consultant oncologist at University Hospitals Birmingham and director of the Birmingham Experimental Cancer Medicine Centre. He was chief investigator of the National Lung Matrix Trial, run from the Cancer Research UK Clinical Trials Unit in Birmingham and delivered across the experimental cancer medicine centre network.\n\nThe trial screened 5,467 patients, found 2,007 molecularly eligible and gave genotype-matched therapy to 302 across 19 drug-biomarker cohorts. Its 2020 Nature paper said plainly that despite the preclinical rationale only a limited number of combinations showed clinically relevant benefit, and that those were concentrated in lung cancers associated with minimal tobacco exposure. A later arm reported that vistusertib, an mTORC1 and mTORC2 inhibitor, could not be recommended in STK11-deficient disease. He is translational lead for DETERMINE, runs a ketogenic diet trial in squamous lung cancer, and his group published the first cellular predictive biomarker for severe immune-related adverse events in lung cancer.","asOf":"2026-09-25","links":[{"label":"University of Birmingham staff page","url":"https://www.birmingham.ac.uk/staff/profiles/immunology-immunotherapy/middleton-gary"}],"tags":["lung","trialist","uk"],"related":["sanjay-popat","alastair-greystoke"],"cancers":["nsclc","lung-cancer","kras-g12c-nsclc"],"sections":["targeted-therapy","immunotherapy"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["birmingham-cancer-centre"],"pathways":[],"terms":[],"trials":["national-lung-matrix-trial"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology, University of Birmingham; Honorary Consultant Oncologist, University Hospitals Birmingham; Director of the Birmingham Experimental Cancer Medicine Centre","institutionId":"birmingham-cancer-centre","specialisms":["Umbrella and platform trials","Immuno-oncology in lung cancer","Biomarker-directed therapy"],"profiles":[{"label":"University of Birmingham staff page","url":"https://www.birmingham.ac.uk/staff/profiles/immunology-immunotherapy/middleton-gary"}],"papers":[{"title":"The National Lung Matrix Trial of personalized therapy in lung cancer","journal":"Nature","year":2020,"doi":"10.1038/s41586-020-2481-8"},{"title":"A phase II trial of mTORC1/2 inhibition in STK11 deficient non small cell lung cancer","journal":"npj Precision Oncology","year":2025,"doi":"10.1038/s41698-025-00814-y"}]},{"id":"narula-gaurav","kind":"person","name":"Gaurav Narula","aka":[],"tldr":"A paediatric oncologist at Tata Memorial who led the leukaemia arm of India's first CAR-T trials and runs national childhood leukaemia protocols.","summary":"Gaurav Narula is a paediatric oncologist at Tata Memorial Hospital whose work spans childhood acute lymphoblastic leukaemia protocols adapted to Indian conditions, the Indian Childhood Collaborative Leukaemia group trials and the clinical development of talicabtagene autoleucel (NexCAR19), for which he was an investigator and an author of the published real-world series. He also works on infection control and supportive care in low-resource paediatric oncology.","asOf":"2026-09-10","links":[{"label":"Tata Memorial Centre","url":"https://tmc.gov.in"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Narula%20G%5BAuthor%5D%20Tata%20Memorial%20paediatric%20leukaemia"}],"tags":[],"related":[],"cancers":["all-leukemia"],"sections":[],"technologies":["car-t"],"targets":[],"drugs":["talicabtagene-autoleucel"],"companies":[],"institutions":["tata-memorial"],"pathways":[],"terms":[],"trials":["talicel-phase-1-2"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["indian-journal-of-cancer"],"dependsOn":[],"notes":[],"role":"Professor of Paediatric Oncology, Tata Memorial Hospital","institutionId":"tata-memorial","specialisms":["Paediatric oncology","Childhood leukaemia","CAR-T cell therapy","Cooperative group trials"],"profiles":[{"label":"Tata Memorial Centre","url":"https://tmc.gov.in"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Narula%20G%5BAuthor%5D%20Tata%20Memorial%20paediatric%20leukaemia"}],"papers":[{"title":"Clinicoepidemiological profiles, clinical practices, and the impact of holistic care interventions on outcomes of pediatric hematolymphoid malignancies - A 7-year audit of the pediatric hematolymphoid disease management group at Tata Memorial Hospital","journal":"Indian Journal of Cancer","year":2017,"doi":"10.4103/ijc.ijc_487_17"},{"title":"Treatment and follow‐up of children with chronic myeloid leukaemia in chronic phase (CML‐CP) in the tyrosine kinase inhibitor (TKI) era—Two decades of experience from the Tata Memorial Hospital paediatric CML (pCML) cohort","journal":"British Journal of Haematology","year":2023,"doi":"10.1111/bjh.19251"},{"title":"Protocol for ICiCLe-ALL-14 (InPOG-ALL-15-01): a prospective, risk stratified, randomised, multicentre, open label, controlled therapeutic trial for newly diagnosed childhood acute lymphoblastic leukaemia in India","journal":"Trials","year":2022,"doi":"10.1186/s13063-022-06033-1"},{"title":"Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: an open-label, multicentre, phase 1/2 study","journal":"Lancet Haematology","year":2025,"url":"https://doi.org/10.1016/S2352-3026(24)00377-6","doi":"10.1016/S2352-3026(24)00377-6"}],"orcid":"0000-0002-8539-295X"},{"id":"li-ge","kind":"person","name":"Ge Li","aka":["李革"],"tldr":"Ge Li founded WuXi AppTec in Shanghai in 2000 and built the contract research and manufacturing network that much of the world's cancer pipeline now depends on.","summary":"A Columbia-trained chemist who created China's first major CRO, then WuXi Biologics and (with Juno) JW Therapeutics; WuXi's discovery chemistry, toxicology and manufacturing services sit behind a large share of Western and Chinese oncology programmes, which is why the company became the focus of the US BIOSECURE Act.","asOf":"2026-09-10","links":[{"label":"WuXi AppTec","url":"https://www.wuxiapptec.com/"}],"tags":["china"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["wuxi-apptec","wuxi-biologics","jw-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Founder, Chairman and CEO, WuXi AppTec","specialisms":["Contract research and manufacturing","Medicinal chemistry","Biotech infrastructure"],"profiles":[{"label":"WuXi AppTec","url":"https://www.wuxiapptec.com/"}],"papers":[]},{"id":"geerard-beets","kind":"person","name":"Geerard Beets","aka":[],"tldr":"Colorectal surgeon and ESSO President, internationally known for watch-and-wait organ preservation in rectal cancer.","summary":"Geerard Beets is President of the European Society of Surgical Oncology (ESSO) and Chair of Surgery at Maastricht University Medical Centre. His research has helped establish organ-preserving 'watch-and-wait' strategies for rectal cancer after complete response to chemoradiotherapy, including the International Watch & Wait Database. He has also held senior roles at the Netherlands Cancer Institute.","asOf":"2026-09-10","links":[{"label":"Society page","url":"https://www.essoweb.org/about/governance/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Beets+GL%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","colorectal cancer","surgical oncology"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["esso"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["critical-reviews-in-oncology-hematology"],"dependsOn":[],"notes":[],"role":"President","institutionId":"esso","specialisms":["Surgical oncology","Colorectal cancer","Rectal cancer organ preservation"],"profiles":[{"label":"Society page","url":"https://www.essoweb.org/about/governance/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Beets+GL%5BAuthor%5D"}],"papers":[{"title":"ECCO Essential Requirements for Quality Cancer Care: Colorectal Cancer. A critical review","journal":"Critical Reviews in Oncology/Hematology","year":2017,"doi":"10.1016/j.critrevonc.2016.12.001"}],"orcid":"0000-0002-1671-9912"},{"id":"gemma-peters","kind":"person","name":"Gemma Peters","aka":[],"tldr":"Chief Executive of Macmillan Cancer Support, the UK charity that provides practical, emotional and financial support to people living with cancer.","summary":"Gemma Peters is Chief Executive Officer of Macmillan Cancer Support, the UK cancer support charity. She joined Macmillan in January 2023, bringing wide ranging expertise in the cancer and charity sectors. She leads an executive team that includes a Chief Medical Officer and a Chief Nursing Officer, with a stated focus on making sure people living with cancer get the support they need.","asOf":"2026-09-10","links":[{"label":"Source: Macmillan leadership team page","url":"https://www.macmillan.org.uk/about-us/organisation/team/leadership"}],"tags":["leadership","charity","supportive-care"],"related":["src-macmillan"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["macmillan-cancer-support"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive Officer, Macmillan Cancer Support","institutionId":"macmillan-cancer-support","specialisms":["Charity leadership","Cancer support services","Fundraising"],"profiles":[{"label":"Macmillan profile","url":"https://www.macmillan.org.uk/about-us/organisation/team/leadership/ceo-gemma-peters"}],"papers":[]},{"id":"geoff-parnell","kind":"person","name":"Geoff Parnell","aka":[],"tldr":"Oesophageal cancer survivor and business executive who chairs the board of GI Cancer Trials (the Australasian Gastro-Intestinal Trials Group).","summary":"Geoff Parnell is Chair of the Board of Directors of the Australasian Gastro-Intestinal Trials Group, now operating as GI Cancer Trials. The group runs multicentre clinical trials in gastrointestinal cancers across Australia and New Zealand. Described on the group's board page as an oesophageal cancer survivor and experienced business executive, he leads a board that also includes senior GI oncologists and surgeons.","asOf":"2026-09-10","links":[{"label":"Society page","url":"https://gicancer.org.au/about-us/board-of-directors/"}],"tags":["leadership","clinical trials","gastrointestinal cancer"],"related":[],"cancers":["esophageal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["agitg"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chair, Board of Directors","institutionId":"agitg","specialisms":["Governance","Consumer advocacy","Gastrointestinal cancer trials"],"profiles":[{"label":"Society page","url":"https://gicancer.org.au/about-us/board-of-directors/"}],"papers":[],"papersExpected":false},{"id":"george-demetri","kind":"person","name":"George D. Demetri","aka":[],"tldr":"Led the imatinib trial in GIST that proved a targeted drug could melt away a solid tumour, and every GIST kinase inhibitor since.","summary":"George Demetri led the 2002 trial showing imatinib produces responses in more than half of patients with KIT-positive metastatic GIST, the first proof that a kinase inhibitor could transform a solid tumour and a founding result for precision oncology. He then led the pivotal trials of sunitinib, regorafenib and ripretinib in GIST and of trabectedin and eribulin in soft-tissue sarcoma. He co-directs the Ludwig Center at Harvard.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/George_D._Demetri","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Demetri%20GD%5BAuthor%5D%20GIST%20imatinib"}],"tags":["gist","sarcoma","targeted-therapy"],"related":[],"cancers":["gist","sarcoma"],"sections":[],"technologies":["kinase-inhibitors"],"targets":["kit"],"drugs":["imatinib"],"companies":[],"institutions":["dana-farber"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-druker-imatinib-phase1-nejm-2001"],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Sarcoma Center and Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute; Professor, Harvard Medical School","institutionId":"dana-farber","specialisms":["Gastrointestinal stromal tumour","Sarcoma","Kinase inhibitors","Early drug development"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Demetri%20GD%5BAuthor%5D%20GIST%20imatinib"}],"papers":[{"title":"Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors","journal":"NEJM","year":2002,"doi":"10.1056/NEJMoa020461"},{"title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial","journal":"Lancet","year":2006,"doi":"10.1016/S0140-6736(06)69446-4"},{"title":"First imatinib trial: a pill that switched off the enzyme driving chronic myeloid leukaemia","journal":"New England Journal of Medicine","year":2001,"url":"https://doi.org/10.1056/NEJM200104053441401","doi":"10.1056/NEJM200104053441401"},{"title":"GRID: regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib","journal":"The Lancet","year":2013,"url":"https://doi.org/10.1016/S0140-6736(12)61857-1","doi":"10.1016/S0140-6736(12)61857-1"}],"orcid":"0000-0002-0045-4809"},{"id":"georges-pascal-haber","kind":"person","name":"Georges-Pascal Haber","aka":[],"tldr":"Urologic oncologist and robotic surgeon who is Chief Executive Officer of Cleveland Clinic Abu Dhabi.","summary":"Georges-Pascal Haber is Chief Executive Officer of Cleveland Clinic Abu Dhabi, the multispecialty hospital operated in partnership with Mubadala Health. A urologic surgeon by training, he is known for his work on robotic and minimally invasive surgery for kidney, prostate and bladder cancers. His publications in European Urology include a critical analysis of laparoscopic and robot-assisted radical cystectomy for bladder cancer, a comparison of perioperative outcomes for robotic versus laparoscopic partial nephrectomy in complex tumours, and the long-term oncologic outcomes of robotic and laparoscopic radical cystectomy. He now combines urologic oncology with leadership of the whole hospital.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.clevelandclinicabudhabi.ae/en/about-us/leadership-team"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Haber+GP%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","urologic oncology","robotic surgery"],"related":[],"cancers":["rcc","prostate","urothelial"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cleveland-clinic-abu-dhabi"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive Officer","institutionId":"cleveland-clinic-abu-dhabi","specialisms":["Urologic oncology","Robotic surgery","Hospital leadership"],"profiles":[{"label":"Institution profile","url":"https://www.clevelandclinicabudhabi.ae/en/about-us/leadership-team"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Haber+GP%5BAuthor%5D"}],"papers":[{"title":"Laparoscopic and Robotic Assisted Radical Cystectomy for Bladder Cancer: A Critical Analysis","journal":"European Urology","year":2008,"doi":"10.1016/j.eururo.2008.03.076"},{"title":"Robotic Versus Laparoscopic Partial Nephrectomy for Complex Tumors: Comparison of Perioperative Outcomes","journal":"European Urology","year":2012,"doi":"10.1016/j.eururo.2012.03.012"},{"title":"Robotic and Laparoscopic Radical Cystectomy for Bladder Cancer: Long-term Oncologic Outcomes","journal":"European Urology","year":2014,"doi":"10.1016/j.eururo.2013.08.021"}]},{"id":"georgina-long","kind":"person","name":"Georgina V. Long","aka":[],"tldr":"Melanoma trialist who led COMBI-d, COMBI-AD and NADINA, moving immunotherapy before surgery for stage III disease.","summary":"Georgina Long (Melanoma Institute Australia) led COMBI-d and COMBI-AD, the trials establishing dabrafenib plus trametinib in metastatic and adjuvant BRAF-mutant melanoma, and co-led NADINA, which showed neoadjuvant nivolumab plus ipilimumab beats adjuvant nivolumab in stage III melanoma and is changing the sequence of surgery and immunotherapy. She also led the ABC trial of immunotherapy for melanoma brain metastases and was 2024 Australian of the Year with Richard Scolyer.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Georgina_Long","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Long%20GV%5BAuthor%5D%20melanoma"}],"tags":["melanoma","neoadjuvant","australia"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":["checkpoint-inhibitor","kinase-inhibitors"],"targets":["braf","pd1","ctla4"],"drugs":["nivolumab","ipilimumab"],"companies":[],"institutions":["melanoma-institute-australia"],"pathways":[],"terms":[],"trials":["combi-ad","nadina"],"people":[],"bottlenecks":[],"keyPapers":["paper-nadina-nejm-2024"],"journals":[],"dependsOn":[],"notes":[],"role":"Co-Medical Director, Melanoma Institute Australia; Chair of Melanoma Medical Oncology and Translational Research, University of Sydney","institutionId":"melanoma-institute-australia","specialisms":["Melanoma","Neoadjuvant immunotherapy","BRAF/MEK targeted therapy","Brain metastases"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Long%20GV%5BAuthor%5D%20melanoma"}],"papers":[{"title":"Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma (NADINA)","journal":"NEJM","year":2024,"doi":"10.1056/NEJMoa2402604"},{"title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma (COMBI-AD)","journal":"NEJM","year":2017,"doi":"10.1056/NEJMoa1708539"},{"title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma (COMBI-d)","journal":"NEJM","year":2014,"doi":"10.1056/NEJMoa1406037"}],"orcid":"0000-0001-8894-3545"},{"id":"georgios-kapetanakis","kind":"person","name":"Georgios Kapetanakis","aka":[],"tldr":"Georgios Kapetanakis represents Hellenic Cancer Federation (ELLOK) in the Organisation of European Cancer Institutes, which lists the organisation among its members in Greece.","summary":"Georgios Kapetanakis is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Hellenic Cancer Federation (ELLOK), its associate member in Greece. OnCo records the name from the OECI membership list so that the organisation's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the organisation's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Hellenic Cancer Federation (ELLOK) website","url":"https://ellok.org/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["hellenic-cancer-federation"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Hellenic Cancer Federation (ELLOK) to the Organisation of European Cancer Institutes","institutionId":"hellenic-cancer-federation","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Hellenic Cancer Federation (ELLOK) website","url":"https://ellok.org/"}],"papers":[]},{"id":"gerald-prager","kind":"person","name":"Gerald W. Prager","aka":[],"tldr":"Vienna oncologist who was lead author of SUNLIGHT, the trial that showed adding bevacizumab to trifluridine-tipiracil lengthens survival in refractory colorectal cancer.","summary":"Gerald Prager is a gastrointestinal medical oncologist at the Medical University of Vienna and chairs ESMO's gastrointestinal cancer faculty. He was first author of the 2023 New England Journal of Medicine report of SUNLIGHT, the phase 3 trial in which trifluridine-tipiracil plus bevacizumab improved overall survival compared with trifluridine-tipiracil alone in refractory metastatic colorectal cancer, establishing the combination as a third-line standard.","asOf":"2026-09-18","links":[],"tags":["colorectal","trialist"],"related":[],"cancers":["kras-g12c-colorectal","colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ccc-vienna"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-prager-sunlight-trifluridine-tipiracil-bevacizumab-nejm-2023"],"journals":[],"dependsOn":[],"notes":[],"role":"Gastrointestinal medical oncologist, Medical University of Vienna","institutionId":"ccc-vienna","specialisms":["Colorectal cancer","Anti-angiogenic therapy","Later-line chemotherapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Prager%5BAuthor%5D"}],"papers":[{"title":"SUNLIGHT: trifluridine-tipiracil plus bevacizumab in refractory metastatic colorectal cancer","journal":"New England Journal of Medicine","year":2023,"url":"https://doi.org/10.1056/NEJMoa2214963","doi":"10.1056/NEJMoa2214963"}]},{"id":"geraline-leusink","kind":"person","name":"Geraline Leusink","aka":[],"tldr":"Chair of the executive board of Rijnstate, the teaching hospital serving Arnhem and the surrounding region of Gelderland.","summary":"Geraline Leusink is voorzitter of the Raad van Bestuur of Rijnstate, the STZ teaching hospital based in Arnhem with sites in Velp, Zevenaar and Arnhem-Zuid. Rijnstate's board page states that the executive board consists of two members, Leusink as chair and Hans Schoo, and that it sets the hospital's strategic direction and carries final responsibility for operations and quality of care. Rijnstate reported in 2024 that she had also been appointed to the supervisory board of UMC Utrecht, and Omroep Gelderland quoted her as Rijnstate's bestuursvoorzitter in a November 2025 report on aggression against hospital staff. The live Rijnstate site blocks automated access, so the board page is cited from an archived copy.","asOf":"2026-09-10","links":[{"label":"Source: Rijnstate Raad van Bestuur page (archived copy, May 2024)","url":"https://web.archive.org/web/20240525134719/https://www.rijnstate.nl/over-rijnstate/organisatie/raad-van-bestuur/"},{"label":"Source: Omroep Gelderland report quoting her as bestuursvoorzitter (November 2025)","url":"https://www.gld.nl/nieuws/8395257/honderden-agressie-incidenten-in-ziekenhuis-rijnstate-je-went-eraan"},{"label":"Source: Rijnstate news on her appointment to the UMC Utrecht supervisory board (archived copy)","url":"https://web.archive.org/web/20250114190714/https://www.rijnstate.nl/over-rijnstate/nieuws/2024/rijnstate-bestuursvoorzitter-geraline-leusink-benoemd-in-rvt-umc-utrecht/"}],"tags":["leadership","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["rijnstate-arnhem"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["cancer-wiley"],"dependsOn":[],"notes":[],"role":"Voorzitter Raad van Bestuur (Chair of the Executive Board), Rijnstate","institutionId":"rijnstate-arnhem","specialisms":["Hospital governance","Health management"],"profiles":[{"label":"Rijnstate Raad van Bestuur page","url":"https://www.rijnstate.nl/over-rijnstate/organisatie/raad-van-bestuur/"}],"papers":[{"title":"Cancer screening participation and outcomes among people with an intellectual disability in the Netherlands: a cross-sectional population-based study","journal":"The Lancet Public Health","year":2025,"doi":"10.1016/s2468-2667(25)00011-8"},{"title":"Cancer incidence and diagnostic characteristics in people with intellectual disabilities in the Netherlands: a national registry-based cohort study","journal":"BMJ Oncology","year":2025,"doi":"10.1136/bmjonc-2024-000686"},{"title":"Cancer‐related mortality among people with intellectual disabilities: A nationwide population‐based cohort study","journal":"Cancer","year":2022,"doi":"10.1002/cncr.34030"}]},{"id":"gerard-zalcman","kind":"person","name":"Gérard Zalcman","aka":[],"tldr":"Gérard Zalcman represents Cancer Institute AP-HP Nord, Université Paris Cité in the Organisation of European Cancer Institutes, which lists the centre among its members in France.","summary":"Gérard Zalcman is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Cancer Institute AP-HP Nord, Université Paris Cité, its member in France. The northern Paris university hospital cancer institute of AP-HP, built around Hôpital Saint-Louis, Europe's historic home of bone marrow transplantation, and accredited by OECI as a Comprehensive Cancer Centre. OnCo records the name from the OECI membership list so that the centre's page has a named contact point; the person's exact title, appointment date and biography are not yet recorded and should be checked on the institution's own pages before being relied on.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Cancer Institute AP-HP Nord, Université Paris Cité website","url":"http://institutducancer-hopitauxnord-u-paris.aphp.fr/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["aphp-nord-cancer-institute"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Cancer Institute AP-HP Nord, Université Paris Cité to the Organisation of European Cancer Institutes","institutionId":"aphp-nord-cancer-institute","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Cancer Institute AP-HP Nord, Université Paris Cité website","url":"http://institutducancer-hopitauxnord-u-paris.aphp.fr/"}],"papers":[{"title":"Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors","journal":"Science","year":2017,"url":"https://doi.org/10.1126/science.aan3706","doi":"10.1126/science.aan3706","note":"OpenAlex author record matched by institution"},{"title":"Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial","journal":"The Lancet Oncology","year":2015,"url":"https://doi.org/10.1016/s1470-2045(15)70054-9","doi":"10.1016/s1470-2045(15)70054-9","note":"OpenAlex author record matched by institution"},{"title":"Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry","journal":"Annals of Oncology","year":2019,"url":"https://doi.org/10.1093/annonc/mdz167","doi":"10.1093/annonc/mdz167","note":"OpenAlex author record matched by institution"}]},{"id":"gerardo-legaspi","kind":"person","name":"Gerardo D. Legaspi","aka":[],"tldr":"Physician who directs the Philippine General Hospital, the largest government tertiary hospital in the Philippines and the national referral centre run by the University of the Philippines Manila.","summary":"Gerardo D. Legaspi, MD, is Director of the Philippine General Hospital (UP-PGH), a tertiary state-owned hospital administered by the University of the Philippines Manila that serves as the national referral centre and treats more than 600,000 patients a year, mostly indigent Filipinos. He heads a leadership team of deputy directors covering health operations, administration, fiscal services, training and research, and nursing.","asOf":"2026-09-10","links":[{"label":"Source: PGH list of officials","url":"https://www.pgh.gov.ph/list-of-officials/"}],"tags":["leadership","clinician-scientist","public-hospital"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["philippine-general-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director of the Philippine General Hospital","institutionId":"philippine-general-hospital","specialisms":["Hospital leadership","Public tertiary care","Academic medicine"],"profiles":[{"label":"PGH list of officials","url":"https://www.pgh.gov.ph/list-of-officials/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Legaspi+GD%5BAuthor%5D"}],"papers":[{"title":"Surgery for orbital metastasis from breast carcinoma initially presenting with progressive proptosis","journal":"BMJ Case Reports","year":2020,"doi":"10.1136/bcr-2020-237158"},{"title":"Cancer disparities in Southeast Asia: intersectionality and a call to action","journal":"The Lancet Regional Health - Western Pacific","year":2023,"doi":"10.1016/j.lanwpc.2023.100971"},{"title":"Intraoperative radiation therapy for glioblastoma and brain metastases: Program development and initial experience from the Philippines","journal":"Journal of Clinical Neuroscience","year":2025,"doi":"10.1016/j.jocn.2025.111524"}]},{"id":"gerhardt-attard","kind":"person","name":"Gerhardt Attard","aka":[],"tldr":"London oncologist who helped develop abiraterone and led the STAMPEDE analysis showing that two years of abiraterone alongside hormone therapy and radiotherapy improves survival in high-risk localised prostate cancer.","summary":"Gerhardt Attard is a medical oncologist at the UCL Cancer Institute who worked on the early clinical development of abiraterone at The Institute of Cancer Research. He was first author of the 2022 Lancet report of the STAMPEDE platform's combined analysis, which showed that adding abiraterone (with or without enzalutamide) to androgen deprivation therapy improved metastasis-free and overall survival in high-risk non-metastatic prostate cancer. His laboratory studies androgen receptor genomics and plasma DNA in prostate cancer.","asOf":"2026-09-18","links":[],"tags":["prostate","trialist"],"related":[],"cancers":["prostate-high-risk","prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["uclh"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-stampede-abiraterone-high-risk-attard-lancet-2022"],"journals":[],"dependsOn":[],"notes":[],"role":"Medical oncologist, UCL Cancer Institute and University College London Hospitals","institutionId":"uclh","specialisms":["Prostate cancer","Androgen receptor signalling","Circulating tumour DNA"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Attard%5BAuthor%5D"}],"papers":[{"title":"STAMPEDE: abiraterone with or without enzalutamide added to androgen deprivation for high-risk non-metastatic prostate cancer","journal":"The Lancet","year":2022,"url":"https://doi.org/10.1016/S0140-6736(21)02437-5","doi":"10.1016/S0140-6736(21)02437-5"}],"orcid":"0000-0002-4811-7983"},{"id":"gert-boyle","kind":"person","name":"Gert Boyle","aka":[],"tldr":"In 2014 the Columbia Sportswear chairwoman gave $100 million to OHSU's Knight Cancer Institute, the largest single contribution toward matching Phil and Penny Knight's $500 million challenge.","summary":"Gert Boyle (1924-2019), who fled Nazi Germany as a child and later ran Columbia Sportswear for decades, gave $100 million in 2014 to the Knight Cancer Institute at Oregon Health & Science University. OHSU's history records the gift as part of how the $1 billion Knight Cancer Challenge was met in 2015: Phil and Penny Knight's $500 million challenge grant was matched by donations including Boyle's and by $200 million in bonds from the Oregon Legislature. The gift was made anonymously at first and acknowledged later. It helped fund the Knight Cancer Research Building and the institute's early detection programme, and it showed how a challenge grant can pull in other large donors rather than crowd them out.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Gert_Boyle","links":[{"label":"OHSU Knight Cancer Institute: mission and history","url":"https://www.ohsu.edu/knight-cancer-institute/knight-cancer-institute-mission-and-history"}],"tags":["hero","donor"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ohsu-knight"],"pathways":[],"terms":[],"trials":[],"people":["phil-knight","brian-druker"],"bottlenecks":["b-funding-allocation"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Columbia Sportswear chairwoman whose $100 million helped Oregon meet the Knight Cancer Challenge","specialisms":["Cancer centre building","Challenge grants"],"profiles":[],"papers":[]},{"id":"gertrude-elion","kind":"person","name":"Gertrude Elion","aka":[],"tldr":"Without a doctorate, she and George Hitchings designed drugs to block DNA building blocks. Their 6-mercaptopurine of 1951 remains part of the cure for childhood leukaemia; she won the Nobel Prize in 1988.","summary":"Gertrude Elion (1918-1999) was turned away from graduate programmes and laboratory jobs as a woman before joining George Hitchings at Burroughs Wellcome in 1944. Rather than screening compounds at random, they studied differences in nucleic acid metabolism between normal and malignant cells and designed purine analogues to exploit them. 6-Mercaptopurine, synthesised in 1951 and approved in 1953, produced remissions in childhood leukaemia and is still given daily in maintenance therapy; thioguanine followed. The same programme produced azathioprine, which made organ transplantation possible, allopurinol for gout and tumour lysis, and aciclovir, the first selective antiviral. She shared the 1988 Nobel Prize in Physiology or Medicine with Hitchings and James Black, and was the first woman inducted into the National Inventors Hall of Fame.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Gertrude_B._Elion","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Gertrude_B._Elion"},{"label":"Nobel Prize biography","url":"https://www.nobelprize.org/prizes/medicine/1988/elion/facts/"}],"tags":["hero","pioneer"],"related":[],"cancers":["all-leukemia"],"sections":["chemotherapy","drug-discovery"],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["tumor-lysis-syndrome"],"trials":[],"people":[],"bottlenecks":["b-rare-cancers"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chemist who designed 6-mercaptopurine and the first rational anticancer drugs","specialisms":["Medicinal chemistry","Purine antimetabolites","Childhood leukaemia"],"profiles":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Gertrude_B._Elion"},{"label":"Nobel Prize biography","url":"https://www.nobelprize.org/prizes/medicine/1988/elion/facts/"}],"papers":[{"title":"The Purine Path to Chemotherapy","journal":"Science","year":1989,"doi":"10.1126/science.2649979"},{"title":"The Purine Path to Chemotherapy (Nobel Lecture)","journal":"Angewandte Chemie International Edition in English","year":1989,"doi":"10.1002/anie.198908701"},{"title":"The purine path to chemotherapy","journal":"Bioscience Reports","year":1989,"doi":"10.1007/bf01119794"}]},{"id":"ghassan-abou-alfa","kind":"person","name":"Ghassan K. Abou-Alfa","aka":[],"tldr":"Led HIMALAYA and ClarIDHy, which gave liver cancer a dual-immunotherapy option and biliary cancer its first targeted drug.","summary":"Ghassan Abou-Alfa was principal investigator of HIMALAYA, which established durvalumab plus a single dose of tremelimumab (STRIDE) as a first-line option in hepatocellular carcinoma, and of ClarIDHy, which won ivosidenib approval for IDH1-mutant cholangiocarcinoma, the first targeted therapy in biliary cancer. He has led biliary trials with Juan Valle for two decades and chairs the ASCO hepatobiliary guideline work.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Abou-Alfa%20GK%5BAuthor%5D%20hepatocellular%20OR%20cholangiocarcinoma"}],"tags":["hcc","biliary","trialist"],"related":[],"cancers":["hcc","cholangiocarcinoma"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["idh","pdl1","ctla4"],"drugs":["durvalumab"],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":["himalaya","claridhy"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nejm-evidence"],"dependsOn":[],"notes":[],"role":"Attending Physician, Gastrointestinal Oncology, Memorial Sloan Kettering Cancer Center","institutionId":"mskcc","specialisms":["Hepatocellular carcinoma","Biliary tract cancer","IDH-targeted therapy","Immunotherapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Abou-Alfa%20GK%5BAuthor%5D%20hepatocellular%20OR%20cholangiocarcinoma"}],"papers":[{"title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (HIMALAYA)","journal":"NEJM Evidence","year":2022,"doi":"10.1056/EVIDoa2100070"},{"title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy)","journal":"Lancet Oncology","year":2020,"doi":"10.1016/S1470-2045(20)30157-1"}],"orcid":"0000-0002-1522-8054"},{"id":"ghayas-issa","kind":"person","name":"Ghayas C. Issa","aka":[],"tldr":"First author of the revumenib trial that created the menin inhibitor class for acute leukaemia.","summary":"Ghayas Issa led and was first author of the AUGMENT-101 phase 1 report in Nature showing the menin inhibitor revumenib produces remissions in heavily pretreated KMT2A-rearranged and NPM1-mutant acute leukaemia, and of the pivotal phase 2 analysis that led to its 2024 approval. He leads menin inhibitor combination trials and studies of resistance (MEN1 mutations) at MD Anderson.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Issa%20GC%5BAuthor%5D%20revumenib%20menin"}],"tags":["aml","menin","targeted-therapy"],"related":[],"cancers":["aml","all-leukemia"],"sections":[],"technologies":[],"targets":["menin"],"drugs":["revumenib"],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":["augment-101"],"people":[],"bottlenecks":[],"keyPapers":["paper-augment-101-revumenib-menin-nature-2023"],"journals":[],"dependsOn":[],"notes":[],"role":"Associate Professor of Leukemia, MD Anderson Cancer Center","institutionId":"md-anderson","specialisms":["Acute leukaemia","Menin inhibitors","KMT2A-rearranged leukaemia","Targeted therapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Issa%20GC%5BAuthor%5D%20revumenib%20menin"}],"papers":[{"title":"The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia","journal":"Nature","year":2023,"doi":"10.1038/s41586-023-05812-3"},{"title":"Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101)","journal":"JCO","year":2025,"doi":"10.1200/JCO.24.00826"},{"title":"AUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation","journal":"Nature","year":2023,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=AUGMENT-101%20revumenib%20menin%20inhibitor%20KMT2A%20NPM1%20Issa%20Nature%202023"}],"orcid":"0000-0002-4339-8683"},{"id":"giampaolo-tortora","kind":"person","name":"Giampaolo Tortora","aka":[],"tldr":"Giampaolo Tortora is a medical oncologist who directs the Gemelli comprehensive cancer centre.","summary":"Giampaolo Tortora is Director of the Comprehensive Cancer Center at Policlinico Universitario A. Gemelli in Rome and Professor of Medical Oncology. His specialisms are medical oncology, pancreatic ductal adenocarcinoma and targeted therapy, with a research background in EGFR signalling and pancreatic cancer. His papers include the Annals of Oncology paper introducing ESCAT, the ESMO Scale for Clinical Actionability of molecular Targets, which ranks genomic alterations as targets for precision medicine, a review of PTEN as predictor and target in colorectal cancer, and a paper on pneumonitis from immune checkpoint inhibitors during COVID-19. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tortora%20G%5BAuthor%5D%20pancreatic"}],"tags":[],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["gemelli"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Comprehensive Cancer Center, Gemelli; Professor of Medical Oncology","institutionId":"gemelli","specialisms":["Medical oncology","Pancreatic cancer","Targeted therapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tortora%20G%5BAuthor%5D%20pancreatic"}],"papers":[{"title":"A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)","journal":"Annals of Oncology","year":2018,"doi":"10.1093/annonc/mdy263"},{"title":"PTEN in Colorectal Cancer: Shedding Light on Its Role as Predictor and Target","journal":"Cancers","year":2019,"doi":"10.3390/cancers11111765"},{"title":"Pneumonitis from immune checkpoint inhibitors and COVID-19: current concern in cancer treatment","journal":"Journal for ImmunoTherapy of Cancer","year":2020,"doi":"10.1136/jitc-2020-000952"}],"orcid":"0000-0002-1378-4962"},{"id":"gianvito-martino","kind":"person","name":"Gianvito Martino","aka":[],"tldr":"Neurologist and neural stem cell researcher who serves as Scientific Director of IRCCS Ospedale San Raffaele in Milan.","summary":"Gianvito Martino is Direttore Scientifico of IRCCS Ospedale San Raffaele, the Milan research hospital that includes a comprehensive cancer centre and major haematology and oncology programmes. A neurologist by training, his research focuses on neuroimmunology and neural stem cells. His role is recorded in the public record for the institution.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://research.hsr.it/en/index.html"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Martino+G%5BAuthor%5D+AND+San+Raffaele"}],"tags":["leadership","research leadership"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["san-raffaele"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nature","plos-medicine"],"dependsOn":[],"notes":[],"role":"Scientific Director (Direttore Scientifico)","institutionId":"san-raffaele","specialisms":["Neuroscience","Neuroimmunology","Research leadership"],"profiles":[{"label":"Institution profile","url":"https://research.hsr.it/en/index.html"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Martino+G%5BAuthor%5D+AND+San+Raffaele"}],"papers":[{"title":"Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis","journal":"Nature","year":2003,"url":"https://doi.org/10.1038/nature01552","doi":"10.1038/nature01552","note":"Europe PMC author record matched by affiliation"},{"title":"Infiltrating blood-derived macrophages are vital cells playing an anti-inflammatory role in recovery from spinal cord injury in mice","journal":"PLoS Medicine","year":2009,"url":"https://doi.org/10.1371/journal.pmed.1000113","doi":"10.1371/journal.pmed.1000113","note":"Europe PMC author record matched by affiliation"},{"title":"Neurosphere-derived multipotent precursors promote neuroprotection by an immunomodulatory mechanism","journal":"Nature","year":2005,"url":"https://doi.org/10.1038/nature03889","doi":"10.1038/nature03889","note":"Europe PMC author record matched by affiliation"}],"orcid":"0000-0003-1295-9131"},{"id":"gilda-radner","kind":"person","name":"Gilda Radner","aka":[],"tldr":"The Saturday Night Live star wrote about her ovarian cancer in It's Always Something and died at 42 in 1989. Her name lives on in Gilda's Club and the familial ovarian cancer registry at Roswell Park.","summary":"Gilda Radner (1946-1989), one of the original cast of Saturday Night Live, was diagnosed with ovarian cancer in 1986 after months of symptoms that were not investigated. Her memoir It's Always Something, published weeks after her death on 20 May 1989, described treatment, remission and relapse with the frankness that made her famous. Her husband Gene Wilder and her psychotherapist Joanna Bull founded Gilda's Club in 1991, offering free psychosocial support to anyone affected by cancer, now part of the Cancer Support Community. Her family history of ovarian cancer led to the renaming of the familial ovarian cancer registry at Roswell Park as the Gilda Radner Familial Ovarian Cancer Registry, one of the earliest resources for studying inherited ovarian cancer risk.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Gilda_Radner","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Gilda_Radner"},{"label":"Cancer Support Community (Gilda's Club)","url":"https://www.cancersupportcommunity.org/"}],"tags":["public-figure","patient"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":["psycho-oncology","germline-testing"],"targets":[],"drugs":[],"companies":[],"institutions":["roswell-park"],"pathways":[],"terms":["hereditary-cancer-syndromes","hgsoc"],"trials":[],"people":[],"bottlenecks":["b-early-detection","b-hereditary-risk"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Comedian whose ovarian cancer inspired Gilda's Club and a hereditary cancer registry","specialisms":["Ovarian cancer","Hereditary cancer","Psychosocial support"],"profiles":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Gilda_Radner"},{"label":"Cancer Support Community (Gilda's Club)","url":"https://www.cancersupportcommunity.org/"}],"papers":[]},{"id":"giles-robinson","kind":"person","name":"Giles W. Robinson","aka":[],"tldr":"Memphis paediatric neuro-oncologist who led the study showing that the Hedgehog inhibitor vismodegib helps only adults and older children whose medulloblastoma belongs to the SHH subgroup, an early example of subgroup-directed brain tumour therapy.","summary":"Giles Robinson is a paediatric neuro-oncologist at St. Jude Children's Research Hospital and leads its medulloblastoma programme, including the SJMB12 trial that treats patients according to molecular subgroup. He was first author of the 2015 Journal of Clinical Oncology report of the vismodegib trials in recurrent medulloblastoma, which showed responses were confined to SHH-subgroup tumours with upstream pathway mutations and that the drug caused growth-plate fusion in growing children.","asOf":"2026-09-18","links":[],"tags":["paediatric","brain","targeted-therapy","trialist"],"related":[],"cancers":["medulloblastoma-shh","medulloblastoma","childhood-cancers"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["st-jude"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-robinson-vismodegib-shh-medulloblastoma-jco-2015"],"journals":[],"dependsOn":[],"notes":[],"role":"Paediatric neuro-oncologist, St. Jude Children's Research Hospital","institutionId":"st-jude","specialisms":["Medulloblastoma","Molecular subgroup-directed therapy","Paediatric brain tumour trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Robinson%5BAuthor%5D"}],"papers":[{"title":"Vismodegib in recurrent sonic hedgehog-subgroup medulloblastoma (PBTC-025B and PBTC-032)","journal":"Journal of Clinical Oncology","year":2015,"url":"https://doi.org/10.1200/JCO.2014.60.1591","doi":"10.1200/JCO.2014.60.1591"}],"orcid":"0000-0001-7441-9486"},{"id":"gilles-salles","kind":"person","name":"Gilles Salles","aka":[],"tldr":"Led PRIMA, which established rituximab maintenance in follicular lymphoma, and co-chaired POLARIX in DLBCL.","summary":"Gilles Salles led PRIMA, the trial showing two years of rituximab maintenance prolongs remission in follicular lymphoma, and co-chaired POLARIX, which showed polatuzumab vedotin plus R-CHP improves progression-free survival over R-CHOP in DLBCL, the first new first-line regimen in two decades. He led the French LYSA group before moving to MSKCC and co-led the tafasitamab and mosunetuzumab programmes.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Gilles_Salles","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Salles%20G%5BAuthor%5D%20lymphoma"}],"tags":["lymphoma","trialist","lysa"],"related":[],"cancers":["follicular-lymphoma","dlbcl"],"sections":[],"technologies":["monoclonal-antibody","adc"],"targets":["cd20"],"drugs":[],"companies":["lysa"],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":["polarix"],"people":[],"bottlenecks":[],"keyPapers":["paper-polarix-polatuzumab-rchp-nejm-2022"],"journals":[],"dependsOn":[],"notes":[],"role":"Chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center","institutionId":"mskcc","specialisms":["Follicular lymphoma","Diffuse large B-cell lymphoma","Anti-CD20 antibodies","Cooperative-group trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Salles%20G%5BAuthor%5D%20lymphoma"}],"papers":[{"title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA)","journal":"Lancet","year":2011,"doi":"10.1016/S0140-6736(10)62175-7"},{"title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma (POLARIX)","journal":"NEJM","year":2022,"doi":"10.1056/NEJMoa2115304"}],"orcid":"0000-0002-9541-8666"},{"id":"gilles-vassal","kind":"person","name":"Gilles Vassal","aka":[],"tldr":"Gustave Roussy paediatric oncologist and past SIOPE president who leads its oncopolicy work and helped shape European paediatric medicines regulation.","summary":"Gilles Vassal is a member of the SIOP Europe board responsible for oncopolicy and is Professor of Paediatric Oncology at Gustave Roussy, Villejuif. A former SIOPE president, he has been a leading advocate for the EU Paediatric Regulation and for the ACCELERATE platform to speed access to innovative medicines for children with cancer, and he founded the Innovative Therapies for Children with Cancer (ITCC) consortium.","asOf":"2026-09-10","links":[{"label":"Society page","url":"https://siope.eu/about-siope/board/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Vassal+G%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","paediatric oncology","regulation"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["itcc"],"institutions":["accelerate-platform","gustave-roussy"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Board member, Oncopolicy","institutionId":"siop-europe","specialisms":["Paediatric oncology","Paediatric drug development","Oncology policy"],"profiles":[{"label":"Society page","url":"https://siope.eu/about-siope/board/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Vassal+G%5BAuthor%5D"}],"papers":[{"title":"10-year report on the European Paediatric Regulation and its impact on new drugs for children's cancers","journal":"The Lancet Oncology","year":2018,"doi":"10.1016/s1470-2045(18)30105-0"},{"title":"Do national cancer control plans address care and research for children, adolescents, and young adults? A review of status, priorities, and recommendations across 41 European countries","journal":"The Lancet Regional Health - Europe","year":2025,"doi":"10.1016/j.lanepe.2024.101155"},{"title":"Defining and listing very rare cancers of paediatric age: consensus of the Joint Action on Rare Cancers in cooperation with the European Cooperative Study Group for Pediatric Rare Tumors","journal":"European Journal of Cancer","year":2019,"doi":"10.1016/j.ejca.2018.12.031"}]},{"id":"giovanni-blandino","kind":"person","name":"Giovanni Blandino","aka":[],"tldr":"Molecular oncologist known for mutant p53 research, appointed Scientific Director of Rome's Regina Elena National Cancer Institute in 2026.","summary":"Giovanni Blandino was confirmed as Scientific Director of the IRCCS Regina Elena National Cancer Institute (IRE), part of the IFO group in Rome, in May 2026. He leads the institute's Translational Oncology Research unit, where his laboratory studies gain-of-function mutant p53, its effects on tumour metabolism and non-coding RNAs, and strategies to target it therapeutically. His appointment is announced on the IFO website.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.ifo.it/2026/05/blandino-cavuto-2-nomine-strategiche-ifo/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Blandino+G%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","molecular oncology","breast cancer"],"related":[],"cancers":["tnbc","head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["regina-elena-rome"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nature-communications","journal-of-experimental-and-clinical-cancer-research"],"dependsOn":[],"notes":[],"role":"Scientific Director, IRCCS Regina Elena National Cancer Institute","institutionId":"regina-elena-rome","specialisms":["Mutant p53 biology","Translational oncology","Cancer metabolism","Breast cancer"],"profiles":[{"label":"Institution profile","url":"https://www.ifo.it/2026/05/blandino-cavuto-2-nomine-strategiche-ifo/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Blandino+G%5BAuthor%5D"}],"papers":[{"title":"Mutant p53 sustains serine-glycine synthesis and essential amino acids intake promoting breast cancer growth","journal":"Nature Communications","year":2023,"url":"https://doi.org/10.1038/s41467-023-42458-1","doi":"10.1038/s41467-023-42458-1"},{"title":"Targeting mutant p53 in cancer: the latest insights","journal":"Journal of Experimental & Clinical Cancer Research","year":2019,"url":"https://doi.org/10.1186/s13046-019-1302-0","doi":"10.1186/s13046-019-1302-0"}]},{"id":"giovanni-scambia","kind":"person","name":"Giovanni Scambia","aka":[],"tldr":"Giovanni Scambia is a gynaecologic oncologist who leads research at the Gemelli hospital.","summary":"Giovanni Scambia is Scientific Director of the Fondazione Policlinico Universitario A. Gemelli IRCCS in Rome and Professor of Gynaecology. His specialisms are gynaecological oncology, ovarian cancer surgery and cervical cancer, and he runs a large surgical and trial programme in ovarian, cervical and endometrial cancer. His papers include the SCORPION randomised trial of primary debulking surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer, the New England Journal of Medicine report of maintenance olaparib in newly diagnosed advanced ovarian cancer, and the long-term follow-up of the SOLO1/GOG 3004 trial of maintenance olaparib in patients with a BRCA mutation. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Scambia%20G%5BAuthor%5D%20ovarian"}],"tags":[],"related":[],"cancers":["ovarian","cervical","endometrial"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["gemelli"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["international-journal-of-gynecological-cancer"],"dependsOn":[],"notes":[],"role":"Scientific Director, Fondazione Policlinico Universitario A. Gemelli IRCCS; Professor of Gynaecology","institutionId":"gemelli","specialisms":["Gynaecological oncology","Ovarian cancer surgery","Cervical cancer"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Scambia%20G%5BAuthor%5D%20ovarian"}],"papers":[{"title":"Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850)","journal":"International Journal of Gynecological Cancer","year":2020,"doi":"10.1136/ijgc-2020-001640"},{"title":"Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer","journal":"New England Journal of Medicine","year":2018,"doi":"10.1056/nejmoa1810858"},{"title":"Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial","journal":"Journal of Clinical Oncology","year":2023,"doi":"10.1200/jco.22.01549"},{"title":"KEYNOTE-A18: pembrolizumab with chemoradiotherapy for locally advanced cervical cancer","journal":"The Lancet","year":2024,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=KEYNOTE-A18+pembrolizumab+chemoradiotherapy+cervical+Lancet"},{"title":"PAOLA-1: olaparib added to bevacizumab maintenance in newly diagnosed ovarian cancer, with benefit confined to HRD-positive tumours","journal":"New England Journal of Medicine","year":2019,"url":"https://doi.org/10.1056/NEJMoa1911361","doi":"10.1056/NEJMoa1911361"}],"orcid":"0000-0002-9503-9041"},{"id":"giuliana-cardenas-gamarra","kind":"person","name":"Giuliana Càrdenas Gamarra","aka":[],"tldr":"Giuliana Càrdenas Gamarra represents Oncosalud (AUNA) in the Organisation of European Cancer Institutes, which lists the centre among its members in Peru.","summary":"Giuliana Càrdenas Gamarra is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Oncosalud (AUNA), its member in Peru. Oncosalud is a private cancer care provider in Lima, part of the AUNA health group, and one of the few OECI members outside Europe, and an associate member of the Organisation of European Cancer Institutes. OnCo records the name from the OECI membership list so that the centre's page has a named contact point; the person's exact title, appointment date and biography are not yet recorded and should be checked on the institution's own pages before being relied on.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Oncosalud (AUNA) website","url":"https://oncosalud.pe/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oncosalud-auna"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Oncosalud (AUNA) to the Organisation of European Cancer Institutes","institutionId":"oncosalud-auna","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Oncosalud (AUNA) website","url":"https://oncosalud.pe/"}],"papers":[]},{"id":"giulio-draetta","kind":"person","name":"Giulio Draetta","aka":[],"tldr":"MD Anderson's chief scientist, a cell-cycle biologist who ran drug discovery in industry before leading the centre's research.","summary":"Giulio Draetta is Chief Scientific Officer of MD Anderson Cancer Center. A cell-cycle biologist specialising in cancer biology, drug discovery and translational research, he discovered key cyclin-dependent kinase regulators early in his career and later led oncology discovery at Pharmacia and Merck. His papers include two 1988 reports, in Nature and Cell, on the human cdc2 protein kinase as a cell-cycle regulated tyrosine kinase substrate and on its activation during mitosis through phosphorylation and subunit rearrangement. As chief scientist he oversees MD Anderson's research programmes, the Institute for Applied Cancer Science and the Therapeutics Discovery division, with interests in CDK4/6 and AI-driven drug and target discovery.","asOf":"2026-09-08","links":[{"label":"MD Anderson faculty","url":"https://faculty.mdanderson.org/search?q=Giulio%20Draetta"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Draetta%20G%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Giulio%20Draetta"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["ai-drug-design"],"targets":["cdk4-6"],"drugs":[],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Scientific Officer, MD Anderson Cancer Center","institutionId":"md-anderson","specialisms":["Cancer biology","Drug discovery","Translational research"],"profiles":[{"label":"MD Anderson faculty","url":"https://faculty.mdanderson.org/search?q=Giulio%20Draetta"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Draetta%20G%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Giulio%20Draetta"}],"papers":[{"title":"Human cdc2 protein kinase is a major cell-cycle regulated tyrosine kinase substrate","journal":"Nature","year":1988,"url":"https://doi.org/10.1038/336738a0","doi":"10.1038/336738a0"},{"title":"Activation of cdc2 protein kinase during mitosis in human cells: cell cycle-dependent phosphorylation and subunit rearrangement","journal":"Cell","year":1988,"url":"https://doi.org/10.1016/0092-8674(88)90175-4","doi":"10.1016/0092-8674(88)90175-4"}],"orcid":"0000-0001-5225-9610"},{"id":"giuseppe-curigliano","kind":"person","name":"Giuseppe Curigliano","aka":[],"tldr":"Breast oncologist and phase 1 leader who co-led DESTINY-Breast06 and shaped the HER2-low concept.","summary":"Giuseppe Curigliano is Director of the Early Drug Development Division at IEO, the European Institute of Oncology, in Milan and Professor of Medical Oncology at the University of Milan, and chairs guideline committees for the European Society for Medical Oncology (ESMO). His specialisms are breast cancer, early drug development, HER2-low disease and cardio-oncology. He is a principal investigator in the DESTINY-Breast programme of trastuzumab deruxtecan and helped shape the HER2-low concept. His New England Journal of Medicine paper on DESTINY-Breast06 reported trastuzumab deruxtecan in HER2-low or HER2-ultralow, hormone receptor-positive metastatic breast cancer. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Curigliano%20G%5BAuthor%5D%20breast%20deruxtecan"}],"tags":[],"related":[],"cancers":["breast-hr-positive","tnbc"],"sections":[],"technologies":[],"targets":["her2"],"drugs":["trastuzumab-deruxtecan"],"companies":[],"institutions":["ieo-milan","esmo"],"pathways":[],"terms":["her2-low"],"trials":["destiny-breast06"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Early Drug Development Division, IEO; Professor of Medical Oncology, University of Milan","institutionId":"ieo-milan","specialisms":["Breast cancer","Early drug development","HER2-low disease","Cardio-oncology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Curigliano%20G%5BAuthor%5D%20breast%20deruxtecan"}],"papers":[{"title":"Trastuzumab deruxtecan in HER2-low or HER2-ultralow, hormone receptor-positive metastatic breast cancer (DESTINY-Breast06)","journal":"NEJM","year":2025,"doi":"10.1056/NEJMoa2407086"},{"title":"DESTINY-Breast03: trastuzumab deruxtecan beats T-DM1 as second-line treatment of HER2-positive metastatic breast cancer","journal":"New England Journal of Medicine","year":2022,"url":"https://doi.org/10.1056/NEJMoa2115022","doi":"10.1056/NEJMoa2115022"},{"title":"DESTINY-Breast06: trastuzumab deruxtecan before any chemotherapy in hormone-receptor-positive, HER2-low or ultralow breast cancer","journal":"New England Journal of Medicine","year":2024,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DESTINY-Breast06+trastuzumab+deruxtecan+HER2-low+chemotherapy-naive"}],"orcid":"0000-0003-1781-2518"},{"id":"giuseppe-tonutti","kind":"person","name":"Giuseppe Tonutti","aka":[],"tldr":"Health manager who serves as Director General of the Centro di Riferimento Oncologico di Aviano, the national cancer research hospital (IRCCS) in Friuli Venezia Giulia.","summary":"Dott. Giuseppe Tonutti is Direttore Generale of the Centro di Riferimento Oncologico (CRO) di Aviano, a public cancer research hospital (IRCCS) in the Friuli Venezia Giulia region of north eastern Italy. The institute's strategic direction page lists him with Dott. Gustavo Baldassarre as Direttore Scientifico, Dott. Valter Gattei as acting Direttore Sanitario and Dott.ssa Cristina Zavagno as Direttore Amministrativo. The page states that its contents were last verified on 1 April 2026.","asOf":"2026-09-10","links":[{"label":"Source: CRO Aviano direzione strategica page","url":"https://www.cro.sanita.fvg.it/it/istituto/direzioni.html"}],"tags":["leadership","hospital-management","research-institute"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cro-aviano"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Direttore Generale (Director General), Centro di Riferimento Oncologico di Aviano (CRO)","institutionId":"cro-aviano","specialisms":["Hospital management","Health administration","Research hospital governance"],"profiles":[{"label":"CRO Aviano strategic direction page","url":"https://www.cro.sanita.fvg.it/it/istituto/direzioni.html"}],"papers":[]},{"id":"goh-boon-cher","kind":"person","name":"Goh Boon Cher","aka":[],"tldr":"Senior medical oncologist and translational researcher who leads research at NCIS, with a long record in experimental therapeutics and head and neck cancer.","summary":"Goh Boon Cher is Deputy Director (Research) at the National University Cancer Institute, Singapore, and a professor at the National University of Singapore. His work centres on early-phase clinical trials, pharmacology of anticancer drugs and head and neck/nasopharyngeal cancers, and he has led many investigator-initiated trials in Asia.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.ncis.com.sg/about-ncis/at-the-helm"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Goh+BC%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","head and neck cancer","drug development"],"related":[],"cancers":["head-and-neck","nasopharyngeal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["nuh-ncis"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["cancer-medicine"],"dependsOn":[],"notes":[],"role":"Deputy Director (Research)","institutionId":"nuh-ncis","specialisms":["Medical oncology","Early-phase drug development","Head and neck cancer","Nasopharyngeal cancer"],"profiles":[{"label":"Institution profile","url":"https://www.ncis.com.sg/about-ncis/at-the-helm"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Goh+BC%5BAuthor%5D"}],"papers":[{"title":"Phase II study of TAS‐106 in patients with platinum‐failure recurrent or metastatic head and neck cancer and nasopharyngeal cancer","journal":"Cancer Medicine","year":2013,"doi":"10.1002/cam4.79"},{"title":"Different treatment efficacies and side effects of cytotoxic chemotherapy","journal":"Journal of Thoracic Disease","year":2020,"doi":"10.21037/jtd.2019.08.63"}]},{"id":"goh-cheng-liang","kind":"person","name":"Goh Cheng Liang","aka":[],"tldr":"His Goh Foundation's $50 million gift built the Goh Cheng Liang Proton Therapy Centre at the National Cancer Centre Singapore, the only public proton therapy service in the country.","summary":"Goh Cheng Liang (1927-2025) built the Nippon Paint business in South East Asia from a small paint shop and became one of Singapore's richest men and quietest donors. The National Cancer Centre Singapore records that its proton therapy centre was made possible by a generous $50 million gift from the Goh Foundation and named the Goh Cheng Liang Proton Therapy Centre. It gives patients in Singapore and the region access to proton beam therapy, which targets tumours while sparing surrounding tissue and matters most for children and for tumours near critical structures; NCCS is the only public healthcare institution in Singapore to offer it. The gift put an expensive technology inside a public system rather than a private clinic.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Goh_Cheng_Liang","links":[{"label":"NCCS: Goh Cheng Liang Proton Therapy Centre","url":"https://www.nccs.com.sg/our-specialties/goh-cheng-liang-proton-therapy-centre.html"}],"tags":["hero","donor"],"related":[],"cancers":[],"sections":[],"technologies":["proton-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":["nccs"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-global-access","b-surgery-radiation-innovation"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Nippon Paint magnate whose Goh Foundation gave $50 million for Singapore's public proton therapy centre","specialisms":["Proton therapy","Cancer care in Asia"],"profiles":[],"papers":[]},{"id":"gordon-freeman","kind":"person","name":"Gordon J. Freeman","aka":[],"tldr":"Showed that PD-L1 is the ligand for PD-1 and that the pair switches T cells off, the foundation of checkpoint immunotherapy.","summary":"Gordon Freeman, with Arlene Sharpe and Tasuku Honjo, identified PD-L1 and PD-L2 as the ligands of PD-1 in 2000 and 2001 and showed that engagement inhibits T-cell activation, defining the pathway that pembrolizumab, nivolumab and atezolizumab block. He holds foundational patents on PD-1 pathway blockade and shared the Warren Alpert Prize; his laboratory continues to study checkpoint mechanisms.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Gordon_J._Freeman","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Freeman%20GJ%5BAuthor%5D%20PD-L1"}],"tags":["immunotherapy","discovery","pd-1"],"related":[],"cancers":[],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["pdl1","pd1"],"drugs":[],"companies":[],"institutions":["dana-farber"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-topalian-anti-pd1-nejm-2012"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medicine, Dana-Farber Cancer Institute and Harvard Medical School","institutionId":"dana-farber","specialisms":["PD-1/PD-L1 pathway","T-cell costimulation","Immune checkpoint biology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Freeman%20GJ%5BAuthor%5D%20PD-L1"}],"papers":[{"title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","journal":"Journal of Experimental Medicine","year":2000,"doi":"10.1084/jem.192.7.1027"},{"title":"PD-L2 is a second ligand for PD-1 and inhibits T cell activation","journal":"Nature Immunology","year":2001,"doi":"10.1038/85330"},{"title":"Topalian 2012: the first large trial of a PD-1 antibody shows durable responses across melanoma, lung and kidney cancer","journal":"New England Journal of Medicine","year":2012,"url":"https://doi.org/10.1056/NEJMoa1200690","doi":"10.1056/NEJMoa1200690"}],"orcid":"0000-0002-7210-5616"},{"id":"govindan-rangarajan","kind":"person","name":"Govindan Rangarajan","aka":[],"tldr":"Mathematician who directs the Indian Institute of Science in Bengaluru, India's leading research university and home to cancer biology and bioengineering groups.","summary":"Professor Govindan Rangarajan is Director of the Indian Institute of Science (IISc), the research university established in Bengaluru in 1909 through a partnership between Jamsetji Nusserwanji Tata, the Mysore royal family and the Government of India. He holds an integrated MSc from BITS Pilani and a PhD from the University of Maryland, worked at Lawrence Berkeley Laboratory, and joined the IISc Department of Mathematics in 1992; his research covers nonlinear dynamics, chaos and time series analysis. Before becoming Director he chaired several departments and divisions, directed the Indo-French Centre for Applied Mathematics and led the institute's international relations and development work. He is a Fellow of the Indian Academy of Sciences and the National Academy of Sciences, India, and a Chevalier dans l'Ordre des Palmes Academiques.","asOf":"2026-09-10","links":[{"label":"Source: IISc administration, Director page","url":"https://www.iisc.ac.in/about/administration/director/"}],"tags":["leadership","research-institute"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["iisc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Indian Institute of Science","institutionId":"iisc","specialisms":["Applied mathematics","Nonlinear dynamics","Time series analysis","Research administration"],"profiles":[{"label":"IISc Director page","url":"https://www.iisc.ac.in/about/administration/director/"},{"label":"Foreword from the Director","url":"https://www.iisc.ac.in/about/foreword-from-the-director/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rangarajan+G%5BAuthor%5D"}],"papers":[{"title":"PAGE4 and Conformational Switching: Insights from Molecular Dynamics Simulations and Implications for Prostate Cancer","journal":"Journal of Molecular Biology","year":2018,"doi":"10.1016/j.jmb.2018.05.011"},{"title":"Dynamic Phenotypic Switching and Group Behavior Help Non-Small Cell Lung Cancer Cells Evade Chemotherapy","journal":"Biomolecules","year":2021,"doi":"10.3390/biom12010008"}]},{"id":"graham-jackson","kind":"person","name":"Graham H. Jackson","aka":[],"tldr":"Led Myeloma XI, the 4,000-patient UK trial that proved lenalidomide maintenance extends survival after transplant.","summary":"Graham Jackson was chief investigator of Myeloma XI, the largest myeloma trial ever run, which showed lenalidomide maintenance improves progression-free and overall survival in transplant-eligible patients and defined the benefit of triplet induction, and of the earlier Myeloma IX trial. He chairs the UK Myeloma Research Alliance and leads the RADAR trial of MRD-guided treatment.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Jackson%20GH%5BAuthor%5D%20myeloma%20XI"}],"tags":["myeloma","maintenance","uk"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":["mrd-testing"],"targets":[],"drugs":[],"companies":[],"institutions":["newcastle-cancer-centre"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Clinical Haematology, Newcastle University; Consultant, Freeman Hospital","institutionId":"newcastle-cancer-centre","specialisms":["Multiple myeloma","Maintenance therapy","Large pragmatic trials","Transplantation"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Jackson%20GH%5BAuthor%5D%20myeloma%20XI"}],"papers":[{"title":"Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial","journal":"Lancet Oncology","year":2019,"doi":"10.1016/S1470-2045(18)30687-9"},{"title":"First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX)","journal":"Lancet","year":2010,"doi":"10.1016/S0140-6736(10)62051-X"}],"orcid":"0000-0003-0756-969X"},{"id":"mcarthur-grant","kind":"person","name":"Grant McArthur","aka":[],"tldr":"A melanoma pioneer who led the vemurafenib and cobimetinib trials and now heads Victoria's cancer alliance.","summary":"Grant McArthur is Executive Director of the Victorian Comprehensive Cancer Centre Alliance and a melanoma medical oncologist at the Peter MacCallum Cancer Centre in Melbourne. He was a principal investigator for BRIM-3 and coBRIM, the trials that established BRAF inhibition with vemurafenib and combined BRAF and MEK inhibition with cobimetinib in melanoma. His publications include the extended follow-up of vemurafenib in BRAF V600E and V600K mutation-positive melanoma from BRIM-3. He has led translational programmes on resistance and on combining targeted therapy with immunotherapy, and now heads Victoria's cancer alliance.","asOf":"2026-09-08","links":[{"label":"Peter MacCallum Cancer Centre","url":"https://www.petermac.org"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=McArthur%20GA%5BAuthor%5D%20melanoma"}],"tags":[],"related":[],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":["braf"],"drugs":["vemurafenib","cobimetinib"],"companies":[],"institutions":["peter-mac"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Executive Director, Victorian Comprehensive Cancer Centre Alliance; melanoma medical oncologist, Peter Mac","institutionId":"peter-mac","specialisms":["Melanoma","BRAF and MEK inhibitors","Immunotherapy","Translational research"],"profiles":[{"label":"Peter MacCallum Cancer Centre","url":"https://www.petermac.org"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=McArthur%20GA%5BAuthor%5D%20melanoma"}],"papers":[{"title":"Safety and efficacy of vemurafenib in BRAF V600E and V600K mutation-positive melanoma (BRIM-3): extended follow-up","journal":"Lancet Oncology","year":2014,"doi":"10.1016/S1470-2045(14)70012-9"},{"title":"CheckMate 067 at ten years: nivolumab plus ipilimumab produces long-term survival in half of patients with advanced melanoma","journal":"New England Journal of Medicine","year":2025,"url":"https://doi.org/10.1056/NEJMoa2407417","doi":"10.1056/NEJMoa2407417"}],"orcid":"0000-0001-8908-6071"},{"id":"gregory-riely","kind":"person","name":"Gregory J. Riely","aka":[],"tldr":"Lung cancer doctor who led PHAROS, the trial that brought the encorafenib and binimetinib pair to BRAF V600E-mutant lung cancer.","summary":"Gregory Riely is a thoracic medical oncologist at Memorial Sloan Kettering Cancer Center. He was first author of the 2023 Journal of Clinical Oncology report of PHAROS, the phase 2 trial of encorafenib plus binimetinib in BRAF V600E-mutant metastatic non-small-cell lung cancer that supported the combination's approval, and has long worked on KRAS-mutant lung cancer and the clinical use of tumour genotyping.","asOf":"2026-09-18","links":[],"tags":["lung","targeted-therapy","trialist"],"related":[],"cancers":["braf-v600e-nsclc","nsclc","lung-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-pharos-encorafenib-binimetinib-riely-jco-2023"],"journals":[],"dependsOn":[],"notes":[],"role":"Thoracic medical oncologist, Memorial Sloan Kettering Cancer Center","institutionId":"mskcc","specialisms":["BRAF-mutant lung cancer","KRAS-mutant lung cancer","Targeted therapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Riely%5BAuthor%5D"}],"papers":[{"title":"PHAROS: encorafenib plus binimetinib in BRAF V600E-mutant metastatic non-small-cell lung cancer","journal":"Journal of Clinical Oncology","year":2023,"url":"https://doi.org/10.1200/JCO.23.00774","doi":"10.1200/JCO.23.00774"}],"orcid":"0000-0001-5357-4313"},{"id":"gunter-von-minckwitz","kind":"person","name":"Gunter von Minckwitz","aka":[],"tldr":"Founded the German Breast Group and led KATHERINE, which made T-DM1 standard after residual disease.","summary":"Gunter von Minckwitz is the founder and former Chair of the German Breast Group (GBG). His specialisms are breast cancer, neoadjuvant chemotherapy and residual disease. He led the GeparTrio and GeparQuinto neoadjuvant trials and was principal investigator of KATHERINE, the trial of adjuvant trastuzumab emtansine for patients with residual invasive HER2-positive breast cancer after neoadjuvant therapy, reported in the New England Journal of Medicine. KATHERINE made T-DM1 the standard after residual disease. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=von%20Minckwitz%20G%5BAuthor%5D%20KATHERINE"}],"tags":[],"related":[],"cancers":["breast-her2-positive"],"sections":[],"technologies":[],"targets":[],"drugs":["trastuzumab-emtansine"],"companies":["gbg"],"institutions":[],"pathways":[],"terms":[],"trials":["katherine"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Founder and former Chair, German Breast Group","institutionId":"gbg","specialisms":["Breast cancer","Neoadjuvant chemotherapy","Residual disease"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=von%20Minckwitz%20G%5BAuthor%5D%20KATHERINE"}],"papers":[{"title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer (KATHERINE)","journal":"NEJM","year":2019,"doi":"10.1056/NEJMoa1814017"}]},{"id":"gustaf-storm","kind":"person","name":"Gustaf Storm","aka":[],"tldr":"Gustaf Storm represents Capio S:t Göran's Hospital in the Organisation of European Cancer Institutes, which lists the organisation among its members in Sweden.","summary":"Gustaf Storm is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Capio S:t Göran's Hospital, its full member in Sweden. OnCo records the name from the OECI membership list so that the organisation's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the organisation's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Capio S:t Göran's Hospital website","url":"https://capiostgoran.se/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["capio-st-goran"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Capio S:t Göran's Hospital to the Organisation of European Cancer Institutes","institutionId":"capio-st-goran","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Capio S:t Göran's Hospital website","url":"https://capiostgoran.se/"}],"papers":[]},{"id":"gustavo-galmozzi","kind":"person","name":"Gustavo Galmozzi","aka":[],"tldr":"Gustavo Galmozzi represents Fondazione IRCCS Istituto Nazionale dei Tumori in the Organisation of European Cancer Institutes, which lists the centre among its members in Italy.","summary":"Gustavo Galmozzi is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Fondazione IRCCS Istituto Nazionale dei Tumori, its full member in Italy. OnCo records the name from the OECI membership list so that the centre's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the institution's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Fondazione IRCCS Istituto Nazionale dei Tumori website","url":"https://www.istitutotumori.mi.it"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["int-milan"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Fondazione IRCCS Istituto Nazionale dei Tumori to the Organisation of European Cancer Institutes","institutionId":"int-milan","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Fondazione IRCCS Istituto Nazionale dei Tumori website","url":"https://www.istitutotumori.mi.it"}],"papers":[{"title":"Hope in Cancer Patients: The Relational Domain as a Crucial Factor","journal":"Tumori Journal","year":2015,"url":"https://doi.org/10.5301/tj.5000366","doi":"10.5301/tj.5000366","note":"OpenAlex author record matched by institution"},{"title":"Response of a comprehensive cancer center to the COVID-19 pandemic: the experience of the Fondazione IRCCS–Istituto Nazionale dei Tumori di Milano","journal":"Tumori Journal","year":2020,"url":"https://doi.org/10.1177/0300891620923790","doi":"10.1177/0300891620923790","note":"OpenAlex author record matched by institution"},{"title":"Thirty-day mortality and five-year survival in thoracic surgery: “real-world” assessment of outcomes from a single-institution audit","journal":"Tumori Journal","year":2017,"url":"https://doi.org/10.5301/tj.5000709","doi":"10.5301/tj.5000709","note":"OpenAlex author record matched by institution"}]},{"id":"miles-prince","kind":"person","name":"H. Miles Prince","aka":[],"tldr":"Melbourne haematologist who led ALCANZA, the trial that showed brentuximab vedotin beats standard treatment for CD30-expressing cutaneous T-cell lymphoma.","summary":"Miles Prince is a haematologist at the Peter MacCallum Cancer Centre and Epworth Healthcare in Melbourne. He was first author of the 2017 Lancet report of ALCANZA, the international phase 3 trial in which brentuximab vedotin produced more lasting responses than physician's choice of methotrexate or bexarotene in previously treated CD30-positive mycosis fungoides or primary cutaneous anaplastic large-cell lymphoma, leading to the drug's approval in this setting.","asOf":"2026-09-18","links":[],"tags":["lymphoma","trialist"],"related":[],"cancers":["cutaneous-t-cell-lymphoma","peripheral-t-cell-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["peter-mac"],"pathways":[],"terms":[],"trials":["alcanza"],"people":[],"bottlenecks":[],"keyPapers":["paper-alcanza-brentuximab-vedotin-lancet-2017"],"journals":[],"dependsOn":[],"notes":[],"role":"Haematologist, Peter MacCallum Cancer Centre and Epworth Healthcare, Melbourne","institutionId":"peter-mac","specialisms":["Cutaneous T-cell lymphoma","Multiple myeloma","Novel agents in lymphoma"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Prince%5BAuthor%5D"}],"papers":[{"title":"ALCANZA: brentuximab vedotin versus physician's choice in CD30-positive cutaneous T-cell lymphoma","journal":"The Lancet","year":2017,"url":"https://doi.org/10.1016/S0140-6736(17)31266-7","doi":"10.1016/S0140-6736(17)31266-7"}]},{"id":"h-m-w-verheul","kind":"person","name":"H.M.W. Verheul","aka":[],"tldr":"H.M.W. Verheul represents Erasmus MC Cancer Institute in the Organisation of European Cancer Institutes, which lists the centre among its members in The Netherlands.","summary":"H.M.W. Verheul is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Erasmus MC Cancer Institute, its full member in The Netherlands. OnCo records the name from the OECI membership list so that the centre's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the institution's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Erasmus MC Cancer Institute website","url":"https://www.erasmusmc.nl/en/cancer-institute"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["erasmus-mc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Erasmus MC Cancer Institute to the Organisation of European Cancer Institutes","institutionId":"erasmus-mc","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Erasmus MC Cancer Institute website","url":"https://www.erasmusmc.nl/en/cancer-institute"}],"papers":[{"title":"Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer","journal":"New England Journal of Medicine","year":2012,"url":"https://doi.org/10.1056/nejmoa1112088","doi":"10.1056/nejmoa1112088","note":"OpenAlex author record matched by institution"},{"title":"Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial","journal":"The Lancet Oncology","year":2015,"url":"https://doi.org/10.1016/s1470-2045(15)00040-6","doi":"10.1016/s1470-2045(15)00040-6","note":"OpenAlex author record matched by institution"},{"title":"RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics","journal":"Cancer Cell","year":2015,"url":"https://doi.org/10.1016/j.ccell.2015.09.018","doi":"10.1016/j.ccell.2015.09.018","note":"OpenAlex author record matched by institution"}]},{"id":"hagen-kennecke","kind":"person","name":"Hagen F. Kennecke","aka":[],"tldr":"Hagen Kennecke is a GI oncologist who leads SWOG's gastrointestinal and melanoma committees.","summary":"Hagen Kennecke is SWOG Executive Officer for Gastrointestinal and Melanoma and Professor at Oregon Health & Science University. A medical oncologist specialising in gastrointestinal oncology and rectal cancer, his work focuses on rectal and colorectal cancer trials, including total neoadjuvant therapy studies. His papers include the primary end point results of the phase II NEO trial (CCTG CO.28) of neoadjuvant chemotherapy, excision and observation for early rectal cancer in the Journal of Clinical Oncology, and an earlier study of the metastatic behaviour of breast cancer subtypes. He now leads SWOG's gastrointestinal and melanoma committees within the SWOG Cancer Research Network.","asOf":"2026-09-08","links":[{"label":"SWOG leadership","url":"https://www.swog.org/about/leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kennecke%20HF%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Hagen%20F.%20Kennecke"}],"tags":[],"related":[],"cancers":["colorectal","melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["swog"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"SWOG Executive Officer, Gastrointestinal and Melanoma; Professor, Oregon Health & Science University","institutionId":"swog","specialisms":["Gastrointestinal oncology","Rectal cancer","Cooperative group trials"],"profiles":[{"label":"SWOG leadership","url":"https://www.swog.org/about/leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kennecke%20HF%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Hagen%20F.%20Kennecke"}],"papers":[{"title":"Neoadjuvant Chemotherapy, Excision, and Observation for Early Rectal Cancer: The Phase II NEO Trial (CCTG CO.28) Primary End Point Results","journal":"Journal of Clinical Oncology","year":2023,"url":"https://doi.org/10.1200/JCO.22.00184","doi":"10.1200/JCO.22.00184"},{"title":"Metastatic behavior of breast cancer subtypes","journal":"Journal of Clinical Oncology","year":2010,"url":"https://doi.org/10.1200/JCO.2009.25.9820","doi":"10.1200/JCO.2009.25.9820"}]},{"id":"hagop-kantarjian","kind":"person","name":"Hagop M. Kantarjian","aka":[],"tldr":"Hagop Kantarjian is one of the most prolific leukaemia investigators alive, and helped bring more than a dozen leukaemia drugs to approval.","summary":"Hagop Kantarjian is Chair of the Department of Leukemia at MD Anderson Cancer Center, a post he has held since 1999. A leukaemia specialist in CML, ALL and drug development, he is one of the most prolific leukaemia investigators alive and led pivotal trials in CML with imatinib, dasatinib and ponatinib, in ALL with inotuzumab and blinatumomab combinations, and in AML. His papers include the New England Journal of Medicine reports of inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukaemia, from the INO-VATE ALL trial, and of blinatumomab versus chemotherapy for advanced acute lymphoblastic leukaemia. He is also a vocal advocate on cancer drug pricing.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Hagop_Kantarjian","links":[{"label":"MD Anderson faculty","url":"https://faculty.mdanderson.org/search?q=Hagop%20M.%20Kantarjian"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kantarjian%20HM%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Hagop%20M.%20Kantarjian"}],"tags":[],"related":[],"cancers":["aml","all-leukemia","cll"],"sections":[],"technologies":[],"targets":[],"drugs":["imatinib","blinatumomab"],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":["ino-vate"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chair, Department of Leukemia, MD Anderson","institutionId":"md-anderson","specialisms":["Leukaemia","CML","ALL","Drug development"],"profiles":[{"label":"MD Anderson faculty","url":"https://faculty.mdanderson.org/search?q=Hagop%20M.%20Kantarjian"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kantarjian%20HM%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Hagop%20M.%20Kantarjian"}],"papers":[{"title":"Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia","journal":"New England Journal of Medicine","year":2016,"url":"https://doi.org/10.1056/NEJMoa1509277","doi":"10.1056/NEJMoa1509277"},{"title":"Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia","journal":"New England Journal of Medicine","year":2017,"url":"https://doi.org/10.1056/NEJMoa1609783","doi":"10.1056/NEJMoa1609783"}]},{"id":"haiko-bloemendal","kind":"person","name":"Haiko Bloemendal","aka":[],"tldr":"Haiko Bloemendal represents Radboudumc Centre for Oncology in the Organisation of European Cancer Institutes, which lists the centre among its members in The Netherlands.","summary":"Haiko Bloemendal is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Radboudumc Centre for Oncology, its member in The Netherlands. The university hospital of Nijmegen, a leading Dutch centre for prostate imaging, dendritic cell vaccines and tumour immunology, currently in OECI accreditation. OnCo records the name from the OECI membership list so that the centre's page has a named contact point; the person's exact title, appointment date and biography are not yet recorded and should be checked on the institution's own pages before being relied on.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Radboudumc Centre for Oncology website","url":"http://www.radboudumc.nl/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["radboudumc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Radboudumc Centre for Oncology to the Organisation of European Cancer Institutes","institutionId":"radboudumc","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Radboudumc Centre for Oncology website","url":"http://www.radboudumc.nl/"}],"papers":[{"title":"A Systematic Review and Multilevel Regression Analysis Reveals the Comorbidity Prevalence in Cancer","journal":"Cancer Res","year":2023,"url":"https://doi.org/10.1158/0008-5472.can-22-1336","doi":"10.1158/0008-5472.can-22-1336","note":"Europe PMC author record matched by affiliation"},{"title":"Cancer treatments touch a wide range of values that count for patients and other stakeholders: What are the implications for decision-making?","journal":"Cancer Med","year":2023,"url":"https://doi.org/10.1002/cam4.5336","doi":"10.1002/cam4.5336","note":"Europe PMC author record matched by affiliation"},{"title":"Cancer incidence and diagnostic characteristics in people with intellectual disabilities in the Netherlands: a national registry-based cohort study","journal":"BMJ Oncol","year":2025,"url":"https://doi.org/10.1136/bmjonc-2024-000686","doi":"10.1136/bmjonc-2024-000686","note":"Europe PMC author record matched by affiliation"}],"orcid":"0000-0002-8902-4337"},{"id":"han-kwang-yang","kind":"person","name":"Han-Kwang Yang","aka":[],"tldr":"Leading Korean gastric cancer surgeon and KLASS trial investigator who is President of the National Cancer Center Korea.","summary":"Han-Kwang Yang is President of the National Cancer Center Korea, the country's national cancer research institute and hospital in Goyang. A gastric cancer surgeon formerly at Seoul National University Hospital, he was a key investigator in the Korean Laparoendoscopic Gastrointestinal Surgery Study (KLASS) trials that established laparoscopic gastrectomy as a standard for early gastric cancer. His role is stated in the President's greeting on the centre's website.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://ncc.re.kr/main.ncc?uri=english/sub01_Greetings"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Yang+HK%5BAuthor%5D+AND+gastric"}],"tags":["leadership","clinician-scientist","gastric cancer","surgical oncology"],"related":[],"cancers":["gastric"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ncc-korea"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["jama-oncology"],"dependsOn":[],"notes":[],"role":"President","institutionId":"ncc-korea","specialisms":["Gastric cancer surgery","Laparoscopic gastrectomy","Surgical trials"],"profiles":[{"label":"Institution profile","url":"https://ncc.re.kr/main.ncc?uri=english/sub01_Greetings"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Yang+HK%5BAuthor%5D+AND+gastric"}],"papers":[{"title":"Effect of Laparoscopic Distal Gastrectomy vs Open Distal Gastrectomy on Long-term Survival Among Patients With Stage I Gastric Cancer: The KLASS-01 Randomized Clinical Trial","journal":"JAMA Oncology","year":2019,"url":"https://doi.org/10.1001/jamaoncol.2018.6727","doi":"10.1001/jamaoncol.2018.6727"},{"title":"Decreased Morbidity of Laparoscopic Distal Gastrectomy Compared With Open Distal Gastrectomy for Stage I Gastric Cancer: Short-term Outcomes From a Multicenter Randomized Controlled Trial (KLASS-01)","journal":"Annals of Surgery","year":2016,"url":"https://doi.org/10.1097/SLA.0000000000001346","doi":"10.1097/SLA.0000000000001346"}],"orcid":"0000-0003-3495-3048"},{"id":"hanno-glimm","kind":"person","name":"Hanno Glimm","aka":[],"tldr":"Medical oncologist who co-directs NCT/UCC Dresden and co-leads the NCT/DKFZ MASTER precision oncology programme for rare and young-onset cancers.","summary":"Hanno Glimm is a Managing Director of the National Center for Tumor Diseases (NCT/UCC) Dresden and heads its Department of Translational Medical Oncology. He co-leads the NCT/DKFZ MASTER programme, which applies whole-genome and transcriptome sequencing to guide treatment of patients with rare cancers and younger adults, and has published on hereditary cancer predisposition detected through comprehensive genomic profiling. His role is listed on the NCT/UCC Direktorium page.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.nct-dresden.de/de/das-nctucc-dresden/organisation/direktorium"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Glimm+H%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","precision oncology","cancer genomics"],"related":[],"cancers":[],"sections":[],"technologies":["cgp"],"targets":[],"drugs":[],"companies":[],"institutions":["nct-dresden"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Managing Director (Geschäftsführender Direktor); Head, Department of Translational Medical Oncology","institutionId":"nct-dresden","specialisms":["Precision oncology","Cancer genomics","Rare cancers","Translational research"],"profiles":[{"label":"Institution profile","url":"https://www.nct-dresden.de/de/das-nctucc-dresden/organisation/direktorium"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Glimm+H%5BAuthor%5D"}],"papers":[{"title":"Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers","journal":"Annals of Oncology","year":2022,"url":"https://doi.org/10.1016/j.annonc.2022.07.008","doi":"10.1016/j.annonc.2022.07.008"},{"title":"NCT/DKFZ MASTER handbook of interpreting whole-genome, transcriptome, and methylome data for precision oncology","journal":"NPJ Precision Oncology","year":2023,"url":"https://doi.org/10.1038/s41698-023-00458-w","doi":"10.1038/s41698-023-00458-w"}],"orcid":"0009-0003-2782-8190"},{"id":"hans-van-goudoever","kind":"person","name":"Hans van Goudoever","aka":[],"tldr":"Chair of the executive board of Amsterdam UMC, the merged university medical centre whose research institute Cancer Center Amsterdam brings together the city's cancer research and care.","summary":"Hans van Goudoever is voorzitter (chair) of the Raad van Bestuur of Amsterdam UMC, the university medical centre formed from the AMC and VUmc, and has held the chair since 1 November 2023. The board also comprises vice-chair Karen Kruijthof, deans Saskia Peerdeman (VU) and Yvo Roos (UvA) and member Yvonne Koppelman. Amsterdam UMC's cancer research is organised through Cancer Center Amsterdam, one of its research institutes; the institute's own pages did not name a separate director when checked.","asOf":"2026-09-10","links":[{"label":"Source: Amsterdam UMC executive board page","url":"https://www.amsterdamumc.org/nl/organisatie/raad-van-bestuur.htm"}],"tags":["leadership","hospital-management","research-institute"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["amsterdam-umc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Voorzitter (Chair) of the Raad van Bestuur, Amsterdam UMC","institutionId":"amsterdam-umc","specialisms":["Academic medicine","Hospital governance","Paediatrics"],"profiles":[{"label":"Amsterdam UMC Raad van Bestuur (Dutch)","url":"https://www.amsterdamumc.org/nl/organisatie/raad-van-bestuur.htm"},{"label":"Amsterdam UMC Board (English)","url":"https://www.amsterdamumc.org/en/organization/board-1"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=van+Goudoever%5BAuthor%5D"}],"papers":[{"title":"Concentrating childhood cancer treatment in the Netherlands","journal":"Pädiatrie & Pädologie","year":2015,"doi":"10.1007/s00608-015-0282-3"}],"orcid":"0000-0003-3960-1703"},{"id":"hans-gustaf-ljunggren","kind":"person","name":"Hans-Gustaf Ljunggren","aka":[],"tldr":"Hans-Gustaf Ljunggren proposed the missing-self hypothesis of NK cell recognition.","summary":"Hans-Gustaf Ljunggren is Professor of Infectious Medicine at Karolinska Institutet and works at the Center for Infectious Medicine at Karolinska University Hospital. His specialisms are NK cell biology, missing-self recognition and cell therapy. With Klas Kärre he formulated the missing-self hypothesis, which explains how natural killer cells attack cells that lack MHC class I molecules. His Immunology Today paper set out this search for the missing self in NK cell recognition. The hypothesis is a foundation for NK-based cancer immunotherapy, including CAR-NK approaches. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ljunggren%20HG%5BAuthor%5D%20missing%20self"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["car-nk-macrophage"],"targets":[],"drugs":[],"companies":[],"institutions":["karolinska"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Infectious Medicine, Karolinska Institutet; Center for Infectious Medicine","institutionId":"karolinska","specialisms":["NK cell biology","Missing-self recognition","Cell therapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ljunggren%20HG%5BAuthor%5D%20missing%20self"}],"papers":[{"title":"In search of the 'missing self': MHC molecules and NK cell recognition","journal":"Immunology Today","year":1990,"doi":"10.1016/0167-5699(90)90097-S"}],"orcid":"0000-0003-0908-7387"},{"id":"hans-peter-kiem","kind":"person","name":"Hans-Peter Kiem","aka":[],"tldr":"Hans-Peter Kiem is a gene and cell therapy researcher working on editing blood stem cells inside the body.","summary":"Hans-Peter Kiem is Director of the Stem Cell and Gene Therapy Program at Fred Hutchinson Cancer Center. A physician-scientist specialising in gene therapy, stem cell transplantation and in vivo gene editing, he leads haematopoietic stem cell gene therapy and in vivo gene delivery research, including glioblastoma chemoprotection strategies and editing of blood stem cells inside the body. His papers include a Journal of Clinical Investigation report that gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patients and a Gene Therapy review of large animal models of haematopoietic stem cell gene therapy. His work touches glioma and glioblastoma, acute myeloid leukaemia, in vivo CAR-T and off-the-shelf cell therapy.","asOf":"2026-09-08","links":[{"label":"Fred Hutch faculty directory","url":"https://www.fredhutch.org/en/faculty-lab-directory.html?q=Hans-Peter%20Kiem"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kiem%20HP%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Hans-Peter%20Kiem"}],"tags":[],"related":[],"cancers":["glioblastoma","aml"],"sections":[],"technologies":["in-vivo-car-t","allogeneic-cell-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":["fred-hutch"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["jci"],"dependsOn":[],"notes":[],"role":"Director, Stem Cell and Gene Therapy Program, Fred Hutchinson Cancer Center","institutionId":"fred-hutch","specialisms":["Gene therapy","Stem cell transplantation","In vivo gene editing"],"profiles":[{"label":"Fred Hutch faculty directory","url":"https://www.fredhutch.org/en/faculty-lab-directory.html?q=Hans-Peter%20Kiem"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kiem%20HP%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Hans-Peter%20Kiem"}],"papers":[{"title":"Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patients","journal":"Journal of Clinical Investigation","year":2014,"url":"https://doi.org/10.1172/JCI76739","doi":"10.1172/JCI76739"},{"title":"Large animal models of hematopoietic stem cell gene therapy","journal":"Gene Therapy","year":2010,"url":"https://doi.org/10.1038/gt.2010.47","doi":"10.1038/gt.2010.47"}],"orcid":"0000-0001-5949-4947"},{"id":"hansjochen-wilke","kind":"person","name":"Hansjochen Wilke","aka":[],"tldr":"German oncologist who led RAINBOW, the trial that made ramucirumab plus paclitaxel a standard second-line treatment for advanced stomach cancer.","summary":"Hansjochen Wilke is a gastrointestinal oncologist at Kliniken Essen-Mitte. He was first author of the 2014 Lancet Oncology report of RAINBOW, which showed that adding the VEGFR2 antibody ramucirumab to paclitaxel lengthened overall survival compared with paclitaxel alone in advanced gastric or gastro-oesophageal junction adenocarcinoma after first-line therapy.","asOf":"2026-09-18","links":[],"tags":["gastric","trialist"],"related":[],"cancers":["gastric-pdl1-high","gastric"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["kliniken-essen-mitte"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-rainbow-ramucirumab-paclitaxel-lancet-oncol-2014"],"journals":[],"dependsOn":[],"notes":[],"role":"Medical oncologist, Kliniken Essen-Mitte","institutionId":"kliniken-essen-mitte","specialisms":["Gastric cancer","Anti-angiogenic therapy","Second-line chemotherapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wilke%5BAuthor%5D"}],"papers":[{"title":"RAINBOW: ramucirumab plus paclitaxel versus placebo plus paclitaxel in previously treated advanced gastric cancer","journal":"The Lancet Oncology","year":2014,"url":"https://doi.org/10.1016/S1470-2045(14)70420-6","doi":"10.1016/S1470-2045(14)70420-6"}]},{"id":"harald-zur-hausen","kind":"person","name":"Harald zur Hausen","aka":[],"tldr":"Against the consensus that herpes was to blame, he proposed in 1976 that papillomaviruses cause cervical cancer and isolated HPV16 and HPV18 from tumours in 1983-84, making vaccination and HPV testing possible. Nobel Prize 2008.","summary":"Harald zur Hausen (1936-2023) proposed in 1976 that human papillomaviruses, then known for warts, were the cause of cervical cancer, when most researchers favoured herpes simplex virus. Working in Freiburg and then in Heidelberg, his group isolated HPV16 from cervical cancer biopsies in 1983 and HPV18, present in the HeLa cell line, in 1984, and showed that these types account for around 70 percent of cervical cancers worldwide. Vaccine companies initially declined his approach to develop a vaccine. From 1983 to 2003 he was scientific director of the German Cancer Research Center (DKFZ). His discovery led directly to the HPV vaccines licensed from 2006, to HPV DNA testing replacing cytology in screening programmes, and to the World Health Organization's 2020 strategy to eliminate cervical cancer as a public health problem. He received the Nobel Prize in Physiology or Medicine in 2008.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Harald_zur_Hausen","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Harald_zur_Hausen"},{"label":"Nobel Prize biography","url":"https://www.nobelprize.org/prizes/medicine/2008/hausen/facts/"}],"tags":["hero","pioneer"],"related":[],"cancers":["cervical","head-and-neck","anal"],"sections":["prevention"],"technologies":["hpv-vaccine","hpv-testing"],"targets":[],"drugs":["gardasil-9"],"companies":[],"institutions":["dkfz"],"pathways":[],"terms":["hpv-p16","cin-hsil"],"trials":[],"people":["ian-frazer","jian-zhou","henrietta-lacks"],"bottlenecks":["b-prevention-adoption"],"keyPapers":[],"journals":["journal-of-cancer-research-and-clinical-oncology"],"dependsOn":[],"notes":[],"role":"Virologist who showed that human papillomavirus causes cervical cancer","specialisms":["Tumour virology","Human papillomavirus","Cervical cancer"],"profiles":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Harald_zur_Hausen"},{"label":"Nobel Prize biography","url":"https://www.nobelprize.org/prizes/medicine/2008/hausen/facts/"}],"papers":[{"title":"Human papillomaviruses in the pathogenesis of anogenital cancer","journal":"Virology","year":1991,"doi":"10.1016/0042-6822(91)90816-t"},{"title":"Viruses in Human Cancers","journal":"Science","year":1991,"doi":"10.1126/science.1659743"},{"title":"Roots and perspectives of contemporary papillomavirus research","journal":"Journal of Cancer Research and Clinical Oncology","year":1996,"doi":"10.1007/bf01203067"}]},{"id":"harlan-krumholz","kind":"person","name":"Harlan M. Krumholz","aka":[],"tldr":"Yale outcomes researcher who founded and leads the YODA Project for independent access to clinical trial data.","summary":"Harlan M. Krumholz is Principal Investigator of the Yale University Open Data Access (YODA) Project, which provides independent researchers with access to participant-level clinical trial data from industry partners, including many oncology trials. A cardiologist and Harold H. Hines Jr. Professor of Medicine at Yale, he is a leading advocate for open science and research transparency.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://yoda.yale.edu/about/leadership-contact-information/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Krumholz+HM%5BAuthor%5D"}],"tags":["leadership","data sharing","research transparency"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["yoda-project"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nature","nature-medicine"],"dependsOn":[],"notes":[],"role":"Principal Investigator","institutionId":"yoda-project","specialisms":["Clinical trial data sharing","Outcomes research","Cardiology","Research transparency"],"profiles":[{"label":"Institution profile","url":"https://yoda.yale.edu/about/leadership-contact-information/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Krumholz+HM%5BAuthor%5D"}],"papers":[{"title":"The mutational constraint spectrum quantified from variation in 141,456 humans","journal":"Nature","year":2020,"url":"https://doi.org/10.1038/s41586-020-2308-7","doi":"10.1038/s41586-020-2308-7","note":"Europe PMC author record matched by affiliation"},{"title":"Extrapulmonary manifestations of COVID-19","journal":"Nat Med","year":2020,"url":"https://doi.org/10.1038/s41591-020-0968-3","doi":"10.1038/s41591-020-0968-3","note":"Europe PMC author record matched by affiliation"},{"title":"COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review","journal":"J Am Coll Cardiol","year":2020,"url":"https://doi.org/10.1016/j.jacc.2020.04.031","doi":"10.1016/j.jacc.2020.04.031","note":"Europe PMC author record matched by affiliation"}],"orcid":"0000-0003-2046-127X"},{"id":"harry-de-koning","kind":"person","name":"Harry J. de Koning","aka":[],"tldr":"Led the NELSON trial, which confirmed CT screening cuts lung cancer deaths in Europe and shaped screening policy.","summary":"Harry de Koning was principal investigator of NELSON, the Dutch-Belgian randomised trial showing low-dose CT screening reduces lung cancer mortality by about a quarter in high-risk men, the result that pushed European countries toward screening programmes. His MISCAN microsimulation models underpin US and European screening guidelines for lung, breast, prostate and colorectal cancer.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=de%20Koning%20HJ%5BAuthor%5D%20screening"}],"tags":["screening","lung","epidemiology"],"related":[],"cancers":["nsclc","prostate"],"sections":[],"technologies":["ct"],"targets":[],"drugs":[],"companies":[],"institutions":["erasmus-mc"],"pathways":[],"terms":[],"trials":["nlst-nelson"],"people":[],"bottlenecks":[],"keyPapers":["paper-nelson-nejm-2020","paper-nlst-nejm-2011"],"journals":["annals-internal-medicine"],"dependsOn":[],"notes":[],"role":"Professor of Public Health and Screening Evaluation, Erasmus MC","institutionId":"erasmus-mc","specialisms":["Cancer screening evaluation","Lung cancer CT screening","Microsimulation modelling","Prostate and breast screening"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=de%20Koning%20HJ%5BAuthor%5D%20screening"}],"papers":[{"title":"Reduced lung-cancer mortality with volume CT screening in a randomized trial (NELSON)","journal":"NEJM","year":2020,"doi":"10.1056/NEJMoa1911793"},{"title":"Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force","journal":"Annals of Internal Medicine","year":2014,"doi":"10.7326/M13-2316"},{"title":"NLST: yearly low-dose CT scans cut lung cancer deaths in heavy smokers","journal":"New England Journal of Medicine","year":2011,"url":"https://doi.org/10.1056/NEJMoa1102873","doi":"10.1056/NEJMoa1102873"}],"orcid":"0000-0003-4682-3646"},{"id":"hartmut-dohner","kind":"person","name":"Hartmut Döhner","aka":[],"tldr":"Leads the European LeukemiaNet classification that defines how AML is diagnosed and risk-stratified worldwide.","summary":"Hartmut Döhner (Ulm) chairs the European LeukemiaNet AML working group and is first author of the 2010, 2017 and 2022 ELN recommendations that define AML genetic risk groups and response criteria used in every trial and clinic. He leads the German-Austrian AML Study Group, whose trials characterised NPM1, CEBPA and FLT3 mutations as prognostic markers, and co-led the WHO/ELN genomic classification.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dohner%20H%5BAuthor%5D%20acute%20myeloid%20leukemia%20ELN"}],"tags":["aml","classification","guidelines"],"related":[],"cancers":["aml"],"sections":[],"technologies":[],"targets":["flt3"],"drugs":[],"companies":[],"institutions":["ulm-university-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Medical Director, Department of Internal Medicine III, Ulm University Hospital","institutionId":"ulm-university-hospital","specialisms":["Acute myeloid leukaemia","Genomic classification","Risk stratification","Cooperative-group trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dohner%20H%5BAuthor%5D%20acute%20myeloid%20leukemia%20ELN"}],"papers":[{"title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","journal":"Blood","year":2022,"doi":"10.1182/blood.2022016867"},{"title":"Acute myeloid leukemia","journal":"NEJM","year":2015,"doi":"10.1056/NEJMra1406184"}]},{"id":"fukuda-haruhiko","kind":"person","name":"Haruhiko Fukuda","aka":[],"tldr":"Built the data centre behind the Japan Clinical Oncology Group, the country's main academic trials network.","summary":"Haruhiko Fukuda is the founding director of the JCOG Data Center at the National Cancer Center in Tokyo and a clinical trial methodologist. He established and long led the data centre behind the Japan Clinical Oncology Group, the country's main academic trials network, setting the methodological standards for its cooperative-group surgical, radiotherapy and chemotherapy trials in gastric, oesophageal, lung and other cancers. His publications include the JCOG0802 trial of segmentectomy against lobectomy in small peripheral non-small-cell lung cancer, the JCOG1013 trial of docetaxel added to cisplatin and S-1 in advanced gastric cancer, and the JCOG0603 trial of hepatectomy followed by mFOLFOX6 in liver-only metastatic colorectal cancer. His interests are trial methodology and biostatistics.","asOf":"2026-09-08","links":[{"label":"JCOG","url":"https://jcog.jp/en/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fukuda%20H%5BAuthor%5D%20JCOG"}],"tags":[],"related":[],"cancers":["gastric","esophageal","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["jcog"],"institutions":["ncc-japan"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Founding director of the JCOG Data Center (National Cancer Center); clinical trial methodologist","institutionId":"jcog","specialisms":["Clinical trial methodology","Biostatistics","Cooperative group trials"],"profiles":[{"label":"JCOG","url":"https://jcog.jp/en/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fukuda%20H%5BAuthor%5D%20JCOG"}],"papers":[{"title":"Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial","journal":"The Lancet","year":2022,"doi":"10.1016/s0140-6736(21)02333-3"},{"title":"Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial","journal":"The Lancet Gastroenterology & Hepatology","year":2019,"doi":"10.1016/s2468-1253(19)30083-4"},{"title":"Hepatectomy Followed by mFOLFOX6 Versus Hepatectomy Alone for Liver-Only Metastatic Colorectal Cancer (JCOG0603): A Phase II or III Randomized Controlled Trial","journal":"Journal of Clinical Oncology","year":2021,"doi":"10.1200/jco.21.01032"}],"orcid":"0000-0002-6332-4745"},{"id":"hashim-ahmed","kind":"person","name":"Hashim U. Ahmed","aka":[],"tldr":"Led PROMIS, the trial that showed MRI can safely spare a quarter of men from prostate biopsy.","summary":"Hashim Ahmed (Imperial College London) was chief investigator of PROMIS, which showed multiparametric MRI has far higher sensitivity for clinically significant prostate cancer than TRUS biopsy and could allow 27% of men to avoid biopsy altogether. He leads focal therapy trials of HIFU and cryotherapy and the PART and CHRONOS studies comparing focal and radical treatment.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ahmed%20HU%5BAuthor%5D%20prostate%20PROMIS%20OR%20focal"}],"tags":["prostate","imaging","focal-therapy"],"related":[],"cancers":["prostate"],"sections":[],"technologies":["mri","hifu-histotripsy"],"targets":[],"drugs":[],"companies":[],"institutions":["imperial-cancer-centre"],"pathways":[],"terms":[],"trials":["precision-mri"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chair of Urology, Imperial College London","institutionId":"imperial-cancer-centre","specialisms":["Prostate cancer diagnostics","Focal therapy","HIFU","Diagnostic trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ahmed%20HU%5BAuthor%5D%20prostate%20PROMIS%20OR%20focal"}],"papers":[{"title":"Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS)","journal":"Lancet","year":2017,"doi":"10.1016/S0140-6736(16)32401-1"},{"title":"Focal therapy for localised prostate cancer: a phase I/II trial","journal":"Lancet Oncology","year":2012,"doi":"10.1016/S1470-2045(12)70121-3"}],"orcid":"0000-0003-1674-6723"},{"id":"jain-hasmukh","kind":"person","name":"Hasmukh Jain","aka":[],"tldr":"First author of the phase 1/2 trial of India's first CAR-T therapy, which treated adults with relapsed lymphoma and leukaemia at six Indian centres.","summary":"Hasmukh Jain is a haematolymphoid medical oncologist at Tata Memorial Hospital and first author of the Lancet Haematology report of talicabtagene autoleucel (NexCAR19) in relapsed or refractory B-cell malignancies: 64 patients were enrolled across phase 1 and 2 at six tertiary centres, with an overall response rate of 73% in 51 evaluable patients and two treatment-related deaths. He runs lymphoma and CAR-T programmes at Tata Memorial and is an investigator on Indian and international lymphoma trials.","asOf":"2026-09-10","links":[{"label":"Tata Memorial Centre","url":"https://tmc.gov.in"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Jain%20H%5BAuthor%5D%20Tata%20Memorial%20lymphoma%20CAR"}],"tags":[],"related":[],"cancers":["dlbcl","all-leukemia"],"sections":[],"technologies":["car-t"],"targets":["cd19"],"drugs":["talicabtagene-autoleucel"],"companies":[],"institutions":["tata-memorial"],"pathways":[],"terms":[],"trials":["talicel-phase-1-2"],"people":[],"bottlenecks":[],"keyPapers":["paper-jain-talicabtagene-lancet-haem-2025"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology (adult haematolymphoid), Tata Memorial Hospital","institutionId":"tata-memorial","specialisms":["Lymphoma","Acute leukaemia","CAR-T cell therapy","Clinical trials"],"profiles":[{"label":"Tata Memorial Centre","url":"https://tmc.gov.in"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Jain%20H%5BAuthor%5D%20Tata%20Memorial%20lymphoma%20CAR"}],"papers":[{"title":"Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: results from an open-label, multicentre, phase 1/2 study","journal":"Lancet Haematology","year":2025,"doi":"10.1016/S2352-3026(24)00377-6"}]},{"id":"hassan-malik","kind":"person","name":"Hassan Malik","aka":[],"tldr":"Liver surgeon at Aintree who co-wrote the BSG cholangiocarcinoma guideline and is a co-author of the UK-wide CAPBIL studies of gallbladder cancer surgery; a past president of the British Association of Surgical Oncology.","summary":"Hassan Malik is a consultant hepatobiliary surgeon at Liverpool University Hospitals, clinical lead for digestive surgery at University Hospital Aintree and an associate professor at the University of Liverpool, where his staff page sits in the Institute of Systems, Molecular and Integrative Biology. He qualified in Glasgow in 1992, was appointed consultant in 2008 and runs a high-volume liver resection practice; he chaired the National Cancer Research Network upper GI group, is a past president of the British Association of Surgical Oncology and president-elect of the European Society of Surgical Oncology. He co-authored the 2023 British Society of Gastroenterology cholangiocarcinoma guideline and both 2026 CAPBIL papers from the UK HPB Research Collaborative Group, which pooled 516 gallbladder cancer operations from 24 UK centres including Aintree. The trust website has no consultant page for him (its search returned none on the check date), so the biography is taken from his HCA Healthcare UK consultant profile.","asOf":"2026-09-24","links":[{"label":"University of Liverpool staff page","url":"https://www.liverpool.ac.uk/people/hassan-malik"},{"label":"HCA Healthcare UK consultant profile (biography)","url":"https://www.hcahealthcare.co.uk/finder/stepconsultantprofile/hassan-malik-2"}],"tags":["biliary","surgeon","uk"],"related":["john-primrose","shahid-khan"],"cancers":["gallbladder","biliary-tract-cancer","cholangiocarcinoma","hcc"],"sections":[],"technologies":["hepatectomy"],"targets":[],"drugs":[],"companies":[],"institutions":["liverpool-hpb-centre"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Consultant Hepatobiliary Surgeon and Clinical Lead for Digestive Surgery, Liverpool University Hospitals (Aintree); Associate Professor, University of Liverpool","institutionId":"liverpool-hpb-centre","specialisms":["Hepatobiliary surgery","Liver resection","Retroperitoneal sarcoma","Surgical oncology"],"profiles":[{"label":"University of Liverpool staff page","url":"https://www.liverpool.ac.uk/people/hassan-malik"},{"label":"HCA Healthcare UK consultant profile (biography)","url":"https://www.hcahealthcare.co.uk/finder/stepconsultantprofile/hassan-malik-2"}],"papers":[{"title":"Surgical outcomes in gallbladder cancer: evidence from the UK nationwide CAPBIL study","journal":"HPB","year":2026,"doi":"10.1016/j.hpb.2026.06.009"},{"title":"Management of incidental gallbladder cancer in the nationwide CAPBIL study","journal":"British Journal of Surgery","year":2026,"doi":"10.1093/bjs/znag050"},{"title":"British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma","journal":"Gut","year":2023,"doi":"10.1136/gutjnl-2023-330029"}]},{"id":"hatem-soliman","kind":"person","name":"Hatem Soliman","aka":[],"tldr":"Hatem Soliman is a breast oncologist leading immunotherapy and genomic-assay trials, including in triple-negative disease.","summary":"Hatem Soliman is Medical Director of the Clinical Trials Office and a breast oncologist at Moffitt Cancer Center. He is known for leading immunotherapy and genomic-assay trials in breast cancer, including in triple-negative disease, and for work validating breast genomic classifiers. His selected paper reports a phase 2 study of the IDO inhibitor indoximod with chemotherapy in metastatic breast cancer. He now runs Moffitt's clinical trials office and continues as an investigator in triple-negative and hormone receptor-positive breast cancer studies.","asOf":"2026-09-08","links":[{"label":"Moffitt profile","url":"https://www.moffitt.org/providers/hatem-soliman/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Soliman%20H%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["tnbc","breast-hr-positive"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["moffitt"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["cancer-immunology-research"],"dependsOn":[],"notes":[],"role":"Medical Director, Clinical Trials Office; Breast Oncology","institutionId":"moffitt","specialisms":["Breast cancer","Immunotherapy","Genomic assays"],"profiles":[{"label":"Moffitt profile","url":"https://www.moffitt.org/providers/hatem-soliman/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Soliman%20H%5BAuthor%5D"}],"papers":[{"title":"A phase 2 study of the IDO inhibitor indoximod with chemotherapy in metastatic breast cancer","journal":"Cancer Immunology Research","year":2018}],"orcid":"0000-0001-6644-2264"},{"id":"heather-wakelee","kind":"person","name":"Heather A. Wakelee","aka":[],"tldr":"Heather Wakelee is a lung cancer leader who led the first adjuvant immunotherapy trial to change practice.","summary":"Heather Wakelee is Chief of the Division of Medical Oncology and Deputy Director of the Stanford Cancer Institute, and a past president of the International Association for the Study of Lung Cancer. A thoracic medical oncologist specialising in lung cancer and perioperative immunotherapy, she was principal investigator of IMpower010, the adjuvant atezolizumab trial that was the first adjuvant immunotherapy trial to change practice, and of KEYNOTE-671, the perioperative pembrolizumab trial. Her papers report IMpower010 in the Lancet and perioperative pembrolizumab for early-stage non-small-cell lung cancer in the New England Journal of Medicine. Her work spans immune checkpoint inhibitors and global oncology.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Heather_Wakelee","links":[{"label":"Stanford profile","url":"https://profiles.stanford.edu/search?q=Heather%20A.%20Wakelee"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wakelee%20HA%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Heather%20A.%20Wakelee"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["atezolizumab","pembrolizumab"],"companies":[],"institutions":["stanford"],"pathways":[],"terms":[],"trials":["keynote-671"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief, Division of Medical Oncology; Deputy Director, Stanford Cancer Institute","institutionId":"stanford","specialisms":["Lung cancer","Perioperative immunotherapy","Global oncology"],"profiles":[{"label":"Stanford profile","url":"https://profiles.stanford.edu/search?q=Heather%20A.%20Wakelee"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wakelee%20HA%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Heather%20A.%20Wakelee"}],"papers":[{"title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial","journal":"Lancet","year":2021,"url":"https://doi.org/10.1016/S0140-6736(21)02098-5","doi":"10.1016/S0140-6736(21)02098-5"},{"title":"Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer","journal":"New England Journal of Medicine","year":2023,"url":"https://doi.org/10.1056/NEJMoa2302983","doi":"10.1056/NEJMoa2302983"}],"orcid":"0000-0003-1136-980X"},{"id":"hedy-kindler","kind":"person","name":"Hedy L. Kindler","aka":[],"tldr":"Senior investigator of POLO and a leader in mesothelioma trials, including the ASCO guidelines for the disease.","summary":"Hedy Kindler was senior author of the POLO trial of olaparib in BRCA-mutant pancreatic cancer and chaired the ASCO mesothelioma guideline. She has led national trials of bevacizumab and other agents in pancreatic cancer and mesothelioma through CALGB and Alliance. She directs GI oncology and mesothelioma programmes at the University of Chicago.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kindler%20HL%5BAuthor%5D%20mesothelioma%20OR%20pancreatic"}],"tags":["pancreatic","mesothelioma","guidelines"],"related":[],"cancers":["pancreatic","mesothelioma"],"sections":[],"technologies":[],"targets":[],"drugs":["olaparib"],"companies":[],"institutions":["uchicago-cancer"],"pathways":[],"terms":[],"trials":["polo"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medicine and Director of Gastrointestinal Oncology and Mesothelioma Programs, University of Chicago","institutionId":"uchicago-cancer","specialisms":["Pancreatic cancer","Mesothelioma","Targeted therapy","Cooperative-group trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kindler%20HL%5BAuthor%5D%20mesothelioma%20OR%20pancreatic"}],"papers":[{"title":"Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer (POLO)","journal":"NEJM","year":2019,"doi":"10.1056/NEJMoa1903387"},{"title":"Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology clinical practice guideline","journal":"JCO","year":2018,"doi":"10.1200/JCO.2017.76.6394"}]},{"id":"heikki-joensuu","kind":"person","name":"Heikki Joensuu","aka":[],"tldr":"Finnish oncologist who treated the first GIST patient with imatinib in 2000 and led SSG XVIII, the trial that showed three years of adjuvant imatinib beats one year after surgery for high-risk GIST.","summary":"Heikki Joensuu is professor of oncology at Helsinki University Hospital. In 2001 he reported the first patient with metastatic gastrointestinal stromal tumour treated with imatinib, opening the era of targeted therapy for the disease. He was first author of the 2012 JAMA report of the Scandinavian Sarcoma Group XVIII trial, which showed that three years of adjuvant imatinib improved recurrence-free and overall survival compared with one year in high-risk resected GIST, now the standard. He has also led adjuvant trastuzumab trials in breast cancer.","asOf":"2026-09-18","links":[],"tags":["gist","trialist"],"related":[],"cancers":["gist-kit-exon-11","gist","sarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["helsinki-hus"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-ssg-xviii-adjuvant-imatinib-joensuu-jama-2012"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Oncology, Helsinki University Hospital","institutionId":"helsinki-hus","specialisms":["Gastrointestinal stromal tumour","Adjuvant imatinib","Breast cancer trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Joensuu%5BAuthor%5D"}],"papers":[{"title":"SSG XVIII/AIO: one versus three years of adjuvant imatinib for operable gastrointestinal stromal tumour","journal":"JAMA","year":2012,"url":"https://doi.org/10.1001/jama.2012.347","doi":"10.1001/jama.2012.347"}],"orcid":"0000-0003-0281-2507"},{"id":"heinz-josef-lenz","kind":"person","name":"Heinz-Josef Lenz","aka":[],"tldr":"Colorectal oncologist who led CheckMate 142 and co-led CheckMate 8HW, bringing nivolumab plus ipilimumab to MSI-high disease.","summary":"Heinz-Josef Lenz was a lead investigator of CheckMate 142 and CheckMate 8HW, which established nivolumab plus ipilimumab in MSI-high colorectal cancer, and led the analyses of CALGB/SWOG 80405 showing that primary tumour side predicts benefit from anti-EGFR therapy. He has long studied pharmacogenomics of fluoropyrimidines and leads SWOG GI trials.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lenz%20HJ%5BAuthor%5D%20colorectal%20nivolumab"}],"tags":["colorectal","immunotherapy","swog"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["pd1","ctla4"],"drugs":["nivolumab","ipilimumab"],"companies":[],"institutions":["usc-norris"],"pathways":[],"terms":[],"trials":["checkmate-8hw"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medicine and Co-Director, Colorectal Center, USC Norris Comprehensive Cancer Center","institutionId":"usc-norris","specialisms":["Colorectal cancer","Immunotherapy","Pharmacogenomics","Tumour sidedness"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lenz%20HJ%5BAuthor%5D%20colorectal%20nivolumab"}],"papers":[{"title":"First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study","journal":"JCO","year":2022,"doi":"10.1200/JCO.21.01015"},{"title":"Impact of primary (1º) tumor location on overall survival and progression-free survival in patients with metastatic colorectal cancer: analysis of CALGB/SWOG 80405 (Alliance)","journal":"JCO","year":2016}]},{"id":"helen-diller","kind":"person","name":"Helen Diller","aka":["Helen and Sanford Diller"],"tldr":"The cancer centre at UCSF carries her name, and in 2017 the Helen Diller Foundation gave UCSF $500 million, the largest gift in its history, bringing the family's total there to $650 million.","summary":"Helen Diller (1918-2011) and her husband Sanford Diller, a San Francisco property developer, gave the gift that named the UCSF Helen Diller Family Comprehensive Cancer Center at Mission Bay in 2003. In January 2017 UCSF announced a $500 million gift from the Helen Diller Foundation, the largest single donation in its history, with $400 million endowing faculty and student support and $100 million as a discretionary innovation fund, and stated that it brought the family's total giving to UCSF to $650 million. In February 2018 the Foundation committed a further $500 million toward planning a new UCSF hospital. The cancer centre that bears her name is one of the largest on the US west coast, and the endowments fund the people who work in it.","asOf":"2026-09-10","links":[{"label":"UCSF: largest-ever gift honours Helen Diller (2017)","url":"https://www.ucsf.edu/news/2017/01/405476/largest-ever-gift-ucsf-honors-philanthropist-helen-diller"},{"label":"Sanford Diller (Wikipedia)","url":"https://en.wikipedia.org/wiki/Sanford_Diller"}],"tags":["hero","donor"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ucsf"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-funding-allocation"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Namesake of the UCSF Helen Diller Family Comprehensive Cancer Center; the Diller family's UCSF giving reached $650 million by 2017","specialisms":["Cancer centre building","University philanthropy"],"profiles":[],"papers":[]},{"id":"helen-mertens","kind":"person","name":"Helen Mertens","aka":[],"tldr":"Gynaecologist with a doctorate in gynaecological cancer research who chairs the executive board of Maastricht UMC+, the university medical centre that runs the Maastricht comprehensive cancer centre.","summary":"Helen Mertens is Voorzitter (chair) of the Raad van Bestuur of academisch ziekenhuis Maastricht and Maastricht UMC+, the university medical centre whose Oncologiecentrum operates as the Maastricht UMC+ Comprehensive Cancer Center. She studied medicine in Maastricht, specialised in obstetrics and gynaecology and obtained her PhD in 2002 on gynaecological cancer research; before joining the board she was medical director at Orbis Medisch Centrum. The board page lists her alongside vice-chair Annemie Schols, chief financial officer Véronique Thoelen, Stef Kremers and Jos Maessen.","asOf":"2026-09-10","links":[{"label":"Source: Maastricht UMC+ executive board page","url":"https://www.mumc.nl/over-mumc/bestuur-en-organisatie/bestuur"}],"tags":["leadership","hospital-management","clinician-scientist"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["maastricht-umc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Voorzitter Raad van Bestuur (Chair of the Executive Board), Maastricht UMC+","institutionId":"maastricht-umc","specialisms":["Gynaecology and obstetrics","Gynaecological oncology research","Hospital governance"],"profiles":[{"label":"Maastricht UMC+ Raad van Bestuur page","url":"https://www.mumc.nl/over-mumc/bestuur-en-organisatie/bestuur"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mertens+H%5BAuthor%5D+AND+Maastricht"}],"papers":[{"title":"Simple Rules, Not So Simple: The Use of International Ovarian Tumor Analysis (IOTA) Terminology and Simple Rules in Inexperienced Hands in a Prospective Multicenter Cohort Study","journal":"Ultraschall in der Medizin - European Journal of Ultrasound","year":2017,"doi":"10.1055/s-0043-113819"}]},{"id":"helena-yu","kind":"person","name":"Helena A. Yu","aka":[],"tldr":"Mapped how EGFR-mutant lung cancers resist osimertinib and led the HER3-directed ADC trials that followed.","summary":"Helena A. Yu is a Medical Oncologist on the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center, specialising in EGFR-mutant lung cancer. She is known for mapping how EGFR-mutant lung cancers resist EGFR inhibitors such as osimertinib, including the T790M mutation and histological transformation, and for leading the HER3-directed antibody-drug conjugate trials that followed. Her selected papers analyse tumour specimens at the time of acquired resistance to EGFR inhibitors in 155 patients, and report HERTHENA-Lung01, a phase 2 trial of patritumab deruxtecan in EGFR-mutated lung cancer after prior therapy. She continues to study resistance mechanisms and ADCs in non-small-cell lung cancer.","asOf":"2026-09-08","links":[{"label":"MSK profile","url":"https://www.mskcc.org/cancer-care/doctors/helena-yu"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Yu%20HA%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":["egfr","her3"],"drugs":["osimertinib","patritumab-deruxtecan"],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Medical Oncologist, Thoracic Oncology Service","institutionId":"mskcc","specialisms":["EGFR-mutant lung cancer","Resistance mechanisms","ADCs in lung cancer"],"profiles":[{"label":"MSK profile","url":"https://www.mskcc.org/cancer-care/doctors/helena-yu"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Yu%20HA%5BAuthor%5D"}],"papers":[{"title":"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers","journal":"Clinical Cancer Research","year":2013,"url":"https://doi.org/10.1158/1078-0432.CCR-12-2246","doi":"10.1158/1078-0432.CCR-12-2246"},{"title":"HERTHENA-Lung01, a phase II trial of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC after EGFR TKI therapy and platinum-based chemotherapy","journal":"Journal of Clinical Oncology","year":2023,"url":"https://doi.org/10.1200/JCO.23.01476","doi":"10.1200/JCO.23.01476"}],"orcid":"0000-0002-0377-9510"},{"id":"helena-earl","kind":"person","name":"Helena Earl","aka":[],"tldr":"Led PERSEPHONE, which showed six months of trastuzumab is nearly as good as twelve for most patients.","summary":"Helena Earl was chief investigator of PERSEPHONE, the 4,000-patient UK trial showing six months of adjuvant trastuzumab is non-inferior to twelve months with less cardiotoxicity, and of the neoadjuvant ARTemis and Neo-tAnGo trials. Her work anchors the de-escalation debate in HER2-positive early breast cancer.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Earl%20HM%5BAuthor%5D%20PERSEPHONE"}],"tags":["breast","de-escalation","her2"],"related":[],"cancers":["breast-her2-positive"],"sections":[],"technologies":[],"targets":["her2"],"drugs":["trastuzumab"],"companies":[],"institutions":["cruk-cambridge-centre"],"pathways":[],"terms":[],"trials":["persephone"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Emeritus Professor of Clinical Cancer Medicine, University of Cambridge","institutionId":"cruk-cambridge-centre","specialisms":["HER2-positive breast cancer","Treatment de-escalation","Neoadjuvant trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Earl%20HM%5BAuthor%5D%20PERSEPHONE"}],"papers":[{"title":"6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE)","journal":"Lancet","year":2019,"doi":"10.1016/S0140-6736(19)30650-6"},{"title":"Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis)","journal":"Lancet Oncology","year":2015,"doi":"10.1016/S1470-2045(15)00086-8"}],"orcid":"0000-0003-1549-8094"},{"id":"helena-isabal-roca","kind":"person","name":"Helena Isàbal Roca","aka":[],"tldr":"Helena Isàbal Roca represents Catalan Institute of Oncology (ICO) in the Organisation of European Cancer Institutes, which lists the centre among its members in Spain.","summary":"Helena Isàbal Roca is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Catalan Institute of Oncology (ICO), its full member in Spain. OnCo records the name from the OECI membership list so that the centre's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the institution's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Catalan Institute of Oncology (ICO) website","url":"https://ico.gencat.cat"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ico-catalonia"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Catalan Institute of Oncology (ICO) to the Organisation of European Cancer Institutes","institutionId":"ico-catalonia","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Catalan Institute of Oncology (ICO) website","url":"https://ico.gencat.cat"}],"papers":[]},{"id":"henrietta-lacks","kind":"person","name":"Henrietta Lacks","aka":[],"tldr":"Her cervical cancer cells, taken in 1951 without her knowledge, became HeLa, the first immortal human cell line. Her story changed how consent and family rights in research are handled.","summary":"Henrietta Lacks (1920-1951) was treated for cervical cancer at Johns Hopkins Hospital in 1951. Cells taken from her tumour without her knowledge grew indefinitely in culture, becoming the HeLa line, the first immortal human cell line and the workhorse of the polio vaccine, virology, and cancer biology, including the work that tied HPV18 to cervical cancer. She died in October 1951 at 31. Her family learned of the cells only in the 1970s. Rebecca Skloot's 2010 book brought the case to public attention; in 2013 the NIH reached an agreement with the family giving them a say in access to the HeLa genome, and in 2023 the family settled a lawsuit against Thermo Fisher Scientific over commercial use. Her case is now the standard teaching example for consent, privacy and benefit-sharing in tissue research.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Henrietta_Lacks","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Henrietta_Lacks"},{"label":"Henrietta Lacks Foundation","url":"https://henriettalacksfoundation.org/"},{"label":"Johns Hopkins Medicine: Henrietta Lacks","url":"https://www.hopkinsmedicine.org/henrietta-lacks"}],"tags":["hero","patient"],"related":[],"cancers":["cervical"],"sections":[],"technologies":["biobanking","hpv-testing"],"targets":[],"drugs":[],"companies":[],"institutions":["johns-hopkins"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-patient-voice","b-trial-diversity"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Patient whose cells became the HeLa line; the case that reshaped research consent","specialisms":["Cervical cancer","Research ethics","Cell lines"],"profiles":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Henrietta_Lacks"},{"label":"Henrietta Lacks Foundation","url":"https://henriettalacksfoundation.org/"},{"label":"Johns Hopkins Medicine: Henrietta Lacks","url":"https://www.hopkinsmedicine.org/henrietta-lacks"}],"papers":[]},{"id":"henrique-prata","kind":"person","name":"Henrique Prata","aka":[],"tldr":"Health manager who presides over Hospital de Amor in Barretos, one of the largest philanthropic cancer hospitals in Latin America.","summary":"Henrique Prata is President of Hospital de Amor (formerly Hospital de Câncer de Barretos) and of its parent body, the Fundação Pio XII, a philanthropic cancer hospital network based in Barretos, São Paulo state, that treats patients through Brazil's public health system. He is the son of the hospital's founders, Paulo Prata and Scylla Duarte Prata, joined the administration in 1989 and led the construction of the new hospital complex opened in 1991. The hospital describes him as a health manager with more than three decades of oncology management in the SUS.","asOf":"2026-09-10","links":[{"label":"Source: Hospital de Amor news article (president of HA)","url":"https://hospitaldeamor.com.br/henrique-prata-lanca-seu-novo-livro-o-parque-dos-lobos/"}],"tags":["leadership","hospital-management","philanthropy"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["hospital-de-amor-barretos"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President of Hospital de Amor and the Fundação Pio XII","institutionId":"hospital-de-amor-barretos","specialisms":["Health management","Cancer care access","Philanthropic healthcare"],"profiles":[{"label":"Hospital de Amor article naming him as president","url":"https://hospitaldeamor.com.br/henrique-prata-lanca-seu-novo-livro-o-parque-dos-lobos/"},{"label":"Wikipedia (Portuguese)","url":"https://pt.wikipedia.org/wiki/Henrique_Prata"}],"papers":[]},{"id":"herbert-irving","kind":"person","name":"Herbert Irving","aka":["Herbert and Florence Irving"],"tldr":"Herbert and Florence Irving's gifts to Columbia began with $8.5 million in 1987, founded its cancer centre in 1995 and ended with a $700 million bequest in 2017 for cancer research; the total passed $900 million.","summary":"Herbert Irving (1918-2016), a co-founder of the food distributor Sysco, and his wife Florence (1920-2018) were the largest donors in the history of Columbia University Irving Medical Center and NewYork-Presbyterian. The cancer centre's own account of the Irving family records a first gift of $8.5 million in 1987, the founding of the Herbert Irving Comprehensive Cancer Center in 1995, and a posthumous gift of $700 million in 2017 to advance research and clinical programmes for the treatment of cancer, spanning cancer genomics, immunology, computational biology, pathology and biomedical engineering. Cumulative Irving giving exceeded $900 million over three decades. The 2017 bequest is among the largest single gifts ever directed to cancer research and funded a wave of recruitment and new laboratories.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Herbert_Irving","links":[{"label":"Herbert Irving Comprehensive Cancer Center: the Irving family","url":"https://www.cancer.columbia.edu/about-us/irving-family"}],"tags":["hero","donor"],"related":[],"cancers":[],"sections":[],"technologies":["cgp","immunotherapy"],"targets":[],"drugs":[],"companies":[],"institutions":["columbia-hicc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-funding-allocation"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Sysco co-founder whose family gave more than $900 million to Columbia, founding the Herbert Irving Comprehensive Cancer Center","specialisms":["Cancer centre building","Cancer genomics","Estate philanthropy"],"profiles":[],"papers":[]},{"id":"hermann-brenner","kind":"person","name":"Hermann Brenner","aka":[],"tldr":"Epidemiologist whose studies underpin colonoscopy and stool-test screening for bowel cancer.","summary":"Hermann Brenner is Head of Clinical Epidemiology and Aging Research at the German Cancer Research Center (DKFZ) in Heidelberg. An epidemiologist, his specialisms are cancer epidemiology, colorectal cancer screening and early detection. His population studies quantified the protective effect of colonoscopy and measured the performance of faecal immunochemical tests, informing bowel cancer screening programmes across Europe. His Annals of Internal Medicine paper was a population-based case-control study of protection from colorectal cancer after colonoscopy. His work underpins colonoscopy and stool-test screening, and his publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Brenner%20H%5BAuthor%5D%20colorectal%20screening"}],"tags":[],"related":[],"cancers":["colorectal"],"sections":[],"technologies":["colorectal-screening"],"targets":[],"drugs":[],"companies":[],"institutions":["dkfz"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["annals-internal-medicine"],"dependsOn":[],"notes":[],"role":"Head of Clinical Epidemiology and Aging Research, DKFZ","institutionId":"dkfz","specialisms":["Cancer epidemiology","Colorectal cancer screening","Early detection"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Brenner%20H%5BAuthor%5D%20colorectal%20screening"}],"papers":[{"title":"Protection from colorectal cancer after colonoscopy: a population-based, case-control study","journal":"Annals of Internal Medicine","year":2011,"doi":"10.7326/0003-4819-154-1-201101040-00004"}]},{"id":"herve-dombret","kind":"person","name":"Hervé Dombret","aka":[],"tldr":"Paris haematologist who led AZA-AML-001, the trial that showed azacitidine can extend survival for older people with acute myeloid leukaemia who cannot have intensive chemotherapy.","summary":"Hervé Dombret is a haematologist at Hôpital Saint-Louis in Paris and a long-standing leader of the French ALFA and GRAALL leukaemia cooperative groups. He was first author of the 2015 Blood report of AZA-AML-001, the international phase 3 trial of azacitidine against conventional care regimens in older patients with newly diagnosed AML and more than 30 percent marrow blasts, which supported azacitidine's use in this population.","asOf":"2026-09-18","links":[],"tags":["leukaemia","trialist"],"related":[],"cancers":["aml-older-unfit","aml"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["aphp-nord-cancer-institute"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-aza-aml-001-dombret-blood-2015"],"journals":[],"dependsOn":[],"notes":[],"role":"Haematologist, Hôpital Saint-Louis (AP-HP), Paris","institutionId":"aphp-nord-cancer-institute","specialisms":["Acute myeloid leukaemia","Acute lymphoblastic leukaemia","Cooperative-group trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dombret%5BAuthor%5D"}],"papers":[{"title":"AZA-AML-001: azacitidine versus conventional care in older patients with acute myeloid leukaemia and more than 30 percent blasts","journal":"Blood","year":2015,"url":"https://doi.org/10.1182/blood-2015-01-621664","doi":"10.1182/blood-2015-01-621664"}]},{"id":"herve-tilly","kind":"person","name":"Hervé Tilly","aka":[],"tldr":"Principal investigator of POLARIX, the trial that gave DLBCL its first improvement on R-CHOP in twenty years.","summary":"Hervé Tilly (Rouen) was principal investigator and first author of POLARIX, which showed replacing vincristine with the CD79b ADC polatuzumab vedotin in R-CHOP reduces progression or death by 27% in previously untreated DLBCL. He has led LYSA trials for decades, including LNH03-6B in older patients, and chaired the ESMO DLBCL guidelines.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tilly%20H%5BAuthor%5D%20lymphoma%20polatuzumab"}],"tags":["lymphoma","adc","lysa"],"related":[],"cancers":["dlbcl"],"sections":[],"technologies":["adc"],"targets":["cd20"],"drugs":[],"companies":["lysa"],"institutions":[],"pathways":[],"terms":[],"trials":["polarix"],"people":[],"bottlenecks":[],"keyPapers":["paper-polarix-polatuzumab-rchp-nejm-2022"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Hematology, Centre Henri Becquerel and University of Rouen; LYSA","institutionId":"lysa","specialisms":["Diffuse large B-cell lymphoma","Antibody-drug conjugates","Cooperative-group trials","Lymphoma guidelines"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tilly%20H%5BAuthor%5D%20lymphoma%20polatuzumab"}],"papers":[{"title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma (POLARIX)","journal":"NEJM","year":2022,"doi":"10.1056/NEJMoa2115304"},{"title":"Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","journal":"Annals of Oncology","year":2015,"doi":"10.1093/annonc/mdv304"}]},{"id":"hidetoshi-hayashi","kind":"person","name":"Hidetoshi Hayashi","aka":[],"tldr":"Vice-President of JSMO and thoracic medical oncologist at Kindai University known for clinical trials of targeted therapies in lung cancer.","summary":"Hidetoshi Hayashi is Vice-President of the Japanese Society of Medical Oncology and a member of the Department of Medical Oncology at Kindai University Faculty of Medicine. His research focuses on non-small cell lung cancer, including EGFR-targeted therapy and immunotherapy trials conducted through Japanese cooperative groups.","asOf":"2026-09-10","links":[{"label":"Society page","url":"https://www.jsmo.or.jp/eng/about/directors/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hayashi+H%5BAuthor%5D+Kindai+lung"}],"tags":["leadership","clinician-scientist","lung cancer"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["jsmo"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Vice-President","institutionId":"jsmo","specialisms":["Thoracic oncology","Lung cancer","Targeted therapy"],"profiles":[{"label":"Society page","url":"https://www.jsmo.or.jp/eng/about/directors/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hayashi+H%5BAuthor%5D+Kindai+lung"}],"papers":[{"title":"Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site","journal":"JAMA Oncology","year":2020,"doi":"10.1001/jamaoncol.2020.4643"},{"title":"Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site","journal":"Journal of Clinical Oncology","year":2019,"doi":"10.1200/jco.18.00771"},{"title":"Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer","journal":"JAMA Oncology","year":2018,"doi":"10.1001/jamaoncol.2017.2925"}]},{"id":"hien-le","kind":"person","name":"Hien Le","aka":[],"tldr":"Adelaide radiation oncologist who chairs TROG's Scientific Committee and is its President Elect.","summary":"Hien Le is President Elect of TROG Cancer Research and chairs its Scientific Committee, which oversees the group's radiotherapy trial portfolio. A professor and radiation oncologist based in Adelaide, his interests include clinical trials of advanced radiotherapy techniques including proton therapy. His roles are listed on TROG's board page.","asOf":"2026-09-10","links":[{"label":"Society page","url":"https://trog.com.au/about-us/our-board/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Le+H%5BAuthor%5D+AND+radiation+oncology+Adelaide"}],"tags":["leadership","clinician-scientist","radiotherapy"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["trog"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["supportive-care-in-cancer"],"dependsOn":[],"notes":[],"role":"President Elect and Chair of the Scientific Committee","institutionId":"trog","specialisms":["Radiation oncology","Clinical trials","Proton therapy"],"profiles":[{"label":"Society page","url":"https://trog.com.au/about-us/our-board/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Le+H%5BAuthor%5D+AND+radiation+oncology+Adelaide"}],"papers":[{"title":"Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II)","journal":"JAMA Oncology","year":2021,"doi":"10.1001/jamaoncol.2021.2939"},{"title":"Long-Term Outcomes of TROG 13.01 SAFRON II Randomized Trial of Single- Versus Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases","journal":"Journal of Clinical Oncology","year":2023,"doi":"10.1200/jco.23.00150"},{"title":"Baseline gut microbiota composition is associated with oral mucositis and tumour recurrence in patients with head and neck cancer: a pilot study","journal":"Supportive Care in Cancer","year":2023,"doi":"10.1007/s00520-022-07559-5"}],"orcid":"0000-0002-1527-5889"},{"id":"hisham-mehanna","kind":"person","name":"Hisham Mehanna","aka":[],"tldr":"Surgeon who led De-ESCALaTE and PET-NECK, two trials that changed how HPV-positive throat cancer is treated and followed up.","summary":"Hisham Mehanna was chief investigator of De-ESCALaTE HPV, which showed cetuximab is inferior to cisplatin with radiotherapy in HPV-positive oropharyngeal cancer (mirroring RTOG 1016), and of PET-NECK, which showed PET-CT surveillance safely avoids neck dissection after chemoradiotherapy. He leads the UK's head and neck trials portfolio and the Institute of Head and Neck Studies and Education.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Hisham_Mehanna","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mehanna%20H%5BAuthor%5D%20oropharyngeal"}],"tags":["head-and-neck","surgery","de-escalation","uk"],"related":[],"cancers":["head-and-neck"],"sections":[],"technologies":["fdg-pet","imrt-igrt"],"targets":[],"drugs":[],"companies":[],"institutions":["birmingham-cancer-centre"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Head and Neck Surgery and Director, Institute of Head and Neck Studies and Education, University of Birmingham","institutionId":"birmingham-cancer-centre","specialisms":["Head and neck surgery","HPV-positive oropharyngeal cancer","De-escalation","PET-guided surveillance"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mehanna%20H%5BAuthor%5D%20oropharyngeal"}],"papers":[{"title":"Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV)","journal":"Lancet","year":2019,"doi":"10.1016/S0140-6736(18)32752-1"},{"title":"PET-CT surveillance versus neck dissection in advanced head and neck cancer (PET-NECK)","journal":"NEJM","year":2016,"doi":"10.1056/NEJMoa1514493"}],"orcid":"0000-0002-5544-6224"},{"id":"hitoshi-ishikawa","kind":"person","name":"Hitoshi Ishikawa","aka":[],"tldr":"Radiation specialist who has directed QST Hospital in Chiba, Japan's pioneering carbon ion radiotherapy hospital, since April 2024.","summary":"Hitoshi Ishikawa is Director of QST Hospital, the clinical arm of Japan's National Institutes for Quantum Science and Technology and a centre for carbon ion radiotherapy, a role he has held since April 2024. In his director's message he prioritises validating heavy ion therapy across cancers and extending Japanese insurance coverage, the Quantum Scalpel project to build compact multi-ion accelerators with clinical use planned from 2028, and translating QST research such as radioisotope therapy and PET imaging into practice. The hospital also serves as a designated advanced medical facility for Chiba Prefecture.","asOf":"2026-09-10","links":[{"label":"Source: QST Hospital director's greeting","url":"https://www.qst.go.jp/site/hospital/aboutus-greeting.html"}],"tags":["leadership","clinician-scientist","radiotherapy","particle-therapy"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["qst-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["cancer-science"],"dependsOn":[],"notes":[],"role":"Director of QST Hospital","institutionId":"qst-hospital","specialisms":["Radiation oncology","Carbon ion radiotherapy","Heavy ion therapy"],"profiles":[{"label":"QST Hospital director's greeting","url":"https://www.qst.go.jp/site/hospital/aboutus-greeting.html"},{"label":"QST Hospital (English)","url":"https://www.qst.go.jp/site/hospital-en/"}],"papers":[{"title":"Carbon‐ion radiotherapy for urological cancers","journal":"International Journal of Urology","year":2022,"doi":"10.1111/iju.14950"},{"title":"Long‐term clinical outcomes after 12‐fractionated carbon‐ion radiotherapy for localized prostate cancer","journal":"Cancer Science","year":2021,"doi":"10.1111/cas.15019"},{"title":"Long Term Results of Single-Fraction Carbon-Ion Radiotherapy for Non-small Cell Lung Cancer","journal":"Cancers","year":2020,"doi":"10.3390/cancers13010112"}],"orcid":"0000-0002-0046-9787"},{"id":"hitoshi-katai","kind":"person","name":"Hitoshi Katai","aka":[],"tldr":"Japanese surgeon who led JCOG0912, the trial that confirmed laparoscopic gastrectomy is not inferior to open surgery for early stomach cancer.","summary":"Hitoshi Katai is a gastric surgeon at the National Cancer Center Hospital in Tokyo. He was first author of the 2020 Lancet Gastroenterology and Hepatology report of JCOG0912, the Japan Clinical Oncology Group trial that showed laparoscopy-assisted distal gastrectomy was non-inferior to open distal gastrectomy for clinical stage I gastric cancer in relapse-free survival.","asOf":"2026-09-18","links":[],"tags":["gastric","surgery","trialist"],"related":[],"cancers":["early-gastric-cancer","gastric"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ncc-japan"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-jcog0912-katai-lancet-gastroenterol-hepatol-2020"],"journals":[],"dependsOn":[],"notes":[],"role":"Gastric surgeon, National Cancer Center Hospital, Tokyo","institutionId":"ncc-japan","specialisms":["Gastric surgery","Laparoscopic gastrectomy","JCOG trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Katai%5BAuthor%5D"}],"papers":[{"title":"JCOG0912: laparoscopy-assisted versus open distal gastrectomy for clinical stage IA or IB gastric cancer","journal":"The Lancet Gastroenterology and Hepatology","year":2020,"url":"https://doi.org/10.1016/S2468-1253(19)30332-2","doi":"10.1016/S2468-1253(19)30332-2"}]},{"id":"nakagama-hitoshi","kind":"person","name":"Hitoshi Nakagama","aka":[],"tldr":"Leads Japan's national cancer centre, the hub of the country's genomic medicine and early-phase trial programmes.","summary":"Hitoshi Nakagama is President of the National Cancer Center Japan, the hub of the country's genomic medicine and early-phase trial programmes. A molecular carcinogenesis researcher, he oversees the centre's hospitals in Tokyo and Kashiwa, its research institute, and national programmes such as SCRUM-Japan and cancer genomic medicine built on comprehensive genomic profiling. His publications include a study of how the tumour-suppressive microRNA miR-34a induces senescence-like growth arrest through the E2F pathway in colon cancer cells, and a review of fatty pancreas as a possible risk factor for pancreatic cancer. His interests span cancer research leadership, prevention and molecular carcinogenesis.","asOf":"2026-09-08","links":[{"label":"National Cancer Center Japan","url":"https://www.ncc.go.jp/en/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Nakagama%20H%5BAuthor%5D%20National%20Cancer%20Center"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["cgp"],"targets":[],"drugs":[],"companies":[],"institutions":["ncc-japan"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["cancer-science"],"dependsOn":[],"notes":[],"role":"President, National Cancer Center Japan","institutionId":"ncc-japan","specialisms":["Cancer research leadership","Cancer prevention","Molecular carcinogenesis"],"profiles":[{"label":"National Cancer Center Japan","url":"https://www.ncc.go.jp/en/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Nakagama%20H%5BAuthor%5D%20National%20Cancer%20Center"}],"papers":[{"title":"Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells","journal":"Proceedings of the National Academy of Sciences","year":2007,"doi":"10.1073/pnas.0707351104"},{"title":"Fatty pancreas: A possible risk factor for pancreatic cancer in animals and humans","journal":"Cancer Science","year":2018,"doi":"10.1111/cas.13766"}]},{"id":"lim-ho-yeong","kind":"person","name":"Ho Yeong Lim","aka":[],"tldr":"A liver cancer oncologist who has been on the steering group of several global HCC trials with strong Asian enrolment.","summary":"Ho Yeong Lim is Professor of Medical Oncology at Samsung Medical Center in Seoul, specialising in hepatocellular carcinoma. He has served on the steering groups of several global liver cancer trials with strong Asian enrolment, including IMbrave150, which tested atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. His publications include the IMbrave150 report, and he has contributed to immunotherapy combination trials and Asian subgroup analyses of first-line regimens. His interests are systemic therapy and clinical trials in liver cancer.","asOf":"2026-09-08","links":[{"label":"Samsung Medical Center","url":"https://www.samsunghospital.com/gb/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lim%20HY%5BAuthor%5D%20hepatocellular%20carcinoma%20Samsung"}],"tags":[],"related":[],"cancers":["hcc"],"sections":[],"technologies":[],"targets":[],"drugs":["atezolizumab"],"companies":[],"institutions":["samsung-medical-center"],"pathways":[],"terms":[],"trials":["imbrave150"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology; hepatocellular carcinoma","institutionId":"samsung-medical-center","specialisms":["Hepatocellular carcinoma","Systemic therapy","Clinical trials"],"profiles":[{"label":"Samsung Medical Center","url":"https://www.samsunghospital.com/gb/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lim%20HY%5BAuthor%5D%20hepatocellular%20carcinoma%20Samsung"}],"papers":[{"title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma (IMbrave150)","journal":"NEJM","year":2020,"doi":"10.1056/NEJMoa1915745"}]},{"id":"hope-rugo","kind":"person","name":"Hope S. Rugo","aka":[],"tldr":"Breast oncologist who led key ADC and CDK4/6 trials and moved from UCSF to City of Hope in 2024.","summary":"Hope Rugo is Division Chief of Breast Medical Oncology and Director of the Women's Cancers Program at City of Hope, which she joined from UCSF in 2024. A breast medical oncologist specialising in antibody-drug conjugates and supportive care, she was principal investigator of TROPiCS-02, the trial of sacituzumab govitecan in hormone receptor-positive breast cancer, and a leader in scalp cooling and toxicity management studies. Her papers report sacituzumab govitecan in HR-positive, HER2-negative metastatic breast cancer in the Journal of Clinical Oncology and the association between scalp cooling device use and alopecia after chemotherapy in JAMA. Her work links TROP2, palbociclib and cold cap scalp cooling.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Hope_Rugo","links":[{"label":"City of Hope research faculty","url":"https://www.cityofhope.org/research/find-a-researcher"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rugo%20HS%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Hope%20S.%20Rugo"}],"tags":[],"related":[],"cancers":["breast-hr-positive","tnbc"],"sections":[],"technologies":["adc","scalp-cooling"],"targets":["trop2"],"drugs":["sacituzumab-govitecan","palbociclib"],"companies":[],"institutions":["city-of-hope"],"pathways":[],"terms":[],"trials":["tropics-02"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Division Chief, Breast Medical Oncology; Director, Women's Cancers Program, City of Hope","institutionId":"city-of-hope","specialisms":["Breast cancer","ADCs","Supportive care"],"profiles":[{"label":"City of Hope research faculty","url":"https://www.cityofhope.org/research/find-a-researcher"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rugo%20HS%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Hope%20S.%20Rugo"}],"papers":[{"title":"Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer","journal":"Journal of Clinical Oncology","year":2022,"url":"https://doi.org/10.1200/JCO.22.01002","doi":"10.1200/JCO.22.01002"},{"title":"Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer","journal":"JAMA","year":2017,"url":"https://doi.org/10.1001/jama.2016.21038","doi":"10.1001/jama.2016.21038"},{"title":"ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer","journal":"New England Journal of Medicine","year":2021,"url":"https://doi.org/10.1056/NEJMoa2028485","doi":"10.1056/NEJMoa2028485"},{"title":"DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group","journal":"New England Journal of Medicine","year":2022,"url":"https://doi.org/10.1056/NEJMoa2203690","doi":"10.1056/NEJMoa2203690"}],"orcid":"0000-0001-6710-4814"},{"id":"howard-scher","kind":"person","name":"Howard I. Scher","aka":[],"tldr":"Defined how prostate cancer trials are run and read, from PSA working-group criteria to circulating tumour cell biomarkers.","summary":"Howard I. Scher is a Member of the Genitourinary Oncology Service and Head of the Biomarker Development Program at Memorial Sloan Kettering Cancer Center. He is known for defining how prostate cancer trials are run and read, leading the Prostate Cancer Clinical Trials Working Group criteria used across the field and the Prostate Cancer Foundation clinical trials consortium. He showed that the AR-V7 variant in circulating tumour cells predicts resistance to abiraterone and enzalutamide. His selected papers report enzalutamide in prostate cancer after chemotherapy and AR-V7 on circulating tumour cells as a treatment-specific biomarker in castration-resistant prostate cancer.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Howard_Scher","links":[{"label":"MSK profile","url":"https://www.mskcc.org/cancer-care/doctors/howard-scher"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Scher%20HI%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":["androgen-receptor"],"drugs":["enzalutamide","abiraterone"],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["jama-oncology"],"dependsOn":[],"notes":[],"role":"Member, Genitourinary Oncology Service; Head, Biomarker Development Program","institutionId":"mskcc","specialisms":["Prostate cancer","Circulating tumour cells","AR-V7","Clinical trial endpoints"],"profiles":[{"label":"MSK profile","url":"https://www.mskcc.org/cancer-care/doctors/howard-scher"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Scher%20HI%5BAuthor%5D"}],"papers":[{"title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","journal":"New England Journal of Medicine","year":2012,"url":"https://doi.org/10.1056/NEJMoa1207506","doi":"10.1056/NEJMoa1207506"},{"title":"Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer","journal":"JAMA Oncology","year":2016,"url":"https://doi.org/10.1001/jamaoncol.2016.1828","doi":"10.1001/jamaoncol.2016.1828"}]},{"id":"howard-kaufman","kind":"person","name":"Howard L. Kaufman","aka":[],"tldr":"Led OPTiM, the trial that made talimogene laherparepvec the first approved oncolytic virus therapy.","summary":"Howard Kaufman was a lead investigator and senior author of OPTiM, the phase 3 trial showing the herpes-based oncolytic virus talimogene laherparepvec improves durable response rates in advanced melanoma, leading to the first approval of an oncolytic virus in 2015. He led the JAVELIN Merkel 200 trial of avelumab and was president of the Society for Immunotherapy of Cancer.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kaufman%20HL%5BAuthor%5D%20talimogene%20oncolytic"}],"tags":["immunotherapy","oncolytic-virus","melanoma"],"related":[],"cancers":["melanoma","merkel-cell-carcinoma"],"sections":[],"technologies":["oncolytic-virus"],"targets":[],"drugs":["talimogene-laherparepvec"],"companies":[],"institutions":["mgh","sitc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nature-reviews-drug-discovery"],"dependsOn":[],"notes":[],"role":"Surgical Oncologist, Massachusetts General Hospital; Chief Medical Officer, Ankyra Therapeutics","institutionId":"mgh","specialisms":["Oncolytic virus therapy","Melanoma","Intratumoural immunotherapy","Merkel cell carcinoma"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kaufman%20HL%5BAuthor%5D%20talimogene%20oncolytic"}],"papers":[{"title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma (OPTiM)","journal":"JCO","year":2015,"doi":"10.1200/JCO.2014.58.3377"},{"title":"Oncolytic viruses: a new class of immunotherapy drugs","journal":"Nature Reviews Drug Discovery","year":2015,"doi":"10.1038/nrd4663"}],"orcid":"0000-0003-1131-004X"},{"id":"hu-junbo","kind":"person","name":"Hu Junbo","aka":[],"tldr":"Gastrointestinal surgeon who has been President of Tongji Hospital in Wuhan, one of China's top-ranked general hospitals, since December 2023.","summary":"Hu Junbo (胡俊波) is Deputy Party Secretary and President (院长) of Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, in Wuhan, and Dean of its Second Clinical College; the hospital's leadership page says he presides over the hospital's administrative work and oversees discipline building, performance management and audit. He is a chief physician and Level 2 professor specialising in gastrointestinal surgery, a doctoral supervisor and recipient of a State Council special allowance, has led three major national research projects, published around 200 papers including in Cell and Nature Communications, and won a first-class Hubei Provincial Science and Technology Progress Award in 2024; his appointment was announced in December 2023. Tongji Hospital, founded in 1900 by the German physician Erich Paulun, is a Grade A tertiary teaching hospital with about 2,000 beds and 40 national key clinical specialties, ranked sixth nationally in the Fudan China Hospital Ranking.","asOf":"2026-09-10","links":[{"label":"Source: Tongji Hospital current leadership page for the President","url":"https://www.tjh.com.cn/CurrentLeader/51393.html"},{"label":"Source: Wikipedia article on Tongji Hospital","url":"https://en.wikipedia.org/wiki/Tongji_Hospital"}],"tags":["leadership","clinician-scientist","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["tongji-hospital-wuhan"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President (院长) and Deputy Party Secretary, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","institutionId":"tongji-hospital-wuhan","specialisms":["Gastrointestinal surgery","Surgical oncology","Hospital management"],"profiles":[{"label":"Tongji Hospital current leadership page (Chinese)","url":"https://www.tjh.com.cn/CurrentLeader/51393.html"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hu+J%5BAuthor%5D+AND+Tongji+Hospital+Wuhan"}],"papers":[]},{"id":"huang-guo","kind":"person","name":"Huang Guo","aka":[],"tldr":"Commissioner of China's National Medical Products Administration, the regulator whose Center for Drug Evaluation reviews new cancer drugs for the Chinese market.","summary":"Huang Guo (黄果) is Commissioner of the National Medical Products Administration (NMPA), the Chinese regulator for drugs, medical devices and cosmetics, and the parent body of the Center for Drug Evaluation (CDE), which conducts technical review of new drug applications. The NMPA's English leadership page lists him as NMPA Commissioner, Secretary of the NMPA Leading Party Members' Group and a member of the Leading Party Members' Group of the State Administration for Market Regulation, alongside Deputy Commissioners Lei Ping, Yang Sheng and Wang Weidong. The Chinese Wikipedia article on the NMPA dates his appointment as Commissioner to April 2026. The CDE's own website did not return readable leadership information for this record.","asOf":"2026-09-10","links":[{"label":"Source: NMPA English leadership page","url":"https://english.nmpa.gov.cn/leadership.html"},{"label":"Wikipedia (Chinese) article on the NMPA","url":"https://zh.wikipedia.org/wiki/国家药品监督管理局"}],"tags":["leadership","regulation","government"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["nmpa-cde"],"pathways":[],"terms":["bla-nda"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Commissioner, National Medical Products Administration (NMPA), China","institutionId":"nmpa-cde","specialisms":["Drug regulation","Medical device regulation","Public administration"],"profiles":[{"label":"NMPA leadership page (English)","url":"https://english.nmpa.gov.cn/leadership.html"}],"papers":[]},{"id":"hubert-serve","kind":"person","name":"Hubert Serve","aka":[],"tldr":"Leukaemia specialist heading haematology and oncology at University Hospital Frankfurt and co-author of the pivotal RATIFY midostaurin trial.","summary":"Hubert Serve is Director of the Department of Internal Medicine 2 (Hematology/Oncology) at University Hospital Frankfurt and a member of the UCT Frankfurt directorate. His research on FLT3 signalling in acute myeloid leukaemia contributed to the development of FLT3 inhibitors, including the international RATIFY trial of midostaurin published in the New England Journal of Medicine in 2017.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.uct-frankfurt.de/ueber-uns/direktorium/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Serve+H%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","leukaemia","haematology"],"related":[],"cancers":["aml"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["uct-frankfurt"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Department of Internal Medicine 2 (Hematology/Oncology)","institutionId":"uct-frankfurt","specialisms":["Acute myeloid leukaemia","Haematology","Targeted therapy"],"profiles":[{"label":"Institution profile","url":"https://www.uct-frankfurt.de/ueber-uns/direktorium/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Serve+H%5BAuthor%5D"}],"papers":[{"title":"Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation","journal":"New England Journal of Medicine","year":2017,"url":"https://doi.org/10.1056/NEJMoa1614359","doi":"10.1056/NEJMoa1614359"}],"orcid":"0000-0001-8472-5516"},{"id":"hugo-ford","kind":"person","name":"Hugo Ford","aka":[],"tldr":"Hugo Ford represents Cancer Research UK Cambridge Centre / CRUK Cambridge Institute in the Organisation of European Cancer Institutes, which lists the centre among its members in United Kingdom.","summary":"Hugo Ford is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Cancer Research UK Cambridge Centre / CRUK Cambridge Institute, its associate member in United Kingdom. OnCo records the name from the OECI membership list so that the centre's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the institution's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Cancer Research UK Cambridge Centre / CRUK Cambridge Institute website","url":"https://www.cruk.cam.ac.uk"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cruk-cambridge-centre"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Cancer Research UK Cambridge Centre / CRUK Cambridge Institute to the Organisation of European Cancer Institutes","institutionId":"cruk-cambridge-centre","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Cancer Research UK Cambridge Centre / CRUK Cambridge Institute website","url":"https://www.cruk.cam.ac.uk"}],"papers":[]},{"id":"hussein-tawbi","kind":"person","name":"Hussein A. Tawbi","aka":[],"tldr":"Led RELATIVITY-047, which made relatlimab the first approved LAG-3 inhibitor, and the trial that showed immunotherapy works in melanoma brain metastases.","summary":"Hussein Tawbi was principal investigator of RELATIVITY-047, which showed nivolumab plus relatlimab improves progression-free survival over nivolumab alone and led to the first approval of a LAG-3-targeted therapy, and of CheckMate 204, which showed nivolumab plus ipilimumab produces durable intracranial responses in melanoma brain metastases, changing their management. He leads brain metastasis research at MD Anderson.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tawbi%20HA%5BAuthor%5D%20melanoma%20relatlimab%20OR%20brain"}],"tags":["melanoma","lag3","brain-metastases"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["lag3","pd1"],"drugs":["relatlimab-nivolumab","nivolumab","ipilimumab"],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":["relativity-047","relativity-098"],"people":[],"bottlenecks":[],"keyPapers":["paper-relativity-047-nejm-2022"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor and Deputy Chair, Department of Melanoma Medical Oncology, MD Anderson Cancer Center","institutionId":"md-anderson","specialisms":["Melanoma","Brain metastases","LAG-3 blockade","Immunotherapy combinations"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tawbi%20HA%5BAuthor%5D%20melanoma%20relatlimab%20OR%20brain"}],"papers":[{"title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma (RELATIVITY-047)","journal":"NEJM","year":2022,"doi":"10.1056/NEJMoa2109970"},{"title":"Combined nivolumab and ipilimumab in melanoma metastatic to the brain (CheckMate 204)","journal":"NEJM","year":2018,"doi":"10.1056/NEJMoa1805453"},{"title":"SARC028: pembrolizumab in advanced soft tissue and bone sarcoma","journal":"The Lancet Oncology","year":2017,"url":"https://doi.org/10.1016/S1470-2045(17)30624-1","doi":"10.1016/S1470-2045(17)30624-1"}]},{"id":"kim-hye-ryun","kind":"person","name":"Hye Ryun Kim","aka":[],"tldr":"A Yonsei oncologist who has led checkpoint-inhibitor and combination trials in lung and head-and-neck cancer.","summary":"Hye Ryun Kim is Professor of Medical Oncology at Severance Hospital, Yonsei University, in Seoul, working in thoracic and head and neck oncology. She has led checkpoint-inhibitor and combination trials in lung cancer and head and neck cancer, including trials of PD-1 combinations in non-small-cell lung cancer and head and neck squamous cell carcinoma. Her work also includes immunotherapy biomarker studies that seek to identify which patients respond to immune checkpoint inhibitors. Her interests are lung cancer, head and neck cancer and immunotherapy.","asOf":"2026-09-08","links":[{"label":"Yonsei Cancer Center","url":"https://sev.severance.healthcare"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kim%20HR%5BAuthor%5D%20Yonsei%20lung%20cancer%20immunotherapy"}],"tags":[],"related":[],"cancers":["nsclc","head-and-neck"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":[],"companies":[],"institutions":["severance"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology; thoracic and head-and-neck oncology","institutionId":"severance","specialisms":["Lung cancer","Head and neck cancer","Immunotherapy"],"profiles":[{"label":"Yonsei Cancer Center","url":"https://sev.severance.healthcare"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kim%20HR%5BAuthor%5D%20Yonsei%20lung%20cancer%20immunotherapy"}],"papers":[{"title":"Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451","journal":"Journal of Clinical Oncology","year":2021,"doi":"10.1200/jco.20.02212"},{"title":"Fibroblast Growth Factor Receptor 1 Gene Amplification Is Associated With Poor Survival and Cigarette Smoking Dosage in Patients With Resected Squamous Cell Lung Cancer","journal":"Journal of Clinical Oncology","year":2013,"doi":"10.1200/jco.2012.43.8622"},{"title":"PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients","journal":"Scientific Reports","year":2016,"doi":"10.1038/srep36956"}]},{"id":"hyung-ho-kim","kind":"person","name":"Hyung-Ho Kim","aka":[],"tldr":"Korean surgeon who led KLASS-01, the trial that showed keyhole gastrectomy is as safe and effective as open surgery for early stomach cancer.","summary":"Hyung-Ho Kim is a gastric surgeon at Seoul National University Bundang Hospital and a leader of the Korean Laparoendoscopic Gastrointestinal Surgery Study group. He was first author of the 2019 JAMA Oncology report of KLASS-01, which found no difference in overall survival between laparoscopic and open distal gastrectomy for stage I gastric cancer, supporting the minimally invasive approach.","asOf":"2026-09-18","links":[],"tags":["gastric","surgery","trialist"],"related":[],"cancers":["early-gastric-cancer","gastric"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["snu-bundang-hospital"],"pathways":[],"terms":[],"trials":["klass-01"],"people":[],"bottlenecks":[],"keyPapers":["paper-klass-01-kim-jama-oncol-2019"],"journals":[],"dependsOn":[],"notes":[],"role":"Gastric surgeon, Seoul National University Bundang Hospital","institutionId":"snu-bundang-hospital","specialisms":["Laparoscopic gastrectomy","Early gastric cancer","Surgical trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kim%5BAuthor%5D"}],"papers":[{"title":"KLASS-01: laparoscopic versus open distal gastrectomy for stage I gastric cancer, long-term survival","journal":"JAMA Oncology","year":2019,"url":"https://doi.org/10.1001/jamaoncol.2018.6727","doi":"10.1001/jamaoncol.2018.6727"}],"orcid":"0000-0002-3693-6500"},{"id":"hywel-williams","kind":"person","name":"Hywel Williams","aka":[],"tldr":"The Nottingham epidemiologist who founded British evidence-based dermatology and ran the trial that answered whether a cream can replace surgery for the commonest cancer there is.","summary":"Hywel Williams trained in medicine at Charing Cross Hospital and in dermatology in London, took an MSc in clinical epidemiology at the London School of Hygiene and Tropical Medicine on a Wellcome Trust fellowship, and was appointed to Nottingham in 1994, becoming Foundation Professor of Dermato-Epidemiology in 1998. He founded the Centre of Evidence Based Dermatology there and still co-directs it with Kim Thomas.\n\nFor skin cancer his central contribution is SINS, the multicentre non-inferiority randomised trial of excisional surgery against imiquimod 5% cream for nodular and superficial basal cell carcinoma at low-risk sites, which recruited 501 people at twelve UK centres between 2003 and 2007 and reported three-year results in the Lancet Oncology in 2014 and five-year results in the Journal of Investigative Dermatology in 2017. He directed the NIHR Health Technology Assessment Programme from 2015 to 2020, was awarded the British Association of Dermatologists' Sir Archibald Gray medal in 2017 and an OBE in 2021, and his university page records that he has published over 640 peer-reviewed articles.","asOf":"2026-09-25","links":[{"label":"University of Nottingham profile","url":"https://www.nottingham.ac.uk/medicine/people/hywel.williams"},{"label":"Centre of Evidence Based Dermatology","url":"https://www.nottingham.ac.uk/research/groups/cebd/index.aspx"}],"tags":["uk","trialist","skin","dermatology"],"related":[],"cancers":["basal-cell-carcinoma","skin-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["sins-trial"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Dermato-Epidemiology and Co-Director of the Centre of Evidence Based Dermatology, University of Nottingham","specialisms":["Dermato-epidemiology","Randomised trials in skin disease","Systematic reviews"],"profiles":[{"label":"University of Nottingham profile","url":"https://www.nottingham.ac.uk/medicine/people/hywel.williams"},{"label":"Centre of Evidence Based Dermatology","url":"https://www.nottingham.ac.uk/research/groups/cebd/index.aspx"}],"papers":[]},{"id":"iain-foulkes","kind":"person","name":"Iain Foulkes","aka":[],"tldr":"Iain Foulkes directs the research portfolio of Cancer Research UK.","summary":"Iain Foulkes is Executive Director of Research and Innovation at Cancer Research UK. His specialisms are research strategy, translational funding and innovation partnerships. He oversees the charity's research and innovation strategy, including its institutes, centres, clinical trials units and commercial partnerships. His Nature Reviews Cancer papers argued that funding bodies should foster partnerships between industry and academia, and described embedding a positive research culture that fosters innovation. His Cancer Research UK profile is linked.","asOf":"2026-09-08","links":[{"label":"Cancer Research UK","url":"https://www.cancerresearchuk.org/"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cruk"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Executive Director of Research and Innovation, Cancer Research UK","institutionId":"cruk","specialisms":["Research strategy","Translational funding","Innovation partnerships"],"profiles":[{"label":"Cancer Research UK","url":"https://www.cancerresearchuk.org/"}],"papers":[{"title":"Funding bodies should foster partnerships between industry and academia","journal":"Nature Reviews Cancer","year":2021,"doi":"10.1038/s41568-020-00326-w"},{"title":"Embedding a positive research culture that fosters innovation","journal":"Nature Reviews Cancer","year":2019,"doi":"10.1038/s41568-019-0127-7"}]},{"id":"ian-chau","kind":"person","name":"Ian Chau","aka":[],"tldr":"A Royal Marsden gastrointestinal oncologist who has shaped UK colorectal and upper gastrointestinal trials and who works on the blood test for residual disease after bowel surgery.","summary":"Ian Chau is a consultant medical oncologist in the gastrointestinal and lymphoma units at The Royal Marsden and a professor at the Institute of Cancer Research in London and Surrey. He has served on the UK National Cancer Research Institute's colorectal cancer and pancreatic cancer clinical study groups, and in 2026 was named a Fellow of the American Society of Clinical Oncology. He is an author on the TRACC Part B minimal residual disease analysis.","asOf":"2026-09-24","links":[{"label":"The Royal Marsden consultant directory","url":"https://www.royalmarsden.nhs.uk/our-consultants-units-and-wards/consultant-directory/professor-ian-chau"}],"tags":["colorectal","uk","trialist"],"related":["naureen-starling"],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["royal-marsden","icr-london"],"pathways":[],"terms":[],"trials":["tracc"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Consultant Medical Oncologist, The Royal Marsden; Professor, The Institute of Cancer Research","institutionId":"royal-marsden","specialisms":["Gastrointestinal cancer","Immunotherapy","Clinical trial design"],"profiles":[{"label":"The Royal Marsden consultant directory","url":"https://www.royalmarsden.nhs.uk/our-consultants-units-and-wards/consultant-directory/professor-ian-chau"}],"papers":[{"title":"Tissue-free liquid biopsies combining genomic and methylation signals for minimal residual disease detection in patients with early colorectal cancer from the UK TRACC Part B study","journal":"Clinical Cancer Research","year":2024,"doi":"10.1158/1078-0432.CCR-24-0226"}]},{"id":"cree-ian","kind":"person","name":"Ian Cree","aka":[],"tldr":"Ian Cree edits the WHO 'Blue Books', the classification every pathologist uses to name a cancer.","summary":"Ian Cree is Head of the WHO Classification of Tumours programme at the International Agency for Research on Cancer. He edits the WHO Blue Books, the classification every pathologist uses to name a cancer, coordinating the fifth edition across all tumour types and introducing evidence-based methods into tumour classification. His publications include a common classification framework for neuroendocrine neoplasms, a revision of the classification of female genital tract tumours, and a summary of the WHO classification of tumours of the central nervous system. His interests are pathology, tumour classification and evidence-based diagnosis, including histopathology and DNA methylation profiling.","asOf":"2026-09-08","links":[{"label":"WHO Classification of Tumours","url":"https://tumourclassification.iarc.who.int"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cree%20IA%5BAuthor%5D%20WHO%20classification%20of%20tumours"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["histopathology-ihc","methylation-profiling"],"targets":[],"drugs":[],"companies":[],"institutions":["iarc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Head, WHO Classification of Tumours programme, IARC","institutionId":"iarc","specialisms":["Pathology","Tumour classification","Evidence-based diagnosis"],"profiles":[{"label":"WHO Classification of Tumours","url":"https://tumourclassification.iarc.who.int"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cree%20IA%5BAuthor%5D%20WHO%20classification%20of%20tumours"}],"papers":[{"title":"A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal","journal":"Modern Pathology","year":2018,"doi":"10.1038/s41379-018-0110-y"},{"title":"Revising the WHO classification: female genital tract tumours","journal":"Histopathology","year":2019,"doi":"10.1111/his.13977"},{"title":"The 2021 WHO Classification of Tumors of the Central Nervous System: a summary","journal":"Neuro-Oncology","year":2021,"doi":"10.1093/neuonc/noab106"}]},{"id":"ian-davis","kind":"person","name":"Ian Davis","aka":[],"tldr":"Melbourne medical oncologist who chairs ANZUP, the Australia and New Zealand urogenital and prostate cancer trials group.","summary":"Ian Davis is Chair of the ANZUP Cancer Trials Group and Head of the Eastern Health Clinical School at Monash University. He is a medical oncologist whose research focuses on prostate, kidney, bladder and testicular cancers, including practice-changing trials such as ENZAMET in metastatic prostate cancer. He has been a central figure in building Australasia's genitourinary cancer trials infrastructure.","asOf":"2026-09-10","links":[{"label":"Society page","url":"https://anzup.org.au/about-us/board/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Davis+ID%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","prostate cancer","genitourinary oncology"],"related":[],"cancers":["prostate","rcc","urothelial"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["anzup"],"institutions":[],"pathways":[],"terms":[],"trials":["propsma"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chair","institutionId":"anzup","specialisms":["Genitourinary oncology","Prostate cancer","Clinical trials"],"profiles":[{"label":"Society page","url":"https://anzup.org.au/about-us/board/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Davis+ID%5BAuthor%5D"}],"papers":[{"title":"Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer","journal":"New England Journal of Medicine","year":2019,"doi":"10.1056/nejmoa1903835"},{"title":"TheraP: a randomized phase 2 trial of 177 Lu‐ PSMA ‐617 theranostic treatment vs cabazitaxel in progressive metastatic castration‐resistant prostate cancer (Clinical Trial Protocol ANZUP 1603)","journal":"BJU International","year":2019,"doi":"10.1111/bju.14876"},{"title":"Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial","journal":"The Lancet Oncology","year":2020,"doi":"10.1016/s1470-2045(20)30456-3"}],"orcid":"0000-0002-9066-8244"},{"id":"ian-krop","kind":"person","name":"Ian E. Krop","aka":[],"tldr":"Breast oncologist who took T-DM1 and then trastuzumab deruxtecan from first-in-human studies to approval.","summary":"Ian Krop (Yale Cancer Center) led the early development of trastuzumab emtansine including its phase 1 and TH3RESA trials, and was a lead investigator of the DESTINY-Breast programme that made trastuzumab deruxtecan standard second-line therapy for HER2-positive disease. He chairs the Translational Breast Cancer Research Consortium and leads early-phase ADC trials.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Krop%20IE%5BAuthor%5D%20trastuzumab%20emtansine%20OR%20deruxtecan"}],"tags":["breast","adc","her2"],"related":[],"cancers":["breast-her2-positive"],"sections":[],"technologies":["adc"],"targets":["her2"],"drugs":["trastuzumab-emtansine","trastuzumab-deruxtecan"],"companies":[],"institutions":["yale-cancer-center"],"pathways":[],"terms":[],"trials":["destiny-breast03"],"people":[],"bottlenecks":[],"keyPapers":["paper-destiny-breast03-nejm-2022"],"journals":[],"dependsOn":[],"notes":[],"role":"Associate Cancer Center Director for Clinical Research, Yale Cancer Center","institutionId":"yale-cancer-center","specialisms":["HER2-positive breast cancer","Antibody-drug conjugates","Early drug development"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Krop%20IE%5BAuthor%5D%20trastuzumab%20emtansine%20OR%20deruxtecan"}],"papers":[{"title":"Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA)","journal":"Lancet Oncology","year":2017,"doi":"10.1016/S1470-2045(17)30312-1"},{"title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer (DESTINY-Breast03)","journal":"NEJM","year":2022,"doi":"10.1056/NEJMoa2115022"}],"orcid":"0000-0002-6380-5944"},{"id":"ian-tannock","kind":"person","name":"Ian F. Tannock","aka":[],"tldr":"Led TAX 327, which made docetaxel the first life-extending chemotherapy for prostate cancer, and has spent decades pressing for higher trial standards.","summary":"Ian Tannock was principal investigator of TAX 327, the trial showing docetaxel improves survival in metastatic castration-resistant prostate cancer, the first chemotherapy to do so. He co-authored the textbook The Basic Science of Oncology, helped create the ESMO Magnitude of Clinical Benefit Scale, and has been a leading critic of trials that rely on surrogate endpoints, control-arm deficiencies and inadequate quality-of-life reporting. He is a founder of Common Sense Oncology.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tannock%20IF%5BAuthor%5D%20prostate%20docetaxel%20OR%20clinical%20benefit"}],"tags":["evidence","methodology","prostate"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":["docetaxel"],"companies":[],"institutions":["princess-margaret"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-prasad-surrogate-endpoints-jama-im-2015","paper-drug-dosing-conundrum-nejm-2021"],"journals":[],"dependsOn":[],"notes":[],"role":"Emeritus Professor of Medical Oncology, Princess Margaret Cancer Centre and University of Toronto","institutionId":"princess-margaret","specialisms":["Trial methodology","Prostate cancer","Clinical benefit assessment","Tumour biology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tannock%20IF%5BAuthor%5D%20prostate%20docetaxel%20OR%20clinical%20benefit"}],"papers":[{"title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer (TAX 327)","journal":"NEJM","year":2004,"doi":"10.1056/NEJMoa040720"},{"title":"Relevance of randomised controlled trials in oncology","journal":"Lancet Oncology","year":2016,"doi":"10.1016/S1470-2045(16)30572-1"},{"title":"Prasad: most surrogate endpoints in cancer trials correlate poorly with survival","journal":"JAMA Internal Medicine","year":2015,"url":"https://doi.org/10.1001/jamainternmed.2015.2829","doi":"10.1001/jamainternmed.2015.2829"},{"title":"FDA's Project Optimus manifesto: cancer drugs are approved at doses that are too high","journal":"New England Journal of Medicine","year":2021,"url":"https://doi.org/10.1056/NEJMp2109826","doi":"10.1056/NEJMp2109826"}]},{"id":"ian-frazer","kind":"person","name":"Ian Frazer","aka":[],"tldr":"In 1991 he and Jian Zhou made HPV virus-like particles in the laboratory, the basis of the vaccines that could eliminate cervical cancer. Australia, where the vaccine was rolled out first, is on course to do so.","summary":"Ian Frazer, a Scottish-born clinical immunologist at the University of Queensland, worked with the virologist Jian Zhou from 1990 on how to make a vaccine against a virus that could not be grown in culture. In 1991 they assembled the HPV L1 capsid protein into empty virus-like particles that carried the shape of the virus without its DNA, and patented the approach; parallel work at the US National Cancer Institute by Douglas Lowy and John Schiller, at Georgetown and at Rochester contributed to the vaccines. Gardasil was licensed in 2006 and Cervarix in 2007. Australia introduced school-based vaccination in 2007 and, combined with HPV-based screening, is projected to become the first country to eliminate cervical cancer as a public health problem. Frazer was named Australian of the Year in 2006 and led the Translational Research Institute in Brisbane.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Ian_Frazer","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Ian_Frazer"},{"label":"University of Queensland: the HPV vaccine","url":"https://www.uq.edu.au/"}],"tags":["hero","pioneer"],"related":[],"cancers":["cervical"],"sections":["prevention"],"technologies":["hpv-vaccine"],"targets":[],"drugs":["gardasil-9"],"companies":[],"institutions":["uq-frazer-institute"],"pathways":[],"terms":[],"trials":["ken-she"],"people":["jian-zhou","harald-zur-hausen","douglas-lowy","denise-galloway"],"bottlenecks":["b-prevention-adoption","b-global-access"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Immunologist who, with Jian Zhou, created the technology behind the HPV vaccine","institutionId":"uq-frazer-institute","specialisms":["Immunology","HPV vaccines","Cervical cancer prevention"],"profiles":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Ian_Frazer"},{"label":"University of Queensland: the HPV vaccine","url":"https://www.uq.edu.au/"}],"papers":[{"title":"Prevention of cervical cancer through papillomavirus vaccination","journal":"Nature Reviews Immunology","year":2004,"doi":"10.1038/nri1260"},{"title":"Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX? adjuvant in women with cervical intraepithelial neoplasia","journal":"Vaccine","year":2004,"doi":"10.1016/j.vaccine.2004.05.013"},{"title":"Interferon-γ derived from cytotoxic lymphocytes directly enhances their motility and cytotoxicity","journal":"Cell Death & Disease","year":2017,"doi":"10.1038/cddis.2017.67"}]},{"id":"ida-danmark","kind":"person","name":"Ida Danmark","aka":[],"tldr":"Regional health manager who heads the Centre for Surgery, Orthopaedics and Cancer Care, the Region Östergötland centre that runs cancer services at Linköping University Hospital.","summary":"Ida Danmark is Centrumchef (head of centre) of Centrum för kirurgi, ortopedi och cancervård (CKOC), the Region Östergötland organisational centre responsible for surgery, orthopaedics and cancer care, including the cancer services delivered at Universitetssjukhuset i Linköping. Region Östergötland's health and care leadership group page lists her among the centre heads reporting to care directors Jessica Frisk and Ninnie Borendal Wodlin; the region as a whole is led by regiondirektör Mikael Borin. No appointment date is given on the page.","asOf":"2026-09-10","links":[{"label":"Source: Region Östergötland hälso- och sjukvårdens ledningsgrupp page","url":"https://www.regionostergotland.se/ro/om-region-ostergotland/organisation/halso--och-sjukvardens-ledningsgrupp"}],"tags":["leadership","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["linkoping-university-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Centrumchef, Centrum för kirurgi, ortopedi och cancervård (CKOC), Region Östergötland","institutionId":"linkoping-university-hospital","specialisms":["Cancer care management","Surgical services","Regional health administration"],"profiles":[{"label":"Region Östergötland health and care leadership group","url":"https://www.regionostergotland.se/ro/om-region-ostergotland/organisation/halso--och-sjukvardens-ledningsgrupp"}],"papers":[]},{"id":"ignace-vergote","kind":"person","name":"Ignace Vergote","aka":[],"tldr":"Led the EORTC trial that made neoadjuvant chemotherapy acceptable in ovarian cancer and innovaTV 301, the first ADC survival win in cervical cancer.","summary":"Ignace Vergote was principal investigator of EORTC 55971, which showed neoadjuvant chemotherapy followed by interval surgery is non-inferior to primary surgery in advanced ovarian cancer with less morbidity, and of innovaTV 301, in which tisotumab vedotin improved survival in recurrent cervical cancer. He founded the ENGOT network of European gynaecological trial groups and has led more than 30 phase 3 trials.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Vergote%20I%5BAuthor%5D%20ovarian%20OR%20cervical"}],"tags":["ovarian","cervical","adc","cooperative-group"],"related":[],"cancers":["ovarian","cervical"],"sections":[],"technologies":["adc"],"targets":["tissue-factor"],"drugs":["tisotumab-vedotin"],"companies":[],"institutions":["uz-leuven"],"pathways":[],"terms":[],"trials":["innovatv-301"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Emeritus Professor of Gynaecologic Oncology, University Hospitals Leuven; Chair, BGOG and ENGOT","institutionId":"uz-leuven","specialisms":["Gynaecologic oncology","Neoadjuvant chemotherapy","Antibody-drug conjugates","Cervical cancer"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Vergote%20I%5BAuthor%5D%20ovarian%20OR%20cervical"}],"papers":[{"title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer (EORTC 55971)","journal":"NEJM","year":2010,"doi":"10.1056/NEJMoa0908806"},{"title":"Tisotumab vedotin as second- or third-line therapy for recurrent cervical cancer (innovaTV 301)","journal":"NEJM","year":2024,"doi":"10.1056/NEJMoa2313811"}]},{"id":"ignacio-melero","kind":"person","name":"Ignacio Melero","aka":[],"tldr":"Spanish immunologist who pioneered CD137 agonist antibodies and intratumoural immunotherapy.","summary":"Ignacio Melero showed in 1997 that agonist antibodies to CD137 (4-1BB) eradicate established tumours in mice, founding the field of costimulatory agonist immunotherapy, and has led early-phase trials of CD137 agonists, intratumoural immunostimulants and combination immunotherapy in liver cancer. He co-authored the CheckMate 040 nivolumab studies in hepatocellular carcinoma and leads immunotherapy research at CIMA and Clínica Universidad de Navarra.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Melero%20I%5BAuthor%5D%20immunotherapy%20CD137"}],"tags":["immunotherapy","costimulation","spain"],"related":[],"cancers":["hcc"],"sections":[],"technologies":["checkpoint-inhibitor","cytokine-therapy"],"targets":[],"drugs":["nivolumab"],"companies":[],"institutions":["cun-navarra"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nature-reviews-clinical-oncology"],"dependsOn":[],"notes":[],"role":"Professor of Immunology, Universidad de Navarra; Senior Consultant, Clínica Universidad de Navarra","institutionId":"cun-navarra","specialisms":["Tumour immunology","Intratumoural immunotherapy","Costimulatory agonists (CD137, OX40)","Early-phase immunotherapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Melero%20I%5BAuthor%5D%20immunotherapy%20CD137"}],"papers":[{"title":"Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors","journal":"Nature Medicine","year":1997,"doi":"10.1038/nm0697-682"},{"title":"Intratumoural administration and tumour tissue targeting of cancer immunotherapies","journal":"Nature Reviews Clinical Oncology","year":2021,"doi":"10.1038/s41571-021-00507-y"}]},{"id":"igor-kiss","kind":"person","name":"Igor Kiss","aka":[],"tldr":"Medical oncologist responsible for clinical care at Masaryk Memorial Cancer Institute, with expertise in gastrointestinal oncology.","summary":"Prof. Igor Kiss is Director for Medical Care at the Masaryk Memorial Cancer Institute in Brno. He is a medical oncologist whose clinical and research work concentrates on gastrointestinal malignancies, particularly colorectal and hepatobiliary cancers. He has been active in Czech and European clinical trial networks.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.mou.cz/en/management/t1644"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kiss+I%5BAuthor%5D+Brno"}],"tags":["leadership","clinician-scientist","colorectal cancer","medical oncology"],"related":[],"cancers":["colorectal","hcc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["mou-brno"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["anticancer-research"],"dependsOn":[],"notes":[],"role":"Director for Medical Care","institutionId":"mou-brno","specialisms":["Medical oncology","Gastrointestinal cancers","Colorectal cancer"],"profiles":[{"label":"Institution profile","url":"https://www.mou.cz/en/management/t1644"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kiss+I%5BAuthor%5D+Brno"}],"papers":[{"title":"Efficacy and Toxicity of Panitumumab After Progression on Cetuximab and Predictive Value of MiR-31-5p in Metastatic Wild-type KRAS Colorectal Cancer Patients","journal":"Anticancer Research","year":2016,"doi":"10.21873/anticanres.11063"},{"title":"Second primary malignancies in colorectal cancer patients","journal":"Scientific Reports","year":2021,"doi":"10.1038/s41598-021-82248-7"},{"title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial","journal":"The Lancet","year":2023,"doi":"10.1016/s0140-6736(23)01366-1"}]},{"id":"igor-puzanov","kind":"person","name":"Igor Puzanov","aka":[],"tldr":"Led the first talimogene laherparepvec plus ipilimumab study and co-wrote the immune toxicity management guidelines.","summary":"Igor Puzanov is Director of the Early Phase Clinical Trials Program and Chief of the Melanoma Section at Roswell Park Comprehensive Cancer Center. He is a melanoma oncologist known for leading the first study of the oncolytic virus talimogene laherparepvec combined with ipilimumab, and for co-writing the guidelines on managing immune-related toxicity. His selected paper reports talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB to IV melanoma. He now directs Roswell Park's phase 1 programme and continues to work on oncolytic viruses.","asOf":"2026-09-08","links":[{"label":"Roswell Park profile","url":"https://www.roswellpark.org/igor-puzanov"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Puzanov%20I%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["melanoma"],"sections":[],"technologies":["oncolytic-virus"],"targets":[],"drugs":["talimogene-laherparepvec","ipilimumab"],"companies":[],"institutions":["roswell-park"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Early Phase Clinical Trials Program; Chief, Melanoma Section","institutionId":"roswell-park","specialisms":["Melanoma","Oncolytic viruses","Immune-related toxicity"],"profiles":[{"label":"Roswell Park profile","url":"https://www.roswellpark.org/igor-puzanov"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Puzanov%20I%5BAuthor%5D"}],"papers":[{"title":"Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma","journal":"Journal of Clinical Oncology","year":2016,"url":"https://doi.org/10.1200/JCO.2016.67.1529","doi":"10.1200/JCO.2016.67.1529"}],"orcid":"0000-0002-9803-3497"},{"id":"igor-stojkovski","kind":"person","name":"Igor Stojkovski","aka":[],"tldr":"Igor Stojkovski represents University Clinic for Radiotherapy and Oncology, Skopje in the Organisation of European Cancer Institutes, which lists the centre among its members in North Macedonia.","summary":"Igor Stojkovski is listed by the Organisation of European Cancer Institutes (OECI) as the representative of University Clinic for Radiotherapy and Oncology, Skopje, its member in North Macedonia. University Clinic for Radiotherapy and Oncology, Skopje is North Macedonia's national centre for radiotherapy and medical oncology, on the Skopje clinical campus, and an associate member of the Organisation of European Cancer Institutes. OnCo records the name from the OECI membership list so that the centre's page has a named contact point; the person's exact title, appointment date and biography are not yet recorded and should be checked on the institution's own pages before being relied on.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"University Clinic for Radiotherapy and Oncology, Skopje website","url":"https://www.oncology.org.mk/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["university-clinic-radiotherapy-oncology-skopje"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of University Clinic for Radiotherapy and Oncology, Skopje to the Organisation of European Cancer Institutes","institutionId":"university-clinic-radiotherapy-oncology-skopje","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"University Clinic for Radiotherapy and Oncology, Skopje website","url":"https://www.oncology.org.mk/"}],"papers":[{"title":"Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries","journal":"Eur J Cancer","year":2018,"url":"https://doi.org/10.1016/j.ejca.2018.09.013","doi":"10.1016/j.ejca.2018.09.013","note":"Europe PMC author record matched by affiliation"},{"title":"A review of the international early recommendations for departments organization and cancer management priorities during the global COVID-19 pandemic: applicability in low- and middle-income countries","journal":"Eur J Cancer","year":2020,"url":"https://doi.org/10.1016/j.ejca.2020.05.015","doi":"10.1016/j.ejca.2020.05.015","note":"Europe PMC author record matched by affiliation"},{"title":"Concurrent radiochemotherapy in advanced hypopharyngeal cancer","journal":"Radiat Oncol","year":2010,"url":"https://doi.org/10.1186/1748-717x-5-39","doi":"10.1186/1748-717x-5-39","note":"Europe PMC author record matched by affiliation"}],"orcid":"0000-0002-5770-2578"},{"id":"ilaria-panzini","kind":"person","name":"Ilaria Panzini","aka":[],"tldr":"Ilaria Panzini represents IRCCS Ospedale Policlinico San Martino in the Organisation of European Cancer Institutes, which lists the centre among its members in Italy.","summary":"Ilaria Panzini is listed by the Organisation of European Cancer Institutes (OECI) as the representative of IRCCS Ospedale Policlinico San Martino, its member in Italy. Genoa's university hospital, which absorbed Italy's National Cancer Research Institute (IST) and is an OECI Comprehensive Cancer Centre. OnCo records the name from the OECI membership list so that the centre's page has a named contact point; the person's exact title, appointment date and biography are not yet recorded and should be checked on the institution's own pages before being relied on.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"IRCCS Ospedale Policlinico San Martino website","url":"https://www.ospedalesanmartino.it/it/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["san-martino-genoa"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of IRCCS Ospedale Policlinico San Martino to the Organisation of European Cancer Institutes","institutionId":"san-martino-genoa","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"IRCCS Ospedale Policlinico San Martino website","url":"https://www.ospedalesanmartino.it/it/"}],"papers":[]},{"id":"inge-buyse","kind":"person","name":"Inge Buyse","aka":[],"tldr":"Chief executive who runs AZ Groeninge in Kortrijk, the large Belgian general hospital whose cancer centre serves the south of West Flanders.","summary":"Inge Buyse is CEO of AZ Groeninge, the general hospital in Kortrijk, Belgium, whose cancer centre (kankercentrum) delivers oncology care for the region. The hospital's governance page states that the directiecomité (management committee), which meets weekly, is chaired by CEO Inge Buyse, and describes the board, general services and committees of the hospital. The page did not give an appointment date or biographical detail.","asOf":"2026-09-10","links":[{"label":"Source: AZ Groeninge 'Bestuur - Directie - Comités' page","url":"https://www.azgroeninge.be/nl/patient/bestuur-directie-comites"}],"tags":["leadership","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["az-groeninge-kortrijk"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"CEO (Algemeen Directeur), AZ Groeninge, Kortrijk","institutionId":"az-groeninge-kortrijk","specialisms":["Hospital management","Healthcare governance"],"profiles":[{"label":"AZ Groeninge board, management and committees (Dutch)","url":"https://www.azgroeninge.be/nl/patient/bestuur-directie-comites"}],"papers":[]},{"id":"inge-van-der-sluis","kind":"person","name":"Inge M. van der Sluis","aka":[],"tldr":"Dutch paediatric oncologist who led the study showing that adding one course of blinatumomab to chemotherapy sharply improves survival for babies with KMT2A-rearranged leukaemia.","summary":"Inge van der Sluis is a paediatric oncologist at the Princess Máxima Center in Utrecht. She was first author of the 2023 New England Journal of Medicine report of the Interfant pilot study in which a single 28-day course of the bispecific antibody blinatumomab added to Interfant-06 chemotherapy gave two-year disease-free survival of over 80 percent in infants with KMT2A-rearranged acute lymphoblastic leukaemia, far higher than historical controls. She also studies asparaginase pharmacology.","asOf":"2026-09-18","links":[],"tags":["paediatric","leukaemia","immunotherapy","trialist"],"related":[],"cancers":["all-infant","all-leukemia","childhood-cancers"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["princess-maxima"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-blinatumomab-infant-all-van-der-sluis-nejm-2023"],"journals":[],"dependsOn":[],"notes":[],"role":"Paediatric oncologist, Princess Máxima Center for Pediatric Oncology","institutionId":"princess-maxima","specialisms":["Infant leukaemia","Immunotherapy in paediatric leukaemia","Asparaginase"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sluis%5BAuthor%5D"}],"papers":[{"title":"Blinatumomab added to chemotherapy in infant KMT2A-rearranged acute lymphoblastic leukaemia","journal":"New England Journal of Medicine","year":2023,"url":"https://doi.org/10.1056/NEJMoa2214171","doi":"10.1056/NEJMoa2214171"}],"orcid":"0000-0002-5822-7668"},{"id":"inge-marie-svane","kind":"person","name":"Inge Marie Svane","aka":[],"tldr":"Led the Dutch-Danish trial that proved TIL therapy beats ipilimumab in melanoma, the first randomised win for a cell therapy in a solid tumour.","summary":"Inge Marie Svane (Herlev, Denmark) co-led with John Haanen the randomised phase 3 trial showing tumour-infiltrating lymphocyte therapy doubles progression-free survival compared with ipilimumab in advanced melanoma, the first randomised evidence for any cell therapy in a solid tumour. She built Denmark's academic TIL manufacturing programme and leads trials of TIL in other cancers and of peptide vaccines targeting IDO and PD-L1.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Svane%20IM%5BAuthor%5D%20tumor-infiltrating%20lymphocytes%20melanoma"}],"tags":["cell-therapy","til","melanoma"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":["til-therapy"],"targets":[],"drugs":["lifileucel","ipilimumab"],"companies":[],"institutions":["herlev-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-rohaas-til-vs-ipilimumab-nejm-2022"],"journals":[],"dependsOn":[],"notes":[],"role":"Director, National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital Herlev","institutionId":"herlev-hospital","specialisms":["Tumour-infiltrating lymphocyte therapy","Melanoma immunotherapy","Cancer vaccines","Cell therapy manufacturing"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Svane%20IM%5BAuthor%5D%20tumor-infiltrating%20lymphocytes%20melanoma"}],"papers":[{"title":"Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma","journal":"NEJM","year":2022,"doi":"10.1056/NEJMoa2210233"},{"title":"Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated IL2 regimen","journal":"Clinical Cancer Research","year":2016,"doi":"10.1158/1078-0432.CCR-15-1879"}],"orcid":"0000-0002-9451-6037"},{"id":"ingo-mellinghoff","kind":"person","name":"Ingo K. Mellinghoff","aka":[],"tldr":"Led INDIGO, the trial that made vorasidenib the first targeted therapy for low-grade IDH-mutant glioma.","summary":"Ingo Mellinghoff was principal investigator of INDIGO, which showed the dual IDH1/2 inhibitor vorasidenib more than doubles progression-free survival and delays the need for chemoradiotherapy in grade 2 IDH-mutant glioma, the first targeted drug approved for glioma and a shift away from early radiation for young patients. His laboratory studies signalling and metabolism in glioma and he leads neuro-oncology drug development at MSKCC.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mellinghoff%20IK%5BAuthor%5D%20glioma%20vorasidenib"}],"tags":["glioma","idh","targeted-therapy"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":["idh"],"drugs":["vorasidenib"],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":["indigo"],"people":[],"bottlenecks":[],"keyPapers":["paper-indigo-nejm-2023"],"journals":[],"dependsOn":[],"notes":[],"role":"Chair, Department of Neurology, Memorial Sloan Kettering Cancer Center","institutionId":"mskcc","specialisms":["Glioma","IDH-mutant tumours","Targeted therapy","Neuro-oncology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mellinghoff%20IK%5BAuthor%5D%20glioma%20vorasidenib"}],"papers":[{"title":"Vorasidenib in IDH1- or IDH2-mutant low-grade glioma (INDIGO)","journal":"NEJM","year":2023,"doi":"10.1056/NEJMoa2304194"},{"title":"Vorasidenib, a dual inhibitor of mutant IDH1/2, in recurrent or progressive glioma; results of a first-in-human phase I trial","journal":"Clinical Cancer Research","year":2021,"doi":"10.1158/1078-0432.CCR-20-4164"}],"orcid":"0000-0002-4347-8149"},{"id":"irving-weissman","kind":"person","name":"Irving L. Weissman","aka":[],"tldr":"Isolated the first blood stem cells and discovered the 'don't eat me' signal CD47 on cancer cells.","summary":"Irving Weissman is Virginia and D.K. Ludwig Professor and Founding Director of the Stanford Institute for Stem Cell Biology and Regenerative Medicine, within the Stanford Cancer Institute. A stem cell biologist, he first purified haematopoietic stem cells, defined leukaemia stem cells and identified CD47 as a macrophage checkpoint, the don't eat me signal on cancer cells, leading to magrolimab and the innate checkpoint field. His papers include the Cell report that CD47 is upregulated on circulating haematopoietic stem cells and leukaemia cells to avoid phagocytosis and a PNAS study of the CD47-SIRPa interaction as a therapeutic target in solid tumours. His work bears on acute myeloid leukaemia and diffuse large B-cell lymphoma.","asOf":"2026-09-08","links":[{"label":"Stanford profile","url":"https://profiles.stanford.edu/search?q=Irving%20L.%20Weissman"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Weissman%20IL%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Irving%20L.%20Weissman"}],"tags":[],"related":[],"cancers":["aml","dlbcl"],"sections":[],"technologies":[],"targets":["cd47"],"drugs":["magrolimab"],"companies":[],"institutions":["stanford"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Virginia and D.K. Ludwig Professor; Founding Director, Stanford Institute for Stem Cell Biology and Regenerative Medicine","institutionId":"stanford","specialisms":["Stem cell biology","Cancer stem cells","Innate immune checkpoints"],"profiles":[{"label":"Stanford profile","url":"https://profiles.stanford.edu/search?q=Irving%20L.%20Weissman"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Weissman%20IL%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Irving%20L.%20Weissman"}],"papers":[{"title":"CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis","journal":"Cell","year":2009,"url":"https://doi.org/10.1016/j.cell.2009.05.046","doi":"10.1016/j.cell.2009.05.046"},{"title":"The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors","journal":"Proceedings of the National Academy of Sciences of the United States of America","year":2012,"url":"https://doi.org/10.1073/pnas.1121623109","doi":"10.1073/pnas.1121623109"},{"title":"Reya 2001: stem cells, cancer and cancer stem cells","journal":"Nature","year":2001,"url":"https://doi.org/10.1038/35102167","doi":"10.1038/35102167"}],"orcid":"0000-0002-9077-7467"},{"id":"isabel-rubio","kind":"person","name":"Isabel T. Rubio","aka":[],"tldr":"Breast surgeon and ESSO Past-President who heads breast surgical oncology at Clínica Universidad de Navarra in Madrid.","summary":"Isabel-Teresa Rubio is Past-President of ESSO and Head of Breast Surgical Oncology at Clínica Universidad de Navarra, Madrid. Her work focuses on axillary management, de-escalation of breast surgery and oncoplastic techniques, and she has led European efforts to define breast surgical oncology training and certification.","asOf":"2026-09-10","links":[{"label":"Society page","url":"https://www.essoweb.org/about/governance/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rubio+IT%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","breast cancer","surgical oncology"],"related":[],"cancers":["breast-hr-positive","breast-her2-positive","tnbc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["esso"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["annals-of-surgical-oncology","european-journal-of-surgical-oncology"],"dependsOn":[],"notes":[],"role":"Past-President","institutionId":"esso","specialisms":["Breast surgical oncology","Breast cancer","Oncoplastic surgery"],"profiles":[{"label":"Society page","url":"https://www.essoweb.org/about/governance/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rubio+IT%5BAuthor%5D"}],"papers":[{"title":"European guidelines for the diagnosis, treatment and follow-up of breast lesions with uncertain malignant potential (B3 lesions) developed jointly by EUSOMA, EUSOBI, ESP (BWG) and ESSO","journal":"European Journal of Surgical Oncology","year":2024,"doi":"10.1016/j.ejso.2023.107292"},{"title":"Variability in breast cancer surgery training across Europe: An ESSO-EUSOMA international survey","journal":"European Journal of Surgical Oncology","year":2019,"doi":"10.1016/j.ejso.2019.01.003"},{"title":"Global Forum of Cancer Surgeons: Cancer Surgery During the COVID-19 Pandemic: Impact and Lessons Learned","journal":"Annals of Surgical Oncology","year":2022,"doi":"10.1245/s10434-022-11506-3"}]},{"id":"isabelle-ray-coquard","kind":"person","name":"Isabelle Ray-Coquard","aka":[],"tldr":"Led PAOLA-1, which showed olaparib plus bevacizumab helps women with HRD-positive ovarian cancer beyond BRCA carriers.","summary":"Isabelle Ray-Coquard was principal investigator of PAOLA-1, the ENGOT/GINECO trial showing maintenance olaparib added to bevacizumab improves progression-free and overall survival in first-line advanced ovarian cancer with homologous recombination deficiency, which made HRD testing a standard part of ovarian cancer care. She leads the French GINECO group and international networks for rare gynaecological cancers.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ray-Coquard%20I%5BAuthor%5D%20ovarian%20PAOLA"}],"tags":["ovarian","parp","hrd"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":["parp-inhibitor","hrd-testing","antiangiogenic"],"targets":["parp","brca","vegf"],"drugs":["olaparib"],"companies":["arcagy-gineco"],"institutions":["centre-leon-berard"],"pathways":[],"terms":[],"trials":["paola-1"],"people":[],"bottlenecks":[],"keyPapers":["paper-paola-1-nejm-2019"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology, Centre Léon Bérard and Université Claude Bernard Lyon 1; President, GINECO","institutionId":"centre-leon-berard","specialisms":["Ovarian cancer","Rare gynaecological tumours","PARP inhibitor combinations","Sarcoma"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ray-Coquard%20I%5BAuthor%5D%20ovarian%20PAOLA"}],"papers":[{"title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer (PAOLA-1)","journal":"NEJM","year":2019,"doi":"10.1056/NEJMoa1911361"},{"title":"Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial","journal":"Annals of Oncology","year":2023,"doi":"10.1016/j.annonc.2023.05.005"}]},{"id":"ivan-s-stilidi","kind":"person","name":"Ivan S. Stilidi","aka":[],"tldr":"Ivan S. Stilidi represents N. N. Blokhin National Medical Research Center of Oncology in the Organisation of European Cancer Institutes, which lists the centre among its associate members in the Russian Federation.","summary":"Ivan S. Stilidi is listed by the Organisation of European Cancer Institutes (OECI) as the representative of N. N. Blokhin National Medical Research Center of Oncology, its associate member in the Russian Federation. OnCo records the name from the OECI membership list so that the centre's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the institution's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"N. N. Blokhin National Medical Research Center of Oncology website","url":"https://www.ronc.ru"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["blokhin-cancer-center"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of N. N. Blokhin National Medical Research Center of Oncology to the Organisation of European Cancer Institutes","institutionId":"blokhin-cancer-center","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"N. N. Blokhin National Medical Research Center of Oncology website","url":"https://www.ronc.ru"}],"papers":[{"title":"Thyroid cancer overdiagnosis revisited","journal":"Cancer Epidemiol","year":2021,"url":"https://doi.org/10.1016/j.canep.2021.102014","doi":"10.1016/j.canep.2021.102014","note":"Europe PMC author record matched by affiliation"},{"title":"Oncobox Bioinformatical Platform for Selecting Potentially Effective Combinations of Target Cancer Drugs Using High-Throughput Gene Expression Data","journal":"Cancers (Basel)","year":2018,"url":"https://doi.org/10.3390/cancers10100365","doi":"10.3390/cancers10100365","note":"Europe PMC author record matched by affiliation"},{"title":"The Features of Immune Checkpoint Gene Regulation by microRNA in Cancer","journal":"Int J Mol Sci","year":2022,"url":"https://doi.org/10.3390/ijms23169324","doi":"10.3390/ijms23169324","note":"Europe PMC author record matched by affiliation"}]},{"id":"iwona-lugowska","kind":"person","name":"Iwona Ługowska","aka":[],"tldr":"Polish medical oncologist and sarcoma specialist who serves as President of the Organisation of European Cancer Institutes.","summary":"Iwona Ługowska is President of the Organisation of European Cancer Institutes (OECI), the network that runs the European accreditation and designation programme for cancer centres. She is a medical oncologist based in Poland whose clinical and research work focuses on soft-tissue sarcoma and early-phase drug development. In the OECI role she leads the board that sets the organisation's quality and collaboration agenda across European cancer institutes.","asOf":"2026-09-10","links":[{"label":"Society page","url":"https://www.oeci.eu/Governance.aspx"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lugowska+I%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","sarcoma","cancer centre accreditation"],"related":[],"cancers":["sarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President","institutionId":"oeci","specialisms":["Sarcoma","Early-phase clinical trials","Cancer centre accreditation"],"profiles":[{"label":"Society page","url":"https://www.oeci.eu/Governance.aspx"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lugowska+I%5BAuthor%5D"}],"papers":[{"title":"A prognostic evaluation of vascular endothelial growth factor in children and young adults with osteosarcoma","journal":"Pediatric Blood & Cancer","year":2011,"doi":"10.1002/pbc.23021"},{"title":"Follow-up in soft tissue sarcomas","journal":"memo - Magazine of European Medical Oncology","year":2014,"doi":"10.1007/s12254-014-0146-8"},{"title":"Follow-up in melanoma patients","journal":"memo - Magazine of European Medical Oncology","year":2014,"doi":"10.1007/s12254-014-0151-y"}]},{"id":"iwona-maroszynska","kind":"person","name":"Iwona Maroszyńska","aka":[],"tldr":"Iwona Maroszyńska represents Polish Mother's Memorial Hospital Research Institute in the Organisation of European Cancer Institutes, which lists the centre among its members in Poland.","summary":"Iwona Maroszyńska is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Polish Mother's Memorial Hospital Research Institute, its member in Poland. The Polish Mother's Memorial Hospital Research Institute in Łódź is a national research hospital for women's and children's health, including gynaecological and paediatric cancers, and a full member of the Organisation of European Cancer Institutes. OnCo records the name from the OECI membership list so that the centre's page has a named contact point; the person's exact title, appointment date and biography are not yet recorded and should be checked on the institution's own pages before being relied on.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Polish Mother's Memorial Hospital Research Institute website","url":"https://www.iczmp.edu.pl/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["polish-mothers-memorial-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Polish Mother's Memorial Hospital Research Institute to the Organisation of European Cancer Institutes","institutionId":"polish-mothers-memorial-hospital","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Polish Mother's Memorial Hospital Research Institute website","url":"https://www.iczmp.edu.pl/"}],"papers":[{"title":"Newborn Infant Parasympathetic Evaluation Index for the Assessment of Procedural Pain in Nonanesthetized Infants: A Multicenter Pilot Study","journal":"American Journal of Perinatology","year":2020,"url":"https://doi.org/10.1055/s-0040-1709458","doi":"10.1055/s-0040-1709458","note":"OpenAlex author record matched by institution"},{"title":"Procedural Pain Assessment in Infants Without Analgosedation: Comparison of Newborn Infant Parasympathetic Evaluation and Skin Conductance Activity - A Pilot Study","journal":"Frontiers in Pediatrics","year":2022,"url":"https://doi.org/10.3389/fped.2021.746504","doi":"10.3389/fped.2021.746504","note":"OpenAlex author record matched by institution"}]},{"id":"jan-van-lanschot","kind":"person","name":"J. Jan B. van Lanschot","aka":[],"tldr":"Surgeon who led the CROSS trial, which made chemoradiotherapy before surgery the standard for oesophageal cancer.","summary":"Jan van Lanschot led the Dutch CROSS trial showing neoadjuvant carboplatin, paclitaxel and radiotherapy followed by surgery nearly doubles median survival compared with surgery alone in oesophageal and junctional cancer, a regimen adopted worldwide. He then led the SANO trial of active surveillance after complete clinical response, opening organ preservation in oesophageal cancer.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=van%20Lanschot%20JJB%5BAuthor%5D%20esophageal%20CROSS"}],"tags":["esophageal","surgery","chemoradiotherapy"],"related":[],"cancers":["esophageal"],"sections":[],"technologies":[],"targets":[],"drugs":["carboplatin","paclitaxel"],"companies":[],"institutions":["erasmus-mc"],"pathways":[],"terms":[],"trials":["cross","sano"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Emeritus Professor of Surgery, Erasmus MC","institutionId":"erasmus-mc","specialisms":["Oesophageal surgery","Neoadjuvant chemoradiotherapy","Organ preservation"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=van%20Lanschot%20JJB%5BAuthor%5D%20esophageal%20CROSS"}],"papers":[{"title":"Preoperative chemoradiotherapy for esophageal or junctional cancer (CROSS)","journal":"NEJM","year":2012,"doi":"10.1056/NEJMoa1112088"},{"title":"Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial","journal":"Lancet Oncology","year":2015,"doi":"10.1016/S1470-2045(15)00040-6"}]},{"id":"j-silvio-gutkind","kind":"person","name":"J. Silvio Gutkind","aka":[],"tldr":"Cancer pharmacologist at UC San Diego known for work on G-protein signalling and mTOR-targeted therapy in head and neck cancer.","summary":"J. Silvio Gutkind, PhD, is Associate Director for Basic Science at UC San Diego Moores Cancer Center and Chair of the Department of Pharmacology. His laboratory studies G-protein-coupled receptor and PI3K/mTOR signalling in cancer, translating these findings into clinical trials of mTOR inhibitors and immunotherapy combinations in head and neck squamous cell carcinoma.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://moorescancercenter.ucsd.edu/about/leadership/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gutkind+JS%5BAuthor%5D"}],"tags":["clinician-scientist","head and neck cancer","signalling"],"related":[],"cancers":["head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ucsd-moores"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["oncogene-journal"],"dependsOn":[],"notes":[],"role":"Associate Director, Basic Science; Professor and Chair, Department of Pharmacology","institutionId":"ucsd-moores","specialisms":["Head and neck cancer","Signal transduction","Cancer pharmacology"],"profiles":[{"label":"Institution profile","url":"https://moorescancercenter.ucsd.edu/about/leadership/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gutkind+JS%5BAuthor%5D"}],"papers":[{"title":"Inactivating mutations in GNA13 and RHOA in Burkitt’s lymphoma and diffuse large B-cell lymphoma: a tumor suppressor function for the Gα13/RhoA axis in B cells","journal":"Oncogene","year":2015,"doi":"10.1038/onc.2015.442"},{"title":"Monomethyl auristatin antibody and peptide drug conjugates for trimodal cancer chemo-radio-immunotherapy","journal":"Nature Communications","year":2022,"doi":"10.1038/s41467-022-31601-z"},{"title":"Redirecting extracellular proteases to molecularly guide radiosensitizing drugs to tumors","journal":"Biomaterials","year":2020,"doi":"10.1016/j.biomaterials.2020.120032"}]},{"id":"jacinta-abraham","kind":"person","name":"Jacinta Abraham","aka":[],"tldr":"Jacinta Abraham represents Velindre Cancer Centre in the Organisation of European Cancer Institutes, which lists the centre among its members in United Kingdom.","summary":"Jacinta Abraham is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Velindre Cancer Centre, its associate member in United Kingdom. OnCo records the name from the OECI membership list so that the centre's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the institution's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Velindre Cancer Centre website","url":"https://velindre.nhs.wales"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["velindre-cardiff"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Velindre Cancer Centre to the Organisation of European Cancer Institutes","institutionId":"velindre-cardiff","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Velindre Cancer Centre website","url":"https://velindre.nhs.wales"}],"papers":[{"title":"Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial","journal":"Nat Med","year":2018,"url":"https://doi.org/10.1038/s41591-018-0009-7","doi":"10.1038/s41591-018-0009-7","note":"Europe PMC author record matched by affiliation"},{"title":"Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial","journal":"J Clin Oncol","year":2020,"url":"https://doi.org/10.1200/jco.19.00368","doi":"10.1200/jco.19.00368","note":"Europe PMC author record matched by affiliation"}]},{"id":"jacinta-reddan","kind":"person","name":"Jacinta Reddan","aka":[],"tldr":"Chief executive of Cancer Council Australia, the national body of Australia's state and territory cancer councils, which leads cancer control advocacy and research funding.","summary":"Jacinta Reddan is Chief Executive Officer of Cancer Council Australia, the national organisation that brings together the state and territory Cancer Councils. She brings leadership experience across financial services, defence, tourism, public health and infrastructure in Australia and the Asia-Pacific region, and previously held an advocacy leadership role covering Far North Queensland. She holds a degree in international relations and anthropology from Deakin University, a public health qualification from HarvardX, and is a Graduate of the Australian Institute of Company Directors.","asOf":"2026-09-10","links":[{"label":"Source: Cancer Council Australia CEO page","url":"https://www.cancer.org.au/about-us/about-cancer-council/australia/ceo"}],"tags":["leadership","charity","advocacy"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cancer-council-australia"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive Officer, Cancer Council Australia","institutionId":"cancer-council-australia","specialisms":["Non-profit leadership","Public health advocacy","Stakeholder engagement"],"profiles":[{"label":"Institution profile","url":"https://www.cancer.org.au/about-us/about-cancer-council/australia/ceo"}],"papers":[]},{"id":"jack-cuzick","kind":"person","name":"Jack Cuzick","aka":[],"tldr":"Epidemiologist who led IBIS-I and IBIS-II, proving tamoxifen and anastrozole prevent breast cancer in high-risk women.","summary":"Jack Cuzick led the IBIS-I trial (tamoxifen) and IBIS-II (anastrozole) that established chemoprevention of breast cancer in high-risk women, and was the lead statistician of the ATAC trial that made aromatase inhibitors standard adjuvant therapy. He developed the Tyrer-Cuzick risk model and has led HPV-testing studies in cervical screening. His work continues on prevention and risk-based screening.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cuzick%20J%5BAuthor%5D%20breast%20prevention"}],"tags":["prevention","epidemiology","breast"],"related":[],"cancers":["breast-hr-positive","cervical"],"sections":[],"technologies":["chemoprevention","endocrine-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":["barts-cancer-institute"],"pathways":[],"terms":[],"trials":["ibis-i","ibis-ii"],"people":[],"bottlenecks":[],"keyPapers":["paper-ibis-i-tamoxifen-lancet-oncol-2015"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Epidemiology, Wolfson Institute of Population Health, Queen Mary University of London","institutionId":"barts-cancer-institute","specialisms":["Breast cancer prevention","Screening epidemiology","Aromatase inhibitors","Risk prediction"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cuzick%20J%5BAuthor%5D%20breast%20prevention"}],"papers":[{"title":"Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial","journal":"Lancet Oncology","year":2015,"doi":"10.1016/S1470-2045(14)71171-4"},{"title":"Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial","journal":"Lancet","year":2020,"doi":"10.1016/S0140-6736(19)32955-1"}]},{"id":"jackson-orem","kind":"person","name":"Jackson Orem","aka":[],"tldr":"Medical oncologist who has led the Uganda Cancer Institute in Kampala, East Africa's principal cancer research and treatment centre.","summary":"Dr. Jackson Orem is Director of the Uganda Cancer Institute (UCI) in Kampala, Uganda's national cancer centre and a regional centre of excellence for East Africa. His research, much of it through the UCI-Fred Hutchinson Cancer Center collaboration, has focused on infection-associated malignancies such as Burkitt lymphoma and Kaposi sarcoma in sub-Saharan Africa. He has been a prominent voice on cancer care capacity in low- and middle-income countries.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Jackson_Orem","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Orem+J%5BAuthor%5D+Uganda"}],"tags":["leadership","clinician-scientist","global oncology","lymphoma"],"related":[],"cancers":["kaposi-sarcoma","dlbcl"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["uganda-cancer-institute"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director","institutionId":"uganda-cancer-institute","specialisms":["Medical oncology","Infection-related cancers","Burkitt lymphoma"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Orem+J%5BAuthor%5D+Uganda"}],"papers":[{"title":"Clinical characteristics and outcome of children with Burkitt lymphoma in Uganda according to HIV infection","journal":"Pediatric Blood & Cancer","year":2009,"doi":"10.1002/pbc.21769"},{"title":"Burkitt lymphoma in UGANDA, the legacy of Denis Burkitt and an update on the disease status","journal":"British Journal of Haematology","year":2012,"doi":"10.1111/j.1365-2141.2012.09027.x"},{"title":"Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma","journal":"Blood","year":2019,"doi":"10.1182/blood-2018-09-871418"}]},{"id":"jacob-schachter","kind":"person","name":"Jacob Schachter","aka":[],"tldr":"Built the melanoma and immunotherapy institute at Sheba that has been growing patients' own tumour-infiltrating lymphocytes and giving them back since 2006, more than a decade before any regulator approved the idea.","summary":"Jacob Schachter directs the Ella Lemelbaum Institute for Immuno-Oncology and Melanoma at Sheba Medical Center, one of very few centres outside the United States to run a tumour-infiltrating lymphocyte programme at scale and for long enough to report durable outcomes. The institute's intent-to-treat analysis, published in Clinical Cancer Research with Michal Besser as first author, enrolled 80 patients with stage IV melanoma and treated 57 with unselected or \"young\" TIL and high-dose interleukin-2 after non-myeloablative lymphodepletion. The overall response rate was 29 percent for all enrolled patients and 40 percent for those treated, with five complete and 18 partial remissions; all complete responders remained in unmaintained remission at a median 28 months and three-year survival among responders was 78 percent. Twenty-three patients could not be treated, mostly because they deteriorated while the cells were being grown, which is the honest cost of a three-week manufacturing step. Schachter has also been an investigator on the pivotal pembrolizumab melanoma trials.","asOf":"2026-09-25","links":[{"label":"Ella Lemelbaum Institute, Sheba Medical Center","url":"https://www.shebaonline.org/departments/cancer-center/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schachter%20J%5BAuthor%5D%20melanoma%20Sheba"}],"tags":["clinician-scientist","immunotherapy"],"related":[],"cancers":["melanoma"],"sections":["cell-therapy","immunotherapy"],"technologies":["til-therapy","checkpoint-inhibitor"],"targets":[],"drugs":["pembrolizumab"],"companies":[],"institutions":["sheba","tel-aviv-university"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-manufacturing-cell-therapy"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Ella Lemelbaum Institute for Immuno-Oncology and Melanoma, Sheba Medical Center","institutionId":"sheba","specialisms":["Melanoma","Immunotherapy","Adoptive cell therapy","Clinical trials"],"profiles":[{"label":"Ella Lemelbaum Institute, Sheba Medical Center","url":"https://www.shebaonline.org/departments/cancer-center/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schachter%20J%5BAuthor%5D%20melanoma%20Sheba"}],"papers":[{"title":"Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies","journal":"Clinical Cancer Research","year":2013,"doi":"10.1158/1078-0432.ccr-13-0380"},{"title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results","journal":"The Lancet","year":2017,"doi":"10.1016/S0140-6736(17)31601-X"}]},{"id":"jacques-grill","kind":"person","name":"Jacques Grill","aka":[],"tldr":"Paris paediatric neuro-oncologist who led HERBY, the trial that showed adding bevacizumab does not help children with high-grade glioma, and who leads European trials in diffuse midline glioma.","summary":"Jacques Grill leads paediatric neuro-oncology at Gustave Roussy and the BIOMEDE programme of biology-driven trials for diffuse intrinsic pontine glioma. He was first author of the 2018 Journal of Clinical Oncology report of HERBY, the randomised trial in which bevacizumab added to radiotherapy and temozolomide did not improve event-free survival in children with newly diagnosed non-brainstem high-grade glioma. He chairs the SIOP Europe high-grade glioma group.","asOf":"2026-09-18","links":[],"tags":["paediatric","brain","trialist"],"related":[],"cancers":["paediatric-high-grade-glioma","glioblastoma","childhood-cancers"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["gustave-roussy"],"pathways":[],"terms":[],"trials":["herby"],"people":[],"bottlenecks":[],"keyPapers":["paper-mackay-paediatric-hgg-cancer-cell-2017","paper-jacques-grill-cell-2016","paper-jacques-grill-acta-neuropathol-2015"],"journals":[],"dependsOn":[],"notes":[],"role":"Paediatric neuro-oncologist, Gustave Roussy","institutionId":"gustave-roussy","specialisms":["Paediatric high-grade glioma","Diffuse midline glioma","Paediatric brain tumour trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Grill%5BAuthor%5D"}],"papers":[{"title":"Integrated molecular meta-analysis of 1,000 paediatric high-grade and diffuse intrinsic pontine gliomas","journal":"Cancer Cell","year":2017,"url":"https://doi.org/10.1016/j.ccell.2017.08.017","doi":"10.1016/j.ccell.2017.08.017","note":"Europe PMC author record matched by affiliation (Gustave Roussy); 974 citations on Europe PMC."},{"title":"New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs","journal":"Cell","year":2016,"url":"https://doi.org/10.1016/j.cell.2016.01.015","doi":"10.1016/j.cell.2016.01.015","note":"Europe PMC author record matched by affiliation (Gustave Roussy); 730 citations on Europe PMC."},{"title":"Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes","journal":"Acta neuropathologica","year":2015,"url":"https://doi.org/10.1007/s00401-015-1478-0","doi":"10.1007/s00401-015-1478-0","note":"Europe PMC author record matched by affiliation (Gustave Roussy); 477 citations on Europe PMC."}],"orcid":"0000-0003-4773-3001"},{"id":"jade-goody","kind":"person","name":"Jade Goody","aka":[],"tldr":"A reality-television star whose cervical cancer and death at 27 in 2009 were followed by hundreds of thousands of extra cervical screening tests in England: the \"Jade Goody effect\".","summary":"Jade Goody (1981-2009) rose to fame on Big Brother in 2002. In August 2008 she learned she had cervical cancer while appearing on the Indian version of the show. She chose to live the last months of her life in public, including her wedding, and died on 22 March 2009, Mother's Day, at 27. Cervical screening attendance in England, which had been falling for a decade, rose sharply in 2008-09; NHS analyses attributed several hundred thousand additional tests to her case, with the largest rise among women in their twenties. The effect faded within a few years, a lesson often cited in screening policy about the difference between awareness and durable uptake.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Jade_Goody","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Jade_Goody"},{"label":"Jo's Cervical Cancer Trust","url":"https://www.jostrust.org.uk/"}],"tags":["public-figure","patient"],"related":[],"cancers":["cervical"],"sections":[],"technologies":["hpv-testing","colposcopy-excision","hpv-vaccine"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["cin-hsil"],"trials":[],"people":[],"bottlenecks":["b-prevention-adoption","b-early-detection"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Patient whose public illness lifted cervical screening attendance in Britain","specialisms":["Cervical cancer","Cervical screening","Public awareness"],"profiles":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Jade_Goody"},{"label":"Jo's Cervical Cancer Trust","url":"https://www.jostrust.org.uk/"}],"papers":[]},{"id":"jae-park","kind":"person","name":"Jae H. Park","aka":[],"tldr":"Ran the long-term CD19 CAR-T studies in adult leukaemia that showed durable remissions and defined toxicity risk.","summary":"Jae H. Park is Director of the Cellular Therapy Service at Memorial Sloan Kettering Cancer Center. He is known for running the long-term CD19 CAR-T studies in adult acute lymphoblastic leukaemia that showed durable remissions and defined toxicity risk, leading MSK's 19-28z CAR-T trials. That work showed that low disease burden at infusion predicts durable remission and lower toxicity. His selected paper reports long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukaemia, and he now directs cellular immunotherapy at MSK.","asOf":"2026-09-08","links":[{"label":"MSK profile","url":"https://www.mskcc.org/cancer-care/doctors/jae-park"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Park%20JH%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["all-leukemia"],"sections":[],"technologies":["car-t"],"targets":["cd19"],"drugs":[],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Cellular Therapy Service","institutionId":"mskcc","specialisms":["CAR-T therapy","Acute lymphoblastic leukaemia","Cellular immunotherapy"],"profiles":[{"label":"MSK profile","url":"https://www.mskcc.org/cancer-care/doctors/jae-park"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Park%20JH%5BAuthor%5D"}],"papers":[{"title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","journal":"New England Journal of Medicine","year":2018,"url":"https://doi.org/10.1056/NEJMoa1709919","doi":"10.1056/NEJMoa1709919"}]},{"id":"lee-jae-lyun","kind":"person","name":"Jae Lyun Lee","aka":[],"tldr":"Jae Lyun Lee is a genitourinary oncologist who brought Korean cohorts into the enfortumab, pembrolizumab, and PARP-inhibitor GU trials.","summary":"Jae Lyun Lee is Professor of Medical Oncology at Asan Medical Center in Seoul, where he runs genitourinary medical oncology. He brought Korean cohorts into the enfortumab vedotin, pembrolizumab and PARP-inhibitor trials in genitourinary cancers, with investigator roles in EV-302 in untreated advanced urothelial cancer and KEYNOTE-426 in renal cell carcinoma, as well as prostate PARP-inhibitor trials. His publications include the EV-302 report on enfortumab vedotin and pembrolizumab in urothelial cancer. He also studies the Asian pharmacogenomics of androgen receptor pathway inhibitors, with interests spanning prostate, kidney and urothelial cancer and immunotherapy.","asOf":"2026-09-08","links":[{"label":"Asan Medical Center","url":"https://eng.amc.seoul.kr"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lee%20JL%5BAuthor%5D%20Asan%20urothelial"}],"tags":[],"related":[],"cancers":["urothelial","prostate","rcc"],"sections":[],"technologies":[],"targets":[],"drugs":["enfortumab-vedotin","pembrolizumab"],"companies":[],"institutions":["asan-medical-center"],"pathways":[],"terms":[],"trials":["ev-302","keynote-426"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology; genitourinary cancers","institutionId":"asan-medical-center","specialisms":["Prostate cancer","Renal cell carcinoma","Urothelial cancer","Immunotherapy"],"profiles":[{"label":"Asan Medical Center","url":"https://eng.amc.seoul.kr"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lee%20JL%5BAuthor%5D%20Asan%20urothelial"}],"papers":[{"title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer (EV-302)","journal":"NEJM","year":2024,"doi":"10.1056/NEJMoa2312117"},{"title":"KEYNOTE-564: a year of pembrolizumab after kidney cancer surgery","journal":"New England Journal of Medicine","year":2021,"url":"https://doi.org/10.1056/NEJMoa2106391","doi":"10.1056/NEJMoa2106391"}]},{"id":"jaffer-ajani","kind":"person","name":"Jaffer A. Ajani","aka":[],"tldr":"Gastro-oesophageal oncologist who co-led CheckMate 649, the trial that added nivolumab to first-line gastric cancer chemotherapy.","summary":"Jaffer Ajani was a lead investigator of CheckMate 649, which showed nivolumab plus chemotherapy improves survival in first-line advanced gastric, gastro-oesophageal junction and oesophageal adenocarcinoma, and of CheckMate 648 in oesophageal squamous cancer. He chaired the NCCN gastric and oesophageal guideline panels for many years and studies the biology of peritoneal metastasis.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ajani%20JA%5BAuthor%5D%20gastric%20nivolumab"}],"tags":["gastric","esophageal","immunotherapy"],"related":[],"cancers":["gastric","esophageal"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["pd1"],"drugs":["nivolumab"],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":["checkmate-649","checkmate-648"],"people":[],"bottlenecks":[],"keyPapers":["paper-checkmate-649-lancet-2021"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Gastrointestinal Medical Oncology, MD Anderson Cancer Center","institutionId":"md-anderson","specialisms":["Gastric cancer","Oesophageal cancer","Immunotherapy","Preoperative therapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ajani%20JA%5BAuthor%5D%20gastric%20nivolumab"}],"papers":[{"title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649)","journal":"Lancet","year":2021,"doi":"10.1016/S0140-6736(21)00797-2"},{"title":"Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma (CheckMate 648)","journal":"NEJM","year":2022,"doi":"10.1056/NEJMoa2111380"},{"title":"CheckMate 649: nivolumab plus chemotherapy as first treatment for advanced gastric, gastro-oesophageal junction and oesophageal adenocarcinoma","journal":"The Lancet","year":2021,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CheckMate+649+nivolumab+chemotherapy+gastric+Janjigian+Lancet+2021"}],"orcid":"0000-0001-9946-0629"},{"id":"jaime-feliu","kind":"person","name":"Jaime Feliu","aka":[],"tldr":"Heads medical oncology at La Paz with a focus on gastrointestinal and older-patient oncology.","summary":"Jaime Feliu is Head of Medical Oncology at Hospital Universitario La Paz in Madrid. His specialisms are medical oncology, gastrointestinal cancers and geriatric oncology, and he researches geriatric assessment and colorectal cancer treatment. His papers include a Journal of Geriatric Oncology study of undertreatment and overtreatment in older patients receiving chemotherapy, a study correlating hypertension and proteinuria with outcome in elderly bevacizumab-treated patients with metastatic colorectal cancer, and a multicentre prospective study predicting chemotherapy toxicity in older patients with cancer. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Feliu%20J%5BAuthor%5D%20geriatric%20oncology"}],"tags":[],"related":[],"cancers":["colorectal"],"sections":[],"technologies":["geriatric-assessment"],"targets":[],"drugs":[],"companies":[],"institutions":["la-paz"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["journal-of-geriatric-oncology","the-oncologist"],"dependsOn":[],"notes":[],"role":"Head of Medical Oncology, Hospital Universitario La Paz","institutionId":"la-paz","specialisms":["Medical oncology","Gastrointestinal cancers","Geriatric oncology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Feliu%20J%5BAuthor%5D%20geriatric%20oncology"}],"papers":[{"title":"Undertreatment and overtreatment in older patients treated with chemotherapy","journal":"Journal of Geriatric Oncology","year":2021,"doi":"10.1016/j.jgo.2020.10.010"},{"title":"Correlation of Hypertension and Proteinuria with Outcome in Elderly Bevacizumab-Treated Patients with Metastatic Colorectal Cancer","journal":"PLOS ONE","year":2015,"doi":"10.1371/journal.pone.0116527"},{"title":"Predicting Chemotherapy Toxicity in Older Patients with Cancer: A Multicenter Prospective Study","journal":"The Oncologist","year":2020,"doi":"10.1634/theoncologist.2019-0701"}]},{"id":"jakob-nikolas-kather","kind":"person","name":"Jakob Nikolas Kather","aka":[],"tldr":"Showed that deep learning can read genetic features like microsatellite instability directly from routine pathology slides.","summary":"Jakob Nikolas Kather led the 2019 Nature Medicine study showing a deep-learning model can predict microsatellite instability from standard H&E slides in gastrointestinal cancer, opening the field of inferring molecular biomarkers from routine histology, and subsequent pan-cancer work predicting mutations and outcomes. He leads clinical AI research in Dresden, evaluates large language models for oncology, and is a practising GI oncologist.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kather%20JN%5BAuthor%5D%20deep%20learning%20histology"}],"tags":["ai","pathology","biomarkers","germany"],"related":[],"cancers":["colorectal","gastric"],"sections":[],"technologies":["digital-pathology-ai","pathology-foundation-model"],"targets":[],"drugs":[],"companies":[],"institutions":["nct-dresden"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nature-cancer"],"dependsOn":[],"notes":[],"role":"Professor of Clinical Artificial Intelligence, Else Kröner Fresenius Center for Digital Health, TU Dresden; Medical Oncologist, NCT Dresden","institutionId":"nct-dresden","specialisms":["AI in oncology","Deep learning on histology","Biomarker prediction from slides","Large language models in medicine"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kather%20JN%5BAuthor%5D%20deep%20learning%20histology"}],"papers":[{"title":"Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer","journal":"Nature Medicine","year":2019,"doi":"10.1038/s41591-019-0462-y"},{"title":"Pan-cancer image-based detection of clinically actionable genetic alterations","journal":"Nature Cancer","year":2020,"doi":"10.1038/s43018-020-0087-6"}],"orcid":"0000-0002-3730-5348"},{"id":"jakub-kraszewski","kind":"person","name":"Jakub Kraszewski","aka":[],"tldr":"Jakub Kraszewski represents University Clinical Centre, Gdańsk in the Organisation of European Cancer Institutes, which lists the centre among its members in Poland.","summary":"Jakub Kraszewski is listed by the Organisation of European Cancer Institutes (OECI) as the representative of University Clinical Centre, Gdańsk, its member in Poland. The University Clinical Centre in Gdańsk is the teaching hospital of the Medical University of Gdańsk, the largest hospital in northern Poland, and a full member of the Organisation of European Cancer Institutes. OnCo records the name from the OECI membership list so that the centre's page has a named contact point; the person's exact title, appointment date and biography are not yet recorded and should be checked on the institution's own pages before being relied on.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"University Clinical Centre, Gdańsk website","url":"https://www.uck.pl/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["uck-gdansk"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of University Clinical Centre, Gdańsk to the Organisation of European Cancer Institutes","institutionId":"uck-gdansk","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"University Clinical Centre, Gdańsk website","url":"https://www.uck.pl/"}],"papers":[]},{"id":"jalid-sehouli","kind":"person","name":"Jalid Sehouli","aka":[],"tldr":"Berlin gynaecological oncologist and ESGO President, a leading ovarian cancer surgeon and trialist within the AGO study group.","summary":"Jalid Sehouli is President of the European Society of Gynaecological Oncology (ESGO) and Director of the Department of Gynecology at Charité University Hospital, Berlin. He is a leading investigator in ovarian cancer surgery and systemic therapy and a co-author of the DESKTOP III trial of secondary cytoreductive surgery for relapsed ovarian cancer. He has long been active in the AGO Study Group and in international ovarian cancer trial collaborations.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Jalid_Sehouli","links":[{"label":"Society page","url":"https://www.esgo.org/about/council/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sehouli+J%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","gynaecological oncology","ovarian cancer"],"related":[],"cancers":["ovarian","endometrial","cervical"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["esgo"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President","institutionId":"esgo","specialisms":["Gynaecological oncology","Ovarian cancer","Cytoreductive surgery"],"profiles":[{"label":"Society page","url":"https://www.esgo.org/about/council/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sehouli+J%5BAuthor%5D"}],"papers":[{"title":"Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer","journal":"New England Journal of Medicine","year":2021,"url":"https://doi.org/10.1056/NEJMoa2103294","doi":"10.1056/NEJMoa2103294"}],"orcid":"0000-0002-5963-6623"},{"id":"jame-abraham","kind":"person","name":"Jame Abraham","aka":[],"tldr":"Jame Abraham leads medical oncology at Cleveland Clinic and its breast cancer trial programme.","summary":"Jame Abraham is Chair of the Department of Hematology and Medical Oncology at Cleveland Clinic Taussig Cancer Institute. He is a breast medical oncologist known for leading Cleveland Clinic's breast cancer trial programme and for his role on the NCCN breast cancer guideline panel. His selected paper reports the ATEMPT trial of adjuvant trastuzumab emtansine versus paclitaxel with trastuzumab for stage I HER2-positive breast cancer. He leads medical oncology at Cleveland Clinic and remains an investigator in adjuvant and metastatic breast cancer trials, with an interest in cancer care delivery.","asOf":"2026-09-08","links":[{"label":"Cleveland Clinic profile","url":"https://my.clevelandclinic.org/staff/17181-jame-abraham"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Abraham%20J%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["breast-her2-positive","breast-hr-positive"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cleveland-clinic"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chair, Department of Hematology and Medical Oncology","institutionId":"cleveland-clinic","specialisms":["Breast cancer","Clinical trials","Cancer care delivery"],"profiles":[{"label":"Cleveland Clinic profile","url":"https://my.clevelandclinic.org/staff/17181-jame-abraham"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Abraham%20J%5BAuthor%5D"}],"papers":[{"title":"Adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT)","journal":"Journal of Clinical Oncology","year":2021}]},{"id":"james-brenton","kind":"person","name":"James Brenton","aka":[],"tldr":"Cambridge medical oncologist and Interim Deputy Director of the CRUK Cambridge Institute, a leader in ovarian cancer genomics and ctDNA monitoring.","summary":"James Brenton is Interim Deputy Director and a Senior Group Leader at the Cancer Research UK Cambridge Institute, and a consultant medical oncologist at Cambridge University Hospitals. His research focuses on the genomics and evolution of high-grade serous ovarian cancer and on circulating tumour DNA as a tool for treatment monitoring. He leads the ovarian cancer programme within the CRUK Cambridge Centre.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/James_D._Brenton","links":[{"label":"Institution profile","url":"https://www.cruk.cam.ac.uk/leadership/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Brenton+JD%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","ovarian cancer","cancer genomics"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cruk-cambridge-centre"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["plos-medicine"],"dependsOn":[],"notes":[],"role":"Interim Deputy Director","institutionId":"cruk-cambridge-centre","specialisms":["Ovarian cancer","Cancer genomics","Circulating tumour DNA"],"profiles":[{"label":"Institution profile","url":"https://www.cruk.cam.ac.uk/leadership/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Brenton+JD%5BAuthor%5D"}],"papers":[{"title":"Copy number signatures and mutational processes in ovarian carcinoma","journal":"Nature Genetics","year":2018,"doi":"10.1038/s41588-018-0179-8"},{"title":"Liquid biopsies come of age: towards implementation of circulating tumour DNA","journal":"Nature Reviews Cancer","year":2017,"doi":"10.1038/nrc.2017.7"},{"title":"Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study","journal":"PLOS Medicine","year":2016,"doi":"10.1371/journal.pmed.1002198"}],"orcid":"0000-0002-5738-6683"},{"id":"james-yao","kind":"person","name":"James C. Yao","aka":[],"tldr":"Led the RADIANT trials that made everolimus a standard therapy for pancreatic and other neuroendocrine tumours.","summary":"James Yao was principal investigator of RADIANT-3 and RADIANT-4, which established everolimus for progressive pancreatic and then non-functional lung and GI neuroendocrine tumours, and authored the SEER analysis that documented the rising incidence of NETs. He chairs GI medical oncology at MD Anderson and co-led the NET Task Force of the NCI GI steering committee.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Yao%20JC%5BAuthor%5D%20neuroendocrine%20everolimus"}],"tags":["neuroendocrine","mtor","trialist"],"related":[],"cancers":["neuroendocrine"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":[],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":["radiant-3-4"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chair, Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center","institutionId":"md-anderson","specialisms":["Neuroendocrine tumours","mTOR inhibitors","Epidemiology","Gastrointestinal oncology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Yao%20JC%5BAuthor%5D%20neuroendocrine%20everolimus"}],"papers":[{"title":"Everolimus for advanced pancreatic neuroendocrine tumors (RADIANT-3)","journal":"NEJM","year":2011,"doi":"10.1056/NEJMoa1009290"},{"title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4)","journal":"Lancet","year":2016,"doi":"10.1016/S0140-6736(15)00817-X"},{"title":"One hundred years after 'carcinoid': epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","journal":"JCO","year":2008,"doi":"10.1200/JCO.2007.15.4377"}],"orcid":"0000-0002-1875-3962"},{"id":"james-gulley","kind":"person","name":"James L. Gulley","aka":[],"tldr":"Runs NCI's immuno-oncology clinical programme, from prostate cancer vaccines to bifunctional checkpoint fusion proteins.","summary":"James L. Gulley is Co-Director of the Center for Immuno-Oncology in the Center for Cancer Research at the National Cancer Institute. He is a medical oncologist who runs NCI's immuno-oncology clinical programme, from prostate cancer vaccines to bifunctional checkpoint fusion proteins, having led the PROSTVAC programme and early studies of bintrafusp alfa. His selected paper reports the phase 3 trial of PROSTVAC in asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. He coordinates immuno-oncology trials across NCI's intramural programme in prostate, bladder and other genitourinary cancers.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/James_L._Gulley","links":[{"label":"NCI CCR profile","url":"https://ccr.cancer.gov/staff-directory/james-l-gulley"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gulley%20JL%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["prostate","urothelial"],"sections":[],"technologies":["shared-antigen-vaccine","checkpoint-inhibitor"],"targets":[],"drugs":[],"companies":[],"institutions":["nci"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Co-Director, Center for Immuno-Oncology, Center for Cancer Research","institutionId":"nci","specialisms":["Genitourinary cancers","Cancer vaccines","Bifunctional immunotherapies"],"profiles":[{"label":"NCI CCR profile","url":"https://ccr.cancer.gov/staff-directory/james-l-gulley"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gulley%20JL%5BAuthor%5D"}],"papers":[{"title":"Phase III trial of PROSTVAC in asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer","journal":"Journal of Clinical Oncology","year":2019}]},{"id":"james-larkin","kind":"person","name":"James Larkin","aka":[],"tldr":"Melanoma and kidney cancer trialist who co-led CheckMate 067, the trial with 10-year immunotherapy survival data.","summary":"James Larkin is a consultant medical oncologist at The Royal Marsden and Professor at The Institute of Cancer Research. His specialisms are melanoma, renal cell carcinoma and immunotherapy combinations. He was a lead investigator of CheckMate 067, the trial of nivolumab plus ipilimumab in advanced melanoma, and of CheckMate 9ER in renal cell carcinoma, work that shaped first-line immunotherapy in both diseases. His New England Journal of Medicine paper reported the long-term results of combined nivolumab and ipilimumab in advanced melanoma from CheckMate 067. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Larkin%20J%5BAuthor%5D%20melanoma%20nivolumab%20ipilimumab"}],"tags":[],"related":[],"cancers":["melanoma","rcc"],"sections":[],"technologies":[],"targets":[],"drugs":["nivolumab","ipilimumab"],"companies":[],"institutions":["royal-marsden","icr-london"],"pathways":[],"terms":[],"trials":["checkmate-067","checkmate-9er"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Consultant Medical Oncologist, Royal Marsden; Professor, ICR","institutionId":"royal-marsden","specialisms":["Melanoma","Renal cell carcinoma","Immunotherapy combinations"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Larkin%20J%5BAuthor%5D%20melanoma%20nivolumab%20ipilimumab"}],"papers":[{"title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma (CheckMate 067)","journal":"NEJM","year":2019,"doi":"10.1056/NEJMoa1910836"},{"title":"CheckMate 067 at ten years: half of melanoma patients treated with nivolumab plus ipilimumab were alive a decade later","journal":"New England Journal of Medicine","year":2025,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CheckMate%20067%2010-year%20nivolumab%20ipilimumab%20melanoma%20Wolchok%20NEJM%202025"},{"title":"CheckMate 067 at ten years: nivolumab plus ipilimumab produces long-term survival in half of patients with advanced melanoma","journal":"New England Journal of Medicine","year":2025,"url":"https://doi.org/10.1056/NEJMoa2407417","doi":"10.1056/NEJMoa2407417"}],"orcid":"0000-0001-5569-9523"},{"id":"james-allison","kind":"person","name":"James P. Allison","aka":[],"tldr":"Discovered that blocking CTLA-4 unleashes T cells against cancer, the work behind ipilimumab and the 2018 Nobel Prize.","summary":"James Allison is Chair of the Department of Immunology and Director of the James P. Allison Institute at MD Anderson Cancer Center. An immunologist specialising in tumour immunology and T-cell biology, his 1990s work showing that CTLA-4 blockade causes tumour rejection in mice led to ipilimumab, the first checkpoint inhibitor, and he shared the 2018 Nobel Prize in Physiology or Medicine with Tasuku Honjo. His papers include the Science report on enhancement of antitumour immunity by CTLA-4 blockade and a Cell review of immune checkpoint targeting and combination strategies with curative potential. He leads the Allison Institute and the immunotherapy platform at MD Anderson, with work spanning CTLA-4, PD-1 and melanoma.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/James_P._Allison","links":[{"label":"MD Anderson faculty","url":"https://faculty.mdanderson.org/search?q=James%20P.%20Allison"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Allison%20JP%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=James%20P.%20Allison"}],"tags":[],"related":[],"cancers":["melanoma"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["ctla4","pd1"],"drugs":["ipilimumab"],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chair, Department of Immunology; Director, James P. Allison Institute, MD Anderson","institutionId":"md-anderson","specialisms":["Tumour immunology","Immune checkpoint blockade","T-cell biology"],"profiles":[{"label":"MD Anderson faculty","url":"https://faculty.mdanderson.org/search?q=James%20P.%20Allison"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Allison%20JP%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=James%20P.%20Allison"}],"papers":[{"title":"Enhancement of antitumor immunity by CTLA-4 blockade","journal":"Science","year":1996,"url":"https://doi.org/10.1126/science.271.5256.1734","doi":"10.1126/science.271.5256.1734"},{"title":"Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential","journal":"Cell","year":2015,"url":"https://doi.org/10.1016/j.cell.2015.03.030","doi":"10.1016/j.cell.2015.03.030"},{"title":"Hodi 2010: ipilimumab, the first checkpoint inhibitor, extends survival in metastatic melanoma","journal":"New England Journal of Medicine","year":2010,"url":"https://doi.org/10.1056/NEJMoa1003466","doi":"10.1056/NEJMoa1003466"},{"title":"Iwai and Honjo: tumours use PD-L1 to escape T cells, and blocking it restores attack","journal":"PNAS","year":2002,"url":"https://doi.org/10.1073/pnas.192461099","doi":"10.1073/pnas.192461099"}],"orcid":"0000-0001-8980-5697"},{"id":"james-r-downing","kind":"person","name":"James R. Downing","aka":[],"tldr":"Hematopathologist and cancer genomics pioneer who has led St. Jude Children's Research Hospital since 2014.","summary":"James R. Downing, MD, is President and Chief Executive Officer of St. Jude Children's Research Hospital in Memphis, a role he has held since July 2014. A hematopathologist, he previously served as St. Jude's Scientific Director and co-led the St. Jude-Washington University Pediatric Cancer Genome Project, which mapped the genomic landscape of childhood leukemias and solid tumours. Under his leadership St. Jude has expanded its research capacity and its global paediatric cancer programmes.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/James_R._Downing","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Downing+JR%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","paediatric oncology","leukemia"],"related":[],"cancers":["all-leukemia","aml"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["st-jude"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President and Chief Executive Officer","institutionId":"st-jude","specialisms":["Paediatric leukemia genomics","Hematopathology","Cancer genomics"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Downing+JR%5BAuthor%5D"}],"papers":[{"title":"AML1, the Target of Multiple Chromosomal Translocations in Human Leukemia, Is Essential for Normal Fetal Liver Hematopoiesis","journal":"Cell","year":1996,"doi":"10.1016/s0092-8674(00)80986-1"},{"title":"Germline Mutations in Predisposition Genes in Pediatric Cancer","journal":"New England Journal of Medicine","year":2015,"doi":"10.1056/nejmoa1508054"},{"title":"Genomic Analysis of the Clonal Origins of Relapsed Acute Lymphoblastic Leukemia","journal":"Science","year":2008,"doi":"10.1126/science.1164266"}],"orcid":"0000-0003-4931-2913"},{"id":"jan-burger","kind":"person","name":"Jan A. Burger","aka":[],"tldr":"Leukaemia specialist who was lead author of RESONATE-2, the trial that made ibrutinib a first-line treatment for chronic lymphocytic leukaemia in older patients.","summary":"Jan Burger is a haematologist and laboratory investigator at MD Anderson Cancer Center. He was first author of the 2015 New England Journal of Medicine report of RESONATE-2, which showed that ibrutinib improved progression-free and overall survival compared with chlorambucil in previously untreated older patients with CLL, establishing BTK inhibition as first-line therapy. His laboratory studies how the tissue microenvironment supports CLL cells.","asOf":"2026-09-18","links":[],"tags":["leukaemia","targeted-therapy","trialist"],"related":[],"cancers":["cll-treatment-naive","cll"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":["resonate-2"],"people":[],"bottlenecks":[],"keyPapers":["paper-jan-burger-n-engl-j-med-2015","paper-jan-burger-blood-2015","paper-jan-burger-blood-2009"],"journals":[],"dependsOn":[],"notes":[],"role":"Haematologist, MD Anderson Cancer Center","institutionId":"md-anderson","specialisms":["Chronic lymphocytic leukaemia","BTK inhibitors","Leukaemia microenvironment"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Burger%5BAuthor%5D"}],"papers":[{"title":"Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia","journal":"New England Journal of Medicine","year":2015,"url":"https://doi.org/10.1056/nejmoa1509388","doi":"10.1056/nejmoa1509388","note":"Europe PMC author record matched by affiliation (MD Anderson Cancer Center); 1283 citations on Europe PMC."},{"title":"Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib","journal":"Blood","year":2015,"url":"https://doi.org/10.1182/blood-2014-10-606038","doi":"10.1182/blood-2014-10-606038","note":"Europe PMC author record matched by affiliation (MD Anderson Cancer Center); 524 citations on Europe PMC."},{"title":"The microenvironment in mature B-cell malignancies: a target for new treatment strategies","journal":"Blood","year":2009,"url":"https://doi.org/10.1182/blood-2009-06-225326","doi":"10.1182/blood-2009-06-225326","note":"Europe PMC author record matched by affiliation (MD Anderson Cancer Center); 426 citations on Europe PMC."}],"orcid":"0000-0002-6177-7572"},{"id":"jan-vermorken","kind":"person","name":"Jan B. Vermorken","aka":[],"tldr":"Led EXTREME and TAX 323, which defined the chemotherapy standards for head and neck cancer for a decade.","summary":"Jan Vermorken (Antwerp University Hospital) was principal investigator of EXTREME, which showed adding cetuximab to platinum-fluorouracil improves survival in recurrent or metastatic head and neck cancer and became the comparator arm for KEYNOTE-048, and of TAX 323, which established docetaxel-based induction chemotherapy. He also led early cisplatin-based trials in cervical cancer and has chaired EORTC head and neck research.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Vermorken%20JB%5BAuthor%5D%20head%20neck%20cetuximab"}],"tags":["head-and-neck","chemotherapy","eortc"],"related":[],"cancers":["head-and-neck"],"sections":[],"technologies":["monoclonal-antibody","platinum"],"targets":["egfr"],"drugs":[],"companies":[],"institutions":["antwerp-university-hospital"],"pathways":[],"terms":[],"trials":["extreme"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Emeritus Professor of Oncology, Antwerp University Hospital","institutionId":"antwerp-university-hospital","specialisms":["Head and neck cancer","Chemotherapy","Anti-EGFR therapy","Cervical cancer"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Vermorken%20JB%5BAuthor%5D%20head%20neck%20cetuximab"}],"papers":[{"title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer (EXTREME)","journal":"NEJM","year":2008,"doi":"10.1056/NEJMoa0802656"},{"title":"Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer (TAX 323)","journal":"NEJM","year":2007,"doi":"10.1056/NEJMoa071028"}],"orcid":"0000-0001-8515-7848"},{"id":"jan-buckner","kind":"person","name":"Jan C. Buckner","aka":[],"tldr":"Mayo Clinic neuro-oncologist who was lead author of the long-term RTOG 9802 results, which showed that adding PCV chemotherapy to radiotherapy roughly doubles survival in high-risk low-grade glioma.","summary":"Jan Buckner is a medical oncologist at Mayo Clinic in Rochester and a long-standing leader of the Alliance for Clinical Trials in Oncology neuro-oncology committee. He was first author of the 2016 New England Journal of Medicine report of RTOG 9802, which showed that radiotherapy followed by procarbazine, lomustine and vincristine lengthened median survival from 7.8 to 13.3 years compared with radiotherapy alone in grade 2 glioma patients who were over 40 or had subtotal resection, changing the standard of care.","asOf":"2026-09-18","links":[],"tags":["brain","trialist"],"related":[],"cancers":["idh-mutant-astrocytoma","oligodendroglioma","brain-tumours"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["mayo-clinic"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-rtog-9802-buckner-nejm-2016"],"journals":[],"dependsOn":[],"notes":[],"role":"Medical oncologist, Mayo Clinic","institutionId":"mayo-clinic","specialisms":["Low-grade glioma","Neuro-oncology","Cooperative-group trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Buckner%5BAuthor%5D"}],"papers":[{"title":"RTOG 9802: radiation plus procarbazine, lomustine and vincristine in high-risk low-grade glioma","journal":"New England Journal of Medicine","year":2016,"url":"https://doi.org/10.1056/NEJMoa1500925","doi":"10.1056/NEJMoa1500925"}]},{"id":"jane-cooke-wright","kind":"person","name":"Jane Cooke Wright","aka":[],"tldr":"At Harlem Hospital in the 1950s she showed methotrexate could shrink breast and skin cancers, tested drugs on patients' own tumour cells, and in 1964 was the only woman among the seven founders of ASCO.","summary":"Jane Cooke Wright (1919-2013) joined her father Louis Wright's Cancer Research Foundation at Harlem Hospital in 1949 and became its director in 1952. At a time when chemotherapy was regarded as a last resort for leukaemia, she showed that methotrexate produced responses in breast cancer, mycosis fungoides and other solid tumours, and pioneered testing candidate drugs against a patient's own tumour cells in culture to guide treatment, an idea now returning as functional precision medicine. She developed regional perfusion of chemotherapy for hard-to-reach tumours. In 1964 she was the only woman and the only African American among the seven founders of the American Society of Clinical Oncology, and in 1967 became associate dean of New York Medical College, then the highest post held by a Black woman at a US medical school. She served on the President's Commission on Heart Disease, Cancer and Stroke.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Jane_Cooke_Wright","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Jane_Cooke_Wright"},{"label":"ASCO","url":"https://www.asco.org/"}],"tags":["hero","pioneer"],"related":[],"cancers":[],"sections":["chemotherapy"],"technologies":["cytotoxic-chemotherapy","functional-drug-testing"],"targets":[],"drugs":["methotrexate"],"companies":[],"institutions":["asco"],"pathways":[],"terms":["cancer-health-disparities"],"trials":[],"people":[],"bottlenecks":["b-trial-diversity"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Pioneer of chemotherapy for solid tumours; co-founder of ASCO","specialisms":["Medical oncology","Chemotherapy","Drug testing in patient tissue"],"profiles":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Jane_Cooke_Wright"},{"label":"ASCO","url":"https://www.asco.org/"}],"papers":[],"papersExpected":true},{"id":"dancey-janet","kind":"person","name":"Janet Dancey","aka":[],"tldr":"Runs Canada's academic cancer trials network, which has led practice-changing trials from PA.3 to CO.17 and beyond.","summary":"Janet Dancey is Director of the Canadian Cancer Trials Group and Professor of Oncology at Queen's University. She runs Canada's academic cancer trials network, which has led practice-changing trials from PA.3 to CO.17, coordinating national and international studies across cancers, and she previously led precision medicine efforts at the Ontario Institute for Cancer Research and drug development at the US National Cancer Institute. Her publications include an adaptive phase 2 trial using circulating tumour DNA response after pembrolizumab in non-small-cell lung cancer, a review of mTOR signalling and drug development, and the iRECIST guidelines for response criteria in immunotherapy trials. Her interests are clinical trials, precision oncology and cooperative groups.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Janet_Dancey","links":[{"label":"Canadian Cancer Trials Group","url":"https://www.ctg.queensu.ca"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dancey%20J%5BAuthor%5D%20Canadian%20Cancer%20Trials%20Group"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["cgp"],"targets":[],"drugs":[],"companies":["cctg"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Canadian Cancer Trials Group; Professor of Oncology, Queen's University","institutionId":"cctg","specialisms":["Clinical trials","Precision oncology","Drug development","Cooperative groups"],"profiles":[{"label":"Canadian Cancer Trials Group","url":"https://www.ctg.queensu.ca"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dancey%20J%5BAuthor%5D%20Canadian%20Cancer%20Trials%20Group"}],"papers":[{"title":"ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results","journal":"Nature Medicine","year":2023,"doi":"10.1038/s41591-023-02598-9"},{"title":"mTOR signaling and drug development in cancer","journal":"Nature Reviews Clinical Oncology","year":2010,"doi":"10.1038/nrclinonc.2010.21"},{"title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","journal":"The Lancet Oncology","year":2017,"doi":"10.1016/s1470-2045(17)30074-8"},{"title":"CHALLENGE: a structured exercise programme after chemotherapy improves survival in colon cancer","journal":"New England Journal of Medicine","year":2025,"url":"https://doi.org/10.1056/NEJMoa2502760","doi":"10.1056/NEJMoa2502760"}]},{"id":"janet-rowley","kind":"person","name":"Janet Rowley","aka":[],"tldr":"Working part-time at her dining-room table in 1972, she showed the Philadelphia chromosome in CML is a swap between chromosomes 9 and 22. Cancer had a genetic cause, and imatinib later hit the fused gene.","summary":"Janet Rowley (1925-2013) entered medical school at the University of Chicago at 19 and for years worked part-time while raising four sons. Using new banding stains in 1972, she showed that the abnormally short Philadelphia chromosome in chronic myeloid leukaemia, described by Peter Nowell and David Hungerford in 1960, was not a deletion but a reciprocal translocation between chromosomes 9 and 22, and she went on to identify the t(8;21) translocation in acute myeloid leukaemia and the t(15;17) in acute promyelocytic leukaemia. Her papers were initially rejected as coincidence. They established that specific genetic changes cause specific cancers; the 9;22 fusion was later shown to create the BCR-ABL kinase that imatinib inhibits, and the 15;17 fusion explained the response of APL to retinoic acid. She received the Lasker Award in 1998, the Presidential Medal of Freedom in 2009 and the Japan Prize in 2012, and worked until shortly before her death from ovarian cancer.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Janet_Rowley","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Janet_Rowley"},{"label":"University of Chicago Medicine","url":"https://www.uchicagomedicine.org/"}],"tags":["hero","pioneer"],"related":[],"cancers":["cml","aml"],"sections":["diagnostics","targeted-therapy"],"technologies":["cytogenetics-fish"],"targets":["bcr-abl"],"drugs":["imatinib","tretinoin-atra"],"companies":[],"institutions":[],"pathways":[],"terms":["gene-fusion","differentiation-syndrome"],"trials":[],"people":["brian-druker"],"bottlenecks":["b-translational-valley"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Geneticist who showed that chromosomal translocations cause cancer","specialisms":["Cytogenetics","Leukaemia genetics","Chronic myeloid leukaemia"],"profiles":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Janet_Rowley"},{"label":"University of Chicago Medicine","url":"https://www.uchicagomedicine.org/"}],"papers":[{"title":"Chromosome translocations: dangerous liaisons revisited","journal":"Nature Reviews Cancer","year":2001,"doi":"10.1038/35106108"},{"title":"AML1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia","journal":"Blood","year":1995,"doi":"10.1182/blood.v86.1.1.bloodjournal8611"},{"title":"THE CRITICAL ROLE OF CHROMOSOME TRANSLOCATIONS IN HUMAN LEUKEMIAS","journal":"Annual Review of Genetics","year":1998,"doi":"10.1146/annurev.genet.32.1.495"}]},{"id":"janja-ocvirk","kind":"person","name":"Janja Ocvirk","aka":[],"tldr":"Medical oncologist and Medical Director of the Institute of Oncology Ljubljana, with research in melanoma and colorectal cancer.","summary":"Janja Ocvirk is Medical Director (Strokovna direktorica) of the Institute of Oncology Ljubljana and a professor of medical oncology. Her clinical research has focused on systemic therapy of melanoma and colorectal cancer, including participation in international trials of targeted agents and immunotherapy. Her papers cover metastatic melanoma treated with vemurafenib alone or combined with cobimetinib, the AVEX randomised phase 3 trial of bevacizumab plus capecitabine versus capecitabine alone in elderly patients with untreated metastatic colorectal cancer, and biomarkers of outcome in first-line immune checkpoint inhibitor treatment of metastatic melanoma. She is responsible for the clinical direction of Slovenia's national cancer institute.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.onko-i.si/o-nas/sektorji-in-oddelki/vodstvo"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ocvirk+J%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","melanoma","colorectal cancer"],"related":[],"cancers":["melanoma","colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["onkoloski-institut-ljubljana"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Medical Director (Strokovna direktorica)","institutionId":"onkoloski-institut-ljubljana","specialisms":["Medical oncology","Melanoma","Colorectal cancer"],"profiles":[{"label":"Institution profile","url":"https://www.onko-i.si/o-nas/sektorji-in-oddelki/vodstvo"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ocvirk+J%5BAuthor%5D"}],"papers":[{"title":"Patients with metastatic melanoma treated with vemurafenib as monotherapy or in combination with cobimetinib.","journal":"Journal of Clinical Oncology","year":2017,"doi":"10.1200/jco.2017.35.15_suppl.e21016"},{"title":"Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial","journal":"The Lancet Oncology","year":2013,"doi":"10.1016/s1470-2045(13)70154-2"},{"title":"Biomarkers for Outcome in Metastatic Melanoma in First Line Treatment with Immune Checkpoint Inhibitors","journal":"Biomedicines","year":2023,"doi":"10.3390/biomedicines11030749"}]},{"id":"jannick-brennum","kind":"person","name":"Jannick Brennum","aka":[],"tldr":"Jannick Brennum represents Rigshospitalet, Copenhagen University Hospital in the Organisation of European Cancer Institutes, which lists the centre among its members in Denmark.","summary":"Jannick Brennum is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Rigshospitalet, Copenhagen University Hospital, its full member in Denmark. OnCo records the name from the OECI membership list so that the centre's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the institution's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Rigshospitalet, Copenhagen University Hospital website","url":"https://www.rigshospitalet.dk/english"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["rigshospitalet"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Rigshospitalet, Copenhagen University Hospital to the Organisation of European Cancer Institutes","institutionId":"rigshospitalet","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Rigshospitalet, Copenhagen University Hospital website","url":"https://www.rigshospitalet.dk/english"}],"papers":[{"title":"A randomized double-blind crossover trial comparing subthalamic and pallidal deep brain stimulation for dystonia","journal":"J Neurosurg","year":2013,"url":"https://doi.org/10.3171/2013.8.jns13844","doi":"10.3171/2013.8.jns13844","note":"Europe PMC author record matched by affiliation"},{"title":"Ictal and interictal electric source imaging in pre-surgical evaluation: a prospective study","journal":"Eur J Neurol","year":2018,"url":"https://doi.org/10.1111/ene.13676","doi":"10.1111/ene.13676","note":"Europe PMC author record matched by affiliation"},{"title":"Pain treatment after craniotomy:  where is the (procedure-specific) evidence? A qualitative systematic review","journal":"Eur J Anaesthesiol","year":2011,"url":"https://doi.org/10.1097/eja.0b013e32834a0255","doi":"10.1097/eja.0b013e32834a0255","note":"Europe PMC author record matched by affiliation"}],"orcid":"0000-0002-7961-0156"},{"id":"jaroslaw-maciejewski","kind":"person","name":"Jaroslaw P. Maciejewski","aka":[],"tldr":"Jaroslaw Maciejewski is a leukaemia geneticist who defined the mutational landscape of myelodysplastic syndromes.","summary":"Jaroslaw P. Maciejewski is Chair of the Department of Translational Hematology and Oncology Research at Cleveland Clinic Taussig Cancer Institute. He is a leukaemia geneticist known for defining the mutational landscape of myelodysplastic syndromes, discovering somatic mutations in MDS and aplastic anaemia including in splicing factors and TET2. His selected paper reports somatic mutations and clonal haematopoiesis in aplastic anaemia. He now studies clonal evolution in bone marrow failure and its progression towards acute myeloid leukaemia.","asOf":"2026-09-08","links":[{"label":"Cleveland Clinic profile","url":"https://www.lerner.ccf.org/thor/maciejewski/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Maciejewski%20JP%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["aml"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cleveland-clinic"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chair, Department of Translational Hematology and Oncology Research","institutionId":"cleveland-clinic","specialisms":["Myelodysplastic syndromes","Bone marrow failure","Clonal haematopoiesis"],"profiles":[{"label":"Cleveland Clinic profile","url":"https://www.lerner.ccf.org/thor/maciejewski/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Maciejewski%20JP%5BAuthor%5D"}],"papers":[{"title":"Somatic mutations and clonal hematopoiesis in aplastic anemia","journal":"New England Journal of Medicine","year":2015,"url":"https://doi.org/10.1056/NEJMoa1414799","doi":"10.1056/NEJMoa1414799"}],"orcid":"0000-0002-6837-4346"},{"id":"jasna-trifunovic","kind":"person","name":"Jasna Trifunovic","aka":[],"tldr":"Jasna Trifunovic represents Oncology Institute of Vojvodina in the Organisation of European Cancer Institutes, which lists the centre among its members in Serbia.","summary":"Jasna Trifunovic is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Oncology Institute of Vojvodina, its member in Serbia. The Oncology Institute of Vojvodina, near Novi Sad, is the cancer centre for northern Serbia and an associate member of the Organisation of European Cancer Institutes. OnCo records the name from the OECI membership list so that the centre's page has a named contact point; the person's exact title, appointment date and biography are not yet recorded and should be checked on the institution's own pages before being relied on.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Oncology Institute of Vojvodina website","url":"http://www.onk.ns.ac.rs/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oncology-institute-of-vojvodina"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Oncology Institute of Vojvodina to the Organisation of European Cancer Institutes","institutionId":"oncology-institute-of-vojvodina","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Oncology Institute of Vojvodina website","url":"http://www.onk.ns.ac.rs/"}],"papers":[{"title":"Increasing frequency of soft tissue sarcomas in Vojvodina - comparison with the literature","journal":"Asian Pac J Cancer Prev","year":2014,"url":"https://doi.org/10.7314/apjcp.2014.15.2.1011","doi":"10.7314/apjcp.2014.15.2.1011","note":"Europe PMC author record matched by affiliation"},{"title":"Factors influencing time to seeking medical advice and onset of treatment in women who are diagnosed with breast cancer in Serbia","journal":"Psychooncology","year":2018,"url":"https://doi.org/10.1002/pon.4551","doi":"10.1002/pon.4551","note":"Europe PMC author record matched by affiliation"}]},{"id":"jason-carroll","kind":"person","name":"Jason Carroll","aka":[],"tldr":"Molecular oncologist and Interim Director of the Cancer Research UK Cambridge Institute, known for mapping how the oestrogen receptor drives breast cancer.","summary":"Jason Carroll is Interim Director of the Cancer Research UK Cambridge Institute, where he is a Senior Group Leader, and Professor of Molecular Oncology at the University of Cambridge. His laboratory studies oestrogen receptor and FOXA1 transcriptional networks in breast cancer, including the landmark demonstration that differential ER binding patterns predict clinical outcome. His work underpins efforts to overcome endocrine therapy resistance.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.cruk.cam.ac.uk/leadership/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Carroll+JS%5BAuthor%5D+Cambridge"}],"tags":["leadership","clinician-scientist","breast cancer","basic science"],"related":[],"cancers":["breast-hr-positive"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cruk-cambridge-centre"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Interim Director","institutionId":"cruk-cambridge-centre","specialisms":["Breast cancer","Oestrogen receptor biology","Transcriptional regulation"],"profiles":[{"label":"Institution profile","url":"https://www.cruk.cam.ac.uk/leadership/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Carroll+JS%5BAuthor%5D+Cambridge"}],"papers":[{"title":"Differential oestrogen receptor binding is associated with clinical outcome in breast cancer","journal":"Nature","year":2012,"url":"https://doi.org/10.1038/nature10730","doi":"10.1038/nature10730"}],"orcid":"0000-0003-3643-0080"},{"id":"jason-luke","kind":"person","name":"Jason J. Luke","aka":[],"tldr":"Led KEYNOTE-716, which extended adjuvant pembrolizumab to high-risk stage II melanoma.","summary":"Jason Luke was principal investigator of KEYNOTE-716, which showed adjuvant pembrolizumab reduces recurrence and distant metastasis in resected stage IIB and IIC melanoma, the first adjuvant immunotherapy approval in stage II disease. He runs one of the largest early-phase immunotherapy programmes in the United States and studies mechanisms of primary resistance to checkpoint blockade. He is active in SITC leadership.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Luke%20JJ%5BAuthor%5D%20melanoma%20pembrolizumab"}],"tags":["melanoma","adjuvant","early-phase"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["pd1"],"drugs":["pembrolizumab"],"companies":[],"institutions":["upmc-hillman","sitc"],"pathways":[],"terms":[],"trials":["keynote-716"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nature-reviews-clinical-oncology"],"dependsOn":[],"notes":[],"role":"Director, Cancer Immunotherapeutics Center, UPMC Hillman Cancer Center","institutionId":"upmc-hillman","specialisms":["Melanoma","Adjuvant immunotherapy","Early-phase immunotherapy","Immune resistance"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Luke%20JJ%5BAuthor%5D%20melanoma%20pembrolizumab"}],"papers":[{"title":"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716)","journal":"Lancet","year":2022,"doi":"10.1016/S0140-6736(22)00562-1"},{"title":"Targeted agents and immunotherapies: optimizing outcomes in melanoma","journal":"Nature Reviews Clinical Oncology","year":2017,"doi":"10.1038/nrclinonc.2017.43"}]},{"id":"jason-westin","kind":"person","name":"Jason R. Westin","aka":[],"tldr":"Led the ZUMA-7 overall survival analysis that made CAR-T the standard second-line therapy for early-relapsing lymphoma.","summary":"Jason Westin was first author of the ZUMA-7 overall survival report, which showed axicabtagene ciloleucel improves survival compared with standard chemoimmunotherapy and transplant in primary refractory or early relapsed large B-cell lymphoma, the first randomised survival benefit for a CAR-T therapy and the trial that moved CAR-T into second line. He leads the Smart Start precision-medicine trials in DLBCL and lymphoma clinical research at MD Anderson.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Westin%20JR%5BAuthor%5D%20axicabtagene%20ZUMA-7"}],"tags":["lymphoma","car-t","second-line"],"related":[],"cancers":["dlbcl"],"sections":[],"technologies":["car-t"],"targets":["cd19"],"drugs":["axicabtagene-ciloleucel"],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":["zuma-7"],"people":[],"bottlenecks":[],"keyPapers":["paper-zuma-7-axi-cel-second-line-nejm-2022"],"journals":[],"dependsOn":[],"notes":[],"role":"Director of Lymphoma Clinical Research, MD Anderson Cancer Center","institutionId":"md-anderson","specialisms":["Large B-cell lymphoma","CAR T-cell therapy","Second-line therapy","Precision medicine in lymphoma"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Westin%20JR%5BAuthor%5D%20axicabtagene%20ZUMA-7"}],"papers":[{"title":"Survival with axicabtagene ciloleucel in large B-cell lymphoma (ZUMA-7)","journal":"NEJM","year":2023,"doi":"10.1056/NEJMoa2301665"},{"title":"Smart Start: rituximab, lenalidomide, and ibrutinib in patients with newly diagnosed large B-cell lymphoma","journal":"JCO","year":2023,"doi":"10.1200/JCO.22.00597"},{"title":"ZUMA-7: axi-cel CAR-T instead of salvage chemotherapy and transplant for large B-cell lymphoma that relapses early","journal":"New England Journal of Medicine","year":2022,"url":"https://doi.org/10.1056/NEJMoa2116133","doi":"10.1056/NEJMoa2116133"}]},{"id":"jason-lewis","kind":"person","name":"Jason S. Lewis","aka":[],"tldr":"Radiochemist who built the zirconium-89 immuno-PET platform and MSKCC's radiopharmaceutical pipeline.","summary":"Jason Lewis developed methods for labelling antibodies with zirconium-89 that made immuno-PET a clinical reality, including 89Zr-trastuzumab and 89Zr-J591 PSMA imaging, and leads a laboratory translating new radiotracers and radioligand therapies from chemistry to first-in-human trials. He directs radiochemistry at MSKCC and has trained many of the field's leaders.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lewis%20JS%5BAuthor%5D%20zirconium-89%20PET"}],"tags":["radiochemistry","immuno-pet","theranostics"],"related":[],"cancers":[],"sections":[],"technologies":["immuno-pet","her2-pet","radioligand-therapy"],"targets":["her2","psma"],"drugs":[],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["journal-of-nuclear-medicine"],"dependsOn":[],"notes":[],"role":"Emily Tow Jackson Chair in Oncology and Chief Attending, Radiochemistry and Imaging Sciences Service, Memorial Sloan Kettering Cancer Center","institutionId":"mskcc","specialisms":["Radiochemistry","Immuno-PET","Radiopharmaceutical development","Targeted radiotherapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lewis%20JS%5BAuthor%5D%20zirconium-89%20PET"}],"papers":[{"title":"89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo","journal":"Journal of Nuclear Medicine","year":2010,"doi":"10.2967/jnumed.110.077982"},{"title":"Immuno-PET of HER2-positive breast cancer with 89Zr-trastuzumab: a first-in-human study","journal":"Journal of Nuclear Medicine","year":2016}]},{"id":"jaume-raventos-i-monjo","kind":"person","name":"Jaume Raventós i Monjo","aka":[],"tldr":"Managing Director of Hospital del Mar in Barcelona, an academic hospital with a strong cancer research institute.","summary":"Jaume Raventós i Monjo is Managing Director (gerent) of Hospital del Mar and the Parc de Salut Mar health consortium in Barcelona. His background is in hospital management and health services. He leads the academic hospital that hosts the Hospital del Mar Research Institute, one of Spain's leading centres for translational cancer research, and is responsible for the running of the hospital and the consortium's services. His role is one of management rather than clinical research, and the institution profile is the public record of his appointment.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.hospitaldelmar.cat/en/info-corp/organs-de-govern/"}],"tags":["leadership","hospital management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["hospital-del-mar"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Managing Director (Gerent)","institutionId":"hospital-del-mar","specialisms":["Hospital management","Health services"],"profiles":[{"label":"Institution profile","url":"https://www.hospitaldelmar.cat/en/info-corp/organs-de-govern/"}],"papers":[]},{"id":"javier-arcos","kind":"person","name":"Javier Arcos","aka":["Javier Arcos Campillo"],"tldr":"Physician and hospital manager who is Gerente of Hospital Universitario Fundación Jiménez Díaz, the Quirónsalud-run public university hospital in Madrid.","summary":"Javier Arcos is Gerente of the Hospital Universitario Fundación Jiménez Díaz, a public university hospital in Madrid managed by Quirónsalud within the Madrid regional health service. In October 2025 he received, as gerente, the Top 20 award for 'Gestión Hospitalaria Global' on behalf of the hospital, alongside deputy manager Ana Posada, medical director Marta Cremades and nursing director Ana Gloria Moreno. In June 2026 the hospital's cancer centre, directed by Jesús García-Foncillas, was accredited by the OECI as a Comprehensive Cancer Center. The hospital's own website blocked automated access, so no appointment date is given. He is also the hospital's representative to the Organisation of European Cancer Institutes (OECI), which lists it as a member in Spain.","asOf":"2026-09-10","links":[{"label":"Source: The Objective, Top 20 award report naming the Gerente (October 2025)","url":"https://theobjective.com/actualidad/2025-10-17/fundacion-jimenez-diaz-premio-gestion-hospitalaria/"},{"label":"Source: The Objective, OECI Comprehensive Cancer Center accreditation (June 2026)","url":"https://theobjective.com/actualidad/2026-06-22/fundacion-jimenez-diaz-comprehensive-cancer/"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Hospital Universitario Fundación Jiménez Díaz website","url":"https://www.fjd.es/"}],"tags":["leadership","hospital-management","oeci-representative"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["fundacion-jimenez-diaz"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Gerente (Chief Executive), Hospital Universitario Fundación Jiménez Díaz, Madrid","institutionId":"fundacion-jimenez-diaz","specialisms":["Hospital management","Healthcare quality"],"profiles":[{"label":"The Objective report naming the hospital Gerente (October 2025)","url":"https://theobjective.com/actualidad/2025-10-17/fundacion-jimenez-diaz-premio-gestion-hospitalaria/"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Hospital Universitario Fundación Jiménez Díaz website","url":"https://www.fjd.es/"}],"papers":[]},{"id":"javier-cortes","kind":"person","name":"Javier Cortés","aka":[],"tldr":"Breast oncologist who led DESTINY-Breast03 and DESTINY-Breast09, the trials that made Enhertu the HER2-positive standard.","summary":"Javier Cortés is Head of the International Breast Cancer Center (IBCC) in Barcelona, having built his career at Vall d'Hebron University Hospital and VHIO. His specialisms are breast cancer, HER2-positive disease and antibody-drug conjugates. He was principal investigator of DESTINY-Breast03, which compared trastuzumab deruxtecan with trastuzumab emtansine and was reported in the New England Journal of Medicine, and of DESTINY-Breast09, which tested trastuzumab deruxtecan plus pertuzumab in the first line. He also co-led CLEOPATRA and PHERGain. These trials made trastuzumab deruxtecan the HER2-positive standard, and his publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cortes%20J%5BAuthor%5D%20trastuzumab%20deruxtecan"}],"tags":[],"related":[],"cancers":["breast-her2-positive"],"sections":[],"technologies":[],"targets":["her2"],"drugs":["trastuzumab-deruxtecan","pertuzumab","trastuzumab-emtansine"],"companies":[],"institutions":["vall-dhebron"],"pathways":[],"terms":[],"trials":["destiny-breast03","destiny-breast09","cleopatra","phergain"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Head, International Breast Cancer Center (IBCC), Barcelona; formerly Vall d'Hebron","institutionId":"vall-dhebron","specialisms":["Breast cancer","HER2-positive disease","Antibody-drug conjugates"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cortes%20J%5BAuthor%5D%20trastuzumab%20deruxtecan"}],"papers":[{"title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer (DESTINY-Breast03)","journal":"NEJM","year":2022,"doi":"10.1056/NEJMoa2115022"},{"title":"ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer","journal":"New England Journal of Medicine","year":2021,"url":"https://doi.org/10.1056/NEJMoa2028485","doi":"10.1056/NEJMoa2028485"},{"title":"KEYNOTE-522: adding pembrolizumab before and after surgery in early triple-negative breast cancer","journal":"New England Journal of Medicine","year":2022,"url":"https://doi.org/10.1056/NEJMoa2112651","doi":"10.1056/NEJMoa2112651"},{"title":"monarchE: two years of abemaciclib after surgery in high-risk, hormone-receptor-positive early breast cancer","journal":"Journal of Clinical Oncology","year":2020,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=monarchE+abemaciclib+adjuvant+Johnston+2020"}],"orcid":"0000-0001-7623-1583"},{"id":"jay-schnitzer","kind":"person","name":"Jay Schnitzer","aka":[],"tldr":"Physician-scientist who directs the Frederick National Laboratory for Cancer Research, the US national laboratory dedicated to cancer and AIDS research.","summary":"Jay Schnitzer is Director of the Frederick National Laboratory for Cancer Research, the federally funded research and development centre operated by Leidos Biomedical Research for the National Cancer Institute, with about 2,400 staff. A surgeon by training with prior leadership roles at MITRE and DARPA, he oversees the laboratory's programmes in cancer, HIV/AIDS and infectious disease, including the RAS Initiative and the NCI's biopharmaceutical development facility.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://frederick.cancer.gov/about/leadership"}],"tags":["leadership","translational research","national laboratory"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["frederick-national-lab"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Frederick National Laboratory","institutionId":"frederick-national-lab","specialisms":["Biomedical research management","Surgery","Technology development"],"profiles":[{"label":"Institution profile","url":"https://frederick.cancer.gov/about/leadership"}],"papers":[{"title":"The diagnosis of acute appendicitis in a pediatric population: to CT or not to CT","journal":"Journal of Pediatric Surgery","year":2003,"url":"https://doi.org/10.1053/jpsu.2003.50110","doi":"10.1053/jpsu.2003.50110","note":"Europe PMC author record matched by affiliation (Massachusetts General Hospital, paediatric surgery, before MITRE and Frederick)"},{"title":"Prenatal glucocorticoid therapy reverses pulmonary immaturity in congenital diaphragmatic hernia in fetal sheep","journal":"Annals of Surgery","year":1996,"url":"https://doi.org/10.1097/00000658-199610000-00002","doi":"10.1097/00000658-199610000-00002","note":"Europe PMC author record matched by affiliation (Massachusetts General Hospital, paediatric surgery, before MITRE and Frederick)"},{"title":"Prenatal hormonal therapy improves pulmonary compliance in the nitrofen-induced CDH rat model","journal":"Journal of Pediatric Surgery","year":1995,"url":"https://doi.org/10.1016/0022-3468(95)90046-2","doi":"10.1016/0022-3468(95)90046-2","note":"Europe PMC author record matched by affiliation (Massachusetts General Hospital, paediatric surgery, before MITRE and Frederick)"}]},{"id":"jean-abraham","kind":"person","name":"Jean Abraham","aka":[],"tldr":"Chief investigator of PARTNER, the UK trial of neoadjuvant olaparib with platinum chemotherapy in triple-negative and BRCA-associated breast cancer, run from Addenbrooke's across 23 NHS sites (30 on the ClinicalTrials.gov record).","summary":"Jean Abraham is Professor of Precision Breast Cancer Medicine and an honorary consultant in medical oncology at the University of Cambridge, where she directs the Precision Breast Cancer Institute and co-leads the Breast Programme of the Cancer Research UK Cambridge Centre. Her department page lists the development of clinical trials in high-risk and hereditary early breast cancer as a research aim. She was chief investigator of PARTNER (Nature 2024), the Cambridge-sponsored phase 2/3 trial that added olaparib to platinum-based neoadjuvant chemotherapy in triple-negative and germline BRCA breast cancer; the University's news release reports 100 percent three-year survival in the 39 germline BRCA patients given chemotherapy followed by olaparib after a 48-hour gap, against 88 percent in the 45 control patients. She was also a co-author of the TNT trial and of the Neo-tAnGo and ARTemis neoadjuvant trials.","asOf":"2026-09-24","links":[{"label":"University of Cambridge Department of Oncology profile","url":"https://www.oncology.cam.ac.uk/directory/j-abraham"},{"label":"University of Cambridge news: PARTNER results","url":"https://www.cam.ac.uk/research/news/new-approach-to-treating-aggressive-breast-cancers-shows-significant-improvement-in-survival"}],"tags":["breast","trialist","uk"],"related":["andrew-tutt"],"cancers":["tnbc","tnbc-early"],"sections":[],"technologies":["parp-inhibitor","platinum"],"targets":["brca"],"drugs":["olaparib","carboplatin"],"companies":[],"institutions":["addenbrookes-cambridge","cruk-cambridge-centre"],"pathways":[],"terms":[],"trials":["partner","tnt"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Precision Breast Cancer Medicine and Honorary Consultant in Medical Oncology, University of Cambridge; Director, Precision Breast Cancer Institute; Consultant, Addenbrooke's Hospital","institutionId":"addenbrookes-cambridge","specialisms":["Triple-negative breast cancer","Hereditary (BRCA) breast cancer","Neoadjuvant trials","Precision breast cancer medicine"],"profiles":[{"label":"University of Cambridge Department of Oncology profile","url":"https://www.oncology.cam.ac.uk/directory/j-abraham"},{"label":"University of Cambridge news: PARTNER results","url":"https://www.cam.ac.uk/research/news/new-approach-to-treating-aggressive-breast-cancers-shows-significant-improvement-in-survival"}],"papers":[{"title":"The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer","journal":"Nature","year":2024,"doi":"10.1038/s41586-024-07384-2"},{"title":"Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial","journal":"Nature Medicine","year":2018,"doi":"10.1038/s41591-018-0009-7"}]},{"id":"jean-bourhis","kind":"person","name":"Jean Bourhis","aka":[],"tldr":"Radiation oncologist behind the MACH-NC meta-analyses that proved chemoradiotherapy helps head and neck cancer, and the first FLASH-treated patient.","summary":"Jean Bourhis led the MACH-NC individual patient data meta-analyses showing that concomitant chemotherapy adds about 6.5% absolute survival to radiotherapy in head and neck cancer, and the MARCH meta-analysis of altered fractionation, both of which set global standards. He treated the first patient with FLASH radiotherapy in 2018 and leads the clinical FLASH programme at CHUV.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bourhis%20J%5BAuthor%5D%20head%20neck%20meta-analysis%20OR%20FLASH"}],"tags":["head-and-neck","radiotherapy","flash"],"related":[],"cancers":["head-and-neck"],"sections":[],"technologies":["imrt-igrt","flash-rt"],"targets":[],"drugs":[],"companies":[],"institutions":["chuv-lausanne"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["radiotherapy-and-oncology"],"dependsOn":[],"notes":[],"role":"Head of Radiation Oncology, Lausanne University Hospital (CHUV)","institutionId":"chuv-lausanne","specialisms":["Head and neck radiotherapy","Meta-analysis","Altered fractionation","FLASH radiotherapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bourhis%20J%5BAuthor%5D%20head%20neck%20meta-analysis%20OR%20FLASH"}],"papers":[{"title":"Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients","journal":"Radiotherapy and Oncology","year":2009,"doi":"10.1016/j.radonc.2009.04.014"},{"title":"Treatment of a first patient with FLASH-radiotherapy","journal":"Radiotherapy and Oncology","year":2019,"doi":"10.1016/j.radonc.2019.06.019"}],"orcid":"0000-0001-5162-1171"},{"id":"jean-lessi","kind":"person","name":"Jean Lessi","aka":[],"tldr":"Director General of the Haute Autorité de Santé, responsible for the agency's operations since January 2024.","summary":"Jean Lessi is Director General (Directeur général) of the Haute Autorité de Santé (HAS), the French authority responsible for assessing health technologies and producing quality and practice standards, including for oncology. A senior public official and former Conseil d'État member, he has led the agency's administration since January 2024.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.has-sante.fr/jcms/c_1002210/en/governance"}],"tags":["leadership","regulation","health technology assessment"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["has-france"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director General","institutionId":"has-france","specialisms":["Public administration","Health regulation"],"profiles":[{"label":"Institution profile","url":"https://www.has-sante.fr/jcms/c_1002210/en/governance"}],"papers":[]},{"id":"jean-charles-soria","kind":"person","name":"Jean-Charles Soria","aka":[],"tldr":"Ran the phase 1 unit that pioneered many targeted therapies, and led the FLAURA trial that made osimertinib first-line.","summary":"Jean-Charles Soria is Professor of Medicine at Paris-Saclay and a former Director General of Gustave Roussy. His specialisms are early drug development, EGFR-mutant lung cancer and phase 1 trials. He built the DITEP early-phase unit at Gustave Roussy, which pioneered many targeted therapies, and led FLAURA, the New England Journal of Medicine trial of osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer that made osimertinib the first-line standard. He later served as Director General and as an industry research and development leader before returning to academic medicine. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Soria%20JC%5BAuthor%5D%20osimertinib"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":["egfr"],"drugs":["osimertinib"],"companies":[],"institutions":["gustave-roussy"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medicine, Paris-Saclay; former Director General, Gustave Roussy","institutionId":"gustave-roussy","specialisms":["Early drug development","EGFR-mutant lung cancer","Phase 1 trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Soria%20JC%5BAuthor%5D%20osimertinib"}],"papers":[{"title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer (FLAURA)","journal":"NEJM","year":2018,"doi":"10.1056/NEJMoa1713137"}],"orcid":"0000-0001-9597-0701"},{"id":"jean-francois-fortin-verreault","kind":"person","name":"Jean-François Fortin Verreault","aka":[],"tldr":"Chief executive of the CIUSSS de l'Est-de-l'Île-de-Montréal, the Quebec health authority that runs Hôpital Maisonneuve-Rosemont and its haemato-oncology and cell therapy institute.","summary":"Jean-François Fortin Verreault is Président-directeur général of the CIUSSS de l'Est-de-l'Île-de-Montréal, the integrated university health and social services centre that operates Hôpital Maisonneuve-Rosemont, Hôpital Santa Cabrini Ospedale and the Institut universitaire d'hémato-oncologie et de thérapie cellulaire. The CIUSSS senior management organisation chart dated 8 December 2025 names him as PDG reporting to the board of directors, with the haemato-oncology and cell therapy institute shown within the senior structure. The chart gives no appointment date.","asOf":"2026-09-10","links":[{"label":"Source: CIUSSS de l'Est-de-l'Île-de-Montréal senior management organigramme (PDF, December 2025)","url":"https://ciusss-estmtl.gouv.qc.ca/sites/ciusssemtl/files/media/document/PDF_organigramme_decembre2025_CIUSSS-EMTL.pdf"}],"tags":["leadership","hospital-management","government"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ciusss-emtl-maisonneuve-rosemont"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Président-directeur général, CIUSSS de l'Est-de-l'Île-de-Montréal","institutionId":"ciusss-emtl-maisonneuve-rosemont","specialisms":["Health system management","Public administration"],"profiles":[{"label":"CIUSSS organisation chart page","url":"https://ciusss-estmtl.gouv.qc.ca/ressources/documentation/organigramme"}],"papers":[]},{"id":"jean-jacques-grob","kind":"person","name":"Jean-Jacques Grob","aka":[],"tldr":"Marseille dermatologist who led KEYNOTE-629, which established pembrolizumab for advanced cutaneous squamous-cell carcinoma, and who has been a senior investigator on many European melanoma trials.","summary":"Jean-Jacques Grob is professor of dermatology at Aix-Marseille University and a leader of the French and European melanoma trial groups. He was first author of the 2020 Journal of Clinical Oncology report of KEYNOTE-629, in which pembrolizumab produced durable responses in recurrent or metastatic cutaneous squamous-cell carcinoma, and a lead investigator on the COMBI-d, KEYNOTE-054 and CheckMate 238 melanoma trials.","asOf":"2026-09-18","links":[],"tags":["skin","melanoma","immunotherapy","trialist"],"related":[],"cancers":["advanced-cutaneous-scc","melanoma","skin-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ap-hm-timone"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-keynote-629-pembrolizumab-cscc-grob-jco-2020"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Dermatology, Aix-Marseille University, Hôpital de la Timone","institutionId":"ap-hm-timone","specialisms":["Melanoma","Cutaneous squamous-cell carcinoma","Adjuvant immunotherapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Grob%5BAuthor%5D"}],"papers":[{"title":"KEYNOTE-629: pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma","journal":"Journal of Clinical Oncology","year":2020,"url":"https://doi.org/10.1200/JCO.19.03054","doi":"10.1200/JCO.19.03054"}]},{"id":"jean-pascal-machiels","kind":"person","name":"Jean-Pascal Machiels","aka":[],"tldr":"Brussels oncologist who led KEYNOTE-412, the trial that tested adding pembrolizumab to chemoradiotherapy for locally advanced head and neck cancer.","summary":"Jean-Pascal Machiels heads medical oncology at Cliniques universitaires Saint-Luc in Brussels and chairs the EORTC head and neck cancer group. He was first author of the 2024 Lancet Oncology report of KEYNOTE-412, the phase 3 trial of pembrolizumab with and after cisplatin-based chemoradiotherapy in locally advanced head and neck squamous-cell carcinoma, which did not reach statistical significance for event-free survival, and of the European guidelines for the disease.","asOf":"2026-09-18","links":[],"tags":["head-and-neck","immunotherapy","trialist"],"related":[],"cancers":["hpv-negative-head-and-neck-cancer","head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["king-albert-ii-cancer-institute"],"pathways":[],"terms":[],"trials":["keynote-412"],"people":[],"bottlenecks":[],"keyPapers":["paper-jean-pascal-machiels-lancet-2019","paper-jean-pascal-machiels-ann-oncol-2020","paper-jean-pascal-machiels-ann-oncol-2021"],"journals":[],"dependsOn":[],"notes":[],"role":"Head of Medical Oncology, Cliniques universitaires Saint-Luc, Brussels","institutionId":"king-albert-ii-cancer-institute","specialisms":["Head and neck cancer","Chemoradiotherapy with immunotherapy","Early-phase trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Machiels%5BAuthor%5D"}],"papers":[{"title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study","journal":"The Lancet","year":2019,"url":"https://doi.org/10.1016/s0140-6736(18)31999-8","doi":"10.1016/s0140-6736(18)31999-8","note":"Europe PMC author record matched by affiliation (King Albert II Cancer Institute, Cliniques universitaires Saint-Luc); 1354 citations on Europe PMC."},{"title":"Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up","journal":"Annals of Oncology","year":2020,"url":"https://doi.org/10.1016/j.annonc.2020.07.011","doi":"10.1016/j.annonc.2020.07.011","note":"Europe PMC author record matched by affiliation (King Albert II Cancer Institute, Cliniques universitaires Saint-Luc); 672 citations on Europe PMC."},{"title":"Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up †","journal":"Annals of Oncology","year":2021,"url":"https://doi.org/10.1016/j.annonc.2020.12.007","doi":"10.1016/j.annonc.2020.12.007","note":"Europe PMC author record matched by affiliation (King Albert II Cancer Institute, Cliniques universitaires Saint-Luc); 332 citations on Europe PMC."}]},{"id":"jean-philippe-spano","kind":"person","name":"Jean-Philippe Spano","aka":[],"tldr":"Jean-Philippe Spano represents Institut Universitaire de Cancérologie AP-HP Sorbonne Université in the Organisation of European Cancer Institutes, which lists the centre among its members in France.","summary":"Jean-Philippe Spano is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Institut Universitaire de Cancérologie AP-HP Sorbonne Université, its member in France. The university cancer institute of AP-HP and Sorbonne Université, spanning the Pitié-Salpêtrière, Saint-Antoine and Tenon hospitals, and accredited by OECI as a Comprehensive Cancer Centre. OnCo records the name from the OECI membership list so that the centre's page has a named contact point; the person's exact title, appointment date and biography are not yet recorded and should be checked on the institution's own pages before being relied on.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Institut Universitaire de Cancérologie AP-HP Sorbonne Université website","url":"https://iuc-aphp-sorbonneuniversite.com/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["iuc-aphp-sorbonne"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Institut Universitaire de Cancérologie AP-HP Sorbonne Université to the Organisation of European Cancer Institutes","institutionId":"iuc-aphp-sorbonne","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Institut Universitaire de Cancérologie AP-HP Sorbonne Université website","url":"https://iuc-aphp-sorbonneuniversite.com/"}],"papers":[{"title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","journal":"Lancet Oncol","year":2018,"url":"https://doi.org/10.1016/s1470-2045(18)30608-9","doi":"10.1016/s1470-2045(18)30608-9","note":"Europe PMC author record matched by affiliation"},{"title":"Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study","journal":"Lancet","year":2008,"url":"https://doi.org/10.1016/s0140-6736(08)60661-3","doi":"10.1016/s0140-6736(08)60661-3","note":"Europe PMC author record matched by affiliation"},{"title":"Comprehensive analysis of long non-coding RNAs in human breast cancer clinical subtypes","journal":"Oncotarget","year":2014,"url":"https://doi.org/10.18632/oncotarget.2454","doi":"10.18632/oncotarget.2454","note":"Europe PMC author record matched by affiliation"}],"orcid":"0000-0002-3921-2479"},{"id":"jean-pierre-delord","kind":"person","name":"Jean-Pierre Delord","aka":[],"tldr":"Medical oncologist who leads the IUCT Oncopole cooperation group in Toulouse and runs early-phase cancer drug trials.","summary":"Jean-Pierre Delord is a professor of medical oncology and the administrator of the healthcare cooperation group (GCS) that runs IUCT Oncopole, the Toulouse university cancer institute combining the Oncopole Claudius Regaud and CHU de Toulouse teams. His research centres on early-phase clinical trials of new cancer drugs, including first-in-human studies such as the netrin-1 antibody programme published in Nature in 2023.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.iuct-oncopole.fr/la-gouvernance"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Delord+JP%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","early-phase trials","medical oncology"],"related":[],"cancers":["endometrial","head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["iuct-oncopole"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Administrator of the GCS (Groupement de Coopération Sanitaire)","institutionId":"iuct-oncopole","specialisms":["Medical oncology","Early-phase clinical trials","Head and neck cancer"],"profiles":[{"label":"Institution profile","url":"https://www.iuct-oncopole.fr/la-gouvernance"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Delord+JP%5BAuthor%5D"}],"papers":[{"title":"Netrin-1 blockade inhibits tumour growth and EMT features in endometrial cancer","journal":"Nature","year":2023,"url":"https://doi.org/10.1038/s41586-023-06367-z","doi":"10.1038/s41586-023-06367-z"}]},{"id":"jean-yves-blay","kind":"person","name":"Jean-Yves Blay","aka":[],"tldr":"Sarcoma expert who leads Centre Léon Bérard and the French cancer centre network UNICANCER.","summary":"Jean-Yves Blay is Director General of Centre Léon Bérard in Lyon and President of UNICANCER, the French network of cancer centres. His specialisms are sarcoma, GIST, rare cancers and precision oncology, with a focus on the KIT target and imatinib. He coordinates the French NETSARC reference network for sarcomas, and his trials include studies of imatinib duration in GIST and the ProfiLER precision oncology programme. His papers include the ESMO consensus report on the management of gastrointestinal stromal tumours, the INVICTUS phase 3 trial of ripretinib in advanced GIST, and a phase 3 trial comparing doxorubicin alone with intensified doxorubicin plus ifosfamide as first-line treatment for advanced soft-tissue sarcoma. His UNICANCER profile and PubMed listing are linked.","asOf":"2026-09-08","links":[{"label":"UNICANCER","url":"https://www.unicancer.fr/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Blay%20JY%5BAuthor%5D%20sarcoma"}],"tags":[],"related":[],"cancers":["sarcoma"],"sections":[],"technologies":[],"targets":["kit"],"drugs":["imatinib"],"companies":["unicancer"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director General, Centre Léon Bérard, Lyon; President, UNICANCER","institutionId":"unicancer","specialisms":["Sarcoma","GIST","Rare cancers","Precision oncology"],"profiles":[{"label":"UNICANCER","url":"https://www.unicancer.fr/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Blay%20JY%5BAuthor%5D%20sarcoma"}],"papers":[{"title":"Consensus meeting for the management of gastrointestinal stromal tumors Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO","journal":"Annals of Oncology","year":2005,"doi":"10.1093/annonc/mdi127"},{"title":"Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial","journal":"The Lancet Oncology","year":2020,"doi":"10.1016/s1470-2045(20)30168-6"},{"title":"Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial","journal":"The Lancet Oncology","year":2014,"doi":"10.1016/s1470-2045(14)70063-4"},{"title":"SPEARHEAD-1: afamitresgene autoleucel, the first engineered T-cell receptor therapy approved for a solid tumour, in synovial sarcoma","journal":"The Lancet","year":2024,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=SPEARHEAD-1+afamitresgene+autoleucel+synovial+sarcoma+Lancet"}],"orcid":"0000-0001-7190-120X"},{"id":"jeanne-tie","kind":"person","name":"Jeanne Tie","aka":[],"tldr":"Led DYNAMIC, the first randomised trial to show ctDNA can safely guide who needs chemotherapy after colon cancer surgery.","summary":"Jeanne Tie led DYNAMIC, which showed that using ctDNA to decide adjuvant chemotherapy in stage II colon cancer halves chemotherapy use without worsening recurrence-free survival, the first randomised proof that ctDNA-guided de-escalation works. Her 2016 study established post-operative ctDNA as a powerful marker of residual disease. She now leads DYNAMIC-III and DYNAMIC-Rectal.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tie%20J%5BAuthor%5D%20ctDNA%20colon"}],"tags":["ctdna","colorectal","de-escalation"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":["liquid-biopsy","mrd-testing"],"targets":[],"drugs":["signatera"],"companies":[],"institutions":["wehi","peter-mac"],"pathways":[],"terms":[],"trials":["dynamic","circulate-japan"],"people":[],"bottlenecks":[],"keyPapers":["paper-dynamic-nejm-2022","paper-galaxy-signatera-nat-med-2023"],"journals":["science-translational-medicine"],"dependsOn":[],"notes":[],"role":"Medical Oncologist, Peter MacCallum Cancer Centre; Laboratory Head, Walter and Eliza Hall Institute","institutionId":"wehi","specialisms":["Circulating tumour DNA","Colorectal cancer","Adjuvant therapy","Minimal residual disease"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tie%20J%5BAuthor%5D%20ctDNA%20colon"}],"papers":[{"title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer (DYNAMIC)","journal":"NEJM","year":2022,"doi":"10.1056/NEJMoa2200075"},{"title":"Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer","journal":"Science Translational Medicine","year":2016,"doi":"10.1126/scitranslmed.aaf6219"},{"title":"GALAXY: tumour DNA in blood four weeks after bowel cancer surgery predicts relapse tenfold","journal":"Nature Medicine","year":2023,"url":"https://doi.org/10.1038/s41591-022-02115-4","doi":"10.1038/s41591-022-02115-4"}],"orcid":"0000-0001-9244-2057"},{"id":"jedd-wolchok","kind":"person","name":"Jedd D. Wolchok","aka":[],"tldr":"Led CheckMate 067, the trial whose ten-year data showed half of advanced melanoma patients on nivolumab plus ipilimumab are alive.","summary":"Jedd Wolchok (Weill Cornell Medicine; formerly MSKCC) was principal investigator of CheckMate 067, which established nivolumab plus ipilimumab as the most durable therapy in advanced melanoma with median survival beyond six years and ten-year melanoma-specific survival near 50%. He led early ipilimumab development, defined the immune-related response criteria, and co-founded the Parker Institute network. His laboratory studies mechanisms of checkpoint blockade.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wolchok%20JD%5BAuthor%5D%20melanoma%20ipilimumab%20nivolumab"}],"tags":["melanoma","immunotherapy","trialist"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["pd1","ctla4"],"drugs":["nivolumab","ipilimumab"],"companies":[],"institutions":["weill-cornell-meyer-cancer-center"],"pathways":[],"terms":[],"trials":["checkmate-067"],"people":[],"bottlenecks":[],"keyPapers":["paper-checkmate-067-10-year-nejm-2025","paper-hodi-ipilimumab-melanoma-nejm-2010"],"journals":[],"dependsOn":[],"notes":[],"role":"Meyer Director, Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine","institutionId":"weill-cornell-meyer-cancer-center","specialisms":["Melanoma immunotherapy","Checkpoint inhibitor combinations","Immune-related response criteria","Tumour immunology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wolchok%20JD%5BAuthor%5D%20melanoma%20ipilimumab%20nivolumab"}],"papers":[{"title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma (CheckMate 067)","journal":"NEJM","year":2015,"doi":"10.1056/NEJMoa1504030"},{"title":"Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma","journal":"JCO","year":2022,"doi":"10.1200/JCO.21.02229"},{"title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","journal":"Clinical Cancer Research","year":2009,"doi":"10.1158/1078-0432.CCR-09-1624"},{"title":"Ribas and Wolchok 2018: cancer immunotherapy using checkpoint blockade","journal":"Science","year":2018,"url":"https://doi.org/10.1126/science.aar4060","doi":"10.1126/science.aar4060"},{"title":"CheckMate 067 at ten years: half of melanoma patients treated with nivolumab plus ipilimumab were alive a decade later","journal":"New England Journal of Medicine","year":2025,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CheckMate%20067%2010-year%20nivolumab%20ipilimumab%20melanoma%20Wolchok%20NEJM%202025"},{"title":"Hodi 2010: ipilimumab, the first checkpoint inhibitor, extends survival in metastatic melanoma","journal":"New England Journal of Medicine","year":2010,"url":"https://doi.org/10.1056/NEJMoa1003466","doi":"10.1056/NEJMoa1003466"},{"title":"CheckMate 067 at ten years: nivolumab plus ipilimumab produces long-term survival in half of patients with advanced melanoma","journal":"New England Journal of Medicine","year":2025,"url":"https://doi.org/10.1056/NEJMoa2407417","doi":"10.1056/NEJMoa2407417"}],"orcid":"0000-0001-6718-2222"},{"id":"lee-jeeyun","kind":"person","name":"Jeeyun Lee","aka":[],"tldr":"A gastric cancer trialist who pioneered biomarker-driven umbrella trials in Korea and helped bring HER2 and Claudin 18.2 agents to Asian patients.","summary":"Jeeyun Lee is Professor of Medical Oncology at Samsung Medical Center in Seoul, working in gastrointestinal cancer and precision oncology. She pioneered biomarker-driven umbrella trials in Korea, and her group runs molecularly stratified trials in gastric and other gastrointestinal cancers, including the VIKTORY umbrella trial. She has been an investigator on gastric cancer studies of zolbetuximab, which targets Claudin 18.2, of the HER2-directed antibody zanidatamab, and of pembrolizumab, helping to bring these agents to Asian patients. Her publications include the VIKTORY report on using tumour genomic profiling to guide patients with metastatic gastric cancer to targeted treatment.","asOf":"2026-09-08","links":[{"label":"Samsung Medical Center","url":"https://www.samsunghospital.com/gb/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lee%20J%5BAuthor%5D%20Samsung%20Medical%20Center%20gastric%20cancer"}],"tags":[],"related":[],"cancers":["gastric"],"sections":[],"technologies":["cgp"],"targets":["her2","cldn18-2"],"drugs":["zolbetuximab","zanidatamab"],"companies":[],"institutions":["samsung-medical-center"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology; gastrointestinal cancer and precision oncology","institutionId":"samsung-medical-center","specialisms":["Gastric cancer","Precision oncology","Molecular profiling","Clinical trials"],"profiles":[{"label":"Samsung Medical Center","url":"https://www.samsunghospital.com/gb/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lee%20J%5BAuthor%5D%20Samsung%20Medical%20Center%20gastric%20cancer"}],"papers":[{"title":"Tumor genomic profiling guides patients with metastatic gastric cancer to targeted treatment: the VIKTORY umbrella trial","journal":"Cancer Discovery","year":2019,"doi":"10.1158/2159-8290.CD-19-0442"}]},{"id":"jeffrey-bluestone","kind":"person","name":"Jeffrey A. Bluestone","aka":[],"tldr":"The immunologist who ran the Parker Institute from its launch in 2016, building a shared research network across leading US cancer centres; he came from UCSF and now leads a regulatory T cell company.","summary":"Jeffrey Bluestone is a T cell immunologist whose laboratory work on CTLA-4 and on regulatory T cells underpins both checkpoint immunotherapy and cell therapies for autoimmunity. He was the Parker Institute for Cancer Immunotherapy's founding President and Chief Executive Officer from its public launch in 2016, and remains on its board, which lists him as Chief Executive Officer and President of Sonoma BioTherapeutics. His UCSF profile records him as the A.W. and Mary Margaret Clausen Distinguished Professor of Metabolism and Endocrinology and Professor Emeritus in the Diabetes Center. His publications are listed on PubMed.","asOf":"2026-09-17","links":[{"label":"UCSF profile","url":"https://profiles.ucsf.edu/jeffrey.bluestone"},{"label":"PICI leadership and board","url":"https://www.parkerici.org/about/leadership-staff/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bluestone+JA%5BAuthor%5D"}],"tags":["leadership","immunotherapy"],"related":[],"cancers":[],"sections":[],"technologies":["checkpoint-inhibitor","immunotherapy"],"targets":["ctla4"],"drugs":[],"companies":[],"institutions":["parker-institute","ucsf"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Founding President and Chief Executive Officer, Parker Institute for Cancer Immunotherapy (2016 to 2021); Chief Executive Officer and President, Sonoma BioTherapeutics","institutionId":"parker-institute","specialisms":["T cell immunology","Immune tolerance and regulatory T cells","Checkpoint biology (CTLA-4)","Research institute leadership"],"profiles":[{"label":"UCSF profile","url":"https://profiles.ucsf.edu/jeffrey.bluestone"},{"label":"PICI leadership and board","url":"https://www.parkerici.org/about/leadership-staff/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bluestone+JA%5BAuthor%5D"}],"papers":[{"title":"CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells","journal":"Journal of Experimental Medicine","year":2006,"url":"https://doi.org/10.1084/jem.20060772","doi":"10.1084/jem.20060772","note":"Europe PMC author record matched by affiliation"},{"title":"Innate immunity and intestinal microbiota in the development of Type 1 diabetes","journal":"Nature","year":2008,"url":"https://doi.org/10.1038/nature07336","doi":"10.1038/nature07336","note":"Europe PMC author record matched by affiliation"},{"title":"Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo","journal":"Nature Immunology","year":2009,"url":"https://doi.org/10.1038/ni.1774","doi":"10.1038/ni.1774","note":"Europe PMC author record matched by affiliation"}]},{"id":"jeffrey-bradley","kind":"person","name":"Jeffrey D. Bradley","aka":[],"tldr":"Led RTOG 0617, the trial that showed higher radiation doses do not help in stage III lung cancer and set today's 60 Gy standard.","summary":"Jeffrey Bradley was principal investigator of RTOG 0617, which unexpectedly found that escalating the dose to 74 Gy worsened survival compared with 60 Gy in stage III NSCLC, a result that fixed the standard dose and refocused the field on precision and cardiac sparing. He led the NRG proton-versus-photon lung trial and chairs thoracic radiotherapy committees in NRG Oncology.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bradley%20JD%5BAuthor%5D%20RTOG%200617"}],"tags":["radiotherapy","lung","nrg-oncology"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["imrt-igrt","proton-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":["penn-abramson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor and Vice Chair of Radiation Oncology, University of Pennsylvania Perelman School of Medicine","institutionId":"penn-abramson","specialisms":["Thoracic radiation oncology","Dose escalation","Proton therapy","Cooperative-group trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bradley%20JD%5BAuthor%5D%20RTOG%200617"}],"papers":[{"title":"Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617)","journal":"Lancet Oncology","year":2015,"doi":"10.1016/S1470-2045(14)71207-0"},{"title":"Long-term results of NRG Oncology RTOG 0617","journal":"JCO","year":2020,"doi":"10.1200/JCO.19.01162"}]},{"id":"jeffrey-gershenwald","kind":"person","name":"Jeffrey E. Gershenwald","aka":[],"tldr":"Houston surgeon who chaired the melanoma expert panel for the eighth edition of the AJCC staging system, the classification doctors use to describe how far a melanoma has spread.","summary":"Jeffrey Gershenwald is a surgical oncologist at MD Anderson Cancer Center. He chaired the American Joint Committee on Cancer melanoma expert panel and was first author of the 2017 CA: A Cancer Journal for Clinicians paper presenting the eighth-edition melanoma staging system, which refined the T, N and M categories using data from more than 46,000 patients. He also studies sentinel node biopsy and the molecular biology of melanoma progression.","asOf":"2026-09-18","links":[],"tags":["melanoma","surgery","staging"],"related":[],"cancers":["stage-ii-melanoma","stage-iii-melanoma","melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-ajcc-8-melanoma-gershenwald-ca-2017"],"journals":[],"dependsOn":[],"notes":[],"role":"Surgical oncologist, MD Anderson Cancer Center","institutionId":"md-anderson","specialisms":["Melanoma surgery","Staging","Sentinel lymph node biopsy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gershenwald%5BAuthor%5D"}],"papers":[{"title":"Melanoma staging: evidence-based changes in the AJCC eighth edition cancer staging manual","journal":"CA: A Cancer Journal for Clinicians","year":2017,"url":"https://doi.org/10.3322/caac.21409","doi":"10.3322/caac.21409"}]},{"id":"jeffrey-lancet","kind":"person","name":"Jeffrey E. Lancet","aka":[],"tldr":"Florida leukaemia doctor who led the phase 3 trial of CPX-351, the liposomal form of daunorubicin and cytarabine that lengthened survival for older people with secondary acute myeloid leukaemia.","summary":"Jeffrey Lancet chairs the malignant haematology department at Moffitt Cancer Center in Tampa. He was first author of the 2018 Journal of Clinical Oncology report of the phase 3 trial in which CPX-351, a liposomal fixed-ratio formulation of daunorubicin and cytarabine, improved overall survival compared with standard 7+3 induction in patients aged 60 to 75 with newly diagnosed secondary AML, the basis of the drug's approval.","asOf":"2026-09-18","links":[],"tags":["leukaemia","trialist"],"related":[],"cancers":["aml-secondary","aml"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["moffitt"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-cpx-351-study-301-lancet-je-jco-2018"],"journals":[],"dependsOn":[],"notes":[],"role":"Haematologist, Moffitt Cancer Center","institutionId":"moffitt","specialisms":["Acute myeloid leukaemia","Secondary AML","Novel formulations of chemotherapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lancet%5BAuthor%5D"}],"papers":[{"title":"CPX-351 versus 7+3 chemotherapy in older adults with newly diagnosed secondary acute myeloid leukaemia","journal":"Journal of Clinical Oncology","year":2018,"url":"https://doi.org/10.1200/JCO.2017.77.6112","doi":"10.1200/JCO.2017.77.6112"}]},{"id":"jeffrey-miller","kind":"person","name":"Jeffrey Miller","aka":[],"tldr":"Physician who directs the Masonic Cancer Center at the University of Minnesota, the NCI-designated comprehensive cancer centre in Minneapolis.","summary":"Jeffrey Miller, MD, is Director of the Masonic Cancer Center, University of Minnesota. The centre's leadership directory lists him at the head of a senior team that includes Deputy Director David Largaespada, PhD, and Executive Director and Associate Director of Administration Aaron Schilz, MPA, together with associate directors for translational research, clinical research, basic sciences, training and education, population sciences and data sciences. The directory page gives no appointment date or biography.","asOf":"2026-09-10","links":[{"label":"Source: Masonic Cancer Center leadership directory","url":"https://cancer.umn.edu/about/leadership"}],"tags":["leadership","clinician-scientist","comprehensive-cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["minnesota-masonic"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["blood-advances","blood"],"dependsOn":[],"notes":[],"role":"Director, Masonic Cancer Center, University of Minnesota","institutionId":"minnesota-masonic","specialisms":["Haematology and oncology","Cancer immunotherapy","Cancer centre leadership"],"profiles":[{"label":"Masonic Cancer Center leadership page","url":"https://cancer.umn.edu/about/leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Miller+JS%5BAuthor%5D+AND+Minnesota"}],"papers":[{"title":"First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia","journal":"Blood Advances","year":2019,"doi":"10.1182/bloodadvances.2018028332"},{"title":"Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation","journal":"Blood","year":2018,"doi":"10.1182/blood-2017-08-752170"},{"title":"161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS","journal":"Blood Advances","year":2018,"doi":"10.1182/bloodadvances.2017012369"}]},{"id":"jeffrey-dome","kind":"person","name":"Jeffrey S. Dome","aka":[],"tldr":"Led the COG renal tumour committee that used biology to tailor Wilms tumour treatment.","summary":"Jeffrey Dome (Children's National Hospital) chaired the Children's Oncology Group renal tumour committee and led the AREN trials that incorporated loss of heterozygosity at 1p and 16q and lung nodule response into risk-adapted Wilms tumour therapy, allowing many children to avoid lung radiotherapy or doxorubicin. His laboratory studies telomerase and relapse biology in Wilms tumour.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dome%20JS%5BAuthor%5D%20Wilms"}],"tags":["paediatric","wilms-tumor","cooperative-group"],"related":[],"cancers":["wilms-tumor"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["childrens-national-hospital"],"pathways":[],"terms":["radiotherapy","de-escalation"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Senior Vice President, Center for Cancer and Blood Disorders, Children's National Hospital, Washington DC","institutionId":"childrens-national-hospital","specialisms":["Wilms tumour","Paediatric renal tumours","Risk-adapted therapy","Cooperative-group trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dome%20JS%5BAuthor%5D%20Wilms"}],"papers":[{"title":"Advances in Wilms tumor treatment and biology: progress through international collaboration","journal":"JCO","year":2015,"doi":"10.1200/JCO.2015.62.1888"},{"title":"Treatment of stage IV favorable histology Wilms tumor with lung metastases: a report from the Children's Oncology Group AREN0533 study","journal":"JCO","year":2018,"doi":"10.1200/JCO.2017.77.1931"}]},{"id":"jeffrey-weber","kind":"person","name":"Jeffrey S. Weber","aka":[],"tldr":"Led CheckMate 238, which made adjuvant nivolumab standard after melanoma surgery, and co-led the mRNA vaccine trial KEYNOTE-942.","summary":"Jeffrey Weber was principal investigator of CheckMate 238, which showed adjuvant nivolumab beats ipilimumab in resected stage III-IV melanoma with far less toxicity, and of KEYNOTE-942, the randomised trial showing the individualised mRNA neoantigen vaccine mRNA-4157 plus pembrolizumab reduces recurrence versus pembrolizumab alone. He has led immunotherapy development since the interleukin-2 era and directs melanoma research at NYU.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Weber%20JS%5BAuthor%5D%20melanoma%20adjuvant"}],"tags":["melanoma","adjuvant","vaccine"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":["checkpoint-inhibitor","neoantigen-mrna-vaccine"],"targets":["pd1"],"drugs":["nivolumab","ipilimumab","intismeran-autogene","pembrolizumab"],"companies":[],"institutions":["nyu-perlmutter"],"pathways":[],"terms":[],"trials":["interpath-001"],"people":[],"bottlenecks":[],"keyPapers":["paper-keynote-942-lancet-2024"],"journals":[],"dependsOn":[],"notes":[],"role":"Deputy Director, NYU Langone Perlmutter Cancer Center; Professor of Medicine","institutionId":"nyu-perlmutter","specialisms":["Melanoma","Adjuvant immunotherapy","Cancer vaccines","Tumour immunology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Weber%20JS%5BAuthor%5D%20melanoma%20adjuvant"}],"papers":[{"title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma (CheckMate 238)","journal":"NEJM","year":2017,"doi":"10.1056/NEJMoa1709030"},{"title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942)","journal":"Lancet","year":2024,"doi":"10.1016/S0140-6736(23)02268-7"},{"title":"KEYNOTE-942: a personalised mRNA cancer vaccine plus pembrolizumab after melanoma surgery","journal":"The Lancet","year":2024,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=mRNA-4157+V940+pembrolizumab+melanoma+KEYNOTE-942+Lancet"}]},{"id":"jennifer-chan","kind":"person","name":"Jennifer A. Chan","aka":[],"tldr":"Boston oncologist who led CABINET, the trial that showed cabozantinib delays progression of advanced neuroendocrine tumours after other treatments have failed.","summary":"Jennifer Chan directs the neuroendocrine and carcinoid tumour programme at Dana-Farber Cancer Institute. She was the study chair and first author of the 2024 New England Journal of Medicine report of the Alliance CABINET trial, in which cabozantinib improved progression-free survival compared with placebo in previously treated advanced pancreatic and extra-pancreatic neuroendocrine tumours, supporting its approval in both groups.","asOf":"2026-09-18","links":[],"tags":["neuroendocrine","targeted-therapy","trialist"],"related":[],"cancers":["pancreatic-net","small-intestinal-net","lung-net","neuroendocrine"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["dana-farber"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-cabinet-cabozantinib-nejm-2024"],"journals":[],"dependsOn":[],"notes":[],"role":"Clinical Director, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute","institutionId":"dana-farber","specialisms":["Neuroendocrine tumours","Targeted therapy","Cooperative-group trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chan%5BAuthor%5D"}],"papers":[{"title":"CABINET (Alliance A021602): cabozantinib for advanced neuroendocrine tumours","journal":"New England Journal of Medicine","year":2025,"url":"https://doi.org/10.1056/NEJMoa2403991","doi":"10.1056/NEJMoa2403991"}]},{"id":"jennifer-wargo","kind":"person","name":"Jennifer A. Wargo","aka":[],"tldr":"Surgeon-scientist who showed the gut microbiome shapes response to immunotherapy and led early neoadjuvant melanoma trials.","summary":"Jennifer Wargo led the 2018 Science paper showing that gut microbiome composition predicts response to PD-1 blockade in melanoma patients, alongside parallel work from Gustave Roussy and Chicago that founded microbiome-directed immuno-oncology. She led one of the first randomised neoadjuvant immunotherapy trials in melanoma and co-leads the International Neoadjuvant Melanoma Consortium. Her laboratory now studies diet, fibre and microbiome modulation.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wargo%20JA%5BAuthor%5D%20microbiome%20melanoma"}],"tags":["melanoma","microbiome","neoadjuvant"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["nivolumab","ipilimumab"],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":["fmt-pd1-refractory-melanoma-pitt"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Genomic Medicine and Surgical Oncology, MD Anderson Cancer Center","institutionId":"md-anderson","specialisms":["Melanoma","Microbiome and immunotherapy","Neoadjuvant immunotherapy","Surgical oncology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wargo%20JA%5BAuthor%5D%20microbiome%20melanoma"}],"papers":[{"title":"Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients","journal":"Science","year":2018,"doi":"10.1126/science.aan4236"},{"title":"Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma","journal":"Nature Medicine","year":2018,"doi":"10.1038/s41591-018-0197-1"}]},{"id":"jennifer-woyach","kind":"person","name":"Jennifer A. Woyach","aka":[],"tldr":"Led Alliance A041202, which showed ibrutinib beats chemoimmunotherapy in older CLL patients, and discovered BTK C481S resistance.","summary":"Jennifer Woyach was principal investigator of Alliance A041202, the trial showing ibrutinib with or without rituximab beats bendamustine-rituximab in older patients with untreated CLL and ending chemoimmunotherapy for this group, and first author of the study identifying BTK C481S and PLCG2 mutations as the mechanisms of ibrutinib resistance. She chairs the Alliance CLL committee and leads trials of fixed-duration combinations.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Woyach%20JA%5BAuthor%5D%20chronic%20lymphocytic%20leukemia"}],"tags":["cll","btk","alliance"],"related":[],"cancers":["cll"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":[],"companies":[],"institutions":["osu-james"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-amplify-acalabrutinib-venetoclax-nejm-2025"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Internal Medicine, Division of Hematology, Ohio State University Comprehensive Cancer Center","institutionId":"osu-james","specialisms":["Chronic lymphocytic leukaemia","BTK inhibitors","Older patients","Resistance mutations"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Woyach%20JA%5BAuthor%5D%20chronic%20lymphocytic%20leukemia"}],"papers":[{"title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL (Alliance A041202)","journal":"NEJM","year":2018,"doi":"10.1056/NEJMoa1812836"},{"title":"Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib","journal":"NEJM","year":2014,"doi":"10.1056/NEJMoa1400029"},{"title":"AMPLIFY: fixed-duration acalabrutinib plus venetoclax, with or without obinutuzumab, versus chemo-immunotherapy in fit CLL patients","journal":"New England Journal of Medicine","year":2025,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=AMPLIFY%20acalabrutinib%20venetoclax%20obinutuzumab%20Brown%20NEJM%202025"}]},{"id":"jennifer-litton","kind":"person","name":"Jennifer K. Litton","aka":[],"tldr":"Jennifer Litton led the EMBRACA trial that brought talazoparib to BRCA-mutated breast cancer.","summary":"Jennifer Litton is Vice President for Clinical Research and Professor of Breast Medical Oncology at MD Anderson Cancer Center. A breast medical oncologist specialising in BRCA and PARP inhibitors, she was principal investigator of EMBRACA, the trial that brought talazoparib to BRCA-mutated breast cancer, and of neoadjuvant talazoparib studies in germline BRCA carriers. Her papers report talazoparib in advanced breast cancer with a germline BRCA mutation in the New England Journal of Medicine and neoadjuvant talazoparib for operable breast cancer with a germline BRCA pathogenic variant in the Journal of Clinical Oncology. She oversees clinical research operations across MD Anderson, with work spanning triple-negative and HR-positive breast cancer and germline testing.","asOf":"2026-09-08","links":[{"label":"MD Anderson faculty","url":"https://faculty.mdanderson.org/search?q=Jennifer%20K.%20Litton"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Litton%20JK%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Jennifer%20K.%20Litton"}],"tags":[],"related":[],"cancers":["tnbc","breast-hr-positive"],"sections":[],"technologies":["parp-inhibitor","germline-testing"],"targets":["brca","parp"],"drugs":["talazoparib"],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Vice President, Clinical Research; Professor of Breast Medical Oncology, MD Anderson","institutionId":"md-anderson","specialisms":["Breast cancer","BRCA","PARP inhibitors"],"profiles":[{"label":"MD Anderson faculty","url":"https://faculty.mdanderson.org/search?q=Jennifer%20K.%20Litton"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Litton%20JK%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Jennifer%20K.%20Litton"}],"papers":[{"title":"Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation","journal":"New England Journal of Medicine","year":2018,"url":"https://doi.org/10.1056/NEJMoa1802905","doi":"10.1056/NEJMoa1802905"},{"title":"Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant","journal":"Journal of Clinical Oncology","year":2020,"url":"https://doi.org/10.1200/JCO.19.01304","doi":"10.1200/JCO.19.01304"}],"orcid":"0000-0001-8390-4985"},{"id":"jennifer-brown","kind":"person","name":"Jennifer R. Brown","aka":[],"tldr":"Led ALPINE, the first head-to-head trial in which a next-generation BTK inhibitor (zanubrutinib) beat ibrutinib.","summary":"Jennifer Brown was principal investigator of ALPINE, which showed zanubrutinib improves progression-free survival and causes fewer cardiac events than ibrutinib in relapsed CLL, and led early work on idelalisib and the genetics of familial CLL. She directs the CLL centre at Dana-Farber and leads trials of non-covalent BTK inhibitors and BTK degraders for resistant disease.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Brown%20JR%5BAuthor%5D%20chronic%20lymphocytic%20leukemia%20zanubrutinib"}],"tags":["cll","btk","trialist"],"related":[],"cancers":["cll"],"sections":[],"technologies":["kinase-inhibitors","protac-degrader"],"targets":[],"drugs":[],"companies":[],"institutions":["dana-farber"],"pathways":[],"terms":[],"trials":["alpine","bruin-cll-321"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, CLL Center, Dana-Farber Cancer Institute; Worthington and Margaret Collette Professor of Medicine, Harvard Medical School","institutionId":"dana-farber","specialisms":["Chronic lymphocytic leukaemia","BTK inhibitors","CLL genetics","Novel agents"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Brown%20JR%5BAuthor%5D%20chronic%20lymphocytic%20leukemia%20zanubrutinib"}],"papers":[{"title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia (ALPINE)","journal":"NEJM","year":2023,"doi":"10.1056/NEJMoa2211582"},{"title":"Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia","journal":"Blood","year":2014,"doi":"10.1182/blood-2013-11-535047"}]},{"id":"jennifer-temel","kind":"person","name":"Jennifer S. Temel","aka":[],"tldr":"Showed that early palliative care helps lung cancer patients live better and longer, changing oncology guidelines worldwide.","summary":"Jennifer Temel led the 2010 NEJM randomised trial showing that early palliative care integrated with standard oncology care improves quality of life and mood and extends survival in metastatic lung cancer, the study that made early palliative care an ASCO recommendation. She has since shown telehealth palliative care is equivalent to in-person care and leads supportive care research at MGH.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Temel%20JS%5BAuthor%5D%20palliative%20care"}],"tags":["supportive-care","palliative-care","outcomes"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["mgh"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-temel-early-palliative-care-nejm-2010"],"journals":[],"dependsOn":[],"notes":[],"role":"Clinical Director of Thoracic Oncology and Co-Director, Cancer Outcomes Research and Education Program, Massachusetts General Hospital Cancer Center","institutionId":"mgh","specialisms":["Palliative care integration","Thoracic oncology","Patient-reported outcomes","Supportive care trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Temel%20JS%5BAuthor%5D%20palliative%20care"}],"papers":[{"title":"Early palliative care for patients with metastatic non-small-cell lung cancer","journal":"NEJM","year":2010,"doi":"10.1056/NEJMoa1000678"},{"title":"Telehealth vs in-person early palliative care for patients with advanced lung cancer: a multisite randomized clinical trial","journal":"JAMA","year":2024,"doi":"10.1001/jama.2024.13964"}]},{"id":"jennifer-welsh","kind":"person","name":"Jennifer Welsh","aka":[],"tldr":"Chief executive since October 2025 of Belfast Trust, which runs the Northern Ireland Cancer Centre at Belfast City Hospital.","summary":"Jennifer Welsh is Chief Executive of the Belfast Health and Social Care Trust, the trust that operates the Northern Ireland Cancer Centre at Belfast City Hospital, the regional radiotherapy and cancer centre for Northern Ireland. She took up the post in October 2025, having been Chief Executive of the Northern Health and Social Care Trust, and the Trust describes more than 25 years of experience as a director within Northern Ireland's health and social care service with expertise in strategy, operations, performance and capital development. She succeeded Maureen Edwards, who served as Interim Chief Executive from September 2024 to October 2025, and works with Trust chairman Professor Stuart Elborn.","asOf":"2026-09-10","links":[{"label":"Source: Belfast Trust 'Key people' page (Chief Executive)","url":"https://belfasttrust.hscni.net/about/corporate-info/key-people/"},{"label":"Source: Belfast Trust executive team page","url":"https://belfasttrust.hscni.net/about/corporate-info/key-people/executive-team/"}],"tags":["leadership","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["northern-ireland-cancer-centre"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive, Belfast Health and Social Care Trust","institutionId":"northern-ireland-cancer-centre","specialisms":["Health and social care management","Strategy and operations","Capital development"],"profiles":[{"label":"Belfast Trust key people page","url":"https://belfasttrust.hscni.net/about/corporate-info/key-people/"}],"papers":[]},{"id":"jenny-donovan","kind":"person","name":"Jenny Donovan","aka":[],"tldr":"The Bristol social scientist who worked out how to recruit men into a trial that asked them to accept a coin toss between surgery, radiotherapy and doing nothing, and then measured honestly what each did to their lives.","summary":"Jenny Donovan is Professor of Social Medicine at the University of Bristol and was co-lead of ProtecT with Freddie Hamdy and Athene Lane. Her contribution was methodological and is now used across British trials: the QuinteT approach, which studies how clinicians actually describe a randomised comparison to a patient, finds the places where the description makes one arm sound like the sensible choice, and fixes them. Without it ProtecT would not have randomised 1,643 men into a comparison that included no immediate treatment at all.\n\nShe is also first author of the trial's patient-reported outcomes papers, which are the part of ProtecT that most changes a conversation in clinic: at six years, moderate to severe urinary incontinence was reported by 13 in 100 men after prostatectomy, 5 after radiotherapy and 8 on active monitoring, and moderate or severe erectile dysfunction by 50, 36 and 40 respectively. Those are the numbers NICE prints in box 2 of NG131.","asOf":"2026-09-25","links":[{"label":"University of Bristol research information","url":"https://research-information.bris.ac.uk/en/persons/jenny-l-donovan"}],"tags":["prostate","trialist","uk"],"related":["freddie-hamdy"],"cancers":["prostate","prostate-low-risk","prostate-intermediate-risk"],"sections":["surgery","radiation"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["bristol-haematology-oncology-centre"],"pathways":[],"terms":[],"trials":["protect"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Social Medicine, Bristol Population Health Science Institute, University of Bristol","institutionId":"bristol-haematology-oncology-centre","specialisms":["Recruitment to difficult randomised trials","Patient-reported outcomes","Qualitative research inside trials"],"profiles":[{"label":"University of Bristol research information","url":"https://research-information.bris.ac.uk/en/persons/jenny-l-donovan"}],"papers":[{"title":"Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer","journal":"New England Journal of Medicine","year":2016,"doi":"10.1056/NEJMoa1606221"},{"title":"Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer","journal":"New England Journal of Medicine","year":2023,"doi":"10.1056/NEJMoa2214122"}]},{"id":"jens-hoeppner","kind":"person","name":"Jens Höppner","aka":[],"tldr":"German surgeon who led ESOPEC, the trial that compared FLOT chemotherapy with CROSS chemoradiotherapy before surgery for oesophageal adenocarcinoma and found FLOT gave longer survival.","summary":"Jens Höppner is a gastrointestinal surgeon who conceived and led the German ESOPEC trial. Its 2025 New England Journal of Medicine report, of which he was first author, showed that perioperative FLOT chemotherapy improved overall survival compared with neoadjuvant CROSS chemoradiotherapy in resectable oesophageal adenocarcinoma, shifting practice towards perioperative chemotherapy for this disease.","asOf":"2026-09-18","links":[],"tags":["oesophageal","surgery","trialist"],"related":[],"cancers":["oesophageal-adenocarcinoma","esophageal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["esopec"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Oesophago-gastric surgeon and trial lead","specialisms":["Oesophageal adenocarcinoma","Perioperative therapy","Surgical trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=H%C3%B6ppner%5BAuthor%5D"}],"papers":[]},{"id":"jens-overgaard","kind":"person","name":"Jens Overgaard","aka":[],"tldr":"Pioneering radiation oncologist at Aarhus who led the DAHANCA trials on hypoxia modification and radiotherapy for head and neck cancer.","summary":"Jens Overgaard is Professor in the Department of Oncology at Aarhus University and Aarhus University Hospital, where he founded the Department of Experimental Clinical Oncology. He has led the Danish Head and Neck Cancer Group (DAHANCA) trials for decades, establishing the role of hypoxic modification and altered fractionation in radiotherapy, and has been a central figure in European radiation oncology research.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://pure.au.dk/portal/en/persons/jens-overgaard"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Overgaard+J%5BAuthor%5D"}],"tags":["clinician-scientist","radiotherapy","head and neck cancer"],"related":[],"cancers":["head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["aarhus-university-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["radiotherapy-and-oncology"],"dependsOn":[],"notes":[],"role":"Professor, Department of Clinical Medicine - The Department of Oncology","institutionId":"aarhus-university-hospital","specialisms":["Radiation oncology","Head and neck cancer","Tumour hypoxia","Clinical trials"],"profiles":[{"label":"Institution profile","url":"https://pure.au.dk/portal/en/persons/jens-overgaard"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Overgaard+J%5BAuthor%5D"}],"papers":[{"title":"A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85","journal":"Radiotherapy and Oncology","year":1998,"url":"https://doi.org/10.1016/S0167-8140(97)00220-X","doi":"10.1016/S0167-8140(97)00220-X"}]},{"id":"jeremie-calais","kind":"person","name":"Jeremie Calais","aka":[],"tldr":"Runs the UCLA theranostics trials that test PSMA imaging against conventional scans and lutetium against chemotherapy.","summary":"Jeremie Calais is Associate Professor and Director of the Clinical Research Program in the Ahmanson Translational Theranostics Division at UCLA, part of the UCLA Jonsson Comprehensive Cancer Center. A nuclear medicine physician specialising in PSMA PET and radioligand therapy, he leads prospective PSMA PET and PSMA radioligand therapy trials, including the head-to-head comparison of PSMA PET with fluciclovine PET and dosimetry research. His papers include the Lancet Oncology comparative imaging trial of 18F-fluciclovine and 68Ga-PSMA-11 PET-CT in early biochemical recurrence after prostatectomy and the Journal of Nuclear Medicine RESIST-PC phase 2 trial of 177Lu-PSMA-617 in the UCLA cohort. His work centres on prostate cancer theranostics.","asOf":"2026-09-08","links":[{"label":"UCLA profile","url":"https://www.uclahealth.org/providers?q=Jeremie%20Calais"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Calais%20J%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Jeremie%20Calais"}],"tags":[],"related":[],"cancers":["prostate"],"sections":[],"technologies":["psma-pet","radioligand-therapy"],"targets":["psma"],"drugs":[],"companies":[],"institutions":["ucla-jonsson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["journal-of-nuclear-medicine"],"dependsOn":[],"notes":[],"role":"Associate Professor; Director, Clinical Research Program, Ahmanson Translational Theranostics Division, UCLA","institutionId":"ucla-jonsson","specialisms":["PSMA PET","Radioligand therapy","Clinical trials"],"profiles":[{"label":"UCLA profile","url":"https://www.uclahealth.org/providers?q=Jeremie%20Calais"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Calais%20J%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Jeremie%20Calais"}],"papers":[{"title":"18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial","journal":"Lancet Oncology","year":2019,"url":"https://doi.org/10.1016/s1470-2045(19)30415-2","doi":"10.1016/s1470-2045(19)30415-2"},{"title":"Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with (177)Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort","journal":"Journal of Nuclear Medicine","year":2021,"url":"https://doi.org/10.2967/jnumed.121.261982","doi":"10.2967/jnumed.121.261982"}]},{"id":"jerome-coffey","kind":"person","name":"Jerome Coffey","aka":[],"tldr":"Jerome Coffey represents Mater Private Network in the Organisation of European Cancer Institutes, which lists the centre among its members in Ireland.","summary":"Jerome Coffey is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Mater Private Network, its member in Ireland. Mater Private Network is an Irish private hospital group whose Dublin hospital sits beside the Mater Misericordiae, and a full member of the Organisation of European Cancer Institutes. OnCo records the name from the OECI membership list so that the centre's page has a named contact point; the person's exact title, appointment date and biography are not yet recorded and should be checked on the institution's own pages before being relied on.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Mater Private Network website","url":"https://www.materprivate.ie/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["mater-private"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Mater Private Network to the Organisation of European Cancer Institutes","institutionId":"mater-private","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Mater Private Network website","url":"https://www.materprivate.ie/"}],"papers":[]},{"id":"jesse-otegbayo","kind":"person","name":"Jesse Abiodun Otegbayo","aka":[],"tldr":"Professor of medicine and gastroenterologist who is Chief Medical Director of University College Hospital, Ibadan, Nigeria's oldest teaching hospital.","summary":"Professor Jesse Abiodun Otegbayo is Chief Medical Director of University College Hospital (UCH), Ibadan, the teaching hospital of the University of Ibadan and Nigeria's first teaching hospital. The hospital's website records his appointment as Chief Medical Director from 1 March 2019 and continued to list him in that office in September 2026. He qualified in medicine at the University of Ibadan in 1989, holds an MSc and PhD in chemical pathology and immunology, and became Professor of Medicine in 2008; he is a Fellow of the West African College of Physicians, the American College of Gastroenterology and the Royal College of Physicians of Glasgow, with more than 100 publications.","asOf":"2026-09-10","links":[{"label":"Source: UCH Ibadan website naming the Chief Medical Director","url":"https://uch-ibadan.org.ng"}],"tags":["leadership","clinician-scientist","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["uch-ibadan"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Medical Director, University College Hospital, Ibadan","institutionId":"uch-ibadan","specialisms":["Gastroenterology","Internal medicine","Hospital management"],"profiles":[{"label":"UCH Ibadan Chief Medical Director profile (archived copy)","url":"https://web.archive.org/web/20250117063852/https://uch-ibadan.org.ng/member/professor-jesse-abiodun-otegbayo/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Otegbayo+JA%5BAuthor%5D"}],"papers":[{"title":"Temporal and biological trends in liver cancers at a University hospital in Southwest Nigeria","journal":"Tropical Doctor","year":2006,"doi":"10.1258/004947506775598941"}],"orcid":"0000-0001-8992-9411"},{"id":"jesus-fernandez-galan","kind":"person","name":"Jesús Fernández Galán","aka":[],"tldr":"Jesús Fernández Galán represents Hospital Universitario Virgen de la Victoria in the Organisation of European Cancer Institutes, which lists the centre among its members in Spain.","summary":"Jesús Fernández Galán is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Hospital Universitario Virgen de la Victoria, its member in Spain. Hospital Universitario Virgen de la Victoria is one of the two public university hospitals of Málaga in the Andalusian health service, and a full member of the Organisation of European Cancer Institutes. OnCo records the name from the OECI membership list so that the centre's page has a named contact point; the person's exact title, appointment date and biography are not yet recorded and should be checked on the institution's own pages before being relied on.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Hospital Universitario Virgen de la Victoria website","url":"https://www.sspa.juntadeandalucia.es/servicioandaluzdesalud/hospital/virgen-victoria/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["virgen-de-la-victoria-malaga"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Hospital Universitario Virgen de la Victoria to the Organisation of European Cancer Institutes","institutionId":"virgen-de-la-victoria-malaga","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Hospital Universitario Virgen de la Victoria website","url":"https://www.sspa.juntadeandalucia.es/servicioandaluzdesalud/hospital/virgen-victoria/"}],"papers":[]},{"id":"jesus-berdeja","kind":"person","name":"Jesús G. Berdeja","aka":[],"tldr":"Led CARTITUDE-1, the trial that brought ciltacabtagene autoleucel, the most active myeloma CAR-T, to approval.","summary":"Jesús Berdeja (Sarah Cannon Research Institute, Nashville) was principal investigator and first author of CARTITUDE-1, the pivotal trial showing the BCMA CAR-T ciltacabtagene autoleucel produces responses in 98% of heavily pretreated myeloma patients with median progression-free survival near three years, the deepest responses seen in relapsed myeloma. He runs a large community-based early-phase programme.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Berdeja%20JG%5BAuthor%5D%20ciltacabtagene"}],"tags":["myeloma","car-t","community-research"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":["car-t"],"targets":["bcma"],"drugs":["ciltacabtagene-autoleucel"],"companies":[],"institutions":["tennessee-oncology"],"pathways":[],"terms":[],"trials":["cartitude-1"],"people":[],"bottlenecks":[],"keyPapers":["paper-cartitude-1-cilta-cel-lancet-2021"],"journals":[],"dependsOn":[],"notes":[],"role":"Director of Myeloma Research, Greco-Hainsworth Centers for Research, Tennessee Oncology; Sarah Cannon Research Institute","institutionId":"tennessee-oncology","specialisms":["Multiple myeloma","CAR T-cell therapy","Early drug development","Community-based trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Berdeja%20JG%5BAuthor%5D%20ciltacabtagene"}],"papers":[{"title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study","journal":"Lancet","year":2021,"doi":"10.1016/S0140-6736(21)00933-8"},{"title":"Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE-1 final results","journal":"JCO","year":2025},{"title":"CARTITUDE-1: cilta-cel, a BCMA CAR-T, in heavily pretreated myeloma","journal":"The Lancet","year":2021,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CARTITUDE-1%20ciltacabtagene%20autoleucel%20Berdeja%20Lancet%202021"}]},{"id":"jesus-san-miguel","kind":"person","name":"Jesús San Miguel","aka":[],"tldr":"Hematologist who chairs the Cancer Center CUN internal scientific committee and is one of the most influential clinical investigators in multiple myeloma.","summary":"Jesús San Miguel presides over the Internal Scientific Committee of the Cancer Center Clínica Universidad de Navarra and is Director of Clinical and Translational Medicine at the University of Navarra. He has led numerous pivotal trials in multiple myeloma with the Spanish Myeloma Group (GEM/PETHEMA) and pioneered flow-cytometry-based minimal residual disease assessment. He has received the Ham-Wasserman and Waldenström awards among other international recognitions.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://cancercenter.cun.es/cancer-center/organigrama"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=San-Miguel+JF%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","multiple myeloma","hematology"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cun-navarra"],"pathways":[],"terms":[],"trials":["cartitude-4"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President, Internal Scientific Committee","institutionId":"cun-navarra","specialisms":["Multiple myeloma","Hematology","Minimal residual disease"],"profiles":[{"label":"Institution profile","url":"https://cancercenter.cun.es/cancer-center/organigrama"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=San-Miguel+JF%5BAuthor%5D"}],"papers":[{"title":"Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial","journal":"The Lancet Oncology","year":2016,"doi":"10.1016/s1470-2045(16)30124-3"},{"title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","journal":"The Lancet Oncology","year":2013,"doi":"10.1016/s1470-2045(13)70380-2"},{"title":"Defining and treating high-risk multiple myeloma","journal":"Leukemia","year":2015,"doi":"10.1038/leu.2015.209"}]},{"id":"fan-jia","kind":"person","name":"Jia Fan","aka":["樊嘉","jia-fan"],"tldr":"Jia Fan leads one of the world's busiest liver cancer surgery and transplant programmes and the proteogenomic studies that mapped how hepatitis B-related liver cancer differs at the molecular level.","summary":"Liver surgeon and academician of the Chinese Academy of Sciences whose Liver Cancer Institute at Zhongshan Hospital performs thousands of resections and transplants a year; senior author of the integrated proteogenomic characterisation of HBV-related HCC (Cell 2019) and of work on circulating tumour cells, recurrence prediction and immune microenvironment; leads Chinese guidelines on HCC and on liver transplantation criteria.","asOf":"2026-09-10","links":[{"label":"Zhongshan Hospital","url":"https://www.zs-hospital.sh.cn/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fan%20J%5BAuthor%5D%20hepatocellular%20carcinoma%20Zhongshan%20Hospital%20Fudan"}],"tags":["china","leadership","clinician-scientist","liver cancer","surgical oncology"],"related":[],"cancers":["hcc","cholangiocarcinoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["zhongshan-hospital-fudan"],"pathways":[],"terms":["hbv-hcv","hepatectomy"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President, Zhongshan Hospital, Fudan University; Liver Cancer Institute","institutionId":"zhongshan-hospital-fudan","specialisms":["Liver surgery","Liver transplantation","Hepatocellular carcinoma","Tumour microenvironment"],"profiles":[{"label":"Zhongshan Hospital","url":"https://www.zs-hospital.sh.cn/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fan%20J%5BAuthor%5D%20hepatocellular%20carcinoma%20Zhongshan%20Hospital%20Fudan"}],"papers":[{"title":"Integrated proteogenomic characterization of HBV-related hepatocellular carcinoma","journal":"Cell","year":2019,"doi":"10.1016/j.cell.2019.08.052"},{"title":"Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma","journal":"Cell","year":2021,"doi":"10.1016/j.cell.2020.11.041"},{"title":"Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition)","journal":"Liver Cancer","year":2020,"doi":"10.1159/000509424"}]},{"id":"jian-zhou","kind":"person","name":"Jian Zhou","aka":[],"tldr":"A Chinese virologist whose skill in expressing viral proteins made the first HPV virus-like particles in 1991. He died in 1999 at 42, seven years before the vaccine reached the public.","summary":"Jian Zhou (1957-1999) trained in medicine and virology in China and worked in Cambridge before joining Ian Frazer in Brisbane in 1990. It was his expertise in expressing papillomavirus proteins in cells that allowed the L1 capsid protein to self-assemble into virus-like particles in 1991, the discovery at the heart of the HPV vaccines. He and Frazer filed the patent together and he continued to work on HPV therapeutic vaccines in Australia and at Loyola University Chicago. He died suddenly in 1999 while visiting China, before Gardasil was licensed in 2006. His contribution was recognised posthumously with the European Inventor Award in 2015, shared with Frazer, and Australia's Prime Minister's Prize for Science; his widow, Xiao-Yi Sun, who worked alongside him, continues to represent his legacy.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Jian_Zhou","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Jian_Zhou"},{"label":"European Patent Office","url":"https://www.epo.org/"}],"tags":["hero","pioneer"],"related":[],"cancers":["cervical"],"sections":["prevention"],"technologies":["hpv-vaccine"],"targets":[],"drugs":["gardasil-9"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["ian-frazer","harald-zur-hausen"],"bottlenecks":["b-prevention-adoption"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Virologist who co-invented the HPV virus-like particle vaccine","specialisms":["Molecular virology","HPV vaccines"],"profiles":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Jian_Zhou"},{"label":"European Patent Office","url":"https://www.epo.org/"}],"papers":[{"title":"Papillomavirus Capsid Protein Expression Level Depends on the Match between Codon Usage and tRNA Availability","journal":"Journal of Virology","year":1999,"doi":"10.1128/jvi.73.6.4972-4982.1999"},{"title":"Interaction of human papillomavirus (HPV) type 16 capsid proteins with HPV DNA requires an intact L2 N-terminal sequence","journal":"Journal of Virology","year":1994,"doi":"10.1128/jvi.68.2.619-625.1994"}]},{"id":"xu-jianming","kind":"person","name":"Jianming Xu","aka":["Xu Jian-Ming","徐建明"],"tldr":"Jianming Xu led the Chinese stomach cancer trials of sintilimab, the ADC disitamab vedotin and other domestic drugs, in the country with the most stomach cancer patients.","summary":"Jianming Xu is Professor of Gastrointestinal Oncology at the Fifth Medical Center of the Chinese PLA General Hospital in Beijing. He is best known as principal investigator of ORIENT-16, the randomised trial of sintilimab plus chemotherapy in first-line unresectable gastric and gastro-oesophageal junction cancer reported in JAMA, and of the pivotal gastric cancer study of the HER2 antibody-drug conjugate disitamab vedotin. He has led many Chinese phase 3 trials in gastric, colorectal and oesophageal cancer and is a leading figure in the CSCO gastric cancer guidelines. His trials have brought domestic drugs to the country with the most stomach cancer patients.","asOf":"2026-09-10","links":[{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Xu%20J%5BAuthor%5D%20gastric%20cancer%20307%20Hospital%20PLA"}],"tags":["china"],"related":[],"cancers":["gastric"],"sections":[],"technologies":[],"targets":[],"drugs":["sintilimab","disitamab-vedotin"],"companies":[],"institutions":["pla-general-hospital"],"pathways":[],"terms":[],"trials":["orient-16"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Gastrointestinal Oncology; Fifth Medical Center, Chinese PLA General Hospital, Beijing","institutionId":"pla-general-hospital","specialisms":["Gastric cancer","Gastrointestinal oncology","Clinical trials","HER2 ADCs"],"profiles":[{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Xu%20J%5BAuthor%5D%20gastric%20cancer%20307%20Hospital%20PLA"}],"papers":[{"title":"Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial","journal":"JAMA","year":2023,"doi":"10.1001/jama.2023.19918"}]},{"id":"he-jie","kind":"person","name":"Jie He","aka":[],"tldr":"Runs China's national cancer centre and the registry that reports the country's cancer statistics.","summary":"Jie He is President of the Cancer Hospital of the Chinese Academy of Medical Sciences, Director of the National Cancer Center of China and a thoracic surgeon. He runs China's national cancer centre and the registry that reports the country's cancer statistics, overseeing the national cancer registry, screening programmes and clinical research infrastructure. His publications include the report on cancer incidence and mortality in China in 2022. His interests span thoracic surgery, lung and oesophageal cancer, cancer registry and statistics, and screening policy.","asOf":"2026-09-08","links":[{"label":"Cancer Hospital, CAMS","url":"https://www.cicams.ac.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=He%20J%5BAuthor%5D%20National%20Cancer%20Center%20China%20cancer%20statistics"}],"tags":[],"related":[],"cancers":["nsclc","esophageal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cams-cancer-hospital","ncc-china"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President, Cancer Hospital, Chinese Academy of Medical Sciences; Director, National Cancer Center of China; thoracic surgeon","institutionId":"cams-cancer-hospital","specialisms":["Thoracic surgery","Lung and oesophageal cancer","Cancer registry and statistics","Screening policy"],"profiles":[{"label":"Cancer Hospital, CAMS","url":"https://www.cicams.ac.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=He%20J%5BAuthor%5D%20National%20Cancer%20Center%20China%20cancer%20statistics"}],"papers":[{"title":"Cancer incidence and mortality in China, 2022","journal":"Journal of the National Cancer Center","year":2024,"doi":"10.1016/j.jncc.2024.01.006"},{"title":"ADAURA: three years of osimertinib after surgery for EGFR-mutated lung cancer","journal":"New England Journal of Medicine","year":2020,"url":"https://doi.org/10.1056/NEJMoa2027071","doi":"10.1056/NEJMoa2027071"}]},{"id":"wang-jie-cams","kind":"person","name":"Jie Wang","aka":[],"tldr":"Led the RATIONALE trials of tislelizumab in lung cancer and many other Chinese registrational NSCLC studies.","summary":"Jie Wang is Professor of Medical Oncology at the Cancer Hospital of the Chinese Academy of Medical Sciences in Beijing. She led the RATIONALE-304 and RATIONALE-307 trials of tislelizumab, the PD-1 antibody from BeOne Medicines, formerly BeiGene, in non-small-cell lung cancer, and has been principal investigator on many other Chinese registrational lung cancer studies. These include EGFR tyrosine kinase inhibitor and ALK trials in non-small-cell lung cancer and studies of Chinese PD-1 antibodies in small-cell lung cancer. Her interests are lung cancer, immunotherapy, targeted therapy and clinical trials.","asOf":"2026-09-08","links":[{"label":"Cancer Hospital, CAMS","url":"https://www.cicams.ac.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wang%20J%5BAuthor%5D%20Chinese%20Academy%20of%20Medical%20Sciences%20tislelizumab%20lung"}],"tags":[],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["tislelizumab"],"companies":["beone"],"institutions":["cams-cancer-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology; Cancer Hospital, Chinese Academy of Medical Sciences","institutionId":"cams-cancer-hospital","specialisms":["Lung cancer","Immunotherapy","Targeted therapy","Clinical trials"],"profiles":[{"label":"Cancer Hospital, CAMS","url":"https://www.cicams.ac.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wang%20J%5BAuthor%5D%20Chinese%20Academy%20of%20Medical%20Sciences%20tislelizumab%20lung"}],"papers":[{"title":"Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer","journal":"JAMA Oncology","year":2021,"doi":"10.1001/jamaoncol.2021.0366"},{"title":"Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non–Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel","journal":"JAMA Oncology","year":2019,"doi":"10.1001/jamaoncol.2018.7098"},{"title":"Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","journal":"The Lancet Oncology","year":2022,"doi":"10.1016/s1470-2045(22)00224-8"}]},{"id":"jihui-hao","kind":"person","name":"Jihui Hao","aka":[],"tldr":"Physician-scientist who is President of Tianjin Medical University Cancer Institute and Hospital, one of China's largest specialist cancer hospitals and a National Clinical Research Center for Malignant Tumors.","summary":"Jihui Hao (MD, PhD) is President of Tianjin Medical University Cancer Institute and Hospital (TMUCIH), the specialist tertiary cancer hospital of Tianjin Medical University in Hexi District, Tianjin. The hospital's English leadership page lists him as President alongside Party Secretary Jianguo Liu and vice presidents Xiaohui Cao, Lan Zhang, Jing Hei, Jun Shen, Dingzhi Huang and Hui Li. TMUCIH traces its origins to an 1861 clinic, opened China's first tumour ward in 1952 under Jin Xianzhai, took its current name in 1997 and was designated a National Clinical Research Center for Malignant Tumors in 2013, operating 36 clinical departments across several Tianjin campuses.","asOf":"2026-09-10","links":[{"label":"Source: TMUCIH leadership page","url":"http://www.tmucih.com/index/about/leaderships.html"},{"label":"Source: Wikipedia article on TMUCIH","url":"https://en.wikipedia.org/wiki/Tianjin_Medical_University_Cancer_Institute_and_Hospital"}],"tags":["leadership","clinician-scientist","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["tmucih"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["oncotarget","nature-communications"],"dependsOn":[],"notes":[],"role":"President, Tianjin Medical University Cancer Institute and Hospital","institutionId":"tmucih","specialisms":["Surgical oncology","Hospital management","Cancer research"],"profiles":[{"label":"TMUCIH leadership page (English)","url":"http://www.tmucih.com/index/about/leaderships.html"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hao+J%5BAuthor%5D+AND+Tianjin+Medical+University+Cancer"}],"papers":[{"title":"Co-delivery of HIF1α siRNA and gemcitabine via biocompatible lipid-polymer hybrid nanoparticles for effective treatment of pancreatic cancer","journal":"Biomaterials","year":2015,"doi":"10.1016/j.biomaterials.2014.12.028"},{"title":"Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma","journal":"Oncotarget","year":2014,"doi":"10.18632/oncotarget.2948"},{"title":"Tumour-derived Interleukin 35 promotes pancreatic ductal adenocarcinoma cell extravasation and metastasis by inducing ICAM1 expression","journal":"Nature Communications","year":2017,"doi":"10.1038/ncomms14035"}]},{"id":"jim-valvano","kind":"person","name":"Jim Valvano","aka":[],"tldr":"Dying of metastatic cancer, he told an audience in 1993, \"Don't give up, don't ever give up,\" and announced a foundation that has since granted hundreds of millions of dollars to cancer research.","summary":"Jim Valvano (1946-1993) coached North Carolina State to the 1983 NCAA basketball championship and later worked as a broadcaster. In June 1992 he was diagnosed with metastatic adenocarcinoma of unknown primary. On 4 March 1993, eight weeks before his death, he accepted the inaugural Arthur Ashe Courage Award at the ESPY Awards with a speech in which he announced The V Foundation for Cancer Research, founded with ESPN, and closed with the words that became its motto. He died on 28 April 1993 at 47. The V Foundation has since awarded more than $350 million in research grants, with a scientific advisory committee choosing recipients and all direct donations going to research.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Jim_Valvano","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Jim_Valvano"},{"label":"The V Foundation","url":"https://www.v.org/"}],"tags":["public-figure","patient","advocate"],"related":[],"cancers":["cancer-of-unknown-primary"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-funding-allocation"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Basketball coach whose ESPY speech founded the V Foundation for Cancer Research","specialisms":["Cancer research funding","Public advocacy"],"profiles":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Jim_Valvano"},{"label":"The V Foundation","url":"https://www.v.org/"}],"papers":[]},{"id":"jim-woodgett","kind":"person","name":"Jim Woodgett","aka":[],"tldr":"Cell signalling scientist who has been President and Scientific Director of the Terry Fox Research Institute, the research arm of The Terry Fox Foundation, since 2021.","summary":"Dr Jim Woodgett is President and Scientific Director of the Terry Fox Research Institute (TFRI), established in 2007 as the research arm of The Terry Fox Foundation to invest in collaborative cancer research teams across Canada, and he also sits on its Board of Directors. He took up the role on 1 August 2021, having directed research at the Lunenfeld-Tanenbaum Research Institute at Sinai Health from 2005 to 2021, where he remains a Senior Scientist; he is also Professor of Medical Biophysics at the University of Toronto. He earned his PhD in biochemistry at the University of Dundee in 1984, did postdoctoral work at the Salk Institute, is a Fellow of the Royal Society of Canada and has published more than 300 papers on signal transduction in cancer, degenerative disease and diabetes.","asOf":"2026-09-10","links":[{"label":"Source: TFRI leadership biography","url":"https://www.tfri.ca/about/team/bio/jim-woodgett"},{"label":"Source: TFRI team page","url":"https://www.tfri.ca/about/team"}],"tags":["leadership","clinician-scientist","research-institute","philanthropy"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["terry-fox-foundation"],"pathways":[],"terms":[],"trials":[],"people":["terry-fox"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President and Scientific Director, Terry Fox Research Institute","institutionId":"terry-fox-research-institute","specialisms":["Cell signalling","Cancer biology","Research funding leadership"],"profiles":[{"label":"TFRI biography","url":"https://www.tfri.ca/about/team/bio/jim-woodgett"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Woodgett+JR%5BAuthor%5D"}],"papers":[{"title":"Glycogen Synthase Kinase-3 and Cancer: Good Cop, Bad Cop?","journal":"Cancer Cell","year":2008,"doi":"10.1016/j.ccr.2008.10.013"}]},{"id":"jimmie-holland","kind":"person","name":"Jimmie Holland","aka":[],"tldr":"A psychiatrist who set up the first full-time psychiatry service in a cancer hospital at Memorial Sloan Kettering in 1977, founded the field's societies and journal, and made distress a vital sign in cancer care.","summary":"Jimmie Holland (1928-2017) trained in psychiatry in Texas and moved to New York with her husband, the oncologist James Holland. In 1977 she founded the Psychiatry Service at Memorial Sloan Kettering Cancer Center, the first full-time service of its kind, at a time when a patient's emotional state was regarded as outside the oncologist's remit and often not discussed. She founded the International Psycho-Oncology Society in 1984 and the American Psychosocial Oncology Society in 1986, edited the first textbook of psycho-oncology, and launched the journal Psycho-Oncology. She led the NCCN panel that defined distress as the sixth vital sign and produced the Distress Thermometer, a single-item screen now used in cancer centres worldwide. Her later work focused on the psychological needs of older patients.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Jimmie_Holland","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Jimmie_Holland"},{"label":"International Psycho-Oncology Society","url":"https://ipos-society.org/"}],"tags":["hero","pioneer"],"related":[],"cancers":[],"sections":["supportive-care"],"technologies":["psycho-oncology"],"targets":[],"drugs":[],"companies":[],"institutions":["mskcc","nccn-org"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-toxicity-qol","b-patient-voice"],"keyPapers":[],"journals":["psycho-oncology-journal"],"dependsOn":[],"notes":[],"role":"Founder of psycho-oncology","specialisms":["Psycho-oncology","Psychiatry","Distress screening"],"profiles":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Jimmie_Holland"},{"label":"International Psycho-Oncology Society","url":"https://ipos-society.org/"}],"papers":[{"title":"Rapid screening for psychologic distress in men with prostate carcinoma","journal":"Cancer","year":1998,"doi":"10.1002/(sici)1097-0142(19980515)82:10<1904::aid-cncr13>3.0.co;2-x"},{"title":"History of Psycho-Oncology: Overcoming Attitudinal and Conceptual Barriers","journal":"Psychosomatic Medicine","year":2002,"doi":"10.1097/00006842-200203000-00004"},{"title":"A brief spiritual beliefs inventory for use in quality of life research in life-threatening illness","journal":"Psycho-Oncology","year":1998,"doi":"10.1002/(sici)1099-1611(199811/12)7:6<460::aid-pon328>3.0.co;2-r"}]},{"id":"jimmy-so","kind":"person","name":"Jimmy So","aka":[],"tldr":"Gastric cancer surgeon who heads surgical oncology at NCIS and coordinates its multidisciplinary tumour groups.","summary":"Jimmy So is Head of the Division of Surgical Oncology and Associate Director (Tumour Groups) at the National University Cancer Institute, Singapore. A professor of surgery at the National University of Singapore, his clinical and research focus is upper gastrointestinal surgery and gastric cancer, including screening and minimally invasive approaches.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.ncis.com.sg/about-ncis/at-the-helm"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=So+JB%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","gastric cancer","surgical oncology"],"related":[],"cancers":["gastric","esophageal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["nuh-ncis"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Head, Division of Surgical Oncology; Associate Director (Tumour Groups)","institutionId":"nuh-ncis","specialisms":["Surgical oncology","Gastric cancer","Upper gastrointestinal surgery"],"profiles":[{"label":"Institution profile","url":"https://www.ncis.com.sg/about-ncis/at-the-helm"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=So+JB%5BAuthor%5D"}],"papers":[{"title":"Single-Cell Atlas of Lineage States, Tumor Microenvironment, and Subtype-Specific Expression Programs in Gastric Cancer","journal":"Cancer Discovery","year":2022,"doi":"10.1158/2159-8290.cd-21-0683"},{"title":"Integration of Genomic Biology Into Therapeutic Strategies of Gastric Cancer Peritoneal Metastasis","journal":"Journal of Clinical Oncology","year":2022,"doi":"10.1200/jco.21.02745"},{"title":"ADAR-Mediated RNA Editing Predicts Progression and Prognosis of Gastric Cancer","journal":"Gastroenterology","year":2016,"doi":"10.1053/j.gastro.2016.06.043"}],"orcid":"0000-0002-9772-7905"},{"id":"li-jin-fuscc","kind":"person","name":"Jin Li","aka":[],"tldr":"Principal investigator of FRESCO, the Chinese trial that first proved fruquintinib works in refractory colorectal cancer.","summary":"Jin Li is Professor of Medical Oncology at Fudan University Shanghai Cancer Center and Shanghai East Hospital, specialising in gastrointestinal oncology. He was principal investigator of FRESCO, the Chinese trial that first showed fruquintinib works in previously treated metastatic colorectal cancer, a result later extended internationally in FRESCO-2. He has also led other Chinese gastrointestinal oncology trials, including apatinib in gastric cancer, contributing drugs now used around the world. His publications include the FRESCO randomised trial of fruquintinib against placebo in refractory colorectal cancer.","asOf":"2026-09-08","links":[{"label":"Fudan University Shanghai Cancer Center","url":"https://www.shca.org.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Li%20J%5BAuthor%5D%20fruquintinib%20FRESCO"}],"tags":[],"related":[],"cancers":["colorectal","gastric"],"sections":[],"technologies":[],"targets":[],"drugs":["fruquintinib"],"companies":[],"institutions":["fuscc"],"pathways":[],"terms":[],"trials":["fresco-2"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology, Fudan University Shanghai Cancer Center and Shanghai East Hospital; gastrointestinal oncology","institutionId":"fuscc","specialisms":["Colorectal cancer","Gastric cancer","Targeted therapy","Clinical trials"],"profiles":[{"label":"Fudan University Shanghai Cancer Center","url":"https://www.shca.org.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Li%20J%5BAuthor%5D%20fruquintinib%20FRESCO"}],"papers":[{"title":"Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO randomized clinical trial","journal":"JAMA","year":2018,"doi":"10.1001/jama.2018.7855"}]},{"id":"jin-seok-ahn","kind":"person","name":"Jin Seok Ahn","aka":[],"tldr":"Medical oncologist serving as 14th President of the Korean Cancer Study Group, Korea's main academic cooperative trials group.","summary":"Jin Seok Ahn (안진석) is the 14th President of the Korean Cancer Study Group (KCSG), the multicentre cooperative group that runs investigator-initiated cancer trials across Korea. He is a medical oncologist at Samsung Medical Center, Sungkyunkwan University, whose clinical research centres on lung cancer, including targeted and immune-based therapies.","asOf":"2026-09-10","links":[{"label":"Society page","url":"https://www.kcsg.org/web/information/ceo01.do"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ahn+JS%5BAuthor%5D+Samsung+lung"}],"tags":["leadership","clinician-scientist","lung cancer","clinical trials"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["kcsg"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President (14th)","institutionId":"kcsg","specialisms":["Medical oncology","Lung cancer","Cooperative group trials"],"profiles":[{"label":"Society page","url":"https://www.kcsg.org/web/information/ceo01.do"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ahn+JS%5BAuthor%5D+Samsung+lung"}],"papers":[{"title":"Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non–Small-Cell Lung Cancer: KCSG-LU05-04","journal":"Journal of Clinical Oncology","year":2015,"doi":"10.1200/jco.2014.60.0130"},{"title":"Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer","journal":"New England Journal of Medicine","year":2017,"doi":"10.1056/nejmoa1704795"},{"title":"Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study","journal":"Annals of Oncology","year":2020,"doi":"10.1016/j.annonc.2020.04.478"}]},{"id":"huang-jing-cams","kind":"person","name":"Jing Huang","aka":[],"tldr":"Principal investigator of ESCORT, the trial that established camrelizumab in oesophageal squamous cell carcinoma.","summary":"Jing Huang is Professor of Medical Oncology at the Cancer Hospital of the Chinese Academy of Medical Sciences in Beijing. She was principal investigator of ESCORT, the trial that established the PD-1 antibody camrelizumab in oesophageal squamous cell carcinoma, and of ESCORT-1st, which tested it in the first-line setting. Her publications include the ESCORT report comparing camrelizumab with investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma. She also leads studies of other PD-1 antibodies in oesophageal cancer, with interests in immunotherapy and clinical trials.","asOf":"2026-09-08","links":[{"label":"Cancer Hospital, CAMS","url":"https://www.cicams.ac.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Huang%20J%5BAuthor%5D%20camrelizumab%20esophageal%20ESCORT"}],"tags":[],"related":[],"cancers":["esophageal"],"sections":[],"technologies":[],"targets":[],"drugs":["camrelizumab"],"companies":[],"institutions":["cams-cancer-hospital"],"pathways":[],"terms":[],"trials":["escort-1st"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology; Cancer Hospital, Chinese Academy of Medical Sciences","institutionId":"cams-cancer-hospital","specialisms":["Oesophageal cancer","Immunotherapy","Clinical trials"],"profiles":[{"label":"Cancer Hospital, CAMS","url":"https://www.cicams.ac.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Huang%20J%5BAuthor%5D%20camrelizumab%20esophageal%20ESCORT"}],"papers":[{"title":"Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT)","journal":"Lancet Oncology","year":2020,"doi":"10.1016/S1470-2045(20)30110-8"}]},{"id":"joan-spencer","kind":"person","name":"Joan Spencer","aka":[],"tldr":"Cancer nurse by training who became Chief Executive of The Clatterbridge Cancer Centre NHS Foundation Trust in March 2025 after six years as its Chief Operating Officer.","summary":"Joan Spencer is Chief Executive of The Clatterbridge Cancer Centre NHS Foundation Trust, the specialist cancer trust serving Cheshire and Merseyside from hospitals in Wirral, Liverpool and Aintree plus satellite clinics, and home to the UK's only low-energy proton therapy unit for eye tumours. The trust announced in November 2024 that she would take over from Liz Bishop, who retired after 42 years in the NHS, on 31 March 2025; the trust's news pages later record her permanent appointment as Chief Executive in April 2026 following a national recruitment process. A cancer nurse by training, she joined Clatterbridge in 2014 as General Manager of Chemotherapy, developed its networked care model and launched Clatterbridge in the Community, the UK's first chemotherapy-at-home service, before serving as Chief Operating Officer and Deputy Chief Executive from April 2019.","asOf":"2026-09-10","links":[{"label":"Source: Oncology News Today report of the trust's announcement (26 November 2024)","url":"https://oncologynewstoday.co.uk/the-clatterbridge-cancer-centre-announces-new-chief-executive-from-march-2025/"},{"label":"Source: Wikipedia article on the trust","url":"https://en.wikipedia.org/wiki/Clatterbridge_Cancer_Centre_NHS_Foundation_Trust"}],"tags":["leadership","hospital-management","comprehensive-cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":["proton-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":["clatterbridge"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive, The Clatterbridge Cancer Centre NHS Foundation Trust","institutionId":"clatterbridge","specialisms":["Cancer nursing","Networked cancer care","NHS management"],"profiles":[{"label":"Trust announcement of permanent appointment","url":"https://www.clatterbridgecc.nhs.uk/about-us/news/trust-appoints-joan-spencer-chief-executive"},{"label":"Trust board page","url":"https://www.clatterbridgecc.nhs.uk/about-us/our-board"}],"papers":[{"title":"Putting patients first: an inventive service delivering cancer treatment at home","journal":"Journal of Comparative Effectiveness Research","year":2019,"doi":"10.2217/cer-2019-0038"}]},{"id":"joann-sweasy","kind":"person","name":"Joann B. Sweasy","aka":[],"tldr":"DNA repair scientist who directs the Fred & Pamela Buffett Cancer Center in Omaha and the UNMC Eppley Institute.","summary":"Joann B. Sweasy, PhD, is Director of the Fred & Pamela Buffett Cancer Center at the University of Nebraska Medical Center (UNMC) in Omaha, where she holds the Robert F. and Myrna L. Krohn Chair in Cancer Research and also directs the UNMC Eppley Institute. Her research focuses on DNA repair. The centre's leadership page lists her senior team, including deputy directors Kathleen Moore (phase 1 oncology trials) and Thomas A. Sellers (population science), and gives no appointment date.","asOf":"2026-09-10","links":[{"label":"Source: Fred & Pamela Buffett Cancer Center leadership page","url":"https://www.unmc.edu/cancercenter/about/leadership.html"}],"tags":["leadership","clinician-scientist","research-institute"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["nebraska-buffett"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["pnas"],"dependsOn":[],"notes":[],"role":"Director, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center","institutionId":"nebraska-buffett","specialisms":["DNA repair","Cancer biology","Cancer centre management"],"profiles":[{"label":"Cancer centre leadership page","url":"https://www.unmc.edu/cancercenter/about/leadership.html"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sweasy+JB%5BAuthor%5D"}],"papers":[{"title":"Expression of DNA polymerase β cancer-associated variants in mouse cells results in cellular transformation","journal":"Proceedings of the National Academy of Sciences","year":2005,"doi":"10.1073/pnas.0505166102"},{"title":"Is There a Link Between DNA Polymerase Beta and Cancer?","journal":"Cell Cycle","year":2004,"doi":"10.4161/cc.3.8.1062"},{"title":"Is Base Excision Repair a Tumor Suppressor Mechanism?","journal":"Cell Cycle","year":2006,"doi":"10.4161/cc.5.3.2414"}]},{"id":"joanna-lorenc","kind":"person","name":"Joanna Lorenc","aka":[],"tldr":"Joanna Lorenc represents AidPort Clinical Trial Hospital in the Organisation of European Cancer Institutes, which lists the organisation among its members in Poland.","summary":"Joanna Lorenc is listed by the Organisation of European Cancer Institutes (OECI) as the representative of AidPort Clinical Trial Hospital, its associate member in Poland. OnCo records the name from the OECI membership list so that the organisation's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the organisation's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"AidPort Clinical Trial Hospital website","url":"https://www.aidport.pl/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["aidport"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of AidPort Clinical Trial Hospital to the Organisation of European Cancer Institutes","institutionId":"aidport","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"AidPort Clinical Trial Hospital website","url":"https://www.aidport.pl/"}],"papers":[]},{"id":"joaquim-bellmunt","kind":"person","name":"Joaquim Bellmunt","aka":[],"tldr":"Led KEYNOTE-045, the first trial to show immunotherapy beats chemotherapy in advanced bladder cancer.","summary":"Joaquim Bellmunt was principal investigator of KEYNOTE-045, which showed pembrolizumab improves survival over second-line chemotherapy in platinum-refractory urothelial cancer, the first randomised survival benefit for immunotherapy in the disease. He developed the Bellmunt prognostic score and led the vinflunine and TCGA bladder subtype work. He directs the bladder cancer centre at Dana-Farber.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bellmunt%20J%5BAuthor%5D%20urothelial%20pembrolizumab"}],"tags":["urothelial","immunotherapy"],"related":[],"cancers":["urothelial"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["pd1"],"drugs":["pembrolizumab"],"companies":[],"institutions":["dana-farber"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Bladder Cancer Center, Dana-Farber Cancer Institute; Associate Professor, Harvard Medical School","institutionId":"dana-farber","specialisms":["Urothelial cancer","Immunotherapy","Chemotherapy","Molecular subtypes"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bellmunt%20J%5BAuthor%5D%20urothelial%20pembrolizumab"}],"papers":[{"title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma (KEYNOTE-045)","journal":"NEJM","year":2017,"doi":"10.1056/NEJMoa1613683"},{"title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","journal":"Cell","year":2017,"doi":"10.1016/j.cell.2017.09.007"}]},{"id":"joaquin-arribas","kind":"person","name":"Joaquín Arribas","aka":[],"tldr":"Cancer biologist who characterised truncated HER2 (p95HER2) and develops p95HER2-targeted T-cell engagers.","summary":"Joaquín Arribas is Director of the Hospital del Mar Research Institute in Barcelona and an ICREA Professor, having led the Growth Factors group at the Vall d'Hebron Institute of Oncology (VHIO) for two decades. His specialisms are HER2 biology, resistance to anti-HER2 therapy and T-cell bispecifics. He characterised truncated HER2, known as p95HER2, showed how it confers resistance to trastuzumab in HER2-positive breast cancer, and develops T-cell engagers directed against it. His papers include a study of defective cyclin B1 induction in acquired resistance to trastuzumab emtansine, a Nature Communications report on CAR T cells targeting p95HER2 in solid tumours, and a Cancer Discovery paper on detecting early-stage breast cancer in breast milk. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Arribas%20J%5BAuthor%5D%20p95HER2"}],"tags":[],"related":[],"cancers":["breast-her2-positive"],"sections":[],"technologies":["t-cell-engager"],"targets":["her2"],"drugs":[],"companies":[],"institutions":["vall-dhebron"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Hospital del Mar Research Institute; ICREA Professor; formerly VHIO","institutionId":"vall-dhebron","specialisms":["HER2 biology","Resistance to anti-HER2 therapy","T-cell bispecifics"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Arribas%20J%5BAuthor%5D%20p95HER2"}],"papers":[{"title":"Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer","journal":"Clinical Cancer Research","year":2017,"doi":"10.1158/1078-0432.ccr-17-0696"},{"title":"Generation of chimeric antigen receptor T cells targeting p95HER2 in solid tumors","journal":"Nature Communications","year":2024,"doi":"10.1038/s41467-024-53265-7"},{"title":"Early-Stage Breast Cancer Detection in Breast Milk","journal":"Cancer Discovery","year":2023,"doi":"10.1158/2159-8290.cd-22-1340"}],"orcid":"0000-0002-0504-0664"},{"id":"joaquin-martinez-lopez","kind":"person","name":"Joaquín Martínez-López","aka":[],"tldr":"Haematologist who heads the Haematology Department at Hospital 12 de Octubre and the joint H12O-CNIO haematological malignancies unit, known for myeloma and MRD research.","summary":"Joaquín Martínez-López is Head of the Haematology Department at Hospital Universitario 12 de Octubre in Madrid and heads the H12O-CNIO Haematological Malignancies Clinical Research Unit. His research centres on multiple myeloma, including minimal residual disease assessment and novel therapies. He is a professor at the Complutense University of Madrid.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.cnio.es/en/the-cnio/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Martinez-Lopez+J%5BAuthor%5D+myeloma"}],"tags":["clinician-scientist","haematology","multiple myeloma"],"related":[],"cancers":["multiple-myeloma","myeloproliferative-neoplasms"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["12-de-octubre"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["blood-cancer-journal"],"dependsOn":[],"notes":[],"role":"Head of the Haematology Department","institutionId":"12-de-octubre","specialisms":["Multiple myeloma","Haematological malignancies","Minimal residual disease"],"profiles":[{"label":"Institution profile","url":"https://www.cnio.es/en/the-cnio/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Martinez-Lopez+J%5BAuthor%5D+myeloma"}],"papers":[{"title":"Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma","journal":"Blood","year":2014,"doi":"10.1182/blood-2014-01-550020"},{"title":"Long-term prognostic significance of response in multiple myeloma after stem cell transplantation","journal":"Blood","year":2011,"doi":"10.1182/blood-2011-01-332320"},{"title":"Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality","journal":"Blood Cancer Journal","year":2020,"doi":"10.1038/s41408-020-00372-5"}],"orcid":"0000-0001-7908-0063"},{"id":"joe-chang","kind":"person","name":"Joe Y. Chang","aka":[],"tldr":"Led the trials comparing stereotactic radiotherapy with surgery for operable early lung cancer.","summary":"Joe Chang led the pooled STARS and ROSEL analysis and the revised STARS trial suggesting stereotactic ablative radiotherapy matches lobectomy for operable stage I NSCLC, results that opened the surgery-versus-SABR debate. He directs thoracic radiation oncology at MD Anderson and studies proton therapy and radiotherapy-immunotherapy combinations.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chang%20JY%5BAuthor%5D%20stereotactic%20ablative%20lung"}],"tags":["radiotherapy","sbrt","lung"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["sbrt","proton-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Radiation Oncology, MD Anderson Cancer Center","institutionId":"md-anderson","specialisms":["Stereotactic ablative radiotherapy","Proton therapy","Lung cancer","Immunotherapy-radiotherapy combinations"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chang%20JY%5BAuthor%5D%20stereotactic%20ablative%20lung"}],"papers":[{"title":"Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials","journal":"Lancet Oncology","year":2015,"doi":"10.1016/S1470-2045(15)70168-3"},{"title":"Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery","journal":"Lancet Oncology","year":2021,"doi":"10.1016/S1470-2045(21)00401-0"}],"orcid":"0000-0002-8435-2083"},{"id":"joel-guigay","kind":"person","name":"Joël Guigay","aka":[],"tldr":"Nice oncologist who led TPExtreme, the GORTEC trial that showed the shorter TPEx regimen is a reasonable alternative to EXTREME for recurrent or metastatic head and neck cancer.","summary":"Joël Guigay is a medical oncologist at Centre Antoine Lacassagne in Nice and a leader of the French GORTEC head and neck group. He was first author of the 2021 Lancet Oncology report of TPExtreme, the phase 2 trial comparing docetaxel, cisplatin and cetuximab (TPEx) with the EXTREME regimen as first-line treatment for recurrent or metastatic head and neck squamous-cell carcinoma; TPEx did not lengthen survival but was less toxic and shorter, and is used as an alternative.","asOf":"2026-09-18","links":[],"tags":["head-and-neck","trialist"],"related":[],"cancers":["recurrent-metastatic-hnscc","head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["centre-antoine-lacassagne"],"pathways":[],"terms":[],"trials":["tpextreme"],"people":[],"bottlenecks":[],"keyPapers":["paper-tpextreme-lancet-oncol-2021"],"journals":[],"dependsOn":[],"notes":[],"role":"Medical oncologist, Centre Antoine Lacassagne, Nice","institutionId":"centre-antoine-lacassagne","specialisms":["Head and neck cancer","Chemotherapy regimens","GORTEC trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Guigay%5BAuthor%5D"}],"papers":[{"title":"TPExtreme (GORTEC 2014-01): docetaxel, cisplatin and cetuximab versus the EXTREME regimen in recurrent or metastatic head and neck cancer","journal":"The Lancet Oncology","year":2021,"url":"https://doi.org/10.1016/S1470-2045(20)30755-5","doi":"10.1016/S1470-2045(20)30755-5"}]},{"id":"johann-de-bono","kind":"person","name":"Johann de Bono","aka":[],"tldr":"Johann de Bono led the trials that brought abiraterone and olaparib to prostate cancer patients.","summary":"Johann de Bono is Regius Professor of Cancer Research at The Institute of Cancer Research and Head of the Drug Development Unit at The Royal Marsden, one of Europe's largest phase 1 units. His specialisms are prostate cancer, early drug development, PARP inhibitors and androgen receptor targeting. He led the pivotal COU-AA-301 trial of abiraterone in metastatic castration-resistant prostate cancer and PROfound, the trial of olaparib in prostate cancer with homologous recombination repair mutations, both reported in the New England Journal of Medicine. These trials brought abiraterone and olaparib to prostate cancer patients. His ICR profile and PubMed listing are linked.","asOf":"2026-09-08","links":[{"label":"ICR profile","url":"https://www.icr.ac.uk/research-and-discoveries/our-research/researchers/professor-johann-de-bono"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=de%20Bono%20JS%5BAuthor%5D%20prostate"}],"tags":[],"related":[],"cancers":["prostate"],"sections":[],"technologies":["parp-inhibitor","androgen-deprivation"],"targets":["androgen-receptor","parp","brca"],"drugs":["abiraterone","olaparib"],"companies":[],"institutions":["royal-marsden","icr-london"],"pathways":[],"terms":[],"trials":["profound"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Regius Professor of Cancer Research, ICR; Head of Drug Development Unit, Royal Marsden","institutionId":"royal-marsden","specialisms":["Prostate cancer","Early drug development","PARP inhibitors","Androgen receptor targeting"],"profiles":[{"label":"ICR profile","url":"https://www.icr.ac.uk/research-and-discoveries/our-research/researchers/professor-johann-de-bono"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=de%20Bono%20JS%5BAuthor%5D%20prostate"}],"papers":[{"title":"Abiraterone and increased survival in metastatic prostate cancer (COU-AA-301)","journal":"NEJM","year":2011,"doi":"10.1056/NEJMoa1014618"},{"title":"Olaparib for metastatic castration-resistant prostate cancer (PROfound)","journal":"NEJM","year":2020,"doi":"10.1056/NEJMoa1911440"},{"title":"STAMPEDE: adding abiraterone to hormone therapy at diagnosis of advanced prostate cancer","journal":"New England Journal of Medicine","year":2017,"url":"https://doi.org/10.1056/NEJMoa1702900","doi":"10.1056/NEJMoa1702900"},{"title":"VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer","journal":"New England Journal of Medicine","year":2021,"url":"https://doi.org/10.1056/NEJMoa2107322","doi":"10.1056/NEJMoa2107322"}],"orcid":"0000-0002-2034-595X"},{"id":"johanna-joyce","kind":"person","name":"Johanna Joyce","aka":[],"tldr":"Tumour immunologist at Ludwig Lausanne who began a two-year term as President of the European Association for Cancer Research in June 2026.","summary":"Johanna Joyce is President of the European Association for Cancer Research (EACR), the European membership society for cancer researchers, having begun her two-year term on 11 June 2026 after serving as President-Elect from September 2024. She is a Member of the Ludwig Institute for Cancer Research in Lausanne, Switzerland, where she has worked since January 2016. Her research investigates how the tumour microenvironment regulates cancer progression, metastasis and therapeutic response, with a particular focus on glioblastoma and brain metastases. The EACR board page lists Arkaitz Carracedo as President-Elect, Yardena Samuels as Past President, Caroline Dive as Treasurer and Andreas Trumpp as Secretary General.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Johanna_Joyce","links":[{"label":"Source: EACR board page","url":"https://www.eacr.org/governance/board"}],"tags":["leadership","clinician-scientist","immunology","society"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["eacr"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President of the European Association for Cancer Research (2026-2028)","institutionId":"eacr","specialisms":["Tumour immunology","Tumour microenvironment","Brain tumours","Cancer research policy"],"profiles":[{"label":"Institution profile","url":"https://www.ludwigcancerresearch.org/scientist/johanna-joyce/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Joyce+JA%5BAuthor%5D"}],"papers":[{"title":"The Microenvironmental Landscape of Brain Tumors","journal":"Cancer Cell","year":2017,"doi":"10.1016/j.ccell.2017.02.009"},{"title":"Interrogation of the Microenvironmental Landscape in Brain Tumors Reveals Disease-Specific Alterations of Immune Cells","journal":"Cell","year":2020,"doi":"10.1016/j.cell.2020.05.007"},{"title":"T cell exclusion, immune privilege, and the tumor microenvironment","journal":"Science","year":2015,"doi":"10.1126/science.aaa6204"},{"title":"Quail and Joyce 2013: microenvironmental regulation of tumour progression and metastasis","journal":"Nature Medicine","year":2013,"url":"https://doi.org/10.1038/nm.3394","doi":"10.1038/nm.3394"}],"orcid":"0000-0002-6332-2598"},{"id":"johanna-mattson","kind":"person","name":"Johanna Mattson","aka":[],"tldr":"Oncologist who directs the HUS Comprehensive Cancer Center in Helsinki, Finland's largest cancer treatment centre.","summary":"Johanna Mattson is Senior Medical Director, Director of Division and Associate Professor at the HUS Comprehensive Cancer Center, part of Helsinki University Hospital and described by HUS as Finland's largest and most versatile cancer treatment centre. The centre was the first Nordic and second European cancer centre to receive OECI Comprehensive Cancer Center accreditation in 2014, is a member of the EURACAN rare adult solid cancer network and received Magnet recognition for nursing in 2024. It provides radiotherapy, chemotherapy, haematological disease treatment, breast surgery and palliative care for the Uusimaa region. She leads it alongside research director Peeter Karihtala and chief nursing officer Vuokko Kolhonen.","asOf":"2026-09-10","links":[{"label":"Source: HUS Comprehensive Cancer Center leadership listing","url":"https://www.hus.fi/en/about-us/departments/comprehensive-cancer-center"}],"tags":["leadership","clinician-scientist","comprehensive-cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["helsinki-hus"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["acta-oncologica","bmc-cancer","jmir-cancer"],"dependsOn":[],"notes":[],"role":"Senior Medical Director and Director of Division, HUS Comprehensive Cancer Center","institutionId":"helsinki-hus","specialisms":["Oncology","Cancer centre management","Radiotherapy and chemotherapy services"],"profiles":[{"label":"HUS Comprehensive Cancer Center page","url":"https://www.hus.fi/en/about-us/departments/comprehensive-cancer-center"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mattson+J%5BAuthor%5D+AND+Helsinki"}],"papers":[{"title":"Digital solution in the follow-up of early breast cancer a randomized study","journal":"Acta Oncologica","year":2023,"doi":"10.1080/0284186x.2023.2212409"},{"title":"Comparing the Costs of Surveillance of Early-Stage Breast Cancer by Digital or Traditional Follow-Up Methods: Randomized Crossover Study","journal":"JMIR Cancer","year":2025,"doi":"10.2196/58113"},{"title":"Primary neuroendocrine breast carcinomas are associated with poor local control despite favourable biological profile: a retrospective clinical study","journal":"BMC Cancer","year":2017,"doi":"10.1186/s12885-017-3056-4"}]},{"id":"johannes-czernin","kind":"person","name":"Johannes Czernin","aka":[],"tldr":"Nuclear medicine leader who helped bring PSMA PET and radioligand therapy to the United States.","summary":"Johannes Czernin is Chief of the Ahmanson Translational Theranostics Division at UCLA, within the UCLA Jonsson Comprehensive Cancer Center, and editor-in-chief of the Journal of Nuclear Medicine. A nuclear medicine physician specialising in PSMA theranostics and PET imaging, he co-led the UCLA and UCSF prospective PSMA PET trials behind FDA approval and the US experience with 177Lu-PSMA-617, now known as lutetium-177 vipivotide tetraxetan. His papers include the JAMA Oncology prospective single-arm trial assessing 68Ga-PSMA-11 PET accuracy in localising recurrent prostate cancer and an Annual Review of Medicine article on molecular imaging in the development of cancer therapeutics. He helped bring PSMA PET and radioligand therapy to the United States.","asOf":"2026-09-08","links":[{"label":"UCLA profile","url":"https://www.uclahealth.org/providers?q=Johannes%20Czernin"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Czernin%20J%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Johannes%20Czernin"}],"tags":[],"related":[],"cancers":["prostate"],"sections":[],"technologies":["psma-pet","radioligand-therapy","pet"],"targets":["psma"],"drugs":["pluvicto"],"companies":[],"institutions":["ucla-jonsson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief, Ahmanson Translational Theranostics Division, UCLA","institutionId":"ucla-jonsson","specialisms":["Nuclear medicine","PSMA theranostics","PET imaging"],"profiles":[{"label":"UCLA profile","url":"https://www.uclahealth.org/providers?q=Johannes%20Czernin"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Czernin%20J%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Johannes%20Czernin"}],"papers":[{"title":"Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial","journal":"JAMA Oncology","year":2019,"url":"https://doi.org/10.1001/jamaoncol.2019.0096","doi":"10.1001/jamaoncol.2019.0096"},{"title":"Molecular imaging in the development of cancer therapeutics","journal":"Annual Review of Medicine","year":2006,"url":"https://doi.org/10.1146/annurev.med.57.080904.190431","doi":"10.1146/annurev.med.57.080904.190431"}]},{"id":"john-bridgewater","kind":"person","name":"John Bridgewater","aka":[],"tldr":"Senior author of the UK's two standard-setting biliary trials, ABC-02 and BILCAP, chief investigator of ABC-06, and UK lead of the first-line precision medicine trial SAFIR-ABC10.","summary":"John Bridgewater is professor of medical oncology at the UCL Cancer Institute and a consultant at UCLH. He was senior author on ABC-02 (gemcitabine plus cisplatin as first-line standard) and BILCAP (adjuvant capecitabine), chief investigator of ABC-06 (second-line FOLFOX) and leads the National Cancer Research Institute biliary tract subgroup. He leads the UK arm of SAFIR-ABC10, sponsored by UCL and UCLH, which profiles tumours and matches patients with cholangiocarcinoma or gallbladder cancer to one of seven targeted therapies, and co-authored the 2023 British Society of Gastroenterology cholangiocarcinoma guideline.","asOf":"2026-09-24","links":[{"label":"UCL profile","url":"https://profiles.ucl.ac.uk/824-john-bridgewater"},{"label":"UCLH consultant page","url":"https://www.uclh.nhs.uk/our-services/find-consultant/professor-john-bridgewater"}],"tags":["biliary","trialist","uk"],"related":["mairead-mcnamara"],"cancers":["gallbladder","biliary-tract-cancer","cholangiocarcinoma"],"sections":[],"technologies":[],"targets":[],"drugs":["capecitabine","gemcitabine","cisplatin"],"companies":[],"institutions":["uclh","ammf"],"pathways":[],"terms":[],"trials":["abc-02","abc-06","bilcap"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology, UCL Cancer Institute; Consultant Medical Oncologist, University College London Hospitals; Medical Adviser, AMMF","institutionId":"uclh","specialisms":["Biliary tract cancer","Carcinoma of unknown primary","Gastrointestinal oncology","Precision medicine trials"],"profiles":[{"label":"UCL profile","url":"https://profiles.ucl.ac.uk/824-john-bridgewater"},{"label":"UCLH consultant page","url":"https://www.uclh.nhs.uk/our-services/find-consultant/professor-john-bridgewater"}],"papers":[{"title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP)","journal":"Lancet Oncology","year":2019,"doi":"10.1016/S1470-2045(18)30915-X"},{"title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06)","journal":"Lancet Oncology","year":2021,"doi":"10.1016/S1470-2045(21)00027-9"},{"title":"British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma","journal":"Gut","year":2023,"doi":"10.1136/gutjnl-2023-330029"}]},{"id":"john-burn","kind":"person","name":"John Burn","aka":[],"tldr":"The Newcastle geneticist whose CAPP2 trial showed that two years of aspirin cuts bowel cancer in people born with Lynch syndrome, a result that still shapes NHS advice.","summary":"Sir John Burn has been Professor of Clinical Genetics at Newcastle University since 1991, was a consultant clinical geneticist with the Northern Genetics Service from 1984, and chaired Newcastle Hospitals NHS Foundation Trust from 2017 to 2023. He was first author of CAPP2, which randomised carriers of a mismatch repair gene variant to aspirin or placebo and found a reduction in cancer incidence, and of the 10-year follow-up with registry-based 20-year data that confirmed the effect lasted. NICE NG151 recommendation 1.1.1 asks clinicians to consider daily aspirin for more than two years to reduce colorectal cancer risk in Lynch syndrome; the CAPP3 study is testing which dose.","asOf":"2026-09-24","links":[{"label":"Newcastle University staff page","url":"https://www.ncl.ac.uk/medical-sciences/people/profile/johnburn.html"}],"tags":["colorectal","genetics","uk","prevention"],"related":[],"cancers":["colorectal","early-onset-colorectal"],"sections":["prevention"],"technologies":[],"targets":[],"drugs":["aspirin"],"companies":[],"institutions":["newcastle-cancer-centre"],"pathways":[],"terms":["lynch-syndrome"],"trials":["capp2"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Clinical Genetics, Newcastle University","institutionId":"newcastle-cancer-centre","specialisms":["Inherited cancer predisposition","Lynch syndrome","Chemoprevention"],"profiles":[{"label":"Newcastle University staff page","url":"https://www.ncl.ac.uk/medical-sciences/people/profile/johnburn.html"}],"papers":[{"title":"Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial","journal":"Lancet","year":2011,"doi":"10.1016/S0140-6736(11)61049-0"},{"title":"Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study","journal":"Lancet","year":2020,"doi":"10.1016/S0140-6736(20)30366-4"}]},{"id":"john-bell","kind":"person","name":"John C. Bell","aka":[],"tldr":"John Bell's laboratory showed that cancer cells which have broken their interferon alarm cannot defend themselves against a virus, the mechanism the whole field is built on.","summary":"John Bell leads a laboratory in the Cancer Research Program of the Ottawa Hospital Research Institute, where he is listed as a senior scientist, and publishes with a University of Ottawa affiliation. In 2000 his laboratory published the experiment that explains oncolytic selectivity in one sentence: vesicular stomatitis virus, a virus exquisitely sensitive to interferon, replicated in and killed human tumour cell lines at interferon doses that completely protected normal human primary cultures, because those tumour cells had already lost the interferon response as part of becoming cancers.\n\nThe work led to the vesicular stomatitis virus and vaccinia platforms that dominate the field's pipeline, to attenuated derivatives designed to remove neurotoxicity, and to the strategy of using two different viruses in sequence so that antibodies raised against the first do not neutralise the second. He co-wrote the 2012 Nature Biotechnology review with Stephen Russell and Kah-Whye Peng that named the field's four unsolved problems: platform proliferation, the conflicting need to suppress and then unleash the immune system, poor preclinical models, and manufacturing yield.","asOf":"2026-09-25","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bell%20JC%5BAuthor%5D%20oncolytic"},{"label":"Ottawa Hospital Research Institute","url":"https://www.ohri.ca/profile/jbell"}],"tags":["oncolytic-virus","immunotherapy","canada"],"related":[],"cancers":[],"sections":[],"technologies":["oncolytic-virus"],"targets":[],"drugs":[],"companies":[],"institutions":["ottawa-hospital"],"pathways":[],"terms":[],"trials":[],"people":["stephen-russell"],"bottlenecks":[],"keyPapers":["paper-stojdl-vsv-interferon-defect-natmed-2000","paper-russell-peng-bell-oncolytic-virotherapy-natbiotech-2012"],"journals":[],"dependsOn":[],"notes":[],"role":"Senior Scientist, Cancer Research Program, Ottawa Hospital Research Institute; University of Ottawa","institutionId":"ottawa-hospital","specialisms":["Oncolytic virotherapy","Vesicular stomatitis virus","Vaccinia virus","Tumour immunology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bell%20JC%5BAuthor%5D%20oncolytic"},{"label":"Ottawa Hospital Research Institute","url":"https://www.ohri.ca/profile/jbell"}],"papers":[{"title":"Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus","journal":"Nature Medicine","year":2000,"doi":"10.1038/77558"},{"title":"Oncolytic virotherapy","journal":"Nature Biotechnology","year":2012,"doi":"10.1038/nbt.2287"},{"title":"Advances in oncolytic virotherapy","journal":"Communications Medicine","year":2022,"doi":"10.1038/s43856-022-00098-4"}]},{"id":"john-byrd","kind":"person","name":"John C. Byrd","aka":[],"tldr":"Led the ibrutinib trials that turned CLL from a chemotherapy disease into one treated with pills.","summary":"John Byrd (University of Cincinnati; formerly Ohio State) led the pivotal phase 1b/2 and RESONATE trials of ibrutinib in chronic lymphocytic leukaemia, the results that made BTK inhibition the standard of care and displaced chemoimmunotherapy, and the ELEVATE-RR head-to-head trial showing acalabrutinib is better tolerated. His laboratory helped develop acalabrutinib and continues work on resistance and AML therapeutics.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Byrd%20JC%5BAuthor%5D%20chronic%20lymphocytic%20leukemia%20ibrutinib"}],"tags":["cll","btk","targeted-therapy"],"related":[],"cancers":["cll"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":[],"companies":[],"institutions":["cincinnati-cancer-center"],"pathways":[],"terms":[],"trials":["resonate","elevate-tn"],"people":[],"bottlenecks":[],"keyPapers":["paper-elevate-tn-acalabrutinib-lancet-2020"],"journals":[],"dependsOn":[],"notes":[],"role":"Chair, Department of Internal Medicine, University of Cincinnati College of Medicine","institutionId":"cincinnati-cancer-center","specialisms":["Chronic lymphocytic leukaemia","BTK inhibitors","Drug development","Leukaemia biology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Byrd%20JC%5BAuthor%5D%20chronic%20lymphocytic%20leukemia%20ibrutinib"}],"papers":[{"title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","journal":"NEJM","year":2013,"doi":"10.1056/NEJMoa1215637"},{"title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia (RESONATE)","journal":"NEJM","year":2014,"doi":"10.1056/NEJMoa1400376"},{"title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial (ELEVATE-RR)","journal":"JCO","year":2021,"doi":"10.1200/JCO.21.01210"},{"title":"ELEVATE-TN: acalabrutinib, alone or with obinutuzumab, against chemo-immunotherapy in untreated CLL","journal":"The Lancet","year":2020,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ELEVATE-TN%20acalabrutinib%20obinutuzumab%20chlorambucil%20Sharman%20Lancet%202020"}]},{"id":"john-d-rockefeller-jr","kind":"person","name":"John D. Rockefeller Jr.","aka":[],"tldr":"In 1936 he donated the land on York Avenue to which Memorial Hospital moved; Memorial Sloan Kettering has been there ever since.","summary":"John D. Rockefeller Jr. (1874-1960), the philanthropist son of the Standard Oil founder, gave the land that fixed the geography of American cancer care. Memorial Sloan Kettering's history records that in 1936 the hospital began a move to its present location on York Avenue, on land donated by John D. Rockefeller Jr. The move put Memorial Hospital beside the Rockefeller Institute and what became Weill Cornell, creating the medical corridor on Manhattan's East Side in which the Sloan Kettering Institute was later built and where MSK's laboratory towers and outpatient buildings, funded by later donors such as Mortimer Zuckerman and David Koch, now stand. His family's medical philanthropy also built the Rockefeller Institute for Medical Research and funded public health worldwide.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/John_D._Rockefeller_Jr.","links":[{"label":"MSK: history and milestones","url":"https://www.mskcc.org/about/history-milestones"}],"tags":["hero","donor"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":[],"people":["alfred-sloan","charles-kettering","mortimer-zuckerman","david-koch"],"bottlenecks":["b-funding-allocation"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Donor of the York Avenue land on which Memorial Sloan Kettering stands","specialisms":["Cancer hospital building","Land gifts"],"profiles":[],"papers":[]},{"id":"john-dick","kind":"person","name":"John E. Dick","aka":[],"tldr":"Discovered cancer stem cells, showing leukaemia is driven by a rare population of self-renewing cells.","summary":"John E. Dick is a Senior Scientist at the Princess Margaret Cancer Centre and Canada Research Chair in Stem Cell Biology. He is known for discovering cancer stem cells, identifying leukaemic stem cells in acute myeloid leukaemia between 1994 and 1997 and later pre-leukaemic haematopoietic stem cells, which defined the hierarchical model of cancer. His selected papers show that human AML is organised as a hierarchy originating from a primitive haematopoietic cell, and identify pre-leukaemic haematopoietic stem cells in acute leukaemia. A Gairdner and Keio Prize laureate, he continues to study leukaemia stem cells, haematopoiesis and pre-leukaemic clones.","asOf":"2026-09-08","links":[{"label":"Dick lab","url":"https://www.uhnresearch.ca/researcher/john-e-dick"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dick%20JE%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["aml"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["princess-margaret"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Senior Scientist, Princess Margaret Cancer Centre; Canada Research Chair in Stem Cell Biology","institutionId":"princess-margaret","specialisms":["Leukaemia stem cells","Haematopoiesis","Pre-leukaemic clones"],"profiles":[{"label":"Dick lab","url":"https://www.uhnresearch.ca/researcher/john-e-dick"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dick%20JE%5BAuthor%5D"}],"papers":[{"title":"Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell","journal":"Nature Medicine","year":1997,"url":"https://doi.org/10.1038/nm0797-730","doi":"10.1038/nm0797-730"},{"title":"Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia","journal":"Nature","year":2014,"url":"https://doi.org/10.1038/nature13038","doi":"10.1038/nature13038"}],"orcid":"0000-0002-9527-8317"},{"id":"john-dipersio","kind":"person","name":"John F. DiPersio","aka":[],"tldr":"Transplant pioneer who developed plerixafor for stem-cell mobilisation and CD7 CAR-T for T-cell leukaemia.","summary":"John F. DiPersio is the Virginia E. and Sam J. Golman Professor of Medicine and Director of the Center for Gene and Cellular Immunotherapy at Siteman Cancer Center, Washington University. He is a transplant pioneer known for developing plerixafor for stem cell mobilisation, JAK inhibition for graft-versus-host disease and fratricide-resistant CD7-directed CAR-T for T-cell leukaemia. His selected paper reports plerixafor plus G-CSF versus placebo plus G-CSF to mobilise haematopoietic stem cells for autologous transplantation in multiple myeloma. A former chief of oncology at WashU, he continues to work on allogeneic and autologous transplantation and CAR-T.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=DiPersio%20JF%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["aml","all-leukemia","multiple-myeloma"],"sections":[],"technologies":["allogeneic-hsct","autologous-stem-cell-transplant","car-t"],"targets":[],"drugs":[],"companies":[],"institutions":["wustl-siteman"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Virginia E. and Sam J. Golman Professor of Medicine; Director, Center for Gene and Cellular Immunotherapy","institutionId":"wustl-siteman","specialisms":["Stem cell transplant","CAR-T for T-cell malignancies","Graft-versus-host disease"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=DiPersio%20JF%5BAuthor%5D"}],"papers":[{"title":"Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma","journal":"Blood","year":2009}],"orcid":"0000-0002-0429-3133"},{"id":"john-seymour","kind":"person","name":"John F. Seymour","aka":[],"tldr":"Led MURANO, which established venetoclax plus rituximab as fixed-duration therapy for relapsed CLL.","summary":"John Seymour was principal investigator of MURANO, the trial showing two years of venetoclax plus rituximab dramatically improves progression-free and overall survival compared with bendamustine-rituximab in relapsed CLL, the first randomised proof of venetoclax's benefit and the first fixed-duration targeted regimen. He co-led the first-in-human venetoclax studies with the Melbourne group that discovered BCL2 inhibition and leads haematology at Peter Mac.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Seymour%20JF%5BAuthor%5D%20venetoclax%20MURANO"}],"tags":["cll","venetoclax","australia"],"related":[],"cancers":["cll"],"sections":[],"technologies":["mrd-testing"],"targets":["bcl2","cd20"],"drugs":["venetoclax"],"companies":[],"institutions":["peter-mac"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-murano-venetoclax-rituximab-nejm-2018"],"journals":[],"dependsOn":[],"notes":[],"role":"Director of Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital","institutionId":"peter-mac","specialisms":["Chronic lymphocytic leukaemia","Venetoclax","Lymphoma","BCL2 inhibition"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Seymour%20JF%5BAuthor%5D%20venetoclax%20MURANO"}],"papers":[{"title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia (MURANO)","journal":"NEJM","year":2018,"doi":"10.1056/NEJMoa1713976"},{"title":"Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study","journal":"Lancet Oncology","year":2017,"doi":"10.1016/S1470-2045(17)30012-8"}],"orcid":"0000-0003-2188-6835"},{"id":"john-field","kind":"person","name":"John Field","aka":[],"tldr":"The Liverpool scientist behind the UK Lung Cancer Screening trial and the Liverpool Lung Project risk model, which is one of the two rules the NHS uses to decide who is invited for a scan.","summary":"John Field holds a personal clinical chair in molecular oncology at the University of Liverpool and is Director of Research of the Roy Castle Lung Cancer Research Programme. He was chief investigator of the UK Lung Cancer Screening trial, which approached 247,354 people, randomised 4,055 and found 42 cancers, 85.7 percent of them at stage 1 or 2; its 2021 mortality paper reported 30 lung cancer deaths in the screened arm against 46 in the control arm, a relative rate of 0.65 that did not reach significance on its own, and pooled it with eight other trials for a relative rate of 0.84.\n\nHis Liverpool Lung Project risk model, in its second version, is one of the two risk rules used to decide eligibility in UK lung health checks, alongside PLCOm2012. He chaired the International Association for the Study of Lung Cancer's screening, prevention and early detection committee, founded its strategic screening advisory group, and received the association's Joseph Cullen Award in 2011 for lifetime achievement in lung cancer prevention research. He remains a principal investigator on live work, including a home urine collection study inside the Liverpool lung health check.","asOf":"2026-09-25","links":[{"label":"University of Liverpool staff page","url":"https://www.liverpool.ac.uk/people/john-field"}],"tags":["lung","screening","uk"],"related":["philip-crosbie","david-baldwin"],"cancers":["nsclc","lung-cancer"],"sections":["early-detection","prevention"],"technologies":["low-dose-ct-screening"],"targets":[],"drugs":[],"companies":[],"institutions":["liverpool-heart-and-chest","roy-castle-lung-cancer-foundation"],"pathways":[],"terms":[],"trials":["ukls"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Molecular Oncology, Institute of Systems, Molecular and Integrative Biology, University of Liverpool","institutionId":"liverpool-heart-and-chest","specialisms":["Lung cancer screening","Risk prediction models","Molecular oncology of the lung"],"profiles":[{"label":"University of Liverpool staff page","url":"https://www.liverpool.ac.uk/people/john-field"}],"papers":[{"title":"The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer","journal":"Health Technology Assessment","year":2016,"doi":"10.3310/hta20400"},{"title":"Lung cancer mortality reduction by LDCT screening: UKLS randomised trial results and international meta-analysis","journal":"Lancet Regional Health Europe","year":2021,"doi":"10.1016/j.lanepe.2021.100179"}]},{"id":"john-strickler","kind":"person","name":"John H. Strickler","aka":[],"tldr":"Duke oncologist who led MOUNTAINEER, the trial that made tucatinib plus trastuzumab the first approved HER2-directed treatment for colorectal cancer.","summary":"John Strickler is a gastrointestinal medical oncologist at Duke Cancer Institute. He was first author of the 2023 Lancet Oncology report of MOUNTAINEER, the phase 2 trial in which tucatinib plus trastuzumab produced durable responses in chemotherapy-refractory HER2-positive, RAS wild-type metastatic colorectal cancer, leading to accelerated approval. He also led early work on sotorasib in KRAS G12C colorectal cancer and studies ctDNA to guide therapy.","asOf":"2026-09-18","links":[],"tags":["colorectal","targeted-therapy","trialist"],"related":[],"cancers":["her2-amplified-colorectal","colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["duke-cancer-institute"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-strickler-mountaineer-tucatinib-trastuzumab-lancet-oncol-2023"],"journals":[],"dependsOn":[],"notes":[],"role":"Gastrointestinal medical oncologist, Duke Cancer Institute","institutionId":"duke-cancer-institute","specialisms":["HER2-amplified colorectal cancer","Targeted therapy","Circulating tumour DNA"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Strickler%5BAuthor%5D"}],"papers":[{"title":"MOUNTAINEER: tucatinib plus trastuzumab for HER2-positive, RAS wild-type metastatic colorectal cancer","journal":"The Lancet Oncology","year":2023,"url":"https://doi.org/10.1016/S1470-2045(23)00150-X","doi":"10.1016/S1470-2045(23)00150-X"}],"orcid":"0000-0001-7579-1175"},{"id":"john-haanen","kind":"person","name":"John Haanen","aka":[],"tldr":"John Haanen led the first randomised phase 3 trial of TIL therapy, which beat ipilimumab in melanoma.","summary":"John Haanen is a medical oncologist at the Netherlands Cancer Institute (NKI-AvL) and Professor at Leiden University Medical Center. His specialisms are melanoma, TIL therapy and immunotherapy. He led the first randomised phase 3 trial of tumour-infiltrating lymphocyte therapy, a Dutch and Danish study comparing TIL treatment with ipilimumab in advanced melanoma, reported in the New England Journal of Medicine, in which the cell therapy beat ipilimumab on progression-free survival. He also helped write the ESMO guidelines on immunotherapy toxicity. His record links him to lifileucel and ipilimumab, and his publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Haanen%20JB%5BAuthor%5D%20tumor-infiltrating%20lymphocytes"}],"tags":[],"related":[],"cancers":["melanoma"],"sections":[],"technologies":["til-therapy"],"targets":[],"drugs":["lifileucel","ipilimumab"],"companies":[],"institutions":["nki"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Medical Oncologist, Netherlands Cancer Institute; Professor, Leiden University Medical Center","institutionId":"nki","specialisms":["Melanoma","TIL therapy","Immunotherapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Haanen%20JB%5BAuthor%5D%20tumor-infiltrating%20lymphocytes"}],"papers":[{"title":"Treatment with tumor-infiltrating lymphocytes or ipilimumab in advanced melanoma","journal":"NEJM","year":2022,"doi":"10.1056/NEJMoa2210233"},{"title":"CheckMate 067 at ten years: nivolumab plus ipilimumab produces long-term survival in half of patients with advanced melanoma","journal":"New England Journal of Medicine","year":2025,"url":"https://doi.org/10.1056/NEJMoa2407417","doi":"10.1056/NEJMoa2407417"},{"title":"NADINA: two doses of ipilimumab plus nivolumab before surgery beat a year of nivolumab after surgery in stage III melanoma","journal":"New England Journal of Medicine","year":2024,"url":"https://doi.org/10.1056/NEJMoa2402604","doi":"10.1056/NEJMoa2402604"},{"title":"NICHE-2: a month of nivolumab and ipilimumab before surgery clears mismatch-repair-deficient colon cancer in most patients","journal":"New England Journal of Medicine","year":2024,"url":"https://doi.org/10.1056/NEJMoa2400634","doi":"10.1056/NEJMoa2400634"}],"orcid":"0000-0001-5884-7704"},{"id":"john-jacob-astor-iii","kind":"person","name":"John Jacob Astor III","aka":["John and Charlotte Astor"],"tldr":"In 1884 he and his wife Charlotte were among the group who founded New York Cancer Hospital, the institution that became Memorial Sloan Kettering Cancer Center.","summary":"John Jacob Astor III (1822-1890), head of the Astor family fortune, and his wife Charlotte Augusta Gibbes Astor were among the group that founded New York Cancer Hospital in 1884 on Manhattan's Upper West Side, as Memorial Sloan Kettering's own history records. At a time when cancer patients were often turned away by general hospitals, the new hospital was devoted to their care and to the study of the disease. It was renamed Memorial Hospital, moved in the 1930s to land on York Avenue given by John D. Rockefeller Jr., and joined with the Sloan Kettering Institute to become the centre that now bears both names. The Astors' hospital is the oldest thread in the story of the largest private cancer centre in the world.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/John_Jacob_Astor_III","links":[{"label":"MSK: history and milestones","url":"https://www.mskcc.org/about/history-milestones"}],"tags":["hero","donor"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":[],"people":["john-d-rockefeller-jr","alfred-sloan","charles-kettering"],"bottlenecks":["b-funding-allocation"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"With his wife Charlotte, among the founders of New York Cancer Hospital in 1884, now Memorial Sloan Kettering","specialisms":["Cancer hospital founding","Nineteenth-century philanthropy"],"profiles":[],"papers":[]},{"id":"john-kennedy","kind":"person","name":"John Kennedy","aka":[],"tldr":"Professor who is Medical Director of Trinity St James's Cancer Institute, Ireland's first academic comprehensive cancer institute, in Dublin.","summary":"Professor John Kennedy is Medical Director of Trinity St James's Cancer Institute (TSJCI), a partnership between St James's Hospital and Trinity College Dublin on Ireland's largest academic health campus. The institute describes itself as the first of its kind in Ireland, building on the campus's long tradition of comprehensive cancer care. He leads it alongside Academic Director Professor Maeve Lowery, whose stated ambition for the institute is to develop a comprehensive cancer centre with national services in areas such as genomics and immunology.","asOf":"2026-09-10","links":[{"label":"Source: St James's Hospital cancer institute page naming the directors","url":"https://www.stjames.ie/cancer/"}],"tags":["leadership","clinician-scientist","comprehensive-cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["trinity-st-jamess-cancer-institute"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["clinical-breast-cancer","jitc"],"dependsOn":[],"notes":[],"role":"Medical Director, Trinity St James's Cancer Institute","institutionId":"trinity-st-jamess-cancer-institute","specialisms":["Oncology","Comprehensive cancer care","Academic cancer centre leadership"],"profiles":[{"label":"Trinity St James's Cancer Institute page","url":"https://www.stjames.ie/cancer/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kennedy+J%5BAuthor%5D+AND+St+James%27s+Dublin"}],"papers":[{"title":"Real-World Experience of Palbociclib-Induced Adverse Events and Compliance With Complete Blood Count Monitoring in Women With Hormone Receptor–Positive/HER2-Negative Metastatic Breast Cancer","journal":"Clinical Breast Cancer","year":2019,"doi":"10.1016/j.clbc.2018.09.002"},{"title":"TGFβ drives NK cell metabolic dysfunction in human metastatic breast cancer","journal":"Journal for ImmunoTherapy of Cancer","year":2021,"doi":"10.1136/jitc-2020-002044"},{"title":"Current targeted therapies in the treatment of advanced colorectal cancer: a review","journal":"Therapeutic Advances in Medical Oncology","year":2016,"doi":"10.1177/1758834016646734"}]},{"id":"john-kirkwood","kind":"person","name":"John M. Kirkwood","aka":[],"tldr":"Pittsburgh melanoma doctor who ran the interferon trials that were the first adjuvant treatment for high-risk melanoma, and later led CheckMate 76K on adjuvant nivolumab for stage II disease.","summary":"John Kirkwood leads the melanoma programme at UPMC Hillman Cancer Center and led the ECOG trials of high-dose interferon alfa-2b in the 1990s, the first adjuvant therapy shown to reduce melanoma relapse. He was first author of the 2023 Nature Medicine report of CheckMate 76K, in which adjuvant nivolumab improved recurrence-free survival compared with placebo in resected stage IIB or IIC melanoma.","asOf":"2026-09-18","links":[],"tags":["melanoma","adjuvant","trialist"],"related":[],"cancers":["stage-ii-melanoma","stage-iii-melanoma","melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["upmc-hillman"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-checkmate-76k-nat-med-2023"],"journals":[],"dependsOn":[],"notes":[],"role":"Melanoma medical oncologist, UPMC Hillman Cancer Center","institutionId":"upmc-hillman","specialisms":["Adjuvant therapy for melanoma","Interferon","Immunotherapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kirkwood%5BAuthor%5D"}],"papers":[{"title":"CheckMate 76K: adjuvant nivolumab in resected stage IIB or IIC melanoma","journal":"Nature Medicine","year":2023,"url":"https://doi.org/10.1038/s41591-023-02583-2","doi":"10.1038/s41591-023-02583-2"}],"orcid":"0000-0002-3570-4476"},{"id":"john-maris","kind":"person","name":"John M. Maris","aka":[],"tldr":"Neuroblastoma geneticist whose lab found the ALK mutations and immunotherapy targets now in paediatric trials.","summary":"John Maris led the discovery that ALK mutations drive familial and sporadic neuroblastoma, the first targetable oncogene in the disease, and genome-wide association studies of neuroblastoma susceptibility. His laboratory identified GPC2 and other cell-surface targets for paediatric immunotherapy and he co-leads the NCI Pediatric Immunotherapy Discovery and Development Network.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/John_M._Maris","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Maris%20JM%5BAuthor%5D%20neuroblastoma"}],"tags":["paediatric","neuroblastoma","genomics"],"related":[],"cancers":["neuroblastoma"],"sections":[],"technologies":["wes-wgs"],"targets":["alk"],"drugs":[],"companies":[],"institutions":["chop"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Giulio D'Angio Chair in Neuroblastoma Research, Children's Hospital of Philadelphia","institutionId":"chop","specialisms":["Neuroblastoma genomics","Paediatric oncology","Immunotherapy targets","Precision medicine"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Maris%20JM%5BAuthor%5D%20neuroblastoma"}],"papers":[{"title":"Identification of ALK as a major familial neuroblastoma predisposition gene","journal":"Nature","year":2008,"doi":"10.1038/nature07261"},{"title":"Recent advances in neuroblastoma","journal":"NEJM","year":2010,"doi":"10.1056/NEJMra0804577"}]},{"id":"john-primrose","kind":"person","name":"John N. Primrose","aka":[],"tldr":"British surgeon who led BILCAP, the trial that made six months of capecitabine the standard after surgery for bile duct and gallbladder cancer.","summary":"John Primrose is professor of surgery at the University of Southampton. He was chief investigator and first author of the 2019 Lancet Oncology report of BILCAP, the UK trial that compared adjuvant capecitabine with observation after resection of biliary tract cancer. The survival benefit in the per-protocol analysis led guidelines to adopt capecitabine as the standard adjuvant treatment.","asOf":"2026-09-18","links":[],"tags":["biliary","surgery","trialist"],"related":[],"cancers":["extrahepatic-cholangiocarcinoma","intrahepatic-cholangiocarcinoma","biliary-tract-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["southampton-cancer"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-bilcap-lancet-oncol-2019"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Surgery, University of Southampton","institutionId":"southampton-cancer","specialisms":["Hepatobiliary surgery","Biliary tract cancer","Adjuvant therapy trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Primrose%5BAuthor%5D"}],"papers":[{"title":"BILCAP: capecitabine compared with observation in resected biliary tract cancer","journal":"The Lancet Oncology","year":2019,"url":"https://doi.org/10.1016/S1470-2045(18)30915-X","doi":"10.1016/S1470-2045(18)30915-X"}],"orcid":"0000-0002-2069-7605"},{"id":"oyler-john","kind":"person","name":"John Oyler","aka":[],"tldr":"John Oyler co-founded BeiGene in Beijing in 2010 and built it into the first China-born biotech to run global trials, win FDA approvals and out-sell Western rivals with zanubrutinib.","summary":"An American entrepreneur who co-founded BeiGene with Xiaodong Wang; the company took zanubrutinib through global head-to-head trials (ALPINE against ibrutinib) to leadership of the BTK inhibitor class, developed tislelizumab and sonrotoclax, built manufacturing in Suzhou, Guangzhou and New Jersey, and in 2025 renamed itself BeOne Medicines and redomiciled to Switzerland while keeping most of its research in China.","asOf":"2026-09-10","links":[{"label":"BeOne Medicines","url":"https://www.beonemedicines.com/"}],"tags":["china"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["zanubrutinib","tislelizumab"],"companies":["beone"],"institutions":[],"pathways":[],"terms":[],"trials":["alpine","sequoia"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Co-founder, Chairman and CEO, BeOne Medicines (formerly BeiGene)","specialisms":["Biotech leadership","Global clinical development","Oncology commercialisation"],"profiles":[{"label":"BeOne Medicines","url":"https://www.beonemedicines.com/"}],"papers":[]},{"id":"john-leonard","kind":"person","name":"John P. Leonard","aka":[],"tldr":"New York lymphoma specialist who led AUGMENT, the trial that established lenalidomide plus rituximab as a chemotherapy-free option for relapsed follicular and marginal zone lymphoma.","summary":"John Leonard is a lymphoma specialist and senior leader at Weill Cornell Medicine in New York. He was first author of the 2019 Journal of Clinical Oncology report of AUGMENT, which showed that lenalidomide plus rituximab improved progression-free survival compared with rituximab alone in relapsed or refractory indolent lymphoma, leading to the combination's approval. He has led many cooperative-group trials in indolent and aggressive B-cell lymphoma.","asOf":"2026-09-18","links":[],"tags":["lymphoma","trialist"],"related":[],"cancers":["follicular-lymphoma","marginal-zone-lymphoma","non-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["weill-cornell-meyer-cancer-center"],"pathways":[],"terms":[],"trials":["augment"],"people":[],"bottlenecks":[],"keyPapers":["paper-augment-lenalidomide-rituximab-leonard-jco-2019"],"journals":[],"dependsOn":[],"notes":[],"role":"Haematologist-oncologist, Weill Cornell Medicine","institutionId":"weill-cornell-meyer-cancer-center","specialisms":["Follicular lymphoma","Marginal zone lymphoma","Immunomodulatory therapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Leonard%5BAuthor%5D"}],"papers":[{"title":"AUGMENT: lenalidomide plus rituximab versus rituximab alone in relapsed indolent lymphoma","journal":"Journal of Clinical Oncology","year":2019,"url":"https://doi.org/10.1200/JCO.19.00010","doi":"10.1200/JCO.19.00010"}]},{"id":"john-stagg","kind":"person","name":"John Stagg","aka":[],"tldr":"Immunologist who studies why tumours resist immunotherapy and directs the Goodman Cancer Institute, McGill University's cancer research institute in Montreal.","summary":"Professor John Stagg is Director of the Rosalind and Morris Goodman Cancer Institute at McGill University, succeeding Morag Park who completed a 12-year term as Director in September 2025. He is Professor in McGill's Department of Microbiology and Immunology and Associate Professor at the Faculty of Pharmacy, Universite de Montreal. His laboratory investigates how cancers develop resistance to immunotherapy, including the effect of adenosine on immune cells, and uses multi-omics data to identify targets and develop biologic anti-cancer treatments.","asOf":"2026-09-10","links":[{"label":"Source: Goodman Cancer Institute about page","url":"https://www.goodmancancer.ca/en/about-us"}],"tags":["leadership","clinician-scientist","immunotherapy"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["mcgill-goodman"],"pathways":[],"terms":["immunotherapy-term","immune-system"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director of the Rosalind and Morris Goodman Cancer Institute","institutionId":"mcgill-goodman","specialisms":["Cancer immunotherapy","Immuno-oncology","Therapeutic target discovery"],"profiles":[{"label":"Goodman Cancer Institute profile","url":"https://www.goodmancancer.ca/en/principal-investigators/john-stagg"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Stagg+J%5BAuthor%5D"}],"papers":[{"title":"The adenosine pathway in immuno-oncology","journal":"Nature Reviews Clinical Oncology","year":2020,"doi":"10.1038/s41571-020-0382-2"},{"title":"CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer","journal":"Proceedings of the National Academy of Sciences","year":2013,"doi":"10.1073/pnas.1222251110"},{"title":"Targeting G Protein–Coupled Receptors in Immuno-Oncological Therapies","journal":"Annual Review of Pharmacology and Toxicology","year":2025,"doi":"10.1146/annurev-pharmtox-061724-080852"}],"orcid":"0000-0001-7833-4228"},{"id":"john-heymach","kind":"person","name":"John V. Heymach","aka":[],"tldr":"Lung cancer leader behind trials that changed treatment of EGFR-mutant and stage III disease.","summary":"John Heymach is Chair of Thoracic/Head and Neck Medical Oncology at MD Anderson Cancer Center. A medical oncologist and cancer biologist specialising in lung cancer, targeted therapy and immunotherapy, he was principal investigator of AEGEAN, the perioperative durvalumab trial, and leads EGFR and KRAS-directed programmes including work on osimertinib in stage III disease in the LAURA trial and on targeting drug-tolerant persister cells. His papers report perioperative durvalumab for resectable non-small-cell lung cancer in the New England Journal of Medicine and the ZODIAC phase 3 trial of vandetanib plus docetaxel as second-line treatment in advanced non-small-cell lung cancer. His work also covers small-cell lung cancer and head and neck squamous cell carcinoma.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/John_V._Heymach","links":[{"label":"MD Anderson faculty","url":"https://faculty.mdanderson.org/search?q=John%20V.%20Heymach"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Heymach%20JV%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=John%20V.%20Heymach"}],"tags":[],"related":[],"cancers":["nsclc","sclc","head-and-neck"],"sections":[],"technologies":[],"targets":["egfr","kras"],"drugs":["osimertinib","durvalumab"],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chair, Thoracic/Head and Neck Medical Oncology, MD Anderson","institutionId":"md-anderson","specialisms":["Lung cancer","Targeted therapy","Immunotherapy"],"profiles":[{"label":"MD Anderson faculty","url":"https://faculty.mdanderson.org/search?q=John%20V.%20Heymach"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Heymach%20JV%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=John%20V.%20Heymach"}],"papers":[{"title":"Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer","journal":"New England Journal of Medicine","year":2023,"url":"https://doi.org/10.1056/NEJMoa2304875","doi":"10.1056/NEJMoa2304875"},{"title":"Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial","journal":"Lancet Oncology","year":2010,"url":"https://doi.org/10.1016/S1470-2045(10)70132-7","doi":"10.1016/S1470-2045(10)70132-7"}],"orcid":"0000-0001-9068-8942"},{"id":"john-arne-rottingen","kind":"person","name":"John-Arne Røttingen","aka":[],"tldr":"Norwegian physician and global health leader who has been Chief Executive of Wellcome, one of the world's largest biomedical research funders, since 2024.","summary":"John-Arne Røttingen is Chief Executive Officer of Wellcome, the London-based charitable foundation that funds discovery science and health research, including cancer biology and genomics through institutions such as the Wellcome Sanger Institute. A physician and former Norwegian ambassador for global health, he previously led the Research Council of Norway and was founding CEO of CEPI.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rottingen+JA%5BAuthor%5D"}],"tags":["leadership","research funding","global health"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["wellcome"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive Officer","institutionId":"wellcome","specialisms":["Global health","Research funding","Health policy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rottingen+JA%5BAuthor%5D"}],"papers":[]},{"id":"jon-irish","kind":"person","name":"Jon Irish","aka":[],"tldr":"Head and neck surgical oncologist who leads the cancer programmes of Ontario Health, the agency that absorbed Cancer Care Ontario, and chairs its Clinical Council.","summary":"Jon Irish is Vice President, Clinical, Cancer Programs at Ontario Health, the provincial agency that took over the functions of Cancer Care Ontario, and chairs the Ontario Health Clinical Council. He is also Head of the Division of Head and Neck Oncology and Reconstructive Surgery at University Health Network in Toronto. Ontario Health's clinical leadership page describes its clinical leads as province-wide clinicians who shape strategy, set clinical standards and guidelines and design system improvements. Ontario Health's President and CEO is Matthew Anderson.","asOf":"2026-09-10","links":[{"label":"Source: Ontario Health clinical leadership page","url":"https://www.ontariohealth.ca/about/who-we-are/clinical-leadership.html"},{"label":"Ontario Health senior leadership page","url":"https://www.ontariohealth.ca/about/who-we-are/senior-leadership.html"}],"tags":["leadership","clinician-scientist","government"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ontario-health-cancer-care-ontario"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["current-oncology-mdpi"],"dependsOn":[],"notes":[],"role":"Vice President, Clinical, Cancer Programs, Ontario Health","institutionId":"ontario-health-cancer-care-ontario","specialisms":["Head and neck surgical oncology","Reconstructive surgery","Cancer system leadership"],"profiles":[{"label":"Ontario Health clinical leadership page","url":"https://www.ontariohealth.ca/about/who-we-are/clinical-leadership.html"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Irish+JC%5BAuthor%5D"}],"papers":[{"title":"Organizational Guidance for the Care of Patients with Head-and-Neck Cancer in Ontario","journal":"Current Oncology","year":2020,"doi":"10.3747/co.27.5873"},{"title":"The Crucial Role of Clinician Engagement in System-Wide Quality Improvement: The Cancer Care Ontario Experience","journal":"Healthcare Quarterly","year":2012,"doi":"10.12927/hcq.2012.23157"},{"title":"Comparison of Use of Neoadjuvant Systemic Treatment for Breast Cancer and Short-term Outcomes Before vs During the COVID-19 Era in Ontario, Canada","journal":"JAMA Network Open","year":2022,"doi":"10.1001/jamanetworkopen.2022.25118"}]},{"id":"jon-huntsman","kind":"person","name":"Jon M. Huntsman Sr.","aka":["Jon and Karen Huntsman"],"tldr":"A chemicals billionaire treated for cancer several times, he and his wife Karen founded Huntsman Cancer Institute in 1995 and their family gave more than $400 million to build its research institute and hospital.","summary":"Jon M. Huntsman Sr. (1937-2018) built Huntsman Corporation and, after his own cancer diagnoses and the deaths of both parents from cancer, decided to build a cancer centre in Utah. Huntsman Cancer Institute records that it was founded in 1995 by Jon M. Huntsman Sr. and his wife Karen, and the Huntsman Cancer Foundation states that the family's landmark gifts total more than $400 million to build the Institute and its hospital. The Institute became an NCI-designated comprehensive cancer centre and, drawing on Utah's population database, a leading centre for hereditary cancer genetics, including the discovery of genes behind familial melanoma and colon cancer. Huntsman's insistence that the hospital feel like a hotel rather than a ward shaped its design.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Jon_Huntsman_Sr.","links":[{"label":"Huntsman Cancer Institute: about us","url":"https://healthcare.utah.edu/huntsmancancerinstitute/about-us"},{"label":"Huntsman Cancer Foundation: about us","url":"https://healthcare.utah.edu/huntsmancancerinstitute/foundation/about-us"}],"tags":["hero","donor","patient"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["huntsman"],"pathways":[],"terms":["hereditary-cancer-syndromes"],"trials":[],"people":[],"bottlenecks":["b-funding-allocation","b-hereditary-risk"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Cancer survivor who founded and funded Huntsman Cancer Institute","specialisms":["Cancer centre building","Hereditary cancer research","Patient care"],"profiles":[],"papers":[]},{"id":"jonas-bergh","kind":"person","name":"Jonas Bergh","aka":[],"tldr":"Jonas Bergh is a breast oncologist and long-standing leader of Swedish and European breast cancer trials.","summary":"Jonas Bergh is Professor of Oncology at Karolinska Institutet and a senior physician at Karolinska University Hospital in Stockholm. His specialisms are breast cancer, adjuvant therapy and dose-dense chemotherapy. He has co-led trials of dose-dense chemotherapy and tailored adjuvant therapy within the Swedish Breast Cancer Group and the Early Breast Cancer Trialists' Collaborative Group. His papers include the New England Journal of Medicine report of pembrolizumab for early triple-negative breast cancer, an analysis of long-term breast cancer recurrence risk after stopping endocrine therapy at five years, and a study from the EORTC 10994/BIG 1-00 trial of pathological complete response after neoadjuvant chemotherapy across intrinsic subtypes. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bergh%20J%5BAuthor%5D%20breast%20cancer%20adjuvant"}],"tags":[],"related":[],"cancers":["breast-hr-positive","breast-her2-positive"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["karolinska"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Oncology, Karolinska Institutet; Senior Physician, Karolinska University Hospital","institutionId":"karolinska","specialisms":["Breast cancer","Adjuvant therapy","Dose-dense chemotherapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bergh%20J%5BAuthor%5D%20breast%20cancer%20adjuvant"}],"papers":[{"title":"Pembrolizumab for Early Triple-Negative Breast Cancer","journal":"New England Journal of Medicine","year":2020,"doi":"10.1056/nejmoa1910549"},{"title":"20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years","journal":"New England Journal of Medicine","year":2017,"doi":"10.1056/nejmoa1701830"},{"title":"Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial","journal":"Annals of Oncology","year":2014,"doi":"10.1093/annonc/mdu118"},{"title":"KEYNOTE-522: adding pembrolizumab before and after surgery in early triple-negative breast cancer","journal":"New England Journal of Medicine","year":2022,"url":"https://doi.org/10.1056/NEJMoa2112651","doi":"10.1056/NEJMoa2112651"}],"orcid":"0000-0001-5526-1847"},{"id":"jonas-claesson","kind":"person","name":"Jonas Claesson","aka":[],"tldr":"Jonas Claesson represents Örebro University Hospital in the Organisation of European Cancer Institutes, which lists the centre among its members in Sweden.","summary":"Jonas Claesson is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Örebro University Hospital, its member in Sweden. Örebro University Hospital is the university hospital of central Sweden's Region Örebro and a full member of the Organisation of European Cancer Institutes as the Örebro Comprehensive Cancer Centre. OnCo records the name from the OECI membership list so that the centre's page has a named contact point; the person's exact title, appointment date and biography are not yet recorded and should be checked on the institution's own pages before being relied on.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Örebro University Hospital website","url":"https://www.regionorebrolan.se/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["orebro-university-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Örebro University Hospital to the Organisation of European Cancer Institutes","institutionId":"orebro-university-hospital","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Örebro University Hospital website","url":"https://www.regionorebrolan.se/"}],"papers":[]},{"id":"jonathan-ledermann","kind":"person","name":"Jonathan A. Ledermann","aka":[],"tldr":"Led Study 19, the trial that first showed PARP inhibitor maintenance works in ovarian cancer.","summary":"Jonathan Ledermann led Study 19, the randomised trial showing maintenance olaparib prolongs progression-free survival in platinum-sensitive relapsed ovarian cancer with the largest effect in BRCA-mutant disease, the proof of concept for every subsequent PARP inhibitor maintenance approval. He has led the ICON trials, chaired the Gynecologic Cancer InterGroup, and led ESMO-ESGO ovarian cancer guidelines.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ledermann%20JA%5BAuthor%5D%20ovarian%20olaparib"}],"tags":["ovarian","parp","uk"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":["parp-inhibitor"],"targets":["parp","brca"],"drugs":["olaparib"],"companies":[],"institutions":["uclh"],"pathways":[],"terms":[],"trials":["gog-0218-icon7"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology, UCL Cancer Institute; Consultant, UCLH","institutionId":"uclh","specialisms":["Ovarian cancer","PARP inhibitors","Cooperative-group trials","Guidelines"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ledermann%20JA%5BAuthor%5D%20ovarian%20olaparib"}],"papers":[{"title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer (Study 19)","journal":"NEJM","year":2012,"doi":"10.1056/NEJMoa1105535"},{"title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial","journal":"Lancet Oncology","year":2014,"doi":"10.1016/S1470-2045(14)70228-1"}],"orcid":"0000-0003-3799-3539"},{"id":"jonathan-benger","kind":"person","name":"Jonathan Benger","aka":[],"tldr":"Emergency physician who became Chief Executive of NICE, the body that appraises new cancer medicines and issues clinical guidance for the NHS, in December 2025.","summary":"Professor Jonathan Benger is Chief Executive of the National Institute for Health and Care Excellence (NICE), the English body that produces clinical guidelines and appraises the cost effectiveness of new treatments, including cancer drugs. He joined NICE in January 2023 as Chief Medical Officer, became interim director of the centre for guidelines in March 2023, was appointed deputy chief executive in May 2024 and chief executive in December 2025. Earlier he was interim chief clinical information officer at NHS England, Chief Medical Officer of NHS Digital and national clinical director for urgent and emergency care.","asOf":"2026-09-10","links":[{"label":"Source: NICE executive team page","url":"https://www.nice.org.uk/about-us/executive-team"}],"tags":["leadership","clinician-scientist","hta","policy"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["nice"],"pathways":[],"terms":["hta"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive of NICE (since December 2025)","institutionId":"nice","specialisms":["Health technology assessment","Clinical guidelines","Emergency medicine"],"profiles":[{"label":"NICE executive team","url":"https://www.nice.org.uk/about-us/executive-team"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Benger+JR%5BAuthor%5D"}],"papers":[{"title":"Effect of a Strategy of a Supraglottic Airway Device vs Tracheal Intubation During Out-of-Hospital Cardiac Arrest on Functional Outcome: The AIRWAYS-2 Randomized Clinical Trial","journal":"JAMA","year":2018,"url":"https://doi.org/10.1001/jama.2018.11597","doi":"10.1001/jama.2018.11597","note":"Europe PMC author record matched by affiliation"},{"title":"Effect of an extended scope physiotherapy service on patient satisfaction and the outcome of soft tissue injuries in an adult emergency department","journal":"Emergency Medicine Journal","year":2006,"url":"https://doi.org/10.1136/emj.2005.029231","doi":"10.1136/emj.2005.029231","note":"Europe PMC author record matched by affiliation"},{"title":"Early and Empirical High-Dose Cryoprecipitate for Hemorrhage After Traumatic Injury: The CRYOSTAT-2 Randomized Clinical Trial","journal":"JAMA","year":2023,"url":"https://doi.org/10.1001/jama.2023.21019","doi":"10.1001/jama.2023.21019","note":"Europe PMC author record matched by affiliation"}],"orcid":"0000-0001-6131-0916"},{"id":"jonathan-brotherton","kind":"person","name":"Jonathan Brotherton","aka":[],"tldr":"Chief executive of the Birmingham hospital trust that runs the Queen Elizabeth Hospital and its regional cancer services.","summary":"Jonathan Brotherton is Chief Executive of University Hospitals Birmingham NHS Foundation Trust, which runs four hospitals including the Queen Elizabeth Hospital Birmingham and provides adult district general and specialist services for the West Midlands. He has worked in Birmingham and Solihull since 2014, joining Heart of England NHS Foundation Trust as Director of Operations before becoming Chief Operating Officer. The trust's Chief Medical Officer is Professor Kiran Patel, a consultant cardiologist who joined in March 2024.","asOf":"2026-09-10","links":[{"label":"Source: UHB Board of Directors page","url":"https://www.uhb.nhs.uk/about/trust-management/bod/"}],"tags":["leadership","hospital-management","nhs"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["birmingham-cancer-centre"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive, University Hospitals Birmingham NHS Foundation Trust","institutionId":"birmingham-cancer-centre","specialisms":["Hospital operations","NHS leadership","Acute care management"],"profiles":[{"label":"UHB Board of Directors","url":"https://www.uhb.nhs.uk/about/trust-management/bod/"}],"papers":[]},{"id":"jonathan-rosenberg","kind":"person","name":"Jonathan E. Rosenberg","aka":[],"tldr":"Led the early enfortumab vedotin trials and the atezolizumab study that first brought immunotherapy to bladder cancer.","summary":"Jonathan Rosenberg led IMvigor210, the first pivotal study of a PD-L1 inhibitor in urothelial cancer, and EV-201, the trial that won enfortumab vedotin accelerated approval, and was a lead investigator of EV-103 and EV-302. He has also led erdafitinib and other FGFR3-directed studies. He chairs GU oncology at MSKCC and the Alliance GU committee.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rosenberg%20JE%5BAuthor%5D%20urothelial%20enfortumab"}],"tags":["urothelial","adc","immunotherapy"],"related":[],"cancers":["urothelial"],"sections":[],"technologies":["adc","checkpoint-inhibitor"],"targets":["nectin4","pdl1"],"drugs":["enfortumab-vedotin","atezolizumab"],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":["ev-302"],"people":[],"bottlenecks":[],"keyPapers":["paper-ev-302-nejm-2024"],"journals":[],"dependsOn":[],"notes":[],"role":"Chief, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center","institutionId":"mskcc","specialisms":["Urothelial cancer","Antibody-drug conjugates","FGFR-targeted therapy","Immunotherapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rosenberg%20JE%5BAuthor%5D%20urothelial%20enfortumab"}],"papers":[{"title":"Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy (EV-201)","journal":"JCO","year":2019,"doi":"10.1200/JCO.19.01140"},{"title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy (IMvigor210)","journal":"Lancet","year":2016,"doi":"10.1016/S0140-6736(16)00561-4"},{"title":"EV-302: enfortumab vedotin plus pembrolizumab replaces chemotherapy as first treatment for advanced bladder cancer","journal":"New England Journal of Medicine","year":2024,"url":"https://doi.org/10.1056/NEJMoa2312117","doi":"10.1056/NEJMoa2312117"}],"orcid":"0000-0003-2637-4249"},{"id":"jonathan-strosberg","kind":"person","name":"Jonathan R. Strosberg","aka":[],"tldr":"Led NETTER-1, the trial that made lutetium dotatate the first approved radioligand therapy for neuroendocrine tumours.","summary":"Jonathan Strosberg was principal investigator of NETTER-1, which showed 177Lu-DOTATATE reduces the risk of progression by 79% in midgut neuroendocrine tumours and led to Lutathera's approval, the first radioligand therapy approved for a solid tumour and the template for PSMA-targeted therapy. He co-leads the NETTER-2 and COMPETE programmes and chairs the North American Neuroendocrine Tumor Society guidelines.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Strosberg%20J%5BAuthor%5D%20neuroendocrine%20lutetium"}],"tags":["neuroendocrine","radioligand","trialist"],"related":[],"cancers":["neuroendocrine"],"sections":[],"technologies":["radioligand-therapy"],"targets":["sstr2"],"drugs":["lutathera"],"companies":[],"institutions":["moffitt"],"pathways":[],"terms":[],"trials":["compete"],"people":[],"bottlenecks":[],"keyPapers":["paper-netter-2-lancet-2024"],"journals":[],"dependsOn":[],"notes":[],"role":"Section Head, Neuroendocrine Tumor Program, Moffitt Cancer Center","institutionId":"moffitt","specialisms":["Neuroendocrine tumours","Peptide receptor radionuclide therapy","Somatostatin analogues","Radioligand trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Strosberg%20J%5BAuthor%5D%20neuroendocrine%20lutetium"}],"papers":[{"title":"Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors (NETTER-1)","journal":"NEJM","year":2017,"doi":"10.1056/NEJMoa1607427"},{"title":"177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results","journal":"Lancet Oncology","year":2021,"doi":"10.1016/S1470-2045(21)00572-6"},{"title":"NETTER-2: lutetium-177 dotatate as first treatment for higher-grade gastroenteropancreatic neuroendocrine tumours","journal":"The Lancet","year":2024,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NETTER-2+lutetium+dotatate+first-line+Singh+Lancet"}]},{"id":"jonathan-spicer","kind":"person","name":"Jonathan Spicer","aka":[],"tldr":"The surgeon on CheckMate 816 who showed neoadjuvant immunotherapy does not make lung cancer operations harder.","summary":"Jonathan Spicer led the surgical analyses of CheckMate 816, demonstrating that neoadjuvant nivolumab plus chemotherapy did not delay or complicate surgery and increased the rate of complete resection, which removed a key objection to neoadjuvant immunotherapy. He co-authored the five-year update and leads perioperative surgical research at McGill.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Spicer%20JD%5BAuthor%5D%20neoadjuvant%20lung%20surgery"}],"tags":["lung","surgery","neoadjuvant"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["nivolumab"],"companies":[],"institutions":["mcgill-goodman"],"pathways":[],"terms":[],"trials":["checkmate-816"],"people":[],"bottlenecks":[],"keyPapers":["paper-checkmate-816-nejm-2022"],"journals":[],"dependsOn":[],"notes":[],"role":"Thoracic Surgeon and Associate Professor of Surgery, McGill University Health Centre","institutionId":"mcgill-goodman","specialisms":["Thoracic surgery","Neoadjuvant immunotherapy","Surgical outcomes in trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Spicer%20JD%5BAuthor%5D%20neoadjuvant%20lung%20surgery"}],"papers":[{"title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer (CheckMate 816)","journal":"NEJM","year":2022,"doi":"10.1056/NEJMoa2202170"},{"title":"Surgical outcomes from the phase 3 CheckMate 816 trial: nivolumab plus platinum-doublet chemotherapy vs chemotherapy alone as neoadjuvant treatment for resectable non-small cell lung cancer","journal":"JAMA Oncology","year":2023}],"orcid":"0000-0003-2708-1309"},{"id":"jong-mu-sun","kind":"person","name":"Jong-Mu Sun","aka":[],"tldr":"Korean oncologist who was lead author of KEYNOTE-590, the trial that added pembrolizumab to first-line chemotherapy for advanced oesophageal cancer.","summary":"Jong-Mu Sun is a medical oncologist at Samsung Medical Center in Seoul. He was first author of the 2021 Lancet report of KEYNOTE-590, which showed that pembrolizumab plus cisplatin and fluorouracil improved overall survival compared with chemotherapy alone in untreated advanced oesophageal cancer, the basis for pembrolizumab's approval in this setting. He also runs thoracic oncology trials.","asOf":"2026-09-18","links":[],"tags":["oesophageal","immunotherapy","trialist"],"related":[],"cancers":["oesophageal-squamous-cell-carcinoma","oesophageal-adenocarcinoma","esophageal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["samsung-medical-center"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-keynote-590-lancet-2021"],"journals":[],"dependsOn":[],"notes":[],"role":"Medical oncologist, Samsung Medical Center, Seoul","institutionId":"samsung-medical-center","specialisms":["Oesophageal cancer","Lung cancer","Immunotherapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sun%5BAuthor%5D"}],"papers":[{"title":"KEYNOTE-590: pembrolizumab plus chemotherapy for first-line treatment of advanced oesophageal cancer","journal":"The Lancet","year":2021,"url":"https://doi.org/10.1016/S0140-6736(21)01234-4","doi":"10.1016/S0140-6736(21)01234-4"}]},{"id":"sohn-joohyuk","kind":"person","name":"Joohyuk Sohn","aka":[],"tldr":"Joohyuk Sohn is a Yonsei breast oncologist and investigator on the DESTINY-Breast and TROPION trials.","summary":"Joohyuk Sohn is Professor of Medical Oncology at Severance Hospital, Yonsei University, in Seoul, specialising in breast cancer. He leads breast medical oncology trials at Yonsei Cancer Center and has been an investigator on the DESTINY-Breast trials of trastuzumab deruxtecan and the TROPION trials of datopotamab deruxtecan, bringing Korean cohorts into HER2-low, TROP2 antibody-drug conjugate and CDK4/6 studies. His publications include work on cMET activation and resistance to EGFR-directed therapy in triple-negative breast cancer, the D-CARE trial of adjuvant denosumab in early breast cancer, and a phase 3 trial of polymeric micelle-formulated paclitaxel in HER2-negative breast cancer. His interests are HER2-low disease and antibody-drug conjugates.","asOf":"2026-09-08","links":[{"label":"Yonsei Cancer Center","url":"https://sev.severance.healthcare"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sohn%20J%5BAuthor%5D%20Yonsei%20breast%20cancer"}],"tags":[],"related":[],"cancers":["breast-hr-positive","breast-her2-positive"],"sections":[],"technologies":[],"targets":["her2","trop2"],"drugs":["trastuzumab-deruxtecan","datopotamab-deruxtecan"],"companies":[],"institutions":["severance"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["cancer-research-and-treatment"],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology; breast cancer","institutionId":"severance","specialisms":["Breast cancer","HER2-low","Antibody-drug conjugates"],"profiles":[{"label":"Yonsei Cancer Center","url":"https://sev.severance.healthcare"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sohn%20J%5BAuthor%5D%20Yonsei%20breast%20cancer"}],"papers":[{"title":"cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer","journal":"Journal of Cancer","year":2014,"doi":"10.7150/jca.9696"},{"title":"Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial","journal":"The Lancet Oncology","year":2020,"doi":"10.1016/s1470-2045(19)30687-4"},{"title":"An Open-Label, Randomized, Parallel, Phase III Trial Evaluating the Efficacy and Safety of Polymeric Micelle-Formulated Paclitaxel Compared to Conventional Cremophor EL-Based Paclitaxel for Recurrent or Metastatic HER2-Negative Breast Cancer","journal":"Cancer Research and Treatment","year":2017,"doi":"10.4143/crt.2016.289"},{"title":"DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group","journal":"New England Journal of Medicine","year":2022,"url":"https://doi.org/10.1056/NEJMoa2203690","doi":"10.1056/NEJMoa2203690"},{"title":"DESTINY-Breast06: trastuzumab deruxtecan before any chemotherapy in hormone-receptor-positive, HER2-low or ultralow breast cancer","journal":"New England Journal of Medicine","year":2024,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DESTINY-Breast06+trastuzumab+deruxtecan+HER2-low+chemotherapy-naive"},{"title":"monarchE: two years of abemaciclib after surgery in high-risk, hormone-receptor-positive early breast cancer","journal":"Journal of Clinical Oncology","year":2020,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=monarchE+abemaciclib+adjuvant+Johnston+2020"}]},{"id":"jordi-bruix","kind":"person","name":"Jordi Bruix","aka":[],"tldr":"Barcelona liver specialist who co-created the BCLC staging system used worldwide to decide how liver cancer is treated, and led STORM, which showed adjuvant sorafenib does not help after curative treatment.","summary":"Jordi Bruix led the Barcelona Clinic Liver Cancer (BCLC) group at Hospital Clínic de Barcelona, whose staging and treatment algorithm is the reference framework for hepatocellular carcinoma. He was first author of the 2015 Lancet Oncology report of STORM, which found that sorafenib after resection or ablation did not improve recurrence-free survival, and a senior investigator on the SHARP trial that established sorafenib for advanced disease.","asOf":"2026-09-18","links":[],"tags":["hcc","trialist"],"related":[],"cancers":["hcc-early","hcc-advanced","hcc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["hospital-clinic-barcelona"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-storm-adjuvant-sorafenib-bruix-lancet-oncol-2015"],"journals":[],"dependsOn":[],"notes":[],"role":"Hepatologist, Barcelona Clinic Liver Cancer group, Hospital Clínic de Barcelona","institutionId":"hospital-clinic-barcelona","specialisms":["Hepatocellular carcinoma","BCLC staging","Systemic therapy trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bruix%5BAuthor%5D"}],"papers":[{"title":"STORM: adjuvant sorafenib after resection or ablation of hepatocellular carcinoma","journal":"The Lancet Oncology","year":2015,"url":"https://doi.org/10.1016/S1470-2045(15)00198-9","doi":"10.1016/S1470-2045(15)00198-9"}]},{"id":"jose-baselga","kind":"person","name":"José Baselga","aka":[],"tldr":"Spanish oncologist who helped develop trastuzumab, pertuzumab and everolimus for breast cancer, and was lead author of BOLERO-2, which established everolimus plus exemestane for hormone-receptor-positive disease.","summary":"José Baselga was a leading figure in breast cancer drug development. He founded the Vall d'Hebron Institute of Oncology in Barcelona, served as physician-in-chief at Memorial Sloan Kettering Cancer Center and later led oncology research and development at AstraZeneca. He was first author of the 2012 New England Journal of Medicine report of BOLERO-2, which showed that adding everolimus to exemestane lengthened progression-free survival in hormone-receptor-positive advanced breast cancer after non-steroidal aromatase inhibitors, and of the CLEOPATRA trial of pertuzumab. He died in 2021.","asOf":"2026-09-18","wikipedia":"https://en.wikipedia.org/wiki/Jos%C3%A9_Baselga","links":[],"tags":["breast","targeted-therapy","trialist"],"related":[],"cancers":["breast-hr-positive","hr-positive-metastatic-post-cdk46","breast-her2-positive","breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["bolero-2"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Medical oncologist and drug developer (1959–2021)","specialisms":["HER2-positive breast cancer","PI3K and mTOR inhibitors","Translational oncology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Baselga%5BAuthor%5D"}],"papers":[]},{"id":"jose-julian-diaz-melguizo","kind":"person","name":"Jose Julián Díaz Melguizo","aka":[],"tldr":"Jose Julián Díaz Melguizo represents Hospital Universitario de La Princesa in the Organisation of European Cancer Institutes, which lists the centre among its full members in Spain.","summary":"Jose Julián Díaz Melguizo is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Hospital Universitario de La Princesa, its full member in Spain. OnCo records the name from the OECI membership list so that the centre's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the institution's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Hospital Universitario de La Princesa website","url":"https://www.comunidad.madrid/hospital/laprincesa/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["la-princesa"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Hospital Universitario de La Princesa to the Organisation of European Cancer Institutes","institutionId":"la-princesa","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Hospital Universitario de La Princesa website","url":"https://www.comunidad.madrid/hospital/laprincesa/"}],"papers":[]},{"id":"jose-luis-poveda-andres","kind":"person","name":"José Luis Poveda Andrés","aka":[],"tldr":"Chief executive (Gerente) of Hospital Universitari i Politècnic La Fe in Valencia, one of Spain's largest public university hospitals.","summary":"José Luis Poveda Andrés is Gerente of the Hospital Universitari i Politècnic La Fe, the tertiary public university hospital of the Departamento de Salud Valencia La Fe within the Valencian regional health service. The governance pages of the hospital's research institute, IIS La Fe, list him in that capacity as President of the institute's Junta de Gobierno and Vice President of its Patronato, which is chaired by the regional health minister Marciano Gómez Gómez. He works alongside medical director María Salomé Matoses Jaén and economic director Alejandro Colomer Real. The hospital's own website could not be reached.","asOf":"2026-09-10","links":[{"label":"Source: IIS La Fe Junta de Gobierno page","url":"https://www.iislafe.es/es/el-iis-la-fe/estructura-organizativa/junta-de-gobierno/"},{"label":"Source: IIS La Fe Patronato page","url":"https://www.iislafe.es/es/el-iis-la-fe/estructura-organizativa/patronato/"}],"tags":["leadership","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["la-fe-valencia"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Gerente (Chief Executive), Hospital Universitari i Politècnic La Fe, Valencia","institutionId":"la-fe-valencia","specialisms":["Hospital management","Health services management"],"profiles":[{"label":"IIS La Fe Junta de Gobierno page listing the hospital Gerente","url":"https://www.iislafe.es/es/el-iis-la-fe/estructura-organizativa/junta-de-gobierno/"}],"papers":[]},{"id":"josep-llovet","kind":"person","name":"Josep M. Llovet","aka":["Josep Maria Llovet","Josep Llovet"],"tldr":"Led SHARP, which made sorafenib the first systemic therapy for liver cancer, and created the BCLC staging system.","summary":"Josep Llovet was principal investigator of SHARP, the 2008 trial showing sorafenib improves survival in advanced hepatocellular carcinoma, the first systemic therapy to do so, and co-created the Barcelona Clinic Liver Cancer staging and treatment algorithm used worldwide. His laboratory defined the molecular classes of HCC and he has led guidelines for the EASL and AASLD. He continues to work on biomarkers for immunotherapy in liver cancer. Alongside the Mount Sinai directorship he leads the Translational Research in Hepatic Oncology group at IDIBAPS, Hospital Clínic de Barcelona, and is among the most cited researchers in hepatocellular carcinoma.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Llovet%20JM%5BAuthor%5D%20hepatocellular"},{"label":"Institution profile","url":"https://www.clinicbarcelona.org/en/idibaps/about-us/scientific-organizational-structure"}],"tags":["hcc","staging","trialist","clinician-scientist","liver cancer","hepatocellular carcinoma"],"related":[],"cancers":["hcc"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":[],"companies":[],"institutions":["mount-sinai","hospital-clinic-barcelona"],"pathways":[],"terms":[],"trials":["sharp"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Liver Cancer Program, Icahn School of Medicine at Mount Sinai; Professor, University of Barcelona","institutionId":"mount-sinai","specialisms":["Hepatocellular carcinoma","Targeted therapy","Staging systems","Molecular classification","Liver cancer systemic therapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Llovet%20JM%5BAuthor%5D%20hepatocellular"},{"label":"Institution profile","url":"https://www.clinicbarcelona.org/en/idibaps/about-us/scientific-organizational-structure"}],"papers":[{"title":"Sorafenib in advanced hepatocellular carcinoma (SHARP)","journal":"NEJM","year":2008,"doi":"10.1056/NEJMoa0708857"},{"title":"Hepatocellular carcinoma","journal":"Nature Reviews Disease Primers","year":2021,"doi":"10.1038/s41572-020-00240-3"},{"title":"Hepatocellular carcinoma","journal":"Nature Reviews Disease Primers","year":2016,"url":"https://doi.org/10.1038/nrdp.2016.18","doi":"10.1038/nrdp.2016.18"}],"orcid":"0000-0003-0547-2667"},{"id":"josep-maria-campistol","kind":"person","name":"Josep Maria Campistol","aka":[],"tldr":"Nephrologist and CEO of Hospital Clínic de Barcelona, one of Spain's leading academic hospitals.","summary":"Josep Maria Campistol is Chief Executive Officer of Hospital Clínic de Barcelona. A nephrologist and transplant physician, he leads a university hospital that integrates clinical care with the IDIBAPS research institute and hosts one of Spain's major cancer programmes. He is responsible for the hospital's overall strategy, including its oncology and translational research activities.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.clinicbarcelona.org/en/assistance/management-board"}],"tags":["leadership","hospital management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["hospital-clinic-barcelona"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive Officer","institutionId":"hospital-clinic-barcelona","specialisms":["Hospital management","Nephrology and transplantation","Academic medicine"],"profiles":[{"label":"Institution profile","url":"https://www.clinicbarcelona.org/en/assistance/management-board"}],"papers":[{"title":"Kaposi's sarcoma in renal transplant recipients--the impact of proliferation signal inhibitors","journal":"Nephrology Dialysis Transplantation","year":2007,"doi":"10.1093/ndt/gfm089"},{"title":"Conversion to sirolimus: a successful treatment for posttransplantation Kaposi???s sarcoma12","journal":"Transplantation","year":2004,"doi":"10.1097/01.tp.0000115344.18025.0b"},{"title":"New concepts and best practices for management of pre- and post-transplantation cancer","journal":"Transplantation Reviews","year":2012,"doi":"10.1016/j.trre.2012.07.001"}]},{"id":"josep-tabernero","kind":"person","name":"Josep Tabernero","aka":[],"tldr":"Colorectal cancer trialist who led BEACON and BREAKWATER, bringing targeted therapy to BRAF-mutant disease; former ESMO President.","summary":"Josep Tabernero is Director of the Vall d'Hebron Institute of Oncology (VHIO) and Head of Medical Oncology at Vall d'Hebron University Hospital in Barcelona, and served as President of the European Society for Medical Oncology (ESMO) in 2018-2019. His specialisms are colorectal cancer, gastrointestinal oncology, early drug development and precision medicine, with a focus on BRAF and EGFR. He led BEACON CRC, the New England Journal of Medicine trial of encorafenib, binimetinib and cetuximab in BRAF V600E-mutated colorectal cancer, and BREAKWATER, which combined encorafenib and cetuximab with mFOLFOX6 and established first-line targeted therapy for BRAF-mutant disease. His VHIO profile and PubMed listing are linked.","asOf":"2026-09-08","links":[{"label":"VHIO","url":"https://vhio.net/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tabernero%20J%5BAuthor%5D%20colorectal"}],"tags":[],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":["braf","egfr"],"drugs":["encorafenib","cetuximab"],"companies":[],"institutions":["vall-dhebron","esmo"],"pathways":[],"terms":[],"trials":["breakwater"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Vall d'Hebron Institute of Oncology (VHIO); Head of Medical Oncology, Vall d'Hebron University Hospital","institutionId":"vall-dhebron","specialisms":["Colorectal cancer","Gastrointestinal oncology","Early drug development","Precision medicine"],"profiles":[{"label":"VHIO","url":"https://vhio.net/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tabernero%20J%5BAuthor%5D%20colorectal"}],"papers":[{"title":"Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer (BEACON)","journal":"NEJM","year":2019,"doi":"10.1056/NEJMoa1908075"},{"title":"Encorafenib, cetuximab, and mFOLFOX6 in BRAF-mutated colorectal cancer (BREAKWATER)","journal":"NEJM","year":2025,"doi":"10.1056/NEJMoa2501912"},{"title":"BREAKWATER: encorafenib plus cetuximab with chemotherapy as first treatment for BRAF V600E-mutated colorectal cancer","journal":"New England Journal of Medicine","year":2025,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BREAKWATER+encorafenib+cetuximab+mFOLFOX6+colorectal"}],"orcid":"0000-0002-2495-8139"},{"id":"joseph-sparano","kind":"person","name":"Joseph A. Sparano","aka":[],"tldr":"Led TAILORx, which showed most women with intermediate Oncotype scores can safely skip chemotherapy.","summary":"Joseph Sparano was study chair of TAILORx, the ECOG-ACRIN trial of 10,000 women that showed endocrine therapy alone is non-inferior to chemo-endocrine therapy for HR-positive, node-negative breast cancer with a mid-range 21-gene recurrence score. The result spared tens of thousands of patients chemotherapy each year and made genomic assays standard in early breast cancer. He continues to lead ECOG-ACRIN breast trials on treatment de-escalation and ctDNA.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sparano%20JA%5BAuthor%5D%20TAILORx"}],"tags":["breast","de-escalation","ecog-acrin"],"related":[],"cancers":["breast-hr-positive"],"sections":[],"technologies":["companion-diagnostic"],"targets":[],"drugs":["oncotype-dx"],"companies":[],"institutions":["mount-sinai"],"pathways":[],"terms":[],"trials":["tailorx"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai","institutionId":"mount-sinai","specialisms":["Early breast cancer","Genomic assays","Chemotherapy de-escalation","Cooperative-group trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sparano%20JA%5BAuthor%5D%20TAILORx"}],"papers":[{"title":"Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer (TAILORx)","journal":"NEJM","year":2018,"doi":"10.1056/NEJMoa1804710"},{"title":"Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer","journal":"NEJM","year":2019,"doi":"10.1056/NEJMoa1904819"}],"orcid":"0000-0002-9031-2010"},{"id":"joseph-gligorov","kind":"person","name":"Joseph Gligorov","aka":[],"tldr":"Medical oncologist at Hôpital Tenon who is executive director of the Institut Universitaire de Cancérologie AP-HP Sorbonne Université, the OECI-accredited university cancer institute in Paris.","summary":"Joseph Gligorov is Directeur Exécutif of the Institut Universitaire de Cancérologie (IUC) AP-HP Sorbonne Université, which coordinates cancer care, teaching and research across the AP-HP Sorbonne Université hospital group and the university's health faculty. He is professor of medical oncology at Sorbonne Université, practises in the medical oncology department of Hôpital Tenon in Paris and belongs to the Inserm U938 team on cancer biology and treatment; his research concerns breast cancer and predictive factors of response to anticancer treatment, he directs the Nice-St Paul de Vence breast cancer guidelines conference and he co-founded and chairs the Mediterranean oncology association AROME. In a 2023 interview with the Sorbonne Université Faculté de Santé, as director of the IUC, he described the institute's creation by Dean Serge Uzan and its accreditation as an OECI 'Comprehensive Cancer Center', and AP-HP reported in February 2026 on the institute's annual scientific day.","asOf":"2026-09-10","links":[{"label":"Source: Alliance Sorbonne Université Global Health Institute profile naming him Directeur Exécutif of the IUC","url":"https://asu-ghi.sorbonne-universite.fr/lasu-ghi/membres/joseph-gligorov"},{"label":"Source: Sorbonne Université Faculté de Santé interview with the IUC director on OECI accreditation (2023)","url":"https://sante.sorbonne-universite.fr/actualites/linstitut-universitaire-de-cancerologie-iuc-decroche-laccreditation-comprehensive-cancer"}],"tags":["leadership","clinician-scientist","comprehensive-cancer-centre"],"related":[],"cancers":["breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Directeur Exécutif (Executive Director), Institut Universitaire de Cancérologie AP-HP Sorbonne Université","institutionId":"iuc-aphp-sorbonne","specialisms":["Medical oncology","Breast cancer","Predictive factors of treatment response"],"profiles":[{"label":"ASU-GHI member profile (Sorbonne Université)","url":"https://asu-ghi.sorbonne-universite.fr/lasu-ghi/membres/joseph-gligorov"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gligorov+J%5BAuthor%5D"}],"papers":[{"title":"Efficacy of Circulating Tumor Cell Count–Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer","journal":"JAMA Oncology","year":2021,"doi":"10.1001/jamaoncol.2020.5660"},{"title":"COVID-19 et personnes suivies pour un cancer du sein : recommandations françaises pour la pratique clinique de Nice-St Paul de Vence, en collaboration avec le Collège Nationale des Gynécologues et Obstétriciens Français (CNGOF), la Société d’Imagerie de la Femme (SIFEM), la Société Française de Chirurgie Oncologique (SFCO), la Société Française de Sénologie et Pathologie Mammaire (SFSPM) et le French Breast Cancer Intergroup-UNICANCER (UCBG)","journal":"Bulletin du Cancer","year":2020,"doi":"10.1016/j.bulcan.2020.03.008"},{"title":"Patients' preference of trastuzumab administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: Results of the randomised MetaspHer study","journal":"European Journal of Cancer","year":2017,"doi":"10.1016/j.ejca.2017.05.009"}],"orcid":"0000-0002-9900-6386"},{"id":"joseph-connors","kind":"person","name":"Joseph M. Connors","aka":[],"tldr":"Led ECHELON-1, which replaced bleomycin with brentuximab vedotin in first-line advanced Hodgkin lymphoma.","summary":"Joseph Connors was principal investigator of ECHELON-1, the trial showing brentuximab vedotin plus AVD improves progression-free and later overall survival compared with ABVD in advanced Hodgkin lymphoma, the first change to first-line therapy in decades. He built the BC Cancer lymphoid cancer database and population-based treatment guidelines that document real-world outcomes across all lymphomas.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Connors%20JM%5BAuthor%5D%20Hodgkin%20brentuximab"}],"tags":["hodgkin","adc","canada"],"related":[],"cancers":["hodgkin-lymphoma"],"sections":[],"technologies":["adc"],"targets":[],"drugs":["brentuximab-vedotin"],"companies":[],"institutions":["bc-cancer"],"pathways":[],"terms":[],"trials":["echelon-1"],"people":[],"bottlenecks":[],"keyPapers":["paper-echelon-1-brentuximab-avd-nejm-2018"],"journals":[],"dependsOn":[],"notes":[],"role":"Clinical Professor Emeritus, BC Cancer Centre for Lymphoid Cancer, University of British Columbia","institutionId":"bc-cancer","specialisms":["Hodgkin lymphoma","Population-based lymphoma care","Antibody-drug conjugates","Treatment guidelines"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Connors%20JM%5BAuthor%5D%20Hodgkin%20brentuximab"}],"papers":[{"title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma (ECHELON-1)","journal":"NEJM","year":2018,"doi":"10.1056/NEJMoa1708984"},{"title":"Overall survival with brentuximab vedotin in stage III or IV Hodgkin's lymphoma","journal":"NEJM","year":2022,"doi":"10.1056/NEJMoa2206125"}]},{"id":"joseph-unger","kind":"person","name":"Joseph M. Unger","aka":[],"tldr":"Biostatistician who showed most patients are excluded from trials by structural barriers, not by unwillingness to take part.","summary":"Joseph Unger led the systematic review and meta-analysis showing that more than half of cancer patients cannot enrol in trials because none is available locally or they fail eligibility, and that when offered, more than half agree to participate regardless of race, reframing under-representation as a structural problem. His SWOG analyses have quantified the survival benefits of trial participation and the effects of Medicaid expansion.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Unger%20JM%5BAuthor%5D%20clinical%20trial%20participation"}],"tags":["trials","disparities","biostatistics"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["fred-hutch"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-unger-trial-participation-barriers-jnci-2019"],"journals":[],"dependsOn":[],"notes":[],"role":"Associate Professor, Public Health Sciences and SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Center","institutionId":"fred-hutch","specialisms":["Trial participation and access","Health disparities","Biostatistics","Cooperative-group trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Unger%20JM%5BAuthor%5D%20clinical%20trial%20participation"}],"papers":[{"title":"Systematic review and meta-analysis of the magnitude of structural, clinical, and physician and patient barriers to cancer clinical trial participation","journal":"JNCI","year":2019,"doi":"10.1093/jnci/djy221"},{"title":"'When offered to participate': a systematic review and meta-analysis of patient agreement to participate in cancer clinical trials","journal":"JNCI","year":2021,"doi":"10.1093/jnci/djaa155"}],"orcid":"0000-0002-5191-0317"},{"id":"joseph-martin","kind":"person","name":"Joseph Martin","aka":[],"tldr":"Joseph Martin represents University of Galway / Saolta Cancer Centre in the Organisation of European Cancer Institutes, which lists the centre among its members in Ireland.","summary":"Joseph Martin is listed by the Organisation of European Cancer Institutes (OECI) as the representative of University of Galway / Saolta Cancer Centre, its full member in Ireland. OnCo records the name from the OECI membership list so that the centre's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the institution's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"University of Galway / Saolta Cancer Centre website","url":"https://www.saolta.ie"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["galway-university-hospital-cancer-centre"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of University of Galway / Saolta Cancer Centre to the Organisation of European Cancer Institutes","institutionId":"galway-university-hospital-cancer-centre","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"University of Galway / Saolta Cancer Centre website","url":"https://www.saolta.ie"}],"papers":[]},{"id":"joseph-ross","kind":"person","name":"Joseph S. Ross","aka":[],"tldr":"Yale health policy researcher on the YODA Project leadership team, known for work on FDA regulation and trial transparency.","summary":"Joseph S. Ross is Professor of Medicine and of Public Health at Yale and part of the leadership of the YODA Project. His research examines drug and device regulation, the evidence supporting FDA approvals, and clinical trial reporting and data sharing, topics that bear directly on how new cancer therapies reach patients.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://yoda.yale.edu/about/leadership-contact-information/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ross+JS%5BAuthor%5D"}],"tags":["clinician-scientist","regulation","data sharing"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["yoda-project"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["jama-internal-medicine","jama"],"dependsOn":[],"notes":[],"role":"Professor of Medicine (General Medicine) and of Public Health (Health Policy)","institutionId":"yoda-project","specialisms":["Drug regulation","Clinical trial transparency","Health policy"],"profiles":[{"label":"Institution profile","url":"https://yoda.yale.edu/about/leadership-contact-information/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ross+JS%5BAuthor%5D"}],"papers":[{"title":"National trends in US hospital admissions for hyperglycemia and hypoglycemia among Medicare beneficiaries, 1999 to 2011","journal":"JAMA Internal Medicine","year":2014,"url":"https://doi.org/10.1001/jamainternmed.2014.1824","doi":"10.1001/jamainternmed.2014.1824","note":"Europe PMC author record matched by affiliation and by co-author Harlan Krumholz"},{"title":"Association of Use of an Intravascular Microaxial Left Ventricular Assist Device vs Intra-aortic Balloon Pump With In-Hospital Mortality and Major Bleeding Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock","journal":"JAMA","year":2020,"url":"https://doi.org/10.1001/jama.2020.0254","doi":"10.1001/jama.2020.0254","note":"Europe PMC author record matched by affiliation and by co-author Harlan Krumholz"},{"title":"Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006-2013","journal":"Diabetes Care","year":2017,"url":"https://doi.org/10.2337/dc16-0985","doi":"10.2337/dc16-0985","note":"Europe PMC author record matched by affiliation and by co-author Harlan Krumholz"}],"orcid":"0000-0002-9218-3320"},{"id":"trapani-joseph","kind":"person","name":"Joseph Trapani","aka":[],"tldr":"An immunologist who worked out how killer T cells destroy their targets, and now directs research at Australia's cancer hospital.","summary":"Joseph Trapani is an immunologist and Executive Director of Cancer Research at the Peter MacCallum Cancer Centre in Melbourne. His laboratory defined the perforin and granzyme pathway by which cytotoxic lymphocytes kill their targets, and applied that understanding to immunotherapy and CAR-T cell research. His publications include a review of the pro-apoptotic, antiviral and antitumour functions of granzyme B, the discovery that CMTM6 maintains PD-L1 expression and regulates anti-tumour immunity, and a study showing that tumour immune evasion can arise through loss of TNF sensitivity. He now leads the research division at Australia's cancer hospital, with interests in cancer immunology, cell therapy and immune checkpoint inhibitors.","asOf":"2026-09-08","links":[{"label":"Peter MacCallum Cancer Centre","url":"https://www.petermac.org"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Trapani%20JA%5BAuthor%5D%20perforin"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["car-t","checkpoint-inhibitor"],"targets":[],"drugs":[],"companies":[],"institutions":["peter-mac"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Executive Director, Cancer Research, Peter Mac; immunologist","institutionId":"peter-mac","specialisms":["Cancer immunology","Cytotoxic lymphocytes","Perforin and granzymes","Cell therapy"],"profiles":[{"label":"Peter MacCallum Cancer Centre","url":"https://www.petermac.org"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Trapani%20JA%5BAuthor%5D%20perforin"}],"papers":[{"title":"Granzyme B: pro-apoptotic, antiviral and antitumor functions","journal":"Current Opinion in Immunology","year":2003,"doi":"10.1016/s0952-7915(03)00107-9"},{"title":"CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity","journal":"Nature","year":2017,"doi":"10.1038/nature23643"},{"title":"Tumor immune evasion arises through loss of TNF sensitivity","journal":"Science Immunology","year":2018,"doi":"10.1126/sciimmunol.aar3451"}]},{"id":"joshua-brody","kind":"person","name":"Joshua Brody","aka":[],"tldr":"Developed in situ vaccination, turning a single injected lymphoma tumour into a vaccine against the rest.","summary":"Joshua Brody is Director of the Lymphoma Immunotherapy Program at The Mount Sinai Hospital and Tisch Cancer Institute. He is a haematologist-oncologist known for developing in situ vaccination, turning a single injected lymphoma tumour into a vaccine against the rest by combining Flt3L, radiation and a TLR agonist to induce systemic responses. His selected paper reports systemic clinical tumour regressions and potentiation of PD-1 blockade with in situ vaccination. He now leads bispecific antibody and CAR-T trials in diffuse large B-cell lymphoma.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Brody%20JD%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["dlbcl"],"sections":[],"technologies":["shared-antigen-vaccine","t-cell-engager"],"targets":[],"drugs":[],"companies":[],"institutions":["mount-sinai"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Lymphoma Immunotherapy Program","institutionId":"mount-sinai","specialisms":["Lymphoma","In situ vaccination","Bispecific antibodies"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Brody%20JD%5BAuthor%5D"}],"papers":[{"title":"Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination","journal":"Nature Medicine","year":2019,"url":"https://doi.org/10.1038/s41591-019-0410-x","doi":"10.1038/s41591-019-0410-x"}]},{"id":"juan-valle","kind":"person","name":"Juan W. Valle","aka":[],"tldr":"Led ABC-02, which made gemcitabine plus cisplatin the global standard for biliary cancer, and co-led TOPAZ-1.","summary":"Juan Valle was chief investigator of ABC-02, the UK trial that established gemcitabine plus cisplatin as first-line therapy for advanced biliary tract cancer, and a lead investigator of TOPAZ-1, which added durvalumab to that backbone. He has led the ABC series of biliary trials and international guidelines on cholangiocarcinoma. He now leads research strategy at the Cholangiocarcinoma Foundation.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Valle%20JW%5BAuthor%5D%20biliary"}],"tags":["biliary","chemotherapy","trialist"],"related":[],"cancers":["cholangiocarcinoma"],"sections":[],"technologies":[],"targets":[],"drugs":["durvalumab"],"companies":[],"institutions":["the-christie"],"pathways":[],"terms":[],"trials":["abc-02","topaz-1"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Medical Officer, Cholangiocarcinoma Foundation; Honorary Professor of Medical Oncology, University of Manchester and The Christie","institutionId":"the-christie","specialisms":["Biliary tract cancer","Cholangiocarcinoma","Chemotherapy and immunotherapy","Rare GI cancers"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Valle%20JW%5BAuthor%5D%20biliary"}],"papers":[{"title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer (ABC-02)","journal":"NEJM","year":2010,"doi":"10.1056/NEJMoa0908721"},{"title":"Biliary tract cancer","journal":"Lancet","year":2021,"doi":"10.1016/S0140-6736(21)00153-7"}],"orcid":"0000-0002-1999-0863"},{"id":"judah-folkman","kind":"person","name":"Judah Folkman","aka":[],"tldr":"In 1971 he proposed that tumours cannot grow beyond a few millimetres without recruiting blood vessels, and that blocking them could treat cancer. Dismissed for decades, the idea produced bevacizumab and a class of drugs.","summary":"Judah Folkman (1933-2008) was a paediatric surgeon at Boston Children's Hospital when, in a 1971 New England Journal of Medicine paper, he proposed that solid tumours are angiogenesis-dependent, secreting factors that recruit new blood vessels, and that anti-angiogenesis could be a form of therapy. The hypothesis was met with scepticism, grant rejections and ridicule for much of two decades while his laboratory isolated the first angiogenic factors and inhibitors, including angiostatin and endostatin. The identification of VEGF by Napoleone Ferrara at Genentech and the approval of the anti-VEGF antibody bevacizumab for colorectal cancer in 2004 confirmed the principle, and anti-angiogenic drugs are now standard in kidney, liver, lung, colorectal and other cancers, as well as in eye disease. He trained many of the field's leaders and died suddenly in 2008.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Judah_Folkman","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Judah_Folkman"},{"label":"Boston Children's Hospital","url":"https://www.childrenshospital.org/"}],"tags":["hero","pioneer"],"related":[],"cancers":[],"sections":["targeted-therapy"],"technologies":["antiangiogenic"],"targets":["vegf"],"drugs":["bevacizumab"],"companies":[],"institutions":[],"pathways":[],"terms":["inducing-angiogenesis","hallmarks-of-cancer"],"trials":[],"people":[],"bottlenecks":["b-translational-valley","b-funding-allocation"],"keyPapers":[],"journals":["seminars-in-oncology"],"dependsOn":[],"notes":[],"role":"Surgeon-scientist who proposed and proved that tumours depend on new blood vessels","specialisms":["Angiogenesis","Tumour biology","Anti-angiogenic therapy"],"profiles":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Judah_Folkman"},{"label":"Boston Children's Hospital","url":"https://www.childrenshospital.org/"}],"papers":[{"title":"Angiogenesis in cancer, vascular, rheumatoid and other disease","journal":"Nature Medicine","year":1995,"doi":"10.1038/nm0195-27"},{"title":"Induction of angiogenesis during the transition from hyperplasia to neoplasia","journal":"Nature","year":1989,"doi":"10.1038/339058a0"},{"title":"Role of angiogenesis in tumor growth and metastasis","journal":"Seminars in Oncology","year":2002,"doi":"10.1053/sonc.2002.37263"}]},{"id":"judith-bliss","kind":"person","name":"Judith M. Bliss","aka":[],"tldr":"Statistician who ran the START, FAST-Forward and POETIC trials that reshaped breast cancer radiotherapy and endocrine therapy.","summary":"Judith Bliss directs the ICR Clinical Trials and Statistics Unit, which ran the UK START and FAST-Forward hypofractionation trials, IMPORT LOW and HIGH, POETIC and PERSEPHONE among many others, making it one of the most productive academic trial units in oncology. She has led methodological work on non-inferiority designs and long-term follow-up and is a senior author on most UK breast radiotherapy trials.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bliss%20JM%5BAuthor%5D%20breast%20radiotherapy%20trial"}],"tags":["biostatistics","breast","radiotherapy"],"related":[],"cancers":["breast-hr-positive"],"sections":[],"technologies":["imrt-igrt"],"targets":[],"drugs":[],"companies":[],"institutions":["icr-london"],"pathways":[],"terms":[],"trials":["persephone"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Clinical Trials and Director, ICR Clinical Trials and Statistics Unit, Institute of Cancer Research","institutionId":"icr-london","specialisms":["Clinical trial statistics","Breast cancer trials","Radiotherapy trials","Trial methodology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bliss%20JM%5BAuthor%5D%20breast%20radiotherapy%20trial"}],"papers":[{"title":"The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials","journal":"Lancet Oncology","year":2013,"doi":"10.1016/S1470-2045(13)70386-3"},{"title":"Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial","journal":"Lancet","year":2020,"doi":"10.1016/S0140-6736(20)30932-6"}]},{"id":"judy-garber","kind":"person","name":"Judy E. Garber","aka":[],"tldr":"A leading authority on inherited cancer risk and how BRCA carriers should be treated and screened.","summary":"Judy E. Garber is Chief of the Division of Cancer Genetics and Prevention and holds the Susan F. Smith Chair at Dana-Farber Brigham Cancer Center. She is a leading authority on inherited cancer risk and on how BRCA carriers should be treated and screened, having contributed to the TBCRC neoadjuvant cisplatin trials in BRCA-associated breast cancer and to the OlympiA trial. Her selected paper reports adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. She directs cancer genetics and prevention at Dana-Farber, spanning germline testing, chemoprevention and risk-reducing surgery.","asOf":"2026-09-08","links":[{"label":"Dana-Farber profile","url":"https://www.dana-farber.org/find-a-doctor/judy-e-garber"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Garber%20JE%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["tnbc","breast-hr-positive","ovarian"],"sections":[],"technologies":["germline-testing","chemoprevention"],"targets":["brca"],"drugs":[],"companies":[],"institutions":["dana-farber"],"pathways":[],"terms":[],"trials":["olympia"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief, Division of Cancer Genetics and Prevention; Susan F. Smith Chair","institutionId":"dana-farber","specialisms":["Hereditary cancer","BRCA1/2","Cancer prevention"],"profiles":[{"label":"Dana-Farber profile","url":"https://www.dana-farber.org/find-a-doctor/judy-e-garber"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Garber%20JE%5BAuthor%5D"}],"papers":[{"title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer","journal":"New England Journal of Medicine","year":2021,"url":"https://doi.org/10.1056/NEJMoa2105215","doi":"10.1056/NEJMoa2105215"}],"orcid":"0000-0001-9449-3982"},{"id":"juha-korpelainen","kind":"person","name":"Juha Korpelainen","aka":[],"tldr":"Juha Korpelainen represents Oulu University Hospital in the Organisation of European Cancer Institutes, which lists the centre among its members in Finland.","summary":"Juha Korpelainen is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Oulu University Hospital, its member in Finland. Oulu University Hospital is the northernmost of Finland's five university hospitals and a full member of the Organisation of European Cancer Institutes. OnCo records the name from the OECI membership list so that the centre's page has a named contact point; the person's exact title, appointment date and biography are not yet recorded and should be checked on the institution's own pages before being relied on.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Oulu University Hospital website","url":"http://www.ppshp.fi/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oulu-university-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Oulu University Hospital to the Organisation of European Cancer Institutes","institutionId":"oulu-university-hospital","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Oulu University Hospital website","url":"http://www.ppshp.fi/"}],"papers":[{"title":"Aphasia, depression, and non-verbal cognitive impairment in ischaemic stroke","journal":"Cerebrovasc Dis","year":2000,"url":"https://doi.org/10.1159/000016107","doi":"10.1159/000016107","note":"Europe PMC author record matched by affiliation"},{"title":"Poststroke depression correlates with cognitive impairment and neurological deficits","journal":"Stroke","year":1999,"url":"https://doi.org/10.1161/01.str.30.9.1875","doi":"10.1161/01.str.30.9.1875","note":"Europe PMC author record matched by affiliation"},{"title":"Abnormal heart rate variability as a manifestation of autonomic dysfunction in hemispheric brain infarction","journal":"Stroke","year":1996,"url":"https://doi.org/10.1161/01.str.27.11.2059","doi":"10.1161/01.str.27.11.2059","note":"Europe PMC author record matched by affiliation"}]},{"id":"julian-adams","kind":"person","name":"Julian Adams","aka":[],"tldr":"Medicinal chemist who led the discovery of the proteasome inhibitor bortezomib and now heads Stand Up To Cancer as President and CEO.","summary":"Julian Adams, PhD, is President and CEO of Stand Up To Cancer, the US charity that funds collaborative 'Dream Team' cancer research. A drug-discovery scientist, he led the development of the proteasome inhibitor bortezomib (Velcade), a cornerstone therapy in multiple myeloma. He joined SU2C in July 2023 and was subsequently promoted to President and CEO, according to the organisation's leadership page.","asOf":"2026-09-10","links":[{"label":"Society page","url":"https://standuptocancer.org/about-us/leadership/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Adams+J%5BAuthor%5D+AND+proteasome"}],"tags":["leadership","drug development","research funding"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["stand-up-to-cancer"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["cancer-investigation","the-oncologist"],"dependsOn":[],"notes":[],"role":"President and CEO","institutionId":"stand-up-to-cancer","specialisms":["Drug discovery","Proteasome inhibitors","Multiple myeloma","Research funding"],"profiles":[{"label":"Society page","url":"https://standuptocancer.org/about-us/leadership/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Adams+J%5BAuthor%5D+AND+proteasome"}],"papers":[{"title":"The development of proteasome inhibitors as anticancer drugs","journal":"Cancer Cell","year":2004,"doi":"10.1016/s1535-6108(04)00120-5"},{"title":"Development of the Proteasome Inhibitor Velcade™ (Bortezomib)","journal":"Cancer Investigation","year":2004,"doi":"10.1081/cnv-120030218"},{"title":"Development of the Proteasome Inhibitor PS-341","journal":"The Oncologist","year":2002,"doi":"10.1634/theoncologist.7-1-9"}]},{"id":"julian-malicki","kind":"person","name":"Julian Malicki","aka":[],"tldr":"Julian Malicki represents Greater Poland Cancer Centre in the Organisation of European Cancer Institutes, which lists the centre among its full members in Poland.","summary":"Julian Malicki is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Greater Poland Cancer Centre, its full member in Poland. OnCo records the name from the OECI membership list so that the centre's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the institution's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Greater Poland Cancer Centre website","url":"http://www.wco.pl/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["greater-poland-cancer-centre"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Greater Poland Cancer Centre to the Organisation of European Cancer Institutes","institutionId":"greater-poland-cancer-centre","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Greater Poland Cancer Centre website","url":"http://www.wco.pl/"}],"papers":[{"title":"Radiotherapy equipment and departments in the European countries: final results from the ESTRO-HERO survey","journal":"Radiother Oncol","year":2014,"url":"https://doi.org/10.1016/j.radonc.2014.08.029","doi":"10.1016/j.radonc.2014.08.029","note":"Europe PMC author record matched by affiliation"},{"title":"The optimal utilization proportion of external beam radiotherapy in European countries: An ESTRO-HERO analysis","journal":"Radiother Oncol","year":2015,"url":"https://doi.org/10.1016/j.radonc.2015.04.018","doi":"10.1016/j.radonc.2015.04.018","note":"Europe PMC author record matched by affiliation"},{"title":"Oral cavity and oropharyngeal squamous cell carcinoma in young adults: a review of the literature","journal":"Radiol Oncol","year":2014,"url":"https://doi.org/10.2478/raon-2013-0057","doi":"10.2478/raon-2013-0057","note":"Europe PMC author record matched by affiliation"}],"orcid":"0000-0002-5558-5558"},{"id":"julian-redhead","kind":"person","name":"Julian Redhead","aka":[],"tldr":"Emergency medicine consultant who became Trust Chief Executive of Imperial College Healthcare NHS Trust in April 2026 after serving as its medical director.","summary":"Professor Julian Redhead is Trust Chief Executive of Imperial College Healthcare NHS Trust, the London teaching hospital trust whose sites include Charing Cross, Hammersmith and St Mary's hospitals and which hosts cancer care and research with Imperial College London. He took up the post in April 2026, having previously been the Trust's medical director alongside a national role as NHS England's clinical director for urgent and emergency care. He joined the Trust full time in 2004 as a consultant in emergency medicine after four years as a consultant at Ealing Hospital, became chief of service for emergency medicine in 2008, and has since held roles including clinical programme group director for medicine, divisional director for investigative and supporting sciences, associate medical director for professional development and interim chief executive. The Trust's chief executive is accountable to the chief executive of the North West London Acute Group.","asOf":"2026-09-10","links":[{"label":"Source: Imperial College Healthcare NHS Trust executive team page","url":"https://www.imperial.nhs.uk/about-us/how-we-are-run/our-executive-team"}],"tags":["leadership","hospital-management","clinician-scientist"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["imperial-cancer-centre"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Trust Chief Executive, Imperial College Healthcare NHS Trust","institutionId":"imperial-cancer-centre","specialisms":["Emergency medicine","Hospital management","Urgent and emergency care policy"],"profiles":[{"label":"Imperial College Healthcare executive team page","url":"https://www.imperial.nhs.uk/about-us/how-we-are-run/our-executive-team"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Redhead+J%5BAuthor%5D"}],"papers":[]},{"id":"julie-brahmer","kind":"person","name":"Julie R. Brahmer","aka":[],"tldr":"Led CheckMate 017, the first trial to show immunotherapy beats chemotherapy in lung cancer.","summary":"Julie R. Brahmer is Director of Thoracic Oncology and Co-Director of the Upper Aerodigestive Department at the Bloomberg~Kimmel Institute, Johns Hopkins Hospital and Sidney Kimmel Comprehensive Cancer Center. She is a thoracic oncologist known for leading CheckMate 017, the first trial to show immunotherapy beats chemotherapy in lung cancer, alongside early PD-L1 antibody work. Her selected paper reports nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. She is also a long-term follow-up author of the first-line pembrolizumab trials and works on mesothelioma.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Julie_Brahmer","links":[{"label":"Hopkins profile","url":"https://www.hopkinsmedicine.org/profiles/details/julie-brahmer"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Brahmer%20JR%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["nsclc","mesothelioma"],"sections":[],"technologies":[],"targets":["pd1"],"drugs":["nivolumab","pembrolizumab"],"companies":[],"institutions":["johns-hopkins"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Thoracic Oncology; Co-Director, Upper Aerodigestive Department, Bloomberg~Kimmel Institute","institutionId":"johns-hopkins","specialisms":["Lung cancer immunotherapy","PD-1/PD-L1","Mesothelioma"],"profiles":[{"label":"Hopkins profile","url":"https://www.hopkinsmedicine.org/profiles/details/julie-brahmer"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Brahmer%20JR%5BAuthor%5D"}],"papers":[{"title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","journal":"New England Journal of Medicine","year":2015,"url":"https://doi.org/10.1056/NEJMoa1504627","doi":"10.1056/NEJMoa1504627"},{"title":"CheckMate 816: three cycles of nivolumab plus chemotherapy before lung cancer surgery","journal":"New England Journal of Medicine","year":2022,"url":"https://doi.org/10.1056/NEJMoa2202170","doi":"10.1056/NEJMoa2202170"},{"title":"Topalian 2012: the first large trial of a PD-1 antibody shows durable responses across melanoma, lung and kidney cancer","journal":"New England Journal of Medicine","year":2012,"url":"https://doi.org/10.1056/NEJMoa1200690","doi":"10.1056/NEJMoa1200690"}]},{"id":"julie-park","kind":"person","name":"Julie R. Park","aka":[],"tldr":"Julie Park led the COG trial that made tandem transplant standard for high-risk neuroblastoma.","summary":"Julie Park is Chair of the Department of Oncology at St. Jude Children's Research Hospital and a neuroblastoma investigator with the Children's Oncology Group (COG). A paediatric oncologist specialising in neuroblastoma and immunotherapy, she was study chair of COG ANBL0532, the randomised trial of tandem versus single autologous stem cell transplant in high-risk neuroblastoma that made tandem transplant standard, and is a leader in anti-GD2 immunotherapy studies linked to COG ANBL0032 and dinutuximab. Her papers report the tandem transplant trial in JAMA and the revised International Neuroblastoma Response Criteria consensus statement in the Journal of Clinical Oncology. Her work centres on GD2-directed therapy in paediatric neuroblastoma.","asOf":"2026-09-08","links":[{"label":"Children's Oncology Group","url":"https://childrensoncologygroup.org"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Park%20JR%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Julie%20R.%20Park"}],"tags":[],"related":[],"cancers":["neuroblastoma"],"sections":[],"technologies":[],"targets":["gd2"],"drugs":["dinutuximab"],"companies":["childrens-oncology-group"],"institutions":[],"pathways":[],"terms":[],"trials":["anbl0032","anbl0532"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chair, Department of Oncology, St. Jude Children's Research Hospital; Children's Oncology Group neuroblastoma investigator","institutionId":"childrens-oncology-group","specialisms":["Neuroblastoma","Immunotherapy","Paediatric oncology"],"profiles":[{"label":"Children's Oncology Group","url":"https://childrensoncologygroup.org"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Park%20JR%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Julie%20R.%20Park"}],"papers":[{"title":"Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial","journal":"JAMA","year":2019,"url":"https://doi.org/10.1001/jama.2019.11642","doi":"10.1001/jama.2019.11642"},{"title":"Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting","journal":"Journal of Clinical Oncology","year":2017,"url":"https://doi.org/10.1200/JCO.2016.72.0177","doi":"10.1200/JCO.2016.72.0177"}],"orcid":"0000-0002-6777-9165"},{"id":"julien-hadoux","kind":"person","name":"Julien Hadoux","aka":[],"tldr":"Paris endocrine oncologist who was lead author of LIBRETTO-531, the trial that showed the selective RET inhibitor selpercatinib beats older kinase inhibitors as first treatment for advanced medullary thyroid cancer.","summary":"Julien Hadoux is an endocrine oncologist at Gustave Roussy who treats thyroid and neuroendocrine cancers. He was first author of the 2023 New England Journal of Medicine report of LIBRETTO-531, the phase 3 trial in which selpercatinib lengthened progression-free survival compared with cabozantinib or vandetanib in untreated RET-mutant advanced medullary thyroid cancer, establishing the selective RET inhibitor as first-line therapy.","asOf":"2026-09-18","links":[],"tags":["thyroid","targeted-therapy","trialist"],"related":[],"cancers":["medullary-thyroid-cancer","thyroid"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["gustave-roussy"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-libretto-531-nejm-2023"],"journals":[],"dependsOn":[],"notes":[],"role":"Endocrine oncologist, Gustave Roussy","institutionId":"gustave-roussy","specialisms":["Medullary thyroid cancer","RET inhibitors","Neuroendocrine tumours"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hadoux%5BAuthor%5D"}],"papers":[{"title":"LIBRETTO-531: selpercatinib versus cabozantinib or vandetanib in advanced RET-mutant medullary thyroid cancer","journal":"New England Journal of Medicine","year":2023,"url":"https://doi.org/10.1056/NEJMoa2309719","doi":"10.1056/NEJMoa2309719"}],"orcid":"0000-0002-1276-3289"},{"id":"julio-garcia-pondal","kind":"person","name":"Julio García Pondal","aka":[],"tldr":"Julio García Pondal represents Hospital Universitario Puerta de Hierro Majadahonda in the Organisation of European Cancer Institutes, which lists the centre among its full members in Spain.","summary":"Julio García Pondal is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Hospital Universitario Puerta de Hierro Majadahonda, its full member in Spain. OnCo records the name from the OECI membership list so that the centre's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the institution's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Hospital Universitario Puerta de Hierro Majadahonda website","url":"https://www.comunidad.madrid/hospital/puertadehierro/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["puerta-de-hierro"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Hospital Universitario Puerta de Hierro Majadahonda to the Organisation of European Cancer Institutes","institutionId":"puerta-de-hierro","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Hospital Universitario Puerta de Hierro Majadahonda website","url":"https://www.comunidad.madrid/hospital/puertadehierro/"}],"papers":[]},{"id":"julio-garcia-aguilar","kind":"person","name":"Julio Garcia-Aguilar","aka":[],"tldr":"Surgeon who led OPRA, showing half of rectal cancer patients can keep their rectum with total neoadjuvant therapy and watch-and-wait.","summary":"Julio Garcia-Aguilar led the OPRA trial, which showed total neoadjuvant therapy followed by watch-and-wait for complete responders preserves the rectum in about half of patients with locally advanced rectal cancer without compromising survival, and that consolidation chemotherapy after chemoradiation is the better sequence. He chairs colorectal surgery at MSKCC and leads organ-preservation trials in the Alliance.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Garcia-Aguilar%20J%5BAuthor%5D%20rectal%20organ%20preservation"}],"tags":["colorectal","surgery","organ-preservation"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":["robotic-surgery"],"targets":[],"drugs":[],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-cercek-dostarlimab-rectal-nejm-2022"],"journals":[],"dependsOn":[],"notes":[],"role":"Chief, Colorectal Service, Memorial Sloan Kettering Cancer Center","institutionId":"mskcc","specialisms":["Rectal cancer surgery","Organ preservation","Total neoadjuvant therapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Garcia-Aguilar%20J%5BAuthor%5D%20rectal%20organ%20preservation"}],"papers":[{"title":"Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy (OPRA)","journal":"JCO","year":2022,"doi":"10.1200/JCO.22.00032"},{"title":"Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial","journal":"Lancet Oncology","year":2015,"doi":"10.1016/S1470-2045(15)00004-2"},{"title":"Cercek 2022: six months of dostarlimab alone made rectal cancer disappear in every patient with mismatch-repair deficiency","journal":"New England Journal of Medicine","year":2022,"url":"https://doi.org/10.1056/NEJMoa2201445","doi":"10.1056/NEJMoa2201445"}],"orcid":"0000-0003-2451-0948"},{"id":"julio-oliveira","kind":"person","name":"Júlio Oliveira","aka":[],"tldr":"Medical oncologist who chairs the board of IPO Porto, the public cancer hospital serving northern Portugal, since 2022.","summary":"Júlio Oliveira is Presidente do Conselho de Administração of the Instituto Português de Oncologia do Porto Francisco Gentil (IPO Porto), the National Health Service oncology hospital that is the reference cancer centre for northern Portugal. A medical oncologist, he has chaired the board since it took office in October 2022 and was reappointed for a further three-year term in 2026. In 2024 he was elected to the board of the Organisation of European Cancer Institutes (OECI) as Executive Secretary for the 2024 to 2027 term, and in 2025 he led the creation of an association to promote clinical research at the institute.","asOf":"2026-09-10","links":[{"label":"Source: IPO Porto news on clinical research association, May 2025","url":"https://www.ipoporto.pt/ipo-porto-cria-associacao-para-impusionar-a-investigacao-clinica/"}],"tags":["leadership","clinician-scientist","medical-oncology"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ipo-lisboa","oeci"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Presidente do Conselho de Administração (Chair of the Board of Directors) of IPO Porto","institutionId":"ipo-porto","specialisms":["Medical oncology","Cancer centre management","Clinical research"],"profiles":[{"label":"Institution news: elected to OECI board","url":"https://www.ipoporto.pt/presidente-do-ipo-porto-eleito-para-a-nova-direcao-da-oeci/"}],"papers":[{"title":"Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial","journal":"Cancer Discovery","year":2023,"doi":"10.1158/2159-8290.cd-23-0436"}]},{"id":"julio-saez-rodriguez","kind":"person","name":"Julio Saez-Rodriguez","aka":[],"tldr":"Systems biologist heading research at EMBL-EBI, known for computational methods to model signalling networks and predict cancer drug response.","summary":"Julio Saez-Rodriguez is Head of Research at EMBL-EBI. His group develops computational methods that integrate omics data to model cell signalling and predict drug response, and he has co-led community benchmarking efforts such as DREAM challenges in cancer pharmacogenomics. He also holds a professorship at Heidelberg University.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.ebi.ac.uk/about/leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Saez-Rodriguez+J%5BAuthor%5D"}],"tags":["clinician-scientist","computational biology","drug response"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["embl-ebi"],"pathways":[],"terms":["signalling-pathway"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Head of Research","institutionId":"embl-ebi","specialisms":["Computational biology","Systems biology","Drug response modelling"],"profiles":[{"label":"Institution profile","url":"https://www.ebi.ac.uk/about/leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Saez-Rodriguez+J%5BAuthor%5D"}],"papers":[{"title":"Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen","journal":"Nature Communications","year":2019,"doi":"10.1038/s41467-019-09799-2"},{"title":"Perturbation-response genes reveal signaling footprints in cancer gene expression","journal":"Nature Communications","year":2018,"doi":"10.1038/s41467-017-02391-6"},{"title":"Modeling Signaling Networks to Advance New Cancer Therapies","journal":"Annual Review of Biomedical Engineering","year":2015,"doi":"10.1146/annurev-bioeng-071813-104927"}],"orcid":"0000-0002-8552-8976"},{"id":"guo-jun","kind":"person","name":"Jun Guo","aka":["郭军"],"tldr":"Jun Guo built China's melanoma programme around the acral and mucosal subtypes common in Asia, and led the trials that made toripalimab the first domestic PD-1 antibody approved.","summary":"Guo's department at Peking University Cancer Hospital is the largest melanoma unit in Asia; he led the registration study of toripalimab in previously treated melanoma (China's first domestic PD-1 approval, December 2018), trials of toripalimab plus axitinib in mucosal melanoma, and work defining KIT and other targets in acral melanoma. Past president of CSCO.","asOf":"2026-09-10","links":[{"label":"Peking University Cancer Hospital","url":"https://www.bjcancer.org/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Guo%20J%5BAuthor%5D%20melanoma%20Peking%20University%20Cancer%20Hospital%20toripalimab"}],"tags":["china"],"related":["csco"],"cancers":["melanoma","rcc"],"sections":[],"technologies":[],"targets":[],"drugs":["toripalimab"],"companies":[],"institutions":["pku-cancer-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor; Department of Renal Cancer and Melanoma, Peking University Cancer Hospital","institutionId":"pku-cancer-hospital","specialisms":["Melanoma","Acral and mucosal melanoma","Renal cell carcinoma","Immunotherapy"],"profiles":[{"label":"Peking University Cancer Hospital","url":"https://www.bjcancer.org/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Guo%20J%5BAuthor%5D%20melanoma%20Peking%20University%20Cancer%20Hospital%20toripalimab"}],"papers":[{"title":"Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G4 Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial","journal":"Journal of Clinical Oncology","year":2019,"doi":"10.1200/jco.19.00210"},{"title":"The natural history and patterns of metastases from mucosal melanoma: an analysis of 706 prospectively-followed patients","journal":"Annals of Oncology","year":2017,"doi":"10.1093/annonc/mdw694"},{"title":"Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboring c-Kit Mutation or Amplification","journal":"Journal of Clinical Oncology","year":2011,"doi":"10.1200/jco.2010.33.9275"}]},{"id":"ma-jun","kind":"person","name":"Jun Ma","aka":[],"tldr":"Jun Ma is the world's leading nasopharyngeal carcinoma trialist, whose randomised studies define induction chemotherapy and immunotherapy for the disease.","summary":"Jun Ma is Professor of Radiation Oncology and leads the nasopharyngeal carcinoma programme at Sun Yat-sen University Cancer Center in Guangzhou. He is the world's leading nasopharyngeal carcinoma trialist, and his randomised studies established gemcitabine plus cisplatin induction chemotherapy, defined the role of Epstein-Barr virus DNA in risk stratification and, with colleagues in JUPITER-02, tested PD-1 blockade in the disease. His publications include the trial of gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma. His work, built on modern intensity-modulated radiotherapy, shapes international guidelines for this cancer.","asOf":"2026-09-08","links":[{"label":"Sun Yat-sen University Cancer Center","url":"https://www.sysucc.org.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ma%20J%5BAuthor%5D%20nasopharyngeal%20carcinoma%20Sun%20Yat-sen"}],"tags":[],"related":[],"cancers":["head-and-neck"],"sections":[],"technologies":["imrt-igrt"],"targets":[],"drugs":[],"companies":[],"institutions":["sysucc"],"pathways":[],"terms":[],"trials":["jupiter-02"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Radiation Oncology; nasopharyngeal carcinoma programme, Sun Yat-sen University Cancer Center","institutionId":"sysucc","specialisms":["Nasopharyngeal carcinoma","Radiation oncology","Induction chemotherapy","EBV DNA"],"profiles":[{"label":"Sun Yat-sen University Cancer Center","url":"https://www.sysucc.org.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ma%20J%5BAuthor%5D%20nasopharyngeal%20carcinoma%20Sun%20Yat-sen"}],"papers":[{"title":"Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma","journal":"NEJM","year":2019,"doi":"10.1056/NEJMoa1905287"}]},{"id":"juergen-debus","kind":"person","name":"Jürgen Debus","aka":[],"tldr":"Jürgen Debus leads Europe's pioneering heavy-ion therapy centre.","summary":"Jürgen Debus is Head of Radiation Oncology at Heidelberg University Hospital and Director of the HIT Heidelberg Ion-Beam Therapy Center, working within the NCT and DKFZ network. His specialisms are particle therapy, carbon-ion radiotherapy and radiation oncology. He leads Europe's pioneering heavy-ion therapy centre, which delivers proton and carbon-ion treatment and runs the trials evaluating them. His paper in Cancer reported carbon ion radiotherapy for chordomas and low-grade chondrosarcomas of the skull base. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Debus%20J%5BAuthor%5D%20carbon%20ion"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["carbon-ion","proton-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":["heidelberg-nct"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["cancer-wiley"],"dependsOn":[],"notes":[],"role":"Head of Radiation Oncology, Heidelberg University Hospital; Director, HIT Heidelberg Ion-Beam Therapy Center","institutionId":"heidelberg-nct","specialisms":["Particle therapy","Carbon-ion radiotherapy","Radiation oncology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Debus%20J%5BAuthor%5D%20carbon%20ion"}],"papers":[{"title":"Carbon ion radiotherapy for chordomas and low-grade chondrosarcomas of the skull base","journal":"Cancer","year":2004}]},{"id":"jurgen-kuball","kind":"person","name":"Jürgen Kuball","aka":[],"tldr":"Utrecht haematologist and immunotherapy researcher on the daily board of UMC Utrecht's cancer programme, known for gamma-delta T cell receptor-engineered cell therapies.","summary":"Jürgen Kuball is Professor of Haematology at UMC Utrecht and a member of the Daily Board of its Strategic Program Cancer. He leads the haematology department and a translational research group developing gamma-delta T cell receptor-based cellular immunotherapies for haematological and solid cancers. His work spans allogeneic stem cell transplantation and engineered T cell products.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://research.umcutrecht.nl/strategic-programs/cancer/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kuball+J%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","haematology","immunotherapy"],"related":[],"cancers":["aml","multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["umc-utrecht"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["haematologica"],"dependsOn":[],"notes":[],"role":"Daily Board member, Strategic Program Cancer","institutionId":"umc-utrecht","specialisms":["Haematology","Cellular immunotherapy","Stem cell transplantation"],"profiles":[{"label":"Institution profile","url":"https://research.umcutrecht.nl/strategic-programs/cancer/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kuball+J%5BAuthor%5D"}],"papers":[{"title":"Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis","journal":"The Lancet Haematology","year":2019,"doi":"10.1016/s2352-3026(19)30158-9"},{"title":"Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma","journal":"Haematologica","year":2016,"doi":"10.3324/haematol.2015.137620"},{"title":"Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis","journal":"The Lancet Haematology","year":2015,"doi":"10.1016/s2352-3026(15)00148-9"}],"orcid":"0000-0002-3914-7806"},{"id":"jurgen-weitz","kind":"person","name":"Jürgen Weitz","aka":[],"tldr":"Surgical oncologist who co-directs NCT/UCC Dresden and leads gastrointestinal cancer surgery at University Hospital Carl Gustav Carus.","summary":"Jürgen Weitz is a Managing Director of the National Center for Tumor Diseases (NCT/UCC) Dresden and Director of the Department of Visceral, Thoracic and Vascular Surgery at University Hospital Carl Gustav Carus, TU Dresden. His clinical and research work centres on surgical oncology of colorectal, pancreatic and hepatobiliary cancers, including surgical trials and technology-assisted surgery. His role is listed on the NCT/UCC Direktorium page.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.nct-dresden.de/de/das-nctucc-dresden/organisation/direktorium"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Weitz+J%5BAuthor%5D+AND+Dresden"}],"tags":["leadership","clinician-scientist","surgical oncology","gastrointestinal cancer"],"related":[],"cancers":["colorectal","pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["nct-dresden"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Managing Director (Geschäftsführender Direktor); Director, Department of Visceral, Thoracic and Vascular Surgery","institutionId":"nct-dresden","specialisms":["Surgical oncology","Colorectal cancer","Pancreatic cancer","Liver surgery"],"profiles":[{"label":"Institution profile","url":"https://www.nct-dresden.de/de/das-nctucc-dresden/organisation/direktorium"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Weitz+J%5BAuthor%5D+AND+Dresden"}],"papers":[{"title":"Mouse Models of Human Gastric Cancer Subtypes With Stomach-Specific CreERT2-Mediated Pathway Alterations","journal":"Gastroenterology","year":2019,"doi":"10.1053/j.gastro.2019.09.026"},{"title":"Oncological liver resection in elderly – A retrospective comparative study","journal":"International Journal of Surgery","year":2022,"doi":"10.1016/j.ijsu.2022.106729"},{"title":"Transfusions of packed red blood cells in surgery for liver cancer: predictor of impaired overall survival but not recurrence-free survival – impact of blood transfusions in liver surgery","journal":"Journal of Gastrointestinal Surgery","year":2024,"doi":"10.1016/j.gassur.2023.12.019"}]},{"id":"juergen-wolf","kind":"person","name":"Jürgen Wolf","aka":[],"tldr":"Built the Network Genomic Medicine that brought molecular testing to lung cancer patients across Germany, and led the capmatinib GEOMETRY trial.","summary":"Jürgen Wolf is Medical Director of the Lung Cancer Group Cologne and Head of Network Genomic Medicine at Uniklinik Köln (CIO). His specialisms are lung cancer, molecular diagnostics networks and MET- and KRAS-targeted therapy, using comprehensive genomic profiling. He founded Network Genomic Medicine, which brought molecular testing to lung cancer patients across Germany by sequencing non-small-cell lung cancer across hundreds of centres. He was principal investigator of GEOMETRY mono-1, the New England Journal of Medicine trial of capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wolf%20J%5BAuthor%5D%20capmatinib"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["cgp"],"targets":["met"],"drugs":["capmatinib-tepotinib"],"companies":[],"institutions":["uniklinik-koeln"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Medical Director, Lung Cancer Group Cologne; Head of Network Genomic Medicine","institutionId":"uniklinik-koeln","specialisms":["Lung cancer","Molecular diagnostics networks","MET and KRAS-targeted therapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wolf%20J%5BAuthor%5D%20capmatinib"}],"papers":[{"title":"Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer (GEOMETRY mono-1)","journal":"NEJM","year":2020,"doi":"10.1056/NEJMoa2002787"},{"title":"DeLLphi-301: tarlatamab, a DLL3-targeting T-cell engager, in previously treated small-cell lung cancer","journal":"New England Journal of Medicine","year":2023,"url":"https://doi.org/10.1056/NEJMoa2307980","doi":"10.1056/NEJMoa2307980"}]},{"id":"justin-lathia","kind":"person","name":"Justin D. Lathia","aka":[],"tldr":"Justin Lathia studies glioblastoma stem cells and why brain tumours differ between men and women.","summary":"Justin D. Lathia holds the Melvin H. Burkhardt Endowed Chair for Neuro-Oncology Clinical Research and is Vice Chair of Cardiovascular and Metabolic Sciences at Cleveland Clinic Taussig Cancer Institute. He is a neuro-oncology researcher known for defining cancer stem cell niches in glioblastoma and for studying why brain tumours differ between men and women. His selected paper reviews cancer stem cells in glioblastoma. He directs the Brain Tumor Research Center and continues to study sex-specific tumour biology and the tumour microenvironment.","asOf":"2026-09-08","links":[{"label":"Cleveland Clinic profile","url":"https://www.lerner.ccf.org/cardiovascular-metabolic/lathia/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lathia%20JD%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cleveland-clinic"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["genes-and-development"],"dependsOn":[],"notes":[],"role":"Melvin H. Burkhardt Endowed Chair for Neuro-Oncology Clinical Research; Vice Chair, Cardiovascular and Metabolic Sciences","institutionId":"cleveland-clinic","specialisms":["Glioblastoma stem cells","Sex differences in cancer","Tumour microenvironment"],"profiles":[{"label":"Cleveland Clinic profile","url":"https://www.lerner.ccf.org/cardiovascular-metabolic/lathia/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lathia%20JD%5BAuthor%5D"}],"papers":[{"title":"Cancer stem cells in glioblastoma","journal":"Genes & Development","year":2015,"url":"https://doi.org/10.1101/gad.261982.115","doi":"10.1101/gad.261982.115"}]},{"id":"justin-gainor","kind":"person","name":"Justin F. Gainor","aka":[],"tldr":"Showed that oncogene-driven lung cancers respond poorly to immunotherapy and led the pivotal RET and ALK inhibitor studies.","summary":"Justin F. Gainor is Director of the Center for Thoracic Cancers at Massachusetts General Hospital Cancer Center. He is known for showing that oncogene-driven lung cancers respond poorly to immunotherapy and for leading the pivotal RET and ALK inhibitor studies, including the ARROW trial of pralsetinib and key analyses of ALK resistance. His selected papers report pralsetinib for RET fusion-positive non-small-cell lung cancer and the low response rates to PD-1 pathway blockade in EGFR-mutant and ALK-rearranged lung cancer. He now directs thoracic cancers at MGH, with continued work on lorlatinib and RET-directed therapy.","asOf":"2026-09-08","links":[{"label":"MGH profile","url":"https://www.massgeneral.org/doctors/19962/justin-gainor"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gainor%20JF%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":["alk","ret"],"drugs":["pralsetinib","lorlatinib"],"companies":[],"institutions":["mgh"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Center for Thoracic Cancers","institutionId":"mgh","specialisms":["ALK and ROS1 lung cancer","Immunotherapy in oncogene-driven NSCLC","RET"],"profiles":[{"label":"MGH profile","url":"https://www.massgeneral.org/doctors/19962/justin-gainor"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gainor%20JF%5BAuthor%5D"}],"papers":[{"title":"Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW)","journal":"Lancet Oncology","year":2021,"url":"https://doi.org/10.1016/S1470-2045(21)00247-3","doi":"10.1016/S1470-2045(21)00247-3"},{"title":"EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer","journal":"Clinical Cancer Research","year":2016,"url":"https://doi.org/10.1158/1078-0432.CCR-15-3101","doi":"10.1158/1078-0432.CCR-15-3101"}]},{"id":"kadir-mutlu-hayran","kind":"person","name":"Kadir Mutlu Hayran","aka":[],"tldr":"Professor who directs the Hacettepe University Cancer Institute in Ankara, one of Turkey's leading academic cancer research and treatment institutes.","summary":"Kadir Mutlu Hayran is Director of the Hacettepe University Cancer Institute in Ankara, the university's academic institute for cancer research, education and treatment, as listed on the institute's management page. His curriculum vitae is published through the Hacettepe research portal. The institute's management also includes deputy directors listed on its website.","asOf":"2026-09-10","links":[{"label":"Source: Hacettepe Cancer Institute director page","url":"https://kanser.hacettepe.edu.tr/?sayfa=yonetim-mudur"}],"tags":["leadership","clinician-scientist","academic-oncology"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["hacettepe-cancer-institute"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["international-journal-of-cancer"],"dependsOn":[],"notes":[],"role":"Director of the Hacettepe University Cancer Institute","institutionId":"hacettepe-cancer-institute","specialisms":["Oncology research","Academic oncology","Cancer institute management"],"profiles":[{"label":"Institution profile","url":"https://research.hacettepe.edu.tr/en/persons/kadir-mutlu-hayran-10/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hayran+KM%5BAuthor%5D"}],"papers":[{"title":"Immunogenicity of two doses of inactive COVID‐19 vaccine and third booster dose mRNA vaccine in patients with cancer receiving active systemic therapy","journal":"International Journal of Cancer","year":2022,"doi":"10.1002/ijc.34280"}]},{"id":"yonemori-kan","kind":"person","name":"Kan Yonemori","aka":[],"tldr":"A breast and gynaecologic oncologist deeply involved in the early trastuzumab deruxtecan studies and in Japanese ADC development.","summary":"Kan Yonemori is Chief of the Department of Medical Oncology at the National Cancer Center Hospital in Tokyo. A breast and gynaecologic oncologist, he was deeply involved in the early studies of trastuzumab deruxtecan and in Japanese antibody-drug conjugate development, serving as an investigator on the DESTINY-Breast trials. His publications include the phase 1 dose-escalation study of trastuzumab deruxtecan in advanced breast and gastric tumours, a phase 1/2 trial of the HER3-directed conjugate patritumab deruxtecan in metastatic breast cancer, and the long-term analysis of DESTINY-Breast03 comparing trastuzumab deruxtecan with trastuzumab emtansine. He leads medical oncology across breast, gynaecologic and sarcoma indications.","asOf":"2026-09-08","links":[{"label":"National Cancer Center Hospital","url":"https://www.ncc.go.jp/en/ncch/index.html"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Yonemori%20K%5BAuthor%5D%20National%20Cancer%20Center"}],"tags":[],"related":[],"cancers":["breast-her2-positive","breast-hr-positive","ovarian"],"sections":[],"technologies":["adc"],"targets":[],"drugs":["trastuzumab-deruxtecan"],"companies":[],"institutions":["ncc-japan"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief, Department of Medical Oncology, National Cancer Center Hospital","institutionId":"ncc-japan","specialisms":["Breast cancer","Antibody-drug conjugates","Gynaecologic oncology","Sarcoma"],"profiles":[{"label":"National Cancer Center Hospital","url":"https://www.ncc.go.jp/en/ncch/index.html"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Yonemori%20K%5BAuthor%5D%20National%20Cancer%20Center"}],"papers":[{"title":"Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3–Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3–Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial","journal":"Journal of Clinical Oncology","year":2023,"doi":"10.1200/jco.23.00882"},{"title":"Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study","journal":"The Lancet Oncology","year":2017,"doi":"10.1016/s1470-2045(17)30604-6"},{"title":"Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial","journal":"Nature Medicine","year":2024,"doi":"10.1038/s41591-024-03021-7"},{"title":"DESTINY-Breast06: trastuzumab deruxtecan before any chemotherapy in hormone-receptor-positive, HER2-low or ultralow breast cancer","journal":"New England Journal of Medicine","year":2024,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DESTINY-Breast06+trastuzumab+deruxtecan+HER2-low+chemotherapy-naive"}]},{"id":"kara-kelly","kind":"person","name":"Kara M. Kelly","aka":[],"tldr":"Leads the COG Hodgkin lymphoma committee and the trials bringing brentuximab and nivolumab to children with the disease.","summary":"Kara Kelly chairs the Children's Oncology Group Hodgkin lymphoma committee and was study chair of AHOD1331, which showed brentuximab vedotin with chemotherapy improves event-free survival in high-risk paediatric Hodgkin lymphoma and led to the first paediatric approval, and co-leads AHOD2131 testing nivolumab with reduced therapy. Her work focuses on curing children with fewer late effects.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kelly%20KM%5BAuthor%5D%20Hodgkin%20children"}],"tags":["paediatric","hodgkin","cooperative-group"],"related":[],"cancers":["hodgkin-lymphoma"],"sections":[],"technologies":["adc","checkpoint-inhibitor"],"targets":[],"drugs":["brentuximab-vedotin","nivolumab"],"companies":[],"institutions":["roswell-park"],"pathways":[],"terms":[],"trials":["ahod2131","swog-s1826"],"people":[],"bottlenecks":[],"keyPapers":["paper-swog-s1826-nivolumab-avd-nejm-2024"],"journals":[],"dependsOn":[],"notes":[],"role":"Chair of Pediatric Oncology, Roswell Park Comprehensive Cancer Center; Division Chief, Pediatric Hematology/Oncology, University at Buffalo","institutionId":"roswell-park","specialisms":["Paediatric Hodgkin lymphoma","Response-adapted therapy","Cooperative-group trials","Survivorship"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kelly%20KM%5BAuthor%5D%20Hodgkin%20children"}],"papers":[{"title":"Brentuximab vedotin with chemotherapy in pediatric high-risk Hodgkin's lymphoma (AHOD1331)","journal":"NEJM","year":2022,"doi":"10.1056/NEJMoa2206660"},{"title":"Nivolumab plus AVD in advanced-stage classic Hodgkin's lymphoma (SWOG S1826)","journal":"NEJM","year":2024,"doi":"10.1056/NEJMoa2405888"}]},{"id":"karen-knudsen","kind":"person","name":"Karen E. Knudsen","aka":[],"tldr":"The cancer biologist and former American Cancer Society chief executive who now runs the Parker Institute for Cancer Immunotherapy.","summary":"Karen Knudsen is Chief Executive Officer and a board member of the Parker Institute for Cancer Immunotherapy, which describes her as a globally recognised cancer scientist and executive leader focused on turning all cancers into curable diseases. Before joining PICI in 2024 she was Chief Executive Officer of the American Cancer Society and its advocacy arm, and earlier directed the Sidney Kimmel Cancer Center at Thomas Jefferson University in Philadelphia. Her own research concerned prostate cancer, in particular the androgen receptor and DNA repair. Her publications are listed on PubMed.","asOf":"2026-09-17","links":[{"label":"PICI profile","url":"https://www.parkerici.org/person/karen-e-knudsen/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Knudsen+KE%5BAuthor%5D+prostate"}],"tags":["leadership","immunotherapy"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["parker-institute"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive Officer and Board Member, Parker Institute for Cancer Immunotherapy","institutionId":"parker-institute","specialisms":["Prostate cancer biology","Cancer centre leadership","Research strategy and partnerships"],"profiles":[{"label":"PICI profile","url":"https://www.parkerici.org/person/karen-e-knudsen/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Knudsen+KE%5BAuthor%5D+prostate"}],"papers":[{"title":"DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer","journal":"New England Journal of Medicine","year":2015,"url":"https://doi.org/10.1056/NEJMoa1506859","doi":"10.1056/NEJMoa1506859","note":"Europe PMC author record matched by affiliation"},{"title":"Prostate cancer","journal":"Nature Reviews Disease Primers","year":2021,"url":"https://doi.org/10.1038/s41572-020-00243-0","doi":"10.1038/s41572-020-00243-0","note":"Europe PMC author record matched by affiliation"},{"title":"Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer","journal":"Cell","year":2018,"url":"https://doi.org/10.1016/j.cell.2018.06.039","doi":"10.1016/j.cell.2018.06.039","note":"Europe PMC author record matched by affiliation"}]},{"id":"karen-lu","kind":"person","name":"Karen H. Lu","aka":[],"tldr":"Gynecologic oncologist known for research on hereditary and early-detection strategies in gynecologic cancers; SGO Immediate Past President.","summary":"Karen H. Lu is Immediate Past President of the Society of Gynecologic Oncology. She is a gynecologic oncologist whose research addresses hereditary gynecologic cancer syndromes such as Lynch syndrome, ovarian cancer screening and prevention, and clinical trials in endometrial cancer. She has played a leading role in national gynecologic oncology research and professional leadership.","asOf":"2026-09-10","links":[{"label":"Society page","url":"https://www.sgo.org/about-sgo/bod/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lu+KH%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","gynecologic oncology","cancer prevention"],"related":[],"cancers":["ovarian","endometrial"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["sgo"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Immediate Past President","institutionId":"sgo","specialisms":["Gynecologic oncology","Hereditary cancer syndromes","Cancer prevention"],"profiles":[{"label":"Society page","url":"https://www.sgo.org/about-sgo/bod/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lu+KH%5BAuthor%5D"}],"papers":[{"title":"Addressing the Role of Obesity in Endometrial Cancer Risk, Prevention, and Treatment","journal":"Journal of Clinical Oncology","year":2016,"doi":"10.1200/jco.2016.69.4638"},{"title":"Endometrial Cancer","journal":"New England Journal of Medicine","year":2020,"doi":"10.1056/nejmra1514010"},{"title":"Gynecologic Cancer as a “Sentinel Cancer” for Women With Hereditary Nonpolyposis Colorectal Cancer Syndrome","journal":"Obstetrics & Gynecology","year":2005,"doi":"10.1097/01.aog.0000154885.44002.ae"}]},{"id":"karen-kelly","kind":"person","name":"Karen Kelly","aka":[],"tldr":"Thoracic medical oncologist who serves as CEO of the International Association for the Study of Lung Cancer.","summary":"Karen Kelly is Chief Executive Officer of the International Association for the Study of Lung Cancer (IASLC). A thoracic medical oncologist, she previously led cooperative-group lung cancer trials in the United States and held academic leadership roles before moving to lead the society. She oversees IASLC's scientific meetings, staging project and global education programmes.","asOf":"2026-09-10","links":[{"label":"Society page","url":"https://www.iaslc.org/learn-about-us/board-directors"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kelly+K%5BAuthor%5D+lung+cancer"}],"tags":["leadership","clinician-scientist","lung cancer"],"related":[],"cancers":["nsclc","sclc","mesothelioma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["iaslc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive Officer","institutionId":"iaslc","specialisms":["Thoracic oncology","Lung cancer clinical trials","Professional society leadership"],"profiles":[{"label":"Society page","url":"https://www.iaslc.org/learn-about-us/board-directors"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kelly+K%5BAuthor%5D+lung+cancer"}],"papers":[{"title":"Neoadjuvant and Adjuvant Treatments for Early Stage Resectable NSCLC: Consensus Recommendations From the International Association for the Study of Lung Cancer","journal":"Journal of Thoracic Oncology","year":2024,"doi":"10.1016/j.jtho.2024.06.010"},{"title":"The 2024 International Association for the Study of Lung Cancer Global Survey on Biomarker Testing","journal":"Journal of Thoracic Oncology","year":2025,"doi":"10.1016/j.jtho.2025.07.114"},{"title":"Atezolizumab plus stereotactic ablative radiotherapy for medically inoperable patients with early-stage non-small cell lung cancer: a multi-institutional phase I trial","journal":"Nature Communications","year":2023,"doi":"10.1038/s41467-023-40813-w"}]},{"id":"karim-fizazi","kind":"person","name":"Karim Fizazi","aka":[],"tldr":"Led LATITUDE and PEACE-1, which put abiraterone into first-line metastatic prostate cancer.","summary":"Karim Fizazi is Head of Medical Oncology at Gustave Roussy and Professor at Paris-Saclay, with links to Centre Oscar Lambret. His specialisms are prostate cancer, genitourinary oncology, hormone therapy and radioligand therapy. He is one of the most influential prostate cancer trialists of the past two decades, leading LATITUDE, the New England Journal of Medicine trial of abiraterone plus prednisone in high-risk metastatic castration-sensitive prostate cancer, and PEACE-1, the Lancet trial adding abiraterone to androgen deprivation therapy and docetaxel in de novo metastatic disease. He has also led studies of radium-223 and PSMA radioligands, and is linked to the ALSYMPCA trial. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fizazi%20K%5BAuthor%5D%20prostate%20abiraterone"}],"tags":[],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":["androgen-receptor"],"drugs":["abiraterone","radium-223"],"companies":[],"institutions":["gustave-roussy","centre-oscar-lambret"],"pathways":[],"terms":[],"trials":["latitude","peace-1","alsympca"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Head of Medical Oncology, Gustave Roussy; Professor, Paris-Saclay","institutionId":"gustave-roussy","specialisms":["Prostate cancer","Genitourinary oncology","Hormone therapy","Radioligand therapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fizazi%20K%5BAuthor%5D%20prostate%20abiraterone"}],"papers":[{"title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer (LATITUDE)","journal":"NEJM","year":2017,"doi":"10.1056/NEJMoa1704174"},{"title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1)","journal":"Lancet","year":2022,"doi":"10.1016/S0140-6736(22)00367-1"},{"title":"VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer","journal":"New England Journal of Medicine","year":2021,"url":"https://doi.org/10.1056/NEJMoa2107322","doi":"10.1056/NEJMoa2107322"},{"title":"ARAMIS: darolutamide in non-metastatic castration-resistant prostate cancer","journal":"New England Journal of Medicine","year":2019,"url":"https://doi.org/10.1056/NEJMoa1815671","doi":"10.1056/NEJMoa1815671"}]},{"id":"karim-vermaelen","kind":"person","name":"Karim Vermaelen","aka":[],"tldr":"Thoracic oncologist and tumour immunologist who chairs the Cancer Research Institute Ghent at Ghent University / UZ Gent.","summary":"Karim Vermaelen is Chairperson of the Steering Committee of the Cancer Research Institute Ghent (CRIG) for 2026-2028, the interfaculty cancer research institute linking Ghent University, Ghent University Hospital and VIB. A thoracic oncologist at UZ Gent, his research focuses on tumour immunology and immunotherapy of lung cancer, including dendritic-cell and vaccine approaches.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.crig.ugent.be/en/management"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Vermaelen+K%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","lung cancer","immunotherapy"],"related":[],"cancers":["nsclc","mesothelioma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["uz-gent"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["oncoimmunology"],"dependsOn":[],"notes":[],"role":"Chairperson, CRIG Steering Committee (2026-2028)","institutionId":"uz-gent","specialisms":["Thoracic oncology","Tumour immunology","Immunotherapy"],"profiles":[{"label":"Institution profile","url":"https://www.crig.ugent.be/en/management"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Vermaelen+K%5BAuthor%5D"}],"papers":[{"title":"Vaccine Strategies to Improve Anti-cancer Cellular Immune Responses","journal":"Frontiers in Immunology","year":2019,"doi":"10.3389/fimmu.2019.00008"},{"title":"Dendritic Cell-Based Immunotherapy in Lung Cancer","journal":"Frontiers in Immunology","year":2020,"doi":"10.3389/fimmu.2020.620374"},{"title":"The transcriptome of lung tumor-infiltrating dendritic cells reveals a tumor-supporting phenotype and a microRNA signature with negative impact on clinical outcome","journal":"OncoImmunology","year":2016,"doi":"10.1080/2162402x.2016.1253655"}]},{"id":"karl-landergren","kind":"person","name":"Karl Landergren","aka":[],"tldr":"Karl Landergren represents Linköping University Hospital Cancer Center in the Organisation of European Cancer Institutes, which lists the centre among its members in Sweden.","summary":"Karl Landergren is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Linköping University Hospital Cancer Center, its full member in Sweden. OnCo records the name from the OECI membership list so that the centre's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the institution's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Linköping University Hospital Cancer Center website","url":"https://www.regionostergotland.se"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["linkoping-university-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Linköping University Hospital Cancer Center to the Organisation of European Cancer Institutes","institutionId":"linkoping-university-hospital","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Linköping University Hospital Cancer Center website","url":"https://www.regionostergotland.se"}],"papers":[]},{"id":"karl-munslow-ong","kind":"person","name":"Karl Munslow-Ong","aka":[],"tldr":"Chief Executive of Great Ormond Street Hospital, the UK's leading children's hospital, since June 2026.","summary":"Karl Munslow-Ong is Chief Executive of Great Ormond Street Hospital for Children NHS Foundation Trust, joining in June 2026 after serving as Deputy Chief Executive at The Royal Marsden NHS Foundation Trust. He leads one of Europe's largest paediatric hospitals, which includes a major children's cancer service.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.gosh.nhs.uk/about-us/who-we-are/organisational-structure/trust-board/"}],"tags":["leadership","paediatric oncology","hospital management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["royal-marsden"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive","institutionId":"great-ormond-street","specialisms":["Hospital management","Paediatric health services"],"profiles":[{"label":"Institution profile","url":"https://www.gosh.nhs.uk/about-us/who-we-are/organisational-structure/trust-board/"}],"papers":[]},{"id":"karolina-palucka","kind":"person","name":"Karolina Palucka","aka":[],"tldr":"Immunologist who directs the NCI-designated JAX Cancer Center at The Jackson Laboratory and holds its Edison T. Liu Endowed Chair in Cancer Research.","summary":"Karolina Palucka (MD, PhD) is Director of the JAX Cancer Center and holds the Edison T. Liu Endowed Chair in Cancer Research at The Jackson Laboratory, where she is a professor based in Farmington, Connecticut. Her laboratory works on human immunology and experimental immunotherapy, including dendritic cell-based vaccines for cancer and HIV, and uses single-cell genomics to understand immune cell mechanisms. The JAX Cancer Center has been an NCI-designated basic laboratory cancer centre since 1983, one of only seven in the United States, focuses on the genetic and genomic mechanisms of ageing-related inflammation and cellular dysfunction in cancer, and earned an 'exceptional' rating on its most recent Cancer Center Support Grant renewal.","asOf":"2026-09-10","links":[{"label":"Source: JAX research leadership page naming the Cancer Center Director","url":"https://www.jax.org/research-and-faculty/research-overview/research-leadership"},{"label":"Source: JAX Cancer Center page","url":"https://www.jax.org/research-and-faculty/research-centers/the-jackson-laboratory-cancer-center"}],"tags":["leadership","clinician-scientist","research-institute"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["jackson-laboratory"],"pathways":[],"terms":["immunotherapy-term","immune-system","inflammation"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, JAX Cancer Center, The Jackson Laboratory","institutionId":"jackson-laboratory","specialisms":["Human immunology","Cancer immunotherapy","Dendritic cell vaccines"],"profiles":[{"label":"JAX faculty profile","url":"https://www.jax.org/research-and-faculty/faculty/karolina-palucka"},{"label":"JAX research leadership page","url":"https://www.jax.org/research-and-faculty/research-overview/research-leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Palucka+K%5BAuthor%5D"}],"papers":[{"title":"Cancer vaccines on the move","journal":"Nature Reviews Clinical Oncology","year":2018,"doi":"10.1038/nrclinonc.2017.149"},{"title":"Cancer immunotherapy via dendritic cells","journal":"Nature Reviews Cancer","year":2012,"doi":"10.1038/nrc3258"},{"title":"Dendritic-Cell-Based Therapeutic Cancer Vaccines","journal":"Immunity","year":2013,"doi":"10.1016/j.immuni.2013.07.004"}],"orcid":"0000-0002-1600-6066"},{"id":"katy-rezvani","kind":"person","name":"Katayoun Rezvani","aka":[],"tldr":"Created cord blood-derived CAR-NK cells, the first off-the-shelf CAR cell therapy to show remissions in lymphoma.","summary":"Katy Rezvani led the development and first-in-human trial of CD19-directed CAR natural killer cells derived from cord blood, which produced remissions in most patients with relapsed CLL and lymphoma without cytokine release syndrome or graft-versus-host disease, establishing NK cells as an allogeneic platform. Her laboratory engineers NK cells against solid tumour and myeloid targets and she directs the cell therapy programme at MD Anderson.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rezvani%20K%5BAuthor%5D%20CAR%20NK"}],"tags":["cell-therapy","nk-cells","off-the-shelf"],"related":[],"cancers":["cll","dlbcl"],"sections":[],"technologies":["car-nk-macrophage","allogeneic-cell-therapy"],"targets":["cd19"],"drugs":[],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["leukemia"],"dependsOn":[],"notes":[],"role":"Professor of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center","institutionId":"md-anderson","specialisms":["CAR-NK cell therapy","Cord blood-derived cell therapy","Allogeneic immunotherapy","Transplant immunology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rezvani%20K%5BAuthor%5D%20CAR%20NK"}],"papers":[{"title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","journal":"NEJM","year":2020,"doi":"10.1056/NEJMoa1910607"},{"title":"Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity","journal":"Leukemia","year":2018,"doi":"10.1038/leu.2017.226"}]},{"id":"kate-granger","kind":"person","name":"Kate Granger","aka":[],"tldr":"A geriatrician with a rare sarcoma who noticed that the staff treating her did not introduce themselves. Her 2013 campaign, #hellomynameis, was adopted by hundreds of thousands of health workers.","summary":"Kate Granger (1981-2016) was a consultant geriatrician in Yorkshire when, in 2011 at 29, she was diagnosed with desmoplastic small round cell tumour, a rare and aggressive sarcoma. During a hospital admission in 2013 she observed that many of the staff caring for her did not tell her their names, and with her husband Chris Pointon launched #hellomynameis, a campaign asking every health worker to introduce themselves to every patient. It was adopted by more than 400,000 NHS staff and spread to health systems in more than 20 countries. She wrote two books about being a doctor and a patient, raised more than £250,000 for the Yorkshire Cancer Centre, and was appointed MBE in 2015. She died on 23 July 2016 at 34. The campaign continues under her husband's leadership.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Kate_Granger","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Kate_Granger"},{"label":"#hellomynameis","url":"https://www.hellomynameis.org.uk/"}],"tags":["hero","patient","advocate"],"related":[],"cancers":["sarcoma"],"sections":[],"technologies":["oncology-nursing","palliative-care"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-patient-voice","b-toxicity-qol"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Doctor and patient who started #hellomynameis","specialisms":["Sarcoma","Compassionate care","Patient experience"],"profiles":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Kate_Granger"},{"label":"#hellomynameis","url":"https://www.hellomynameis.org.uk/"}],"papers":[]},{"id":"katherine-matthay","kind":"person","name":"Katherine K. Matthay","aka":[],"tldr":"Paediatric oncologist whose trials established transplant and 13-cis-retinoic acid for high-risk neuroblastoma.","summary":"Katherine Matthay is Professor Emerita of Pediatrics at UCSF, within the UCSF Helen Diller Family Comprehensive Cancer Center, and a neuroblastoma investigator with the Children's Oncology Group (COG). A paediatric oncologist and long-time chair of COG neuroblastoma studies, she led the CCG-3891 trial establishing myeloablative therapy and 13-cis-retinoic acid in high-risk neuroblastoma and pioneered 131I-MIBG therapy for relapsed disease. Her papers report the Children's Cancer Group trial of intensive chemotherapy, radiotherapy, autologous bone marrow transplantation and 13-cis-retinoic acid, and the long-term results of that randomised trial. Her work links iobenguane I-131 and radioligand therapy to paediatric neuroblastoma.","asOf":"2026-09-08","links":[{"label":"UCSF profile","url":"https://profiles.ucsf.edu/search/?searchtype=people&searchfor=Katherine%20K.%20Matthay"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Matthay%20KK%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Katherine%20K.%20Matthay"}],"tags":[],"related":[],"cancers":["neuroblastoma"],"sections":[],"technologies":["radioligand-therapy"],"targets":[],"drugs":["i131-mibg"],"companies":["childrens-oncology-group"],"institutions":["ucsf"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor Emerita of Pediatrics, UCSF; Children's Oncology Group neuroblastoma investigator","institutionId":"ucsf","specialisms":["Paediatric oncology","Neuroblastoma","MIBG therapy"],"profiles":[{"label":"UCSF profile","url":"https://profiles.ucsf.edu/search/?searchtype=people&searchfor=Katherine%20K.%20Matthay"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Matthay%20KK%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Katherine%20K.%20Matthay"}],"papers":[{"title":"Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group","journal":"New England Journal of Medicine","year":1999,"url":"https://doi.org/10.1056/NEJM199910143411601","doi":"10.1056/NEJM199910143411601"},{"title":"Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study","journal":"Journal of Clinical Oncology","year":2009,"url":"https://doi.org/10.1200/JCO.2007.13.8925","doi":"10.1200/JCO.2007.13.8925"}]},{"id":"kathleen-moore","kind":"person","name":"Kathleen N. Moore","aka":[],"tldr":"Led SOLO-1 and MIRASOL, which gave ovarian cancer a maintenance PARP inhibitor and its first ADC with a survival benefit.","summary":"Kathleen Moore was principal investigator of SOLO-1, which showed two years of maintenance olaparib after first-line chemotherapy dramatically extends progression-free survival in BRCA-mutant ovarian cancer and later showed a survival benefit, and of MIRASOL, which showed mirvetuximab soravtansine improves survival in platinum-resistant folate receptor alpha-high disease, the first ADC to do so in ovarian cancer. She is associate director of the GOG Partners programme and leads early-phase gynaecological trials.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Moore%20KN%5BAuthor%5D%20ovarian%20olaparib%20OR%20mirvetuximab"}],"tags":["ovarian","parp","adc","trialist"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":["parp-inhibitor","adc"],"targets":["parp","brca","folr1"],"drugs":["olaparib","mirvetuximab-soravtansine"],"companies":["gog-foundation"],"institutions":["stephenson-oklahoma"],"pathways":[],"terms":[],"trials":["solo-1","mirasol"],"people":[],"bottlenecks":[],"keyPapers":["paper-solo-1-nejm-2018"],"journals":[],"dependsOn":[],"notes":[],"role":"Associate Director of Clinical Research, Stephenson Cancer Center, University of Oklahoma","institutionId":"stephenson-oklahoma","specialisms":["Ovarian cancer","PARP inhibitors","Antibody-drug conjugates","Early drug development"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Moore%20KN%5BAuthor%5D%20ovarian%20olaparib%20OR%20mirvetuximab"}],"papers":[{"title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer (SOLO-1)","journal":"NEJM","year":2018,"doi":"10.1056/NEJMoa1810858"},{"title":"Mirvetuximab soravtansine in FRα-positive, platinum-resistant ovarian cancer (MIRASOL)","journal":"NEJM","year":2023,"doi":"10.1056/NEJMoa2309169"}]},{"id":"kathleen-ruddy","kind":"person","name":"Kathleen Ruddy","aka":[],"tldr":"Non-profit leader who is Chief Executive Officer of the St. Baldrick's Foundation, the volunteer and donor powered charity that funds childhood cancer research.","summary":"Kathleen Ruddy is Chief Executive Officer of the St. Baldrick's Foundation, a 501(c)(3) non-profit based in Monrovia, California, that raises money through head-shaving events and other fundraising to fund childhood cancer research grants. The foundation's staff leadership page says she joined the childhood cancer community in early 2001 and has been instrumental in the foundation's growth, comes from a family with an inherited gene mutation that causes multiple cancers, is a two-time shavee and also serves on the foundation's Board of Directors. She leads a team that includes Chief Financial Officer Jennifer McCabe, Chief Development Officer Michael T. Lockard and Chief Mission Officer Becky Weaver.","asOf":"2026-09-10","links":[{"label":"Source: St. Baldrick's Foundation staff leadership page","url":"https://www.stbaldricks.org/staff-leadership/"}],"tags":["leadership","philanthropy"],"related":["st-baldricks"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["st-baldricks-foundation"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive Officer, St. Baldrick's Foundation","institutionId":"st-baldricks-foundation","specialisms":["Non-profit leadership","Childhood cancer research funding","Volunteer fundraising"],"profiles":[{"label":"St. Baldrick's staff leadership page","url":"https://www.stbaldricks.org/staff-leadership/"}],"papers":[]},{"id":"kathy-albain","kind":"person","name":"Kathy S. Albain","aka":[],"tldr":"Breast and lung oncologist who led the trials showing gene tests can guide chemotherapy decisions.","summary":"Kathy Albain is Vice Chair for Clinical Trials Partnerships at SWOG and Professor of Medicine at Loyola University Chicago. A breast and lung medical oncologist specialising in genomic assays, she led SWOG 8814, the study of Oncotype DX in node-positive disease, co-led RxPONDER (SWOG S1007), and chaired SWOG trials in stage III lung cancer. Her papers include a Lancet Oncology retrospective analysis of the prognostic and predictive value of the 21-gene recurrence score in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy and the New England Journal of Medicine report of the 21-gene assay to inform chemotherapy benefit in node-positive breast cancer. Her record also links to TAILORx.","asOf":"2026-09-08","links":[{"label":"SWOG leadership","url":"https://www.swog.org/about/leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Albain%20KS%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Kathy%20S.%20Albain"}],"tags":[],"related":[],"cancers":["breast-hr-positive","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["oncotype-dx"],"companies":["swog"],"institutions":[],"pathways":[],"terms":[],"trials":["rxponder","tailorx"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Vice Chair, Clinical Trials Partnerships, SWOG; Professor of Medicine, Loyola University Chicago","institutionId":"swog","specialisms":["Breast cancer","Lung cancer","Genomic assays"],"profiles":[{"label":"SWOG leadership","url":"https://www.swog.org/about/leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Albain%20KS%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Kathy%20S.%20Albain"}],"papers":[{"title":"Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial","journal":"Lancet Oncology","year":2010,"url":"https://doi.org/10.1016/S1470-2045(09)70314-6","doi":"10.1016/S1470-2045(09)70314-6"},{"title":"21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer","journal":"New England Journal of Medicine","year":2021,"url":"https://doi.org/10.1056/NEJMoa2108873","doi":"10.1056/NEJMoa2108873"}]},{"id":"katie-couric","kind":"person","name":"Katie Couric","aka":[],"tldr":"After her husband died of colon cancer at 42, she had a colonoscopy live on national television in 2000. Screening rates rose measurably afterwards: the \"Couric effect\".","summary":"Katie Couric's husband, the lawyer and broadcaster Jay Monahan, died of colon cancer in January 1998 at 42. In March 2000, as co-anchor of NBC's Today, she underwent a colonoscopy on air to demystify the test. A study in Archives of Internal Medicine in 2003 found colonoscopy rates in the United States rose by around a fifth in the months that followed and stayed higher, a finding that entered the literature as the Couric effect. She co-founded the National Colorectal Cancer Research Alliance in 2000 and Stand Up To Cancer in 2008, which funds collaborative dream teams across institutions. In 2022 she disclosed her own diagnosis of breast cancer and again used it to urge people to keep up with screening.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Katie_Couric","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Katie_Couric"},{"label":"Stand Up To Cancer","url":"https://standuptocancer.org/"}],"tags":["public-figure","carer","advocate","patient"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":["colorectal-screening","mammography"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["stage-shift"],"trials":[],"people":[],"bottlenecks":["b-prevention-adoption","b-early-detection","b-knowledge-diffusion"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Widow, journalist and later patient; the on-air colonoscopy that lifted screening rates","specialisms":["Colorectal cancer screening","Cancer awareness","Breast cancer"],"profiles":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Katie_Couric"},{"label":"Stand Up To Cancer","url":"https://standuptocancer.org/"}],"papers":[]},{"id":"katsuhiko-uesaka","kind":"person","name":"Katsuhiko Uesaka","aka":[],"tldr":"Physician who has led Shizuoka Cancer Center, one of Japan's three largest cancer centres by patient volume, since April 2023.","summary":"Katsuhiko Uesaka, MD, PhD, was appointed President of Shizuoka Cancer Center in April 2023, succeeding Ken Yamaguchi. The centre, founded in 2002, is the designated cancer hospital for Shizuoka Prefecture, a Special Functioning Hospital and a Cancer Genomic Medicine Core Hospital, and describes itself as one of the three top cancer centres in Japan by patient numbers. It emphasises multidisciplinary team care, runs Japan's first Supportive Therapy Center and conducts genomic research through Project HOPE, which has analysed tumours from more than 10,000 patients.","asOf":"2026-09-10","links":[{"label":"Source: Shizuoka Cancer Center president's greeting","url":"https://www.scchr.jp/en/index.html"}],"tags":["leadership","clinician-scientist","cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["shizuoka-cancer-center"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["annals-of-surgical-oncology"],"dependsOn":[],"notes":[],"role":"President of Shizuoka Cancer Center","institutionId":"shizuoka-cancer-center","specialisms":["Cancer centre leadership","Multidisciplinary cancer care","Cancer genomic medicine"],"profiles":[{"label":"President's greeting","url":"https://www.scchr.jp/en/index.html"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Uesaka+K%5BAuthor%5D"}],"papers":[{"title":"Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)","journal":"The Lancet","year":2016,"doi":"10.1016/s0140-6736(16)30583-9"},{"title":"Characterization of Intraductal Papillary Neoplasm of the Bile Duct with Respect to the Histopathologic Similarities to Pancreatic Intraductal Papillary Mucinous Neoplasm","journal":"Gut and Liver","year":2019,"doi":"10.5009/gnl18476"},{"title":"Reconsidering the Optimal Regional Lymph Node Station According to Tumor Location for Pancreatic Cancer","journal":"Annals of Surgical Oncology","year":2020,"doi":"10.1245/s10434-020-09066-5"}]},{"id":"keith-bible","kind":"person","name":"Keith C. Bible","aka":[],"tldr":"Mayo Clinic oncologist who chaired the American Thyroid Association guidelines for anaplastic thyroid cancer, one of the fastest-growing human cancers.","summary":"Keith Bible is a medical oncologist at Mayo Clinic in Rochester who specialises in advanced thyroid cancers. He chaired the American Thyroid Association task forces that produced the 2012 and 2021 guidelines for the management of anaplastic thyroid cancer, the latter incorporating BRAF-directed therapy and immunotherapy, and has led clinical trials of kinase inhibitors and combination therapy in the disease.","asOf":"2026-09-18","links":[],"tags":["thyroid","guidelines"],"related":[],"cancers":["anaplastic-thyroid-cancer","thyroid"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["mayo-clinic"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-ata-anaplastic-thyroid-guideline-bible-thyroid-2021"],"journals":[],"dependsOn":[],"notes":[],"role":"Medical oncologist, Mayo Clinic","institutionId":"mayo-clinic","specialisms":["Anaplastic thyroid cancer","Advanced thyroid cancer","Clinical guidelines"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bible%5BAuthor%5D"}],"papers":[{"title":"2021 American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer","journal":"Thyroid","year":2021,"url":"https://doi.org/10.1089/thy.2020.0944","doi":"10.1089/thy.2020.0944"}]},{"id":"keith-flaherty","kind":"person","name":"Keith T. Flaherty","aka":[],"tldr":"Led the first trials of BRAF inhibition in melanoma and chairs the NCI-MATCH precision medicine trial.","summary":"Keith T. Flaherty is Director of Clinical Research at the Mass General Cancer Center. He is a melanoma oncologist known for leading the first trials of BRAF inhibition, as first author of the 2010 vemurafenib study, and for the dabrafenib plus trametinib combination work that followed. His selected papers report inhibition of mutated, activated BRAF in metastatic melanoma and combined BRAF and MEK inhibition in BRAF V600-mutant melanoma. He co-chairs the NCI-MATCH precision medicine trial and continues to work on small-molecule kinase inhibitors.","asOf":"2026-09-08","links":[{"label":"MGH profile","url":"https://www.massgeneral.org/doctors/16888/keith-flaherty"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Flaherty%20KT%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["melanoma"],"sections":[],"technologies":["kinase-inhibitors"],"targets":["braf"],"drugs":["vemurafenib","dabrafenib-trametinib"],"companies":[],"institutions":["mgh"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director of Clinical Research, Mass General Cancer Center","institutionId":"mgh","specialisms":["Melanoma","BRAF and MEK inhibitors","Precision oncology trials"],"profiles":[{"label":"MGH profile","url":"https://www.massgeneral.org/doctors/16888/keith-flaherty"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Flaherty%20KT%5BAuthor%5D"}],"papers":[{"title":"Inhibition of mutated, activated BRAF in metastatic melanoma","journal":"New England Journal of Medicine","year":2010,"url":"https://doi.org/10.1056/NEJMoa1002011","doi":"10.1056/NEJMoa1002011"},{"title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","journal":"New England Journal of Medicine","year":2012,"url":"https://doi.org/10.1056/NEJMoa1210093","doi":"10.1056/NEJMoa1210093"}],"orcid":"0000-0002-3402-0478"},{"id":"kellie-smith","kind":"person","name":"Kellie N. Smith","aka":[],"tldr":"Developed the MANAFEST assay to track the tumour-specific T cells that immunotherapy awakens.","summary":"Kellie N. Smith is Associate Professor of Oncology at the Bloomberg~Kimmel Institute, Johns Hopkins Hospital and Sidney Kimmel Comprehensive Cancer Center. She is a T-cell immunologist known for developing the MANAFEST assay, which detects and tracks the mutation-associated neoantigen-specific T cells that immunotherapy awakens. Her selected paper describes MANAFEST as a functional assay for neoantigen-specific T cells. She now applies these assays to neoadjuvant immunotherapy trials, with relevance to checkpoint inhibitors and personalised neoantigen vaccines.","asOf":"2026-09-08","links":[{"label":"Hopkins profile","url":"https://www.hopkinsmedicine.org/profiles/details/kellie-smith"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Smith%20KN%5BAuthor%5D"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["neoantigen-mrna-vaccine","checkpoint-inhibitor"],"targets":[],"drugs":[],"companies":[],"institutions":["johns-hopkins"],"pathways":[],"terms":["neoantigen"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["cancer-immunology-research"],"dependsOn":[],"notes":[],"role":"Associate Professor of Oncology; Bloomberg~Kimmel Institute","institutionId":"johns-hopkins","specialisms":["T-cell immunology","Neoantigen-specific T cells","MANAFEST assay"],"profiles":[{"label":"Hopkins profile","url":"https://www.hopkinsmedicine.org/profiles/details/kellie-smith"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Smith%20KN%5BAuthor%5D"}],"papers":[{"title":"MANAFEST: a functional assay to detect and track mutation-associated neoantigen-specific T cells","journal":"Cancer Immunology Research","year":2018}]},{"id":"ken-herrmann","kind":"person","name":"Ken Herrmann","aka":[],"tldr":"Nuclear medicine leader who co-led VISION and runs one of the world's largest theranostics programmes.","summary":"Ken Herrmann was a lead investigator of VISION and of the German multicentre 177Lu-PSMA-617 registry, and leads the Essen theranostics centre that has treated thousands of patients with PSMA and somatostatin receptor radioligands. He has chaired the EANM oncology committee, co-authored the Lancet Oncology series on theranostics, and leads trials of alpha emitters and new targets such as FAP.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Herrmann%20K%5BAuthor%5D%20theranostics%20PSMA"}],"tags":["radioligand","nuclear-medicine","germany"],"related":[],"cancers":["prostate","neuroendocrine"],"sections":[],"technologies":["radioligand-therapy","psma-pet","fapi-pet"],"targets":["psma","fap"],"drugs":["pluvicto","lutathera"],"companies":[],"institutions":["essen-wtz","eanm"],"pathways":[],"terms":[],"trials":["vision"],"people":[],"bottlenecks":[],"keyPapers":["paper-vision-nejm-2021"],"journals":[],"dependsOn":[],"notes":[],"role":"Chair of Nuclear Medicine, University Hospital Essen","institutionId":"essen-wtz","specialisms":["Theranostics","PSMA radioligand therapy","Nuclear medicine","Radiopharmaceutical trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Herrmann%20K%5BAuthor%5D%20theranostics%20PSMA"}],"papers":[{"title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer (VISION)","journal":"NEJM","year":2021,"doi":"10.1056/NEJMoa2107322"},{"title":"Radiotheranostics: a roadmap for future development","journal":"Lancet Oncology","year":2020,"doi":"10.1016/S1470-2045(19)30821-6"}],"orcid":"0000-0002-9662-7259"},{"id":"ken-kato","kind":"person","name":"Ken Kato","aka":[],"tldr":"Japanese oncologist who led ATTRACTION-3 and KEYNOTE-590, bringing immunotherapy to oesophageal cancer.","summary":"Ken Kato was principal investigator of ATTRACTION-3, the first trial to show a checkpoint inhibitor (nivolumab) improves survival in previously treated oesophageal squamous cell carcinoma, and co-led KEYNOTE-590, which established pembrolizumab plus chemotherapy first line. He leads JCOG oesophageal trials and heads oesophageal medical oncology at Japan's National Cancer Center.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kato%20K%5BAuthor%5D%20esophageal%20nivolumab%20OR%20pembrolizumab"}],"tags":["esophageal","immunotherapy","japan"],"related":[],"cancers":["esophageal","head-and-neck"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["pd1"],"drugs":["nivolumab","pembrolizumab"],"companies":[],"institutions":["ncc-japan"],"pathways":[],"terms":[],"trials":["keynote-590"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief, Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo","institutionId":"ncc-japan","specialisms":["Oesophageal squamous cell carcinoma","Immunotherapy","Head and neck cancer","Japanese cooperative trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kato%20K%5BAuthor%5D%20esophageal%20nivolumab%20OR%20pembrolizumab"}],"papers":[{"title":"Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3)","journal":"Lancet Oncology","year":2019,"doi":"10.1016/S1470-2045(19)30626-6"},{"title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590)","journal":"Lancet","year":2021,"doi":"10.1016/S0140-6736(21)01234-4"}]},{"id":"ken-smith","kind":"person","name":"Ken Smith","aka":[],"tldr":"Clinician-scientist and immunologist who directs WEHI, Australia's oldest medical research institute and a major centre for cancer biology.","summary":"Ken Smith is Director of WEHI (the Walter and Eliza Hall Institute of Medical Research) in Melbourne. The institute has a long record in cancer research, including the discovery of the BCL-2 family's role in cell survival that underpinned the leukaemia drug venetoclax. A clinician-scientist and immunologist, he leads WEHI's research strategy across cancer, infection, immunity and healthy development. His role is listed on WEHI's About page.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.wehi.edu.au/about/"}],"tags":["leadership","clinician-scientist","immunology"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["wehi"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director","institutionId":"wehi","specialisms":["Immunology","Medical research leadership","Translational medicine"],"profiles":[{"label":"Institution profile","url":"https://www.wehi.edu.au/about/"}],"papers":[{"title":"Intratumoral antigen signaling traps CD8 + T cells to confine exhaustion to the tumor site","journal":"Science Immunology","year":2024,"doi":"10.1126/sciimmunol.ade2094"}]},{"id":"kenneth-anderson","kind":"person","name":"Kenneth C. Anderson","aka":[],"tldr":"Translated bortezomib and lenalidomide from bench to bedside, helping turn myeloma from a two-year to a decade-plus disease.","summary":"Kenneth C. Anderson is the Kraft Family Professor of Medicine and Director of the Jerome Lipper Multiple Myeloma Center at Dana-Farber Brigham Cancer Center. He is a myeloma pioneer known for translating bortezomib and lenalidomide from bench to bedside, with laboratory and clinical work that underpinned their approval and that of later novel agents. His selected paper reports bortezomib versus high-dose dexamethasone for relapsed multiple myeloma. He remains long-time director of the Lipper Myeloma Center, working on proteasome inhibitors and immunomodulatory drugs.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Kenneth_C._Anderson_(physician)","links":[{"label":"Dana-Farber profile","url":"https://www.dana-farber.org/find-a-doctor/kenneth-c-anderson"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Anderson%20KC%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":["bortezomib","lenalidomide"],"companies":[],"institutions":["dana-farber"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Kraft Family Professor of Medicine; Director, Jerome Lipper Multiple Myeloma Center","institutionId":"dana-farber","specialisms":["Multiple myeloma","Proteasome inhibitors","Immunomodulatory drugs"],"profiles":[{"label":"Dana-Farber profile","url":"https://www.dana-farber.org/find-a-doctor/kenneth-c-anderson"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Anderson%20KC%5BAuthor%5D"}],"papers":[{"title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","journal":"New England Journal of Medicine","year":2005,"url":"https://doi.org/10.1056/NEJMoa043445","doi":"10.1056/NEJMoa043445"}]},{"id":"kenneth-tanabe","kind":"person","name":"Kenneth K. Tanabe","aka":[],"tldr":"Massachusetts General Hospital surgical oncologist and 2026-2027 President of the Society of Surgical Oncology, with expertise in liver cancer and melanoma.","summary":"Kenneth Tanabe is President of the Society of Surgical Oncology for 2026-2027 and Chief of Surgical Oncology at Massachusetts General Hospital, where he is a professor of surgery at Harvard Medical School. His clinical and research work focuses on hepatobiliary malignancies and melanoma, including hepatocellular carcinoma biology and oncolytic virus therapy. He has held numerous leadership roles in US surgical oncology.","asOf":"2026-09-10","links":[{"label":"Society page","url":"https://www.surgonc.org/about-sso/leadership/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tanabe+KK%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","surgical oncology","liver cancer"],"related":[],"cancers":["hcc","melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["sso"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["annals-of-surgical-oncology"],"dependsOn":[],"notes":[],"role":"President","institutionId":"sso","specialisms":["Surgical oncology","Hepatobiliary cancer","Melanoma"],"profiles":[{"label":"Society page","url":"https://www.surgonc.org/about-sso/leadership/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tanabe+KK%5BAuthor%5D"}],"papers":[{"title":"Epidermal Growth Factor Gene Functional Polymorphism and the Risk of Hepatocellular Carcinoma in Patients With Cirrhosis","journal":"JAMA","year":2008,"doi":"10.1001/jama.2007.65"},{"title":"Prognostic and Therapeutic Implications of Microvascular Invasion in Hepatocellular Carcinoma","journal":"Annals of Surgical Oncology","year":2019,"doi":"10.1245/s10434-019-07227-9"},{"title":"Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma","journal":"Journal of Clinical Oncology","year":2016,"doi":"10.1200/jco.2015.64.2710"}]},{"id":"kenneth-kinzler","kind":"person","name":"Kenneth W. Kinzler","aka":[],"tldr":"Co-discovered APC, the gatekeeper gene of colorectal cancer, and co-led the first cancer genome sequences.","summary":"Kenneth W. Kinzler is Professor of Oncology and Co-Director of the Ludwig Center at Johns Hopkins Hospital and the Sidney Kimmel Comprehensive Cancer Center. He is known for co-discovering APC, the gatekeeper gene of colorectal cancer, and for co-leading the first cancer genome sequences with his long-time partner Bert Vogelstein. His selected paper reports the identification of familial adenomatous polyposis locus genes from chromosome 5q21. He also developed the digital PCR and Safe-SeqS methods behind liquid biopsy, and continues to work on APC and Wnt signalling and genome sequencing.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Kenneth_W._Kinzler","links":[{"label":"Ludwig Center","url":"https://www.hopkinsmedicine.org/kimmel-cancer-center/research/ludwig-center"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kinzler%20KW%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["colorectal"],"sections":[],"technologies":["liquid-biopsy"],"targets":[],"drugs":[],"companies":[],"institutions":["johns-hopkins"],"pathways":["wnt"],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Oncology; Co-Director, Ludwig Center","institutionId":"johns-hopkins","specialisms":["Cancer genetics","APC and Wnt signalling","Genome sequencing"],"profiles":[{"label":"Ludwig Center","url":"https://www.hopkinsmedicine.org/kimmel-cancer-center/research/ludwig-center"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kinzler%20KW%5BAuthor%5D"}],"papers":[{"title":"Identification of FAP locus genes from chromosome 5q21","journal":"Science","year":1991,"url":"https://doi.org/10.1126/science.1651174","doi":"10.1126/science.1651174"},{"title":"Cancer genome landscapes: about 140 driver genes, and each tumour needs only a handful","journal":"Science","year":2013,"url":"https://doi.org/10.1126/science.1235122","doi":"10.1126/science.1235122"},{"title":"DETECT-A: a blood test plus PET-CT found treatable cancers in 10,000 women with no symptoms","journal":"Science","year":2020,"url":"https://doi.org/10.1126/science.abb9601","doi":"10.1126/science.abb9601"},{"title":"DYNAMIC: a blood test safely halved chemotherapy use after surgery for stage II colon cancer","journal":"New England Journal of Medicine","year":2022,"url":"https://doi.org/10.1056/NEJMoa2200075","doi":"10.1056/NEJMoa2200075"}],"orcid":"0000-0001-5591-1176"},{"id":"kent-stobart","kind":"person","name":"Kent Stobart","aka":[],"tldr":"Paediatric oncologist and certified physician executive who has led CancerCare Manitoba, the provincial cancer agency, as President and CEO since November 2025.","summary":"Dr Kent Stobart joined CancerCare Manitoba as President and Chief Executive Officer in November 2025. He is a clinical paediatric oncologist and a Canadian Certified Physician Executive (CCPE), with a background in oncology services, medical education and health system administration. During postgraduate studies at Queen's University he held a Terry Fox Research Scholarship from the National Cancer Institute of Canada, and in 2024 he received the Association of Faculties of Medicine of Canada President's Award for exemplary national leadership. CancerCare Manitoba is the provincial agency responsible for cancer and blood disorder services in Manitoba; its executive team also includes Dr Donna Turner (Population Oncology), Dr Arbind Dubey (Chief Medical Officer) and Brent Gibson (Corporate Services).","asOf":"2026-09-10","links":[{"label":"Source: CancerCare Manitoba executive leadership page","url":"https://www.cancercare.mb.ca/About-Us/leadership-team/"}],"tags":["leadership","clinician-scientist","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cancercare-manitoba"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["pediatric-blood-and-cancer"],"dependsOn":[],"notes":[],"role":"President and Chief Executive Officer, CancerCare Manitoba","institutionId":"cancercare-manitoba","specialisms":["Paediatric oncology","Health system administration","Medical education"],"profiles":[{"label":"CancerCare Manitoba executive leadership page","url":"https://www.cancercare.mb.ca/About-Us/leadership-team/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Stobart+K%5BAuthor%5D"}],"papers":[{"title":"Childhood cancer trends in a western Canadian province: A population‐based 22‐year retrospective study","journal":"Pediatric Blood & Cancer","year":2010,"doi":"10.1002/pbc.22785"},{"title":"Central nervous system (CNS) tumor trends in children in a western Canadian province: a population-based 22-year retrospective study","journal":"Journal of Neurology","year":2012,"doi":"10.1007/s00415-011-6314-4"},{"title":"Aprepitant for the prevention of chemotherapy‐induced nausea and vomiting in adolescents","journal":"Pediatric Blood & Cancer","year":2009,"doi":"10.1002/pbc.22120"}],"orcid":"0000-0002-0638-6018"},{"id":"kerry-courneya","kind":"person","name":"Kerry S. Courneya","aka":[],"tldr":"Exercise scientist behind CHALLENGE, the first trial to show a structured exercise programme improves survival after colon cancer.","summary":"Kerry Courneya (University of Alberta) co-led with Christopher Booth the CCTG CHALLENGE trial, which showed a three-year structured exercise programme after adjuvant chemotherapy for colon cancer improves disease-free and overall survival, the first randomised evidence that exercise changes cancer outcomes. He led the START and CARE trials of exercise during breast cancer chemotherapy and founded the field of exercise oncology.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Courneya%20KS%5BAuthor%5D%20exercise%20cancer"}],"tags":["exercise","survivorship","supportive-care"],"related":[],"cancers":["colorectal","breast-hr-positive"],"sections":[],"technologies":["exercise-oncology"],"targets":[],"drugs":[],"companies":[],"institutions":["university-of-alberta"],"pathways":[],"terms":[],"trials":["challenge"],"people":[],"bottlenecks":[],"keyPapers":["paper-challenge-exercise-nejm-2025"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor and Canada Research Chair in Physical Activity and Cancer, University of Alberta","institutionId":"university-of-alberta","specialisms":["Exercise oncology","Behavioural interventions","Survivorship","Randomised exercise trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Courneya%20KS%5BAuthor%5D%20exercise%20cancer"}],"papers":[{"title":"Structured exercise after adjuvant chemotherapy for colon cancer (CHALLENGE)","journal":"NEJM","year":2025},{"title":"Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial (START)","journal":"JCO","year":2007,"doi":"10.1200/JCO.2006.08.2024"},{"title":"CHALLENGE: a structured exercise programme after chemotherapy improves survival in colon cancer","journal":"New England Journal of Medicine","year":2025,"url":"https://doi.org/10.1056/NEJMoa2502760","doi":"10.1056/NEJMoa2502760"}]},{"id":"keunchil-park","kind":"person","name":"Keunchil Park","aka":[],"tldr":"Korean lung cancer specialist who led CHRYSALIS, the first human study of amivantamab, whose exon 20 insertion cohort earned the drug its first approval.","summary":"Keunchil Park is a thoracic medical oncologist at Samsung Medical Center in Seoul. He was first author of the 2021 Journal of Clinical Oncology report of the CHRYSALIS study, which showed that the EGFR-MET bispecific antibody amivantamab produced durable responses in EGFR exon 20 insertion non-small-cell lung cancer after platinum chemotherapy, the basis of the drug's first approval. He has led many EGFR-directed lung cancer trials in Asia.","asOf":"2026-09-18","links":[],"tags":["lung","targeted-therapy","trialist"],"related":[],"cancers":["egfr-mutant-nsclc","nsclc","lung-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["samsung-medical-center"],"pathways":[],"terms":[],"trials":["chrysalis"],"people":[],"bottlenecks":[],"keyPapers":["paper-keunchil-park-lancet-2017","paper-keunchil-park-lancet-2016","paper-keunchil-park-n-engl-j-med-2019"],"journals":[],"dependsOn":[],"notes":[],"role":"Medical oncologist and trial lead, Samsung Medical Center, Seoul","institutionId":"samsung-medical-center","specialisms":["EGFR-mutant lung cancer","Bispecific antibodies","Early-phase trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Park%5BAuthor%5D"}],"papers":[{"title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","journal":"The Lancet","year":2017,"url":"https://doi.org/10.1016/s0140-6736(16)32517-x","doi":"10.1016/s0140-6736(16)32517-x","note":"Europe PMC author record matched by affiliation (Samsung Medical Center); 3857 citations on Europe PMC."},{"title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","journal":"The Lancet","year":2016,"url":"https://doi.org/10.1016/s0140-6736(16)00587-0","doi":"10.1016/s0140-6736(16)00587-0","note":"Europe PMC author record matched by affiliation (Samsung Medical Center); 2326 citations on Europe PMC."},{"title":"Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer","journal":"New England Journal of Medicine","year":2019,"url":"https://doi.org/10.1056/nejmoa1910231","doi":"10.1056/nejmoa1910231","note":"Europe PMC author record matched by affiliation (Samsung Medical Center); 2265 citations on Europe PMC."}],"orcid":"0000-0002-4846-7449"},{"id":"kevan-shokat","kind":"person","name":"Kevan M. Shokat","aka":[],"tldr":"The chemist whose lab found the hidden pocket in KRAS G12C that made the 'undruggable' target druggable.","summary":"Kevan Shokat is Professor of Cellular and Molecular Pharmacology at UCSF, within the UCSF Helen Diller Family Comprehensive Cancer Center, and an Investigator of the Howard Hughes Medical Institute. A chemical biologist specialising in KRAS and kinase inhibitors, his 2013 discovery of covalent inhibitors binding the switch-II pocket of KRAS G12C made a target long called undruggable druggable and opened the path to sotorasib and adagrasib. His papers include the Nature report that K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions and the Nature paper on a chemical switch for inhibitor-sensitive alleles of any protein kinase, the bump-hole approach. His work bears on lung, colorectal and pancreatic cancer.","asOf":"2026-09-08","links":[{"label":"UCSF profile","url":"https://profiles.ucsf.edu/search/?searchtype=people&searchfor=Kevan%20M.%20Shokat"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Shokat%20KM%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Kevan%20M.%20Shokat"}],"tags":[],"related":[],"cancers":["nsclc","colorectal","pancreatic"],"sections":[],"technologies":["kras-inhibitors","kinase-inhibitors"],"targets":["kras"],"drugs":["sotorasib","adagrasib"],"companies":[],"institutions":["ucsf"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Cellular and Molecular Pharmacology, UCSF; Investigator, Howard Hughes Medical Institute","institutionId":"ucsf","specialisms":["Chemical biology","KRAS","Kinase inhibitors"],"profiles":[{"label":"UCSF profile","url":"https://profiles.ucsf.edu/search/?searchtype=people&searchfor=Kevan%20M.%20Shokat"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Shokat%20KM%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Kevan%20M.%20Shokat"}],"papers":[{"title":"K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions","journal":"Nature","year":2013,"url":"https://doi.org/10.1038/nature12796","doi":"10.1038/nature12796"},{"title":"A chemical switch for inhibitor-sensitive alleles of any protein kinase","journal":"Nature","year":2000,"url":"https://doi.org/10.1038/35030148","doi":"10.1038/35030148"}],"orcid":"0000-0001-8590-7741"},{"id":"kevin-harrington","kind":"person","name":"Kevin Harrington","aka":[],"tldr":"Kevin Harrington is a head and neck oncologist and oncolytic virus pioneer who led the OPTiM trial of T-VEC.","summary":"Kevin Harrington is Professor of Biological Cancer Therapies at The Institute of Cancer Research and a consultant clinical oncologist at The Royal Marsden. His specialisms are head and neck cancer, oncolytic viruses and radiotherapy-immunotherapy combinations. He led OPTiM, the Journal of Clinical Oncology trial showing that talimogene laherparepvec improves durable response rate in advanced melanoma, which brought the oncolytic virus to approval. He now studies combinations of radiotherapy, viruses and immunotherapy in head and neck squamous cell carcinoma and melanoma, including the newer oncolytic agent vusolimogene oderparepvec. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Harrington%20KJ%5BAuthor%5D%20oncolytic"}],"tags":[],"related":[],"cancers":["head-and-neck","melanoma"],"sections":[],"technologies":["oncolytic-virus"],"targets":[],"drugs":["talimogene-laherparepvec","vusolimogene-oderparepvec"],"companies":[],"institutions":["icr-london","royal-marsden"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Biological Cancer Therapies, ICR; Consultant Clinical Oncologist, Royal Marsden","institutionId":"icr-london","specialisms":["Head and neck cancer","Oncolytic viruses","Radiotherapy-immunotherapy combinations"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Harrington%20KJ%5BAuthor%5D%20oncolytic"}],"papers":[{"title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma (OPTiM)","journal":"JCO","year":2015,"doi":"10.1200/JCO.2014.58.3377"},{"title":"KEYNOTE-048: pembrolizumab, alone or with chemotherapy, as first treatment for recurrent or metastatic head and neck cancer","journal":"The Lancet","year":2019,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=KEYNOTE-048+pembrolizumab+head+and+neck+Burtness+Lancet+2019"}]},{"id":"kevin-kalinsky","kind":"person","name":"Kevin Kalinsky","aka":[],"tldr":"Led RxPONDER, which showed postmenopausal women with 1-3 positive nodes and low recurrence scores do not need chemotherapy.","summary":"Kevin Kalinsky was principal investigator of SWOG S1007 (RxPONDER), which extended the TAILORx result to node-positive disease: postmenopausal women with one to three positive nodes and a recurrence score of 25 or less gained nothing from chemotherapy, while premenopausal women did. He directs breast oncology at Winship and leads SWOG breast trials on ctDNA-guided escalation.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kalinsky%20K%5BAuthor%5D%20RxPONDER"}],"tags":["breast","de-escalation","swog"],"related":[],"cancers":["breast-hr-positive"],"sections":[],"technologies":[],"targets":[],"drugs":["oncotype-dx"],"companies":[],"institutions":["emory-winship"],"pathways":[],"terms":[],"trials":["rxponder"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Glenn Family Breast Center, Winship Cancer Institute of Emory University","institutionId":"emory-winship","specialisms":["Breast cancer","Genomic assays","Node-positive disease","SWOG trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kalinsky%20K%5BAuthor%5D%20RxPONDER"}],"papers":[{"title":"21-gene assay to inform chemotherapy benefit in node-positive breast cancer (RxPONDER)","journal":"NEJM","year":2021,"doi":"10.1056/NEJMoa2108873"},{"title":"Randomized phase II trial of endocrine therapy with or without ribociclib after neoadjuvant chemotherapy in HR-positive breast cancer (NeoPAL and related studies)","journal":"Clinical Cancer Research","year":2020}],"orcid":"0000-0002-3113-7902"},{"id":"kim-chi","kind":"person","name":"Kim N. Chi","aka":[],"tldr":"Led TITAN and MAGNITUDE, bringing apalutamide to hormone-sensitive disease and niraparib to HRR-mutant prostate cancer.","summary":"Kim Chi was principal investigator of TITAN, which established apalutamide with androgen deprivation in metastatic hormone-sensitive prostate cancer, and of MAGNITUDE, which showed niraparib plus abiraterone benefits patients with HRR gene alterations. His group at the Vancouver Prostate Centre pioneered ctDNA profiling of androgen receptor alterations. He also co-led the CCTG PR.20 and PR.17 studies.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chi%20KN%5BAuthor%5D%20prostate%20apalutamide%20OR%20niraparib"}],"tags":["prostate","trialist","canada"],"related":[],"cancers":["prostate"],"sections":[],"technologies":["parp-inhibitor","liquid-biopsy"],"targets":["androgen-receptor","parp","brca"],"drugs":["niraparib","abiraterone"],"companies":[],"institutions":["bc-cancer"],"pathways":[],"terms":[],"trials":["magnitude"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Medical Oncologist and Chief Medical Officer, BC Cancer; Professor, University of British Columbia","institutionId":"bc-cancer","specialisms":["Prostate cancer","Androgen receptor inhibitors","PARP inhibitor combinations","Circulating tumour DNA"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chi%20KN%5BAuthor%5D%20prostate%20apalutamide%20OR%20niraparib"}],"papers":[{"title":"Apalutamide for metastatic, castration-sensitive prostate cancer (TITAN)","journal":"NEJM","year":2019,"doi":"10.1056/NEJMoa1903307"},{"title":"Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer (MAGNITUDE)","journal":"JCO","year":2023,"doi":"10.1200/JCO.22.01649"}]},{"id":"kimberly-dunsmore","kind":"person","name":"Kimberly P. Dunsmore","aka":[],"tldr":"Paediatric oncologist who chaired COG AALL0434, the largest trial ever run in childhood T-cell leukaemia, which showed that adding nelarabine improves disease-free survival.","summary":"Kimberly Dunsmore chaired the Children's Oncology Group trial AALL0434 in T-cell acute lymphoblastic leukaemia and lymphoma. She was first author of its 2020 Journal of Clinical Oncology report, which showed that adding nelarabine to augmented BFM chemotherapy improved disease-free survival in children and young adults with T-ALL, and that the regimen produced the best outcomes yet reported for the disease. She has held paediatric oncology leadership roles at the University of Virginia and Carilion Clinic.","asOf":"2026-09-18","links":[],"tags":["paediatric","leukaemia","trialist"],"related":[],"cancers":["all-paediatric-high-risk","all-leukemia","childhood-cancers"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["carilion-clinic"],"pathways":[],"terms":[],"trials":["aall0434"],"people":[],"bottlenecks":[],"keyPapers":["paper-aall0434-nelarabine-t-all-dunsmore-jco-2020"],"journals":[],"dependsOn":[],"notes":[],"role":"Paediatric oncologist and Children's Oncology Group trial chair","institutionId":"carilion-clinic","specialisms":["T-cell acute lymphoblastic leukaemia","Paediatric leukaemia trials","Nelarabine"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dunsmore%5BAuthor%5D"}],"papers":[{"title":"AALL0434: nelarabine in newly diagnosed T-cell acute lymphoblastic leukaemia in children and young adults","journal":"Journal of Clinical Oncology","year":2020,"url":"https://doi.org/10.1200/JCO.20.00256","doi":"10.1200/JCO.20.00256"}],"orcid":"0000-0002-6631-5174"},{"id":"mazumdar-shaw-kiran","kind":"person","name":"Kiran Mazumdar-Shaw","aka":[],"tldr":"Founded Biocon in a garage in 1978 and turned it into the company behind the world's first approved trastuzumab biosimilar, and co-founded a 1,400-bed cancer campus in Bengaluru.","summary":"Kiran Mazumdar-Shaw started Biocon in Bengaluru in 1978 with 10,000 rupees of seed capital and built it into India's largest biopharmaceutical company; she is executive chairperson of Biocon and Biocon Biologics, whose portfolio includes trastuzumab (CANMAb in India, 2014; Ogivri in the US, 2017) and bevacizumab biosimilars and which acquired Viatris's biosimilars business in 2022. In 2009 she established the Mazumdar-Shaw Medical Centre with Devi Shetty at Narayana Health City, a 1,400-bed cancer and multispecialty campus. She holds the Padma Shri (1989), Padma Bhushan (2005) and the Othmer Gold Medal (2014).","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Kiran_Mazumdar-Shaw","links":[{"label":"Biocon","url":"https://www.biocon.com"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Kiran_Mazumdar-Shaw"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["monoclonal-antibody"],"targets":[],"drugs":["trastuzumab-biosimilars"],"companies":["biocon","biocon-biologics"],"institutions":["narayana-health"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-drug-pricing","b-global-access"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Executive Chairperson and founder, Biocon and Biocon Biologics","specialisms":["Biosimilars","Biotechnology entrepreneurship","Affordable cancer care","Philanthropy"],"profiles":[{"label":"Biocon","url":"https://www.biocon.com"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Kiran_Mazumdar-Shaw"}],"papers":[]},{"id":"kirsten-fischer","kind":"person","name":"Kirsten Fischer","aka":[],"tldr":"Led CLL14, which established one year of venetoclax plus obinutuzumab as a fixed-duration, chemotherapy-free CLL treatment.","summary":"Kirsten Fischer was principal investigator of CLL14, the German CLL Study Group trial showing twelve months of venetoclax plus obinutuzumab produces deep, MRD-negative remissions and superior progression-free survival compared with chlorambucil-obinutuzumab in unfit patients with untreated CLL, creating the fixed-duration treatment paradigm. She coordinated the CLL8 and CLL10 chemoimmunotherapy trials and leads long-term follow-up of CLL14.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fischer%20K%5BAuthor%5D%20CLL14%20venetoclax"}],"tags":["cll","venetoclax","fixed-duration"],"related":[],"cancers":["cll"],"sections":[],"technologies":["mrd-testing"],"targets":["bcl2","cd20"],"drugs":["venetoclax"],"companies":[],"institutions":["uniklinik-koeln"],"pathways":[],"terms":[],"trials":["cll14"],"people":[],"bottlenecks":[],"keyPapers":["paper-cll14-venetoclax-obinutuzumab-nejm-2019"],"journals":[],"dependsOn":[],"notes":[],"role":"Senior Physician and Study Coordinator, German CLL Study Group, University Hospital Cologne","institutionId":"uniklinik-koeln","specialisms":["Chronic lymphocytic leukaemia","Fixed-duration therapy","Venetoclax combinations","Cooperative-group trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fischer%20K%5BAuthor%5D%20CLL14%20venetoclax"}],"papers":[{"title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions (CLL14)","journal":"NEJM","year":2019,"doi":"10.1056/NEJMoa1815281"},{"title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial","journal":"Lancet Oncology","year":2020,"doi":"10.1016/S1470-2045(20)30443-5"}]},{"id":"kirsten-major","kind":"person","name":"Kirsten Major","aka":[],"tldr":"NHS chief executive who leads Sheffield Teaching Hospitals NHS Foundation Trust, the trust that runs Weston Park Cancer Centre.","summary":"Kirsten Major is Chief Executive of Sheffield Teaching Hospitals NHS Foundation Trust, one of the largest NHS trusts in England and the operator of Weston Park Cancer Centre, one of the few dedicated cancer hospitals in the UK. The trust's Wikipedia article names her as chief executive alongside chief nurse Chris Morley and medical directors Jennifer Hill and David Black. The trust and Weston Park websites did not respond to the fetch, so the role is recorded from Wikipedia.","asOf":"2026-09-10","links":[{"label":"Source: Wikipedia article on Sheffield Teaching Hospitals naming the chief executive","url":"https://en.wikipedia.org/wiki/Sheffield_Teaching_Hospitals_NHS_Foundation_Trust"}],"tags":["leadership","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["weston-park-sheffield"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive, Sheffield Teaching Hospitals NHS Foundation Trust","institutionId":"weston-park-sheffield","specialisms":["NHS management","Hospital leadership"],"profiles":[{"label":"Wikipedia: Sheffield Teaching Hospitals NHS Foundation Trust","url":"https://en.wikipedia.org/wiki/Sheffield_Teaching_Hospitals_NHS_Foundation_Trust"}],"papers":[]},{"id":"kirsten-schmieder","kind":"person","name":"Kirsten Schmieder","aka":[],"tldr":"Neurosurgeon who serves as Medical Director and Chair of the Board of University Hospital Düsseldorf, home of the CIO Düsseldorf cancer centre.","summary":"Kirsten Schmieder is Medical Director (Ärztliche Direktorin) and Chair of the Board of Universitätsklinikum Düsseldorf. A professor of neurosurgery, she previously chaired the neurosurgery department at Ruhr University Bochum. As Medical Director she leads the hospital's clinical enterprise, which includes the Center for Integrated Oncology (CIO) Düsseldorf, part of the CIO Aachen Bonn Cologne Düsseldorf consortium.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.uniklinik-duesseldorf.de/ueber-das-ukd/unternehmen/vorstand"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schmieder+K%5BAuthor%5D+neurosurgery"}],"tags":["leadership","neurosurgery"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["uk-duesseldorf"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["journal-of-cancer-research-and-clinical-oncology"],"dependsOn":[],"notes":[],"role":"Medical Director and Chair of the Board","institutionId":"uk-duesseldorf","specialisms":["Neurosurgery","Hospital leadership","Neuro-oncology"],"profiles":[{"label":"Institution profile","url":"https://www.uniklinik-duesseldorf.de/ueber-das-ukd/unternehmen/vorstand"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schmieder+K%5BAuthor%5D+neurosurgery"}],"papers":[{"title":"The Interdisciplinary Management of Brain Metastases","journal":"Deutsches Ärzteblatt international","year":2016,"doi":"10.3238/arztebl.2016.0415"},{"title":"Risk factors for glioblastoma therapy associated complications","journal":"Clinical Neurology and Neurosurgery","year":2015,"doi":"10.1016/j.clineuro.2015.01.006"},{"title":"Charlson comorbidity index: an additional prognostic parameter for preoperative glioblastoma patient stratification","journal":"Journal of Cancer Research and Clinical Oncology","year":2015,"doi":"10.1007/s00432-014-1907-9"}]},{"id":"kjetil-tasken","kind":"person","name":"Kjetil Taskén","aka":[],"tldr":"Immunologist and head of the Institute for Cancer Research at Oslo University Hospital's Norwegian Radium Hospital, leading Norway's largest cancer research institute.","summary":"Kjetil Taskén is Head of the Institute for Cancer Research at Oslo University Hospital, The Norwegian Radium Hospital, and a professor at the University of Oslo. His research focuses on signal transduction in immune cells, T cell regulation in the tumour microenvironment, and functional precision medicine through drug sensitivity screening. The institute he leads comprises departments spanning cancer genetics, immunology, molecular oncology, radiation biology and tumour biology.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.ous-research.no/institute/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tasken+K%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","immunology","precision oncology"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oslo-radium-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["acta-oncologica"],"dependsOn":[],"notes":[],"role":"Head of the Institute for Cancer Research","institutionId":"oslo-radium-hospital","specialisms":["Cancer immunology","Signal transduction","Precision oncology"],"profiles":[{"label":"Institution profile","url":"https://www.ous-research.no/institute/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tasken+K%5BAuthor%5D"}],"papers":[{"title":"A national precision cancer medicine implementation initiative for Norway","journal":"Nature Medicine","year":2022,"doi":"10.1038/s41591-022-01777-4"},{"title":"B cell signalling pathways—New targets for precision medicine in chronic lymphocytic leukaemia","journal":"Scandinavian Journal of Immunology","year":2020,"doi":"10.1111/sji.12931"},{"title":"PCM4EU and PRIME-ROSE: Collaboration for implementation of precision cancer medicine in Europe","journal":"Acta Oncologica","year":2024,"doi":"10.2340/1651-226x.2024.34791"}],"orcid":"0000-0003-2841-4697"},{"id":"klaus-pantel","kind":"person","name":"Klaus Pantel","aka":[],"tldr":"Klaus Pantel is a pioneer of circulating tumour cell research and the liquid biopsy field.","summary":"Klaus Pantel is Director of the Institute of Tumor Biology at Universitätsklinikum Hamburg-Eppendorf. His specialisms are liquid biopsy, circulating tumour cells and minimal residual disease. His work on disseminated and circulating tumour cells established liquid biopsy as a research discipline, and he coordinated the European CANCER-ID consortium. His Nature Reviews Clinical Oncology paper reviewed liquid biopsy and minimal residual disease, and their implications for cure. He is a pioneer of circulating tumour cell research, working across circulating tumour DNA and molecular residual disease testing. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Pantel%20K%5BAuthor%5D%20circulating%20tumor%20cells"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["liquid-biopsy","mrd-testing"],"targets":[],"drugs":[],"companies":[],"institutions":["uke-hamburg"],"pathways":[],"terms":["mrd"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nature-reviews-clinical-oncology"],"dependsOn":[],"notes":[],"role":"Director, Institute of Tumor Biology, UKE Hamburg","institutionId":"uke-hamburg","specialisms":["Liquid biopsy","Circulating tumour cells","Minimal residual disease"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Pantel%20K%5BAuthor%5D%20circulating%20tumor%20cells"}],"papers":[{"title":"Liquid biopsy and minimal residual disease: latest advances and implications for cure","journal":"Nature Reviews Clinical Oncology","year":2019,"doi":"10.1038/s41571-019-0187-3"}]},{"id":"shitara-kohei","kind":"person","name":"Kohei Shitara","aka":[],"tldr":"Principal investigator of SPOTLIGHT and DESTINY-Gastric01, two trials that created new drug classes for stomach cancer.","summary":"Kohei Shitara is Chief of the Department of Gastrointestinal Oncology at the National Cancer Center Hospital East in Japan. He was principal investigator of SPOTLIGHT, which tested the Claudin 18.2 antibody zolbetuximab with mFOLFOX6, and of DESTINY-Gastric01, which tested trastuzumab deruxtecan in previously treated HER2-positive gastric cancer, two trials that created new drug classes for stomach cancer. He also led KEYNOTE-062 and sits on the steering committees of most current gastric cancer phase 3 trials, including GLOW and DESTINY-Gastric04. His publications include the DESTINY-Gastric01 and SPOTLIGHT reports, and his interests span HER2, Claudin 18.2, immunotherapy and antibody-drug conjugates.","asOf":"2026-09-08","links":[{"label":"National Cancer Center Hospital East","url":"https://www.ncc.go.jp/en/ncce/index.html"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Shitara%20K%5BAuthor%5D%20gastric%20cancer"}],"tags":[],"related":[],"cancers":["gastric"],"sections":[],"technologies":[],"targets":["her2","cldn18-2"],"drugs":["zolbetuximab","trastuzumab-deruxtecan"],"companies":[],"institutions":["ncc-japan"],"pathways":[],"terms":[],"trials":["spotlight-glow","destiny-gastric04","toga"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief, Department of Gastrointestinal Oncology, National Cancer Center Hospital East","institutionId":"ncc-japan","specialisms":["Gastric cancer","HER2 and Claudin 18.2","Immunotherapy","Antibody-drug conjugates"],"profiles":[{"label":"National Cancer Center Hospital East","url":"https://www.ncc.go.jp/en/ncce/index.html"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Shitara%20K%5BAuthor%5D%20gastric%20cancer"}],"papers":[{"title":"Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer (DESTINY-Gastric01)","journal":"NEJM","year":2020,"doi":"10.1056/NEJMoa2004413"},{"title":"Zolbetuximab plus mFOLFOX6 in CLDN18.2-positive gastric or GEJ adenocarcinoma (SPOTLIGHT)","journal":"Lancet","year":2023,"doi":"10.1016/S0140-6736(23)00620-7"},{"title":"CheckMate 649: nivolumab plus chemotherapy as first treatment for advanced gastric, gastro-oesophageal junction and oesophageal adenocarcinoma","journal":"The Lancet","year":2021,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CheckMate+649+nivolumab+chemotherapy+gastric+Janjigian+Lancet+2021"},{"title":"SPOTLIGHT: zolbetuximab, the first Claudin 18.2 antibody, added to chemotherapy in gastric cancer","journal":"The Lancet","year":2023,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=SPOTLIGHT+zolbetuximab+mFOLFOX6+Shitara+Lancet"},{"title":"KEYNOTE-062: pembrolizumab or pembrolizumab plus chemotherapy versus chemotherapy in PD-L1-positive advanced gastric cancer","journal":"JAMA Oncology","year":2020,"url":"https://doi.org/10.1001/jamaoncol.2020.3370","doi":"10.1001/jamaoncol.2020.3370"}]},{"id":"koichi-fukunaga","kind":"person","name":"Koichi Fukunaga","aka":[],"tldr":"Respiratory physician who heads Keio University Hospital in Tokyo, a leading Japanese academic hospital with designated cancer centre status.","summary":"Koichi Fukunaga is Director General of Keio University Hospital in Tokyo and a professor in the Division of Pulmonary Medicine at Keio University School of Medicine. He oversees the hospital's mission across clinical care, research and education, including its cancer centre and clinical trials infrastructure.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.hosp.keio.ac.jp/en/about/incho/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fukunaga+K%5BAuthor%5D+Keio"}],"tags":["leadership","clinician-scientist","respiratory medicine"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["keio-university-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["molecular-cancer-research"],"dependsOn":[],"notes":[],"role":"Director General","institutionId":"keio-university-hospital","specialisms":["Respiratory medicine","Hospital leadership","Lung disease"],"profiles":[{"label":"Institution profile","url":"https://www.hosp.keio.ac.jp/en/about/incho/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fukunaga+K%5BAuthor%5D+Keio"}],"papers":[{"title":"Upregulation of FGF9 in Lung Adenocarcinoma Transdifferentiation to Small Cell Lung Cancer","journal":"Cancer Research","year":2021,"doi":"10.1158/0008-5472.can-20-4048"},{"title":"IGF2 Autocrine-Mediated IGF1R Activation Is a Clinically Relevant Mechanism of Osimertinib Resistance in Lung Cancer","journal":"Molecular Cancer Research","year":2020,"doi":"10.1158/1541-7786.mcr-19-0956"},{"title":"Genotype-phenotype mapping of a patient-derived lung cancer organoid biobank identifies NKX2-1-defined Wnt dependency in lung adenocarcinoma","journal":"Cell Reports","year":2023,"doi":"10.1016/j.celrep.2023.112212"}]},{"id":"goto-koichi","kind":"person","name":"Koichi Goto","aka":[],"tldr":"Leads thoracic oncology at NCC East and the LC-SCRUM-Japan network that connects rare-driver lung cancer patients to trials.","summary":"Koichi Goto is Chief of the Department of Thoracic Oncology at the National Cancer Center Hospital East in Japan. He has led Japanese and global trials of RET, ROS1, MET and HER2 inhibitors in non-small-cell lung cancer, including selpercatinib and trastuzumab deruxtecan, and directs the clinical side of LC-SCRUM-Japan, one of the largest genomic screening efforts in lung cancer, which connects patients with rare drivers to trials. His publications include the DESTINY-Lung02 trial of trastuzumab deruxtecan in HER2-mutant lung cancer, a phase 2 study of crizotinib in East Asian patients with ROS1-positive disease, and the LURET trial of vandetanib in RET-rearranged lung cancer. His interests are rare oncogenic drivers and genomic screening.","asOf":"2026-09-08","links":[{"label":"National Cancer Center Hospital East","url":"https://www.ncc.go.jp/en/ncce/index.html"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Goto%20K%5BAuthor%5D%20National%20Cancer%20Center%20Hospital%20East%20lung"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":["ret","ros1","met","her2"],"drugs":["selpercatinib","trastuzumab-deruxtecan"],"companies":[],"institutions":["ncc-japan"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief, Department of Thoracic Oncology, National Cancer Center Hospital East","institutionId":"ncc-japan","specialisms":["Lung cancer","Rare oncogenic drivers","Genomic screening","Clinical trials"],"profiles":[{"label":"National Cancer Center Hospital East","url":"https://www.ncc.go.jp/en/ncce/index.html"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Goto%20K%5BAuthor%5D%20National%20Cancer%20Center%20Hospital%20East%20lung"}],"papers":[{"title":"Trastuzumab Deruxtecan in Patients With HER2 -Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial","journal":"Journal of Clinical Oncology","year":2023,"doi":"10.1200/jco.23.01361"},{"title":"Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non–Small-Cell Lung Cancer","journal":"Journal of Clinical Oncology","year":2018,"doi":"10.1200/jco.2017.75.5587"},{"title":"Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial","journal":"The Lancet Respiratory Medicine","year":2017,"doi":"10.1016/s2213-2600(16)30322-8"}]},{"id":"komal-jhaveri","kind":"person","name":"Komal Jhaveri","aka":[],"tldr":"Leads the next wave of endocrine therapy: oral SERDs like imlunestrant and the PI3K inhibitor inavolisib.","summary":"Komal Jhaveri led EMBER-3, which showed the oral SERD imlunestrant plus abemaciclib improves progression-free survival in ER-positive advanced breast cancer after aromatase inhibitors, and was a lead investigator on INAVO120 (inavolisib for PIK3CA-mutant disease). She heads endocrine therapy research at MSKCC and runs early-phase trials of degraders and PI3K pathway agents.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Jhaveri%20K%5BAuthor%5D%20breast%20SERD"}],"tags":["breast","endocrine","early-phase"],"related":[],"cancers":["breast-hr-positive"],"sections":[],"technologies":["endocrine-therapy","protac-degrader"],"targets":["estrogen-receptor","pik3ca"],"drugs":["inavolisib","palbociclib","abemaciclib"],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":["ember-3","inavo120"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Section Head, Endocrine Therapy Research, Memorial Sloan Kettering Cancer Center","institutionId":"mskcc","specialisms":["HR-positive breast cancer","Oral SERDs","PI3K/AKT pathway","Early drug development"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Jhaveri%20K%5BAuthor%5D%20breast%20SERD"}],"papers":[{"title":"Imlunestrant with or without abemaciclib in advanced breast cancer (EMBER-3)","journal":"NEJM","year":2025,"doi":"10.1056/NEJMoa2410858"},{"title":"Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer (INAVO120)","journal":"NEJM","year":2024,"doi":"10.1056/NEJMoa2404625"}]},{"id":"konstanze-doehner","kind":"person","name":"Konstanze Döhner","aka":[],"tldr":"Ulm haematologist and President of the European Hematology Association, a leading figure in the molecular genetics and risk classification of acute myeloid leukaemia.","summary":"Konstanze Döhner is President of the European Hematology Association (EHA) and a professor of haematology at Ulm University, Germany. Her research focuses on the molecular genetics of acute myeloid leukaemia and its translation into risk stratification and therapy. She is a co-author of the European LeukemiaNet recommendations for the diagnosis and management of AML.","asOf":"2026-09-10","links":[{"label":"Society page","url":"https://ehaweb.org/about-eha/organization/eha-board"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dohner+K%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","haematology","leukaemia"],"related":[],"cancers":["aml"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["eha"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President","institutionId":"eha","specialisms":["Acute myeloid leukaemia","Molecular genetics of leukaemia","Clinical haematology"],"profiles":[{"label":"Society page","url":"https://ehaweb.org/about-eha/organization/eha-board"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dohner+K%5BAuthor%5D"}],"papers":[{"title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","journal":"Blood","year":2022,"url":"https://doi.org/10.1182/blood.2022016867","doi":"10.1182/blood.2022016867"}]},{"id":"kris-hallenga","kind":"person","name":"Kris Hallenga","aka":[],"tldr":"Diagnosed with incurable breast cancer at 23 after her symptoms were dismissed, she founded CoppaFeel! in 2009 to teach young people to check their chests. She lived with the disease for fifteen years.","summary":"Kris Hallenga (1985-2024) was diagnosed with stage IV breast cancer in February 2009 at 23, having been turned away by her GP for eight months. Within weeks she and her twin sister Maren founded CoppaFeel!, the first UK charity dedicated to breast awareness among young people, using festivals, universities and the Boob Team to make regular self-checking normal and to press GPs to take young women's symptoms seriously. She wrote a column for The Sun, made the BBC documentary Kris: Dying to Live, and published a memoir in 2021. In 2022 she held a living funeral. She died in May 2024 at 38; CoppaFeel! continues its work in schools and workplaces.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Kris_Hallenga","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Kris_Hallenga"},{"label":"CoppaFeel!","url":"https://coppafeel.org/"}],"tags":["hero","patient","advocate"],"related":[],"cancers":[],"sections":[],"technologies":["mammography"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["aya-oncology"],"trials":[],"people":[],"bottlenecks":["b-early-detection","b-patient-voice","b-knowledge-diffusion"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Founder of CoppaFeel!, the first breast cancer charity aimed at young people","specialisms":["Breast cancer in young women","Early detection","Cancer charities"],"profiles":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Kris_Hallenga"},{"label":"CoppaFeel!","url":"https://coppafeel.org/"}],"papers":[]},{"id":"krishnansu-tewari","kind":"person","name":"Krishnansu S. Tewari","aka":[],"tldr":"California gynaecologic oncologist who led GOG 240, the trial that made bevacizumab the first targeted drug to lengthen survival in advanced cervical cancer, and EMPOWER-Cervical 1, which did the same for the PD-1 antibody cemiplimab.","summary":"Krishnansu Tewari is a gynaecologic oncologist at the University of California, Irvine. He was first author of the 2014 New England Journal of Medicine report of GOG 240, in which adding bevacizumab to chemotherapy improved overall survival in recurrent, persistent or metastatic cervical cancer, and of the 2022 New England Journal of Medicine report of EMPOWER-Cervical 1, in which cemiplimab lengthened survival compared with chemotherapy after platinum failure.","asOf":"2026-09-18","links":[],"tags":["cervical","gynaecological","trialist"],"related":[],"cancers":["recurrent-metastatic-cervical-cancer","cervical"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["uci-chao"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-empower-cervical-1-cemiplimab-nejm-2022","paper-gog-240-bevacizumab-cervical-nejm-2014"],"journals":[],"dependsOn":[],"notes":[],"role":"Gynaecologic oncologist, Chao Family Comprehensive Cancer Center, UC Irvine","institutionId":"uci-chao","specialisms":["Cervical cancer","Anti-angiogenic therapy","Immunotherapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tewari%5BAuthor%5D"}],"papers":[{"title":"EMPOWER-Cervical 1: cemiplimab versus chemotherapy in recurrent cervical cancer after platinum","journal":"New England Journal of Medicine","year":2022,"url":"https://doi.org/10.1056/NEJMoa2112187","doi":"10.1056/NEJMoa2112187"},{"title":"GOG 240: bevacizumab added to chemotherapy for advanced cervical cancer","journal":"New England Journal of Medicine","year":2014,"url":"https://doi.org/10.1056/NEJMoa1309748","doi":"10.1056/NEJMoa1309748"}]},{"id":"kristian-helin","kind":"person","name":"Kristian Helin","aka":[],"tldr":"Epigenetics researcher who leads the ICR, the academic institution with the most cancer drug discoveries.","summary":"Kristian Helin is Chief Executive of The Institute of Cancer Research in London, the academic institution with the most cancer drug discoveries. His specialisms are epigenetics, chromatin and transcription, and institute leadership. He became Chief Executive in 2021 after leading the cell biology programme at Memorial Sloan Kettering and the Biotech Research and Innovation Centre in Copenhagen. His research concerns polycomb complexes, histone demethylases and epigenetic drug targets such as EZH2, and his PLoS Biology paper showed that the polycomb group protein EZH2 is required for mammalian circadian clock function. His ICR profile and PubMed listing are linked.","asOf":"2026-09-08","links":[{"label":"ICR","url":"https://www.icr.ac.uk/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Helin%20K%5BAuthor%5D%20epigenetic"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["epigenetic-drugs"],"targets":["ezh2"],"drugs":[],"companies":[],"institutions":["icr-london"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive, The Institute of Cancer Research","institutionId":"icr-london","specialisms":["Epigenetics","Chromatin and transcription","Institute leadership"],"profiles":[{"label":"ICR","url":"https://www.icr.ac.uk/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Helin%20K%5BAuthor%5D%20epigenetic"}],"papers":[{"title":"The polycomb group protein EZH2 is required for mammalian circadian clock function","journal":"PLoS Biology","year":2014}],"orcid":"0000-0003-1975-6097"},{"id":"kristina-lang","kind":"person","name":"Kristina Lång","aka":[],"tldr":"Led MASAI, the first randomised trial of AI-supported mammography screening, which found more cancers with half the radiologist workload.","summary":"Kristina Lång is principal investigator of MASAI, the Swedish randomised trial of 100,000 women showing that AI-supported screen reading detects 29% more cancers than standard double reading while cutting radiologist workload by 44%, without increasing false positives. She also led the Malmö Breast Tomosynthesis Screening Trial. Her work is the strongest evidence yet for deploying AI in population screening.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lang%20K%5BAuthor%5D%20mammography%20artificial%20intelligence"}],"tags":["screening","ai","breast","sweden"],"related":[],"cancers":["breast-hr-positive"],"sections":[],"technologies":["radiology-ai-screening","mammography"],"targets":[],"drugs":[],"companies":[],"institutions":["lund-skane"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-masai-lancet-oncol-2023"],"journals":[],"dependsOn":[],"notes":[],"role":"Associate Professor of Diagnostic Radiology, Lund University; Breast Radiologist, Skåne University Hospital","institutionId":"lund-skane","specialisms":["Breast imaging","AI in mammography screening","Screening trials","Digital breast tomosynthesis"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lang%20K%5BAuthor%5D%20mammography%20artificial%20intelligence"}],"papers":[{"title":"Artificial intelligence-supported screen reading versus standard double reading in the Mammography Screening with Artificial Intelligence trial (MASAI): a clinical safety analysis of a randomised, controlled, non-inferiority, single-blinded, screening accuracy study","journal":"Lancet Oncology","year":2023,"doi":"10.1016/S1470-2045(23)00298-X"},{"title":"Screening performance of digital breast tomosynthesis vs digital mammography in the Malmö Breast Tomosynthesis Screening Trial","journal":"Lancet Oncology","year":2018,"doi":"10.1016/S1470-2045(18)30610-0"}]},{"id":"kristo-erikson","kind":"person","name":"Kristo Erikson","aka":[],"tldr":"Kristo Erikson represents North Estonia Medical Centre in the Organisation of European Cancer Institutes, which lists the centre among its members in Estonia.","summary":"Kristo Erikson is listed by the Organisation of European Cancer Institutes (OECI) as the representative of North Estonia Medical Centre, its member in Estonia. The North Estonia Medical Centre in Tallinn is one of Estonia's two main cancer treatment hospitals and a full member of the Organisation of European Cancer Institutes. OnCo records the name from the OECI membership list so that the centre's page has a named contact point; the person's exact title, appointment date and biography are not yet recorded and should be checked on the institution's own pages before being relied on.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"North Estonia Medical Centre website","url":"http://www.regionaalhaigla.ee/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["north-estonia-medical-centre"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of North Estonia Medical Centre to the Organisation of European Cancer Institutes","institutionId":"north-estonia-medical-centre","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"North Estonia Medical Centre website","url":"http://www.regionaalhaigla.ee/"}],"papers":[{"title":"Brain tight junction protein expression in sepsis in an autopsy series","journal":"Critical Care","year":2020,"url":"https://doi.org/10.1186/s13054-020-03101-3","doi":"10.1186/s13054-020-03101-3","note":"OpenAlex author record matched by institution"},{"title":"Elevated serum S‐100β in patients with septic shock is associated with delirium","journal":"Acta Anaesthesiologica Scandinavica","year":2018,"url":"https://doi.org/10.1111/aas.13228","doi":"10.1111/aas.13228","note":"OpenAlex author record matched by institution"},{"title":"Retinal arterial blood flow and retinal changes in patients with sepsis: preliminary study using fluorescein angiography","journal":"Critical Care","year":2017,"url":"https://doi.org/10.1186/s13054-017-1676-3","doi":"10.1186/s13054-017-1676-3","note":"OpenAlex author record matched by institution"}]},{"id":"krisztina-bogos","kind":"person","name":"Krisztina Bogos","aka":[],"tldr":"Krisztina Bogos represents National Korányi Institute for Pulmonology in the Organisation of European Cancer Institutes, which lists the organisation among its members in Hungary.","summary":"Krisztina Bogos is listed by the Organisation of European Cancer Institutes (OECI) as the representative of National Korányi Institute for Pulmonology, its full member in Hungary. OnCo records the name from the OECI membership list so that the organisation's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the organisation's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"National Korányi Institute for Pulmonology website","url":"http://www.koranyi.hu"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["koranyi-institute-budapest"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of National Korányi Institute for Pulmonology to the Organisation of European Cancer Institutes","institutionId":"koranyi-institute-budapest","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"National Korányi Institute for Pulmonology website","url":"http://www.koranyi.hu"}],"papers":[{"title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial","journal":"Lancet Oncol","year":2021,"url":"https://doi.org/10.1016/s1470-2045(20)30539-8","doi":"10.1016/s1470-2045(20)30539-8","note":"Europe PMC author record matched by affiliation"},{"title":"Identification and clinical significance of circulating endothelial progenitor cells in human non-small cell lung cancer","journal":"Cancer Res","year":2006,"url":"https://doi.org/10.1158/0008-5472.can-05-4654","doi":"10.1158/0008-5472.can-05-4654","note":"Europe PMC author record matched by affiliation"},{"title":"Molecular profiles of small cell lung cancer subtypes: therapeutic implications","journal":"Mol Ther Oncolytics","year":2021,"url":"https://doi.org/10.1016/j.omto.2021.02.004","doi":"10.1016/j.omto.2021.02.004","note":"Europe PMC author record matched by affiliation"}],"orcid":"0009-0003-3719-0944"},{"id":"prabhash-kumar","kind":"person","name":"Kumar Prabhash","aka":[],"tldr":"Leads medical oncology at Tata Memorial and its programme of pragmatic trials that make treatments affordable.","summary":"Kumar Prabhash is Professor and Head of the Department of Medical Oncology at Tata Memorial Hospital, part of the Tata Memorial Centre in Mumbai. He leads the department's programme of pragmatic trials that make treatments affordable, including trials of oral metronomic chemotherapy in head and neck cancer, low-cost EGFR tyrosine kinase inhibitor strategies in lung cancer and low-dose immunotherapy studies. His publications include a trial comparing gefitinib alone with gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-mutated lung cancer. His interests are head and neck cancer, lung cancer, metronomic chemotherapy and pragmatic trials.","asOf":"2026-09-08","links":[{"label":"Tata Memorial Centre","url":"https://tmc.gov.in"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Prabhash%20K%5BAuthor%5D%20Tata%20Memorial"}],"tags":[],"related":[],"cancers":["head-and-neck","nsclc"],"sections":[],"technologies":[],"targets":["egfr"],"drugs":[],"companies":[],"institutions":["tata-memorial"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor and Head, Department of Medical Oncology, Tata Memorial Hospital","institutionId":"tata-memorial","specialisms":["Head and neck cancer","Lung cancer","Metronomic chemotherapy","Pragmatic trials"],"profiles":[{"label":"Tata Memorial Centre","url":"https://tmc.gov.in"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Prabhash%20K%5BAuthor%5D%20Tata%20Memorial"}],"papers":[{"title":"Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-mutated lung cancer","journal":"Journal of Clinical Oncology","year":2020,"doi":"10.1200/JCO.19.01154"},{"title":"Low-dose immunotherapy in head and neck cancer: a randomised study (Tata Memorial)","journal":"Journal of Clinical Oncology","year":2023,"url":"https://doi.org/10.1200/JCO.22.01015","doi":"10.1200/JCO.22.01015"},{"title":"MARIPOSA: amivantamab plus lazertinib versus osimertinib as first treatment for EGFR-mutated lung cancer","journal":"New England Journal of Medicine","year":2024,"url":"https://doi.org/10.1056/NEJMoa2403614","doi":"10.1056/NEJMoa2403614"}]},{"id":"kunle-odunsi","kind":"person","name":"Kunle Odunsi","aka":[],"tldr":"Gynaecologic oncologist and immunotherapy researcher who directs the University of Chicago Medicine Comprehensive Cancer Center.","summary":"Kunle Odunsi, MD, PhD, is Director of the University of Chicago Medicine Comprehensive Cancer Center, an NCI-designated comprehensive cancer centre. A gynaecologic oncologist, his research focuses on immunotherapy and vaccine therapy for cancer, particularly ovarian cancer, including NY-ESO-1 targeted vaccines and adoptive T-cell approaches. His role is listed on the centre's leadership page.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Kunle_Odunsi","links":[{"label":"Institution profile","url":"https://www.uchicagomedicine.org/cancer/about-us/leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Odunsi+K%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","immunotherapy","ovarian cancer"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["uchicago-cancer"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director","institutionId":"uchicago-cancer","specialisms":["Gynaecologic oncology","Cancer immunotherapy","Cancer vaccines","Ovarian cancer"],"profiles":[{"label":"Institution profile","url":"https://www.uchicagomedicine.org/cancer/about-us/leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Odunsi+K%5BAuthor%5D"}],"papers":[{"title":"CXCR6 by increasing retention of memory CD8 + T cells in the ovarian tumor microenvironment promotes immunosurveillance and control of ovarian cancer","journal":"Journal for ImmunoTherapy of Cancer","year":2021,"doi":"10.1136/jitc-2021-003329"},{"title":"Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responses","journal":"Science Translational Medicine","year":2022,"doi":"10.1126/scitranslmed.abg8402"},{"title":"IDO1 Expression in Ovarian Cancer Induces PD-1 in T Cells via Aryl Hydrocarbon Receptor Activation","journal":"Frontiers in Immunology","year":2021,"doi":"10.3389/fimmu.2021.678999"}],"orcid":"0000-0002-4444-7651"},{"id":"ls-shashidhara","kind":"person","name":"L. S. Shashidhara","aka":[],"tldr":"Geneticist and developmental biologist who directs the National Centre for Biological Sciences in Bengaluru, a research unit of the Tata Institute of Fundamental Research.","summary":"L. S. Shashidhara is Centre Director of the National Centre for Biological Sciences (NCBS) in Bengaluru, a unit of the Tata Institute of Fundamental Research that conducts research across biological scales and increasingly combines experiment with computational approaches. His research concerns the gene regulatory mechanisms that position cells, tissues and organs during development, with applications to cancer research. He studied genetics and plant breeding at the University of Agricultural Sciences, Dharwad, took his PhD at the University of Cambridge and did postdoctoral work there on Hox protein function in Drosophila. He was a founding academic member of IISER Pune and Ashoka University, is a former Vice-President of the Indian National Science Academy, is President of the International Union of Biological Sciences, and has received the Shanti Swarup Bhatnagar Prize and a J. C. Bose National Fellowship.","asOf":"2026-09-10","links":[{"label":"Source: NCBS profile page for the Director","url":"https://www.ncbs.res.in/people/lsshashidhara"}],"tags":["leadership","research-institute","clinician-scientist"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ncbs"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["oncogene-journal"],"dependsOn":[],"notes":[],"role":"Centre Director, National Centre for Biological Sciences (NCBS), Bengaluru","institutionId":"ncbs","specialisms":["Developmental genetics","Evolutionary biology","Cancer biology","Science policy"],"profiles":[{"label":"NCBS profile","url":"https://www.ncbs.res.in/people/lsshashidhara"},{"label":"Director's message","url":"https://www.ncbs.res.in/director-message"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Shashidhara+LS%5BAuthor%5D"}],"papers":[{"title":"Studies on human colon cancer gene APC by targeted expression in Drosophila","journal":"Oncogene","year":2001,"doi":"10.1038/sj.onc.1204849"},{"title":"Promoter Proximal Pausing Limits Tumorous Growth Induced by the Yki Transcription Factor in Drosophila","journal":"Genetics","year":2020,"doi":"10.1534/genetics.120.303419"}]},{"id":"lp-mtshali","kind":"person","name":"L.P. Mtshali","aka":[],"tldr":"Acting chief executive who heads Inkosi Albert Luthuli Central Hospital, the KwaZulu-Natal Department of Health's central referral hospital.","summary":"Dr L.P. Mtshali is listed as Acting Chief Executive Officer of Inkosi Albert Luthuli Central Hospital (IALCH) on the hospital's senior management page, alongside acting nurse manager Dr H. Ndemera and acting senior manager for medical services Dr S. Singh. IALCH is a public central hospital run by the KwaZulu-Natal Department of Health, which lists it among the province's provincial hospitals. The hospital website was unreachable at the time of this check, so the page was read from an archived copy captured in June 2025; the hospital does not publish a full first name or biography for the acting chief executive.","asOf":"2026-09-10","links":[{"label":"Source: IALCH senior management page (archived copy)","url":"https://web.archive.org/web/20250623085121/https://www.ialch.co.za/senior-management/"},{"label":"Source: KwaZulu-Natal Department of Health provincial hospitals listing","url":"https://www.kznhealth.gov.za/provincial-hospitals/"}],"tags":["leadership","hospital-management","government"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["inkosi-albert-luthuli-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Acting Chief Executive Officer, Inkosi Albert Luthuli Central Hospital","institutionId":"inkosi-albert-luthuli-hospital","specialisms":["Hospital management","Public health services"],"profiles":[{"label":"IALCH senior management page (archived copy, June 2025)","url":"https://web.archive.org/web/20250623085121/https://www.ialch.co.za/senior-management/"}],"papers":[]},{"id":"ladislav-dusek","kind":"person","name":"Ladislav Dušek","aka":[],"tldr":"Ladislav Dušek represents Institute of Biostatistics and Analyses, Masaryk University in the Organisation of European Cancer Institutes, which lists the organisation among its members in Czech Republic.","summary":"Ladislav Dušek is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Institute of Biostatistics and Analyses, Masaryk University, its associate member in Czech Republic. OnCo records the name from the OECI membership list so that the organisation's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the organisation's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Institute of Biostatistics and Analyses, Masaryk University website","url":"https://iba.med.muni.cz/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["iba-masaryk"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Institute of Biostatistics and Analyses, Masaryk University to the Organisation of European Cancer Institutes","institutionId":"iba-masaryk","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Institute of Biostatistics and Analyses, Masaryk University website","url":"https://iba.med.muni.cz/"}],"papers":[{"title":"Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries","journal":"Lancet","year":2018,"url":"https://doi.org/10.1016/s0140-6736(17)33326-3","doi":"10.1016/s0140-6736(17)33326-3","note":"Europe PMC author record matched by affiliation"},{"title":"Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet-a population-based study","journal":"Lancet Oncol","year":2017,"url":"https://doi.org/10.1016/s1470-2045(17)30445-x","doi":"10.1016/s1470-2045(17)30445-x","note":"Europe PMC author record matched by affiliation"},{"title":"Survival of women with cancers of breast and genital organs in Europe 1999-2007: Results of the EUROCARE-5 study","journal":"Eur J Cancer","year":2015,"url":"https://doi.org/10.1016/j.ejca.2015.07.022","doi":"10.1016/j.ejca.2015.07.022","note":"Europe PMC author record matched by affiliation"}]},{"id":"lajos-pusztai","kind":"person","name":"Lajos Pusztai","aka":[],"tldr":"Translational breast oncologist who co-leads the I-SPY2 platform trial and helped show immunotherapy works in early TNBC.","summary":"Lajos Pusztai (Yale Cancer Center) co-leads the I-SPY2 adaptive neoadjuvant platform, whose durvalumab and pembrolizumab arms provided the first randomised evidence that checkpoint inhibitors raise pathological complete response in triple-negative breast cancer, before KEYNOTE-522 confirmed it. He led the SWOG S1418 adjuvant pembrolizumab trial and has published widely on immune gene signatures. His current focus is response-adapted de-escalation.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Pusztai%20L%5BAuthor%5D%20triple-negative%20I-SPY"}],"tags":["tnbc","platform-trial","biomarkers"],"related":[],"cancers":["tnbc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["pembrolizumab","durvalumab"],"companies":[],"institutions":["yale-cancer-center"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["cancer-cell"],"dependsOn":[],"notes":[],"role":"Professor of Medicine and Co-Leader, Genetics, Genomics and Epigenetics Program, Yale Cancer Center","institutionId":"yale-cancer-center","specialisms":["Triple-negative breast cancer","Adaptive platform trials","Immune biomarkers","Neoadjuvant therapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Pusztai%20L%5BAuthor%5D%20triple-negative%20I-SPY"}],"papers":[{"title":"Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: results from the adaptively randomized I-SPY2 trial","journal":"Cancer Cell","year":2021,"doi":"10.1016/j.ccell.2021.05.009"},{"title":"Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial","journal":"JAMA Oncology","year":2020,"doi":"10.1001/jamaoncol.2019.6650"}],"orcid":"0000-0001-9632-6686"},{"id":"lance-armstrong","kind":"person","name":"Lance Armstrong","aka":[],"tldr":"Treated in 1996 for testicular cancer that had spread to his lungs and brain, he founded the foundation that made survivorship a public cause and sold 80 million yellow wristbands. His doping and its exposure in 2012 complicate the legacy.","summary":"Lance Armstrong was diagnosed in October 1996 at 25 with advanced testicular cancer with metastases to the lungs and brain, and was treated with surgery and cisplatin-based chemotherapy at Indiana University. He founded the Lance Armstrong Foundation in 1997, which, as Livestrong, put the word survivorship into common use, funded navigation services and survivorship research, and distributed more than 80 million yellow wristbands from 2004. His seven Tour de France wins from 1999 to 2005 were stripped in 2012 after the US Anti-Doping Agency's investigation, and he admitted doping in 2013 and left the foundation's board. Livestrong continues under its own name. His story is included here because the survivorship movement it started outlived the sporting fraud, and because the field should remember both.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Lance_Armstrong","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Lance_Armstrong"},{"label":"Livestrong Foundation","url":"https://www.livestrong.org/"}],"tags":["public-figure","patient","advocate"],"related":[],"cancers":["testicular"],"sections":[],"technologies":["survivorship-care-plan"],"targets":[],"drugs":["cisplatin","etoposide","ifosfamide"],"companies":[],"institutions":[],"pathways":[],"terms":["aya-oncology"],"trials":[],"people":[],"bottlenecks":["b-survivorship","b-patient-voice"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Survivor who built the Livestrong survivorship movement; later disgraced in sport","specialisms":["Testicular cancer","Survivorship","Cancer advocacy"],"profiles":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Lance_Armstrong"},{"label":"Livestrong Foundation","url":"https://www.livestrong.org/"}],"papers":[]},{"id":"larry-ellison","kind":"person","name":"Larry Ellison","aka":[],"tldr":"In 2016 he founded an institute in Los Angeles to reimagine cancer care, and his Ellison Institute of Technology is building an Oxford campus with a £130 million alliance with the university.","summary":"Larry Ellison, co-founder of Oracle, founded the Lawrence J. Ellison Institute for Transformative Medicine in 2016 with a mission, in its own words, to reimagine and redefine cancer care by combining a clinic, laboratories and technology development in one building in Los Angeles. The Ellison Institute of Technology in Oxford extends the model to health and medical science, generative biology, AI and robotics, pathogens and food security. EIT's own site describes a campus set for completion in 2027, eventually two million square feet for up to 7,000 people, a strategic alliance with the University of Oxford involving an investment of £130 million, a collaboration with Cleveland Clinic to advance research, education and patient care, and scholarships that fully fund Oxford degrees. The founding sums for the Los Angeles institute are not stated on its own pages and are not repeated here.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Larry_Ellison","links":[{"label":"Ellison Institute of Technology: about","url":"https://eit.org/about/"},{"label":"Ellison Medical Institute","url":"https://ellisonmedicalinstitute.org/"}],"tags":["hero","donor"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ellison-institute","cleveland-clinic"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-funding-allocation","b-translational-valley"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Oracle founder behind the Ellison Institute for Transformative Medicine and the Ellison Institute of Technology","specialisms":["Cancer care redesign","Research institute building","Technology and medicine"],"profiles":[],"papers":[]},{"id":"lars-bullinger","kind":"person","name":"Lars Bullinger","aka":[],"tldr":"Lars Bullinger is a haematologist and AML genomics researcher leading Charité's haematology department.","summary":"Lars Bullinger is Director of the Department of Hematology, Oncology and Tumor Immunology at Charité Universitätsmedizin Berlin. A haematologist, his specialisms are acute myeloid leukaemia, leukaemia genomics and haematology. His work on gene expression and genomic classification of acute myeloid leukaemia contributed to the risk stratification systems used in the disease. His Blood papers include a study of clonal evolution in FLT3-ITD acute myeloid leukaemia under midostaurin, an international study of the genomic landscape and clonal evolution of leukaemia with t(8;21), and a report on measurable residual disease monitoring in t(8;21) leukaemia from the AML Study Group. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bullinger%20L%5BAuthor%5D%20AML"}],"tags":[],"related":[],"cancers":["aml"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["charite"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Department of Hematology, Oncology and Tumor Immunology, Charité","institutionId":"charite","specialisms":["Acute myeloid leukaemia","Leukaemia genomics","Haematology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bullinger%20L%5BAuthor%5D%20AML"}],"papers":[{"title":"Clonal evolution of acute myeloid leukemia with FLT3 -ITD mutation under treatment with midostaurin","journal":"Blood","year":2021,"doi":"10.1182/blood.2020007626"},{"title":"Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients","journal":"Blood","year":2019,"doi":"10.1182/blood-2018-05-852822"},{"title":"Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group","journal":"Blood","year":2019,"doi":"10.1182/blood.2019001425"}],"orcid":"0000-0002-5890-5510"},{"id":"lars-dahl-pedersen","kind":"person","name":"Lars Dahl Pedersen","aka":[],"tldr":"Lars Dahl Pedersen represents Aalborg University Hospital in the Organisation of European Cancer Institutes, which lists the centre among its members in Denmark.","summary":"Lars Dahl Pedersen is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Aalborg University Hospital, its member in Denmark. Aalborg University Hospital is the largest hospital in the North Denmark Region and a full member of the Organisation of European Cancer Institutes. OnCo records the name from the OECI membership list so that the centre's page has a named contact point; the person's exact title, appointment date and biography are not yet recorded and should be checked on the institution's own pages before being relied on.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Aalborg University Hospital website","url":"https://aalborguh.rn.dk/da/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["aalborg-university-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Aalborg University Hospital to the Organisation of European Cancer Institutes","institutionId":"aalborg-university-hospital","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Aalborg University Hospital website","url":"https://aalborguh.rn.dk/da/"}],"papers":[]},{"id":"lars-zender","kind":"person","name":"Lars Zender","aka":[],"tldr":"Medical oncologist and cancer biologist at Tübingen, known for work on senescence surveillance and functional genomics in liver cancer.","summary":"Prof. Lars Zender is Deputy Speaker of the CCC Tübingen-Stuttgart and Medical Director of Internal Medicine VIII (Medical Oncology and Pulmonology) at Tübingen University Hospital. His laboratory uses mouse models and in vivo RNAi/CRISPR screens to study hepatocellular carcinoma and the immune surveillance of senescent pre-malignant cells, and he has received the Gottfried Wilhelm Leibniz Prize.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.medizin.uni-tuebingen.de/de/das-klinikum/einrichtungen/zentren/tumorzentrum-ccc/vorstand"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Zender+L%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","liver cancer","cancer biology"],"related":[],"cancers":["hcc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ccc-tuebingen"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Deputy Speaker; Medical Director, Internal Medicine VIII (Medical Oncology and Pulmonology)","institutionId":"ccc-tuebingen","specialisms":["Medical oncology","Liver cancer biology","Senescence and tumour surveillance"],"profiles":[{"label":"Institution profile","url":"https://www.medizin.uni-tuebingen.de/de/das-klinikum/einrichtungen/zentren/tumorzentrum-ccc/vorstand"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Zender+L%5BAuthor%5D"}],"papers":[{"title":"Senescence surveillance of pre-malignant hepatocytes limits liver cancer development","journal":"Nature","year":2011,"doi":"10.1038/nature10599"},{"title":"Distinct Functions of Senescence-Associated Immune Responses in Liver Tumor Surveillance and Tumor Progression","journal":"Cancer Cell","year":2016,"doi":"10.1016/j.ccell.2016.09.003"},{"title":"Identification and Validation of Oncogenes in Liver Cancer Using an Integrative Oncogenomic Approach","journal":"Cell","year":2006,"doi":"10.1016/j.cell.2006.05.030"}]},{"id":"laura-brady","kind":"person","name":"Laura Brady","aka":[],"tldr":"Chief executive of Worldwide Cancer Research, a charity that funds early-stage discovery research into cancer in more than 30 countries.","summary":"Laura Brady is Chief Executive of Worldwide Cancer Research, a charity that has invested over 220 million pounds in early-stage discovery research across more than 30 countries. She was appointed in 2026, succeeding Dr Helen Rippon after Rippon's decade as Chief Executive, having previously been the charity's Director of Marketing and Fundraising and led its strategic rebrand. She has set out an aim to accelerate high-potential research into treatments by growing the charity's community of more than 90,000 supporters and its partnerships.","asOf":"2026-09-10","links":[{"label":"Source: Worldwide Cancer Research, Who we are page","url":"https://www.worldwidecancerresearch.org/who-we-are/"}],"tags":["leadership","research-funding","charity"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["worldwide-cancer-research"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive, Worldwide Cancer Research","institutionId":"worldwide-cancer-research","specialisms":["Charity leadership","Fundraising and marketing","Research funding"],"profiles":[{"label":"Worldwide Cancer Research, Who we are","url":"https://www.worldwidecancerresearch.org/who-we-are/"}],"papers":[]},{"id":"laura-esserman","kind":"person","name":"Laura J. Esserman","aka":[],"tldr":"Breast surgeon who built the I-SPY platform, the adaptive trial that tests new drugs before surgery.","summary":"Laura Esserman is Director of the UCSF Carol Franc Buck Breast Care Center at the UCSF Helen Diller Family Comprehensive Cancer Center and Principal Investigator of the I-SPY trials. A breast surgeon and trial innovator, she built I-SPY 2, the adaptive neoadjuvant platform trial that tests new drugs before surgery, and leads the WISDOM study of risk-based breast screening. Her papers include the New England Journal of Medicine report on adaptive randomisation of neratinib in early breast cancer and a JAMA article rethinking screening for breast cancer and prostate cancer. A prominent voice on overdiagnosis and de-escalation, her work spans triple-negative, HR-positive and HER2-positive breast cancer, mammography and AI in radiology.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Laura_J._Esserman","links":[{"label":"UCSF profile","url":"https://profiles.ucsf.edu/search/?searchtype=people&searchfor=Laura%20J.%20Esserman"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Esserman%20LJ%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Laura%20J.%20Esserman"}],"tags":[],"related":[],"cancers":["tnbc","breast-hr-positive","breast-her2-positive"],"sections":[],"technologies":["mammography","radiology-ai-screening"],"targets":[],"drugs":[],"companies":[],"institutions":["ucsf"],"pathways":[],"terms":["pcr","basket-umbrella-platform","rcb"],"trials":["i-spy-1","i-spy-2","i-spy-2-2","wisdom-trial"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, UCSF Carol Franc Buck Breast Care Center; Principal Investigator, I-SPY trials","institutionId":"ucsf","specialisms":["Breast cancer","Adaptive trial design","Screening"],"profiles":[{"label":"UCSF profile","url":"https://profiles.ucsf.edu/search/?searchtype=people&searchfor=Laura%20J.%20Esserman"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Esserman%20LJ%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Laura%20J.%20Esserman"}],"papers":[{"title":"Adaptive Randomization of Neratinib in Early Breast Cancer","journal":"New England Journal of Medicine","year":2016,"url":"https://doi.org/10.1056/NEJMc1609993","doi":"10.1056/NEJMc1609993"},{"title":"Rethinking screening for breast cancer and prostate cancer","journal":"JAMA","year":2009,"url":"https://doi.org/10.1001/jama.2009.1498","doi":"10.1001/jama.2009.1498"}]},{"id":"laura-skaife-knight","kind":"person","name":"Laura Skaife-Knight","aka":[],"tldr":"NHS leader who has been Chief Executive of NHS Grampian, the health board that runs the ANCHOR Centre at Aberdeen Royal Infirmary, since September 2025.","summary":"Laura Skaife-Knight is Chief Executive of NHS Grampian, the Scottish health board responsible for Aberdeen Royal Infirmary and its ANCHOR Centre for cancer and haematology care. She joined NHS Grampian as chief executive in September 2025 after serving as chief executive of NHS Orkney from 2023 to 2025, and was previously deputy chief executive at The Queen Elizabeth Hospital King's Lynn NHS Foundation Trust, where she was part of the executive team that led the trust out of special measures. Her board biography describes more than 20 years in the NHS, including board-level communications roles, and involvement in Scotland's national reform and renewal agenda. The Grampian NHS Board page lists her alongside chair Alison Evison and medical director Hugh Bishop.","asOf":"2026-09-10","links":[{"label":"Source: Grampian NHS Board membership page","url":"https://www.nhsgrampian.org/about-us/grampian-nhs-board/"},{"label":"Source: NHS Grampian chief executive biography","url":"https://www.nhsgrampian.org/siteassets/about-us/nhsg-board/laura_skaife-knight_biography.pdf"}],"tags":["leadership","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["anchor-centre-aberdeen"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive, NHS Grampian","institutionId":"anchor-centre-aberdeen","specialisms":["Health board leadership","NHS management","Communications and partnership working"],"profiles":[{"label":"NHS Grampian board page","url":"https://www.nhsgrampian.org/about-us/grampian-nhs-board/"},{"label":"Chief Executive biography (PDF)","url":"https://www.nhsgrampian.org/siteassets/about-us/nhsg-board/laura_skaife-knight_biography.pdf"}],"papers":[]},{"id":"laurence-albiges","kind":"person","name":"Laurence Albiges","aka":[],"tldr":"French kidney cancer specialist who co-led CheckMate 214 and the belzutifan trials.","summary":"Laurence Albiges was a lead investigator of CheckMate 214 (nivolumab plus ipilimumab) and of the LITESPARK trials that established belzutifan, the first HIF-2 alpha inhibitor, for previously treated clear-cell renal cell carcinoma. She led the CheckMate 214 long-term follow-up analyses and chairs the ESMO renal cancer guideline group. She heads medical oncology at Gustave Roussy.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Albiges%20L%5BAuthor%5D%20renal%20cell"}],"tags":["rcc","hif2a","guidelines"],"related":[],"cancers":["rcc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["hif2a","pd1"],"drugs":["belzutifan","nivolumab","ipilimumab"],"companies":[],"institutions":["gustave-roussy"],"pathways":[],"terms":[],"trials":["checkmate-214","litespark-005"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["esmo-open"],"dependsOn":[],"notes":[],"role":"Head of the Department of Medical Oncology, Gustave Roussy","institutionId":"gustave-roussy","specialisms":["Renal cell carcinoma","Immunotherapy","HIF-2 alpha inhibition","Treatment sequencing"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Albiges%20L%5BAuthor%5D%20renal%20cell"}],"papers":[{"title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial","journal":"ESMO Open","year":2020,"doi":"10.1016/j.esmoop.2020.001079"},{"title":"Belzutifan versus everolimus for advanced renal-cell carcinoma (LITESPARK-005)","journal":"NEJM","year":2024,"doi":"10.1056/NEJMoa2313906"}]},{"id":"laurence-zitvogel","kind":"person","name":"Laurence Zitvogel","aka":[],"tldr":"Immunologist who showed that the gut microbiome shapes responses to immunotherapy and chemotherapy.","summary":"Laurence Zitvogel is Research Director of INSERM U1015 at Gustave Roussy. An immunologist, her specialisms are tumour immunology, the gut microbiome and immunotherapy, and immunogenic cell death. With Guido Kroemer she co-discovered immunogenic cell death, and she led the studies linking gut microbiota composition to the response to immune checkpoint inhibitors. Her Science paper showed that the gut microbiome influences the efficacy of PD-1-based immunotherapy against epithelial tumours. This work opened the field of microbiome-directed cancer therapy, and her publications are listed on PubMed.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Laurence_Zitvogel","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Zitvogel%20L%5BAuthor%5D%20microbiome"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":[],"companies":[],"institutions":["gustave-roussy"],"pathways":[],"terms":["immunogenic-cell-death"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Research Director, INSERM U1015, Gustave Roussy","institutionId":"gustave-roussy","specialisms":["Tumour immunology","Gut microbiome and immunotherapy","Immunogenic cell death"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Zitvogel%20L%5BAuthor%5D%20microbiome"}],"papers":[{"title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors","journal":"Science","year":2018,"doi":"10.1126/science.aan3706"}],"orcid":"0000-0003-1596-0998"},{"id":"laurene-powell-jobs","kind":"person","name":"Laurene Powell Jobs","aka":[],"tldr":"Founder and President of Emerson Collective, the organisation that backs purpose-driven ventures in education, immigration, the environment and economic mobility.","summary":"Laurene Powell Jobs is Founder and President of Emerson Collective, an organisation that invests in purpose-driven entrepreneurs working on education, economic mobility, immigration and environmental issues. She leads the organisation and its staff, who are listed on the Emerson Collective about page. Emerson Collective works across investing, philanthropy and advocacy to address complex social challenges.","asOf":"2026-09-10","links":[{"label":"Source: Emerson Collective about page","url":"https://www.emersoncollective.com/about"}],"tags":["leadership","philanthropy","funding"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["emerson-collective"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Founder and President of Emerson Collective","institutionId":"emerson-collective","specialisms":["Philanthropy","Impact investing","Social change organisations"],"profiles":[{"label":"Institution profile","url":"https://www.emersoncollective.com/about"}],"papers":[]},{"id":"laurie-sehn","kind":"person","name":"Laurie H. Sehn","aka":[],"tldr":"Lymphoma specialist who wrote the definitive DLBCL review and helped establish polatuzumab and other new agents.","summary":"Laurie Sehn developed the revised International Prognostic Index for the rituximab era, led the BC Cancer population-based studies that showed R-CHOP's real-world impact, and was a lead investigator of the GO29365 trial establishing polatuzumab vedotin in relapsed DLBCL and of POLARIX. She authored the 2021 NEJM review of DLBCL and chairs lymphoma care in British Columbia.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sehn%20LH%5BAuthor%5D%20diffuse%20large%20B-cell%20lymphoma"}],"tags":["lymphoma","canada","outcomes"],"related":[],"cancers":["dlbcl"],"sections":[],"technologies":["adc"],"targets":["cd20"],"drugs":[],"companies":[],"institutions":["bc-cancer"],"pathways":[],"terms":[],"trials":["polarix"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chair, Lymphoma Tumour Group, BC Cancer; Clinical Professor, University of British Columbia","institutionId":"bc-cancer","specialisms":["Diffuse large B-cell lymphoma","Population-based outcomes","Novel agents","Prognostic indices"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sehn%20LH%5BAuthor%5D%20diffuse%20large%20B-cell%20lymphoma"}],"papers":[{"title":"Diffuse large B-cell lymphoma","journal":"NEJM","year":2021,"doi":"10.1056/NEJMra2027612"},{"title":"Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma","journal":"JCO","year":2020,"doi":"10.1200/JCO.19.00172"}]},{"id":"lauris-vidzis","kind":"person","name":"Lauris Vidzis","aka":[],"tldr":"Lauris Vidzis represents Pauls Stradiņš Clinical University Hospital in the Organisation of European Cancer Institutes, which lists the centre among its members in Latvia.","summary":"Lauris Vidzis is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Pauls Stradiņš Clinical University Hospital, its full member in Latvia. OnCo records the name from the OECI membership list so that the centre's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the institution's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Pauls Stradiņš Clinical University Hospital website","url":"https://www.stradini.lv"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["pauls-stradins-clinical-university-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Pauls Stradiņš Clinical University Hospital to the Organisation of European Cancer Institutes","institutionId":"pauls-stradins-clinical-university-hospital","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Pauls Stradiņš Clinical University Hospital website","url":"https://www.stradini.lv"}],"papers":[]},{"id":"lawrence-tallon","kind":"person","name":"Lawrence Tallon","aka":[],"tldr":"Chief Executive of the UK Medicines and Healthcare products Regulatory Agency, the body that approves and monitors cancer medicines and devices in the UK.","summary":"Lawrence Tallon is Chief Executive of the Medicines and Healthcare products Regulatory Agency (MHRA), the UK regulator for medicines, medical devices and blood components. He leads the agency's executive team, including its chief medical and scientific officer and chief safety officer. The MHRA is responsible for licensing oncology drugs and for post-marketing safety surveillance in the UK.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency"}],"tags":["leadership","regulation"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["mhra"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive","institutionId":"mhra","specialisms":["Medicines regulation","Health system leadership","Patient safety"],"profiles":[{"label":"Institution profile","url":"https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency"}],"papers":[]},{"id":"le-van-quang","kind":"person","name":"Lê Văn Quảng","aka":["Quang Le Van","Le Van Quang"],"tldr":"Surgical oncologist who has directed Vietnam National Cancer Hospital (K Hospital) in Hanoi since 2020.","summary":"Lê Văn Quảng is Director of Vietnam National Cancer Hospital (Bệnh viện K) in Hanoi, the country's leading cancer hospital, a role he has held since June 2020. A professor and head and neck surgical oncologist, he also chairs oncology teaching at Hanoi Medical University and has led national cancer control and training initiatives. He represents the hospital in the Organisation of European Cancer Institutes (OECI), which lists it as an associate member in Viet Nam.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Le+VQ%5BAuthor%5D+Vietnam"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Vietnam National Cancer Hospital (K Hospital) website","url":"https://benhvienk.vn"}],"tags":["leadership","clinician-scientist","head and neck cancer","global oncology","oeci-representative"],"related":["oeci"],"cancers":["head-and-neck","thyroid"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["k-hospital-hanoi"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director","institutionId":"k-hospital-hanoi","specialisms":["Head and neck surgical oncology","Cancer hospital leadership","Oncology training"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Le+VQ%5BAuthor%5D+Vietnam"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Vietnam National Cancer Hospital (K Hospital) website","url":"https://benhvienk.vn"}],"papers":[{"title":"Epidemiological Characteristics of Advanced Hepatocellular Carcinoma in the Northern Region of Vietnam","journal":"Cancer Control","year":2019,"doi":"10.1177/1073274819862793"},{"title":"Feasibility and Safety of Endoscopic Thyroidectomy Via a Unilateral Axillobreast Approach for Unilateral Benign Thyroid Tumor in Vietnam","journal":"Surgical Laparoscopy, Endoscopy & Percutaneous Techniques","year":2019,"doi":"10.1097/sle.0000000000000621"},{"title":"Role of Baseline Albumin-Bilirubin Grade on Predict Overall Survival Among Sorafenib-Treated Patients With Hepatocellular Carcinoma in Vietnam","journal":"Cancer Control","year":2019,"doi":"10.1177/1073274819865269"}],"orcid":"0000-0003-0344-0653"},{"id":"leandro-pinheiro-safatle","kind":"person","name":"Leandro Pinheiro Safatle","aka":[],"tldr":"Director-President of Anvisa, the Brazilian health regulatory agency that authorises medicines, including cancer treatments, for the Brazilian market.","summary":"Leandro Pinheiro Safatle is Diretor-Presidente of the Agência Nacional de Vigilância Sanitária (Anvisa), Brazil's federal health regulatory agency, created by law 9.782 of January 1999. He heads the agency's Diretoria Colegiada, the collegiate board that takes regulatory decisions on medicines, medical devices and other health products. His official page on the Anvisa site lists him in the role with the contact details of the presidency office.","asOf":"2026-09-10","links":[{"label":"Source: Anvisa Diretor-Presidente page","url":"https://www.gov.br/anvisa/pt-br/composicao/diretor-presidente"}],"tags":["leadership","regulator","government"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["anvisa"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Diretor-Presidente (Director-President) of Anvisa","institutionId":"anvisa","specialisms":["Health regulation","Medicines regulation","Public health policy"],"profiles":[{"label":"Institution profile","url":"https://www.gov.br/anvisa/pt-br/composicao/diretor-presidente/antonio-barra-torres"}],"papers":[]},{"id":"lecia-sequist","kind":"person","name":"Lecia V. Sequist","aka":[],"tldr":"Defined EGFR resistance mechanisms in lung cancer and now leads early-detection research including the Sybil AI lung-risk model.","summary":"Lecia V. Sequist is Director of the Center for Innovation in Early Cancer Detection and Landry Family Professor of Medicine at Massachusetts General Hospital Cancer Center. She is a thoracic oncologist known for defining EGFR resistance mechanisms in lung cancer, leading the 2011 analysis of resistance to EGFR inhibitors and early osimertinib development. Her selected papers report the genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors, and Sybil, a validated deep learning model that predicts future lung cancer risk from a single low-dose chest CT scan. She now directs MGH's early cancer detection centre and works on low-dose CT screening and AI risk models.","asOf":"2026-09-08","links":[{"label":"MGH profile","url":"https://www.massgeneral.org/doctors/17170/lecia-sequist"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sequist%20LV%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["low-dose-ct-screening","radiology-ai-screening"],"targets":["egfr"],"drugs":[],"companies":[],"institutions":["mgh"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["science-translational-medicine"],"dependsOn":[],"notes":[],"role":"Director, Center for Innovation in Early Cancer Detection; Landry Family Professor of Medicine","institutionId":"mgh","specialisms":["Lung cancer","EGFR resistance","Early detection","AI risk models"],"profiles":[{"label":"MGH profile","url":"https://www.massgeneral.org/doctors/17170/lecia-sequist"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sequist%20LV%5BAuthor%5D"}],"papers":[{"title":"Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors","journal":"Science Translational Medicine","year":2011,"url":"https://doi.org/10.1126/scitranslmed.3002003","doi":"10.1126/scitranslmed.3002003"},{"title":"Sybil: a validated deep learning model to predict future lung cancer risk from a single low-dose chest computed tomography","journal":"Journal of Clinical Oncology","year":2023,"url":"https://doi.org/10.1200/JCO.22.01345","doi":"10.1200/JCO.22.01345"}]},{"id":"lehlohonolo-majake","kind":"person","name":"Lehlohonolo Majake","aka":[],"tldr":"Public health medicine specialist who has been Chief Executive Officer of Steve Biko Academic Hospital in Pretoria, the University of Pretoria's main teaching hospital, since 2024.","summary":"Dr Lehlohonolo Majake is Chief Executive Officer of Steve Biko Academic Hospital, an 832-bed tertiary public hospital in Pretoria that serves as the main teaching hospital of the University of Pretoria's Faculty of Health Sciences. His appointment was announced by the Gauteng Department of Health on 8 March 2024, when MEC Nomantu Nkomo-Ralehoko congratulated him together with the new chief executives of Chris Hani Baragwanath and Dr George Mukhari academic hospitals; the statement gives his start date as 1 March 2024. Search listings describe him as a public health medicine specialist.","asOf":"2026-09-10","links":[{"label":"Source: South African Government media statement on the appointment (8 March 2024)","url":"https://www.gov.za/news/media-statements/gauteng-health-announces-appointment-three-ceos-academic-hospitals-08-mar"},{"label":"Source: Wikipedia article on Steve Biko Academic Hospital","url":"https://en.wikipedia.org/wiki/Steve_Biko_Academic_Hospital"}],"tags":["leadership","hospital-management","government"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["steve-biko-academic-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive Officer, Steve Biko Academic Hospital","institutionId":"steve-biko-academic-hospital","specialisms":["Public health medicine","Hospital management"],"profiles":[{"label":"Gauteng Health appointment statement (gov.za)","url":"https://www.gov.za/news/media-statements/gauteng-health-announces-appointment-three-ceos-academic-hospitals-08-mar"}],"papers":[]},{"id":"lei-zheng","kind":"person","name":"Lei Zheng","aka":[],"tldr":"Physician-scientist who is Executive Director of the Mays Cancer Center at UT Health San Antonio, the only NCI-designated cancer centre in South Texas.","summary":"Lei Zheng, MD, PhD, is Executive Director of the Mays Cancer Center at UT Health San Antonio and the university's Vice President for Oncology. UT Health San Antonio news items from May, June and August 2026 quote him in that role, including the August 2026 announcement naming Georg Aue inaugural director of the centre's stem cell transplant and cellular therapy programme. The centre, which also uses the name UT Health San Antonio MD Anderson Cancer Center, has served South Texas since 1974 and is described by the university as the only NCI-designated cancer centre in the region.","asOf":"2026-09-10","links":[{"label":"Source: UT Health San Antonio news release naming Lei Zheng as Executive Director","url":"https://news.uthscsa.edu/ut-health-san-antonio-names-nih-expert-inaugural-director-of-stem-cell-transplant-and-cellular-therapy-program/"},{"label":"Source: Mays Cancer Center about page","url":"https://cancer.uthscsa.edu/about/about-uthealthsa-mdanderson-cancer-center"}],"tags":["leadership","clinician-scientist","comprehensive-cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":["stem-cell"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Executive Director, Mays Cancer Center, and Vice President for Oncology, UT Health San Antonio","institutionId":"mays-cancer-center","specialisms":["Medical oncology","Cancer immunology","Cancer centre leadership"],"profiles":[{"label":"UT Health San Antonio news (August 2026) quoting the Executive Director","url":"https://news.uthscsa.edu/ut-health-san-antonio-names-nih-expert-inaugural-director-of-stem-cell-transplant-and-cellular-therapy-program/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Zheng+L%5BAuthor%5D+AND+San+Antonio"}],"papers":[{"title":"The tumour microenvironment in pancreatic cancer — clinical challenges and opportunities","journal":"Nature Reviews Clinical Oncology","year":2020,"doi":"10.1038/s41571-020-0363-5"},{"title":"Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells","journal":"OncoImmunology","year":2015,"doi":"10.1080/2162402x.2015.1016700"},{"title":"Immunotherapy Converts Nonimmunogenic Pancreatic Tumors into Immunogenic Foci of Immune Regulation","journal":"Cancer Immunology Research","year":2014,"doi":"10.1158/2326-6066.cir-14-0027"}]},{"id":"leif-ellisen","kind":"person","name":"Leif W. Ellisen","aka":[],"tldr":"Runs breast medical oncology at MGH and studies the tumour-suppressor biology behind hereditary and triple-negative breast cancer.","summary":"Leif W. Ellisen is Program Director of Breast Medical Oncology at Massachusetts General Hospital Cancer Center. He is a physician-scientist known for studying the tumour-suppressor biology behind hereditary and triple-negative breast cancer, with laboratory work on the p53 family members p63 and p73 and the DNA damage response in breast and squamous cancers. His selected paper shows that the p63 isoform delta-Np63-alpha represses anti-proliferative genes through H2A.Z deposition. He runs MGH's breast oncology programme while continuing research on TP53, BRCA1 and BRCA2 and cancer predisposition.","asOf":"2026-09-08","links":[{"label":"MGH profile","url":"https://www.massgeneral.org/doctors/17039/leif-ellisen"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ellisen%20LW%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["tnbc","breast-hr-positive"],"sections":[],"technologies":[],"targets":["tp53","brca"],"drugs":[],"companies":[],"institutions":["mgh"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["genes-and-development"],"dependsOn":[],"notes":[],"role":"Program Director, Breast Medical Oncology","institutionId":"mgh","specialisms":["Breast cancer genetics","p53 family and p63","Cancer predisposition"],"profiles":[{"label":"MGH profile","url":"https://www.massgeneral.org/doctors/17039/leif-ellisen"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ellisen%20LW%5BAuthor%5D"}],"papers":[{"title":"ΔNp63α represses anti-proliferative genes via H2A.Z deposition","journal":"Genes & Development","year":2012}],"orcid":"0000-0003-0444-7910"},{"id":"leon-black","kind":"person","name":"Leon Black","aka":[],"tldr":"After his wife Debra's melanoma diagnosis in 2007 the couple founded the Melanoma Research Alliance, which has put more than $200 million into research while they pay its running costs so every donated dollar goes to science.","summary":"Leon Black, co-founder of Apollo Global Management, and his wife Debra founded the Melanoma Research Alliance in 2007 after Debra was diagnosed with melanoma. MRA's own overview states that it has directly invested over $200 million through more than 500 grant awards, that MRA-funded researchers have contributed to 20 new FDA-approved melanoma treatments since its founding, and that because of the founders' ongoing support 100% of every donation goes to melanoma research, with administrative and fundraising costs covered by the Blacks. The years since 2007 saw melanoma go from a disease with almost no effective drugs for advanced cases to the proving ground for checkpoint immunotherapy and BRAF-targeted therapy; MRA funded young investigators and team science through that change.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Leon_Black","links":[{"label":"Melanoma Research Alliance: overview","url":"https://www.curemelanoma.org/mra-overview/mra-overview"}],"tags":["hero","donor"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":["checkpoint-inhibitor","immunotherapy"],"targets":[],"drugs":[],"companies":[],"institutions":["mra"],"pathways":[],"terms":[],"trials":[],"people":["debra-black","james-allison"],"bottlenecks":["b-funding-allocation","b-translational-valley"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Co-founder, with Debra Black, of the Melanoma Research Alliance","specialisms":["Melanoma research funding","Philanthropy"],"profiles":[],"papers":[]},{"id":"leonard-abramson","kind":"person","name":"Leonard Abramson","aka":["Leonard and Madlyn Abramson"],"tldr":"In 1997 he and his wife Madlyn, a cancer survivor, gave the University of Pennsylvania the gift that created the Abramson Cancer Center, where CAR-T therapy was later developed.","summary":"Leonard Abramson (1932-2026) founded the health maintenance organisation U.S. Healthcare and, with his wife Madlyn (who died in 2020 and had herself been treated for cancer), made a December 1997 gift to the University of Pennsylvania that created the Abramson Cancer Center and its research institute. Published figures for the gift differ between sources, so none is given here. The family also funded the Leonard and Madlyn Abramson Pediatric Research Center at Children's Hospital of Philadelphia and professorships at Penn and Johns Hopkins. The Abramson Cancer Center became the home of Carl June's CD19 CAR-T programme, whose first paediatric patient, Emily Whitehead, was treated across the street at CHOP in 2012; it is now an NCI-designated comprehensive cancer centre.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Leonard_Abramson","links":[{"label":"Penn Medicine: remembering Madlyn Abramson","url":"https://www.pennmedicine.org/cancer/about/remembering-madlyn-abramson"}],"tags":["hero","donor"],"related":[],"cancers":[],"sections":[],"technologies":["car-t"],"targets":[],"drugs":[],"companies":[],"institutions":["penn-abramson","chop"],"pathways":[],"terms":[],"trials":[],"people":["carl-june","emily-whitehead"],"bottlenecks":["b-funding-allocation"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"U.S. Healthcare founder whose 1997 gift created Penn's Abramson Cancer Center","specialisms":["Cancer centre building","Paediatric cancer research"],"profiles":[],"papers":[]},{"id":"leonor-beleza","kind":"person","name":"Leonor Beleza","aka":[],"tldr":"President of the Champalimaud Foundation in Lisbon, home to the Champalimaud Clinical Centre for cancer care and research.","summary":"Leonor Beleza is President of the Champalimaud Foundation in Lisbon, a private foundation for biomedical research and clinical care whose Champalimaud Clinical Centre focuses on cancer, including the Botton-Champalimaud Pancreatic Cancer Centre. A former Portuguese Minister of Health, she has led the Foundation since its establishment.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://fchampalimaud.org/champalimaud-foundation/team"}],"tags":["leadership","research funding","health policy"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["champalimaud"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President","institutionId":"champalimaud","specialisms":["Foundation governance","Health policy","Biomedical research funding"],"profiles":[{"label":"Institution profile","url":"https://fchampalimaud.org/champalimaud-foundation/team"}],"papers":[]},{"id":"li-ding","kind":"person","name":"Li Ding","aka":[],"tldr":"Li Ding is the computational leader of TCGA and CPTAC analyses linking genomes to proteins across cancers.","summary":"Li Ding is the David English Smith Distinguished Professor of Medicine and Director of Computational Biology in the Division of Oncology at Siteman Cancer Center, Washington University. She is the computational leader of The Cancer Genome Atlas and CPTAC analyses that link genomes to proteins across cancers, having led pan-cancer analyses of driver mutations and proteogenomic studies connecting genomic alterations to signalling and drug targets. Her selected paper reports the comprehensive characterisation of cancer driver genes and mutations. She continues to work on proteogenomics, whole-genome sequencing and clonal evolution.","asOf":"2026-09-08","links":[{"label":"Ding lab","url":"https://dinglab.wustl.edu"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ding%20L%5BAuthor%5D"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["proteomics","wes-wgs"],"targets":[],"drugs":[],"companies":[],"institutions":["wustl-siteman"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"David English Smith Distinguished Professor of Medicine; Director of Computational Biology, Division of Oncology","institutionId":"wustl-siteman","specialisms":["Cancer genomics","Proteogenomics","Clonal evolution"],"profiles":[{"label":"Ding lab","url":"https://dinglab.wustl.edu"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ding%20L%5BAuthor%5D"}],"papers":[{"title":"Comprehensive characterization of cancer driver genes and mutations","journal":"Cell","year":2018,"url":"https://doi.org/10.1016/j.cell.2018.02.060","doi":"10.1016/j.cell.2018.02.060"}]},{"id":"li-ka-shing","kind":"person","name":"Li Ka-shing","aka":[],"tldr":"Since 1980 he has put more than HK$30 billion into his foundation; its Heart of Gold programme gave free hospice care to tens of thousands of poor terminal cancer patients, and its gift built the Cambridge centre that houses Cancer Research UK's institute there.","summary":"Li Ka-shing built Cheung Kong and Hutchison Whampoa into one of Asia's largest business groups and founded the Li Ka Shing Foundation in 1980, which states that he has invested over HK$30 billion in it, more than 80% of it in mainland China and Hong Kong. Its cornerstone is Shantou University, founded in 1981 and supported with HK$12 billion, whose medical college trains doctors for southern China. Its Heart of Gold hospice programme in Hong Kong ran from 2007 to 2020 through ten centres and served over 38,000 low-income terminal cancer patients and their families with palliative care, mental and spiritual support, alongside the foundation's national hospice network in mainland hospitals. In Cambridge, the Cancer Research UK Cambridge Institute is housed in the Li Ka Shing Centre on Robinson Way, built with the foundation's gift. Few donors have funded both the end of cancer care and its research front.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Li_Ka-shing","links":[{"label":"Li Ka Shing Foundation","url":"https://www.lksf.org/"},{"label":"Heart of Gold hospice programme","url":"https://www.lksf.org/heart-of-gold/"},{"label":"CRUK Cambridge Institute: about us","url":"https://www.cruk.cam.ac.uk/about-us"}],"tags":["hero","donor"],"related":[],"cancers":[],"sections":[],"technologies":["palliative-care"],"targets":[],"drugs":[],"companies":[],"institutions":["li-ka-shing-foundation","cruk-cambridge-centre"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-palliative","b-global-access","b-funding-allocation"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Hong Kong entrepreneur whose foundation funded free hospice care for poor cancer patients and the building that houses the CRUK Cambridge Institute","specialisms":["Hospice and palliative care","Medical education in China","Cancer research buildings"],"profiles":[],"papers":[]},{"id":"zhang-li-sysucc","kind":"person","name":"Li Zhang","aka":[],"tldr":"Led the Chinese trials of PD-1 blockade in nasopharyngeal and lung cancer and the early studies of the EGFR×HER3 bispecific ADC iza-bren.","summary":"Li Zhang is Professor of Medical Oncology and Director of the Department of Medical Oncology at Sun Yat-sen University Cancer Center in Guangzhou. He led the Chinese trials of PD-1 blockade with camrelizumab and toripalimab in nasopharyngeal carcinoma and lung cancer, and the early-phase studies of izalontamab brengitecan, the EGFR and HER3 bispecific antibody-drug conjugate from SystImmune and Sichuan Biokin, in non-small-cell lung cancer and nasopharyngeal carcinoma. His publications include the CAPTAIN-1st trial of camrelizumab added to gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma. His interests are lung cancer, nasopharyngeal carcinoma, immunotherapy and antibody-drug conjugates.","asOf":"2026-09-08","links":[{"label":"Sun Yat-sen University Cancer Center","url":"https://www.sysucc.org.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Zhang%20L%5BAuthor%5D%20Sun%20Yat-sen%20lung%20cancer%20camrelizumab"}],"tags":[],"related":[],"cancers":["nsclc","head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":["izalontamab-brengitecan","camrelizumab","toripalimab"],"companies":["systimmune"],"institutions":["sysucc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology; Director, Department of Medical Oncology, Sun Yat-sen University Cancer Center","institutionId":"sysucc","specialisms":["Lung cancer","Nasopharyngeal carcinoma","Immunotherapy","Antibody-drug conjugates"],"profiles":[{"label":"Sun Yat-sen University Cancer Center","url":"https://www.sysucc.org.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Zhang%20L%5BAuthor%5D%20Sun%20Yat-sen%20lung%20cancer%20camrelizumab"}],"papers":[{"title":"Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st)","journal":"Lancet Oncology","year":2021,"doi":"10.1016/S1470-2045(21)00302-8"}]},{"id":"lieping-chen","kind":"person","name":"Lieping Chen","aka":[],"tldr":"Discovered PD-L1 (B7-H1) and showed tumours use it to escape immunity, the biology behind every anti-PD-1 drug.","summary":"Lieping Chen (Yale) identified B7-H1, later named PD-L1, in 1999, showed in 2002 that tumours express it to kill or disable T cells and that blocking it restores anti-tumour immunity, and initiated the first anti-PD-1/PD-L1 clinical trials with Johns Hopkins colleagues. He received the Warren Alpert Prize with Honjo, Freeman and Sharpe and continues to discover normalisation-cancer-immunotherapy targets such as Siglec-15.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chen%20L%5BAuthor%5D%20B7-H1%20PD-L1"}],"tags":["immunotherapy","discovery","pd-l1"],"related":[],"cancers":[],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["pdl1","pd1"],"drugs":[],"companies":[],"institutions":["yale-school-of-medicine"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-iwai-pdl1-tumour-escape-pnas-2002","paper-topalian-anti-pd1-nejm-2012"],"journals":[],"dependsOn":[],"notes":[],"role":"United Technologies Corporation Professor in Cancer Research, Yale School of Medicine","institutionId":"yale-school-of-medicine","specialisms":["PD-L1 biology","Tumour immune evasion","Checkpoint discovery","Immunotherapy targets"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chen%20L%5BAuthor%5D%20B7-H1%20PD-L1"}],"papers":[{"title":"B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion","journal":"Nature Medicine","year":1999,"doi":"10.1038/70932"},{"title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","journal":"Nature Medicine","year":2002,"doi":"10.1038/nm730"},{"title":"Iwai and Honjo: tumours use PD-L1 to escape T cells, and blocking it restores attack","journal":"PNAS","year":2002,"url":"https://doi.org/10.1073/pnas.192461099","doi":"10.1073/pnas.192461099"},{"title":"Topalian 2012: the first large trial of a PD-1 antibody shows durable responses across melanoma, lung and kidney cancer","journal":"New England Journal of Medicine","year":2012,"url":"https://doi.org/10.1056/NEJMoa1200690","doi":"10.1056/NEJMoa1200690"}],"orcid":"0000-0002-6825-3069"},{"id":"lillian-siu","kind":"person","name":"Lillian L. Siu","aka":[],"tldr":"Runs one of the world's largest phase 1 programmes and led trials that shaped head and neck cancer immunotherapy.","summary":"Lillian L. Siu is Director of the Phase I Program and holds the BMO Chair in Precision Cancer Genomics at the Princess Margaret Cancer Centre. She is a medical oncologist who runs one of the world's largest phase 1 programmes and led KEYNOTE and other immunotherapy studies that shaped head and neck cancer treatment. Her selected paper reports the CONDOR trial of durvalumab with or without tremelimumab in PD-L1-low or negative recurrent or metastatic head and neck squamous cell carcinoma. She pioneers ctDNA-guided early trials and is AACR president for 2025 to 2026.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Lillian_Siu","links":[{"label":"UHN profile","url":"https://www.uhnresearch.ca/researcher/lillian-l-siu"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Siu%20LL%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["head-and-neck"],"sections":[],"technologies":["liquid-biopsy","checkpoint-inhibitor"],"targets":[],"drugs":[],"companies":[],"institutions":["princess-margaret"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Phase I Program; BMO Chair in Precision Cancer Genomics","institutionId":"princess-margaret","specialisms":["Early drug development","Head and neck cancer","Immunotherapy","ctDNA"],"profiles":[{"label":"UHN profile","url":"https://www.uhnresearch.ca/researcher/lillian-l-siu"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Siu%20LL%5BAuthor%5D"}],"papers":[{"title":"Safety and efficacy of durvalumab with or without tremelimumab in patients with PD-L1-low/negative recurrent or metastatic HNSCC (CONDOR)","journal":"JAMA Oncology","year":2019,"url":"https://doi.org/10.1001/jamaoncol.2018.4628","doi":"10.1001/jamaoncol.2018.4628"}]},{"id":"lim-soon-thye","kind":"person","name":"Lim Soon Thye","aka":[],"tldr":"Lymphoma specialist and Chief Executive Officer of the National Cancer Centre Singapore, the country's largest public cancer centre.","summary":"Lim Soon Thye is Chief Executive Officer of the National Cancer Centre Singapore (NCCS), part of the SingHealth cluster. A medical oncologist specialising in lymphoma, he has led research on T-cell and NK/T-cell lymphomas prevalent in Asian populations and co-founded regional lymphoma study groups. As CEO he oversees NCCS's clinical services, research divisions and education programmes.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.nccs.com.sg/about-nccs/leadership.html"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lim+ST%5BAuthor%5D+Singapore+lymphoma"}],"tags":["leadership","clinician-scientist","lymphoma"],"related":[],"cancers":["peripheral-t-cell-lymphoma","dlbcl"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["nccs"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["asco-educational-book","journal-of-hematology-and-oncology"],"dependsOn":[],"notes":[],"role":"Chief Executive Officer","institutionId":"nccs","specialisms":["Lymphoma","Medical oncology","Health system leadership"],"profiles":[{"label":"Institution profile","url":"https://www.nccs.com.sg/about-nccs/leadership.html"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lim+ST%5BAuthor%5D+Singapore+lymphoma"}],"papers":[{"title":"Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial","journal":"Blood","year":2018,"doi":"10.1182/blood-2017-09-804641"},{"title":"Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group","journal":"Journal of Hematology & Oncology","year":2020,"doi":"10.1186/s13045-020-00855-9"},{"title":"Current Management Concepts: Primary Central Nervous System Lymphoma, Natural Killer T-Cell Lymphoma Nasal Type, and Post-transplant Lymphoproliferative Disorder","journal":"American Society of Clinical Oncology Educational Book","year":2016,"doi":"10.1200/edbk_159030"}]},{"id":"shen-lin","kind":"person","name":"Lin Shen","aka":[],"tldr":"Led the CT041 trials that produced the first CAR-T therapy approved for a solid tumour, in gastric cancer.","summary":"Lin Shen is Professor and Director of the Department of Gastrointestinal Oncology at Peking University Cancer Hospital in Beijing. Her group ran the phase 1 and randomised phase 2 trials of satricabtagene autoleucel, the Claudin 18.2 CAR-T cell therapy from CARsgen Therapeutics also known as CT041, which produced the first CAR-T therapy approved for a solid tumour, in gastric cancer. Her publications include the interim phase 1 results of Claudin 18.2-specific CAR T cells in gastrointestinal cancers, which also included pancreatic cancer patients. She leads Chinese gastric cancer immunotherapy and HER2 studies, with interests in CAR-T for solid tumours and immunotherapy.","asOf":"2026-09-08","links":[{"label":"Peking University Cancer Hospital","url":"https://www.bjcancer.org"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Shen%20L%5BAuthor%5D%20Peking%20University%20Cancer%20Hospital%20claudin18.2%20CAR-T"}],"tags":[],"related":[],"cancers":["gastric","pancreatic"],"sections":[],"technologies":["car-t"],"targets":["cldn18-2"],"drugs":["satricabtagene-autoleucel"],"companies":["carsgen"],"institutions":["pku-cancer-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor and Director, Department of GI Oncology, Peking University Cancer Hospital","institutionId":"pku-cancer-hospital","specialisms":["Gastric cancer","Claudin 18.2","CAR-T for solid tumours","Immunotherapy"],"profiles":[{"label":"Peking University Cancer Hospital","url":"https://www.bjcancer.org"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Shen%20L%5BAuthor%5D%20Peking%20University%20Cancer%20Hospital%20claudin18.2%20CAR-T"}],"papers":[{"title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results","journal":"Nature Medicine","year":2022,"doi":"10.1038/s41591-022-01800-8"},{"title":"BREAKWATER: encorafenib plus cetuximab with chemotherapy as first treatment for BRAF V600E-mutated colorectal cancer","journal":"New England Journal of Medicine","year":2025,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BREAKWATER+encorafenib+cetuximab+mFOLFOX6+colorectal"},{"title":"CheckMate 649: nivolumab plus chemotherapy as first treatment for advanced gastric, gastro-oesophageal junction and oesophageal adenocarcinoma","journal":"The Lancet","year":2021,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CheckMate+649+nivolumab+chemotherapy+gastric+Janjigian+Lancet+2021"}]},{"id":"lin-tongyu","kind":"person","name":"Lin Tongyu","aka":[],"tldr":"Physician who is President of Sichuan Cancer Hospital, the provincial specialist cancer hospital and institute in Chengdu with campuses in Wuhou and Tianfu.","summary":"Lin Tongyu (林桐榆) is President (院长) of Sichuan Cancer Hospital (四川省肿瘤医院, Sichuan Cancer Hospital and Institute), the provincial cancer hospital in Chengdu. The hospital's current leadership page lists him as President alongside Party Secretary Yi Qun, Deputy Party Secretary Fan Wei and vice presidents Liao Hong, Lu Shun, Li Chao and Lu Man. The hospital operates two campuses, at Wuhou on Renmin South Road and at Tianfu New Area, and its homepage describes him attending to patients on the wards.","asOf":"2026-09-10","links":[{"label":"Source: Sichuan Cancer Hospital current leadership page","url":"https://www.sichuancancer.org/yygk/xrld1.htm"}],"tags":["leadership","clinician-scientist","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["sichuan-cancer-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["jama","international-journal-of-oncology"],"dependsOn":[],"notes":[],"role":"President (院长), Sichuan Cancer Hospital","institutionId":"sichuan-cancer-hospital","specialisms":["Oncology","Hospital management"],"profiles":[{"label":"Hospital current leadership page (Chinese)","url":"https://www.sichuancancer.org/yygk/xrld1.htm"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lin+T%5BAuthor%5D+AND+Sichuan+Cancer+Hospital"}],"papers":[{"title":"Entecavir vs Lamivudine for Prevention of Hepatitis B Virus Reactivation Among Patients With Untreated Diffuse Large B-Cell Lymphoma Receiving R-CHOP Chemotherapy","journal":"JAMA","year":2014,"doi":"10.1001/jama.2014.15704"},{"title":"Immunotherapy for nasopharyngeal carcinoma: Current status and prospects (Review)","journal":"International Journal of Oncology","year":2023,"doi":"10.3892/ijo.2023.5545"}]},{"id":"linda-mileshkin","kind":"person","name":"Linda Mileshkin","aka":[],"tldr":"Led OUTBACK, which showed adding chemotherapy after chemoradiation does not help cervical cancer, a key negative result.","summary":"Linda Mileshkin was principal investigator of OUTBACK, the ANZGOG-led international trial showing that adjuvant carboplatin-paclitaxel after chemoradiotherapy does not improve survival in locally advanced cervical cancer, sparing patients unnecessary toxicity. She also leads the CUPISCO and other trials in cancer of unknown primary and directs clinical trials at Peter Mac.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mileshkin%20L%5BAuthor%5D%20cervical%20OUTBACK"}],"tags":["cervical","australia","cooperative-group"],"related":[],"cancers":["cervical","cancer-of-unknown-primary"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["peter-mac"],"pathways":[],"terms":[],"trials":["outback"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Medical Oncologist and Director of Clinical Trials, Peter MacCallum Cancer Centre","institutionId":"peter-mac","specialisms":["Cervical cancer","Gynaecologic oncology","Cancer of unknown primary","Cooperative-group trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mileshkin%20L%5BAuthor%5D%20cervical%20OUTBACK"}],"papers":[{"title":"Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK)","journal":"Lancet Oncology","year":2023,"doi":"10.1016/S1470-2045(23)00147-X"},{"title":"Cancer of unknown primary: challenges and progress in clinical management","journal":"Lancet Oncology","year":2018}],"orcid":"0000-0001-6826-6014"},{"id":"linda-tantawi","kind":"person","name":"Linda Tantawi","aka":[],"tldr":"Chief Executive Officer of the Lustgarten Foundation, the largest private funder of pancreatic cancer research.","summary":"Linda Tantawi is Chief Executive Officer of the Lustgarten Foundation, a US non-profit dedicated to funding pancreatic cancer research. She leads the foundation's strategy, fundraising and research investment programme. The foundation supports laboratories and clinical trials aimed at earlier detection and better treatment of pancreatic cancer.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://lustgarten.org/who-we-are/"}],"tags":["leadership","pancreatic cancer","research funding"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["lustgarten-foundation"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive Officer","institutionId":"lustgarten-foundation","specialisms":["Non-profit leadership","Pancreatic cancer research funding"],"profiles":[{"label":"Institution profile","url":"https://lustgarten.org/who-we-are/"}],"papers":[]},{"id":"lionel-collet","kind":"person","name":"Lionel Collet","aka":[],"tldr":"Physician and former university president who chairs the Haute Autorité de Santé, France's health technology assessment and quality body.","summary":"Lionel Collet is President of the Collège of the Haute Autorité de Santé (HAS), the independent French authority that assesses medicines including cancer drugs, medical devices and clinical practice, and issues guidelines, a role he has held since 2023. A professor of medicine and former president of Université Claude Bernard Lyon 1, he previously chaired the board of the Assistance Publique-Hôpitaux de Paris.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Collet+L%5BAuthor%5D+Lyon"}],"tags":["leadership","health technology assessment","regulation"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["has-france"],"pathways":[],"terms":["hta"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President of the Collège","institutionId":"has-france","specialisms":["Health technology assessment","Health policy","Otolaryngology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Collet+L%5BAuthor%5D+Lyon"}],"papers":[]},{"id":"lipika-goyal","kind":"person","name":"Lipika Goyal","aka":[],"tldr":"Led the futibatinib trial and defined how FGFR2-driven bile duct cancers become resistant to targeted drugs.","summary":"Lipika Goyal was principal investigator of FOENIX-CCA2, which won futibatinib approval for FGFR2 fusion-positive cholangiocarcinoma, and used serial ctDNA to describe the polyclonal FGFR2 kinase domain mutations that drive acquired resistance to FGFR inhibitors. She directs GI oncology at Stanford and leads trials of next-generation FGFR inhibitors.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Goyal%20L%5BAuthor%5D%20FGFR2%20cholangiocarcinoma"}],"tags":["biliary","fgfr2","targeted-therapy"],"related":[],"cancers":["cholangiocarcinoma"],"sections":[],"technologies":["kinase-inhibitors","liquid-biopsy"],"targets":["fgfr2"],"drugs":[],"companies":[],"institutions":["stanford"],"pathways":[],"terms":[],"trials":["foenix-cca2"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Associate Professor of Medicine and Director of Gastrointestinal Oncology, Stanford Cancer Institute","institutionId":"stanford","specialisms":["Cholangiocarcinoma","FGFR2-targeted therapy","Acquired resistance","Circulating tumour DNA"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Goyal%20L%5BAuthor%5D%20FGFR2%20cholangiocarcinoma"}],"papers":[{"title":"Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma (FOENIX-CCA2)","journal":"NEJM","year":2023,"doi":"10.1056/NEJMoa2206834"},{"title":"Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma","journal":"Cancer Discovery","year":2017,"doi":"10.1158/2159-8290.CD-16-1000"}],"orcid":"0000-0002-9777-6221"},{"id":"lisbet-isenbeg-ravn","kind":"person","name":"Lisbet Isenbeg Ravn","aka":[],"tldr":"Lisbet Isenbeg Ravn represents Herlev Hospital, Copenhagen University Hospital in the Organisation of European Cancer Institutes, which lists the centre among its full members in Denmark.","summary":"Lisbet Isenbeg Ravn is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Herlev Hospital, Copenhagen University Hospital, its full member in Denmark. OnCo records the name from the OECI membership list so that the centre's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the institution's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Herlev Hospital, Copenhagen University Hospital website","url":"https://www.herlevhospital.dk/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["herlev-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Herlev Hospital, Copenhagen University Hospital to the Organisation of European Cancer Institutes","institutionId":"herlev-hospital","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Herlev Hospital, Copenhagen University Hospital website","url":"https://www.herlevhospital.dk/"}],"papers":[]},{"id":"livio-de-angelis","kind":"person","name":"Livio De Angelis","aka":[],"tldr":"Livio De Angelis represents IRCCS Regina Elena National Cancer Institute in the Organisation of European Cancer Institutes, which lists the centre among its members in Italy.","summary":"Livio De Angelis is listed by the Organisation of European Cancer Institutes (OECI) as the representative of IRCCS Regina Elena National Cancer Institute, its full member in Italy. OnCo records the name from the OECI membership list so that the centre's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the institution's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"IRCCS Regina Elena National Cancer Institute website","url":"https://www.ifo.it/en/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["regina-elena-rome"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of IRCCS Regina Elena National Cancer Institute to the Organisation of European Cancer Institutes","institutionId":"regina-elena-rome","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"IRCCS Regina Elena National Cancer Institute website","url":"https://www.ifo.it/en/"}],"papers":[]},{"id":"lori-pierce","kind":"person","name":"Lori J. Pierce","aka":[],"tldr":"Lori Pierce is a breast radiation oncologist and ASCO past president focused on equity in cancer care.","summary":"Lori Pierce is Professor of Radiation Oncology and Vice Provost at the University of Michigan, within the University of Michigan Rogel Cancer Center, a senior NRG Oncology investigator and past president of the American Society of Clinical Oncology (ASCO) for 2020 to 2021. A breast radiation oncologist, she studies radiotherapy in BRCA carriers and breast cancer outcomes by race, with a focus on health equity. Her papers include a comparison of breast conservation and mastectomy in BRCA1 and BRCA2 mutation carriers with operable breast cancer and ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. Her work spans triple-negative and HR-positive breast cancer and modern radiotherapy.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Lori_J._Pierce","links":[{"label":"Michigan Medicine","url":"https://medicine.umich.edu/dept/radiation-oncology"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Pierce%20LJ%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Lori%20J.%20Pierce"}],"tags":[],"related":[],"cancers":["tnbc","breast-hr-positive"],"sections":[],"technologies":["imrt-igrt"],"targets":["brca"],"drugs":[],"companies":["nrg-oncology"],"institutions":["michigan-rogel","asco"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["breast-cancer-research-and-treatment"],"dependsOn":[],"notes":[],"role":"Professor of Radiation Oncology and Vice Provost, University of Michigan; NRG Oncology investigator; ASCO Past President (2020-2021)","institutionId":"michigan-rogel","specialisms":["Breast radiotherapy","Health equity","Radiation oncology"],"profiles":[{"label":"Michigan Medicine","url":"https://medicine.umich.edu/dept/radiation-oncology"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Pierce%20LJ%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Lori%20J.%20Pierce"}],"papers":[{"title":"Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy","journal":"Breast Cancer Research and Treatment","year":2010,"url":"https://doi.org/10.1007/s10549-010-0894-z","doi":"10.1007/s10549-010-0894-z"},{"title":"Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer","journal":"Journal of Clinical Oncology","year":2006,"url":"https://doi.org/10.1200/JCO.2005.02.7888","doi":"10.1200/JCO.2005.02.7888"}]},{"id":"lori-wirth","kind":"person","name":"Lori J. Wirth","aka":[],"tldr":"Led LIBRETTO-001 in thyroid cancer, which made selpercatinib the first RET-selective drug approved for RET-driven tumours.","summary":"Lori Wirth led the thyroid cancer cohorts of LIBRETTO-001, showing selpercatinib produces high, durable response rates in RET-mutant medullary and RET fusion-positive thyroid cancer, and co-led LIBRETTO-531, which showed it beats cabozantinib or vandetanib first line. She also led trials of lenvatinib and immunotherapy in anaplastic and head and neck cancers and directs the head and neck cancer centre at MGH.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wirth%20LJ%5BAuthor%5D%20thyroid%20selpercatinib"}],"tags":["thyroid","ret","targeted-therapy"],"related":[],"cancers":["thyroid","head-and-neck"],"sections":[],"technologies":["kinase-inhibitors"],"targets":["ret"],"drugs":["selpercatinib"],"companies":[],"institutions":["mgh"],"pathways":[],"terms":[],"trials":["libretto-531"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Medical Director, Center for Head and Neck Cancers, Massachusetts General Hospital Cancer Center","institutionId":"mgh","specialisms":["Thyroid cancer","RET-targeted therapy","Head and neck cancer","Kinase inhibitors"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wirth%20LJ%5BAuthor%5D%20thyroid%20selpercatinib"}],"papers":[{"title":"Efficacy of selpercatinib in RET-altered thyroid cancers (LIBRETTO-001)","journal":"NEJM","year":2020,"doi":"10.1056/NEJMoa2005651"},{"title":"Selpercatinib in RET-mutant medullary thyroid cancer (LIBRETTO-531)","journal":"NEJM","year":2023,"doi":"10.1056/NEJMoa2309719"}]},{"id":"louis-chesler","kind":"person","name":"Louis Chesler","aka":[],"tldr":"Paediatric oncologist and neuroblastoma researcher who leads Children's Cancer Institute in Sydney, Australia's dedicated childhood cancer research institute.","summary":"Professor Louis Chesler is Executive Director of Children's Cancer Institute (CCI) in Sydney, which partners with the Sydney Children's Hospitals Network on paediatric oncology research and the Zero Childhood Cancer precision medicine programme. He is a paediatric oncologist whose laboratory research focuses on MYCN-driven neuroblastoma and paediatric brain tumours and on developing targeted therapies for children. He previously led paediatric solid tumour biology at The Institute of Cancer Research, London.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.ccia.org.au/about-cci/our-people"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chesler+L%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","paediatric oncology","neuroblastoma"],"related":[],"cancers":["neuroblastoma","medulloblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["sydney-childrens-hospitals-network"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Executive Director, Children's Cancer Institute","institutionId":"sydney-childrens-hospitals-network","specialisms":["Paediatric oncology","Neuroblastoma","Paediatric drug development"],"profiles":[{"label":"Institution profile","url":"https://www.ccia.org.au/about-cci/our-people"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chesler+L%5BAuthor%5D"}],"papers":[{"title":"Inhibition of Phosphatidylinositol 3-Kinase Destabilizes Mycn Protein and Blocks Malignant Progression in Neuroblastoma","journal":"Cancer Research","year":2006,"doi":"10.1158/0008-5472.can-05-2769"},{"title":"Small Molecule Inhibitors of Aurora-A Induce Proteasomal Degradation of N-Myc in Childhood Neuroblastoma","journal":"Cancer Cell","year":2013,"doi":"10.1016/j.ccr.2013.05.005"},{"title":"Targeting MYCN and ALK in resistant and relapsing neuroblastoma","journal":"Cancer Drug Resistance","year":2019,"doi":"10.20517/cdr.2019.009"}]},{"id":"louis-staudt","kind":"person","name":"Louis M. Staudt","aka":[],"tldr":"Louis Staudt defined the molecular subtypes of large B-cell lymphoma that guide targeted therapy.","summary":"Louis M. Staudt is Director of the Center for Cancer Genomics and Chief of the Lymphoid Malignancies Branch at the National Cancer Institute. He is known for defining the molecular subtypes of diffuse large B-cell lymphoma that guide targeted therapy, discovering the germinal-centre and activated B-cell subtypes and the chronic active B-cell receptor signalling that made BTK inhibitors work in lymphoma. His selected papers report distinct types of diffuse large B-cell lymphoma identified by gene expression profiling, and review the genetics and pathogenesis of the disease. He now directs NCI's cancer genomics centre.","asOf":"2026-09-08","links":[{"label":"NCI CCR profile","url":"https://ccr.cancer.gov/staff-directory/louis-m-staudt"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Staudt%20LM%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["dlbcl"],"sections":[],"technologies":["rna-seq"],"targets":["btk"],"drugs":[],"companies":[],"institutions":["nci"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Center for Cancer Genomics; Chief, Lymphoid Malignancies Branch","institutionId":"nci","specialisms":["Lymphoma genomics","Molecular subtypes of DLBCL","BTK signalling"],"profiles":[{"label":"NCI CCR profile","url":"https://ccr.cancer.gov/staff-directory/louis-m-staudt"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Staudt%20LM%5BAuthor%5D"}],"papers":[{"title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","journal":"Nature","year":2000,"url":"https://doi.org/10.1038/35000501","doi":"10.1038/35000501"},{"title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","journal":"New England Journal of Medicine","year":2018,"url":"https://doi.org/10.1056/NEJMoa1801445","doi":"10.1056/NEJMoa1801445"}]},{"id":"louise-emmett","kind":"person","name":"Louise Emmett","aka":[],"tldr":"Nuclear medicine physician who leads ENZA-p and the PSMA imaging trials shaping Australian theranostics.","summary":"Louise Emmett (St Vincent's Hospital, Sydney) was principal investigator of ENZA-p, the ANZUP trial showing that adding 177Lu-PSMA-617 to enzalutamide delays progression in castration-resistant prostate cancer, and led the PRIMARY study of PSMA PET for diagnosis. She co-leads the ANZUP theranostics programme and writes widely used guidance on PSMA PET reporting.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Emmett%20L%5BAuthor%5D%20PSMA"}],"tags":["prostate","radioligand","australia"],"related":[],"cancers":["prostate"],"sections":[],"technologies":["psma-pet","radioligand-therapy"],"targets":["psma"],"drugs":["pluvicto"],"companies":[],"institutions":["garvan-institute"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["european-urology"],"dependsOn":[],"notes":[],"role":"Director of Theranostics and Nuclear Medicine, St Vincent's Hospital Sydney; Professor, UNSW","institutionId":"garvan-institute","specialisms":["PSMA theranostics","Nuclear medicine","Prostate cancer imaging","Radioligand trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Emmett%20L%5BAuthor%5D%20PSMA"}],"papers":[{"title":"[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial","journal":"Lancet Oncology","year":2024},{"title":"The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (PRIMARY)","journal":"European Urology","year":2021,"doi":"10.1016/j.eururo.2021.08.002"}],"orcid":"0000-0002-4895-7384"},{"id":"luca-gianni","kind":"person","name":"Luca Gianni","aka":[],"tldr":"Milan oncologist who led NeoSphere, the trial that showed adding pertuzumab to trastuzumab and docetaxel before surgery clears more HER2-positive breast cancers, the basis for pertuzumab's neoadjuvant approval.","summary":"Luca Gianni led medical oncology at the Istituto Nazionale dei Tumori and then at San Raffaele Hospital in Milan, and now leads the Fondazione Michelangelo. He was first author of the 2012 Lancet Oncology report of NeoSphere, the phase 2 trial in which pertuzumab plus trastuzumab and docetaxel produced a higher pathological complete response rate than trastuzumab and docetaxel, and of the NOAH trial of neoadjuvant trastuzumab. His trials helped establish pathological complete response as an endpoint for accelerated approval.","asOf":"2026-09-18","links":[],"tags":["breast","neoadjuvant","trialist"],"related":[],"cancers":["her2-positive-early-breast-cancer","breast-her2-positive"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["fondazione-michelangelo"],"pathways":[],"terms":[],"trials":["neosphere"],"people":[],"bottlenecks":[],"keyPapers":["paper-luca-gianni-j-clin-oncol-2022","paper-luca-gianni-cancer-med-2023","paper-luca-gianni-j-natl-cancer-inst-2022"],"journals":[],"dependsOn":[],"notes":[],"role":"Medical oncologist and President, Fondazione Michelangelo, Milan","institutionId":"fondazione-michelangelo","specialisms":["HER2-positive breast cancer","Neoadjuvant therapy","Pathological complete response"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gianni%5BAuthor%5D"}],"papers":[{"title":"Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study","journal":"Journal of Clinical Oncology","year":2022,"url":"https://doi.org/10.1200/jco.21.00896","doi":"10.1200/jco.21.00896","note":"Europe PMC author record matched by affiliation (Fondazione Michelangelo); 68 citations on Europe PMC."},{"title":"Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma","journal":"Cancer medicine","year":2023,"url":"https://doi.org/10.1002/cam4.5893","doi":"10.1002/cam4.5893","note":"Europe PMC author record matched by affiliation (Fondazione Michelangelo); 50 citations on Europe PMC."},{"title":"Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Trastuzumab","journal":"JNCI: Journal of the National Cancer Institute","year":2022,"url":"https://doi.org/10.1093/jnci/djac126","doi":"10.1093/jnci/djac126","note":"Europe PMC author record matched by affiliation (Fondazione Michelangelo); 30 citations on Europe PMC."}],"orcid":"0000-0002-2372-9625"},{"id":"lucie-opatrny","kind":"person","name":"Lucie Opatrny","aka":[],"tldr":"Physician and hospital executive who is President and Executive Director of the McGill University Health Centre, the Montreal academic health network that includes the Cedars Cancer Centre.","summary":"Dr Lucie Opatrny is President and Executive Director of the McGill University Health Centre (MUHC), the Montreal academic health network whose cancer services are delivered through the Cedars Cancer Centre. The MUHC senior management page lists her at the head of a team that includes Associate President and Executive Director Colleen Timm, Associate Director General for Administration Caroline Dubé, Director of Medical and Professional Services Nicolas Gillot, Director of The Neuro Edward A. Fon and Director of Nursing Alain Biron. The page does not give an appointment date.","asOf":"2026-09-10","links":[{"label":"Source: MUHC senior management profiles page","url":"https://muhc.ca/corporate-leadership/senior-management-profiles"}],"tags":["leadership","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["muhc-cedars-cancer-centre"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President and Executive Director, McGill University Health Centre","institutionId":"muhc-cedars-cancer-centre","specialisms":["Hospital management","Internal medicine","Health system leadership"],"profiles":[{"label":"MUHC senior management profiles","url":"https://muhc.ca/corporate-leadership/senior-management-profiles"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Opatrny+L%5BAuthor%5D"}],"papers":[{"title":"Risk of thrombosis in patients with malignancy and heparin‐induced thrombocytopenia","journal":"American Journal of Hematology","year":2004,"doi":"10.1002/ajh.20098"},{"title":"Hormone replacement therapy use and variations in the risk of breast cancer","journal":"BJOG: An International Journal of Obstetrics & Gynaecology","year":2007,"doi":"10.1111/j.1471-0528.2007.01520.x"}],"orcid":"0009-0004-4982-9490"},{"id":"lucille-markey","kind":"person","name":"Lucille P. Markey","aka":[],"tldr":"In the late 1970s the owner of Calumet Farm approved a $1 million gift, the first of many, and in 1983 the Lucille Parker Markey Cancer Center was founded in her name in Lexington.","summary":"Lucille Parker Markey (1896-1982) owned Calumet Farm, the Thoroughbred breeding and training operation in Lexington whose horses won the Kentucky Derby eight times. The University of Kentucky's account records that in the late 1970s the Markey Cancer Foundation approached her and she approved a $1 million donation, the first of many gifts she would make, and that in 1983 the Lucille Parker Markey Cancer Center was founded. The centre serves Kentucky and central Appalachia, a region with some of the highest cancer incidence and mortality in the United States, and became an NCI-designated comprehensive cancer centre. After her death the Lucille P. Markey Charitable Trust spent its entire endowment on biomedical research within fifteen years, an unusual and studied decision in philanthropy.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Lucille_P._Markey","links":[{"label":"UK Markey Cancer Center: about","url":"https://ukhealthcare.uky.edu/markey-cancer-center/about"}],"tags":["hero","donor"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["kentucky-markey"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-funding-allocation","b-global-access"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Calumet Farm owner whose gifts founded the University of Kentucky Markey Cancer Center","specialisms":["Cancer centre founding","Appalachian cancer care"],"profiles":[],"papers":[]},{"id":"ludmil-alexandrov","kind":"person","name":"Ludmil B. Alexandrov","aka":[],"tldr":"Created the mathematical framework for extracting mutational signatures from cancer genomes and the COSMIC signature catalogue.","summary":"Ludmil Alexandrov developed the computational method that decomposes cancer genomes into mutational signatures and led the 2013 Nature analysis of 7,000 cancers and the 2020 Pan-Cancer Analysis of Whole Genomes catalogue, which together define the COSMIC signatures used to infer causes such as tobacco, UV and APOBEC. His laboratory studies signatures of environmental exposures and the origins of cancer in never-smokers.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Alexandrov%20LB%5BAuthor%5D%20mutational%20signatures"}],"tags":["genomics","mutational-signatures","computational"],"related":[],"cancers":[],"sections":[],"technologies":["wes-wgs"],"targets":[],"drugs":[],"companies":[],"institutions":["ucsd-moores"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-vogelstein-cancer-genome-landscapes-science-2013","paper-martincorena-somatic-mutations-normal-skin-science-2015"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Cellular and Molecular Medicine and Bioengineering, UC San Diego","institutionId":"ucsd-moores","specialisms":["Mutational signatures","Cancer genomics","Computational biology","Carcinogen exposure"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Alexandrov%20LB%5BAuthor%5D%20mutational%20signatures"}],"papers":[{"title":"Signatures of mutational processes in human cancer","journal":"Nature","year":2013,"doi":"10.1038/nature12477"},{"title":"The repertoire of mutational signatures in human cancer","journal":"Nature","year":2020,"doi":"10.1038/s41586-020-1943-3"},{"title":"Cancer genome landscapes: about 140 driver genes, and each tumour needs only a handful","journal":"Science","year":2013,"url":"https://doi.org/10.1126/science.1235122","doi":"10.1126/science.1235122"},{"title":"Martincorena: normal sun-exposed skin is a patchwork of cancer-mutation clones","journal":"Science","year":2015,"url":"https://doi.org/10.1126/science.aaa6806","doi":"10.1126/science.aaa6806"}]},{"id":"luigi-cajazzo","kind":"person","name":"Luigi Cajazzo","aka":[],"tldr":"Director general who runs ASST Spedali Civili di Brescia, the large public hospital trust in Lombardy whose Brescia campus hosts university oncology and haematology services.","summary":"Luigi Cajazzo is Direttore Generale of ASST Spedali Civili di Brescia, the Azienda Socio Sanitaria Territoriale that runs the Spedali Civili hospital in Brescia and its associated hospitals in Lombardy. The trust's 'Chi siamo' page lists him at the head of the direzione strategica together with Direttore Sanitario Frida Fagandini, Direttore Socio Sanitario Enrico Burato and Direttore Amministrativo Fabio Agrò. The trust's page describes the Direttore Generale as the legal representative appointed by the regional authority with responsibility for strategic and administrative direction; the Italian Wikipedia article on the hospital also names him in the role.","asOf":"2026-09-10","links":[{"label":"Source: ASST Spedali Civili di Brescia direzione strategica listing","url":"https://www.asst-spedalicivili.it/chi-siamo"}],"tags":["leadership","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["spedali-civili-brescia"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Direttore Generale, ASST Spedali Civili di Brescia","institutionId":"spedali-civili-brescia","specialisms":["Public hospital management","Health administration"],"profiles":[{"label":"ASST Spedali Civili 'Chi siamo' page","url":"https://www.asst-spedalicivili.it/chi-siamo"},{"label":"Direttore Generale page","url":"https://www.asst-spedalicivili.it/luigi-cajazzo-direttore-generale"}],"papers":[]},{"id":"luis-diaz","kind":"person","name":"Luis A. Diaz Jr.","aka":[],"tldr":"Co-led the work that made pembrolizumab the first tumour-agnostic cancer drug approval, for mismatch-repair-deficient tumours.","summary":"Trained at Johns Hopkins with Vogelstein and Kinzler, where he co-founded Personal Genome Diagnostics and helped establish circulating tumour DNA as a clinical tool. The 2015 and 2017 studies of PD-1 blockade in dMMR tumours led to the 2017 tissue-agnostic approval of pembrolizumab. At MSK he co-led the dostarlimab rectal cancer programme.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Diaz%20LA%20Jr%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["colorectal"],"sections":[],"technologies":["liquid-biopsy","checkpoint-inhibitor"],"targets":["pd1"],"drugs":["pembrolizumab","dostarlimab"],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Head, Division of Solid Tumor Oncology","institutionId":"mskcc","specialisms":["MSI-high / dMMR tumours","Immunotherapy","Liquid biopsy","Colorectal cancer"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Diaz%20LA%20Jr%5BAuthor%5D"}],"papers":[{"title":"PD-1 blockade in tumors with mismatch-repair deficiency","journal":"New England Journal of Medicine","year":2015,"url":"https://doi.org/10.1056/NEJMoa1500596","doi":"10.1056/NEJMoa1500596"},{"title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","journal":"Science","year":2017,"url":"https://doi.org/10.1126/science.aan6733","doi":"10.1126/science.aan6733"},{"title":"Cercek 2022: six months of dostarlimab alone made rectal cancer disappear in every patient with mismatch-repair deficiency","journal":"New England Journal of Medicine","year":2022,"url":"https://doi.org/10.1056/NEJMoa2201445","doi":"10.1056/NEJMoa2201445"},{"title":"KEYNOTE-177: pembrolizumab instead of chemotherapy as first treatment for mismatch-repair-deficient metastatic colorectal cancer","journal":"New England Journal of Medicine","year":2020,"url":"https://doi.org/10.1056/NEJMoa2017699","doi":"10.1056/NEJMoa2017699"}]},{"id":"luis-eduardo-martin-rodriguez","kind":"person","name":"Luis Eduardo Martín Rodríguez","aka":[],"tldr":"Physician who directs Cuba's Instituto Nacional de Oncología y Radiobiología in Havana, the country's lead institution for cancer treatment, research and training.","summary":"Dr Luis Eduardo Martín Rodríguez is Director of the Instituto de Oncología y Radiobiología (INOR) in the Plaza de la Revolución municipality of Havana, which the institute describes as the Ministry of Public Health's national reference centre (centro rector) for cancer treatment, research, training and the national cancer registry. Cubadebate named him as director on 4 June 2026, when the institute opened a new outpatient treatment unit for chemotherapy, immunotherapy and supportive care in the year of its 60th anniversary, and reported that he had hosted President Díaz-Canel's visit to the institute in February 2026. The institute's own website does not list its management, so the role was confirmed from the Cuban press.","asOf":"2026-09-10","links":[{"label":"Source: Cubadebate article on the opening of INOR's outpatient treatment unit (4 June 2026)","url":"http://www.cubadebate.cu/noticias/2026/06/04/inauguran-unidad-de-tratamiento-ambulatorio-de-oncologia-en-hospital-capitalino/"},{"label":"Source: INOR 'Quiénes somos' page (institution description)","url":"https://instituciones.sld.cu/inor/quienes-somos-2/"}],"tags":["leadership","clinician-scientist","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["inor-cuba"],"pathways":[],"terms":["chemotherapy-term","immunotherapy-term","palliative-treatment"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Instituto Nacional de Oncología y Radiobiología (INOR), Havana","institutionId":"inor-cuba","specialisms":["Oncology","Cancer care management"],"profiles":[{"label":"Cubadebate report naming him as director (June 2026)","url":"http://www.cubadebate.cu/noticias/2026/06/04/inauguran-unidad-de-tratamiento-ambulatorio-de-oncologia-en-hospital-capitalino/"}],"papers":[]},{"id":"luis-ibanez-gadea","kind":"person","name":"Luis Ibáñez Gadea","aka":[],"tldr":"Luis Ibáñez Gadea represents Hospital Universitario Doctor Peset in the Organisation of European Cancer Institutes, which lists the centre among its members in Spain.","summary":"Luis Ibáñez Gadea is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Hospital Universitario Doctor Peset, its member in Spain. Hospital Universitario Doctor Peset is a public university hospital of the Valencian health service, and a full member of the Organisation of European Cancer Institutes. OnCo records the name from the OECI membership list so that the centre's page has a named contact point; the person's exact title, appointment date and biography are not yet recorded and should be checked on the institution's own pages before being relied on.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Hospital Universitario Doctor Peset website","url":"https://doctorpeset.san.gva.es/es/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["doctor-peset-valencia"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Hospital Universitario Doctor Peset to the Organisation of European Cancer Institutes","institutionId":"doctor-peset-valencia","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Hospital Universitario Doctor Peset website","url":"https://doctorpeset.san.gva.es/es/"}],"papers":[]},{"id":"luis-paz-ares","kind":"person","name":"Luis Paz-Ares","aka":[],"tldr":"Madrid medical oncologist who heads the joint 12 de Octubre-CNIO lung cancer clinical research unit and led the KEYNOTE-407 trial in squamous lung cancer.","summary":"Luis Paz-Ares heads the H12O-CNIO Lung Cancer Clinical Research Unit, a joint unit of Hospital Universitario 12 de Octubre and the Spanish National Cancer Research Centre (CNIO), and leads medical oncology at 12 de Octubre. He was first author of the KEYNOTE-407 trial that established pembrolizumab plus chemotherapy as first-line treatment for squamous non-small-cell lung cancer. His work spans thoracic oncology and early-phase drug development.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.cnio.es/en/research/research-programmes/clinical-research-programme/h12o-cnio-lung-cancer-clinical-research-unit/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Paz-Ares+L%5BAuthor%5D"}],"tags":["clinician-scientist","lung cancer","immunotherapy"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["12-de-octubre"],"pathways":[],"terms":[],"trials":["caspian","dellphi-304"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Head of the H12O-CNIO Lung Cancer Clinical Research Unit","institutionId":"12-de-octubre","specialisms":["Lung cancer","Thoracic oncology","Early-phase clinical trials"],"profiles":[{"label":"Institution profile","url":"https://www.cnio.es/en/research/research-programmes/clinical-research-programme/h12o-cnio-lung-cancer-clinical-research-unit/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Paz-Ares+L%5BAuthor%5D"}],"papers":[{"title":"Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer","journal":"New England Journal of Medicine","year":2018,"url":"https://doi.org/10.1056/NEJMoa1810865","doi":"10.1056/NEJMoa1810865"}],"orcid":"0000-0002-1947-3364"},{"id":"lukas-b-been","kind":"person","name":"Lukas B. Been","aka":[],"tldr":"Lukas B. Been represents University Medical Center Groningen Comprehensive Cancer Center in the Organisation of European Cancer Institutes, which lists the centre among its members in The Netherlands.","summary":"Lukas B. Been is listed by the Organisation of European Cancer Institutes (OECI) as the representative of University Medical Center Groningen Comprehensive Cancer Center, its full member in The Netherlands. OnCo records the name from the OECI membership list so that the centre's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the institution's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"University Medical Center Groningen Comprehensive Cancer Center website","url":"https://www.umcg.nl"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["umcg-groningen"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of University Medical Center Groningen Comprehensive Cancer Center to the Organisation of European Cancer Institutes","institutionId":"umcg-groningen","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"University Medical Center Groningen Comprehensive Cancer Center website","url":"https://www.umcg.nl"}],"papers":[{"title":"[18F]FLT-PET in oncology: current status and opportunities","journal":"European Journal of Nuclear Medicine and Molecular Imaging","year":2004,"url":"https://doi.org/10.1007/s00259-004-1687-6","doi":"10.1007/s00259-004-1687-6","note":"OpenAlex author record matched by institution"},{"title":"Molecular fluorescence-guided surgery of peritoneal carcinomatosis of colorectal origin: a single-centre feasibility study","journal":"˜The œLancet. Gastroenterology & hepatology","year":2016,"url":"https://doi.org/10.1016/s2468-1253(16)30082-6","doi":"10.1016/s2468-1253(16)30082-6","note":"OpenAlex author record matched by institution"},{"title":"Exploiting metabolic acidosis in solid cancers using a tumor-agnostic pH-activatable nanoprobe for fluorescence-guided surgery","journal":"Nature Communications","year":2020,"url":"https://doi.org/10.1038/s41467-020-16814-4","doi":"10.1038/s41467-020-16814-4","note":"OpenAlex author record matched by institution"}]},{"id":"lyn-simpson","kind":"person","name":"Lyn Simpson","aka":[],"tldr":"Nurse-trained NHS executive who has been Group Chief Executive of NHS Humber Health Partnership, which runs the Queen's Centre at Castle Hill Hospital, since July 2025.","summary":"Lyn Simpson is Group Chief Executive of NHS Humber Health Partnership, the group formed by Hull University Teaching Hospitals NHS Trust and Northern Lincolnshire and Goole NHS Foundation Trust, whose hospitals include Castle Hill Hospital and its Queen's Centre for Oncology and Haematology. She took up the post in July 2025 on secondment from North Cumbria Integrated Care NHS Foundation Trust. She trained as a nurse, health visitor and midwife, has served as an executive board director since 1992, and her earlier roles include Executive Director of Patient Services at Newcastle Hospitals and national Director of NHS Operations at the Department of Health and NHS England. She works alongside Group Chair Alan Downey and Group Chief Medical Officer Kate Wood.","asOf":"2026-09-10","links":[{"label":"Source: NHS Humber Health Partnership group board page","url":"https://www.nlg.nhs.uk/about/how-we-are-run/board/"}],"tags":["leadership","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["queens-centre-hull"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Group Chief Executive, NHS Humber Health Partnership (Hull University Teaching Hospitals NHS Trust)","institutionId":"queens-centre-hull","specialisms":["Nursing","NHS operations","Hospital management"],"profiles":[{"label":"NHS Humber Health Partnership board page","url":"https://www.nlg.nhs.uk/about/how-we-are-run/board/"}],"papers":[]},{"id":"lynn-schuchter","kind":"person","name":"Lynn M. Schuchter","aka":[],"tldr":"Lynn Schuchter is a melanoma oncologist who led ASCO in 2023-24.","summary":"Lynn Schuchter is Chief of Hematology-Oncology at the University of Pennsylvania, within the Abramson Cancer Center, and served as President of the American Society of Clinical Oncology (ASCO) for 2023 to 2024. A medical oncologist specialising in melanoma and immunotherapy, her work includes adjuvant immunotherapy and targeted therapy trials. Her papers include a Journal of Clinical Oncology editorial weighing the dose of adjuvant interferon therapy for melanoma and an Annals of Internal Medicine prognostic model for patients with primary melanoma from the Pigmented Lesion Group. She combines melanoma clinical research with professional leadership.","asOf":"2026-09-08","links":[{"label":"ASCO leadership","url":"https://www.asco.org/about-asco/asco-leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schuchter%20LM%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Lynn%20M.%20Schuchter"}],"tags":[],"related":[],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["asco","penn-abramson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["annals-internal-medicine"],"dependsOn":[],"notes":[],"role":"ASCO President 2023-2024; Chief, Hematology-Oncology, University of Pennsylvania","institutionId":"asco","specialisms":["Melanoma","Immunotherapy","Professional leadership"],"profiles":[{"label":"ASCO leadership","url":"https://www.asco.org/about-asco/asco-leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schuchter%20LM%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Lynn%20M.%20Schuchter"}],"papers":[{"title":"Adjuvant Interferon Therapy for Melanoma: High-Dose, Low-Dose, No Dose, Which Dose?","journal":"Journal of Clinical Oncology","year":2004,"url":"https://doi.org/10.1200/jco.2004.10.907","doi":"10.1200/jco.2004.10.907"},{"title":"A prognostic model for predicting 10-year survival in patients with primary melanoma. The Pigmented Lesion Group","journal":"Annals of Internal Medicine","year":1996,"url":"https://doi.org/10.7326/0003-4819-125-5-199609010-00003","doi":"10.7326/0003-4819-125-5-199609010-00003"}]},{"id":"madeline-bell","kind":"person","name":"Madeline Bell","aka":[],"tldr":"Chief Executive Officer of Children's Hospital of Philadelphia, one of the world's leading paediatric hospitals and a major centre for childhood cancer care and research.","summary":"Madeline Bell is Chief Executive Officer of Children's Hospital of Philadelphia (CHOP), a health system with annual revenues of about five billion dollars. A nurse by training, she has led CHOP since 2015 and oversees its clinical, research and educational enterprise. CHOP's Cancer Center is among the largest paediatric oncology programmes in the United States and a pioneer of CAR T-cell therapy for childhood leukaemia.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.chop.edu/about-us/executive-leadership"}],"tags":["leadership","paediatrics"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["chop"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive Officer","institutionId":"chop","specialisms":["Paediatric health system leadership","Nursing","Hospital operations"],"profiles":[{"label":"Institution profile","url":"https://www.chop.edu/about-us/executive-leadership"}],"papers":[]},{"id":"maeve-lowery","kind":"person","name":"Maeve Lowery","aka":[],"tldr":"Maeve Lowery represents Trinity St James's Cancer Institute in the Organisation of European Cancer Institutes, which lists the centre among its members in Ireland.","summary":"Maeve Lowery is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Trinity St James's Cancer Institute, its member in Ireland. Ireland's first OECI-accredited Comprehensive Cancer Centre, a partnership between St James's Hospital and Trinity College Dublin. OnCo records the name from the OECI membership list so that the centre's page has a named contact point; the person's exact title, appointment date and biography are not yet recorded and should be checked on the institution's own pages before being relied on.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Trinity St James's Cancer Institute website","url":"http://www.stjames.ie/cancer"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["trinity-st-jamess-cancer-institute"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Trinity St James's Cancer Institute to the Organisation of European Cancer Institutes","institutionId":"trinity-st-jamess-cancer-institute","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Trinity St James's Cancer Institute website","url":"http://www.stjames.ie/cancer"}],"papers":[{"title":"OncoKB: A Precision Oncology Knowledge Base","journal":"JCO Precis Oncol","year":2017,"url":"https://doi.org/10.1200/po.17.00011","doi":"10.1200/po.17.00011","note":"Europe PMC author record matched by affiliation"},{"title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","journal":"Lancet Oncol","year":2020,"url":"https://doi.org/10.1016/s1470-2045(20)30157-1","doi":"10.1016/s1470-2045(20)30157-1","note":"Europe PMC author record matched by affiliation"},{"title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","journal":"Lancet Oncol","year":2023,"url":"https://doi.org/10.1016/s1470-2045(23)00515-6","doi":"10.1016/s1470-2045(23)00515-6","note":"Europe PMC author record matched by affiliation"}],"orcid":"0000-0003-1354-7606"},{"id":"mafalda-oliveira","kind":"person","name":"Mafalda Oliveira","aka":[],"tldr":"Barcelona breast oncologist who leads SOLTI, the Spanish academic breast cancer research group, and co-authors pivotal endocrine therapy trials.","summary":"Mafalda Oliveira is President of SOLTI Cancer Research Group, the Spanish academic cooperative group focused on breast cancer clinical and translational research. A medical oncologist at Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology in Barcelona, she has been an investigator on major trials of novel endocrine and targeted agents in hormone receptor-positive breast cancer, including CAPItello-291 and SERENA-2. Her role is listed on SOLTI's board page.","asOf":"2026-09-10","links":[{"label":"Society page","url":"https://www.gruposolti.org/junta-directiva/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Oliveira+M%5BAuthor%5D+AND+SOLTI"}],"tags":["leadership","clinician-scientist","breast cancer","clinical trials"],"related":[],"cancers":["breast-hr-positive"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["solti"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President (Presidenta)","institutionId":"solti","specialisms":["Breast cancer","Medical oncology","Endocrine therapy","Clinical trials"],"profiles":[{"label":"Society page","url":"https://www.gruposolti.org/junta-directiva/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Oliveira+M%5BAuthor%5D+AND+SOLTI"}],"papers":[{"title":"Capivasertib and fulvestrant for hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291)","journal":"Lancet Oncology","year":2024,"url":"https://doi.org/10.1016/S1470-2045(24)00373-5","doi":"10.1016/S1470-2045(24)00373-5"},{"title":"Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2)","journal":"Lancet Oncology","year":2024,"url":"https://doi.org/10.1016/S1470-2045(24)00387-5","doi":"10.1016/S1470-2045(24)00387-5"}],"orcid":"0000-0001-9152-8799"},{"id":"magdolna-dank","kind":"person","name":"Magdolna Dank","aka":[],"tldr":"Hungarian oncologist who is Director-General of the National Institute of Oncology in Budapest, Hungary's national cancer centre.","summary":"Professor Magdolna Dank is Director-General and Chief Physician (Foigazgato Foorvos) of the National Institute of Oncology (Orszagos Onkologiai Intezet) in Budapest, Hungary's national comprehensive cancer centre. She heads a directorate that includes a medical director, a scientific director and a nursing director. Her welcome message on the institute's home page introduces her in the role of Director-General.","asOf":"2026-09-10","links":[{"label":"Source: National Institute of Oncology directors page","url":"https://onkol.hu/igazgatok/"}],"tags":["leadership","clinician-scientist","medical-oncology"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["noi-budapest"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["lancet-oncology","nature-communications"],"dependsOn":[],"notes":[],"role":"Director-General and Chief Physician, National Institute of Oncology, Budapest","institutionId":"noi-budapest","specialisms":["Clinical oncology","Medical oncology","Cancer centre management"],"profiles":[{"label":"Institute directors page","url":"https://onkol.hu/igazgatok/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dank+M%5BAuthor%5D"}],"papers":[{"title":"Are Calculated Immune Markers with or Without Comorbidities Good Predictors of Colorectal Cancer Survival? The Results of a Longitudinal Study","journal":"Medical Sciences","year":2025,"doi":"10.3390/medsci13030108"},{"title":"Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial","journal":"The Lancet Oncology","year":2016,"doi":"10.1016/s1470-2045(16)30154-1"},{"title":"Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations","journal":"Nature Communications","year":2017,"doi":"10.1038/ncomms14944"}]},{"id":"maha-hussain","kind":"person","name":"Maha Hussain","aka":[],"tldr":"Led PROSPER and the PROfound survival analysis, and settled the intermittent hormone therapy question with SWOG 9346.","summary":"Maha Hussain led SWOG 9346, the trial that showed intermittent androgen deprivation is not non-inferior to continuous therapy in metastatic prostate cancer, and was principal investigator of PROSPER (enzalutamide in non-metastatic CRPC) and first author of the PROfound overall survival report establishing olaparib in HRR-mutant disease. She chairs the SWOG GU committee's prostate programme.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Maha_H._Hussain","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hussain%20M%5BAuthor%5D%20prostate%20olaparib%20OR%20enzalutamide"}],"tags":["prostate","swog","parp"],"related":[],"cancers":["prostate"],"sections":[],"technologies":["parp-inhibitor","androgen-deprivation"],"targets":["parp","brca","androgen-receptor"],"drugs":["olaparib"],"companies":[],"institutions":["northwestern-lurie"],"pathways":[],"terms":[],"trials":["profound"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Genevieve E. Teuton Professor of Medicine and Deputy Director, Robert H. Lurie Comprehensive Cancer Center of Northwestern University","institutionId":"northwestern-lurie","specialisms":["Prostate cancer","PARP inhibitors","Androgen deprivation strategies","Cooperative-group trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hussain%20M%5BAuthor%5D%20prostate%20olaparib%20OR%20enzalutamide"}],"papers":[{"title":"Survival with olaparib in metastatic castration-resistant prostate cancer (PROfound)","journal":"NEJM","year":2020,"doi":"10.1056/NEJMoa2022485"},{"title":"Intermittent versus continuous androgen deprivation in prostate cancer (SWOG 9346)","journal":"NEJM","year":2013,"doi":"10.1056/NEJMoa1212299"},{"title":"PROSPER: enzalutamide in men with non-metastatic castration-resistant prostate cancer","journal":"New England Journal of Medicine","year":2018,"url":"https://doi.org/10.1056/NEJMoa1800536","doi":"10.1056/NEJMoa1800536"}],"orcid":"0000-0003-0380-9465"},{"id":"mahesh-parmar","kind":"person","name":"Mahesh K. B. Parmar","aka":[],"tldr":"Statistician who invented the multi-arm multi-stage design behind STAMPEDE, letting one trial test many treatments at once.","summary":"Mahesh Parmar developed the multi-arm multi-stage (MAMS) platform trial design and applied it in STAMPEDE, which tested ten treatment approaches for advanced prostate cancer in a single trial and established docetaxel and abiraterone as standards. He directs the MRC Clinical Trials Unit at UCL, which runs trials across cancer, HIV and tuberculosis, and has led methodological work on adaptive designs and meta-analysis.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Parmar%20MKB%5BAuthor%5D%20multi-arm%20multi-stage"}],"tags":["biostatistics","trial-design","platform-trials"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["uclh"],"pathways":[],"terms":[],"trials":["stampede"],"people":[],"bottlenecks":[],"keyPapers":["paper-stampede-abiraterone-nejm-2017"],"journals":[],"dependsOn":[],"notes":[],"role":"Director, MRC Clinical Trials Unit at UCL; Professor of Medical Statistics and Epidemiology","institutionId":"uclh","specialisms":["Multi-arm multi-stage trial design","Prostate cancer trials","Biostatistics","Trial methodology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Parmar%20MKB%5BAuthor%5D%20multi-arm%20multi-stage"}],"papers":[{"title":"Speeding up the evaluation of new agents in cancer","journal":"JNCI","year":2008,"doi":"10.1093/jnci/djn267"},{"title":"Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol","journal":"Annals of Oncology","year":2018,"doi":"10.1093/annonc/mdy072"},{"title":"STAMPEDE: adding abiraterone to hormone therapy at diagnosis of advanced prostate cancer","journal":"New England Journal of Medicine","year":2017,"url":"https://doi.org/10.1056/NEJMoa1702900","doi":"10.1056/NEJMoa1702900"}],"orcid":"0000-0003-0166-1700"},{"id":"maike-sander","kind":"person","name":"Maike Sander","aka":[],"tldr":"Stem-cell and pancreas biologist who has led the Max Delbrück Center as Scientific Director since November 2022.","summary":"Maike Sander is Scientific Director and Chair of the Board of the Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin. Her research uses stem-cell-derived pancreatic islet organoids and organ-on-chip systems to understand beta-cell development and failure in diabetes. As head of the MDC she oversees its molecular medicine portfolio, including its cancer research programmes.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.mdc-berlin.de/maike-sander"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sander+M%5BAuthor%5D+pancreas"}],"tags":["leadership","stem cells","molecular medicine"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["mdc-berlin"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nature"],"dependsOn":[],"notes":[],"role":"Scientific Director and Chair of the Board","institutionId":"mdc-berlin","specialisms":["Stem cell biology","Pancreatic islet biology","Organoid models","Research leadership"],"profiles":[{"label":"Institution profile","url":"https://www.mdc-berlin.de/maike-sander"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sander+M%5BAuthor%5D+pancreas"}],"papers":[{"title":"Loss of Pten and Activation of Kras Synergistically Induce Formation of Intraductal Papillary Mucinous Neoplasia From Pancreatic Ductal Cells in Mice","journal":"Gastroenterology","year":2018,"doi":"10.1053/j.gastro.2017.12.007"},{"title":"Image-based detection and targeting of therapy resistance in pancreatic adenocarcinoma","journal":"Nature","year":2016,"doi":"10.1038/nature17988"}],"orcid":"0000-0001-5308-7785"},{"id":"mairead-mcnamara","kind":"person","name":"Mairéad McNamara","aka":[],"tldr":"Leads biliary tract cancer trials at The Christie, the Manchester centre behind the ABC trial series, and is a member of the international biliary trial collaborations.","summary":"Mairéad McNamara is a senior lecturer in medical oncology at the University of Manchester and honorary consultant at The Christie, where she treats hepato-pancreato-biliary and neuroendocrine cancers and leads biliary tract cancer trials with colleagues in the Manchester group that ran the ABC series. She is a member of the International Biliary Tract Cancer Collaborators and the International Cholangiocarcinoma Research Network and co-authored ABC-06.","asOf":"2026-09-24","links":[{"label":"University of Manchester Research Explorer","url":"https://research.manchester.ac.uk/en/persons/mairead.mcnamara/"},{"label":"The Christie consultant page","url":"https://www.christie.nhs.uk/your-treatment-and-care/find-your-consultant/mcnamara-mairead"}],"tags":["biliary","trialist","uk"],"related":[],"cancers":["gallbladder","biliary-tract-cancer","cholangiocarcinoma","neuroendocrine"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["the-christie"],"pathways":[],"terms":[],"trials":["abc-06"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Senior Lecturer in Medical Oncology, University of Manchester; Honorary Consultant, The Christie","institutionId":"the-christie","specialisms":["Biliary tract cancer","Hepato-pancreato-biliary cancers","Neuroendocrine neoplasms","Clinical trials"],"profiles":[{"label":"University of Manchester Research Explorer","url":"https://research.manchester.ac.uk/en/persons/mairead.mcnamara/"},{"label":"The Christie consultant page","url":"https://www.christie.nhs.uk/your-treatment-and-care/find-your-consultant/mcnamara-mairead"}],"papers":[{"title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06)","journal":"Lancet Oncology","year":2021,"doi":"10.1016/S1470-2045(21)00027-9"}]},{"id":"majid-alfayyadh","kind":"person","name":"Majid Ibrahim Alfayyadh","aka":[],"tldr":"Physician and CEO of King Faisal Specialist Hospital and Research Centre, Saudi Arabia's flagship tertiary and oncology referral centre.","summary":"Majid Ibrahim Alfayyadh is Chief Executive Officer of King Faisal Specialist Hospital and Research Centre (KFSHRC), which operates major oncology centres in Riyadh, Jeddah and Madinah. Trained in paediatric cardiology, he has led the institution's corporatisation and its drive to become a leading academic medical centre in the region.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Alfayyadh+M%5BAuthor%5D"}],"tags":["leadership","hospital management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["kfshrc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive Officer","institutionId":"kfshrc","specialisms":["Paediatric cardiology","Hospital leadership","Health system transformation"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Alfayyadh+M%5BAuthor%5D"}],"papers":[]},{"id":"malachi-griffith","kind":"person","name":"Malachi Griffith","aka":[],"tldr":"Co-created CIViC, the open database of what cancer mutations mean, and the pVACtools neoantigen pipeline.","summary":"Malachi Griffith is Associate Professor of Medicine and Genetics and Assistant Director of the McDonnell Genome Institute at Siteman Cancer Center, Washington University. With Obi Griffith he co-created CIViC, the open community database of what cancer mutations mean, and the pVACtools neoantigen prediction pipeline. His selected paper describes CIViC as a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer. He now designs personalised neoantigen vaccine trials at WashU and continues to work on clinical genomics.","asOf":"2026-09-08","links":[{"label":"Griffith lab","url":"https://griffithlab.org"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Griffith%20M%5BAuthor%5D"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["cgp","neoantigen-mrna-vaccine"],"targets":[],"drugs":[],"companies":[],"institutions":["wustl-siteman"],"pathways":[],"terms":["neoantigen"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nature-genetics"],"dependsOn":[],"notes":[],"role":"Associate Professor of Medicine and Genetics; Assistant Director, McDonnell Genome Institute","institutionId":"wustl-siteman","specialisms":["Clinical genomics","CIViC knowledge base","Neoantigen prediction"],"profiles":[{"label":"Griffith lab","url":"https://griffithlab.org"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Griffith%20M%5BAuthor%5D"}],"papers":[{"title":"CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer","journal":"Nature Genetics","year":2017,"url":"https://doi.org/10.1038/ng.3774","doi":"10.1038/ng.3774"}]},{"id":"maneesha-inamdar","kind":"person","name":"Maneesha S Inamdar","aka":[],"tldr":"Stem cell biologist who directs BRIC-inStem in Bengaluru, India's national institute for stem cell science and regenerative medicine.","summary":"Professor Maneesha S Inamdar is Director of the Institute for Stem Cell Science and Regenerative Medicine (BRIC-inStem), the Bengaluru institute under India's Biotechnology Research and Innovation Council that describes itself as the country's premier hub for stem cell science and regenerative medicine, working under the motto 'Without Barriers; Across Disciplines'. In her Director's note for 2024 to 2025 she highlights a new BSL-3 facility under the National One Health Mission, the flagship ESCORT and WoRtH programmes, the launch of CReATE for embryology research, a myogenesis experiment flown on the International Space Station during the Axiom-4 mission, completion by the Centre for Stem Cell Research of India's first gene therapy trial for haemophilia A, and the commercialisation of the Kisan Kavach anti-pesticide bodysuit through the spin-off Sepio Health.","asOf":"2026-09-10","links":[{"label":"Source: inStem Director's note","url":"https://instem.res.in/directors-message/"}],"tags":["leadership","research-institute"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["instem"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["pnas"],"dependsOn":[],"notes":[],"role":"Director, Institute for Stem Cell Science and Regenerative Medicine (BRIC-inStem)","institutionId":"instem","specialisms":["Stem cell science","Regenerative medicine","Research institute leadership"],"profiles":[{"label":"inStem Director's note","url":"https://instem.res.in/directors-message/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Inamdar+MS%5BAuthor%5D"}],"papers":[{"title":"ISSCR standards for the use of human stem cells in basic research","journal":"Stem Cell Reports","year":2023,"url":"https://doi.org/10.1016/j.stemcr.2023.08.003","doi":"10.1016/j.stemcr.2023.08.003","note":"Europe PMC author record matched by affiliation"},{"title":"Conserved regulation of the Jak/STAT pathway by the endosomal protein asrij maintains stem cell potency","journal":"Cell Reports","year":2013,"url":"https://doi.org/10.1016/j.celrep.2013.07.029","doi":"10.1016/j.celrep.2013.07.029","note":"Europe PMC author record matched by affiliation"},{"title":"ARF1-GTP regulates Asrij to provide endocytic control of Drosophila blood cell homeostasis","journal":"PNAS","year":2014,"url":"https://doi.org/10.1073/pnas.1303559111","doi":"10.1073/pnas.1303559111","note":"Europe PMC author record matched by affiliation"}]},{"id":"manish-shah","kind":"person","name":"Manish A. Shah","aka":[],"tldr":"New York oncologist who was lead author of GLOW, one of the two trials that established zolbetuximab, the first drug aimed at claudin 18.2, for stomach cancer.","summary":"Manish Shah leads gastrointestinal oncology at Weill Cornell Medicine in New York. He was first author of the 2023 Nature Medicine report of GLOW, in which zolbetuximab plus CAPOX lengthened progression-free and overall survival in claudin 18.2-positive, HER2-negative advanced gastric or gastro-oesophageal junction adenocarcinoma. His research covers the molecular classification of gastric cancer and its differences between Asian and Western patients.","asOf":"2026-09-18","links":[],"tags":["gastric","trialist"],"related":[],"cancers":["gastric-cldn18-2-positive","gastric"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["weill-cornell-meyer-cancer-center"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-glow-zolbetuximab-nat-med-2023"],"journals":[],"dependsOn":[],"notes":[],"role":"Gastrointestinal medical oncologist, Weill Cornell Medicine","institutionId":"weill-cornell-meyer-cancer-center","specialisms":["Gastric cancer","Claudin 18.2","Molecular subtypes of gastric cancer"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Shah%5BAuthor%5D"}],"papers":[{"title":"GLOW: zolbetuximab plus CAPOX in claudin 18.2-positive, HER2-negative gastric or gastro-oesophageal junction adenocarcinoma","journal":"Nature Medicine","year":2023,"url":"https://doi.org/10.1038/s41591-023-02465-7","doi":"10.1038/s41591-023-02465-7"}],"orcid":"0000-0002-6913-9655"},{"id":"mansoor-raza-mirza","kind":"person","name":"Mansoor Raza Mirza","aka":[],"tldr":"Led NOVA and RUBY, the trials that established niraparib maintenance in ovarian cancer and dostarlimab in advanced endometrial cancer.","summary":"Mansoor Raza Mirza was principal investigator of NOVA, the first trial showing PARP inhibitor maintenance (niraparib) benefits recurrent ovarian cancer regardless of BRCA status, and of RUBY, which showed dostarlimab plus chemotherapy improves survival in primary advanced or recurrent endometrial cancer, most dramatically in mismatch repair-deficient disease. He chairs ENGOT and leads the Nordic Society of Gynaecological Oncology trial unit.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mirza%20MR%5BAuthor%5D%20niraparib%20OR%20dostarlimab"}],"tags":["endometrial","ovarian","trialist"],"related":[],"cancers":["endometrial","ovarian"],"sections":[],"technologies":["parp-inhibitor","checkpoint-inhibitor"],"targets":["parp","pd1"],"drugs":["niraparib","dostarlimab"],"companies":["nordic-lymphoma-group"],"institutions":["rigshospitalet"],"pathways":[],"terms":[],"trials":["ruby"],"people":[],"bottlenecks":[],"keyPapers":["paper-ruby-nejm-2023"],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Oncologist, Rigshospitalet, Copenhagen University Hospital; Chair, ENGOT","institutionId":"rigshospitalet","specialisms":["Endometrial cancer","Ovarian cancer","PARP inhibitors","Immunotherapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mirza%20MR%5BAuthor%5D%20niraparib%20OR%20dostarlimab"}],"papers":[{"title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer (NOVA)","journal":"NEJM","year":2016,"doi":"10.1056/NEJMoa1611310"},{"title":"Dostarlimab for primary advanced or recurrent endometrial cancer (RUBY)","journal":"NEJM","year":2023,"doi":"10.1056/NEJMoa2216334"}],"orcid":"0000-0002-8085-1010"},{"id":"manuel-llombart-fuertes","kind":"person","name":"Manuel Llombart Fuertes","aka":[],"tldr":"Manuel Llombart Fuertes represents Fundación Instituto Valenciano de Oncología (IVO) in the Organisation of European Cancer Institutes, which lists the centre among its members in Spain.","summary":"Manuel Llombart Fuertes is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Fundación Instituto Valenciano de Oncología (IVO), its full member in Spain. OnCo records the name from the OECI membership list so that the centre's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the institution's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Fundación Instituto Valenciano de Oncología (IVO) website","url":"https://www.ivo.es"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ivo-valencia"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Fundación Instituto Valenciano de Oncología (IVO) to the Organisation of European Cancer Institutes","institutionId":"ivo-valencia","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Fundación Instituto Valenciano de Oncología (IVO) website","url":"https://www.ivo.es"}],"papers":[]},{"id":"marc-besselink","kind":"person","name":"Marc G. Besselink","aka":[],"tldr":"Dutch surgeon who leads the PREOPANC trials testing chemotherapy or chemoradiation before pancreatic cancer surgery.","summary":"Marc Besselink (Amsterdam UMC) leads the Dutch Pancreatic Cancer Group and was senior investigator of PREOPANC, the randomised trial showing neoadjuvant chemoradiotherapy improves long-term survival in resectable and borderline resectable pancreatic cancer, and of PREOPANC-2 comparing neoadjuvant FOLFIRINOX. He has led the DIPLOMA and LEOPARD trials of minimally invasive pancreatic surgery.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Besselink%20MG%5BAuthor%5D%20pancreatic%20PREOPANC"}],"tags":["pancreatic","surgery","neoadjuvant"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":["robotic-surgery"],"targets":[],"drugs":[],"companies":[],"institutions":["amsterdam-umc"],"pathways":[],"terms":[],"trials":["preopanc"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Pancreatic and Hepatobiliary Surgery, Amsterdam UMC","institutionId":"amsterdam-umc","specialisms":["Pancreatic surgery","Neoadjuvant therapy","Minimally invasive pancreatectomy","Surgical trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Besselink%20MG%5BAuthor%5D%20pancreatic%20PREOPANC"}],"papers":[{"title":"Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC trial","journal":"JCO","year":2020,"doi":"10.1200/JCO.19.02274"},{"title":"Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial","journal":"JCO","year":2022,"doi":"10.1200/JCO.21.02233"}],"orcid":"0000-0003-2650-9350"},{"id":"marc-raaijmakers","kind":"person","name":"Marc H.G.P. Raaijmakers","aka":[],"tldr":"Erasmus MC haematologist and HOVON Vice Chair known for research on the bone marrow microenvironment in MDS.","summary":"Marc H.G.P. Raaijmakers is Vice Chair of the HOVON Board and a professor of haematology at Erasmus MC in Rotterdam. His laboratory studies how the bone marrow microenvironment contributes to myelodysplastic syndromes and leukaemia. He combines clinical haematology with translational research and cooperative-group leadership.","asOf":"2026-09-10","links":[{"label":"Society page","url":"https://hovon.nl/en/about-hovon"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Raaijmakers+MHGP%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","haematology","MDS"],"related":[],"cancers":["mds","aml"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["hovon"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Vice Chair","institutionId":"hovon","specialisms":["Myelodysplastic syndromes","Bone marrow niche biology","Haematology"],"profiles":[{"label":"Society page","url":"https://hovon.nl/en/about-hovon"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Raaijmakers+MHGP%5BAuthor%5D"}],"papers":[{"title":"Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia","journal":"Nature","year":2010,"doi":"10.1038/nature08851"},{"title":"Myelodysplastic syndromes: revisiting the role of the bone marrow microenvironment in disease pathogenesis","journal":"International Journal of Hematology","year":2012,"doi":"10.1007/s12185-011-1001-x"},{"title":"Deconstructing Niche Contributions to Bone Marrow Failure and Leukemogenesis in Shwachman-Diamond Syndrome","journal":"Blood","year":2017,"doi":"10.1182/blood.v130.suppl_1.sci-24.sci-24"}]},{"id":"marc-lustgarten","kind":"person","name":"Marc Lustgarten","aka":[],"tldr":"Diagnosed with pancreatic cancer in 1998 at 51, he set up a foundation that awarded ten $100,000 grants in its first year and became the largest private funder of pancreatic cancer research; he died in 1999.","summary":"Marc Lustgarten (1947-1999), vice chairman of Cablevision, was diagnosed with pancreatic cancer in 1998 at the age of 51. The Foundation's own account records that pancreatic cancer was then considered an orphan disease with very little research money and virtually no long-term treatment options, and that in its first year the Foundation awarded ten $100,000 grants totalling $1 million. Before he died in 1999 his vision for the Lustgarten Foundation was, in its words, well underway, supported by Cablevision's founder Charles Dolan and chief executive James Dolan. The Foundation states that its support of pancreatic cancer research helped stimulate the National Cancer Institute to increase its own pancreatic cancer funding to more than $182.1 million in 2018. It funds early detection, organoid and immunotherapy research, much of it at Cold Spring Harbor Laboratory.","asOf":"2026-09-10","links":[{"label":"Lustgarten Foundation: the Lustgarten story","url":"https://lustgarten.org/leadership/story/"}],"tags":["hero","donor","patient"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["lustgarten-foundation","cold-spring-harbor"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-funding-allocation","b-rare-cancers","b-early-detection"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Cablevision executive whose pancreatic cancer diagnosis launched the Lustgarten Foundation","specialisms":["Pancreatic cancer research funding","Patient-founded foundations"],"profiles":[],"papers":[]},{"id":"marc-ychou","kind":"person","name":"Marc Ychou","aka":[],"tldr":"Medical oncologist who is Director General of the Institut du Cancer de Montpellier, the reference cancer centre for eastern Occitanie founded in 1923.","summary":"Professor Marc Ychou is Directeur Général of the Institut du Cancer de Montpellier (ICM), the Centre de Lutte Contre le Cancer of reference for Occitanie Est and a member of the Unicancer network; founded in 1923, it is one of the oldest French cancer centres and runs radiotherapy, medical oncology, surgery and nuclear medicine departments. The ICM governance page names him as Directeur Général working with Laetitia Brini as Directrice Générale Adjointe, with Chantal Mauchet, Préfète de l'Hérault, presiding over the Conseil d'Administration and Dr Fabienne Portalès presiding over the Conférence Médicale d'Établissement. The page gives no appointment date.","asOf":"2026-09-10","links":[{"label":"Source: ICM governance page","url":"https://www.icm.unicancer.fr/fr/linstitut-du-cancer-de-montpellier/decouvrir-licm/gouvernance"}],"tags":["leadership","clinician-scientist","comprehensive-cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["icm-montpellier"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["jco","annals-of-oncology"],"dependsOn":[],"notes":[],"role":"Directeur Général (Director General), Institut du Cancer de Montpellier","institutionId":"icm-montpellier","specialisms":["Medical oncology","Digestive oncology","Cancer centre management"],"profiles":[{"label":"ICM governance page","url":"https://www.icm.unicancer.fr/fr/linstitut-du-cancer-de-montpellier/decouvrir-licm/gouvernance"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ychou+M%5BAuthor%5D"}],"papers":[{"title":"Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial","journal":"Journal of Clinical Oncology","year":2011,"doi":"10.1200/jco.2010.33.0597"},{"title":"A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer","journal":"Annals of Oncology","year":2009,"doi":"10.1093/annonc/mdp236"},{"title":"A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802)","journal":"Annals of Oncology","year":2009,"doi":"10.1093/annonc/mdn680"}]},{"id":"marcela-maus","kind":"person","name":"Marcela V. Maus","aka":[],"tldr":"Cell therapy engineer whose CAR-TEAM cells produced rapid regressions of recurrent glioblastoma.","summary":"Marcela Maus leads a laboratory that engineers CAR T cells to overcome the barriers of solid tumours, including the CARv3-TEAM-E cells that secrete a T-cell-engaging antibody against EGFR and produced dramatic, if transient, radiographic regressions in recurrent glioblastoma in a 2024 first-in-human trial. She previously led the first EGFRvIII CAR-T trial at Penn and directs cellular immunotherapy at MGH.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Maus%20MV%5BAuthor%5D%20CAR%20T%20glioblastoma"}],"tags":["cell-therapy","car-t","solid-tumours"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":["car-t","armored-car"],"targets":["egfr"],"drugs":[],"companies":[],"institutions":["mgh"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["science-translational-medicine"],"dependsOn":[],"notes":[],"role":"Director, Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center; Professor, Harvard Medical School","institutionId":"mgh","specialisms":["CAR T-cell therapy","Solid tumour cell therapy","Glioblastoma","CAR engineering"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Maus%20MV%5BAuthor%5D%20CAR%20T%20glioblastoma"}],"papers":[{"title":"Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma","journal":"NEJM","year":2024,"doi":"10.1056/NEJMoa2314390"},{"title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","journal":"Science Translational Medicine","year":2017,"doi":"10.1126/scitranslmed.aaa0984"}]},{"id":"marcia-brose","kind":"person","name":"Marcia S. Brose","aka":[],"tldr":"Led DECISION, the trial that made sorafenib the first approved targeted drug for radioiodine-refractory thyroid cancer.","summary":"Marcia Brose was principal investigator of DECISION, the phase 3 trial that showed sorafenib doubles progression-free survival in radioiodine-refractory differentiated thyroid cancer and became the first targeted therapy approved for the disease in 40 years. She has led cabozantinib (COSMIC-311) and RET-inhibitor trials in thyroid cancer and chairs medical oncology at Jefferson.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Brose%20MS%5BAuthor%5D%20thyroid%20sorafenib%20OR%20cabozantinib"}],"tags":["thyroid","targeted-therapy"],"related":[],"cancers":["thyroid"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":[],"companies":[],"institutions":["jefferson-kimmel"],"pathways":[],"terms":[],"trials":["decision-sorafenib"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chair of Medical Oncology, Sidney Kimmel Cancer Center at Jefferson Health","institutionId":"jefferson-kimmel","specialisms":["Thyroid cancer","Kinase inhibitors","Precision oncology","Head and neck cancer"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Brose%20MS%5BAuthor%5D%20thyroid%20sorafenib%20OR%20cabozantinib"}],"papers":[{"title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer (DECISION)","journal":"Lancet","year":2014,"doi":"10.1016/S0140-6736(14)60421-9"},{"title":"Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311)","journal":"Lancet Oncology","year":2021,"doi":"10.1016/S1470-2045(21)00332-6"}]},{"id":"marco-centenari","kind":"person","name":"Marco Centenari","aka":[],"tldr":"Marco Centenari represents IRCCS Ospedale San Raffaele in the Organisation of European Cancer Institutes, which lists the centre among its members in Italy.","summary":"Marco Centenari is listed by the Organisation of European Cancer Institutes (OECI) as the representative of IRCCS Ospedale San Raffaele, its full member in Italy. OnCo records the name from the OECI membership list so that the centre's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the institution's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"IRCCS Ospedale San Raffaele website","url":"https://www.hsr.it"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["san-raffaele"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of IRCCS Ospedale San Raffaele to the Organisation of European Cancer Institutes","institutionId":"san-raffaele","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"IRCCS Ospedale San Raffaele website","url":"https://www.hsr.it"}],"papers":[]},{"id":"marco-guzzo","kind":"person","name":"Marco Guzzo","aka":[],"tldr":"Marco Guzzo is a head and neck surgeon at INT Milan.","summary":"Marco Guzzo is Head of Head and Neck Surgery at the Fondazione IRCCS Istituto Nazionale dei Tumori in Milan. His specialisms are head and neck surgery and salivary gland tumours, with a research focus on salivary gland and oral cavity cancers and head and neck squamous cell carcinoma. His papers include two reviews of major and minor salivary gland tumours in Critical Reviews in Oncology/Hematology and a Pediatric Blood & Cancer report of the Istituto Nazionale Tumori's experience with salivary gland neoplasms in children. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Guzzo%20M%5BAuthor%5D%20salivary"}],"tags":[],"related":[],"cancers":["head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["int-milan"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["critical-reviews-in-oncology-hematology"],"dependsOn":[],"notes":[],"role":"Head, Head and Neck Surgery, INT Milan","institutionId":"int-milan","specialisms":["Head and neck surgery","Salivary gland tumours"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Guzzo%20M%5BAuthor%5D%20salivary"}],"papers":[{"title":"Major and minor salivary gland tumors","journal":"Critical Reviews in Oncology/Hematology","year":2010,"doi":"10.1016/j.critrevonc.2009.10.004"},{"title":"Salivary gland neoplasms in children: The experience of the Istituto Nazionale Tumori of Milan","journal":"Pediatric Blood & Cancer","year":2006,"doi":"10.1002/pbc.20637"},{"title":"Major and minor salivary gland tumours","journal":"Critical Reviews in Oncology/Hematology","year":2020,"doi":"10.1016/j.critrevonc.2020.102959"}],"orcid":"0000-0002-7153-6406"},{"id":"marco-herold","kind":"person","name":"Marco Herold","aka":[],"tldr":"Cancer biologist who leads the Olivia Newton-John Cancer Research Institute, the research arm of the Olivia Newton-John Cancer Wellness and Research Centre in Melbourne.","summary":"Professor Marco Herold is Chief Executive Officer of the Olivia Newton-John Cancer Research Institute (ONJCRI), the research institute embedded in the Olivia Newton-John Cancer Wellness and Research Centre, an Austin Health comprehensive cancer service in Heidelberg, Melbourne. He also heads the Blood Cancer and Immunotherapy Laboratory and La Trobe University's School of Cancer Medicine, and joined ONJCRI in 2023 from the Walter and Eliza Hall Institute. His research applies genome wide CRISPR screening to find drug resistance factors and targets that enhance immune therapies.","asOf":"2026-09-10","links":[{"label":"Source: ONJCRI our people page","url":"https://www.onjcri.org.au/our-people/"}],"tags":["leadership","clinician-scientist","immunotherapy","genome-editing"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["wehi"],"pathways":[],"terms":["immunotherapy-term","leukaemia-type"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive Officer, Olivia Newton-John Cancer Research Institute","institutionId":"onj-cancer-centre","specialisms":["Blood cancer","Cancer immunotherapy","CRISPR genome editing"],"profiles":[{"label":"ONJCRI profile","url":"https://www.onjcri.org.au/about/marco-herold/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Herold+MJ%5BAuthor%5D"}],"papers":[{"title":"Genome-wide in vivo CRISPR screens identify GATOR1 complex as a tumor suppressor in Myc-driven lymphoma","journal":"Nature Communications","year":2025,"doi":"10.1038/s41467-025-62615-y"},{"title":"Genome-wide CRISPR screening identifies a role for ARRDC3 in TRP53-mediated responses","journal":"Cell Death & Differentiation","year":2023,"doi":"10.1038/s41418-023-01249-3"},{"title":"Re-appraising assays on permeabilized blood cancer cells testing venetoclax or other BH3 mimetic agents selectively targeting pro-survival BCL2 proteins","journal":"Cell Death & Differentiation","year":2025,"doi":"10.1038/s41418-025-01487-7"}],"orcid":"0000-0001-7539-7581"},{"id":"marco-vignetti","kind":"person","name":"Marco Vignetti","aka":[],"tldr":"Haematologist who presides over GIMEMA, Italy's adult haematological malignancies cooperative group, and co-authored its chemotherapy-free Ph+ ALL trial.","summary":"Marco Vignetti is President of Fondazione GIMEMA (Gruppo Italiano Malattie Ematologiche dell'Adulto), the Italian cooperative group that runs multicentre trials in adult haematological malignancies. He has co-authored landmark GIMEMA studies including the dasatinib-blinatumomab trial in Philadelphia-positive acute lymphoblastic leukaemia and the description of NPM1 mutations in normal-karyotype AML.","asOf":"2026-09-10","links":[{"label":"Society page","url":"https://www.gimema.it/organigramma/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Vignetti+M%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","leukaemia","clinical trials"],"related":[],"cancers":["all-leukemia","aml"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["gimema"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President","institutionId":"gimema","specialisms":["Haematology","Acute leukaemia","Clinical trials"],"profiles":[{"label":"Society page","url":"https://www.gimema.it/organigramma/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Vignetti+M%5BAuthor%5D"}],"papers":[{"title":"Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults","journal":"New England Journal of Medicine","year":2020,"url":"https://doi.org/10.1056/NEJMoa2016272","doi":"10.1056/NEJMoa2016272"},{"title":"Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype","journal":"New England Journal of Medicine","year":2005,"url":"https://doi.org/10.1056/NEJMoa041974","doi":"10.1056/NEJMoa041974"}]},{"id":"marek-svoboda","kind":"person","name":"Marek Svoboda","aka":[],"tldr":"Medical oncologist who leads the Masaryk Memorial Cancer Institute in Brno, the Czech Republic's largest dedicated cancer centre.","summary":"Prof. Marek Svoboda is General Director of the Masaryk Memorial Cancer Institute (MOU) in Brno. He is a medical oncologist whose research has focused on breast cancer, hereditary cancer syndromes and molecular oncology. Under his leadership MOU operates as a comprehensive cancer centre combining clinical care, research and education.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.mou.cz/en/management/t1644"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Svoboda+M%5BAuthor%5D+Brno"}],"tags":["leadership","clinician-scientist","breast cancer","medical oncology"],"related":[],"cancers":["breast-hr-positive","breast-her2-positive"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["mou-brno"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["oncotarget","radiation-oncology"],"dependsOn":[],"notes":[],"role":"General Director","institutionId":"mou-brno","specialisms":["Medical oncology","Breast cancer","Cancer genetics"],"profiles":[{"label":"Institution profile","url":"https://www.mou.cz/en/management/t1644"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Svoboda+M%5BAuthor%5D+Brno"}],"papers":[{"title":"MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients","journal":"Radiation Oncology","year":2012,"doi":"10.1186/1748-717x-7-195"},{"title":"Long non-coding RNA ZFAS1 interacts with CDK1 and is involved in p53-dependent cell cycle control and apoptosis in colorectal cancer","journal":"Oncotarget","year":2015,"doi":"10.18632/oncotarget.5807"},{"title":"MiR-215-5p is a tumor suppressor in colorectal cancer targeting EGFR ligand epiregulin and its transcriptional inducer HOXB9","journal":"Oncogenesis","year":2017,"doi":"10.1038/s41389-017-0006-6"}]},{"id":"margaret-foti","kind":"person","name":"Margaret Foti","aka":[],"tldr":"Has led AACR for more than four decades, growing it into the world's largest cancer research society.","summary":"Margaret Foti is Chief Executive Officer of the American Association for Cancer Research (AACR), a role she has held since 1982. Specialising in cancer research advocacy, scientific publishing and policy, she has grown AACR into the world's largest cancer research society over more than four decades. She built its portfolio of journals, the Annual Meeting, Project GENIE and the AACR Cancer Progress Report, and her papers include the AACR Cancer Progress Report 2015 published in Clinical Cancer Research. She remains a leading advocate for federal research funding.","asOf":"2026-09-08","links":[{"label":"AACR officers","url":"https://www.aacr.org/about-the-aacr/leadership/officers/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Foti%20M%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Margaret%20Foti"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["aacr"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["clinical-cancer-research"],"dependsOn":[],"notes":[],"role":"Chief Executive Officer, American Association for Cancer Research","institutionId":"aacr","specialisms":["Cancer research advocacy","Scientific publishing","Policy"],"profiles":[{"label":"AACR officers","url":"https://www.aacr.org/about-the-aacr/leadership/officers/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Foti%20M%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Margaret%20Foti"}],"papers":[{"title":"AACR Cancer Progress Report 2015","journal":"Clinical Cancer Research","year":2015,"url":"https://doi.org/10.1158/1078-0432.CCR-15-1846","doi":"10.1158/1078-0432.CCR-15-1846"}]},{"id":"maria-de-santis","kind":"person","name":"Maria De Santis","aka":[],"tldr":"Berlin oncologist who led SEMPET, the study showing that a PET scan can tell which residual masses after chemotherapy for seminoma still contain cancer, sparing many men further treatment.","summary":"Maria De Santis is a genitourinary medical oncologist at Charité in Berlin. She was first author of the 2004 Journal of Clinical Oncology report of the SEMPET study, which showed that FDG-PET reliably distinguished viable tumour from fibrosis in residual masses after chemotherapy for seminoma, particularly for masses over 3 cm, a finding adopted into guidelines. She is also a leading investigator in urothelial cancer and chairs the EAU testis cancer guideline panel.","asOf":"2026-09-18","links":[],"tags":["testis","imaging","trialist"],"related":[],"cancers":["seminoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["charite"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-sempet-de-santis-jco-2004"],"journals":[],"dependsOn":[],"notes":[],"role":"Genitourinary medical oncologist, Charité Universitätsmedizin Berlin","institutionId":"charite","specialisms":["Germ cell tumours","Bladder cancer","Positron emission tomography in oncology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Santis%5BAuthor%5D"}],"papers":[{"title":"SEMPET: FDG-PET as a predictor of viable tumour in post-chemotherapy seminoma residuals","journal":"Journal of Clinical Oncology","year":2004,"url":"https://doi.org/10.1200/JCO.2004.07.188","doi":"10.1200/JCO.2004.07.188"}],"orcid":"0000-0003-4969-0877"},{"id":"maria-cabanillas","kind":"person","name":"Maria E. Cabanillas","aka":[],"tldr":"Turned anaplastic thyroid cancer, once measured in months, into a treatable disease with BRAF-targeted therapy and neoadjuvant strategies.","summary":"Maria Cabanillas led the anaplastic thyroid cancer work within the ROAR basket trial that won dabrafenib plus trametinib approval for BRAF V600E-mutant disease, and pioneered neoadjuvant BRAF/MEK inhibition to make previously unresectable tumours operable, which has raised one-year survival in her centre's series from near zero to above 50%. She leads the anaplastic thyroid cancer programme at MD Anderson.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cabanillas%20ME%5BAuthor%5D%20anaplastic%20thyroid"}],"tags":["thyroid","braf","neoadjuvant"],"related":[],"cancers":["thyroid"],"sections":[],"technologies":["kinase-inhibitors"],"targets":["braf"],"drugs":[],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":["roar-atc"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Endocrine Neoplasia and Hormonal Disorders, MD Anderson Cancer Center","institutionId":"md-anderson","specialisms":["Anaplastic thyroid cancer","BRAF/MEK targeted therapy","Neoadjuvant therapy","Endocrine oncology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cabanillas%20ME%5BAuthor%5D%20anaplastic%20thyroid"}],"papers":[{"title":"Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer (ROAR)","journal":"JCO","year":2018,"doi":"10.1200/JCO.2017.73.6785"},{"title":"Neoadjuvant BRAF- and immune-directed therapy for anaplastic thyroid carcinoma","journal":"Thyroid","year":2018,"doi":"10.1089/thy.2018.0060"}]},{"id":"maria-kane","kind":"person","name":"Maria Kane","aka":[],"tldr":"NHS leader who has been joint chief executive of University Hospitals Bristol and Weston and North Bristol since July 2024, the trusts that run the Bristol Haematology and Oncology Centre.","summary":"Maria Kane OBE is Chief Executive of University Hospitals Bristol and Weston NHS Foundation Trust, the trust that runs the Bristol Haematology and Oncology Centre, and holds the post jointly with the chief executive role at North Bristol NHS Trust. She took up the joint role in July 2024, having been chief executive of North Bristol NHS Trust since April 2021 and previously of North Middlesex University Hospital NHS Trust (2017 to 2021) and Barnet, Enfield and Haringey Mental Health NHS Trust (2007 to 2017). She was made an OBE in 2019 for services to healthcare leadership and has chaired Bristol Health Partners.","asOf":"2026-09-10","links":[{"label":"Source: UHBW 'Chief executive and executive directors' page","url":"https://www.bristolft.nhs.uk/about-us/our-board/chief-executive-and-executive-directors"}],"tags":["leadership","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["bristol-haematology-oncology-centre"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive, University Hospitals Bristol and Weston NHS Foundation Trust (joint with North Bristol NHS Trust)","institutionId":"bristol-haematology-oncology-centre","specialisms":["NHS management","Health system leadership"],"profiles":[{"label":"UHBW board: chief executive and executive directors","url":"https://www.bristolft.nhs.uk/about-us/our-board/chief-executive-and-executive-directors"}],"papers":[]},{"id":"maria-margarida-torres-de-ornelas","kind":"person","name":"Maria Margarida Torres de Ornelas","aka":["Maria Margarida Torres Ornelas"],"tldr":"Chair of the board of directors of IPO Coimbra, the Portuguese public oncology institute in Coimbra, reappointed with her board for the 2024 to 2026 mandate.","summary":"Maria Margarida Torres de Ornelas is Presidente do Conselho de Administração of the Instituto Português de Oncologia de Coimbra Francisco Gentil, E.P.E. (IPO Coimbra), a public oncology institute within Portugal's Serviço Nacional de Saúde. The institute announced in January 2024 that the executive directorate of the SNS had reappointed the sitting board for a new 2024 to 2026 mandate by order published in the Diário da República, with Luís Miguel Santos Filipe and Catarina Raquel Jorge Lopes Monteiro as executive members (vogais); the board page also lists a clinical director and a nursing director. The institute's website blocked automated access at the time of this check, so the announcement was read from an archived copy. She also represents IPO Coimbra in the Organisation of European Cancer Institutes (OECI), which lists the institute as a full member in Portugal.","asOf":"2026-09-10","links":[{"label":"Source: IPO Coimbra notice of the board's reappointment for 2024 to 2026 (archived copy)","url":"https://web.archive.org/web/20240225223721/https://www.ipocoimbra.min-saude.pt/2024/01/22/nomeacao-do-ca-do-ipo-de-coimbra/"},{"label":"Source: IPO Coimbra Conselho de Administração page (archived copy)","url":"https://web.archive.org/web/20231211122757/https://www.ipocoimbra.min-saude.pt/2021/01/27/conselho-de-administracao/"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"IPO Coimbra website","url":"https://www.ipocoimbra.min-saude.pt"}],"tags":["leadership","hospital-management","oeci-representative"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ipo-coimbra","ipo-lisboa"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Presidente do Conselho de Administração, Instituto Português de Oncologia de Coimbra Francisco Gentil, E.P.E.","institutionId":"ipo-coimbra","specialisms":["Hospital administration","Cancer care management"],"profiles":[{"label":"IPO Coimbra board appointment notice (archived copy)","url":"https://web.archive.org/web/20240225223721/https://www.ipocoimbra.min-saude.pt/2024/01/22/nomeacao-do-ca-do-ipo-de-coimbra/"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"IPO Coimbra website","url":"https://www.ipocoimbra.min-saude.pt"}],"papers":[]},{"id":"maria-rosaria-iardino","kind":"person","name":"Maria Rosaria Iardino","aka":[],"tldr":"Maria Rosaria Iardino represents Fondazione The Bridge in the Organisation of European Cancer Institutes, which lists the organisation among its members in Italy.","summary":"Maria Rosaria Iardino is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Fondazione The Bridge, its associate member in Italy. OnCo records the name from the OECI membership list so that the organisation's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the organisation's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Fondazione The Bridge website","url":"https://www.fondazionethebridge.it/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["fondazione-the-bridge"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Fondazione The Bridge to the Organisation of European Cancer Institutes","institutionId":"fondazione-the-bridge","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Fondazione The Bridge website","url":"https://www.fondazionethebridge.it/"}],"papers":[],"orcid":"0009-0003-8474-644X"},{"id":"maria-victoria-mateos","kind":"person","name":"María-Victoria Mateos","aka":[],"tldr":"Led ALCYONE and the smouldering myeloma trials that showed treating early can delay progression to active disease.","summary":"María-Victoria Mateos (Salamanca) was principal investigator of ALCYONE, which established daratumumab with bortezomib-melphalan-prednisone in transplant-ineligible myeloma, and of the Spanish QuiRedex and the international AQUILA trials showing that treating high-risk smouldering myeloma with lenalidomide-dexamethasone or daratumumab delays progression and improves survival. She leads the Spanish Myeloma Group and IMWG guideline work.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mateos%20MV%5BAuthor%5D%20myeloma"}],"tags":["myeloma","smouldering","spain"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":["monoclonal-antibody"],"targets":["cd38"],"drugs":[],"companies":[],"institutions":["hospital-universitario-salamanca"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Consultant Hematologist and Director of the Myeloma Program, University Hospital of Salamanca","institutionId":"hospital-universitario-salamanca","specialisms":["Multiple myeloma","Smouldering myeloma","Daratumumab combinations","Early intervention"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mateos%20MV%5BAuthor%5D%20myeloma"}],"papers":[{"title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma (ALCYONE)","journal":"NEJM","year":2018,"doi":"10.1056/NEJMoa1714678"},{"title":"Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma","journal":"NEJM","year":2013,"doi":"10.1056/NEJMoa1300439"}]},{"id":"mariana-chavez-macgregor","kind":"person","name":"Mariana Chavez-MacGregor","aka":[],"tldr":"Mariana Chavez-MacGregor is a breast oncologist who studies how care is delivered and leads SWOG's international work.","summary":"Mariana Chavez-MacGregor is Professor of Breast Medical Oncology and Health Services Research at MD Anderson Cancer Center and SWOG Executive Officer for International Affairs. A medical oncologist and health services researcher, she studies treatment timing, disparities and outcomes in breast cancer and how care is delivered. Her papers include a JAMA Oncology study of delayed initiation of adjuvant chemotherapy among patients with breast cancer and a JAMA Oncology evaluation of COVID-19 outcomes in US patients with or without cancer. She leads SWOG's international work within the SWOG Cancer Research Network, with a focus on triple-negative and HR-positive breast cancer and cooperative group trials.","asOf":"2026-09-08","links":[{"label":"MD Anderson faculty","url":"https://faculty.mdanderson.org/search?q=Mariana%20Chavez-MacGregor"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chavez-MacGregor%20M%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Mariana%20Chavez-MacGregor"}],"tags":[],"related":[],"cancers":["tnbc","breast-hr-positive"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["swog"],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor, Breast Medical Oncology and Health Services Research, MD Anderson; SWOG Executive Officer for International Affairs","institutionId":"md-anderson","specialisms":["Breast cancer","Health services research","Cooperative group trials"],"profiles":[{"label":"MD Anderson faculty","url":"https://faculty.mdanderson.org/search?q=Mariana%20Chavez-MacGregor"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chavez-MacGregor%20M%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Mariana%20Chavez-MacGregor"}],"papers":[{"title":"Delayed Initiation of Adjuvant Chemotherapy Among Patients With Breast Cancer","journal":"JAMA Oncology","year":2016,"url":"https://doi.org/10.1001/jamaoncol.2015.3856","doi":"10.1001/jamaoncol.2015.3856"},{"title":"Evaluation of COVID-19 Mortality and Adverse Outcomes in US Patients With or Without Cancer","journal":"JAMA Oncology","year":2022,"url":"https://doi.org/10.1001/jamaoncol.2021.5148","doi":"10.1001/jamaoncol.2021.5148"}]},{"id":"marianne-van-rooijen","kind":"person","name":"Marianne van Rooijen","aka":[],"tldr":"Hospital Director of Akademiska sjukhuset, Uppsala University Hospital, one of Sweden's largest university hospitals and a national cancer centre.","summary":"Marianne van Rooijen is Sjukhusdirektör (Hospital Director) of Akademiska sjukhuset, the university hospital of Uppsala University. The hospital provides regional and national specialised cancer care, including radiotherapy and the Skandion proton therapy partnership, and conducts research with Uppsala University. Her role is listed on the hospital's management page.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.akademiska.se/om-oss/sjukhusets-organisation/sjukhusledningen/"}],"tags":["leadership","hospital management"],"related":[],"cancers":[],"sections":[],"technologies":["proton-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":["uppsala-akademiska"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Hospital Director (Sjukhusdirektör)","institutionId":"uppsala-akademiska","specialisms":["Hospital management","Health system leadership"],"profiles":[{"label":"Institution profile","url":"https://www.akademiska.se/om-oss/sjukhusets-organisation/sjukhusledningen/"}],"papers":[]},{"id":"marie-plante","kind":"person","name":"Marie Plante","aka":[],"tldr":"Quebec surgeon who pioneered fertility-sparing surgery for cervical cancer and led SHAPE, the trial that showed a simple hysterectomy is enough for low-risk early cervical cancer.","summary":"Marie Plante is a gynaecologic oncologist at CHU de Québec - Université Laval and a pioneer of radical trachelectomy, which lets young women with early cervical cancer keep their fertility. She was first author of the 2024 New England Journal of Medicine report of the Canadian Cancer Trials Group SHAPE trial, which showed that simple hysterectomy was non-inferior to radical hysterectomy for pelvic recurrence in low-risk early-stage cervical cancer, with fewer urinary complications.","asOf":"2026-09-18","links":[],"tags":["cervical","surgery","de-escalation","trialist"],"related":[],"cancers":["early-cervical-cancer","cervical"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["chu-de-quebec"],"pathways":[],"terms":[],"trials":["shape"],"people":[],"bottlenecks":[],"keyPapers":["paper-shape-nejm-2024"],"journals":[],"dependsOn":[],"notes":[],"role":"Gynaecologic oncologist, CHU de Québec - Université Laval","institutionId":"chu-de-quebec","specialisms":["Cervical cancer surgery","Fertility-sparing surgery","Radical trachelectomy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Plante%5BAuthor%5D"}],"papers":[{"title":"SHAPE: simple versus radical hysterectomy in low-risk early cervical cancer","journal":"New England Journal of Medicine","year":2024,"url":"https://doi.org/10.1056/NEJMoa2308900","doi":"10.1056/NEJMoa2308900"}]},{"id":"marie-catherine-vozenin","kind":"person","name":"Marie-Catherine Vozenin","aka":[],"tldr":"Radiobiologist who discovered the FLASH effect: ultra-fast radiation spares healthy tissue while still killing tumours.","summary":"Marie-Catherine Vozenin led the 2014 study showing that radiation delivered at ultra-high dose rates (over 40 Gy per second) spares normal lung tissue in mice while retaining anti-tumour efficacy, the FLASH effect, and went on to confirm it in mini-pigs, cats and the first human patient with Jean Bourhis. Her work launched a global effort to build FLASH-capable machines and understand the underlying biology.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Vozenin%20MC%5BAuthor%5D%20FLASH"}],"tags":["radiotherapy","flash","radiobiology"],"related":[],"cancers":[],"sections":[],"technologies":["flash-rt"],"targets":[],"drugs":[],"companies":[],"institutions":["hug-geneva","chuv-lausanne"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["science-translational-medicine"],"dependsOn":[],"notes":[],"role":"Head of the Radiotherapy and Radiobiology Laboratory, Geneva University Hospitals; Professor, University of Geneva","institutionId":"hug-geneva","specialisms":["FLASH radiotherapy","Radiobiology","Normal tissue protection","Ultra-high dose rate radiation"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Vozenin%20MC%5BAuthor%5D%20FLASH"}],"papers":[{"title":"Ultrahigh dose-rate FLASH irradiation increases the differential response between normal and tumor tissue in mice","journal":"Science Translational Medicine","year":2014,"doi":"10.1126/scitranslmed.3008973"},{"title":"The advantage of FLASH radiotherapy confirmed in mini-pig and cat-cancer patients","journal":"Clinical Cancer Research","year":2019,"doi":"10.1158/1078-0432.CCR-17-3375"}],"orcid":"0000-0002-2109-8073"},{"id":"marie-eve-desrosiers","kind":"person","name":"Marie-Eve Desrosiers","aka":[],"tldr":"President and chief executive of the CHUM, the University of Montreal's teaching hospital and one of Canada's largest academic health centres.","summary":"Marie-Eve Desrosiers is Présidente-directrice générale of the Centre hospitalier de l'Université de Montréal (CHUM), a university teaching hospital in Montreal. The CHUM's executive organisation chart dated July 2026 names her in the role at the head of the hospital's management committee. The French Wikipedia article on the CHUM also records her as the new president and chief executive.","asOf":"2026-09-10","links":[{"label":"Source: CHUM executive organisation chart (July 2026, PDF)","url":"https://www.chumontreal.qc.ca/sites/default/files/2026-07/Organigramme%20exe%CC%81cutif.pdf"}],"tags":["leadership","hospital"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["chum"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Présidente-directrice générale of the CHUM","institutionId":"chum","specialisms":["Hospital leadership","Health system management","Academic medicine"],"profiles":[{"label":"Institution leadership page","url":"https://www.chumontreal.qc.ca/propos-chum/leadership-organisationnel"}],"papers":[],"orcid":"0000-0002-5208-9604","papersExpected":false},{"id":"mario-campone","kind":"person","name":"Mario Campone","aka":[],"tldr":"Medical oncologist who is Director General of the Institut de Cancérologie de l'Ouest, the regional cancer centre for western France with sites in Angers and Nantes.","summary":"Professor Mario Campone is Directeur Général of the Institut de Cancérologie de l'Ouest (ICO), the Centre de Lutte Contre le Cancer for the Pays de la Loire region, which operates from two sites, in Angers and in Saint-Herblain near Nantes, with its registered office in Angers. The institute's own presentation page lists him as Directeur Général and as a consultative member of the Conseil d'Administration, alongside a published governance charter. The French Wikipedia article on the institute likewise states that it is directed by Professor Campone. Neither source gives his appointment date.","asOf":"2026-09-10","links":[{"label":"Source: ICO institutional page naming the Directeur Général","url":"https://www.institut-cancerologie-ouest.com/linstitut-de-cancerologie-de-louest"},{"label":"Source: Wikipedia (French), Institut de cancérologie de l'Ouest","url":"https://fr.wikipedia.org/wiki/Institut_de_canc%C3%A9rologie_de_l%27Ouest"}],"tags":["leadership","clinician-scientist","comprehensive-cancer-centre"],"related":[],"cancers":["breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ico-angers-nantes"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Directeur Général (Director General), Institut de Cancérologie de l'Ouest","institutionId":"ico-angers-nantes","specialisms":["Medical oncology","Breast cancer","Cancer centre management"],"profiles":[{"label":"ICO institutional presentation page","url":"https://www.institut-cancerologie-ouest.com/linstitut-de-cancerologie-de-louest"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Campone+M%5BAuthor%5D"}],"papers":[{"title":"Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial","journal":"Annals of Oncology","year":2014,"doi":"10.1093/annonc/mdu118"},{"title":"UCBG 2-08: 5-year efficacy results from the UNICANCER-PACS08 randomised phase III trial of adjuvant treatment with FEC100 and then either docetaxel or ixabepilone in patients with early-stage, poor prognosis breast cancer","journal":"European Journal of Cancer","year":2018,"doi":"10.1016/j.ejca.2018.06.025"},{"title":"Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages","journal":"Annals of Oncology","year":2019,"doi":"10.1093/annonc/mdz163"}]},{"id":"mario-taccolini","kind":"person","name":"Mario Taccolini","aka":[],"tldr":"Mario Taccolini represents Fondazione Poliambulanza in the Organisation of European Cancer Institutes, which lists the centre among its members in Italy.","summary":"Mario Taccolini is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Fondazione Poliambulanza, its member in Italy. Fondazione Poliambulanza is a non-profit hospital in Brescia, northern Italy, with a cancer programme, and a full member of the Organisation of European Cancer Institutes. OnCo records the name from the OECI membership list so that the centre's page has a named contact point; the person's exact title, appointment date and biography are not yet recorded and should be checked on the institution's own pages before being relied on.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Fondazione Poliambulanza website","url":"https://www.poliambulanza.it/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["fondazione-poliambulanza"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Fondazione Poliambulanza to the Organisation of European Cancer Institutes","institutionId":"fondazione-poliambulanza","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Fondazione Poliambulanza website","url":"https://www.poliambulanza.it/"}],"papers":[]},{"id":"mark-faries","kind":"person","name":"Mark B. Faries","aka":[],"tldr":"Surgeon who led MSLT-II, showing that removing all lymph nodes after a positive sentinel node does not improve melanoma survival.","summary":"Mark Faries was principal investigator of MSLT-II, the randomised trial showing completion lymph node dissection after a positive sentinel node biopsy does not improve melanoma-specific survival, which ended routine completion dissection worldwide, and a senior investigator of MSLT-I with Donald Morton. He leads surgical aspects of neoadjuvant immunotherapy trials and the melanoma programme at the Angeles Clinic.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Faries%20MB%5BAuthor%5D%20melanoma%20sentinel"}],"tags":["melanoma","surgery","de-escalation"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":["sentinel-node"],"targets":[],"drugs":[],"companies":[],"institutions":["cedars-sinai-cancer"],"pathways":[],"terms":[],"trials":["mslt-ii"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Co-Director, Melanoma Program, The Angeles Clinic and Research Institute, Cedars-Sinai","institutionId":"cedars-sinai-cancer","specialisms":["Melanoma surgery","Sentinel node biopsy","Surgical oncology","Neoadjuvant therapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Faries%20MB%5BAuthor%5D%20melanoma%20sentinel"}],"papers":[{"title":"Completion dissection or observation for sentinel-node metastasis in melanoma (MSLT-II)","journal":"NEJM","year":2017,"doi":"10.1056/NEJMoa1613210"},{"title":"Final trial report of sentinel-node biopsy versus nodal observation in melanoma (MSLT-I)","journal":"NEJM","year":2014,"doi":"10.1056/NEJMoa1310460"}],"orcid":"0000-0003-1752-7282"},{"id":"mark-de-ridder","kind":"person","name":"Mark De Ridder","aka":[],"tldr":"Mark De Ridder represents Brussels Cancer Centre (UZ Brussel) in the Organisation of European Cancer Institutes, which lists the centre among its members in Belgium.","summary":"Mark De Ridder is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Brussels Cancer Centre (UZ Brussel), its member in Belgium. Brussels Cancer Centre is the cancer centre of UZ Brussel, the university hospital of the Vrije Universiteit Brussel in Jette, and a full member of the Organisation of European Cancer Institutes. OnCo records the name from the OECI membership list so that the centre's page has a named contact point; the person's exact title, appointment date and biography are not yet recorded and should be checked on the institution's own pages before being relied on.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Brussels Cancer Centre (UZ Brussel) website","url":"http://www.uzbrussel.be/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["uz-brussel-cancer-centre"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Brussels Cancer Centre (UZ Brussel) to the Organisation of European Cancer Institutes","institutionId":"uz-brussel-cancer-centre","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Brussels Cancer Centre (UZ Brussel) website","url":"http://www.uzbrussel.be/"}],"papers":[{"title":"Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using <i>ex vivo</i> myeloid-derived suppressor cells as a readout of therapeutic efficacy","journal":"Oncoimmunology","year":2014,"url":"https://doi.org/10.4161/21624011.2014.945378","doi":"10.4161/21624011.2014.945378","note":"Europe PMC author record matched by affiliation"},{"title":"Chronic hypoxia modulates tumour cell radioresponse through cytokine-inducible nitric oxide synthase","journal":"Br J Cancer","year":2001,"url":"https://doi.org/10.1054/bjoc.2000.1719","doi":"10.1054/bjoc.2000.1719","note":"Europe PMC author record matched by affiliation"},{"title":"NF-kappaB inhibition impairs the radioresponse of hypoxic EMT-6 tumour cells through downregulation of inducible nitric oxide synthase","journal":"Br J Cancer","year":2003,"url":"https://doi.org/10.1038/sj.bjc.6600678","doi":"10.1038/sj.bjc.6600678","note":"Europe PMC author record matched by affiliation"}],"orcid":"0000-0003-4433-8807"},{"id":"mark-burkard","kind":"person","name":"Mark E. Burkard","aka":[],"tldr":"Breast cancer physician scientist who has directed the Holden Comprehensive Cancer Center at the University of Iowa since October 2024.","summary":"Mark E. Burkard, MD, PhD, became Director of the Holden Comprehensive Cancer Center on 1 October 2024. He holds the C.E. Block Chair of Cancer Research and is Professor and Associate Dean for Cancer in the University of Iowa Carver College of Medicine. His research focuses on understanding the drivers of genomic changes in breast cancer and developing precision treatments. The centre's leadership page lists Jon C. Houtman as Deputy Director of Research.","asOf":"2026-09-10","links":[{"label":"Source: Holden Comprehensive Cancer Center leadership page","url":"https://holden.uihealthcare.org/about/leadership"}],"tags":["leadership","clinician-scientist","comprehensive-cancer-centre"],"related":[],"cancers":["breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["iowa-holden"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Holden Comprehensive Cancer Center, University of Iowa","institutionId":"iowa-holden","specialisms":["Breast cancer","Cancer genomics","Precision oncology"],"profiles":[{"label":"Holden leadership page","url":"https://holden.uihealthcare.org/about/leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Burkard+ME%5BAuthor%5D"}],"papers":[{"title":"Centrosome amplification induces high grade features and is prognostic of worse outcomes in breast cancer","journal":"BMC Cancer","year":2016,"doi":"10.1186/s12885-016-2083-x"},{"title":"Paclitaxel Induces Micronucleation and Activates Pro-Inflammatory cGAS–STING Signaling in Triple-Negative Breast Cancer","journal":"Molecular Cancer Therapeutics","year":2021,"doi":"10.1158/1535-7163.mct-21-0195"},{"title":"E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor–Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group","journal":"Journal of Clinical Oncology","year":2021,"doi":"10.1200/jco.21.00944"}],"orcid":"0000-0002-4215-7722"},{"id":"mark-robson","kind":"person","name":"Mark E. Robson","aka":[],"tldr":"New York breast oncologist and cancer geneticist who led OlympiAD, the trial that made olaparib the first PARP inhibitor approved for BRCA-mutated breast cancer.","summary":"Mark Robson leads the breast medicine service at Memorial Sloan Kettering Cancer Center and works at the interface of clinical genetics and breast oncology. He was first author of the 2017 New England Journal of Medicine report of OlympiAD, which showed that olaparib improved progression-free survival compared with standard chemotherapy in HER2-negative metastatic breast cancer with a germline BRCA mutation, the first PARP inhibitor approval in breast cancer.","asOf":"2026-09-18","links":[],"tags":["breast","genetics","trialist"],"related":[],"cancers":["tnbc-metastatic","breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-olympiad-nejm-2017"],"journals":[],"dependsOn":[],"notes":[],"role":"Chief of the Breast Medicine Service, Memorial Sloan Kettering Cancer Center","institutionId":"mskcc","specialisms":["Hereditary breast cancer","PARP inhibitors","Clinical cancer genetics"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Robson%5BAuthor%5D"}],"papers":[{"title":"OlympiAD: olaparib versus chemotherapy in metastatic breast cancer with a germline BRCA mutation","journal":"New England Journal of Medicine","year":2017,"url":"https://doi.org/10.1056/NEJMoa1706450","doi":"10.1056/NEJMoa1706450"}],"orcid":"0000-0002-3109-1692"},{"id":"mark-emberton","kind":"person","name":"Mark Emberton","aka":[],"tldr":"Urologist behind PROMIS and PRECISION, which put MRI before biopsy in the prostate cancer pathway.","summary":"Mark Emberton was senior investigator of PROMIS and PRECISION, the trials showing that multiparametric MRI before biopsy detects more clinically significant prostate cancers and fewer insignificant ones than standard systematic biopsy, which rewrote diagnostic guidelines worldwide. He pioneered focal therapy with HIFU and cryotherapy and leads interventional oncology research at UCL.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Mark_Emberton","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Emberton%20M%5BAuthor%5D%20prostate%20MRI"}],"tags":["prostate","imaging","focal-therapy"],"related":[],"cancers":["prostate"],"sections":[],"technologies":["mri","hifu-histotripsy"],"targets":[],"drugs":[],"companies":[],"institutions":["uclh"],"pathways":[],"terms":[],"trials":["precision-mri"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Interventional Oncology and Dean of the Faculty of Medical Sciences, University College London","institutionId":"uclh","specialisms":["Prostate cancer diagnostics","MRI-guided biopsy","Focal therapy","Interventional oncology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Emberton%20M%5BAuthor%5D%20prostate%20MRI"}],"papers":[{"title":"MRI-targeted or standard biopsy for prostate-cancer diagnosis (PRECISION)","journal":"NEJM","year":2018,"doi":"10.1056/NEJMoa1801993"},{"title":"Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS)","journal":"Lancet","year":2017,"doi":"10.1016/S0140-6736(16)32401-1"}],"orcid":"0000-0003-4230-0338"},{"id":"mark-middleton","kind":"person","name":"Mark Middleton","aka":[],"tldr":"Medical oncologist who co-directs Oxford Cancer, the city-wide partnership between the University of Oxford and Oxford University Hospitals.","summary":"Mark Middleton is one of three Directors of Oxford Cancer, the network and partnership between the University of Oxford and Oxford University Hospitals NHS Trust, alongside Tim Elliott and Adam Mead, and he co-chairs its Governance Board. He is Head of the Department of Oncology, Professor of Experimental Cancer Medicine and a Consultant Medical Oncologist at the Oxford Cancer and Haematology Centre, working on early phase, melanoma and upper gastrointestinal cancer trials. He trained at Cambridge, Oxford and the Christie Hospital and has been chief or principal investigator on more than 100 trials.","asOf":"2026-09-10","links":[{"label":"Source: Oxford Cancer, Our Team","url":"https://www.cancer.ox.ac.uk/about/our-team"}],"tags":["leadership","clinician-scientist","medical-oncology","early-phase-trials"],"related":[],"cancers":["melanoma","gastric","esophageal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oxford-cancer"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Oxford Cancer (co-director with Tim Elliott and Adam Mead)","institutionId":"oxford-cancer","specialisms":["Experimental cancer medicine","Melanoma","Upper gastrointestinal cancer","Early phase trials"],"profiles":[{"label":"Department of Oncology profile","url":"https://www.oncology.ox.ac.uk/team/mark-middleton"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Middleton+MR%5BAuthor%5D"}],"papers":[{"title":"Safety and feasibility of ultrasound-triggered targeted drug delivery of doxorubicin from thermosensitive liposomes in liver tumours (TARDOX): a single-centre, open-label, phase 1 trial","journal":"The Lancet Oncology","year":2018,"doi":"10.1016/s1470-2045(18)30332-2"},{"title":"A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer","journal":"Cancer","year":2018,"doi":"10.1002/cncr.31791"},{"title":"A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424","journal":"British Journal of Cancer","year":2018,"doi":"10.1038/bjc.2017.484"}],"orcid":"0000-0003-0167-1685"},{"id":"mark-litzow","kind":"person","name":"Mark R. Litzow","aka":[],"tldr":"Leukaemia specialist who led E1910, the trial that put blinatumomab into frontline treatment for adults in remission.","summary":"Mark Litzow is Professor of Medicine at Mayo Clinic, Chair of the ECOG-ACRIN Leukemia Committee and Study Chair of E1910. A haematologist specialising in acute lymphoblastic leukaemia, immunotherapy and transplant, he chaired ECOG-ACRIN E1910, the trial that put blinatumomab consolidation into frontline treatment for adults in MRD-negative remission and led to a 2024 label change. His papers report blinatumomab for MRD-negative acute lymphoblastic leukaemia in adults in the New England Journal of Medicine and allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukaemia in Blood. His work centres on CD19 and CD3 directed therapy in B-ALL.","asOf":"2026-09-08","links":[{"label":"Mayo Clinic research faculty","url":"https://www.mayo.edu/research/faculty"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Litzow%20MR%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Mark%20R.%20Litzow"}],"tags":[],"related":[],"cancers":["all-leukemia"],"sections":[],"technologies":[],"targets":["cd19","cd3"],"drugs":["blinatumomab"],"companies":["ecog-acrin"],"institutions":["mayo-clinic"],"pathways":[],"terms":[],"trials":["e1910"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medicine, Mayo Clinic; Chair, ECOG-ACRIN Leukemia Committee; Study Chair, E1910","institutionId":"mayo-clinic","specialisms":["Acute lymphoblastic leukaemia","Immunotherapy","Transplant"],"profiles":[{"label":"Mayo Clinic research faculty","url":"https://www.mayo.edu/research/faculty"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Litzow%20MR%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Mark%20R.%20Litzow"}],"papers":[{"title":"Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults","journal":"New England Journal of Medicine","year":2024,"url":"https://doi.org/10.1056/NEJMoa2312948","doi":"10.1056/NEJMoa2312948"},{"title":"Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia","journal":"Blood","year":2010,"url":"https://doi.org/10.1182/blood-2009-10-249128","doi":"10.1182/blood-2009-10-249128"}]},{"id":"mark-schiffman","kind":"person","name":"Mark Schiffman","aka":[],"tldr":"NCI epidemiologist whose HPV natural history studies underpin HPV-based cervical screening and risk-based management worldwide.","summary":"Mark Schiffman led the Guanacaste and Portland Kaiser cohorts that defined the natural history of HPV infection and cervical precancer, work that established HPV testing as a screening test, single-dose vaccine efficacy signals, and the risk-based ASCCP management guidelines. He leads NCI efforts on automated visual evaluation with AI and self-sampling to bring screening to low-resource settings.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schiffman%20M%5BAuthor%5D%20HPV%20cervical"}],"tags":["hpv","screening","epidemiology"],"related":[],"cancers":["cervical"],"sections":[],"technologies":["hpv-vaccine","radiology-ai-screening"],"targets":[],"drugs":[],"companies":[],"institutions":["nci"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-hpv-self-sampling-bmj-2018"],"journals":[],"dependsOn":[],"notes":[],"role":"Senior Investigator, Division of Cancer Epidemiology and Genetics, National Cancer Institute","institutionId":"nci","specialisms":["HPV natural history","Cervical screening","Risk-based management","Global cervical cancer prevention"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schiffman%20M%5BAuthor%5D%20HPV%20cervical"}],"papers":[{"title":"Human papillomavirus and cervical cancer","journal":"Lancet","year":2007,"doi":"10.1016/S0140-6736(07)61416-0"},{"title":"Carcinogenic human papillomavirus infection","journal":"Nature Reviews Disease Primers","year":2016,"doi":"10.1038/nrdp.2016.86"},{"title":"Self-collected HPV samples are as accurate as clinician samples and reach women who never attend screening","journal":"BMJ","year":2018,"url":"https://doi.org/10.1136/bmj.k4823","doi":"10.1136/bmj.k4823"}]},{"id":"mark-suzman","kind":"person","name":"Mark Suzman","aka":[],"tldr":"CEO of the Gates Foundation, the world's largest private philanthropy in global health, including cervical cancer elimination and HPV vaccination.","summary":"Mark Suzman is Chief Executive Officer and a board member of the Gates Foundation, which funds global health, vaccines and development programmes. Its portfolio includes HPV vaccination and cervical cancer elimination efforts in low- and middle-income countries. Suzman joined the foundation in 2007 and has served as CEO since 2020.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.gatesfoundation.org/about/leadership"}],"tags":["leadership","global health","philanthropy"],"related":[],"cancers":["cervical"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["gates-foundation"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive Officer","institutionId":"gates-foundation","specialisms":["Global health philanthropy","Development policy"],"profiles":[{"label":"Institution profile","url":"https://www.gatesfoundation.org/about/leadership"}],"papers":[]},{"id":"markus-g-manz","kind":"person","name":"Markus G. Manz","aka":[],"tldr":"Markus G. Manz represents University Hospital Zurich / Comprehensive Cancer Center Zurich in the Organisation of European Cancer Institutes, which lists the centre among its members in Switzerland.","summary":"Markus G. Manz is listed by the Organisation of European Cancer Institutes (OECI) as the representative of University Hospital Zurich / Comprehensive Cancer Center Zurich, its associate member in Switzerland. OnCo records the name from the OECI membership list so that the centre's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the institution's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"University Hospital Zurich / Comprehensive Cancer Center Zurich website","url":"https://www.usz.ch/en/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["usz-zurich"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of University Hospital Zurich / Comprehensive Cancer Center Zurich to the Organisation of European Cancer Institutes","institutionId":"usz-zurich","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"University Hospital Zurich / Comprehensive Cancer Center Zurich website","url":"https://www.usz.ch/en/"}],"papers":[{"title":"Development of monocytes, macrophages, and dendritic cells","journal":"Science","year":2010,"url":"https://doi.org/10.1126/science.1178331","doi":"10.1126/science.1178331","note":"Europe PMC author record matched by affiliation"},{"title":"Emergency granulopoiesis","journal":"Nat Rev Immunol","year":2014,"url":"https://doi.org/10.1038/nri3660","doi":"10.1038/nri3660","note":"Europe PMC author record matched by affiliation"},{"title":"Chronic interleukin-1 exposure drives haematopoietic stem cells towards precocious myeloid differentiation at the expense of self-renewal","journal":"Nat Cell Biol","year":2016,"url":"https://doi.org/10.1038/ncb3346","doi":"10.1038/ncb3346","note":"Europe PMC author record matched by affiliation"}],"orcid":"0000-0002-4676-7931"},{"id":"markus-graefen","kind":"person","name":"Markus Graefen","aka":[],"tldr":"Markus Graefen leads the Martini-Klinik, the world's highest-volume prostate surgery centre.","summary":"Markus Graefen is Medical Director of the Martini-Klinik Prostate Cancer Center at Universitätsklinikum Hamburg-Eppendorf, the world's highest-volume prostate surgery centre. His specialisms are prostate cancer surgery, radical prostatectomy and functional outcomes, including robotic and minimally invasive approaches. The Martini-Klinik performs thousands of radical prostatectomies a year and publishes outcome data on continence and potency preservation. His papers include a comparison of adjuvant and early salvage radiotherapy for men at high risk of recurrence after prostatectomy, a JAMA Oncology comparison of surgery and radiotherapy for Gleason score 9-10 prostate cancer, and a European Urology study of persistent PSA after radical prostatectomy. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Graefen%20M%5BAuthor%5D%20prostatectomy"}],"tags":[],"related":[],"cancers":["prostate"],"sections":[],"technologies":["robotic-surgery"],"targets":[],"drugs":[],"companies":[],"institutions":["uke-hamburg"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Medical Director, Martini-Klinik Prostate Cancer Center, UKE Hamburg","institutionId":"uke-hamburg","specialisms":["Prostate cancer surgery","Radical prostatectomy","Functional outcomes"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Graefen%20M%5BAuthor%5D%20prostatectomy"}],"papers":[{"title":"Adjuvant Versus Early Salvage Radiation Therapy for Men at High Risk for Recurrence Following Radical Prostatectomy for Prostate Cancer and the Risk of Death","journal":"Journal of Clinical Oncology","year":2021,"doi":"10.1200/jco.20.03714"},{"title":"Surgery vs Radiotherapy in the Management of Biopsy Gleason Score 9-10 Prostate Cancer and the Risk of Mortality","journal":"JAMA Oncology","year":2019,"doi":"10.1001/jamaoncol.2018.4836"},{"title":"Persistent Prostate-Specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes","journal":"European Urology","year":2019,"doi":"10.1016/j.eururo.2019.01.048"}]},{"id":"martha-ingram","kind":"person","name":"Martha Rivers Ingram","aka":["E. Bronson Ingram","Ingram family"],"tldr":"In 1999 the Ingram family made what Vanderbilt calls a transformational gift in honour of the late E. Bronson Ingram; the centre took the family's name and became Tennessee's leading cancer research centre.","summary":"Martha Rivers Ingram (1935-2026) chaired Ingram Industries after the death of her husband E. Bronson Ingram in 1995 and became one of the largest donors in Vanderbilt University's history. Vanderbilt-Ingram Cancer Center's history records that in 1999 Nashville's Ingram family made a transformational gift in honour of the late E. Bronson Ingram, philanthropist, businessman and civic leader; formally named the E. Bronson Ingram Cancer Center at Vanderbilt University, it quickly became known as the Vanderbilt-Ingram Cancer Center. The centre is an NCI-designated comprehensive cancer centre and the only one in Tennessee, with programmes in cancer genomics, immunotherapy and the health of rural and underserved populations across the mid-South.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Martha_Rivers_Ingram","links":[{"label":"Vanderbilt-Ingram Cancer Center: history","url":"https://www.vicc.org/about/history"}],"tags":["hero","donor"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["vanderbilt-ingram"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-funding-allocation"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Businesswoman whose family's 1999 gift named Vanderbilt-Ingram Cancer Center in memory of E. Bronson Ingram","specialisms":["Cancer centre building","Family philanthropy"],"profiles":[],"papers":[]},{"id":"martin-armstrong","kind":"person","name":"Martin Armstrong","aka":[],"tldr":"NHS chief executive who leads East and North Hertfordshire Teaching NHS Trust, the trust that runs Mount Vernon Cancer Centre in Northwood.","summary":"Martin Armstrong is Chief Executive of East and North Hertfordshire Teaching NHS Trust, which runs Mount Vernon Cancer Centre in Northwood, Middlesex, alongside Lister Hospital and its other Hertfordshire sites. The trust describes Mount Vernon as a specialist cancer centre with more than 500 staff whose consultants each specialise in one or two particular cancers. The trust's executive team page lists him alongside Medical Director Justin Daniels, Chief Operating Officer Lucy Davies, Chief Nurse Theresa Murphy and Chief People Officer Penny St Martin, without giving appointment dates.","asOf":"2026-09-10","links":[{"label":"Source: East and North Hertfordshire Teaching NHS Trust executive team page","url":"https://www.enherts-tr.nhs.uk/about/board/meet-the-trusts-executive-team/"},{"label":"Source: Mount Vernon Cancer Centre page on the trust website","url":"https://www.enherts-tr.nhs.uk/hospitals/mount-vernon/"}],"tags":["leadership","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["mount-vernon-cancer-centre"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive, East and North Hertfordshire Teaching NHS Trust (Mount Vernon Cancer Centre)","institutionId":"mount-vernon-cancer-centre","specialisms":["NHS management","Hospital leadership"],"profiles":[{"label":"East and North Hertfordshire executive team page","url":"https://www.enherts-tr.nhs.uk/about/board/meet-the-trusts-executive-team/"}],"papers":[]},{"id":"martin-beaumont","kind":"person","name":"Martin Beaumont","aka":[],"tldr":"Chief executive of CHU de Québec - Université Laval, the university hospital network in Quebec City that houses the region's cancer services.","summary":"Martin Beaumont is Président-directeur général of CHU de Québec - Université Laval, the multi-site university hospital centre affiliated with Université Laval in Quebec City. The CHU's directions page, updated 26 June 2026, lists him with Danielle Goulet as Présidente-directrice générale adjointe, Christine Mimeault as Directrice générale adjointe for major projects, Dr Julien Clément heading the Direction médicale and Vanessa Blouin heading the Direction de la cancérologie. The CHU's cancer services are organised through that cancer care directorate.","asOf":"2026-09-10","links":[{"label":"Source: CHU de Québec directions page","url":"https://www.chudequebec.ca/a-propos-de-nous/direction-et-gouvernance/directions.aspx"}],"tags":["leadership","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["chu-de-quebec"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Président-directeur général (President and CEO), CHU de Québec - Université Laval","institutionId":"chu-de-quebec","specialisms":["Hospital management","Health system governance"],"profiles":[{"label":"CHU de Québec directions page","url":"https://www.chudequebec.ca/a-propos-de-nous/direction-et-gouvernance/directions.aspx"}],"papers":[]},{"id":"martin-bornhauser","kind":"person","name":"Martin Bornhäuser","aka":[],"tldr":"Dresden haematologist and transplant physician who co-directs the NCT/UCC Dresden cancer centre and leads AML transplant trials.","summary":"Martin Bornhäuser is one of three Managing Directors of the National Center for Tumor Diseases (NCT/UCC) Dresden and Director of Medizinische Klinik und Poliklinik I at University Hospital Carl Gustav Carus. His research focuses on allogeneic stem cell transplantation and acute myeloid leukaemia, including the ASAP trial of immediate transplantation in relapsed or refractory AML. His role is listed on the NCT/UCC Direktorium page.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.nct-dresden.de/de/das-nctucc-dresden/organisation/direktorium"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bornhauser+M%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","haematology","leukaemia"],"related":[],"cancers":["aml","multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["nct-dresden"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Managing Director (Geschäftsführender Direktor); Director, Medizinische Klinik und Poliklinik I","institutionId":"nct-dresden","specialisms":["Haematology","Stem cell transplantation","Acute myeloid leukaemia","Multiple myeloma"],"profiles":[{"label":"Institution profile","url":"https://www.nct-dresden.de/de/das-nctucc-dresden/organisation/direktorium"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bornhauser+M%5BAuthor%5D"}],"papers":[{"title":"Multiple myeloma","journal":"Lancet","year":2015,"url":"https://doi.org/10.1016/S0140-6736(14)60493-1","doi":"10.1016/S0140-6736(14)60493-1"},{"title":"Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP)","journal":"Lancet Haematology","year":2024,"url":"https://doi.org/10.1016/S2352-3026(24)00065-6","doi":"10.1016/S2352-3026(24)00065-6"}],"orcid":"0000-0002-5916-3029"},{"id":"martin-dreyling","kind":"person","name":"Martin Dreyling","aka":[],"tldr":"Chairs the European MCL Network and led TRIANGLE, which showed ibrutinib can replace transplant in younger mantle cell lymphoma patients.","summary":"Martin Dreyling leads the European Mantle Cell Lymphoma Network, whose MCL Younger and Elderly trials established cytarabine-based induction with autologous transplant and rituximab maintenance, and was principal investigator of TRIANGLE, which showed adding ibrutinib to first-line therapy improves outcomes and that transplant adds nothing once ibrutinib is given, a shift toward chemotherapy-light care. He chairs ESMO lymphoma guideline work.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dreyling%20M%5BAuthor%5D%20mantle%20cell%20lymphoma"}],"tags":["lymphoma","mantle-cell","cooperative-group"],"related":[],"cancers":["mantle-cell-lymphoma"],"sections":[],"technologies":["kinase-inhibitors"],"targets":["cd20"],"drugs":[],"companies":[],"institutions":["lmu-munich"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medicine and Head of the Lymphoma Program, LMU University Hospital Munich; Chair, European MCL Network","institutionId":"lmu-munich","specialisms":["Mantle cell lymphoma","First-line therapy","BTK inhibitors","European cooperative trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dreyling%20M%5BAuthor%5D%20mantle%20cell%20lymphoma"}],"papers":[{"title":"Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE)","journal":"Lancet","year":2024,"doi":"10.1016/S0140-6736(24)00184-0"},{"title":"Treatment of older patients with mantle-cell lymphoma (MCL Elderly)","journal":"NEJM","year":2012,"doi":"10.1056/NEJMoa1200920"}]},{"id":"martin-van-den-bent","kind":"person","name":"Martin J. van den Bent","aka":[],"tldr":"Led the EORTC glioma trials that established chemotherapy for anaplastic gliomas and the value of 1p/19q and IDH status.","summary":"Martin van den Bent led EORTC 26951, which showed adjuvant PCV chemotherapy doubles survival in 1p/19q-codeleted anaplastic oligodendroglioma, and the CATNON trial establishing adjuvant temozolomide in non-codeleted anaplastic glioma. He chaired the EORTC Brain Tumour Group and led the EANO glioma guidelines. His work built the molecular framework for glioma classification and treatment.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=van%20den%20Bent%20MJ%5BAuthor%5D%20glioma"}],"tags":["glioma","eortc","chemotherapy"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["erasmus-mc"],"pathways":[],"terms":[],"trials":["eortc-26981"],"people":[],"bottlenecks":[],"keyPapers":["paper-stupp-temozolomide-nejm-2005"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Neuro-Oncology, Erasmus MC Cancer Institute","institutionId":"erasmus-mc","specialisms":["Glioma","Anaplastic glioma","Chemoradiotherapy","EORTC trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=van%20den%20Bent%20MJ%5BAuthor%5D%20glioma"}],"papers":[{"title":"Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma","journal":"Lancet","year":2017,"doi":"10.1016/S0140-6736(17)31442-3"},{"title":"Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951","journal":"JCO","year":2013,"doi":"10.1200/JCO.2012.43.2229"},{"title":"Stupp 2005: temozolomide added to radiotherapy for newly diagnosed glioblastoma","journal":"New England Journal of Medicine","year":2005,"url":"https://doi.org/10.1056/NEJMoa043330","doi":"10.1056/NEJMoa043330"}],"orcid":"0000-0001-5710-5127"},{"id":"martin-jan-schalij","kind":"person","name":"Martin Jan Schalij","aka":[],"tldr":"Cardiologist who chairs the Executive Board of Leiden University Medical Center.","summary":"Martin Jan Schalij, MD, PhD, is Chair of the Executive Board of Leiden University Medical Center (LUMC), the academic hospital of Leiden University and a partner in the Netherlands' university cancer centres. A cardiologist by background, he leads the board alongside the Dean of the Faculty of Medicine and other members. His role is listed on LUMC's management and organisation page.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.lumc.nl/en/about-lumc/het-lumc/management-and-organization/"}],"tags":["leadership","hospital management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["lumc-leiden"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["radiotherapy-and-oncology","annals-of-oncology"],"dependsOn":[],"notes":[],"role":"Chair of the Executive Board","institutionId":"lumc-leiden","specialisms":["Cardiology","Hospital leadership"],"profiles":[{"label":"Institution profile","url":"https://www.lumc.nl/en/about-lumc/het-lumc/management-and-organization/"}],"papers":[{"title":"Different manifestation of irradiation induced coronary artery disease detected with coronary computed tomography compared with matched non-irradiated controls","journal":"Radiotherapy and Oncology","year":2017,"doi":"10.1016/j.radonc.2017.09.008"},{"title":"Screening for coronary artery disease after mediastinal irradiation in Hodgkin lymphoma survivors: phase II study of indication and acceptance","journal":"Annals of Oncology","year":2014,"doi":"10.1093/annonc/mdu130"},{"title":"Outcome After ST Elevation Myocardial Infarction in Patients With Cancer Treated With Primary Percutaneous Coronary Intervention","journal":"The American Journal of Cardiology","year":2013,"doi":"10.1016/j.amjcard.2013.08.019"}]},{"id":"martin-reck","kind":"person","name":"Martin Reck","aka":[],"tldr":"Led KEYNOTE-024, the trial that made pembrolizumab alone first-line therapy for PD-L1-high lung cancer.","summary":"Martin Reck (LungenClinic Grosshansdorf, Germany) was principal investigator of KEYNOTE-024, which showed pembrolizumab beats platinum chemotherapy in NSCLC with PD-L1 of 50% or more, the first time a checkpoint inhibitor replaced chemotherapy first line. He has led IMpower150 and numerous SCLC immunotherapy trials and has chaired ESMO's lung cancer guideline group.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Reck%20M%5BAuthor%5D%20pembrolizumab%20lung"}],"tags":["lung","immunotherapy","trialist"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["pd1"],"drugs":["pembrolizumab","atezolizumab"],"companies":[],"institutions":["lungenclinic-grosshansdorf"],"pathways":[],"terms":[],"trials":["keynote-024-189"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Head of Thoracic Oncology, LungenClinic Grosshansdorf","institutionId":"lungenclinic-grosshansdorf","specialisms":["Lung cancer immunotherapy","First-line NSCLC therapy","Small-cell lung cancer"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Reck%20M%5BAuthor%5D%20pembrolizumab%20lung"}],"papers":[{"title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer (KEYNOTE-024)","journal":"NEJM","year":2016,"doi":"10.1056/NEJMoa1606774"},{"title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater","journal":"JCO","year":2021,"doi":"10.1200/JCO.21.00174"}]},{"id":"martin-schlumberger","kind":"person","name":"Martin Schlumberger","aka":[],"tldr":"Led SELECT (lenvatinib) and the ESTIMABL trials that showed many thyroid cancer patients can have lower radioiodine doses or none at all.","summary":"Martin Schlumberger was principal investigator of SELECT, which established lenvatinib for radioiodine-refractory differentiated thyroid cancer, and led ESTIMABL1 and ESTIMABL2, the French trials showing that low-dose radioiodine, and for low-risk patients no radioiodine, are non-inferior to standard ablation, sharply de-escalating thyroid cancer treatment. He has chaired the European Thyroid Association and ATA guideline work.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schlumberger%20M%5BAuthor%5D%20thyroid"}],"tags":["thyroid","radioiodine","de-escalation"],"related":[],"cancers":["thyroid"],"sections":[],"technologies":["radioligand-therapy","kinase-inhibitors"],"targets":[],"drugs":[],"companies":[],"institutions":["gustave-roussy"],"pathways":[],"terms":[],"trials":["select-lenvatinib","estimabl2"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Emeritus Professor of Oncology, Gustave Roussy and Université Paris-Saclay","institutionId":"gustave-roussy","specialisms":["Thyroid cancer","Radioiodine therapy","Kinase inhibitors","Nuclear medicine"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schlumberger%20M%5BAuthor%5D%20thyroid"}],"papers":[{"title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer (SELECT)","journal":"NEJM","year":2015,"doi":"10.1056/NEJMoa1406470"},{"title":"Thyroidectomy without radioiodine in patients with low-risk thyroid cancer (ESTIMABL2)","journal":"NEJM","year":2022,"doi":"10.1056/NEJMoa2111953"},{"title":"Strategies of radioiodine ablation in patients with low-risk thyroid cancer (ESTIMABL1)","journal":"NEJM","year":2012,"doi":"10.1056/NEJMoa1108586"}]},{"id":"martin-schuler","kind":"person","name":"Martin Schuler","aka":[],"tldr":"Medical oncologist and lung cancer trialist who is Deputy Director of the West German Cancer Center in Essen.","summary":"Martin Schuler is Deputy Director of the West German Cancer Center at University Hospital Essen and represents the Comprehensive Cancer Center Essen and NCT West on the WTZ directorate. He is a medical oncologist whose research concentrates on thoracic malignancies, particularly targeted therapies for oncogene-driven non-small cell lung cancer. He has been an investigator on many international lung cancer trials.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://wtz-essen.de/direktorium-wtz-essen/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schuler+M%5BAuthor%5D+lung"}],"tags":["leadership","clinician-scientist","lung cancer"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["essen-wtz"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Deputy Director WTZ Essen","institutionId":"essen-wtz","specialisms":["Thoracic oncology","Lung cancer","Targeted therapy"],"profiles":[{"label":"Institution profile","url":"https://wtz-essen.de/direktorium-wtz-essen/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schuler+M%5BAuthor%5D+lung"}],"papers":[{"title":"Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial","journal":"Nature Medicine","year":2024,"doi":"10.1038/s41591-024-02965-0"},{"title":"Facts and Hopes in Neoadjuvant Immunotherapy Combinations in Resectable Non–Small Cell Lung Cancer","journal":"Clinical Cancer Research","year":2025,"doi":"10.1158/1078-0432.ccr-24-1441"},{"title":"Treatment Sequences in BRAF-V600–Mutated NSCLC: First-Line Targeted Therapy Versus First-Line (Chemo-) Immunotherapy","journal":"Journal of Thoracic Oncology","year":2025,"doi":"10.1016/j.jtho.2025.04.016"}],"orcid":"0000-0002-2166-3394"},{"id":"martin-siess","kind":"person","name":"Martin Siess","aka":[],"tldr":"Medical Director and board chair of TUM Klinikum rechts der Isar, the university hospital of the Technical University of Munich.","summary":"Martin Siess is Vorstandsvorsitzender (Chairman of the Board) and Ärztlicher Direktor (Medical Director) of TUM Klinikum rechts der Isar in Munich. The hospital is the academic medical centre of the Technical University of Munich and a partner in the Comprehensive Cancer Center München. His role is recorded in the public record for the hospital.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.mri.tum.de"}],"tags":["leadership","hospital management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["tum-munich"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chairman of the Board and Medical Director","institutionId":"tum-munich","specialisms":["Hospital management","Academic medicine"],"profiles":[{"label":"Institution profile","url":"https://www.mri.tum.de"}],"papers":[]},{"id":"martine-piccart","kind":"person","name":"Martine Piccart","aka":[],"tldr":"Co-founded the Breast International Group and led HERA, the trial that made adjuvant trastuzumab standard.","summary":"Martine Piccart is Scientific Director of Institut Jules Bordet in Brussels and co-founder of the Breast International Group (BIG), and a past president of the European Society for Medical Oncology (ESMO) and of the European CanCer Organisation. Her specialisms are breast cancer, adjuvant trastuzumab and international trial networks. She led HERA, the New England Journal of Medicine trial of one year of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer, which made adjuvant trastuzumab the standard. Her record links her to the HERA, NSABP B-31 and NCCTG N9831 adjuvant trastuzumab trials. Her publications are listed on PubMed.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Martine_Piccart","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Piccart%20M%5BAuthor%5D%20HERA%20trastuzumab"}],"tags":[],"related":[],"cancers":["breast-her2-positive"],"sections":[],"technologies":[],"targets":[],"drugs":["trastuzumab"],"companies":["big"],"institutions":["esmo"],"pathways":[],"terms":[],"trials":["hera-b31-n9831"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Scientific Director, Institut Jules Bordet; Co-founder, Breast International Group","institutionId":"big","specialisms":["Breast cancer","Adjuvant trastuzumab","International trial networks"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Piccart%20M%5BAuthor%5D%20HERA%20trastuzumab"}],"papers":[{"title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer (HERA)","journal":"NEJM","year":2005,"doi":"10.1056/NEJMoa052306"},{"title":"ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer","journal":"New England Journal of Medicine","year":2021,"url":"https://doi.org/10.1056/NEJMoa2028485","doi":"10.1056/NEJMoa2028485"},{"title":"OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer","journal":"New England Journal of Medicine","year":2021,"url":"https://doi.org/10.1056/NEJMoa2105215","doi":"10.1056/NEJMoa2105215"}],"orcid":"0000-0001-9068-8504"},{"id":"martyn-caplin","kind":"person","name":"Martyn E. Caplin","aka":[],"tldr":"Led CLARINET, which showed lanreotide slows tumour growth and made somatostatin analogues first-line antiproliferative therapy for NETs.","summary":"Martyn Caplin (Royal Free Hospital, London) was principal investigator of CLARINET, the trial showing lanreotide markedly prolongs progression-free survival in non-functioning gastroenteropancreatic neuroendocrine tumours, establishing somatostatin analogues as antiproliferative therapy rather than only symptom control. He leads one of Europe's largest NET centres and has chaired the European Neuroendocrine Tumor Society.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Caplin%20ME%5BAuthor%5D%20neuroendocrine%20lanreotide"}],"tags":["neuroendocrine","somatostatin","uk"],"related":[],"cancers":["neuroendocrine"],"sections":[],"technologies":[],"targets":["sstr2"],"drugs":[],"companies":[],"institutions":["royal-free-hospital"],"pathways":[],"terms":[],"trials":["clarinet"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["endocrine-related-cancer"],"dependsOn":[],"notes":[],"role":"Professor of Gastroenterology and Neuroendocrine Tumours, Royal Free Hospital and UCL","institutionId":"royal-free-hospital","specialisms":["Neuroendocrine tumours","Somatostatin analogues","Gastroenterology","Guidelines"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Caplin%20ME%5BAuthor%5D%20neuroendocrine%20lanreotide"}],"papers":[{"title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors (CLARINET)","journal":"NEJM","year":2014,"doi":"10.1056/NEJMoa1316158"},{"title":"Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study","journal":"Endocrine-Related Cancer","year":2016,"doi":"10.1530/ERC-15-0490"}],"orcid":"0000-0003-0177-1352"},{"id":"mary-lasker","kind":"person","name":"Mary Lasker","aka":[],"tldr":"She turned the American Cancer Society into a research funder in the 1940s, built the Lasker Awards, and led the lobbying that produced the 1971 National Cancer Act and the modern NCI budget.","summary":"Mary Lasker (1900-1994) and her husband Albert founded the Lasker Foundation in 1942 and its awards, which have often anticipated the Nobel Prize. She helped reorganise the American Society for the Control of Cancer into the American Cancer Society and pushed it to commit a quarter of its income to research. From the late 1940s she lobbied Congress year after year for the National Institutes of Health, cultivating members and testifying alongside clinicians such as Sidney Farber, whom she recruited as a witness. Her Citizens Committee for the Conquest of Cancer ran the 1969 campaign, including a full-page advertisement telling President Nixon that he could cure cancer, that led to the National Cancer Act signed on 23 December 1971. The act created the modern National Cancer Institute, its cancer centres and its budget, and remains the template for disease-specific advocacy.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Mary_Lasker","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Mary_Lasker"},{"label":"Lasker Foundation","url":"https://laskerfoundation.org/"}],"tags":["hero","advocate"],"related":["american-cancer-society"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["nci"],"pathways":[],"terms":[],"trials":[],"people":["sidney-farber"],"bottlenecks":["b-funding-allocation","b-incentive-misalignment"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Philanthropist and lobbyist behind the National Cancer Act of 1971","specialisms":["Research funding","Health policy","Cancer advocacy"],"profiles":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Mary_Lasker"},{"label":"Lasker Foundation","url":"https://laskerfoundation.org/"}],"papers":[]},{"id":"mary-mccormack","kind":"person","name":"Mary McCormack","aka":[],"tldr":"Led INTERLACE, which showed a short course of chemotherapy before chemoradiation cuts cervical cancer deaths using cheap, available drugs.","summary":"Mary McCormack was chief investigator of INTERLACE, the international trial showing six weeks of induction carboplatin and paclitaxel before standard chemoradiotherapy improves progression-free and overall survival in locally advanced cervical cancer, a result immediately implementable in low-resource settings where most cervical cancer occurs. She leads gynaecological radiotherapy research at UCLH.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=McCormack%20M%5BAuthor%5D%20INTERLACE%20cervical"}],"tags":["cervical","chemoradiotherapy","global-health"],"related":[],"cancers":["cervical"],"sections":[],"technologies":["imrt-igrt","brachytherapy"],"targets":[],"drugs":["carboplatin","paclitaxel"],"companies":[],"institutions":["uclh"],"pathways":[],"terms":[],"trials":["interlace"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["british-journal-of-cancer"],"dependsOn":[],"notes":[],"role":"Consultant Clinical Oncologist, University College London Hospitals","institutionId":"uclh","specialisms":["Cervical cancer","Chemoradiotherapy","Induction chemotherapy","Gynaecological radiotherapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=McCormack%20M%5BAuthor%5D%20INTERLACE%20cervical"}],"papers":[{"title":"Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE)","journal":"Lancet","year":2024,"doi":"10.1016/S0140-6736(24)01438-7"},{"title":"A phase II study of weekly neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancer","journal":"British Journal of Cancer","year":2013,"doi":"10.1038/bjc.2013.230"}]},{"id":"mary-claire-king","kind":"person","name":"Mary-Claire King","aka":[],"tldr":"In 1990 she showed that a single gene on chromosome 17, BRCA1, causes inherited breast and ovarian cancer, when most of the field doubted such a gene existed. Genetic testing and risk-reducing care followed.","summary":"Mary-Claire King, then at the University of California, Berkeley, spent seventeen years studying families with many cases of breast cancer and in 1990 published linkage of early-onset breast cancer to a region of chromosome 17q21, establishing that a hereditary form of the disease existed and naming the gene BRCA1. The gene itself was cloned in 1994 by Mark Skolnick's team at Myriad Genetics and Utah, and BRCA2 was identified in 1995 by Michael Stratton's group. Her finding opened clinical genetic testing, risk-reducing surgery and surveillance for carriers, and later the PARP inhibitors that exploit BRCA-deficient tumours. She has argued for population screening of BRCA1 and BRCA2 in all women over 30. King also used mitochondrial DNA to reunite children abducted during Argentina's dictatorship with their grandmothers, and received the Lasker Award in 2014 and the National Medal of Science in 2016.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Mary-Claire_King","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Mary-Claire_King"},{"label":"Lasker Foundation","url":"https://laskerfoundation.org/"}],"tags":["hero","pioneer"],"related":[],"cancers":["ovarian","tnbc"],"sections":["prevention"],"technologies":["germline-testing","parp-inhibitor","hrd-testing"],"targets":["brca"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["hereditary-cancer-syndromes","germline-vs-somatic"],"trials":[],"people":["angelina-jolie","judy-garber"],"bottlenecks":["b-hereditary-risk"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Geneticist who proved inherited breast cancer exists and mapped BRCA1","specialisms":["Human genetics","Hereditary breast and ovarian cancer","BRCA1"],"profiles":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Mary-Claire_King"},{"label":"Lasker Foundation","url":"https://laskerfoundation.org/"}],"papers":[{"title":"Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2","journal":"Science","year":2003,"doi":"10.1126/science.1088759"},{"title":"Tamoxifen and Breast Cancer Incidence Among Women With Inherited Mutations in BRCA1 and BRCA2","journal":"JAMA","year":2001,"doi":"10.1001/jama.286.18.2251"},{"title":"Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families","journal":"Nature Genetics","year":1994,"doi":"10.1038/ng1294-399"}]},{"id":"masatoshi-kudo","kind":"person","name":"Masatoshi Kudo","aka":[],"tldr":"Japanese hepatologist who led REFLECT, the trial that made lenvatinib a first-line option for liver cancer.","summary":"Masatoshi Kudo (Kindai University, Osaka) was principal investigator of REFLECT, which showed lenvatinib is non-inferior to sorafenib in unresectable hepatocellular carcinoma and became the first new first-line option in a decade. He has published extensively on combining systemic therapy with transarterial chemoembolisation and edits the journal Liver Cancer. He continues to lead HCC trials across Asia.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kudo%20M%5BAuthor%5D%20hepatocellular%20lenvatinib"}],"tags":["hcc","japan","trialist"],"related":[],"cancers":["hcc"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":[],"companies":[],"institutions":["kindai-university-hospital"],"pathways":[],"terms":[],"trials":["reflect"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor and Chairman, Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine","institutionId":"kindai-university-hospital","specialisms":["Hepatocellular carcinoma","Lenvatinib","Locoregional therapy","Hepatology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kudo%20M%5BAuthor%5D%20hepatocellular%20lenvatinib"}],"papers":[{"title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial (REFLECT)","journal":"Lancet","year":2018,"doi":"10.1016/S0140-6736(18)30207-1"},{"title":"Lenvatinib plus transarterial chemoembolization for unresectable hepatocellular carcinoma (LAUNCH)","journal":"JCO","year":2023}],"orcid":"0000-0002-4102-3474"},{"id":"massimo-cristofanilli","kind":"person","name":"Massimo Cristofanilli","aka":[],"tldr":"Showed that counting tumour cells in blood predicts survival in breast cancer and co-led PALOMA-3, which brought palbociclib to endocrine-resistant disease.","summary":"Massimo Cristofanilli (Weill Cornell Medicine, New York) led the 2004 study showing that circulating tumour cell counts predict survival in metastatic breast cancer, the founding clinical result for liquid biopsy. He was co-principal investigator of PALOMA-3, which established palbociclib plus fulvestrant after endocrine progression, and has led inflammatory breast cancer programmes. His work now focuses on ctDNA and CTC-guided treatment.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cristofanilli%20M%5BAuthor%5D%20breast%20circulating"}],"tags":["breast","liquid-biopsy"],"related":[],"cancers":["breast-hr-positive"],"sections":[],"technologies":["liquid-biopsy","cdk46-inhibitor"],"targets":["cdk4-6","estrogen-receptor"],"drugs":["palbociclib"],"companies":[],"institutions":["weill-cornell-meyer-cancer-center"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medicine and Director of Breast Medical Oncology, Weill Cornell Medicine","institutionId":"weill-cornell-meyer-cancer-center","specialisms":["Metastatic breast cancer","Circulating tumour cells","CDK4/6 inhibitors","Inflammatory breast cancer"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cristofanilli%20M%5BAuthor%5D%20breast%20circulating"}],"papers":[{"title":"Circulating tumor cells, disease progression, and survival in metastatic breast cancer","journal":"NEJM","year":2004,"doi":"10.1056/NEJMoa040766"},{"title":"Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3)","journal":"Lancet Oncology","year":2016,"doi":"10.1016/S1470-2045(15)00613-0"}],"orcid":"0000-0002-4194-7175"},{"id":"massimo-de-fino","kind":"person","name":"Massimo De Fino","aka":[],"tldr":"Health manager who has been Director General of IRCCS CROB, the Basilicata regional cancer reference centre in Rionero in Vulture, since late 2023.","summary":"Massimo De Fino is Direttore Generale of the IRCCS CROB (Centro di Riferimento Oncologico della Basilicata) in Rionero in Vulture, the Basilicata region's research cancer institute. His appointment was announced on 22 November 2023 by regional president Vito Bardi and vice president Francesco Fanelli after a public selection procedure, and he formally took up the post in December 2023, having previously worked in the Basilicata health service. Regional news coverage in August 2026 of the confirmation of the institute's IRCCS scientific status still describes CROB as led by director Massimo De Fino.","asOf":"2026-09-10","links":[{"label":"Source: ivl24 appointment report (November 2023)","url":"https://ivl24.it/massimo-de-fino-nuovo-direttore-generale-del-crob/"},{"label":"Source: ivl24 report naming him as director of CROB (August 2026)","url":"https://ivl24.it/il-vescovo-fanelli-al-fianco-della-ricerca-oncologica-la-conferma-del-carattere-scientifico-del-crob-e-una-vittoria-della-vita/"}],"tags":["leadership","hospital-management","research-institute"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["crob-rionero"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Direttore Generale (Director General), IRCCS CROB, Rionero in Vulture","institutionId":"crob-rionero","specialisms":["Health service management","Cancer centre management"],"profiles":[{"label":"ivl24 report of his appointment as Direttore Generale (November 2023)","url":"https://ivl24.it/massimo-de-fino-nuovo-direttore-generale-del-crob/"}],"papers":[]},{"id":"matt-seymour","kind":"person","name":"Matt Seymour","aka":[],"tldr":"The Leeds oncologist behind the FOCUS trials, which asked how best to sequence chemotherapy for advanced bowel cancer, and a leader of FOxTROT, which moved chemotherapy before surgery in colon cancer.","summary":"Matt Seymour has been Professor of Gastrointestinal Cancer Medicine at the University of Leeds since 2004 and has served as clinical research director of the National Cancer Research Institute. He was first author of MRC FOCUS, the trial that compared sequential and combination chemotherapy strategies in advanced colorectal cancer, and is second author of the mature FOxTROT results, which showed that six weeks of preoperative oxaliplatin and fluoropyrimidine chemotherapy for operable colon cancer downstaged tumours, made resections more often histopathologically complete (94 percent against 89 percent) and cut residual or recurrent disease at two years.","asOf":"2026-09-24","links":[{"label":"University of Leeds staff page","url":"https://medicinehealth.leeds.ac.uk/medicine/staff/3085/professor-matt-seymour"}],"tags":["colorectal","trialist","uk"],"related":["david-sebag-montefiore","tim-maughan"],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":["folfox","capox"],"companies":[],"institutions":["leeds-cancer-centre"],"pathways":[],"terms":[],"trials":["foxtrot","focus4"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Gastrointestinal Cancer Research, University of Leeds","institutionId":"leeds-cancer-centre","specialisms":["Advanced colorectal cancer chemotherapy","Trial strategy and design","Neoadjuvant treatment of colon cancer"],"profiles":[{"label":"University of Leeds staff page","url":"https://medicinehealth.leeds.ac.uk/medicine/staff/3085/professor-matt-seymour"}],"papers":[{"title":"Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial","journal":"Lancet","year":2007,"doi":"10.1016/S0140-6736(07)61087-3"},{"title":"Preoperative chemotherapy for operable colon cancer: mature results of an international randomized controlled trial (FOxTROT)","journal":"Journal of Clinical Oncology","year":2023,"doi":"10.1200/JCO.22.00046"}]},{"id":"matthew-powell","kind":"person","name":"Matthew A. Powell","aka":[],"tldr":"Gynecologic oncologist and endometrial cancer trialist who is President of the Society of Gynecologic Oncology.","summary":"Matthew A. Powell is President of the Society of Gynecologic Oncology. He is a gynecologic oncologist whose research focuses on endometrial cancer, including leadership of cooperative-group trials of immunotherapy combined with chemotherapy in advanced disease. As SGO President he leads the society's executive committee and board.","asOf":"2026-09-10","links":[{"label":"Society page","url":"https://www.sgo.org/about-sgo/bod/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Powell+MA%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","gynecologic oncology","endometrial cancer"],"related":[],"cancers":["endometrial","ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["sgo"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President","institutionId":"sgo","specialisms":["Gynecologic oncology","Endometrial cancer","Clinical trials"],"profiles":[{"label":"Society page","url":"https://www.sgo.org/about-sgo/bod/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Powell+MA%5BAuthor%5D"}],"papers":[{"title":"Four-year survival outcomes with dostarlimab plus chemotherapy in mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer in the RUBY trial","journal":"Gynecologic Oncology","year":2026,"doi":"10.1016/j.ygyno.2026.05.008"}]},{"id":"matthew-callister","kind":"person","name":"Matthew Callister","aka":[],"tldr":"The Leeds respiratory physician who ran the Yorkshire Lung Screening Trial, the trial that worked out which risk rule the NHS should use to decide who gets a screening scan.","summary":"Matthew Callister is a consultant in respiratory medicine at Leeds Teaching Hospitals NHS Trust, where his listed special interests are general respiratory medicine, lung cancer, mesothelioma and endobronchial ultrasound, and an honorary professor at the University of Leeds. He is the named scientific contact on the Yorkshire Lung Screening Trial and senior author on its main results.\n\nThe trial, funded by Yorkshire Cancer Research and run from mobile CT vans in the community, invited 44,943 people and enrolled 8,847. Its participation paper showed response falling with current smoking and with deprivation, which is the central problem of lung screening. Its eligibility paper compared the three rules the programme might use and found that the PLCOm2012 risk model at a threshold of 1.51 percent identified 91.1 percent of the cancers, against 62.8 percent for the 2013 United States Preventive Services Task Force criteria. Its cost-effectiveness paper put every option well below the 20,000 pound per quality-adjusted life-year threshold. He is also the scientific contact on YorQuit, which is testing which stop-smoking offer works best alongside screening.","asOf":"2026-09-25","links":[{"label":"Leeds Teaching Hospitals consultant page","url":"https://www.leedsth.nhs.uk/consultants/professor-matthew-callister/"}],"tags":["lung","screening","uk"],"related":["philip-crosbie","david-baldwin"],"cancers":["nsclc","lung-cancer"],"sections":["early-detection"],"technologies":["low-dose-ct-screening"],"targets":[],"drugs":[],"companies":[],"institutions":["leeds-cancer-centre"],"pathways":[],"terms":[],"trials":["ylst"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Consultant in Respiratory Medicine, Leeds Teaching Hospitals NHS Trust; Honorary Professor, University of Leeds","institutionId":"leeds-cancer-centre","specialisms":["Lung cancer screening","Endobronchial ultrasound","Mesothelioma"],"profiles":[{"label":"Leeds Teaching Hospitals consultant page","url":"https://www.leedsth.nhs.uk/consultants/professor-matthew-callister/"}],"papers":[{"title":"Participation in community-based lung cancer screening: the Yorkshire Lung Screening Trial","journal":"European Respiratory Journal","year":2022,"doi":"10.1183/13993003.00483-2022"},{"title":"Comparing strategies for lung cancer screening eligibility: results from the Yorkshire Lung Screening Trial","journal":"Journal of Thoracic Oncology","year":2025,"doi":"10.1016/j.jtho.2024.12.011"}]},{"id":"matthew-galsky","kind":"person","name":"Matthew D. Galsky","aka":[],"tldr":"Led trials that brought immunotherapy into bladder cancer and tested skipping cystectomy in responders.","summary":"Matthew D. Galsky is Director of Genitourinary Medical Oncology and Co-Director of the Center of Excellence for Bladder Cancer at The Mount Sinai Hospital and Tisch Cancer Institute. He is a genitourinary oncologist known for leading trials that brought immunotherapy into bladder cancer, including IMvigor130, and for testing whether responders to chemo-immunotherapy can skip cystectomy. His selected paper reports atezolizumab with or without chemotherapy in metastatic urothelial cancer in IMvigor130. He continues to study bladder preservation in muscle-invasive disease and immunotherapy with atezolizumab and nivolumab.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Galsky%20MD%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["urothelial"],"sections":[],"technologies":[],"targets":["pdl1"],"drugs":["atezolizumab","nivolumab"],"companies":[],"institutions":["mount-sinai"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Genitourinary Medical Oncology; Co-Director, Center of Excellence for Bladder Cancer","institutionId":"mount-sinai","specialisms":["Bladder cancer","Immunotherapy","Bladder preservation"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Galsky%20MD%5BAuthor%5D"}],"papers":[{"title":"Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130)","journal":"Lancet","year":2020,"url":"https://doi.org/10.1016/S0140-6736(20)30230-0","doi":"10.1016/S0140-6736(20)30230-0"},{"title":"NIAGARA: durvalumab before and after cystectomy for muscle-invasive bladder cancer","journal":"New England Journal of Medicine","year":2024,"url":"https://doi.org/10.1056/NEJMoa2408154","doi":"10.1056/NEJMoa2408154"}]},{"id":"matthew-hellmann","kind":"person","name":"Matthew D. Hellmann","aka":[],"tldr":"Lung cancer doctor who was the lead author of CheckMate 227, the trial that showed the immunotherapy pair nivolumab and ipilimumab helps people with advanced lung cancer live longer than chemotherapy alone.","summary":"Matthew Hellmann was first author of the CheckMate 227 reports in the New England Journal of Medicine, including the 2019 overall-survival analysis of nivolumab plus ipilimumab in previously untreated advanced non-small-cell lung cancer. His research at Memorial Sloan Kettering Cancer Center, where he practised as a thoracic oncologist, centred on tumour mutational burden and other predictors of response to immune checkpoint blockade.","asOf":"2026-09-18","links":[],"tags":["lung","immunotherapy","trialist"],"related":[],"cancers":["pdl1-high-nsclc","nsclc","lung-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["checkmate-227"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Medical oncologist and trial lead, thoracic immunotherapy","specialisms":["Non-small-cell lung cancer","Immune checkpoint inhibitors","Tumour mutational burden"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hellmann%5BAuthor%5D"}],"papers":[{"title":"Rizvi 2015: the mutational landscape determines who responds to PD-1 blockade in lung cancer","journal":"Science","year":2015,"url":"https://doi.org/10.1126/science.aaa1348","doi":"10.1126/science.aaa1348"}]},{"id":"matthew-hurles","kind":"person","name":"Matthew Hurles","aka":[],"tldr":"Human geneticist who directs the Wellcome Sanger Institute, a world centre for cancer genome research.","summary":"Matthew Hurles is Director of the Wellcome Sanger Institute and a Senior Group Leader there. His own research focuses on identifying disease-causing genetic variants in developmental disorders through large-scale sequencing studies such as Deciphering Developmental Disorders. As Director he oversees the institute's programmes including cancer, ageing and somatic mutation genomics.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.sanger.ac.uk/person/hurles-matthew/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hurles+ME%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","genomics"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["wellcome-sanger"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nature-genetics"],"dependsOn":[],"notes":[],"role":"Director of the Wellcome Sanger Institute and Senior Group Leader","institutionId":"wellcome-sanger","specialisms":["Human genetics","Genomic medicine","Developmental disorders"],"profiles":[{"label":"Institution profile","url":"https://www.sanger.ac.uk/person/hurles-matthew/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hurles+ME%5BAuthor%5D"}],"papers":[{"title":"Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing","journal":"Nature Genetics","year":2008,"doi":"10.1038/ng.128"}],"orcid":"0000-0002-2333-7015"},{"id":"matthew-meyerson","kind":"person","name":"Matthew Meyerson","aka":[],"tldr":"Co-discovered EGFR mutations in lung cancer and linked Fusobacterium to colorectal cancer.","summary":"Matthew Meyerson is Director of the Center for Cancer Genomics at Dana-Farber and an Institute Member of the Broad Institute of MIT and Harvard. He is a genomicist known for co-discovering EGFR mutations in lung cancer in 2004, mapping lung adenocarcinoma genomes for The Cancer Genome Atlas, and identifying enrichment of Fusobacterium nucleatum in colorectal tumours. His selected papers report EGFR mutations in lung cancer correlating with response to gefitinib, and the genomic analysis associating Fusobacterium with colorectal carcinoma. He continues to work on lung cancer genomics and the microbiome in cancer.","asOf":"2026-09-08","links":[{"label":"Broad bio","url":"https://www.broadinstitute.org/bios/matthew-meyerson"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Meyerson%20M%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["nsclc","colorectal"],"sections":[],"technologies":[],"targets":["egfr"],"drugs":[],"companies":[],"institutions":["broad-institute"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Center for Cancer Genomics, Dana-Farber; Institute Member, Broad","institutionId":"broad-institute","specialisms":["Lung cancer genomics","EGFR mutations","Microbiome and cancer"],"profiles":[{"label":"Broad bio","url":"https://www.broadinstitute.org/bios/matthew-meyerson"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Meyerson%20M%5BAuthor%5D"}],"papers":[{"title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","journal":"Science","year":2004,"url":"https://doi.org/10.1126/science.1099314","doi":"10.1126/science.1099314"},{"title":"Genomic analysis identifies association of Fusobacterium with colorectal carcinoma","journal":"Genome Research","year":2012,"url":"https://doi.org/10.1101/gr.126573.111","doi":"10.1101/gr.126573.111"}],"orcid":"0000-0002-9133-8108"},{"id":"matthew-goetz","kind":"person","name":"Matthew P. Goetz","aka":[],"tldr":"Breast oncologist who led MONARCH 3 and studies how genetics shapes response to endocrine therapy.","summary":"Matthew Goetz is Professor of Oncology and Pharmacology and Co-leader of the Women's Cancer Program at Mayo Clinic. A breast medical oncologist and pharmacologist specialising in pharmacogenomics and CDK4/6 inhibitors, he was principal investigator of MONARCH 3, the trial of abemaciclib as initial therapy for advanced breast cancer, and of tamoxifen pharmacogenomics work on how genetics shapes response to endocrine therapy. His papers report MONARCH 3 in the Journal of Clinical Oncology and the final overall survival results of abemaciclib plus a nonsteroidal aromatase inhibitor in HR-positive, HER2-negative advanced breast cancer in Annals of Oncology. He co-leads the breast cancer programme at Mayo Clinic, working on CDK4/6 and the oestrogen receptor.","asOf":"2026-09-08","links":[{"label":"Mayo Clinic research faculty","url":"https://www.mayo.edu/research/faculty"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Goetz%20MP%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Matthew%20P.%20Goetz"}],"tags":[],"related":[],"cancers":["breast-hr-positive"],"sections":[],"technologies":[],"targets":["cdk4-6","estrogen-receptor"],"drugs":["abemaciclib"],"companies":[],"institutions":["mayo-clinic"],"pathways":[],"terms":[],"trials":["monarch-3"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Oncology and Pharmacology; Co-leader, Women's Cancer Program, Mayo Clinic","institutionId":"mayo-clinic","specialisms":["Breast cancer","Pharmacogenomics","CDK4/6 inhibitors"],"profiles":[{"label":"Mayo Clinic research faculty","url":"https://www.mayo.edu/research/faculty"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Goetz%20MP%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Matthew%20P.%20Goetz"}],"papers":[{"title":"MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer","journal":"Journal of Clinical Oncology","year":2017,"url":"https://doi.org/10.1200/JCO.2017.75.6155","doi":"10.1200/JCO.2017.75.6155"},{"title":"Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3","journal":"Annals of Oncology","year":2024,"url":"https://doi.org/10.1016/j.annonc.2024.04.013","doi":"10.1016/j.annonc.2024.04.013"}],"orcid":"0000-0002-4383-270X"},{"id":"matthew-smith","kind":"person","name":"Matthew R. Smith","aka":[],"tldr":"Led ARASENS and SPARTAN, trials that established darolutamide triplet therapy and apalutamide for prostate cancer.","summary":"Matthew Smith was principal investigator of ARASENS, which showed darolutamide added to androgen deprivation and docetaxel improves survival in metastatic hormone-sensitive prostate cancer, and of SPARTAN, which established apalutamide for non-metastatic castration-resistant disease. He has led landmark studies of bone loss and denosumab in men on hormone therapy.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Smith%20MR%5BAuthor%5D%20darolutamide%20OR%20apalutamide"}],"tags":["prostate","trialist"],"related":[],"cancers":["prostate"],"sections":[],"technologies":["androgen-deprivation"],"targets":["androgen-receptor"],"drugs":[],"companies":[],"institutions":["mgh"],"pathways":[],"terms":[],"trials":["arasens"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Genitourinary Malignancies Program, Massachusetts General Hospital Cancer Center","institutionId":"mgh","specialisms":["Prostate cancer","Androgen receptor inhibitors","Bone health","Non-metastatic castration-resistant disease"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Smith%20MR%5BAuthor%5D%20darolutamide%20OR%20apalutamide"}],"papers":[{"title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer (ARASENS)","journal":"NEJM","year":2022,"doi":"10.1056/NEJMoa2119115"},{"title":"Apalutamide treatment and metastasis-free survival in prostate cancer (SPARTAN)","journal":"NEJM","year":2018,"doi":"10.1056/NEJMoa1715546"}]},{"id":"matthew-reed","kind":"person","name":"Matthew Reed","aka":[],"tldr":"Chief Executive of Marie Curie, the UK end of life care charity, since February 2019.","summary":"Matthew Reed has been Chief Executive of Marie Curie, the UK's leading end of life charity, since February 2019. He previously served as Chief Executive of The Children's Society and of the Cystic Fibrosis Trust and as a director at Christian Aid. The charity's Board of Trustees delegates day to day management to him, and its Executive Team reports to him.","asOf":"2026-09-10","links":[{"label":"Source: Marie Curie, Who we are","url":"https://www.mariecurie.org.uk/about-us/who-we-are"}],"tags":["leadership","charity","palliative-care"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["marie-curie-uk"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive, Marie Curie","institutionId":"marie-curie-uk","specialisms":["Charity leadership","Palliative and end of life care","Social policy"],"profiles":[{"label":"Marie Curie profile","url":"https://www.mariecurie.org.uk/about-us/governance/matthew-reed-chief-executive"}],"papers":[]},{"id":"matthew-vander-heiden","kind":"person","name":"Matthew Vander Heiden","aka":[],"tldr":"Physician-scientist and cancer metabolism expert who directs MIT's Koch Institute for Integrative Cancer Research.","summary":"Matthew Vander Heiden is Director of the Koch Institute for Integrative Cancer Research at MIT, with scientific, strategic and operational oversight of the institute. His laboratory studies how cell metabolism supports tumour growth, and he is a practising medical oncologist at Dana-Farber Cancer Institute. His 2009 Science review on the Warburg effect is one of the most cited papers in the field.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://ki.mit.edu/people/institute-directorship"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Vander+Heiden+MG%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","cancer metabolism"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["mit-koch"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director","institutionId":"mit-koch","specialisms":["Cancer metabolism","Medical oncology","Cell biology"],"profiles":[{"label":"Institution profile","url":"https://ki.mit.edu/people/institute-directorship"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Vander+Heiden+MG%5BAuthor%5D"}],"papers":[{"title":"Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation","journal":"Science","year":2009,"url":"https://doi.org/10.1126/science.1160809","doi":"10.1126/science.1160809"}]},{"id":"matthias-guckenberger","kind":"person","name":"Matthias Guckenberger","aka":[],"tldr":"Zurich radiation oncologist and ESTRO Past-President, a leading voice on stereotactic radiotherapy for oligometastases.","summary":"Matthias Guckenberger is Past-President of ESTRO and serves on its board; he is a radiation oncologist at University Hospital Zurich. His research focuses on stereotactic body radiotherapy, the characterisation and treatment of oligometastatic disease, and radiotherapy for lung cancer. He has led European consensus work defining oligometastatic disease and its treatment.","asOf":"2026-09-10","links":[{"label":"Society page","url":"https://www.estro.org/About/ESTRO-Organisation-Structure/Board"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Guckenberger+M%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","radiotherapy","lung cancer"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["estro"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Past-President","institutionId":"estro","specialisms":["Stereotactic body radiotherapy","Oligometastatic disease","Lung cancer radiotherapy"],"profiles":[{"label":"Society page","url":"https://www.estro.org/About/ESTRO-Organisation-Structure/Board"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Guckenberger+M%5BAuthor%5D"}],"papers":[{"title":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","journal":"The Lancet Oncology","year":2020,"doi":"10.1016/s1470-2045(19)30718-1"},{"title":"Short interactive workshops reduce variability in contouring treatment volumes for spine stereotactic body radiation therapy: Experience with the ESTRO FALCON programme and EduCase™ training tool","journal":"Radiotherapy and Oncology","year":2018,"doi":"10.1016/j.radonc.2017.10.038"}],"orcid":"0000-0002-7146-9071"},{"id":"maura-gillison","kind":"person","name":"Maura L. Gillison","aka":[],"tldr":"Established that HPV causes a distinct, better-prognosis form of throat cancer and led RTOG 1016 on how to treat it.","summary":"Maura Gillison's work established human papillomavirus as the cause of a rising epidemic of oropharyngeal cancer with a far better prognosis than tobacco-related disease, leading to a separate staging system. She led RTOG 0129 analyses defining HPV as a prognostic factor and RTOG 1016, which showed cetuximab cannot replace cisplatin in HPV-positive disease, a key de-escalation failure. Her work continues on ctDNA and HPV-directed therapy.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Maura_L._Gillison","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gillison%20ML%5BAuthor%5D%20HPV%20oropharyngeal"}],"tags":["head-and-neck","hpv","de-escalation"],"related":[],"cancers":["head-and-neck"],"sections":[],"technologies":["hpv-vaccine","liquid-biopsy"],"targets":[],"drugs":[],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":["rtog-0129"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center","institutionId":"md-anderson","specialisms":["HPV-associated oropharyngeal cancer","Head and neck cancer","Viral oncology","De-escalation trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gillison%20ML%5BAuthor%5D%20HPV%20oropharyngeal"}],"papers":[{"title":"Human papillomavirus and survival of patients with oropharyngeal cancer (RTOG 0129)","journal":"NEJM","year":2010,"doi":"10.1056/NEJMoa0912217"},{"title":"Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016)","journal":"Lancet","year":2019,"doi":"10.1016/S0140-6736(18)32779-X"}]},{"id":"maurice-van-den-bosch","kind":"person","name":"Maurice van den Bosch","aka":[],"tldr":"Maurice van den Bosch represents Netherlands Cancer Institute (NKI-AvL) in the Organisation of European Cancer Institutes, which lists the centre among its members in The Netherlands.","summary":"Maurice van den Bosch is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Netherlands Cancer Institute (NKI-AvL), its full member in The Netherlands. OnCo records the name from the OECI membership list so that the centre's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the institution's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Netherlands Cancer Institute (NKI-AvL) website","url":"https://www.nki.nl"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["nki"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Netherlands Cancer Institute (NKI-AvL) to the Organisation of European Cancer Institutes","institutionId":"nki","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Netherlands Cancer Institute (NKI-AvL) website","url":"https://www.nki.nl"}],"papers":[{"title":"Oral Contraceptives and the Risk of Myocardial Infarction","journal":"New England Journal of Medicine","year":2001,"url":"https://doi.org/10.1056/nejmoa003216","doi":"10.1056/nejmoa003216","note":"OpenAlex author record matched by institution"},{"title":"Preoperative MRI and surgical management in patients with nonpalpable breast cancer: The MONET – Randomised controlled trial","journal":"European Journal of Cancer","year":2010,"url":"https://doi.org/10.1016/j.ejca.2010.11.035","doi":"10.1016/j.ejca.2010.11.035","note":"OpenAlex author record matched by institution"},{"title":"Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) Study","journal":"Stroke","year":2002,"url":"https://doi.org/10.1161/01.str.0000015345.61324.3f","doi":"10.1161/01.str.0000015345.61324.3f","note":"OpenAlex author record matched by institution"}]},{"id":"mauricio-cuello","kind":"person","name":"Mauricio Cuello","aka":[],"tldr":"Physician listed as Director of Uruguay's Instituto Nacional del Cáncer, the national oncology reference hospital in Montevideo run by ASSE.","summary":"Mauricio Cuello is listed as Director of the Instituto Nacional del Cáncer (INCA) in Montevideo, the national reference centre for cancer care in Uruguay, which traces its origins to the Instituto de Radiología founded in 1913 and operates under the Administración de los Servicios de Salud del Estado (ASSE). The Spanish Wikipedia article on the institute names him as Director but gives no appointment date or biography. The institute's own website could not be reached when this record was checked, so the listing should be re-verified against an official source.","asOf":"2026-09-10","links":[{"label":"Source: Wikipedia (Spanish) article on the institute","url":"https://es.wikipedia.org/wiki/Instituto_Nacional_del_C%C3%A1ncer_(Uruguay)"}],"tags":["leadership","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["inca-uruguay"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Instituto Nacional del Cáncer (Uruguay)","institutionId":"inca-uruguay","specialisms":["Oncology","Hospital management"],"profiles":[{"label":"Wikipedia (Spanish), Instituto Nacional del Cáncer (Uruguay)","url":"https://es.wikipedia.org/wiki/Instituto_Nacional_del_C%C3%A1ncer_(Uruguay)"}],"papers":[{"title":"Updated Frequency of EGFR and KRAS Mutations in NonSmall-Cell Lung Cancer in Latin America: The Latin-American Consortium for the Investigation of Lung Cancer (CLICaP)","journal":"J Thorac Oncol","year":2015,"url":"https://doi.org/10.1097/jto.0000000000000481","doi":"10.1097/jto.0000000000000481","note":"Europe PMC author record matched by affiliation"},{"title":"Predictors of Survival After Head and Neck Squamous Cell Carcinoma in South America: The InterCHANGE Study","journal":"JCO Glob Oncol","year":2020,"url":"https://doi.org/10.1200/go.20.00014","doi":"10.1200/go.20.00014","note":"Europe PMC author record matched by affiliation"}]},{"id":"maurizio-di-mauro","kind":"person","name":"Maurizio Di Mauro","aka":[],"tldr":"Physician and hospital manager who is General Director of the Pascale, the national cancer institute in Naples.","summary":"Maurizio Di Mauro is Direttore Generale of the Istituto Nazionale Tumori IRCCS Fondazione G. Pascale in Naples, southern Italy's national cancer institute for research and care. He graduated in medicine and surgery at the University Federico II of Naples, specialised in infectious diseases and holds a master's degree in health economics and management. He was previously Medical Director of the Pascale, General Director of the Ospedali dei Colli hospital company and General Director of the university hospital of the Second University of Naples, and he was quoted as the institute's General Director in national press coverage in January 2026.","asOf":"2026-09-10","links":[{"label":"Source: ANSA report quoting the Pascale General Director, January 2026","url":"https://www.ansa.it/campania/notizie/2026/01/19/al-pascale-primo-prelievo-di-cornee-svolta-per-listituto-tumori-di-napoli_c083e153-1312-4491-b9c3-cd318b98edea.html"}],"tags":["leadership","health-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["pascale-naples"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Direttore Generale (General Director) of Istituto Nazionale Tumori IRCCS Fondazione G. Pascale","institutionId":"pascale-naples","specialisms":["Healthcare management","Hospital administration","Infectious diseases"],"profiles":[{"label":"FIASO profile","url":"https://www.fiaso.it/fiaso/organizzazione/maurizio-di-mauro/"}],"papers":[]},{"id":"max-wicha","kind":"person","name":"Max S. Wicha","aka":[],"tldr":"Max Wicha identified breast cancer stem cells and made them a therapeutic target.","summary":"Max S. Wicha is the Madeline and Sidney Forbes Professor of Oncology and Founding Director of the Rogel Cancer Center at the University of Michigan. He is known for identifying breast cancer stem cells and making them a therapeutic target, as co-author of the 2003 paper that isolated tumorigenic breast cancer cells. His selected paper reports the prospective identification of tumorigenic breast cancer cells. He founded Michigan's cancer centre and continues to study stem cell pathways such as IL-6/STAT3 and Notch in triple-negative and hormone receptor-positive breast cancer.","asOf":"2026-09-08","links":[{"label":"Michigan profile","url":"https://www.rogelcancercenter.org/max-s-wicha-md"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wicha%20MS%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["tnbc","breast-hr-positive"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["michigan-rogel"],"pathways":["emt"],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Madeline and Sidney Forbes Professor of Oncology; Founding Director, Rogel Cancer Center","institutionId":"michigan-rogel","specialisms":["Cancer stem cells","Breast cancer","Stem cell targeting"],"profiles":[{"label":"Michigan profile","url":"https://www.rogelcancercenter.org/max-s-wicha-md"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wicha%20MS%5BAuthor%5D"}],"papers":[{"title":"Prospective identification of tumorigenic breast cancer cells","journal":"PNAS","year":2003,"url":"https://doi.org/10.1073/pnas.0530291100","doi":"10.1073/pnas.0530291100"}],"orcid":"0000-0003-4180-7727"},{"id":"maximilian-diehn","kind":"person","name":"Maximilian Diehn","aka":[],"tldr":"Radiation oncologist who showed a blood test can detect leftover lung cancer months before scans.","summary":"Maximilian Diehn is Professor of Radiation Oncology at Stanford University, within the Stanford Cancer Institute. A radiation oncologist and physician-scientist specialising in circulating tumour DNA and lung cancer, he co-developed CAPP-Seq with Ash Alizadeh and demonstrated ctDNA-based detection of minimal residual disease after curative lung cancer treatment, showing a blood test can find leftover cancer months before scans. His papers include the Cancer Discovery report on early detection of molecular residual disease in localised lung cancer by ctDNA profiling and a Nature study integrating genomic features for non-invasive early lung cancer detection. He also studies radiation biology, personalised radiotherapy and stereotactic techniques in non-small-cell lung cancer.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Maximilian_Diehn","links":[{"label":"Stanford profile","url":"https://profiles.stanford.edu/search?q=Maximilian%20Diehn"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Diehn%20M%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Maximilian%20Diehn"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["mrd-testing","liquid-biopsy","sbrt"],"targets":[],"drugs":[],"companies":[],"institutions":["stanford"],"pathways":[],"terms":["mrd"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Radiation Oncology, Stanford University","institutionId":"stanford","specialisms":["Radiation oncology","Circulating tumour DNA","Lung cancer"],"profiles":[{"label":"Stanford profile","url":"https://profiles.stanford.edu/search?q=Maximilian%20Diehn"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Diehn%20M%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Maximilian%20Diehn"}],"papers":[{"title":"Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling","journal":"Cancer Discovery","year":2017,"url":"https://doi.org/10.1158/2159-8290.CD-17-0716","doi":"10.1158/2159-8290.CD-17-0716"},{"title":"Integrating genomic features for non-invasive early lung cancer detection","journal":"Nature","year":2020,"url":"https://doi.org/10.1038/s41586-020-2140-0","doi":"10.1038/s41586-020-2140-0"}],"orcid":"0000-0003-2032-0581"},{"id":"maximilian-niyazi","kind":"person","name":"Maximilian Niyazi","aka":[],"tldr":"Radiation oncologist who speaks for the Comprehensive Cancer Center Tübingen-Stuttgart and directs radiation oncology at Tübingen University Hospital.","summary":"Prof. Maximilian Niyazi is Speaker of the Comprehensive Cancer Center Tübingen-Stuttgart and Medical Director of the University Clinic for Radiation Oncology in Tübingen. His research focuses on radiotherapy for brain tumours, including target volume delineation guidelines for glioblastoma and combined radio-immunotherapy approaches.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.medizin.uni-tuebingen.de/de/das-klinikum/einrichtungen/zentren/tumorzentrum-ccc/vorstand"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Niyazi+M%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","radiotherapy","neuro-oncology"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ccc-tuebingen"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["radiation-oncology"],"dependsOn":[],"notes":[],"role":"Speaker (Sprecher) of the CCC Tübingen-Stuttgart","institutionId":"ccc-tuebingen","specialisms":["Radiation oncology","Neuro-oncology","Glioblastoma"],"profiles":[{"label":"Institution profile","url":"https://www.medizin.uni-tuebingen.de/de/das-klinikum/einrichtungen/zentren/tumorzentrum-ccc/vorstand"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Niyazi+M%5BAuthor%5D"}],"papers":[{"title":"Counting colonies of clonogenic assays by using densitometric software","journal":"Radiation Oncology","year":2007,"doi":"10.1186/1748-717x-2-4"},{"title":"Fractionated radiotherapy for spinal tumors: A literature review regarding spinal glioma, ependymoma, and meningioma","journal":"Neuro-Oncology Advances","year":2024,"doi":"10.1093/noajnl/vdad158"},{"title":"Dosimetric feasibility analysis and presentation of an isotoxic dose-escalated radiation therapy concept for glioblastoma used in the PRIDE trial (NOA-28; ARO-2022-12)","journal":"Clinical and Translational Radiation Oncology","year":2024,"doi":"10.1016/j.ctro.2023.100706"}],"orcid":"0000-0002-7711-9486"},{"id":"mel-greaves","kind":"person","name":"Mel Greaves","aka":[],"tldr":"Showed that childhood leukaemia begins before birth and framed cancer as an evolutionary process.","summary":"Mel Greaves is Professor of Cell Biology at The Institute of Cancer Research and Founding Director of its Centre for Evolution and Cancer. His specialisms are cancer evolution, childhood leukaemia and cancer origins. He traced the prenatal origins of childhood acute lymphoblastic leukaemia using twin studies and neonatal blood spots, showing that the disease begins before birth, and framed cancer as an evolutionary process. His Nature Reviews Cancer paper proposed a causal mechanism for childhood acute lymphoblastic leukaemia, the delayed-infection hypothesis for its aetiology. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Greaves%20M%5BAuthor%5D%20leukaemia%20evolution"}],"tags":[],"related":[],"cancers":["all-leukemia"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["icr-london"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nature-reviews-cancer"],"dependsOn":[],"notes":[],"role":"Professor of Cell Biology, ICR; Founding Director, Centre for Evolution and Cancer","institutionId":"icr-london","specialisms":["Cancer evolution","Childhood leukaemia","Cancer origins"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Greaves%20M%5BAuthor%5D%20leukaemia%20evolution"}],"papers":[{"title":"A causal mechanism for childhood acute lymphoblastic leukaemia","journal":"Nature Reviews Cancer","year":2018,"doi":"10.1038/s41568-018-0015-6"}]},{"id":"meletios-dimopoulos","kind":"person","name":"Meletios A. Dimopoulos","aka":[],"tldr":"Greek haematologist who led POLLUX and CANDOR, two of the pivotal daratumumab combination trials in relapsed myeloma.","summary":"Meletios Dimopoulos (University of Athens) was principal investigator of POLLUX, which established daratumumab plus lenalidomide-dexamethasone in relapsed myeloma, and CANDOR (daratumumab plus carfilzomib), and co-led APOLLO and the ELOQUENT trials. He has authored the IMWG guidelines on renal impairment in myeloma and led the international consensus on Waldenström macroglobulinaemia treatment.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dimopoulos%20MA%5BAuthor%5D%20myeloma%20daratumumab"}],"tags":["myeloma","trialist","greece"],"related":[],"cancers":["multiple-myeloma","waldenstrom"],"sections":[],"technologies":["monoclonal-antibody"],"targets":["cd38"],"drugs":[],"companies":[],"institutions":["nkua-athens"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Hematology and Medical Oncology, National and Kapodistrian University of Athens","institutionId":"nkua-athens","specialisms":["Multiple myeloma","Waldenström macroglobulinaemia","Daratumumab and carfilzomib combinations","Renal impairment"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dimopoulos%20MA%5BAuthor%5D%20myeloma%20daratumumab"}],"papers":[{"title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma (POLLUX)","journal":"NEJM","year":2016,"doi":"10.1056/NEJMoa1607751"},{"title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR)","journal":"Lancet","year":2020,"doi":"10.1016/S0140-6736(20)30734-0"},{"title":"AQUILA: daratumumab versus active monitoring in high-risk smouldering multiple myeloma","journal":"New England Journal of Medicine","year":2025,"url":"https://doi.org/10.1056/NEJMoa2409029","doi":"10.1056/NEJMoa2409029"}],"orcid":"0000-0001-8990-3254"},{"id":"meredith-irwin","kind":"person","name":"Meredith Irwin","aka":[],"tldr":"Paediatric oncologist and neuroblastoma researcher who serves as Paediatrician-in-Chief at SickKids in Toronto.","summary":"Meredith Irwin, MD, is Paediatrician-in-Chief at The Hospital for Sick Children (SickKids) and Chair of Paediatrics at the University of Toronto. A paediatric oncologist, her research has focused on neuroblastoma biology, including p53-family signalling and risk stratification, and she has contributed to Children's Oncology Group neuroblastoma classification and biology committees.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.sickkids.ca/en/about/leadership/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Irwin+MS%5BAuthor%5D+neuroblastoma"}],"tags":["leadership","clinician-scientist","paediatric oncology","neuroblastoma"],"related":[],"cancers":["neuroblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["sickkids"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Paediatrician-in-Chief","institutionId":"sickkids","specialisms":["Paediatric oncology","Neuroblastoma","Tumour biology"],"profiles":[{"label":"Institution profile","url":"https://www.sickkids.ca/en/about/leadership/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Irwin+MS%5BAuthor%5D+neuroblastoma"}],"papers":[{"title":"An upfront immunomodulatory therapy protocol for pediatric opsoclonus‐myoclonus syndrome","journal":"Pediatric Blood & Cancer","year":2019,"doi":"10.1002/pbc.27776"}],"orcid":"0000-0002-2452-5181"},{"id":"michael-caligiuri","kind":"person","name":"Michael A. Caligiuri","aka":[],"tldr":"Michael Caligiuri is an NK cell immunologist and past AACR president who leads City of Hope's hospital.","summary":"Michael Caligiuri is President of City of Hope National Medical Center, Deana and Steve Campbell Physician-in-Chief, and Treasurer of the American Association for Cancer Research (AACR), of which he is a past president. A physician-scientist specialising in natural killer cells, leukaemia and immunotherapy, he is known for work on natural killer cell biology, IL-15 and NK-based immunotherapy, and formerly directed Ohio State's cancer centre. His papers include a Blood review of human natural killer cells and a Blood study showing CD56bright natural killer cells in human lymph nodes are activated by T cell-derived IL-2, linking adaptive and innate immunity. His work bears on acute myeloid leukaemia, CAR-NK therapy and engineered cytokines.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Michael_A._Caligiuri","links":[{"label":"City of Hope research faculty","url":"https://www.cityofhope.org/research/find-a-researcher"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Caligiuri%20MA%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Michael%20A.%20Caligiuri"}],"tags":[],"related":[],"cancers":["aml"],"sections":[],"technologies":["car-nk-macrophage","cytokine-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":["city-of-hope","aacr"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President, City of Hope National Medical Center; Deana and Steve Campbell Physician-in-Chief; AACR Treasurer","institutionId":"city-of-hope","specialisms":["Natural killer cells","Leukaemia","Immunotherapy"],"profiles":[{"label":"City of Hope research faculty","url":"https://www.cityofhope.org/research/find-a-researcher"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Caligiuri%20MA%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Michael%20A.%20Caligiuri"}],"papers":[{"title":"Human natural killer cells","journal":"Blood","year":2008,"url":"https://doi.org/10.1182/blood-2007-09-077438","doi":"10.1182/blood-2007-09-077438"},{"title":"CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity","journal":"Blood","year":2003,"url":"https://doi.org/10.1182/blood-2002-09-2876","doi":"10.1182/blood-2002-09-2876"}]},{"id":"michael-postow","kind":"person","name":"Michael A. Postow","aka":[],"tldr":"Led CheckMate 069, the first randomised trial of nivolumab plus ipilimumab, and defines how to manage immunotherapy side effects.","summary":"Michael Postow led CheckMate 069, the randomised phase 2 trial that first showed nivolumab plus ipilimumab dramatically improves response rates over ipilimumab alone in melanoma and set up CheckMate 067. He wrote the widely cited NEJM review of immune-related adverse events and leads trials of adaptive dosing and treatment discontinuation. He chairs the melanoma service at MSKCC.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Postow%20MA%5BAuthor%5D%20melanoma%20immune"}],"tags":["melanoma","immunotherapy","toxicity"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["pd1","ctla4"],"drugs":["nivolumab","ipilimumab"],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":["checkmate-067"],"people":[],"bottlenecks":[],"keyPapers":["paper-asco-irae-guideline-jco-2021"],"journals":[],"dependsOn":[],"notes":[],"role":"Chief, Melanoma Service, Memorial Sloan Kettering Cancer Center","institutionId":"mskcc","specialisms":["Melanoma","Immunotherapy","Immune-related adverse events","Treatment duration"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Postow%20MA%5BAuthor%5D%20melanoma%20immune"}],"papers":[{"title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma (CheckMate 069)","journal":"NEJM","year":2015,"doi":"10.1056/NEJMoa1414428"},{"title":"Immune-related adverse events associated with immune checkpoint blockade","journal":"NEJM","year":2018,"doi":"10.1056/NEJMra1703481"},{"title":"ASCO 2021 guideline: how to recognise and manage the immune-related side effects of checkpoint inhibitors","journal":"Journal of Clinical Oncology","year":2021,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Management%20of%20Immune-Related%20Adverse%20Events%20ASCO%20Guideline%20Update%20Schneider%20JCO%202021"}]},{"id":"michael-teitell","kind":"person","name":"Michael A. Teitell","aka":[],"tldr":"Michael Teitell is a pathologist and cancer biologist who directs UCLA's cancer centre.","summary":"Michael Teitell is Director of the UCLA Jonsson Comprehensive Cancer Center, a post he has held since 2015. A pathologist and physician-scientist specialising in cancer metabolism and lymphoma biology, his laboratory studies metabolism, mitochondrial function and lymphomagenesis. His papers include a Cell Stem Cell review of metabolic regulation in pluripotent stem cells during reprogramming and self-renewal and an EMBO Journal study showing that UCP2 regulates energy metabolism and differentiation potential of human pluripotent stem cells. His work links cancer metabolism to diffuse large B-cell lymphoma alongside his cancer centre leadership.","asOf":"2026-09-08","links":[{"label":"UCLA profile","url":"https://www.uclahealth.org/providers?q=Michael%20A.%20Teitell"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Teitell%20MA%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Michael%20A.%20Teitell"}],"tags":[],"related":[],"cancers":["dlbcl"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ucla-jonsson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["cell-stem-cell"],"dependsOn":[],"notes":[],"role":"Director, UCLA Jonsson Comprehensive Cancer Center","institutionId":"ucla-jonsson","specialisms":["Cancer metabolism","Lymphoma biology","Cancer center leadership"],"profiles":[{"label":"UCLA profile","url":"https://www.uclahealth.org/providers?q=Michael%20A.%20Teitell"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Teitell%20MA%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Michael%20A.%20Teitell"}],"papers":[{"title":"Metabolic regulation in pluripotent stem cells during reprogramming and self-renewal","journal":"Cell Stem Cell","year":2012,"url":"https://doi.org/10.1016/j.stem.2012.10.005","doi":"10.1016/j.stem.2012.10.005"},{"title":"UCP2 regulates energy metabolism and differentiation potential of human pluripotent stem cells","journal":"EMBO Journal","year":2016,"url":"https://doi.org/10.15252/embj.201694054","doi":"10.15252/embj.201694054"}]},{"id":"michael-atkins","kind":"person","name":"Michael B. Atkins","aka":[],"tldr":"Washington oncologist who led DREAMseq, the trial that showed people with BRAF-mutant melanoma live longer if immunotherapy is given before targeted therapy rather than after.","summary":"Michael Atkins is deputy director of Georgetown Lombardi Comprehensive Cancer Center and a long-time investigator of immunotherapy in melanoma and kidney cancer, from high-dose interleukin-2 to checkpoint inhibitors. He was first author of the 2023 Journal of Clinical Oncology report of the DREAMseq trial, which found that starting with nivolumab plus ipilimumab and switching to dabrafenib plus trametinib on progression gave better two-year overall survival than the reverse sequence in BRAF V600-mutant metastatic melanoma.","asOf":"2026-09-18","links":[],"tags":["melanoma","immunotherapy","trialist"],"related":[],"cancers":["advanced-melanoma","braf-v600-melanoma","melanoma","rcc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["georgetown-lombardi"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-dreamseq-jco-2023"],"journals":[],"dependsOn":[],"notes":[],"role":"Deputy Director, Georgetown Lombardi Comprehensive Cancer Center","institutionId":"georgetown-lombardi","specialisms":["Melanoma","Kidney cancer","Immunotherapy sequencing"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Atkins%5BAuthor%5D"}],"papers":[{"title":"DREAMseq (ECOG-ACRIN EA6134): sequencing dabrafenib-trametinib and nivolumab-ipilimumab in BRAF-mutant metastatic melanoma","journal":"Journal of Clinical Oncology","year":2023,"url":"https://doi.org/10.1200/JCO.22.01763","doi":"10.1200/JCO.22.01763"}],"orcid":"0000-0003-3901-9924"},{"id":"michael-baumann","kind":"person","name":"Michael Baumann","aka":[],"tldr":"Michael Baumann is a radiation oncologist who leads Germany's national cancer research centre.","summary":"Michael Baumann is Chairman and Scientific Director of the German Cancer Research Center (DKFZ) in Heidelberg, Germany's national cancer research centre. A radiation oncologist, his specialisms are radiation oncology, radiobiology and research leadership, with links to modern image-guided external beam and proton therapy. He has chaired the DKFZ since 2016 and previously led radiation oncology in Dresden, with research on tumour hypoxia, biomarkers and personalised radiotherapy. His papers include a Nature Reviews Cancer article on radiation oncology in the era of precision medicine, the first clinical application of a prompt gamma-based in vivo proton range verification system, and a Nature Medicine piece on caring for patients with cancer in the COVID-19 era. His DKFZ profile is linked.","asOf":"2026-09-08","links":[{"label":"DKFZ","url":"https://www.dkfz.de/"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["imrt-igrt","proton-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":["dkfz"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chairman and Scientific Director, German Cancer Research Center (DKFZ)","institutionId":"dkfz","specialisms":["Radiation oncology","Radiobiology","Research leadership"],"profiles":[{"label":"DKFZ","url":"https://www.dkfz.de/"}],"papers":[{"title":"Radiation oncology in the era of precision medicine","journal":"Nature Reviews Cancer","year":2016,"doi":"10.1038/nrc.2016.18"},{"title":"First clinical application of a prompt gamma based in vivo proton range verification system","journal":"Radiotherapy and Oncology","year":2016,"doi":"10.1016/j.radonc.2016.01.004"},{"title":"Caring for patients with cancer in the COVID-19 era","journal":"Nature Medicine","year":2020,"doi":"10.1038/s41591-020-0874-8"}]},{"id":"michael-bloomberg","kind":"person","name":"Michael Bloomberg","aka":[],"tldr":"In 2016 his $50 million, matched by Sidney Kimmel and others to $125 million, launched a Johns Hopkins institute that put more than a hundred scientists and clinicians to work on cancer immunotherapy.","summary":"Michael Bloomberg's gifts to Johns Hopkins, his alma mater, exceeded $1.2 billion by 2016 according to the university. In March 2016 he gave $50 million, matched by $50 million from Sidney Kimmel and $25 million from a dozen other donors, to found the Bloomberg~Kimmel Institute for Cancer Immunotherapy, uniting more than 100 Hopkins scientists and clinicians on the biology of immune checkpoints, T-cell engineering and the tumour microenvironment, in coordination with the national Cancer Moonshot then led by Vice President Biden. The institute built on Hopkins work that had helped establish PD-1 blockade and the use of mismatch-repair deficiency as a marker for who responds to it. His broader public health philanthropy, on tobacco control in particular, bears on cancer prevention worldwide.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Michael_Bloomberg","links":[{"label":"Johns Hopkins Hub: cancer immunotherapy institute launch (2016)","url":"https://hub.jhu.edu/2016/03/29/cancer-immunotherapy-center-bloomberg-kimmel/"}],"tags":["hero","donor"],"related":[],"cancers":[],"sections":[],"technologies":["immunotherapy","checkpoint-inhibitor"],"targets":[],"drugs":[],"companies":[],"institutions":["johns-hopkins"],"pathways":[],"terms":[],"trials":[],"people":["drew-pardoll","suzanne-topalian","sidney-kimmel"],"bottlenecks":["b-funding-allocation","b-immunotherapy-response","b-prevention-adoption"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Johns Hopkins' largest benefactor; co-founder of the Bloomberg~Kimmel Institute for Cancer Immunotherapy","specialisms":["Cancer immunotherapy","Institute building","Public health philanthropy"],"profiles":[],"papers":[]},{"id":"michael-boyer","kind":"person","name":"Michael Boyer","aka":[],"tldr":"Thoracic medical oncologist who has been chief executive of Chris O'Brien Lifehouse, Sydney's not-for-profit cancer hospital, since 2023.","summary":"Professor Michael Boyer AM is Chief Executive Officer of Chris O'Brien Lifehouse, a not-for-profit comprehensive cancer hospital in Sydney, and Conjoint Chair of Medical Oncology (Thoracic Oncology). A medical oncologist for more than 20 years specialising in thoracic and head and neck cancers, he was appointed Chief Clinical Officer at Lifehouse in 2011 and Chief Executive Officer in 2023, and also sits on its Board of Directors. He was previously director of the Sydney Cancer Centre and area director of Cancer Services for the Sydney South West Area Health Service.","asOf":"2026-09-10","links":[{"label":"Source: Lifehouse our people page","url":"https://www.mylifehouse.org.au/about-us/our-people/"}],"tags":["leadership","clinician-scientist","thoracic-oncology"],"related":[],"cancers":["nsclc","sclc","head-and-neck","mesothelioma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["chris-obrien-lifehouse"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive Officer of Chris O'Brien Lifehouse","institutionId":"chris-obrien-lifehouse","specialisms":["Medical oncology","Thoracic cancers","Head and neck cancer","Clinical trials"],"profiles":[{"label":"Institution profile","url":"https://www.mylifehouse.org.au/team/michael-boyer/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Boyer+MJ%5BAuthor%5D+lung"}],"papers":[{"title":"Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study","journal":"Journal of Clinical Oncology","year":2021,"doi":"10.1200/jco.20.03579"},{"title":"Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study","journal":"The Lancet Oncology","year":2017,"doi":"10.1016/s1470-2045(17)30621-6"},{"title":"Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189","journal":"Annals of Oncology","year":2021,"doi":"10.1016/j.annonc.2021.04.008"}],"orcid":"0000-0002-0452-2987"},{"id":"michael-bretthauer","kind":"person","name":"Michael Bretthauer","aka":[],"tldr":"Led NordICC, the first randomised trial of screening colonoscopy, which found smaller benefits than many expected.","summary":"Michael Bretthauer (University of Oslo) was principal investigator of NordICC, the Nordic and Polish randomised trial of invitation to screening colonoscopy, whose 2022 result of an 18% reduction in colorectal cancer incidence and no significant mortality benefit in the intention-to-screen analysis reset expectations for colonoscopy screening. He leads the Clinical Effectiveness Research Group and works on screening quality and trial methodology.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bretthauer%20M%5BAuthor%5D%20colonoscopy%20screening"}],"tags":["screening","colorectal","epidemiology"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oslo-radium-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-nordicc-nejm-2022"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medicine, University of Oslo; Gastroenterologist, Oslo University Hospital","institutionId":"oslo-radium-hospital","specialisms":["Colorectal cancer screening","Colonoscopy trials","Screening epidemiology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bretthauer%20M%5BAuthor%5D%20colonoscopy%20screening"}],"papers":[{"title":"Effect of colonoscopy screening on risks of colorectal cancer and related death (NordICC)","journal":"NEJM","year":2022,"doi":"10.1056/NEJMoa2208375"},{"title":"Population-based colonoscopy screening for colorectal cancer: a randomized clinical trial","journal":"JAMA Internal Medicine","year":2016,"doi":"10.1001/jamainternmed.2016.0960"}],"orcid":"0000-0001-9653-6886"},{"id":"michael-heinrich","kind":"person","name":"Michael C. Heinrich","aka":[],"tldr":"Oregon physician-scientist who showed that the KIT mutation type in a GIST predicts how well imatinib works, discovered PDGFRA mutations in the tumours without KIT mutations, and led NAVIGATOR, which established avapritinib for PDGFRA D842V disease.","summary":"Michael Heinrich is a medical oncologist and laboratory investigator at Oregon Health & Science University and the Portland VA Medical Center. With Christopher Corless he reported PDGFRA-activating mutations in KIT-negative gastrointestinal stromal tumours in Science in 2003 and showed in the same year that KIT exon 11 mutations predict response to imatinib. He was first author of the 2020 Lancet Oncology report of NAVIGATOR, in which avapritinib produced high response rates in PDGFRA D842V-mutant GIST, an indication resistant to earlier drugs.","asOf":"2026-09-18","links":[],"tags":["gist","targeted-therapy","trialist"],"related":[],"cancers":["gist-pdgfra-d842v","gist-kit-exon-11","gist","sarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ohsu-knight"],"pathways":[],"terms":[],"trials":["navigator"],"people":[],"bottlenecks":[],"keyPapers":["paper-heinrich-kit-mutation-imatinib-response-jco-2003","paper-navigator-avapritinib-heinrich-lancet-oncol-2020","paper-heinrich-pdgfra-gist-science-2003"],"journals":[],"dependsOn":[],"notes":[],"role":"Medical oncologist and laboratory scientist, Oregon Health & Science University and Portland VA","institutionId":"ohsu-knight","specialisms":["Gastrointestinal stromal tumour","KIT and PDGFRA mutations","Kinase inhibitor development"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Heinrich%5BAuthor%5D"}],"papers":[{"title":"Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumour","journal":"Journal of Clinical Oncology","year":2003,"url":"https://doi.org/10.1200/JCO.2003.04.190","doi":"10.1200/JCO.2003.04.190"},{"title":"NAVIGATOR: avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour","journal":"The Lancet Oncology","year":2020,"url":"https://doi.org/10.1016/S1470-2045(20)30269-2","doi":"10.1016/S1470-2045(20)30269-2"},{"title":"PDGFRA activating mutations in gastrointestinal stromal tumours","journal":"Science","year":2003,"url":"https://doi.org/10.1126/science.1079666","doi":"10.1126/science.1079666"}],"orcid":"0000-0003-3790-0478"},{"id":"michael-taylor","kind":"person","name":"Michael D. Taylor","aka":[],"tldr":"Neurosurgeon-scientist who defined the four molecular subgroups of medulloblastoma that now guide therapy.","summary":"Michael Taylor led the international consensus that divided medulloblastoma into WNT, SHH, Group 3 and Group 4 subgroups, a classification adopted by the WHO that underpins current risk-stratified and de-escalated treatment trials. His laboratory showed that medulloblastoma metastases diverge genetically from the primary tumour and that the tumours spread via blood. He moved from SickKids Toronto to Texas Children's in 2023.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Taylor%20MD%5BAuthor%5D%20medulloblastoma"}],"tags":["paediatric","medulloblastoma","genomics"],"related":[],"cancers":["medulloblastoma"],"sections":[],"technologies":["methylation-profiling","wes-wgs"],"targets":[],"drugs":[],"companies":[],"institutions":["texas-childrens"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["cancer-cell"],"dependsOn":[],"notes":[],"role":"Professor of Pediatrics and Neurosurgery, Baylor College of Medicine and Texas Children's Hospital","institutionId":"texas-childrens","specialisms":["Medulloblastoma","Paediatric neurosurgery","Brain tumour genomics","Metastasis biology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Taylor%20MD%5BAuthor%5D%20medulloblastoma"}],"papers":[{"title":"Molecular subgroups of medulloblastoma: the current consensus","journal":"Acta Neuropathologica","year":2012,"doi":"10.1007/s00401-011-0922-z"},{"title":"Intertumoral heterogeneity within medulloblastoma subgroups","journal":"Cancer Cell","year":2017,"doi":"10.1016/j.ccell.2017.05.005"}]},{"id":"michael-dickinson","kind":"person","name":"Michael Dickinson","aka":[],"tldr":"Led the pivotal glofitamab trial, establishing off-the-shelf bispecific antibodies for relapsed large B-cell lymphoma.","summary":"Michael Dickinson was principal investigator and first author of the pivotal phase 2 trial of glofitamab, the CD20xCD3 bispecific antibody that produces durable complete remissions in about 40% of patients with relapsed or refractory large B-cell lymphoma after two or more lines, including after CAR-T, leading to its approval. He leads bispecific and CAR-T trials at Peter Mac and the Australasian Leukaemia and Lymphoma Group aggressive lymphoma programme.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dickinson%20MJ%5BAuthor%5D%20glofitamab"}],"tags":["lymphoma","bispecific","australia"],"related":[],"cancers":["dlbcl"],"sections":[],"technologies":["bispecific-antibody","t-cell-engager"],"targets":["cd20","cd3"],"drugs":["glofitamab"],"companies":[],"institutions":["peter-mac"],"pathways":[],"terms":[],"trials":["starglo"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Lead, Aggressive Lymphoma Program, Peter MacCallum Cancer Centre and Royal Melbourne Hospital","institutionId":"peter-mac","specialisms":["Aggressive lymphoma","Bispecific antibodies","CAR T-cell therapy","Early drug development"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dickinson%20MJ%5BAuthor%5D%20glofitamab"}],"papers":[{"title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","journal":"NEJM","year":2022,"doi":"10.1056/NEJMoa2206913"},{"title":"Glofitamab plus gemcitabine and oxaliplatin in relapsed or refractory diffuse large B-cell lymphoma (STARGLO)","journal":"Lancet","year":2024}],"orcid":"0000-0002-1492-5966"},{"id":"michael-berger","kind":"person","name":"Michael F. Berger","aka":[],"tldr":"Built MSK-IMPACT, the tumour sequencing test used on more than 100,000 patients and the first FDA-authorised hospital panel.","summary":"Michael Berger led the development of MSK-IMPACT, the hybrid-capture sequencing assay that profiles hundreds of cancer genes in every MSKCC patient and became the first laboratory-developed tumour panel authorised by the FDA. The 2017 Nature Medicine paper on 10,000 profiled patients showed how prospective clinical sequencing enables trial matching. He also co-developed MSK-ACCESS for ctDNA and OncoKB with Debyani Chakravarty.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Berger%20MF%5BAuthor%5D%20MSK-IMPACT"}],"tags":["genomics","precision-oncology","diagnostics"],"related":[],"cancers":[],"sections":[],"technologies":["cgp","liquid-biopsy","companion-diagnostic"],"targets":[],"drugs":["foundationone-cdx"],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-tcga-pancancer-atlas-cell-2018"],"journals":[],"dependsOn":[],"notes":[],"role":"Associate Director, Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center","institutionId":"mskcc","specialisms":["Clinical cancer genomics","Tumour sequencing assays","Computational biology","Precision oncology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Berger%20MF%5BAuthor%5D%20MSK-IMPACT"}],"papers":[{"title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","journal":"Nature Medicine","year":2017,"doi":"10.1038/nm.4333"},{"title":"Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology","journal":"Journal of Molecular Diagnostics","year":2015,"doi":"10.1016/j.jmoldx.2014.12.006"},{"title":"TCGA Pan-Cancer Atlas: 10,000 tumours across 33 cancer types, classified by molecular features","journal":"Cell","year":2018,"url":"https://doi.org/10.1016/j.cell.2018.03.022","doi":"10.1016/j.cell.2018.03.022"}]},{"id":"michael-gnant","kind":"person","name":"Michael Gnant","aka":[],"tldr":"Viennese surgical oncologist who presides over the ABCSG and has led landmark adjuvant breast cancer trials such as ABCSG-12, ABCSG-18 and PALLAS.","summary":"Michael Gnant is President of the Austrian Breast & Colorectal Cancer Study Group (ABCSG) and a professor of surgery at the Medical University of Vienna's Comprehensive Cancer Center. He has led major academic trials in early breast cancer, including studies of adjuvant zoledronic acid and denosumab and the PALLAS trial of adjuvant palbociclib, shaping international treatment standards.","asOf":"2026-09-10","links":[{"label":"Society page","url":"https://www.abcsg.org/en/about-us/board/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gnant+M%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","breast cancer","clinical trials"],"related":[],"cancers":["breast-hr-positive","breast-her2-positive"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["abcsg"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President","institutionId":"abcsg","specialisms":["Breast cancer","Surgical oncology","Adjuvant therapy trials"],"profiles":[{"label":"Society page","url":"https://www.abcsg.org/en/about-us/board/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gnant+M%5BAuthor%5D"}],"papers":[{"title":"Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)","journal":"Journal of Clinical Oncology","year":2022,"url":"https://doi.org/10.1200/JCO.21.02554","doi":"10.1200/JCO.21.02554"}],"orcid":"0000-0003-1002-2118"},{"id":"michael-hallek","kind":"person","name":"Michael Hallek","aka":[],"tldr":"Leads the German CLL Study Group, whose trials (CLL8, CLL14, CLL13) set global standards for CLL treatment.","summary":"Michael Hallek is Director of Department I of Internal Medicine at University Hospital Cologne (CIO) and Head of the German CLL Study Group. His specialisms are chronic lymphocytic leukaemia, chemoimmunotherapy and targeted therapy trials, with a focus on BCL-2 and CD20. He led CLL8, which established the FCR regimen, CLL14, the New England Journal of Medicine trial of venetoclax and obinutuzumab in patients with CLL and coexisting conditions, and CLL13/GAIA. These trials moved CLL from chemotherapy to fixed-duration targeted therapy and set global standards. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hallek%20M%5BAuthor%5D%20CLL"}],"tags":[],"related":[],"cancers":["cll"],"sections":[],"technologies":[],"targets":["bcl2","cd20"],"drugs":["venetoclax","obinutuzumab"],"companies":[],"institutions":["uniklinik-koeln"],"pathways":[],"terms":[],"trials":["cll14","cll13-gaia"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Department I of Internal Medicine, University Hospital Cologne; Head, German CLL Study Group","institutionId":"uniklinik-koeln","specialisms":["Chronic lymphocytic leukaemia","Chemoimmunotherapy","Targeted therapy trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hallek%20M%5BAuthor%5D%20CLL"}],"papers":[{"title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions (CLL14)","journal":"NEJM","year":2019,"doi":"10.1056/NEJMoa1815281"}],"orcid":"0000-0002-7425-4455"},{"id":"hofman-michael","kind":"person","name":"Michael Hofman","aka":[],"tldr":"Led proPSMA and TheraP, the trials that proved PSMA PET beats conventional imaging and that lutetium-PSMA beats chemotherapy.","summary":"Michael Hofman is Professor of Nuclear Medicine and Director of the Prostate Cancer Theranostics and Imaging Centre of Excellence at the Peter MacCallum Cancer Centre in Melbourne. He led proPSMA, which proved that PSMA PET-CT beats conventional imaging for staging high-risk prostate cancer before curative-intent surgery or radiotherapy, and TheraP, the ANZUP trial that showed lutetium-177 PSMA-617 beats cabazitaxel chemotherapy in metastatic castration-resistant prostate cancer. His publications include the proPSMA and TheraP reports, and his trials made Australia a global centre of theranostics. He now leads trials of earlier-line and combination radioligand therapy.","asOf":"2026-09-08","links":[{"label":"Peter MacCallum Cancer Centre","url":"https://www.petermac.org"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hofman%20MS%5BAuthor%5D%20PSMA"}],"tags":[],"related":[],"cancers":["prostate"],"sections":[],"technologies":["psma-pet","radioligand-therapy"],"targets":["psma"],"drugs":["pluvicto"],"companies":[],"institutions":["peter-mac"],"pathways":[],"terms":[],"trials":["propsma","therap"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Nuclear Medicine; Director, Prostate Cancer Theranostics and Imaging Centre of Excellence","institutionId":"peter-mac","specialisms":["Theranostics","PSMA PET","Lutetium-PSMA therapy","Nuclear medicine"],"profiles":[{"label":"Peter MacCallum Cancer Centre","url":"https://www.petermac.org"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hofman%20MS%5BAuthor%5D%20PSMA"}],"papers":[{"title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA)","journal":"Lancet","year":2020,"doi":"10.1016/S0140-6736(20)30314-7"},{"title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP)","journal":"Lancet","year":2021,"doi":"10.1016/S0140-6736(21)00237-3"}],"orcid":"0000-0001-8622-159X"},{"id":"michael-morris","kind":"person","name":"Michael J. Morris","aka":[],"tldr":"Principal investigator of the VISION trial that made lutetium-PSMA a standard prostate cancer treatment.","summary":"Michael J. Morris is Prostate Cancer Section Head on the Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center. He is a medical oncologist known as principal investigator of the VISION trial, which made lutetium-177 PSMA radioligand therapy a standard prostate cancer treatment, and co-led PSMAfore and PSMA PET studies. His selected papers report lutetium-177 PSMA-617 for metastatic castration-resistant prostate cancer and the PSMAfore comparison against a change of androgen receptor pathway inhibitor in taxane-naive patients. He chaired the Alliance genitourinary committee and focuses on radioligand therapy and imaging biomarkers.","asOf":"2026-09-08","links":[{"label":"MSK profile","url":"https://www.mskcc.org/cancer-care/doctors/michael-morris"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Morris%20MJ%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["prostate"],"sections":[],"technologies":["radioligand-therapy","psma-pet"],"targets":["psma"],"drugs":["pluvicto"],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":["vision","psmafore"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Prostate Cancer Section Head, Genitourinary Oncology Service","institutionId":"mskcc","specialisms":["Prostate cancer","Radiopharmaceuticals","PSMA theranostics"],"profiles":[{"label":"MSK profile","url":"https://www.mskcc.org/cancer-care/doctors/michael-morris"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Morris%20MJ%5BAuthor%5D"}],"papers":[{"title":"Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer","journal":"New England Journal of Medicine","year":2021,"url":"https://doi.org/10.1056/NEJMoa2107322","doi":"10.1056/NEJMoa2107322"},{"title":"177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore)","journal":"Lancet","year":2024,"url":"https://doi.org/10.1016/S0140-6736(24)01653-2","doi":"10.1016/S0140-6736(24)01653-2"}]},{"id":"michael-kerin","kind":"person","name":"Michael Kerin","aka":[],"tldr":"Professor who is Clinical Director of the Saolta Cancer Managed Clinical Academic Network, the cancer centre serving the west and north west of Ireland from Galway.","summary":"Professor Michael Kerin is Clinical Director of the Saolta Cancer Managed Clinical Academic Network (Saolta Cancer MCAN), the cancer programme of the Saolta University Health Care Group centred on University Hospital Galway and linked with the University of Galway. The Saolta cancer centre page names him in that role in connection with his commentary on new breast cancer screening technology. The Galway centre is one of Ireland's designated cancer centres and provides cancer services for the HSE West and North West region.","asOf":"2026-09-10","links":[{"label":"Source: Saolta cancer centre page naming the Clinical Director","url":"https://www.saolta.ie/cancer-centre"}],"tags":["leadership","clinician-scientist","comprehensive-cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["galway-university-hospital-cancer-centre"],"pathways":[],"terms":["screening"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Clinical Director, Saolta Cancer Managed Clinical Academic Network (Saolta Cancer MCAN), Galway University Hospitals","institutionId":"galway-university-hospital-cancer-centre","specialisms":["Breast cancer","Cancer network leadership","Academic medicine"],"profiles":[{"label":"Saolta cancer centre page","url":"https://www.saolta.ie/cancer-centre"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kerin+MJ%5BAuthor%5D"}],"papers":[{"title":"Clinicopathological response to neoadjuvant therapies and pathological complete response as a biomarker of survival in human epidermal growth factor receptor-2 enriched breast cancer – A retrospective cohort study","journal":"The Breast","year":2021,"doi":"10.1016/j.breast.2021.06.005"},{"title":"Clinicopathological and prognostic significance of programmed cell death ligand 1 expression in patients diagnosed with breast cancer: meta-analysis","journal":"British Journal of Surgery","year":2021,"doi":"10.1093/bjs/znab103"},{"title":"Clinicopathological correlates, oncological impact, and validation of Oncotype DX™ in a European Tertiary Referral Centre","journal":"The Breast Journal","year":2021,"doi":"10.1111/tbj.14217"}],"orcid":"0000-0003-4164-5561"},{"id":"michael-wang","kind":"person","name":"Michael L. Wang","aka":[],"tldr":"Led the ibrutinib and brexucabtagene autoleucel trials that transformed mantle cell lymphoma treatment.","summary":"Michael Wang was principal investigator of the pivotal trial of ibrutinib in relapsed mantle cell lymphoma, the first BTK inhibitor approval in the disease, and of ZUMA-2, which established brexucabtagene autoleucel CAR-T therapy for relapsed MCL. He led the chemotherapy-free ibrutinib-rituximab WINDOW trials and the SYMPATICO trial of ibrutinib plus venetoclax. He directs the mantle cell lymphoma programme at MD Anderson.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wang%20ML%5BAuthor%5D%20mantle%20cell%20lymphoma"}],"tags":["lymphoma","mantle-cell","car-t"],"related":[],"cancers":["mantle-cell-lymphoma"],"sections":[],"technologies":["car-t","kinase-inhibitors"],"targets":["cd19","bcl2"],"drugs":["venetoclax"],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-zuma-2-brexu-cel-mantle-cell-nejm-2020"],"journals":[],"dependsOn":[],"notes":[],"role":"Puddin Clarke Endowed Professor, Department of Lymphoma and Myeloma, MD Anderson Cancer Center","institutionId":"md-anderson","specialisms":["Mantle cell lymphoma","BTK inhibitors","CAR T-cell therapy","Chemotherapy-free regimens"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wang%20ML%5BAuthor%5D%20mantle%20cell%20lymphoma"}],"papers":[{"title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma (ZUMA-2)","journal":"NEJM","year":2020,"doi":"10.1056/NEJMoa1914347"},{"title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","journal":"NEJM","year":2013,"doi":"10.1056/NEJMoa1306220"}]},{"id":"michael-leblanc","kind":"person","name":"Michael LeBlanc","aka":[],"tldr":"Michael LeBlanc is the statistician behind SWOG's trials, based at Fred Hutch's statistical centre.","summary":"Michael LeBlanc is Group Statistician of the SWOG Cancer Research Network and a Member of the Public Health Sciences Division at Fred Hutchinson Cancer Center. A biostatistician specialising in clinical trial design, he leads the SWOG Statistics and Data Management Center at Fred Hutch's statistical centre and develops methods for survival analysis, treatment selection and adaptive design in cancer trials. His papers include a Journal of the American Statistical Association article on survival trees by goodness of split and a Biometrics paper on relative risk trees for censored survival data. He is the statistician behind SWOG's trials.","asOf":"2026-09-08","links":[{"label":"Fred Hutch faculty directory","url":"https://www.fredhutch.org/en/faculty-lab-directory.html?q=Michael%20LeBlanc"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=LeBlanc%20M%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Michael%20LeBlanc"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["swog"],"institutions":["fred-hutch"],"pathways":[],"terms":["hazard-ratio","pfs","os"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Group Statistician, SWOG Cancer Research Network; Member, Public Health Sciences Division, Fred Hutchinson Cancer Center","institutionId":"fred-hutch","specialisms":["Biostatistics","Clinical trial design"],"profiles":[{"label":"Fred Hutch faculty directory","url":"https://www.fredhutch.org/en/faculty-lab-directory.html?q=Michael%20LeBlanc"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=LeBlanc%20M%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Michael%20LeBlanc"}],"papers":[{"title":"Survival Trees by Goodness of Split","journal":"Journal of the American Statistical Association","year":1993,"url":"https://doi.org/10.1080/01621459.1993.10476296","doi":"10.1080/01621459.1993.10476296"},{"title":"Relative risk trees for censored survival data","journal":"Biometrics","year":1992}],"orcid":"0000-0001-7192-2860"},{"id":"michael-milken","kind":"person","name":"Michael Milken","aka":[],"tldr":"Diagnosed with advanced prostate cancer in 1993, the financier founded the Prostate Cancer Foundation, whose grants helped pay for the science behind abiraterone and enzalutamide and built a network of precision oncology centres for US veterans.","summary":"Michael Milken, the financier whose junk-bond career ended in a securities-fraud conviction, was diagnosed with advanced prostate cancer in 1993 and, as the Prostate Cancer Foundation's history records, founded the Foundation that year, transforming research, collaboration and awareness. PCF funds investigators and teams rather than running its own laboratories and insists on speed: short applications, fast decisions and a yearly retreat where grantees share unpublished data. Its own history credits $8 million of PCF funding toward the development of abiraterone (Zytiga) and $14.75 million toward enzalutamide (Xtandi), and a $65 million partnership with the US Department of Veterans Affairs in 2016 that established 22 precision oncology centres of excellence. Milken also founded FasterCures, part of the Milken Institute, to speed medical research more broadly.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Michael_Milken","links":[{"label":"Prostate Cancer Foundation: our history","url":"https://www.pcf.org/about/our-history/"}],"tags":["hero","donor","patient"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":["abiraterone","enzalutamide"],"companies":[],"institutions":["pcf"],"pathways":[],"terms":[],"trials":[],"people":["charles-sawyers","david-koch"],"bottlenecks":["b-funding-allocation","b-translational-valley"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Prostate cancer patient who founded the Prostate Cancer Foundation in 1993","specialisms":["Prostate cancer research funding","Medical research philanthropy","Research acceleration"],"profiles":[],"papers":[]},{"id":"michael-migden","kind":"person","name":"Michael R. Migden","aka":[],"tldr":"Houston dermatologist who led the trials that established cemiplimab, the first drug approved for advanced cutaneous squamous-cell carcinoma, and sonidegib for basal cell carcinoma.","summary":"Michael Migden is a dermatologist and Mohs surgeon at MD Anderson Cancer Center who runs trials of systemic therapy for non-melanoma skin cancer. He was first author of the 2018 New England Journal of Medicine report of cemiplimab in advanced cutaneous squamous-cell carcinoma (EMPOWER-CSCC 1 and its phase 1 expansion), which led to the first approval for this disease, and of the 2015 Lancet Oncology report of the BOLT trial of sonidegib in advanced basal cell carcinoma.","asOf":"2026-09-18","links":[],"tags":["skin","immunotherapy","trialist"],"related":[],"cancers":["advanced-cutaneous-scc","locally-advanced-bcc","skin-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-empower-cscc-1-cemiplimab-migden-nejm-2018","paper-bolt-sonidegib-migden-lancet-oncol-2015"],"journals":[],"dependsOn":[],"notes":[],"role":"Dermatologist and Mohs surgeon, MD Anderson Cancer Center","institutionId":"md-anderson","specialisms":["Cutaneous squamous-cell carcinoma","Basal cell carcinoma","Systemic therapy for skin cancer"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Migden%5BAuthor%5D"}],"papers":[{"title":"BOLT: two doses of sonidegib in locally advanced or metastatic basal cell carcinoma","journal":"The Lancet Oncology","year":2015,"url":"https://doi.org/10.1016/S1470-2045(15)70100-2","doi":"10.1016/S1470-2045(15)70100-2"},{"title":"PD-1 blockade with cemiplimab in advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1)","journal":"New England Journal of Medicine","year":2018,"url":"https://doi.org/10.1056/NEJMoa1805131","doi":"10.1056/NEJMoa1805131"}]},{"id":"michael-stratton","kind":"person","name":"Michael Stratton","aka":[],"tldr":"Pioneer of cancer genome sequencing and mutational signatures; led the Cancer Genome Project and formerly directed the Sanger Institute.","summary":"Michael Stratton is a senior group leader at the Wellcome Sanger Institute and served as its Director from 2010 until 2023. He led the Cancer Genome Project and was a founder of the International Cancer Genome Consortium, and his group established the concept of mutational signatures in human cancer. His work has defined much of the modern understanding of somatic mutation in cancer.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Stratton+MR%5BAuthor%5D"}],"tags":["clinician-scientist","cancer genomics","mutational signatures"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["wellcome-sanger"],"pathways":[],"terms":["mutational-signature"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Senior Group Leader; former Director","institutionId":"wellcome-sanger","specialisms":["Cancer genomics","Mutational signatures","Somatic mutation"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Stratton+MR%5BAuthor%5D"}],"papers":[{"title":"Landscape of somatic mutations in 560 breast cancer whole-genome sequences","journal":"Nature","year":2016,"doi":"10.1038/nature17676"},{"title":"The cancer genome","journal":"Nature","year":2009,"doi":"10.1038/nature07943"},{"title":"Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets","journal":"Nature Genetics","year":2015,"doi":"10.1038/ng.3252"}],"orcid":"0000-0001-6035-153X"},{"id":"michael-von-bergwelt","kind":"person","name":"Michael von Bergwelt","aka":[],"tldr":"Michael von Bergwelt is a haematologist who leads LMU's cell therapy and immuno-oncology programme.","summary":"Michael von Bergwelt is Director of the Department of Medicine III (Hematology and Oncology) at LMU Klinikum München. A haematologist, his specialisms are haematology, cell therapy and immunotherapy toxicity. He leads LMU's cell therapy and immuno-oncology programme, with research on CAR-T cell therapy, T-cell engaging bispecific antibodies and the management of immune-related toxicities. His department combines clinical haematology and oncology with the delivery of these newer immune therapies. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=von%20Bergwelt-Baildon%20M%5BAuthor%5D%20CAR%20T"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["car-t","t-cell-engager"],"targets":[],"drugs":[],"companies":[],"institutions":["lmu-munich"],"pathways":[],"terms":["crs"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Department of Medicine III (Hematology and Oncology), LMU Munich","institutionId":"lmu-munich","specialisms":["Haematology","Cell therapy","Immunotherapy toxicity"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=von%20Bergwelt-Baildon%20M%5BAuthor%5D%20CAR%20T"}],"papers":[{"title":"Cytokine release syndrome","journal":"Journal for ImmunoTherapy of Cancer","year":2018,"doi":"10.1186/s40425-018-0343-9"},{"title":"Advances in cancer immunotherapy 2019 – latest trends","journal":"Journal of Experimental & Clinical Cancer Research","year":2019,"doi":"10.1186/s13046-019-1266-0"},{"title":"CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition","journal":"Blood","year":2006,"doi":"10.1182/blood-2005-08-3507"}]},{"id":"michael-weller","kind":"person","name":"Michael Weller","aka":[],"tldr":"Neuro-oncologist who leads the EORTC Brain Tumor Group and co-authors the European glioma guidelines.","summary":"Michael Weller is Chair of the Department of Neurology at University Hospital Zurich and Chair of the EORTC Brain Tumor Group. A neuro-oncologist, his specialisms are neuro-oncology, glioma and clinical trials. He led the European Association for Neuro-Oncology (EANO) guidelines on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas, anaplastic gliomas and glioblastoma, and diffuse gliomas of adulthood, published in The Lancet Oncology and Nature Reviews Clinical Oncology. His trials include studies of temozolomide, lomustine and targeted agents in glioblastoma, and he is linked to the EORTC 26981/NCIC CE.3 trial. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Weller%20M%5BAuthor%5D%20glioblastoma"}],"tags":[],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":["temozolomide","lomustine"],"companies":["curie-nki-eortc"],"institutions":[],"pathways":[],"terms":[],"trials":["eortc-26981"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chair, Department of Neurology, University Hospital Zurich; Chair, EORTC Brain Tumor Group","institutionId":"curie-nki-eortc","specialisms":["Neuro-oncology","Glioma","Clinical trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Weller%20M%5BAuthor%5D%20glioblastoma"}],"papers":[{"title":"European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas","journal":"The Lancet Oncology","year":2017,"doi":"10.1016/s1470-2045(17)30194-8"},{"title":"EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma","journal":"The Lancet Oncology","year":2014,"doi":"10.1016/s1470-2045(14)70011-7"},{"title":"EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood","journal":"Nature Reviews Clinical Oncology","year":2020,"doi":"10.1038/s41571-020-00447-z"},{"title":"Stupp 2005: temozolomide added to radiotherapy for newly diagnosed glioblastoma","journal":"New England Journal of Medicine","year":2005,"url":"https://doi.org/10.1056/NEJMoa043330","doi":"10.1056/NEJMoa043330"}],"orcid":"0000-0002-1748-174X"},{"id":"yu-michael","kind":"person","name":"Michael Yu (Yu De-Chao)","aka":["De-Chao Yu","俞德超"],"tldr":"Michael Yu founded Innovent in Suzhou in 2011 and made sintilimab one of China's best-selling cancer drugs before turning the company into a supplier of new medicines to Roche and Takeda.","summary":"Yu earlier co-invented Oncorine (H101), the world's first approved oncolytic virus (China, 2005), and the anti-VEGF conbercept; at Innovent he built an integrated antibody company with sintilimab, four biosimilars, the CAR-T eque-cel partnership, KRAS G12C inhibitor fulzerasib and the IBI363 and IBI343 programmes licensed to Takeda in 2025.","asOf":"2026-09-10","links":[{"label":"Innovent Biologics","url":"https://www.innoventbio.com/"}],"tags":["china"],"related":[],"cancers":[],"sections":[],"technologies":["oncolytic-virus"],"targets":[],"drugs":["sintilimab","fulzerasib","equecabtagene-autoleucel"],"companies":["innovent"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Founder, Chairman and CEO, Innovent Biologics","specialisms":["Antibody therapeutics","Biotech leadership","Biosimilars"],"profiles":[{"label":"Innovent Biologics","url":"https://www.innoventbio.com/"}],"papers":[]},{"id":"michal-besser","kind":"person","name":"Michal Besser","aka":[],"tldr":"Runs the laboratory that actually grows the cells. Her papers are the reason anyone outside the United States believed a hospital could manufacture tumour-infiltrating lymphocytes reliably.","summary":"Michal Besser leads cell therapy laboratory work at Sheba's Ella Lemelbaum Institute and is first author of its intent-to-treat report on tumour-infiltrating lymphocyte therapy in metastatic melanoma, which found blood lactate dehydrogenase, sex, days in culture and the number of infused CD8-positive cells to be independent predictors of outcome. Her laboratory has published the practical protocols that others copy: how to establish and expand TIL cultures, how to transduce them retrovirally with a chimeric antigen receptor or a T-cell receptor, and how microRNA expression in the infused product tracks with response. Work of this kind is why a small country with one dominant referral centre can run a cell therapy programme that larger health systems find hard to reproduce.","asOf":"2026-09-25","links":[{"label":"Sheba Medical Center cancer centre","url":"https://www.shebaonline.org/departments/cancer-center/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Besser%20MJ%5BAuthor%5D%20tumor-infiltrating%20lymphocytes"}],"tags":["scientist","cell-therapy"],"related":[],"cancers":["melanoma"],"sections":["cell-therapy"],"technologies":["til-therapy","car-t"],"targets":[],"drugs":[],"companies":[],"institutions":["sheba","tel-aviv-university"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-manufacturing-cell-therapy"],"keyPapers":["paper-besser-til-melanoma-intent-to-treat-ccr-2013"],"journals":[],"dependsOn":[],"notes":[],"role":"Head of the Ella Lemelbaum Institute cell therapy laboratory, Sheba Medical Center; Gray Faculty of Medical and Health Sciences, Tel Aviv University","institutionId":"sheba","specialisms":["Tumour-infiltrating lymphocytes","Adoptive cell therapy","T-cell manufacturing","Genetic modification of T cells"],"profiles":[{"label":"Sheba Medical Center cancer centre","url":"https://www.shebaonline.org/departments/cancer-center/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Besser%20MJ%5BAuthor%5D%20tumor-infiltrating%20lymphocytes"}],"papers":[{"title":"Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies","journal":"Clinical Cancer Research","year":2013,"doi":"10.1158/1078-0432.ccr-13-0380"},{"title":"Genetic modification of tumor-infiltrating lymphocytes via retroviral transduction","journal":"Frontiers in Immunology","year":2020,"doi":"10.3389/fimmu.2020.584148"}]},{"id":"michal-mekel","kind":"person","name":"Michal Mekel","aka":[],"tldr":"Endocrine surgeon who leads Rambam Health Care Campus, the largest hospital in northern Israel, after nearly three decades at the institution.","summary":"Dr Michal Mekel is Director General of Rambam Health Care Campus in Haifa, the tertiary referral hospital for northern Israel. She trained at the Technion Faculty of Medicine, became Israel's first endocrine surgeon in 2009 and developed the specialty nationally, and moved into management in 2013 before appointment as Deputy Director in 2017 and then to the top role. She leads a management team including deputy directors for medical operations, paediatrics, surgery and hospitalisation logistics.","asOf":"2026-09-10","links":[{"label":"Source: Rambam about and leadership pages","url":"https://www.rambam.org.il/en/about_rambam/"}],"tags":["leadership","clinician-scientist","surgery"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["rambam"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["annals-of-surgical-oncology","surgical-oncology"],"dependsOn":[],"notes":[],"role":"Director General of Rambam Health Care Campus","institutionId":"rambam","specialisms":["Endocrine surgery","Hospital management","Surgical oncology"],"profiles":[{"label":"Rambam leadership page","url":"https://www.rambam.org.il/en/about_rambam/leadership/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mekel+M%5BAuthor%5D"}],"papers":[{"title":"Parathyroid Surgery in the Elderly: Should Minimally Invasive Surgery Be Abandoned?","journal":"Annals of Surgical Oncology","year":2013,"doi":"10.1245/s10434-013-3402-y"},{"title":"Parathyroid carcinoma","journal":"Surgical Oncology","year":2014,"doi":"10.1016/j.suronc.2014.03.005"},{"title":"Computerized cytometry and wavelet analysis of follicular lesions for detecting malignancy: A pilot study in thyroid cytology","journal":"Surgery","year":2017,"doi":"10.1016/j.surg.2016.06.078"}]},{"id":"michal-mikula","kind":"person","name":"Michał Mikula","aka":[],"tldr":"Molecular geneticist who leads the scientific programme of Poland's National Research Institute of Oncology.","summary":"Michał Mikula is Deputy Director for Scientific Affairs at the Maria Skłodowska-Curie National Research Institute of Oncology in Warsaw, a role he has held since May 2022. A professor of medical sciences, his research concerns the molecular genetics of gastrointestinal and colorectal cancers. His role is listed on the institute's management page.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://nio.gov.pl/dyrekcja-instytutu"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mikula+M%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","cancer genetics"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["nio-warsaw"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["journal-of-experimental-and-clinical-cancer-research"],"dependsOn":[],"notes":[],"role":"Deputy Director for Scientific Affairs","institutionId":"nio-warsaw","specialisms":["Cancer genetics","Colorectal cancer","Translational research"],"profiles":[{"label":"Institution profile","url":"https://nio.gov.pl/dyrekcja-instytutu"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mikula+M%5BAuthor%5D"}],"papers":[{"title":"Microbial and Metabolic Gut Profiling across Seven Malignancies Identifies Fecal Faecalibacillus intestinalis and Formic Acid as Commonly Altered in Cancer Patients","journal":"International Journal of Molecular Sciences","year":2024,"doi":"10.3390/ijms25158026"},{"title":"Loss of epidermal MCPIP1 is associated with aggressive squamous cell carcinoma","journal":"Journal of Experimental & Clinical Cancer Research","year":2021,"doi":"10.1186/s13046-021-02202-3"},{"title":"High Prevalence of Genetically Related Clostridium Difficile Strains at a Single Hemato-Oncology Ward Over 10 Years","journal":"Frontiers in Microbiology","year":2020,"doi":"10.3389/fmicb.2020.01618"}]},{"id":"michel-attal","kind":"person","name":"Michel Attal","aka":[],"tldr":"French haematologist whose trials established autologous stem-cell transplantation for myeloma in the 1990s and, in IFM 2009, showed that transplant still adds benefit in the era of lenalidomide, bortezomib and dexamethasone.","summary":"Michel Attal is a haematologist at the IUCT Oncopole in Toulouse and a leader of the Intergroupe Francophone du Myélome. His 1996 New England Journal of Medicine trial showed high-dose therapy with autologous transplantation improved survival over conventional chemotherapy in myeloma. He was first author of the 2017 New England Journal of Medicine report of IFM 2009, which found that adding early transplantation to RVD induction lengthened progression-free survival compared with RVD alone in transplant-eligible patients.","asOf":"2026-09-18","links":[],"tags":["myeloma","transplant","trialist"],"related":[],"cancers":["myeloma-transplant-eligible","multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["iuct-oncopole"],"pathways":[],"terms":[],"trials":["ifm-2009"],"people":[],"bottlenecks":[],"keyPapers":["paper-ifm-2009-attal-nejm-2017"],"journals":[],"dependsOn":[],"notes":[],"role":"Haematologist and Director General, IUCT Oncopole, Toulouse","institutionId":"iuct-oncopole","specialisms":["Multiple myeloma","Autologous stem-cell transplantation","Intergroupe Francophone du Myélome trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Attal%5BAuthor%5D"}],"papers":[{"title":"IFM 2009: lenalidomide, bortezomib and dexamethasone with or without upfront transplantation for myeloma","journal":"New England Journal of Medicine","year":2017,"url":"https://doi.org/10.1056/NEJMoa1611750","doi":"10.1056/NEJMoa1611750"}]},{"id":"michel-sadelain","kind":"person","name":"Michel Sadelain","aka":[],"tldr":"Designed the second-generation CAR with a CD28 costimulatory domain that made CAR-T therapy work.","summary":"Michel Sadelain's laboratory at MSKCC created the CD19-targeted second-generation chimeric antigen receptor with a CD28 signalling domain, the design underlying axicabtagene ciloleucel and brexucabtagene autoleucel, and showed that costimulation was the key to making engineered T cells persist and kill. He led the first CD19 CAR-T trials in adult ALL with Renier Brentjens and pioneered CRISPR-targeted CAR insertion into the TRAC locus. He moved to Columbia in 2024.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sadelain%20M%5BAuthor%5D%20chimeric%20antigen%20receptor"}],"tags":["cell-therapy","car-t","engineering"],"related":[],"cancers":["all-leukemia","dlbcl"],"sections":[],"technologies":["car-t","in-vivo-car-t"],"targets":["cd19"],"drugs":[],"companies":[],"institutions":["columbia-hicc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-zuma-1-axi-cel-nejm-2017"],"journals":["science-translational-medicine"],"dependsOn":[],"notes":[],"role":"Director, Columbia Initiative in Cell Engineering and Therapy, Columbia University Irving Medical Center","institutionId":"columbia-hicc","specialisms":["CAR T-cell engineering","Gene therapy","Synthetic immunology","Cell therapy manufacturing"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sadelain%20M%5BAuthor%5D%20chimeric%20antigen%20receptor"}],"papers":[{"title":"The basic principles of chimeric antigen receptor design","journal":"Cancer Discovery","year":2013,"doi":"10.1158/2159-8290.CD-13-0148"},{"title":"CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","journal":"Science Translational Medicine","year":2013,"doi":"10.1126/scitranslmed.3005930"},{"title":"Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection","journal":"Nature","year":2017,"doi":"10.1038/nature21405"},{"title":"ZUMA-1: axicabtagene ciloleucel for refractory large B-cell lymphoma, the first CAR-T approved for lymphoma","journal":"New England Journal of Medicine","year":2017,"url":"https://doi.org/10.1056/NEJMoa1707447","doi":"10.1056/NEJMoa1707447"}],"orcid":"0000-0002-9031-8025"},{"id":"michelle-mitchell","kind":"person","name":"Michelle Mitchell","aka":[],"tldr":"Michelle Mitchell is chief executive of the world's largest independent cancer research charity.","summary":"Michelle Mitchell is Chief Executive of Cancer Research UK, the world's largest independent cancer research charity. Her specialisms are charity leadership, research funding strategy and cancer policy. She has led the charity since 2018, overseeing its research strategy, the Cancer Grand Challenges partnership with the US National Cancer Institute, and its policy work on early diagnosis and prevention. She is responsible for the direction of one of the largest funders of cancer research in the world. Her Cancer Research UK profile is linked.","asOf":"2026-09-08","links":[{"label":"Cancer Research UK","url":"https://www.cancerresearchuk.org/"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cruk"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive, Cancer Research UK","institutionId":"cruk","specialisms":["Charity leadership","Research funding strategy","Cancer policy"],"profiles":[{"label":"Cancer Research UK","url":"https://www.cancerresearchuk.org/"}],"papers":[]},{"id":"michelle-monje","kind":"person","name":"Michelle Monje","aka":[],"tldr":"Founded cancer neuroscience and led the GD2 CAR-T trial that produced the first regressions of diffuse midline glioma.","summary":"Michelle Monje showed that neuronal activity drives glioma growth through neuroligin-3 and synaptic integration, founding the field of cancer neuroscience, and led the first-in-human trial of GD2-directed CAR T cells in H3K27M-mutant diffuse midline glioma that produced radiographic and clinical improvements in a disease with no effective therapy. She was awarded a MacArthur Fellowship and leads paediatric neuro-oncology research at Stanford.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Michelle_Monje","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Monje%20M%5BAuthor%5D%20glioma%20GD2%20OR%20neuroligin"}],"tags":["paediatric","glioma","car-t","cancer-neuroscience"],"related":[],"cancers":[],"sections":[],"technologies":["car-t"],"targets":[],"drugs":[],"companies":[],"institutions":["stanford","hhmi"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Neurology and Neurological Sciences, Stanford University; HHMI Investigator","institutionId":"stanford","specialisms":["Paediatric high-grade glioma","Cancer neuroscience","GD2 CAR T cells","Diffuse midline glioma"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Monje%20M%5BAuthor%5D%20glioma%20GD2%20OR%20neuroligin"}],"papers":[{"title":"GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas","journal":"Nature","year":2022,"doi":"10.1038/s41586-022-04489-4"},{"title":"Neuronal activity promotes glioma growth through neuroligin-3 secretion","journal":"Cell","year":2015,"doi":"10.1016/j.cell.2015.04.012"},{"title":"Electrical and synaptic integration of glioma into neural circuits","journal":"Nature","year":2019,"doi":"10.1038/s41586-019-1563-y"}],"orcid":"0000-0002-3547-237X"},{"id":"xia-michelle","kind":"person","name":"Michelle Xia (Xia Yu)","aka":["Yu Xia","夏瑜"],"tldr":"Michelle Xia founded Akeso, the Zhongshan company whose bispecific antibody ivonescimab was the first drug to beat pembrolizumab in a head-to-head trial.","summary":"A returnee antibody scientist who founded Akeso in 2012 and built the Tetrabody platform behind cadonilimab (PD-1 x CTLA-4, approved 2022), ivonescimab (PD-1 x VEGF, approved 2024, HARMONi-2 win over pembrolizumab) and penpulimab (FDA approved 2025); licensed ivonescimab's Western rights to Summit Therapeutics for $500 million upfront.","asOf":"2026-09-10","links":[{"label":"Akeso","url":"https://www.akesobio.com/"}],"tags":["china"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["ivonescimab","cadonilimab","penpulimab"],"companies":["akeso"],"institutions":[],"pathways":[],"terms":[],"trials":["harmoni-2","harmoni-a"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Founder, Chairwoman and CEO, Akeso","specialisms":["Bispecific antibodies","Antibody discovery","Biotech leadership"],"profiles":[{"label":"Akeso","url":"https://www.akesobio.com/"}],"papers":[{"title":"Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors","journal":"Journal for ImmunoTherapy of Cancer","year":2024,"doi":"10.1136/jitc-2023-008037"},{"title":"Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity","journal":"Journal for ImmunoTherapy of Cancer","year":2022,"doi":"10.1136/jitc-2022-005517"},{"title":"CD74 is associated with inflamed tumor immune microenvironment and predicts responsiveness to PD-1/CTLA-4 bispecific antibody in patients with solid tumors","journal":"Cancer Immunology, Immunotherapy","year":2024,"doi":"10.1007/s00262-023-03604-2"}]},{"id":"miguel-sanz","kind":"person","name":"Miguel A. Sanz","aka":[],"tldr":"Spanish haematologist who led the PETHEMA trials that tailored acute promyelocytic leukaemia treatment to relapse risk, and who chaired the European LeukemiaNet recommendations for the disease.","summary":"Miguel Sanz is a haematologist at Hospital La Fe in Valencia and a founder of the Spanish PETHEMA cooperative group. He led the PETHEMA LPA trials that established risk-adapted ATRA and anthracycline therapy for acute promyelocytic leukaemia and defined the Sanz risk score based on white cell and platelet counts. He was first author of the 2019 Blood update of the European LeukemiaNet recommendations for managing the disease.","asOf":"2026-09-18","links":[],"tags":["leukaemia","guidelines"],"related":[],"cancers":["apl","aml"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["la-fe-valencia"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-eln-apl-sanz-blood-2019"],"journals":[],"dependsOn":[],"notes":[],"role":"Haematologist, Hospital Universitari i Politècnic La Fe, Valencia","institutionId":"la-fe-valencia","specialisms":["Acute promyelocytic leukaemia","Risk-adapted therapy","PETHEMA trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sanz%5BAuthor%5D"}],"papers":[{"title":"European LeukemiaNet recommendations for the management of acute promyelocytic leukaemia (2019 update)","journal":"Blood","year":2019,"url":"https://doi.org/10.1182/blood-2019-01-894980","doi":"10.1182/blood-2019-01-894980"}],"orcid":"0000-0003-1489-1177"},{"id":"miguel-martin","kind":"person","name":"Miguel Martín","aka":[],"tldr":"Miguel Martín is the founder of the Spanish breast cancer group GEICAM and a leader of adjuvant chemotherapy trials.","summary":"Miguel Martín is Head of Medical Oncology at Hospital General Universitario Gregorio Marañón in Madrid and Chairman of GEICAM, the Spanish breast cancer research group he founded. His specialisms are breast cancer, adjuvant chemotherapy and cooperative group trials. He led trials of adjuvant docetaxel-based regimens, including BCIRG 001, the New England Journal of Medicine trial of adjuvant docetaxel for node-positive breast cancer. He has also been involved in CDK4/6 inhibitor trials including PALLAS and monarchE, which tested palbociclib and abemaciclib. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Martin%20M%5BAuthor%5D%20GEICAM%20breast"}],"tags":[],"related":[],"cancers":["breast-hr-positive","tnbc"],"sections":[],"technologies":[],"targets":[],"drugs":["abemaciclib","palbociclib"],"companies":[],"institutions":["gregorio-maranon"],"pathways":[],"terms":[],"trials":["pallas-penelope-b","monarche"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Head of Medical Oncology, Hospital General Universitario Gregorio Marañón; Chairman, GEICAM","institutionId":"gregorio-maranon","specialisms":["Breast cancer","Adjuvant chemotherapy","Cooperative group trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Martin%20M%5BAuthor%5D%20GEICAM%20breast"}],"papers":[{"title":"Adjuvant docetaxel for node-positive breast cancer (BCIRG 001)","journal":"NEJM","year":2005,"doi":"10.1056/NEJMoa043681"},{"title":"monarchE: two years of abemaciclib after surgery in high-risk, hormone-receptor-positive early breast cancer","journal":"Journal of Clinical Oncology","year":2020,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=monarchE+abemaciclib+adjuvant+Johnston+2020"},{"title":"NATALEE: three years of ribociclib after surgery in a broad population of hormone-receptor-positive early breast cancer","journal":"New England Journal of Medicine","year":2024,"url":"https://doi.org/10.1056/NEJMoa2305488","doi":"10.1056/NEJMoa2305488"}]},{"id":"ryu-min-hee","kind":"person","name":"Min-Hee Ryu","aka":[],"tldr":"Min-Hee Ryu is a gastric cancer and GIST trialist central to the Asian arms of ramucirumab, pembrolizumab, and zolbetuximab studies.","summary":"Min-Hee Ryu is Professor of Medical Oncology at Asan Medical Center in Seoul, specialising in gastric cancer and gastrointestinal stromal tumours. He co-leads gastrointestinal oncology at the centre and has been central to the Asian arms of the ramucirumab, pembrolizumab and zolbetuximab studies, with steering roles in RAINBOW-Asia, GLOW and the KEYNOTE gastric trials, as well as in studies of tyrosine kinase inhibitor sequencing in GIST. His publications include the GLOW trial of zolbetuximab plus CAPOX in Claudin 18.2-positive gastric or gastro-oesophageal junction adenocarcinoma. His interests are gastric cancer, GIST and clinical trials.","asOf":"2026-09-08","links":[{"label":"Asan Medical Center","url":"https://eng.amc.seoul.kr"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ryu%20MH%5BAuthor%5D%20Asan%20gastric"}],"tags":[],"related":[],"cancers":["gastric","sarcoma"],"sections":[],"technologies":[],"targets":["cldn18-2"],"drugs":["zolbetuximab","ramucirumab"],"companies":[],"institutions":["asan-medical-center"],"pathways":[],"terms":[],"trials":["spotlight-glow","rainbow"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology; gastric cancer and GIST","institutionId":"asan-medical-center","specialisms":["Gastric cancer","GIST","Clinical trials"],"profiles":[{"label":"Asan Medical Center","url":"https://eng.amc.seoul.kr"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ryu%20MH%5BAuthor%5D%20Asan%20gastric"}],"papers":[{"title":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or GEJ adenocarcinoma (GLOW)","journal":"Nature Medicine","year":2023,"doi":"10.1038/s41591-023-02465-7"}]},{"id":"mirela-grosu","kind":"person","name":"Mirela Grosu","aka":[],"tldr":"Mirela Grosu represents Iași Regional Oncology Institute in the Organisation of European Cancer Institutes, which lists the centre among its members in Romania.","summary":"Mirela Grosu is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Iași Regional Oncology Institute, its member in Romania. Iași Regional Oncology Institute is the regional cancer institute for north-eastern Romania, opened in Iași in 2012, and an associate member of the Organisation of European Cancer Institutes. OnCo records the name from the OECI membership list so that the centre's page has a named contact point; the person's exact title, appointment date and biography are not yet recorded and should be checked on the institution's own pages before being relied on.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Iași Regional Oncology Institute website","url":"https://www.iroiasi.ro/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["iasi-regional-oncology-institute"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Iași Regional Oncology Institute to the Organisation of European Cancer Institutes","institutionId":"iasi-regional-oncology-institute","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Iași Regional Oncology Institute website","url":"https://www.iroiasi.ro/"}],"papers":[]},{"id":"miriam-merad","kind":"person","name":"Miriam Merad","aka":[],"tldr":"Mapped how macrophages and dendritic cells in tumours suppress immunity, opening new immunotherapy targets.","summary":"Miriam Merad is Director of the Marc and Jennifer Lipschultz Precision Immunology Institute and Chair of the Department of Immunology and Immunotherapy at The Mount Sinai Hospital and Tisch Cancer Institute. She is an immunologist known for mapping how macrophages and dendritic cells in tumours suppress immunity, defining tissue-resident macrophage biology and using single-cell atlases of lung tumours to identify myeloid programmes such as TREM2 that shape response to immunotherapy. Her selected paper reports the innate immune landscape in early lung adenocarcinoma by paired single-cell analyses. She is president of the American Association of Immunologists and continues single-cell work in lung and liver cancer.","asOf":"2026-09-08","links":[{"label":"Mount Sinai profile","url":"https://profiles.mountsinai.org/miriam-merad"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Merad%20M%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["nsclc","hcc"],"sections":[],"technologies":["single-cell-spatial"],"targets":[],"drugs":[],"companies":[],"institutions":["mount-sinai"],"pathways":[],"terms":["cold-vs-hot"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Marc and Jennifer Lipschultz Precision Immunology Institute; Chair, Department of Immunology and Immunotherapy","institutionId":"mount-sinai","specialisms":["Myeloid cells","Tumour-associated macrophages","Single-cell immunology"],"profiles":[{"label":"Mount Sinai profile","url":"https://profiles.mountsinai.org/miriam-merad"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Merad%20M%5BAuthor%5D"}],"papers":[{"title":"Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses","journal":"Cell","year":2017,"url":"https://doi.org/10.1016/j.cell.2017.04.014","doi":"10.1016/j.cell.2017.04.014"}]},{"id":"miroslav-chovanec","kind":"person","name":"Miroslav Chovanec","aka":[],"tldr":"Miroslav Chovanec represents Biomedical Research Center of the Slovak Academy of Sciences in the Organisation of European Cancer Institutes, which lists the organisation among its members in Slovakia.","summary":"Miroslav Chovanec is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Biomedical Research Center of the Slovak Academy of Sciences, its associate member in Slovakia. OnCo records the name from the OECI membership list so that the organisation's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the organisation's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Biomedical Research Center of the Slovak Academy of Sciences website","url":"http://www.biomedcentrum.sav.sk/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["biomedical-research-center-sas"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Biomedical Research Center of the Slovak Academy of Sciences to the Organisation of European Cancer Institutes","institutionId":"biomedical-research-center-sas","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Biomedical Research Center of the Slovak Academy of Sciences website","url":"http://www.biomedcentrum.sav.sk/"}],"papers":[{"title":"Selenium: a double-edged sword for defense and offence in cancer","journal":"Arch Toxicol","year":2010,"url":"https://doi.org/10.1007/s00204-010-0595-8","doi":"10.1007/s00204-010-0595-8","note":"Europe PMC author record matched by affiliation"},{"title":"Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium","journal":"J Clin Oncol","year":2021,"url":"https://doi.org/10.1200/jco.20.03296","doi":"10.1200/jco.20.03296","note":"Europe PMC author record matched by affiliation"},{"title":"DNA double-strand break repair by homologous recombination","journal":"Mutat Res","year":2004,"url":"https://doi.org/10.1016/j.mrrev.2003.07.001","doi":"10.1016/j.mrrev.2003.07.001","note":"Europe PMC author record matched by affiliation"}]},{"id":"mitch-dowsett","kind":"person","name":"Mitch Dowsett","aka":[],"tldr":"The translational scientist behind the aromatase inhibitor era and the Ki67 response test used in POETIC.","summary":"Mitch Dowsett's laboratory established the pharmacology of aromatase inhibitors and the biomarker work that supported the ATAC trial, and defined Ki67 change after two weeks of endocrine therapy as a predictor of outcome (POETIC). He chaired the International Ki67 Working Group and led the IMPACT and POETIC trials with Ian Smith. His current work focuses on endocrine resistance biology and biomarker standardisation.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dowsett%20M%5BAuthor%5D%20Ki67%20endocrine"}],"tags":["breast","biomarkers","translational"],"related":[],"cancers":["breast-hr-positive"],"sections":[],"technologies":["endocrine-therapy","histopathology-ihc"],"targets":["estrogen-receptor"],"drugs":[],"companies":[],"institutions":["icr-london","royal-marsden"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Biochemical Endocrinology, Institute of Cancer Research and Royal Marsden","institutionId":"icr-london","specialisms":["Endocrine therapy biology","Ki67 and biomarkers","Aromatase inhibitors","Translational breast research"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dowsett%20M%5BAuthor%5D%20Ki67%20endocrine"}],"papers":[{"title":"Assessment of Ki67 in breast cancer: updated recommendations from the International Ki67 in Breast Cancer Working Group","journal":"JNCI","year":2021,"doi":"10.1093/jnci/djaa201"},{"title":"Peri-operative aromatase inhibitor treatment in determining or predicting longterm outcome in early breast cancer (POETIC)","journal":"Lancet Oncology","year":2020,"doi":"10.1016/S1470-2045(20)30458-7"}],"orcid":"0000-0003-4122-744X"},{"id":"mitchel-berger","kind":"person","name":"Mitchel S. Berger","aka":[],"tldr":"Neurosurgeon who proved that removing more of a glioma extends survival and pioneered awake mapping to do it safely.","summary":"Mitchel Berger led the studies establishing that extent of resection independently predicts survival in low-grade and high-grade glioma, which shifted neurosurgical practice toward maximal safe resection, and developed intraoperative brain mapping techniques that make aggressive surgery near language and motor areas possible. He directed the UCSF Brain Tumor Center and has been president of the American Association of Neurological Surgeons.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Berger%20MS%5BAuthor%5D%20glioma%20resection"}],"tags":["glioma","surgery","neurosurgery"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":["fluorescence-guided-surgery"],"targets":[],"drugs":[],"companies":[],"institutions":["ucsf"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Neurological Surgery and Director, Brain Tumor Center, UCSF","institutionId":"ucsf","specialisms":["Neurosurgical oncology","Extent of resection","Awake brain mapping","Low-grade glioma"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Berger%20MS%5BAuthor%5D%20glioma%20resection"}],"papers":[{"title":"Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas","journal":"JCO","year":2008,"doi":"10.1200/JCO.2007.13.9337"},{"title":"An extent of resection threshold for newly diagnosed glioblastomas","journal":"Journal of Neurosurgery","year":2011,"doi":"10.3171/2011.2.JNS10998"}]},{"id":"mitchell-schnall","kind":"person","name":"Mitchell D. Schnall","aka":[],"tldr":"Mitchell Schnall is the radiologist who brought imaging research into the ECOG-ACRIN cooperative group.","summary":"Mitchell Schnall is Group Co-Chair of the ECOG-ACRIN Cancer Research Group and Chair of Radiology at the University of Pennsylvania, within the Abramson Cancer Center. A radiologist and former ACRIN network chair specialising in breast MRI and imaging trials, he brought imaging research into the cooperative group and led multicentre trials of breast MRI and imaging biomarkers, including the TMIST tomosynthesis screening trial. His papers include the New England Journal of Medicine study of MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer and a Radiology multicentre study of diagnostic architectural and dynamic features at breast MR imaging. His work spans MRI, mammography and tomosynthesis, and PET/CT.","asOf":"2026-09-08","links":[{"label":"ECOG-ACRIN","url":"https://ecog-acrin.org"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schnall%20MD%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Mitchell%20D.%20Schnall"}],"tags":[],"related":[],"cancers":["tnbc","breast-hr-positive"],"sections":[],"technologies":["mri","mammography","pet-ct"],"targets":[],"drugs":[],"companies":["ecog-acrin"],"institutions":["penn-abramson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["radiology"],"dependsOn":[],"notes":[],"role":"Group Co-Chair, ECOG-ACRIN Cancer Research Group; Chair of Radiology, University of Pennsylvania","institutionId":"ecog-acrin","specialisms":["Imaging","Breast MRI","Imaging trials"],"profiles":[{"label":"ECOG-ACRIN","url":"https://ecog-acrin.org"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schnall%20MD%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Mitchell%20D.%20Schnall"}],"papers":[{"title":"MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer","journal":"New England Journal of Medicine","year":2007,"url":"https://doi.org/10.1056/NEJMoa065447","doi":"10.1056/NEJMoa065447"},{"title":"Diagnostic architectural and dynamic features at breast MR imaging: multicenter study","journal":"Radiology","year":2006,"url":"https://doi.org/10.1148/radiol.2381042117","doi":"10.1148/radiol.2381042117"}]},{"id":"mitsuru-sasako","kind":"person","name":"Mitsuru Sasako","aka":[],"tldr":"Japanese surgeon whose JCOG trials defined D2 gastrectomy and adjuvant S-1 as standards for gastric cancer.","summary":"Mitsuru Sasako (Tokyo and Hyogo) led the JCOG 9501 trial showing that extended para-aortic nodal dissection adds nothing to D2 gastrectomy, and co-led the ACTS-GC trial that established adjuvant S-1 after D2 surgery in Japan. His surgical standards and training work underpin the D2 approach now recommended in Western guidelines. He remains an advisor to international gastric cancer surgical trials.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sasako%20M%5BAuthor%5D%20gastric%20D2"}],"tags":["gastric","surgery","japan"],"related":[],"cancers":["gastric"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["gastrectomy","lymphadenectomy"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor Emeritus, Hyogo College of Medicine; former Chief of Gastric Surgery, National Cancer Center Hospital Tokyo","specialisms":["Gastric cancer surgery","D2 lymphadenectomy","Adjuvant therapy","Surgical trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sasako%20M%5BAuthor%5D%20gastric%20D2"}],"papers":[{"title":"D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer (JCOG 9501)","journal":"NEJM","year":2008,"doi":"10.1056/NEJMoa0707035"},{"title":"Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer (ACTS-GC)","journal":"JCO","year":2011,"doi":"10.1200/JCO.2011.36.5908"}]},{"id":"mohamed-abdel-moaty-samra","kind":"person","name":"Mohamed Abdel Moaty Samra","aka":[],"tldr":"Professor who serves as Dean of the National Cancer Institute at Cairo University, Egypt's national cancer teaching hospital and research institute.","summary":"Professor Mohamed Abdel Moaty Samra is Dean of the National Cancer Institute, Cairo University, the Egyptian national cancer teaching hospital and research institute. He heads the institute's senior administration, which includes vice deans for postgraduate studies and research and for community service, and a hospital director. He presided over the institute's graduation ceremony in February 2025.","asOf":"2026-09-10","links":[{"label":"Source: NCI Cairo senior administration page","url":"https://nci.cu.edu.eg/%D8%A7%D9%84%D8%A5%D8%AF%D8%A7%D8%B1%D8%A9-%D8%A7%D9%84%D8%B9%D9%84%D9%8A%D8%A7/"}],"tags":["leadership","clinician-scientist","africa"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["nci-cairo"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["clinical-lymphoma-myeloma-and-leukemia","journal-of-the-egyptian-national-cancer-institute"],"dependsOn":[],"notes":[],"role":"Dean of the National Cancer Institute, Cairo University","institutionId":"nci-cairo","specialisms":["Oncology","Academic leadership","Cancer care in Egypt"],"profiles":[{"label":"NCI Cairo senior administration","url":"https://nci.cu.edu.eg/%D8%A7%D9%84%D8%A5%D8%AF%D8%A7%D8%B1%D8%A9-%D8%A7%D9%84%D8%B9%D9%84%D9%8A%D8%A7/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Samra+MA%5BAuthor%5D+Cairo"}],"papers":[{"title":"The prognostic significance of minimal residual disease in adult Egyptian patients with precursor acute lymphoblastic leukemia","journal":"Journal of the Egyptian National Cancer Institute","year":2013,"doi":"10.1016/j.jnci.2013.05.004"},{"title":"Prognostic and Therapeutic Value of Day 14 Bone Marrow Aspiration in Adult Acute Myeloid Leukemia Patients","journal":"Clinical Lymphoma Myeloma and Leukemia","year":2019,"doi":"10.1016/j.clml.2019.03.024"},{"title":"Outcome of Core Binding Factor Acute Myeloid Leukemia by Receptor Tyrosine Kinase Mutation","journal":"Clinical Lymphoma Myeloma and Leukemia","year":2020,"doi":"10.1016/j.clml.2020.02.002"}]},{"id":"mohammed-bin-khalifa-al-suwaidi","kind":"person","name":"Mohammed bin Khalifa Al Suwaidi","aka":[],"tldr":"Managing Director of Hamad Medical Corporation, Qatar's principal public healthcare provider and the parent of the National Center for Cancer Care and Research in Doha.","summary":"Mohammed bin Khalifa Al Suwaidi is Managing Director of Hamad Medical Corporation (HMC), the principal public healthcare provider in the State of Qatar and the parent organisation of the National Center for Cancer Care and Research (NCCCR) in Doha. HMC's January 2026 announcement of the Qatar Health Congress 2026 names him in that role and quotes him as saying that HMC's core focus remains delivering world-class specialist healthcare services and that improving access to care, through digital solutions and expanded community services, is a key priority. HMC's website did not name a separate director for the NCCCR.","asOf":"2026-09-10","links":[{"label":"Source: HMC press release, Qatar Health Congress 2026 (January 2026)","url":"https://www.hamad.qa/EN/news/2026/January/Pages/Qatar-Health-Congress-2026-inaugurated-to-Advance-Healthcare-Quality-and-Patient-Safety.aspx"}],"tags":["leadership","hospital-management","government"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["hamad-medical-corporation"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Managing Director, Hamad Medical Corporation","institutionId":"hamad-medical-corporation","specialisms":["Health system management","Public healthcare","Hospital governance"],"profiles":[{"label":"HMC press release naming the Managing Director (January 2026)","url":"https://www.hamad.qa/EN/news/2026/January/Pages/Qatar-Health-Congress-2026-inaugurated-to-Advance-Healthcare-Quality-and-Patient-Safety.aspx"}],"papers":[]},{"id":"mohd-zukiflee-abu-bakar","kind":"person","name":"Mohd Zukiflee Abu Bakar","aka":[],"tldr":"Director of the University of Malaya Medical Centre, the academic teaching hospital of Universiti Malaya in Kuala Lumpur.","summary":"Professor Dr Mohd Zukiflee bin Abu Bakar is Director of the University of Malaya Medical Centre (UMMC, also known as PPUM), the academic medical centre affiliated with Universiti Malaya in Kuala Lumpur. He leads a management team of deputy directors covering professional services, clinical services (medical and surgical) and management. The centre's governance is shared with the university's Faculty of Medicine.","asOf":"2026-09-10","links":[{"label":"Source: UMMC Principal Officers page","url":"https://www.ummc.edu.my/ummc/principal-officer.asp"}],"tags":["leadership","hospital-management","malaysia"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ummc-kuala-lumpur"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, University of Malaya Medical Centre","institutionId":"ummc-kuala-lumpur","specialisms":["Hospital leadership","Academic medicine","Clinical services management"],"profiles":[{"label":"UMMC Principal Officers","url":"https://www.ummc.edu.my/ummc/principal-officer.asp"}],"papers":[{"title":"A preliminary report on the role of endoscopic endonasal nasopharyngectomy in recurrent rT3 and rT4 nasopharyngeal carcinoma","journal":"Eur Arch Otorhinolaryngol","year":2017,"url":"https://doi.org/10.1007/s00405-016-4248-2","doi":"10.1007/s00405-016-4248-2","note":"Europe PMC author record matched by affiliation"},{"title":"Post-traumatic brain injury olfactory dysfunction: factors influencing quality of life","journal":"Eur Arch Otorhinolaryngol","year":2020,"url":"https://doi.org/10.1007/s00405-020-05823-0","doi":"10.1007/s00405-020-05823-0","note":"Europe PMC author record matched by affiliation"}]},{"id":"monica-calamai","kind":"person","name":"Monica Calamai","aka":[],"tldr":"Hospital executive who serves as Direttore Generale of IRCCS Ospedale Policlinico San Martino, the university research hospital in Genoa.","summary":"Monica Calamai is Direttore Generale of IRCCS Ospedale Policlinico San Martino in Genoa, a public research hospital (IRCCS) whose organisational chart places her at the head of the Direzione Strategica. The hospital's organigramma lists the strategic direction as four people: the Direttore Generale, Direttore Scientifico (acting) Angelo Schenone, Direttore Sanitario Marta Caltabellotta and Direttore Amministrativo Fabrizio Figallo. The hospital website did not give further biographical detail or an appointment date.","asOf":"2026-09-10","links":[{"label":"Source: IRCCS Ospedale Policlinico San Martino organigramma page","url":"https://www.ospedalesanmartino.it/it/chi-siamo/organigramma.html"}],"tags":["leadership","hospital-management","research-institute"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["san-martino-genoa"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Direttore Generale (General Director), IRCCS Ospedale Policlinico San Martino","institutionId":"san-martino-genoa","specialisms":["Hospital management","Public health administration"],"profiles":[{"label":"San Martino organisational chart (Direzione Strategica)","url":"https://www.ospedalesanmartino.it/it/chi-siamo/organigramma.html"}],"papers":[]},{"id":"monica-morrow","kind":"person","name":"Monica Morrow","aka":[],"tldr":"Breast surgeon whose margin and axillary guidelines cut unnecessary re-excisions and lymph node surgery worldwide.","summary":"Monica Morrow co-chaired the SSO-ASTRO consensus that defined 'no ink on tumour' as an adequate margin for breast conservation, sharply reducing re-excision rates, and has led the evidence for omitting axillary dissection after positive sentinel nodes. She chairs the breast service at MSKCC and has been president of the Society of Surgical Oncology. Her work continues on tailoring surgery to response after neoadjuvant therapy.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Morrow%20M%5BAuthor%5D%20breast%20margins"}],"tags":["breast","surgery","de-escalation"],"related":[],"cancers":["breast-hr-positive","tnbc","breast-her2-positive"],"sections":[],"technologies":["sentinel-node"],"targets":[],"drugs":[],"companies":[],"institutions":["mskcc","sso"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief, Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center","institutionId":"mskcc","specialisms":["Breast surgery","Surgical margins","Axillary management","Surgical de-escalation"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Morrow%20M%5BAuthor%5D%20breast%20margins"}],"papers":[{"title":"Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer","journal":"JCO","year":2014,"doi":"10.1200/JCO.2013.53.3935"},{"title":"Surgeon recommendations and receipt of mastectomy for treatment of breast cancer","journal":"JAMA","year":2009,"doi":"10.1001/jama.2009.1450"}]},{"id":"monika-hegi","kind":"person","name":"Monika E. Hegi","aka":[],"tldr":"Showed that MGMT promoter methylation predicts benefit from temozolomide, the biomarker every glioblastoma patient is now tested for.","summary":"Monika Hegi led the 2005 NEJM study, companion to the Stupp trial, showing that glioblastoma patients with a methylated MGMT promoter gain most from temozolomide chemoradiotherapy, establishing the first predictive biomarker in neuro-oncology and the basis for treatment selection in elderly patients. She leads translational research for EORTC brain tumour trials.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hegi%20ME%5BAuthor%5D%20MGMT"}],"tags":["glioma","biomarkers","mgmt"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":["methylation-profiling"],"targets":[],"drugs":[],"companies":[],"institutions":["chuv-lausanne"],"pathways":[],"terms":[],"trials":["eortc-26981"],"people":[],"bottlenecks":[],"keyPapers":["paper-stupp-temozolomide-nejm-2005"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor and Head of the Laboratory of Brain Tumor Biology and Genetics, Lausanne University Hospital (CHUV)","institutionId":"chuv-lausanne","specialisms":["Glioblastoma","MGMT methylation","Tumour biomarkers","Translational neuro-oncology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hegi%20ME%5BAuthor%5D%20MGMT"}],"papers":[{"title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","journal":"NEJM","year":2005,"doi":"10.1056/NEJMoa043331"},{"title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","journal":"Lancet Oncology","year":2009,"doi":"10.1016/S1470-2045(09)70025-7"},{"title":"Stupp 2005: temozolomide added to radiotherapy for newly diagnosed glioblastoma","journal":"New England Journal of Medicine","year":2005,"url":"https://doi.org/10.1056/NEJMoa043330","doi":"10.1056/NEJMoa043330"}],"orcid":"0000-0003-0855-6495"},{"id":"monika-janicke","kind":"person","name":"Monika Jänicke","aka":[],"tldr":"Chief Executive Officer of University Hospital Zurich, home of the Comprehensive Cancer Center Zurich.","summary":"Monika Jänicke is CEO and Chair of the Hospital Executive Board (Spitaldirektion) of University Hospital Zurich (USZ). She leads one of Switzerland's largest university hospitals, which hosts the Comprehensive Cancer Center Zurich and extensive oncology research programmes. Her responsibilities span the hospital's clinical, research and operational strategy.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.usz.ch/ueber-uns/spitaldirektion/"}],"tags":["leadership","hospital management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["usz-zurich"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"CEO, Chair of the Hospital Executive Board","institutionId":"usz-zurich","specialisms":["Hospital management","Healthcare leadership"],"profiles":[{"label":"Institution profile","url":"https://www.usz.ch/ueber-uns/spitaldirektion/"}],"papers":[]},{"id":"monika-krzyzanowska","kind":"person","name":"Monika Krzyzanowska","aka":[],"tldr":"Medical oncologist and health services researcher who leads the Odette Cancer Program at Sunnybrook in Toronto, one of Canada's largest cancer centres.","summary":"Dr Monika Krzyzanowska is Chief of the Odette Cancer Program at Sunnybrook Health Sciences Centre in Toronto, Regional Vice President of Cancer Services at Ontario Health (Cancer Care Ontario) for the Toronto Central North region, and Professor of Medicine at the University of Toronto. A medical oncologist and health services researcher trained at the University of Toronto with a fellowship at Dana-Farber Cancer Institute and Harvard, she founded the Cancer Quality Lab and focuses on optimising the quality of cancer care and new care delivery models such as remote monitoring. In October 2025 she launched the programme's Cancer Care at Home model.","asOf":"2026-09-10","links":[{"label":"Source: Sunnybrook Cancer Care at Home news release","url":"https://sunnybrook.ca/2025/10/sunnybrooks-odette-cancer-program-launches-cancer-care-at-home/"}],"tags":["leadership","clinician-scientist","medical-oncology","health-services"],"related":[],"cancers":["thyroid"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["sunnybrook-odette"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief, Odette Cancer Program, Sunnybrook Health Sciences Centre","institutionId":"sunnybrook-odette","specialisms":["Medical oncology","Health services research","Quality of cancer care","Digital health"],"profiles":[{"label":"Sunnybrook profile","url":"https://sunnybrook.ca/find-a-doctor/monika-krzyzanowska/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Krzyzanowska+MK%5BAuthor%5D"}],"papers":[{"title":"Setting Quality Improvement Priorities for Women Receiving Systemic Therapy for Early-Stage Breast Cancer by Using Population-Level Administrative Data","journal":"Journal of Clinical Oncology","year":2017,"doi":"10.1200/jco.2016.70.7950"},{"title":"Population-Based Assessment of Emergency Room Visits and Hospitalizations Among Women Receiving Adjuvant Chemotherapy for Early Breast Cancer","journal":"Journal of Oncology Practice","year":2015,"doi":"10.1200/jop.2014.001073"},{"title":"Remote, proactive, telephone based management of toxicity in outpatients during adjuvant or neoadjuvant chemotherapy for early stage breast cancer: pragmatic, cluster randomised trial","journal":"BMJ","year":2021,"doi":"10.1136/bmj-2021-066588"}]},{"id":"monroe-anderson","kind":"person","name":"Monroe Dunaway Anderson","aka":[],"tldr":"He never saw the hospital: his foundation, left $19 million on his death in 1939, matched the State of Texas's $500,000 in 1941 on condition the new cancer hospital be built in Houston and carry his name.","summary":"Monroe Dunaway Anderson (1873-1939), born in Jackson, Tennessee, made his fortune in the cotton firm Anderson, Clayton and Company in Houston. MD Anderson's own account records that in the mid-1930s he established a charitable foundation in his name with about $300,000, and that the foundation was destined to receive $19,000,000 more after his death in 1939. When the 1941 Texas Legislature authorised the University of Texas to establish a hospital for cancer research and treatment, the Anderson Foundation agreed to match the state's $500,000 appropriation if the hospital was built in Houston and named after Anderson; it was renamed M. D. Anderson Hospital for Cancer Research of the University of Texas in 1942. The foundation's land and money also seeded the Texas Medical Center around it. The hospital became the largest cancer centre in the United States.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Monroe_Dunaway_Anderson","links":[{"label":"MD Anderson: who was MD Anderson?","url":"https://www.mdanderson.org/about-md-anderson/facts-history/who-was-md-anderson.html"}],"tags":["hero","donor"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-funding-allocation"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Cotton merchant and banker whose foundation's bequest created MD Anderson Cancer Center","specialisms":["Cancer hospital founding","Estate philanthropy"],"profiles":[],"papers":[]},{"id":"mortimer-zuckerman","kind":"person","name":"Mortimer Zuckerman","aka":[],"tldr":"His 2006 pledge of $100 million, then the largest individual commitment in MSK's history, built a 23-storey laboratory tower that nearly doubled the centre's research space.","summary":"Mortimer Zuckerman, the real-estate developer and publisher of U.S. News & World Report and the New York Daily News, pledged $100 million to Memorial Sloan Kettering Cancer Center in May 2006. MSK's announcement called it the largest single commitment by an individual in its history. The gift funded the Mortimer B. Zuckerman Research Center, a 693,000 square foot complex whose 23-storey tower holds sixteen floors of laboratories, designed to nearly double MSK's research capacity and to house the Sloan Kettering Institute's programmes in cancer biology, immunology, structural biology and computational biology. It is the kind of gift that changes what an institution can attempt: space for hundreds of new scientists rather than a single programme.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Mortimer_Zuckerman","links":[{"label":"MSK press release: record $100 million gift (2006)","url":"https://www.mskcc.org/press-releases/mskcc-receives-record-gift-100-million-mortimer-b-zuckerman-research-facility"}],"tags":["hero","donor"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-funding-allocation"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Publisher and developer whose $100 million built Memorial Sloan Kettering's Zuckerman Research Center","specialisms":["Research buildings","Basic cancer science"],"profiles":[],"papers":[]},{"id":"moshe-oren","kind":"person","name":"Moshe Oren","aka":[],"tldr":"Cloned p53 and then spent a career on what it does. The field's first reading of his own 1984 result, that p53 was an oncogene, turned out to be wrong, and the correction is the better story.","summary":"Moshe Oren cloned the p53 gene at the start of the 1980s with David Givol and Arnold Levine, and his laboratory at the Weizmann Institute has worked on it ever since, with Varda Rotter's group alongside. The two groups published back to back in the same issue of Nature in 1984, on pages 646 and 649, showing that p53 cooperates with ras to transform cells, and both read it at the time as an oncogene. It took until the end of that decade for the field to re-read the result: the clones in hand were mutant, and wild-type p53 is a tumour suppressor. That reversal is worth stating plainly rather than tidying away, because what followed from it is the modern position that mutant p53 does not merely lose the old function but acquires new and harmful ones, which is why mutant-p53 reactivators and selective degraders are a drug class at all. Oren's recent work is on how p53 restrains stemness by controlling histone modifiers.","asOf":"2026-09-25","links":[{"label":"Oren laboratory, Weizmann Institute","url":"https://www.weizmann.ac.il/mcb/oren/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Oren%20M%5BAuthor%5D%20p53%20Weizmann"}],"tags":["scientist","cancer-biology"],"related":[],"cancers":[],"sections":["drug-discovery"],"technologies":["protac-degrader"],"targets":["tp53"],"drugs":[],"companies":[],"institutions":["weizmann"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor, Department of Molecular Cell Biology, Weizmann Institute of Science","institutionId":"weizmann","specialisms":["p53 biology","Mutant p53 gain of function","Tumour suppression","Cancer cell plasticity"],"profiles":[{"label":"Oren laboratory, Weizmann Institute","url":"https://www.weizmann.ac.il/mcb/oren/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Oren%20M%5BAuthor%5D%20p53%20Weizmann"}],"papers":[{"title":"Participation of p53 cellular tumour antigen in transformation of normal embryonic cells","journal":"Nature","year":1984,"doi":"10.1038/312646a0","note":"Eliyahu D, Raz A, Gruss P, Givol D, Oren M. Published back to back with Parada, Land, Weinberg, Wolf and Rotter on pages 646 and 649 of the same issue."},{"title":"Molecular cloning of a cDNA specific for the murine p53 cellular tumor antigen","journal":"Proceedings of the National Academy of Sciences","year":1983,"note":"Oren M, Levine AJ. PMID 6296874."},{"title":"p53 regulates the expression of histone modifiers to restrict stemness and maintain differentiation","year":2025,"note":"Department of Molecular Cell Biology, Weizmann Institute of Science; indexed on Europe PMC"}]},{"id":"mostafa-aziz-sumon","kind":"person","name":"Mostafa Aziz Sumon","aka":[],"tldr":"Radiation oncologist who directs the National Institute of Cancer Research and Hospital in Dhaka, Bangladesh's only tertiary government hospital dedicated to cancer.","summary":"Mostafa Aziz Sumon is Director (In-charge) of the National Institute of Cancer Research and Hospital (NICRH) at Mohakhali, Dhaka, and a Professor (CC) in its Department of Radiation Oncology. The institute describes itself as the country's only tertiary-level government hospital dedicated to cancer care. In his director's message he emphasises combining advanced technology with compassionate care, and points to the addition of a linear accelerator in the Radiation Oncology Department as a step toward making treatment more accessible to the general public.","asOf":"2026-09-10","links":[{"label":"Source: NICRH Director page","url":"https://nicrh.gov.bd/administrator/director"}],"tags":["leadership","clinician-scientist","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["nicrh-dhaka"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["lancet-oncology"],"dependsOn":[],"notes":[],"role":"Director (In-charge) and Professor, Radiation Oncology, National Institute of Cancer Research and Hospital, Dhaka","institutionId":"nicrh-dhaka","specialisms":["Radiation oncology","Hospital management","Cancer care access"],"profiles":[{"label":"NICRH Director page","url":"https://nicrh.gov.bd/administrator/director"},{"label":"Director's message","url":"https://nicrh.gov.bd/administrator/directors-message"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sumon+MA%5BAuthor%5D"}],"papers":[{"title":"Cervical Cancer in Bangladesh","journal":"South Asian Journal of Cancer","year":2023,"doi":"10.1055/s-0043-1764202"},{"title":"Cancer research in South Asian Association for Regional Cooperation (SAARC) countries","journal":"The Lancet Oncology","year":2024,"doi":"10.1016/s1470-2045(24)00518-7"},{"title":"Cancer education and training within the South Asian Association for Regional Cooperation (SAARC) countries","journal":"The Lancet Oncology","year":2024,"doi":"10.1016/s1470-2045(24)00517-5"}],"orcid":"0000-0001-6472-2713"},{"id":"zeng-mu-sheng","kind":"person","name":"Mu-Sheng Zeng","aka":[],"tldr":"Virologist who mapped how Epstein-Barr virus drives nasopharyngeal cancer and is developing vaccines against it.","summary":"Mu-Sheng Zeng is Professor and Director of the State Key Laboratory of Oncology in South China at Sun Yat-sen University Cancer Center in Guangzhou. A virologist, he mapped how Epstein-Barr virus drives nasopharyngeal carcinoma, and his group identified high-risk EBV subtypes linked to the disease and studies how the virus enters cells. His publications include a genome sequencing analysis identifying Epstein-Barr virus subtypes associated with a high risk of nasopharyngeal carcinoma. He is now developing prophylactic vaccine candidates against EBV, with interests in viral oncology and nasopharyngeal carcinoma biology.","asOf":"2026-09-08","links":[{"label":"Sun Yat-sen University Cancer Center","url":"https://www.sysucc.org.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Zeng%20MS%5BAuthor%5D%20Epstein-Barr%20virus%20nasopharyngeal"}],"tags":[],"related":[],"cancers":["head-and-neck"],"sections":[],"technologies":["hpv-vaccine"],"targets":[],"drugs":[],"companies":[],"institutions":["sysucc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nature-genetics"],"dependsOn":[],"notes":[],"role":"Professor; Director, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center","institutionId":"sysucc","specialisms":["Epstein-Barr virus","Nasopharyngeal carcinoma biology","Viral oncology","Prophylactic vaccines"],"profiles":[{"label":"Sun Yat-sen University Cancer Center","url":"https://www.sysucc.org.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Zeng%20MS%5BAuthor%5D%20Epstein-Barr%20virus%20nasopharyngeal"}],"papers":[{"title":"Genome sequencing analysis identifies Epstein-Barr virus subtypes associated with high risk of nasopharyngeal carcinoma","journal":"Nature Genetics","year":2019,"doi":"10.1038/s41588-019-0436-5"}]},{"id":"myriam-chalabi","kind":"person","name":"Myriam Chalabi","aka":[],"tldr":"Led NICHE-2, in which almost every mismatch-repair-deficient colon cancer responded to short pre-surgery immunotherapy.","summary":"Myriam Chalabi is a medical oncologist and group leader at the Netherlands Cancer Institute (NKI-AvL). Her specialisms are gastrointestinal oncology, neoadjuvant immunotherapy and mismatch-repair-deficient cancers. Her NICHE and NICHE-2 trials showed that a brief course of neoadjuvant nivolumab plus ipilimumab produces pathological responses in nearly all mismatch-repair-deficient colon cancers, reshaping the treatment paradigm. Her New England Journal of Medicine paper on NICHE-2 reported neoadjuvant immunotherapy in locally advanced mismatch repair-deficient colon cancer. Her publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chalabi%20M%5BAuthor%5D%20NICHE"}],"tags":[],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":["nivolumab","ipilimumab"],"companies":[],"institutions":["nki"],"pathways":[],"terms":["msi"],"trials":["niche-2"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Medical Oncologist and Group Leader, Netherlands Cancer Institute","institutionId":"nki","specialisms":["Gastrointestinal oncology","Neoadjuvant immunotherapy","Mismatch-repair-deficient cancers"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chalabi%20M%5BAuthor%5D%20NICHE"}],"papers":[{"title":"Neoadjuvant immunotherapy in locally advanced mismatch repair-deficient colon cancer (NICHE-2)","journal":"NEJM","year":2024,"doi":"10.1056/NEJMoa2400634"},{"title":"NICHE-2: a single dose of ipilimumab and two of nivolumab before surgery clears dMMR colon cancer in most patients","journal":"New England Journal of Medicine","year":2024,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NICHE-2%20neoadjuvant%20nivolumab%20ipilimumab%20dMMR%20colon%20cancer%20Chalabi%20NEJM%202024"}]},{"id":"ahn-myung-ju","kind":"person","name":"Myung-Ju Ahn","aka":[],"tldr":"Myung-Ju Ahn is one of Asia's most prolific lung cancer trialists, a steady presence on the steering committees of the EGFR, ALK, and immunotherapy trials that set today's standards.","summary":"Myung-Ju Ahn leads thoracic medical oncology at Samsung Medical Center and has been a principal or co-investigator on many of the pivotal NSCLC trials of the last decade, including osimertinib, lorlatinib, and checkpoint-inhibitor studies with large Korean enrolment. Her work spans EGFR resistance, ALK inhibitors, and head-and-neck immunotherapy.","asOf":"2026-09-08","links":[{"label":"Samsung Medical Center","url":"https://www.samsunghospital.com/gb/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ahn%20MJ%5BAuthor%5D%20Samsung%20Medical%20Center"}],"tags":["lung"],"related":[],"cancers":["nsclc","head-and-neck"],"sections":[],"technologies":[],"targets":["egfr","alk"],"drugs":["osimertinib","lorlatinib"],"companies":[],"institutions":["samsung-medical-center"],"pathways":[],"terms":[],"trials":["crown"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor, Division of Hematology-Oncology; thoracic and head-and-neck medical oncology","institutionId":"samsung-medical-center","specialisms":["Lung cancer","Head and neck cancer","Targeted therapy","Immunotherapy","Clinical trials"],"profiles":[{"label":"Samsung Medical Center","url":"https://www.samsunghospital.com/gb/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ahn%20MJ%5BAuthor%5D%20Samsung%20Medical%20Center"}],"papers":[{"title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer (FLAURA)","journal":"NEJM","year":2018,"doi":"10.1056/NEJMoa1713137"},{"title":"Lorlatinib versus crizotinib in advanced ALK-positive NSCLC (CROWN)","journal":"NEJM","year":2020,"doi":"10.1056/NEJMoa2027187"},{"title":"DeLLphi-301: tarlatamab, a DLL3-targeting T-cell engager, in previously treated small-cell lung cancer","journal":"New England Journal of Medicine","year":2023,"url":"https://doi.org/10.1056/NEJMoa2307980","doi":"10.1056/NEJMoa2307980"}]},{"id":"nadia-harbeck","kind":"person","name":"Nadia Harbeck","aka":[],"tldr":"German breast oncologist whose ADAPT trials use biology to decide who can have less chemotherapy.","summary":"Nadia Harbeck leads the West German Study Group ADAPT programme, which uses genomic assays and early response to tailor neoadjuvant and adjuvant therapy, and chaired the 2019 Nature Reviews Disease Primer on breast cancer. She is a co-author of the St Gallen consensus and of monarchE, and directs one of Europe's largest breast centres. Her focus is biology-driven de-escalation of chemotherapy.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Harbeck%20N%5BAuthor%5D%20breast%20ADAPT"}],"tags":["breast","de-escalation","guidelines"],"related":[],"cancers":["breast-hr-positive","breast-her2-positive"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["lmu-munich"],"pathways":[],"terms":[],"trials":["monarche"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Head of the Breast Center, LMU University Hospital Munich; Chair, West German Study Group","institutionId":"lmu-munich","specialisms":["Early breast cancer","Biomarker-driven de-escalation","HER2-positive disease","Guidelines"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Harbeck%20N%5BAuthor%5D%20breast%20ADAPT"}],"papers":[{"title":"Breast cancer","journal":"Nature Reviews Disease Primers","year":2019,"doi":"10.1038/s41572-019-0111-2"},{"title":"De-escalation strategies in HER2-positive early breast cancer (WSG-ADAPT HER2+/HR-)","journal":"Annals of Oncology","year":2017}]},{"id":"nadine-karema","kind":"person","name":"Nadine Karema","aka":[],"tldr":"Executive Director of Partners In Health Rwanda, the organisation whose programme in northern Rwanda includes the Butaro Cancer Center of Excellence.","summary":"Nadine Karema is Executive Director of Partners In Health Rwanda, known locally as Inshuti Mu Buzima, the Rwandan arm of Partners In Health. The organisation supports district health programmes in Burera, Kirehe and Kayonza and the Butaro Cancer Center of Excellence, which Partners In Health describes as a centre for cancer care and medical education in East Africa. She leads an executive team that includes chief officers for policy and partnerships, finance, operations and human resources.","asOf":"2026-09-10","links":[{"label":"Source: PIH Rwanda team page","url":"https://pihrwanda.org/about-us/our-team"}],"tags":["leadership","global-oncology","non-profit"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["butaro-cancer-center"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["jco"],"dependsOn":[],"notes":[],"role":"Executive Director, Partners In Health Rwanda (Inshuti Mu Buzima)","institutionId":"butaro-cancer-center","specialisms":["Global health delivery","Health systems strengthening","Non-profit leadership"],"profiles":[{"label":"Institution profile","url":"https://pihrwanda.org/about-us/our-team"}],"papers":[{"title":"Implementation Science for Global Oncology: The Imperative to Evaluate the Safety and Efficacy of Cancer Care Delivery","journal":"Journal of Clinical Oncology","year":2016,"doi":"10.1200/jco.2015.61.7738"},{"title":"Impact of COVID-19 on access to cancer care in Rwanda: a retrospective time-series study using electronic medical records data","journal":"BMJ Open","year":2022,"doi":"10.1136/bmjopen-2022-065398"}]},{"id":"nai-kong-cheung","kind":"person","name":"Nai-Kong V. Cheung","aka":[],"tldr":"Developed the anti-GD2 antibodies 3F8 and naxitamab that treat relapsed neuroblastoma.","summary":"Nai-Kong Cheung developed the murine anti-GD2 antibody 3F8 in the 1980s and its humanised successor naxitamab, which won FDA approval in 2020 for relapsed or refractory high-risk neuroblastoma in bone or bone marrow, and has led decades of MSKCC trials of antibody-based immunotherapy in children. His laboratory engineers bispecific antibodies and CAR T cells against GD2 and other paediatric targets.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cheung%20NK%5BAuthor%5D%20neuroblastoma%20GD2"}],"tags":["paediatric","neuroblastoma","immunotherapy"],"related":[],"cancers":["neuroblastoma"],"sections":[],"technologies":["monoclonal-antibody","bispecific-antibody"],"targets":[],"drugs":[],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":["naxitamab-201"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Enid A. Haupt Chair in Pediatric Oncology, Memorial Sloan Kettering Cancer Center","institutionId":"mskcc","specialisms":["Neuroblastoma","Anti-GD2 antibodies","Paediatric immunotherapy","Antibody engineering"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cheung%20NK%5BAuthor%5D%20neuroblastoma%20GD2"}],"papers":[{"title":"Naxitamab for high-risk neuroblastoma: a phase II trial","journal":"JCO","year":2020},{"title":"Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission","journal":"JCO","year":2012,"doi":"10.1200/JCO.2011.41.3807"}]},{"id":"nancy-brinker","kind":"person","name":"Nancy Brinker","aka":[],"tldr":"She promised her dying sister, Susan Komen, that she would end breast cancer, and in 1982 founded the organisation that created the Race for the Cure and made breast cancer a mainstream cause.","summary":"Nancy Brinker's sister Susan Goodman Komen died of breast cancer in 1980 at 36. Brinker founded the Susan G. Komen Breast Cancer Foundation in Dallas in 1982 with $200 and a shoebox of names, held the first Race for the Cure in 1983, and built it into the world's largest breast cancer organisation, funding research, screening and patient support and making the pink ribbon a global symbol from 1991. She was later diagnosed with breast cancer herself. She served as US Ambassador to Hungary, as Chief of Protocol, and as a World Health Organization Goodwill Ambassador for Cancer Control, and received the Presidential Medal of Freedom in 2009. Komen's model of survivor-led fundraising and mass participation events has been copied across cancer types and countries.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Nancy_Brinker","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Nancy_Brinker"},{"label":"Susan G. Komen","url":"https://www.komen.org/"}],"tags":["hero","advocate","carer"],"related":["susan-g-komen"],"cancers":[],"sections":[],"technologies":["mammography"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-funding-allocation","b-early-detection"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Founder of Susan G. Komen","specialisms":["Breast cancer advocacy","Cancer fundraising","Global cancer policy"],"profiles":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Nancy_Brinker"},{"label":"Susan G. Komen","url":"https://www.komen.org/"}],"papers":[]},{"id":"nancy-lin","kind":"person","name":"Nancy U. Lin","aka":[],"tldr":"Nancy Lin is the leading authority on brain metastases from breast cancer, including the HER2CLIMB tucatinib data in patients with active brain disease.","summary":"Nancy U. Lin is Director of the Metastatic Breast Cancer Program and Associate Chief of the Division of Breast Oncology at Dana-Farber Brigham Cancer Center. She is the leading authority on brain metastases from breast cancer, known for the HER2CLIMB analyses of tucatinib in patients with active brain disease and for defining the RANO-BM central nervous system response criteria used across trials. Her selected paper reports intracranial efficacy of tucatinib plus trastuzumab and capecitabine in previously treated HER2-positive breast cancer with brain metastases. She directs the metastatic breast cancer programme and continues work on CNS pharmacology in HER2-positive disease.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Nancy_Lin","links":[{"label":"Dana-Farber profile","url":"https://www.dana-farber.org/find-a-doctor/nancy-u-lin"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lin%20NU%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["breast-her2-positive"],"sections":[],"technologies":[],"targets":["her2"],"drugs":["tucatinib"],"companies":[],"institutions":["dana-farber"],"pathways":[],"terms":[],"trials":["her2climb"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Metastatic Breast Cancer Program; Associate Chief, Division of Breast Oncology","institutionId":"dana-farber","specialisms":["Breast cancer brain metastases","HER2-positive breast cancer","CNS pharmacology"],"profiles":[{"label":"Dana-Farber profile","url":"https://www.dana-farber.org/find-a-doctor/nancy-u-lin"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lin%20NU%5BAuthor%5D"}],"papers":[{"title":"Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial","journal":"Journal of Clinical Oncology","year":2020,"url":"https://doi.org/10.1200/JCO.20.00775","doi":"10.1200/JCO.20.00775"}],"orcid":"0000-0003-2263-5413"},{"id":"naoto-ueno","kind":"person","name":"Naoto T. Ueno","aka":[],"tldr":"Breast cancer physician-scientist who directs the University of Hawai'i Cancer Center, the NCI-designated cancer centre in Honolulu.","summary":"Naoto T. Ueno, MD, PhD, FACP, is Director of the University of Hawai'i Cancer Center and a full member of its Cancer Biology Program, where his focus is translational and clinical research. He is Professor at the cancer centre and in the Department of Medicine of the John A. Burns School of Medicine, University of Hawai'i at Manoa. He trained in medicine at Wakayama Medical College in Japan, completed a PhD in cancer biology at the University of Texas Graduate School of Biomedical Sciences, an internal medicine residency at the University of Pittsburgh Medical Center and fellowships in medical oncology and blood and marrow transplantation at MD Anderson Cancer Center. His research centres on triple-negative and inflammatory breast cancer and the tumour microenvironment, and he has led more than 50 clinical trials.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Naoto_Ueno","links":[{"label":"Source: University of Hawai'i Cancer Center leadership page","url":"https://www.uhcancercenter.org/about-us/leadership"}],"tags":["leadership","clinician-scientist","comprehensive-cancer-centre"],"related":[],"cancers":["breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, University of Hawai'i Cancer Center","institutionId":"hawaii-cancer-center","specialisms":["Breast medical oncology","Inflammatory breast cancer","Early-phase clinical trials"],"profiles":[{"label":"UH Cancer Center leadership page","url":"https://www.uhcancercenter.org/about-us/leadership"},{"label":"UH Cancer Center profile","url":"https://www.uhcancercenter.org/ueno-naoto"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ueno+NT%5BAuthor%5D"}],"papers":[{"title":"EGFR is a master switch between immunosuppressive and immunoactive tumor microenvironment in inflammatory breast cancer","journal":"Science Advances","year":2022,"doi":"10.1126/sciadv.abn7983"},{"title":"Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study","journal":"Cancer Research Communications","year":2024,"doi":"10.1158/2767-9764.crc-24-0255"},{"title":"Genomic and transcriptomic analyses identify distinctive features of triple-negative inflammatory breast cancer","journal":"npj Precision Oncology","year":2024,"doi":"10.1038/s41698-024-00729-0"}],"orcid":"0000-0002-0166-7275"},{"id":"nariaki-matsuura","kind":"person","name":"Nariaki Matsuura","aka":[],"tldr":"President of the Osaka International Cancer Institute, the Osaka prefectural cancer centre that relocated to a new hospital in central Osaka in 2017.","summary":"Nariaki Matsuura (Matsuura Nariaki) is President (Socho) of the Osaka International Cancer Institute, the Osaka Prefectural Hospital Organization's cancer centre, which was founded in 1959 as the Osaka Prefectural Adult Disease Centre and took its current name on moving to Otemae, Osaka, in 2017. In his greeting he describes the institute's aims of delivering the best available treatment, developing new therapies and supporting patients' quality of life under the philosophy of advanced cancer care based on the patient's perspective. The institute is a designated prefectural cancer care hub and a cancer genomic medicine hub hospital.","asOf":"2026-09-10","links":[{"label":"Source: Osaka International Cancer Institute centre overview page","url":"https://oici.jp/center/outline/overview/"}],"tags":["leadership","clinician-scientist","japan"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["osaka-international-cancer-institute"],"pathways":[],"terms":["quality-of-life"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President (Socho), Osaka International Cancer Institute","institutionId":"osaka-international-cancer-institute","specialisms":["Cancer centre management","Pathology","Cancer medicine"],"profiles":[{"label":"Institute overview and president's greeting (Japanese)","url":"https://oici.jp/center/outline/overview/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Matsuura+Nariaki%5BAuthor%5D"}],"papers":[{"title":"Features of electrocoagulation syndrome after endoscopic submucosal dissection for colorectal neoplasm","journal":"Journal of Gastroenterology and Hepatology","year":2016,"doi":"10.1111/jgh.13052"},{"title":"Inhibitory Effects of Dopamine Receptor D1 Agonist on Mammary Tumor and Bone Metastasis","journal":"Scientific Reports","year":2017,"doi":"10.1038/srep45686"},{"title":"Real-time assessment of video images for esophageal squamous cell carcinoma invasion depth using artificial intelligence","journal":"Journal of Gastroenterology","year":2020,"doi":"10.1007/s00535-020-01716-5"}]},{"id":"natasha-leighl","kind":"person","name":"Natasha B. Leighl","aka":[],"tldr":"Lung cancer oncologist who showed plasma genotyping matches tissue and leads Canadian lung trials.","summary":"Natasha B. Leighl is Lung Site Lead in Medical Oncology and holds the OSI Pharmaceuticals Foundation Chair in Cancer New Drug Development at the Princess Margaret Cancer Centre. She is a lung cancer oncologist known for leading the NILE study, which showed that plasma cell-free DNA genotyping matches tissue testing in non-small-cell lung cancer, and for leading numerous Canadian Cancer Trials Group lung studies. Her selected paper reports the clinical utility of comprehensive cell-free DNA analysis in newly diagnosed metastatic lung cancer. A past president of the IASLC, she continues to work on liquid biopsy and health economics.","asOf":"2026-09-08","links":[{"label":"UHN profile","url":"https://www.uhnresearch.ca/researcher/natasha-b-leighl"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Leighl%20NB%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["liquid-biopsy"],"targets":[],"drugs":[],"companies":[],"institutions":["princess-margaret"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Lung Site Lead, Medical Oncology; OSI Pharmaceuticals Foundation Chair in Cancer New Drug Development","institutionId":"princess-margaret","specialisms":["Lung cancer","Liquid biopsy","Health economics"],"profiles":[{"label":"UHN profile","url":"https://www.uhnresearch.ca/researcher/natasha-b-leighl"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Leighl%20NB%5BAuthor%5D"}],"papers":[{"title":"Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer","journal":"Clinical Cancer Research","year":2019,"url":"https://doi.org/10.1158/1078-0432.CCR-19-0624","doi":"10.1158/1078-0432.CCR-19-0624"}]},{"id":"nathan-pennell","kind":"person","name":"Nathan A. Pennell","aka":[],"tldr":"Lung cancer oncologist who has pushed for universal biomarker testing and better trial design.","summary":"Nathan A. Pennell is Vice Chair of Clinical Research at the Taussig Cancer Institute and a member of the Lung Cancer Medical Oncology Program at Cleveland Clinic. He is a lung cancer oncologist known for pushing for universal biomarker testing in non-small-cell lung cancer and for better trial design, and he is an ASCO educational leader on molecular testing. His selected paper addresses the real-world issues and tough choices in biomarker testing for advanced non-small-cell lung cancer. He now leads lung cancer clinical research and research operations at Cleveland Clinic.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Pennell%20NA%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["cgp"],"targets":[],"drugs":[],"companies":[],"institutions":["cleveland-clinic"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["asco-educational-book"],"dependsOn":[],"notes":[],"role":"Vice Chair of Clinical Research, Taussig Cancer Institute; Lung Cancer Medical Oncology Program","institutionId":"cleveland-clinic","specialisms":["Lung cancer","Biomarker testing","Clinical research operations"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Pennell%20NA%5BAuthor%5D"}],"papers":[{"title":"Biomarker testing for patients with advanced non-small cell lung cancer: real-world issues and tough choices","journal":"ASCO Educational Book","year":2019}],"orcid":"0000-0002-1458-0064"},{"id":"nathan-cherny","kind":"person","name":"Nathan Cherny","aka":[],"tldr":"Created the ESMO Magnitude of Clinical Benefit Scale, the standard tool for grading how much a cancer drug really helps.","summary":"Nathan Cherny is Director of Cancer Pain and Palliative Medicine at Shaare Zedek Medical Center in Jerusalem and Chair of the ESMO-MCBS Working Group of the European Society for Medical Oncology (ESMO). His specialisms are palliative medicine, value assessment of cancer drugs and ethics. He created the ESMO Magnitude of Clinical Benefit Scale, which grades trial results by the size of the benefit they show and is used by health systems worldwide as the standard tool for judging how much a cancer drug really helps. His Annals of Oncology paper described this standardised, validated approach to stratifying clinical benefit. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cherny%20NI%5BAuthor%5D%20ESMO-MCBS"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["esmo"],"pathways":[],"terms":["standard-of-care"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Cancer Pain and Palliative Medicine, Shaare Zedek Medical Center; Chair, ESMO-MCBS Working Group","institutionId":"esmo","specialisms":["Palliative medicine","Value assessment of cancer drugs","Ethics"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cherny%20NI%5BAuthor%5D%20ESMO-MCBS"}],"papers":[{"title":"A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS)","journal":"Annals of Oncology","year":2015,"doi":"10.1093/annonc/mdv249"}]},{"id":"naureen-starling","kind":"person","name":"Naureen Starling","aka":[],"tldr":"The Royal Marsden oncologist who runs the UK trial testing whether a blood test for leftover tumour DNA can decide who needs chemotherapy after bowel cancer surgery.","summary":"Naureen Starling is a consultant medical oncologist at The Royal Marsden specialising in gastrointestinal cancers, director of the Royal Marsden Clinical Trials Unit and a reader in the Division of Clinical Studies at the Institute of Cancer Research; she is training programme director for medical oncology and chairs the pan-London specialist training committee. She is a senior author on the TRACC Part B analysis, which showed that a tissue-free assay combining genomic and methylation signals can detect minimal residual disease after surgery for early colorectal cancer across a UK multicentre cohort.","asOf":"2026-09-24","links":[{"label":"The Royal Marsden consultant directory","url":"https://www.royalmarsden.nhs.uk/our-consultants-units-and-wards/consultant-directory/naureen-starling"}],"tags":["colorectal","trialist","uk"],"related":["ian-chau"],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["royal-marsden","icr-london"],"pathways":[],"terms":[],"trials":["tracc"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Consultant Medical Oncologist and Director of the Clinical Trials Unit, The Royal Marsden; Reader, The Institute of Cancer Research","institutionId":"royal-marsden","specialisms":["Gastrointestinal cancer","Circulating tumour DNA","Early-phase and translational trials"],"profiles":[{"label":"The Royal Marsden consultant directory","url":"https://www.royalmarsden.nhs.uk/our-consultants-units-and-wards/consultant-directory/naureen-starling"}],"papers":[{"title":"Tissue-free liquid biopsies combining genomic and methylation signals for minimal residual disease detection in patients with early colorectal cancer from the UK TRACC Part B study","journal":"Clinical Cancer Research","year":2024,"doi":"10.1158/1078-0432.CCR-24-0226"}]},{"id":"neeraj-agarwal","kind":"person","name":"Neeraj Agarwal","aka":[],"tldr":"GU oncologist who led TALAPRO-2 and other trials combining PARP inhibitors with hormone therapy.","summary":"Neeraj Agarwal is SWOG Executive Officer for Genitourinary and Early Therapeutics and Professor of Medicine at the Huntsman Cancer Institute, University of Utah. A medical oncologist specialising in prostate and kidney cancer and targeted therapy, he was principal investigator of TALAPRO-2, the trial of talazoparib plus enzalutamide, and of CONTACT-03. His papers report the TALAPRO-2 randomised, placebo-controlled phase 3 trial in first-line metastatic castration-resistant prostate cancer in the Lancet and the design of CONTACT-02, a phase III study of cabozantinib plus atezolizumab versus a second novel hormone therapy in the same disease. He directs genitourinary oncology at Huntsman and works on PARP and the androgen receptor in prostate and renal cell carcinoma.","asOf":"2026-09-08","links":[{"label":"SWOG leadership","url":"https://www.swog.org/about/leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Agarwal%20N%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Neeraj%20Agarwal"}],"tags":[],"related":[],"cancers":["prostate","rcc"],"sections":[],"technologies":[],"targets":["parp","androgen-receptor"],"drugs":["talazoparib"],"companies":["swog"],"institutions":[],"pathways":[],"terms":[],"trials":["talapro-2","contact-03"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["future-oncology"],"dependsOn":[],"notes":[],"role":"SWOG Executive Officer, Genitourinary and Early Therapeutics; Professor of Medicine, Huntsman Cancer Institute, University of Utah","institutionId":"swog","specialisms":["Prostate cancer","Kidney cancer","Targeted therapy"],"profiles":[{"label":"SWOG leadership","url":"https://www.swog.org/about/leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Agarwal%20N%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Neeraj%20Agarwal"}],"papers":[{"title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","journal":"Lancet","year":2023,"url":"https://doi.org/10.1016/S0140-6736(23)01055-3","doi":"10.1016/S0140-6736(23)01055-3"},{"title":"A Phase III, Randomized, Open-Label Study (CONTACT-02) of Cabozantinib Plus Atezolizumab Versus Second Novel Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer","journal":"Future Oncology","year":2022,"url":"https://doi.org/10.2217/fon-2021-1096","doi":"10.2217/fon-2021-1096"}]},{"id":"nei-min-chu","kind":"person","name":"Nei-Min Chu","aka":[],"tldr":"Medical oncologist who became President of Taipei's Koo Foundation Sun Yat-Sen Cancer Center in late 2024 after nearly three decades on its staff.","summary":"Nei-Min Chu (褚乃銘) is President of the Koo Foundation Sun Yat-Sen Cancer Center, the specialised private cancer hospital in Taipei founded in 1990 and known for its multidisciplinary team model. A medical oncology specialist whose clinical work has focused on lung and breast cancer, he trained in internal medicine in the United States and completed a haematology-oncology fellowship at the University of Florida before joining the centre in 1996. He was previously Vice President and took office as President in November 2024, succeeding founder Andrew T. Huang, who now serves as Chairman.","asOf":"2026-09-10","links":[{"label":"Source: KFSYSCC medical oncology team page listing the President","url":"https://www.kfsyscc.org/department_team/medicaloncology"}],"tags":["leadership","clinician-scientist","medical-oncology"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["koo-foundation-sun-yat-sen-cancer-center"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["lung-cancer-journal"],"dependsOn":[],"notes":[],"role":"President (院長) of Koo Foundation Sun Yat-Sen Cancer Center","institutionId":"koo-foundation-sun-yat-sen-cancer-center","specialisms":["Medical oncology","Haematology-oncology","Lung cancer","Breast cancer"],"profiles":[{"label":"Institution medical oncology team page","url":"https://www.kfsyscc.org/department_team/medicaloncology"},{"label":"President's message","url":"https://www.kfsyscc.org/deans_words/3"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chu+NM%5BAuthor%5D+AND+Taiwan"}],"papers":[{"title":"Sex-associated differences in non-small cell lung cancer in the new era: Is gender an independent prognostic factor?","journal":"Lung Cancer","year":2009,"doi":"10.1016/j.lungcan.2009.01.020"},{"title":"Impact of Early versus Delayed G-CSF Administration on Clinical Outcomes in Chemotherapy-induced Neutropenia: A Propensity Score-matching Cohort Study","journal":"Journal of Cancer Research and Practice","year":2026,"doi":"10.4103/ejcrp.ejcrp-d-25-00039"}]},{"id":"neil-gross","kind":"person","name":"Neil D. Gross","aka":[],"tldr":"Houston surgeon who led the trial showing that giving cemiplimab before surgery can eliminate cutaneous squamous-cell carcinoma in about half of patients, sparing many from extensive operations.","summary":"Neil Gross is a head and neck surgical oncologist at MD Anderson Cancer Center. He was first author of the 2022 New England Journal of Medicine report of a phase 2 trial of neoadjuvant cemiplimab in resectable stage II to IV cutaneous squamous-cell carcinoma, in which about half of patients had a pathological complete response at surgery, and leads studies of neoadjuvant immunotherapy in head and neck cancers.","asOf":"2026-09-18","links":[],"tags":["skin","surgery","immunotherapy","trialist"],"related":[],"cancers":["advanced-cutaneous-scc","head-and-neck","skin-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-gross-neoadjuvant-cemiplimab-cscc-nejm-2022"],"journals":[],"dependsOn":[],"notes":[],"role":"Head and neck surgeon, MD Anderson Cancer Center","institutionId":"md-anderson","specialisms":["Cutaneous squamous-cell carcinoma","Neoadjuvant immunotherapy","Head and neck surgery"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gross%5BAuthor%5D"}],"papers":[{"title":"Neoadjuvant cemiplimab for stage II to IV cutaneous squamous cell carcinoma","journal":"New England Journal of Medicine","year":2022,"url":"https://doi.org/10.1056/NEJMoa2209813","doi":"10.1056/NEJMoa2209813"}],"orcid":"0000-0002-9427-0743"},{"id":"nicholas-james","kind":"person","name":"Nicholas James","aka":[],"tldr":"Nicholas James is chief investigator of STAMPEDE, the platform trial that reshaped treatment of advanced prostate cancer.","summary":"Nicholas James is Professor of Prostate and Bladder Cancer Research at The Institute of Cancer Research and a consultant clinical oncologist at The Royal Marsden. His specialisms are prostate cancer, bladder cancer, multi-arm platform trials and radiotherapy. He is chief investigator of STAMPEDE, the multi-arm multi-stage platform trial that established docetaxel and abiraterone in hormone-sensitive metastatic prostate cancer, with the New England Journal of Medicine paper reporting abiraterone for prostate cancer not previously treated with hormone therapy. He has also led trials of chemoradiotherapy in bladder and urothelial cancer. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=James%20ND%5BAuthor%5D%20STAMPEDE"}],"tags":[],"related":[],"cancers":["prostate","urothelial"],"sections":[],"technologies":[],"targets":[],"drugs":["abiraterone","docetaxel"],"companies":[],"institutions":["royal-marsden","icr-london"],"pathways":[],"terms":["basket-umbrella-platform"],"trials":["stampede"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Prostate and Bladder Cancer Research, ICR; Consultant Clinical Oncologist, Royal Marsden","institutionId":"royal-marsden","specialisms":["Prostate cancer","Bladder cancer","Multi-arm platform trials","Radiotherapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=James%20ND%5BAuthor%5D%20STAMPEDE"}],"papers":[{"title":"Abiraterone for prostate cancer not previously treated with hormone therapy (STAMPEDE)","journal":"NEJM","year":2017,"doi":"10.1056/NEJMoa1702900"}],"orcid":"0000-0002-7314-8204"},{"id":"nicholas-turner","kind":"person","name":"Nicholas Turner","aka":[],"tldr":"Breast cancer researcher who turned ctDNA into a tool for choosing treatment, leading SERENA-6 and CAPItello-291.","summary":"Nicholas Turner is Professor of Molecular Oncology at The Institute of Cancer Research and a consultant medical oncologist at The Royal Marsden, where he leads the Ralph Lauren Centre for Breast Cancer Research. His specialisms are breast cancer, circulating tumour DNA, endocrine resistance and the CDK4/6 and PI3K pathway. He turned circulating tumour DNA into a tool for choosing treatment through plasmaMATCH, the Lancet Oncology trial of ctDNA analysis to direct therapy in advanced breast cancer, and SERENA-6, which tests camizestrant. He also led the capivasertib programme, with CAPItello-291 reported in the New England Journal of Medicine in hormone receptor-positive advanced breast cancer. His ICR profile and PubMed listing are linked.","asOf":"2026-09-08","links":[{"label":"ICR profile","url":"https://www.icr.ac.uk/research-and-discoveries/our-research/researchers/professor-nicholas-turner"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Turner%20NC%5BAuthor%5D%20breast%20ctDNA"}],"tags":[],"related":[],"cancers":["breast-hr-positive"],"sections":[],"technologies":["liquid-biopsy"],"targets":["estrogen-receptor","akt"],"drugs":["capivasertib","camizestrant"],"companies":[],"institutions":["royal-marsden","icr-london"],"pathways":[],"terms":[],"trials":["capitello-291","serena-6"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Molecular Oncology, ICR; Consultant Medical Oncologist, Royal Marsden","institutionId":"royal-marsden","specialisms":["Breast cancer","Circulating tumour DNA","Endocrine resistance","CDK4/6 and PI3K pathway"],"profiles":[{"label":"ICR profile","url":"https://www.icr.ac.uk/research-and-discoveries/our-research/researchers/professor-nicholas-turner"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Turner%20NC%5BAuthor%5D%20breast%20ctDNA"}],"papers":[{"title":"Capivasertib in hormone receptor-positive advanced breast cancer (CAPItello-291)","journal":"NEJM","year":2023,"doi":"10.1056/NEJMoa2214131"},{"title":"Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH)","journal":"Lancet Oncology","year":2020,"doi":"10.1016/S1470-2045(20)30444-7"}],"orcid":"0000-0001-8937-0873"},{"id":"nicholas-van-as","kind":"person","name":"Nicholas van As","aka":[],"tldr":"The Royal Marsden oncologist who ran the trial that cut a four-week course of prostate radiotherapy to five treatments, and published the higher urinary side-effect rate alongside the good news.","summary":"Nicholas van As is Medical Director of The Royal Marsden and Professor in Precision Prostate Radiotherapy at the Institute of Cancer Research. He was chief investigator of PACE-B, which randomised 874 men with low or intermediate risk localised prostate cancer, none of them on androgen deprivation therapy, between 36.25 Gy in five fractions of stereotactic body radiotherapy and conventionally fractionated or moderately hypofractionated radiotherapy.\n\nAt a median 74 months, freedom from biochemical or clinical failure was 95.8 percent with the five-fraction schedule against 94.6 percent with the longer course, meeting the non-inferiority margin. The trial also reported what it cost: late genitourinary toxicity of grade 2 or worse at five years was 26.9 percent with stereotactic radiotherapy against 18.3 percent with the comparator, though the five-year patient-reported outcomes found no difference in pad use, leakage, sexual problems or bowel problems. NHS England's June 2026 commissioning policy for prostate stereotactic ablative radiotherapy is written on PACE-B's eligibility criteria and cites the trial by name.","asOf":"2026-09-25","links":[{"label":"The Royal Marsden consultant directory","url":"https://www.royalmarsden.nhs.uk/our-consultants-units-and-wards/consultant-directory/prof-nicholas-van-as"}],"tags":["prostate","radiotherapy","uk"],"related":["nicholas-james","johann-de-bono"],"cancers":["prostate","prostate-low-risk","prostate-intermediate-risk"],"sections":["radiation"],"technologies":["sbrt"],"targets":[],"drugs":[],"companies":[],"institutions":["royal-marsden","icr-london"],"pathways":[],"terms":[],"trials":["pace-b"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Medical Director and Consultant Clinical Oncologist, The Royal Marsden NHS Foundation Trust; Professor in Precision Prostate Radiotherapy, The Institute of Cancer Research","institutionId":"royal-marsden","specialisms":["Stereotactic body radiotherapy for prostate cancer","Image-guided radiotherapy","Radiotherapy trial design"],"profiles":[{"label":"The Royal Marsden consultant directory","url":"https://www.royalmarsden.nhs.uk/our-consultants-units-and-wards/consultant-directory/prof-nicholas-van-as"}],"papers":[{"title":"Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer","journal":"New England Journal of Medicine","year":2024,"doi":"10.1056/NEJMoa2403365"}]},{"id":"nick-levell","kind":"person","name":"Nick Levell","aka":[],"tldr":"The Norwich dermatologist who wrote the national audit of British dermatology, and whose report is the reason anyone can say how many Mohs surgeons England has.","summary":"Nick Levell has been a consultant dermatologist at the Norfolk and Norwich University Hospital for thirty years and is its senior dermatologist. He is the Getting It Right First Time national clinical lead for dermatology, national specialty lead for dermatology for the National Institute for Health and Care Research, a past president of the British Association of Dermatologists and of the British Society for Medical Dermatology, and chairs the national dermatology therapy and guidelines committee. He was awarded an MBE for services to the care of people with skin diseases in the King's Birthday Honours in 2024.\n\nThe GIRFT dermatology national specialty report he led, published in September 2021, is the source for most of what is publicly known about the shape of the English service: 508 whole-time-equivalent trained dermatologists against 159 vacant posts, at least ten trusts with no dermatologist at all, over 200,000 surgical excisions a year, and 79 doctors in the whole of England doing Mohs surgery in fewer than 30 centres. He was also a clinical representative on the NHS England task and finish group that wrote the timed skin cancer diagnostic pathway.","asOf":"2026-09-25","links":[{"label":"Getting It Right First Time: dermatology","url":"https://gettingitrightfirsttime.co.uk/medical_specialties/dermatology/"},{"label":"Norfolk and Norwich University Hospitals: dermatology","url":"https://www.nnuh.nhs.uk/departments/dermatology/"}],"tags":["uk","dermatology","service-design"],"related":[],"cancers":["skin-cancer","basal-cell-carcinoma","cutaneous-scc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Consultant dermatologist, Norfolk and Norwich University Hospitals NHS Foundation Trust; Getting It Right First Time national clinical lead for dermatology","specialisms":["Skin cancer epidemiology","Dermatology service design","Health economics"],"profiles":[{"label":"Getting It Right First Time: dermatology","url":"https://gettingitrightfirsttime.co.uk/medical_specialties/dermatology/"},{"label":"Norfolk and Norwich University Hospitals: dermatology","url":"https://www.nnuh.nhs.uk/departments/dermatology/"}],"papers":[]},{"id":"nickolas-papadopoulos","kind":"person","name":"Nickolas Papadopoulos","aka":[],"tldr":"Co-developed CancerSEEK, the blood test that showed multi-cancer early detection is possible, and ran the first prospective screening study of it.","summary":"Nickolas Papadopoulos co-led with Bert Vogelstein and Kenneth Kinzler the development of CancerSEEK, the blood test combining ctDNA mutations and protein markers that detected eight cancer types, and the DETECT-A study, the first prospective trial to show a blood test can find cancers in asymptomatic women and lead to curative surgery. He co-founded Thrive (now part of Exact Sciences) and discovered mismatch repair genes with the Hopkins group.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Papadopoulos%20N%5BAuthor%5D%20CancerSEEK%20OR%20liquid%20biopsy"}],"tags":["early-detection","liquid-biopsy","mced"],"related":[],"cancers":[],"sections":[],"technologies":["mced","liquid-biopsy"],"targets":[],"drugs":[],"companies":[],"institutions":["johns-hopkins"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-detect-a-science-2020"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Oncology and Pathology, Ludwig Center and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","institutionId":"johns-hopkins","specialisms":["Early cancer detection","Liquid biopsy","Cancer genetics","Multi-cancer screening"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Papadopoulos%20N%5BAuthor%5D%20CancerSEEK%20OR%20liquid%20biopsy"}],"papers":[{"title":"Detection and localization of surgically resectable cancers with a multi-analyte blood test (CancerSEEK)","journal":"Science","year":2018,"doi":"10.1126/science.aar3247"},{"title":"Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention (DETECT-A)","journal":"Science","year":2020,"doi":"10.1126/science.abb9601"}]},{"id":"nicola-gokbuget","kind":"person","name":"Nicola Gökbuget","aka":[],"tldr":"Leads the German GMALL group and showed blinatumomab clears residual leukaemia in adults with ALL.","summary":"Nicola Gökbuget leads the German Multicenter Study Group for Adult ALL (GMALL), whose trials defined risk-adapted therapy and MRD-guided treatment in adult ALL, and was principal investigator of the BLAST trial showing blinatumomab converts most MRD-positive patients to MRD-negative with improved survival, the basis for its MRD indication. She co-authored the European guidelines on adult ALL.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gokbuget%20N%5BAuthor%5D%20acute%20lymphoblastic%20leukemia"}],"tags":["all","mrd","cooperative-group"],"related":[],"cancers":["all-leukemia"],"sections":[],"technologies":["mrd-testing","t-cell-engager"],"targets":["cd19"],"drugs":["blinatumomab"],"companies":[],"institutions":["uct-frankfurt"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-e1910-blinatumomab-mrd-negative-all-nejm-2024"],"journals":[],"dependsOn":[],"notes":[],"role":"Head of the GMALL Study Group; Professor of Medicine, University Hospital Frankfurt","institutionId":"uct-frankfurt","specialisms":["Adult acute lymphoblastic leukaemia","Measurable residual disease","Cooperative-group trials","Immunotherapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gokbuget%20N%5BAuthor%5D%20acute%20lymphoblastic%20leukemia"}],"papers":[{"title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia (BLAST)","journal":"Blood","year":2018,"doi":"10.1182/blood-2017-08-798322"},{"title":"Adult acute lymphoblastic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","journal":"Annals of Oncology","year":2016,"doi":"10.1093/annonc/mdw025"},{"title":"ECOG-ACRIN E1910: adding blinatumomab to chemotherapy for adults with B-cell ALL already in MRD-negative remission","journal":"New England Journal of Medicine","year":2024,"url":"https://doi.org/10.1056/NEJMoa2312948","doi":"10.1056/NEJMoa2312948"}]},{"id":"nicola-normanno","kind":"person","name":"Nicola Normanno","aka":[],"tldr":"Nicola Normanno represents IRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' (IRST) in the Organisation of European Cancer Institutes, which lists the centre among its members in Italy.","summary":"Nicola Normanno is listed by the Organisation of European Cancer Institutes (OECI) as the representative of IRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' (IRST), its full member in Italy. OnCo records the name from the OECI membership list so that the centre's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the institution's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"IRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' (IRST) website","url":"https://www.irst.emr.it"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["irst-meldola"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of IRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' (IRST) to the Organisation of European Cancer Institutes","institutionId":"irst-meldola","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"IRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' (IRST) website","url":"https://www.irst.emr.it"}],"papers":[{"title":"Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group","journal":"Ann Oncol","year":2024,"url":"https://doi.org/10.1016/j.annonc.2024.04.005","doi":"10.1016/j.annonc.2024.04.005","note":"Europe PMC author record matched by affiliation"},{"title":"EGFR mutation testing practices within the Asia Pacific region: results of a multicenter diagnostic survey","journal":"J Thorac Oncol","year":2015,"url":"https://doi.org/10.1097/jto.0000000000000422","doi":"10.1097/jto.0000000000000422","note":"Europe PMC author record matched by affiliation"},{"title":"Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial","journal":"JAMA Oncol","year":2021,"url":"https://doi.org/10.1001/jamaoncol.2021.2915","doi":"10.1001/jamaoncol.2021.2915","note":"Europe PMC author record matched by affiliation"}]},{"id":"nicolaas-schaap","kind":"person","name":"Nicolaas P.M. Schaap","aka":[],"tldr":"Radboudumc haematologist who chairs HOVON, the Dutch-Belgian haemato-oncology cooperative group.","summary":"Nicolaas P.M. Schaap is Chair of the HOVON Board, the Dutch-Belgian cooperative trial group for haematological malignancies in adults. He is a haematologist at Radboud University Medical Center in Nijmegen with expertise in allogeneic stem cell transplantation and cellular therapy. As chair he oversees HOVON's scientific and operational governance.","asOf":"2026-09-10","links":[{"label":"Society page","url":"https://hovon.nl/en/about-hovon"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schaap+NPM%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","haematology","stem cell transplantation"],"related":[],"cancers":["aml","multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["hovon"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["haematologica"],"dependsOn":[],"notes":[],"role":"Chair","institutionId":"hovon","specialisms":["Haematology","Stem cell transplantation","Cellular therapy"],"profiles":[{"label":"Society page","url":"https://hovon.nl/en/about-hovon"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schaap+NPM%5BAuthor%5D"}],"papers":[{"title":"Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study","journal":"Blood","year":2012,"doi":"10.1182/blood-2011-11-393801"},{"title":"Reduced relapse rate in upfront tandem autologous/reduced-intensity allogeneic transplantation in multiple myeloma only results in borderline non-significant prolongation of progression-free but not overall survival","journal":"Haematologica","year":2015,"doi":"10.3324/haematol.2015.128728"},{"title":"Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia – a matched pair analysis by the Acute Leukaemia Working Party of EBMT","journal":"British Journal of Haematology","year":2018,"doi":"10.1111/bjh.15691"}],"orcid":"0000-0001-7696-4752"},{"id":"nicolas-penel","kind":"person","name":"Nicolas Penel","aka":[],"tldr":"Medical oncologist and sarcoma specialist who directs Institut Bergonié, the regional cancer centre for Nouvelle-Aquitaine in Bordeaux.","summary":"Nicolas Penel is Directeur Général of Institut Bergonié, the regional comprehensive cancer centre (Centre de Lutte Contre le Cancer) for Nouvelle-Aquitaine, based in Bordeaux with around 1,000 staff, more than 100 physicians and 159 beds serving nearly six million inhabitants. He is a medical oncologist and university professor at the University of Lille whose expertise is in sarcoma management and early-phase clinical trials, and he has authored or co-authored more than 450 indexed publications. Before joining Bergonié he spent ten years as Director of Clinical Research and Innovation at Centre Oscar Lambret in Lille. He was appointed to lead the institute's new strategic establishment project, working with deputy director general Céline Etchetto and research director Pierre Soubeyran.","asOf":"2026-09-10","links":[{"label":"Source: Institut Bergonié institutional page naming the direction","url":"https://www.bergonie.fr/linstitut/"}],"tags":["leadership","clinician-scientist","sarcoma","clinical-trials"],"related":[],"cancers":["sarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["institut-bergonie"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["current-opinion-in-oncology"],"dependsOn":[],"notes":[],"role":"Directeur Général (Director General) of Institut Bergonié","institutionId":"institut-bergonie","specialisms":["Medical oncology","Sarcoma","Early-phase clinical trials"],"profiles":[{"label":"Institut Bergonié presentation page","url":"https://www.bergonie.fr/linstitut/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Penel+N%5BAuthor%5D"}],"papers":[{"title":"Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma: A Randomized Phase II Trial","journal":"Journal of Clinical Oncology","year":2015,"doi":"10.1200/jco.2015.60.8505"},{"title":"Adult desmoid tumors: biology, management and ongoing trials","journal":"Current Opinion in Oncology","year":2017,"doi":"10.1097/cco.0000000000000374"},{"title":"Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: A nationwide prospective cohort from the French Sarcoma Group","journal":"European Journal of Cancer","year":2017,"doi":"10.1016/j.ejca.2017.06.017"}],"orcid":"0000-0001-5243-1548"},{"id":"nicolas-revel","kind":"person","name":"Nicolas Revel","aka":[],"tldr":"Director general of AP-HP, the Paris public hospital group whose northern cancer institute holds the OECI Comprehensive Cancer Centre label.","summary":"Nicolas Revel is Directeur General of AP-HP, the Paris university hospital group that hosts the Institut du Cancer AP-HP. Nord, Universite Paris Cite, which brings together cancer care, research and teaching at the Beaujon, Bichat Claude-Bernard, Louis-Mourier and Saint-Louis hospitals. An AP-HP news item reports that he opened the institute's first day for cancer and haemato-oncology nurses at hopital Saint-Louis on 27 November 2025, placing it within the improvement dynamic of the institute's OECI accreditation. AP-HP reports that the institute received the OECI 'Comprehensive Cancer Centre' label on 20 December 2024, with the diploma presented in June 2025 and a positive first follow-up evaluation in early 2026. The AP-HP pages fetched do not name an individual director for the institute itself.","asOf":"2026-09-10","links":[{"label":"Source: AP-HP article naming Nicolas Revel as directeur general (archived copy, December 2025)","url":"https://web.archive.org/web/20251230054709/https://www.aphp.fr/actualites/retour-sur-la-1re-journee-des-infirmiers-en-cancerologie-de-linstitut-du-cancer-ap-hp"},{"label":"Source: AP-HP article on the institute one year after the OECI label (archived copy, March 2026)","url":"https://web.archive.org/web/20260419021737/https://www.aphp.fr/actualites/institut-du-cancer-ap-hp-nord-universite-paris-cite-des-avancees-concretes-un-apres"}],"tags":["leadership","hospital-management","comprehensive-cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["aphp-nord-cancer-institute"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Directeur General of AP-HP (Assistance Publique-Hopitaux de Paris), parent body of the Institut du Cancer AP-HP. Nord, Universite Paris Cite","institutionId":"aphp-nord-cancer-institute","specialisms":["Public hospital administration","Health system governance"],"profiles":[{"label":"AP-HP news: first cancer nursing day of the Institut du Cancer AP-HP. Nord (December 2025)","url":"https://www.aphp.fr/actualites/retour-sur-la-1re-journee-des-infirmiers-en-cancerologie-de-linstitut-du-cancer-ap-hp"}],"papers":[]},{"id":"nicolas-scotte","kind":"person","name":"Nicolas Scotté","aka":[],"tldr":"Director General of the Institut National du Cancer, responsible for running France's national cancer agency since October 2024.","summary":"Nicolas Scotté is Director General (Directeur général) of the Institut National du Cancer (INCa), the French public agency that coordinates the national cancer strategy, research funding, screening programmes and public information. He has held the role since October 2024. His work sits at the meeting point of health policy, public administration and cancer control, and he is responsible for running France's national cancer agency and its programmes. The institution profile is the public record of his appointment.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.cancer.fr/l-institut-national-du-cancer/notre-organisation/instances"}],"tags":["leadership","cancer policy","public health"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["inca"],"pathways":[],"terms":["screening"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director General","institutionId":"inca","specialisms":["Health policy","Public administration","Cancer control"],"profiles":[{"label":"Institution profile","url":"https://www.cancer.fr/l-institut-national-du-cancer/notre-organisation/instances"}],"papers":[]},{"id":"nicole-boutilier","kind":"person","name":"Nicole Boutilier","aka":[],"tldr":"Family physician who is President and CEO of Nova Scotia Health, the provincial health authority that runs the Cancer Care Program centred on the QEII Health Sciences Centre.","summary":"Nicole Boutilier is President and Chief Executive Officer of Nova Scotia Health, the provincial authority that operates the Nova Scotia Health Cancer Care Program. A family physician from Pictou County, she graduated from Dalhousie Medical School and completed her family medicine residency in Calgary, and has more than 30 years in medicine and 21 years in leadership roles. She was previously Executive Vice President of Medicine and Clinical Operations at Nova Scotia Health and co-lead of the Nova Scotia Office of Healthcare Professional Recruitment, led the organisation's Operational Excellence transformation, and received the 2026 Chris Carruthers Excellence in Medical Leadership Award. Nova Scotia Health's Cancer Care Program pages do not name a separate programme lead.","asOf":"2026-09-10","links":[{"label":"Source: Nova Scotia Health executive team page","url":"https://www.nshealth.ca/about-us/executive-team"}],"tags":["leadership","hospital-management","government"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["nova-scotia-cancer-care"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President and Chief Executive Officer, Nova Scotia Health","institutionId":"nova-scotia-cancer-care","specialisms":["Family medicine","Health system leadership","Physician leadership"],"profiles":[{"label":"Nova Scotia Health profile","url":"https://www.nshealth.ca/featured-people/dr-nicole-boutilier"},{"label":"Nova Scotia Health executive team","url":"https://www.nshealth.ca/about-us/executive-team"}],"papers":[]},{"id":"nicole-concin","kind":"person","name":"Nicole Concin","aka":[],"tldr":"Gynaecologic oncologist who leads Vienna's women's clinic and is first author of the ESGO/ESTRO/ESP endometrial cancer guidelines.","summary":"Nicole Concin heads the Department of Obstetrics and Gynecology at the Medical University of Vienna and AKH and coordinates the Gynecologic Cancer Unit within the Comprehensive Cancer Center Vienna. She is first author of the European ESGO/ESTRO/ESP guidelines for endometrial carcinoma (2021 and the 2025 update) and has served as President of the European Society of Gynaecological Oncology.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://ccc.meduniwien.ac.at/ueber-uns/die-leitung-des-comprehensive-cancer-center/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Concin+N%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","gynaecologic oncology","endometrial cancer"],"related":[],"cancers":["endometrial","ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ccc-vienna"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["international-journal-of-gynecological-cancer"],"dependsOn":[],"notes":[],"role":"Coordinator, Gynecologic Cancer Unit; Head, Department of Obstetrics and Gynecology","institutionId":"ccc-vienna","specialisms":["Gynaecologic oncology","Endometrial cancer","Ovarian cancer","Clinical guidelines"],"profiles":[{"label":"Institution profile","url":"https://ccc.meduniwien.ac.at/ueber-uns/die-leitung-des-comprehensive-cancer-center/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Concin+N%5BAuthor%5D"}],"papers":[{"title":"ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma","journal":"International Journal of Gynecological Cancer","year":2021,"url":"https://doi.org/10.1136/ijgc-2020-002230","doi":"10.1136/ijgc-2020-002230"},{"title":"ESGO-ESTRO-ESP guidelines for the management of patients with endometrial carcinoma: update 2025","journal":"Lancet Oncology","year":2025,"url":"https://doi.org/10.1016/S1470-2045(25)00167-6","doi":"10.1016/S1470-2045(25)00167-6"}]},{"id":"nicole-scobie","kind":"person","name":"Nicole Scobie","aka":[],"tldr":"Patient advocate from Switzerland who chairs the board of ACCELERATE, the European multi-stakeholder platform speeding up new medicines for children and adolescents with cancer.","summary":"Nicole Scobie is Chair of the Board of Directors of ACCELERATE, a multi-stakeholder platform bringing together academia, patient advocates, regulators and industry with the stated goal of making research into therapies for children and adolescents with cancer 'go further, faster'. The platform's leadership page lists her as a patient advocate based in Switzerland, alongside Vice-Chair Elizabeth Fox of St Jude Children's Research Hospital and Treasurer Sam Daems. The Scientific Committee is chaired by Gilles Vassal of Gustave Roussy, and day to day operations are run from a Brussels office. The page gives no appointment date.","asOf":"2026-09-10","links":[{"label":"Source: ACCELERATE 'Our Leadership' page","url":"https://www.accelerate-platform.org/our-leadership"}],"tags":["leadership","professional-society","philanthropy"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["accelerate-platform"],"pathways":[],"terms":[],"trials":[],"people":["gilles-vassal"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chair of the Board of Directors, ACCELERATE","institutionId":"accelerate-platform","specialisms":["Patient advocacy","Paediatric oncology drug development","Multi-stakeholder governance"],"profiles":[{"label":"ACCELERATE leadership page","url":"https://www.accelerate-platform.org/our-leadership"}],"papers":[{"title":"ACCELERATE Paediatric Strategy Forums: an advance for oncological drug development?","journal":"The Lancet Oncology","year":2022,"doi":"10.1016/s1470-2045(22)00619-2"},{"title":"The RACE to accelerate drug development for children with cancer","journal":"The Lancet Child & Adolescent Health","year":2020,"doi":"10.1016/s2352-4642(20)30247-9"},{"title":"The Crucial Role of Patient Advocates in Pediatric Oncology Research—Insights From ACCELERATE","journal":"JAMA Pediatrics","year":2024,"doi":"10.1001/jamapediatrics.2024.1877"}]},{"id":"nicoletta-colombo","kind":"person","name":"Nicoletta Colombo","aka":[],"tldr":"Led KEYNOTE-826, which made pembrolizumab plus chemotherapy the first-line standard for recurrent or metastatic cervical cancer.","summary":"Nicoletta Colombo was principal investigator of KEYNOTE-826, which showed pembrolizumab added to chemotherapy with or without bevacizumab improves survival in persistent, recurrent or metastatic cervical cancer, the first immunotherapy survival gain in the disease. She has chaired ESMO-ESGO ovarian cancer consensus conferences and led MITO and ENGOT trials. She directs gynaecologic oncology at IEO.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Colombo%20N%5BAuthor%5D%20cervical%20pembrolizumab"}],"tags":["cervical","immunotherapy","guidelines"],"related":[],"cancers":["cervical","ovarian"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["pd1","vegf"],"drugs":["pembrolizumab"],"companies":[],"institutions":["ieo-milan","esgo"],"pathways":[],"terms":[],"trials":["keynote-826"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director of Gynaecologic Oncology, European Institute of Oncology (IEO), Milan; Professor, University of Milan-Bicocca","institutionId":"ieo-milan","specialisms":["Cervical cancer","Ovarian cancer","Immunotherapy","Guidelines"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Colombo%20N%5BAuthor%5D%20cervical%20pembrolizumab"}],"papers":[{"title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826)","journal":"NEJM","year":2021,"doi":"10.1056/NEJMoa2112435"},{"title":"ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease","journal":"Annals of Oncology","year":2019,"doi":"10.1093/annonc/mdz062"}]},{"id":"niels-norgaard-pedersen","kind":"person","name":"Niels Nørgaard Pedersen","aka":[],"tldr":"Niels Nørgaard Pedersen represents Odense University Hospital in the Organisation of European Cancer Institutes, which lists the centre among its members in Denmark.","summary":"Niels Nørgaard Pedersen is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Odense University Hospital, its member in Denmark. Odense University Hospital is the university hospital of the Region of Southern Denmark and a full member of the Organisation of European Cancer Institutes. OnCo records the name from the OECI membership list so that the centre's page has a named contact point; the person's exact title, appointment date and biography are not yet recorded and should be checked on the institution's own pages before being relied on.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Odense University Hospital website","url":"https://en.ouh.dk/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["odense-university-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Odense University Hospital to the Organisation of European Cancer Institutes","institutionId":"odense-university-hospital","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Odense University Hospital website","url":"https://en.ouh.dk/"}],"papers":[]},{"id":"nikhil-munshi","kind":"person","name":"Nikhil C. Munshi","aka":[],"tldr":"Led KarMMa, which brought idecabtagene vicleucel, the first CAR-T for myeloma, to approval.","summary":"Nikhil Munshi was principal investigator of KarMMa, the pivotal trial showing the BCMA-directed CAR-T idecabtagene vicleucel produces responses in nearly three-quarters of heavily pretreated myeloma patients, leading to the first CAR-T approval in the disease, and of KarMMa-3 comparing it with standard regimens. His laboratory studies myeloma genomics and he led the meta-analysis establishing MRD negativity as a surrogate for survival.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Munshi%20NC%5BAuthor%5D%20myeloma%20idecabtagene"}],"tags":["myeloma","car-t","genomics"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":["car-t","mrd-testing"],"targets":["bcma"],"drugs":[],"companies":[],"institutions":["dana-farber"],"pathways":[],"terms":[],"trials":["karmma-3"],"people":[],"bottlenecks":[],"keyPapers":["paper-karmma-3-ide-cel-nejm-2023"],"journals":[],"dependsOn":[],"notes":[],"role":"Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute","institutionId":"dana-farber","specialisms":["Multiple myeloma","CAR T-cell therapy","Myeloma genomics","Minimal residual disease"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Munshi%20NC%5BAuthor%5D%20myeloma%20idecabtagene"}],"papers":[{"title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma (KarMMa)","journal":"NEJM","year":2021,"doi":"10.1056/NEJMoa2024850"},{"title":"Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis","journal":"JAMA Oncology","year":2017,"doi":"10.1001/jamaoncol.2016.3160"},{"title":"KarMMa-3: ide-cel CAR-T versus standard regimens in triple-class-exposed relapsed myeloma","journal":"New England Journal of Medicine","year":2023,"url":"https://doi.org/10.1056/NEJMoa2213614","doi":"10.1056/NEJMoa2213614"}]},{"id":"nikhil-tandon","kind":"person","name":"Nikhil Tandon","aka":[],"tldr":"Endocrinologist appointed Director of AIIMS New Delhi in 2026, India's premier public medical institute and home to the Dr. B.R. Ambedkar Institute Rotary Cancer Hospital.","summary":"Dr. Nikhil Tandon is Director of the All India Institute of Medical Sciences, New Delhi, assuming office in 2026 according to public records. A professor of endocrinology and metabolism at AIIMS, his research has focused on diabetes, thyroid disease and cardiometabolic risk in Indian populations. AIIMS houses the Dr. B.R. Ambedkar Institute Rotary Cancer Hospital, one of India's largest public cancer centres.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tandon+N%5BAuthor%5D+AIIMS"}],"tags":["leadership","endocrinology"],"related":[],"cancers":["thyroid"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["aiims-delhi"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director","institutionId":"aiims-delhi","specialisms":["Endocrinology","Metabolic disease","Academic medicine leadership"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tandon+N%5BAuthor%5D+AIIMS"}],"papers":[{"title":"The genetic architecture of type 2 diabetes","journal":"Nature","year":2016,"url":"https://doi.org/10.1038/nature18642","doi":"10.1038/nature18642","note":"Europe PMC author record matched by affiliation"},{"title":"Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study","journal":"The Lancet Diabetes and Endocrinology","year":2023,"url":"https://doi.org/10.1016/s2213-8587(23)00119-5","doi":"10.1016/s2213-8587(23)00119-5","note":"Europe PMC author record matched by affiliation"},{"title":"Prevalence and significance of low 25-hydroxyvitamin D concentrations in healthy subjects in Delhi","journal":"American Journal of Clinical Nutrition","year":2000,"url":"https://doi.org/10.1093/ajcn/72.2.472","doi":"10.1093/ajcn/72.2.472","note":"Europe PMC author record matched by affiliation"}]},{"id":"nikki-gallagher","kind":"person","name":"Nikki Gallagher","aka":[],"tldr":"Advocacy and governance leader who is Chief Executive of the Irish Cancer Society, Ireland's national cancer charity.","summary":"Nikki Gallagher is Chief Executive Officer of the Irish Cancer Society, the national cancer charity that funds research and provides support services and advocacy for people affected by cancer in Ireland. The society describes her as a purpose-driven leader with experience in strategic leadership, advocacy and governance across the private, public and charity sectors, including central roles in campaigns on children's rights, reproductive healthcare, equality and education reform. She holds an MSc in Strategic Management, a Diploma in Law and a professional certificate in Governance, and leads the organisation with its Executive Leadership Team under a voluntary Board of Directors.","asOf":"2026-09-10","links":[{"label":"Source: Irish Cancer Society leadership page","url":"https://www.cancer.ie/about-our-work/our-leadership"}],"tags":["leadership","advocacy","charity"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["irish-cancer-society"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive Officer of the Irish Cancer Society","institutionId":"irish-cancer-society","specialisms":["Charity leadership","Advocacy and public policy","Governance"],"profiles":[{"label":"Institution leadership page","url":"https://www.cancer.ie/about-our-work/our-leadership"}],"papers":[]},{"id":"nikolai-goncharenko","kind":"person","name":"Nikolai Goncharenko","aka":[],"tldr":"Nikolai Goncharenko represents Institut National du Cancer, Luxembourg in the Organisation of European Cancer Institutes, which lists the organisation among its associate members in Luxembourg.","summary":"Nikolai Goncharenko is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Institut National du Cancer, Luxembourg, its associate member in Luxembourg. OnCo records the name from the OECI membership list so that the organisation's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the organisation's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Institut National du Cancer, Luxembourg website","url":"https://institutnationalducancer.lu/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["inc-luxembourg"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Institut National du Cancer, Luxembourg to the Organisation of European Cancer Institutes","institutionId":"inc-luxembourg","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Institut National du Cancer, Luxembourg website","url":"https://institutnationalducancer.lu/"}],"papers":[{"title":"Parkinson's disease-associated alterations of the gut microbiome predict disease-relevant changes in metabolic functions","journal":"BMC Biol","year":2020,"url":"https://doi.org/10.1186/s12915-020-00775-7","doi":"10.1186/s12915-020-00775-7","note":"Europe PMC author record matched by affiliation"},{"title":"The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases","journal":"Front Neurol","year":2015,"url":"https://doi.org/10.3389/fneur.2015.00216","doi":"10.3389/fneur.2015.00216","note":"Europe PMC author record matched by affiliation"},{"title":"Serum bile acids and GLP-1 decrease following telemetric induced weight loss: results of a randomized controlled trial","journal":"Sci Rep","year":2016,"url":"https://doi.org/10.1038/srep30173","doi":"10.1038/srep30173","note":"Europe PMC author record matched by affiliation"}],"orcid":"0000-0002-9873-1885"},{"id":"nikolaos-zamboglou","kind":"person","name":"Nikolaos Zamboglou","aka":[],"tldr":"Nikolaos Zamboglou represents German Oncology Center in the Organisation of European Cancer Institutes, which lists the centre among its members in Cyprus.","summary":"Nikolaos Zamboglou is listed by the Organisation of European Cancer Institutes (OECI) as the representative of German Oncology Center, its member in Cyprus. German Oncology Center is a private cancer centre in Limassol offering radiotherapy, medical oncology and diagnostics, and a full member of the Organisation of European Cancer Institutes. OnCo records the name from the OECI membership list so that the centre's page has a named contact point; the person's exact title, appointment date and biography are not yet recorded and should be checked on the institution's own pages before being relied on.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"German Oncology Center website","url":"https://www.goc.com.cy/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["german-oncology-center-limassol"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of German Oncology Center to the Organisation of European Cancer Institutes","institutionId":"german-oncology-center-limassol","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"German Oncology Center website","url":"https://www.goc.com.cy/"}],"papers":[{"title":"MR relaxation times of agar-based tissue-mimicking phantoms","journal":"J Appl Clin Med Phys","year":2022,"url":"https://doi.org/10.1002/acm2.13533","doi":"10.1002/acm2.13533","note":"Europe PMC author record matched by affiliation"},{"title":"High dose rate brachytherapy as monotherapy for localised prostate cancer","journal":"Radiother Oncol","year":2018,"url":"https://doi.org/10.1016/j.radonc.2017.09.038","doi":"10.1016/j.radonc.2017.09.038","note":"Europe PMC author record matched by affiliation"},{"title":"Narrative Review of High-Dose-Rate Interstitial Brachytherapy in Primary or Secondary Liver Tumors","journal":"Front Oncol","year":2022,"url":"https://doi.org/10.3389/fonc.2022.800920","doi":"10.3389/fonc.2022.800920","note":"Europe PMC author record matched by affiliation"}]},{"id":"nikolaus-rajewsky","kind":"person","name":"Nikolaus Rajewsky","aka":[],"tldr":"Systems biologist at the MDC known for microRNA and circular RNA discoveries and for single-cell and spatial genomics applied to cancer.","summary":"Nikolaus Rajewsky leads the Systems Biology of Gene Regulatory Elements laboratory at the Max Delbrück Center and heads its Berlin Institute for Medical Systems Biology (BIMSB). His group combines computational and experimental approaches to study non-coding RNAs, organoids and spatial transcriptomics, with disease programmes in triple-negative breast cancer, non-small cell lung cancer and neuroblastoma in collaboration with Charité.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.mdc-berlin.de/n-rajewsky"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rajewsky+N%5BAuthor%5D"}],"tags":["clinician-scientist","systems biology","genomics","breast cancer"],"related":[],"cancers":["tnbc","nsclc","neuroblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["mdc-berlin"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Group Leader, Systems Biology of Gene Regulatory Elements; Scientific Director, Berlin Institute for Medical Systems Biology (MDC-BIMSB)","institutionId":"mdc-berlin","specialisms":["Systems biology","Single-cell and spatial transcriptomics","Non-coding RNA","Triple-negative breast cancer"],"profiles":[{"label":"Institution profile","url":"https://www.mdc-berlin.de/n-rajewsky"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rajewsky+N%5BAuthor%5D"}],"papers":[{"title":"The oncogenic role of circPVT1 in head and neck squamous cell carcinoma is mediated through the mutant p53/YAP/TEAD transcription-competent complex","journal":"Genome Biology","year":2017,"doi":"10.1186/s13059-017-1368-y"}],"orcid":"0000-0002-4785-4332"},{"id":"nina-bhardwaj","kind":"person","name":"Nina Bhardwaj","aka":[],"tldr":"Nina Bhardwaj is a dendritic-cell immunologist running personalised neoantigen vaccine trials.","summary":"Nina Bhardwaj is Director of Immunotherapy and holds the Ward-Coleman Chair in Cancer Research at The Mount Sinai Hospital and Tisch Cancer Institute. She is a dendritic cell immunologist and a pioneer of dendritic cell biology in human immunity. She leads the PGV001 personalised neoantigen peptide vaccine programme, and her selected paper reports a phase 1 trial of the safety and immunogenicity of a multi-peptide personalised genomic vaccine as adjuvant treatment of solid cancers. Her current work spans personalised neoantigen vaccines and off-the-shelf cancer vaccines.","asOf":"2026-09-08","links":[{"label":"Mount Sinai profile","url":"https://profiles.mountsinai.org/nina-bhardwaj"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bhardwaj%20N%5BAuthor%5D"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["neoantigen-mrna-vaccine","shared-antigen-vaccine"],"targets":[],"drugs":[],"companies":[],"institutions":["mount-sinai"],"pathways":[],"terms":["neoantigen"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director of Immunotherapy; Ward-Coleman Chair in Cancer Research","institutionId":"mount-sinai","specialisms":["Dendritic cells","Cancer vaccines","Personalised neoantigen vaccines"],"profiles":[{"label":"Mount Sinai profile","url":"https://profiles.mountsinai.org/nina-bhardwaj"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bhardwaj%20N%5BAuthor%5D"}],"papers":[{"title":"A phase I trial of the safety and immunogenicity of a multi-peptide personalized genomic vaccine in the adjuvant treatment of solid cancers","journal":"Cancer Discovery","year":2024}]},{"id":"nirali-shah","kind":"person","name":"Nirali N. Shah","aka":[],"tldr":"Nirali Shah developed CD22 CAR-T for children whose leukaemia escaped CD19 therapy.","summary":"Nirali N. Shah is Head of the Hematologic Malignancies Section in the Pediatric Oncology Branch at the National Cancer Institute. She is a paediatric leukaemia specialist known for developing CD22-directed CAR-T for children whose acute lymphoblastic leukaemia escaped CD19 therapy, addressing CD19-negative relapse after tisagenlecleucel and blinatumomab. Her selected paper reports that CD22-targeted CAR T cells induce remission in B-cell acute lymphoblastic leukaemia that is naive or resistant to CD19-targeted CAR immunotherapy. She leads paediatric CAR-T trials at NCI.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Nirali_N._Shah","links":[{"label":"NCI CCR profile","url":"https://ccr.cancer.gov/staff-directory/nirali-n-shah"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Shah%20NN%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["all-leukemia"],"sections":[],"technologies":["car-t"],"targets":["cd22","cd19"],"drugs":[],"companies":[],"institutions":["nci"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Head, Hematologic Malignancies Section, Pediatric Oncology Branch","institutionId":"nci","specialisms":["Paediatric leukaemia","CAR-T","CD22"],"profiles":[{"label":"NCI CCR profile","url":"https://ccr.cancer.gov/staff-directory/nirali-n-shah"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Shah%20NN%5BAuthor%5D"}],"papers":[{"title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","journal":"Nature Medicine","year":2018,"url":"https://doi.org/10.1038/nm.4441","doi":"10.1038/nm.4441"}]},{"id":"nitzan-rosenfeld","kind":"person","name":"Nitzan Rosenfeld","aka":[],"tldr":"Showed that whole-exome sequencing of blood can track how a cancer evolves, and co-founded Inivata.","summary":"Nitzan Rosenfeld led the 2013 Nature study showing that exome sequencing of circulating tumour DNA tracks the evolution of resistance across multiple cancers, and the earlier work using tagged-amplicon sequencing to monitor breast cancer, both foundational to liquid biopsy. He developed methods for detecting ctDNA at very low fractions and co-founded Inivata, now part of NeoGenomics. He moved from Cambridge to Barts in 2023.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rosenfeld%20N%5BAuthor%5D%20circulating%20tumor%20DNA"}],"tags":["ctdna","liquid-biopsy","genomics"],"related":[],"cancers":[],"sections":[],"technologies":["liquid-biopsy","mrd-testing","wes-wgs"],"targets":[],"drugs":[],"companies":[],"institutions":["barts-cancer-institute","cruk-cambridge-centre"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Cancer Genomics, Barts Cancer Institute; former Senior Group Leader, CRUK Cambridge Institute","institutionId":"barts-cancer-institute","specialisms":["Circulating tumour DNA","Liquid biopsy methods","Cancer genomics","Early detection"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rosenfeld%20N%5BAuthor%5D%20circulating%20tumor%20DNA"}],"papers":[{"title":"Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA","journal":"Nature","year":2013,"doi":"10.1038/nature12065"},{"title":"Analysis of circulating tumor DNA to monitor metastatic breast cancer","journal":"NEJM","year":2013,"doi":"10.1056/NEJMoa1213261"}]},{"id":"yamamoto-noboru","kind":"person","name":"Noboru Yamamoto","aka":[],"tldr":"Runs Japan's largest first-in-human oncology unit, where many Daiichi Sankyo DXd ADCs were first given to patients.","summary":"Noboru Yamamoto is Director of the Department of Experimental Therapeutics at the National Cancer Center Hospital in Tokyo. He runs Japan's largest first-in-human oncology unit, where many of the Daiichi Sankyo DXd antibody-drug conjugates were first given to patients, including trastuzumab deruxtecan and datopotamab deruxtecan. His publications include the TROPION-PanTumor01 first-in-human study of datopotamab deruxtecan in non-small-cell lung cancer, the REMORA phase 2 trial of lenvatinib in advanced thymic carcinoma, and a phase 1 study of the anti-CCR4 antibody mogamulizumab combined with nivolumab in solid tumours. His interests are phase 1 trials, drug development and lung cancer.","asOf":"2026-09-08","links":[{"label":"National Cancer Center Hospital","url":"https://www.ncc.go.jp/en/ncch/index.html"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Yamamoto%20N%5BAuthor%5D%20National%20Cancer%20Center%20phase%201"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["adc"],"targets":[],"drugs":["trastuzumab-deruxtecan","datopotamab-deruxtecan"],"companies":["daiichi-sankyo"],"institutions":["ncc-japan"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Department of Experimental Therapeutics, National Cancer Center Hospital","institutionId":"ncc-japan","specialisms":["Phase 1 trials","Drug development","Lung cancer","Antibody-drug conjugates"],"profiles":[{"label":"National Cancer Center Hospital","url":"https://www.ncc.go.jp/en/ncch/index.html"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Yamamoto%20N%5BAuthor%5D%20National%20Cancer%20Center%20phase%201"}],"papers":[{"title":"First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2–Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non–Small-Cell Lung Cancer: TROPION-PanTumor01","journal":"Journal of Clinical Oncology","year":2023,"doi":"10.1200/jco.23.00059"},{"title":"Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial","journal":"The Lancet Oncology","year":2020,"doi":"10.1016/s1470-2045(20)30162-5"},{"title":"A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors","journal":"Clinical Cancer Research","year":2019,"doi":"10.1158/1078-0432.ccr-19-1090"}]},{"id":"nobuyuki-yamamoto","kind":"person","name":"Nobuyuki Yamamoto","aka":[],"tldr":"Lung cancer specialist at Wakayama Medical University who chairs the West Japan Oncology Group cooperative trials network.","summary":"Nobuyuki Yamamoto is Chairman of the West Japan Oncology Group (WJOG), a cooperative clinical trials group established in 2000 to run lung cancer studies and since expanded to gastrointestinal, breast and basket trials. He is a professor of respiratory medicine and medical oncology at Wakayama Medical University with an extensive record in lung cancer clinical trials.","asOf":"2026-09-10","links":[{"label":"Society page","url":"https://www.wjog.jp/en/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Yamamoto+N%5BAuthor%5D+lung"}],"tags":["leadership","clinician-scientist","lung cancer","clinical trials"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["wjog"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["clinical-lung-cancer"],"dependsOn":[],"notes":[],"role":"Chairman","institutionId":"wjog","specialisms":["Thoracic oncology","Lung cancer","Clinical trials"],"profiles":[{"label":"Society page","url":"https://www.wjog.jp/en/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Yamamoto+N%5BAuthor%5D+lung"}],"papers":[{"title":"Randomized Phase III Trial Comparing Weekly Docetaxel Plus Cisplatin Versus Docetaxel Monotherapy Every 3 Weeks in Elderly Patients With Advanced Non–Small-Cell Lung Cancer: The Intergroup Trial JCOG0803/WJOG4307L","journal":"Journal of Clinical Oncology","year":2015,"doi":"10.1200/jco.2014.55.8627"},{"title":"Randomized Phase III Study of Cisplatin With Pemetrexed and Cisplatin With Vinorelbine for Completely Resected Nonsquamous Non–Small-Cell Lung Cancer: The JIPANG Study Protocol","journal":"Clinical Lung Cancer","year":2018,"doi":"10.1016/j.cllc.2017.05.020"},{"title":"Current status and future perspectives of cooperative study groups for lung cancer in Japan","journal":"Respiratory Investigation","year":2014,"doi":"10.1016/j.resinv.2014.06.004"}],"orcid":"0000-0002-7342-0853"},{"id":"noopur-raje","kind":"person","name":"Noopur Raje","aka":[],"tldr":"Led the first-in-human trial of BCMA CAR-T (bb2121) in myeloma and studies of bone disease treatment.","summary":"Noopur Raje led the first-in-human trial of bb2121 (idecabtagene vicleucel), which showed deep responses in heavily pretreated myeloma and launched BCMA-directed CAR-T therapy, and the trial establishing denosumab as an alternative to zoledronic acid for myeloma bone disease. She directs the myeloma centre at MGH and leads trials of bispecifics and next-generation cell therapies.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Raje%20N%5BAuthor%5D%20myeloma%20BCMA"}],"tags":["myeloma","car-t","bone-disease"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":["car-t"],"targets":["bcma"],"drugs":[],"companies":[],"institutions":["mgh"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-karmma-3-ide-cel-nejm-2023"],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center","institutionId":"mgh","specialisms":["Multiple myeloma","CAR T-cell therapy","Bone disease","Novel agents"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Raje%20N%5BAuthor%5D%20myeloma%20BCMA"}],"papers":[{"title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","journal":"NEJM","year":2019,"doi":"10.1056/NEJMoa1817226"},{"title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study","journal":"Lancet Oncology","year":2018,"doi":"10.1016/S1470-2045(18)30072-X"},{"title":"KarMMa-3: ide-cel CAR-T versus standard regimens in triple-class-exposed relapsed myeloma","journal":"New England Journal of Medicine","year":2023,"url":"https://doi.org/10.1056/NEJMoa2213614","doi":"10.1056/NEJMoa2213614"}]},{"id":"norbert-vey","kind":"person","name":"Norbert Vey","aka":[],"tldr":"Haematologist specialising in leukaemia who has directed Institut Paoli-Calmettes, the Marseille comprehensive cancer centre, since May 2022.","summary":"Norbert Vey is Directeur Général of Institut Paoli-Calmettes (IPC), the Centre de Lutte Contre le Cancer in Marseille, accredited as a Comprehensive Cancer Center by the OECI. He took office on 13 May 2022 for a five-year term following a ministerial decree, succeeding Patrice Viens, who had led the institute since 2007. He is a professor of haematology at Aix-Marseille University and a hospital practitioner specialising in the treatment of leukaemia, and previously directed the institute's haematology department.","asOf":"2026-09-10","links":[{"label":"Source: Institut Paoli-Calmettes appointment announcement","url":"https://www.institutpaolicalmettes.fr/le-pr-norbert-vey-nomme-directeur-general-de-linstitut-paoli-calmettes/"}],"tags":["leadership","clinician-scientist","haematology"],"related":[],"cancers":["aml","all-leukemia"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["institut-paoli-calmettes"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Directeur Général (Director General) of Institut Paoli-Calmettes","institutionId":"institut-paoli-calmettes","specialisms":["Haematology","Leukaemia","Cancer centre management"],"profiles":[{"label":"IPC announcement of appointment","url":"https://www.institutpaolicalmettes.fr/le-pr-norbert-vey-nomme-directeur-general-de-linstitut-paoli-calmettes/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Vey+N%5BAuthor%5D"}],"papers":[{"title":"Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study","journal":"The Lancet Haematology","year":2016,"doi":"10.1016/s2352-3026(15)00247-1"},{"title":"Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia","journal":"New England Journal of Medicine","year":2016,"doi":"10.1056/nejmoa1605085"},{"title":"Low-intensity regimens versus standard-intensity induction strategies in acute myeloid leukemia","journal":"Therapeutic Advances in Hematology","year":2020,"doi":"10.1177/2040620720913010"}],"orcid":"0000-0001-7027-040X"},{"id":"norman-wolmark","kind":"person","name":"Norman Wolmark","aka":[],"tldr":"Surgical oncologist and long-time Chairman of the NSABP, whose trials established breast-conserving surgery and adjuvant therapy standards in breast and colorectal cancer.","summary":"Norman Wolmark is Chairman of the NSABP Foundation and Professor of Surgery at the University of Pittsburgh. He has led the National Surgical Adjuvant Breast and Bowel Project for decades, overseeing landmark trials including B-06 on breast-conserving surgery and the tamoxifen prevention and trastuzumab adjuvant trials. His work has defined much of the evidence base for adjuvant treatment of breast and colorectal cancer.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.nsabp.org/about-us/the-team/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wolmark+N%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","breast cancer","clinical trials"],"related":[],"cancers":["breast-hr-positive","breast-her2-positive","colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["nsabp-foundation"],"institutions":[],"pathways":[],"terms":[],"trials":["hera-b31-n9831"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chairman","institutionId":"nsabp-foundation","specialisms":["Breast cancer","Colorectal cancer","Adjuvant therapy trials"],"profiles":[{"label":"Institution profile","url":"https://www.nsabp.org/about-us/the-team/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wolmark+N%5BAuthor%5D"}],"papers":[{"title":"Twenty-Year Follow-up of a Randomized Trial Comparing Total Mastectomy, Lumpectomy, and Lumpectomy plus Irradiation for the Treatment of Invasive Breast Cancer","journal":"New England Journal of Medicine","year":2002,"url":"https://doi.org/10.1056/NEJMoa022152","doi":"10.1056/NEJMoa022152"}]},{"id":"nu-zhang","kind":"person","name":"Nu Zhang","aka":[],"tldr":"President of Guangdong Provincial People's Hospital in Guangzhou, one of China's largest tertiary hospitals and home to the Guangdong Lung Cancer Institute.","summary":"Nu Zhang (Zhang Nu) is President and Deputy Party Secretary of Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences) in Guangzhou. The hospital is a major tertiary centre in southern China and hosts the Guangdong Lung Cancer Institute, a leading site for thoracic oncology trials. His role is listed on the hospital's current-leadership page.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.gdghospital.org.cn/thecurrentleader/list.html"}],"tags":["leadership","hospital management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["guangdong-provincial-peoples-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President (Yuanzhang) and Deputy Party Secretary","institutionId":"guangdong-provincial-peoples-hospital","specialisms":["Hospital leadership"],"profiles":[{"label":"Institution profile","url":"https://www.gdghospital.org.cn/thecurrentleader/list.html"}],"papers":[]},{"id":"nubia-munoz","kind":"person","name":"Nubia Muñoz","aka":[],"tldr":"Colombian epidemiologist whose IARC studies proved HPV causes cervical cancer and identified the types the vaccines target.","summary":"Nubia Muñoz led the IARC multicentre case-control studies across four continents that established human papillomavirus as the necessary cause of cervical cancer and the 2003 classification of high-risk HPV types that determined which types the prophylactic vaccines should cover. She was a principal investigator in the Costa Rica and quadrivalent vaccine trials and received the Gairdner Global Health Award.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Munoz%20N%5BAuthor%5D%20human%20papillomavirus%20cervical"}],"tags":["hpv","epidemiology","prevention","latin-america"],"related":[],"cancers":["cervical"],"sections":[],"technologies":["hpv-vaccine"],"targets":[],"drugs":[],"companies":[],"institutions":["inc-colombia","iarc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-hpv-vaccine-sweden-nejm-2020"],"journals":[],"dependsOn":[],"notes":[],"role":"Emeritus Professor, National Cancer Institute of Colombia; former Chief of Field and Intervention Studies, IARC","institutionId":"inc-colombia","specialisms":["HPV epidemiology","Cervical cancer causation","Cancer prevention","Global health"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Munoz%20N%5BAuthor%5D%20human%20papillomavirus%20cervical"}],"papers":[{"title":"Epidemiologic classification of human papillomavirus types associated with cervical cancer","journal":"NEJM","year":2003,"doi":"10.1056/NEJMoa021641"},{"title":"Human papillomavirus is a necessary cause of invasive cervical cancer worldwide","journal":"Journal of Pathology","year":1999,"doi":"10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F"},{"title":"Swedish registry study: HPV vaccination almost eliminates cervical cancer when given before 17","journal":"New England Journal of Medicine","year":2020,"url":"https://doi.org/10.1056/NEJMoa1917338","doi":"10.1056/NEJMoa1917338"}],"orcid":"0000-0002-6732-9973"},{"id":"obi-griffith","kind":"person","name":"Obi L. Griffith","aka":[],"tldr":"Obi Griffith co-leads CIViC and the open tooling that lets clinicians interpret tumour sequencing.","summary":"Obi L. Griffith is Associate Professor of Medicine and Assistant Director of the McDonnell Genome Institute at Siteman Cancer Center, Washington University. He is a computational biologist who co-leads CIViC, DoCM and pVACtools, the open tooling that lets clinicians interpret tumour sequencing, and the ClinGen somatic working group. His selected paper describes CIViC as a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer. He continues to work on clinical genomics, variant interpretation and open-source bioinformatics.","asOf":"2026-09-08","links":[{"label":"Griffith lab","url":"https://griffithlab.org"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Griffith%20OL%5BAuthor%5D"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["cgp"],"targets":[],"drugs":[],"companies":[],"institutions":["wustl-siteman"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nature-genetics"],"dependsOn":[],"notes":[],"role":"Associate Professor of Medicine; Assistant Director, McDonnell Genome Institute","institutionId":"wustl-siteman","specialisms":["Clinical genomics","Variant interpretation","Open-source bioinformatics"],"profiles":[{"label":"Griffith lab","url":"https://griffithlab.org"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Griffith%20OL%5BAuthor%5D"}],"papers":[{"title":"CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer","journal":"Nature Genetics","year":2017,"url":"https://doi.org/10.1038/ng.3774","doi":"10.1038/ng.3774"}],"orcid":"0000-0002-0843-4271"},{"id":"oddbjorn-straume","kind":"person","name":"Oddbjorn Straume","aka":[],"tldr":"Oddbjorn Straume represents Haukeland University Hospital in the Organisation of European Cancer Institutes, which lists the centre among its members in Norway.","summary":"Oddbjorn Straume is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Haukeland University Hospital, its full member in Norway. OnCo records the name from the OECI membership list so that the centre's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the institution's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Haukeland University Hospital website","url":"https://helse-bergen.no"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["haukeland-university-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Haukeland University Hospital to the Organisation of European Cancer Institutes","institutionId":"haukeland-university-hospital","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Haukeland University Hospital website","url":"https://helse-bergen.no"}],"papers":[{"title":"Are 90% of deaths from cancer caused by metastases?","journal":"Cancer Med","year":2019,"url":"https://doi.org/10.1002/cam4.2474","doi":"10.1002/cam4.2474","note":"Europe PMC author record matched by affiliation"},{"title":"EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast","journal":"J Clin Oncol","year":2006,"url":"https://doi.org/10.1200/jco.2005.01.5180","doi":"10.1200/jco.2005.01.5180","note":"Europe PMC author record matched by affiliation"},{"title":"Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance","journal":"Clin Cancer Res","year":2009,"url":"https://doi.org/10.1158/1078-0432.ccr-08-2904","doi":"10.1158/1078-0432.ccr-08-2904","note":"Europe PMC author record matched by affiliation"}]},{"id":"ofer-merin","kind":"person","name":"Ofer Merin","aka":[],"tldr":"Cardiac surgeon and former IDF field hospital commander who serves as Director General of Shaare Zedek Medical Center in Jerusalem.","summary":"Ofer Merin is Director General of Shaare Zedek Medical Center, a major Jerusalem teaching hospital that was the first in Israel to integrate oncology and palliative medicine services. A cardiothoracic surgeon, he previously commanded the Israel Defense Forces field hospital deployed to international disasters. His role is recorded in the public record for the institution.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.szmc.org.il/eng/"}],"tags":["leadership","hospital management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["shaare-zedek"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director General","institutionId":"shaare-zedek","specialisms":["Cardiothoracic surgery","Hospital leadership","Disaster medicine"],"profiles":[{"label":"Institution profile","url":"https://www.szmc.org.il/eng/"}],"papers":[{"title":"Ethical and clinical dilemmas in patients with head and neck tumors visiting a field hospital in the Philippines","journal":"American Journal of Disaster Medicine","year":2014,"doi":"10.5055/ajdm.2014.0172"}],"orcid":"0000-0002-1090-9416"},{"id":"olena-yefimenko","kind":"person","name":"Olena Yefimenko","aka":[],"tldr":"Olena Yefimenko represents National Cancer Institute of Ukraine in the Organisation of European Cancer Institutes, which lists the organisation among its associate members in Ukraine.","summary":"Olena Yefimenko is listed by the Organisation of European Cancer Institutes (OECI) as the representative of National Cancer Institute of Ukraine, its associate member in Ukraine. OnCo records the name from the OECI membership list so that the organisation's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the organisation's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"National Cancer Institute of Ukraine website","url":"https://unci.org.ua/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["nci-ukraine"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of National Cancer Institute of Ukraine to the Organisation of European Cancer Institutes","institutionId":"nci-ukraine","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"National Cancer Institute of Ukraine website","url":"https://unci.org.ua/"}],"papers":[]},{"id":"olivier-delattre","kind":"person","name":"Olivier Delattre","aka":[],"tldr":"Olivier Delattre discovered the EWS-FLI1 fusion that defines Ewing sarcoma.","summary":"Olivier Delattre is Director of the Research Center at Institut Curie in Paris and Head of Genetics and Biology of Cancers. His specialisms are paediatric sarcoma, Ewing sarcoma genetics and cancer genomics. He identified the EWSR1-FLI1 gene fusion that defines Ewing sarcoma in 1992, reported in Nature as a gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. He has since led paediatric cancer genomics and now directs the Institut Curie research centre. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Delattre%20O%5BAuthor%5D%20Ewing"}],"tags":[],"related":[],"cancers":["sarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["institut-curie"],"pathways":[],"terms":["gene-fusion"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Research Center, Institut Curie; Head, Genetics and Biology of Cancers","institutionId":"institut-curie","specialisms":["Paediatric sarcoma","Ewing sarcoma genetics","Cancer genomics"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Delattre%20O%5BAuthor%5D%20Ewing"}],"papers":[{"title":"Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours","journal":"Nature","year":1992,"doi":"10.1038/359162a0"}]},{"id":"olivier-chinot","kind":"person","name":"Olivier L. Chinot","aka":[],"tldr":"Marseille neuro-oncologist who was lead author of AVAglio, the trial that showed adding bevacizumab to standard glioblastoma treatment delays progression but does not lengthen life.","summary":"Olivier Chinot leads neuro-oncology at Hôpital de la Timone in Marseille. He was first author of the 2014 New England Journal of Medicine report of AVAglio, the phase 3 trial in which bevacizumab added to radiotherapy and temozolomide improved progression-free survival but not overall survival in newly diagnosed glioblastoma, a result echoed by the parallel RTOG 0825 trial and which limited the drug's role in the disease.","asOf":"2026-09-18","links":[],"tags":["brain","trialist"],"related":[],"cancers":["glioblastoma","brain-tumours"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ap-hm-timone"],"pathways":[],"terms":[],"trials":["avaglio"],"people":[],"bottlenecks":[],"keyPapers":["paper-olivier-chinot-n-engl-j-med-2014","paper-olivier-chinot-nat-rev-clin-oncol-2021","paper-olivier-chinot-cancer-treat-rev-2020"],"journals":[],"dependsOn":[],"notes":[],"role":"Neuro-oncologist, Aix-Marseille University and Hôpital de la Timone","institutionId":"ap-hm-timone","specialisms":["Glioblastoma","Anti-angiogenic therapy","Neuro-oncology trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chinot%5BAuthor%5D"}],"papers":[{"title":"Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma","journal":"New England Journal of Medicine","year":2014,"url":"https://doi.org/10.1056/nejmoa1308345","doi":"10.1056/nejmoa1308345","note":"Europe PMC author record matched by affiliation (Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille); 1936 citations on Europe PMC."},{"title":"EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood","journal":"Nature Reviews Clinical Oncology","year":2021,"url":"https://doi.org/10.1038/s41571-020-00447-z","doi":"10.1038/s41571-020-00447-z","note":"Europe PMC author record matched by affiliation (Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille); 1583 citations on Europe PMC."},{"title":"Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook","journal":"Cancer treatment reviews","year":2020,"url":"https://doi.org/10.1016/j.ctrv.2020.102017","doi":"10.1016/j.ctrv.2020.102017","note":"Europe PMC author record matched by affiliation (Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille); 933 citations on Europe PMC."}],"orcid":"0000-0001-6317-9691"},{"id":"oscar-arrieta-rodriguez","kind":"person","name":"Óscar Gerardo Arrieta Rodríguez","aka":[],"tldr":"Medical oncologist specialising in lung cancer who directs Mexico's national cancer institute, INCan, in Mexico City.","summary":"Óscar Gerardo Arrieta Rodríguez is Director General of the Instituto Nacional de Cancerología (INCan), Mexico's national cancer institute and one of the country's National Institutes of Health. He is a medical oncologist and researcher with a longstanding interest in translational research in thoracic oncology, and he founded and led INCan's Thoracic Oncology Unit before his appointment. He was designated Director General in 2023 for the 2023 to 2028 term and was named in that role in a Ministry of Health press release marking the institute's 79th anniversary in November 2025.","asOf":"2026-09-10","links":[{"label":"Source: Mexican Ministry of Health press release, November 2025","url":"https://www.gob.mx/salud/prensa/225-instituto-nacional-de-cancerologia-cumple-79-anos-con-avances-tecnologicos-y-mayor-capacidad-de-atencion"}],"tags":["leadership","clinician-scientist","thoracic-oncology"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["incan-mexico"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director General of the Instituto Nacional de Cancerología (INCan)","institutionId":"incan-mexico","specialisms":["Medical oncology","Thoracic oncology","Translational research"],"profiles":[{"label":"Institution directory","url":"https://incan.salud.gob.mx/directorio/direccion-general"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Arrieta+O%5BAuthor%5D+AND+Cancerologia"}],"papers":[]},{"id":"owen-witte","kind":"person","name":"Owen N. Witte","aka":[],"tldr":"Discovered the BCR-ABL kinase activity that imatinib blocks and now hunts for new prostate cancer targets.","summary":"Owen Witte is University Professor and Founding Director Emeritus of the Broad Stem Cell Research Center at UCLA, within the UCLA Jonsson Comprehensive Cancer Center. A molecular biologist specialising in prostate cancer biology and kinase signalling, he identified the tyrosine kinase activity of the BCR-ABL oncoprotein, the basis of imatinib. His papers include the Cell report that an alteration of the human c-abl protein in K562 leukaemia cells unmasks associated tyrosine kinase activity and a Science study reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage. His laboratory now defines prostate cancer lineage plasticity and hunts for immunotherapy targets such as PSCA and STEAP1, alongside PSMA and the androgen receptor.","asOf":"2026-09-08","links":[{"label":"UCLA profile","url":"https://www.uclahealth.org/providers?q=Owen%20N.%20Witte"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Witte%20ON%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Owen%20N.%20Witte"}],"tags":[],"related":[],"cancers":["prostate","cll"],"sections":[],"technologies":[],"targets":["psma","androgen-receptor","bcr-abl","steap1"],"drugs":["imatinib"],"companies":[],"institutions":["ucla-jonsson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"University Professor; Founding Director Emeritus, Broad Stem Cell Research Center, UCLA","institutionId":"ucla-jonsson","specialisms":["Prostate cancer biology","Kinase signalling","Immunotherapy targets"],"profiles":[{"label":"UCLA profile","url":"https://www.uclahealth.org/providers?q=Owen%20N.%20Witte"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Witte%20ON%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Owen%20N.%20Witte"}],"papers":[{"title":"An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity","journal":"Cell","year":1984,"url":"https://doi.org/10.1016/0092-8674(84)90438-0","doi":"10.1016/0092-8674(84)90438-0"},{"title":"Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage","journal":"Science","year":2018,"url":"https://doi.org/10.1126/science.aat5749","doi":"10.1126/science.aat5749"}]},{"id":"owen-sansom","kind":"person","name":"Owen Sansom","aka":[],"tldr":"Glasgow cancer biologist who directs the CRUK Scotland Institute and is Scientific Director of the CRUK Scotland Centre, known for mouse models of colorectal and pancreatic cancer.","summary":"Prof. Owen Sansom is Scientific Director of the CRUK Scotland Centre and Director of the Cancer Research UK Scotland Institute (formerly the Beatson Institute) in Glasgow. His laboratory uses genetically engineered mouse models to dissect Wnt/APC signalling and tumour initiation in the intestine and pancreas, informing prevention and therapy strategies. He is a Fellow of the Royal Society of Edinburgh.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.crukscotlandcentre.ac.uk/about-us/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sansom+OJ%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","colorectal cancer","pancreatic cancer"],"related":[],"cancers":["colorectal","pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["beatson-glasgow"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Scientific Director, CRUK Scotland Centre","institutionId":"beatson-glasgow","specialisms":["Colorectal cancer biology","Pancreatic cancer","Wnt signalling"],"profiles":[{"label":"Institution profile","url":"https://www.crukscotlandcentre.ac.uk/about-us/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sansom+OJ%5BAuthor%5D"}],"papers":[{"title":"Epithelial NOTCH Signaling Rewires the Tumor Microenvironment of Colorectal Cancer to Drive Poor-Prognosis Subtypes and Metastasis","journal":"Cancer Cell","year":2019,"doi":"10.1016/j.ccell.2019.08.003"},{"title":"Reserve stem cells: Differentiated cells reprogram to fuel repair, metaplasia, and neoplasia in the adult gastrointestinal tract","journal":"Science Signaling","year":2015,"doi":"10.1126/scisignal.aaa7540"},{"title":"mTORC1-mediated translational elongation limits intestinal tumour initiation and growth","journal":"Nature","year":2014,"doi":"10.1038/nature13896"}],"orcid":"0000-0001-9540-3010"},{"id":"oystein-maeland","kind":"person","name":"Øystein Mæland","aka":[],"tldr":"Øystein Mæland represents Akershus University Hospital in the Organisation of European Cancer Institutes, which lists the centre among its members in Norway.","summary":"Øystein Mæland is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Akershus University Hospital, its full member in Norway. OnCo records the name from the OECI membership list so that the centre's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the institution's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Akershus University Hospital website","url":"https://www.ahus.no"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["akershus-university-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Akershus University Hospital to the Organisation of European Cancer Institutes","institutionId":"akershus-university-hospital","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Akershus University Hospital website","url":"https://www.ahus.no"}],"papers":[]},{"id":"paa-kwesi-baidoo","kind":"person","name":"Paa Kwesi Baidoo","aka":[],"tldr":"Physician who is Chief Executive Officer of Komfo Anokye Teaching Hospital in Kumasi, the main teaching and referral hospital for northern and central Ghana.","summary":"Dr (Med) Paa Kwesi Baidoo is Chief Executive Officer of Komfo Anokye Teaching Hospital (KATH) in Kumasi, Ghana. The hospital's management page lists him at the head of a management team that includes Medical Director Prof. Yaw Ampem Amoako, Director of Nursing and Midwifery Services Comfort Asoogo, Director of Finance Elvis Kusi, Director of Pharmacy Kwaku Sarfo and Director of Administration George Fuseini. The hospital describes the team as providing strategic leadership, operational oversight and administrative direction. No appointment date is given on the page.","asOf":"2026-09-10","links":[{"label":"Source: Komfo Anokye Teaching Hospital management page","url":"https://kath.gov.gh/management/"}],"tags":["leadership","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["komfo-anokye-teaching-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive Officer, Komfo Anokye Teaching Hospital","institutionId":"komfo-anokye-teaching-hospital","specialisms":["Hospital management","Medicine","Health service leadership"],"profiles":[{"label":"KATH management page","url":"https://kath.gov.gh/management/"}],"papers":[]},{"id":"padmanee-sharma","kind":"person","name":"Padmanee Sharma","aka":[],"tldr":"Runs the platform that studies patients' tumours before and after immunotherapy to learn why checkpoint drugs work or fail.","summary":"Padmanee Sharma is Professor of Genitourinary Medical Oncology and Immunology and Scientific Director of the Immunotherapy Platform at MD Anderson Cancer Center. A medical oncologist and immunologist, she pioneered pre-surgical immunotherapy trials that study drug mechanisms in human tissue, examining patients' tumours before and after treatment to learn why checkpoint drugs work or fail. She co-leads the Parker Institute site at MD Anderson and the immunotherapy platform with James Allison, with work on ICOS, VISTA and resistance to checkpoint blockade. Her papers include a Cell review of primary, adaptive and acquired resistance to cancer immunotherapy and a Science perspective on the future of immune checkpoint therapy, spanning CTLA-4 and PD-1 in prostate, bladder and kidney cancer.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Padmanee_Sharma","links":[{"label":"MD Anderson faculty","url":"https://faculty.mdanderson.org/search?q=Padmanee%20Sharma"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sharma%20P%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Padmanee%20Sharma"}],"tags":[],"related":[],"cancers":["prostate","urothelial","rcc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["ctla4","pd1"],"drugs":[],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Genitourinary Medical Oncology and Immunology; Scientific Director, Immunotherapy Platform, MD Anderson","institutionId":"md-anderson","specialisms":["Immunotherapy","Genitourinary oncology","Translational immunology"],"profiles":[{"label":"MD Anderson faculty","url":"https://faculty.mdanderson.org/search?q=Padmanee%20Sharma"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sharma%20P%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Padmanee%20Sharma"}],"papers":[{"title":"Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy","journal":"Cell","year":2017,"url":"https://doi.org/10.1016/j.cell.2017.01.017","doi":"10.1016/j.cell.2017.01.017"},{"title":"The future of immune checkpoint therapy","journal":"Science","year":2015,"url":"https://doi.org/10.1126/science.aaa8172","doi":"10.1126/science.aaa8172"},{"title":"Hodi 2010: ipilimumab, the first checkpoint inhibitor, extends survival in metastatic melanoma","journal":"New England Journal of Medicine","year":2010,"url":"https://doi.org/10.1056/NEJMoa1003466","doi":"10.1056/NEJMoa1003466"},{"title":"Leach, Krummel and Allison: releasing the CTLA-4 brake makes mice reject tumours","journal":"Science","year":1996,"url":"https://doi.org/10.1126/science.271.5256.1734","doi":"10.1126/science.271.5256.1734"}]},{"id":"pamela-buchwald","kind":"person","name":"Pamela Buchwald","aka":[],"tldr":"Pamela Buchwald represents Skåne University Hospital / Lund University Cancer Centre in the Organisation of European Cancer Institutes, which lists the centre among its members in Sweden.","summary":"Pamela Buchwald is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Skåne University Hospital / Lund University Cancer Centre, its full member in Sweden. OnCo records the name from the OECI membership list so that the centre's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the institution's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Skåne University Hospital / Lund University Cancer Centre website","url":"https://www.skane.se/en/skane-university-hospital"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["lund-skane"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Skåne University Hospital / Lund University Cancer Centre to the Organisation of European Cancer Institutes","institutionId":"lund-skane","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Skåne University Hospital / Lund University Cancer Centre website","url":"https://www.skane.se/en/skane-university-hospital"}],"papers":[{"title":"Multisocietal European consensus on the terminology, diagnosis, and management of patients with synchronous colorectal cancer and liver metastases: an E-AHPBA consensus in partnership with ESSO, ESCP, ESGAR, and CIRSE","journal":"Br J Surg","year":2023,"url":"https://doi.org/10.1093/bjs/znad124","doi":"10.1093/bjs/znad124","note":"Europe PMC author record matched by affiliation"},{"title":"Laparoscopic Lavage vs Primary Resection for Acute Perforated Diverticulitis: Long-term Outcomes From the Scandinavian Diverticulitis (SCANDIV) Randomized Clinical Trial","journal":"JAMA Surg","year":2021,"url":"https://doi.org/10.1001/jamasurg.2020.5618","doi":"10.1001/jamasurg.2020.5618","note":"Europe PMC author record matched by affiliation"},{"title":"High Risk of Low Anterior Resection Syndrome in Long-term Follow-up After Anastomotic Leakage in Anterior Resection for Rectal Cancer","journal":"Dis Colon Rectum","year":2022,"url":"https://doi.org/10.1097/dcr.0000000000002334","doi":"10.1097/dcr.0000000000002334","note":"Europe PMC author record matched by affiliation"}]},{"id":"pamela-kearns","kind":"person","name":"Pamela Kearns","aka":[],"tldr":"Paediatric oncologist and emeritus professor at the University of Birmingham who presides over ITCC, the European consortium for early-phase trials in childhood cancer.","summary":"Professor Pamela Kearns is President of Innovative Therapies for Children with Cancer (ITCC), the European academic consortium established in 2003 as a not-for-profit organisation under French law to develop new medicines for children and adolescents with cancer; it was recognised as a European Category 1 Network for Paediatric Research by the European Medicines Agency's Enpr-EMA in January 2011. She is Emeritus Professor of Clinical Paediatric Oncology at the University of Birmingham. The consortium's governance page also lists Professor Gilles Vassal (University Paris Saclay and Gustave Roussy) as Chair of the Industry Strategy Committee and Carole Lecinse as Director of Operations, with disease committees co-chaired by clinicians from Milan, Utrecht, Heidelberg, Frankfurt, San Francisco and Copenhagen.","asOf":"2026-09-10","links":[{"label":"Source: ITCC governance page","url":"https://www.itcc-consortium.org/governance"}],"tags":["leadership","professional-society","clinician-scientist"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["itcc"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["gilles-vassal"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President, Innovative Therapies for Children with Cancer (ITCC)","institutionId":"itcc","specialisms":["Paediatric oncology","Early-phase clinical trials","Paediatric drug development"],"profiles":[{"label":"ITCC governance page","url":"https://www.itcc-consortium.org/governance"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kearns+PR%5BAuthor%5D"}],"papers":[{"title":"Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia: Results of the CA180-018 Phase I Dose-Escalation Study of the Innovative Therapies for Children With Cancer Consortium","journal":"Journal of Clinical Oncology","year":2013,"doi":"10.1200/jco.2012.46.8280"},{"title":"Severity of COVID-19 in children with cancer: Report from the United Kingdom Paediatric Coronavirus Cancer Monitoring Project","journal":"British Journal of Cancer","year":2020,"doi":"10.1038/s41416-020-01181-0"},{"title":"New drug development in childhood cancer","journal":"Current Opinion in Pediatrics","year":2014,"doi":"10.1097/mop.0000000000000054"}]},{"id":"pamela-ohashi","kind":"person","name":"Pamela S. Ohashi","aka":[],"tldr":"Immunologist who built Canada's TIL therapy programme and defined T-cell tolerance mechanisms.","summary":"Pamela S. Ohashi is Director of the Tumour Immunotherapy Program and Co-Director of the Campbell Family Institute for Breast Cancer Research at the Princess Margaret Cancer Centre. She is an immunologist known for defining mechanisms of T-cell tolerance and for building Canada's tumour-infiltrating lymphocyte therapy programme. Her selected paper reports the ablation of tolerance and induction of diabetes by virus infection in viral antigen transgenic mice. She now runs TIL trials in melanoma and other solid tumours and studies T-cell activation thresholds.","asOf":"2026-09-08","links":[{"label":"UHN profile","url":"https://www.uhnresearch.ca/researcher/pamela-s-ohashi"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ohashi%20PS%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["melanoma"],"sections":[],"technologies":["til-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":["princess-margaret"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Tumour Immunotherapy Program; Co-Director, Campbell Family Institute for Breast Cancer Research","institutionId":"princess-margaret","specialisms":["T-cell tolerance","TIL therapy","Tumour immunology"],"profiles":[{"label":"UHN profile","url":"https://www.uhnresearch.ca/researcher/pamela-s-ohashi"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ohashi%20PS%5BAuthor%5D"}],"papers":[{"title":"Ablation of tolerance and induction of diabetes by virus infection in viral antigen transgenic mice","journal":"Cell","year":1991}],"orcid":"0000-0003-2915-9317"},{"id":"panagiotis-klirides","kind":"person","name":"Panagiotis Klirides","aka":[],"tldr":"Panagiotis Klirides represents Saint Savvas General Oncology Hospital of Athens in the Organisation of European Cancer Institutes, which lists the centre among its members in Greece.","summary":"Panagiotis Klirides is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Saint Savvas General Oncology Hospital of Athens, its full member in Greece. OnCo records the name from the OECI membership list so that the centre's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the institution's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Saint Savvas General Oncology Hospital of Athens website","url":"https://www.agsavvas-hosp.gr"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["saint-savvas-athens"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Saint Savvas General Oncology Hospital of Athens to the Organisation of European Cancer Institutes","institutionId":"saint-savvas-athens","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Saint Savvas General Oncology Hospital of Athens website","url":"https://www.agsavvas-hosp.gr"}],"papers":[]},{"id":"chaturvedi-pankaj","kind":"person","name":"Pankaj Chaturvedi","aka":["pankaj-chaturvedi"],"tldr":"A surgeon and public-health campaigner whose work links oral cancer to tobacco and drives prevention policy in India.","summary":"Pankaj Chaturvedi is a head and neck surgical oncologist and Director of the Centre for Cancer Epidemiology at the Tata Memorial Centre in Mumbai. He combines surgery with epidemiology and public-health advocacy, and his work linking oral cancer to tobacco and areca nut drives prevention policy in India. His publications include a prospective study of ultrasound-guided fine-needle aspiration and sentinel node biopsy in staging early oral cancer, an analysis of optimum surgical margins in squamous cell carcinoma of the oral tongue, and a study of lymphatic metastasis in relation to the submandibular gland in oral cavity cancer. His interests are head and neck surgery, tobacco control, cancer prevention and epidemiology. He is Director of the Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), the research and development wing of Tata Memorial Centre in Navi Mumbai, and a leading advocate for tobacco regulation and cancer prevention policy in India.","asOf":"2026-09-08","links":[{"label":"Tata Memorial Centre","url":"https://tmc.gov.in"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chaturvedi%20P%5BAuthor%5D%20Tata%20Memorial%20oral%20cancer%20tobacco"},{"label":"ACTREC","url":"https://actrec.gov.in/"}],"tags":["leadership","clinician-scientist","head and neck cancer","cancer prevention"],"related":[],"cancers":["head-and-neck"],"sections":[],"technologies":["chemoprevention"],"targets":[],"drugs":[],"companies":[],"institutions":["tata-memorial","actrec"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["head-and-neck-journal","oral-oncology"],"dependsOn":[],"notes":[],"role":"Head and neck surgical oncologist; Director, Centre for Cancer Epidemiology, Tata Memorial Centre","institutionId":"tata-memorial","specialisms":["Head and neck surgery","Tobacco control","Cancer prevention","Epidemiology","Oral cancer"],"profiles":[{"label":"Tata Memorial Centre","url":"https://tmc.gov.in"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chaturvedi%20P%5BAuthor%5D%20Tata%20Memorial%20oral%20cancer%20tobacco"},{"label":"ACTREC","url":"https://actrec.gov.in/"}],"papers":[{"title":"Prospective study of ultrasound‐guided fine‐needle aspiration cytology and sentinel node biopsy in the staging of clinically negative T1 and T2 oral cancer","journal":"Head & Neck","year":2014,"doi":"10.1002/hed.23787"},{"title":"Optimum surgical margins in squamous cell carcinoma of the oral tongue: Is the current definition adequate?","journal":"Oral Oncology","year":2020,"doi":"10.1016/j.oraloncology.2020.104938"},{"title":"Prospective study of the pattern of lymphatic metastasis in relation to the submandibular gland in patients with carcinoma of the oral cavity","journal":"Head & Neck","year":2016,"doi":"10.1002/hed.24508"},{"title":"Head and neck cancer burden in India: an analysis from published data of 37 population-based cancer registries","journal":"ecancermedicalscience","year":2023,"doi":"10.3332/ecancer.2023.1603"},{"title":"Systematic review and meta-analysis of randomized controlled trials comparing elective neck dissection versus sentinel lymph node biopsy in early-stage clinically node-negative oral and/or oropharyngeal squamous cell carcinoma: Evidence-base for practice and implications for research","journal":"Oral Oncology","year":2022,"doi":"10.1016/j.oraloncology.2021.105642"},{"title":"Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial","journal":"Journal of Clinical Oncology","year":2018,"doi":"10.1200/jco.2017.74.9457"}],"orcid":"0000-0002-3520-1342"},{"id":"panos-ergatoudes","kind":"person","name":"Panos Ergatoudes","aka":[],"tldr":"Panos Ergatoudes represents Bank of Cyprus Oncology Centre in the Organisation of European Cancer Institutes, which lists the centre among its members in Cyprus.","summary":"Panos Ergatoudes is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Bank of Cyprus Oncology Centre, its full member in Cyprus. OnCo records the name from the OECI membership list so that the centre's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the institution's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Bank of Cyprus Oncology Centre website","url":"https://www.bococ.org.cy"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["bank-of-cyprus-oncology-centre"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Bank of Cyprus Oncology Centre to the Organisation of European Cancer Institutes","institutionId":"bank-of-cyprus-oncology-centre","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Bank of Cyprus Oncology Centre website","url":"https://www.bococ.org.cy"}],"papers":[]},{"id":"paola-anna-erba","kind":"person","name":"Paola Anna Erba","aka":[],"tldr":"Italian nuclear medicine physician serving as President of the European Association of Nuclear Medicine.","summary":"Paola Anna Erba is President of the European Association of Nuclear Medicine (EANM) for the 2025-2026 term. She is a nuclear medicine physician and academic in Italy whose research covers molecular imaging, radioligand therapy and infection and inflammation imaging. As EANM President she leads the society's congress, guidelines and advocacy for nuclear medicine in oncology.","asOf":"2026-09-10","links":[{"label":"Society page","url":"https://eanm.org/the-eanm-community/organisation/board/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Erba+PA%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","nuclear medicine","theranostics"],"related":[],"cancers":["neuroendocrine","prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["eanm"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["radiation-oncology"],"dependsOn":[],"notes":[],"role":"President (2025-2026)","institutionId":"eanm","specialisms":["Nuclear medicine","Theranostics","Molecular imaging"],"profiles":[{"label":"Society page","url":"https://eanm.org/the-eanm-community/organisation/board/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Erba+PA%5BAuthor%5D"}],"papers":[{"title":"[18F]Choline PET/CT and stereotactic body radiotherapy on treatment decision making of oligometastatic prostate cancer patients: preliminary results","journal":"Radiation Oncology","year":2016,"doi":"10.1186/s13014-016-0586-x"},{"title":"Artificial intelligence and hybrid imaging: the best match for personalized medicine in oncology","journal":"European Journal of Hybrid Imaging","year":2020,"doi":"10.1186/s41824-020-00094-8"},{"title":"Differentiated Thyroid Cancer: A New Perspective with Radiolabeled Somatostatin Analogues for Imaging and Treatment of Patients","journal":"Thyroid®","year":2014,"doi":"10.1089/thy.2013.0225"}]},{"id":"paolo-ascierto","kind":"person","name":"Paolo A. Ascierto","aka":[],"tldr":"Italian melanoma oncologist who co-led CheckMate 238, CheckMate 067 and the COLUMBUS BRAF/MEK trial.","summary":"Paolo Ascierto has been a lead investigator on most of the pivotal melanoma trials of the past decade, including CheckMate 238 (adjuvant nivolumab), CheckMate 067, COLUMBUS (encorafenib plus binimetinib) and the CheckMate 915 and RELATIVITY programmes. He founded the Melanoma Bridge and Immunotherapy Bridge meetings and leads one of Europe's largest melanoma units in Naples.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ascierto%20PA%5BAuthor%5D%20melanoma"}],"tags":["melanoma","immunotherapy","italy"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":["checkpoint-inhibitor","kinase-inhibitors"],"targets":["pd1","braf"],"drugs":["nivolumab","ipilimumab","encorafenib"],"companies":[],"institutions":["pascale-naples"],"pathways":[],"terms":[],"trials":["columbus","checkmate-067"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples","institutionId":"pascale-naples","specialisms":["Melanoma","Immunotherapy","Adjuvant therapy","Combination strategies"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ascierto%20PA%5BAuthor%5D%20melanoma"}],"papers":[{"title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma (CheckMate 238): 4-year results","journal":"Lancet Oncology","year":2020,"doi":"10.1016/S1470-2045(20)30494-0"},{"title":"Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS)","journal":"Lancet Oncology","year":2018,"doi":"10.1016/S1470-2045(18)30142-6"}]},{"id":"paolo-veronesi","kind":"person","name":"Paolo Veronesi","aka":[],"tldr":"Breast surgeon leading the IEO programme founded by Umberto Veronesi, pioneer of breast conservation.","summary":"Paolo Veronesi is Director of Breast Surgery at IEO, the European Institute of Oncology, in Milan and Professor at the University of Milan. His specialisms are breast surgery, sentinel node biopsy and surgical de-escalation. He leads the programme founded by Umberto Veronesi, the pioneer of breast conservation, continuing the institute's tradition of de-escalation from quadrantectomy to sentinel node biopsy and axillary sparing. His papers include the long-term follow-up of the IBCSG 23-01 trial of axillary dissection versus no dissection in patients with sentinel-node micrometastases, a historical perspective on axillary surgery in breast cancer, and a ten-year follow-up of sentinel node biopsy after neoadjuvant treatment. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Veronesi%20P%5BAuthor%5D%20breast%20sentinel"}],"tags":[],"related":[],"cancers":["tnbc","breast-hr-positive"],"sections":[],"technologies":["sentinel-node"],"targets":[],"drugs":[],"companies":[],"institutions":["ieo-milan"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["european-journal-of-surgical-oncology","seminars-in-oncology"],"dependsOn":[],"notes":[],"role":"Director, Breast Surgery, IEO; Professor, University of Milan","institutionId":"ieo-milan","specialisms":["Breast surgery","Sentinel node biopsy","Surgical de-escalation"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Veronesi%20P%5BAuthor%5D%20breast%20sentinel"}],"papers":[{"title":"Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial","journal":"The Lancet Oncology","year":2018,"doi":"10.1016/s1470-2045(18)30380-2"},{"title":"Axillary surgery in breast cancer: An updated historical perspective","journal":"Seminars in Oncology","year":2020,"doi":"10.1053/j.seminoncol.2020.09.001"},{"title":"Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten-year follow-up","journal":"European Journal of Surgical Oncology","year":2021,"doi":"10.1016/j.ejso.2020.10.014"}]},{"id":"paris-ann-ingledew","kind":"person","name":"Paris-Ann Ingledew","aka":[],"tldr":"Radiation oncologist and educator who is the executive lead for BC Cancer, the provincial cancer agency of British Columbia, Canada.","summary":"Paris-Ann Ingledew is Executive Vice President and Chief Medical Officer of BC Cancer, the provincial cancer programme within the Provincial Health Services Authority of British Columbia. A radiation oncologist, she has held leadership roles across BC Cancer's regional centres, including department head of radiation oncology at BC Cancer Vancouver, and is past president of BC Cancer's Medical Dental Staff Association. She holds a master's degree in health professions education, is a clinical professor at the University of British Columbia and chairs the Royal College specialty committee for radiation oncology.","asOf":"2026-09-10","links":[{"label":"Source: PHSA executive leadership page","url":"http://www.phsa.ca/about/leadership/phsa-executive"}],"tags":["leadership","clinician-scientist","radiation-oncology"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["bc-cancer"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["journal-of-cancer-education","supportive-care-in-cancer"],"dependsOn":[],"notes":[],"role":"Executive Vice President and Chief Medical Officer, BC Cancer","institutionId":"bc-cancer","specialisms":["Radiation oncology","Medical education","Health leadership"],"profiles":[{"label":"PHSA executive team","url":"http://www.phsa.ca/about/leadership/phsa-executive"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ingledew+PA%5BAuthor%5D"}],"papers":[{"title":"Peering into the Deep: Characterizing the Internet Search Patterns of Patients with Gynecologic Cancers","journal":"Journal of Cancer Education","year":2017,"doi":"10.1007/s13187-016-1002-9"},{"title":"Assessment of Lung Cancer YouTube Videos for Patient Education","journal":"Journal of Cancer Education","year":2023,"doi":"10.1007/s13187-023-02332-6"},{"title":"Evaluating the childcare needs of cancer patients undergoing radiation therapy","journal":"Supportive Care in Cancer","year":2023,"doi":"10.1007/s00520-023-07923-z"}]},{"id":"basu-partha","kind":"person","name":"Partha Basu","aka":[],"tldr":"Leads IARC's early detection and prevention work, central to the WHO cervical cancer elimination strategy.","summary":"Partha Basu is Head of the Early Detection, Prevention and Infections Branch at the International Agency for Research on Cancer. A gynaecologic oncologist, he leads IARC's early detection and prevention work, which is central to the WHO cervical cancer elimination strategy, running implementation research on HPV vaccination and screening, particularly in low- and middle-income countries. His publications include a report on HPV vaccination and cervical screening across Asian National Cancer Centers Alliance member countries, a description of IARC's role in strengthening cancer prevention and early detection, and an argument for gender-neutral HPV vaccination. His interests include HPV DNA testing and self-sampling in low-resource settings.","asOf":"2026-09-08","links":[{"label":"IARC","url":"https://www.iarc.who.int"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Basu%20P%5BAuthor%5D%20IARC%20cervical%20screening"}],"tags":[],"related":[],"cancers":["cervical"],"sections":[],"technologies":["hpv-vaccine","hpv-testing"],"targets":[],"drugs":[],"companies":[],"institutions":["iarc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["jnci-monographs"],"dependsOn":[],"notes":[],"role":"Head, Early Detection, Prevention and Infections Branch, IARC","institutionId":"iarc","specialisms":["Cervical cancer screening","HPV","Early detection in low-resource settings","Implementation research"],"profiles":[{"label":"IARC","url":"https://www.iarc.who.int"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Basu%20P%5BAuthor%5D%20IARC%20cervical%20screening"}],"papers":[{"title":"Towards elimination of cervical cancer – human papillomavirus (HPV) vaccination and cervical cancer screening in Asian National Cancer Centers Alliance (ANCCA) member countries","journal":"The Lancet Regional Health - Western Pacific","year":2023,"doi":"10.1016/j.lanwpc.2023.100860"},{"title":"From evidence to action: the IARC’s role in strengthening cancer prevention and early detection","journal":"JNCI Monographs","year":2026,"doi":"10.1093/jncimonographs/lgag001"},{"title":"Building resilient cervical cancer prevention through gender-neutral HPV vaccination","journal":"eLife","year":2023,"doi":"10.7554/elife.85735"},{"title":"Vaccine efficacy against persistent HPV 16/18 infection at 10 years after one, two and three doses of quadrivalent HPV vaccine in girls in India","journal":"Lancet Oncology","year":2021,"url":"https://doi.org/10.1016/S1470-2045(21)00453-8","doi":"10.1016/S1470-2045(21)00453-8"}]},{"id":"pascal-hammel","kind":"person","name":"Pascal Hammel","aka":[],"tldr":"Pascal Hammel represents AP-HP Paris-Saclay University Hospitals Cancer Institute in the Organisation of European Cancer Institutes, which lists the centre among its full members in France.","summary":"Pascal Hammel is listed by the Organisation of European Cancer Institutes (OECI) as the representative of AP-HP Paris-Saclay University Hospitals Cancer Institute, its full member in France. OnCo records the name from the OECI membership list so that the centre's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the institution's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"AP-HP Paris-Saclay University Hospitals Cancer Institute website","url":"https://institutducancer-hopitaux-universiteparissaclay.aphp.fr/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["aphp-paris-saclay-cancer-institute"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of AP-HP Paris-Saclay University Hospitals Cancer Institute to the Organisation of European Cancer Institutes","institutionId":"aphp-paris-saclay-cancer-institute","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"AP-HP Paris-Saclay University Hospitals Cancer Institute website","url":"https://institutducancer-hopitaux-universiteparissaclay.aphp.fr/"}],"papers":[{"title":"FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer","journal":"N Engl J Med","year":2018,"url":"https://doi.org/10.1056/nejmoa1809775","doi":"10.1056/nejmoa1809775","note":"Europe PMC author record matched by affiliation"},{"title":"Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial","journal":"JAMA Oncol","year":2022,"url":"https://doi.org/10.1001/jamaoncol.2022.3829","doi":"10.1001/jamaoncol.2022.3829","note":"Europe PMC author record matched by affiliation"}]},{"id":"pasi-janne","kind":"person","name":"Pasi A. Jänne","aka":[],"tldr":"Co-discovered EGFR mutations in lung cancer and has led the drug development that followed, from osimertinib to KRAS G12C inhibitors.","summary":"Pasi A. Jänne is Director of the Lowe Center for Thoracic Oncology and the Belfer Center for Applied Cancer Science at Dana-Farber Brigham Cancer Center. He is known for co-discovering in 2004 that EGFR mutations predict response to gefitinib in lung cancer, and for leading the drug development that followed, including FLAURA2 with osimertinib plus chemotherapy and the KRYSTAL-1 adagrasib lung study. His selected papers cover the activating EGFR mutations underlying gefitinib responsiveness, adagrasib in KRAS G12C-mutant lung cancer, and osimertinib with or without chemotherapy in EGFR-mutated lung cancer. He directs Dana-Farber's thoracic oncology centre and studies targeted therapy resistance.","asOf":"2026-09-08","links":[{"label":"Dana-Farber profile","url":"https://www.dana-farber.org/find-a-doctor/pasi-a-janne"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Janne%20PA%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":["egfr","kras"],"drugs":["osimertinib","adagrasib"],"companies":[],"institutions":["dana-farber"],"pathways":[],"terms":[],"trials":["flaura2"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Lowe Center for Thoracic Oncology; Director, Belfer Center for Applied Cancer Science","institutionId":"dana-farber","specialisms":["EGFR-mutant lung cancer","Targeted therapy resistance","KRAS G12C"],"profiles":[{"label":"Dana-Farber profile","url":"https://www.dana-farber.org/find-a-doctor/pasi-a-janne"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Janne%20PA%5BAuthor%5D"}],"papers":[{"title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","journal":"New England Journal of Medicine","year":2004,"url":"https://doi.org/10.1056/NEJMoa040938","doi":"10.1056/NEJMoa040938"},{"title":"Adagrasib in non-small-cell lung cancer harboring a KRAS G12C mutation","journal":"New England Journal of Medicine","year":2022,"url":"https://doi.org/10.1056/NEJMoa2204619","doi":"10.1056/NEJMoa2204619"},{"title":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","journal":"New England Journal of Medicine","year":2023,"url":"https://doi.org/10.1056/NEJMoa2306434","doi":"10.1056/NEJMoa2306434"}]},{"id":"patricia-pautier","kind":"person","name":"Patricia Pautier","aka":[],"tldr":"Paris oncologist who led LMS-04, the trial that showed doxorubicin plus trabectedin lengthens survival in advanced leiomyosarcoma compared with doxorubicin alone.","summary":"Patricia Pautier is a medical oncologist at Gustave Roussy who treats sarcomas and gynaecological cancers. She was first author of the 2022 Lancet Oncology report of the French Sarcoma Group LMS-04 trial, in which doxorubicin plus trabectedin followed by trabectedin maintenance improved progression-free survival compared with doxorubicin alone as first-line treatment for metastatic or unresectable leiomyosarcoma; the 2024 update showed an overall survival gain.","asOf":"2026-09-18","links":[],"tags":["sarcoma","trialist"],"related":[],"cancers":["leiomyosarcoma","extremity-soft-tissue-sarcoma","retroperitoneal-sarcoma","sarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["gustave-roussy"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-lms-04-doxorubicin-trabectedin-lancet-oncol-2022"],"journals":[],"dependsOn":[],"notes":[],"role":"Medical oncologist, Gustave Roussy","institutionId":"gustave-roussy","specialisms":["Leiomyosarcoma","Gynaecological sarcomas","Ovarian cancer"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Pautier%5BAuthor%5D"}],"papers":[{"title":"LMS-04: doxorubicin plus trabectedin followed by trabectedin maintenance versus doxorubicin alone in metastatic leiomyosarcoma","journal":"The Lancet Oncology","year":2022,"url":"https://doi.org/10.1016/S1470-2045(22)00380-1","doi":"10.1016/S1470-2045(22)00380-1"}]},{"id":"patrick-morris","kind":"person","name":"Patrick G. Morris","aka":[],"tldr":"Physician who is Medical Director of the Beaumont RCSI Cancer Centre, the OECI accredited cancer centre on the Beaumont Hospital campus in Dublin.","summary":"Patrick G. Morris (MD, FRCPI) is Medical Director of the Beaumont RCSI Cancer Centre in Dublin, and welcomes visitors to the centre's website in that role. The centre is a partnership of Beaumont Hospital, RCSI University of Medicine and Health Sciences and St Luke's Radiation Oncology Network, and in 2022 received Cancer Centre accreditation from the Organisation of European Cancer Institutes (OECI). Beaumont Hospital itself is led by Chief Executive Anne Coyle. The website did not give an appointment date.","asOf":"2026-09-10","links":[{"label":"Source: Beaumont RCSI Cancer Centre homepage naming the Medical Director","url":"https://beaumontrcsicancercentre.ie/"},{"label":"Source: Beaumont Hospital 'Our People' page (hospital executive)","url":"https://www.beaumont.ie/pages/about-pages/our-people"}],"tags":["leadership","clinician-scientist","comprehensive-cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Medical Director, Beaumont RCSI Cancer Centre, Dublin","institutionId":"beaumont-rcsi-cancer-centre","specialisms":["Medical oncology","Cancer centre leadership"],"profiles":[{"label":"Beaumont RCSI Cancer Centre homepage (Medical Director's welcome)","url":"https://beaumontrcsicancercentre.ie/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Morris+PG%5BAuthor%5D+AND+Dublin"}],"papers":[{"title":"Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast Cancer","journal":"Clinical Breast Cancer","year":2018,"doi":"10.1016/j.clbc.2018.03.010"},{"title":"Emergence of MRSA in positive blood cultures from patients with febrile neutropenia—a cause for concern","journal":"Supportive Care in Cancer","year":2008,"doi":"10.1007/s00520-007-0398-5"},{"title":"Profile of Trastuzumab Deruxtecan in the Management of Patients with HER2-Positive Unresectable or Metastatic Breast Cancer: An Evidence-Based Review","journal":"Breast Cancer: Targets and Therapy","year":2021,"doi":"10.2147/bctt.s245024"}],"orcid":"0000-0002-6055-5273"},{"id":"patrick-hwu","kind":"person","name":"Patrick Hwu","aka":[],"tldr":"Patrick Hwu is an immunotherapy pioneer who trained with Rosenberg and now leads Moffitt.","summary":"Patrick Hwu is President and Chief Executive Officer of Moffitt Cancer Center. He is a tumour immunologist and immunotherapy pioneer who trained with Steven Rosenberg and helped develop tumour-infiltrating lymphocyte and gene-modified T cell therapies at the National Cancer Institute and MD Anderson. His selected paper reviews adoptive cell therapy for melanoma. He became Moffitt's chief executive in 2020 and retains interests in TIL and TCR-T cell therapy for melanoma.","asOf":"2026-09-08","links":[{"label":"Moffitt leadership","url":"https://www.moffitt.org/about-moffitt/leadership/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hwu%20P%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["melanoma"],"sections":[],"technologies":["til-therapy","tcr-t"],"targets":[],"drugs":[],"companies":[],"institutions":["moffitt"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["the-cancer-journal"],"dependsOn":[],"notes":[],"role":"President and Chief Executive Officer","institutionId":"moffitt","specialisms":["Tumour immunology","Adoptive cell therapy","Melanoma"],"profiles":[{"label":"Moffitt leadership","url":"https://www.moffitt.org/about-moffitt/leadership/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hwu%20P%5BAuthor%5D"}],"papers":[{"title":"Adoptive cell therapy for melanoma","journal":"Cancer Journal","year":2012}]},{"id":"patrick-forde","kind":"person","name":"Patrick M. Forde","aka":[],"tldr":"Led CheckMate 816, which established neoadjuvant chemo-immunotherapy for resectable lung cancer.","summary":"Patrick M. Forde is Director of the Thoracic Oncology Clinical Research Program at Johns Hopkins Hospital and the Sidney Kimmel Comprehensive Cancer Center. He is known for pioneering neoadjuvant PD-1 blockade in resectable non-small-cell lung cancer, from a 2018 pilot study to leading the CheckMate 816 phase 3 trial that established neoadjuvant nivolumab plus chemotherapy as a standard. His selected papers report neoadjuvant PD-1 blockade in resectable lung cancer and neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. He also leads mesothelioma trials.","asOf":"2026-09-08","links":[{"label":"Hopkins profile","url":"https://www.hopkinsmedicine.org/profiles/details/patrick-forde"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Forde%20PM%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["nsclc","mesothelioma"],"sections":[],"technologies":[],"targets":["pd1"],"drugs":["nivolumab"],"companies":[],"institutions":["johns-hopkins"],"pathways":[],"terms":[],"trials":["checkmate-816"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Thoracic Oncology Clinical Research Program","institutionId":"johns-hopkins","specialisms":["Neoadjuvant immunotherapy","Lung cancer","Mesothelioma"],"profiles":[{"label":"Hopkins profile","url":"https://www.hopkinsmedicine.org/profiles/details/patrick-forde"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Forde%20PM%5BAuthor%5D"}],"papers":[{"title":"Neoadjuvant PD-1 blockade in resectable lung cancer","journal":"New England Journal of Medicine","year":2018,"url":"https://doi.org/10.1056/NEJMoa1716078","doi":"10.1056/NEJMoa1716078"},{"title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","journal":"New England Journal of Medicine","year":2022,"url":"https://doi.org/10.1056/NEJMoa2202170","doi":"10.1056/NEJMoa2202170"}]},{"id":"patrick-mehlen","kind":"person","name":"Patrick Mehlen","aka":[],"tldr":"Cancer biologist who discovered the dependence-receptor concept and took netrin-1 blockade from bench to clinical trials at Centre Léon Bérard.","summary":"Patrick Mehlen directs fundamental and translational research at Centre Léon Bérard and leads the Cancer Research Center of Lyon (CRCL). His laboratory established the concept of dependence receptors and showed that blocking netrin-1 can inhibit tumour growth, work that led to the anti-netrin-1 antibody now in clinical trials and reported in Nature in 2023.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.centreleonberard.fr/comment-est-organise-le-centre-leon-berard"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mehlen+P%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","cancer biology","drug development"],"related":[],"cancers":["endometrial"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["centre-leon-berard"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director of Fundamental and Translational Research and of the Cancer Research Center of Lyon (CRCL)","institutionId":"centre-leon-berard","specialisms":["Cancer cell biology","Dependence receptors","Netrin-1","Translational research"],"profiles":[{"label":"Institution profile","url":"https://www.centreleonberard.fr/comment-est-organise-le-centre-leon-berard"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mehlen+P%5BAuthor%5D"}],"papers":[{"title":"Netrin-1 blockade inhibits tumour growth and EMT features in endometrial cancer","journal":"Nature","year":2023,"url":"https://doi.org/10.1038/s41586-023-06367-z","doi":"10.1038/s41586-023-06367-z"}],"orcid":"0000-0003-1743-5417"},{"id":"patrick-schoffski","kind":"person","name":"Patrick Schöffski","aka":[],"tldr":"Leuven oncologist who led the trial that showed eribulin lengthens survival in advanced liposarcoma, the basis of the drug's approval for that disease.","summary":"Patrick Schöffski heads general medical oncology at UZ Leuven and chairs the EORTC soft tissue and bone sarcoma group's early-phase work. He was first author of the 2016 Lancet report of the phase 3 trial in which eribulin improved overall survival compared with dacarbazine in previously treated advanced liposarcoma or leiomyosarcoma, with the benefit concentrated in liposarcoma, leading to eribulin's approval for that indication.","asOf":"2026-09-18","wikipedia":"https://en.wikipedia.org/wiki/Patrick_Sch%C3%B6ffski","links":[],"tags":["sarcoma","trialist"],"related":[],"cancers":["liposarcoma","leiomyosarcoma","sarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["uz-leuven"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-eribulin-liposarcoma-schoffski-lancet-2016"],"journals":[],"dependsOn":[],"notes":[],"role":"Head of General Medical Oncology, UZ Leuven and Leuven Cancer Institute","institutionId":"uz-leuven","specialisms":["Soft tissue sarcoma","Early-phase drug development","Rare cancers"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sch%C3%B6ffski%5BAuthor%5D"}],"papers":[{"title":"Eribulin versus dacarbazine in previously treated advanced liposarcoma or leiomyosarcoma","journal":"The Lancet","year":2016,"url":"https://doi.org/10.1016/S0140-6736(15)01283-0","doi":"10.1016/S0140-6736(15)01283-0"}]},{"id":"patrick-wen","kind":"person","name":"Patrick Y. Wen","aka":[],"tldr":"Neuro-oncologist who created the RANO response criteria used in every brain tumour trial and leads glioblastoma drug development.","summary":"Patrick Wen led the Response Assessment in Neuro-Oncology (RANO) working group that replaced the Macdonald criteria and standardised how glioma trials measure response, and has been principal investigator of numerous targeted therapy trials in glioblastoma including the INDIGO steering committee. He directs neuro-oncology at Dana-Farber, edits Neuro-Oncology, and co-chairs the Society for Neuro-Oncology's trial initiatives.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wen%20PY%5BAuthor%5D%20glioblastoma%20RANO"}],"tags":["glioma","response-criteria","neuro-oncology"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":["mri"],"targets":[],"drugs":["vorasidenib"],"companies":[],"institutions":["dana-farber"],"pathways":[],"terms":[],"trials":["indigo"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["neuro-oncology"],"dependsOn":[],"notes":[],"role":"Director, Center for Neuro-Oncology, Dana-Farber Cancer Institute; Professor of Neurology, Harvard Medical School","institutionId":"dana-farber","specialisms":["Neuro-oncology","Glioblastoma","Response assessment","Targeted therapy trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wen%20PY%5BAuthor%5D%20glioblastoma%20RANO"}],"papers":[{"title":"Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology working group (RANO)","journal":"JCO","year":2010,"doi":"10.1200/JCO.2009.26.3541"},{"title":"Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions","journal":"Neuro-Oncology","year":2020,"doi":"10.1093/neuonc/noaa106"}]},{"id":"patrik-rossi","kind":"person","name":"Patrik Rossi","aka":[],"tldr":"Patrik Rossi represents Karolinska University Hospital in the Organisation of European Cancer Institutes, which lists the centre among its members in Sweden.","summary":"Patrik Rossi is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Karolinska University Hospital, its member in Sweden. Sweden's leading cancer hospital, linked to the Karolinska Institutet and Nobel Assembly, with strong registry-based research. OnCo records the name from the OECI membership list so that the centre's page has a named contact point; the person's exact title, appointment date and biography are not yet recorded and should be checked on the institution's own pages before being relied on.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Karolinska University Hospital website","url":"https://ki.se/en/collaboration/healthcare-services/karolinska-comprehensive-cancer-centre"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["karolinska"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Karolinska University Hospital to the Organisation of European Cancer Institutes","institutionId":"karolinska","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Karolinska University Hospital website","url":"https://ki.se/en/collaboration/healthcare-services/karolinska-comprehensive-cancer-centre"}],"papers":[{"title":"Comparison of a single indicator and gravimetric technique for estimation of extravascular lung water in endotoxemic pigs","journal":"Critical Care Medicine","year":2006,"url":"https://doi.org/10.1097/01.ccm.0000215830.48977.29","doi":"10.1097/01.ccm.0000215830.48977.29","note":"OpenAlex author record matched by institution"},{"title":"Palmar skin conductance variability and the relation to stimulation, pain and the motor activity assessment scale in intensive care unit patients","journal":"Critical Care","year":2013,"url":"https://doi.org/10.1186/cc12571","doi":"10.1186/cc12571","note":"OpenAlex author record matched by institution"},{"title":"Differentiated and dose-related cardiovascular effects of a dual endothelin receptor antagonist in endotoxin shock","journal":"Critical Care Medicine","year":2004,"url":"https://doi.org/10.1097/01.ccm.0000126262.23422.f0","doi":"10.1097/01.ccm.0000126262.23422.f0","note":"OpenAlex author record matched by institution"}]},{"id":"patrizia-simionato","kind":"person","name":"Patrizia Simionato","aka":[],"tldr":"General Director of the Istituto Oncologico Veneto, the Veneto region's IRCCS cancer institute in Padua.","summary":"Patrizia Simionato is General Director (Direttore Generale) of the Istituto Oncologico Veneto IRCCS, the public research cancer institute of the Veneto region based in Padua and Castelfranco Veneto. She is responsible for the institute's overall administration, clinical services and strategic planning.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.ioveneto.it/"}],"tags":["leadership","hospital management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["iov-veneto"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"General Director","institutionId":"iov-veneto","specialisms":["Health administration","Cancer institute management"],"profiles":[{"label":"Institution profile","url":"https://www.ioveneto.it/"}],"papers":[]},{"id":"paul-chapman","kind":"person","name":"Paul B. Chapman","aka":[],"tldr":"New York melanoma doctor who was lead author of BRIM-3, the trial that showed vemurafenib lengthens survival in BRAF-mutant melanoma and launched targeted therapy for the disease.","summary":"Paul Chapman is a melanoma medical oncologist at Memorial Sloan Kettering Cancer Center. He was first author of the 2011 New England Journal of Medicine report of BRIM-3, the phase 3 trial in which the BRAF inhibitor vemurafenib improved overall and progression-free survival compared with dacarbazine in previously untreated BRAF V600E-mutant metastatic melanoma, the first targeted drug to do so in the disease.","asOf":"2026-09-18","links":[],"tags":["melanoma","targeted-therapy","trialist"],"related":[],"cancers":["braf-v600-melanoma","melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-chapman-vemurafenib-nejm-2011"],"journals":[],"dependsOn":[],"notes":[],"role":"Melanoma medical oncologist, Memorial Sloan Kettering Cancer Center","institutionId":"mskcc","specialisms":["Melanoma","BRAF inhibitors","Immunotherapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chapman%5BAuthor%5D"}],"papers":[{"title":"BRIM-3: improved survival with vemurafenib in melanoma with BRAF V600E mutation","journal":"New England Journal of Medicine","year":2011,"url":"https://doi.org/10.1056/NEJMoa1103782","doi":"10.1056/NEJMoa1103782"}]},{"id":"paul-baas","kind":"person","name":"Paul Baas","aka":[],"tldr":"Led CheckMate 743, the trial that gave mesothelioma its first new first-line therapy in 16 years.","summary":"Paul Baas was principal investigator of CheckMate 743, which showed nivolumab plus ipilimumab improves overall survival over platinum-pemetrexed in unresectable malignant pleural mesothelioma, the first positive first-line trial since 2004 and the basis for immunotherapy's approval in the disease. He has led ESMO and IASLC mesothelioma guidelines and chaired the IASLC mesothelioma staging work.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Baas%20P%5BAuthor%5D%20mesothelioma%20nivolumab"}],"tags":["mesothelioma","immunotherapy"],"related":[],"cancers":["mesothelioma"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["pd1","ctla4"],"drugs":["nivolumab","ipilimumab"],"companies":[],"institutions":["nki"],"pathways":[],"terms":[],"trials":["checkmate-743"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Thoracic Oncologist, Netherlands Cancer Institute; Professor, University of Amsterdam","institutionId":"nki","specialisms":["Mesothelioma","Thoracic oncology","Immunotherapy","Guidelines"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Baas%20P%5BAuthor%5D%20mesothelioma%20nivolumab"}],"papers":[{"title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743)","journal":"Lancet","year":2021,"doi":"10.1016/S0140-6736(20)32714-8"},{"title":"Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","journal":"Annals of Oncology","year":2015,"doi":"10.1093/annonc/mdv199"}],"orcid":"0000-0001-7018-9556"},{"id":"paul-boutros","kind":"person","name":"Paul Boutros","aka":[],"tldr":"Computational cancer biologist who directs the NCI-designated Cancer Center at Sanford Burnham Prebys in La Jolla and leads its data sciences work.","summary":"Paul Boutros (PhD, MBA) is Director and Professor of the NCI-Designated Cancer Center at Sanford Burnham Prebys Medical Discovery Institute in La Jolla, California. The institute's leadership page also lists him as Senior Vice President for Data Sciences and a member of its Center for Data Science and Artificial Intelligence. Sanford Burnham Prebys is an independent non-profit biomedical research institute whose cancer centre has held National Cancer Institute designation as a basic laboratory cancer centre.","asOf":"2026-09-10","links":[{"label":"Source: Sanford Burnham Prebys leadership page","url":"https://www.sbpdiscovery.org/about-us/leadership/"}],"tags":["leadership","clinician-scientist","research-institute"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["sanford-burnham-prebys"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["cancer-discovery"],"dependsOn":[],"notes":[],"role":"Director, NCI-Designated Cancer Center, Sanford Burnham Prebys","institutionId":"sanford-burnham-prebys","specialisms":["Cancer genomics","Computational biology","Data science"],"profiles":[{"label":"Sanford Burnham Prebys leadership page","url":"https://www.sbpdiscovery.org/about-us/leadership/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Boutros+PC%5BAuthor%5D"}],"papers":[{"title":"Sex differences in the cancer proteome","journal":"BMJ Oncology","year":2026,"doi":"10.1136/bmjonc-2026-001130"},{"title":"The Landscape of Prostate Tumor Methylation","journal":"Cancer Discovery","year":2026,"doi":"10.1158/2159-8290.cd-25-0761"},{"title":"Quantifying rate-limiting genetic variation in breast and ovarian tumourigenesis","journal":"eBioMedicine","year":2026,"doi":"10.1016/j.ebiom.2026.106181"}]},{"id":"paul-brown","kind":"person","name":"Paul D. Brown","aka":[],"tldr":"Mayo Clinic radiation oncologist whose trials showed that focused radiosurgery preserves thinking and memory better than whole-brain radiotherapy for brain metastases, and that sparing the hippocampus reduces cognitive harm when whole-brain treatment is needed.","summary":"Paul Brown is a radiation oncologist at Mayo Clinic in Rochester who leads the North American cooperative-group trials on brain metastases. He was first author of the 2016 JAMA report of Alliance N0574, which showed less cognitive decline with radiosurgery alone than with radiosurgery plus whole-brain radiotherapy for one to three brain metastases; of the 2017 Lancet Oncology report of N107C, which established postoperative radiosurgery to the surgical cavity; and of the 2020 Journal of Clinical Oncology report of NRG CC001, which showed hippocampal avoidance with memantine reduces cognitive toxicity of whole-brain radiotherapy.","asOf":"2026-09-18","links":[],"tags":["brain","radiotherapy","trialist"],"related":[],"cancers":["secondary-brain-tumours","brain-tumours"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["mayo-clinic"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-alliance-n0574-brown-jama-2016","paper-n107c-brown-lancet-oncol-2017","paper-nrg-cc001-brown-jco-2020"],"journals":[],"dependsOn":[],"notes":[],"role":"Radiation oncologist, Mayo Clinic","institutionId":"mayo-clinic","specialisms":["Brain metastases","Stereotactic radiosurgery","Cognitive outcomes of radiotherapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Brown%5BAuthor%5D"}],"papers":[{"title":"Alliance N0574: radiosurgery alone versus radiosurgery plus whole-brain radiotherapy for one to three brain metastases","journal":"JAMA","year":2016,"url":"https://doi.org/10.1001/jama.2016.9839","doi":"10.1001/jama.2016.9839"},{"title":"N107C/CEC.3: postoperative radiosurgery versus whole-brain radiotherapy after resection of a brain metastasis","journal":"The Lancet Oncology","year":2017,"url":"https://doi.org/10.1016/S1470-2045(17)30441-2","doi":"10.1016/S1470-2045(17)30441-2"},{"title":"NRG CC001: hippocampal-avoidance whole-brain radiotherapy plus memantine for brain metastases","journal":"Journal of Clinical Oncology","year":2020,"url":"https://doi.org/10.1200/JCO.19.02767","doi":"10.1200/JCO.19.02767"}]},{"id":"paul-richardson","kind":"person","name":"Paul G. Richardson","aka":[],"tldr":"Led the DETERMINATION trial and many of the myeloma drug approvals of the past two decades.","summary":"Paul G. Richardson is Clinical Program Leader and Director of Clinical Research at the Jerome Lipper Multiple Myeloma Center, Dana-Farber Brigham Cancer Center. He is known for leading many of the myeloma drug approvals of the past two decades as principal investigator on pivotal trials of bortezomib, lenalidomide-based regimens and newer agents. He led the DETERMINATION trial, which tested delayed versus upfront autologous transplant in the lenalidomide era, and his selected paper reports triplet therapy, transplantation and maintenance until progression in myeloma. He continues to work on novel agents and transplant-deferral strategies.","asOf":"2026-09-08","links":[{"label":"Dana-Farber profile","url":"https://www.dana-farber.org/find-a-doctor/paul-g-richardson"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Richardson%20PG%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":["autologous-stem-cell-transplant"],"targets":[],"drugs":["bortezomib","lenalidomide"],"companies":[],"institutions":["dana-farber"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Clinical Program Leader and Director of Clinical Research, Jerome Lipper Multiple Myeloma Center","institutionId":"dana-farber","specialisms":["Multiple myeloma","Novel agents","Transplant-deferral strategies"],"profiles":[{"label":"Dana-Farber profile","url":"https://www.dana-farber.org/find-a-doctor/paul-g-richardson"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Richardson%20PG%5BAuthor%5D"}],"papers":[{"title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","journal":"New England Journal of Medicine","year":2022,"url":"https://doi.org/10.1056/NEJMoa2204925","doi":"10.1056/NEJMoa2204925"}]},{"id":"paul-herijgers","kind":"person","name":"Paul Herijgers","aka":[],"tldr":"Chief executive of the Leuven university hospital, whose Leuven Cancer Institute brings clinicians and scientists together to treat and study cancer.","summary":"Professor Paul Herijgers is Chief Executive Officer of UZ Leuven, the university hospital of KU Leuven and one of the largest hospitals in Belgium. He took over from Wim Robberecht on 1 August 2024 and chairs a management committee that includes Medical Director Gert Van Assche and Dean of Medicine Chris Verslype. UZ Leuven's Leuven Cancer Institute (LKI) unites physicians, nurses, basic scientists and clinical researchers in cancer care and research and includes the hospital's proton therapy centre.","asOf":"2026-09-10","links":[{"label":"Source: UZ Leuven management committee page","url":"https://www.uzleuven.be/en/about-us/management-committee"}],"tags":["leadership","hospital-management","belgium"],"related":[],"cancers":[],"sections":[],"technologies":["proton-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":["uz-leuven"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive Officer, UZ Leuven","institutionId":"uz-leuven","specialisms":["Hospital leadership","Academic medicine","Health system governance"],"profiles":[{"label":"UZ Leuven management committee","url":"https://www.uzleuven.be/en/about-us/management-committee"}],"papers":[{"title":"Primary atrial fibrosarcoma of the heart","journal":"Cardiovascular Pathology","year":2008,"doi":"10.1016/j.carpath.2007.04.010"},{"title":"Pericardial synovial sarcoma: 14-year survival with multimodality therapy","journal":"The Annals of Thoracic Surgery","year":2004,"doi":"10.1016/j.athoracsur.2004.02.011"}],"orcid":"0000-0003-0951-8132"},{"id":"paul-paik","kind":"person","name":"Paul K. Paik","aka":[],"tldr":"Lung cancer doctor who was lead author of VISION, the trial that established tepotinib for lung cancers with MET exon 14 skipping mutations.","summary":"Paul Paik is a thoracic medical oncologist at Memorial Sloan Kettering Cancer Center. He was first author of the 2020 New England Journal of Medicine report of the VISION trial, in which the MET inhibitor tepotinib produced durable responses in MET exon 14 skipping non-small-cell lung cancer, and earlier helped characterise MET exon 14 alterations as a targetable driver. He also studies squamous-cell lung cancer.","asOf":"2026-09-18","links":[],"tags":["lung","targeted-therapy","trialist"],"related":[],"cancers":["met-altered-nsclc","nsclc","lung-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-vision-tepotinib-paik-nejm-2020"],"journals":[],"dependsOn":[],"notes":[],"role":"Thoracic medical oncologist, Memorial Sloan Kettering Cancer Center","institutionId":"mskcc","specialisms":["MET exon 14 lung cancer","Squamous lung cancer","Targeted therapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Paik%5BAuthor%5D"}],"papers":[{"title":"VISION: tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations","journal":"New England Journal of Medicine","year":2020,"url":"https://doi.org/10.1056/NEJMoa2004407","doi":"10.1056/NEJMoa2004407"}]},{"id":"paul-nathan","kind":"person","name":"Paul Nathan","aka":[],"tldr":"Led the tebentafusp trial, the first treatment ever to extend survival in metastatic uveal melanoma.","summary":"Paul Nathan (Mount Vernon Cancer Centre) was principal investigator of IMCgp100-202, the randomised trial showing the gp100-directed bispecific T-cell engager tebentafusp improves overall survival in HLA-A*02:01-positive metastatic uveal melanoma, the first drug to do so and the first approved TCR-based therapy. He has led UK melanoma and renal trials and chairs national melanoma guideline groups.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Nathan%20P%5BAuthor%5D%20tebentafusp"}],"tags":["uveal-melanoma","bispecific","uk"],"related":[],"cancers":["uveal-melanoma","melanoma"],"sections":[],"technologies":["t-cell-engager"],"targets":["gp100","cd3"],"drugs":["tebentafusp"],"companies":[],"institutions":["mount-vernon-cancer-centre"],"pathways":[],"terms":[],"trials":["imcgp100-202"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Consultant Medical Oncologist, Mount Vernon Cancer Centre, London","institutionId":"mount-vernon-cancer-centre","specialisms":["Uveal melanoma","Melanoma","Renal cell carcinoma","Bispecific T-cell engagers"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Nathan%20P%5BAuthor%5D%20tebentafusp"}],"papers":[{"title":"Overall survival benefit with tebentafusp in metastatic uveal melanoma (IMCgp100-202)","journal":"NEJM","year":2021,"doi":"10.1056/NEJMoa2103485"},{"title":"Three-year overall survival with tebentafusp in metastatic uveal melanoma","journal":"NEJM","year":2023,"doi":"10.1056/NEJMoa2304753"}]},{"id":"paul-nurse","kind":"person","name":"Paul Nurse","aka":[],"tldr":"Nobel laureate who discovered how cyclin-dependent kinases control cell division, and founding director of the Crick.","summary":"Paul Nurse is Director of The Francis Crick Institute in London and a Nobel laureate. His specialisms are the cell cycle, cyclin-dependent kinases and institute leadership. He shared the 2001 Nobel Prize for discovering key regulators of the cell cycle, the biology behind the CDK4/6 inhibitors now used in cancer treatment. His Nature paper on the genetic control of cell size at cell division in yeast was part of that foundational work. He has led the Francis Crick Institute since its foundation, and his Crick profile is linked.","asOf":"2026-09-08","links":[{"label":"Crick","url":"https://www.crick.ac.uk/"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["cdk4-6"],"drugs":[],"companies":[],"institutions":["francis-crick"],"pathways":["p53-cell-cycle"],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Francis Crick Institute; Nobel laureate","institutionId":"francis-crick","specialisms":["Cell cycle","Cyclin-dependent kinases","Institute leadership"],"profiles":[{"label":"Crick","url":"https://www.crick.ac.uk/"}],"papers":[{"title":"Genetic control of cell size at cell division in yeast","journal":"Nature","year":1975,"doi":"10.1038/256547a0"}],"orcid":"0000-0002-9244-7787"},{"id":"paul-workman","kind":"person","name":"Paul Workman","aka":[],"tldr":"Drug-discovery pioneer who built the ICR's Cancer Therapeutics Unit and championed the 'pharmacological audit trail'.","summary":"Paul Workman is Harrap Professor of Pharmacology and Therapeutics at The Institute of Cancer Research and its former Chief Executive. His specialisms are drug discovery, molecular pharmacology, and kinase and chaperone inhibitors. He led the ICR from 2014 to 2021 and directed its Cancer Research UK Cancer Therapeutics Unit, which discovered or contributed to abiraterone acetate, capivasertib, and HSP90 and PI3K inhibitors, and he championed the pharmacological audit trail as a framework for drug development. His Chemistry & Biology paper on probing the probes set out fitness factors for small-molecule chemical tools. His publications are listed on PubMed.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Paul_Workman_(pharmacologist)","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Workman%20P%5BAuthor%5D%20drug%20discovery"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["ai-drug-design","kinase-inhibitors"],"targets":[],"drugs":["capivasertib","abiraterone"],"companies":[],"institutions":["icr-london"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Harrap Professor of Pharmacology and Therapeutics, ICR; former Chief Executive","institutionId":"icr-london","specialisms":["Drug discovery","Molecular pharmacology","Kinase and chaperone inhibitors"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Workman%20P%5BAuthor%5D%20drug%20discovery"}],"papers":[{"title":"Probing the probes: fitness factors for small molecule tools","journal":"Chemistry & Biology","year":2010,"doi":"10.1016/j.chembiol.2010.05.013"}]},{"id":"paula-ghaneh","kind":"person","name":"Paula Ghaneh","aka":[],"tldr":"Liverpool pancreatic surgeon, chief investigator of ESPAC5, the UK trial of short-course neoadjuvant treatment for borderline resectable pancreatic cancer, and a co-author of ESPAC-3 and ESPAC-4.","summary":"Paula Ghaneh is Professor of Surgery in the Department of Molecular and Clinical Cancer Medicine at the University of Liverpool (Institute of Systems, Molecular and Integrative Biology). She was first author of ESPAC5 (Lancet Gastroenterology and Hepatology 2023), the four-arm phase 2 trial that compared immediate surgery with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX or chemoradiotherapy in borderline resectable pancreatic cancer, and a co-author of ESPAC-3 (JAMA 2010) and ESPAC-4 (Lancet 2017), the Liverpool-led adjuvant trials whose result, gemcitabine plus capecitabine after resection, is NICE NG85's adjuvant recommendation.","asOf":"2026-09-24","links":[{"label":"University of Liverpool staff page","url":"https://www.liverpool.ac.uk/people/paula-ghaneh"}],"tags":["pancreatic","trialist","uk","surgeon"],"related":["daniel-palmer","chris-halloran"],"cancers":["pancreatic","borderline-resectable-pdac","resectable-pdac"],"sections":[],"technologies":[],"targets":[],"drugs":["gemcitabine","capecitabine","folfirinox"],"companies":[],"institutions":["liverpool-hpb-centre"],"pathways":[],"terms":[],"trials":["espac-3","espac-4","espac-5"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Surgery, Molecular and Clinical Cancer Medicine, University of Liverpool","institutionId":"liverpool-hpb-centre","specialisms":["Pancreatic surgery","Adjuvant and neoadjuvant trials","Surgical oncology"],"profiles":[{"label":"University of Liverpool staff page","url":"https://www.liverpool.ac.uk/people/paula-ghaneh"}],"papers":[{"title":"Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5)","journal":"Lancet Gastroenterology and Hepatology","year":2023,"doi":"10.1016/S2468-1253(22)00348-X"},{"title":"Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4)","journal":"Lancet","year":2017,"doi":"10.1016/S0140-6736(16)32409-6"},{"title":"Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection (ESPAC-3)","journal":"JAMA","year":2010,"doi":"10.1001/jama.2010.1275"}]},{"id":"hoff-paulo","kind":"person","name":"Paulo Hoff","aka":[],"tldr":"Brazil's most prominent GI oncologist, a former MD Anderson faculty member who built oncology programmes at Sírio-Libanês and ICESP.","summary":"Paulo Hoff is a medical oncologist specialising in gastrointestinal cancer and a leader of Brazilian oncology through Hospital Sírio-Libanês, the University of São Paulo and Oncologia D'Or. A former MD Anderson faculty member, he led research on capecitabine and colorectal cancer there before returning to Brazil, where he directed the oncology centre at Sírio-Libanês and the São Paulo State Cancer Institute and later led Oncologia D'Or. His publications include the trial comparing oral capecitabine with intravenous fluorouracil plus leucovorin as first-line treatment for metastatic colorectal cancer. He is Brazil's most prominent gastrointestinal oncologist, with interests in colorectal cancer, clinical trials and oncology leadership.","asOf":"2026-09-08","links":[{"label":"Hospital Sírio-Libanês","url":"https://www.hospitalsiriolibanes.org.br"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hoff%20PM%5BAuthor%5D%20colorectal%20capecitabine"}],"tags":[],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":["folfox"],"companies":[],"institutions":["sirio-libanes"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Medical oncologist; gastrointestinal oncology; Brazilian oncology leadership (Sírio-Libanês, USP, Oncologia D'Or)","institutionId":"sirio-libanes","specialisms":["Colorectal cancer","Gastrointestinal oncology","Clinical trials","Oncology leadership"],"profiles":[{"label":"Hospital Sírio-Libanês","url":"https://www.hospitalsiriolibanes.org.br"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hoff%20PM%5BAuthor%5D%20colorectal%20capecitabine"}],"papers":[{"title":"Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in patients with metastatic colorectal cancer","journal":"Journal of Clinical Oncology","year":2001,"doi":"10.1200/JCO.2001.19.8.2282"}]},{"id":"pavan-reddy","kind":"person","name":"Pavan Reddy","aka":[],"tldr":"Physician who directs the Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine in Houston, an NCI-designated comprehensive cancer centre.","summary":"Pavan Reddy, MD, is Director of the Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine in Houston, Texas. The National Cancer Institute's cancer centre listing names him as Director and records that the centre, formed in 2006, received NCI designation in 2007 and comprehensive status in 2015. The Baylor College of Medicine pages for the centre could not be fetched, so this record relies on the NCI listing.","asOf":"2026-09-10","links":[{"label":"Source: National Cancer Institute cancer centre listing naming the Director","url":"https://www.cancer.gov/research/infrastructure/cancer-centers/find/baylorduncan"}],"tags":["leadership","clinician-scientist","comprehensive-cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["baylor-duncan"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nature-medicine","blood-advances"],"dependsOn":[],"notes":[],"role":"Director, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine","institutionId":"baylor-duncan","specialisms":["Haematology and oncology","Stem cell transplantation","Cancer centre leadership"],"profiles":[{"label":"NCI cancer centre listing: Dan L Duncan Comprehensive Cancer Center","url":"https://www.cancer.gov/research/infrastructure/cancer-centers/find/baylorduncan"},{"label":"Baylor College of Medicine cancer centre website","url":"https://www.bcm.edu/centers/cancer-center"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Reddy+P%5BAuthor%5D+AND+Baylor"}],"papers":[{"title":"Feasibility of a dietary intervention to modify gut microbial metabolism in patients with hematopoietic stem cell transplantation","journal":"Nature Medicine","year":2023,"doi":"10.1038/s41591-023-02587-y"},{"title":"Ambient oxygen levels regulate intestinal dysbiosis and GVHD severity after allogeneic stem cell transplantation","journal":"Immunity","year":2023,"doi":"10.1016/j.immuni.2023.01.007"},{"title":"PD-1 inhibition for relapse after allogeneic transplantation in acute myeloid leukemia and myelodysplastic syndrome","journal":"Blood Advances","year":2025,"doi":"10.1182/bloodadvances.2024015200"}]},{"id":"pawel-kalinski","kind":"person","name":"Pawel Kalinski","aka":[],"tldr":"Pawel Kalinski is an immunologist reprogramming tumour microenvironments so T cells can enter.","summary":"Pawel Kalinski is Vice Chair for Translational Research in the Department of Medicine and Chief of Translational Immuno-Oncology at Roswell Park Comprehensive Cancer Center. He is an immunologist known for reprogramming tumour microenvironments so that T cells can enter, developing chemokine-modulating regimens that combine interferon, TLR3 agonists and COX-2 inhibition, alongside dendritic cell vaccines. His selected paper reviews chemokine modulation to enhance T cell infiltration of tumours. He continues to work on converting immune-excluded tumours to respond to checkpoint inhibitors.","asOf":"2026-09-08","links":[{"label":"Roswell Park profile","url":"https://www.roswellpark.org/pawel-kalinski"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kalinski%20P%5BAuthor%5D"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":[],"companies":[],"institutions":["roswell-park"],"pathways":[],"terms":["cold-vs-hot"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["cancer-immunology-research"],"dependsOn":[],"notes":[],"role":"Vice Chair for Translational Research, Department of Medicine; Chief, Translational Immuno-Oncology","institutionId":"roswell-park","specialisms":["Dendritic cell vaccines","Chemokine modulation","Tumour microenvironment"],"profiles":[{"label":"Roswell Park profile","url":"https://www.roswellpark.org/pawel-kalinski"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kalinski%20P%5BAuthor%5D"}],"papers":[{"title":"Chemokine modulation to enhance T cell infiltration of tumors","journal":"Cancer Immunology Research","year":2019}],"orcid":"0000-0001-7025-3562"},{"id":"pedro-ramirez","kind":"person","name":"Pedro T. Ramirez","aka":[],"tldr":"Surgeon who led the LACC trial, which unexpectedly showed keyhole hysterectomy worsens survival in early cervical cancer.","summary":"Pedro Ramirez (Houston Methodist; formerly MD Anderson) was principal investigator of LACC, the randomised trial showing minimally invasive radical hysterectomy leads to more recurrences and deaths than open surgery in early-stage cervical cancer, a result that reversed a decade of surgical practice. He has since led work on the mechanisms of this finding and on surgical technique modifications.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ramirez%20PT%5BAuthor%5D%20cervical%20LACC"}],"tags":["cervical","surgery"],"related":[],"cancers":["cervical"],"sections":[],"technologies":["robotic-surgery"],"targets":[],"drugs":[],"companies":[],"institutions":["houston-methodist-neal-cancer-center"],"pathways":[],"terms":[],"trials":["lacc"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chair, Department of Obstetrics and Gynecology, Houston Methodist Hospital","institutionId":"houston-methodist-neal-cancer-center","specialisms":["Gynaecologic oncology surgery","Minimally invasive surgery","Radical hysterectomy","Surgical trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ramirez%20PT%5BAuthor%5D%20cervical%20LACC"}],"papers":[{"title":"Minimally invasive versus abdominal radical hysterectomy for cervical cancer (LACC)","journal":"NEJM","year":2018,"doi":"10.1056/NEJMoa1806395"},{"title":"Open vs minimally invasive radical hysterectomy in early cervical cancer: LACC trial final analysis","journal":"JCO","year":2024}]},{"id":"per-hall","kind":"person","name":"Per Hall","aka":[],"tldr":"Per Hall is the epidemiologist behind KARMA and the risk-based breast screening programme.","summary":"Per Hall is Professor of Radiation Epidemiology at Karolinska Institutet in Stockholm, working with Karolinska University Hospital. His specialisms are breast cancer epidemiology, risk-based screening and mammographic density. He leads the KARMA cohort and developed risk models that combine mammographic density, genetics and lifestyle to personalise the interval between breast screens. His Lancet Digital Health paper reported a prospective, population-based, paired-reader study of artificial intelligence for breast cancer detection in screening mammography in Sweden. His work spans mammography, tomosynthesis and AI in radiology, and his publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hall%20P%5BAuthor%5D%20mammographic%20density%20risk"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["mammography","radiology-ai-screening"],"targets":[],"drugs":[],"companies":[],"institutions":["karolinska"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["lancet-digital-health"],"dependsOn":[],"notes":[],"role":"Professor of Radiation Epidemiology, Karolinska Institutet","institutionId":"karolinska","specialisms":["Breast cancer epidemiology","Risk-based screening","Mammographic density"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hall%20P%5BAuthor%5D%20mammographic%20density%20risk"}],"papers":[{"title":"Artificial intelligence for breast cancer detection in screening mammography in Sweden: a prospective, population-based, paired-reader, non-inferiority study","journal":"Lancet Digital Health","year":2023,"doi":"10.1016/S2589-7500(23)00153-X"}],"orcid":"0000-0002-5640-9126"},{"id":"peter-bartenstein","kind":"person","name":"Peter Bartenstein","aka":[],"tldr":"Peter Bartenstein is a nuclear medicine head whose department is a leading European PSMA theranostics centre.","summary":"Peter Bartenstein is Director of the Department of Nuclear Medicine at LMU Klinikum München. His specialisms are nuclear medicine, PSMA theranostics and neuro-imaging. His department is a leading European centre for PSMA PET and lutetium-177 PSMA radioligand therapy, and it co-developed 177Lu-PSMA-I&T. His papers include a dosimetry study of 177Lu-DKFZ-PSMA-617 as a new radiopharmaceutical for metastatic prostate cancer, the first clinical results of 18F-SiFAlin-TATE PET for imaging neuroendocrine tumours, and a European Urology study showing that 68Ga-PSMA PET/CT accurately stages lymph node regions before dissection in prostate cancer. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bartenstein%20P%5BAuthor%5D%20PSMA"}],"tags":[],"related":[],"cancers":["prostate"],"sections":[],"technologies":["psma-pet","radioligand-therapy"],"targets":["psma"],"drugs":["lu177-psma-it"],"companies":[],"institutions":["lmu-munich"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Department of Nuclear Medicine, LMU Munich","institutionId":"lmu-munich","specialisms":["Nuclear medicine","PSMA theranostics","Neuro-imaging"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bartenstein%20P%5BAuthor%5D%20PSMA"}],"papers":[{"title":"Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer","journal":"European Journal of Nuclear Medicine and Molecular Imaging","year":2015,"doi":"10.1007/s00259-015-3174-7"},{"title":"Biodistribution and first clinical results of 18F-SiFAlin-TATE PET: a novel 18F-labeled somatostatin analog for imaging of neuroendocrine tumors","journal":"European Journal of Nuclear Medicine and Molecular Imaging","year":2019,"doi":"10.1007/s00259-019-04501-6"},{"title":"68Ga-PSMA Positron Emission Tomography/Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prostate Cancer","journal":"European Urology","year":2016,"doi":"10.1016/j.eururo.2015.12.051"}]},{"id":"peter-borchmann","kind":"person","name":"Peter Borchmann","aka":[],"tldr":"Leads the German Hodgkin Study Group and HD21, which made BrECADD the most effective and least toxic regimen for advanced Hodgkin lymphoma.","summary":"Peter Borchmann chairs the German Hodgkin Study Group and was principal investigator of HD21, which showed the brentuximab-based BrECADD regimen is both more effective and less toxic than escalated BEACOPP in advanced-stage Hodgkin lymphoma with 95% three-year progression-free survival, and of HD18, which used PET to reduce treatment from six cycles to four. He leads GHSG trials of immunotherapy in first-line disease.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Borchmann%20P%5BAuthor%5D%20Hodgkin"}],"tags":["hodgkin","ghsg","trialist"],"related":[],"cancers":["hodgkin-lymphoma"],"sections":[],"technologies":["adc","fdg-pet"],"targets":[],"drugs":["brentuximab-vedotin"],"companies":["ghsg"],"institutions":["uniklinik-koeln"],"pathways":[],"terms":[],"trials":["hd21"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medicine and Head of the German Hodgkin Study Group, University Hospital Cologne","institutionId":"uniklinik-koeln","specialisms":["Hodgkin lymphoma","PET-guided therapy","Antibody-drug conjugates","Cooperative-group trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Borchmann%20P%5BAuthor%5D%20Hodgkin"}],"papers":[{"title":"Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial","journal":"Lancet","year":2024,"doi":"10.1016/S0140-6736(24)01315-1"},{"title":"PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group","journal":"Lancet","year":2017,"doi":"10.1016/S0140-6736(17)32134-7"}]},{"id":"peter-hillmen","kind":"person","name":"Peter Hillmen","aka":[],"tldr":"Led FLAIR, the UK trial showing MRD-guided ibrutinib plus venetoclax outperforms chemoimmunotherapy in CLL.","summary":"Peter Hillmen (Leeds) was chief investigator of the UK NCRI FLAIR trial, which showed ibrutinib plus venetoclax with MRD-guided duration improves progression-free and overall survival compared with FCR in untreated CLL, and of the CLARITY trial that first tested this combination. He led the UK CLL trials group for two decades and was also central to the development of eculizumab for PNH.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hillmen%20P%5BAuthor%5D%20chronic%20lymphocytic%20leukemia%20FLAIR"}],"tags":["cll","mrd","uk"],"related":[],"cancers":["cll"],"sections":[],"technologies":["mrd-testing","kinase-inhibitors"],"targets":["bcl2"],"drugs":["venetoclax"],"companies":[],"institutions":["leeds-cancer-centre"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Emeritus Professor of Experimental Haematology, University of Leeds","institutionId":"leeds-cancer-centre","specialisms":["Chronic lymphocytic leukaemia","MRD-guided therapy","Paroxysmal nocturnal haemoglobinuria","UK cooperative trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hillmen%20P%5BAuthor%5D%20chronic%20lymphocytic%20leukemia%20FLAIR"}],"papers":[{"title":"Ibrutinib plus venetoclax with MRD-directed duration of treatment is superior to FCR and is a new standard of care for previously untreated CLL (FLAIR)","journal":"NEJM","year":2024},{"title":"Ibrutinib plus venetoclax in relapsed/refractory chronic lymphocytic leukemia: the CLARITY study","journal":"JCO","year":2019,"doi":"10.1200/JCO.19.00894"}]},{"id":"peter-odwyer","kind":"person","name":"Peter J. O'Dwyer","aka":[],"tldr":"Peter O'Dwyer is a GI oncologist who co-leads ECOG-ACRIN, one of the NCI's national trial networks.","summary":"Peter O'Dwyer is Group Co-Chair of the ECOG-ACRIN Cancer Research Group and Professor of Medicine at the University of Pennsylvania, within the Abramson Cancer Center. A gastrointestinal medical oncologist with a background in pharmacology and early drug development, he co-chairs ECOG-ACRIN with Mitchell Schnall and directs the Penn Developmental Therapeutics Program. His papers include the Eastern Cooperative Oncology Group study E3200 of bevacizumab combined with FOLFOX4 for previously treated metastatic colorectal cancer and a New England Journal of Medicine review of the status of etoposide as an active anticancer drug. His work spans colorectal cancer, pancreatic ductal adenocarcinoma and cooperative group trials.","asOf":"2026-09-08","links":[{"label":"ECOG-ACRIN","url":"https://ecog-acrin.org"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=O'Dwyer%20PJ%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Peter%20J.%20O'Dwyer"}],"tags":[],"related":[],"cancers":["colorectal","pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["ecog-acrin"],"institutions":["penn-abramson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Group Co-Chair, ECOG-ACRIN Cancer Research Group; Professor of Medicine, University of Pennsylvania","institutionId":"ecog-acrin","specialisms":["Gastrointestinal oncology","Drug development","Cooperative group trials"],"profiles":[{"label":"ECOG-ACRIN","url":"https://ecog-acrin.org"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=O'Dwyer%20PJ%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Peter%20J.%20O'Dwyer"}],"papers":[{"title":"Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200","journal":"Journal of Clinical Oncology","year":2023,"url":"https://doi.org/10.1200/JCO.22.02761","doi":"10.1200/JCO.22.02761"},{"title":"Etoposide (VP-16-213). Current status of an active anticancer drug","journal":"New England Journal of Medicine","year":1985,"url":"https://doi.org/10.1056/NEJM198503143121106","doi":"10.1056/NEJM198503143121106"}]},{"id":"peter-johnson","kind":"person","name":"Peter Johnson","aka":[],"tldr":"Southampton lymphoma specialist who led the RATHL trial of PET-guided therapy in Hodgkin lymphoma and serves as NHS England's National Clinical Director for Cancer.","summary":"Peter Johnson is Professor of Medical Oncology at the University of Southampton and University Hospital Southampton, working within the Centre for Cancer Immunology, the UK's first dedicated cancer immunology centre. He was chief investigator of the RATHL trial, which established interim PET-CT guided de-escalation of chemotherapy in advanced Hodgkin lymphoma, and his research focuses on antibody and vaccine immunotherapy for lymphoma. He also serves as National Clinical Director for Cancer at NHS England.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.southampton.ac.uk/research/institutes-centres/centre-for-cancer-immunology"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Johnson+PW%5BAuthor%5D+AND+lymphoma"}],"tags":["clinician-scientist","lymphoma","immunotherapy"],"related":[],"cancers":["hodgkin-lymphoma","dlbcl"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["southampton-cancer"],"pathways":[],"terms":[],"trials":["rathl"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology","institutionId":"southampton-cancer","specialisms":["Lymphoma","Cancer immunotherapy","Medical oncology","Clinical trials"],"profiles":[{"label":"Institution profile","url":"https://www.southampton.ac.uk/research/institutes-centres/centre-for-cancer-immunology"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Johnson+PW%5BAuthor%5D+AND+lymphoma"}],"papers":[{"title":"Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma","journal":"New England Journal of Medicine","year":2016,"url":"https://doi.org/10.1056/NEJMoa1510093","doi":"10.1056/NEJMoa1510093"}],"orcid":"0000-0003-2306-4974"},{"id":"peter-sasieni","kind":"person","name":"Peter Sasieni","aka":[],"tldr":"Epidemiologist who showed HPV vaccination has nearly eliminated cervical cancer in vaccinated English women and leads NHS-Galleri.","summary":"Peter Sasieni led the 2021 Lancet analysis showing the English HPV vaccination programme cut cervical cancer by 87% in women vaccinated at 12-13, one of the clearest demonstrations of cancer prevention ever recorded, and the modelling that underpins HPV-based and extended-interval cervical screening. He co-leads the NHS-Galleri trial of multi-cancer early detection and directs the Cancer Prevention Trials Unit.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sasieni%20P%5BAuthor%5D%20cervical%20screening%20HPV"}],"tags":["screening","hpv","prevention"],"related":[],"cancers":["cervical"],"sections":[],"technologies":["hpv-vaccine","mced"],"targets":[],"drugs":["galleri"],"companies":[],"institutions":["barts-cancer-institute","cruk"],"pathways":[],"terms":[],"trials":["nhs-galleri"],"people":[],"bottlenecks":[],"keyPapers":["paper-hpv-vaccine-england-lancet-2021","paper-nhs-galleri-design-cancers-2022"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Cancer Epidemiology, Queen Mary University of London; Director, Cancer Prevention Trials Unit","institutionId":"barts-cancer-institute","specialisms":["Cervical screening","HPV vaccination evaluation","Screening trial design","Cancer prevention epidemiology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sasieni%20P%5BAuthor%5D%20cervical%20screening%20HPV"}],"papers":[{"title":"The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study","journal":"Lancet","year":2021,"doi":"10.1016/S0140-6736(21)02178-4"},{"title":"Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data","journal":"BMJ","year":2009,"doi":"10.1136/bmj.b2968"},{"title":"NHS-Galleri: design of the largest randomised trial of a multi-cancer blood test","journal":"Cancers","year":2022,"url":"https://doi.org/10.3390/cancers14194818","doi":"10.3390/cancers14194818"}],"orcid":"0000-0003-1509-8744"},{"id":"peter-schmid","kind":"person","name":"Peter Schmid","aka":[],"tldr":"Led KEYNOTE-522 and IMpassion130, the trials that brought immunotherapy into triple-negative breast cancer.","summary":"Peter Schmid was principal investigator of IMpassion130, the first positive immunotherapy trial in breast cancer, and of KEYNOTE-522, which showed neoadjuvant pembrolizumab with chemotherapy raises pathological complete response and improves event-free and overall survival in stage II-III TNBC. KEYNOTE-522 is now the global standard for early TNBC. He leads experimental cancer medicine at Barts and continues to run immunotherapy and ADC combination trials.","asOf":"2026-09-10","links":[{"label":"Barts Cancer Institute","url":"https://www.bartscancer.london/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schmid%20P%5BAuthor%5D%20pembrolizumab%20triple-negative"}],"tags":["tnbc","immunotherapy","trialist"],"related":[],"cancers":["tnbc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["pd1","pdl1"],"drugs":["pembrolizumab","atezolizumab"],"companies":[],"institutions":["barts-cancer-institute"],"pathways":[],"terms":[],"trials":["keynote-522","impassion130"],"people":[],"bottlenecks":[],"keyPapers":["paper-keynote-522-nejm-2022"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Cancer Medicine and Lead, Centre for Experimental Cancer Medicine, Barts Cancer Institute","institutionId":"barts-cancer-institute","specialisms":["Triple-negative breast cancer","Immunotherapy","Neoadjuvant therapy","Early drug development"],"profiles":[{"label":"Barts Cancer Institute","url":"https://www.bartscancer.london/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schmid%20P%5BAuthor%5D%20pembrolizumab%20triple-negative"}],"papers":[{"title":"Pembrolizumab for early triple-negative breast cancer (KEYNOTE-522)","journal":"NEJM","year":2020,"doi":"10.1056/NEJMoa1910549"},{"title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer (IMpassion130)","journal":"NEJM","year":2018,"doi":"10.1056/NEJMoa1809615"},{"title":"Overall survival with pembrolizumab in early-stage triple-negative breast cancer","journal":"NEJM","year":2024,"doi":"10.1056/NEJMoa2409932"},{"title":"KEYNOTE-522: adding pembrolizumab before and after surgery in early triple-negative breast cancer","journal":"New England Journal of Medicine","year":2022,"url":"https://doi.org/10.1056/NEJMoa2112651","doi":"10.1056/NEJMoa2112651"}],"orcid":"0000-0001-9817-5228"},{"id":"peter-thuss-patience","kind":"person","name":"Peter Thuss-Patience","aka":[],"tldr":"Berlin oncologist who led GATSBY, the trial showing that the antibody-drug conjugate T-DM1 did not beat taxane chemotherapy in previously treated HER2-positive stomach cancer.","summary":"Peter Thuss-Patience is a gastrointestinal oncologist at Charité in Berlin. He led the German AIO trial that established second-line irinotecan over best supportive care in gastric cancer, and was first author of the 2017 Lancet Oncology report of GATSBY, in which trastuzumab emtansine failed to improve survival over taxane chemotherapy in HER2-positive advanced gastric cancer after first-line treatment.","asOf":"2026-09-18","links":[],"tags":["gastric","trialist"],"related":[],"cancers":["gastric-her2-positive","gastric"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["charite"],"pathways":[],"terms":[],"trials":["gatsby"],"people":[],"bottlenecks":[],"keyPapers":["paper-flot4-lancet-2019","paper-peter-thuss-patience-eur-j-cancer-2011","paper-peter-thuss-patience-ann-oncol-2019"],"journals":[],"dependsOn":[],"notes":[],"role":"Medical oncologist, Charité Universitätsmedizin Berlin","institutionId":"charite","specialisms":["Gastric and oesophageal cancer","Second-line chemotherapy","Antibody-drug conjugates"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Thuss-Patience%5BAuthor%5D"}],"papers":[{"title":"FLOT4-AIO: perioperative FLOT versus ECF/ECX for resectable gastric or gastro-oesophageal junction adenocarcinoma","journal":"The Lancet","year":2019,"url":"https://doi.org/10.1016/S0140-6736(18)32557-1","doi":"10.1016/S0140-6736(18)32557-1","note":"Europe PMC author record matched by affiliation (Charité Universitätsmedizin Berlin); 2016 citations on Europe PMC."},{"title":"Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)","journal":"European Journal of Cancer","year":2011,"url":"https://doi.org/10.1016/j.ejca.2011.06.002","doi":"10.1016/j.ejca.2011.06.002","note":"Europe PMC author record matched by affiliation (Charité Universitätsmedizin Berlin); 448 citations on Europe PMC."},{"title":"A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study","journal":"Annals of Oncology","year":2019,"url":"https://doi.org/10.1093/annonc/mdz199","doi":"10.1093/annonc/mdz199","note":"Europe PMC author record matched by affiliation (Charité Universitätsmedizin Berlin); 204 citations on Europe PMC."}]},{"id":"peter-pisters","kind":"person","name":"Peter W. T. Pisters","aka":[],"tldr":"Peter Pisters is the surgeon who has run the world's largest cancer centre since 2017.","summary":"Peter Pisters is President of MD Anderson Cancer Center, a role he has held since 2017, and was previously CEO of University Health Network in Toronto. A surgical oncologist specialising in soft-tissue sarcoma and pancreatic cancer, he now runs the world's largest cancer centre and leads its Moon Shots programme and its clinical and research enterprise. His papers include a Journal of Clinical Oncology report on rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy and intraoperative radiation therapy for resectable pancreatic adenocarcinoma and the long-term results of a prospective randomised trial of adjuvant brachytherapy in soft tissue sarcoma. His record links to sarcomas including GIST, pancreatic ductal adenocarcinoma and robotic and minimally invasive surgery.","asOf":"2026-09-08","links":[{"label":"MD Anderson faculty","url":"https://faculty.mdanderson.org/search?q=Peter%20W.%20T.%20Pisters"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Pisters%20PWT%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Peter%20W.%20T.%20Pisters"}],"tags":[],"related":[],"cancers":["sarcoma","pancreatic"],"sections":[],"technologies":["robotic-surgery"],"targets":[],"drugs":[],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President, MD Anderson Cancer Center","institutionId":"md-anderson","specialisms":["Surgical oncology","Sarcoma","Health system leadership"],"profiles":[{"label":"MD Anderson faculty","url":"https://faculty.mdanderson.org/search?q=Peter%20W.%20T.%20Pisters"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Pisters%20PWT%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Peter%20W.%20T.%20Pisters"}],"papers":[{"title":"Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma","journal":"Journal of Clinical Oncology","year":1998,"url":"https://doi.org/10.1200/JCO.1998.16.12.3843","doi":"10.1200/JCO.1998.16.12.3843"},{"title":"Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma","journal":"Journal of Clinical Oncology","year":1996,"url":"https://doi.org/10.1200/JCO.1996.14.3.859","doi":"10.1200/JCO.1996.14.3.859"}],"orcid":"0000-0001-6406-3420"},{"id":"petr-poloucek","kind":"person","name":"Petr Polouček","aka":[],"tldr":"Petr Polouček represents Motol University Hospital in the Organisation of European Cancer Institutes, which lists the centre among its members in Czech Republic.","summary":"Petr Polouček is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Motol University Hospital, its full member in Czech Republic. OnCo records the name from the OECI membership list so that the centre's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the institution's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Motol University Hospital website","url":"https://www.fnmotol.cz"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["motol-university-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Motol University Hospital to the Organisation of European Cancer Institutes","institutionId":"motol-university-hospital","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Motol University Hospital website","url":"https://www.fnmotol.cz"}],"papers":[{"title":"Impaired healing of pancreatic anastomoses (in Czech)","journal":"Rozhledy v chirurgii","year":2001,"note":"Europe PMC author record matched by affiliation"},{"title":"Bronchoplastic surgery for non-small-cell lung cancer (in Czech)","journal":"Rozhledy v chirurgii","year":2007,"note":"Europe PMC author record matched by affiliation"},{"title":"Long-term results after radical resections for pancreatic ductal adenocarcinoma (in Czech)","journal":"Rozhledy v chirurgii","year":2007,"note":"Europe PMC author record matched by affiliation"}]},{"id":"phil-knight","kind":"person","name":"Phil Knight","aka":["Phil and Penny Knight"],"tldr":"Phil and Penny Knight gave OHSU $100 million in 2008, a $500 million challenge in 2013 that Oregon met within two years, and $2 billion in 2025, described by OHSU as the largest gift to a US university.","summary":"Phil Knight, co-founder of Nike, and his wife Penny have made the Knight Cancer Institute at Oregon Health & Science University one of the best-funded cancer centres in the world. OHSU's history records a $100 million gift in 2008, after which the institute took the Knights' name; a $500 million challenge grant in 2013 that required OHSU to raise a matching $500 million; and, in 2015, the meeting of the $1 billion Knight Cancer Challenge with the help of a $100 million gift from Gert Boyle and $200 million in bonds from the Oregon Legislature. In 2025 the Knights gave a further $2 billion, described by OHSU as the largest gift to a US university in history, to fund Brian Druker's vision of transforming cancer care. Druker, the institute's director, led the clinical development of imatinib, the first targeted cancer drug; the Knight money built the Knight Cancer Research Building and a programme aimed at detecting lethal cancers early.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Phil_Knight","links":[{"label":"OHSU Knight Cancer Institute: mission and history","url":"https://www.ohsu.edu/knight-cancer-institute/knight-cancer-institute-mission-and-history"}],"tags":["hero","donor"],"related":[],"cancers":[],"sections":[],"technologies":["early-detection"],"targets":[],"drugs":["imatinib"],"companies":[],"institutions":["ohsu-knight"],"pathways":[],"terms":[],"trials":[],"people":["brian-druker","gert-boyle"],"bottlenecks":["b-funding-allocation","b-early-detection"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Nike co-founder whose gifts to OHSU Knight Cancer Institute total more than $2.6 billion","specialisms":["Cancer centre building","Early detection research","Challenge grants"],"profiles":[],"papers":[]},{"id":"philip-crosbie","kind":"person","name":"Philip Crosbie","aka":[],"tldr":"The Manchester respiratory physician who showed that if you park a CT scanner in a supermarket car park in a poor part of the city, people come, and the cancers you find are early ones.","summary":"Philip Crosbie is Clinical Professor of Respiratory Medicine at the University of Manchester and an honorary consultant at Wythenshawe Hospital, where the North West Lung Centre sits, with a visiting senior lectureship at the University of Leeds. His page says his research and clinical focus is the early detection of lung cancer, specifically targeted community-based low-dose CT screening.\n\nHe is first author of the Manchester Lung Health Check pilot papers in Thorax: the baseline round found that 75 percent of attendees came from the poorest fifth of the population and that 80 percent of the cancers detected were early stage, and the second round found 90 percent adherence, 79 percent of cancers at stage 1 and no interval cancers. A companion paper showed that location mattered: nearly a quarter of attendees said they would have been less likely to come to a hospital, and that was truest of current smokers and of the most deprived. He is co-chief investigator of the Yorkshire Lung Screening Trial with Matthew Callister and scientific lead on PROMINENT, a Cancer Research UK cohort study of the molecular signatures of smoking cessation.","asOf":"2026-09-25","links":[{"label":"University of Manchester staff page","url":"https://research.manchester.ac.uk/en/persons/philip.crosbie"}],"tags":["lung","screening","uk"],"related":["matthew-callister","john-field"],"cancers":["nsclc","lung-cancer"],"sections":["early-detection"],"technologies":["low-dose-ct-screening"],"targets":[],"drugs":[],"companies":[],"institutions":["the-christie"],"pathways":[],"terms":[],"trials":["ylst"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Respiratory Medicine, University of Manchester; Honorary Consultant, Wythenshawe Hospital, Manchester University NHS Foundation Trust","institutionId":"the-christie","specialisms":["Early detection of lung cancer","Community low-dose CT screening","Lung health checks"],"profiles":[{"label":"University of Manchester staff page","url":"https://research.manchester.ac.uk/en/persons/philip.crosbie"}],"papers":[{"title":"Implementing lung cancer screening: baseline results from a community-based Lung Health Check pilot in deprived areas of Manchester","journal":"Thorax","year":2019,"doi":"10.1136/thoraxjnl-2017-211377"},{"title":"Second round results from the Manchester Lung Health Check community-based targeted lung cancer screening pilot","journal":"Thorax","year":2019,"doi":"10.1136/thoraxjnl-2018-212547"}]},{"id":"philip-greenberg","kind":"person","name":"Philip D. Greenberg","aka":[],"tldr":"Immunologist who spent four decades engineering T cells to attack leukaemia and solid tumours.","summary":"Philip Greenberg is Head of the Program in Immunology at Fred Hutchinson Cancer Center and a past president of the American Association for Cancer Research (AACR). An immunologist who has spent four decades engineering T cells to attack leukaemia and solid tumours, he pioneered T-cell receptor-engineered cell therapy, including WT1-specific TCR-T for acute myeloid leukaemia after transplant and mesothelin-directed TCR-T for pancreatic cancer. His papers include a Nature Medicine report that T cell receptor gene therapy targeting WT1 prevents acute myeloid leukaemia relapse after transplant and an Advances in Immunology review of the mechanisms by which adoptively transferred T cells recognise and eliminate tumour cells. His work spans TCR-T and CAR-T cell therapy.","asOf":"2026-09-08","links":[{"label":"Fred Hutch faculty directory","url":"https://www.fredhutch.org/en/faculty-lab-directory.html?q=Philip%20D.%20Greenberg"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Greenberg%20PD%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Philip%20D.%20Greenberg"}],"tags":[],"related":[],"cancers":["aml","pancreatic"],"sections":[],"technologies":["tcr-t","car-t"],"targets":["mesothelin"],"drugs":[],"companies":[],"institutions":["fred-hutch","aacr"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Head, Program in Immunology, Fred Hutchinson Cancer Center","institutionId":"fred-hutch","specialisms":["T-cell immunotherapy","TCR-T","Leukaemia"],"profiles":[{"label":"Fred Hutch faculty directory","url":"https://www.fredhutch.org/en/faculty-lab-directory.html?q=Philip%20D.%20Greenberg"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Greenberg%20PD%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Philip%20D.%20Greenberg"}],"papers":[{"title":"T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant","journal":"Nature Medicine","year":2019,"url":"https://doi.org/10.1038/s41591-019-0472-9","doi":"10.1038/s41591-019-0472-9"},{"title":"Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells","journal":"Advances in Immunology","year":1991,"url":"https://doi.org/10.1016/s0065-2776(08)60778-6","doi":"10.1016/s0065-2776(08)60778-6"}],"orcid":"0000-0003-3812-647X"},{"id":"philip-kirwa","kind":"person","name":"Philip K. Kirwa","aka":[],"tldr":"Physician who is Chief Executive Officer of Moi Teaching and Referral Hospital in Eldoret, Kenya, the national referral hospital that hosts the AMPATH Oncology programme.","summary":"Dr Philip K. Kirwa is Chief Executive Officer of Moi Teaching and Referral Hospital (MTRH) in Eldoret, Kenya, the public national teaching and referral hospital that hosts the AMPATH Oncology programme. The hospital's management pages show him at the head of the executive structure, with Senior Director for Clinical Services Andrew Wandera and Senior Director for Administration and Finance Tarus B. Kipchumba reporting to him. The pages do not give an appointment date.","asOf":"2026-09-10","links":[{"label":"Source: Moi Teaching and Referral Hospital management team page","url":"https://www.mtrh.go.ke/?page_id=3857"}],"tags":["leadership","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["moi-teaching-referral-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive Officer, Moi Teaching and Referral Hospital","institutionId":"moi-teaching-referral-hospital","specialisms":["Hospital management","Medicine","Public health service leadership"],"profiles":[{"label":"MTRH Office of the CEO","url":"https://www.mtrh.go.ke/?page_id=24"},{"label":"MTRH hospital management team","url":"https://www.mtrh.go.ke/?page_id=3857"}],"papers":[]},{"id":"philip-chiu","kind":"person","name":"Philip Wai Yan Chiu","aka":[],"tldr":"Upper GI surgeon and Dean of the CUHK Faculty of Medicine, the academic home of Prince of Wales Hospital.","summary":"Philip Wai Yan Chiu is Dean of the Faculty of Medicine at The Chinese University of Hong Kong, whose teaching hospital is Prince of Wales Hospital. A professor of surgery, he is known for research on minimally invasive and endoscopic surgery for upper gastrointestinal diseases, including early gastric and oesophageal cancers.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.med.cuhk.edu.hk/staff/deanery"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chiu+PW%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","gastric cancer","surgical oncology"],"related":[],"cancers":["gastric","esophageal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["prince-of-wales-hospital-cuhk"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Dean, Faculty of Medicine","institutionId":"prince-of-wales-hospital-cuhk","specialisms":["Upper gastrointestinal surgery","Endoscopic surgery","Gastric and oesophageal cancer"],"profiles":[{"label":"Institution profile","url":"https://www.med.cuhk.edu.hk/staff/deanery"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chiu+PW%5BAuthor%5D"}],"papers":[{"title":"Long-term survival outcomes after definitive chemoradiation versus surgery in patients with resectable squamous carcinoma of the esophagus: results from a randomized controlled trial","journal":"Annals of Oncology","year":2013,"doi":"10.1093/annonc/mds206"},{"title":"Outcomes of Endoscopic Submucosal Dissection Versus Endoscopic Mucosal Resection in Management of Superficial Squamous Esophageal Neoplasms Outside Japan","journal":"Journal of Clinical Gastroenterology","year":2010,"doi":"10.1097/mcg.0b013e3181ce52fb"}]},{"id":"philippe-armand","kind":"person","name":"Philippe Armand","aka":[],"tldr":"Boston lymphoma doctor who led KEYNOTE-170, the trial that showed pembrolizumab can control relapsed primary mediastinal B-cell lymphoma, and who helped bring PD-1 blockade to Hodgkin lymphoma.","summary":"Philippe Armand is a lymphoma specialist at Dana-Farber Cancer Institute. He was first author of the 2019 Journal of Clinical Oncology report of KEYNOTE-170, in which pembrolizumab produced durable responses in relapsed or refractory primary mediastinal large B-cell lymphoma, supporting its approval in that setting, and was a lead investigator of the trials of nivolumab and pembrolizumab in relapsed classical Hodgkin lymphoma.","asOf":"2026-09-18","links":[],"tags":["lymphoma","immunotherapy","trialist"],"related":[],"cancers":["primary-mediastinal-b-cell-lymphoma","non-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["dana-farber"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-keynote-170-pembrolizumab-pmbcl-armand-jco-2019"],"journals":[],"dependsOn":[],"notes":[],"role":"Lymphoma specialist, Dana-Farber Cancer Institute","institutionId":"dana-farber","specialisms":["Hodgkin lymphoma","Primary mediastinal B-cell lymphoma","Checkpoint inhibitors in lymphoma"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Armand%5BAuthor%5D"}],"papers":[{"title":"KEYNOTE-170: pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma","journal":"Journal of Clinical Oncology","year":2019,"url":"https://doi.org/10.1200/JCO.19.01389","doi":"10.1200/JCO.19.01389"}]},{"id":"philippe-bergerot","kind":"person","name":"Philippe Bergerot","aka":[],"tldr":"Radiation oncologist who has presided over the Ligue nationale contre le cancer, France's national cancer charity, since 2024.","summary":"Philippe Bergerot is President of the Ligue nationale contre le cancer, the French national cancer charity that funds research, supports patients and campaigns on prevention. He is a cancer physician and radiotherapist and was elected to lead the organisation's board in June 2024. He chairs a seven member bureau that prepares and oversees the decisions of the board of directors.","asOf":"2026-09-10","links":[{"label":"Source: Ligue nationale contre le cancer, Qui sommes-nous (bureau)","url":"https://www.ligue-cancer.net/qui-sommesnous"}],"tags":["leadership","clinician-scientist","radiation-oncology","charity"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ligue-contre-le-cancer"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["bulletin-du-cancer"],"dependsOn":[],"notes":[],"role":"President of the Ligue nationale contre le cancer (since 2024)","institutionId":"ligue-contre-le-cancer","specialisms":["Radiation oncology","Cancer charity governance","Patient advocacy"],"profiles":[{"label":"Ligue governance page","url":"https://www.ligue-cancer.net/qui-sommesnous"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bergerot+P%5BAuthor%5D"}],"papers":[{"title":"Patients acteurs et formation en oncologie pour futurs médecins et pharmaciens","journal":"Bulletin du Cancer","year":2021,"doi":"10.1016/j.bulcan.2020.10.023"},{"title":"Randomized Trial of Radiation Therapy Versus Concomitant Chemotherapy and Radiation Therapy for Advanced-Stage Oropharynx Carcinoma","journal":"JNCI: Journal of the National Cancer Institute","year":1999,"doi":"10.1093/jnci/91.24.2081"},{"title":"Late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced-stage oropharynx carcinoma: comparison of LENT/SOMA, RTOG/EORTC, and NCI-CTC scoring systems","journal":"International Journal of Radiation Oncology*Biology*Physics","year":2003,"doi":"10.1016/s0360-3016(02)03819-1"}]},{"id":"philippe-leroy","kind":"person","name":"Philippe Leroy","aka":[],"tldr":"Philippe Leroy represents the King Albert II Cancer Institute of Cliniques universitaires Saint-Luc in the Organisation of European Cancer Institutes, which lists the centre among its full members in Belgium.","summary":"Philippe Leroy is listed by the Organisation of European Cancer Institutes (OECI) as the representative of the King Albert II Cancer Institute at Cliniques universitaires Saint-Luc, its full member in Belgium. OnCo records the name from the OECI membership list so that the centre's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the institution's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Institut Roi Albert II website","url":"https://www.institutroialbertdeux.be/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["king-albert-ii-cancer-institute"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of King Albert II Cancer Institute, Cliniques universitaires Saint-Luc to the Organisation of European Cancer Institutes","institutionId":"king-albert-ii-cancer-institute","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Institut Roi Albert II website","url":"https://www.institutroialbertdeux.be/"}],"papers":[]},{"id":"philippe-moreau","kind":"person","name":"Philippe Moreau","aka":[],"tldr":"Led MajesTEC-1 and CASSIOPEIA, bringing the first bispecific antibody and daratumumab quadruplets to myeloma.","summary":"Philippe Moreau (Nantes) was principal investigator of MajesTEC-1, the pivotal trial of teclistamab, the first BCMA-directed bispecific antibody approved for relapsed myeloma, and of CASSIOPEIA, which established daratumumab with bortezomib-thalidomide-dexamethasone in transplant-eligible patients. He has led IFM trials for two decades including the IFM 2009 transplant study and is a past chair of the IFM.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Moreau%20P%5BAuthor%5D%20myeloma%20teclistamab%20OR%20daratumumab"}],"tags":["myeloma","bispecific","trialist"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":["bispecific-antibody","t-cell-engager"],"targets":["bcma","cd38","cd3"],"drugs":["teclistamab"],"companies":[],"institutions":["chu-nantes"],"pathways":[],"terms":[],"trials":["majestec-1","majestec-3"],"people":[],"bottlenecks":[],"keyPapers":["paper-majestec-1-teclistamab-nejm-2022"],"journals":[],"dependsOn":[],"notes":[],"role":"Head of the Hematology Department, University Hospital Hôtel-Dieu, Nantes","institutionId":"chu-nantes","specialisms":["Multiple myeloma","Bispecific antibodies","Daratumumab combinations","Transplant-eligible myeloma"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Moreau%20P%5BAuthor%5D%20myeloma%20teclistamab%20OR%20daratumumab"}],"papers":[{"title":"Teclistamab in relapsed or refractory multiple myeloma (MajesTEC-1)","journal":"NEJM","year":2022,"doi":"10.1056/NEJMoa2203478"},{"title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA)","journal":"Lancet","year":2019,"doi":"10.1016/S0140-6736(19)31240-1"}]},{"id":"pia-nasvall","kind":"person","name":"Pia Näsvall","aka":[],"tldr":"Pia Näsvall represents Umeå University Hospital (Norrland University Hospital) in the Organisation of European Cancer Institutes, which lists the centre among its members in Sweden.","summary":"Pia Näsvall is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Umeå University Hospital (Norrland University Hospital), its member in Sweden. Umeå University Hospital is the university hospital for northern Sweden, run by Region Västerbotten with Umeå University, and an associate member of the Organisation of European Cancer Institutes. OnCo records the name from the OECI membership list so that the centre's page has a named contact point; the person's exact title, appointment date and biography are not yet recorded and should be checked on the institution's own pages before being relied on.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Umeå University Hospital (Norrland University Hospital) website","url":"https://www.regionvasterbotten.se/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["umea-university-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Umeå University Hospital (Norrland University Hospital) to the Organisation of European Cancer Institutes","institutionId":"umea-university-hospital","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Umeå University Hospital (Norrland University Hospital) website","url":"https://www.regionvasterbotten.se/"}],"papers":[{"title":"Quality of life in patients with a permanent stoma after rectal cancer surgery","journal":"Quality of Life Research","year":2016,"url":"https://doi.org/10.1007/s11136-016-1367-6","doi":"10.1007/s11136-016-1367-6","note":"OpenAlex author record matched by institution"},{"title":"Use of Prophylactic Mesh When Creating a Colostomy Does Not Prevent Parastomal Hernia","journal":"Annals of Surgery","year":2017,"url":"https://doi.org/10.1097/sla.0000000000002542","doi":"10.1097/sla.0000000000002542","note":"OpenAlex author record matched by institution"},{"title":"Parastomal Hernia Repair; Seldom Performed and Seldom Reported: Results From a Nationwide Survey","journal":"Scandinavian Journal of Surgery","year":2018,"url":"https://doi.org/10.1177/1457496918818984","doi":"10.1177/1457496918818984","note":"OpenAlex author record matched by institution"}]},{"id":"pia-vihinen","kind":"person","name":"Pia Vihinen","aka":[],"tldr":"Director who leads FICAN West, the regional cancer centre for western Finland hosted by Turku University Hospital and the Wellbeing services county of Southwest Finland.","summary":"Pia Vihinen is Director (johtaja) of Läntinen Syöpäkeskus, FICAN West, the regional cancer centre for western Finland that is hosted by Turku University Hospital (Tyks) within the Wellbeing services county of Southwest Finland (Varha). FICAN West's organisation page lists her as director and as presenting officer to its steering group, which also includes Mikko Pietilä, Director of Tyks Hospital Services. FICAN West is one of the five regional cancer centres that, with the national coordinating body, make up the Finnish National Cancer Center.","asOf":"2026-09-10","links":[{"label":"Source: FICAN West organisation page naming the director","url":"https://fican.fi/lantinen-syopakeskus/tietoa-meista/organisaatio/"}],"tags":["leadership","clinician-scientist","comprehensive-cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["fican"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["current-cancer-drug-targets","acta-oncologica"],"dependsOn":[],"notes":[],"role":"Director (johtaja), FICAN West (Läntinen Syöpäkeskus), Turku University Hospital","institutionId":"turku-university-hospital","specialisms":["Regional cancer centre management","Cancer research coordination"],"profiles":[{"label":"FICAN West organisation page (Finnish)","url":"https://fican.fi/lantinen-syopakeskus/tietoa-meista/organisaatio/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Vihinen+P%5BAuthor%5D"}],"papers":[{"title":"Matrix Metalloproteinases as Therapeutic Targets in Cancer","journal":"Current Cancer Drug Targets","year":2005,"doi":"10.2174/1568009053765799"},{"title":"Serum VEGF-C is associated with metastatic site in patients with malignant melanoma","journal":"Acta Oncologica","year":2007,"doi":"10.1080/02841860600965020"},{"title":"New prognostic factors and developing therapy of cutaneous melanoma","journal":"Annals of Medicine","year":2003,"doi":"10.1080/07853890310009980"}]},{"id":"sun-piaoyang","kind":"person","name":"Piaoyang Sun","aka":["孙飘扬"],"tldr":"Piaoyang Sun turned a small Lianyungang generics factory into Hengrui, China's largest originator drug company and the source of camrelizumab, apatinib and a dozen other approved cancer drugs.","summary":"Piaoyang Sun is Chairman of Jiangsu Hengrui Pharmaceuticals. He took over Hengrui in 1990 and turned a small Lianyungang generics factory into China's largest originator drug company, the source of camrelizumab, apatinib (rivoceranib), pyrotinib and a dozen other approved cancer drugs. Having reinvested heavily in research from the 2000s, he returned as chairman in 2021 to steer the company through China's generics price cuts toward innovative drugs, international licensing deals with Merck KGaA, IDEAYA and GSK, and the 2025 Hong Kong listing. His approach is pharmaceutical leadership built on a long-term research and development strategy.","asOf":"2026-09-10","links":[{"label":"Jiangsu Hengrui Pharmaceuticals","url":"https://www.hengrui.com/en/"}],"tags":["china"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["camrelizumab","rivoceranib","pyrotinib"],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chairman, Jiangsu Hengrui Pharmaceuticals","specialisms":["Pharmaceutical leadership","Research and development strategy"],"profiles":[{"label":"Jiangsu Hengrui Pharmaceuticals","url":"https://www.hengrui.com/en/"}],"papers":[]},{"id":"pier-giuseppe-pelicci","kind":"person","name":"Pier Giuseppe Pelicci","aka":[],"tldr":"Molecular oncologist who characterised PML-RARα in acute promyelocytic leukaemia and studies cancer stem cells.","summary":"Pier Giuseppe Pelicci is Director of Research at IEO, the European Institute of Oncology, in Milan and Professor at the University of Milan. A molecular oncologist, his specialisms are cancer biology, leukaemia, cancer stem cells and epigenetics. He characterised PML-RARα in acute promyelocytic leukaemia, and his work on that disease, on p66Shc and on stem cell self-renewal made IEO a leading basic research centre. His papers include a Cell Reports study of how p53 loss in breast cancer leads to Myc activation and increased cell plasticity, a study of humanised mice failing to reject human acute myeloid leukaemia cells, and a Nature Communications paper showing caloric restriction expands druggable LSD1-dependent cancer stem cells. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Pelicci%20PG%5BAuthor%5D%20leukemia"}],"tags":[],"related":[],"cancers":["aml"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ieo-milan"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director of Research, IEO; Professor, University of Milan","institutionId":"ieo-milan","specialisms":["Cancer biology","Leukaemia","Cancer stem cells","Epigenetics"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Pelicci%20PG%5BAuthor%5D%20leukemia"}],"papers":[{"title":"p53 Loss in Breast Cancer Leads to Myc Activation, Increased Cell Plasticity, and Expression of a Mitotic Signature with Prognostic Value","journal":"Cell Reports","year":2019,"doi":"10.1016/j.celrep.2018.12.071"},{"title":"Human cord blood (hCB)-CD34+ humanized mice fail to reject human acute myeloid leukemia cells","journal":"PLOS ONE","year":2019,"doi":"10.1371/journal.pone.0217345"},{"title":"Caloric restriction leads to druggable LSD1-dependent cancer stem cells expansion","journal":"Nature Communications","year":2024,"doi":"10.1038/s41467-023-44348-y"}]},{"id":"pierre-fenaux","kind":"person","name":"Pierre Fenaux","aka":[],"tldr":"Led AZA-001, which showed azacitidine extends survival in high-risk MDS and made hypomethylating agents standard.","summary":"Pierre Fenaux (Hôpital Saint-Louis, Paris) was principal investigator of AZA-001, the trial that showed azacitidine improves overall survival compared with conventional care in higher-risk myelodysplastic syndromes, the first drug to do so and the foundation of hypomethylating therapy in MDS and AML. He co-led the European APL trials with Laurent Degos that established all-trans retinoic acid and leads the Groupe Francophone des Myélodysplasies.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fenaux%20P%5BAuthor%5D%20azacitidine%20myelodysplastic"}],"tags":["mds","epigenetics","france"],"related":[],"cancers":["mds","aml"],"sections":[],"technologies":["epigenetic-drugs"],"targets":[],"drugs":[],"companies":[],"institutions":["aphp-nord-cancer-institute"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-imerge-imetelstat-mds-lancet-2024"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Hematology, Hôpital Saint-Louis, Université Paris Cité","institutionId":"aphp-nord-cancer-institute","specialisms":["Myelodysplastic syndromes","Hypomethylating agents","Acute promyelocytic leukaemia","Older patients with AML"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fenaux%20P%5BAuthor%5D%20azacitidine%20myelodysplastic"}],"papers":[{"title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study (AZA-001)","journal":"Lancet Oncology","year":2009,"doi":"10.1016/S1470-2045(09)70003-8"},{"title":"Myelodysplastic syndromes","journal":"Lancet","year":2014},{"title":"IMerge: imetelstat, a telomerase inhibitor, for transfusion-dependent lower-risk MDS after erythropoietin has failed","journal":"The Lancet","year":2024,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=IMerge%20imetelstat%20lower-risk%20MDS%20Platzbecker%20Lancet%202024"}]},{"id":"pierre-laurent-puig","kind":"person","name":"Pierre Laurent-Puig","aka":[],"tldr":"Oncology professor and Inserm team leader who directs the Institut du Cancer Paris CARPEM, the OECI-accredited comprehensive cancer centre of AP-HP Centre in Paris.","summary":"Professor Pierre Laurent-Puig is Director of the Institut du Cancer Paris CARPEM and of the SIRIC CARPEM, the integrated cancer research site certified by the Institut National du Cancer since 2012 and now in its CARPEM3 programme for 2023 to 2027. He is a professor of oncology at Université Paris Cité, leads a research team at the Centre de Recherche des Cordeliers (Inserm U1138) and practises at the Hôpital Européen Georges-Pompidou. The institute was created by the SIRIC CARPEM and AP-HP Centre Université Paris Cité to bring together adult cancer care, research and teaching across the group's hospitals, and was accredited as a Comprehensive Cancer Center by the OECI in 2022, the first within AP-HP. He is supported by co-deputy directors Professor Michaela Fontenay, head of biological haematology at AP-HP Centre, and Judith Favier, an Inserm research director at PARCC.","asOf":"2026-09-10","links":[{"label":"Source: CARPEM governance page","url":"https://carpem.fr/gouvernance/"},{"label":"Source: Institut du Cancer Paris CARPEM presentation","url":"https://carpem.fr/linstitut/"}],"tags":["leadership","clinician-scientist","comprehensive-cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["inca","oeci"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Institut du Cancer Paris CARPEM and SIRIC CARPEM, AP-HP Centre Université Paris Cité","institutionId":"carpem-aphp-centre","specialisms":["Oncology","Cancer genetics","Molecular biology","Precision medicine"],"profiles":[{"label":"CARPEM governance page","url":"https://carpem.fr/gouvernance/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Laurent-Puig+P%5BAuthor%5D"}],"papers":[{"title":"Clinical Relevance of KRAS -Mutated Subclones Detected with Picodroplet Digital PCR in Advanced Colorectal Cancer Treated with Anti-EGFR Therapy","journal":"Clinical Cancer Research","year":2015,"doi":"10.1158/1078-0432.ccr-14-0983"},{"title":"Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","journal":"Annals of Oncology","year":2020,"doi":"10.1016/j.annonc.2020.06.022"},{"title":"Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France Trial","journal":"Clinical Cancer Research","year":2021,"doi":"10.1158/1078-0432.ccr-21-0271"}]},{"id":"pierre-vera","kind":"person","name":"Pierre Vera","aka":[],"tldr":"Nuclear medicine physician who directs Centre Henri Becquerel, the comprehensive cancer centre for the Rouen area in Normandy.","summary":"Professeur Pierre Vera is Directeur Général of Centre Henri Becquerel, the Centre de Lutte Contre le Cancer in Rouen. He is a nuclear medicine physician, and the centre's organisation page records his appointment to a five-year term beginning in 2017. He works with Artus Paty, Directeur Général Adjoint, who has been at the centre since 2016, supported by a Comité de Direction (CODIR) and a Conférence Médicale d'Etablissement (CME). The centre is overseen by a board of directors chaired by a representative of the State.","asOf":"2026-09-10","links":[{"label":"Source: Centre Henri Becquerel organisation page","url":"https://www.becquerel.fr/le-centre/decouvrir-le-centre/organisation/"}],"tags":["leadership","clinician-scientist","comprehensive-cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["centre-henri-becquerel"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["lancet-oncology","critical-reviews-in-oncology-hematology","blood-cancer-journal"],"dependsOn":[],"notes":[],"role":"Directeur Général (Director General), Centre Henri Becquerel","institutionId":"centre-henri-becquerel","specialisms":["Nuclear medicine","Cancer imaging","Cancer centre management"],"profiles":[{"label":"Centre Henri Becquerel organisation page","url":"https://www.becquerel.fr/le-centre/decouvrir-le-centre/organisation/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Vera+P%5BAuthor%5D+AND+Rouen"}],"papers":[{"title":"Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7–IFCT-1402): a multicentre, randomised, controlled phase 2 trial","journal":"The Lancet Oncology","year":2024,"doi":"10.1016/s1470-2045(24)00320-6"},{"title":"Radiomics: Principles and radiotherapy applications","journal":"Critical Reviews in Oncology/Hematology","year":2019,"doi":"10.1016/j.critrevonc.2019.03.015"},{"title":"Non-invasive monitoring of diffuse large B-cell lymphoma by cell-free DNA high-throughput targeted sequencing: analysis of a prospective cohort","journal":"Blood Cancer Journal","year":2018,"doi":"10.1038/s41408-018-0111-6"}]},{"id":"pieter-sonneveld","kind":"person","name":"Pieter Sonneveld","aka":[],"tldr":"Led PERSEUS, which established daratumumab-VRd as the standard for transplant-eligible myeloma.","summary":"Pieter Sonneveld was principal investigator of PERSEUS, the trial showing daratumumab added to bortezomib-lenalidomide-dexamethasone before and after transplant improves progression-free survival and MRD negativity in newly diagnosed myeloma, and led the HOVON-65/GMMG-HD4 trial that established bortezomib in induction. He chairs the European Myeloma Network and has led HOVON myeloma trials for three decades.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sonneveld%20P%5BAuthor%5D%20myeloma%20daratumumab%20PERSEUS"}],"tags":["myeloma","transplant","hovon"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":["monoclonal-antibody","mrd-testing"],"targets":["cd38"],"drugs":[],"companies":["hovon"],"institutions":["erasmus-mc"],"pathways":[],"terms":[],"trials":["perseus"],"people":[],"bottlenecks":[],"keyPapers":["paper-perseus-dara-vrd-transplant-nejm-2024"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Hematology, Erasmus MC Cancer Institute; Chair, European Myeloma Network","institutionId":"erasmus-mc","specialisms":["Multiple myeloma","Transplant-eligible myeloma","Daratumumab quadruplets","Cooperative-group trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sonneveld%20P%5BAuthor%5D%20myeloma%20daratumumab%20PERSEUS"}],"papers":[{"title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma (PERSEUS)","journal":"NEJM","year":2024,"doi":"10.1056/NEJMoa2312054"},{"title":"Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial","journal":"JCO","year":2012,"doi":"10.1200/JCO.2011.39.6820"}]},{"id":"pilar-garrido","kind":"person","name":"Pilar Garrido","aka":[],"tldr":"Pilar Garrido is a thoracic oncologist and past president of the Spanish Society of Medical Oncology.","summary":"Pilar Garrido is Head of Medical Oncology at Hospital Universitario Ramón y Cajal in Madrid, Professor at the Universidad de Alcalá and a former Council member of the European Society for Medical Oncology (ESMO). A thoracic oncologist, her specialisms are lung cancer, precision oncology and health policy, and she is a past president of the Spanish Society of Medical Oncology. Her papers include the Spanish Lung Cancer Group Trial 9901 on complete resection after induction chemotherapy in stage III non-small-cell lung cancer, a JAMA Oncology study of the Lung Immune Prognostic Index and immune checkpoint inhibitor outcomes, and the Spanish national consensus on predictive biomarker testing in advanced non-small-cell lung cancer. Her publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Garrido%20P%5BAuthor%5D%20lung%20cancer"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["esmo"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["clinical-and-translational-oncology"],"dependsOn":[],"notes":[],"role":"Head of Medical Oncology, Hospital Universitario Ramón y Cajal; Professor, Universidad de Alcalá; former ESMO Council member","institutionId":"esmo","specialisms":["Lung cancer","Precision oncology","Health policy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Garrido%20P%5BAuthor%5D%20lung%20cancer"}],"papers":[{"title":"Long-Term Survival Associated With Complete Resection After Induction Chemotherapy in Stage IIIA (N2) and IIIB (T4N0-1) Non–Small-Cell Lung Cancer Patients: The Spanish Lung Cancer Group Trial 9901","journal":"Journal of Clinical Oncology","year":2007,"doi":"10.1200/jco.2007.12.0014"},{"title":"Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer","journal":"JAMA Oncology","year":2018,"doi":"10.1001/jamaoncol.2017.4771"},{"title":"Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology","journal":"Clinical and Translational Oncology","year":2019,"doi":"10.1007/s12094-019-02218-4"}]},{"id":"piotr-rutkowski","kind":"person","name":"Piotr Rutkowski","aka":[],"tldr":"Polish surgical oncologist who led the pooled EORTC and SWOG trials showing that imatinib shrinks dermatofibrosarcoma protuberans, a rare skin sarcoma driven by a PDGFB fusion.","summary":"Piotr Rutkowski heads the department of soft tissue and bone sarcoma and melanoma at the National Research Institute of Oncology in Warsaw. He was first author of the 2010 Journal of Clinical Oncology report pooling the EORTC and SWOG phase 2 trials of imatinib in locally advanced or metastatic dermatofibrosarcoma protuberans, which established the drug for unresectable disease. He is a leading investigator in European melanoma and GIST trials.","asOf":"2026-09-18","links":[],"tags":["sarcoma","melanoma","surgery","trialist"],"related":[],"cancers":["dermatofibrosarcoma-protuberans","melanoma","gist","sarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["nio-warsaw"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-imatinib-dfsp-eortc-swog-rutkowski-jco-2010"],"journals":[],"dependsOn":[],"notes":[],"role":"Surgical oncologist and head of soft tissue, bone sarcoma and melanoma, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw","institutionId":"nio-warsaw","specialisms":["Melanoma","Sarcoma and GIST","Dermatofibrosarcoma protuberans"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rutkowski%5BAuthor%5D"}],"papers":[{"title":"Imatinib in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase 2 trials (EORTC 62027 and SWOG S0345)","journal":"Journal of Clinical Oncology","year":2010,"url":"https://doi.org/10.1200/JCO.2009.25.7899","doi":"10.1200/JCO.2009.25.7899"}]},{"id":"polina-stepensky","kind":"person","name":"Polina Stepensky","aka":[],"tldr":"Runs a hospital department that makes its own CAR-T cells and gives them fresh, without freezing, at a fraction of what a commercial product costs.","summary":"Polina Stepensky directs bone marrow transplantation and cancer immunotherapy at Hadassah Medical Center, which manufactures its own chimeric antigen receptor T cells on site. Its anti-BCMA product HBI0101, later licensed as NXC-201, was given fresh without cryopreservation in a phase 1 dose-escalation study (NCT04720313). The first 20 heavily pretreated patients with relapsed or refractory multiple myeloma, reported in Haematologica in 2023, had an overall response rate of 75 percent with stringent or complete response in half, cytokine release syndrome only at grade 1 or 2 in 90 percent, and no neurotoxicity of any grade. The programme has since grown: a 2025 report in Cancers analyses coagulopathy in 108 patients treated on the same single-centre trial. The point of the work is not only the product but the model, that a hospital can make cell therapy for its own region rather than shipping cells across continents.","asOf":"2026-09-25","links":[{"label":"Hadassah Medical Center","url":"https://www.hadassah.org.il/en/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Stepensky%20P%5BAuthor%5D%20CAR"}],"tags":["clinician-scientist","cell-therapy"],"related":[],"cancers":["multiple-myeloma","dlbcl"],"sections":["cell-therapy"],"technologies":["car-t","allogeneic-cell-therapy"],"targets":["bcma","cd19"],"drugs":[],"companies":[],"institutions":["hadassah","hebrew-university-of-jerusalem"],"pathways":[],"terms":[],"trials":["nxc-201-mm"],"people":[],"bottlenecks":["b-manufacturing-cell-therapy"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah Medical Center","institutionId":"hadassah","specialisms":["Haematopoietic stem cell transplantation","Academic CAR-T manufacture","Multiple myeloma","Paediatric immunology"],"profiles":[{"label":"Hadassah Medical Center","url":"https://www.hadassah.org.il/en/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Stepensky%20P%5BAuthor%5D%20CAR"}],"papers":[{"title":"Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: results from a phase I clinical trial (HBI0101)","journal":"Haematologica","year":2023,"doi":"10.3324/haematol.2022.281628"},{"title":"High rate of cytokine release syndrome-related coagulopathy with low incidence of bleeding and thrombosis in patients treated with BCMA-targeted CAR-T","journal":"Cancers","year":2025,"doi":"10.3390/cancers17213551"}]},{"id":"poornima-parameswaran","kind":"person","name":"Poornima Parameswaran","aka":[],"tldr":"Poornima Parameswaran leads Future of Cancer Care Today, the Sijbrandij Foundation's free navigation service for cancer patients; she is a genomics scientist and entrepreneur.","summary":"Poornima Parameswaran is a scientist and entrepreneur whose work has focused on bridging scientific discovery and real-world impact. At Stanford University she developed technology that increased the scale and cut the cost of DNA sequencing by fifty-fold and taught the first course on applications of genomics, and she co-founded a genomics company before leading FCCT, whose PhD-led team surfaces diagnostic and treatment options for patients and curates suppliers who work beyond standard protocols.","asOf":"2026-09-10","links":[{"label":"FCCT","url":"https://sijbrandijfoundation.org/fcct"}],"tags":["leader","patient-first"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["future-of-cancer-care-today","sijbrandij-foundation"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive Officer, Future of Cancer Care Today (Sijbrandij Foundation)","specialisms":["Genomics","Patient navigation"],"profiles":[{"label":"FCCT","url":"https://sijbrandijfoundation.org/fcct"}],"papers":[]},{"id":"mathur-prashant","kind":"person","name":"Prashant Mathur","aka":[],"tldr":"Directs the institute that runs India's cancer registries and is first author of the national report estimating 1.39 million new cancers in 2020.","summary":"Prashant Mathur leads the ICMR institute in Bengaluru that coordinates the National Cancer Registry Programme and other noncommunicable disease registries. He is first author of Cancer Statistics, 2020: Report From National Cancer Registry Programme, India (JCO Global Oncology), which used 28 population-based and 58 hospital-based registries to project 1,392,179 cancers in 2020 and documented that most breast, cervical and head and neck cancers present at a locally advanced stage, and a senior author of the 2022 estimates and 2025 projections.","asOf":"2026-09-10","links":[{"label":"ICMR-NINE","url":"https://icmrnine.org"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mathur%20P%5BAuthor%5D%20National%20Cancer%20Registry%20Programme%20India"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["cancer-registries-surveillance"],"targets":[],"drugs":[],"companies":[],"institutions":["icmr-ncrp","icmr"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-data-silos"],"keyPapers":["paper-mathur-ncrp-cancer-statistics-2020"],"journals":[],"dependsOn":[],"notes":[],"role":"Director, ICMR-National Institute of Noncommunicable Disease Epidemiology (formerly NCDIR), Bengaluru","institutionId":"icmr-ncrp","specialisms":["Cancer registries","Cancer epidemiology","Noncommunicable disease surveillance","Health informatics"],"profiles":[{"label":"ICMR-NINE","url":"https://icmrnine.org"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mathur%20P%5BAuthor%5D%20National%20Cancer%20Registry%20Programme%20India"}],"papers":[{"title":"Cancer Statistics, 2020: Report From National Cancer Registry Programme, India","journal":"JCO Global Oncology","year":2020,"doi":"10.1200/GO.20.00122"},{"title":"Cancer incidence estimates for 2022 and projection for 2025: result from National Cancer Registry Programme, India","journal":"Indian Journal of Medical Research","year":2022,"doi":"10.4103/ijmr.ijmr_1821_22"}],"orcid":"0000-0002-9271-1373"},{"id":"priit-perens","kind":"person","name":"Priit Perens","aka":[],"tldr":"Former Swedbank chief executive who chairs the Executive Board of Tartu University Hospital, Estonia's largest teaching hospital.","summary":"Priit Perens is Chairman of the Executive Board of Tartu University Hospital (Tartu Ülikooli Kliinikum), the University of Tartu's teaching hospital with about 965 beds and roots going back to 1804. He holds a degree in economic cybernetics from the University of Tartu and has an extensive banking background, including serving as CEO of Swedbank AS from 2008 to 2014. He leads a board that includes Chief Medical Officer Dr Liis Salumäe, Head of Nursing and Patient Experience Saima Hinno and Head of Research and Development Professor Joel Starkopf.","asOf":"2026-09-10","links":[{"label":"Source: Tartu University Hospital members of the executive board","url":"https://www.kliinikum.ee/en/about-the-hospital/members-of-the-executive-board/"}],"tags":["leadership","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["tartu-university-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chairman of the Executive Board, Tartu University Hospital","institutionId":"tartu-university-hospital","specialisms":["Hospital management","Finance and governance"],"profiles":[{"label":"Tartu University Hospital executive board page","url":"https://www.kliinikum.ee/en/about-the-hospital/members-of-the-executive-board/"}],"papers":[]},{"id":"primo-lara","kind":"person","name":"Primo N. Lara Jr.","aka":[],"tldr":"Primo Lara is a GU and lung oncologist who co-chairs SWOG and directs UC Davis's cancer centre.","summary":"Primo Lara Jr. is Group Co-Chair of the SWOG Cancer Research Network and Director of the UC Davis Comprehensive Cancer Center. A genitourinary and lung medical oncologist, his research spans bladder, kidney and prostate cancer trials and phase 1 drug development, and he co-chairs SWOG with Dawn Hershman. His papers include a Journal of Clinical Oncology randomised phase III trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan in advanced non-small-cell lung cancer and a Lancet randomised phase 2 comparison of sunitinib with cabozantinib, crizotinib and savolitinib in advanced papillary renal cell carcinoma. His work covers bladder and urothelial cancer, renal cell carcinoma, prostate cancer and non-small-cell lung cancer.","asOf":"2026-09-08","links":[{"label":"SWOG leadership","url":"https://www.swog.org/about/leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lara%20PN%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Primo%20N.%20Lara%20Jr."}],"tags":[],"related":[],"cancers":["urothelial","rcc","prostate","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["swog"],"institutions":["uc-davis-cancer"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Group Co-Chair, SWOG Cancer Research Network; Director, UC Davis Comprehensive Cancer Center","institutionId":"swog","specialisms":["Genitourinary oncology","Lung cancer","Clinical trials"],"profiles":[{"label":"SWOG leadership","url":"https://www.swog.org/about/leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lara%20PN%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Primo%20N.%20Lara%20Jr."}],"papers":[{"title":"Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non–Small-Cell Lung Cancer","journal":"Journal of Clinical Oncology","year":2011,"url":"https://doi.org/10.1200/jco.2011.35.0660","doi":"10.1200/jco.2011.35.0660"},{"title":"A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial","journal":"Lancet","year":2021,"url":"https://doi.org/10.1016/S0140-6736(21)00152-5","doi":"10.1016/S0140-6736(21)00152-5"}]},{"id":"princess-chulabhorn","kind":"person","name":"Princess Chulabhorn","aka":[],"tldr":"Thai princess and professor of organic chemistry who founded and presides over the Chulabhorn Royal Academy, the parent body of Chulabhorn Hospital in Bangkok.","summary":"Princess Chulabhorn (Chulabhorn, Princess Srisavangavadhana) leads the Chulabhorn Royal Academy, the Thai royal academy whose departments include Chulabhorn Hospital in Bangkok. The Thai Wikipedia article on the Academy lists her as President of the Academy Council and Acting Secretary-General; the English article records that she is president of the Chulabhorn Research Institute and a Professor of Organic Chemistry at Mahidol University, having received her doctorate in chemistry in 1985 and the UNESCO Einstein Medal in 1986. The hospital's own website does not name a hospital director.","asOf":"2026-09-10","links":[{"label":"Source: Thai Wikipedia article on the Chulabhorn Royal Academy","url":"https://th.wikipedia.org/wiki/%E0%B8%A3%E0%B8%B2%E0%B8%8A%E0%B8%A7%E0%B8%B4%E0%B8%97%E0%B8%A2%E0%B8%B2%E0%B8%A5%E0%B8%B1%E0%B8%A2%E0%B8%88%E0%B8%B8%E0%B8%AC%E0%B8%B2%E0%B8%A0%E0%B8%A3%E0%B8%93%E0%B9%8C"}],"tags":["leadership","clinician-scientist","thailand"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["chulabhorn-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President of the Chulabhorn Royal Academy Council and Acting Secretary-General","institutionId":"chulabhorn-hospital","specialisms":["Organic chemistry","Scientific research leadership","Cancer care institutions"],"profiles":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Princess_Chulabhorn"}],"papers":[]},{"id":"priscilla-chan","kind":"person","name":"Priscilla Chan","aka":["Priscilla Chan and Mark Zuckerberg","Chan Zuckerberg Initiative"],"tldr":"She and Mark Zuckerberg founded the Chan Zuckerberg Biohub with the stated mission to cure or prevent all disease; its programmes include engineering the immune system to detect cancer and other diseases early.","summary":"Priscilla Chan, a paediatrician, and her husband Mark Zuckerberg founded the Chan Zuckerberg Initiative in 2015 and the Chan Zuckerberg Biohub in 2016 with UCSF, Stanford and UC Berkeley. The Biohub states its mission as to cure or prevent all disease, and its programmes include programming the immune system for early detection of disease, developing AI models and engineered cells to detect early signs of age-related diseases including cancer, and building tools for molecular-level measurement of inflammation in human tissues. CZI's science funding is deliberately disease-agnostic: cell atlases, imaging, open software and AI models of cells are meant to serve every disease, cancer among them. Founding sums are not stated on the pages consulted for this record and are not repeated here.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Priscilla_Chan","links":[{"label":"Chan Zuckerberg Biohub","url":"https://biohub.org/"},{"label":"Chan Zuckerberg Science","url":"https://chanzuckerberg.com/science/"}],"tags":["hero","donor"],"related":[],"cancers":[],"sections":[],"technologies":["early-detection","immunotherapy"],"targets":[],"drugs":[],"companies":[],"institutions":["cz-biohub","ucsf","stanford"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-early-detection","b-funding-allocation","b-data-silos"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Paediatrician who, with Mark Zuckerberg, founded the Chan Zuckerberg Initiative and the CZ Biohub","specialisms":["Basic biology funding","Cell atlases","Disease-agnostic science philanthropy"],"profiles":[],"papers":[]},{"id":"priya-rastogi","kind":"person","name":"Priya Rastogi","aka":[],"tldr":"Pittsburgh medical oncologist who serves as CEO and Medical Director of the NSABP Foundation, leading its breast cancer trial portfolio.","summary":"Priya Rastogi is Chief Executive Officer and Medical Director of the NSABP Foundation and Associate Professor of Medicine at the University of Pittsburgh. A breast medical oncologist, she was first author of the long-term update of the NSABP B-18 and B-27 neoadjuvant chemotherapy trials. She oversees the foundation's clinical trial operations and its participation in the NRG Oncology cooperative group.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.nsabp.org/about-us/the-team/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rastogi+P%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","breast cancer","clinical trials"],"related":[],"cancers":["breast-hr-positive","breast-her2-positive","tnbc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["nsabp-foundation"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive Officer & Medical Director","institutionId":"nsabp-foundation","specialisms":["Breast cancer","Neoadjuvant therapy","Clinical trials"],"profiles":[{"label":"Institution profile","url":"https://www.nsabp.org/about-us/the-team/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rastogi+P%5BAuthor%5D"}],"papers":[{"title":"Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27","journal":"Journal of Clinical Oncology","year":2008,"url":"https://doi.org/10.1200/JCO.2007.15.0235","doi":"10.1200/JCO.2007.15.0235"}]},{"id":"priyanka-sharma","kind":"person","name":"Priyanka Sharma","aka":[],"tldr":"Priyanka Sharma is a TNBC trialist testing whether anthracyclines can be dropped from pre-surgery treatment.","summary":"Priyanka Sharma is Professor of Medicine at The University of Kansas Cancer Center and Study Chair of SWOG S2212 (SCARLET) within the SWOG Cancer Research Network. A breast medical oncologist specialising in triple-negative breast cancer, platinum chemotherapy and de-escalation trials, she led NeoSTOP and now leads SCARLET, which compares anthracycline-free carboplatin and docetaxel plus pembrolizumab with the KEYNOTE-522 regimen, testing whether anthracyclines can be dropped from pre-surgery treatment. Her papers report the NeoSTOP randomised phase II trial of anthracycline-free and anthracycline-containing neoadjuvant carboplatin regimens in triple-negative breast cancer and a combined two-cohort analysis of neoadjuvant carboplatin plus docetaxel in the same disease.","asOf":"2026-09-08","links":[{"label":"SWOG leadership","url":"https://www.swog.org/about/leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sharma%20P%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Priyanka%20Sharma"}],"tags":[],"related":[],"cancers":["tnbc"],"sections":[],"technologies":[],"targets":[],"drugs":["carboplatin","pembrolizumab"],"companies":["swog"],"institutions":["ku-cancer-center"],"pathways":[],"terms":[],"trials":["scarlet-s2212"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medicine, University of Kansas Cancer Center; Study Chair, SWOG S2212 (SCARLET)","institutionId":"swog","specialisms":["Triple-negative breast cancer","Platinum chemotherapy","De-escalation trials"],"profiles":[{"label":"SWOG leadership","url":"https://www.swog.org/about/leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sharma%20P%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Priyanka%20Sharma"}],"papers":[{"title":"Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I-III Triple-negative Breast Cancer (NeoSTOP)","journal":"Clinical Cancer Research","year":2021,"url":"https://doi.org/10.1158/1078-0432.CCR-20-3646","doi":"10.1158/1078-0432.CCR-20-3646"},{"title":"Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts","journal":"Clinical Cancer Research","year":2017,"url":"https://doi.org/10.1158/1078-0432.CCR-16-0162","doi":"10.1158/1078-0432.CCR-16-0162"}]},{"id":"prudence-francis","kind":"person","name":"Prudence A. Francis","aka":[],"tldr":"Led SOFT and TEXT, the trials that showed ovarian suppression plus exemestane helps young women with breast cancer.","summary":"Prudence Francis chaired the IBCSG SOFT trial and co-led the joint SOFT/TEXT analysis showing that adding ovarian function suppression to tamoxifen, or using it with exemestane, reduces recurrence and improves survival in premenopausal HR-positive breast cancer. The results set the standard for adjuvant endocrine therapy in younger women. She leads breast medical oncology at Peter Mac and Breast Cancer Trials studies in Australia and New Zealand.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Francis%20PA%5BAuthor%5D%20SOFT%20TEXT"}],"tags":["breast","premenopausal","ibcsg"],"related":[],"cancers":["breast-hr-positive"],"sections":[],"technologies":["endocrine-therapy"],"targets":[],"drugs":[],"companies":["breast-cancer-trials"],"institutions":["peter-mac"],"pathways":[],"terms":[],"trials":["soft-text"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Head of Breast Medical Oncology, Peter MacCallum Cancer Centre","institutionId":"peter-mac","specialisms":["Premenopausal breast cancer","Ovarian function suppression","Adjuvant endocrine therapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Francis%20PA%5BAuthor%5D%20SOFT%20TEXT"}],"papers":[{"title":"Tailoring adjuvant endocrine therapy for premenopausal breast cancer (SOFT/TEXT)","journal":"NEJM","year":2018,"doi":"10.1056/NEJMoa1803164"},{"title":"Adjuvant ovarian suppression in premenopausal breast cancer (SOFT)","journal":"NEJM","year":2015,"doi":"10.1056/NEJMoa1412379"}],"orcid":"0000-0002-7207-9286"},{"id":"purnima-sundaresan","kind":"person","name":"Purnima Sundaresan","aka":[],"tldr":"Sydney radiation oncologist who is President of TROG Cancer Research, Australasia's radiation oncology trials group.","summary":"Purnima Sundaresan is President of the Board of TROG Cancer Research (Trans Tasman Radiation Oncology Group), the cooperative group that designs and runs radiotherapy clinical trials across Australia and New Zealand. A radiation oncologist and professor in Sydney, her research interests include clinical trials and health services research in radiation oncology. Her role is listed on TROG's board page.","asOf":"2026-09-10","links":[{"label":"Society page","url":"https://trog.com.au/about-us/our-board/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sundaresan+P%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","radiotherapy","clinical trials"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["trog"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["journal-of-medical-imaging-and-radiation-oncology"],"dependsOn":[],"notes":[],"role":"President","institutionId":"trog","specialisms":["Radiation oncology","Clinical trials","Health services research"],"profiles":[{"label":"Society page","url":"https://trog.com.au/about-us/our-board/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sundaresan+P%5BAuthor%5D"}],"papers":[{"title":"Adapting to a global pandemic through live virtual delivery of a cancer collaborative trial group conference: The TROG 2020 experience","journal":"Journal of Medical Imaging and Radiation Oncology","year":2020,"doi":"10.1111/1754-9485.13047"},{"title":"A review of the barriers to using Patient‐Reported Outcomes (PROs) and Patient‐Reported Outcome Measures (PROMs) in routine cancer care","journal":"Journal of Medical Radiation Sciences","year":2020,"doi":"10.1002/jmrs.421"},{"title":"Characteristics of chief investigators and principal investigators in Australian and New Zealand radiation oncology clinical trials","journal":"Journal of Medical Imaging and Radiation Oncology","year":2023,"doi":"10.1111/1754-9485.13564"}]},{"id":"qing-zhou","kind":"person","name":"Qing Zhou","aka":[],"tldr":"Chinese thoracic oncologist behind HARMONi-2, where the PD-1/VEGF bispecific ivonescimab beat pembrolizumab head to head.","summary":"Qing Zhou led HARMONi-2, the first randomised trial in which a new agent (ivonescimab, a PD-1 and VEGF bispecific antibody) beat pembrolizumab on progression-free survival in PD-L1-positive NSCLC, and HARMONi-A in EGFR-mutant disease after TKI failure. She works alongside Yi-Long Wu at the Guangdong Lung Cancer Institute and leads CTONG trials.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Zhou%20Q%5BAuthor%5D%20ivonescimab"}],"tags":["lung","bispecific","china"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["bispecific-antibody"],"targets":["pd1","vegf"],"drugs":["ivonescimab","pembrolizumab"],"companies":[],"institutions":["guangdong-provincial-peoples-hospital","csco"],"pathways":[],"terms":[],"trials":["harmoni-2"],"people":[],"bottlenecks":[],"keyPapers":["paper-harmoni-2-lancet-2025"],"journals":[],"dependsOn":[],"notes":[],"role":"Chief of Pulmonary Oncology, Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital","institutionId":"guangdong-provincial-peoples-hospital","specialisms":["EGFR-mutant lung cancer","Bispecific antibodies","Immunotherapy","Chinese lung cancer trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Zhou%20Q%5BAuthor%5D%20ivonescimab"}],"papers":[{"title":"Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2)","journal":"Lancet","year":2025},{"title":"Ivonescimab plus chemotherapy in non-small cell lung cancer with EGFR variant (HARMONi-A)","journal":"JAMA","year":2024,"doi":"10.1001/jama.2024.10613"},{"title":"HARMONi-2: ivonescimab, a PD-1 x VEGF bispecific, beats pembrolizumab head-to-head in PD-L1-positive lung cancer","journal":"The Lancet","year":2025,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=HARMONi-2+ivonescimab+pembrolizumab+Lancet"}]},{"id":"quincy-chu","kind":"person","name":"Quincy Chu","aka":[],"tldr":"Edmonton oncologist who was lead author of KEYNOTE-483 (CCTG IND.227), the trial that showed adding pembrolizumab to chemotherapy lengthens survival in pleural mesothelioma.","summary":"Quincy Chu is a medical oncologist at the Cross Cancer Institute in Edmonton and a thoracic disease site leader in the Canadian Cancer Trials Group. He was first author of the 2023 Lancet report of IND.227/KEYNOTE-483, the international phase 3 trial in which pembrolizumab plus platinum-pemetrexed chemotherapy improved overall survival compared with chemotherapy alone in untreated unresectable pleural mesothelioma, leading to the combination's approval.","asOf":"2026-09-18","links":[],"tags":["mesothelioma","immunotherapy","trialist"],"related":[],"cancers":["pleural-mesothelioma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cancer-care-alberta"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-keynote-483-lancet-2023"],"journals":[],"dependsOn":[],"notes":[],"role":"Medical oncologist, Cross Cancer Institute and University of Alberta, Edmonton","institutionId":"cancer-care-alberta","specialisms":["Mesothelioma","Lung cancer","Canadian Cancer Trials Group studies"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chu%5BAuthor%5D"}],"papers":[{"title":"KEYNOTE-483 (CCTG IND.227): pembrolizumab plus chemotherapy versus chemotherapy in untreated pleural mesothelioma","journal":"The Lancet","year":2023,"url":"https://doi.org/10.1016/S0140-6736(23)01613-6","doi":"10.1016/S0140-6736(23)01613-6"}]},{"id":"quynh-thu-le","kind":"person","name":"Quynh-Thu Le","aka":[],"tldr":"Chairs NRG Oncology, the largest US radiotherapy cooperative group, and leads head and neck de-escalation trials.","summary":"Quynh-Thu Le is group chair of NRG Oncology, which runs the national radiotherapy-based trials in the United States, and has led NRG head and neck studies including HN002 and HN005 on de-escalating radiotherapy for HPV-positive oropharyngeal cancer. Her laboratory studies tumour hypoxia and galectin-1 as targets and biomarkers, and she chairs radiation oncology at Stanford.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Quynh-Thu_Le","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Le%20QT%5BAuthor%5D%20head%20neck%20radiotherapy%20hypoxia"}],"tags":["radiotherapy","head-and-neck","nrg-oncology"],"related":[],"cancers":["head-and-neck"],"sections":[],"technologies":["imrt-igrt"],"targets":[],"drugs":[],"companies":[],"institutions":["stanford"],"pathways":[],"terms":[],"trials":["nrg-hn002-hn005"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Katharine Dexter McCormick and Stanley McCormick Memorial Professor and Chair of Radiation Oncology, Stanford University; Group Chair, NRG Oncology","institutionId":"stanford","specialisms":["Head and neck radiotherapy","Tumour hypoxia","Cooperative-group leadership","Biomarkers"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Le%20QT%5BAuthor%5D%20head%20neck%20radiotherapy%20hypoxia"}],"papers":[{"title":"Reduced-dose radiation therapy for HPV-associated oropharyngeal carcinoma (NRG Oncology HN002)","journal":"JCO","year":2021,"doi":"10.1200/JCO.20.03128"},{"title":"Galectin-1: a link between tumor hypoxia and tumor immune privilege","journal":"JCO","year":2005,"doi":"10.1200/jco.2005.02.0206"}],"orcid":"0000-0002-3682-1439"},{"id":"r-angelo-de-claro","kind":"person","name":"R. Angelo de Claro","aka":[],"tldr":"Haematologist-oncologist who has directed the FDA's Oncology Center of Excellence since March 2025 and previously led its global clinical sciences programme, including Project Orbis.","summary":"Angelo de Claro is Director of the Oncology Center of Excellence (OCE), the US Food and Drug Administration centre that coordinates the review of oncology products across the agency, a role he has held since March 2025 alongside a dual appointment as Deputy Office Director in the Office of Oncologic Diseases. A haematologist-oncologist, he joined the FDA in 2010 as a medical officer, became a team leader in 2012 and a Division Director in the Office of Oncologic Diseases in 2019. He has led OCE's global clinical sciences programme since 2019, including coordination of Project Orbis, and was instrumental in launching the Real-Time Oncology Review programme. He trained at the University of the Philippines and completed fellowship training at the University of Washington.","asOf":"2026-09-10","links":[{"label":"Source: OCE Who We Are page","url":"https://www.fda.gov/about-fda/oncology-center-excellence/who-we-are-oncology-center-excellence"}],"tags":["leadership","clinician-scientist","regulatory","haematology"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["fda-oce"],"pathways":[],"terms":["project-orbis"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Oncology Center of Excellence, US Food and Drug Administration","institutionId":"fda-oce","specialisms":["Regulatory oncology","Haematology-oncology","Global regulatory collaboration"],"profiles":[{"label":"Institution profile","url":"https://www.fda.gov/about-fda/fda-organization/r-angelo-de-claro"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=de+Claro+RA%5BAuthor%5D"}],"papers":[{"title":"U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma","journal":"Clinical Cancer Research","year":2012,"doi":"10.1158/1078-0432.ccr-12-1803"},{"title":"Project Orbis: Global Collaborative Review Program","journal":"Clinical Cancer Research","year":2020,"doi":"10.1158/1078-0432.ccr-20-3292"},{"title":"U.S. Food and Drug Administration: Initial Experience with the Real-Time Oncology Review Program","journal":"Clinical Cancer Research","year":2021,"doi":"10.1158/1078-0432.ccr-20-2220"}]},{"id":"r-r-w-j-van-der-hulst","kind":"person","name":"R.R.W.J. van der Hulst","aka":[],"tldr":"R.R.W.J. van der Hulst represents Maastricht UMC+ Comprehensive Cancer Center and OncoZON Comprehensive Cancer Network in the Organisation of European Cancer Institutes, which lists both among its members in The Netherlands.","summary":"R.R.W.J. van der Hulst is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Maastricht UMC+ Comprehensive Cancer Center and of OncoZON Comprehensive Cancer Network, its full members in The Netherlands. OnCo records the name from the OECI membership list so that the centre's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the institution's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Maastricht UMC+ Comprehensive Cancer Center website","url":"https://www.mumc.nl"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oncozon"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Maastricht UMC+ Comprehensive Cancer Center and OncoZON Comprehensive Cancer Network to the Organisation of European Cancer Institutes","institutionId":"maastricht-umc","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Maastricht UMC+ Comprehensive Cancer Center website","url":"https://www.mumc.nl"}],"papers":[{"title":"Glutamine and the preservation of gut integrity","journal":"The Lancet","year":1993,"url":"https://doi.org/10.1016/0140-6736(93)90939-e","doi":"10.1016/0140-6736(93)90939-e","note":"OpenAlex author record matched by institution"},{"title":"Breast Implants and the Risk of Anaplastic Large-Cell Lymphoma in the Breast","journal":"JAMA Oncology","year":2018,"url":"https://doi.org/10.1001/jamaoncol.2017.4510","doi":"10.1001/jamaoncol.2017.4510","note":"OpenAlex author record matched by institution"},{"title":"Increase of prevalence of craniosynostosis","journal":"Journal of Cranio-Maxillofacial Surgery","year":2016,"url":"https://doi.org/10.1016/j.jcms.2016.07.007","doi":"10.1016/j.jcms.2016.07.007","note":"OpenAlex author record matched by institution"}]},{"id":"raajit-rampal","kind":"person","name":"Raajit K. Rampal","aka":[],"tldr":"New York haematologist who led MANIFEST-2, the trial testing whether adding the BET inhibitor pelabresib to ruxolitinib helps people with myelofibrosis more than ruxolitinib alone.","summary":"Raajit Rampal directs the myeloproliferative neoplasms programme at Memorial Sloan Kettering Cancer Center. He was the global lead investigator and first author of the primary report of MANIFEST-2, the phase 3 trial of pelabresib plus ruxolitinib against placebo plus ruxolitinib in JAK inhibitor-naive myelofibrosis, which met its spleen-volume primary endpoint. His research covers the genetics of progression from chronic myeloproliferative neoplasms to acute leukaemia.","asOf":"2026-09-18","links":[],"tags":["mpn","trialist"],"related":[],"cancers":["primary-myelofibrosis","myeloproliferative-neoplasms"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":["manifest-2"],"people":[],"bottlenecks":[],"keyPapers":["paper-raajit-rampal-nature-2020","paper-raajit-rampal-blood-2014","paper-raajit-rampal-cancer-discov-2015"],"journals":[],"dependsOn":[],"notes":[],"role":"Haematologist, Memorial Sloan Kettering Cancer Center","institutionId":"mskcc","specialisms":["Myelofibrosis","Myeloproliferative neoplasms","Combination therapy trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rampal%5BAuthor%5D"}],"papers":[{"title":"Single-cell mutation analysis of clonal evolution in myeloid malignancies","journal":"Nature","year":2020,"url":"https://doi.org/10.1038/s41586-020-2864-x","doi":"10.1038/s41586-020-2864-x","note":"Europe PMC author record matched by affiliation (Memorial Sloan Kettering Cancer Center); 456 citations on Europe PMC."},{"title":"Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis","journal":"Blood","year":2014,"url":"https://doi.org/10.1182/blood-2014-02-554634","doi":"10.1182/blood-2014-02-554634","note":"Europe PMC author record matched by affiliation (Memorial Sloan Kettering Cancer Center); 349 citations on Europe PMC."},{"title":"JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response","journal":"Cancer Discovery","year":2015,"url":"https://doi.org/10.1158/2159-8290.cd-14-0736","doi":"10.1158/2159-8290.cd-14-0736","note":"Europe PMC author record matched by affiliation (Memorial Sloan Kettering Cancer Center); 279 citations on Europe PMC."}],"orcid":"0000-0002-0355-6368"},{"id":"rachel-dunscombe","kind":"person","name":"Rachel Dunscombe","aka":[],"tldr":"Digital health leader who became Chief Executive Officer of HL7 International in January 2026, succeeding its long-serving CEO Charles Jaffe.","summary":"Rachel Dunscombe is Chief Executive Officer of HL7 International, the standards development organisation behind HL7 v2, CDA and FHIR. Her appointment was announced on 8 January 2026, succeeding Charles Jaffe, who concluded his tenure as CEO that month. She was previously CEO of openEHR International, where she led global adoption of open health data standards, and before that CEO of the NHS Digital Academy; she has advised the UK Secretary of State for Health, served on the UK Government AI Council and holds a visiting professorship at Imperial College London. HL7 Europe's announcement describes her as a globally recognised leader in healthcare interoperability, digital health strategy and standards-based transformation.","asOf":"2026-09-10","links":[{"label":"Source: HL7 Europe news release on the HL7 International CEO appointment (January 2026)","url":"https://hl7europe.org/hl7-international-appoints-professor-rachel-dunscombe-as-ceo-to-lead-next-phase-of-global-interoperability/"}],"tags":["leadership","professional-society"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["hl7"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive Officer, HL7 International","institutionId":"hl7","specialisms":["Health data interoperability","Digital health strategy","Health data standards"],"profiles":[{"label":"HL7 Europe announcement of her appointment as CEO","url":"https://hl7europe.org/hl7-international-appoints-professor-rachel-dunscombe-as-ceo-to-lead-next-phase-of-global-interoperability/"}],"papers":[],"orcid":"0000-0002-2266-7063"},{"id":"rachel-rau","kind":"person","name":"Rachel E. Rau","aka":[],"tldr":"Paediatric oncologist who led the COG trial showing blinatumomab helps children with standard-risk leukaemia.","summary":"Rachel Rau is Associate Professor of Pediatrics at Seattle Children's and the University of Washington and Study Chair of COG AALL1731 within the Children's Oncology Group (COG). A paediatric haematologist-oncologist specialising in paediatric acute lymphoblastic leukaemia, immunotherapy and leukaemia genomics, she led the COG trial that found adding blinatumomab to chemotherapy helps children with newly diagnosed standard-risk B-ALL. Her papers report blinatumomab in standard-risk B-cell acute lymphoblastic leukaemia in children in the New England Journal of Medicine and a Blood study of DOT1L as a therapeutic target in DNMT3A-mutant acute myeloid leukaemia. Her work centres on CD19-directed immunotherapy in childhood leukaemia.","asOf":"2026-09-08","links":[{"label":"Children's Oncology Group","url":"https://childrensoncologygroup.org"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rau%20RE%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Rachel%20E.%20Rau"}],"tags":[],"related":[],"cancers":["all-leukemia"],"sections":[],"technologies":[],"targets":["cd19"],"drugs":["blinatumomab"],"companies":["childrens-oncology-group"],"institutions":[],"pathways":[],"terms":[],"trials":["aall1731"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Associate Professor of Pediatrics, Seattle Children's and University of Washington; Study Chair, COG AALL1731","institutionId":"childrens-oncology-group","specialisms":["Paediatric ALL","Immunotherapy","Leukaemia genomics"],"profiles":[{"label":"Children's Oncology Group","url":"https://childrensoncologygroup.org"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rau%20RE%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Rachel%20E.%20Rau"}],"papers":[{"title":"Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children","journal":"New England Journal of Medicine","year":2025,"url":"https://doi.org/10.1056/NEJMoa2411680","doi":"10.1056/NEJMoa2411680"},{"title":"DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia","journal":"Blood","year":2016,"url":"https://doi.org/10.1182/blood-2015-11-684225","doi":"10.1182/blood-2015-11-684225"},{"title":"Children's Oncology Group AALL1731: blinatumomab added to chemotherapy for children with standard-risk B-cell ALL","journal":"New England Journal of Medicine","year":2025,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=AALL1731%20blinatumomab%20standard-risk%20B-ALL%20children%20Gupta%20NEJM%202025"}],"orcid":"0000-0003-4096-6603"},{"id":"rachel-kerr","kind":"person","name":"Rachel Kerr","aka":[],"tldr":"The Oxford oncologist who led QUASAR 2 and co-led SCOT, the trial that cut adjuvant chemotherapy for bowel cancer from six months to three without losing benefit.","summary":"Rachel Kerr is a medical oncologist and Associate Professor of Gastrointestinal Oncology in the University of Oxford's Department of Oncology, works at Oxford University Hospitals NHS Trust within the colorectal cancer multidisciplinary team, and is clinical director of phase 3 trials at the Oncology Clinical Trials Office. She was first author of QUASAR 2, which showed that adding bevacizumab to adjuvant capecitabine did not improve disease-free survival, and second author of SCOT, which found three months of adjuvant oxaliplatin-fluoropyrimidine chemotherapy non-inferior to six months with far less lasting peripheral neuropathy.","asOf":"2026-09-24","links":[{"label":"University of Oxford staff page","url":"https://www.oncology.ox.ac.uk/team/rachel-kerr"}],"tags":["colorectal","trialist","uk"],"related":["tim-maughan"],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":["capecitabine","oxaliplatin","capox","bevacizumab"],"companies":[],"institutions":["oxford-cancer"],"pathways":[],"terms":[],"trials":["quasar","scot"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Associate Professor of Gastrointestinal Oncology, University of Oxford; Clinical Director of Phase 3 Trials, Oncology Clinical Trials Office","institutionId":"oxford-cancer","specialisms":["Adjuvant chemotherapy","Colorectal cancer trials","Trial methodology"],"profiles":[{"label":"University of Oxford staff page","url":"https://www.oncology.ox.ac.uk/team/rachel-kerr"}],"papers":[{"title":"Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial","journal":"Lancet Oncology","year":2016,"doi":"10.1016/S1470-2045(16)30172-3"},{"title":"3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial","journal":"Lancet Oncology","year":2018,"doi":"10.1016/S1470-2045(18)30093-7"}]},{"id":"rachel-michaelson-cohen","kind":"person","name":"Rachel Michaelson-Cohen","aka":[],"tldr":"Led the work of turning nine Israeli high-risk clinics, which were each doing something different, into one national protocol for looking after the carriers the screening programme keeps finding.","summary":"Rachel Michaelson-Cohen works at Shaare Zedek Medical Center on hereditary breast and ovarian cancer. When Israel began offering BRCA founder testing to all women of Ashkenazi origin in 2020, the number of healthy carriers referred to high-risk surveillance clinics rose sharply and the clinics turned out to disagree with one another: only one offered six-monthly MRI to BRCA1 carriers, five continued surveillance past 75, and one recommended none during pregnancy and breastfeeding. She led the comparative analysis of all nine clinics in the Israeli Consortium for hereditary breast and ovarian cancer and the consensus process that produced a single national protocol, published in Israel Journal of Health Policy Research: annual MRI from 25, mammography added from 30, risk-reducing salpingo-oophorectomy at 35 to 40 for BRCA1 and 40 to 45 for BRCA2, pancreatic surveillance from 50 for BRCA2 carriers, and no ovarian screening after surgery. Her group also published the Israeli cost-effectiveness analysis behind the screening policy.","asOf":"2026-09-25","links":[{"label":"Shaare Zedek Medical Center","url":"https://www.szmc.org.il/eng/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Michaelson-Cohen%20R%5BAuthor%5D%20BRCA"}],"tags":["clinician-scientist","genetics","policy"],"related":[],"cancers":["breast-hr-positive","ovarian","pancreatic"],"sections":["prevention"],"technologies":["germline-testing"],"targets":["brca"],"drugs":[],"companies":[],"institutions":["shaare-zedek"],"pathways":[],"terms":["founder-variant"],"trials":[],"people":[],"bottlenecks":["b-hereditary-risk"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Gynaecologist and medical geneticist, Shaare Zedek Medical Center; chair of the Israeli Consortium harmonising national BRCA carrier care","institutionId":"shaare-zedek","specialisms":["Hereditary breast and ovarian cancer","Risk-reducing surgery","Health policy","Genetic counselling"],"profiles":[{"label":"Shaare Zedek Medical Center","url":"https://www.szmc.org.il/eng/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Michaelson-Cohen%20R%5BAuthor%5D%20BRCA"}],"papers":[{"title":"Managing healthcare for female BRCA carriers in the population screening era: developing a harmonized national policy for surveillance and risk-reduction","journal":"Israel Journal of Health Policy Research","year":2026,"doi":"10.1186/s13584-026-00746-3"},{"title":"Real-world cost-effectiveness of population-based BRCA screening in Israel","journal":"Cancers","year":2022,"doi":"10.3390/cancers14246113"}]},{"id":"rachel-ramoni","kind":"person","name":"Rachel Ramoni","aka":[],"tldr":"Director of the Kaiser Permanente Division of Research, one of the largest health-system research units in the United States.","summary":"Rachel Ramoni is Director of the Kaiser Permanente Division of Research in Northern California, which conducts epidemiological, health services and clinical research using the records of millions of health plan members. Previously Chief Research and Development Officer at the US Department of Veterans Affairs, she leads a division whose cancer programme has shaped screening and outcomes research.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://divisionofresearch.kaiserpermanente.org/our-team/leadership-team/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ramoni+RB%5BAuthor%5D"}],"tags":["leadership","health services research","epidemiology"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["kaiser-permanente-research"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nature-communications"],"dependsOn":[],"notes":[],"role":"Director, Division of Research","institutionId":"kaiser-permanente-research","specialisms":["Health services research","Learning health systems","Research leadership"],"profiles":[{"label":"Institution profile","url":"https://divisionofresearch.kaiserpermanente.org/our-team/leadership-team/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ramoni+RB%5BAuthor%5D"}],"papers":[{"title":"Multi-ancestry GWAS meta-analyses of lung cancer reveal susceptibility loci and elucidate smoking-independent genetic risk","journal":"Nature Communications","year":2024,"doi":"10.1038/s41467-024-52129-4"}]},{"id":"kaliks-rafael","kind":"person","name":"Rafael Kaliks","aka":[],"tldr":"A São Paulo medical oncologist who has helped shape Einstein's precision oncology and quality programmes.","summary":"Rafael Kaliks is a medical oncologist and oncology leader at Hospital Israelita Albert Einstein in São Paulo. He has helped shape the hospital's precision oncology and quality programmes, leading institutional work on access to genomic testing, treatment quality and oncology within the Brazilian health system. His publications include a costing study of a pilot public-private partnership treating public-system breast cancer patients in a private centre, an update on clinical oncology for non-oncologists, and an analysis of how the COVID-19 pandemic could affect the quality of palliative care for cancer patients. His interests are medical oncology, precision oncology and health-system oncology.","asOf":"2026-09-08","links":[{"label":"Hospital Israelita Albert Einstein","url":"https://www.einstein.br"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kaliks%20R%5BAuthor%5D%20Einstein%20oncology"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["cgp"],"targets":[],"drugs":[],"companies":[],"institutions":["einstein-sao-paulo"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Medical oncologist; oncology leadership, Hospital Israelita Albert Einstein","institutionId":"einstein-sao-paulo","specialisms":["Medical oncology","Precision oncology","Health-system oncology"],"profiles":[{"label":"Hospital Israelita Albert Einstein","url":"https://www.einstein.br"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kaliks%20R%5BAuthor%5D%20Einstein%20oncology"}],"papers":[{"title":"Treatment of breast cancer patients from a public healthcare system in a private center: costs of care for a pilot public-private partnership in oncology","journal":"Einstein (São Paulo)","year":2013,"doi":"10.1590/s1679-45082013000200014"},{"title":"An update on clinical oncology for the non-oncologist","journal":"Einstein (São Paulo)","year":2016,"doi":"10.1590/s1679-45082016md3550"},{"title":"Palliative care to cancer patients: how COVID-19 pandemic could affect quality of care","journal":"einstein (São Paulo)","year":2022,"doi":"10.31744/einstein_journal/2022ao6459"}],"orcid":"0000-0003-4728-535X"},{"id":"rafael-mariano-grossi","kind":"person","name":"Rafael Mariano Grossi","aka":[],"tldr":"Argentine diplomat leading the IAEA since 2019, whose Rays of Hope initiative expands radiotherapy and nuclear medicine access in low- and middle-income countries.","summary":"Rafael Mariano Grossi has been Director General of the International Atomic Energy Agency since December 2019. Under his leadership the IAEA launched Rays of Hope, an initiative to close the gap in access to radiotherapy, diagnostic imaging and nuclear medicine for cancer in countries with little or no capacity. His role is recorded in the public record.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.iaea.org/services/rays-of-hope"}],"tags":["leadership","radiotherapy","global health"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["iaea"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["journal-of-cancer-policy"],"dependsOn":[],"notes":[],"role":"Director General","institutionId":"iaea","specialisms":["International diplomacy","Nuclear applications in health","Global cancer care access"],"profiles":[{"label":"Institution profile","url":"https://www.iaea.org/services/rays-of-hope"}],"papers":[{"title":"The IAEA’s Rays of Hope leverages nuclear science and collaboration to fight cancer in developing countries","journal":"Journal of Cancer Policy","year":2022,"doi":"10.1016/j.jcpo.2022.100357"}]},{"id":"rafael-perez-santamarina","kind":"person","name":"Rafael Pérez-Santamarina","aka":[],"tldr":"Rafael Pérez-Santamarina represents Hospital Universitario La Paz in the Organisation of European Cancer Institutes, which lists the centre among its members in Spain.","summary":"Rafael Pérez-Santamarina is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Hospital Universitario La Paz, its full member in Spain. OnCo records the name from the OECI membership list so that the centre's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the institution's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Hospital Universitario La Paz website","url":"https://www.comunidad.madrid/hospital/lapaz"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["la-paz"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Hospital Universitario La Paz to the Organisation of European Cancer Institutes","institutionId":"la-paz","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Hospital Universitario La Paz website","url":"https://www.comunidad.madrid/hospital/lapaz"}],"papers":[{"title":"Determining the value contribution of emicizumab (Hemlibra ® ) for the prophylaxis of haemophilia A with inhibitors in Spain by multi-criteria decision analysis","journal":"Global & Regional Health Technology Assessment","year":2019,"url":"https://doi.org/10.1177/2284240319880534","doi":"10.1177/2284240319880534","note":"OpenAlex author record matched by institution"},{"title":"Determining the value contribution of emicizumab (hemlibra®) for the prophylaxis of haemophilia a patients without inhibitors in Spain by multi-criteria decision analysis (MCDA)","journal":"Economía de la Salud","year":2020,"url":"https://doi.org/10.61679/1503035044","doi":"10.61679/1503035044","note":"OpenAlex author record matched by institution"}]},{"id":"raffit-hassan","kind":"person","name":"Raffit Hassan","aka":[],"tldr":"Made mesothelin a drug target, from immunotoxins to ADCs and CAR-T, and leads NCI's mesothelioma programme.","summary":"Raffit Hassan is Chief of the Thoracic and GI Malignancies Branch at the National Cancer Institute. He is a thoracic oncologist known for making mesothelin a drug target, with work on mesothelin biology and mesothelin-directed agents including the immunotoxins SS1P and LMB-100 and the antibody-drug conjugate anetumab. His selected paper asks whether mesothelin immunotherapy for cancer is ready for prime time. He leads NCI's mesothelioma programme, and his work underpins current CAR-T and ADC efforts in mesothelioma and pancreatic cancer.","asOf":"2026-09-08","links":[{"label":"NCI CCR profile","url":"https://ccr.cancer.gov/staff-directory/raffit-hassan"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hassan%20R%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["mesothelioma","pancreatic"],"sections":[],"technologies":[],"targets":["mesothelin"],"drugs":[],"companies":[],"institutions":["nci"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief, Thoracic and GI Malignancies Branch","institutionId":"nci","specialisms":["Mesothelioma","Mesothelin-targeted therapy","Immunotoxins"],"profiles":[{"label":"NCI CCR profile","url":"https://ccr.cancer.gov/staff-directory/raffit-hassan"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hassan%20R%5BAuthor%5D"}],"papers":[{"title":"Mesothelin immunotherapy for cancer: ready for prime time?","journal":"Journal of Clinical Oncology","year":2016}]},{"id":"rahul-aggarwal","kind":"person","name":"Rahul Aggarwal","aka":[],"tldr":"Prostate oncologist studying how tumours transform to escape hormone therapy and how to target them with radioligands.","summary":"Rahul Aggarwal is Associate Director for Clinical Sciences at the UCSF Helen Diller Family Comprehensive Cancer Center. A medical oncologist specialising in prostate cancer, neuroendocrine prostate cancer and PSMA theranostics, he leads UCSF's early-phase and prostate cancer clinical research and defined treatment-emergent small-cell neuroendocrine prostate cancer, the way tumours transform to escape hormone therapy. His papers include a multi-institutional prospective study characterising that disease clinically and genomically, and a report on heterogeneous flare in PSMA PET tracer uptake after starting androgen pathway blockade. He leads PSMA radioligand and combination trials, including with lutetium-177 vipivotide tetraxetan.","asOf":"2026-09-08","links":[{"label":"UCSF profile","url":"https://profiles.ucsf.edu/search/?searchtype=people&searchfor=Rahul%20Aggarwal"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Aggarwal%20R%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Rahul%20Aggarwal"}],"tags":[],"related":[],"cancers":["prostate"],"sections":[],"technologies":["psma-pet","radioligand-therapy"],"targets":["psma","androgen-receptor"],"drugs":["pluvicto"],"companies":[],"institutions":["ucsf"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["european-urology-oncology"],"dependsOn":[],"notes":[],"role":"Associate Director for Clinical Sciences, UCSF Helen Diller Family Comprehensive Cancer Center","institutionId":"ucsf","specialisms":["Prostate cancer","Neuroendocrine prostate cancer","PSMA theranostics"],"profiles":[{"label":"UCSF profile","url":"https://profiles.ucsf.edu/search/?searchtype=people&searchfor=Rahul%20Aggarwal"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Aggarwal%20R%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Rahul%20Aggarwal"}],"papers":[{"title":"Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study","journal":"Journal of Clinical Oncology","year":2018,"url":"https://doi.org/10.1200/JCO.2017.77.6880","doi":"10.1200/JCO.2017.77.6880"},{"title":"Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer","journal":"European Urology Oncology","year":2018,"url":"https://doi.org/10.1016/j.euo.2018.03.010","doi":"10.1016/j.euo.2018.03.010"}]},{"id":"purwar-rahul","kind":"person","name":"Rahul Purwar","aka":[],"tldr":"The IIT Bombay immunologist whose laboratory designed India's first approved CAR-T therapy and who founded the company that makes it for a fraction of Western prices.","summary":"Rahul Purwar leads an immunology and cell engineering laboratory at IIT Bombay, where work on a humanised CD19 CAR construct began in 2013. He founded ImmunoACT in 2018 as an IIT Bombay spin-off to take the therapy through trials with Tata Memorial Centre, first dosing patients in 2021 and securing DCGI approval for NexCAR19 (talicabtagene autoleucel) in 2023. ImmunoACT reports more than 600 patients treated at over 130 authorised centres, a manufacturing success rate of 98% and a facility capacity of 750 patients a year, expanding to 1,500.","asOf":"2026-09-10","links":[{"label":"ImmunoACT","url":"https://immunoact.com"},{"label":"IIT Bombay","url":"https://www.iitb.ac.in"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Purwar%20R%5BAuthor%5D%20CAR%20T%20India"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["car-t","point-of-care-cell-manufacturing"],"targets":["cd19"],"drugs":["talicabtagene-autoleucel"],"companies":["immunoact"],"institutions":["iit-bombay"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-manufacturing-cell-therapy","b-global-access"],"keyPapers":["paper-jain-talicabtagene-lancet-haem-2025"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor, Department of Biosciences and Bioengineering, IIT Bombay; founder, ImmunoACT","institutionId":"iit-bombay","specialisms":["CAR-T cell engineering","Immunology","Cell therapy manufacturing","Translational research"],"profiles":[{"label":"ImmunoACT","url":"https://immunoact.com"},{"label":"IIT Bombay","url":"https://www.iitb.ac.in"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Purwar%20R%5BAuthor%5D%20CAR%20T%20India"}],"papers":[{"title":"Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: results from an open-label, multicentre, phase 1/2 study","journal":"Lancet Haematology","year":2025,"doi":"10.1016/S2352-3026(24)00377-6"}]},{"id":"rajeev-singh-raghuvanshi","kind":"person","name":"Rajeev Singh Raghuvanshi","aka":[],"tldr":"India's Drugs Controller General, who heads the Central Drugs Standard Control Organisation, the national regulator for medicines, medical devices and clinical trials.","summary":"Dr Rajeev Singh Raghuvanshi is the Drugs Controller General of India (DCGI), the head of the Central Drugs Standard Control Organisation (CDSCO). The CDSCO 'Who's who' page lists him in that role alongside Joint Drugs Controllers including Dr S. Eswara Reddy, Dr V.G. Somani, Dr A. Visala and R. Chandrashekar. CDSCO is the Central Drug Authority under the Drugs and Cosmetics Act, responsible for approving new drugs, regulating clinical trials and setting standards for drugs, cosmetics and medical devices in India.","asOf":"2026-09-10","links":[{"label":"Source: CDSCO Who's who page","url":"https://cdsco.gov.in/opencms/opencms/en/About-us/who/"}],"tags":["leadership","government","regulation"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cdsco"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["critical-reviews-in-oncology-hematology","seminars-in-oncology"],"dependsOn":[],"notes":[],"role":"Drugs Controller General of India, Central Drugs Standard Control Organisation (CDSCO)","institutionId":"cdsco","specialisms":["Drug regulation","Pharmaceutical quality","Public administration"],"profiles":[{"label":"CDSCO Who's who page","url":"https://cdsco.gov.in/opencms/opencms/en/About-us/who/"}],"papers":[{"title":"Expedited pathway insights: Unveiling oncology and non-oncology drug approvals and withdrawals of USFDA and EMA","journal":"Critical Reviews in Oncology/Hematology","year":2025,"doi":"10.1016/j.critrevonc.2024.104539"},{"title":"Exploring the clinical trials, regulatory insights, and challenges of PROTACs in oncology","journal":"Seminars in Oncology","year":2025,"doi":"10.1016/j.seminoncol.2025.152339"}]},{"id":"badwe-rajendra","kind":"person","name":"Rajendra Badwe","aka":[],"tldr":"A surgeon-scientist whose low-cost randomised trials, from peritumoral lidocaine to timing of surgery, challenged assumptions in breast cancer.","summary":"Rajendra Badwe is a breast surgical oncologist and former Director of the Tata Memorial Centre in Mumbai, which he led for more than a decade. He is a surgeon-scientist whose low-cost randomised trials, from peritumoral lidocaine to the timing of surgery, challenged assumptions in breast cancer, and he ran large pragmatic trials in the disease. His publications include the randomised trial of peritumoral infiltration of local anaesthetic before surgery in early breast cancer. His interests are breast surgery, surgical oncology trials and perioperative interventions.","asOf":"2026-09-08","links":[{"label":"Tata Memorial Centre","url":"https://tmc.gov.in"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Badwe%20RA%5BAuthor%5D%20Tata%20Memorial%20breast"}],"tags":[],"related":[],"cancers":["breast-hr-positive","tnbc"],"sections":[],"technologies":["robotic-surgery"],"targets":[],"drugs":[],"companies":[],"institutions":["tata-memorial"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Former Director, Tata Memorial Centre; breast surgical oncologist","institutionId":"tata-memorial","specialisms":["Breast surgery","Surgical oncology trials","Perioperative interventions"],"profiles":[{"label":"Tata Memorial Centre","url":"https://tmc.gov.in"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Badwe%20RA%5BAuthor%5D%20Tata%20Memorial%20breast"}],"papers":[{"title":"Effect of peritumoral infiltration of local anesthetic before surgery on survival in early breast cancer","journal":"Journal of Clinical Oncology","year":2023,"doi":"10.1200/JCO.22.01966"},{"title":"Single-injection depot progesterone before surgery and survival in operable breast cancer","journal":"Journal of Clinical Oncology","year":2011,"url":"https://doi.org/10.1200/JCO.2010.33.0738","doi":"10.1200/JCO.2010.33.0738"}]},{"id":"rajesh-gokhale","kind":"person","name":"Rajesh S. Gokhale","aka":[],"tldr":"Chemical biologist who leads India's Department of Biotechnology as its Secretary, having previously directed the Institute of Genomics and Integrative Biology in New Delhi.","summary":"Rajesh Sudhir Gokhale leads the Department of Biotechnology (DBT) as Secretary to the Government of India; DBT, part of the Ministry of Science and Technology, funds biotechnology research and institutions across India. He is a chemical biologist whose work has focused on the metabolic diversity of pathogens, including the discovery of a family of long chain fatty acyl AMP ligases in Mycobacterium tuberculosis. He was Director of the Institute of Genomics and Integrative Biology from 2009 to 2016, is a professor of biology at IISER Pune, and received the Shanti Swarup Bhatnagar Prize in 2006. The DBT website was unreachable when checked, so this record relies on Wikipedia.","asOf":"2026-09-10","links":[{"label":"Source: Wikipedia article on Rajesh Sudhir Gokhale","url":"https://en.wikipedia.org/wiki/Rajesh_Sudhir_Gokhale"},{"label":"Source: Wikipedia article on the Department of Biotechnology (Secretary field)","url":"https://en.wikipedia.org/wiki/Department_of_Biotechnology"}],"tags":["leadership","government","research-institute"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["dbt-india"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Secretary, Department of Biotechnology, Government of India","institutionId":"dbt-india","specialisms":["Chemical biology","Microbial metabolism","Science administration"],"profiles":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Rajesh_Sudhir_Gokhale"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gokhale+RS%5BAuthor%5D"}],"papers":[{"title":"Enzymic activation and transfer of fatty acids as acyl-adenylates in mycobacteria","journal":"Nature","year":2004,"url":"https://doi.org/10.1038/nature02384","doi":"10.1038/nature02384","note":"Europe PMC author record matched by affiliation"},{"title":"NRPS-PKS: a knowledge-based resource for analysis of NRPS/PKS megasynthases","journal":"Nucleic Acids Res","year":2004,"url":"https://doi.org/10.1093/nar/gkh359","doi":"10.1093/nar/gkh359","note":"Europe PMC author record matched by affiliation"},{"title":"Multifaceted pathways protect human skin from UV radiation","journal":"Nat Chem Biol","year":2014,"url":"https://doi.org/10.1038/nchembio.1548","doi":"10.1038/nchembio.1548","note":"Europe PMC author record matched by affiliation"}]},{"id":"rakesh-heer","kind":"person","name":"Rakesh Heer","aka":[],"tldr":"The Imperial urologist who is research lead on TRANSFORM and joint chief investigator of the trial asking whether taking the lymph nodes out during a prostatectomy does any good.","summary":"Rakesh Heer is Chair of Urology at Imperial College London, where he works alongside Hashim Ahmed on the college's prostate screening and diagnosis programme. He is research lead on TRANSFORM, the multi-arm screening trial funded jointly by Prostate Cancer UK and the National Institute for Health and Care Research, and joint chief investigator with Krishna Narahari of ELIPSE, an NIHR-funded randomised trial of radical prostatectomy with or without pelvic lymph node dissection in high-risk localised disease, sponsored by Cardiff and Vale University Health Board. ELIPSE is the kind of question British surgical trials exist to answer: a step that is done because it has always been done, tested against not doing it.","asOf":"2026-09-25","links":[{"label":"Imperial College London profiles","url":"https://profiles.imperial.ac.uk/r.heer"}],"tags":["prostate","trialist","uk"],"related":["hashim-ahmed","mark-emberton"],"cancers":["prostate","prostate-high-risk"],"sections":["surgery","early-detection"],"technologies":["robotic-surgery"],"targets":[],"drugs":[],"companies":[],"institutions":["imperial-cancer-centre"],"pathways":[],"terms":[],"trials":["transform-prostate"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chair of Urology and Consultant Urological Surgeon, Department of Surgery and Cancer, Imperial College London","institutionId":"imperial-cancer-centre","specialisms":["Urological cancer surgery","Surgical trials","Prostate cancer screening"],"profiles":[{"label":"Imperial College London profiles","url":"https://profiles.imperial.ac.uk/r.heer"}],"papers":[]},{"id":"rakesh-padiyath","kind":"person","name":"Rakesh Padiyath","aka":[],"tldr":"Physician-executive who heads University Hospital Basel, Switzerland's oldest university hospital and home to its Tumour Centre.","summary":"Rakesh Padiyath, MD, MBA HSG, is Spitaldirektor (Hospital Director) of Universitätsspital Basel and chairs its five-member hospital management team. The hospital is a major Swiss academic medical centre whose Tumour Centre coordinates organ-specific cancer care and research with the University of Basel. His role is listed on the hospital's organisation and leadership page.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.unispital-basel.ch/ueber-uns/organisation-und-leitung"}],"tags":["leadership","hospital management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["usb-basel"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Hospital Director (Spitaldirektor) and Chair of Hospital Management","institutionId":"usb-basel","specialisms":["Hospital management","Health system leadership"],"profiles":[{"label":"Institution profile","url":"https://www.unispital-basel.ch/ueber-uns/organisation-und-leitung"}],"papers":[]},{"id":"ralf-c-bargou","kind":"person","name":"Ralf C. Bargou","aka":[],"tldr":"Professor of translational oncology who directs the Comprehensive Cancer Center Mainfranken at University Hospital Würzburg.","summary":"Professor Ralf C. Bargou is Direktor of the Comprehensive Cancer Center Mainfranken (CCC MF), the oncology centre of excellence of University Hospital Würzburg and the University of Würzburg, and holds the Chair of Translational Oncology. He also serves as Sprecher of the hospital's Onkologisches Zentrum. The CCC MF board includes Deputy Director Christoph-Thomas Germer and Managing Director Jutta Riese.","asOf":"2026-09-10","links":[{"label":"Source: CCC Mainfranken Vorstand page","url":"https://www.med.uni-wuerzburg.de/ccc/ueber-uns/vorstand/"}],"tags":["leadership","clinician-scientist","cancer-centre"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ccc-wuerzburg"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director of the Comprehensive Cancer Center Mainfranken","institutionId":"ccc-wuerzburg","specialisms":["Translational oncology","Haematology and oncology","Cancer centre leadership"],"profiles":[{"label":"Institution board page","url":"https://www.med.uni-wuerzburg.de/ccc/ueber-uns/vorstand/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bargou+RC%5BAuthor%5D"}],"papers":[{"title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","journal":"Blood","year":2018,"doi":"10.1182/blood-2017-08-798322"},{"title":"T cell-engaging therapies — BiTEs and beyond","journal":"Nature Reviews Clinical Oncology","year":2020,"doi":"10.1038/s41571-020-0347-5"},{"title":"Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study","journal":"Journal of Clinical Oncology","year":2016,"doi":"10.1200/jco.2014.59.1586"}]},{"id":"ralf-gutzmer","kind":"person","name":"Ralf Gutzmer","aka":[],"tldr":"German dermato-oncologist who was lead author of IMspire150, the trial that added atezolizumab to vemurafenib and cobimetinib in BRAF-mutant melanoma.","summary":"Ralf Gutzmer is a German dermato-oncologist who led skin cancer research at Hannover Medical School before moving to the Mühlenkreiskliniken in Minden. He was first author of the 2020 Lancet report of IMspire150, the phase 3 trial in which atezolizumab plus vemurafenib and cobimetinib lengthened progression-free survival compared with the two targeted drugs alone in untreated BRAF V600-mutant advanced melanoma, the first approval of a triplet combining immunotherapy and BRAF-MEK inhibition.","asOf":"2026-09-18","links":[],"tags":["melanoma","immunotherapy","trialist"],"related":[],"cancers":["braf-v600-melanoma","melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["imspire150"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Dermato-oncologist and trial lead","specialisms":["Melanoma","Targeted plus immunotherapy combinations","Dermato-oncology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gutzmer%5BAuthor%5D"}],"papers":[]},{"id":"ralph-weichselbaum","kind":"person","name":"Ralph Weichselbaum","aka":[],"tldr":"Radiation oncologist at the University of Chicago known for the oligometastasis concept and for research linking radiation with anti-tumour immunity.","summary":"Ralph Weichselbaum, MD, is a member of the Executive Committee of the University of Chicago Medicine Comprehensive Cancer Center and a long-standing leader of its radiation oncology programme. With Samuel Hellman he proposed the oligometastasis hypothesis, and his laboratory studies how radiation interacts with innate and adaptive immunity, including STING pathway signalling. His role is listed on the centre's leadership page.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Ralph_Weichselbaum","links":[{"label":"Institution profile","url":"https://www.uchicagomedicine.org/cancer/about-us/leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Weichselbaum+RR%5BAuthor%5D"}],"tags":["clinician-scientist","radiotherapy","immunotherapy"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["uchicago-cancer"],"pathways":[],"terms":["radiotherapy","immune-system"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Executive Committee Member","institutionId":"uchicago-cancer","specialisms":["Radiation oncology","Oligometastasis","Radiation and immunotherapy"],"profiles":[{"label":"Institution profile","url":"https://www.uchicagomedicine.org/cancer/about-us/leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Weichselbaum+RR%5BAuthor%5D"}],"papers":[{"title":"Radiotherapy and immunotherapy: a beneficial liaison?","journal":"Nature Reviews Clinical Oncology","year":2017,"doi":"10.1038/nrclinonc.2016.211"},{"title":"STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors","journal":"Immunity","year":2014,"doi":"10.1016/j.immuni.2014.10.019"},{"title":"Oligometastases revisited","journal":"Nature Reviews Clinical Oncology","year":2011,"doi":"10.1038/nrclinonc.2011.44"}],"orcid":"0000-0002-5643-8939"},{"id":"ramaswamy-govindan","kind":"person","name":"Ramaswamy Govindan","aka":[],"tldr":"Showed how smoking-related lung cancers carry ten times the mutations of never-smokers' tumours.","summary":"Ramaswamy Govindan holds the Anheuser-Busch Chair in Medical Oncology and is Director of the Section of Medical Oncology at Siteman Cancer Center, Washington University. He is a thoracic oncologist known for leading the genomic characterisation of lung cancer in smokers and never-smokers, showing that smoking-related tumours carry ten times the mutations of never-smokers' tumours. His selected paper reports the genomic landscape of non-small-cell lung cancer in smokers and never-smokers. He has led multiple cooperative-group lung trials and continues to work on immunotherapy in lung cancer.","asOf":"2026-09-08","links":[{"label":"WashU profile","url":"https://oncology.wustl.edu/people/ramaswamy-govindan-md/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Govindan%20R%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["wustl-siteman"],"pathways":[],"terms":["tmb"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Anheuser-Busch Chair in Medical Oncology; Director, Section of Medical Oncology","institutionId":"wustl-siteman","specialisms":["Lung cancer","Genomics of smokers' lung cancer","Immunotherapy"],"profiles":[{"label":"WashU profile","url":"https://oncology.wustl.edu/people/ramaswamy-govindan-md/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Govindan%20R%5BAuthor%5D"}],"papers":[{"title":"Genomic landscape of non-small cell lung cancer in smokers and never-smokers","journal":"Cell","year":2012,"url":"https://doi.org/10.1016/j.cell.2012.08.024","doi":"10.1016/j.cell.2012.08.024"}]},{"id":"ramez-eskander","kind":"person","name":"Ramez N. Eskander","aka":[],"tldr":"Led NRG-GY018, which showed pembrolizumab with chemotherapy helps advanced endometrial cancer in both MMR-deficient and proficient disease.","summary":"Ramez Eskander was principal investigator of NRG-GY018 (KEYNOTE-868), which showed adding pembrolizumab to carboplatin-paclitaxel improves progression-free survival in advanced or recurrent endometrial cancer in both mismatch repair-deficient and proficient populations, published alongside RUBY to establish chemo-immunotherapy as first-line standard. He leads gynaecologic oncology trials at UC San Diego and within NRG Oncology.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Eskander%20RN%5BAuthor%5D%20endometrial%20pembrolizumab"}],"tags":["endometrial","immunotherapy","nrg-oncology"],"related":[],"cancers":["endometrial"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["pd1"],"drugs":["pembrolizumab"],"companies":["gog-foundation"],"institutions":["ucsd-moores"],"pathways":[],"terms":[],"trials":["nrg-gy018-keynote-868"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Obstetrics, Gynecology and Reproductive Sciences, UC San Diego Moores Cancer Center","institutionId":"ucsd-moores","specialisms":["Endometrial cancer","Immunotherapy","Gynaecologic oncology surgery","Cooperative-group trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Eskander%20RN%5BAuthor%5D%20endometrial%20pembrolizumab"}],"papers":[{"title":"Pembrolizumab plus chemotherapy in advanced endometrial cancer (NRG-GY018)","journal":"NEJM","year":2023,"doi":"10.1056/NEJMoa2302312"},{"title":"Pembrolizumab plus chemotherapy in advanced endometrial cancer: overall survival and progression-free survival by mismatch repair status","journal":"JCO","year":2025}],"orcid":"0000-0002-2101-1935"},{"id":"ramon-parsons","kind":"person","name":"Ramon E. Parsons","aka":[],"tldr":"Discovered the tumour-suppressor gene PTEN, one of the most frequently lost genes in cancer.","summary":"Ramon E. Parsons is Director of the Tisch Cancer Institute and Chair of the Department of Oncological Sciences at The Mount Sinai Hospital. He is known for discovering the tumour-suppressor gene PTEN in 1997, one of the most frequently lost genes in cancer, and has since defined its roles in PI3K signalling and cancer predisposition. His selected paper reports PTEN as a putative protein tyrosine phosphatase gene mutated in human brain, breast and prostate cancer. He now directs Mount Sinai's cancer institute while continuing work on PTEN, PI3K and AKT signalling.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Parsons%20R%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["breast-hr-positive","prostate","glioblastoma"],"sections":[],"technologies":[],"targets":["pik3ca","akt"],"drugs":[],"companies":[],"institutions":["mount-sinai"],"pathways":["pi3k-akt-mtor"],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Tisch Cancer Institute; Chair, Department of Oncological Sciences","institutionId":"mount-sinai","specialisms":["PTEN and PI3K signalling","Breast cancer genetics","Tumour suppressors"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Parsons%20R%5BAuthor%5D"}],"papers":[{"title":"PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer","journal":"Science","year":1997,"url":"https://doi.org/10.1126/science.275.5308.1943","doi":"10.1126/science.275.5308.1943"}]},{"id":"ramon-reyes-bori","kind":"person","name":"Ramón Reyes Bori","aka":[],"tldr":"Ramón Reyes Bori represents Spanish Association Against Cancer (AECC) in the Organisation of European Cancer Institutes, which lists the organisation among its members in Spain.","summary":"Ramón Reyes Bori is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Spanish Association Against Cancer (AECC), its associate member in Spain. OnCo records the name from the OECI membership list so that the organisation's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the organisation's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Spanish Association Against Cancer (AECC) website","url":"https://www.contraelcancer.es/es"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["aecc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Spanish Association Against Cancer (AECC) to the Organisation of European Cancer Institutes","institutionId":"aecc","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Spanish Association Against Cancer (AECC) website","url":"https://www.contraelcancer.es/es"}],"papers":[]},{"id":"ramon-salazar-soler","kind":"person","name":"Ramon Salazar i Soler","aka":[],"tldr":"Director general who leads the Institut Català d'Oncologia, the Catalan public cancer institute that runs comprehensive cancer services across several hospital sites.","summary":"Ramon Salazar i Soler leads the Institut Català d'Oncologia (ICO) as director general. The ICO is the public cancer institute of the Generalitat de Catalunya, providing specialist cancer care, research and prevention through centres attached to hospitals in L'Hospitalet de Llobregat, Badalona, Girona and Tarragona. The ICO website's organisation and senior management pages did not display names when fetched, so this record relies on the Catalan Wikipedia article, which reports his appointment citing Redacción Médica.","asOf":"2026-09-10","links":[{"label":"Source: Catalan Wikipedia article on the ICO naming the director general","url":"https://ca.wikipedia.org/wiki/Institut_Catal%C3%A0_d%27Oncologia"}],"tags":["leadership","comprehensive-cancer-centre","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ico-catalonia"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["international-journal-of-cancer"],"dependsOn":[],"notes":[],"role":"Director General, Institut Català d'Oncologia (ICO)","institutionId":"ico-catalonia","specialisms":["Oncology","Cancer centre management","Public health system"],"profiles":[{"label":"Wikipedia (Catalan): Institut Català d'Oncologia","url":"https://ca.wikipedia.org/wiki/Institut_Catal%C3%A0_d%27Oncologia"},{"label":"ICO institutional pages","url":"https://ico.gencat.cat/ca/linstitut/"}],"papers":[{"title":"Post‐surgery level of circulating DNA in stage III colon cancer patients: Impact on the reliability of minimal residual disease detection","journal":"International Journal of Cancer","year":2026,"doi":"10.1002/ijc.70370"}]},{"id":"rana-mckay","kind":"person","name":"Rana McKay","aka":[],"tldr":"Genitourinary medical oncologist at UC San Diego Moores Cancer Center leading clinical science, with a strong trial record in prostate and kidney cancer.","summary":"Rana McKay, MD, is Associate Director for Clinical Science at UC San Diego Moores Cancer Center and a genitourinary medical oncologist. Her research includes investigator-initiated and cooperative-group trials in advanced prostate and renal cell carcinoma, biomarker development and health equity in GU cancers.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://moorescancercenter.ucsd.edu/about/leadership/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=McKay+RR%5BAuthor%5D"}],"tags":["clinician-scientist","prostate cancer","kidney cancer"],"related":[],"cancers":["prostate","rcc","urothelial"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ucsd-moores"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Associate Director, Clinical Science","institutionId":"ucsd-moores","specialisms":["Genitourinary oncology","Prostate cancer","Kidney cancer"],"profiles":[{"label":"Institution profile","url":"https://moorescancercenter.ucsd.edu/about/leadership/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=McKay+RR%5BAuthor%5D"}],"papers":[{"title":"Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone","journal":"Journal of Clinical Oncology","year":2019,"doi":"10.1200/jco.18.01777"},{"title":"Results of a Randomized Phase II Trial of Intense Androgen Deprivation Therapy prior to Radical Prostatectomy in Men with High-Risk Localized Prostate Cancer","journal":"Journal of Urology","year":2021,"doi":"10.1097/ju.0000000000001702"},{"title":"Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade","journal":"Prostate Cancer and Prostatic Diseases","year":2017,"doi":"10.1038/s41391-017-0009-6"}]},{"id":"randy-pausch","kind":"person","name":"Randy Pausch","aka":[],"tldr":"A computer scientist with terminal pancreatic cancer who gave a lecture in 2007 on achieving childhood dreams. Tens of millions watched it, and he testified to Congress for pancreatic cancer research funding before he died at 47.","summary":"Randy Pausch (1960-2008) was a professor of computer science at Carnegie Mellon University, a pioneer of virtual reality teaching and co-founder of its Entertainment Technology Center. He was diagnosed with pancreatic cancer in September 2006 and told in August 2007 that he had months to live. On 18 September 2007 he gave a lecture titled Really Achieving Your Childhood Dreams, which spread across the internet and became the book The Last Lecture, a bestseller in dozens of languages. In March 2008 he testified before a US Senate subcommittee in support of pancreatic cancer research funding through the Pancreatic Cancer Action Network. He died on 25 July 2008. His lecture is one of the most widely shared personal statements about facing a cancer with few treatment options.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Randy_Pausch","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Randy_Pausch"},{"label":"Carnegie Mellon: The Last Lecture","url":"https://www.cmu.edu/randyslecture/"}],"tags":["hero","patient"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-funding-allocation","b-patient-voice","b-palliative"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor whose Last Lecture became a public reckoning with terminal pancreatic cancer","specialisms":["Pancreatic cancer","Public communication","Research advocacy"],"profiles":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Randy_Pausch"},{"label":"Carnegie Mellon: The Last Lecture","url":"https://www.cmu.edu/randyslecture/"}],"papers":[]},{"id":"rashid-khalani","kind":"person","name":"Rashid Khalani","aka":[],"tldr":"Hospital executive who leads Aga Khan University Hospital, Nairobi, the private teaching hospital in Kenya that runs one of East Africa's largest cancer services.","summary":"Rashid Khalani leads Aga Khan University Hospital, Nairobi as Chief Executive Officer, according to the hospital's English Wikipedia article, which notes that he previously served as the hospital's Chief Finance Officer and succeeded Shawn Bolouki in the role. The hospital describes itself as a leading medical institution and teaching hospital for East Africa, with its own profile page setting out its vision, mission and core principles but not naming its executives. The hospital website did not give further biographical detail.","asOf":"2026-09-10","links":[{"label":"Source: Wikipedia article on the hospital (names the CEO)","url":"https://en.wikipedia.org/wiki/Aga_Khan_University_Hospital,_Nairobi"}],"tags":["leadership","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["aga-khan-university-hospital-nairobi"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive Officer, Aga Khan University Hospital, Nairobi","institutionId":"aga-khan-university-hospital-nairobi","specialisms":["Hospital management","Healthcare finance"],"profiles":[{"label":"Wikipedia: Aga Khan University Hospital, Nairobi","url":"https://en.wikipedia.org/wiki/Aga_Khan_University_Hospital,_Nairobi"},{"label":"Hospital profile page","url":"https://hospitals.aku.edu/nairobi/AboutUs/Pages/OurProfile.aspx"}],"papers":[]},{"id":"rashmi-murthy","kind":"person","name":"Rashmi K. Murthy","aka":[],"tldr":"Houston breast cancer doctor who was lead author of HER2CLIMB, the trial that established tucatinib for HER2-positive breast cancer, including in patients with brain metastases.","summary":"Rashmi Murthy is a breast medical oncologist at MD Anderson Cancer Center. She was first author of the 2020 New England Journal of Medicine report of HER2CLIMB, which showed that adding tucatinib to trastuzumab and capecitabine improved progression-free and overall survival in heavily pretreated HER2-positive metastatic breast cancer, with benefit in the large group of patients with brain metastases.","asOf":"2026-09-18","links":[],"tags":["breast","trialist"],"related":[],"cancers":["her2-positive-breast-brain-metastases","breast-her2-positive","breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-her2climb-nejm-2020"],"journals":[],"dependsOn":[],"notes":[],"role":"Breast medical oncologist, MD Anderson Cancer Center","institutionId":"md-anderson","specialisms":["HER2-positive breast cancer","Brain metastases","Tyrosine kinase inhibitors"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Murthy%5BAuthor%5D"}],"papers":[{"title":"HER2CLIMB: tucatinib with trastuzumab and capecitabine for HER2-positive metastatic breast cancer, including brain metastases","journal":"New England Journal of Medicine","year":2020,"url":"https://doi.org/10.1056/NEJMoa1914609","doi":"10.1056/NEJMoa1914609"}]},{"id":"rasmus-mogelvang","kind":"person","name":"Rasmus Møgelvang","aka":[],"tldr":"Cardiologist who has served as Hospital Director of Rigshospitalet, Denmark's largest and most specialised hospital, since 2023.","summary":"Rasmus Møgelvang has been Hospital Director (hospitalsdirektør) of Rigshospitalet, Copenhagen University Hospital, since 2023. A cardiologist by training, he leads Denmark's principal tertiary and quaternary referral hospital. Rigshospitalet hosts the country's largest cancer treatment and research programmes, including its Centre for Cancer and Organ Diseases.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.rigshospitalet.dk/english"}],"tags":["leadership","cardiology"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["rigshospitalet"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Hospital Director","institutionId":"rigshospitalet","specialisms":["Hospital leadership","Cardiology"],"profiles":[{"label":"Institution profile","url":"https://www.rigshospitalet.dk/english"}],"papers":[{"title":"A Randomized Trial of His Pacing Versus Biventricular Pacing in Symptomatic HF Patients With Left Bundle Branch Block (His-Alternative)","journal":"JACC Clin Electrophysiol","year":2021,"url":"https://doi.org/10.1016/j.jacep.2021.04.003","doi":"10.1016/j.jacep.2021.04.003","note":"Europe PMC author record matched by affiliation"},{"title":"Transjugular intrahepatic portosystemic shunt: impact on systemic hemodynamics and renal and cardiac function in patients with cirrhosis","journal":"Am J Physiol Gastrointest Liver Physiol","year":2018,"url":"https://doi.org/10.1152/ajpgi.00094.2017","doi":"10.1152/ajpgi.00094.2017","note":"Europe PMC author record matched by affiliation"},{"title":"Electrocardiographic changes improve risk prediction in asymptomatic persons age 65 years or above without cardiovascular disease","journal":"J Am Coll Cardiol","year":2014,"url":"https://doi.org/10.1016/j.jacc.2014.05.050","doi":"10.1016/j.jacc.2014.05.050","note":"Europe PMC author record matched by affiliation"}]},{"id":"ratan-tata","kind":"person","name":"Ratan Tata","aka":[],"tldr":"Under his chairmanship Tata Trusts launched a cancer care programme in 2017 to bring affordable treatment closer to home: 20 hospitals across seven states and, with the Assam government, a three-level network of 19 cancer facilities across the north-east.","summary":"Ratan Tata (1937-2024) chaired Tata Sons for two decades and Tata Trusts until his death, and made cancer the Trusts' largest healthcare commitment. Tata Trusts records that its Cancer Care Programme was introduced in 2017 with a vision to transform cancer care in India by making affordable, high-quality care available closer to patients' homes, through a distributed model built on access, quality, affordability, and awareness, early detection and palliative care. The Trusts are building a network of 20 hospitals across Andhra Pradesh, Assam, Jharkhand, Maharashtra, Uttar Pradesh, Odisha and Gujarat. The Assam Cancer Care Foundation, established in 2017 in partnership with the Government of Assam, created a three-level network of two apex research centres, twelve district-level treatment facilities and five day-care centres serving the whole north-east. The programme's stated aim is to reverse India's 30:70 ratio of early to late detection. The Tata Medical Center in Kolkata, opened in 2012, serves eastern India.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Ratan_Tata","links":[{"label":"Tata Trusts: cancer care","url":"https://www.tatatrusts.org/our-work/healthcare/cancer-care"}],"tags":["hero","donor"],"related":[],"cancers":[],"sections":[],"technologies":["early-detection","palliative-care"],"targets":[],"drugs":[],"companies":[],"institutions":["tata-trusts","tata-memorial","tata-medical-center-kolkata"],"pathways":[],"terms":[],"trials":[],"people":["dorabji-tata"],"bottlenecks":["b-global-access","b-early-detection","b-care-fragmentation"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chairman of Tata Trusts, whose cancer care programme is building a network of 20 hospitals across seven Indian states","specialisms":["Distributed cancer care","Cancer care in India","Early detection"],"profiles":[],"papers":[]},{"id":"ravindra-uppaluri","kind":"person","name":"Ravindra Uppaluri","aka":[],"tldr":"Surgeon-scientist who led the first neoadjuvant pembrolizumab trial in head and neck cancer and the KEYNOTE-689 study that made it standard.","summary":"Ravindra Uppaluri led the first window-of-opportunity trial of neoadjuvant pembrolizumab in resectable head and neck squamous cell carcinoma, defining pathological response as a marker, and was global principal investigator of KEYNOTE-689, which showed perioperative pembrolizumab improves event-free survival in locally advanced resectable disease, the first new curative-intent approach in two decades. His laboratory studies immune escape in head and neck cancer.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Uppaluri%20R%5BAuthor%5D%20neoadjuvant%20pembrolizumab%20head%20neck"}],"tags":["head-and-neck","surgery","neoadjuvant"],"related":[],"cancers":["head-and-neck"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["pd1"],"drugs":["pembrolizumab"],"companies":[],"institutions":["dana-farber"],"pathways":[],"terms":[],"trials":["keynote-689"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief of Otolaryngology-Head and Neck Surgery, Brigham and Women's Hospital and Dana-Farber Cancer Institute","institutionId":"dana-farber","specialisms":["Head and neck surgery","Neoadjuvant immunotherapy","Tumour immunology","Pathological response"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Uppaluri%20R%5BAuthor%5D%20neoadjuvant%20pembrolizumab%20head%20neck"}],"papers":[{"title":"Neoadjuvant and adjuvant pembrolizumab in advanced head and neck squamous cell carcinoma (KEYNOTE-689)","journal":"NEJM","year":2025},{"title":"Neoadjuvant and adjuvant pembrolizumab in resectable locally advanced, human papillomavirus-unrelated head and neck cancer: a multicenter, phase II trial","journal":"Clinical Cancer Research","year":2020,"doi":"10.1158/1078-0432.CCR-20-1695"}],"orcid":"0000-0001-5988-6828"},{"id":"raymond-dubois","kind":"person","name":"Raymond N. DuBois","aka":[],"tldr":"Physician-scientist known for work on inflammation in gastrointestinal cancers who directs MUSC Hollings Cancer Center, South Carolina's NCI-designated cancer centre.","summary":"Raymond N. DuBois, MD, PhD, is Director of MUSC Hollings Cancer Center, Associate Provost for Cancer Programs and Professor of Biochemistry and Molecular Biology at the Medical University of South Carolina in Charleston. The centre describes him as an internationally known scientist whose research has clarified the role of inflammation in gastrointestinal cancers, with more than 160 peer-reviewed articles among 274 publications cited over 70,000 times, and who was elected to the National Academy of Medicine in 2019. He earned his bachelor's degree from Texas A&M University, his PhD from UT Southwestern and his MD from UT San Antonio, and trained at Johns Hopkins Hospital in the laboratory of Nobel laureate Daniel Nathans.","asOf":"2026-09-10","links":[{"label":"Source: MUSC Hollings Cancer Center leadership page","url":"https://hollingscancercenter.musc.edu/about/leadership"}],"tags":["leadership","clinician-scientist","comprehensive-cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["musc-hollings"],"pathways":[],"terms":["inflammation"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, MUSC Hollings Cancer Center, and Associate Provost for Cancer Programs, Medical University of South Carolina","institutionId":"musc-hollings","specialisms":["Gastrointestinal cancer biology","Inflammation and cancer","Cancer centre leadership"],"profiles":[{"label":"Hollings Cancer Center leadership page","url":"https://hollingscancercenter.musc.edu/about/leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=DuBois+RN%5BAuthor%5D"}],"papers":[{"title":"Role of prostanoids in gastrointestinal cancer","journal":"Journal of Clinical Investigation","year":2018,"doi":"10.1172/jci97953"},{"title":"Cyclooxygenases and Prostaglandins in Tumor Immunology and Microenvironment of Gastrointestinal Cancer","journal":"Gastroenterology","year":2021,"doi":"10.1053/j.gastro.2021.09.059"},{"title":"Prostaglandin E2 Induces miR675-5p to Promote Colorectal Tumor Metastasis via Modulation of p53 Expression","journal":"Gastroenterology","year":2020,"doi":"10.1053/j.gastro.2019.11.013"}],"orcid":"0000-0002-6385-7154"},{"id":"razelle-kurzrock","kind":"person","name":"Razelle Kurzrock","aka":[],"tldr":"Precision oncology pioneer who showed that matching drugs to each patient's mutations, in combination, improves outcomes.","summary":"Razelle Kurzrock (Medical College of Wisconsin; formerly MD Anderson and UC San Diego) built one of the first large precision oncology programmes and led the I-PREDICT trial, which showed that individualised combination therapy matched to a higher fraction of a tumour's alterations improves progression-free survival. She founded the WIN Consortium and the field's methodology for N-of-1 matching, and has led early-phase trials in rare and refractory cancers.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kurzrock%20R%5BAuthor%5D%20precision%20oncology%20matched"}],"tags":["precision-oncology","early-phase","n-of-1"],"related":[],"cancers":[],"sections":[],"technologies":["cgp","ai-trial-matching"],"targets":[],"drugs":[],"companies":[],"institutions":["mcw-cancer-center"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medicine, Medical College of Wisconsin; Linda T. and John A. Mellowes Endowed Chair in Precision Oncology","institutionId":"mcw-cancer-center","specialisms":["Precision oncology","Early-phase trials","N-of-1 combination therapy","Rare cancers"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kurzrock%20R%5BAuthor%5D%20precision%20oncology%20matched"}],"papers":[{"title":"Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study","journal":"Nature Medicine","year":2019,"doi":"10.1038/s41591-019-0407-5"},{"title":"Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative","journal":"Clinical Cancer Research","year":2012,"doi":"10.1158/1078-0432.CCR-12-1627"}]},{"id":"rebecca-auer","kind":"person","name":"Rebecca Auer","aka":[],"tldr":"Cancer surgeon and scientist who leads research and innovation at The Ottawa Hospital and its research institute.","summary":"Rebecca Auer is Executive Vice-President, Research and Innovation at The Ottawa Hospital and a Senior Scientist in cancer research at the Ottawa Hospital Research Institute, the not-for-profit corporation that fulfils the hospital's research mission. A surgical oncologist, her research examines how surgery promotes metastasis through the coagulation and immune systems and tests perioperative interventions, including low molecular weight heparin trials in colorectal surgery patients and oncolytic vaccinia virus therapy for metastatic colorectal cancer. She has led multicentre trials funded by the Canadian Institutes of Health Research.","asOf":"2026-09-10","links":[{"label":"Source: OHRI organisational structure page","url":"https://www.ohri.ca/en/who-we-are/organizational-structure"}],"tags":["leadership","clinician-scientist","surgical-oncology","immunotherapy"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ottawa-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["annals-of-surgical-oncology"],"dependsOn":[],"notes":[],"role":"Executive Vice-President, Research and Innovation, The Ottawa Hospital / Ottawa Hospital Research Institute","institutionId":"ottawa-hospital","specialisms":["Surgical oncology","Perioperative cancer immunology","Oncolytic virus therapy"],"profiles":[{"label":"OHRI profile","url":"http://www.ohri.ca/en/node/3821"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Auer+RC%5BAuthor%5D"}],"papers":[{"title":"A Translational Randomized Trial of Perioperative Arginine Immunonutrition on Natural Killer Cell Function in Colorectal Cancer Surgery Patients","journal":"Annals of Surgical Oncology","year":2022,"doi":"10.1245/s10434-022-12202-y"},{"title":"Natural Killer Cell IFNγ Secretion is Profoundly Suppressed Following Colorectal Cancer Surgery","journal":"Annals of Surgical Oncology","year":2018,"doi":"10.1245/s10434-018-6691-3"},{"title":"Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity","journal":"Nature Medicine","year":2015,"doi":"10.1038/nm.3848"}],"orcid":"0000-0002-3617-0015"},{"id":"rebecca-fitzgerald","kind":"person","name":"Rebecca C. Fitzgerald","aka":[],"tldr":"Invented the Cytosponge, a swallowable sponge-on-a-string that finds Barrett's oesophagus without endoscopy.","summary":"Rebecca Fitzgerald developed the Cytosponge-TFF3 test and led the BEST3 trial in 13,000 patients showing it detects ten times more Barrett's oesophagus than usual care in people with reflux, which is now being rolled out in NHS pilots to catch oesophageal cancer early. She also led the OCCAMS genomic study of oesophageal adenocarcinoma and directs Cambridge's Early Cancer Institute.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Rebecca_Fitzgerald","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fitzgerald%20RC%5BAuthor%5D%20Cytosponge%20Barrett"}],"tags":["early-detection","esophageal","uk"],"related":[],"cancers":["esophageal"],"sections":[],"technologies":["mced"],"targets":[],"drugs":[],"companies":[],"institutions":["cruk-cambridge-centre","cruk"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nature-genetics"],"dependsOn":[],"notes":[],"role":"Director, Early Cancer Institute, University of Cambridge; Professor of Cancer Prevention","institutionId":"cruk-cambridge-centre","specialisms":["Oesophageal cancer early detection","Barrett's oesophagus","Non-endoscopic sampling","Cancer prevention"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fitzgerald%20RC%5BAuthor%5D%20Cytosponge%20Barrett"}],"papers":[{"title":"Cytosponge-trefoil factor 3 versus usual care to identify Barrett's oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial (BEST3)","journal":"Lancet","year":2020,"doi":"10.1016/S0140-6736(20)31099-0"},{"title":"Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis","journal":"Nature Genetics","year":2014,"doi":"10.1038/ng.3013"}],"orcid":"0000-0002-3434-3568"},{"id":"rebecca-dent","kind":"person","name":"Rebecca Dent","aka":[],"tldr":"Breast medical oncologist and Deputy CEO for clinical operations at the National Cancer Centre Singapore, an international leader in triple-negative breast cancer trials.","summary":"Rebecca Dent is Deputy Chief Executive Officer for clinical operations at the National Cancer Centre Singapore and a senior consultant in medical oncology. Her research focuses on triple-negative and early breast cancer, and she has been a lead investigator on international phase 3 trials of immunotherapy and targeted agents in breast cancer. She chairs and contributes to international breast cancer guideline and consensus groups.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.nccs.com.sg/about-nccs/leadership.html"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dent+R%5BAuthor%5D+breast"}],"tags":["leadership","clinician-scientist","breast cancer"],"related":[],"cancers":["tnbc","breast-hr-positive","breast-her2-positive"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["nccs"],"pathways":[],"terms":[],"trials":["keynote-522","impassion130","tropion-breast02"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["breast-cancer-research-and-treatment"],"dependsOn":[],"notes":[],"role":"Deputy Chief Executive Officer (Clinical)","institutionId":"nccs","specialisms":["Breast cancer","Triple-negative breast cancer","Clinical trials"],"profiles":[{"label":"Institution profile","url":"https://www.nccs.com.sg/about-nccs/leadership.html"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dent+R%5BAuthor%5D+breast"}],"papers":[{"title":"Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer","journal":"Breast Cancer Research and Treatment","year":2021,"doi":"10.1007/s10549-021-06143-5"},{"title":"Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial","journal":"The Lancet Oncology","year":2021,"doi":"10.1016/s1470-2045(20)30754-3"},{"title":"Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","journal":"The Lancet Oncology","year":2017,"doi":"10.1016/s1470-2045(17)30450-3"}],"orcid":"0000-0001-6421-7602"},{"id":"rebecca-li","kind":"person","name":"Rebecca Li","aka":[],"tldr":"Leads Vivli, the non-profit global platform for sharing anonymised individual participant data from clinical trials, including oncology studies.","summary":"Rebecca Li, PhD, is Executive Director and CEO of Vivli, the Center for Global Clinical Research Data. Vivli hosts and brokers access to anonymised participant-level clinical trial data from academic and industry sponsors, enabling secondary analyses including in cancer. She previously led the Multi-Regional Clinical Trials Center at Brigham and Women's Hospital and Harvard.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://vivli.org/about/leadership-team/"}],"tags":["leadership","data sharing","clinical trials"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["vivli"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Executive Director and CEO","institutionId":"vivli","specialisms":["Clinical trial data sharing","Research ethics","Data governance"],"profiles":[{"label":"Institution profile","url":"https://vivli.org/about/leadership-team/"}],"papers":[]},{"id":"refik-emre-cecen","kind":"person","name":"Refik Emre Çeçen","aka":[],"tldr":"Refik Emre Çeçen represents Dokuz Eylül University Institute of Oncology in the Organisation of European Cancer Institutes, which lists the centre among its members in Turkey.","summary":"Refik Emre Çeçen is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Dokuz Eylül University Institute of Oncology, its member in Turkey. Dokuz Eylül University Institute of Oncology is the oncology institute of Dokuz Eylül University in İzmir, combining cancer research with graduate training, and an associate member of the Organisation of European Cancer Institutes. OnCo records the name from the OECI membership list so that the centre's page has a named contact point; the person's exact title, appointment date and biography are not yet recorded and should be checked on the institution's own pages before being relied on.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Dokuz Eylül University Institute of Oncology website","url":"https://onkoloji.deu.edu.tr/tr/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["dokuz-eylul-institute-of-oncology"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Dokuz Eylül University Institute of Oncology to the Organisation of European Cancer Institutes","institutionId":"dokuz-eylul-institute-of-oncology","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Dokuz Eylül University Institute of Oncology website","url":"https://onkoloji.deu.edu.tr/tr/"}],"papers":[{"title":"Assessment of Chemo-Immunotherapy Regimens in Patients with Refractory or Relapsed Neuroblastoma: A Systematic Review with Meta-Analysis of Critical Oncological Outcomes","journal":"J Clin Med","year":2025,"url":"https://doi.org/10.3390/jcm14030934","doi":"10.3390/jcm14030934","note":"Europe PMC author record matched by affiliation"},{"title":"The association of miR-204 and mir-483 5p expression with clinicopathological features of Wilms tumor: Could this provide foresight?","journal":"Jpn J Clin Oncol","year":2023,"url":"https://doi.org/10.1093/jjco/hyad113","doi":"10.1093/jjco/hyad113","note":"Europe PMC author record matched by affiliation"}]},{"id":"regina-barzilay","kind":"person","name":"Regina Barzilay","aka":[],"tldr":"Computer scientist who built Mirai and Sybil, AI models that predict breast and lung cancer risk years before diagnosis.","summary":"Regina Barzilay, a breast cancer survivor, led the development of Mirai, which predicts five-year breast cancer risk from mammograms, and Sybil, which predicts six-year lung cancer risk from a single low-dose CT, both validated across international cohorts and now in prospective trials. Her group also uses machine learning for antibiotic and drug discovery. She received the inaugural AAAI Squirrel AI Award and a MacArthur Fellowship.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Barzilay%20R%5BAuthor%5D%20deep%20learning%20cancer%20risk"}],"tags":["ai","risk-prediction","screening"],"related":[],"cancers":["breast-hr-positive","nsclc"],"sections":[],"technologies":["radiology-ai-screening","ai-drug-design"],"targets":[],"drugs":[],"companies":[],"institutions":["mit-koch"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"School of Engineering Distinguished Professor for AI and Health, MIT; AI Faculty Lead, Jameel Clinic","institutionId":"mit-koch","specialisms":["Machine learning for oncology","AI risk prediction from imaging","Drug discovery AI","Natural language processing"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Barzilay%20R%5BAuthor%5D%20deep%20learning%20cancer%20risk"}],"papers":[{"title":"Toward robust mammography-based models for breast cancer risk (Mirai)","journal":"Science Translational Medicine","year":2021,"doi":"10.1126/scitranslmed.aba4373"},{"title":"Sybil: a validated deep learning model to predict future lung cancer risk from a single low-dose chest computed tomography","journal":"JCO","year":2023,"doi":"10.1200/JCO.22.01345"}]},{"id":"reinhard-buettner","kind":"person","name":"Reinhard Büttner","aka":[],"tldr":"Molecular pathologist who co-founded Network Genomic Medicine and characterised lung cancer genomes.","summary":"Reinhard Büttner is Director of the Institute of Pathology at University Hospital Cologne (CIO). A molecular pathologist, his specialisms are molecular pathology, lung cancer genomics and predictive biomarkers, combining histopathology and immunohistochemistry with comprehensive genomic profiling. He co-founded Network Genomic Medicine and co-authored the Clinical Lung Cancer Genome Project analyses that defined targetable alterations in non-small-cell lung cancer. His papers include a review of PD-L1 immunohistochemistry assays and their clinical implementation in lung cancer, a study of KEAP1- and NFE2L2-mutated non-small-cell lung carcinoma, and a review of precision medicine in non-small-cell lung cancer. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Buttner%20R%5BAuthor%5D%20lung%20cancer%20genome"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["histopathology-ihc","cgp"],"targets":[],"drugs":[],"companies":[],"institutions":["uniklinik-koeln"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["seminars-in-cancer-biology"],"dependsOn":[],"notes":[],"role":"Director, Institute of Pathology, University Hospital Cologne","institutionId":"uniklinik-koeln","specialisms":["Molecular pathology","Lung cancer genomics","Predictive biomarkers"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Buttner%20R%5BAuthor%5D%20lung%20cancer%20genome"}],"papers":[{"title":"Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non–Small-Cell Lung Cancer","journal":"Journal of Clinical Oncology","year":2017,"doi":"10.1200/jco.2017.74.7642"},{"title":"Clinical and Pathological Characteristics of KEAP1 - and NFE2L2 -Mutated Non–Small Cell Lung Carcinoma (NSCLC)","journal":"Clinical Cancer Research","year":2018,"doi":"10.1158/1078-0432.ccr-17-3416"},{"title":"Precision medicine in non-small cell lung cancer: Current applications and future directions","journal":"Seminars in Cancer Biology","year":2022,"doi":"10.1016/j.semcancer.2020.07.009"}]},{"id":"reinhard-dummer","kind":"person","name":"Reinhard Dummer","aka":[],"tldr":"Swiss dermato-oncologist who led COLUMBUS and the neoadjuvant talimogene laherparepvec studies.","summary":"Reinhard Dummer was principal investigator of COLUMBUS, which established encorafenib plus binimetinib in BRAF-mutant melanoma, and led the first randomised neoadjuvant trial of the oncolytic virus talimogene laherparepvec. He has led ESMO melanoma guidelines and trials in cutaneous T-cell lymphoma and Merkel cell carcinoma, and heads the skin cancer centre at University Hospital Zurich.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dummer%20R%5BAuthor%5D%20melanoma%20encorafenib%20OR%20talimogene"}],"tags":["melanoma","targeted-therapy","switzerland"],"related":[],"cancers":["melanoma","merkel-cell-carcinoma"],"sections":[],"technologies":["kinase-inhibitors","oncolytic-virus"],"targets":["braf"],"drugs":["encorafenib","talimogene-laherparepvec"],"companies":[],"institutions":["usz-zurich"],"pathways":[],"terms":[],"trials":["columbus"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Dermatology and Vice Chairman, Department of Dermatology, University Hospital Zurich","institutionId":"usz-zurich","specialisms":["Melanoma","BRAF/MEK targeted therapy","Oncolytic virus therapy","Cutaneous lymphoma"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dummer%20R%5BAuthor%5D%20melanoma%20encorafenib%20OR%20talimogene"}],"papers":[{"title":"Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS)","journal":"Lancet Oncology","year":2018,"doi":"10.1016/S1470-2045(18)30497-2"},{"title":"Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB-IVM1a melanoma: a randomized, open-label, phase 2 trial","journal":"Nature Medicine","year":2021,"doi":"10.1038/s41591-021-01510-7"}]},{"id":"remi-nout","kind":"person","name":"Remi A. Nout","aka":[],"tldr":"Dutch radiation oncologist who was lead author of PORTEC-2, the trial that showed vaginal brachytherapy is as good as pelvic radiotherapy for high-intermediate-risk endometrial cancer, with fewer side effects.","summary":"Remi Nout is a radiation oncologist who trained in the Leiden PORTEC group and now leads radiation oncology at Erasmus MC in Rotterdam. He was first author of the 2010 Lancet report of PORTEC-2, in which vaginal brachytherapy gave vaginal recurrence control equivalent to external-beam pelvic radiotherapy in high-intermediate-risk endometrial cancer with less bowel toxicity and better quality of life, making brachytherapy the standard adjuvant treatment for this group. He also leads international trials in cervical cancer radiotherapy.","asOf":"2026-09-18","links":[],"tags":["endometrial","radiotherapy","trialist"],"related":[],"cancers":["endometrial-nsmp","endometrial","cervical"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["erasmus-mc"],"pathways":[],"terms":[],"trials":["portec-2"],"people":[],"bottlenecks":[],"keyPapers":["paper-portec-2-lancet-2010"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Radiation Oncology, Erasmus MC, Rotterdam","institutionId":"erasmus-mc","specialisms":["Endometrial cancer radiotherapy","Vaginal brachytherapy","Cervical cancer radiotherapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Nout%5BAuthor%5D"}],"papers":[{"title":"PORTEC-2: vaginal brachytherapy versus pelvic external beam radiotherapy for high-intermediate-risk endometrial cancer","journal":"The Lancet","year":2010,"url":"https://doi.org/10.1016/S0140-6736(09)62163-2","doi":"10.1016/S0140-6736(09)62163-2"}]},{"id":"renaldas-jurkevicius","kind":"person","name":"Renaldas Jurkevičius","aka":[],"tldr":"Renaldas Jurkevičius represents Hospital of the Lithuanian University of Health Sciences Kauno Klinikos in the Organisation of European Cancer Institutes, which lists the centre among its members in Lithuania.","summary":"Renaldas Jurkevičius is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Hospital of the Lithuanian University of Health Sciences Kauno Klinikos, its member in Lithuania. Hospital of the Lithuanian University of Health Sciences Kauno Klinikos is the largest hospital in Lithuania and the teaching hospital of the Lithuanian University of Health Sciences, and a full member of the Organisation of European Cancer Institutes. OnCo records the name from the OECI membership list so that the centre's page has a named contact point; the person's exact title, appointment date and biography are not yet recorded and should be checked on the institution's own pages before being relied on.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Hospital of the Lithuanian University of Health Sciences Kauno Klinikos website","url":"https://www.kaunoklinikos.lt/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["kauno-klinikos"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Hospital of the Lithuanian University of Health Sciences Kauno Klinikos to the Organisation of European Cancer Institutes","institutionId":"kauno-klinikos","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Hospital of the Lithuanian University of Health Sciences Kauno Klinikos website","url":"https://www.kaunoklinikos.lt/"}],"papers":[{"title":"Impact of Arterial Hypertension on Doxorubicin-Based Chemotherapy-Induced Subclinical Cardiac Damage in Breast Cancer Patients","journal":"Cardiovasc Toxicol","year":2020,"url":"https://doi.org/10.1007/s12012-019-09556-3","doi":"10.1007/s12012-019-09556-3","note":"Europe PMC author record matched by affiliation"},{"title":"Does longitudinal strain predict left ventricular remodeling after myocardial infarction?","journal":"Echocardiography","year":2012,"url":"https://doi.org/10.1111/j.1540-8175.2011.01597.x","doi":"10.1111/j.1540-8175.2011.01597.x","note":"Europe PMC author record matched by affiliation"},{"title":"HFE Gene Variants' Impact on Anthracycline-Based Chemotherapy-Induced Subclinical Cardiotoxicity","journal":"Cardiovasc Toxicol","year":2021,"url":"https://doi.org/10.1007/s12012-020-09595-1","doi":"10.1007/s12012-020-09595-1","note":"Europe PMC author record matched by affiliation"}]},{"id":"renaud-de-crevoisier","kind":"person","name":"Renaud de Crevoisier","aka":[],"tldr":"Professor of medicine who directs Centre Eugène Marquis, the regional comprehensive cancer centre for Brittany in Rennes.","summary":"Professeur Renaud de Crevoisier is Directeur Général of Centre Eugène Marquis, the Centre de Lutte Contre le Cancer for Brittany, based in Rennes. The centre's direction organigramme lists him alongside Julia Le Gouguec, Directrice Générale Adjointe, and Dr Claudia Lefeuvre-Plesse, Présidente de la Commission Médicale d'Etablissement. Centre Eugène Marquis is one of the Unicancer network of French cancer centres, combining treatment, research and teaching.","asOf":"2026-09-10","links":[{"label":"Source: Centre Eugène Marquis organigramme de direction","url":"https://www.centre-eugene-marquis.fr/organigramme-de-direction/"}],"tags":["leadership","clinician-scientist","comprehensive-cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["centre-eugene-marquis"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["annals-of-oncology","radiotherapy-and-oncology"],"dependsOn":[],"notes":[],"role":"Directeur Général (Director General), Centre Eugène Marquis","institutionId":"centre-eugene-marquis","specialisms":["Oncology","Cancer centre management","Academic medicine"],"profiles":[{"label":"Centre Eugène Marquis direction organigramme","url":"https://www.centre-eugene-marquis.fr/organigramme-de-direction/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=de+Crevoisier+R%5BAuthor%5D"}],"papers":[{"title":"Early PSA decrease is an independent predictive factor of clinical failure and specific survival in patients with localized prostate cancer treated by radiotherapy with or without androgen deprivation therapy","journal":"Annals of Oncology","year":2010,"doi":"10.1093/annonc/mdp365"},{"title":"Daily Versus Weekly Prostate Cancer Image Guided Radiation Therapy: Phase 3 Multicenter Randomized Trial","journal":"International Journal of Radiation Oncology*Biology*Physics","year":2018,"doi":"10.1016/j.ijrobp.2018.07.2006"},{"title":"Identification of a rectal subregion highly predictive of rectal bleeding in prostate cancer IMRT","journal":"Radiotherapy and Oncology","year":2016,"doi":"10.1016/j.radonc.2016.04.023"}]},{"id":"renaud-witmeur","kind":"person","name":"Renaud Witmeur","aka":[],"tldr":"Chief executive of the Brussels University Hospital group that runs Institut Jules Bordet, Belgium's dedicated cancer institute.","summary":"Renaud Witmeur holds the Direction Générale of the Hôpital Universitaire de Bruxelles (H.U.B), the university hospital group that brings together Institut Jules Bordet, Hôpital Erasme and the Hôpital Universitaire des Enfants Reine Fabiola. Institut Jules Bordet, founded in 1935 and rebuilt on the Anderlecht campus in 2021, is Belgium's only hospital devoted entirely to cancer and is governed through the H.U.B management council rather than a separate hierarchy. Within that structure the medical direction is led by Directeur Général Médical Jean-Marie Hougardy, and Chloé Spilleboudt serves as Médecin-Cheffe for the Institut Jules Bordet site.","asOf":"2026-09-10","links":[{"label":"Source: Institut Jules Bordet organisation and governance page","url":"https://www.bordet.be/fr/organisation-institut-jules-bordet"}],"tags":["leadership","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["institut-jules-bordet"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Directeur Général of the Hôpital Universitaire de Bruxelles (H.U.B), which includes Institut Jules Bordet","institutionId":"institut-jules-bordet","specialisms":["Hospital management","Health system governance"],"profiles":[{"label":"Institut Jules Bordet organisation page","url":"https://www.bordet.be/fr/organisation-institut-jules-bordet"}],"papers":[]},{"id":"rene-bernards","kind":"person","name":"René Bernards","aka":[],"tldr":"Cancer geneticist who explained why BRAF inhibitors fail in colorectal cancer, leading to the BEACON combination.","summary":"René Bernards is Senior Group Leader at the Netherlands Cancer Institute (NKI-AvL) and Professor at Utrecht University. His specialisms are cancer genetics, drug resistance and functional genomics, with a focus on BRAF and EGFR. His functional genetic screens identified feedback activation of EGFR as the reason BRAF inhibitors fail in colorectal cancer, reported in Nature, and this finding is the rationale behind the encorafenib plus cetuximab combination tested in BEACON. He also co-founded Agendia and developed MammaPrint, the 70-gene signature used in hormone receptor-positive breast cancer. His publications are listed on PubMed.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Ren%C3%A9_Bernards","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bernards%20R%5BAuthor%5D%20BRAF%20colorectal%20EGFR"}],"tags":[],"related":[],"cancers":["colorectal","breast-hr-positive"],"sections":[],"technologies":[],"targets":["braf","egfr"],"drugs":["mammaprint","encorafenib"],"companies":[],"institutions":["nki"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Senior Group Leader, Netherlands Cancer Institute; Professor, Utrecht University","institutionId":"nki","specialisms":["Cancer genetics","Drug resistance","Functional genomics"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bernards%20R%5BAuthor%5D%20BRAF%20colorectal%20EGFR"}],"papers":[{"title":"Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR","journal":"Nature","year":2012,"doi":"10.1038/nature10868"}],"orcid":"0000-0001-8677-3423"},{"id":"rene-medema","kind":"person","name":"René Medema","aka":[],"tldr":"Cancer biologist and former head of the Netherlands Cancer Institute who sits on the three-member executive board of the Princess Máxima Center as Chief Scientific Officer.","summary":"Prof. dr. René Medema is Chief Scientific Officer (CSO) and a member of the Raad van Bestuur of the Prinses Máxima Centrum voor kinderoncologie in Utrecht, the national centre for paediatric oncology in the Netherlands. The centre's board page describes a collegial executive board of three without a designated chair: Medema (scientific), drs. Gita Gallé as COO/CFO (administrative and financial) and prof. dr. Edward Nieuwenhuis as Chief Medical Officer, with mr. Ton van Dooremalen as board secretary. His profile notes a strong scientific track record, a prominent research group and an extensive network, and more than ten years of executive experience as bestuursvoorzitter of the Antoni van Leeuwenhoek (Netherlands Cancer Institute). Alexander Eggermont, previously CSO, no longer appears on the board page.","asOf":"2026-09-10","links":[{"label":"Source: Prinses Máxima Centrum Raad van Bestuur page","url":"https://www.prinsesmaximacentrum.nl/nl/over-ons/organisatie-bestuur-en-advies/raad-van-bestuur"}],"tags":["leadership","clinician-scientist","research-institute"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["nki"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Scientific Officer and member of the Raad van Bestuur, Prinses Máxima Centrum voor kinderoncologie","institutionId":"princess-maxima","specialisms":["Cancer cell biology","Research leadership","Paediatric oncology research"],"profiles":[{"label":"Prinses Máxima Centrum: Raad van Bestuur","url":"https://www.prinsesmaximacentrum.nl/nl/over-ons/organisatie-bestuur-en-advies/raad-van-bestuur"},{"label":"Board member profile","url":"https://www.prinsesmaximacentrum.nl/nl/over-ons/organisatie-bestuur-en-advies/raad-van-bestuur/rene-medema"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Medema+RH%5BAuthor%5D"}],"papers":[{"title":"The same, only different – DNA damage checkpoints and their reversal throughout the cell cycle","journal":"Journal of Cell Science","year":2015,"doi":"10.1242/jcs.163766"}],"orcid":"0000-0002-6754-0381"},{"id":"sankaranarayanan-rengaswamy","kind":"person","name":"Rengaswamy Sankaranarayanan","aka":[],"tldr":"Ran the large Indian trials that showed a single round of HPV testing halves cervical cancer deaths and that visual oral examination cuts deaths in tobacco users, and led the study behind single-dose HPV vaccination.","summary":"Rengaswamy Sankaranarayanan trained at the Cancer Institute (WIA) in Chennai and spent most of his career at the International Agency for Research on Cancer in Lyon, where he headed screening research. He led the Osmanabad cluster-randomised trial (131,746 women), in which one round of HPV testing cut cervical cancer deaths by about half (34 versus 64 deaths; hazard ratio 0.52), the Kerala oral cancer screening trial (191,873 people), which reduced oral cancer deaths by a third among tobacco or alcohol users, and the IARC India HPV vaccine study whose one-dose results underpin the WHO's single-dose recommendation.","asOf":"2026-09-10","links":[{"label":"IARC","url":"https://www.iarc.who.int"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sankaranarayanan%20R%5BAuthor%5D%20screening%20India"}],"tags":[],"related":[],"cancers":["cervical","head-and-neck"],"sections":[],"technologies":["hpv-testing","hpv-vaccine"],"targets":[],"drugs":[],"companies":[],"institutions":["iarc","cancer-institute-adyar"],"pathways":[],"terms":[],"trials":["osmanabad-hpv-screening","kerala-oral-screening","iarc-india-hpv-dose-study"],"people":[],"bottlenecks":[],"keyPapers":["paper-sankaranarayanan-hpv-screening-nejm-2009","paper-sankaranarayanan-oral-screening-lancet-2005","paper-basu-single-dose-hpv-lancet-oncol-2021"],"journals":[],"dependsOn":[],"notes":[],"role":"Former Head, Early Detection and Prevention Section and Screening Group, IARC; screening trialist","institutionId":"iarc","specialisms":["Cancer screening trials","Cervical cancer prevention","Oral cancer screening","HPV vaccination","Global oncology"],"profiles":[{"label":"IARC","url":"https://www.iarc.who.int"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sankaranarayanan%20R%5BAuthor%5D%20screening%20India"}],"papers":[{"title":"HPV screening for cervical cancer in rural India","journal":"New England Journal of Medicine","year":2009,"doi":"10.1056/NEJMoa0808516"},{"title":"Effect of screening on oral cancer mortality in Kerala, India: a cluster-randomised controlled trial","journal":"The Lancet","year":2005,"doi":"10.1016/S0140-6736(05)66658-5"},{"title":"Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India","journal":"Lancet Oncology","year":2016,"doi":"10.1016/S1470-2045(15)00414-3"},{"title":"Vaccine efficacy against persistent HPV 16/18 infection at 10 years after one, two and three doses of quadrivalent HPV vaccine in girls in India","journal":"Lancet Oncology","year":2021,"url":"https://doi.org/10.1016/S1470-2045(21)00453-8","doi":"10.1016/S1470-2045(21)00453-8"}]},{"id":"renier-brentjens","kind":"person","name":"Renier J. Brentjens","aka":[],"tldr":"Built one of the first CD19 CAR-T programmes and invented 'armoured' CAR-T cells that secrete cytokines.","summary":"Renier J. Brentjens is Deputy Director, Chair of the Department of Medicine and the Katherine Anne Gioia Endowed Chair in Cancer Medicine at Roswell Park Comprehensive Cancer Center. He built one of the first CD19 CAR-T programmes, developing the 19-28z CAR at Memorial Sloan Kettering and leading its first leukaemia trials, and invented armoured CAR-T cells that secrete cytokines. His selected paper reports CD19-targeted T cells rapidly inducing molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukaemia. Since moving to Roswell Park in 2021 he has developed IL-18 and IL-12 armoured CARs for solid tumours.","asOf":"2026-09-08","links":[{"label":"Roswell Park profile","url":"https://www.roswellpark.org/renier-brentjens"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Brentjens%20RJ%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["all-leukemia"],"sections":[],"technologies":["car-t","armored-car"],"targets":["cd19"],"drugs":[],"companies":[],"institutions":["roswell-park"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Deputy Director; Chair, Department of Medicine; Katherine Anne Gioia Endowed Chair in Cancer Medicine","institutionId":"roswell-park","specialisms":["CAR-T therapy","Armoured CARs","Leukaemia"],"profiles":[{"label":"Roswell Park profile","url":"https://www.roswellpark.org/renier-brentjens"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Brentjens%20RJ%5BAuthor%5D"}],"papers":[{"title":"CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","journal":"Science Translational Medicine","year":2013,"url":"https://doi.org/10.1126/scitranslmed.3005930","doi":"10.1126/scitranslmed.3005930"}],"orcid":"0000-0002-3364-5388"},{"id":"reuben-shaw","kind":"person","name":"Reuben Shaw","aka":[],"tldr":"Cancer biologist who directs the NCI-designated Salk Cancer Center in La Jolla and holds the William R. Brody Chair at the Salk Institute.","summary":"Reuben Shaw is Director of the NCI-designated Salk Cancer Center and a professor in the Molecular and Cell Biology Laboratory at the Salk Institute for Biological Studies, where he holds the William R. Brody Chair. His laboratory studies how cancer and metabolic diseases such as type 2 diabetes share biochemical pathways, centred on the AMPK pathway and its regulation by the tumour suppressor LKB1, which led him to test whether metabolic drugs such as metformin could be used against cancer. He trained at Cornell (BS), MIT (PhD) and Harvard Medical School (postdoctoral), and received a Howard Hughes Medical Institute Early Career Scientist award in 2009 and a National Cancer Institute Outstanding Investigator Award in 2017.","asOf":"2026-09-10","links":[{"label":"Source: Salk Institute faculty profile naming him Director of the Salk Cancer Center","url":"https://www.salk.edu/scientist/reuben-shaw/"}],"tags":["leadership","clinician-scientist","research-institute"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["hhmi"],"pathways":[],"terms":["tumour-suppressor-gene"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director of the Salk Cancer Center, Salk Institute for Biological Studies","institutionId":"salk-institute","specialisms":["Cancer metabolism","AMPK and LKB1 signalling","Molecular and cell biology"],"profiles":[{"label":"Salk Institute faculty profile","url":"https://www.salk.edu/scientist/reuben-shaw/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Shaw+RJ%5BAuthor%5D+AND+Salk"}],"papers":[{"title":"The LKB1–AMPK pathway: metabolism and growth control in tumour suppression","journal":"Nature Reviews Cancer","year":2009,"doi":"10.1038/nrc2676"},{"title":"Tumor Suppression by LKB1: SIK-ness Prevents Metastasis","journal":"Science Signaling","year":2009,"doi":"10.1126/scisignal.286pe55"},{"title":"Inhibition of acetyl-CoA carboxylase suppresses fatty acid synthesis and tumor growth of non-small-cell lung cancer in preclinical models","journal":"Nature Medicine","year":2016,"doi":"10.1038/nm.4181"}],"orcid":"0000-0002-1555-8977"},{"id":"riccardo-bui","kind":"person","name":"Riccardo Bui","aka":[],"tldr":"Riccardo Bui represents IRCCS Humanitas Research Hospital in the Organisation of European Cancer Institutes, which lists the centre among its members in Italy.","summary":"Riccardo Bui is listed by the Organisation of European Cancer Institutes (OECI) as the representative of IRCCS Humanitas Research Hospital, its full member in Italy. OnCo records the name from the OECI membership list so that the centre's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the institution's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"IRCCS Humanitas Research Hospital website","url":"https://www.humanitas.net"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["humanitas"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of IRCCS Humanitas Research Hospital to the Organisation of European Cancer Institutes","institutionId":"humanitas","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"IRCCS Humanitas Research Hospital website","url":"https://www.humanitas.net"}],"papers":[]},{"id":"ricco-norman-dyhr","kind":"person","name":"Ricco Norman Dyhr","aka":[],"tldr":"Ricco Norman Dyhr represents Zealand University Hospital in the Organisation of European Cancer Institutes, which lists the centre among its members in Denmark.","summary":"Ricco Norman Dyhr is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Zealand University Hospital, its member in Denmark. Zealand University Hospital, on the Køge and Roskilde sites, is the university hospital of Denmark's Region Zealand and a full member of the Organisation of European Cancer Institutes. OnCo records the name from the OECI membership list so that the centre's page has a named contact point; the person's exact title, appointment date and biography are not yet recorded and should be checked on the institution's own pages before being relied on.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Zealand University Hospital website","url":"https://www.nfsygehus.dk/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["zealand-university-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Zealand University Hospital to the Organisation of European Cancer Institutes","institutionId":"zealand-university-hospital","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Zealand University Hospital website","url":"https://www.nfsygehus.dk/"}],"papers":[]},{"id":"richard-barakat","kind":"person","name":"Richard Barakat","aka":[],"tldr":"Physician-in-Chief and Executive Director of the Northwell Cancer Institute, the cancer service of New York's largest health system.","summary":"Richard Barakat, MD, MBA, is Physician-in-Chief and Executive Director of the Northwell Cancer Institute, the cancer programme of Northwell Health, which spans hospitals and cancer centres across New York and Connecticut. In that capacity he announced the September 2026 appointment of a system director of central nervous system cancer and described the institute's aim of connecting laboratory discovery with patient care. Institute leadership also includes a deputy physician-in-chief and director of medical oncology.","asOf":"2026-09-10","links":[{"label":"Source: Northwell Health news release, September 2026","url":"https://www.northwell.edu/news/the-latest/northwell-appoints-system-director-central-nervous-system-cancer"}],"tags":["leadership","clinician-scientist","health-system"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["northwell-cancer-institute"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["gynecologic-oncology"],"dependsOn":[],"notes":[],"role":"Physician-in-Chief and Executive Director, Northwell Cancer Institute","institutionId":"northwell-cancer-institute","specialisms":["Surgical oncology","Cancer service line leadership","Health system oncology"],"profiles":[{"label":"Northwell news release naming role","url":"https://www.northwell.edu/news/the-latest/northwell-appoints-system-director-central-nervous-system-cancer"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Barakat+RR%5BAuthor%5D"}],"papers":[{"title":"GOG 244-The lymphedema and gynecologic cancer (LEG) study: Incidence and risk factors in newly diagnosed patients","journal":"Gynecologic Oncology","year":2020,"doi":"10.1016/j.ygyno.2019.10.009"},{"title":"GOG 244 - The Lymphedema and Gynecologic cancer (LeG) study: The impact of lower-extremity lymphedema on quality of life, psychological adjustment, physical disability, and function","journal":"Gynecologic Oncology","year":2021,"doi":"10.1016/j.ygyno.2020.10.023"},{"title":"GOG 244 - The LymphEdema and Gynecologic cancer (LEG) study: The association between the gynecologic cancer lymphedema questionnaire (GCLQ) and lymphedema of the lower extremity (LLE)","journal":"Gynecologic Oncology","year":2019,"doi":"10.1016/j.ygyno.2019.09.027"}]},{"id":"richard-carvajal","kind":"person","name":"Richard D. Carvajal","aka":[],"tldr":"Melanoma oncologist who led the tebentafusp programme in the United States and defined targeted therapy for rare melanoma subtypes.","summary":"Richard Carvajal co-led the tebentafusp development programme including the pivotal IMCgp100-202 trial in metastatic uveal melanoma and the early trials of MEK inhibition in uveal melanoma, and led studies of imatinib in KIT-mutant melanoma. He directs medical oncology at Northwell and continues to focus on rare melanoma subtypes.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Carvajal%20RD%5BAuthor%5D%20uveal%20melanoma"}],"tags":["uveal-melanoma","rare-cancers"],"related":[],"cancers":["uveal-melanoma","melanoma"],"sections":[],"technologies":["t-cell-engager"],"targets":["gp100","kit"],"drugs":["tebentafusp","imatinib"],"companies":[],"institutions":["northwell-cancer-institute"],"pathways":[],"terms":[],"trials":["imcgp100-202"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Deputy Physician-in-Chief and Director of Medical Oncology, Northwell Health Cancer Institute","institutionId":"northwell-cancer-institute","specialisms":["Uveal melanoma","Mucosal and acral melanoma","KIT-mutant melanoma","Early drug development"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Carvajal%20RD%5BAuthor%5D%20uveal%20melanoma"}],"papers":[{"title":"Overall survival benefit with tebentafusp in metastatic uveal melanoma (IMCgp100-202)","journal":"NEJM","year":2021,"doi":"10.1056/NEJMoa2103485"},{"title":"KIT as a therapeutic target in metastatic melanoma","journal":"JAMA","year":2011,"doi":"10.1001/jama.2011.746"}],"orcid":"0000-0002-3796-1118"},{"id":"richard-gray","kind":"person","name":"Richard Gray","aka":[],"tldr":"Statistician behind the Early Breast Cancer Trialists' meta-analyses that set the global evidence base for adjuvant therapy.","summary":"Richard Gray leads the secretariat of the Early Breast Cancer Trialists' Collaborative Group, whose individual-patient-data meta-analyses of hundreds of trials quantified the benefits of tamoxifen, aromatase inhibitors, chemotherapy, radiotherapy and bisphosphonates and underpin every breast cancer guideline. He also led the QUASAR colorectal adjuvant trials and the aTTom trial of ten years of tamoxifen.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gray%20R%5BAuthor%5D%20EBCTCG%20breast"}],"tags":["meta-analysis","biostatistics","breast"],"related":[],"cancers":["breast-hr-positive","colorectal"],"sections":[],"technologies":["endocrine-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":["oxford-cancer"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Statistics, Nuffield Department of Population Health, University of Oxford; Secretariat, EBCTCG","institutionId":"oxford-cancer","specialisms":["Meta-analysis","Breast cancer adjuvant therapy","Large simple trials","Biostatistics"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gray%20R%5BAuthor%5D%20EBCTCG%20breast"}],"papers":[{"title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials","journal":"Lancet","year":2005,"doi":"10.1016/S0140-6736(05)66544-0"},{"title":"Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials","journal":"Lancet","year":2015,"doi":"10.1016/S0140-6736(15)61074-1"}],"orcid":"0000-0003-4440-574X"},{"id":"richard-lesiyampe","kind":"person","name":"Richard Lesiyampe","aka":[],"tldr":"Chief Executive Officer of Kenyatta National Hospital, Kenya's largest public referral hospital and a major provider of cancer care.","summary":"Richard Lesiyampe is Chief Executive Officer of Kenyatta National Hospital in Nairobi, Kenya's largest public referral hospital and a major provider of cancer care. The hospital is the national teaching and referral hospital and hosts one of Kenya's main public oncology and radiotherapy services. His background is in hospital leadership and public health administration, and he leads the hospital's management team and its capital and service-expansion programmes. His role places him at the centre of public cancer care in Kenya.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://knh.or.ke/index.php/organizational-management/"}],"tags":["leadership","hospital management","global oncology"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["kenyatta-national-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive Officer","institutionId":"kenyatta-national-hospital","specialisms":["Hospital leadership","Public health administration"],"profiles":[{"label":"Institution profile","url":"https://knh.or.ke/index.php/organizational-management/"}],"papers":[]},{"id":"richard-stone","kind":"person","name":"Richard M. Stone","aka":[],"tldr":"Led RATIFY, the trial that made midostaurin the first targeted therapy added to induction chemotherapy for AML.","summary":"Richard Stone was principal investigator of RATIFY (CALGB 10603), the international trial showing midostaurin added to standard chemotherapy improves survival in FLT3-mutant AML, the first new approval in AML induction in 40 years and the first targeted therapy in the disease. He chaired the Alliance leukaemia committee and has led trials across AML, including gemtuzumab and quizartinib studies.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Stone%20RM%5BAuthor%5D%20midostaurin%20RATIFY"}],"tags":["aml","flt3","cooperative-group"],"related":[],"cancers":["aml"],"sections":[],"technologies":["kinase-inhibitors"],"targets":["flt3"],"drugs":[],"companies":[],"institutions":["dana-farber"],"pathways":[],"terms":[],"trials":["ratify","quantum-first"],"people":[],"bottlenecks":[],"keyPapers":["paper-quantum-first-quizartinib-lancet-2023"],"journals":[],"dependsOn":[],"notes":[],"role":"Chief of Staff and Director of Translational Research, Adult Leukemia Program, Dana-Farber Cancer Institute","institutionId":"dana-farber","specialisms":["Acute myeloid leukaemia","FLT3 inhibitors","Cooperative-group trials","Leukaemia therapeutics"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Stone%20RM%5BAuthor%5D%20midostaurin%20RATIFY"}],"papers":[{"title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation (RATIFY)","journal":"NEJM","year":2017,"doi":"10.1056/NEJMoa1614359"},{"title":"Acute myeloid leukemia","journal":"NEJM","year":2015,"doi":"10.1056/NEJMra1406184"},{"title":"QuANTUM-First: quizartinib added to intensive chemotherapy and continued as maintenance in newly diagnosed FLT3-ITD AML","journal":"The Lancet","year":2023,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=QuANTUM-First%20quizartinib%20FLT3-ITD%20Erba%20Lancet%202023"}],"orcid":"0000-0002-7526-2633"},{"id":"richard-mitchell","kind":"person","name":"Richard Mitchell","aka":[],"tldr":"NHS chief executive who leads University Hospitals of Leicester NHS Trust, the hospital partner of the University of Leicester's Leicester Cancer Research Centre.","summary":"Richard Mitchell is Chief Executive of University Hospitals of Leicester NHS Trust, the acute hospital trust for Leicester, Leicestershire and Rutland and the clinical partner of the University of Leicester's Leicester Cancer Research Centre. The trust's board page lists him at the head of an executive team that includes Deputy Chief Executive Simon Barton, Medical Director Gang Xu, Group Chief Nurse Julie Hogg, Chief Operating Officer Helen Hendley and Chief Financial Officer Lee Bond. The University of Leicester's own centre pages could not be read at the time of checking; its Wikipedia coverage names Catrin Pritchard as deputy director of the centre.","asOf":"2026-09-10","links":[{"label":"Source: University Hospitals of Leicester NHS Trust board members page","url":"https://www.uhleicester.nhs.uk/about/board/members/"}],"tags":["leadership","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["leicester-cancer-research-centre"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive, University Hospitals of Leicester NHS Trust","institutionId":"leicester-cancer-research-centre","specialisms":["NHS management","Hospital leadership"],"profiles":[{"label":"UHL Trust Board members page","url":"https://www.uhleicester.nhs.uk/about/board/members/"}],"papers":[]},{"id":"richard-baum","kind":"person","name":"Richard P. Baum","aka":[],"tldr":"One of the pioneers of peptide receptor radionuclide therapy for neuroendocrine tumours, now practising at the Curanosticum theranostics centre in Wiesbaden.","summary":"Richard Baum is a specialist in nuclear medicine whom Curanosticum describes as one of the leading experts in therapeutic nuclear medicine and part of its medical team since 2020. The centre offers PET-CT, radioiodine therapy, PSMA radioligand therapy and DOTATOC receptor radionuclide therapy. Before Wiesbaden he built the theranostics programme at the Zentralklinik Bad Berka, where lutetium-177 and yttrium-90 labelled somatostatin analogues were used to treat thousands of patients with neuroendocrine tumours, work that preceded the approvals of lutetium-177 dotatate and lutetium-177 PSMA-617. His publications are listed on PubMed.","asOf":"2026-09-17","links":[{"label":"Curanosticum","url":"https://www.curanosticum.de/en/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Baum+RP%5BAuthor%5D+radionuclide"}],"tags":["leadership"],"related":[],"cancers":["neuroendocrine","prostate"],"sections":[],"technologies":["radioligand-therapy","lu177-radioligand-therapy","psma-pet"],"targets":[],"drugs":[],"companies":[],"institutions":["curanosticum"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Nuclear medicine specialist, Curanosticum Wiesbaden-Frankfurt","institutionId":"curanosticum","specialisms":["Nuclear medicine","Peptide receptor radionuclide therapy","PSMA radioligand therapy","Theranostics"],"profiles":[{"label":"Curanosticum","url":"https://www.curanosticum.de/en/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Baum+RP%5BAuthor%5D+radionuclide"}],"papers":[{"title":"Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors","journal":"New England Journal of Medicine","year":2017,"url":"https://doi.org/10.1056/NEJMoa1607427","doi":"10.1056/NEJMoa1607427","note":"Europe PMC author record matched by affiliation"},{"title":"FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0","journal":"European Journal of Nuclear Medicine and Molecular Imaging","year":2010,"url":"https://doi.org/10.1007/s00259-009-1297-4","doi":"10.1007/s00259-009-1297-4","note":"Europe PMC author record matched by affiliation"},{"title":"German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients","journal":"Journal of Nuclear Medicine","year":2017,"url":"https://doi.org/10.2967/jnumed.116.183194","doi":"10.2967/jnumed.116.183194","note":"Europe PMC author record matched by affiliation"}]},{"id":"richard-rogel","kind":"person","name":"Richard Rogel","aka":["Richard and Susan Rogel"],"tldr":"Richard and Susan Rogel's 2018 gift to the University of Michigan renamed its NCI-designated comprehensive cancer centre, founded in 1986, the Rogel Cancer Center.","summary":"Richard Rogel, a Michigan alumnus who built and sold the health-benefits firm Preferred Provider Organization of Michigan, and his wife Susan made a 2018 gift to the University of Michigan that led to the renaming of its Comprehensive Cancer Center, an NCI-designated centre since 1986, as the University of Michigan Rogel Cancer Center. The centre's own timeline records the gift; the amount, widely reported at the time, could not be confirmed against that page for this record and is not repeated. The centre is known for the discovery of the TMPRSS2:ERG gene fusion found in about half of prostate cancers and for early work on cancer stem cells, and the Rogel gift funds recruitment, early-career investigators and clinical trials infrastructure.","asOf":"2026-09-10","links":[{"label":"Rogel Cancer Center: timeline","url":"https://www.rogelcancercenter.org/about/timeline"}],"tags":["hero","donor"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["michigan-rogel"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-funding-allocation"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Donor whose 2018 gift renamed the University of Michigan's cancer centre the Rogel Cancer Center","specialisms":["Cancer centre building","University philanthropy"],"profiles":[],"papers":[]},{"id":"richard-finn","kind":"person","name":"Richard S. Finn","aka":[],"tldr":"Led PALOMA-2, which made palbociclib a first-line breast cancer drug, and IMbrave150, which made immunotherapy the standard for liver cancer.","summary":"Richard Finn was principal investigator of PALOMA-2, the trial that established palbociclib plus letrozole as first-line therapy for HR-positive advanced breast cancer and launched the CDK4/6 inhibitor class. He then led IMbrave150, which showed atezolizumab plus bevacizumab beat sorafenib in unresectable hepatocellular carcinoma, ending a decade of sorafenib as the only option. His current work covers next-generation CDK inhibitors and immunotherapy sequencing in liver cancer.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Finn%20RS%5BAuthor%5D%20palbociclib%20OR%20atezolizumab"}],"tags":["breast","hcc","trialist"],"related":[],"cancers":["breast-hr-positive","hcc"],"sections":[],"technologies":["cdk46-inhibitor","checkpoint-inhibitor"],"targets":["cdk4-6","pdl1"],"drugs":["palbociclib","atezolizumab"],"companies":[],"institutions":["ucla-jonsson"],"pathways":[],"terms":[],"trials":["paloma-2","imbrave150"],"people":[],"bottlenecks":[],"keyPapers":["paper-imbrave150-nejm-2020"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medicine, UCLA Jonsson Comprehensive Cancer Center","institutionId":"ucla-jonsson","specialisms":["HR-positive breast cancer","CDK4/6 inhibitors","Hepatocellular carcinoma","Immunotherapy combinations"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Finn%20RS%5BAuthor%5D%20palbociclib%20OR%20atezolizumab"}],"papers":[{"title":"Palbociclib and letrozole in advanced breast cancer (PALOMA-2)","journal":"NEJM","year":2016,"doi":"10.1056/NEJMoa1607303"},{"title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma (IMbrave150)","journal":"NEJM","year":2020,"doi":"10.1056/NEJMoa1915745"}]},{"id":"richard-schulick","kind":"person","name":"Richard Schulick","aka":[],"tldr":"Pancreatic cancer surgeon who has directed the University of Colorado Cancer Center, the state's NCI-designated comprehensive cancer centre, since 2018.","summary":"Richard Schulick is Director of the University of Colorado Cancer Center on the CU Anschutz Medical Campus and Chair of the Department of Surgery at the University of Colorado School of Medicine. A surgical oncologist specialising in pancreatic and hepatobiliary cancers, his research addresses pancreatic cancer immunotherapy and surgical outcomes. He has led the centre since June 2018.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schulick+RD%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","pancreatic cancer","surgical oncology"],"related":[],"cancers":["pancreatic","cholangiocarcinoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["colorado-cancer-center"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director","institutionId":"colorado-cancer-center","specialisms":["Surgical oncology","Pancreatic cancer","Hepatobiliary surgery"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schulick+RD%5BAuthor%5D"}],"papers":[{"title":"Evaluation of Survival Following Surgical Resection for Small Nonfunctional Pancreatic Neuroendocrine Tumors","journal":"JAMA Network Open","year":2023,"doi":"10.1001/jamanetworkopen.2023.4096"},{"title":"Association of Adjuvant Chemotherapy in Patients With Resected Pancreatic Adenocarcinoma After Multiagent Neoadjuvant Chemotherapy","journal":"JAMA Oncology","year":2023,"doi":"10.1001/jamaoncol.2022.5808"},{"title":"Neoadjuvant Chemotherapy Versus Upfront Surgery for Resectable Pancreatic Adenocarcinoma","journal":"Annals of Surgery","year":2023,"doi":"10.1097/sla.0000000000005925"}]},{"id":"richard-van-etten","kind":"person","name":"Richard Van Etten","aka":[],"tldr":"Physician-scientist who directs the Chao Family Comprehensive Cancer Center at UC Irvine, the NCI-designated comprehensive cancer centre for Orange County.","summary":"Richard Van Etten, MD, PhD, is Director of the Chao Family Comprehensive Cancer Center at the University of California, Irvine, and also serves as Senior Associate Dean and Associate Vice Chancellor for Cancer. The centre's leadership page lists Miguel Villalona Calero, MD, Division Chief of Hematology/Oncology, as Deputy Director, with associate directors covering basic science, clinical sciences, translational science, population science, community outreach, shared resources, education and administration. Executive decision-making is vested in a Senior Leadership Council chaired by the Director.","asOf":"2026-09-10","links":[{"label":"Source: Chao Family Comprehensive Cancer Center leadership page","url":"https://cancer.uci.edu/about/leadership/"}],"tags":["leadership","clinician-scientist","comprehensive-cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["uci-chao"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["haematologica","elife"],"dependsOn":[],"notes":[],"role":"Director, Chao Family Comprehensive Cancer Center, University of California, Irvine","institutionId":"uci-chao","specialisms":["Haematological malignancies","Leukaemia biology","Cancer centre leadership"],"profiles":[{"label":"Chao Family Comprehensive Cancer Center leadership page","url":"https://cancer.uci.edu/about/leadership/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Van+Etten+RA%5BAuthor%5D"}],"papers":[{"title":"Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia","journal":"Haematologica","year":2016,"doi":"10.3324/haematol.2016.152710"},{"title":"Alternative approaches to eradicating the malignant clone in chronic myeloid leukemia: tyrosine-kinase inhibitor combinations and beyond","journal":"Hematology","year":2013,"doi":"10.1182/asheducation-2013.1.189"},{"title":"Predictive nonlinear modeling of malignant myelopoiesis and tyrosine kinase inhibitor therapy","journal":"eLife","year":2023,"doi":"10.7554/elife.84149"}],"orcid":"0000-0003-0000-635X"},{"id":"rita-schmutzler","kind":"person","name":"Rita Schmutzler","aka":[],"tldr":"Gynaecological oncologist and hereditary cancer expert who became President of Deutsche Krebshilfe, Germany's largest cancer charity, in 2026.","summary":"Professor Rita Schmutzler is Präsidentin of the Stiftung Deutsche Krebshilfe, the German cancer aid foundation founded in 1974 by Mildred Scheel; German Wikipedia records that she took up the presidency in February 2026, succeeding Anne-Sophie Mutter. A gynaecologist specialising in hereditary breast and ovarian cancer, she directed the Center for Familial Breast and Ovarian Cancer and the National Center for Familial Tumor Diseases at Cologne University Hospital from 2012 until her emeritus status in 2025. The foundation's executive board (Vorstand) comprises Gerd Nettekoven, Lutz M. Heitmüller and Franz Kohlhuber, with Charlotte Niemeyer chairing the Stiftungsrat.","asOf":"2026-09-10","links":[{"label":"Source: Deutsche Krebshilfe organisation page","url":"https://www.krebshilfe.de/informieren/ueber-uns/organisation/"}],"tags":["leadership","clinician-scientist","charity","hereditary-cancer"],"related":[],"cancers":["breast-hr-positive","tnbc","ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["deutsche-krebshilfe"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Präsidentin of the Stiftung Deutsche Krebshilfe (2026-)","institutionId":"deutsche-krebshilfe","specialisms":["Hereditary breast and ovarian cancer","Gynaecological oncology","Cancer prevention","Cancer genetics"],"profiles":[{"label":"Institution organisation page","url":"https://www.krebshilfe.de/informieren/ueber-uns/organisation/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schmutzler+RK%5BAuthor%5D"}],"papers":[{"title":"Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer","journal":"JAMA Oncology","year":2017,"doi":"10.1001/jamaoncol.2017.1007"},{"title":"Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers","journal":"JNCI: Journal of the National Cancer Institute","year":2017,"doi":"10.1093/jnci/djw302"},{"title":"Erste zielgerichtete Therapie bei Ovarialkarzinom für BRCA1/2-Mutationsträgerinnen zugelassen","journal":"Medizinische Genetik","year":2015,"doi":"10.1007/s11825-015-0047-1"}]},{"id":"rob-abbott","kind":"person","name":"Rob Abbott","aka":[],"tldr":"Chief Executive Officer of ISPOR, the professional society for health economics and outcomes research.","summary":"Rob Abbott is Chief Executive Officer of ISPOR, the international professional society for health economics and outcomes research. He leads the society's operations, strategy and global engagement with payers, regulators and researchers on how health interventions, including cancer treatments, are valued.","asOf":"2026-09-10","links":[{"label":"Society page","url":"https://www.ispor.org/about/board-of-directors"}],"tags":["leadership","health economics","health policy"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ispor"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive Officer","institutionId":"ispor","specialisms":["Health economics and outcomes research","Association management","Health policy"],"profiles":[{"label":"Society page","url":"https://www.ispor.org/about/board-of-directors"}],"papers":[]},{"id":"rob-bristow","kind":"person","name":"Rob Bristow","aka":[],"tldr":"Rob Bristow represents The Christie NHS Foundation Trust in the Organisation of European Cancer Institutes, which lists the centre among its members in United Kingdom.","summary":"Rob Bristow is listed by the Organisation of European Cancer Institutes (OECI) as the representative of The Christie NHS Foundation Trust, its member in United Kingdom. The Christie is Europe's largest single-site cancer centre and the UK's first NHS proton therapy centre. OnCo records the name from the OECI membership list so that the centre's page has a named contact point; the person's exact title, appointment date and biography are not yet recorded and should be checked on the institution's own pages before being relied on.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"The Christie NHS Foundation Trust website","url":"http://www.christie.nhs.uk/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["the-christie"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of The Christie NHS Foundation Trust to the Organisation of European Cancer Institutes","institutionId":"the-christie","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"The Christie NHS Foundation Trust website","url":"http://www.christie.nhs.uk/"}],"papers":[{"title":"Prostate cancer","journal":"Nat Rev Dis Primers","year":2021,"url":"https://doi.org/10.1038/s41572-020-00243-0","doi":"10.1038/s41572-020-00243-0","note":"Europe PMC author record matched by affiliation"},{"title":"Molecular landmarks of tumor hypoxia across cancer types","journal":"Nat Genet","year":2019,"url":"https://doi.org/10.1038/s41588-018-0318-2","doi":"10.1038/s41588-018-0318-2","note":"Europe PMC author record matched by affiliation"},{"title":"Prostate cancer","journal":"Lancet","year":2021,"url":"https://doi.org/10.1016/s0140-6736(21)00950-8","doi":"10.1016/s0140-6736(21)00950-8","note":"Europe PMC author record matched by affiliation"}]},{"id":"rob-pieters","kind":"person","name":"Rob Pieters","aka":[],"tldr":"Dutch paediatric oncologist who led the international Interfant trials for babies with leukaemia and helped create the Princess Máxima Center, which brought all Dutch childhood cancer care into one hospital.","summary":"Rob Pieters is a paediatric oncologist and the founding chief medical officer of the Princess Máxima Center in Utrecht, which since 2018 has treated all children with cancer in the Netherlands. He chaired the Interfant-99 and Interfant-06 international trials for infants with acute lymphoblastic leukaemia and was first author of their reports in the Lancet (2007) and Journal of Clinical Oncology (2019), which defined the standard hybrid chemotherapy for this high-risk group and showed that early intensification did not improve outcomes.","asOf":"2026-09-18","links":[],"tags":["paediatric","leukaemia","trialist"],"related":[],"cancers":["all-infant","all-leukemia","childhood-cancers"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["princess-maxima"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-interfant-06-pieters-jco-2019","paper-interfant-99-lancet-2007"],"journals":[],"dependsOn":[],"notes":[],"role":"Paediatric oncologist and Chief Medical Officer, Princess Máxima Center for Pediatric Oncology","institutionId":"princess-maxima","specialisms":["Infant leukaemia","Acute lymphoblastic leukaemia","Paediatric oncology organisation"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Pieters%5BAuthor%5D"}],"papers":[{"title":"Interfant-06: outcome of infants under one year with acute lymphoblastic leukaemia","journal":"Journal of Clinical Oncology","year":2019,"url":"https://doi.org/10.1200/JCO.19.00261","doi":"10.1200/JCO.19.00261"},{"title":"Interfant-99: a treatment protocol for infants under one year with acute lymphoblastic leukaemia","journal":"The Lancet","year":2007,"url":"https://doi.org/10.1016/S0140-6736(07)61126-X","doi":"10.1016/S0140-6736(07)61126-X"}],"orcid":"0000-0003-2997-3570"},{"id":"robbie-majzner","kind":"person","name":"Robbie G. Majzner","aka":[],"tldr":"Led the GD2 CAR-T trial in diffuse midline glioma and defined antigen density as a barrier to CAR-T in solid tumours.","summary":"Robbie Majzner was first author of the Nature trial of GD2-directed CAR T cells in H3K27M-mutant diffuse midline glioma, one of the first cell therapies to show activity in a paediatric brain tumour, and led the work showing CAR T cells need high antigen density and that B7-H3 is a broadly expressed paediatric target. He moved from Stanford to lead solid tumour immunotherapy at St. Jude.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Majzner%20RG%5BAuthor%5D%20CAR%20T"}],"tags":["cell-therapy","car-t","paediatric"],"related":[],"cancers":["neuroblastoma","osteosarcoma"],"sections":[],"technologies":["car-t","armored-car"],"targets":["b7h3"],"drugs":[],"companies":[],"institutions":["st-jude"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director of Solid Tumor Immunotherapy, Department of Oncology, St. Jude Children's Research Hospital","institutionId":"st-jude","specialisms":["Paediatric CAR T-cell therapy","Solid tumour immunotherapy","GD2 and B7-H3 targets","CAR engineering"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Majzner%20RG%5BAuthor%5D%20CAR%20T"}],"papers":[{"title":"GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas","journal":"Nature","year":2022,"doi":"10.1038/s41586-022-04489-4"},{"title":"Tuning the antigen density requirement for CAR T-cell activity","journal":"Cancer Discovery","year":2020,"doi":"10.1158/2159-8290.CD-19-0945"}]},{"id":"robert-fenstermaker","kind":"person","name":"Robert A. Fenstermaker","aka":[],"tldr":"Robert Fenstermaker invented SurVaxM, a survivin-targeted vaccine in late-stage trials for glioblastoma.","summary":"Robert A. Fenstermaker is Chair of the Department of Neurosurgery and Director of the Neuro-Oncology Program at Roswell Park Comprehensive Cancer Center. He is a neurosurgeon-scientist known for inventing SurVaxM, a survivin peptide mimic vaccine for glioblastoma that showed encouraging phase 2 results and advanced to a randomised trial in newly diagnosed disease. His selected paper reports the phase 2 trial of SurVaxM with temozolomide in newly diagnosed glioblastoma. He continues to work on cancer vaccines and glioma while leading neurosurgery at Roswell Park.","asOf":"2026-09-08","links":[{"label":"Roswell Park profile","url":"https://www.roswellpark.org/robert-fenstermaker"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fenstermaker%20RA%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":["shared-antigen-vaccine"],"targets":[],"drugs":[],"companies":[],"institutions":["roswell-park"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chair, Department of Neurosurgery; Director, Neuro-Oncology Program","institutionId":"roswell-park","specialisms":["Glioblastoma","Cancer vaccines","Survivin"],"profiles":[{"label":"Roswell Park profile","url":"https://www.roswellpark.org/robert-fenstermaker"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fenstermaker%20RA%5BAuthor%5D"}],"papers":[{"title":"Phase 2 trial of SurVaxM with temozolomide in newly diagnosed glioblastoma","journal":"Journal of Clinical Oncology","year":2023}],"orcid":"0000-0003-0309-8130"},{"id":"robert-gatenby","kind":"person","name":"Robert A. Gatenby","aka":[],"tldr":"Applies evolutionary game theory to cancer treatment, dosing drugs to control rather than eradicate resistant clones.","summary":"Robert A. Gatenby is Chair of the Department of Radiology and Co-Director of the Center of Excellence for Evolutionary Therapy at Moffitt Cancer Center. He is a radiologist and mathematical oncologist known for applying evolutionary game theory to cancer treatment, dosing drugs to control rather than eradicate resistant clones. He founded Moffitt's Integrated Mathematical Oncology department and ran the first adaptive-therapy trial, using abiraterone in prostate cancer. His selected paper describes integrating evolutionary dynamics into the treatment of metastatic castration-resistant prostate cancer.","asOf":"2026-09-08","links":[{"label":"Moffitt profile","url":"https://www.moffitt.org/research-science/researchers/robert-gatenby/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gatenby%20RA%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":["abiraterone"],"companies":[],"institutions":["moffitt"],"pathways":[],"terms":["resistance"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nature-communications"],"dependsOn":[],"notes":[],"role":"Chair, Department of Radiology; Co-Director, Center of Excellence for Evolutionary Therapy","institutionId":"moffitt","specialisms":["Evolutionary therapy","Mathematical oncology","Adaptive dosing"],"profiles":[{"label":"Moffitt profile","url":"https://www.moffitt.org/research-science/researchers/robert-gatenby/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gatenby%20RA%5BAuthor%5D"}],"papers":[{"title":"Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer","journal":"Nature Communications","year":2017,"url":"https://doi.org/10.1038/s41467-017-01968-5","doi":"10.1038/s41467-017-01968-5"}]},{"id":"robert-winn","kind":"person","name":"Robert A. Winn","aka":[],"tldr":"Physician who leads VCU Massey Comprehensive Cancer Center in Richmond, Virginia, the NCI-designated comprehensive cancer centre of Virginia Commonwealth University.","summary":"Robert A. Winn, MD, leads VCU Massey Comprehensive Cancer Center, the cancer centre of Virginia Commonwealth University in Richmond and an NCI-designated comprehensive cancer centre. The centre's Wikipedia article records that he became director in 2019. The Massey website pages fetched for this record did not expose a leadership page, so the role is recorded from Wikipedia and should be re-checked.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Robert_A._Winn","links":[{"label":"Source: Wikipedia article on VCU Massey Cancer Center naming the director","url":"https://en.wikipedia.org/wiki/VCU_Massey_Cancer_Center"}],"tags":["leadership","clinician-scientist","comprehensive-cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["vcu-massey"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nature-reviews-cancer","cancer-discovery","clinical-cancer-research"],"dependsOn":[],"notes":[],"role":"Director, VCU Massey Comprehensive Cancer Center","institutionId":"vcu-massey","specialisms":["Cancer centre leadership","Academic medicine"],"profiles":[{"label":"Wikipedia: VCU Massey Cancer Center","url":"https://en.wikipedia.org/wiki/VCU_Massey_Cancer_Center"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Winn+RA%5BAuthor%5D"}],"papers":[{"title":"Making cancer research more inclusive","journal":"Nature Reviews Cancer","year":2021,"doi":"10.1038/s41568-021-00369-7"},{"title":"Enrollment Matters: The Reality of Disparity and Pursuit of Equity in Clinical Trials","journal":"Cancer Discovery","year":2022,"doi":"10.1158/2159-8290.cd-22-0319"},{"title":"Optimizing the Use of Telemedicine in Oncology Care: Postpandemic Opportunities","journal":"Clinical Cancer Research","year":2021,"doi":"10.1158/1078-0432.ccr-20-3758"}],"orcid":"0000-0001-5948-9291"},{"id":"robert-doebele","kind":"person","name":"Robert C. Doebele","aka":[],"tldr":"Lung cancer researcher who led the pooled analysis showing that entrectinib shrinks NTRK fusion-positive tumours of many kinds, and who studied how ROS1 and NTRK cancers escape targeted drugs.","summary":"Robert Doebele was first author of the 2020 Lancet Oncology integrated analysis of the entrectinib trials in NTRK fusion-positive solid tumours, part of the evidence for the drug's tumour-agnostic approval. As a physician-scientist at the University of Colorado he described resistance mechanisms in ROS1- and NTRK-driven lung cancers and helped establish patient-derived models of oncogene-addicted cancers.","asOf":"2026-09-18","links":[],"tags":["lung","targeted-therapy"],"related":[],"cancers":["ntrk-fusion-nsclc","ros1-positive-nsclc","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-doebele-entrectinib-ntrk-lancet-oncol-2020"],"journals":[],"dependsOn":[],"notes":[],"role":"Thoracic oncologist and drug developer","specialisms":["NTRK fusions","ROS1-positive lung cancer","Acquired resistance to kinase inhibitors"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Doebele%5BAuthor%5D"}],"papers":[{"title":"Entrectinib in NTRK fusion-positive solid tumours: integrated analysis of three trials","journal":"The Lancet Oncology","year":2020,"url":"https://doi.org/10.1016/S1470-2045(19)30691-6","doi":"10.1016/S1470-2045(19)30691-6"}]},{"id":"robert-schreiber","kind":"person","name":"Robert D. Schreiber","aka":[],"tldr":"Proposed cancer immunoediting and showed neoantigens are the targets of checkpoint immunotherapy.","summary":"Robert D. Schreiber is the Andrew M. and Jane M. Bursky Distinguished Professor and Director of the Bursky Center for Human Immunology and Immunotherapy Programs at Siteman Cancer Center, Washington University. He is an immunologist who proposed the three-phase model of cancer immunoediting and showed that mutant neoantigens are the targets of checkpoint immunotherapy. His selected paper shows that checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. He continues to work on neoantigens, interferon-gamma and the immune control of cancer.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schreiber%20RD%5BAuthor%5D"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":[],"companies":[],"institutions":["wustl-siteman"],"pathways":[],"terms":["neoantigen"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Andrew M. and Jane M. Bursky Distinguished Professor; Director, Bursky Center for Human Immunology and Immunotherapy Programs","institutionId":"wustl-siteman","specialisms":["Cancer immunoediting","Neoantigens","Interferon-gamma"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schreiber%20RD%5BAuthor%5D"}],"papers":[{"title":"Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens","journal":"Nature","year":2014,"url":"https://doi.org/10.1038/nature13988","doi":"10.1038/nature13988"},{"title":"Schreiber, Old and Smyth 2011: cancer immunoediting","journal":"Science","year":2011,"url":"https://doi.org/10.1126/science.1203486","doi":"10.1126/science.1203486"}],"orcid":"0000-0003-1590-2341"},{"id":"robert-timmerman","kind":"person","name":"Robert D. Timmerman","aka":[],"tldr":"Pioneer of stereotactic body radiotherapy, whose RTOG 0236 trial made SBRT the standard for inoperable early lung cancer.","summary":"Robert Timmerman led the Indiana and RTOG 0236 trials that established stereotactic body radiotherapy as a curative option for medically inoperable stage I lung cancer, with local control above 90%. He defined the toxicity limits for central tumours and leads NRG trials of SBRT in operable patients and oligometastatic disease. His work made ablative radiotherapy a mainstream modality.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Timmerman%20RD%5BAuthor%5D%20stereotactic%20lung"}],"tags":["radiotherapy","sbrt","lung"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["sbrt"],"targets":[],"drugs":[],"companies":[],"institutions":["utsw-simmons"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Radiation Oncology, UT Southwestern Simmons Comprehensive Cancer Center","institutionId":"utsw-simmons","specialisms":["Stereotactic body radiotherapy","Early-stage lung cancer","Oligometastatic disease"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Timmerman%20RD%5BAuthor%5D%20stereotactic%20lung"}],"papers":[{"title":"Stereotactic body radiation therapy for inoperable early stage lung cancer (RTOG 0236)","journal":"JAMA","year":2010,"doi":"10.1001/jama.2010.261"},{"title":"Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer","journal":"JCO","year":2006,"doi":"10.1200/JCO.2006.07.5937"}]},{"id":"robert-figlin","kind":"person","name":"Robert Figlin","aka":[],"tldr":"Medical oncologist who has led Cedars-Sinai Cancer in Los Angeles as Interim Director since March 2025.","summary":"Robert Figlin, MD, is Interim Director of Cedars-Sinai Cancer, the cancer programme of Cedars-Sinai in Los Angeles. He was Deputy Director of the cancer centre and took over as Interim Director on 28 February 2025 when Dan Theodorescu stepped down, with Cristina Ferrone as Interim Co-Director for Cancer Clinical Services and Ze'ev Ronai as Interim Cancer Scientific Director. In a March 2026 Becker's Healthcare podcast he was still described as Interim Director, speaking on expanding access to cancer care and bridging discovery with clinical practice.","asOf":"2026-09-10","links":[{"label":"Source: Cedars-Sinai newsroom, director stepping down (Feb 2025)","url":"https://www.cedars-sinai.org/newsroom/cedars-sinai-cancer-director-stepping-down/"}],"tags":["leadership","clinician-scientist","cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cedars-sinai-cancer"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["international-journal-of-cancer","the-oncologist"],"dependsOn":[],"notes":[],"role":"Interim Director of Cedars-Sinai Cancer","institutionId":"cedars-sinai-cancer","specialisms":["Medical oncology","Cancer centre leadership","Translational research"],"profiles":[{"label":"Institution newsroom (March 2026)","url":"https://www.cedars-sinai.org/newsroom/beckers-healthcare-podcast-expanding-access-translational-research-and-the-future-of-cancer-care/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Figlin+RA%5BAuthor%5D"}],"papers":[{"title":"Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma","journal":"The Oncologist","year":2017,"doi":"10.1634/theoncologist.2016-0197"},{"title":"Novel Agents and Approaches for Advanced Renal Cell Carcinoma","journal":"Journal of Urology","year":2012,"doi":"10.1016/j.juro.2012.04.108"},{"title":"Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: New strategies for overcoming resistance to VEGFR and mTORC1 inhibitors","journal":"International Journal of Cancer","year":2013,"doi":"10.1002/ijc.28023"}]},{"id":"robert-uzzo","kind":"person","name":"Robert G. Uzzo","aka":[],"tldr":"Surgeon and cancer centre executive who is President and CEO of Fox Chase Cancer Center in Philadelphia and Executive Vice President for Cancer Services at Temple University Health System.","summary":"Robert G. Uzzo, MD, MBA, FACS, is President and CEO of Fox Chase Cancer Center, the Philadelphia cancer centre that is part of Temple University Health System. Temple Health's leadership directory also lists him as holder of the G. Willing 'Wing' Pepper Chair in Cancer Research at Fox Chase, Executive Vice President for Cancer Services at Temple University Health System, and Senior Associate Dean for Clinical Cancer Research at the Lewis Katz School of Medicine at Temple University. The directory gives no appointment date.","asOf":"2026-09-10","links":[{"label":"Source: Temple University Health System leadership directory","url":"https://www.templehealth.org/about/leadership"}],"tags":["leadership","comprehensive-cancer-centre","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["fox-chase"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["jco"],"dependsOn":[],"notes":[],"role":"President and CEO, Fox Chase Cancer Center","institutionId":"fox-chase","specialisms":["Cancer centre management","Clinical cancer research","Academic medicine"],"profiles":[{"label":"Temple Health leadership directory","url":"https://www.templehealth.org/about/leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Uzzo+RG%5BAuthor%5D"}],"papers":[{"title":"The R.E.N.A.L. Nephrometry Score: A Comprehensive Standardized System for Quantitating Renal Tumor Size, Location and Depth","journal":"Journal of Urology","year":2009,"doi":"10.1016/j.juro.2009.05.035"},{"title":"Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-Up: AUA Guideline: Part I","journal":"Journal of Urology","year":2021,"doi":"10.1097/ju.0000000000001911"},{"title":"Evaluating Overall Survival and Competing Risks of Death in Patients With Localized Renal Cell Carcinoma Using a Comprehensive Nomogram","journal":"Journal of Clinical Oncology","year":2010,"doi":"10.1200/jco.2009.22.4816"}],"orcid":"0000-0003-2398-6530"},{"id":"robert-mach","kind":"person","name":"Robert H. Mach","aka":[],"tldr":"Robert Mach invented the PARP PET tracer FluorThanatrace that images DNA repair capacity in tumours.","summary":"Robert H. Mach is the Britton Chance Professor of Radiology and Director of PET Radiochemistry at the Abramson Cancer Center, University of Pennsylvania. He is a radiochemist known for inventing the PARP PET tracer fluorine-18 FluorThanatrace, which images DNA repair capacity in tumours, alongside other tracers for imaging drug targets. His selected paper reports FluorThanatrace uptake as a marker of PARP1 expression and activity in breast cancer. His laboratory's tracers enable PARP-inhibitor patient selection studies and molecular imaging with PET.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mach%20RH%5BAuthor%5D"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["parp-pet","pet"],"targets":["parp"],"drugs":[],"companies":[],"institutions":["penn-abramson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Britton Chance Professor of Radiology; Director, PET Radiochemistry","institutionId":"penn-abramson","specialisms":["Radiochemistry","PARP PET","Molecular imaging"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mach%20RH%5BAuthor%5D"}],"papers":[{"title":"[18F]FluorThanatrace uptake as a marker of PARP1 expression and activity in breast cancer","journal":"American Journal of Nuclear Medicine and Molecular Imaging","year":2018}],"orcid":"0000-0002-7645-2869"},{"id":"robert-vonderheide","kind":"person","name":"Robert H. Vonderheide","aka":[],"tldr":"Directs Penn's cancer centre and pioneered CD40 agonist immunotherapy for pancreatic cancer.","summary":"Robert H. Vonderheide is Director of the Abramson Cancer Center at the University of Pennsylvania. He is a physician-scientist who pioneered CD40 agonist immunotherapy for pancreatic cancer, showing that CD40 activation can license macrophages and T cells against pancreatic tumours. His selected paper reports that CD40 agonists alter tumour stroma and show efficacy against pancreatic carcinoma in mice and humans. That work led to clinical trials of CD40 agonists with chemotherapy and PD-1 blockade, and he continues to study tumour immunology while directing Penn's cancer centre.","asOf":"2026-09-08","links":[{"label":"Abramson Cancer Center","url":"https://www.pennmedicine.org/cancer"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Vonderheide%20RH%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":["checkpoint-inhibitor","cytokine-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":["penn-abramson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Abramson Cancer Center","institutionId":"penn-abramson","specialisms":["Pancreatic cancer immunotherapy","CD40 agonists","Tumour immunology"],"profiles":[{"label":"Abramson Cancer Center","url":"https://www.pennmedicine.org/cancer"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Vonderheide%20RH%5BAuthor%5D"}],"papers":[{"title":"CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans","journal":"Science","year":2011,"url":"https://doi.org/10.1126/science.1198443","doi":"10.1126/science.1198443"}]},{"id":"robert-motzer","kind":"person","name":"Robert J. Motzer","aka":[],"tldr":"The kidney cancer trialist behind sunitinib, CheckMate 214 and CLEAR, three shifts in first-line standard of care.","summary":"Robert Motzer created the MSKCC prognostic risk model for metastatic renal cell carcinoma and then led the pivotal trials of each successive standard: sunitinib versus interferon (2007), nivolumab plus ipilimumab in CheckMate 214 (2018), and lenvatinib plus pembrolizumab in CLEAR (2021). He also led CheckMate 9ER (cabozantinib plus nivolumab). His trials define almost every first-line option in kidney cancer.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Motzer%20RJ%5BAuthor%5D%20renal%20cell"}],"tags":["rcc","trialist"],"related":[],"cancers":["rcc"],"sections":[],"technologies":["checkpoint-inhibitor","kinase-inhibitors"],"targets":["pd1","ctla4","vegf"],"drugs":["nivolumab","ipilimumab","pembrolizumab"],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":["checkmate-214","clear","checkmate-9er"],"people":[],"bottlenecks":[],"keyPapers":["paper-clear-nejm-2021"],"journals":[],"dependsOn":[],"notes":[],"role":"Jack and Dorothy Byrne Chair in Clinical Oncology, Memorial Sloan Kettering Cancer Center","institutionId":"mskcc","specialisms":["Renal cell carcinoma","Targeted therapy","Immunotherapy combinations","Prognostic models"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Motzer%20RJ%5BAuthor%5D%20renal%20cell"}],"papers":[{"title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma (CheckMate 214)","journal":"NEJM","year":2018,"doi":"10.1056/NEJMoa1712126"},{"title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma (CLEAR)","journal":"NEJM","year":2021,"doi":"10.1056/NEJMoa2035716"},{"title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","journal":"NEJM","year":2007,"doi":"10.1056/NEJMoa065044"}],"orcid":"0000-0001-6925-2327"},{"id":"robert-coleman","kind":"person","name":"Robert L. Coleman","aka":[],"tldr":"Gynaecologic oncologist who led ARIEL3 and GOG-0213, shaping PARP maintenance and secondary surgery in relapsed ovarian cancer.","summary":"Robert Coleman (US Oncology Research, Texas) was principal investigator of ARIEL3, which established rucaparib maintenance in recurrent ovarian cancer, and of GOG-0213, which found no survival benefit from secondary cytoreductive surgery but confirmed bevacizumab's benefit at relapse. He served as GOG programme director and has led many NRG gynaecological trials.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Coleman%20RL%5BAuthor%5D%20ovarian%20rucaparib"}],"tags":["ovarian","parp","surgery"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":["parp-inhibitor","antiangiogenic"],"targets":["parp","vegf"],"drugs":[],"companies":[],"institutions":["us-oncology-network"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Scientific Officer, US Oncology Research; Gynecologic Oncologist, Texas Oncology","institutionId":"us-oncology-network","specialisms":["Ovarian cancer","PARP inhibitors","Antiangiogenic therapy","Surgical trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Coleman%20RL%5BAuthor%5D%20ovarian%20rucaparib"}],"papers":[{"title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3)","journal":"Lancet","year":2017,"doi":"10.1016/S0140-6736(17)32440-6"},{"title":"Secondary surgical cytoreduction for recurrent ovarian cancer (GOG-0213)","journal":"NEJM","year":2019,"doi":"10.1056/NEJMoa1902626"}]},{"id":"robert-ferris","kind":"person","name":"Robert L. Ferris","aka":[],"tldr":"Surgeon and immunologist who led CheckMate 141, the trial that made nivolumab the first drug to lengthen survival in head and neck cancer after platinum failure, and E3311 on transoral surgery for HPV-positive throat cancer.","summary":"Robert Ferris is a head and neck surgical oncologist and tumour immunologist who directed UPMC Hillman Cancer Center before becoming director of UNC Lineberger Comprehensive Cancer Center in 2024. He was first author of the 2016 New England Journal of Medicine report of CheckMate 141, in which nivolumab improved overall survival compared with single-agent chemotherapy in platinum-refractory recurrent or metastatic head and neck squamous-cell carcinoma, and of the 2022 Journal of Clinical Oncology report of ECOG-ACRIN E3311, which tested reduced-dose radiotherapy after transoral surgery in HPV-positive oropharyngeal cancer.","asOf":"2026-09-18","links":[],"tags":["head-and-neck","immunotherapy","surgery","trialist"],"related":[],"cancers":["recurrent-metastatic-hnscc","hpv-positive-oropharyngeal-cancer","oropharyngeal-cancer","head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["unc-lineberger"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-e3311-transoral-surgery-ferris-jco-2022","paper-checkmate-141-ferris-nejm-2016"],"journals":[],"dependsOn":[],"notes":[],"role":"Head and neck surgeon and Director, UNC Lineberger Comprehensive Cancer Center","institutionId":"unc-lineberger","specialisms":["Head and neck cancer","Tumour immunology","Transoral surgery"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ferris%5BAuthor%5D"}],"papers":[{"title":"CheckMate 141: nivolumab for recurrent head and neck squamous cell carcinoma after platinum","journal":"New England Journal of Medicine","year":2016,"url":"https://doi.org/10.1056/NEJMoa1602252","doi":"10.1056/NEJMoa1602252"},{"title":"ECOG-ACRIN E3311: transoral surgery followed by reduced-dose radiotherapy for HPV-positive oropharyngeal cancer","journal":"Journal of Clinical Oncology","year":2022,"url":"https://doi.org/10.1200/JCO.21.01752","doi":"10.1200/JCO.21.01752"}]},{"id":"robert-martuza","kind":"person","name":"Robert L. Martuza","aka":[],"tldr":"Robert Martuza built the first genetically engineered virus designed to treat a cancer, a herpes virus crippled so that it could only replicate in dividing tumour cells.","summary":"Robert Martuza is a neurosurgeon at Massachusetts General Hospital and Harvard Medical School, where he runs the Molecular Neurosurgery Laboratory and works in the Brain Tumor Research Center. In 1991 he and colleagues reported dlsptk, a thymidine-kinase-negative mutant of herpes simplex virus type 1 attenuated for neurovirulence, which killed human glioma cells in culture, inhibited the growth of human gliomas implanted in nude mice, and prolonged survival when injected into intracranial gliomas.\n\nDeleting the viral thymidine kinase makes the virus depend on the host cell's own nucleotide pool, which dividing tumour cells supply and resting brain cells do not. This is the first worked example of the move that defines the modern field: remove a viral gene whose job a cancer cell will do anyway. Every approved herpes-based product, including talimogene laherparepvec and the triple-mutated G47 delta approved in Japan, descends from this line of work, and his laboratory continues to build oncolytic herpes viruses carrying immune payloads.","asOf":"2026-09-25","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Martuza%20RL%5BAuthor%5D"},{"label":"Massachusetts General Hospital","url":"https://www.massgeneral.org/neurosurgery"}],"tags":["oncolytic-virus","neuro-oncology"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":["oncolytic-virus"],"targets":[],"drugs":[],"companies":[],"institutions":["mgh"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-martuza-engineered-hsv-glioma-science-1991"],"journals":[],"dependsOn":[],"notes":[],"role":"Neurosurgeon and researcher, Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School; Molecular Neurosurgery Laboratory and Brain Tumor Research Center","institutionId":"mgh","specialisms":["Neurosurgery","Oncolytic herpes simplex virus","Glioma","Brain tumour biology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Martuza%20RL%5BAuthor%5D"},{"label":"Massachusetts General Hospital","url":"https://www.massgeneral.org/neurosurgery"}],"papers":[{"title":"Experimental therapy of human glioma by means of a genetically engineered virus mutant","journal":"Science","year":1991,"doi":"10.1126/science.1851332"},{"title":"Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival","journal":"Journal for ImmunoTherapy of Cancer","year":2024,"doi":"10.1136/jitc-2024-008880"}]},{"id":"robert-negrin","kind":"person","name":"Robert Negrin","aka":[],"tldr":"Stanford transplant physician and cellular immunologist who is President of the American Society of Hematology for 2026.","summary":"Robert Negrin is President of the American Society of Hematology (ASH) for the 2026 term, serving alongside President-Elect Cindy E. Dunbar and Vice President Alison Loren on the Executive Committee of the professional society for clinicians and scientists in haematology, including blood cancers. He is Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy) at Stanford University, where he chaired the Division of Blood and Marrow Transplantation from 2000 to 2020. His laboratory studies graft versus host and graft versus tumour reactions, regulatory T cell therapy to prevent complications after transplantation, and expansion of cytotoxic cells for immunotherapy.","asOf":"2026-09-10","links":[{"label":"Source: ASH Executive Committee page","url":"https://www.hematology.org/about/governance/executive-committee"}],"tags":["leadership","clinician-scientist","haematology","society"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ash"],"pathways":[],"terms":["immunotherapy-term","leukaemia-type","t-cell"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President of the American Society of Hematology (2026)","institutionId":"ash","specialisms":["Haematology","Blood and marrow transplantation","Cellular therapy"],"profiles":[{"label":"Stanford profile","url":"https://profiles.stanford.edu/robert-negrin"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Negrin+RS%5BAuthor%5D"}],"papers":[{"title":"CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation","journal":"Nature Medicine","year":2003,"doi":"10.1038/nm915"},{"title":"Graft-versus-host disease versus graft-versus-leukemia","journal":"Hematology","year":2015,"doi":"10.1182/asheducation-2015.1.225"}],"orcid":"0009-0004-8868-276X"},{"id":"robert-peel","kind":"person","name":"Robert Peel","aka":[],"tldr":"Kidney specialist from NHS Highland who chairs the Scottish Medicines Consortium, the body that decides which newly licensed medicines are accepted for use in the Scottish health service.","summary":"Dr Robert Peel, Consultant Nephrologist at NHS Highland, is Chair of the Scottish Medicines Consortium (SMC), a committee of clinicians, pharmacists, health board representatives, industry and the public that assesses newly licensed medicines, including cancer drugs, for use by NHSScotland. He is supported by vice chairs Graeme Bryson, Director of Pharmacy at NHS Lanarkshire, and Jane Goddard, Consultant Nephrologist at NHS Lothian.","asOf":"2026-09-10","links":[{"label":"Source: SMC who we are page","url":"https://scottishmedicines.org.uk/about-us/who-we-are/"}],"tags":["leadership","clinician-scientist","health-technology-assessment","drug-reimbursement"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["smc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chair of the Scottish Medicines Consortium","institutionId":"smc","specialisms":["Nephrology","Medicines assessment","Health technology assessment"],"profiles":[{"label":"SMC who we are","url":"https://scottishmedicines.org.uk/about-us/who-we-are/"}],"papers":[]},{"id":"robert-langer","kind":"person","name":"Robert S. Langer","aka":[],"tldr":"Biomedical engineer whose Koch Institute lab pioneered controlled drug delivery and nanomedicine, including approaches to cancer therapy.","summary":"Robert S. Langer is David H. Koch (1962) Institute Professor at MIT and a faculty member of the Koch Institute. His laboratory works at the interface of biotechnology and materials science, developing polymers and lipids for controlled delivery of proteins, DNA and RNA, studying inhibition of tumour blood-vessel growth, and engineering tissues. He is among the most cited engineers in history and a co-founder of Moderna.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://ki.mit.edu/people/faculty/langer"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Langer+R%5BAuthor%5D"}],"tags":["clinician-scientist","drug delivery","nanomedicine"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["moderna"],"institutions":["mit-koch"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"David H. Koch (1962) Institute Professor","institutionId":"mit-koch","specialisms":["Drug delivery","Biomaterials","Nanomedicine","Tissue engineering"],"profiles":[{"label":"Institution profile","url":"https://ki.mit.edu/people/faculty/langer"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Langer+R%5BAuthor%5D"}],"papers":[{"title":"Delivery technologies for cancer immunotherapy","journal":"Nature Reviews Drug Discovery","year":2019,"doi":"10.1038/s41573-018-0006-z"},{"title":"CRISPR-Cas9 Knockin Mice for Genome Editing and Cancer Modeling","journal":"Cell","year":2014,"doi":"10.1016/j.cell.2014.09.014"},{"title":"Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation","journal":"Nature Biotechnology","year":2019,"doi":"10.1038/s41587-019-0247-3"}]},{"id":"robert-mannel","kind":"person","name":"Robert S. Mannel","aka":[],"tldr":"Oklahoma gynecologic oncologist and Senior Vice President of the GOG Foundation.","summary":"Robert S. Mannel is Senior Vice President of The GOG Foundation and holds the Rainbolt Family Endowed Chair in Cancer at the University of Oklahoma Health Sciences Center, where he is Professor of Gynecologic Oncology. He has a long record of leadership in gynecologic cancer cooperative-group research and has served as an investigator on many GOG and NRG Oncology trials.","asOf":"2026-09-10","links":[{"label":"Society page","url":"https://www.gog.org/about/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mannel+RS%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","gynecologic oncology"],"related":[],"cancers":["ovarian","endometrial"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["gog-foundation"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Senior Vice President","institutionId":"gog-foundation","specialisms":["Gynecologic oncology","Cooperative group trials","Ovarian cancer"],"profiles":[{"label":"Society page","url":"https://www.gog.org/about/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mannel+RS%5BAuthor%5D"}],"papers":[{"title":"Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial","journal":"The Lancet Oncology","year":2017,"doi":"10.1016/s1470-2045(17)30279-6"},{"title":"A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: A Gynecologic Oncology Group Study","journal":"Gynecologic Oncology","year":2011,"doi":"10.1016/j.ygyno.2011.03.013"},{"title":"Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study","journal":"Journal of Clinical Oncology","year":2003,"doi":"10.1200/jco.2003.02.153"}],"orcid":"0009-0009-5059-3266"},{"id":"robert-sandler","kind":"person","name":"Robert Sandler","aka":[],"tldr":"A two-year-old with acute leukaemia treated by Sidney Farber with the folate antagonist aminopterin from December 1947. His temporary remission, reported in 1948, was the first evidence that a drug could turn back leukaemia.","summary":"Robert Sandler was two years old and gravely ill with acute lymphoblastic leukaemia at Children's Hospital Boston when, in December 1947, Sidney Farber began treating him with aminopterin, a folic acid antagonist newly synthesised by Yellapragada Subbarow's team at Lederle. Within weeks his blood counts improved and he was well enough to go home. He was one of sixteen children in Farber's June 1948 report in the New England Journal of Medicine, in which ten showed remissions; the effect lasted months, and Robert relapsed and died in 1948. It was the first demonstration that a chemical could induce remission in a childhood cancer, the starting point for methotrexate and for combination chemotherapy. His name is recorded in the histories of the period, including Siddhartha Mukherjee's The Emperor of All Maladies.","asOf":"2026-09-09","links":[{"label":"Farber et al., NEJM 1948","url":"https://www.nejm.org/doi/full/10.1056/NEJM194806032382301"},{"label":"Sidney Farber (Wikipedia)","url":"https://en.wikipedia.org/wiki/Sidney_Farber"}],"tags":["hero","patient"],"related":[],"cancers":["all-leukemia"],"sections":["chemotherapy"],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["methotrexate"],"companies":[],"institutions":["dana-farber"],"pathways":[],"terms":[],"trials":[],"people":["sidney-farber"],"bottlenecks":["b-rare-cancers","b-trial-enrolment"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Child whose remission on aminopterin in 1947 was the first in leukaemia","specialisms":["Acute lymphoblastic leukaemia","History of chemotherapy"],"profiles":[{"label":"Farber et al., NEJM 1948","url":"https://www.nejm.org/doi/full/10.1056/NEJM194806032382301"},{"label":"Sidney Farber (Wikipedia)","url":"https://en.wikipedia.org/wiki/Sidney_Farber"}],"papers":[]},{"id":"robert-separovic","kind":"person","name":"Robert Šeparović","aka":[],"tldr":"Robert Šeparović represents University Hospital for Tumors, Sestre milosrdnice University Hospital Centre in the Organisation of European Cancer Institutes, which lists the centre among its members in Croatia.","summary":"Robert Šeparović is listed by the Organisation of European Cancer Institutes (OECI) as the representative of University Hospital for Tumors, Sestre milosrdnice University Hospital Centre, its full member in Croatia. OnCo records the name from the OECI membership list so that the centre's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the institution's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"University Hospital for Tumors, Sestre milosrdnice University Hospital Centre website","url":"http://www.kbcsm.hr/klinike/klinika-za-tumore"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["sestre-milosrdnice-tumors"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of University Hospital for Tumors, Sestre milosrdnice University Hospital Centre to the Organisation of European Cancer Institutes","institutionId":"sestre-milosrdnice-tumors","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"University Hospital for Tumors, Sestre milosrdnice University Hospital Centre website","url":"http://www.kbcsm.hr/klinike/klinika-za-tumore"}],"papers":[{"title":"PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial","journal":"Breast Cancer Res","year":2019,"url":"https://doi.org/10.1186/s13058-019-1115-2","doi":"10.1186/s13058-019-1115-2","note":"Europe PMC author record matched by affiliation"},{"title":"CHARACTERISTICS AND PROGNOSIS OF TRIPLE-NEGATIVE BREAST CANCER PATIENTS: A CROATIAN SINGLE INstitution RETROSPECTIVE COHORT STUDY","journal":"Acta Clin Croat","year":2020,"url":"https://doi.org/10.20471/acc.2020.59.01.12","doi":"10.20471/acc.2020.59.01.12","note":"Europe PMC author record matched by affiliation"},{"title":"THE ROLE OF SALIVARY AND SERUM CA125 AND ROUTINE BLOOD TESTS IN PATIENTS WITH OVARIAN MALIGNANCIES","journal":"Acta Clin Croat","year":2021,"url":"https://doi.org/10.20471/acc.2021.60.01.08","doi":"10.20471/acc.2021.60.01.08","note":"Europe PMC author record matched by affiliation"}]},{"id":"robert-stone","kind":"person","name":"Robert W. Stone","aka":[],"tldr":"Leads City of Hope, which expanded into a national cancer system with the acquisition of Cancer Treatment Centers of America.","summary":"Robert Stone is President and Chief Executive Officer of City of Hope, where he has been chief executive since 2014. A health system leader, he oversaw City of Hope's growth into a multi-state cancer care and research organisation and its national expansion, including the acquisition of Cancer Treatment Centers of America that turned it into a national cancer system. His record points to the City of Hope research faculty pages, PubMed and Google Scholar for further detail. He continues to lead the organisation's clinical, research and expansion strategy.","asOf":"2026-09-08","links":[{"label":"City of Hope research faculty","url":"https://www.cityofhope.org/research/find-a-researcher"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Stone%20RW%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Robert%20W.%20Stone"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["city-of-hope"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President and Chief Executive Officer, City of Hope","institutionId":"city-of-hope","specialisms":["Health system leadership"],"profiles":[{"label":"City of Hope research faculty","url":"https://www.cityofhope.org/research/find-a-researcher"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Stone%20RW%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Robert%20W.%20Stone"}],"papers":[]},{"id":"robert-woodruff","kind":"person","name":"Robert W. Woodruff","aka":[],"tldr":"After his mother Emily Winship Woodruff died of cancer in 1937, he gave Emory University the gift that founded the Winship Clinic; his foundation's $400 million gift in 2018 is building Winship's new Midtown Atlanta home.","summary":"Robert W. Woodruff (1889-1985) led The Coca-Cola Company for more than three decades and became Atlanta's dominant philanthropist. Winship Cancer Institute's history records that in 1937 the Robert Winship Memorial Clinic was founded at Emory University with a gift from Woodruff after his mother, Emily Winship Woodruff, died of cancer that year; the clinic was named for his maternal grandfather. It was one of the first cancer clinics in the American South and grew into Winship Cancer Institute, Georgia's only NCI-designated comprehensive cancer centre. The Robert W. Woodruff Foundation continues the work: Winship records its 2018 gift of $400 million to Emory University, part of it to build a new Winship facility in Midtown Atlanta.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Robert_W._Woodruff","links":[{"label":"Winship Cancer Institute: history","url":"https://winshipcancer.emory.edu/about-us/history.php"}],"tags":["hero","donor"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["emory-winship"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-funding-allocation","b-global-access"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Coca-Cola president whose 1937 gift founded Emory's Winship Cancer Institute in memory of his mother","specialisms":["Cancer centre founding","Southern US cancer care"],"profiles":[],"papers":[]},{"id":"roberto-cunsolo","kind":"person","name":"Roberto Cunsolo","aka":[],"tldr":"Roberto Cunsolo represents Mediterranean Institute of Oncology (IOM) in the Organisation of European Cancer Institutes, which lists the centre among its members in Italy.","summary":"Roberto Cunsolo is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Mediterranean Institute of Oncology (IOM), its full member in Italy. OnCo records the name from the OECI membership list so that the centre's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the institution's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Mediterranean Institute of Oncology (IOM) website","url":"http://www.grupposamed.com"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["mediterranean-institute-of-oncology"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Mediterranean Institute of Oncology (IOM) to the Organisation of European Cancer Institutes","institutionId":"mediterranean-institute-of-oncology","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Mediterranean Institute of Oncology (IOM) website","url":"http://www.grupposamed.com"}],"papers":[]},{"id":"roberto-de-almeida-gil","kind":"person","name":"Roberto de Almeida Gil","aka":[],"tldr":"Director-General of Brazil's Instituto Nacional de Câncer (INCA), the Ministry of Health body that coordinates national cancer control.","summary":"Roberto de Almeida Gil is Director-General (Diretor-geral) of the Instituto Nacional de Câncer (INCA) in Rio de Janeiro, the Brazilian Ministry of Health institute responsible for national cancer prevention, surveillance, care, teaching and research. A medical oncologist by background, he leads INCA's hospital units and its national cancer control programmes.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.gov.br/inca/pt-br/acesso-a-informacao/institucional/quem-e-quem"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gil+RA%5BAuthor%5D+INCA"}],"tags":["leadership","cancer control","public health"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["inca-brazil"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director-General","institutionId":"inca-brazil","specialisms":["Medical oncology","Cancer control policy","Public health"],"profiles":[{"label":"Institution profile","url":"https://www.gov.br/inca/pt-br/acesso-a-informacao/institucional/quem-e-quem"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gil+RA%5BAuthor%5D+INCA"}],"papers":[{"title":"A randomized trial of chemotherapy followed by pelvic radiation therapy in stage IIIB carcinoma of the cervix.","journal":"Journal of Clinical Oncology","year":1991,"url":"https://doi.org/10.1200/jco.1991.9.6.970","doi":"10.1200/jco.1991.9.6.970","note":"OpenAlex author record matched by institution"},{"title":"A randomized trial comparing radiation therapy versus concomitant radiation therapy and chemotherapy in carcinoma of the thoracic esophagus","journal":"Cancer","year":1991,"url":"https://doi.org/10.1002/1097-0142(19910501)67:9<2258::aid-cncr2820670908>3.0.co;2-g","doi":"10.1002/1097-0142(19910501)67:9<2258::aid-cncr2820670908>3.0.co;2-g","note":"OpenAlex author record matched by institution"},{"title":"Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma","journal":"JAMA Network Open","year":2021,"url":"https://doi.org/10.1001/jamanetworkopen.2021.36128","doi":"10.1001/jamanetworkopen.2021.36128","note":"OpenAlex author record matched by institution"}],"orcid":"0000-0001-9684-415X"},{"id":"roberto-orecchia","kind":"person","name":"Roberto Orecchia","aka":[],"tldr":"Radiation oncologist who led intraoperative radiotherapy trials and directs research at IEO.","summary":"Roberto Orecchia is Scientific Director of IEO, the European Institute of Oncology, in Milan. A radiation oncologist, his specialisms are radiation oncology, intraoperative radiotherapy and proton therapy, alongside modern image-guided external beam techniques. He led ELIOT, the randomised phase 3 equivalence trial of intraoperative electron radiotherapy in early breast cancer, whose long-term recurrence outcomes were reported in The Lancet Oncology. His other papers include a study of seroconversion in patients with cancer and oncology health care workers infected by SARS-CoV-2, and a review of machine learning models for predicting toxicity outcomes in radiotherapy. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Orecchia%20R%5BAuthor%5D%20intraoperative%20radiotherapy"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["imrt-igrt"],"targets":[],"drugs":[],"companies":[],"institutions":["ieo-milan"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Scientific Director, IEO","institutionId":"ieo-milan","specialisms":["Radiation oncology","Intraoperative radiotherapy","Proton therapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Orecchia%20R%5BAuthor%5D%20intraoperative%20radiotherapy"}],"papers":[{"title":"Intraoperative irradiation for early breast cancer (ELIOT): long-term recurrence and survival outcomes from a single-centre, randomised, phase 3 equivalence trial","journal":"The Lancet Oncology","year":2021,"doi":"10.1016/s1470-2045(21)00080-2"},{"title":"Seroconversion in patients with cancer and oncology health care workers infected by SARS-CoV-2","journal":"Annals of Oncology","year":2021,"doi":"10.1016/j.annonc.2020.10.473"},{"title":"Machine Learning-Based Models for Prediction of Toxicity Outcomes in Radiotherapy","journal":"Frontiers in Oncology","year":2020,"doi":"10.3389/fonc.2020.00790"}]},{"id":"robin-kate-kelley","kind":"person","name":"Robin Kate Kelley","aka":[],"tldr":"San Francisco oncologist who was lead author of KEYNOTE-966, which showed that adding pembrolizumab to gemcitabine and cisplatin helps people with advanced bile duct cancer live longer.","summary":"Robin Kate Kelley is a gastrointestinal medical oncologist at UCSF who focuses on liver and biliary cancers. She was first author of the 2023 Lancet report of KEYNOTE-966, in which pembrolizumab plus gemcitabine and cisplatin improved overall survival in advanced biliary tract cancer, and has led early trials of immunotherapy combinations in hepatocellular carcinoma, including the cabozantinib and atezolizumab study COSMIC-312.","asOf":"2026-09-18","links":[],"tags":["biliary","hcc","immunotherapy","trialist"],"related":[],"cancers":["intrahepatic-cholangiocarcinoma","biliary-tract-cancer","hcc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ucsf"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-keynote-966-lancet-2023"],"journals":[],"dependsOn":[],"notes":[],"role":"Gastrointestinal oncologist, UCSF Helen Diller Family Comprehensive Cancer Center","institutionId":"ucsf","specialisms":["Hepatocellular carcinoma","Biliary tract cancer","Immunotherapy combinations"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kelley%5BAuthor%5D"}],"papers":[{"title":"KEYNOTE-966: pembrolizumab plus gemcitabine and cisplatin for advanced biliary tract cancer","journal":"The Lancet","year":2023,"url":"https://doi.org/10.1016/S0140-6736(23)00727-4","doi":"10.1016/S0140-6736(23)00727-4"}]},{"id":"robin-jones","kind":"person","name":"Robin L. Jones","aka":[],"tldr":"London sarcoma specialist who led TAPPAS, the trial that tested the anti-angiogenic protein TRC105 with pazopanib in angiosarcoma, and who has led many international sarcoma trials.","summary":"Robin Jones heads the sarcoma unit at The Royal Marsden and The Institute of Cancer Research. He was first author of the 2022 Journal of Clinical Oncology report of TAPPAS, the phase 3 trial in which adding the endoglin antibody carotuximab (TRC105) to pazopanib did not improve progression-free survival in advanced angiosarcoma. He has been a lead investigator on trials of trabectedin, eribulin and afami-cel in sarcoma.","asOf":"2026-09-18","links":[],"tags":["sarcoma","trialist"],"related":[],"cancers":["angiosarcoma","vascular-tumours","sarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["royal-marsden"],"pathways":[],"terms":[],"trials":["tappas"],"people":[],"bottlenecks":[],"keyPapers":["paper-esmo-sts-guideline-gronchi-ann-oncol-2021","paper-robin-jones-ann-oncol-2018","paper-robin-jones-lancet-2016"],"journals":[],"dependsOn":[],"notes":[],"role":"Head of the Sarcoma Unit, The Royal Marsden and The Institute of Cancer Research","institutionId":"royal-marsden","specialisms":["Soft tissue sarcoma","Angiosarcoma","Sarcoma drug development"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Jones%5BAuthor%5D"}],"papers":[{"title":"Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS clinical practice guideline","journal":"Annals of Oncology","year":2021,"url":"https://doi.org/10.1016/j.annonc.2021.07.006","doi":"10.1016/j.annonc.2021.07.006","note":"Europe PMC author record matched by affiliation (The Royal Marsden); 742 citations on Europe PMC."},{"title":"Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","journal":"Annals of Oncology","year":2018,"url":"https://doi.org/10.1093/annonc/mdy096","doi":"10.1093/annonc/mdy096","note":"Europe PMC author record matched by affiliation (The Royal Marsden); 471 citations on Europe PMC."},{"title":"Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial","journal":"The Lancet","year":2016,"url":"https://doi.org/10.1016/s0140-6736(16)30587-6","doi":"10.1016/s0140-6736(16)30587-6","note":"Europe PMC author record matched by affiliation (The Royal Marsden); 452 citations on Europe PMC."}],"orcid":"0000-0003-4173-3844"},{"id":"robin-zon","kind":"person","name":"Robin T. Zon","aka":[],"tldr":"Community oncologist who led ASCO in 2024-25 with a focus on bringing trials to patients close to home.","summary":"Robin Zon is a medical oncologist in community practice at Michiana Hematology Oncology in Indiana and served as President of the American Society of Clinical Oncology (ASCO) for 2024 to 2025. Specialising in community oncology, clinical trial access and health policy, she is a long-time ASCO volunteer leader on health policy and clinical research access, and her presidency focused on bringing trials to patients close to home. Her papers include the ASCO policy statement on clinical pathways in oncology in the Journal of Oncology Practice and the ASCO policy statement on the role of the oncologist in cancer prevention and risk assessment in the Journal of Clinical Oncology. She brings a community perspective to national oncology leadership.","asOf":"2026-09-08","links":[{"label":"ASCO leadership","url":"https://www.asco.org/about-asco/asco-leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Zon%20RT%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Robin%20T.%20Zon"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["asco"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["jco-oncology-practice"],"dependsOn":[],"notes":[],"role":"ASCO President 2024-2025; Medical Oncologist, Michiana Hematology Oncology","institutionId":"asco","specialisms":["Community oncology","Clinical trial access","Health policy"],"profiles":[{"label":"ASCO leadership","url":"https://www.asco.org/about-asco/asco-leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Zon%20RT%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Robin%20T.%20Zon"}],"papers":[{"title":"American Society of Clinical Oncology Policy Statement on Clinical Pathways in Oncology","journal":"Journal of Oncology Practice","year":2016,"url":"https://doi.org/10.1200/JOP.2015.009134","doi":"10.1200/JOP.2015.009134"},{"title":"American Society of Clinical Oncology policy statement: the role of the oncologist in cancer prevention and risk assessment","journal":"Journal of Clinical Oncology","year":2009,"url":"https://doi.org/10.1200/JCO.2008.16.3691","doi":"10.1200/JCO.2008.16.3691"}]},{"id":"robyn-ward","kind":"person","name":"Robyn Ward","aka":[],"tldr":"Medical oncologist and cancer geneticist who chairs the independent expert committee that recommends which medicines Australia subsidises through the Pharmaceutical Benefits Scheme.","summary":"Professor Robyn Ward AM is Chair of the Pharmaceutical Benefits Advisory Committee (PBAC), the independent expert body appointed by the Australian Government to recommend new medicines for listing on the Pharmaceutical Benefits Scheme. She is Deputy Vice-Chancellor (Research and Enterprise) and Senior Vice-President of Monash University. Her expertise spans medical oncology, cancer genetics and health technology assessment, and she was made a Member of the Order of Australia for service to medical research and patient care in oncology.","asOf":"2026-09-10","links":[{"label":"Source: PBAC membership page","url":"https://www.pbs.gov.au/info/industry/listing/participants/pbac"}],"tags":["leadership","clinician-scientist","health-technology-assessment","drug-reimbursement"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["pbac"],"pathways":[],"terms":["hta"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chair of the Pharmaceutical Benefits Advisory Committee","institutionId":"pbac","specialisms":["Medical oncology","Cancer genetics","Health technology assessment"],"profiles":[{"label":"PBAC membership page","url":"https://www.pbs.gov.au/info/industry/listing/participants/pbac"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ward+RL%5BAuthor%5D"}],"papers":[{"title":"Incidence and severity of self-reported chemotherapy side effects in routine care: A prospective cohort study","journal":"PLOS ONE","year":2017,"doi":"10.1371/journal.pone.0184360"},{"title":"Identification of constitutional MLH1 epimutations and promoter variants in colorectal cancer patients from the Colon Cancer Family Registry","journal":"Genetics in Medicine","year":2013,"doi":"10.1038/gim.2012.91"},{"title":"Tolerance of Whole-Genome Doubling Propagates Chromosomal Instability and Accelerates Cancer Genome Evolution","journal":"Cancer Discovery","year":2014,"doi":"10.1158/2159-8290.cd-13-0285"}],"orcid":"0000-0002-6877-8906"},{"id":"roger-stupp","kind":"person","name":"Roger Stupp","aka":[],"tldr":"Led the EORTC/NCIC trial that made temozolomide with radiotherapy the glioblastoma standard, and the EF-14 trial of tumour treating fields.","summary":"Roger Stupp is Professor of Neurological Surgery and Neurology at Northwestern University in Chicago, having previously worked in Lausanne and with the EORTC. His specialisms are neuro-oncology, glioblastoma and tumour treating fields. He led the EORTC 26981/NCIC CE.3 trial, reported in the New England Journal of Medicine as radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, which defined the Stupp protocol that remains the glioblastoma standard. He also led EF-14, the JAMA trial that added tumour treating fields to maintenance temozolomide, the basis for the Optune device. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Stupp%20R%5BAuthor%5D%20glioblastoma%20temozolomide"}],"tags":[],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":["ttfields"],"targets":[],"drugs":["temozolomide","optune"],"companies":["curie-nki-eortc"],"institutions":[],"pathways":[],"terms":[],"trials":["eortc-26981","ef-14"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Neurological Surgery and Neurology, Northwestern University; formerly Lausanne and EORTC","institutionId":"curie-nki-eortc","specialisms":["Neuro-oncology","Glioblastoma","Tumour treating fields"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Stupp%20R%5BAuthor%5D%20glioblastoma%20temozolomide"}],"papers":[{"title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","journal":"NEJM","year":2005,"doi":"10.1056/NEJMoa043330"},{"title":"Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma (EF-14)","journal":"JAMA","year":2017,"doi":"10.1001/jama.2017.18718"}]},{"id":"rohit-bhargava","kind":"person","name":"Rohit Bhargava","aka":[],"tldr":"Engineer who founded and directs the Cancer Center at Illinois, the University of Illinois Urbana-Champaign centre that applies engineering and basic science to cancer.","summary":"Rohit Bhargava is the Phillip and Ann Sharp Director of the Cancer Center at Illinois and holds the Grainger Distinguished Chair in Engineering at the University of Illinois Urbana-Champaign. The centre's history page records that it began in 2011 as the Cancer Community, led by him and a group of more than 50 Illinois faculty, before becoming a formal centre. His leadership team includes Deputy Director Paul Hergenrother and associate directors for translational research (Timothy Fan), shared resources, education, engagement and administration.","asOf":"2026-09-10","links":[{"label":"Source: Cancer Center at Illinois leadership page","url":"https://cancer.illinois.edu/ccil-leadership/"},{"label":"Source: Cancer Center at Illinois 'About' page (history)","url":"https://cancer.illinois.edu/about"}],"tags":["leadership","clinician-scientist","research-institute"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cancer-center-at-illinois"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["pnas"],"dependsOn":[],"notes":[],"role":"Phillip and Ann Sharp Director, Cancer Center at Illinois","institutionId":"cancer-center-at-illinois","specialisms":["Bioengineering","Chemical imaging","Cancer technology research"],"profiles":[{"label":"Cancer Center at Illinois leadership directory","url":"https://cancer.illinois.edu/ccil-leadership/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bhargava+R%5BAuthor%5D+AND+Illinois"}],"papers":[{"title":"Simultaneous cancer and tumor microenvironment subtyping using confocal infrared microscopy for all-digital molecular histopathology","journal":"Proceedings of the National Academy of Sciences","year":2018,"doi":"10.1073/pnas.1719551115"}]},{"id":"rolando-medeiros","kind":"person","name":"Rolando Medeiros","aka":[],"tldr":"Rolando Medeiros represents Fundación Arturo López Pérez in the Organisation of European Cancer Institutes, which lists the centre among its members in Chile.","summary":"Rolando Medeiros is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Fundación Arturo López Pérez, its associate member in Chile. OnCo records the name from the OECI membership list so that the centre's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the institution's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Fundación Arturo López Pérez website","url":"https://www.falp.org"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["falp-chile"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Fundación Arturo López Pérez to the Organisation of European Cancer Institutes","institutionId":"falp-chile","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Fundación Arturo López Pérez website","url":"https://www.falp.org"}],"papers":[]},{"id":"rolf-stahel","kind":"person","name":"Rolf A. Stahel","aka":[],"tldr":"Founded the European Thoracic Oncology Platform and leads the merged ETOP IBCSG academic trials foundation.","summary":"Rolf Stahel founded the European Thoracic Oncology Platform in 2009 to run academic lung cancer and mesothelioma trials across Europe, including the SAKK mesothelioma surgery trial, BELIEF, SPLENDOUR and the ETOP-led collaborations on ALK and EGFR disease, and now leads the foundation formed by its merger with the International Breast Cancer Study Group. He has been president of ESMO and led the Zurich lung cancer programme.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Stahel%20RA%5BAuthor%5D%20thoracic%20ETOP"}],"tags":["cooperative-group","thoracic","europe"],"related":[],"cancers":["nsclc","mesothelioma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["etop-ibcsg"],"institutions":["usz-zurich"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President, ETOP IBCSG Partners Foundation; Emeritus Professor of Oncology, University of Zurich","institutionId":"etop-ibcsg","specialisms":["Thoracic oncology","Academic cooperative trials","Mesothelioma","European trial networks"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Stahel%20RA%5BAuthor%5D%20thoracic%20ETOP"}],"papers":[{"title":"Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial","journal":"Lancet Oncology","year":2015,"doi":"10.1016/S1470-2045(15)00208-9"},{"title":"Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial","journal":"Lancet Respiratory Medicine","year":2017,"doi":"10.1016/S2213-2600(17)30129-7"}]},{"id":"rolf-kiessling","kind":"person","name":"Rolf Kiessling","aka":[],"tldr":"Rolf Kiessling is the immunologist who first described natural killer cells.","summary":"Rolf Kiessling is Professor of Experimental Oncology at Karolinska Institutet in Stockholm, working with Karolinska University Hospital. His specialisms are tumour immunology, natural killer cells and cancer vaccines. He is the immunologist who first described natural killer cells, co-discovering them in the 1970s; his European Journal of Immunology paper reported natural killer cells in the mouse as cytotoxic cells with specificity for Moloney leukaemia cells. He has since worked on tumour immune escape and cell-based immunotherapy, including CAR-NK approaches. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kiessling%20R%5BAuthor%5D%20natural%20killer"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["car-nk-macrophage"],"targets":[],"drugs":[],"companies":[],"institutions":["karolinska"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Experimental Oncology, Karolinska Institutet","institutionId":"karolinska","specialisms":["Tumour immunology","Natural killer cells","Cancer vaccines"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kiessling%20R%5BAuthor%5D%20natural%20killer"}],"papers":[{"title":"\"Natural\" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells","journal":"European Journal of Immunology","year":1975,"doi":"10.1002/eji.1830050208"}],"orcid":"0000-0003-0663-5763"},{"id":"roman-rouzier","kind":"person","name":"Roman Rouzier","aka":[],"tldr":"Gynaecological and breast surgeon who has directed Centre François Baclesse, the comprehensive cancer centre for Normandy in Caen, since July 2023.","summary":"Professeur Roman Rouzier has been Directeur Général of Centre François Baclesse since 1 July 2023. He is a gynaecological surgeon specialising in breast surgery. The centre's organisation page states that he is supported by Michael Canovas, Directeur Général Adjoint. Centre François Baclesse is the Centre de Lutte Contre le Cancer for Normandy, based in Caen, providing cancer treatment, research and training within the Unicancer network.","asOf":"2026-09-10","links":[{"label":"Source: Centre François Baclesse organisation page","url":"https://www.baclesse.fr/decouvrir-le-centre/organisation/"}],"tags":["leadership","clinician-scientist","comprehensive-cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["centre-francois-baclesse"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["european-journal-of-cancer","journal-of-cancer-policy"],"dependsOn":[],"notes":[],"role":"Directeur Général (Director General), Centre François Baclesse","institutionId":"centre-francois-baclesse","specialisms":["Gynaecological surgery","Breast surgery","Cancer centre management"],"profiles":[{"label":"Centre François Baclesse organisation page","url":"https://www.baclesse.fr/decouvrir-le-centre/organisation/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rouzier+R%5BAuthor%5D"}],"papers":[{"title":"Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trial","journal":"European Journal of Cancer","year":2017,"doi":"10.1016/j.ejca.2016.09.036"},{"title":"Genomic signature to guide adjuvant chemotherapy treatment decisions for early breast cancer patients in France: a cost-effectiveness analysis","journal":"Frontiers in Oncology","year":2023,"doi":"10.3389/fonc.2023.1191943"},{"title":"Current perspectives for external control arms in oncology clinical trials: Analysis of EMA approvals 2016–2021","journal":"Journal of Cancer Policy","year":2023,"doi":"10.1016/j.jcpo.2023.100403"}]},{"id":"roman-thomas","kind":"person","name":"Roman Thomas","aka":[],"tldr":"Roman Thomas is a cancer genomicist who mapped the genomes of small-cell lung cancer.","summary":"Roman Thomas is Director of the Department of Translational Genomics at the University of Cologne (CIO). A cancer genomicist, his specialisms are cancer genomics, small-cell lung cancer and lung cancer biology, with a focus on TP53. He led the comprehensive genomic profiling of small-cell lung cancer, reported in Nature, which showed near-universal loss of TP53 and RB1 in the disease. He has also characterised squamous lung cancer and the neuroendocrine transformation of non-small-cell lung cancer. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Thomas%20RK%5BAuthor%5D%20small%20cell%20lung%20cancer%20genomic"}],"tags":[],"related":[],"cancers":["sclc","nsclc"],"sections":[],"technologies":[],"targets":["tp53"],"drugs":[],"companies":[],"institutions":["uniklinik-koeln"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Department of Translational Genomics, University of Cologne","institutionId":"uniklinik-koeln","specialisms":["Cancer genomics","Small-cell lung cancer","Lung cancer biology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Thomas%20RK%5BAuthor%5D%20small%20cell%20lung%20cancer%20genomic"}],"papers":[{"title":"Comprehensive genomic profiles of small cell lung cancer","journal":"Nature","year":2015,"doi":"10.1038/nature14664"}]},{"id":"rona-yaeger","kind":"person","name":"Rona Yaeger","aka":[],"tldr":"New York oncologist who was lead author of the KRYSTAL-1 colorectal report, which showed adagrasib with cetuximab shrinks KRAS G12C-mutant colorectal cancer and led to the combination's approval.","summary":"Rona Yaeger is a gastrointestinal medical oncologist and physician-scientist at Memorial Sloan Kettering Cancer Center. She was first author of the 2023 New England Journal of Medicine report of the KRYSTAL-1 cohorts in which adagrasib alone and with cetuximab produced responses in heavily pretreated KRAS G12C-mutant metastatic colorectal cancer, the basis of the combination's accelerated approval. Her laboratory studies mechanisms of resistance to RAS and BRAF inhibitors.","asOf":"2026-09-18","links":[],"tags":["colorectal","targeted-therapy","trialist"],"related":[],"cancers":["kras-g12c-colorectal","braf-v600e-colorectal","colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-krystal-1-crc-yaeger-nejm-2023"],"journals":[],"dependsOn":[],"notes":[],"role":"Gastrointestinal medical oncologist, Memorial Sloan Kettering Cancer Center","institutionId":"mskcc","specialisms":["KRAS G12C colorectal cancer","BRAF-mutant colorectal cancer","Resistance to targeted therapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Yaeger%5BAuthor%5D"}],"papers":[{"title":"KRYSTAL-1: adagrasib with or without cetuximab in KRAS G12C-mutated colorectal cancer","journal":"New England Journal of Medicine","year":2023,"url":"https://doi.org/10.1056/NEJMoa2212419","doi":"10.1056/NEJMoa2212419"}]},{"id":"ronald-cohn","kind":"person","name":"Ronald Cohn","aka":[],"tldr":"Clinical geneticist who leads The Hospital for Sick Children in Toronto, one of the world's largest paediatric academic health centres.","summary":"Ronald Cohn, MD, is President and CEO of The Hospital for Sick Children (SickKids) in Toronto. A paediatrician and clinical geneticist, his research has focused on neuromuscular disorders and genome editing, and he has championed SickKids' Precision Child Health strategy. SickKids' Garron Family Cancer Centre is Canada's largest paediatric oncology programme.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.sickkids.ca/en/about/leadership/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cohn+RD%5BAuthor%5D"}],"tags":["leadership","paediatrics","genetics"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["sickkids"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President & CEO","institutionId":"sickkids","specialisms":["Paediatrics","Clinical genetics","Precision child health"],"profiles":[{"label":"Institution profile","url":"https://www.sickkids.ca/en/about/leadership/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cohn+RD%5BAuthor%5D"}],"papers":[{"title":"Improved diagnostic yield compared with targeted gene sequencing panels suggests a role for whole-genome sequencing as a first-tier genetic test","journal":"Genetics in Medicine","year":2018,"url":"https://doi.org/10.1038/gim.2017.119","doi":"10.1038/gim.2017.119","note":"Europe PMC author record matched by affiliation"},{"title":"Whole Genome Sequencing Expands Diagnostic Utility and Improves Clinical Management in Pediatric Medicine","journal":"npj Genomic Medicine","year":2016,"url":"https://doi.org/10.1038/npjgenmed.2015.12","doi":"10.1038/npjgenmed.2015.12","note":"Europe PMC author record matched by affiliation"},{"title":"Expanding the Boundaries of RNA Sequencing as a Diagnostic Tool for Rare Mendelian Disease","journal":"American Journal of Human Genetics","year":2019,"url":"https://doi.org/10.1016/j.ajhg.2019.01.012","doi":"10.1016/j.ajhg.2019.01.012","note":"Europe PMC author record matched by affiliation"}],"orcid":"0000-0002-6775-1496"},{"id":"ronald-levy","kind":"person","name":"Ronald Levy","aka":[],"tldr":"Developed the first antibody treatment for cancer, rituximab, and still works on training the immune system against lymphoma.","summary":"Ronald Levy is Robert K. and Helen K. Summy Professor of Medicine (Oncology) at Stanford University, within the Stanford Cancer Institute. An oncologist specialising in lymphoma and antibody therapy, his anti-idiotype and anti-CD20 antibody work led to rituximab, the first approved cancer antibody. His papers include the New England Journal of Medicine report on treatment of B-cell lymphoma with monoclonal anti-idiotype antibody and a Science Translational Medicine study on eradication of spontaneous malignancy by local immunotherapy. His current work tests in situ vaccination with TLR agonists and anti-OX40 in low-grade lymphoma, linking monoclonal antibodies, CD20 and innate immune agonists to diffuse large B-cell lymphoma.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Ronald_Levy_(scientist)","links":[{"label":"Stanford profile","url":"https://profiles.stanford.edu/search?q=Ronald%20Levy"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Levy%20R%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Ronald%20Levy"}],"tags":[],"related":[],"cancers":["dlbcl"],"sections":[],"technologies":["monoclonal-antibody","sting-agonist"],"targets":["cd20"],"drugs":[],"companies":[],"institutions":["stanford"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Robert K. and Helen K. Summy Professor of Medicine (Oncology), Stanford University","institutionId":"stanford","specialisms":["Lymphoma","Antibody therapy","In situ vaccination"],"profiles":[{"label":"Stanford profile","url":"https://profiles.stanford.edu/search?q=Ronald%20Levy"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Levy%20R%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Ronald%20Levy"}],"papers":[{"title":"Eradication of spontaneous malignancy by local immunotherapy","journal":"Science Translational Medicine","year":2018,"url":"https://doi.org/10.1126/scitranslmed.aan4488","doi":"10.1126/scitranslmed.aan4488"},{"title":"Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody","journal":"New England Journal of Medicine","year":1982,"url":"https://doi.org/10.1056/NEJM198203043060906","doi":"10.1056/NEJM198203043060906"}]},{"id":"ronan-kelly","kind":"person","name":"Ronan J. Kelly","aka":[],"tldr":"Led CheckMate 577, the first trial to show adjuvant immunotherapy helps oesophageal cancer patients with residual disease.","summary":"Ronan Kelly (Baylor Sammons Cancer Center) was principal investigator of CheckMate 577, which showed adjuvant nivolumab doubles disease-free survival in oesophageal and junctional cancer patients with residual disease after chemoradiotherapy and surgery, the first adjuvant immunotherapy approval in a GI cancer. He continues to lead perioperative immunotherapy trials in upper GI cancers.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kelly%20RJ%5BAuthor%5D%20esophageal%20nivolumab"}],"tags":["esophageal","immunotherapy","adjuvant"],"related":[],"cancers":["esophageal","gastric"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["pd1"],"drugs":["nivolumab"],"companies":[],"institutions":["baylor-sammons-dallas"],"pathways":[],"terms":[],"trials":["checkmate-577"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["jnccn"],"dependsOn":[],"notes":[],"role":"Director, Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas","institutionId":"baylor-sammons-dallas","specialisms":["Oesophageal cancer","Gastric cancer","Adjuvant immunotherapy","Thoracic oncology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kelly%20RJ%5BAuthor%5D%20esophageal%20nivolumab"}],"papers":[{"title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (CheckMate 577)","journal":"NEJM","year":2021,"doi":"10.1056/NEJMoa2032125"},{"title":"Emerging multimodality approaches to treat localized esophageal cancer","journal":"Journal of the National Comprehensive Cancer Network","year":2019}],"orcid":"0000-0002-6446-2103"},{"id":"ros-eeles","kind":"person","name":"Rosalind Eeles","aka":[],"tldr":"The oncogeneticist who found most of the common genetic variants that raise a man's risk of prostate cancer, and whose work is the reason the UK's first prostate screening programme is defined by a gene rather than by an age.","summary":"Rosalind Eeles is Professor of Oncogenetics at the Institute of Cancer Research and a consultant in clinical oncology and cancer genetics at The Royal Marsden. She founded the PRACTICAL consortium, the international collaboration that carried out the genome-wide association studies behind the majority of known common prostate cancer risk variants, and she leads the targeted screening studies that follow from them: IMPACT, which screens men with BRCA1 and BRCA2 variants, and BARCODE, which tests whether a polygenic risk score can be used to decide who is invited.\n\nThe UK National Screening Committee's March 2026 recommendation is the first practical outcome of that line of work in NHS policy: biennial PSA testing for men aged 45 to 61 with a pathogenic BRCA2 variant and a relevant family history. The committee was explicit that the evidence for a polygenic route is not yet there, and that TRANSFORM is the trial that will supply it.","asOf":"2026-09-25","links":[{"label":"The Royal Marsden consultant directory","url":"https://www.royalmarsden.nhs.uk/our-consultants-units-and-wards/consultant-directory/professor-rosalind-eeles"}],"tags":["prostate","genetics","uk","screening"],"related":["nicholas-van-as","johann-de-bono"],"cancers":["prostate","prostate-high-risk"],"sections":["early-detection"],"technologies":["germline-testing"],"targets":[],"drugs":[],"companies":[],"institutions":["royal-marsden","icr-london"],"pathways":[],"terms":[],"trials":["transform-prostate"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Oncogenetics, The Institute of Cancer Research; Consultant in Clinical Oncology and Cancer Genetics, The Royal Marsden NHS Foundation Trust","institutionId":"royal-marsden","specialisms":["Inherited susceptibility to prostate cancer","Polygenic risk scores","Targeted screening"],"profiles":[{"label":"The Royal Marsden consultant directory","url":"https://www.royalmarsden.nhs.uk/our-consultants-units-and-wards/consultant-directory/professor-rosalind-eeles"}],"papers":[]},{"id":"rosaline-den-blanken","kind":"person","name":"Rosaline den Blanken","aka":[],"tldr":"Rosaline den Blanken represents Rijnstate in the Organisation of European Cancer Institutes, which lists the centre among its members in The Netherlands.","summary":"Rosaline den Blanken is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Rijnstate, its member in The Netherlands. A large Dutch teaching hospital in Arnhem whose oncology centre is accredited by OECI as a Cancer Centre. OnCo records the name from the OECI membership list so that the centre's page has a named contact point; the person's exact title, appointment date and biography are not yet recorded and should be checked on the institution's own pages before being relied on.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Rijnstate website","url":"http://www.rijnstate.nl/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["rijnstate-arnhem"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Rijnstate to the Organisation of European Cancer Institutes","institutionId":"rijnstate-arnhem","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Rijnstate website","url":"http://www.rijnstate.nl/"}],"papers":[]},{"id":"rose-kushner","kind":"person","name":"Rose Kushner","aka":[],"tldr":"Diagnosed in 1974, she refused the standard practice of biopsy and mastectomy under one anaesthetic without the patient's say. Her campaign made the two-step procedure and informed choice the norm.","summary":"Rose Kushner (1929-1990) was a medical journalist when she found a breast lump in 1974. She refused the then-standard one-step procedure, in which a woman was put under anaesthetic for a biopsy and woke without a breast if the biopsy was positive, and insisted on a separate diagnosis and decision. Her 1975 book Breast Cancer: A Personal History and an Investigative Report challenged the Halsted radical mastectomy and the paternalism around it. She founded the Breast Cancer Advisory Center, testified before Congress, and in 1979 an NIH consensus conference endorsed the two-step approach. In 1980 she became the first patient advocate on the National Cancer Advisory Board, and she worked closely with Bernard Fisher, whose NSABP trials showed less surgery was as effective. She died of breast cancer in 1990.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Rose_Kushner","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Rose_Kushner"}],"tags":["hero","patient","advocate"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["nci"],"pathways":[],"terms":[],"trials":[],"people":["bernard-fisher"],"bottlenecks":["b-patient-voice","b-toxicity-qol","b-trial-design"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Journalist who ended the one-step mastectomy and put patients in the room","specialisms":["Breast cancer","Informed consent","Patient advocacy"],"profiles":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Rose_Kushner"}],"papers":[]},{"id":"ross-levine","kind":"person","name":"Ross L. Levine","aka":[],"tldr":"Discovered the JAK2 mutation behind most myeloproliferative neoplasms and defined the genetics of clonal haematopoiesis.","summary":"Ross L. Levine is Chair of the Center for Hematologic Malignancies and a Member of the Human Oncology and Pathogenesis Program at Memorial Sloan Kettering Cancer Center. He is a physician-scientist known for discovering the JAK2 V617F mutation behind most myeloproliferative neoplasms and for defining the genetics of clonal haematopoiesis through TET2, ASXL1 and other mutations. His selected paper reports the activating JAK2 mutation in polycythaemia vera, essential thrombocythaemia and myeloid metaplasia with myelofibrosis. His laboratory continues to study how these mutations drive leukaemia evolution.","asOf":"2026-09-08","links":[{"label":"MSK lab","url":"https://www.mskcc.org/research-areas/labs/ross-levine"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Levine%20RL%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["aml"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["cancer-cell"],"dependsOn":[],"notes":[],"role":"Chair, Center for Hematologic Malignancies; Member, Human Oncology and Pathogenesis Program","institutionId":"mskcc","specialisms":["Myeloid malignancies","Clonal haematopoiesis","JAK2 and epigenetic regulators"],"profiles":[{"label":"MSK lab","url":"https://www.mskcc.org/research-areas/labs/ross-levine"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Levine%20RL%5BAuthor%5D"}],"papers":[{"title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","journal":"Cancer Cell","year":2005,"url":"https://doi.org/10.1016/j.ccr.2005.03.023","doi":"10.1016/j.ccr.2005.03.023"}],"orcid":"0000-0002-7884-1905"},{"id":"rossella-elisei","kind":"person","name":"Rossella Elisei","aka":[],"tldr":"Pisa endocrinologist who led EXAM, the trial that established cabozantinib for progressive medullary thyroid cancer, and who has studied RET mutations in the disease for decades.","summary":"Rossella Elisei is professor of endocrinology at the University of Pisa, one of the largest thyroid cancer centres in Europe. She was first author of the 2013 Journal of Clinical Oncology report of EXAM, the phase 3 trial in which cabozantinib lengthened progression-free survival compared with placebo in progressive metastatic medullary thyroid cancer, leading to its approval. Her research covers the prognostic value of RET mutations and calcitonin doubling time.","asOf":"2026-09-18","links":[],"tags":["thyroid","targeted-therapy","trialist"],"related":[],"cancers":["medullary-thyroid-cancer","thyroid"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["university-of-pisa"],"pathways":[],"terms":[],"trials":["exam"],"people":[],"bottlenecks":[],"keyPapers":["paper-exam-cabozantinib-mtc-elisei-jco-2013"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Endocrinology, University of Pisa","institutionId":"university-of-pisa","specialisms":["Medullary thyroid cancer","RET mutations","Thyroid cancer kinase inhibitors"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Elisei%5BAuthor%5D"}],"papers":[{"title":"EXAM: cabozantinib in progressive medullary thyroid cancer","journal":"Journal of Clinical Oncology","year":2013,"url":"https://doi.org/10.1200/JCO.2012.48.4659","doi":"10.1200/JCO.2012.48.4659"}]},{"id":"roxana-del-aguila","kind":"person","name":"Roxana del Águila","aka":[],"tldr":"Physician who is Director General of the Instituto de Oncología Ángel H. Roffo, the University of Buenos Aires cancer institute in Argentina.","summary":"Dra. Roxana del Águila holds the Dirección General of the Instituto de Oncología Ángel H. Roffo, the specialist cancer hospital and research institute of the Universidad de Buenos Aires, named after the pioneering Argentine oncologist Ángel Honorio Roffo. The institute's authorities page lists her at the head of a management team that includes Dr Esteban Weisbek as Director General Administrativo, Dra. Valeria Cáceres for the medical area, Dr Sergio Gianni for surgery, Dr Pablo Menéndez for radiotherapy and Dr Alejandro Urtreger for research. The institute provides medical, surgical and radiation oncology, diagnostic imaging and pathology, runs residencies and a nursing school, and publishes treatment guidelines.","asOf":"2026-09-10","links":[{"label":"Source: Instituto Roffo autoridades page","url":"https://institutoroffo.uba.ar/autoridades/"}],"tags":["leadership","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["instituto-roffo"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Directora General, Instituto de Oncología Ángel H. Roffo, Universidad de Buenos Aires","institutionId":"instituto-roffo","specialisms":["Oncology","Hospital management"],"profiles":[{"label":"Instituto Roffo authorities page","url":"https://institutoroffo.uba.ar/autoridades/"}],"papers":[{"title":"Efficacy and safety profile of vismodegib in a real‐world setting cohort of patients with advanced basal cell carcinoma in Argentina","journal":"International Journal of Dermatology","year":2020,"doi":"10.1111/ijd.14780"},{"title":"Neoadjuvant Vismodegib and Mohs Micrographic Surgery for Locally Advanced Periocular Basal Cell Carcinoma","journal":"Ophthalmic Plastic & Reconstructive Surgery","year":2019,"doi":"10.1097/iop.0000000000001166"}],"orcid":"0000-0002-9575-2728"},{"id":"roy-herbst","kind":"person","name":"Roy S. Herbst","aka":[],"tldr":"Lung cancer trialist behind KEYNOTE-010 and the ADAURA adjuvant osimertinib trial.","summary":"Roy Herbst (Yale Cancer Center) led KEYNOTE-010, the trial that established pembrolizumab for previously treated PD-L1-positive NSCLC, and was co-principal investigator of ADAURA, which showed adjuvant osimertinib dramatically cuts recurrence and improves survival in resected EGFR-mutant lung cancer. He co-led the Lung-MAP master protocol and the early atezolizumab biomarker work. His current focus is adjuvant and neoadjuvant targeted therapy.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Roy_S._Herbst","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Herbst%20RS%5BAuthor%5D%20lung%20pembrolizumab%20OR%20osimertinib"}],"tags":["lung","immunotherapy","adjuvant"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":["pd1","egfr"],"drugs":["pembrolizumab","osimertinib","atezolizumab"],"companies":[],"institutions":["yale-cancer-center","dartmouth-cancer-center"],"pathways":[],"terms":[],"trials":["adaura"],"people":[],"bottlenecks":[],"keyPapers":["paper-adaura-nejm-2020"],"journals":[],"dependsOn":[],"notes":[],"role":"Deputy Director and Chief of Medical Oncology, Yale Cancer Center","institutionId":"yale-cancer-center","specialisms":["Lung cancer immunotherapy","Adjuvant targeted therapy","Early drug development","Biomarkers"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Herbst%20RS%5BAuthor%5D%20lung%20pembrolizumab%20OR%20osimertinib"}],"papers":[{"title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010)","journal":"Lancet","year":2016,"doi":"10.1016/S0140-6736(15)01281-7"},{"title":"Adjuvant osimertinib for resected EGFR-mutated NSCLC: overall survival (ADAURA)","journal":"NEJM","year":2023,"doi":"10.1056/NEJMoa2304594"},{"title":"ADAURA: three years of osimertinib after surgery for EGFR-mutated lung cancer","journal":"New England Journal of Medicine","year":2020,"url":"https://doi.org/10.1056/NEJMoa2027071","doi":"10.1056/NEJMoa2027071"}]},{"id":"ruben-mesa","kind":"person","name":"Ruben Mesa","aka":[],"tldr":"Physician who is Executive Director of the NCI-designated Atrium Health Wake Forest Baptist Comprehensive Cancer Center in Winston-Salem and President of its cancer service line.","summary":"Ruben Mesa is Executive Director of the Atrium Health Wake Forest Baptist Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centre in Winston-Salem, North Carolina, and President of the Cancer Service Line. The cancer centre's own website introduces him under the heading 'Meet Dr. Ruben Mesa, Our New Cancer Center Director', asking readers to welcome him as the new Executive Director of the NCI-designated centre. The page did not give an appointment date or further biographical detail.","asOf":"2026-09-10","links":[{"label":"Source: Wake Forest Baptist cancer centre page introducing the director","url":"https://www.wakehealth.edu/cancer"}],"tags":["leadership","clinician-scientist","comprehensive-cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["wake-forest-cancer"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["cancer-medicine","lancet-haematology","cancers-mdpi"],"dependsOn":[],"notes":[],"role":"Executive Director, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, and President of the Cancer Service Line","institutionId":"wake-forest-cancer","specialisms":["Haematology and oncology","Cancer centre leadership","Academic medicine"],"profiles":[{"label":"Atrium Health Wake Forest Baptist cancer pages","url":"https://www.wakehealth.edu/cancer"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mesa+RA%5BAuthor%5D"}],"papers":[{"title":"Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies","journal":"Cancer Medicine","year":2023,"doi":"10.1002/cam4.5799"},{"title":"Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group","journal":"The Lancet Haematology","year":2024,"doi":"10.1016/s2352-3026(23)00305-8"},{"title":"Anemia in Myelofibrosis: A Focus on Proactive Management and the Role of Momelotinib","journal":"Cancers","year":2024,"doi":"10.3390/cancers16234064"}],"orcid":"0000-0001-5880-7972"},{"id":"xu-rui-hua","kind":"person","name":"Rui-Hua Xu","aka":[],"tldr":"Leads China's largest cancer centre and has run the Chinese phase 3 trials that brought PD-1 antibodies into GI cancer.","summary":"Rui-Hua Xu is President of Sun Yat-sen University Cancer Center in Guangzhou, China's largest cancer centre, and Professor of Medical Oncology. A gastrointestinal oncologist, he has run the Chinese phase 3 trials that brought PD-1 antibodies into gastrointestinal cancer, including JUPITER-06 with toripalimab in oesophageal cancer and studies of camrelizumab in ESCORT-1st, fruquintinib and anti-EGFR therapy, establishing immunotherapy and targeted therapy for Chinese patients. His publications include the JUPITER-06 trial of toripalimab plus paclitaxel and cisplatin as first-line treatment for advanced oesophageal squamous cell carcinoma. His interests span colorectal, oesophageal and gastric cancer and immunotherapy.","asOf":"2026-09-08","links":[{"label":"Sun Yat-sen University Cancer Center","url":"https://www.sysucc.org.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Xu%20RH%5BAuthor%5D%20Sun%20Yat-sen%20gastrointestinal"}],"tags":[],"related":[],"cancers":["esophageal","colorectal","gastric"],"sections":[],"technologies":[],"targets":[],"drugs":["toripalimab","camrelizumab","fruquintinib"],"companies":[],"institutions":["sysucc"],"pathways":[],"terms":[],"trials":["escort-1st"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["cancer-cell"],"dependsOn":[],"notes":[],"role":"President, Sun Yat-sen University Cancer Center; Professor of Medical Oncology","institutionId":"sysucc","specialisms":["Gastrointestinal oncology","Colorectal cancer","Oesophageal and gastric cancer","Immunotherapy"],"profiles":[{"label":"Sun Yat-sen University Cancer Center","url":"https://www.sysucc.org.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Xu%20RH%5BAuthor%5D%20Sun%20Yat-sen%20gastrointestinal"}],"papers":[{"title":"Toripalimab plus paclitaxel and cisplatin as first-line treatment for advanced oesophageal squamous cell carcinoma (JUPITER-06)","journal":"Cancer Cell","year":2022,"doi":"10.1016/j.ccell.2022.02.007"},{"title":"SPOTLIGHT: zolbetuximab, the first Claudin 18.2 antibody, added to chemotherapy in gastric cancer","journal":"The Lancet","year":2023,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=SPOTLIGHT+zolbetuximab+mFOLFOX6+Shitara+Lancet"}]},{"id":"rupert-bartsch","kind":"person","name":"Rupert Bartsch","aka":[],"tldr":"Vienna oncologist who led TUXEDO-1, the small trial that showed trastuzumab deruxtecan can shrink active brain metastases from HER2-positive breast cancer.","summary":"Rupert Bartsch is a medical oncologist at the Medical University of Vienna who focuses on brain metastases from breast cancer. He was first author of the 2022 Nature Medicine report of TUXEDO-1, a single-arm phase 2 trial in which trastuzumab deruxtecan produced intracranial responses in most patients with active brain metastases from HER2-positive breast cancer, evidence that the antibody-drug conjugate works in the brain.","asOf":"2026-09-18","links":[],"tags":["breast","brain-metastases","trialist"],"related":[],"cancers":["her2-positive-breast-brain-metastases","breast-her2-positive","breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ccc-vienna"],"pathways":[],"terms":[],"trials":["tuxedo-1"],"people":[],"bottlenecks":[],"keyPapers":["paper-tuxedo-1-trastuzumab-deruxtecan-brain-metastases-nat-med-2022"],"journals":[],"dependsOn":[],"notes":[],"role":"Medical oncologist, Medical University of Vienna","institutionId":"ccc-vienna","specialisms":["Breast cancer brain metastases","HER2-positive breast cancer","Antibody-drug conjugates"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bartsch%5BAuthor%5D"}],"papers":[{"title":"TUXEDO-1: trastuzumab deruxtecan in HER2-positive breast cancer with active brain metastases","journal":"Nature Medicine","year":2022,"url":"https://doi.org/10.1038/s41591-022-01935-8","doi":"10.1038/s41591-022-01935-8"}]},{"id":"ruslan-baltaga","kind":"person","name":"Ruslan Baltaga","aka":[],"tldr":"Ruslan Baltaga represents Oncological Institute of Moldova in the Organisation of European Cancer Institutes, which lists the centre among its members in Moldova.","summary":"Ruslan Baltaga is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Oncological Institute of Moldova, its member in Moldova. Oncological Institute of Moldova is Moldova's national cancer institute in Chișinău, the country's main centre for cancer diagnosis, treatment and registration, and an associate member of the Organisation of European Cancer Institutes. OnCo records the name from the OECI membership list so that the centre's page has a named contact point; the person's exact title, appointment date and biography are not yet recorded and should be checked on the institution's own pages before being relied on.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Oncological Institute of Moldova website","url":"http://onco.md/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oncological-institute-moldova"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Oncological Institute of Moldova to the Organisation of European Cancer Institutes","institutionId":"oncological-institute-moldova","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Oncological Institute of Moldova website","url":"http://onco.md/"}],"papers":[{"title":"Implementation of the World Health Organization surgical safety checklist, including introduction of pulse oximetry, in a resource-limited setting","journal":"Ann Surg","year":2013,"url":"https://doi.org/10.1097/sla.0b013e3182777fa4","doi":"10.1097/sla.0b013e3182777fa4","note":"Europe PMC author record matched by affiliation"},{"title":"Sustainability and long-term effectiveness of the WHO surgical safety checklist combined with pulse oximetry in a resource-limited setting: two-year update from Moldova","journal":"JAMA Surg","year":2015,"url":"https://doi.org/10.1001/jamasurg.2014.3848","doi":"10.1001/jamasurg.2014.3848","note":"Europe PMC author record matched by affiliation"},{"title":"Design and implementation of a humanitarian cancer care programme for Ukrainian refugees in Moldova and Romania","journal":"Lancet Oncol","year":2024,"url":"https://doi.org/10.1016/s1470-2045(23)00629-0","doi":"10.1016/s1470-2045(23)00629-0","note":"Europe PMC author record matched by affiliation"}]},{"id":"ruth-ladenstein","kind":"person","name":"Ruth Ladenstein","aka":[],"tldr":"Chaired the SIOPEN HR-NBL1 trial, the largest neuroblastoma trial ever, which set European standards for high-risk disease.","summary":"Ruth Ladenstein (Vienna) chaired SIOPEN HR-NBL1, the 3,000-patient trial that established busulfan-melphalan as the preferred myeloablative regimen for high-risk neuroblastoma and showed that adding interleukin-2 to dinutuximab beta immunotherapy adds toxicity without benefit. She has led SIOP Europe and coordinates the European neuroblastoma research network.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ladenstein%20R%5BAuthor%5D%20neuroblastoma"}],"tags":["paediatric","neuroblastoma","cooperative-group"],"related":[],"cancers":["neuroblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["st-anna-ccri-vienna"],"pathways":[],"terms":[],"trials":["hr-nbl1"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Paediatrics, St. Anna Children's Hospital and Children's Cancer Research Institute, Vienna","institutionId":"st-anna-ccri-vienna","specialisms":["Neuroblastoma","High-dose chemotherapy","European paediatric trials","Immunotherapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ladenstein%20R%5BAuthor%5D%20neuroblastoma"}],"papers":[{"title":"Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN)","journal":"Lancet Oncology","year":2017,"doi":"10.1016/S1470-2045(17)30070-0"},{"title":"Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN)","journal":"Lancet Oncology","year":2018,"doi":"10.1016/S1470-2045(18)30578-3"}],"orcid":"0000-0001-6548-3873"},{"id":"ruth-plummer","kind":"person","name":"Ruth Plummer","aka":[],"tldr":"Ruth Plummer is an early-phase trialist who ran the first-in-human study of a PARP inhibitor.","summary":"Ruth Plummer is Professor of Experimental Cancer Medicine at Newcastle and Clinical Advisor to Cancer Research UK. Her specialisms are early-phase trials, DNA repair inhibitors and experimental cancer medicine. She led the first clinical trial of a PARP inhibitor, rucaparib, in 2005, and her Clinical Cancer Research paper reported the phase I study of the PARP inhibitor AG014699 combined with temozolomide in patients with advanced solid tumours. She directs experimental cancer medicine in Newcastle within the Cancer Research UK network. Her publications are listed on PubMed.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Ruth_Plummer","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Plummer%20R%5BAuthor%5D%20PARP%20inhibitor%20phase%20I"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["parp"],"drugs":["rucaparib"],"companies":[],"institutions":["cruk"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Experimental Cancer Medicine, Newcastle; Clinical Advisor, Cancer Research UK","institutionId":"cruk","specialisms":["Early-phase trials","DNA repair inhibitors","Experimental cancer medicine"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Plummer%20R%5BAuthor%5D%20PARP%20inhibitor%20phase%20I"}],"papers":[{"title":"Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors","journal":"Clinical Cancer Research","year":2008,"doi":"10.1158/1078-0432.CCR-08-1223"}],"orcid":"0000-0003-0107-1444"},{"id":"ryan-corcoran","kind":"person","name":"Ryan B. Corcoran","aka":[],"tldr":"Worked out why BRAF inhibitors fail in colorectal cancer and how to combine drugs to overcome it.","summary":"Ryan B. Corcoran is Director of the Gastrointestinal Cancer Center and Scientific Director of the Termeer Center for Targeted Therapy at Massachusetts General Hospital Cancer Center. He is a physician-scientist known for working out why BRAF inhibitors fail in colorectal cancer, defining the EGFR-mediated feedback that led to the BRAF plus EGFR combinations of encorafenib and cetuximab now approved. His selected paper shows that EGFR-mediated reactivation of MAPK signalling contributes to the insensitivity of BRAF-mutant colorectal cancers to RAF inhibition with vemurafenib. He now uses ctDNA liquid biopsy to track clonal resistance to BRAF and KRAS-directed therapy.","asOf":"2026-09-08","links":[{"label":"MGH profile","url":"https://www.massgeneral.org/doctors/19556/ryan-corcoran"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Corcoran%20RB%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["colorectal"],"sections":[],"technologies":["liquid-biopsy"],"targets":["braf","kras","egfr"],"drugs":["encorafenib","cetuximab"],"companies":[],"institutions":["mgh"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Gastrointestinal Cancer Center; Scientific Director, Termeer Center for Targeted Therapy","institutionId":"mgh","specialisms":["Colorectal cancer","BRAF and KRAS resistance","Liquid biopsy","Targeted therapy combinations"],"profiles":[{"label":"MGH profile","url":"https://www.massgeneral.org/doctors/19556/ryan-corcoran"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Corcoran%20RB%5BAuthor%5D"}],"papers":[{"title":"EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib","journal":"Cancer Discovery","year":2012,"url":"https://doi.org/10.1158/2159-8290.CD-11-0341","doi":"10.1158/2159-8290.CD-11-0341"}]},{"id":"ryan-sullivan","kind":"person","name":"Ryan J. Sullivan","aka":[],"tldr":"Ryan Sullivan is a melanoma trialist and a leading voice on managing immunotherapy side effects.","summary":"Ryan J. Sullivan is Associate Director of the Melanoma Program at Massachusetts General Hospital Cancer Center. He is a melanoma trialist and a leading voice on managing the side effects of immunotherapy, having co-authored society guidelines on immune-related adverse events. His selected paper is the ASCO guideline update on managing immune-related adverse events in patients treated with immune checkpoint inhibitors. He leads melanoma clinical trials at MGH and studies how to sequence targeted and immune therapy, including DREAMseq-style questions.","asOf":"2026-09-08","links":[{"label":"MGH profile","url":"https://www.massgeneral.org/doctors/19412/ryan-sullivan"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sullivan%20RJ%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["melanoma"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":[],"companies":[],"institutions":["mgh"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Associate Director, Melanoma Program","institutionId":"mgh","specialisms":["Melanoma","Immune-related adverse events","Targeted and immune therapy sequencing"],"profiles":[{"label":"MGH profile","url":"https://www.massgeneral.org/doctors/19412/ryan-sullivan"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sullivan%20RJ%5BAuthor%5D"}],"papers":[{"title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","journal":"Journal of Clinical Oncology","year":2021},{"title":"KEYNOTE-942: a personalised mRNA cancer vaccine plus pembrolizumab after melanoma surgery","journal":"The Lancet","year":2024,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=mRNA-4157+V940+pembrolizumab+melanoma+KEYNOTE-942+Lancet"}]},{"id":"ryan-schoenfeld","kind":"person","name":"Ryan Schoenfeld","aka":[],"tldr":"Medicinal chemist who leads The Mark Foundation for Cancer Research, a funder that turns laboratory discoveries into new cancer tests and treatments.","summary":"Ryan Schoenfeld, PhD, is Chief Executive Officer of The Mark Foundation for Cancer Research, a nonprofit funder that backs high-risk, high-reward science to translate laboratory discoveries into new diagnostics, treatments and prevention strategies. He joined the foundation in 2018 and previously served as its Chief Scientific Officer. Before that he spent 12 years leading medicinal chemistry at Roche, was Scientific Director at the CHDI Foundation and led data science at Janssen, and he holds a PhD in Chemistry from Cornell University.","asOf":"2026-09-10","links":[{"label":"Source: Mark Foundation team page","url":"https://themarkfoundation.org/about/team/"}],"tags":["leadership","clinician-scientist","drug-discovery","research-funding"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["johnson-johnson"],"institutions":["mark-foundation"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive Officer, The Mark Foundation for Cancer Research","institutionId":"mark-foundation","specialisms":["Medicinal chemistry","Drug discovery","Research funding"],"profiles":[{"label":"Mark Foundation team page","url":"https://themarkfoundation.org/about/team/"},{"label":"Mark Foundation biography","url":"https://themarkfoundation.org/team/ryan-schoenfeld/"}],"papers":[]},{"id":"vincent-rajkumar","kind":"person","name":"S. Vincent Rajkumar","aka":[],"tldr":"Myeloma expert who wrote the diagnostic criteria the field uses and a persistent critic of drug prices.","summary":"S. Vincent Rajkumar is Professor of Medicine in the Division of Hematology at Mayo Clinic and editor-in-chief of Blood Cancer Journal. A haematologist specialising in multiple myeloma and plasma cell disorders, he led the International Myeloma Working Group's updated diagnostic criteria, the criteria the field uses, and the randomised trials establishing lenalidomide-dexamethasone dosing. His papers include the Lancet Oncology report of the International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma and the Lancet Oncology open-label randomised trial of lenalidomide plus high-dose versus low-dose dexamethasone as initial therapy for newly diagnosed myeloma. He is also a persistent critic of drug prices, and his record links to BCMA.","asOf":"2026-09-08","links":[{"label":"Mayo Clinic research faculty","url":"https://www.mayo.edu/research/faculty"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rajkumar%20SV%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=S.%20Vincent%20Rajkumar"}],"tags":[],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":["bcma"],"drugs":[],"companies":[],"institutions":["mayo-clinic"],"pathways":[],"terms":["mrd-negativity-myeloma","r-iss"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medicine, Division of Hematology, Mayo Clinic","institutionId":"mayo-clinic","specialisms":["Multiple myeloma","Plasma cell disorders","Drug pricing"],"profiles":[{"label":"Mayo Clinic research faculty","url":"https://www.mayo.edu/research/faculty"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rajkumar%20SV%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=S.%20Vincent%20Rajkumar"}],"papers":[{"title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","journal":"Lancet Oncology","year":2014,"url":"https://doi.org/10.1016/S1470-2045(14)70442-5","doi":"10.1016/S1470-2045(14)70442-5"},{"title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","journal":"Lancet Oncology","year":2010,"url":"https://doi.org/10.1016/S1470-2045(09)70284-0","doi":"10.1016/S1470-2045(09)70284-0"}]},{"id":"saad-usmani","kind":"person","name":"Saad Z. Usmani","aka":[],"tldr":"Saad Usmani led the pivotal teclistamab study, the first bispecific antibody approved for myeloma.","summary":"Saad Z. Usmani is Chief of the Myeloma Service at Memorial Sloan Kettering Cancer Center. He is a multiple myeloma specialist known for leading MajesTEC-1, the pivotal study of teclistamab that produced the first bispecific antibody approved for myeloma, and for contributing to the daratumumab and ciltacabtagene autoleucel programmes. His selected paper reports teclistamab in relapsed or refractory multiple myeloma. He now chairs the myeloma service at MSK, working on BCMA-directed bispecific T-cell engagers and CAR-T.","asOf":"2026-09-08","links":[{"label":"MSK profile","url":"https://www.mskcc.org/cancer-care/doctors/saad-usmani"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Usmani%20SZ%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":["t-cell-engager"],"targets":["bcma"],"drugs":["teclistamab","daratumumab"],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":["majestec-1"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief, Myeloma Service","institutionId":"mskcc","specialisms":["Multiple myeloma","Bispecific antibodies","CAR-T"],"profiles":[{"label":"MSK profile","url":"https://www.mskcc.org/cancer-care/doctors/saad-usmani"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Usmani%20SZ%5BAuthor%5D"}],"papers":[{"title":"Teclistamab in relapsed or refractory multiple myeloma","journal":"New England Journal of Medicine","year":2022,"url":"https://doi.org/10.1056/NEJMoa2203478","doi":"10.1056/NEJMoa2203478"},{"title":"CARTITUDE-1: cilta-cel, a BCMA CAR-T, in heavily pretreated myeloma","journal":"The Lancet","year":2021,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CARTITUDE-1%20ciltacabtagene%20autoleucel%20Berdeja%20Lancet%202021"},{"title":"CEPHEUS: daratumumab quadruplet for newly diagnosed myeloma patients not having a transplant, with MRD-negativity as the main endpoint","journal":"Nature Medicine","year":2025,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CEPHEUS%20daratumumab%20bortezomib%20lenalidomide%20transplant-ineligible%20Usmani%20Nature%20Medicine%202025"}],"orcid":"0000-0002-5484-8731"},{"id":"sabine-linn","kind":"person","name":"Sabine Linn","aka":[],"tldr":"Sabine Linn is a breast oncologist testing DNA-damaging chemotherapy in BRCA-like breast cancer.","summary":"Sabine Linn is a medical oncologist and group leader at the Netherlands Cancer Institute (NKI-AvL) and Professor at Utrecht. Her specialisms are breast cancer, BRCA-like tumours and neoadjuvant trials, with a focus on BRCA1/BRCA2 and homologous recombination deficiency in triple-negative disease. She leads breast cancer trials at NKI, including studies of high-dose alkylating chemotherapy in BRCA1-like tumours and of neoadjuvant immunotherapy. Her papers include the TRAIN-2 phase 3 trial of neoadjuvant chemotherapy with or without anthracyclines alongside dual HER2 blockade and its three-year follow-up, and a study of stromal tumour-infiltrating lymphocytes in young, node-negative, triple-negative patients who received no systemic therapy. Her publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Linn%20SC%5BAuthor%5D%20BRCA-like%20breast"}],"tags":[],"related":[],"cancers":["tnbc"],"sections":[],"technologies":[],"targets":["brca"],"drugs":[],"companies":[],"institutions":["nki"],"pathways":[],"terms":["hrd"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Medical Oncologist and Group Leader, Netherlands Cancer Institute; Professor, Utrecht","institutionId":"nki","specialisms":["Breast cancer","BRCA-like tumours","Neoadjuvant trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Linn%20SC%5BAuthor%5D%20BRCA-like%20breast"}],"papers":[{"title":"Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial","journal":"The Lancet Oncology","year":2018,"doi":"10.1016/s1470-2045(18)30570-9"},{"title":"Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy","journal":"Journal of Clinical Oncology","year":2022,"doi":"10.1200/jco.21.01536"},{"title":"Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2 -Positive Breast Cancer","journal":"JAMA Oncology","year":2021,"doi":"10.1001/jamaoncol.2021.1371"}],"orcid":"0000-0001-5541-0347"},{"id":"sacha-gougnard","kind":"person","name":"Sacha Gougnard","aka":[],"tldr":"Sacha Gougnard represents Institut Jules Bordet in the Organisation of European Cancer Institutes, which lists the centre among its members in Belgium.","summary":"Sacha Gougnard is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Institut Jules Bordet, its full member in Belgium. OnCo records the name from the OECI membership list so that the centre's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the institution's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Institut Jules Bordet website","url":"https://www.bordet.be"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["institut-jules-bordet"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Institut Jules Bordet to the Organisation of European Cancer Institutes","institutionId":"institut-jules-bordet","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Institut Jules Bordet website","url":"https://www.bordet.be"}],"papers":[]},{"id":"sagar-lonial","kind":"person","name":"Sagar Lonial","aka":[],"tldr":"Led SIRIUS and the DREAMM programme, bringing daratumumab monotherapy and the BCMA ADC belantamab to myeloma.","summary":"Sagar Lonial led SIRIUS, the trial that won daratumumab its first approval as monotherapy in relapsed myeloma, and DREAMM-2, the pivotal trial of belantamab mafodotin, the first BCMA-directed ADC. He has led the Emory series showing near-universal deep responses to RVd induction and chairs the myeloma committee of the SWOG cooperative group.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lonial%20S%5BAuthor%5D%20myeloma%20belantamab%20OR%20daratumumab"}],"tags":["myeloma","adc","swog"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":["adc","monoclonal-antibody"],"targets":["bcma","cd38"],"drugs":["belantamab-mafodotin"],"companies":[],"institutions":["emory-winship"],"pathways":[],"terms":[],"trials":["dreamm-7","dreamm-8"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chair of Hematology and Medical Oncology and Chief Medical Officer, Winship Cancer Institute of Emory University","institutionId":"emory-winship","specialisms":["Multiple myeloma","Antibody-drug conjugates","Daratumumab","High-risk myeloma"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lonial%20S%5BAuthor%5D%20myeloma%20belantamab%20OR%20daratumumab"}],"papers":[{"title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS)","journal":"Lancet","year":2016,"doi":"10.1016/S0140-6736(15)01120-4"},{"title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2)","journal":"Lancet Oncology","year":2020,"doi":"10.1016/S1470-2045(19)30788-0"}]},{"id":"chen-saijuan","kind":"person","name":"Saijuan Chen","aka":["Chen Sai-Juan","陈赛娟"],"tldr":"Saijuan Chen helped turn acute promyelocytic leukaemia from a leukaemia that often killed within weeks into one of the most curable, by showing how retinoic acid and arsenic act and combining them.","summary":"With Zhu Chen and Zhen-Yi Wang at the Shanghai Institute of Hematology, Chen dissected the PML-RARA fusion and the mechanisms of all-trans retinoic acid and arsenic trioxide, and led the trials showing that the two drugs together produce high-quality, durable remissions in newly diagnosed APL (PNAS 2004), the basis of chemotherapy-free APL treatment now standard worldwide. Academician of the Chinese Academy of Engineering; her genomics work spans AML, T-ALL and lymphoma.","asOf":"2026-09-10","links":[{"label":"Ruijin Hospital","url":"https://www.rjh.com.cn/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chen%20SJ%5BAuthor%5D%20acute%20promyelocytic%20leukemia%20Shanghai%20Institute%20of%20Hematology"}],"tags":["china"],"related":[],"cancers":["aml"],"sections":[],"technologies":[],"targets":[],"drugs":["tretinoin-atra","arsenic-trioxide"],"companies":[],"institutions":["ruijin-hospital"],"pathways":[],"terms":[],"trials":[],"people":["chen-zhu"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor; Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine","institutionId":"ruijin-hospital","specialisms":["Acute promyelocytic leukaemia","Leukaemia genomics","Differentiation therapy"],"profiles":[{"label":"Ruijin Hospital","url":"https://www.rjh.com.cn/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chen%20SJ%5BAuthor%5D%20acute%20promyelocytic%20leukemia%20Shanghai%20Institute%20of%20Hematology"}],"papers":[{"title":"All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia","journal":"PNAS","year":2004,"doi":"10.1073/pnas.0400053101"}]},{"id":"salah-eddin-al-batran","kind":"person","name":"Salah-Eddin Al-Batran","aka":[],"tldr":"German oncologist who led FLOT4, the trial that made the FLOT chemotherapy regimen the standard before and after surgery for stomach and oesophago-gastric junction cancer.","summary":"Salah-Eddin Al-Batran directs the Institute of Clinical Cancer Research at Krankenhaus Nordwest in Frankfurt and led the German AIO group's FLOT4 trial. Its 2019 Lancet report, of which he was first author, showed that perioperative fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) lengthened survival compared with ECF or ECX in resectable gastric or gastro-oesophageal junction adenocarcinoma, replacing the older regimen across Europe.","asOf":"2026-09-18","links":[],"tags":["gastric","oesophageal","trialist"],"related":[],"cancers":["oesophageal-adenocarcinoma","gastric-her2-positive","esophageal","gastric"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["krankenhaus-nordwest"],"pathways":[],"terms":[],"trials":["flot4"],"people":[],"bottlenecks":[],"keyPapers":["paper-flot4-lancet-2019"],"journals":[],"dependsOn":[],"notes":[],"role":"Medical oncologist and trial lead, Krankenhaus Nordwest and Institute of Clinical Cancer Research, Frankfurt","institutionId":"krankenhaus-nordwest","specialisms":["Gastric and oesophageal cancer","Perioperative chemotherapy","Cooperative-group trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Al-Batran%5BAuthor%5D"}],"papers":[{"title":"FLOT4-AIO: perioperative FLOT versus ECF/ECX for resectable gastric or gastro-oesophageal junction adenocarcinoma","journal":"The Lancet","year":2019,"url":"https://doi.org/10.1016/S0140-6736(18)32557-1","doi":"10.1016/S0140-6736(18)32557-1"}]},{"id":"salvatore-siena","kind":"person","name":"Salvatore Siena","aka":[],"tldr":"Milan oncologist who co-led HERACLES and was lead author of DESTINY-CRC01, which showed trastuzumab deruxtecan is active in HER2-positive colorectal cancer, and a leader of the anti-EGFR antibody trials in the disease.","summary":"Salvatore Siena is professor of medical oncology at the University of Milan and led the Niguarda Cancer Center's oncology programme. He was a senior investigator of HERACLES and first author of the 2021 Lancet Oncology report of DESTINY-CRC01, the phase 2 trial in which trastuzumab deruxtecan produced responses in HER2-positive, RAS wild-type metastatic colorectal cancer after standard therapy. He was also a lead investigator of the panitumumab trials that established RAS testing before anti-EGFR treatment.","asOf":"2026-09-18","wikipedia":"https://en.wikipedia.org/wiki/Salvatore_Siena","links":[],"tags":["colorectal","targeted-therapy","trialist"],"related":[],"cancers":["her2-amplified-colorectal","colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["niguarda-cancer-center"],"pathways":[],"terms":[],"trials":["heracles"],"people":[],"bottlenecks":[],"keyPapers":["paper-siena-destiny-crc01-trastuzumab-deruxtecan-lancet-oncol-2021"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology, University of Milan, and Niguarda Cancer Center","institutionId":"niguarda-cancer-center","specialisms":["Colorectal cancer","HER2-directed therapy","Anti-EGFR therapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Siena%5BAuthor%5D"}],"papers":[{"title":"DESTINY-CRC01: trastuzumab deruxtecan in HER2-expressing metastatic colorectal cancer","journal":"The Lancet Oncology","year":2021,"url":"https://doi.org/10.1016/S1470-2045(21)00086-3","doi":"10.1016/S1470-2045(21)00086-3"}],"orcid":"0000-0002-2681-2846"},{"id":"du-samantha","kind":"person","name":"Samantha Du (Du Ying)","aka":["Ying Du","杜莺"],"tldr":"Samantha Du founded Zai Lab in 2014 to license Western cancer drugs for China, bringing niraparib, zanidatamab and Tumour Treating Fields to Chinese patients years earlier than they would otherwise have arrived.","summary":"Samantha Du (Du Ying) is Founder, Chairperson and CEO of Zai Lab. Formerly at Pfizer and a co-founder of Hutchmed's drug discovery arm, she founded Zai Lab in 2014 to license Western cancer drugs for China, bringing niraparib, zanidatamab and Tumour Treating Fields to Chinese patients years earlier than they would otherwise have arrived. The in-licensing model she created was copied by many Chinese biotechs, and she listed the company on Nasdaq in 2017 and in Hong Kong in 2020. Under her leadership Zai Lab has since built internal DLL3 and LRRC15 antibody-drug conjugate programmes alongside its commercialisation work.","asOf":"2026-09-10","links":[{"label":"Zai Lab","url":"https://www.zailaboratory.com/"}],"tags":["china"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["zai-lab","hutchmed"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Founder, Chairperson and CEO, Zai Lab","specialisms":["In-licensing","Biotech leadership","Oncology commercialisation"],"profiles":[{"label":"Zai Lab","url":"https://www.zailaboratory.com/"}],"papers":[]},{"id":"samantha-oakes","kind":"person","name":"Samantha Oakes","aka":[],"tldr":"Cancer biologist turned research executive who serves as CEO of the ANZUP Cancer Trials Group.","summary":"Samantha Oakes is Chief Executive Officer of the ANZUP Cancer Trials Group, bringing more than twenty years of experience in the health and medical research sector. Trained as a cancer biologist, her earlier research addressed hormone signalling in breast and prostate cancer. She leads the operational and strategic direction of the group's genitourinary cancer trials programme.","asOf":"2026-09-10","links":[{"label":"Society page","url":"https://anzup.org.au/about-us/board/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Oakes+SR%5BAuthor%5D"}],"tags":["leadership","clinical trials","genitourinary oncology"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["anzup"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["breast-cancer-research"],"dependsOn":[],"notes":[],"role":"CEO","institutionId":"anzup","specialisms":["Cancer research management","Breast and prostate cancer biology","Clinical trials operations"],"profiles":[{"label":"Society page","url":"https://anzup.org.au/about-us/board/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Oakes+SR%5BAuthor%5D"}],"papers":[{"title":"Sensitization of BCL-2–expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737","journal":"Proceedings of the National Academy of Sciences","year":2011,"doi":"10.1073/pnas.1104778108"},{"title":"The mammary cellular hierarchy and breast cancer","journal":"Cellular and Molecular Life Sciences","year":2014,"doi":"10.1007/s00018-014-1674-4"},{"title":"Key stages in mammary gland development - The alveolar switch: coordinating the proliferative cues and cell fate decisions that drive the formation of lobuloalveoli from ductal epithelium","journal":"Breast Cancer Research","year":2006,"doi":"10.1186/bcr1411"}],"orcid":"0000-0003-1838-2310"},{"id":"samra-turajlic","kind":"person","name":"Samra Turajlić","aka":[],"tldr":"Medical oncologist and cancer-evolution researcher who leads the TRACERx Renal study and now directs the Cancer Research UK Manchester Institute.","summary":"Samra Turajlić is Director of the Cancer Research UK Manchester Institute, part of the University of Manchester. A medical oncologist specialising in kidney cancer and melanoma, she led the TRACERx Renal programme that mapped the evolutionary trajectories of clear-cell renal cell carcinoma from primary tumour to metastasis. Her appointment as Director is announced on the Institute's website.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.cruk.manchester.ac.uk/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Turajlic+S%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","kidney cancer","cancer evolution"],"related":[],"cancers":["rcc","melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cruk-manchester-institute"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director","institutionId":"cruk-manchester-institute","specialisms":["Renal cell carcinoma","Melanoma","Cancer evolution","Medical oncology"],"profiles":[{"label":"Institution profile","url":"https://www.cruk.manchester.ac.uk/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Turajlic+S%5BAuthor%5D"}],"papers":[{"title":"Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal","journal":"Cell","year":2018,"url":"https://doi.org/10.1016/j.cell.2018.03.057","doi":"10.1016/j.cell.2018.03.057"},{"title":"Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal","journal":"Cell","year":2018,"url":"https://doi.org/10.1016/j.cell.2018.03.043","doi":"10.1016/j.cell.2018.03.043"}]},{"id":"samuel-wells","kind":"person","name":"Samuel A. Wells Jr.","aka":[],"tldr":"American surgeon who pioneered removing the thyroid in children with inherited RET mutations before cancer develops, led ZETA, the trial that established vandetanib for medullary thyroid cancer, and chaired the American Thyroid Association guideline for the disease.","summary":"Samuel Wells Jr. is an endocrine surgeon whose career spanned Duke University, Washington University in St Louis and the National Cancer Institute. He showed that prophylactic thyroidectomy guided by RET mutation testing prevents medullary thyroid cancer in multiple endocrine neoplasia type 2. He was first author of the 2012 Journal of Clinical Oncology report of ZETA, the phase 3 trial in which vandetanib lengthened progression-free survival in advanced medullary thyroid cancer, the first drug approved for the disease, and chaired the 2015 American Thyroid Association guideline.","asOf":"2026-09-18","links":[],"tags":["thyroid","surgery","trialist"],"related":[],"cancers":["medullary-thyroid-cancer","thyroid"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["nci"],"pathways":[],"terms":[],"trials":["zeta"],"people":[],"bottlenecks":[],"keyPapers":["paper-ata-medullary-thyroid-guideline-wells-thyroid-2015","paper-zeta-vandetanib-mtc-wells-jco-2012"],"journals":[],"dependsOn":[],"notes":[],"role":"Endocrine surgeon and clinical investigator","institutionId":"nci","specialisms":["Medullary thyroid cancer","Multiple endocrine neoplasia type 2","Prophylactic thyroidectomy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Jr.%5BAuthor%5D"}],"papers":[{"title":"Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma","journal":"Thyroid","year":2015,"url":"https://doi.org/10.1089/thy.2014.0335","doi":"10.1089/thy.2014.0335"},{"title":"ZETA: vandetanib in locally advanced or metastatic medullary thyroid cancer","journal":"Journal of Clinical Oncology","year":2012,"url":"https://doi.org/10.1200/JCO.2011.35.5040","doi":"10.1200/JCO.2011.35.5040"}]},{"id":"sandile-mfenyana","kind":"person","name":"Sandile Mfenyana","aka":[],"tldr":"Chief executive of Chris Hani Baragwanath Academic Hospital in Soweto, one of the largest hospitals in the world and a major public referral centre for Gauteng.","summary":"Dr Sandile Mfenyana is Chief Executive Officer of Chris Hani Baragwanath Academic Hospital, the large public academic hospital in Soweto, Johannesburg, run by the Gauteng Department of Health and affiliated with the University of the Witwatersrand. The hospital's website names him as CEO but gives no appointment date or biography.","asOf":"2026-09-10","links":[{"label":"Source: hospital website naming the CEO","url":"https://www.chrishanibaragwanathhospital.co.za/"}],"tags":["leadership","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["chris-hani-baragwanath"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive Officer, Chris Hani Baragwanath Academic Hospital","institutionId":"chris-hani-baragwanath","specialisms":["Hospital management","Public health services"],"profiles":[{"label":"Chris Hani Baragwanath Academic Hospital website","url":"https://www.chrishanibaragwanathhospital.co.za/"}],"papers":[]},{"id":"sandra-demaria","kind":"person","name":"Sandra Demaria","aka":[],"tldr":"Weill Cornell pathologist-immunologist known for radiation-immunotherapy research; SITC Vice President.","summary":"Sandra Demaria is Vice President of the Society for Immunotherapy of Cancer for 2025-2026 and a professor at Weill Cornell Medicine. Her laboratory studies how radiotherapy modulates anti-tumour immunity and how it can be combined with immune checkpoint blockade, with a strong focus on breast cancer. She is a widely cited contributor to the field of radiation-induced in situ vaccination.","asOf":"2026-09-10","links":[{"label":"Society page","url":"https://www.sitcancer.org/about/board"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Demaria+S%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","immunotherapy","radiotherapy"],"related":[],"cancers":["breast-hr-positive","tnbc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["sitc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Vice President (2025-2026)","institutionId":"sitc","specialisms":["Radiation and immunotherapy combinations","Tumour immunology","Breast cancer"],"profiles":[{"label":"Society page","url":"https://www.sitcancer.org/about/board"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Demaria+S%5BAuthor%5D"}],"papers":[{"title":"Role of Local Radiation Therapy in Cancer Immunotherapy","journal":"JAMA Oncology","year":2015,"doi":"10.1001/jamaoncol.2015.2756"},{"title":"Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift","journal":"JNCI: Journal of the National Cancer Institute","year":2013,"doi":"10.1093/jnci/djs629"},{"title":"Radiation-Induced CXCL16 Release by Breast Cancer Cells Attracts Effector T Cells","journal":"The Journal of Immunology","year":2008,"doi":"10.4049/jimmunol.181.5.3099"}],"orcid":"0000-0003-4426-0499"},{"id":"sandra-swain","kind":"person","name":"Sandra M. Swain","aka":[],"tldr":"Led CLEOPATRA, which showed dual HER2 blockade with pertuzumab gives an unprecedented 16-month survival gain in metastatic disease.","summary":"Sandra Swain was principal investigator of CLEOPATRA, the trial establishing pertuzumab plus trastuzumab and docetaxel as first-line therapy for HER2-positive metastatic breast cancer with a median survival of 56 months. She has led NSABP trials, chaired ASCO, and published extensively on anthracycline cardiotoxicity. Her current work covers HER2-directed therapy sequencing and disparities in trial access.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Sandra_M._Swain","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Swain%20SM%5BAuthor%5D%20pertuzumab"}],"tags":["breast","her2","trialist"],"related":[],"cancers":["breast-her2-positive"],"sections":[],"technologies":["monoclonal-antibody","cardio-oncology"],"targets":["her2"],"drugs":["trastuzumab"],"companies":[],"institutions":["georgetown-lombardi"],"pathways":[],"terms":[],"trials":["cleopatra"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medicine and Associate Dean for Research Development, Georgetown University Medical Center","institutionId":"georgetown-lombardi","specialisms":["HER2-positive breast cancer","Anti-HER2 combinations","Cardio-oncology","Inflammatory breast cancer"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Swain%20SM%5BAuthor%5D%20pertuzumab"}],"papers":[{"title":"Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer (CLEOPATRA)","journal":"NEJM","year":2015,"doi":"10.1056/NEJMoa1413513"},{"title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","journal":"NEJM","year":2012,"doi":"10.1056/NEJMoa1113216"}],"orcid":"0000-0002-1320-3830"},{"id":"sandra-nolte","kind":"person","name":"Sandra Nolte","aka":[],"tldr":"Monash University researcher who is President of the international society for health-related quality of life research for the 2025 to 2027 term.","summary":"Sandra Nolte, PhD, of Monash University in Victoria, Australia, is President of the International Society for Quality of Life Research (ISOQOL) for the 2025 to 2027 term. ISOQOL describes itself as a global community of researchers, clinicians, health care professionals, industry professionals, consultants and patient research partners advancing health-related quality of life research. Her presidency coincides with the society's 2025 to 2027 governance restructure.","asOf":"2026-09-10","links":[{"label":"Source: ISOQOL Who We Are page","url":"https://www.isoqol.org/who-we-are/"}],"tags":["leadership","clinician-scientist","quality-of-life","patient-reported-outcomes"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["isoqol"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["european-journal-of-cancer"],"dependsOn":[],"notes":[],"role":"President (2025-2027), International Society for Quality of Life Research","institutionId":"isoqol","specialisms":["Health-related quality of life","Patient-reported outcomes","Outcomes research"],"profiles":[{"label":"ISOQOL leadership page","url":"https://www.isoqol.org/who-we-are/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Nolte+S%5BAuthor%5D+AND+quality+of+life"}],"papers":[{"title":"General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States","journal":"European Journal of Cancer","year":2019,"doi":"10.1016/j.ejca.2018.11.024"},{"title":"Understanding the quality of life (QOL) issues in survivors of cancer: towards the development of an EORTC QOL cancer survivorship questionnaire","journal":"Health and Quality of Life Outcomes","year":2018,"doi":"10.1186/s12955-018-0920-0"}],"orcid":"0000-0001-6185-9423"},{"id":"sandra-dangelo","kind":"person","name":"Sandra P. D'Angelo","aka":[],"tldr":"Led SPEARHEAD-1, the trial that made afami-cel the first engineered TCR T-cell therapy approved for a solid tumour.","summary":"Sandra D'Angelo was principal investigator of SPEARHEAD-1, which showed the MAGE-A4-directed TCR T-cell therapy afamitresgene autoleucel produces durable responses in synovial sarcoma and led to its 2024 approval, the first engineered T-cell therapy for a solid tumour. She also led the JAVELIN Merkel 200 trial that won avelumab approval in Merkel cell carcinoma and leads cellular therapy trials in sarcoma at MSKCC.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=D'Angelo%20SP%5BAuthor%5D%20sarcoma%20afamitresgene"}],"tags":["sarcoma","cell-therapy","tcr-t"],"related":[],"cancers":["sarcoma","merkel-cell-carcinoma"],"sections":[],"technologies":["tcr-t"],"targets":["mage-a4"],"drugs":["afamitresgene-autoleucel"],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-spearhead-1-lancet-2024"],"journals":[],"dependsOn":[],"notes":[],"role":"Medical Oncologist, Sarcoma and Melanoma Services, Memorial Sloan Kettering Cancer Center","institutionId":"mskcc","specialisms":["Sarcoma","Engineered T-cell therapy","Merkel cell carcinoma","Immunotherapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=D'Angelo%20SP%5BAuthor%5D%20sarcoma%20afamitresgene"}],"papers":[{"title":"Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1)","journal":"Lancet","year":2024,"doi":"10.1016/S0140-6736(24)00319-2"},{"title":"Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma (JAVELIN Merkel 200)","journal":"Lancet Oncology","year":2016,"doi":"10.1016/S1470-2045(16)30364-3"},{"title":"SPEARHEAD-1: afamitresgene autoleucel, the first engineered T-cell receptor therapy approved for a solid tumour, in synovial sarcoma","journal":"The Lancet","year":2024,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=SPEARHEAD-1+afamitresgene+autoleucel+synovial+sarcoma+Lancet"}],"orcid":"0000-0002-3736-3783"},{"id":"sanford-weill","kind":"person","name":"Sanford I. Weill","aka":["Joan and Sandy Weill"],"tldr":"In May 2025 the Weill Family Foundation's $100 million challenge launched a $200 million, ten-year cancer research partnership between UCSF and Stanford, the two big Bay Area cancer centres that usually compete.","summary":"Sanford I. Weill, the former Citigroup chairman, and his wife Joan had given mainly to medical education, including the gifts that named Weill Cornell Medicine, before turning to cancer. UCSF announced on 20 May 2025 a $100 million matching grant from the Weill Family Foundation to launch the Weill Cancer Hub West, a ten-year, $200 million initiative run jointly by the Stanford Cancer Institute and UCSF's Helen Diller Family Comprehensive Cancer Center. The hub funds four programmes: engineering CAR-T cells inside the body, AI-guided design of cell therapies, diet and metabolism interventions during treatment, and AI-driven personalised care. The condition that two rival institutions work as one is the point of the gift as much as the money.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Sanford_I._Weill","links":[{"label":"UCSF: gift launches $200 million Weill Cancer Hub West (2025)","url":"https://www.ucsf.edu/news/2025/05/430061/gift-launches-200-million-initiative-weill-cancer-hub-west"}],"tags":["hero","donor"],"related":[],"cancers":[],"sections":[],"technologies":["car-t","cell-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":["ucsf","stanford"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-ip-collaboration","b-funding-allocation","b-manufacturing-cell-therapy"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Banker whose $100 million matching grant launched the Weill Cancer Hub West at UCSF and Stanford","specialisms":["Cancer research partnerships","Cell therapy","AI in oncology"],"profiles":[],"papers":[]},{"id":"shin-sang-joon","kind":"person","name":"Sang Joon Shin","aka":[],"tldr":"Sang Joon Shin is a Yonsei medical oncologist active in colorectal cancer and melanoma immunotherapy trials.","summary":"Sang Joon Shin is Professor of Medical Oncology at Severance Hospital, Yonsei University, in Seoul, specialising in colorectal cancer and melanoma. He leads colorectal and melanoma research at Yonsei Cancer Center and is active in immunotherapy trials in both diseases. He has held investigator roles in studies of KRAS G12C inhibitors, anti-EGFR antibodies and checkpoint inhibitors, bringing Korean patients into these programmes. His interests are colorectal cancer, melanoma, immunotherapy and clinical trials.","asOf":"2026-09-08","links":[{"label":"Yonsei Cancer Center","url":"https://sev.severance.healthcare"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Shin%20SJ%5BAuthor%5D%20Yonsei%20colorectal%20melanoma"}],"tags":[],"related":[],"cancers":["colorectal","melanoma"],"sections":[],"technologies":[],"targets":["kras"],"drugs":[],"companies":[],"institutions":["severance"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology; colorectal cancer and melanoma","institutionId":"severance","specialisms":["Colorectal cancer","Melanoma","Immunotherapy","Clinical trials"],"profiles":[{"label":"Yonsei Cancer Center","url":"https://sev.severance.healthcare"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Shin%20SJ%5BAuthor%5D%20Yonsei%20colorectal%20melanoma"}],"papers":[{"title":"Effects of microsatellite instability on recurrence patterns and outcomes in colorectal cancers","journal":"British Journal of Cancer","year":2016,"doi":"10.1038/bjc.2016.161"},{"title":"YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma","journal":"Cancer Immunology Research","year":2018,"doi":"10.1158/2326-6066.cir-17-0320"},{"title":"Ipilimumab Real-World Efficacy and Safety in Korean Melanoma Patients from the Korean Named-Patient Program Cohort","journal":"Cancer Research and Treatment","year":2017,"doi":"10.4143/crt.2016.024"},{"title":"EV-302: enfortumab vedotin plus pembrolizumab replaces chemotherapy as first treatment for advanced bladder cancer","journal":"New England Journal of Medicine","year":2024,"url":"https://doi.org/10.1056/NEJMoa2312117","doi":"10.1056/NEJMoa2312117"}]},{"id":"sanjay-popat","kind":"person","name":"Sanjay Popat","aka":[],"tldr":"The Royal Marsden thoracic oncologist, now its chief medical officer, who has been an investigator on most of the UK trials that put targeted drugs into lung cancer practice.","summary":"Sanjay Popat has been a consultant medical oncologist at The Royal Marsden since 2007 and was appointed its chief medical officer in 2026; he has been Professor of Thoracic Oncology at the Institute of Cancer Research since 2019. His listed specialism is lung cancer. He qualified MBBS at the University of London in 1994 with triple distinction and a first-class BSc in experimental pathology, took a PhD in molecular genetics in 2002 and a post-doctoral fellowship in somatic genomics.\n\nHe is a named investigator on the National Lung Matrix Trial and on the REFINE-Lung and HALT trials, and is one of the clinicians who led the systemic therapy timed pathway inside the National Optimal Lung Cancer Pathway.","asOf":"2026-09-25","links":[{"label":"The Royal Marsden consultant directory","url":"https://www.royalmarsden.nhs.uk/our-consultants-units-and-wards/consultant-directory/professor-sanjay-popat"}],"tags":["lung","trialist","uk"],"related":["gary-middleton","corinne-faivre-finn"],"cancers":["nsclc","lung-cancer","egfr-mutant-nsclc","alk-positive-nsclc"],"sections":["targeted-therapy"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["royal-marsden","icr-london"],"pathways":[],"terms":[],"trials":["national-lung-matrix-trial"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Medical Officer and Consultant Medical Oncologist, The Royal Marsden NHS Foundation Trust; Professor of Thoracic Oncology, The Institute of Cancer Research","institutionId":"royal-marsden","specialisms":["Thoracic oncology","Targeted therapy in lung cancer","Clinical trial design"],"profiles":[{"label":"The Royal Marsden consultant directory","url":"https://www.royalmarsden.nhs.uk/our-consultants-units-and-wards/consultant-directory/professor-sanjay-popat"}],"papers":[{"title":"The National Lung Matrix Trial of personalized therapy in lung cancer","journal":"Nature","year":2020,"doi":"10.1038/s41586-020-2481-8"}]},{"id":"sant-chawla","kind":"person","name":"Sant P. Chawla","aka":[],"tldr":"The Santa Monica medical oncologist whose sarcoma practice has run many of the field's early and late phase drug trials, including the aldoxorubicin programme.","summary":"Sant Chawla is Medical Director of the Sarcoma Oncology Center in Santa Monica, California, a sarcoma-focused practice that its site describes as offering access to clinical trials and novel investigational therapies alongside multimodal treatment planning. He is board certified in internal medicine and medical oncology. OnCo's record of the centre notes that he led the aldoxorubicin trials in soft tissue sarcoma and co-founded Gemini Therapeutics, the company formed to carry aldoxorubicin forward. His publications are listed on PubMed.","asOf":"2026-09-17","links":[{"label":"Sarcoma Oncology Center","url":"https://www.sarcomaoncology.com/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chawla+SP%5BAuthor%5D+sarcoma"}],"tags":["leadership","trialist"],"related":[],"cancers":["sarcoma","osteosarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":["aldoxorubicin"],"companies":["gemini-therapeutics"],"institutions":["sarcoma-oncology-center"],"pathways":[],"terms":[],"trials":["aldoxorubicin-phase-3-sts"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Medical Director, Sarcoma Oncology Center","institutionId":"sarcoma-oncology-center","specialisms":["Sarcoma","Early phase trials","Medical oncology"],"profiles":[{"label":"Sarcoma Oncology Center","url":"https://www.sarcomaoncology.com/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chawla+SP%5BAuthor%5D+sarcoma"}],"papers":[{"title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","journal":"Lancet Oncology","year":2020,"url":"https://doi.org/10.1016/S1470-2045(19)30691-6","doi":"10.1016/S1470-2045(19)30691-6","note":"Europe PMC author record matched by affiliation"},{"title":"Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial","journal":"Lancet Oncology","year":2020,"url":"https://doi.org/10.1016/S1470-2045(20)30068-1","doi":"10.1016/S1470-2045(20)30068-1","note":"Europe PMC author record matched by affiliation"},{"title":"Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial","journal":"Lancet Oncology","year":2017,"url":"https://doi.org/10.1016/S1470-2045(17)30381-9","doi":"10.1016/S1470-2045(17)30381-9","note":"Europe PMC author record matched by affiliation"}]},{"id":"santosh-kesari","kind":"person","name":"Santosh Kesari","aka":[],"tldr":"The neuro-oncologist who founded Asthra Health in Santa Monica, a practice giving outside opinions on complex cancers.","summary":"Santosh Kesari is a board-certified neurologist and neuro-oncologist and the founder of Asthra Health, which its site describes as technology-enabled precision medicine in oncology, neurology, autoimmunity and longevity health for patients with advanced cancers and complex neurological conditions. His clinical and research work concerns brain tumours, including glioblastoma and brain metastases. His publications are listed on PubMed.","asOf":"2026-09-17","links":[{"label":"Asthra Health","url":"https://asthrahealth.com/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kesari+S%5BAuthor%5D+glioblastoma"}],"tags":["leadership"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["asthra-health"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-santosh-kesari-nat-commun-2026"],"journals":[],"dependsOn":[],"notes":[],"role":"Founder, Asthra Health; neuro-oncologist","institutionId":"asthra-health","specialisms":["Neuro-oncology","Brain tumours","Precision medicine second opinions"],"profiles":[{"label":"Asthra Health","url":"https://asthrahealth.com/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kesari+S%5BAuthor%5D+glioblastoma"}],"papers":[{"title":"Drug and single-cell gene expression integration identifies sensitive and resistant glioblastoma cell populations","journal":"Nature Communications","year":2026,"url":"https://doi.org/10.1038/s41467-025-67783-5","doi":"10.1038/s41467-025-67783-5","note":"Europe PMC author record matched by affiliation (Asthra Health); 5 citations on Europe PMC."}]},{"id":"sapna-patel","kind":"person","name":"Sapna P. Patel","aka":[],"tldr":"Led SWOG S1801, the trial that showed giving pembrolizumab before surgery, not just after, improves outcomes in melanoma.","summary":"Sapna Patel was principal investigator of SWOG S1801, which showed that splitting pembrolizumab into neoadjuvant and adjuvant doses improves event-free survival compared with the same total drug given only after surgery in stage III-IV melanoma, a proof of the neoadjuvant principle with the same agent. She chairs the SWOG melanoma committee and leads uveal melanoma trials.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Patel%20SP%5BAuthor%5D%20melanoma%20neoadjuvant%20pembrolizumab"}],"tags":["melanoma","neoadjuvant","swog"],"related":[],"cancers":["melanoma","uveal-melanoma"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["pd1"],"drugs":["pembrolizumab"],"companies":[],"institutions":["colorado-cancer-center"],"pathways":[],"terms":[],"trials":["swog-s1801"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nature-reviews-clinical-oncology"],"dependsOn":[],"notes":[],"role":"Professor of Medicine and Director of Melanoma Medical Oncology, University of Colorado Cancer Center","institutionId":"colorado-cancer-center","specialisms":["Melanoma","Neoadjuvant immunotherapy","Uveal melanoma","Cooperative-group trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Patel%20SP%5BAuthor%5D%20melanoma%20neoadjuvant%20pembrolizumab"}],"papers":[{"title":"Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma (SWOG S1801)","journal":"NEJM","year":2023,"doi":"10.1056/NEJMoa2211437"},{"title":"Neoadjuvant immunotherapy for melanoma: the path forward","journal":"Nature Reviews Clinical Oncology","year":2023}]},{"id":"sara-hurvitz","kind":"person","name":"Sara A. Hurvitz","aka":[],"tldr":"Sara Hurvitz is a breast cancer trialist who led DESTINY-Breast03, the trial where Enhertu beat Kadcyla.","summary":"Sara Hurvitz is Senior Vice President and Director of the Clinical Research Division at Fred Hutchinson Cancer Center and Head of the Division of Hematology and Oncology at the University of Washington, having moved from UCLA in 2023. A breast medical oncologist specialising in HER2 and antibody-drug conjugates, she was principal investigator of DESTINY-Breast03, the trial in which trastuzumab deruxtecan was compared with trastuzumab emtansine, and of many HER2-directed and CDK4/6 studies. Her papers report the updated results of DESTINY-Breast03 in the Lancet and the KRISTINE phase 3 trial of neoadjuvant trastuzumab, pertuzumab and chemotherapy versus trastuzumab emtansine plus pertuzumab in Lancet Oncology. Her work spans HER2-positive, HR-positive and triple-negative breast cancer.","asOf":"2026-09-08","links":[{"label":"Fred Hutch faculty directory","url":"https://www.fredhutch.org/en/faculty-lab-directory.html?q=Sara%20A.%20Hurvitz"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hurvitz%20SA%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Sara%20A.%20Hurvitz"}],"tags":[],"related":[],"cancers":["breast-her2-positive","breast-hr-positive","tnbc"],"sections":[],"technologies":["adc"],"targets":["her2"],"drugs":["trastuzumab-deruxtecan","trastuzumab-emtansine"],"companies":[],"institutions":["fred-hutch"],"pathways":[],"terms":[],"trials":["destiny-breast03"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Senior Vice President and Director, Clinical Research Division, Fred Hutchinson Cancer Center; Head, Division of Hematology and Oncology, University of Washington","institutionId":"fred-hutch","specialisms":["Breast cancer","HER2","ADCs"],"profiles":[{"label":"Fred Hutch faculty directory","url":"https://www.fredhutch.org/en/faculty-lab-directory.html?q=Sara%20A.%20Hurvitz"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hurvitz%20SA%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Sara%20A.%20Hurvitz"}],"papers":[{"title":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial","journal":"Lancet","year":2023,"url":"https://doi.org/10.1016/S0140-6736(22)02420-5","doi":"10.1016/S0140-6736(22)02420-5"},{"title":"Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial","journal":"Lancet Oncology","year":2018,"url":"https://doi.org/10.1016/S1470-2045(17)30716-7","doi":"10.1016/S1470-2045(17)30716-7"},{"title":"ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer","journal":"New England Journal of Medicine","year":2021,"url":"https://doi.org/10.1056/NEJMoa2028485","doi":"10.1056/NEJMoa2028485"},{"title":"DESTINY-Breast03: trastuzumab deruxtecan beats T-DM1 as second-line treatment of HER2-positive metastatic breast cancer","journal":"New England Journal of Medicine","year":2022,"url":"https://doi.org/10.1056/NEJMoa2115022","doi":"10.1056/NEJMoa2115022"},{"title":"NATALEE: three years of ribociclib after surgery in a broad population of hormone-receptor-positive early breast cancer","journal":"New England Journal of Medicine","year":2024,"url":"https://doi.org/10.1056/NEJMoa2305488","doi":"10.1056/NEJMoa2305488"}],"orcid":"0000-0001-7808-7191"},{"id":"sara-lopez-tarruella","kind":"person","name":"Sara López-Tarruella","aka":[],"tldr":"Sara López-Tarruella is a breast oncologist leading GEICAM neoadjuvant studies in triple-negative disease.","summary":"Sara López-Tarruella is a medical oncologist at Hospital General Universitario Gregorio Marañón in Madrid. Her specialisms are breast cancer, triple-negative disease and neoadjuvant trials, and she leads GEICAM neoadjuvant studies of chemotherapy and immunotherapy in triple-negative and HER2-positive breast cancer. Her papers include a Future Oncology piece on how to treat HR-positive, HER2-negative early breast cancer, a study of docetaxel, carboplatin and doxorubicin activity in patient-derived triple-negative xenografts, and an Annals of Oncology report on the TNBC-DX genomic test in early triple-negative breast cancer treated with neoadjuvant taxane-based therapy. Her publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lopez-Tarruella%20S%5BAuthor%5D%20breast%20neoadjuvant"}],"tags":[],"related":[],"cancers":["tnbc","breast-her2-positive"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["gregorio-maranon"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["future-oncology"],"dependsOn":[],"notes":[],"role":"Medical Oncologist, Hospital General Universitario Gregorio Marañón","institutionId":"gregorio-maranon","specialisms":["Breast cancer","Triple-negative disease","Neoadjuvant trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lopez-Tarruella%20S%5BAuthor%5D%20breast%20neoadjuvant"}],"papers":[{"title":"How we Treat HR-Positive, HER2-Negative Early Breast Cancer","journal":"Future Oncology","year":2022,"doi":"10.2217/fon-2021-0668"},{"title":"Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts","journal":"Scientific Reports","year":2021,"doi":"10.1038/s41598-021-85962-4"},{"title":"TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy","journal":"Annals of Oncology","year":2025,"doi":"10.1016/j.annonc.2024.10.012"}],"orcid":"0000-0002-2606-9538"},{"id":"sara-tolaney","kind":"person","name":"Sara M. Tolaney","aka":[],"tldr":"Leads Dana-Farber's breast oncology division and many of the trials that moved ADCs and de-escalated therapy into breast cancer care.","summary":"Sara M. Tolaney is Chief of the Division of Breast Oncology and Associate Director of the Susan F. Smith Center for Women's Cancers at Dana-Farber Brigham Cancer Center. She is known for leading the APT trial that established adjuvant paclitaxel and trastuzumab for small HER2-positive tumours, and for many of the trials that moved antibody-drug conjugates and de-escalated therapy into breast cancer care, as a principal investigator across the DESTINY, TROPION and HER2CLIMB programmes and trials of sacituzumab govitecan in triple-negative disease. Her selected papers report adjuvant paclitaxel and trastuzumab for node-negative HER2-positive breast cancer, and TROPION-Breast01 comparing datopotamab deruxtecan with chemotherapy in hormone receptor-positive, HER2-negative breast cancer.","asOf":"2026-09-08","links":[{"label":"Dana-Farber profile","url":"https://www.dana-farber.org/find-a-doctor/sara-m-tolaney"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tolaney%20SM%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["breast-her2-positive","breast-hr-positive","tnbc"],"sections":[],"technologies":["adc"],"targets":["her2","trop2"],"drugs":["trastuzumab-deruxtecan","datopotamab-deruxtecan","sacituzumab-govitecan","trastuzumab"],"companies":[],"institutions":["dana-farber"],"pathways":[],"terms":[],"trials":["apt-trial","tropion-breast01","destiny-breast09"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief, Division of Breast Oncology; Associate Director, Susan F. Smith Center for Women's Cancers","institutionId":"dana-farber","specialisms":["Breast cancer","HER2-positive breast cancer","Antibody-drug conjugates","De-escalation"],"profiles":[{"label":"Dana-Farber profile","url":"https://www.dana-farber.org/find-a-doctor/sara-m-tolaney"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tolaney%20SM%5BAuthor%5D"}],"papers":[{"title":"Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer","journal":"New England Journal of Medicine","year":2015,"url":"https://doi.org/10.1056/NEJMoa1406281","doi":"10.1056/NEJMoa1406281"},{"title":"Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive HER2-negative breast cancer (TROPION-Breast01)","journal":"Journal of Clinical Oncology","year":2025,"url":"https://doi.org/10.1200/JCO.24.00920","doi":"10.1200/JCO.24.00920"},{"title":"ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer","journal":"New England Journal of Medicine","year":2021,"url":"https://doi.org/10.1056/NEJMoa2028485","doi":"10.1056/NEJMoa2028485"},{"title":"monarchE: two years of abemaciclib after surgery in high-risk, hormone-receptor-positive early breast cancer","journal":"Journal of Clinical Oncology","year":2020,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=monarchE+abemaciclib+adjuvant+Johnston+2020"}]},{"id":"sara-brucker","kind":"person","name":"Sara Y. Brucker","aka":[],"tldr":"Gynaecologist who co-leads the CCC Tübingen-Stuttgart and directs women's health at Tübingen University Hospital, with research in breast and gynaecological cancers.","summary":"Prof. Sara Y. Brucker is Deputy Speaker of the CCC Tübingen-Stuttgart and Medical Director of the Department for Women's Health at the University Women's Clinic, Tübingen. Her clinical and research work spans breast cancer, gynaecological cancer surgery and quality of care in certified breast and gynaecological cancer centres.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.medizin.uni-tuebingen.de/de/das-klinikum/einrichtungen/zentren/tumorzentrum-ccc/vorstand"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Brucker+SY%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","breast cancer","gynaecological oncology"],"related":[],"cancers":["breast-hr-positive","endometrial","ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ccc-tuebingen"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["journal-of-cancer-research-and-clinical-oncology"],"dependsOn":[],"notes":[],"role":"Deputy Speaker; Medical Director, Department for Women's Health","institutionId":"ccc-tuebingen","specialisms":["Gynaecological oncology","Breast cancer","Gynaecological surgery"],"profiles":[{"label":"Institution profile","url":"https://www.medizin.uni-tuebingen.de/de/das-klinikum/einrichtungen/zentren/tumorzentrum-ccc/vorstand"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Brucker+SY%5BAuthor%5D"}],"papers":[{"title":"L1CAM: amending the “low-risk” category in endometrial carcinoma","journal":"Journal of Cancer Research and Clinical Oncology","year":2016,"doi":"10.1007/s00432-016-2276-3"},{"title":"Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study Network","journal":"Geburtshilfe und Frauenheilkunde","year":2015,"doi":"10.1055/s-0034-1396215"},{"title":"Phenotype Discordance between Primary Tumor and Metastasis Impacts Metastasis Site and Outcome: Results of WSG-DETECT-PriMet","journal":"Breast Care","year":2020,"doi":"10.1159/000512416"}],"orcid":"0000-0001-8588-1094"},{"id":"sarah-leary","kind":"person","name":"Sarah E. S. Leary","aka":[],"tldr":"Seattle paediatric neuro-oncologist who led COG ACNS0332, the trial that found adding carboplatin to radiotherapy improves survival in children with high-risk group 3 medulloblastoma but isotretinoin does not help.","summary":"Sarah Leary is a paediatric neuro-oncologist at Seattle Children's Hospital and a leader of the Children's Oncology Group brain tumour committee. She was first author of the 2021 JAMA Oncology report of ACNS0332, the randomised trial in high-risk medulloblastoma in which carboplatin given with radiotherapy improved event-free survival in group 3 tumours, while maintenance isotretinoin did not improve outcomes and was stopped early.","asOf":"2026-09-18","links":[],"tags":["paediatric","brain","trialist"],"related":[],"cancers":["medulloblastoma-group-3-4","medulloblastoma","childhood-cancers"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["seattle-childrens"],"pathways":[],"terms":[],"trials":["acns0332"],"people":[],"bottlenecks":[],"keyPapers":["paper-acns0332-leary-jama-oncol-2021"],"journals":[],"dependsOn":[],"notes":[],"role":"Paediatric neuro-oncologist, Seattle Children's Hospital","institutionId":"seattle-childrens","specialisms":["Medulloblastoma","Paediatric brain tumours","Children's Oncology Group trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Leary%5BAuthor%5D"}],"papers":[{"title":"ACNS0332: carboplatin during radiotherapy and isotretinoin maintenance in high-risk medulloblastoma","journal":"JAMA Oncology","year":2021,"url":"https://doi.org/10.1001/jamaoncol.2021.2224","doi":"10.1001/jamaoncol.2021.2224"}]},{"id":"dawson-sarah-jane","kind":"person","name":"Sarah-Jane Dawson","aka":[],"tldr":"A ctDNA pioneer whose early work showed blood could track breast cancer better than protein markers or imaging.","summary":"Sarah-Jane Dawson is Professor and Head of the Translational Genomics and Epigenomics Laboratory at the Peter MacCallum Cancer Centre in Melbourne, where she is also a medical oncologist. She is a pioneer of circulating tumour DNA, and her early work showed that blood could track metastatic breast cancer better than protein markers or imaging, helping to launch liquid biopsy as a monitoring tool. Her publications include the analysis of circulating tumour DNA to monitor metastatic breast cancer. Her laboratory now develops ctDNA, molecular residual disease and epigenomic approaches across solid and blood cancers.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Sarah-Jane_Dawson","links":[{"label":"Peter MacCallum Cancer Centre","url":"https://www.petermac.org"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dawson%20SJ%5BAuthor%5D%20circulating%20tumor%20DNA"}],"tags":[],"related":[],"cancers":["breast-hr-positive"],"sections":[],"technologies":["liquid-biopsy","mrd-testing"],"targets":[],"drugs":[],"companies":[],"institutions":["peter-mac"],"pathways":[],"terms":["ctdna"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor; Head, Translational Genomics and Epigenomics Laboratory; medical oncologist, Peter Mac","institutionId":"peter-mac","specialisms":["Circulating tumour DNA","Cancer genomics","Breast cancer","Haematologic malignancies"],"profiles":[{"label":"Peter MacCallum Cancer Centre","url":"https://www.petermac.org"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dawson%20SJ%5BAuthor%5D%20circulating%20tumor%20DNA"}],"papers":[{"title":"Analysis of circulating tumor DNA to monitor metastatic breast cancer","journal":"NEJM","year":2013,"doi":"10.1056/NEJMoa1213261"}],"orcid":"0000-0002-8276-0374"},{"id":"sarantos-efstathopoulos","kind":"person","name":"Sarantos Efstathopoulos","aka":[],"tldr":"Sarantos Efstathopoulos represents Metaxa Cancer Hospital, Piraeus in the Organisation of European Cancer Institutes, which lists the centre among its members in Greece.","summary":"Sarantos Efstathopoulos is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Metaxa Cancer Hospital, Piraeus, its full member in Greece. OnCo records the name from the OECI membership list so that the centre's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the institution's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Metaxa Cancer Hospital, Piraeus website","url":"https://www.metaxa-hospital.gov.gr"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["metaxa-cancer-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Metaxa Cancer Hospital, Piraeus to the Organisation of European Cancer Institutes","institutionId":"metaxa-cancer-hospital","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Metaxa Cancer Hospital, Piraeus website","url":"https://www.metaxa-hospital.gov.gr"}],"papers":[]},{"id":"sascha-dietrich","kind":"person","name":"Sascha Dietrich","aka":[],"tldr":"Haematologist-oncologist and Deputy Medical Director at University Hospital Düsseldorf, known for drug-response profiling in lymphoma and leukaemia.","summary":"Sascha Dietrich is Deputy Medical Director on the board of Universitätsklinikum Düsseldorf and a professor of haematology and oncology who directs the hospital's Department of Haematology, Oncology and Clinical Immunology. His research uses ex vivo drug perturbation and multi-omic profiling to guide precision therapy in lymphoid malignancies such as chronic lymphocytic leukaemia and hairy cell leukaemia. He is active in the CIO Düsseldorf cancer centre.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.uniklinik-duesseldorf.de/ueber-das-ukd/unternehmen/vorstand"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dietrich+S%5BAuthor%5D+lymphoma"}],"tags":["leadership","clinician-scientist","haematology","lymphoma"],"related":[],"cancers":["cll","hairy-cell-leukemia","dlbcl"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["uk-duesseldorf"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Deputy Medical Director","institutionId":"uk-duesseldorf","specialisms":["Haematology","Lymphoma","Functional precision oncology"],"profiles":[{"label":"Institution profile","url":"https://www.uniklinik-duesseldorf.de/ueber-das-ukd/unternehmen/vorstand"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dietrich+S%5BAuthor%5D+lymphoma"}],"papers":[{"title":"Recurrent CDKN1B (p27) mutations in hairy cell leukemia","journal":"Blood","year":2015,"doi":"10.1182/blood-2015-04-643361"},{"title":"Ex vivo drug response profiling for response and outcome prediction in hematologic malignancies: the prospective non-interventional SMARTrial","journal":"Nature Cancer","year":2023,"doi":"10.1038/s43018-023-00645-5"},{"title":"Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1","journal":"Blood","year":2022,"doi":"10.1182/blood.2021014241"}]},{"id":"sattva-neelapu","kind":"person","name":"Sattva S. Neelapu","aka":[],"tldr":"Led ZUMA-1, the trial that made axicabtagene ciloleucel the first CAR-T therapy approved for lymphoma.","summary":"Sattva Neelapu was principal investigator of ZUMA-1, which showed axicabtagene ciloleucel produces durable remissions in about 40% of patients with refractory large B-cell lymphoma and led to the first CAR-T approval in lymphoma, and co-led ZUMA-5 in follicular lymphoma. He co-authored the CARTOX consensus on managing cytokine release syndrome and neurotoxicity and studies mechanisms of CAR-T resistance.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Neelapu%20SS%5BAuthor%5D%20axicabtagene"}],"tags":["lymphoma","car-t","cell-therapy"],"related":[],"cancers":["dlbcl","follicular-lymphoma"],"sections":[],"technologies":["car-t"],"targets":["cd19"],"drugs":["axicabtagene-ciloleucel"],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":["zuma-7"],"people":[],"bottlenecks":[],"keyPapers":["paper-zuma-1-axi-cel-nejm-2017"],"journals":["nature-reviews-clinical-oncology"],"dependsOn":[],"notes":[],"role":"Professor and Deputy Chair, Department of Lymphoma and Myeloma, MD Anderson Cancer Center","institutionId":"md-anderson","specialisms":["CAR T-cell therapy","Lymphoma","CAR-T toxicity management","Resistance mechanisms"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Neelapu%20SS%5BAuthor%5D%20axicabtagene"}],"papers":[{"title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma (ZUMA-1)","journal":"NEJM","year":2017,"doi":"10.1056/NEJMoa1707447"},{"title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","journal":"Nature Reviews Clinical Oncology","year":2018,"doi":"10.1038/nrclinonc.2017.148"}],"orcid":"0000-0003-1045-4914"},{"id":"satu-tiainen","kind":"person","name":"Satu Tiainen","aka":[],"tldr":"Chief physician who directs Itäinen syöpäkeskus, the FICAN East regional cancer centre hosted by Kuopio University Hospital and the Pohjois-Savo wellbeing services county.","summary":"Satu Tiainen is listed as Ylilääkäri, Johtaja (chief physician and director) of Itäinen syöpäkeskus, the Eastern Finland cancer centre (FICAN East) whose host organisations include the Pohjois-Savo wellbeing services county, home of Kuopio University Hospital (KYS), together with the University of Eastern Finland and the wellbeing services counties of Central Finland, North Karelia and South Savo. The centre's contact page lists her with development coordinator Jenni Nyrkkö and clinical expert physician Okko Kääriäinen, and she also sits on the centre's clinical working group as a KYS representative. Its governing board is chaired by Outi Kuittinen of the University of Eastern Finland.","asOf":"2026-09-10","links":[{"label":"Source: Itäinen syöpäkeskus (FICAN East) contact and staff page","url":"https://fican.fi/itainen-syopakeskus/yhteystiedot/"},{"label":"Source: FICAN East organisation and board page","url":"https://fican.fi/itainen-syopakeskus/tietoa-meista2/organisaatio-ja-johtoryhma/"}],"tags":["leadership","clinician-scientist","comprehensive-cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["fican"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["breast-cancer-research-and-treatment"],"dependsOn":[],"notes":[],"role":"Ylilääkäri and Johtaja (Chief Physician and Director), Itäinen syöpäkeskus (FICAN East), Kuopio University Hospital","institutionId":"kuopio-university-hospital","specialisms":["Oncology","Cancer centre management","Regional cancer networks"],"profiles":[{"label":"FICAN East contact page","url":"https://fican.fi/itainen-syopakeskus/yhteystiedot/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tiainen+S%5BAuthor%5D+AND+Kuopio"}],"papers":[{"title":"High numbers of macrophages, especially M2‐like ( CD 163‐positive), correlate with hyaluronan accumulation and poor outcome in breast cancer","journal":"Histopathology","year":2015,"doi":"10.1111/his.12607"},{"title":"The prognostic and predictive role of the neutrophil-to-lymphocyte ratio and the monocyte-to-lymphocyte ratio in early breast cancer, especially in the HER2+ subtype","journal":"Breast Cancer Research and Treatment","year":2021,"doi":"10.1007/s10549-020-05925-7"},{"title":"Tumor microenvironment and breast cancer survival: combined effects of breast fat, M2 macrophages and hyaluronan create a dismal prognosis","journal":"Breast Cancer Research and Treatment","year":2019,"doi":"10.1007/s10549-019-05491-7"}]},{"id":"scott-antonia","kind":"person","name":"Scott J. Antonia","aka":[],"tldr":"Led PACIFIC, which made a year of durvalumab after chemoradiation the standard for stage III lung cancer.","summary":"Scott Antonia was principal investigator of PACIFIC, the trial showing consolidation durvalumab after chemoradiotherapy improves progression-free and overall survival in unresectable stage III NSCLC, the first curative-intent immunotherapy result in lung cancer. He also led early nivolumab work in small-cell lung cancer (CheckMate 032). He now directs immunotherapy and cell therapy programmes at Duke.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Antonia%20SJ%5BAuthor%5D%20durvalumab%20PACIFIC"}],"tags":["lung","immunotherapy","stage-iii"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["pdl1"],"drugs":["durvalumab","nivolumab"],"companies":[],"institutions":["duke-cancer-institute"],"pathways":[],"terms":[],"trials":["pacific"],"people":[],"bottlenecks":[],"keyPapers":["paper-pacific-nejm-2017"],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Center for Cancer Immunotherapy, Duke Cancer Institute","institutionId":"duke-cancer-institute","specialisms":["Lung cancer immunotherapy","Stage III NSCLC","Tumour immunology","Cell therapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Antonia%20SJ%5BAuthor%5D%20durvalumab%20PACIFIC"}],"papers":[{"title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer (PACIFIC)","journal":"NEJM","year":2017,"doi":"10.1056/NEJMoa1709937"},{"title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","journal":"NEJM","year":2018,"doi":"10.1056/NEJMoa1809697"}],"orcid":"0000-0002-0029-9685"},{"id":"scott-kopetz","kind":"person","name":"Scott Kopetz","aka":[],"tldr":"Led BEACON and BREAKWATER, the trials that gave BRAF-mutant colorectal cancer its first targeted therapies.","summary":"Scott Kopetz led BEACON CRC, which established encorafenib plus cetuximab for previously treated BRAF V600E colorectal cancer, and BREAKWATER, which moved the combination with chemotherapy into first line with a large survival gain. He co-developed the consensus molecular subtypes of colorectal cancer and leads ctDNA-guided adjuvant trials in the NCI cooperative groups.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kopetz%20S%5BAuthor%5D%20BRAF%20colorectal"}],"tags":["colorectal","braf","targeted-therapy"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":["kinase-inhibitors","liquid-biopsy"],"targets":["braf"],"drugs":["encorafenib"],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":["breakwater"],"people":[],"bottlenecks":[],"keyPapers":["paper-breakwater-nejm-2025"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Gastrointestinal Medical Oncology, MD Anderson Cancer Center","institutionId":"md-anderson","specialisms":["BRAF-mutant colorectal cancer","Targeted therapy","Circulating tumour DNA","Consensus molecular subtypes"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kopetz%20S%5BAuthor%5D%20BRAF%20colorectal"}],"papers":[{"title":"Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer (BEACON)","journal":"NEJM","year":2019,"doi":"10.1056/NEJMoa1908075"},{"title":"The consensus molecular subtypes of colorectal cancer","journal":"Nature Medicine","year":2015,"doi":"10.1038/nm.3967"},{"title":"Encorafenib, cetuximab, and chemotherapy in BRAF-mutated colorectal cancer (BREAKWATER)","journal":"NEJM","year":2025},{"title":"BREAKWATER: encorafenib plus cetuximab with chemotherapy as first treatment for BRAF V600E-mutated colorectal cancer","journal":"New England Journal of Medicine","year":2025,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BREAKWATER+encorafenib+cetuximab+mFOLFOX6+colorectal"}],"orcid":"0000-0001-9647-3416"},{"id":"scott-plotkin","kind":"person","name":"Scott R. Plotkin","aka":[],"tldr":"Boston neuro-oncologist who showed that bevacizumab can shrink vestibular schwannomas and restore hearing in people with neurofibromatosis type 2.","summary":"Scott Plotkin is a neuro-oncologist at Massachusetts General Hospital who directs its neurofibromatosis centre. He was first author of the 2009 New England Journal of Medicine report showing that the VEGF antibody bevacizumab reduced tumour volume and improved hearing in patients with neurofibromatosis type 2 and progressive vestibular schwannomas, the first medical therapy for these tumours. He leads the Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) collaboration.","asOf":"2026-09-18","links":[],"tags":["brain","rare-cancers","trialist"],"related":[],"cancers":["vestibular-schwannoma","brain-tumours"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["mgh"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-plotkin-bevacizumab-nf2-nejm-2009"],"journals":[],"dependsOn":[],"notes":[],"role":"Neuro-oncologist and Director of the Family Center for Neurofibromatosis, Massachusetts General Hospital","institutionId":"mgh","specialisms":["Neurofibromatosis type 2","Schwannomas","Neuro-oncology trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Plotkin%5BAuthor%5D"}],"papers":[{"title":"Hearing improvement after bevacizumab in patients with neurofibromatosis type 2","journal":"New England Journal of Medicine","year":2009,"url":"https://doi.org/10.1056/NEJMoa0902579","doi":"10.1056/NEJMoa0902579"}],"orcid":"0000-0002-6109-6419"},{"id":"lee-se-hoon","kind":"person","name":"Se-Hoon Lee","aka":[],"tldr":"A lung cancer oncologist who has helped test checkpoint inhibitors and next-generation ADCs in Korean patients.","summary":"Se-Hoon Lee is Professor of Internal Medicine at Seoul National University Hospital, working in thoracic oncology and immunotherapy. He has helped test checkpoint inhibitors and next-generation antibody-drug conjugates in Korean patients, including the datopotamab deruxtecan and tarlatamab programmes in non-small-cell and small-cell lung cancer. His publications include a phase 2 trial of vandetanib in pretreated lung cancer harbouring RET rearrangements and a study of the clonal history and genetic predictors of transformation from lung adenocarcinoma into small-cell carcinoma. His interests are lung cancer, immunotherapy and small-cell lung cancer.","asOf":"2026-09-08","links":[{"label":"Seoul National University Hospital","url":"https://www.snuh.org"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lee%20SH%5BAuthor%5D%20Seoul%20National%20University%20lung%20immunotherapy"}],"tags":[],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["datopotamab-deruxtecan","tarlatamab"],"companies":[],"institutions":["snuh"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Internal Medicine; thoracic oncology and immunotherapy","institutionId":"snuh","specialisms":["Lung cancer","Immunotherapy","Small-cell lung cancer"],"profiles":[{"label":"Seoul National University Hospital","url":"https://www.snuh.org"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lee%20SH%5BAuthor%5D%20Seoul%20National%20University%20lung%20immunotherapy"}],"papers":[{"title":"Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial","journal":"Annals of Oncology","year":2017,"doi":"10.1093/annonc/mdw559"},{"title":"Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas","journal":"Journal of Clinical Oncology","year":2017,"doi":"10.1200/jco.2016.71.9096"},{"title":"MARIPOSA: amivantamab plus lazertinib versus osimertinib as first treatment for EGFR-mutated lung cancer","journal":"New England Journal of Medicine","year":2024,"url":"https://doi.org/10.1056/NEJMoa2403614","doi":"10.1056/NEJMoa2403614"}]},{"id":"sean-parker","kind":"person","name":"Sean Parker","aka":[],"tldr":"In 2016 he founded and funded an institute that runs cancer immunotherapy research as one network across a dozen leading cancer centres, sharing data, samples and patents rather than competing for them.","summary":"Sean Parker, the Napster co-founder and first president of Facebook, created the Parker Institute for Cancer Immunotherapy in 2016 through the Parker Foundation. Rather than endowing one hospital, the gift built a network: PICI describes itself as an active research institute, not just a grant maker, whose model removes barriers between institutions and turns ideas into real-world treatments. Its member centres include Stanford Medicine, UCSF, Penn Medicine, Dana-Farber, Memorial Sloan Kettering and MD Anderson, twelve in all, working under shared agreements on data and intellectual property. PICI funds investigators, coordinates multi-centre trials of CAR-T and checkpoint combinations and has spun out companies to carry results forward. The size of the founding grant is widely reported but not stated on the Institute's own pages, so it is not repeated here.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Sean_Parker","links":[{"label":"Parker Institute: about","url":"https://www.parkerici.org/about/"}],"tags":["hero","donor"],"related":[],"cancers":[],"sections":[],"technologies":["immunotherapy","car-t","checkpoint-inhibitor"],"targets":[],"drugs":[],"companies":[],"institutions":["parker-institute","stanford","ucsf","penn-abramson","dana-farber","mskcc","md-anderson"],"pathways":[],"terms":[],"trials":[],"people":["carl-june","james-allison"],"bottlenecks":["b-ip-collaboration","b-immunotherapy-response","b-funding-allocation"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Founder of the Parker Institute for Cancer Immunotherapy","specialisms":["Cancer immunotherapy","Research networks","Philanthropy"],"profiles":[],"papers":[]},{"id":"sebastian-bauer","kind":"person","name":"Sebastian Bauer","aka":[],"tldr":"German sarcoma specialist who was lead author of INTRIGUE, the trial that compared ripretinib with sunitinib as second-line treatment for GIST.","summary":"Sebastian Bauer leads the sarcoma programme at the West German Cancer Center in Essen. He was first author of the 2022 Journal of Clinical Oncology report of INTRIGUE, the phase 3 trial that found ripretinib was not superior to sunitinib in progression-free survival after imatinib in advanced gastrointestinal stromal tumour, though it was better tolerated. His laboratory studies resistance mechanisms in GIST.","asOf":"2026-09-18","links":[],"tags":["gist","sarcoma","trialist"],"related":[],"cancers":["gist-imatinib-resistant","gist","sarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["essen-wtz"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-intrigue-ripretinib-vs-sunitinib-jco-2022"],"journals":[],"dependsOn":[],"notes":[],"role":"Medical oncologist, West German Cancer Center, University Hospital Essen","institutionId":"essen-wtz","specialisms":["Gastrointestinal stromal tumour","Sarcoma","Kinase inhibitors"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bauer%5BAuthor%5D"}],"papers":[{"title":"INTRIGUE: ripretinib versus sunitinib in advanced gastrointestinal stromal tumour after imatinib","journal":"Journal of Clinical Oncology","year":2022,"url":"https://doi.org/10.1200/JCO.22.00294","doi":"10.1200/JCO.22.00294"}]},{"id":"sebastien-armanet","kind":"person","name":"Sébastien Armanet","aka":[],"tldr":"Director General who runs the operational team of ARCAGY-GINECO, the French non-profit academic research group for gynaecological and metastatic breast cancers.","summary":"Sébastien Armanet is Directeur Général of ARCAGY-GINECO, an independent, non-profit academic cooperative group founded more than 30 years ago that runs clinical and translational research in gynaecological cancers and metastatic breast cancer. He leads its operational structure of about 45 staff, organised into clinical operations, quality assurance and regulatory affairs, translational research with a biological resource centre, administration and communication, and a medical unit. The association's board is chaired by President Marc Oberlis, with Alain Dormoy as treasurer, Bernard Poletto as secretary, and GINECO scientific committee members Anne-Claire Hardy-Bessard, Fabrice Lecuru and Bernard Asselain.","asOf":"2026-09-10","links":[{"label":"Source: ARCAGY organisation page","url":"https://arcagy.org/fr/page/50-organisation-d-arcagy.html"}],"tags":["leadership","clinical-trials","cooperative-group"],"related":[],"cancers":["ovarian","endometrial","cervical"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["arcagy-gineco"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Directeur Général (Director General) of ARCAGY-GINECO","institutionId":"arcagy-gineco","specialisms":["Clinical research operations","Gynaecological oncology trials","Academic cooperative groups"],"profiles":[{"label":"Institution profile","url":"https://arcagy.org/fr/page/50-organisation-d-arcagy.html"}],"papers":[]},{"id":"selwyn-vickers","kind":"person","name":"Selwyn M. Vickers","aka":[],"tldr":"Selwyn Vickers is a surgeon-scientist who leads the world's top-ranked cancer hospital.","summary":"Selwyn M. Vickers is President and Chief Executive Officer of Memorial Sloan Kettering Cancer Center, the world's top-ranked cancer hospital, a post he took in 2022. He is a surgeon-scientist and pancreatic surgeon who was previously dean of the UAB School of Medicine, with ties to the O'Neal Comprehensive Cancer Center at UAB. His research focused on pancreatic cancer biology and on disparities in cancer outcomes, and his selected paper addresses pancreatic cancer disparities in African Americans. He now leads MSK with a background in pancreatic surgery, health disparities and academic leadership.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Selwyn_M._Vickers","links":[{"label":"MSK profile","url":"https://www.mskcc.org/about/leadership/office-president"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Vickers%20SM%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["mskcc","oneal-uab"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President and Chief Executive Officer","institutionId":"mskcc","specialisms":["Pancreatic cancer surgery","Health disparities","Academic leadership"],"profiles":[{"label":"MSK profile","url":"https://www.mskcc.org/about/leadership/office-president"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Vickers%20SM%5BAuthor%5D"}],"papers":[{"title":"Pancreatic cancer disparities in African Americans","journal":"Pancreas","year":2019}],"orcid":"0000-0003-3133-5543"},{"id":"semir-beyaz","kind":"person","name":"Semir Beyaz","aka":[],"tldr":"Shows how diet reprogrammes intestinal stem cells and immunity to change colorectal cancer risk.","summary":"Semir Beyaz is Assistant Professor at the Cold Spring Harbor Laboratory Cancer Center, working on diet and cancer. He is known for showing how diet reprogrammes intestinal stem cells and immunity to change colorectal cancer risk, demonstrating that a high-fat diet enhances the tumorigenicity of intestinal stem cells. His selected paper reports that high-fat diet enhances stemness and tumorigenicity of intestinal progenitors. His laboratory now studies dietary and metabolic modulation of anti-tumour immunity and immunometabolism.","asOf":"2026-09-08","links":[{"label":"CSHL profile","url":"https://www.cshl.edu/research/faculty-staff/semir-beyaz/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Beyaz%20S%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["colorectal"],"sections":["prevention"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cold-spring-harbor"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Assistant Professor, CSHL Cancer Center","institutionId":"cold-spring-harbor","specialisms":["Diet and cancer","Intestinal stem cells","Immunometabolism"],"profiles":[{"label":"CSHL profile","url":"https://www.cshl.edu/research/faculty-staff/semir-beyaz/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Beyaz%20S%5BAuthor%5D"}],"papers":[{"title":"High-fat diet enhances stemness and tumorigenicity of intestinal progenitors","journal":"Nature","year":2016,"url":"https://doi.org/10.1038/nature17173","doi":"10.1038/nature17173"}],"orcid":"0000-0003-4730-4012"},{"id":"senda-tounsi","kind":"person","name":"Senda Tounsi","aka":[],"tldr":"Director General of Institut Salah Azaïez in Tunis, Tunisia's national cancer institute with around 208 beds.","summary":"Senda Tounsi is Directeur Général of the Institut Salah Azaïez (ISA), Tunisia's national cancer institute in Tunis, named after the physician Salah Azaïez (1911 to 1953). The institute's administration page lists her as Directeur général de l'I.S.A on a board of administration chaired by Said Gharbi, with Karima Mrad presiding over the medical committee. The institute is organised into two directorates, six sub-directorates and twelve clinical services, with 208 beds and about 740 staff including 85 physicians.","asOf":"2026-09-10","links":[{"label":"Source: Institut Salah Azaïez administration page","url":"http://www.institutsalahazaiez.com/espace-administratif.php?id=1"}],"tags":["leadership","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["institut-salah-azaiez"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Directeur Général (Director General) of Institut Salah Azaïez","institutionId":"institut-salah-azaiez","specialisms":["Hospital administration","Cancer centre management"],"profiles":[{"label":"Institut Salah Azaïez administration page","url":"http://www.institutsalahazaiez.com/espace-administratif.php?id=1"}],"papers":[]},{"id":"senthil-muthuswamy","kind":"person","name":"Senthil K. Muthuswamy","aka":[],"tldr":"Cancer biologist who directs the National Cancer Institute's Center for Cancer Research, the large intramural research programme in Bethesda.","summary":"Senthil K. Muthuswamy is Director of the Center for Cancer Research (CCR), the intramural research programme of the US National Cancer Institute, and a Senior Investigator in its Laboratory of Cancer Biology and Genetics. He pioneered three dimensional organoid culture and co-culture methods for mechanistic, translational and co-clinical studies, and his laboratory defined roles for cell polarity proteins in cancer biology and therapy resistance. His research interests include metastasis, breast and pancreatic cancer and cancer immunotherapy.","asOf":"2026-09-10","links":[{"label":"Source: CCR Office of the Director leadership page","url":"https://ccr.cancer.gov/about/office-of-the-director"}],"tags":["leadership","clinician-scientist","cancer-biology","organoids"],"related":[],"cancers":["pancreatic","breast-hr-positive"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["nci-ccr"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["breast-cancer-research"],"dependsOn":[],"notes":[],"role":"Director, Center for Cancer Research, National Cancer Institute","institutionId":"nci-ccr","specialisms":["Cancer cell biology","Organoid models","Breast and pancreatic cancer"],"profiles":[{"label":"CCR staff profile","url":"https://ccr.cancer.gov/staff-directory/senthil-k-muthuswamy"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Muthuswamy+SK%5BAuthor%5D"}],"papers":[{"title":"Establishing conditions for the generation and maintenance of estrogen receptor-positive organoid models of breast cancer","journal":"Breast Cancer Research","year":2024,"doi":"10.1186/s13058-024-01798-6"},{"title":"Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell– and patient-derived tumor organoids","journal":"Nature Medicine","year":2015,"doi":"10.1038/nm.3973"},{"title":"Organoid Cultures for the Study of Mammary Biology and Breast Cancer: The Promise and Challenges","journal":"Cold Spring Harbor Perspectives in Medicine","year":2023,"doi":"10.1101/cshperspect.a041661"}]},{"id":"im-seock-ah","kind":"person","name":"Seock-Ah Im","aka":[],"tldr":"Led MONALEESA-7, which proved a CDK4/6 inhibitor extends survival in premenopausal breast cancer, and steers Korea's breast cancer trial network.","summary":"Seock-Ah Im is Professor of Internal Medicine at Seoul National University Hospital, specialising in breast medical oncology. She led MONALEESA-7, the trial that proved the CDK4/6 inhibitor ribociclib with endocrine therapy extends survival in premenopausal women with HR-positive, HER2-negative breast cancer, and steers Korea's breast cancer trial network. She is a principal investigator across the ribociclib, palbociclib and antibody-drug conjugate programmes in breast cancer, including triple-negative disease. Her publications include the MONALEESA-7 report on ribociclib plus endocrine therapy, and her interests are CDK4/6 inhibitors, premenopausal breast cancer and antibody-drug conjugates.","asOf":"2026-09-08","links":[{"label":"Seoul National University Hospital","url":"https://www.snuh.org"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Im%20SA%5BAuthor%5D%20Seoul%20National%20University%20breast%20cancer"}],"tags":[],"related":[],"cancers":["breast-hr-positive","tnbc"],"sections":[],"technologies":[],"targets":["cdk4-6","estrogen-receptor"],"drugs":["ribociclib","palbociclib"],"companies":[],"institutions":["snuh"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Internal Medicine; breast medical oncology","institutionId":"snuh","specialisms":["Breast cancer","CDK4/6 inhibitors","Premenopausal breast cancer","Antibody-drug conjugates"],"profiles":[{"label":"Seoul National University Hospital","url":"https://www.snuh.org"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Im%20SA%5BAuthor%5D%20Seoul%20National%20University%20breast%20cancer"}],"papers":[{"title":"Overall survival with ribociclib plus endocrine therapy in breast cancer (MONALEESA-7)","journal":"NEJM","year":2019,"doi":"10.1056/NEJMoa1903765"},{"title":"DESTINY-Breast03: trastuzumab deruxtecan beats T-DM1 as second-line treatment of HER2-positive metastatic breast cancer","journal":"New England Journal of Medicine","year":2022,"url":"https://doi.org/10.1056/NEJMoa2115022","doi":"10.1056/NEJMoa2115022"},{"title":"DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group","journal":"New England Journal of Medicine","year":2022,"url":"https://doi.org/10.1056/NEJMoa2203690","doi":"10.1056/NEJMoa2203690"},{"title":"DESTINY-Breast06: trastuzumab deruxtecan before any chemotherapy in hormone-receptor-positive, HER2-low or ultralow breast cancer","journal":"New England Journal of Medicine","year":2024,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DESTINY-Breast06+trastuzumab+deruxtecan+HER2-low+chemotherapy-naive"},{"title":"NATALEE: three years of ribociclib after surgery in a broad population of hormone-receptor-positive early breast cancer","journal":"New England Journal of Medicine","year":2024,"url":"https://doi.org/10.1056/NEJMoa2305488","doi":"10.1056/NEJMoa2305488"},{"title":"TROPION-Breast01: datopotamab deruxtecan versus chemotherapy in pretreated hormone-receptor-positive breast cancer, and why a PFS win did not translate to survival","journal":"Journal of Clinical Oncology","year":2024,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=TROPION-Breast01+datopotamab+deruxtecan+Bardia"}],"orcid":"0000-0002-5396-6533"},{"id":"serena-nik-zainal","kind":"person","name":"Serena Nik-Zainal","aka":[],"tldr":"Deciphered the mutational signatures written in cancer genomes and turned them into clinical tests like HRDetect.","summary":"Serena Nik-Zainal led the whole-genome analysis of 560 breast cancers that catalogued mutational signatures and rearrangement patterns, and developed HRDetect, which identifies homologous recombination-deficient tumours beyond BRCA carriers and predicts PARP inhibitor sensitivity. Her group analysed the 100,000 Genomes Project cancers and builds signature-based tools for the NHS. She won the Francis Crick Medal in 2019.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Nik-Zainal%20S%5BAuthor%5D%20mutational%20signatures"}],"tags":["genomics","mutational-signatures","uk"],"related":[],"cancers":["tnbc","breast-hr-positive"],"sections":[],"technologies":["wes-wgs","hrd-testing"],"targets":["brca","parp"],"drugs":[],"companies":[],"institutions":["cruk-cambridge-centre"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-vogelstein-cancer-genome-landscapes-science-2013"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Genomic Medicine and Bioinformatics, University of Cambridge; Honorary Consultant in Clinical Genetics","institutionId":"cruk-cambridge-centre","specialisms":["Mutational signatures","Whole-genome sequencing","Breast cancer genomics","Clinical genomics"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Nik-Zainal%20S%5BAuthor%5D%20mutational%20signatures"}],"papers":[{"title":"Landscape of somatic mutations in 560 breast cancer whole-genome sequences","journal":"Nature","year":2016,"doi":"10.1038/nature17676"},{"title":"HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures","journal":"Nature Medicine","year":2017,"doi":"10.1038/nm.4292"},{"title":"Cancer genome landscapes: about 140 driver genes, and each tumour needs only a handful","journal":"Science","year":2013,"url":"https://doi.org/10.1126/science.1235122","doi":"10.1126/science.1235122"}],"orcid":"0000-0001-5054-1727"},{"id":"sergio-roman-roman","kind":"person","name":"Sergio Roman-Roman","aka":[],"tldr":"Directs the translational research department that developed models and targets for uveal melanoma.","summary":"Sergio Roman-Roman is Director of Translational Research at Institut Curie in Paris. His specialisms are translational research, uveal melanoma and preclinical models, including patient-derived xenograft platforms. He directs the department that developed models and targets for uveal melanoma. His papers include the establishment of cell lines recapitulating the genetic landscape of uveal melanoma with preclinical validation of mTOR as a target, a Cancer Discovery study linking SF3B1 mutations to alternative splicing in uveal melanoma, and a Cancer Cell integrative analysis identifying four molecular and clinical subsets of the disease. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Roman-Roman%20S%5BAuthor%5D%20uveal%20melanoma"}],"tags":[],"related":[],"cancers":["melanoma"],"sections":[],"technologies":["pdx-models"],"targets":[],"drugs":[],"companies":[],"institutions":["institut-curie"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["molecular-oncology"],"dependsOn":[],"notes":[],"role":"Director of Translational Research, Institut Curie","institutionId":"institut-curie","specialisms":["Translational research","Uveal melanoma","Preclinical models"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Roman-Roman%20S%5BAuthor%5D%20uveal%20melanoma"}],"papers":[{"title":"Establishment of novel cell lines recapitulating the genetic landscape of uveal melanoma and preclinical validation of mTOR as a therapeutic target","journal":"Molecular Oncology","year":2014,"doi":"10.1016/j.molonc.2014.06.004"},{"title":"SF3B1 Mutations Are Associated with Alternative Splicing in Uveal Melanoma","journal":"Cancer Discovery","year":2013,"doi":"10.1158/2159-8290.cd-13-0330"},{"title":"Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma","journal":"Cancer Cell","year":2017,"doi":"10.1016/j.ccell.2017.07.003"}]},{"id":"seyed-rouhollah-miri","kind":"person","name":"Seyed Rouhollah Miri","aka":[],"tldr":"Surgical oncologist who heads the Cancer Institute of Iran at Tehran's Imam Khomeini Hospital Complex, the country's oldest dedicated cancer institute.","summary":"Seyed Rouhollah Miri, a subspecialist in cancer surgery, is Head of the Cancer Institute at the Imam Khomeini Hospital Complex of Tehran University of Medical Sciences, with Leila Torkzadeh, who holds a doctorate in health policy, as its manager. The institute is one of the complex's hospitals on the eastern side of the campus, and its site describes a hospital cancer registry office set up in 1997, a Cancer Research Centre that grew out of that registry, and a Radiation Oncology Research Centre approved in 2014. The institute page lists seven outpatient and seven inpatient operating room beds.","asOf":"2026-09-10","links":[{"label":"Source: IKHC Cancer Institute hospital page","url":"https://ikhc.tums.ac.ir/%D8%A8%DB%8C%D9%85%D8%A7%D8%B1%D8%B3%D8%AA%D8%A7%D9%86-%D8%A7%D9%86%D8%B3%D8%AA%DB%8C%D8%AA%D9%88-%DA%A9%D8%A7%D9%86%D8%B3%D8%B1"}],"tags":["leadership","clinician-scientist","surgical-oncology"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["tehran-cancer-institute"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Head of the Cancer Institute, Imam Khomeini Hospital Complex","institutionId":"tehran-cancer-institute","specialisms":["Surgical oncology","Cancer surgery","Cancer hospital leadership"],"profiles":[{"label":"Institution page (Persian)","url":"https://ikhc.tums.ac.ir/%D8%A8%DB%8C%D9%85%D8%A7%D8%B1%D8%B3%D8%AA%D8%A7%D9%86-%D8%A7%D9%86%D8%B3%D8%AA%DB%8C%D8%AA%D9%88-%DA%A9%D8%A7%D9%86%D8%B3%D8%B1"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Miri+SR%5BAuthor%5D"}],"papers":[{"title":"The Nuclear Factor Kappa B (NF-kB) signaling in cancer development and immune diseases","journal":"Genes & Diseases","year":2021,"doi":"10.1016/j.gendis.2020.06.005"},{"title":"Duodenal Metastases From Renal Cell Carcinoma Presented With Melena: Review and Case Report","journal":"Iranian Journal of Pathology","year":2017,"doi":"10.30699/ijp.2017.25687"},{"title":"Neuroendocrine tumor of the common bile duct","journal":"International Journal of Surgery Case Reports","year":2020,"doi":"10.1016/j.ijscr.2020.11.027"}]},{"id":"shabir-madhi","kind":"person","name":"Shabir A. Madhi","aka":[],"tldr":"Vaccinologist and Dean of the Wits Faculty of Health Sciences, the academic partner of Charlotte Maxeke Johannesburg Academic Hospital.","summary":"Shabir A. Madhi is Dean of the Faculty of Health Sciences at the University of the Witwatersrand and Professor of Vaccinology. He leads the faculty that partners with Charlotte Maxeke Johannesburg Academic Hospital, one of South Africa's largest public cancer treatment centres, and is internationally known for vaccine trials including HPV, pneumococcal and COVID-19 vaccines.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.wits.ac.za/health/about-us/management-and-governance/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Madhi+SA%5BAuthor%5D"}],"tags":["leadership","academic medicine","vaccinology"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["wits-charlotte-maxeke"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["lancet"],"dependsOn":[],"notes":[],"role":"Dean, Faculty of Health Sciences; Professor of Vaccinology","institutionId":"wits-charlotte-maxeke","specialisms":["Vaccinology","Infectious diseases","Academic medicine"],"profiles":[{"label":"Institution profile","url":"https://www.wits.ac.za/health/about-us/management-and-governance/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Madhi+SA%5BAuthor%5D"}],"papers":[{"title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials","journal":"The Lancet","year":2021,"url":"https://doi.org/10.1016/s0140-6736(20)32661-1","doi":"10.1016/s0140-6736(20)32661-1","note":"Europe PMC author record matched by affiliation"},{"title":"Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis","journal":"The Lancet","year":2010,"url":"https://doi.org/10.1016/s0140-6736(10)60206-1","doi":"10.1016/s0140-6736(10)60206-1","note":"Europe PMC author record matched by affiliation"},{"title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015","journal":"The Lancet","year":2017,"url":"https://doi.org/10.1016/s0140-6736(17)30938-8","doi":"10.1016/s0140-6736(17)30938-8","note":"Europe PMC author record matched by affiliation"}],"orcid":"0000-0002-7629-0636"},{"id":"shaheem-de-vries","kind":"person","name":"Shaheem de Vries","aka":[],"tldr":"Emergency physician and health manager who was appointed Chief Executive Officer of Groote Schuur Hospital, the University of Cape Town's main teaching hospital, in February 2024.","summary":"Shaheem de Vries is Chief Executive Officer of Groote Schuur Hospital in Cape Town, the tertiary teaching hospital of the University of Cape Town's Faculty of Health Sciences. He took up the post on 1 February 2024, succeeding Bhavna Patel, after ten years as head of Western Cape Government Health Emergency Medical Services and some twenty years in emergency medicine; he holds a medical degree and an MBA from the University of Cape Town. The hospital's own website and the Western Cape Government hospital pages could not be reached when this record was checked, so the role is recorded from the dated appointment report in Spotlight and should be re-checked.","asOf":"2026-09-10","links":[{"label":"Source: Spotlight report on his appointment as Groote Schuur CEO (25 April 2024)","url":"https://www.spotlightnsp.co.za/2024/04/25/dr-shaheem-de-vries-comfortable-with-chaos-head-cowboy-takes-charge-of-groote-schuur-hospital/"}],"tags":["leadership","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["groote-schuur-uct"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive Officer, Groote Schuur Hospital","institutionId":"groote-schuur-uct","specialisms":["Emergency medicine","Hospital management","Health system leadership"],"profiles":[{"label":"Spotlight appointment profile (April 2024)","url":"https://www.spotlightnsp.co.za/2024/04/25/dr-shaheem-de-vries-comfortable-with-chaos-head-cowboy-takes-charge-of-groote-schuur-hospital/"}],"papers":[],"orcid":"0000-0003-3986-1652"},{"id":"shahid-khan","kind":"person","name":"Shahid A. Khan","aka":[],"tldr":"Hepatologist who documented the rise of cholangiocarcinoma in the UK and senior author of the 2023 British Society of Gastroenterology guideline that sets out how NHS teams should diagnose and manage it.","summary":"Shahid Khan is professor of practice in hepatology at Imperial College London and a consultant at Imperial College Healthcare since 2007. His research traced the increase in intrahepatic cholangiocarcinoma in the UK. He chairs Cholangiocarcinoma-UK and was senior author of the British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma (Gut 2023), the UK reference for biliary MDTs.","asOf":"2026-09-24","links":[{"label":"Imperial College London profile","url":"https://profiles.imperial.ac.uk/shahid.khan"},{"label":"Imperial College Healthcare consultant page","url":"https://www.imperial.nhs.uk/consultants/shahid-khan"}],"tags":["biliary","guidelines","uk"],"related":[],"cancers":["gallbladder","biliary-tract-cancer","cholangiocarcinoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["imperial-cancer-centre","ammf"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Practice (Hepatology), Imperial College London; Consultant Gastroenterologist and Hepatologist, Imperial College Healthcare NHS Trust; Chair, Cholangiocarcinoma-UK; Medical Adviser, AMMF","institutionId":"imperial-cancer-centre","specialisms":["Cholangiocarcinoma epidemiology","Hepatology","Biliary tract cancer guidelines"],"profiles":[{"label":"Imperial College London profile","url":"https://profiles.imperial.ac.uk/shahid.khan"},{"label":"Imperial College Healthcare consultant page","url":"https://www.imperial.nhs.uk/consultants/shahid-khan"}],"papers":[{"title":"British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma","journal":"Gut","year":2023,"doi":"10.1136/gutjnl-2023-330029"}]},{"id":"sandhu-shahneen","kind":"person","name":"Shahneen Sandhu","aka":[],"tldr":"Runs the medical oncology side of Peter Mac's theranostics programme, combining lutetium-PSMA with hormonal and immune therapies.","summary":"Shahneen Sandhu is a medical oncologist and Lead for Genitourinary Oncology Theranostics at the Peter MacCallum Cancer Centre in Melbourne. She runs the medical oncology side of Peter Mac's theranostics programme, leading combination trials such as PRINCE and UpFrontPSMA that pair lutetium-177 PSMA-617 with androgen receptor pathway inhibitors, chemotherapy and immunotherapy. Her publications include the UpFrontPSMA trial of sequential lutetium-177 PSMA-617 and docetaxel against docetaxel alone in metastatic hormone-sensitive prostate cancer. She also contributes to melanoma and early-phase research.","asOf":"2026-09-08","links":[{"label":"Peter MacCallum Cancer Centre","url":"https://www.petermac.org"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sandhu%20S%5BAuthor%5D%20Peter%20MacCallum%20prostate%20PSMA"}],"tags":[],"related":[],"cancers":["prostate","melanoma"],"sections":[],"technologies":["radioligand-therapy"],"targets":["psma"],"drugs":["pluvicto"],"companies":[],"institutions":["peter-mac"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Medical oncologist; Lead, Genitourinary Oncology Theranostics, Peter Mac","institutionId":"peter-mac","specialisms":["Prostate cancer","Theranostics","Melanoma","Early-phase trials"],"profiles":[{"label":"Peter MacCallum Cancer Centre","url":"https://www.petermac.org"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sandhu%20S%5BAuthor%5D%20Peter%20MacCallum%20prostate%20PSMA"}],"papers":[{"title":"Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in metastatic hormone-sensitive prostate cancer (UpFrontPSMA)","journal":"Lancet Oncology","year":2024,"doi":"10.1016/S1470-2045(24)00440-6"}],"orcid":"0000-0002-8660-4475"},{"id":"shahrokh-f-shariat","kind":"person","name":"Shahrokh F. Shariat","aka":["Shahrokh Shariat"],"tldr":"Prolific urologic oncologist who chairs Vienna's Department of Urology and leads the Comprehensive Cancer Center of MedUni Wien and AKH.","summary":"Shahrokh F. Shariat is Leiter (Head) of the Comprehensive Cancer Center Vienna, the joint cancer centre of the Medical University of Vienna and Vienna General Hospital (AKH), and Head of its Department of Urology. He is among the most published urologic oncologists internationally and co-authors the European Association of Urology guidelines on bladder and upper-tract urothelial carcinoma. He is also the centre's representative to the Organisation of European Cancer Institutes (OECI), which lists CCC Vienna as an associate member in Austria.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://ccc.meduniwien.ac.at/ueber-uns/die-leitung-des-comprehensive-cancer-center/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Shariat+SF%5BAuthor%5D"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"CCC Vienna website","url":"https://www.ccc.ac.at"}],"tags":["leadership","clinician-scientist","urologic oncology","bladder cancer","oeci-representative"],"related":["oeci"],"cancers":["urothelial","prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ccc-vienna"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["european-urology"],"dependsOn":[],"notes":[],"role":"Head of the Comprehensive Cancer Center Vienna; Head, Department of Urology","institutionId":"ccc-vienna","specialisms":["Urologic oncology","Bladder cancer","Prostate cancer","Clinical guidelines"],"profiles":[{"label":"Institution profile","url":"https://ccc.meduniwien.ac.at/ueber-uns/die-leitung-des-comprehensive-cancer-center/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Shariat+SF%5BAuthor%5D"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"CCC Vienna website","url":"https://www.ccc.ac.at"}],"papers":[{"title":"European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ)","journal":"European Urology","year":2022,"url":"https://doi.org/10.1016/j.eururo.2021.08.010","doi":"10.1016/j.eururo.2021.08.010"},{"title":"European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update","journal":"European Urology","year":2023,"url":"https://doi.org/10.1016/j.eururo.2023.03.013","doi":"10.1016/j.eururo.2023.03.013"},{"title":"European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update","journal":"European Urology","year":2019,"url":"https://doi.org/10.1016/j.eururo.2019.08.016","doi":"10.1016/j.eururo.2019.08.016"},{"title":"EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016","journal":"European Urology","year":2017,"url":"https://doi.org/10.1016/j.eururo.2016.05.041","doi":"10.1016/j.eururo.2016.05.041"}]},{"id":"shaikh-fahad-bin-khalifa-al-khalifa","kind":"person","name":"Shaikh Fahad bin Khalifa bin Salman Al Khalifa","aka":[],"tldr":"Major General and physician who commands Bahrain's Royal Medical Services, the health system that runs King Hamad University Hospital and the national Bahrain Oncology Center.","summary":"Major General Dr Shaikh Fahad bin Khalifa bin Salman Al Khalifa is Commander of the Royal Medical Services (RMS) of the Bahrain Defence Force, the government health system whose hospitals include the Military Hospital, King Hamad University Hospital and the Bahrain Oncology Center, a national centre for haematology-oncology, medical oncology, radiotherapy and bone marrow transplantation. The RMS site carries his message as Commander and reports that a Royal Decree promoted him from Brigadier General to Major General, marked at a meeting with the BDF Commander-in-Chief on 19 November 2025. The King Hamad University Hospital website was unreachable when checked, and the RMS pages fetched do not name a separate director for the oncology centre.","asOf":"2026-09-10","links":[{"label":"Source: RMS about page naming the Commander","url":"https://rms.bh/en/about/"},{"label":"Source: RMS news on his promotion to Major General (November 2025)","url":"https://rms.bh/en/news/bdf-commander-in-chief-received-brig-gen-dr-shaikh-fahad-bin-khalifa/"}],"tags":["leadership","government","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["bahrain-oncology-centre"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Commander of the Royal Medical Services, Bahrain Defence Force (parent body of King Hamad University Hospital and the Bahrain Oncology Center)","institutionId":"bahrain-oncology-centre","specialisms":["Military health system leadership","Hospital governance"],"profiles":[{"label":"Royal Medical Services: About RMS (Commander's message)","url":"https://rms.bh/en/about/"}],"papers":[],"papersExpected":false},{"id":"shailender-bhatia","kind":"person","name":"Shailender Bhatia","aka":[],"tldr":"Seattle oncologist who led STAMP, the trial that showed pembrolizumab after surgery reduces recurrence of Merkel cell carcinoma, a rare and aggressive skin cancer.","summary":"Shailender Bhatia is a medical oncologist at Fred Hutchinson Cancer Center and the University of Washington who focuses on Merkel cell carcinoma and melanoma. He was the study chair and first author of the 2025 New England Journal of Medicine report of the ECOG-ACRIN EA6174 STAMP trial, in which adjuvant pembrolizumab improved recurrence-free survival compared with observation after resection of stage I to III Merkel cell carcinoma.","asOf":"2026-09-18","links":[],"tags":["skin","immunotherapy","trialist"],"related":[],"cancers":["merkel-cell-carcinoma","skin-cancer","melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["fred-hutch"],"pathways":[],"terms":[],"trials":["stamp-merkel"],"people":[],"bottlenecks":[],"keyPapers":["paper-shailender-bhatia-cell-2017","paper-checkmate-238-nejm-2017","paper-keynote-017-n-engl-j-med-2016"],"journals":[],"dependsOn":[],"notes":[],"role":"Medical oncologist, Fred Hutchinson Cancer Center and University of Washington","institutionId":"fred-hutch","specialisms":["Merkel cell carcinoma","Melanoma","Immunotherapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bhatia%5BAuthor%5D"}],"papers":[{"title":"Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab","journal":"Cell","year":2017,"url":"https://doi.org/10.1016/j.cell.2017.09.028","doi":"10.1016/j.cell.2017.09.028","note":"Europe PMC author record matched by affiliation (Fred Hutchinson Cancer Center); 1984 citations on Europe PMC."},{"title":"CheckMate 238: adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","journal":"New England Journal of Medicine","year":2017,"url":"https://doi.org/10.1056/NEJMoa1709030","doi":"10.1056/NEJMoa1709030","note":"Europe PMC author record matched by affiliation (Fred Hutchinson Cancer Center); 1713 citations on Europe PMC."},{"title":"PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma","journal":"New England Journal of Medicine","year":2016,"url":"https://doi.org/10.1056/nejmoa1603702","doi":"10.1056/nejmoa1603702","note":"Europe PMC author record matched by affiliation (Fred Hutchinson Cancer Center); 950 citations on Europe PMC."}],"orcid":"0000-0002-3816-2238"},{"id":"shaji-kumar","kind":"person","name":"Shaji K. Kumar","aka":[],"tldr":"Myeloma trialist who led venetoclax and quadruplet studies and helped define MRD response criteria.","summary":"Shaji Kumar is Professor of Medicine and Chair of the Myeloma, Amyloidosis and Dysproteinemia Group at Mayo Clinic, and leads myeloma trials for the ECOG-ACRIN Cancer Research Group. A haematologist leading myeloma clinical research at Mayo Clinic Rochester, he chaired BELLINI, the trial of venetoclax in t(11;14) myeloma, led quadruplet studies and co-authored the International Myeloma Working Group response and minimal residual disease criteria. His papers include the Lancet Oncology consensus criteria for response and minimal residual disease assessment in multiple myeloma and the BELLINI randomised, double-blind phase 3 trial of venetoclax or placebo with bortezomib and dexamethasone in relapsed or refractory myeloma. His work links venetoclax and MRD testing to multiple myeloma.","asOf":"2026-09-08","links":[{"label":"Mayo Clinic research faculty","url":"https://www.mayo.edu/research/faculty"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kumar%20SK%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Shaji%20K.%20Kumar"}],"tags":[],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":["mrd-testing"],"targets":[],"drugs":["venetoclax"],"companies":["ecog-acrin"],"institutions":["mayo-clinic"],"pathways":[],"terms":["mrd-negativity-myeloma"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medicine; Chair, Myeloma, Amyloidosis and Dysproteinemia Group, Mayo Clinic","institutionId":"mayo-clinic","specialisms":["Multiple myeloma","Clinical trials","MRD"],"profiles":[{"label":"Mayo Clinic research faculty","url":"https://www.mayo.edu/research/faculty"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kumar%20SK%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Shaji%20K.%20Kumar"}],"papers":[{"title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","journal":"Lancet Oncology","year":2016,"url":"https://doi.org/10.1016/S1470-2045(16)30206-6","doi":"10.1016/S1470-2045(16)30206-6"},{"title":"Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial","journal":"Lancet Oncology","year":2020,"url":"https://doi.org/10.1016/S1470-2045(20)30525-8","doi":"10.1016/S1470-2045(20)30525-8"}]},{"id":"shalene-curtis-micallef","kind":"person","name":"Shalene Curtis-Micallef","aka":[],"tldr":"Senior public servant who has led Health Canada as Deputy Minister since January 2026, after serving as Canada's Deputy Minister of Justice.","summary":"Shalene Curtis-Micallef is Deputy Minister of Health at Health Canada, the federal department responsible for health policy, regulation and drug and medical device approvals in Canada. She took up the role on 19 January 2026, having previously been Deputy Minister of Justice and Deputy Attorney General of Canada. At Justice Canada she also served as Executive Director and Senior General Counsel for the Health Portfolio, working on files including tobacco control, cannabis regulation, food safety modernisation and public health. She holds a law degree from Osgoode Hall Law School and a business degree from the University of Ottawa.","asOf":"2026-09-10","links":[{"label":"Source: Health Canada Deputy Minister page","url":"https://www.canada.ca/en/health-canada/corporate/about-health-canada/branches-agencies/deputy-minister.html"}],"tags":["leadership","government","regulation"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["health-canada"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Deputy Minister of Health","institutionId":"health-canada","specialisms":["Public administration","Health law and regulation","Health policy"],"profiles":[{"label":"Health Canada profile","url":"https://www.canada.ca/en/health-canada/corporate/about-health-canada/branches-agencies/deputy-minister.html"}],"papers":[]},{"id":"shalini-singh","kind":"person","name":"Shalini Singh","aka":[],"tldr":"Public health researcher who directs ICMR-NICPR in Noida, the Indian Council of Medical Research's national institute for cancer prevention and research.","summary":"Dr (Prof.) Shalini Singh is Director of the ICMR-National Institute of Cancer Prevention and Research (ICMR-NICPR) in Noida, Uttar Pradesh, a permanent institute of the Indian Council of Medical Research under the Department of Health Research that describes itself as India's premier institution for research in cancer prevention. She signs the 'From the Director's Desk' message on the institute's website, and a WHO FCTC summary of the 7th National Conference on Tobacco or Health (NCTOH 2026), organised by ICMR-NICPR, lists her as session moderator and Director of ICMR-NICPR. The institute grew out of ICMR's Cytology Research Centre, established in 1979, and works on cancer registration, cytology and early detection, tobacco control and tobacco cessation. The institute's websites were under maintenance or blocked automated access at the time of this check, so the director's page was read from an archived copy captured in July 2025.","asOf":"2026-09-10","links":[{"label":"Source: ICMR-NICPR 'From the Director's Desk' page (archived copy)","url":"https://web.archive.org/web/20250717031142/https://nicpr.org/from-the-directors-desk/"},{"label":"Source: WHO FCTC summary of NCTOH 2026 panel discussion listing her as Director ICMR-NICPR","url":"https://extranet.who.int/fctcapps/sites/default/files/2026-04/NCTOH2026_Panel_Discussion_Summary_%21.pdf"}],"tags":["leadership","research-institute","government"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["icmr"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, ICMR-National Institute of Cancer Prevention and Research (NICPR), Noida","institutionId":"icmr-nicpr","specialisms":["Cancer prevention","Tobacco control","Public health research"],"profiles":[{"label":"From the Director's Desk (archived copy, July 2025)","url":"https://web.archive.org/web/20250717031142/https://nicpr.org/from-the-directors-desk/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Singh+S%5BAuthor%5D+AND+NICPR"}],"papers":[{"title":"Microbiome and Development of Ovarian Cancer","journal":"Endocrine, Metabolic & Immune Disorders - Drug Targets","year":2022,"doi":"10.2174/1871530322666220509034847"},{"title":"Risk Reversal of Oral, Pharyngeal and Oesophageal Cancers after Cessation of Betel Quid Users: A Systematic Review and Meta-Analysis","journal":"Annals of Global Health","year":2022,"doi":"10.5334/aogh.3643"}]},{"id":"shane-degaris","kind":"person","name":"Shane DeGaris","aka":[],"tldr":"Group Chief Executive of Barts Health NHS Trust, the London hospital group whose cancer services partner with Barts Cancer Institute.","summary":"Shane DeGaris is Group Chief Executive of Barts Health NHS Trust, one of the largest NHS trusts in England, which runs St Bartholomew's Hospital and its cancer centre in partnership with Queen Mary University of London's Barts Cancer Institute. He leads the executive team alongside the Group Chief Medical Officer. His role is listed on the trust's board page.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.bartshealth.nhs.uk/our-board"}],"tags":["leadership","hospital management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["barts-cancer-institute"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Group Chief Executive, Barts Health NHS Trust","institutionId":"barts-cancer-institute","specialisms":["Health system leadership","Hospital management"],"profiles":[{"label":"Institution profile","url":"https://www.bartshealth.nhs.uk/our-board"}],"papers":[]},{"id":"shankar-siva","kind":"person","name":"Shankar Siva","aka":[],"tldr":"Radiation oncologist who established stereotactic radiotherapy as a non-surgical option for primary kidney cancer.","summary":"Shankar Siva led the FASTRACK trials and the International Radiosurgery Oncology Consortium for Kidney pooled analyses showing stereotactic ablative body radiotherapy achieves near-complete local control of primary renal cell carcinoma in patients unfit for surgery, and leads TROG trials of SABR in oligometastatic prostate and lung cancer and of radiotherapy-immunotherapy combinations. He chairs the TROG genitourinary group.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Siva%20S%5BAuthor%5D%20stereotactic%20kidney"}],"tags":["radiotherapy","sbrt","kidney","australia"],"related":[],"cancers":["rcc","prostate"],"sections":[],"technologies":["sbrt"],"targets":[],"drugs":[],"companies":["trog"],"institutions":["peter-mac"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor and Director of Radiation Oncology Research, Peter MacCallum Cancer Centre","institutionId":"peter-mac","specialisms":["Stereotactic radiotherapy","Kidney cancer","Oligometastatic disease","Radiotherapy-immunotherapy combinations"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Siva%20S%5BAuthor%5D%20stereotactic%20kidney"}],"papers":[{"title":"Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial","journal":"Lancet Oncology","year":2024,"doi":"10.1016/S1470-2045(24)00020-2"},{"title":"Five-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK","journal":"Lancet Oncology","year":2022,"doi":"10.1016/S1470-2045(22)00656-8"}]},{"id":"shannon-westin","kind":"person","name":"Shannon N. Westin","aka":[],"tldr":"Houston gynaecologic oncologist who led DUO-E, the trial that added durvalumab, with or without olaparib, to first-line chemotherapy for advanced endometrial cancer.","summary":"Shannon Westin is a gynaecologic oncologist and clinical trialist at MD Anderson Cancer Center. She was first author of the 2023 Journal of Clinical Oncology report of DUO-E, the phase 3 trial in which durvalumab with carboplatin and paclitaxel, followed by durvalumab with or without olaparib maintenance, improved progression-free survival in newly diagnosed advanced or recurrent endometrial cancer, with the largest benefit in mismatch repair-deficient tumours.","asOf":"2026-09-18","links":[],"tags":["endometrial","gynaecological","trialist"],"related":[],"cancers":["advanced-recurrent-endometrial-cancer","endometrial","ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-duo-e-jco-2023"],"journals":[],"dependsOn":[],"notes":[],"role":"Gynaecologic oncologist, MD Anderson Cancer Center","institutionId":"md-anderson","specialisms":["Endometrial cancer","Ovarian cancer","Targeted and immune therapy trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Westin%5BAuthor%5D"}],"papers":[{"title":"DUO-E: durvalumab with carboplatin-paclitaxel and maintenance durvalumab with or without olaparib in advanced endometrial cancer","journal":"Journal of Clinical Oncology","year":2024,"url":"https://doi.org/10.1200/JCO.23.02132","doi":"10.1200/JCO.23.02132"}],"orcid":"0000-0002-1922-0156"},{"id":"shanu-modi","kind":"person","name":"Shanu Modi","aka":[],"tldr":"Led DESTINY-Breast01 and DESTINY-Breast04, the trials that created the HER2-low category and opened T-DXd to most breast cancers.","summary":"Shanu Modi was lead investigator of DESTINY-Breast01, the study that won trastuzumab deruxtecan its first approval, and of DESTINY-Breast04, which showed the ADC halves the risk of progression in HER2-low disease previously treated as HER2-negative. That trial redefined breast cancer classification and extended ADC therapy to roughly half of all patients. She continues to lead ADC trials at MSKCC.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Modi%20S%5BAuthor%5D%20trastuzumab%20deruxtecan"}],"tags":["breast","adc","her2-low"],"related":[],"cancers":["breast-her2-positive","breast-hr-positive","tnbc"],"sections":[],"technologies":["adc"],"targets":["her2"],"drugs":["trastuzumab-deruxtecan"],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":["destiny-breast04"],"people":[],"bottlenecks":[],"keyPapers":["paper-destiny-breast04-nejm-2022"],"journals":[],"dependsOn":[],"notes":[],"role":"Breast Medical Oncologist, Memorial Sloan Kettering Cancer Center","institutionId":"mskcc","specialisms":["HER2-directed therapy","HER2-low breast cancer","Antibody-drug conjugates"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Modi%20S%5BAuthor%5D%20trastuzumab%20deruxtecan"}],"papers":[{"title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer (DESTINY-Breast01)","journal":"NEJM","year":2020,"doi":"10.1056/NEJMoa1914510"},{"title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer (DESTINY-Breast04)","journal":"NEJM","year":2022,"doi":"10.1056/NEJMoa2203690"}],"orcid":"0000-0001-6427-7373"},{"id":"song-shaoli","kind":"person","name":"Shaoli Song","aka":[],"tldr":"Leads the nuclear medicine group behind the first human TROP2 PET imaging, aiming to pick patients for TROP2 ADCs with a scan.","summary":"Shaoli Song is Professor and Director of the Department of Nuclear Medicine at Fudan University Shanghai Cancer Center. Her department developed and imaged the first TROP2-targeted PET tracers in patients with breast and other cancers, with the aim of selecting patients for TROP2 antibody-drug conjugates using a scan, alongside FAPI, HER2 and PSMA theranostic work. Her publications include head-to-head comparisons of FDG and FAPI PET-CT in recurrent soft tissue sarcoma and in platinum-sensitive recurrent ovarian cancer, and a study of preoperative FDG PET parameters for predicting microvascular invasion and recurrence in hepatocellular carcinoma. Her interests are PET tracer development and theranostics.","asOf":"2026-09-08","links":[{"label":"Fudan University Shanghai Cancer Center","url":"https://www.shca.org.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Song%20S%5BAuthor%5D%20Fudan%20TROP2%20PET"}],"tags":[],"related":[],"cancers":["tnbc"],"sections":[],"technologies":["trop2-pet","fapi-pet","her2-pet"],"targets":["trop2","fap"],"drugs":[],"companies":[],"institutions":["fuscc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor and Director, Department of Nuclear Medicine, Fudan University Shanghai Cancer Center","institutionId":"fuscc","specialisms":["Nuclear medicine","PET tracer development","TROP2 and HER2 PET","Theranostics"],"profiles":[{"label":"Fudan University Shanghai Cancer Center","url":"https://www.shca.org.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Song%20S%5BAuthor%5D%20Fudan%20TROP2%20PET"}],"papers":[{"title":"Head-to-head evaluation of [18F]FDG and [68 Ga]Ga-DOTA-FAPI-04 PET/CT in recurrent soft tissue sarcoma","journal":"European Journal of Nuclear Medicine and Molecular Imaging","year":2022,"doi":"10.1007/s00259-022-05700-4"},{"title":"Head-to-head comparison of [18F]-FDG and [68 Ga]-DOTA-FAPI-04 PET/CT for radiological evaluation of platinum-sensitive recurrent ovarian cancer","journal":"European Journal of Nuclear Medicine and Molecular Imaging","year":2023,"doi":"10.1007/s00259-022-06096-x"},{"title":"The value of preoperative 18F-FDG PET metabolic and volumetric parameters in predicting microvascular invasion and postoperative recurrence of hepatocellular carcinoma","journal":"Nuclear Medicine Communications","year":2021,"doi":"10.1097/mnm.0000000000001478"}]},{"id":"shaomeng-wang","kind":"person","name":"Shaomeng Wang","aka":[],"tldr":"Shaomeng Wang is the medicinal chemist behind some of the first clinical MDM2 inhibitors and PROTAC degraders.","summary":"Shaomeng Wang is the Warner-Lambert/Parke-Davis Professor in Medicine and Director of Rogel Cancer Center Drug Discovery at the University of Michigan. He is the medicinal chemist behind some of the first clinical MDM2 inhibitors and PROTAC degraders, having designed MDM2 inhibitors, BET and androgen receptor degraders, and the first STAT3 degrader to enter clinical trials. His selected paper reports a selective small-molecule STAT3 degrader that achieves complete tumour regression in vivo. He has founded several oncology biotechs and continues to work on targeted protein degradation.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wang%20S%5BAuthor%5D"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["protac-degrader"],"targets":["tp53","androgen-receptor"],"drugs":[],"companies":[],"institutions":["michigan-rogel"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Warner-Lambert/Parke-Davis Professor in Medicine; Director, Rogel Cancer Center Drug Discovery","institutionId":"michigan-rogel","specialisms":["Medicinal chemistry","Protein degraders","MDM2 and BET inhibitors"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wang%20S%5BAuthor%5D"}],"papers":[{"title":"A selective small-molecule STAT3 degrader achieves complete tumor regression in vivo","journal":"Cancer Cell","year":2019,"url":"https://doi.org/10.1016/j.ccell.2019.10.002","doi":"10.1016/j.ccell.2019.10.002"}],"orcid":"0000-0002-8782-6950"},{"id":"shari-pilon-thomas","kind":"person","name":"Shari Pilon-Thomas","aka":[],"tldr":"Shari Pilon-Thomas is the immunologist behind Moffitt's TIL manufacturing and the biology of who responds.","summary":"Shari Pilon-Thomas is a Senior Member in Immunology and Scientific Director of Cellular Therapy at Moffitt Cancer Center. She is the immunologist behind Moffitt's tumour-infiltrating lymphocyte manufacturing and the biology of who responds to it, leading translational immunology for the centre's TIL and cell therapy programmes. Her selected paper shows that neutralising tumour acidity improves anti-tumour responses to immunotherapy. She continues to study tumour acidity and resistance to immunotherapy in melanoma.","asOf":"2026-09-08","links":[{"label":"Moffitt profile","url":"https://www.moffitt.org/research-science/researchers/shari-pilon-thomas/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Pilon-Thomas%20S%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["melanoma"],"sections":[],"technologies":["til-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":["moffitt"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["cancer-research"],"dependsOn":[],"notes":[],"role":"Senior Member, Immunology; Scientific Director, Cellular Therapy","institutionId":"moffitt","specialisms":["TIL therapy","Tumour immunology","Immunotherapy resistance"],"profiles":[{"label":"Moffitt profile","url":"https://www.moffitt.org/research-science/researchers/shari-pilon-thomas/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Pilon-Thomas%20S%5BAuthor%5D"}],"papers":[{"title":"Neutralization of tumor acidity improves antitumor responses to immunotherapy","journal":"Cancer Research","year":2016,"url":"https://doi.org/10.1158/0008-5472.CAN-15-1743","doi":"10.1158/0008-5472.CAN-15-1743"}]},{"id":"sharon-armstrong","kind":"person","name":"Sharon Armstrong","aka":[],"tldr":"Clinical Director of specialist oncology services at the Beatson West of Scotland Cancer Centre, Scotland's largest cancer treatment centre.","summary":"Dr Sharon Armstrong is Clinical Director for Specialist Oncology Services at the Beatson West of Scotland Cancer Centre in Glasgow, part of NHS Greater Glasgow and Clyde. She leads the clinical management of the centre, which provides radiotherapy and systemic anti-cancer therapy for the West of Scotland population.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.beatson.scot.nhs.uk/about-us/meet-the-management-team/"}],"tags":["leadership","clinical oncology"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["beatson-glasgow"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Clinical Director Specialist Oncology Services","institutionId":"beatson-glasgow","specialisms":["Clinical oncology","Cancer service leadership"],"profiles":[{"label":"Institution profile","url":"https://www.beatson.scot.nhs.uk/about-us/meet-the-management-team/"}],"papers":[]},{"id":"sharon-belvin","kind":"person","name":"Sharon Belvin","aka":[],"tldr":"Diagnosed with metastatic melanoma at 22, she received the anti-CTLA-4 antibody ipilimumab in an early trial at Memorial Sloan Kettering and has been cancer-free since. Her meeting with James Allison in 2006 is part of immunotherapy's history.","summary":"Sharon Belvin was diagnosed with stage IV melanoma in 2004, at 22, shortly before her wedding, and the disease progressed through chemotherapy and interleukin-2. In 2005 she was enrolled by Jedd Wolchok at Memorial Sloan Kettering in a trial of ipilimumab, the anti-CTLA-4 antibody based on James Allison's work; within months her tumours had gone and they have not returned. In 2006 Wolchok introduced her to Allison, a meeting Allison has described as the point at which he understood that his laboratory work had become a treatment. Ipilimumab was approved by the FDA in March 2011, the first drug to extend survival in metastatic melanoma in a randomised trial, and the first of the checkpoint inhibitors. She appears in the 2019 documentary Jim Allison: Breakthrough and speaks for the early trial participants who took an unproven approach when nothing else worked.","asOf":"2026-09-09","links":[{"label":"James P. Allison (Wikipedia)","url":"https://en.wikipedia.org/wiki/James_P._Allison"},{"label":"Memorial Sloan Kettering","url":"https://www.mskcc.org/"}],"tags":["hero","patient"],"related":[],"cancers":["melanoma"],"sections":["immunotherapy"],"technologies":["checkpoint-inhibitor"],"targets":["ctla4"],"drugs":["ipilimumab","aldesleukin"],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":[],"people":["james-allison"],"bottlenecks":["b-trial-enrolment","b-immunotherapy-response"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Early complete responder to ipilimumab whose recovery Jim Allison called the moment he knew","specialisms":["Melanoma","Checkpoint immunotherapy","Clinical trial participation"],"profiles":[{"label":"James P. Allison (Wikipedia)","url":"https://en.wikipedia.org/wiki/James_P._Allison"},{"label":"Memorial Sloan Kettering","url":"https://www.mskcc.org/"}],"papers":[]},{"id":"loi-sherene","kind":"person","name":"Sherene Loi","aka":[],"tldr":"Showed that immune cells inside breast tumours predict outcome, the basis for de-escalating chemotherapy in TNBC.","summary":"Sherene Loi is Professor and Head of the Translational Breast Cancer Genomics and Therapeutics Laboratory at the Peter MacCallum Cancer Centre in Melbourne, where she is also a medical oncologist. Her work on tumour-infiltrating lymphocytes established them as a prognostic and predictive biomarker in breast cancer, showing that immune cells inside tumours predict outcome and underpinning current efforts to spare patients with stage I triple-negative breast cancer from chemotherapy. Her publications include a pooled individual patient analysis of tumour-infiltrating lymphocytes and prognosis in early-stage triple-negative breast cancer. She leads immunotherapy trials, including work connected to KEYNOTE-522, and chairs the International Immuno-Oncology Biomarker Working Group.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Sherene_Loi","links":[{"label":"Peter MacCallum Cancer Centre","url":"https://www.petermac.org"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Loi%20S%5BAuthor%5D%20tumor%20infiltrating%20lymphocytes%20breast"}],"tags":[],"related":[],"cancers":["tnbc","breast-hr-positive"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":[],"companies":[],"institutions":["peter-mac"],"pathways":[],"terms":["tils"],"trials":["keynote-522"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor and Head, Translational Breast Cancer Genomics and Therapeutics Laboratory; medical oncologist, Peter Mac","institutionId":"peter-mac","specialisms":["Breast cancer","Tumour-infiltrating lymphocytes","Immunotherapy","Triple-negative breast cancer"],"profiles":[{"label":"Peter MacCallum Cancer Centre","url":"https://www.petermac.org"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Loi%20S%5BAuthor%5D%20tumor%20infiltrating%20lymphocytes%20breast"}],"papers":[{"title":"Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers","journal":"Journal of Clinical Oncology","year":2019,"doi":"10.1200/JCO.18.01010"},{"title":"NATALEE: three years of ribociclib after surgery in a broad population of hormone-receptor-positive early breast cancer","journal":"New England Journal of Medicine","year":2024,"url":"https://doi.org/10.1056/NEJMoa2305488","doi":"10.1056/NEJMoa2305488"}]},{"id":"sherif-abouel-naga","kind":"person","name":"Sherif Abouel Naga","aka":[],"tldr":"Paediatric oncologist who is chief executive of the 57357 group and general manager of Children's Cancer Hospital Egypt 57357 in Cairo.","summary":"Prof. Dr. Sherif Abouel Naga is CEO of the 57357 group and General Manager of Hospital 57357, the Children's Cancer Hospital Egypt in Cairo, and Secretary General of the Association of Friends of the National Cancer-free Initiative (AFNCI), the association that governs the hospital. He is Professor of Paediatric Oncology at the National Cancer Institute, Cairo University. The hospital's board of directors page lists him alongside AFNCI board chairman Eng. Lotfy El Badrawy and vice chairman Mahmoud Altohamy. The hospital, named after the donation account number used in its fundraising, opened in 2007 and has about 320 beds.","asOf":"2026-09-10","links":[{"label":"Source: 57357 Board of Directors / AFNCI page (archived copy, December 2025; live site blocks automated access)","url":"https://web.archive.org/web/20251207101158/https://www.57357.org/en/board-of-directors-afnci"},{"label":"Source: Wikipedia article on Children's Cancer Hospital Egypt","url":"https://en.wikipedia.org/wiki/Children%27s_Cancer_Hospital_Egypt"}],"tags":["leadership","hospital-management","philanthropy"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["nci-cairo"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"CEO of the 57357 Group and General Manager of Children's Cancer Hospital Egypt 57357","institutionId":"cche-57357","specialisms":["Paediatric oncology","Hospital management","Philanthropic healthcare"],"profiles":[{"label":"57357 board of directors page","url":"https://www.57357.org/en/board-of-directors-afnci"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Abouelnaga+S%5BAuthor%5D+OR+Abou+El+Naga+S%5BAuthor%5D"}],"papers":[{"title":"The journey to pharmacy residency program accreditation: The Children’s Cancer Hospital–Egypt experience","journal":"American Journal of Health-System Pharmacy","year":2022,"doi":"10.1093/ajhp/zxac214"},{"title":"Outcome and Prognostic Factors of Acute Lymphoblastic Leukemia in Children at the National Cancer Institute, Egypt","journal":"Journal of Pediatric Hematology/Oncology","year":2004,"doi":"10.1097/01.mph.0000132735.93396.92"}]},{"id":"sherry-lansing","kind":"person","name":"Sherry Lansing","aka":[],"tldr":"The former Paramount chief co-founded Stand Up To Cancer, whose televised specials and Dream Teams have pledged over $800 million to collaborative research that fed into several approved cancer drugs.","summary":"Sherry Lansing, the first woman to run a major Hollywood studio, co-founded Stand Up To Cancer in 2008 with Katie Couric, Kathleen Lobb, Lisa Paulsen, Rusty Robertson, Sue Schwartz, Pamela Oas Williams and Ellen Ziffren, after leaving Paramount to work on cancer through the Sherry Lansing Foundation. SU2C's inaugural televised special aired simultaneously on ABC, CBS and NBC. Its own account states that over $800 million has been pledged to its research portfolio and that it has funded more than 3,100 researchers through Dream Teams that must span institutions and share data. SU2C credits research it funded with contributing to approvals including tisagenlecleucel CAR-T therapy, palbociclib with letrozole in breast cancer, olaparib in prostate cancer, alpelisib with fulvestrant, and encorafenib with cetuximab in colorectal cancer. Its model, entertainment money attached to enforced collaboration, has been copied in other diseases.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Sherry_Lansing","links":[{"label":"Stand Up To Cancer: our story","url":"https://standuptocancer.org/who-we-are/our-story/"}],"tags":["public-figure","donor"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["tisagenlecleucel","palbociclib","olaparib","alpelisib","encorafenib"],"companies":[],"institutions":["stand-up-to-cancer"],"pathways":[],"terms":[],"trials":[],"people":["katie-couric"],"bottlenecks":["b-ip-collaboration","b-funding-allocation"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Film executive who co-founded Stand Up To Cancer in 2008","specialisms":["Cancer research fundraising","Team science","Entertainment philanthropy"],"profiles":[],"papers":[]},{"id":"shilpa-gupta","kind":"person","name":"Shilpa Gupta","aka":[],"tldr":"Genitourinary oncologist leading bladder and kidney cancer trials and national guideline work.","summary":"Shilpa Gupta is Director of Genitourinary Medical Oncology at Cleveland Clinic Taussig Cancer Institute. She is a genitourinary oncologist known for leading bladder and kidney cancer trials, as an investigator on enfortumab vedotin, immunotherapy and adjuvant renal cell carcinoma studies, and for national guideline work as co-chair of national bladder cancer committees. Her selected paper reports enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer. She directs GU medical oncology at Cleveland Clinic and continues immunotherapy trials in bladder and kidney cancer.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gupta%20S%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["urothelial","rcc"],"sections":[],"technologies":[],"targets":[],"drugs":["enfortumab-vedotin","pembrolizumab"],"companies":[],"institutions":["cleveland-clinic"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Genitourinary Medical Oncology","institutionId":"cleveland-clinic","specialisms":["Bladder cancer","Kidney cancer","Immunotherapy trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gupta%20S%5BAuthor%5D"}],"papers":[{"title":"Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer","journal":"New England Journal of Medicine","year":2024},{"title":"EV-302: enfortumab vedotin plus pembrolizumab replaces chemotherapy as first treatment for advanced bladder cancer","journal":"New England Journal of Medicine","year":2024,"url":"https://doi.org/10.1056/NEJMoa2312117","doi":"10.1056/NEJMoa2312117"}]},{"id":"shimon-sakaguchi","kind":"person","name":"Shimon Sakaguchi","aka":[],"tldr":"Discovered regulatory T cells, the immune cells that suppress anti-tumour responses and are now a target for cancer therapy.","summary":"Shimon Sakaguchi (Osaka University) identified CD25-positive regulatory T cells in 1995 and demonstrated their role in preventing autoimmunity, a discovery that overturned prevailing dogma and defined a cell type that tumours recruit to escape immune attack. He received the 2025 Nobel Prize in Physiology or Medicine with Mary Brunkow and Fred Ramsdell. His laboratory works on Treg depletion and modulation for cancer immunotherapy.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sakaguchi%20S%5BAuthor%5D%20regulatory%20T%20cells"}],"tags":["immunology","regulatory-t-cells","discovery","japan"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["cd25"],"drugs":[],"companies":[],"institutions":["osaka-university"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["cell"],"dependsOn":[],"notes":[],"role":"Distinguished Professor, Immunology Frontier Research Center, Osaka University","institutionId":"osaka-university","specialisms":["Regulatory T cells","Immune tolerance","Autoimmunity","Tumour immunology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sakaguchi%20S%5BAuthor%5D%20regulatory%20T%20cells"}],"papers":[{"title":"Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25)","journal":"Journal of Immunology","year":1995},{"title":"Regulatory T cells and immune tolerance","journal":"Cell","year":2008,"doi":"10.1016/j.cell.2008.05.009"}],"orcid":"0000-0001-8265-6094"},{"id":"ohno-shinji","kind":"person","name":"Shinji Ohno","aka":[],"tldr":"A senior breast cancer specialist who has led Japanese arms of adjuvant and metastatic breast cancer trials for two decades.","summary":"Shinji Ohno is Director of the Breast Oncology Center at the Cancer Institute Hospital of JFCR in Tokyo. A senior breast cancer specialist, he has led Japanese arms of adjuvant and metastatic breast cancer trials for two decades, serving as an investigator on CDK4/6, HER2 and adjuvant endocrine trials with Japanese cohorts. His publications include the ESMO Clinical Practice Guidelines for early and primary breast cancer and a machine learning study predicting disease-free survival and brain metastasis in HER2-positive patients treated with neoadjuvant chemotherapy plus trastuzumab. His interests are breast cancer, adjuvant therapy and clinical trials.","asOf":"2026-09-08","links":[{"label":"Cancer Institute Hospital of JFCR","url":"https://www.jfcr.or.jp/english/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ohno%20S%5BAuthor%5D%20breast%20cancer%20Cancer%20Institute%20Hospital"}],"tags":[],"related":[],"cancers":["breast-hr-positive","breast-her2-positive"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["jfcr"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["breast-cancer-research-and-treatment"],"dependsOn":[],"notes":[],"role":"Director, Breast Oncology Center, Cancer Institute Hospital of JFCR","institutionId":"jfcr","specialisms":["Breast cancer","Adjuvant therapy","Clinical trials"],"profiles":[{"label":"Cancer Institute Hospital of JFCR","url":"https://www.jfcr.or.jp/english/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ohno%20S%5BAuthor%5D%20breast%20cancer%20Cancer%20Institute%20Hospital"}],"papers":[{"title":"Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","journal":"Annals of Oncology","year":2019,"doi":"10.1093/annonc/mdz173"},{"title":"Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","journal":"Annals of Oncology","year":2015,"doi":"10.1093/annonc/mdv298"},{"title":"Prediction of postoperative disease-free survival and brain metastasis for HER2-positive breast cancer patients treated with neoadjuvant chemotherapy plus trastuzumab using a machine learning algorithm","journal":"Breast Cancer Research and Treatment","year":2018,"doi":"10.1007/s10549-018-4958-9"}]},{"id":"shivaani-kummar","kind":"person","name":"Shivaani Kummar","aka":[],"tldr":"Drug development oncologist who directs the OHSU Knight Cancer Institute.","summary":"Shivaani Kummar is Director of the OHSU Knight Cancer Institute and Chief Scientific and Academic Officer of the Knight Cancer Group. A medical oncologist who previously led early clinical trials programmes at the US National Cancer Institute and Stanford, her research focuses on phase I trials, pharmacodynamic biomarkers and precision oncology.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Shivaani_Kummar","links":[{"label":"Institution profile","url":"https://www.ohsu.edu/knight-cancer-institute/knight-cancer-institute-leaders"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kummar+S%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","drug development","precision oncology"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ohsu-knight"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["cancer-discovery","nature-reviews-cancer","cancers-mdpi"],"dependsOn":[],"notes":[],"role":"Chief Scientific and Academic Officer, Knight Cancer Group and Director, Knight Cancer Institute","institutionId":"ohsu-knight","specialisms":["Early-phase drug development","Medical oncology","Precision oncology"],"profiles":[{"label":"Institution profile","url":"https://www.ohsu.edu/knight-cancer-institute/knight-cancer-institute-leaders"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kummar+S%5BAuthor%5D"}],"papers":[{"title":"Tissue-Agnostic Drug Development: A New Path to Drug Approval","journal":"Cancer Discovery","year":2021,"doi":"10.1158/2159-8290.cd-21-0554"},{"title":"Compressing drug development timelines in oncology using phase '0' trials","journal":"Nature Reviews Cancer","year":2007,"doi":"10.1038/nrc2066"},{"title":"Target-Driven Tissue-Agnostic Drug Approvals—A New Path of Drug Development","journal":"Cancers","year":2024,"doi":"10.3390/cancers16142529"}]},{"id":"shlomi-codish","kind":"person","name":"Shlomi Codish","aka":[],"tldr":"Internal medicine physician and medical informatics specialist who leads Soroka University Medical Center in Beersheba, the largest hospital in southern Israel.","summary":"Prof. Shlomi Codish leads Soroka University Medical Center in Beersheba as Director General. Soroka is a Clalit Health Services hospital with about 1,191 beds, the teaching hospital of Ben-Gurion University's Faculty of Health Sciences and the only major medical centre and Level 1 trauma centre for the roughly one million residents of the Negev; it is home to the Legacy Heritage Oncology Center and Dr Larry Norton Institute. Codish is an internal medicine physician who trained at Ben-Gurion University and Soroka, completed postdoctoral training in medical informatics at Yale, and previously served as Soroka's Deputy Director General and as Medical Director of Clalit's Southern District.","asOf":"2026-09-10","links":[{"label":"Source: Wikipedia article on Soroka Medical Center naming the director general","url":"https://en.wikipedia.org/wiki/Soroka_Medical_Center"},{"label":"Source: Wikipedia biography of Shlomi Codish","url":"https://en.wikipedia.org/wiki/Shlomi_Codish"}],"tags":["leadership","clinician-scientist","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["soroka-medical-center"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director General, Soroka University Medical Center","institutionId":"soroka-medical-center","specialisms":["Internal medicine","Medical informatics","Hospital management"],"profiles":[{"label":"Wikipedia (Soroka Medical Center)","url":"https://en.wikipedia.org/wiki/Soroka_Medical_Center"},{"label":"Wikipedia (Shlomi Codish)","url":"https://en.wikipedia.org/wiki/Shlomi_Codish"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Codish+S%5BAuthor%5D"}],"papers":[{"title":"A randomized, double-blind, placebo-controlled trial of selective digestive decontamination using oral gentamicin and oral polymyxin E for eradication of carbapenem-resistant Klebsiella pneumoniae carriage","journal":"Infect Control Hosp Epidemiol","year":2012,"url":"https://doi.org/10.1086/663206","doi":"10.1086/663206","note":"Europe PMC author record matched by affiliation"},{"title":"Validation of Contact-Free Sleep Monitoring Device with Comparison to Polysomnography","journal":"J Clin Sleep Med","year":2017,"url":"https://doi.org/10.5664/jcsm.6514","doi":"10.5664/jcsm.6514","note":"Europe PMC author record matched by affiliation"},{"title":"The role of cardiac troponin I as a prognosticator in critically ill medical patients: a prospective observational cohort study","journal":"Crit Care","year":2005,"url":"https://doi.org/10.1186/cc3731","doi":"10.1186/cc3731","note":"Europe PMC author record matched by affiliation"}],"orcid":"0009-0002-0737-0795"},{"id":"qin-shukui","kind":"person","name":"Shukui Qin","aka":["Qin Shu-Kui","秦叔逵"],"tldr":"Shukui Qin has led most of the Chinese liver cancer trials of the past decade, including the ones that put camrelizumab plus rivoceranib and donafenib into first-line use.","summary":"Principal investigator of CARES-310 (camrelizumab plus rivoceranib versus sorafenib, Lancet 2023), the donafenib versus sorafenib trial (Journal of Clinical Oncology 2021), apatinib in second-line HCC and many Chinese cohorts of global liver cancer trials; past president of the CSCO and author of its liver cancer guidelines. His trials reflect the hepatitis B-driven Chinese HCC population that differs from Western cohorts.","asOf":"2026-09-10","links":[{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Qin%20S%5BAuthor%5D%20hepatocellular%20carcinoma%20Nanjing"}],"tags":["china"],"related":["csco"],"cancers":["hcc"],"sections":[],"technologies":[],"targets":[],"drugs":["camrelizumab-rivoceranib","donafenib","rivoceranib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["cares-310","zgdh3"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology; Nanjing Tianyinshan Hospital, China Pharmaceutical University (formerly Jinling Hospital, Nanjing)","specialisms":["Hepatocellular carcinoma","Gastrointestinal oncology","Clinical trials"],"profiles":[{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Qin%20S%5BAuthor%5D%20hepatocellular%20carcinoma%20Nanjing"}],"papers":[{"title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310)","journal":"Lancet","year":2023,"doi":"10.1016/S0140-6736(23)00961-3"},{"title":"Donafenib versus sorafenib in first-line treatment of unresectable or metastatic hepatocellular carcinoma (ZGDH3)","journal":"Journal of Clinical Oncology","year":2021,"doi":"10.1200/JCO.20.02672"}]},{"id":"lu-shun","kind":"person","name":"Shun Lu","aka":["shun-lu"],"tldr":"A Shanghai lung cancer trialist who has led many Chinese PD-1 and EGFR-TKI phase 3 studies.","summary":"Shun Lu is Professor and Director of the Shanghai Lung Cancer Center at Shanghai Chest Hospital and a leader of the Chinese Thoracic Oncology Group. He has been principal investigator for many Chinese phase 3 trials, including sintilimab and tislelizumab combinations in non-small-cell lung cancer and studies of furmonertinib and other EGFR inhibitors. His publications include the AENEAS trial of aumolertinib against gefitinib as first-line therapy for EGFR-mutated lung cancer, the trial of osimertinib after chemoradiotherapy in stage III EGFR-mutated disease, and the LUX-Lung 7 comparison of afatinib and gefitinib. His interests are immunotherapy, EGFR tyrosine kinase inhibitors and clinical trials. He has also co-authored global registrational trials of targeted therapy and immunotherapy, including ADAURA, CheckMate 816 and MARIPOSA, and his work has shaped EGFR- and ALK-directed treatment in East Asian populations.","asOf":"2026-09-08","links":[{"label":"Shanghai Chest Hospital","url":"https://www.shxkyy.com"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lu%20S%5BAuthor%5D%20Shanghai%20Chest%20Hospital%20lung%20cancer"}],"tags":["clinician-scientist","lung cancer","targeted therapy"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":[],"targets":["egfr","pd1"],"drugs":["tislelizumab"],"companies":["ctong"],"institutions":["shanghai-chest-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor; Director, Shanghai Lung Cancer Center, Shanghai Chest Hospital","institutionId":"shanghai-chest-hospital","specialisms":["Lung cancer","Immunotherapy","EGFR-TKIs","Clinical trials","Targeted therapy"],"profiles":[{"label":"Shanghai Chest Hospital","url":"https://www.shxkyy.com"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lu%20S%5BAuthor%5D%20Shanghai%20Chest%20Hospital%20lung%20cancer"}],"papers":[{"title":"AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations","journal":"Journal of Clinical Oncology","year":2022,"doi":"10.1200/jco.21.02641"},{"title":"Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC","journal":"New England Journal of Medicine","year":2024,"doi":"10.1056/nejmoa2402614"},{"title":"Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial","journal":"The Lancet Oncology","year":2016,"doi":"10.1016/s1470-2045(16)30033-x"},{"title":"Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer","journal":"New England Journal of Medicine","year":2020,"doi":"10.1056/NEJMoa2027071"},{"title":"Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer","journal":"New England Journal of Medicine","year":2022,"doi":"10.1056/NEJMoa2202170"},{"title":"Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC","journal":"New England Journal of Medicine","year":2024,"doi":"10.1056/NEJMoa2403614"}],"orcid":"0000-0001-8833-7262"},{"id":"takahashi-shunji","kind":"person","name":"Shunji Takahashi","aka":[],"tldr":"Shunji Takahashi leads medical oncology and early-phase trials at Japan's oldest cancer institute.","summary":"Shunji Takahashi is Director of the Department of Medical Oncology at the Cancer Institute Hospital of JFCR, Japan's oldest cancer institute. He leads medical oncology and early-phase trials there, running phase 1 and rare-cancer studies, including sarcoma, and the hospital's genomic medicine programme built on comprehensive genomic profiling. His publications include a phase 1 study of the MDM2 inhibitor milademetan in Japanese patients with solid tumours, a phase 1 study of dasatinib in Japanese patients with solid tumours, and an integrated analysis of osteonecrosis of the jaw across three phase 3 trials in patients with bone metastases. His interests are phase 1 trials, rare cancers and genomic medicine.","asOf":"2026-09-08","links":[{"label":"Cancer Institute Hospital of JFCR","url":"https://www.jfcr.or.jp/english/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Takahashi%20S%5BAuthor%5D%20Cancer%20Institute%20Hospital%20JFCR"}],"tags":[],"related":[],"cancers":["sarcoma"],"sections":[],"technologies":["cgp"],"targets":[],"drugs":[],"companies":[],"institutions":["jfcr"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["cancer-science"],"dependsOn":[],"notes":[],"role":"Director, Department of Medical Oncology, Cancer Institute Hospital of JFCR","institutionId":"jfcr","specialisms":["Medical oncology","Phase 1 trials","Rare cancers","Genomic medicine"],"profiles":[{"label":"Cancer Institute Hospital of JFCR","url":"https://www.jfcr.or.jp/english/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Takahashi%20S%5BAuthor%5D%20Cancer%20Institute%20Hospital%20JFCR"}],"papers":[{"title":"Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study","journal":"Cancer Science","year":2021,"doi":"10.1111/cas.14875"},{"title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","journal":"Annals of Oncology","year":2012,"doi":"10.1093/annonc/mdr435"},{"title":"Phase I study of dasatinib (BMS‐354825) in Japanese patients with solid tumors","journal":"Cancer Science","year":2011,"doi":"10.1111/j.1349-7006.2011.02041.x"}]},{"id":"sibylle-loibl","kind":"person","name":"Sibylle Loibl","aka":[],"tldr":"Leads the German Breast Group, whose GeparX trials defined neoadjuvant chemotherapy and immunotherapy in breast cancer.","summary":"Sibylle Loibl is Chief Executive Officer and Chair of the German Breast Group (GBG). Her specialisms are breast cancer, neoadjuvant trials and pathological complete response. She led GeparSixto, GeparNuevo and GeparDouze, trials of carboplatin and immunotherapy before surgery in triple-negative and HER2-positive breast cancer that shaped today's standards. Her Annals of Oncology paper on GeparNuevo reported a randomised phase II study of durvalumab added to anthracycline and taxane-based neoadjuvant therapy in early triple-negative breast cancer. Her German Breast Group profile and PubMed listing are linked.","asOf":"2026-09-08","links":[{"label":"German Breast Group","url":"https://www.gbg.de/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Loibl%20S%5BAuthor%5D%20neoadjuvant%20breast"}],"tags":[],"related":[],"cancers":["tnbc","breast-her2-positive"],"sections":[],"technologies":[],"targets":[],"drugs":["carboplatin","durvalumab"],"companies":["gbg"],"institutions":[],"pathways":[],"terms":["pcr"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive Officer and Chair, German Breast Group","institutionId":"gbg","specialisms":["Breast cancer","Neoadjuvant trials","Pathologic complete response"],"profiles":[{"label":"German Breast Group","url":"https://www.gbg.de/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Loibl%20S%5BAuthor%5D%20neoadjuvant%20breast"}],"papers":[{"title":"A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer (GeparNuevo)","journal":"Annals of Oncology","year":2019,"doi":"10.1093/annonc/mdz158"},{"title":"ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer","journal":"New England Journal of Medicine","year":2021,"url":"https://doi.org/10.1056/NEJMoa2028485","doi":"10.1056/NEJMoa2028485"},{"title":"KATHERINE: switching to T-DM1 when HER2-positive breast cancer survives pre-surgery treatment","journal":"New England Journal of Medicine","year":2019,"url":"https://doi.org/10.1056/NEJMoa1814017","doi":"10.1056/NEJMoa1814017"},{"title":"OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer","journal":"New England Journal of Medicine","year":2021,"url":"https://doi.org/10.1056/NEJMoa2105215","doi":"10.1056/NEJMoa2105215"}]},{"id":"sid-sijbrandij","kind":"person","name":"Sid Sijbrandij","aka":[],"tldr":"The GitLab co-founder who kept working and writing in public through osteosarcoma treatment, showing what living with a rare bone cancer looks like from the inside.","summary":"Sid Sijbrandij co-founded GitLab, the software development platform, and led it as chief executive until stepping back to chair the board. In 2023 he was diagnosed with osteosarcoma, a rare bone cancer, and chose to describe the diagnosis, chemotherapy and its side effects in public posts rather than step out of view. His account is the kind OnCo exists to connect: a working adult with a rare cancer, treated with the same chemotherapy backbone used for children, explaining decisions as they were made. The record links to his own posts and to the GitLab announcement of his change of role.","asOf":"2026-09-09","links":[{"label":"Sid Sijbrandij on X","url":"https://x.com/sytses"}],"tags":["hero","patient","technology"],"related":[],"cancers":["sarcoma","osteosarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["sijbrandij-foundation","evenone-ventures","future-of-cancer-care-today"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"GitLab co-founder living with osteosarcoma; writes openly about treatment and work","specialisms":["Living with cancer","Rare cancers","Patient voice"],"profiles":[{"label":"Sid Sijbrandij on X","url":"https://x.com/sytses"}],"papers":[]},{"id":"sidney-farber","kind":"person","name":"Sidney Farber","aka":[],"tldr":"In 1947-48 he showed that the folate antagonist aminopterin could send childhood leukaemia into remission, the first drug ever to do so. He then built Dana-Farber and, with Mary Lasker, won the 1971 National Cancer Act.","summary":"Sidney Farber (1903-1973) was a paediatric pathologist at Children's Hospital Boston who, in 1947, tested Yellapragada Subbarow's folic acid antagonists in children with acute leukaemia, a disease then universally and quickly fatal. His June 1948 New England Journal of Medicine paper reported temporary remissions in ten of sixteen children given aminopterin, the first demonstration that a drug could reverse a cancer, and the origin of methotrexate and of chemotherapy as a discipline. He founded the Children's Cancer Research Foundation in 1947, which became the Dana-Farber Cancer Institute, and the 1948 Jimmy Fund broadcast gave it a public base. In the 1950s he showed actinomycin D was active in Wilms tumour. With Mary Lasker he was the most effective scientific witness in the campaign for federal cancer funding that produced the National Cancer Act of 1971.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Sidney_Farber","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Sidney_Farber"},{"label":"Dana-Farber Cancer Institute","url":"https://www.dana-farber.org/"}],"tags":["hero","pioneer"],"related":[],"cancers":["all-leukemia","wilms-tumor"],"sections":["chemotherapy"],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["methotrexate","dactinomycin"],"companies":[],"institutions":["dana-farber"],"pathways":[],"terms":[],"trials":[],"people":["robert-sandler","einar-gustafson","mary-lasker","emil-frei"],"bottlenecks":["b-funding-allocation","b-rare-cancers"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Pathologist who produced the first chemotherapy remissions in childhood leukaemia; father of modern chemotherapy","specialisms":["Paediatric pathology","Acute lymphoblastic leukaemia","Chemotherapy","Research advocacy"],"profiles":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Sidney_Farber"},{"label":"Dana-Farber Cancer Institute","url":"https://www.dana-farber.org/"}],"papers":[{"title":"Temporary Remissions in Acute Leukemia in Children Produced by Folic Acid Antagonist, 4-Aminopteroyl-Glutamic Acid (Aminopterin)","journal":"New England Journal of Medicine","year":1948,"doi":"10.1056/nejm194806032382301"},{"title":"Chemotherapy in the Treatment of Leukemia and Wilms' Tumor","journal":"JAMA: The Journal of the American Medical Association","year":1966,"doi":"10.1001/jama.1966.03110210076025"},{"title":"SOME OBSERVATIONS ON THE EFFECT OF FOLIC ACID ANTAGONISTS ON ACUTE LEUKEMIA AND OTHER FORMS OF INCURABLE CANCER","journal":"Blood","year":1949,"doi":"10.1182/blood.v4.2.160.160"}]},{"id":"sidney-kimmel","kind":"person","name":"Sidney Kimmel","aka":[],"tldr":"The Jones Apparel founder has given $157 million to Johns Hopkins since 2001, which named its cancer centre for him, and put $50 million into the Bloomberg~Kimmel Institute for Cancer Immunotherapy in 2016.","summary":"Sidney Kimmel built Jones Apparel Group and turned much of the proceeds to cancer research through the Sidney Kimmel Foundation for Cancer Research. Johns Hopkins records that since 2001 he has contributed $157 million and that in recognition it named the Sidney Kimmel Comprehensive Cancer Center after him; a further $2.4 million funded the Kimmel Scholars programme for twelve young cancer scientists. In 2016 he gave $50 million alongside Michael Bloomberg's $50 million to found the Bloomberg~Kimmel Institute for Cancer Immunotherapy. Thomas Jefferson University in Philadelphia renamed its medical college and cancer centre for him after a 2014 gift. His foundation's Kimmel Scholar awards, given nationally to early-career investigators, are a model for funding people rather than projects.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Sidney_Kimmel","links":[{"label":"Johns Hopkins Hub: cancer immunotherapy institute launch (2016)","url":"https://hub.jhu.edu/2016/03/29/cancer-immunotherapy-center-bloomberg-kimmel/"}],"tags":["hero","donor"],"related":[],"cancers":[],"sections":[],"technologies":["immunotherapy"],"targets":[],"drugs":[],"companies":[],"institutions":["johns-hopkins","jefferson-kimmel"],"pathways":[],"terms":[],"trials":[],"people":["michael-bloomberg"],"bottlenecks":["b-funding-allocation","b-workforce"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Founder of the Sidney Kimmel Foundation for Cancer Research; namesake of the Johns Hopkins cancer centre and Jefferson's medical college","specialisms":["Cancer research philanthropy","Young investigator funding","Cancer immunotherapy"],"profiles":[],"papers":[]},{"id":"sigurdur-kristinsson","kind":"person","name":"Sigurdur Y. Kristinsson","aka":[],"tldr":"Leads iStopMM, which screened most of Iceland's adults for myeloma precursors to test whether early detection helps.","summary":"Sigurdur Kristinsson (University of Iceland) leads iStopMM, the nationwide study that invited every Icelander over 40 to be screened for monoclonal gammopathy and randomised those found to have MGUS to different follow-up strategies, the first population-based test of whether screening for a myeloma precursor improves outcomes. The study has already refined MGUS prevalence and progression estimates and identified smouldering myeloma in the population.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kristinsson%20SY%5BAuthor%5D%20iStopMM"}],"tags":["myeloma","screening","epidemiology"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["landspitali"],"pathways":[],"terms":[],"trials":["istopmm"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["blood-cancer-journal"],"dependsOn":[],"notes":[],"role":"Professor of Hematology, University of Iceland; Landspitali University Hospital","institutionId":"landspitali","specialisms":["Myeloma precursor conditions","Population screening","Epidemiology","MGUS"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kristinsson%20SY%5BAuthor%5D%20iStopMM"}],"papers":[{"title":"Screening for monoclonal gammopathy of undetermined significance: a population-based randomized clinical trial (iStopMM): first results","journal":"Blood Cancer Journal","year":2021,"doi":"10.1038/s41408-021-00480-w"},{"title":"Prevalence of smoldering multiple myeloma based on nationwide screening","journal":"Nature Medicine","year":2023,"doi":"10.1038/s41591-023-02195-w"}],"orcid":"0000-0002-4964-7476"},{"id":"silke-gillessen","kind":"person","name":"Silke Gillessen","aka":[],"tldr":"Founder and chair of the APCCC consensus conference that guides advanced prostate cancer management worldwide.","summary":"Silke Gillessen (IOSI, Bellinzona) founded the Advanced Prostate Cancer Consensus Conference, whose biennial reports are the most widely used expert guidance on managing advanced prostate cancer where trial evidence is lacking. She was a lead investigator in STAMPEDE and in trials of PSMA radioligand therapy and helped establish the Swiss Group for Clinical Cancer Research GU programme.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gillessen%20S%5BAuthor%5D%20prostate%20consensus"}],"tags":["prostate","guidelines","switzerland"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["iosi-bellinzona"],"pathways":[],"terms":[],"trials":["stampede"],"people":[],"bottlenecks":[],"keyPapers":["paper-stampede-abiraterone-nejm-2017"],"journals":["european-urology"],"dependsOn":[],"notes":[],"role":"Medical and Scientific Director, Oncology Institute of Southern Switzerland (IOSI), Bellinzona","institutionId":"iosi-bellinzona","specialisms":["Prostate cancer","Consensus guidelines","Genitourinary oncology","Treatment sequencing"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gillessen%20S%5BAuthor%5D%20prostate%20consensus"}],"papers":[{"title":"Management of patients with advanced prostate cancer: report from the Advanced Prostate Cancer Consensus Conference 2021","journal":"European Urology","year":2022,"doi":"10.1016/j.eururo.2022.04.002"},{"title":"Abiraterone for prostate cancer not previously treated with hormone therapy (STAMPEDE)","journal":"NEJM","year":2017,"doi":"10.1056/NEJMoa1702900"}],"orcid":"0000-0001-5746-6555"},{"id":"silvana-konermann","kind":"person","name":"Silvana Konermann","aka":[],"tldr":"Neuroscientist and co-founder who runs the Arc Institute, an independent research institute in the San Francisco Bay Area built to tackle complex diseases.","summary":"Silvana Konermann is Co-Founder, Executive Director and a Core Investigator of the Arc Institute, an independent research institute she started with Patrick Hsu and Patrick Collison after the three collaborated on Fast Grants. She is also Assistant Professor of Biochemistry at Stanford, holds a PhD in neuroscience from MIT, and has been a Chan Zuckerberg Biohub Investigator and a Hanna Gray Fellow of the Howard Hughes Medical Institute. Her laboratory uses CRISPR-based transcriptome engineering and functional genomic screens in brain cell models to uncover the molecular pathways behind Alzheimer's disease and other neurodegenerative disorders.","asOf":"2026-09-10","links":[{"label":"Source: Arc Institute About page","url":"https://arcinstitute.org/about"}],"tags":["leadership","clinician-scientist","genomics","research-institute"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cz-biohub","hhmi"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Executive Director and Core Investigator, Arc Institute","institutionId":"arc-institute","specialisms":["Functional genomics","CRISPR technologies","Neurodegeneration"],"profiles":[{"label":"Institution profile","url":"https://arcinstitute.org/labs/konermannlab"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Konermann+S%5BAuthor%5D"}],"papers":[{"title":"DNA targeting specificity of RNA-guided Cas9 nucleases","journal":"Nature Biotechnology","year":2013,"url":"https://doi.org/10.1038/nbt.2647","doi":"10.1038/nbt.2647","note":"Europe PMC author record matched by affiliation"},{"title":"Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity","journal":"Cell","year":2013,"url":"https://doi.org/10.1016/j.cell.2013.08.021","doi":"10.1016/j.cell.2013.08.021","note":"Europe PMC author record matched by affiliation"},{"title":"Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex","journal":"Nature","year":2015,"url":"https://doi.org/10.1038/nature14136","doi":"10.1038/nature14136","note":"Europe PMC author record matched by affiliation"}]},{"id":"silvia-stacchiotti","kind":"person","name":"Silvia Stacchiotti","aka":[],"tldr":"Italian oncologist who leads histology-specific trials in ultra-rare sarcomas and the Connective Tissue Oncology Society.","summary":"Silvia Stacchiotti has led trials of targeted agents in individual rare sarcoma histologies including alveolar soft part sarcoma, solitary fibrous tumour, chordoma, epithelioid haemangioendothelioma and desmoid tumours, establishing the histology-driven model of sarcoma medical oncology. She co-leads the Italian Rare Cancer Network and the European Reference Network EURACAN sarcoma domain and has been president of the Connective Tissue Oncology Society.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Stacchiotti%20S%5BAuthor%5D%20sarcoma"}],"tags":["sarcoma","rare-cancers","italy"],"related":[],"cancers":["sarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["int-milan"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["cancer-wiley"],"dependsOn":[],"notes":[],"role":"Medical Oncologist, Adult Mesenchymal Tumour and Rare Cancer Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan","institutionId":"int-milan","specialisms":["Rare sarcomas","Histology-driven therapy","Chordoma and desmoid tumours","Rare cancer networks"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Stacchiotti%20S%5BAuthor%5D%20sarcoma"}],"papers":[{"title":"Ultra-rare sarcomas: a consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities","journal":"Cancer","year":2021,"doi":"10.1002/cncr.33618"},{"title":"Efficacy and biological activity of imatinib in metastatic dermatofibrosarcoma protuberans (DFSP)","journal":"Clinical Cancer Research","year":2016,"doi":"10.1158/1078-0432.CCR-15-1243"}],"orcid":"0000-0002-1742-8666"},{"id":"simona-sancini","kind":"person","name":"Simona Sancini","aka":[],"tldr":"Medical Director of IRCCS Humanitas Research Hospital in Rozzano (Milan), responsible for clinical governance across the hospital and its cancer center.","summary":"Simona Sancini is the Medical Director (Direttore Sanitario) of IRCCS Humanitas Research Hospital, the research hospital of the Humanitas group near Milan. She oversees clinical organisation and quality across the hospital, including its Cancer Center. Her role is listed on the institution's About Us page.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.humanitas.net/about-us/"}],"tags":["leadership","hospital management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["humanitas"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Medical Director (Direttore Sanitario)","institutionId":"humanitas","specialisms":["Hospital management","Clinical governance"],"profiles":[{"label":"Institution profile","url":"https://www.humanitas.net/about-us/"}],"papers":[]},{"id":"simron-singh","kind":"person","name":"Simron Singh","aka":[],"tldr":"Led NETTER-2, which moved lutetium dotatate into first-line treatment of higher-grade neuroendocrine tumours.","summary":"Simron Singh was principal investigator of NETTER-2, which showed first-line 177Lu-DOTATATE plus octreotide dramatically improves progression-free survival over high-dose octreotide in grade 2-3 gastroenteropancreatic neuroendocrine tumours, extending radioligand therapy to newly diagnosed patients. He has led Canadian and international NET guidelines and studies of NET epidemiology and patient-reported outcomes.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Singh%20S%5BAuthor%5D%20neuroendocrine%20NETTER-2"}],"tags":["neuroendocrine","radioligand","canada"],"related":[],"cancers":["neuroendocrine"],"sections":[],"technologies":["radioligand-therapy"],"targets":["sstr2"],"drugs":["lutathera"],"companies":[],"institutions":["sunnybrook-odette"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-netter-2-lancet-2024"],"journals":["journal-of-thoracic-oncology"],"dependsOn":[],"notes":[],"role":"Medical Oncologist and Co-Director, Susan Leslie Clinic for Neuroendocrine Tumours, Sunnybrook Odette Cancer Centre","institutionId":"sunnybrook-odette","specialisms":["Neuroendocrine tumours","Radioligand therapy","Health services research","Guidelines"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Singh%20S%5BAuthor%5D%20neuroendocrine%20NETTER-2"}],"papers":[{"title":"[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2)","journal":"Lancet","year":2024,"doi":"10.1016/S0140-6736(24)00701-3"},{"title":"Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society guidelines for the diagnosis and management of patients with lung neuroendocrine tumors","journal":"Journal of Thoracic Oncology","year":2020,"doi":"10.1016/j.jtho.2020.06.021"},{"title":"NETTER-2: lutetium-177 dotatate as first treatment for higher-grade gastroenteropancreatic neuroendocrine tumours","journal":"The Lancet","year":2024,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NETTER-2+lutetium+dotatate+first-line+Singh+Lancet"}]},{"id":"chris-hoy","kind":"person","name":"Sir Chris Hoy","aka":[],"tldr":"Britain's most decorated Olympic cyclist made his stage 4 prostate cancer public in 2024 and founded Tour de 4, a mass ride that shows people can live well with advanced cancer and has raised more than £2.7 million for cancer charities.","summary":"Sir Chris Hoy, six-time Olympic gold medallist, disclosed in 2024 that he had prostate cancer that had spread to his bones and was incurable, and chose to speak about it publicly, prompting a documented surge in men seeking prostate checks in the UK. He founded Tour de 4, whose own site states that it exists to shine a spotlight on stage 4 cancer and show that people can live well alongside a stage 4 diagnosis, raising awareness and funds for cancer charities; its first mass ride took place in Glasgow in September 2025 with riders living with cancer among the field. By September 2026 the event reported that together its riders had raised £2,701,687. His account, of training and racing while on treatment, has changed how advanced cancer is talked about in Britain.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Chris_Hoy","links":[{"label":"Tour de 4","url":"https://www.tourde4.com/"},{"label":"Tour de 4: about","url":"https://www.tourde4.com/about"}],"tags":["public-figure","donor","patient"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-patient-voice","b-survivorship","b-early-detection"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Olympic cyclist living with stage 4 prostate cancer; founder of the Tour de 4 charity ride","specialisms":["Prostate cancer","Living with advanced cancer","Cancer fundraising"],"profiles":[],"papers":[]},{"id":"dorabji-tata","kind":"person","name":"Sir Dorabji Tata","aka":["Dorab Tata","Lady Meherbai Tata"],"tldr":"After his wife Meherbai's illness and death in 1931 he founded the Sir Dorabji Tata Trust in 1932 and left it everything he had; the Trust built Tata Memorial in 1941, called the first large contribution of India to the international fight against cancer.","summary":"Sir Dorabji Tata (1859-1932), eldest son of Tata group founder Jamsetji Tata, led the group into steel, power and hotels. His wife Lady Meherbai died in 1931 after an illness treated with the best care then available, which brought home to him how little existed in India for cancer patients. Tata Trusts' history records that the Sir Dorabji Tata Trust was founded in 1932, one of the oldest non-communal, multipurpose charitable trusts in India, and that on his death that year he left his entire fortune, including a 40% share in Tata Sons, to it. The Trust established the Tata Memorial Centre for Cancer Research and Treatment in Bombay in 1941, described at the time as the first large contribution of India to the international fight against cancer; it later passed to the Government of India and is now the country's largest cancer centre. Jamsetji Tata, who died in 1904, had no direct role in the hospital.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Dorabji_Tata","links":[{"label":"Tata Trusts: our history 1907-2000","url":"https://www.tatatrusts.org/about-tatatrusts/our-history/our-history-1907-2000"}],"tags":["hero","donor"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["tata-trusts","tata-memorial"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-global-access","b-funding-allocation"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Industrialist whose trust, endowed with his entire fortune, built the Tata Memorial Hospital in 1941","specialisms":["Cancer hospital founding","Indian philanthropy"],"profiles":[],"papers":[]},{"id":"richard-peto","kind":"person","name":"Sir Richard Peto","aka":[],"tldr":"Epidemiologist who quantified how smoking kills and invented the meta-analysis methods that established adjuvant cancer therapy.","summary":"Richard Peto co-authored with Richard Doll the 50-year follow-up of British doctors showing smokers lose about ten years of life and that stopping at any age helps, and has quantified tobacco deaths worldwide. He founded the Early Breast Cancer Trialists' Collaborative Group and developed the statistical methods for individual-patient-data meta-analysis, and co-designed the large simple trial. He was knighted for services to epidemiology.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Peto%20R%5BAuthor%5D%20smoking%20mortality"}],"tags":["epidemiology","tobacco","meta-analysis"],"related":[],"cancers":["nsclc","breast-hr-positive"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oxford-cancer"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-doll-peto-50-year-doctors-bmj-2004","paper-doll-hill-smoking-lung-cancer-bmj-1950"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Statistics and Epidemiology, University of Oxford","institutionId":"oxford-cancer","specialisms":["Epidemiology","Tobacco and cancer","Meta-analysis","Large-scale trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Peto%20R%5BAuthor%5D%20smoking%20mortality"}],"papers":[{"title":"Mortality in relation to smoking: 50 years' observations on male British doctors","journal":"BMJ","year":2004,"doi":"10.1136/bmj.38142.554479.AE"},{"title":"Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials","journal":"Lancet","year":2005,"doi":"10.1016/S0140-6736(05)67887-7"},{"title":"Doll and Hill 1950: the case-control study that tied smoking to lung cancer","journal":"BMJ","year":1950,"url":"https://doi.org/10.1136/bmj.2.4682.739","doi":"10.1136/bmj.2.4682.739"}]},{"id":"sirkku-jyrkkio","kind":"person","name":"Sirkku Jyrkkiö","aka":[],"tldr":"Sirkku Jyrkkiö represents Turku University Hospital Cancer Centre in the Organisation of European Cancer Institutes, which lists the centre among its members in Finland.","summary":"Sirkku Jyrkkiö is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Turku University Hospital Cancer Centre, its member in Finland. The university hospital of south-west Finland and host of FICAN West, with OECI Cancer Centre accreditation and a strong PET imaging tradition. OnCo records the name from the OECI membership list so that the centre's page has a named contact point; the person's exact title, appointment date and biography are not yet recorded and should be checked on the institution's own pages before being relied on.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Turku University Hospital Cancer Centre website","url":"https://www.tyks.fi/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["turku-university-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Turku University Hospital Cancer Centre to the Organisation of European Cancer Institutes","institutionId":"turku-university-hospital","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Turku University Hospital Cancer Centre website","url":"https://www.tyks.fi/"}],"papers":[{"title":"Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data","journal":"Lancet Oncol","year":2017,"url":"https://doi.org/10.1016/s1470-2045(16)30560-5","doi":"10.1016/s1470-2045(16)30560-5","note":"Europe PMC author record matched by affiliation"},{"title":"Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma","journal":"Blood","year":2022,"url":"https://doi.org/10.1182/blood.2021012852","doi":"10.1182/blood.2021012852","note":"Europe PMC author record matched by affiliation"},{"title":"Metabolic characterization of childhood brain tumors: comparison of 18F-fluorodeoxyglucose and 11C-methionine positron emission tomography","journal":"Cancer","year":2002,"url":"https://doi.org/10.1002/cncr.10798","doi":"10.1002/cncr.10798","note":"Europe PMC author record matched by affiliation"}]},{"id":"sirpa-leppa","kind":"person","name":"Sirpa Leppä","aka":[],"tldr":"Helsinki oncologist who chairs the Nordic Lymphoma Group, the cooperative network that runs lymphoma trials and guidelines across the Nordic countries.","summary":"Sirpa Leppä is Chairperson of the Nordic Lymphoma Group (NLG), the cooperative group of Nordic haematologists and oncologists that develops lymphoma guidelines and protocols and runs multicentre trials. She works in the Department of Oncology at Helsinki University Hospital, Finland. The NLG coordinating group she chairs includes representatives from Finland, Norway, Sweden and Denmark, with Alexander Fosså of Oslo University Hospital as vice-chairman.","asOf":"2026-09-10","links":[{"label":"Source: Nordic Lymphoma Group coordinating group page","url":"https://www.nordic-lymphoma.org/coordinating-group/"}],"tags":["leadership","clinician-scientist","lymphoma","cooperative-group"],"related":[],"cancers":["dlbcl","hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["nordic-lymphoma-group"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["haematologica"],"dependsOn":[],"notes":[],"role":"Chairperson, Nordic Lymphoma Group","institutionId":"nordic-lymphoma-group","specialisms":["Lymphoma","Medical oncology","Clinical trials"],"profiles":[{"label":"NLG coordinating group","url":"https://www.nordic-lymphoma.org/coordinating-group/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lepp%C3%A4+S%5BAuthor%5D"}],"papers":[{"title":"Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma","journal":"Blood","year":2022,"doi":"10.1182/blood.2021012852"},{"title":"Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy","journal":"Blood","year":2007,"doi":"10.1182/blood-2006-09-047068"},{"title":"Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial","journal":"Haematologica","year":2014,"doi":"10.3324/haematol.2014.113472"}]},{"id":"solange-peters","kind":"person","name":"Solange Peters","aka":[],"tldr":"Solange Peters is a lung cancer trialist and past ESMO President who led CheckMate 743 in mesothelioma.","summary":"Solange Peters is Head of Medical Oncology at Lausanne University Hospital (CHUV), working alongside the Ludwig Institute Lausanne, and served as President of the European Society for Medical Oncology (ESMO) in 2020-2021. Her specialisms are thoracic oncology, immunotherapy and mesothelioma. She led CheckMate 743, the Lancet trial of first-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma. Her work spans mesothelioma and non-small-cell lung cancer, and her publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Peters%20S%5BAuthor%5D%20mesothelioma%20nivolumab"}],"tags":[],"related":[],"cancers":["mesothelioma","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["nivolumab","ipilimumab"],"companies":[],"institutions":["esmo","chuv-lausanne"],"pathways":[],"terms":[],"trials":["checkmate-743"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Head of Medical Oncology, Lausanne University Hospital (CHUV); ESMO President 2020-2021","institutionId":"esmo","specialisms":["Thoracic oncology","Immunotherapy","Mesothelioma"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Peters%20S%5BAuthor%5D%20mesothelioma%20nivolumab"}],"papers":[{"title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743)","journal":"Lancet","year":2021,"doi":"10.1016/S0140-6736(20)32714-8"}]},{"id":"sonia-garcia-de-san-jose","kind":"person","name":"Sonia García de San José","aka":[],"tldr":"Sonia García de San José represents Hospital General Universitario Gregorio Marañón in the Organisation of European Cancer Institutes, which lists the centre among its members in Spain.","summary":"Sonia García de San José is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Hospital General Universitario Gregorio Marañón, its full member in Spain. OnCo records the name from the OECI membership list so that the centre's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the institution's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Hospital General Universitario Gregorio Marañón website","url":"https://www.comunidad.madrid/hospital/gregoriomaranon"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["gregorio-maranon"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Hospital General Universitario Gregorio Marañón to the Organisation of European Cancer Institutes","institutionId":"gregorio-maranon","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Hospital General Universitario Gregorio Marañón website","url":"https://www.comunidad.madrid/hospital/gregoriomaranon"}],"papers":[{"title":"Overlapping of Independent SARS-CoV-2 Nosocomial Transmissions in a Complex Outbreak","journal":"mSphere","year":2021,"url":"https://doi.org/10.1128/msphere.00389-21","doi":"10.1128/msphere.00389-21","note":"OpenAlex author record matched by institution"},{"title":"Nosocomial Transmission of SARS-CoV-2 Involving Vaccinated Health Care Workers","journal":"Microbiology Spectrum","year":2022,"url":"https://doi.org/10.1128/spectrum.01532-21","doi":"10.1128/spectrum.01532-21","note":"OpenAlex author record matched by institution"},{"title":"Electronic consultation as an essential implement for Continuity of Care","journal":"International Journal of Integrated Care","year":2015,"url":"https://doi.org/10.5334/ijic.2058","doi":"10.5334/ijic.2058","note":"OpenAlex author record matched by institution"}]},{"id":"sonja-optendrenk","kind":"person","name":"Sonja Optendrenk","aka":[],"tldr":"Impartial chair of Germany's Federal Joint Committee (G-BA), the body that decides which treatments statutory health insurance covers.","summary":"Dr. Sonja Optendrenk is the impartial chair of the Gemeinsamer Bundesausschuss (G-BA), Germany's highest decision-making body in statutory health insurance. The G-BA determines benefit coverage and commissions assessments, including early benefit assessments of new cancer drugs under AMNOG, from IQWiG. Her role is regulatory and policy leadership rather than clinical research.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.g-ba.de/ueber-den-gba/wer-wir-sind/mitglieder/"}],"tags":["leadership","regulation","health technology assessment"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["g-ba-iqwig"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Impartial Chair (Unparteiische Vorsitzende), Gemeinsamer Bundesausschuss","institutionId":"g-ba-iqwig","specialisms":["Health policy","Statutory health insurance benefits","Health technology assessment"],"profiles":[{"label":"Institution profile","url":"https://www.g-ba.de/ueber-den-gba/wer-wir-sind/mitglieder/"}],"papers":[],"papersExpected":false},{"id":"sophia-varadkar","kind":"person","name":"Sophia Varadkar","aka":[],"tldr":"Paediatric neurologist and Chief Medical Officer of Great Ormond Street Hospital, responsible for clinical standards and patient safety.","summary":"Dr Sophia Varadkar is Chief Medical Officer at Great Ormond Street Hospital for Children, responsible for performance and clinical standards including patient safety, and leads the hospital's clinical governance. She is a consultant paediatric neurologist with a research background in childhood epilepsy.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.gosh.nhs.uk/about-us/who-we-are/organisational-structure/trust-board/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Varadkar+S%5BAuthor%5D"}],"tags":["leadership","paediatric oncology","clinical governance"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["great-ormond-street"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Medical Officer","institutionId":"great-ormond-street","specialisms":["Paediatric neurology","Clinical governance","Patient safety"],"profiles":[{"label":"Institution profile","url":"https://www.gosh.nhs.uk/about-us/who-we-are/organisational-structure/trust-board/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Varadkar+S%5BAuthor%5D"}],"papers":[{"title":"Seizure and cognitive outcomes after resection of glioneuronal tumors in children","journal":"Epilepsia","year":2017,"doi":"10.1111/epi.13961"}]},{"id":"srdan-verstovsek","kind":"person","name":"Srdan Verstovsek","aka":[],"tldr":"Haematologist who led the COMFORT-I trial that established ruxolitinib, the first drug approved for myelofibrosis, and MOMENTUM, which established momelotinib for patients with anaemia.","summary":"Srdan Verstovsek led the myeloproliferative neoplasms programme at MD Anderson Cancer Center for many years. He was first author of the 2012 New England Journal of Medicine report of COMFORT-I, the trial that led to ruxolitinib's approval for myelofibrosis, and of the 2023 Lancet report of MOMENTUM, in which momelotinib improved symptoms, spleen size and anaemia compared with danazol in symptomatic, anaemic patients previously treated with a JAK inhibitor.","asOf":"2026-09-18","links":[],"tags":["mpn","trialist"],"related":[],"cancers":["primary-myelofibrosis","myeloproliferative-neoplasms"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["momentum"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Haematologist and trial lead, myeloproliferative neoplasms","specialisms":["Myelofibrosis","JAK inhibitors","Myeloproliferative neoplasms"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Verstovsek%5BAuthor%5D"}],"papers":[{"title":"COMFORT-I: ruxolitinib, the first JAK inhibitor, versus placebo for myelofibrosis","journal":"New England Journal of Medicine","year":2012,"url":"https://doi.org/10.1056/NEJMoa1110557","doi":"10.1056/NEJMoa1110557"},{"title":"MOMENTUM: momelotinib versus danazol for myelofibrosis patients with anaemia after a prior JAK inhibitor","journal":"The Lancet","year":2023,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=MOMENTUM%20momelotinib%20danazol%20myelofibrosis%20anaemia%20Verstovsek%20Lancet%202023"}]},{"id":"stanislaw-klek","kind":"person","name":"Stanislaw Klek","aka":[],"tldr":"Chairman of the European Society for Clinical Nutrition and Metabolism, the society that issues Europe's clinical nutrition guidelines, including those for people with cancer.","summary":"Stanislaw Klek is Chairman of ESPEN, the European Society for Clinical Nutrition and Metabolism, with a term running until 2028 according to the society's committees page. He leads an Executive Committee that also includes Cristina Cuerda as General Secretary and Stephane Schneider as Treasurer, with Matthias Pirlich designated President 2026. ESPEN publishes guidelines and consensus papers on clinical nutrition, runs an annual congress and workshops, and publishes the journal Clinical Nutrition ESPEN.","asOf":"2026-09-10","links":[{"label":"Source: ESPEN committees page","url":"https://www.espen.org/about/committees"}],"tags":["leadership","clinician-scientist","nutrition","society"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["espen"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["annals-of-oncology"],"dependsOn":[],"notes":[],"role":"Chairman of ESPEN (term until 2028)","institutionId":"espen","specialisms":["Clinical nutrition","Metabolism","Nutritional care in cancer"],"profiles":[{"label":"Institution profile","url":"https://www.espen.org/about/committees"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Klek+S%5BAuthor%5D"}],"papers":[{"title":"Perioperative nutrition in malnourished surgical cancer patients – A prospective, randomized, controlled clinical trial","journal":"Clinical Nutrition","year":2011,"doi":"10.1016/j.clnu.2011.07.007"},{"title":"The prognosis of incurable cachectic cancer patients on home parenteral nutrition: a multi-centre observational study with prospective follow-up of 414 patients","journal":"Annals of Oncology","year":2014,"doi":"10.1093/annonc/mdt549"},{"title":"Immunonutrition in cancer patients","journal":"Nutrition","year":2011,"doi":"10.1016/j.nut.2010.07.015"}],"orcid":"0000-0002-7887-3464"},{"id":"stanley-riddell","kind":"person","name":"Stanley R. Riddell","aka":[],"tldr":"Adoptive T-cell therapy pioneer whose defined-composition CAR-T work led to lisocabtagene maraleucel.","summary":"Stanley Riddell is Professor in the Translational Science and Therapeutics Division at Fred Hutchinson Cancer Center. An immunologist specialising in T-cell immunotherapy, CAR-T and adoptive cell transfer, he pioneered antigen-specific T-cell transfer for viral infections after transplant and later CD19 CAR-T with defined CD4:CD8 ratios, the basis of Juno Therapeutics and of lisocabtagene maraleucel (Breyanzi). His papers include the report of CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B-cell ALL and the Science paper on restoring viral immunity in immunodeficient humans by adoptive transfer of T cell clones. He now works on CAR design and solid-tumour targets such as ROR1, with relevance to lymphoma and leukaemia.","asOf":"2026-09-08","links":[{"label":"Fred Hutch faculty directory","url":"https://www.fredhutch.org/en/faculty-lab-directory.html?q=Stanley%20R.%20Riddell"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Riddell%20SR%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Stanley%20R.%20Riddell"}],"tags":[],"related":[],"cancers":["dlbcl","all-leukemia","cll"],"sections":[],"technologies":["car-t"],"targets":["cd19","ror1"],"drugs":["lisocabtagene-maraleucel"],"companies":[],"institutions":["fred-hutch"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["jci"],"dependsOn":[],"notes":[],"role":"Professor, Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center","institutionId":"fred-hutch","specialisms":["T-cell immunotherapy","CAR-T","Adoptive cell transfer"],"profiles":[{"label":"Fred Hutch faculty directory","url":"https://www.fredhutch.org/en/faculty-lab-directory.html?q=Stanley%20R.%20Riddell"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Riddell%20SR%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Stanley%20R.%20Riddell"}],"papers":[{"title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","journal":"Journal of Clinical Investigation","year":2016,"url":"https://doi.org/10.1172/JCI85309","doi":"10.1172/JCI85309"},{"title":"Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones","journal":"Science","year":1992,"url":"https://doi.org/10.1126/science.1352912","doi":"10.1126/science.1352912"}],"orcid":"0000-0002-4688-9920"},{"id":"stefan-froehling","kind":"person","name":"Stefan Fröhling","aka":[],"tldr":"Runs the NCT/DKTK MASTER programme that sequences whole genomes of rare and young-adult cancers to guide therapy.","summary":"Stefan Fröhling is Managing Director of NCT Heidelberg and Head of Translational Medical Oncology at the German Cancer Research Center (DKFZ). His specialisms are precision oncology, sarcoma and genomics-guided trials, using whole-exome and whole-genome sequencing and comprehensive genomic profiling. He runs the NCT/DKTK MASTER programme, which sequences the whole genomes of rare and young-adult cancers to guide therapy. His Cancer Discovery paper on MASTER described comprehensive genomic and transcriptomic analysis for guiding therapeutic decisions in patients with rare cancers. His focus is on sarcomas and rare cancers and on turning genomic findings into molecularly guided treatment. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Frohling%20S%5BAuthor%5D%20MASTER%20precision%20oncology"}],"tags":[],"related":[],"cancers":["sarcoma"],"sections":[],"technologies":["wes-wgs","cgp"],"targets":[],"drugs":[],"companies":[],"institutions":["heidelberg-nct","dkfz"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Managing Director, NCT Heidelberg; Head of Translational Medical Oncology, DKFZ","institutionId":"heidelberg-nct","specialisms":["Precision oncology","Sarcoma","Genomics-guided trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Frohling%20S%5BAuthor%5D%20MASTER%20precision%20oncology"}],"papers":[{"title":"Comprehensive genomic and transcriptomic analysis for guiding therapeutic decisions in patients with rare cancers (MASTER)","journal":"Cancer Discovery","year":2021,"doi":"10.1158/2159-8290.CD-21-0126"}]},{"id":"stefan-pfister","kind":"person","name":"Stefan Pfister","aka":[],"tldr":"Paediatric oncologist whose genomic work redefined childhood brain tumours into molecular subgroups.","summary":"Stefan Pfister is Director of the Hopp Children's Cancer Center Heidelberg (KiTZ) and Head of Pediatric Neurooncology at the German Cancer Research Center (DKFZ), working with Heidelberg University Hospital and the NCT. His specialisms are paediatric neuro-oncology, brain tumour genomics and molecular classification. He led the molecular subgrouping of medulloblastoma and ependymoma, work that redefined childhood brain tumours into molecular subgroups. He also co-developed the DNA methylation-based classifier for central nervous system tumours, reported in Nature. His publications are listed on PubMed.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Stefan_Pfister","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Pfister%20SM%5BAuthor%5D%20medulloblastoma"}],"tags":[],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":["methylation-profiling"],"targets":[],"drugs":[],"companies":[],"institutions":["dkfz","heidelberg-nct"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Hopp Children's Cancer Center Heidelberg (KiTZ); Head of Pediatric Neurooncology, DKFZ","institutionId":"dkfz","specialisms":["Paediatric neuro-oncology","Brain tumour genomics","Molecular classification"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Pfister%20SM%5BAuthor%5D%20medulloblastoma"}],"papers":[{"title":"DNA methylation-based classification of central nervous system tumours","journal":"Nature","year":2018,"doi":"10.1038/nature26000"}],"orcid":"0000-0002-5447-5322"},{"id":"stefan-bielack","kind":"person","name":"Stefan S. Bielack","aka":[],"tldr":"Leads the COSS group and co-led EURAMOS-1, the largest osteosarcoma trial ever run.","summary":"Stefan Bielack (Stuttgart) chairs the Cooperative Osteosarcoma Study Group and was a lead investigator of EURAMOS-1, the 2,260-patient international trial showing that neither adding ifosfamide-etoposide for poor responders nor interferon for good responders improves outcomes over MAP chemotherapy, fixing MAP as the global standard. His COSS registry analyses define prognostic factors in osteosarcoma.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bielack%20SS%5BAuthor%5D%20osteosarcoma"}],"tags":["paediatric","osteosarcoma","cooperative-group"],"related":[],"cancers":["osteosarcoma"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":[],"companies":[],"institutions":["klinikum-stuttgart-olgahospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Head of Paediatric Oncology, Klinikum Stuttgart Olgahospital; Chair, Cooperative Osteosarcoma Study Group","institutionId":"klinikum-stuttgart-olgahospital","specialisms":["Osteosarcoma","Paediatric oncology","Bone tumours","International trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bielack%20SS%5BAuthor%5D%20osteosarcoma"}],"papers":[{"title":"Methotrexate, doxorubicin, and cisplatin (MAP) plus maintenance pegylated interferon alfa-2b versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP (EURAMOS-1)","journal":"JCO","year":2015,"doi":"10.1200/JCO.2014.60.0734"},{"title":"Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols","journal":"JCO","year":2002,"doi":"10.1200/JCO.2002.20.3.776"}]},{"id":"stephan-grupp","kind":"person","name":"Stephan A. Grupp","aka":[],"tldr":"Treated the first child with CAR-T cells and led ELIANA, the trial behind the first CAR-T approval.","summary":"Stephan Grupp treated Emily Whitehead, the first child to receive CD19 CAR-T cells, in 2012 and led the CHOP trials and the global ELIANA study that won tisagenlecleucel the first-ever CAR-T approval in 2017 for relapsed paediatric ALL. He identified tocilizumab as the treatment for cytokine release syndrome, which made CAR-T deliverable, and directs cellular therapy at CHOP.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Stephan_Grupp","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Grupp%20SA%5BAuthor%5D%20tisagenlecleucel"}],"tags":["cell-therapy","car-t","paediatric"],"related":[],"cancers":["all-leukemia"],"sections":[],"technologies":["car-t"],"targets":["cd19"],"drugs":[],"companies":[],"institutions":["chop","penn-abramson"],"pathways":[],"terms":[],"trials":["eliana"],"people":[],"bottlenecks":[],"keyPapers":["paper-eliana-tisagenlecleucel-nejm-2018","paper-maude-ctl019-all-nejm-2014"],"journals":[],"dependsOn":[],"notes":[],"role":"Chief, Cellular Therapy and Transplant Section, Children's Hospital of Philadelphia; Professor of Pediatrics, University of Pennsylvania","institutionId":"chop","specialisms":["Paediatric CAR T-cell therapy","Acute lymphoblastic leukaemia","Cytokine release syndrome","Cellular therapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Grupp%20SA%5BAuthor%5D%20tisagenlecleucel"}],"papers":[{"title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","journal":"NEJM","year":2013,"doi":"10.1056/NEJMoa1215134"},{"title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia (ELIANA)","journal":"NEJM","year":2018,"doi":"10.1056/NEJMoa1709866"},{"title":"Maude 2014: CD19 CAR-T cells produce complete remission in 27 of 30 children and adults with relapsed ALL","journal":"New England Journal of Medicine","year":2014,"url":"https://doi.org/10.1056/NEJMoa1407222","doi":"10.1056/NEJMoa1407222"}],"orcid":"0000-0001-8030-7595"},{"id":"stephen-boorjian","kind":"person","name":"Stephen A. Boorjian","aka":[],"tldr":"Mayo Clinic urologist who led the trial of nadofaragene firadenovec, the first gene therapy approved for bladder cancer that no longer responds to BCG.","summary":"Stephen Boorjian chairs the department of urology at Mayo Clinic in Rochester. He was first author of the 2021 Lancet Oncology report of the phase 3 trial of intravesical nadofaragene firadenovec, an adenoviral vector delivering the interferon alfa-2b gene, in BCG-unresponsive non-muscle-invasive bladder cancer; about half of patients with carcinoma in situ had a complete response, the basis of the first gene therapy approval in bladder cancer. He also publishes on outcomes after cystectomy and nephrectomy.","asOf":"2026-09-18","links":[],"tags":["urothelial","gene-therapy","surgery","trialist"],"related":[],"cancers":["non-muscle-invasive-bladder-cancer","urothelial"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["mayo-clinic"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-nadofaragene-firadenovec-lancet-oncol-2021"],"journals":[],"dependsOn":[],"notes":[],"role":"Chair of Urology, Mayo Clinic","institutionId":"mayo-clinic","specialisms":["Bladder cancer","Intravesical therapy","Urological surgery outcomes"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Boorjian%5BAuthor%5D"}],"papers":[{"title":"Nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer","journal":"The Lancet Oncology","year":2021,"url":"https://doi.org/10.1016/S1470-2045(20)30540-4","doi":"10.1016/S1470-2045(20)30540-4"}]},{"id":"stephen-baylin","kind":"person","name":"Stephen B. Baylin","aka":[],"tldr":"Founder of cancer epigenetics, showing that abnormal DNA methylation silences tumour-suppressor genes and can be reversed by drugs.","summary":"Stephen B. Baylin is the Virginia and D.K. Ludwig Professor of Oncology and Medicine at Johns Hopkins Hospital and the Sidney Kimmel Comprehensive Cancer Center. He is a founder of cancer epigenetics, having established that abnormal promoter DNA methylation silences tumour-suppressor genes in cancer and that this can be reversed by drugs. His selected paper reviews a decade of exploring the cancer epigenome and its biological and translational implications. He led early trials of low-dose azacitidine and HDAC inhibitors in solid tumours and continues to work on epigenetic therapy in lung cancer and acute myeloid leukaemia.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Stephen_B._Baylin","links":[{"label":"Hopkins profile","url":"https://www.hopkinsmedicine.org/profiles/details/stephen-baylin"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Baylin%20SB%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["nsclc","aml"],"sections":[],"technologies":["epigenetic-drugs","methylation-profiling"],"targets":[],"drugs":["azacitidine"],"companies":[],"institutions":["johns-hopkins"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nature-reviews-cancer"],"dependsOn":[],"notes":[],"role":"Virginia and D.K. Ludwig Professor of Oncology and Medicine","institutionId":"johns-hopkins","specialisms":["Cancer epigenetics","DNA methylation","Epigenetic therapy"],"profiles":[{"label":"Hopkins profile","url":"https://www.hopkinsmedicine.org/profiles/details/stephen-baylin"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Baylin%20SB%5BAuthor%5D"}],"papers":[{"title":"A decade of exploring the cancer epigenome — biological and translational implications","journal":"Nature Reviews Cancer","year":2011,"url":"https://doi.org/10.1038/nrc3130","doi":"10.1038/nrc3130"}],"orcid":"0000-0003-3697-3798"},{"id":"stephen-forman","kind":"person","name":"Stephen J. Forman","aka":[],"tldr":"Transplant pioneer who built City of Hope's cell therapy programme, one of the largest in the country.","summary":"Stephen Forman is Director of the Hematologic Malignancies Research Institute and Francis and Kathleen McNamara Distinguished Chair at City of Hope. A haematologist specialising in haematopoietic cell transplantation, CAR-T and lymphoma, he led City of Hope's bone marrow transplant programme for decades and built its cell therapy programme, one of the largest in the country. His papers include a Blood report of phase 1 studies of central memory-derived CD19 CAR T-cell therapy after autologous transplant in B-cell non-Hodgkin lymphoma and a Blood commentary on the myth of the second remission of acute leukaemia in adults. He directs haematologic malignancies research including CAR-T development for lymphoma and leukaemia and off-the-shelf cell therapy.","asOf":"2026-09-08","links":[{"label":"City of Hope research faculty","url":"https://www.cityofhope.org/research/find-a-researcher"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Forman%20SJ%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Stephen%20J.%20Forman"}],"tags":[],"related":[],"cancers":["aml","dlbcl","all-leukemia"],"sections":[],"technologies":["car-t","allogeneic-cell-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":["city-of-hope"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Hematologic Malignancies Research Institute; Francis and Kathleen McNamara Distinguished Chair, City of Hope","institutionId":"city-of-hope","specialisms":["Hematopoietic cell transplantation","CAR-T","Lymphoma"],"profiles":[{"label":"City of Hope research faculty","url":"https://www.cityofhope.org/research/find-a-researcher"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Forman%20SJ%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Stephen%20J.%20Forman"}],"papers":[{"title":"Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL","journal":"Blood","year":2016,"url":"https://doi.org/10.1182/blood-2015-12-686725","doi":"10.1182/blood-2015-12-686725"},{"title":"The myth of the second remission of acute leukemia in the adult","journal":"Blood","year":2013,"url":"https://doi.org/10.1182/blood-2012-08-234492","doi":"10.1182/blood-2012-08-234492"}]},{"id":"stephen-freedland","kind":"person","name":"Stephen J. Freedland","aka":[],"tldr":"Los Angeles urologist who was lead author of EMBARK, the trial that established enzalutamide for men whose prostate cancer is returning fast after surgery or radiotherapy.","summary":"Stephen Freedland is a urologist at Cedars-Sinai in Los Angeles and the Durham VA. He was first author of the 2023 New England Journal of Medicine report of EMBARK, in which enzalutamide with or without leuprolide improved metastasis-free survival compared with leuprolide alone in men with high-risk biochemical recurrence of prostate cancer. His research also covers obesity, diet and outcomes in prostate cancer.","asOf":"2026-09-18","links":[],"tags":["prostate","trialist"],"related":[],"cancers":["prostate-bcr","prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cedars-sinai-cancer"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-embark-nejm-2023"],"journals":[],"dependsOn":[],"notes":[],"role":"Urologist, Cedars-Sinai Cancer","institutionId":"cedars-sinai-cancer","specialisms":["Prostate cancer","Biochemical recurrence","Diet and lifestyle in prostate cancer"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Freedland%5BAuthor%5D"}],"papers":[{"title":"EMBARK: enzalutamide with or without leuprolide in high-risk biochemically recurrent prostate cancer","journal":"New England Journal of Medicine","year":2023,"url":"https://doi.org/10.1056/NEJMoa2303974","doi":"10.1056/NEJMoa2303974"}]},{"id":"stephen-russell","kind":"person","name":"Stephen J. Russell","aka":[],"tldr":"Stephen Russell built the engineered measles viruses used against cancer and reported the case in which one intravenous dose put a patient's myeloma into complete remission.","summary":"Stephen Russell works in the Department of Molecular Medicine at Mayo Clinic in Rochester, and his recent papers also carry an affiliation to Vyriad, the Rochester company developing oncolytic viruses. His programme built MV-NIS, a measles virus engineered to kill myeloma plasma cells and to carry the sodium iodide symporter gene so that virus replication can be imaged non-invasively with radioiodine.\n\nIn 2014 he reported two measles-seronegative patients with drug-refractory myeloma given a single intravenous infusion of 10^11 infectious units of MV-NIS. Both responded and one had a durable complete remission at all disease sites, with imaging confirming virus replication inside the tumours. It remains the most cited demonstration that intravenous oncolytic virotherapy can work, and the clearest illustration of why it usually cannot: the patients were selected for having no pre-existing measles antibodies, which excludes nearly everyone.\n\nWith Kah-Whye Peng and John Bell he wrote the 2012 Nature Biotechnology review that set the field's agenda, and with Eleanor Kelly the 2007 history of oncolytic viruses from the first case reports to genetic engineering. He read and commented on the 2024 Croatian self-experimentation case report before publication, which the authors acknowledge.","asOf":"2026-09-25","links":[{"label":"ORCID","url":"https://orcid.org/0000-0002-0799-6432"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Russell%20SJ%5BAuthor%5D%20oncolytic%20OR%20measles"},{"label":"Mayo Clinic research faculty","url":"https://www.mayo.edu/research/faculty"}],"tags":["oncolytic-virus","immunotherapy","myeloma"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":["oncolytic-virus"],"targets":[],"drugs":[],"companies":[],"institutions":["mayo-clinic"],"pathways":[],"terms":[],"trials":[],"people":["evanthia-galanis","john-bell"],"bottlenecks":[],"keyPapers":["paper-russell-mv-nis-myeloma-mayo-2014","paper-russell-peng-bell-oncolytic-virotherapy-natbiotech-2012","paper-kelly-russell-oncolytic-history-moltherapy-2007"],"journals":[],"dependsOn":[],"notes":[],"role":"Molecular medicine researcher, Mayo Clinic, Rochester; also affiliated with Vyriad, Rochester","institutionId":"mayo-clinic","specialisms":["Oncolytic virotherapy","Engineered measles virus","Myeloma","Gene and virus manufacturing"],"profiles":[{"label":"ORCID","url":"https://orcid.org/0000-0002-0799-6432"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Russell%20SJ%5BAuthor%5D%20oncolytic%20OR%20measles"},{"label":"Mayo Clinic research faculty","url":"https://www.mayo.edu/research/faculty"}],"papers":[{"title":"Remission of disseminated cancer after systemic oncolytic virotherapy","journal":"Mayo Clinic Proceedings","year":2014,"doi":"10.1016/j.mayocp.2014.04.003"},{"title":"Oncolytic virotherapy","journal":"Nature Biotechnology","year":2012,"doi":"10.1038/nbt.2287"},{"title":"History of oncolytic viruses: genesis to genetic engineering","journal":"Molecular Therapy","year":2007,"doi":"10.1038/sj.mt.6300108"}],"orcid":"0000-0002-0799-6432"},{"id":"stephen-schuster","kind":"person","name":"Stephen J. Schuster","aka":[],"tldr":"Led JULIET, which brought tisagenlecleucel, the first CAR-T, to adults with relapsed large B-cell lymphoma.","summary":"Stephen Schuster led the first trial of CTL019 (tisagenlecleucel) in lymphoma and was principal investigator of JULIET, the global trial that won its approval for relapsed or refractory DLBCL, and of the follow-up studies showing durable five-year remissions. He directs the lymphoma programme at Penn and continues to lead trials of next-generation CAR-T and bispecific antibodies.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schuster%20SJ%5BAuthor%5D%20tisagenlecleucel"}],"tags":["lymphoma","car-t","cell-therapy"],"related":[],"cancers":["dlbcl","follicular-lymphoma"],"sections":[],"technologies":["car-t"],"targets":["cd19"],"drugs":[],"companies":[],"institutions":["penn-abramson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-juliet-tisagenlecleucel-dlbcl-nejm-2019"],"journals":[],"dependsOn":[],"notes":[],"role":"Robert and Margarita Louis-Dreyfus Professor in CLL and Lymphoma, Abramson Cancer Center, University of Pennsylvania","institutionId":"penn-abramson","specialisms":["CAR T-cell therapy","Lymphoma","Chronic lymphocytic leukaemia","Cellular immunotherapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schuster%20SJ%5BAuthor%5D%20tisagenlecleucel"}],"papers":[{"title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma (JULIET)","journal":"NEJM","year":2019,"doi":"10.1056/NEJMoa1804980"},{"title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","journal":"NEJM","year":2017,"doi":"10.1056/NEJMoa1708566"}],"orcid":"0000-0002-3376-8978"},{"id":"stephen-johnston","kind":"person","name":"Stephen Johnston","aka":[],"tldr":"Chief investigator of monarchE, the trial that added abemaciclib to adjuvant endocrine therapy for high-risk early breast cancer.","summary":"Stephen Johnston led monarchE, which showed two years of abemaciclib with endocrine therapy cuts recurrence in node-positive, high-risk HR-positive early breast cancer, the first adjuvant CDK4/6 inhibitor approval. His earlier work defined mechanisms of endocrine resistance and the fulvestrant dose used today. He continues to lead adjuvant and oral SERD trials from the Royal Marsden.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Johnston%20SRD%5BAuthor%5D%20abemaciclib"}],"tags":["breast","trialist"],"related":[],"cancers":["breast-hr-positive"],"sections":[],"technologies":["cdk46-inhibitor","endocrine-therapy"],"targets":["cdk4-6","estrogen-receptor"],"drugs":["abemaciclib"],"companies":[],"institutions":["royal-marsden","icr-london"],"pathways":[],"terms":[],"trials":["monarche"],"people":[],"bottlenecks":[],"keyPapers":["paper-monarche-jco-2020"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Breast Cancer Medicine, Royal Marsden and Institute of Cancer Research","institutionId":"royal-marsden","specialisms":["HR-positive breast cancer","Adjuvant CDK4/6 inhibition","Endocrine resistance"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Johnston%20SRD%5BAuthor%5D%20abemaciclib"}],"papers":[{"title":"Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE)","journal":"JCO","year":2020,"doi":"10.1200/JCO.20.02514"},{"title":"Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial","journal":"Lancet Oncology","year":2023},{"title":"monarchE: two years of abemaciclib after surgery in high-risk, hormone-receptor-positive early breast cancer","journal":"Journal of Clinical Oncology","year":2020,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=monarchE+abemaciclib+adjuvant+Johnston+2020"}],"orcid":"0000-0002-9072-2749"},{"id":"stephen-hunger","kind":"person","name":"Stephen P. Hunger","aka":[],"tldr":"Chaired the COG leukaemia committee through the era that pushed childhood ALL cure rates above 90%.","summary":"Stephen Hunger chaired the Children's Oncology Group acute lymphoblastic leukaemia committee from 2008 to 2016 and led the analyses documenting improved survival across successive trials, the Ph-like ALL discovery work with Charles Mullighan, and the trials that added imatinib to chemotherapy for Philadelphia-positive ALL. He co-authored the NEJM review of childhood ALL and leads oncology at CHOP.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Stephen_P._Hunger","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hunger%20SP%5BAuthor%5D%20acute%20lymphoblastic%20leukemia%20children"}],"tags":["paediatric","all","cooperative-group"],"related":[],"cancers":["all-leukemia"],"sections":[],"technologies":[],"targets":[],"drugs":["imatinib","blinatumomab"],"companies":[],"institutions":["chop"],"pathways":[],"terms":[],"trials":["aall1731"],"people":[],"bottlenecks":[],"keyPapers":["paper-aall1731-blinatumomab-children-nejm-2025"],"journals":[],"dependsOn":[],"notes":[],"role":"Chief, Division of Oncology, Children's Hospital of Philadelphia; Jeffrey E. Perelman Distinguished Chair in Pediatrics","institutionId":"chop","specialisms":["Paediatric acute lymphoblastic leukaemia","Cooperative-group trials","Leukaemia genomics","Risk stratification"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hunger%20SP%5BAuthor%5D%20acute%20lymphoblastic%20leukemia%20children"}],"papers":[{"title":"Acute lymphoblastic leukemia in children","journal":"NEJM","year":2015,"doi":"10.1056/NEJMra1400972"},{"title":"Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the Children's Oncology Group","journal":"JCO","year":2012,"doi":"10.1200/JCO.2011.37.8018"},{"title":"Children's Oncology Group AALL1731: blinatumomab added to chemotherapy for children with standard-risk B-cell ALL","journal":"New England Journal of Medicine","year":2025,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=AALL1731%20blinatumomab%20standard-risk%20B-ALL%20children%20Gupta%20NEJM%202025"}],"orcid":"0000-0002-5492-3957"},{"id":"stephen-scherer","kind":"person","name":"Stephen Scherer","aka":[],"tldr":"Genome scientist who heads research at SickKids and co-discovered genome-wide copy number variation in humans.","summary":"Stephen Scherer, PhD, is Chief of Research at The Hospital for Sick Children (SickKids) and Director of The Centre for Applied Genomics. His work on human genome structural variation and the genetics of autism spectrum disorder is among the most cited in genomics, and he oversees the SickKids Research Institute, which includes paediatric cancer research programmes.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.sickkids.ca/en/about/leadership/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Scherer+SW%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","genomics"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["sickkids"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nature"],"dependsOn":[],"notes":[],"role":"Chief of Research","institutionId":"sickkids","specialisms":["Genomics","Copy number variation","Autism genetics"],"profiles":[{"label":"Institution profile","url":"https://www.sickkids.ca/en/about/leadership/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Scherer+SW%5BAuthor%5D"}],"papers":[{"title":"Global variation in copy number in the human genome","journal":"Nature","year":2006,"url":"https://doi.org/10.1038/nature05329","doi":"10.1038/nature05329","note":"Europe PMC author record matched by affiliation"},{"title":"Synaptic, transcriptional and chromatin genes disrupted in autism","journal":"Nature","year":2014,"url":"https://doi.org/10.1038/nature13772","doi":"10.1038/nature13772","note":"Europe PMC author record matched by affiliation"},{"title":"Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies","journal":"Am J Hum Genet","year":2010,"url":"https://doi.org/10.1016/j.ajhg.2010.04.006","doi":"10.1016/j.ajhg.2010.04.006","note":"Europe PMC author record matched by affiliation"}],"orcid":"0000-0002-8326-1999"},{"id":"stephen-sutton","kind":"person","name":"Stephen Sutton","aka":[],"tldr":"Diagnosed with bowel cancer at 15, he turned his final years into a public campaign that raised more than £5 million for the Teenage Cancer Trust before he died at 19.","summary":"Stephen Sutton (1994-2014), from Burntwood, Staffordshire, was diagnosed with metastatic colorectal cancer at 15, an age at which the disease is rare and easily missed. Rather than pursue his planned medical degree, he wrote a bucket list and shared it online; his final item was to raise £10,000 for the Teenage Cancer Trust. A photograph of him giving a thumbs-up from his hospital bed in April 2014 went viral, and donations passed £3 million within days. He died on 14 May 2014 at 19, having been appointed MBE; the total passed £5 million. His campaign put early-onset bowel cancer and the specific needs of teenage and young adult patients in front of a national audience.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Stephen_Sutton","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Stephen_Sutton"},{"label":"Teenage Cancer Trust","url":"https://www.teenagecancertrust.org/"}],"tags":["hero","patient"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["teenage-cancer-trust"],"pathways":[],"terms":["aya-oncology"],"trials":[],"people":[],"bottlenecks":["b-early-detection","b-patient-voice"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Teenage patient whose bucket list raised millions for young people with cancer","specialisms":["Colorectal cancer","Adolescent and young adult cancer","Cancer fundraising"],"profiles":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Stephen_Sutton"},{"label":"Teenage Cancer Trust","url":"https://www.teenagecancertrust.org/"}],"papers":[]},{"id":"steve-jobs","kind":"person","name":"Steve Jobs","aka":[],"tldr":"Diagnosed in 2003 with a rare, slow-growing pancreatic neuroendocrine tumour, he put off surgery for about nine months while trying diet and alternative approaches. His case is the standard example in discussions of delay and unproven therapies.","summary":"Steve Jobs (1955-2011) was diagnosed in October 2003 with a pancreatic neuroendocrine tumour, a rarer and generally slower-growing disease than pancreatic adenocarcinoma and often curable by surgery when caught early. According to his authorised biographer, Walter Isaacson, he resisted an operation for around nine months, pursuing diet-based and alternative treatments, before undergoing a Whipple procedure in July 2004; Isaacson reported that Jobs later regretted the delay. He had a liver transplant in 2009 for metastatic disease, and had his tumour and germline genomes sequenced, an early instance of personal cancer genomics. He died on 5 October 2011 at 56. Clinicians cannot know whether earlier surgery would have changed his outcome, and his case is cited here not as a verdict but as the reason the conversation about delay, evidence and patient autonomy is had so often.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Steve_Jobs","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Steve_Jobs"}],"tags":["public-figure","patient"],"related":[],"cancers":["neuroendocrine"],"sections":[],"technologies":["liver-transplant-oncology","wes-wgs"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["unproven-diet-claims","net-grade-ki67"],"trials":[],"people":[],"bottlenecks":["b-misinformation","b-patient-voice"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Patient whose delay of surgery for a neuroendocrine tumour became a public debate","specialisms":["Pancreatic neuroendocrine tumour","Treatment decisions","Unproven therapies"],"profiles":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Steve_Jobs"}],"papers":[]},{"id":"steven-rosenberg","kind":"person","name":"Steven A. Rosenberg","aka":[],"tldr":"Father of cancer immunotherapy: first to cure patients with IL-2 and with their own tumour-infiltrating lymphocytes.","summary":"Steven A. Rosenberg is Chief of the Surgery Branch in the Center for Cancer Research at the National Cancer Institute. He is regarded as the father of cancer immunotherapy, the first to cure patients with interleukin-2 and with their own tumour-infiltrating lymphocytes, and over four decades at NCI he pioneered IL-2, TIL therapy and gene-modified T cells. His selected papers report cancer regression after transfer of genetically engineered lymphocytes and T-cell transfer therapy targeting mutant KRAS. His branch's TIL work led to lifileucel and to neoantigen-specific TCR-T cells against KRAS and TP53 mutations in melanoma and colorectal cancer.","asOf":"2026-09-08","links":[{"label":"NCI CCR profile","url":"https://ccr.cancer.gov/staff-directory/steven-a-rosenberg"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rosenberg%20SA%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["melanoma","colorectal"],"sections":[],"technologies":["til-therapy","tcr-t","cytokine-therapy"],"targets":["kras","tp53"],"drugs":["lifileucel"],"companies":[],"institutions":["nci"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief, Surgery Branch, Center for Cancer Research","institutionId":"nci","specialisms":["Adoptive cell therapy","TIL therapy","Neoantigen-specific T cells"],"profiles":[{"label":"NCI CCR profile","url":"https://ccr.cancer.gov/staff-directory/steven-a-rosenberg"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rosenberg%20SA%5BAuthor%5D"}],"papers":[{"title":"Cancer regression in patients after transfer of genetically engineered lymphocytes","journal":"Science","year":2006,"url":"https://doi.org/10.1126/science.1129003","doi":"10.1126/science.1129003"},{"title":"T-cell transfer therapy targeting mutant KRAS in cancer","journal":"New England Journal of Medicine","year":2016,"url":"https://doi.org/10.1056/NEJMoa1609279","doi":"10.1056/NEJMoa1609279"},{"title":"C-144-01: lifileucel, tumour-infiltrating lymphocytes grown from a patient's own tumour, in melanoma after checkpoint inhibitors have failed","journal":"Journal of Clinical Oncology","year":2021,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=C-144-01%20lifileucel%20tumor-infiltrating%20lymphocyte%20melanoma%20Sarnaik%20JCO%202021"}]},{"id":"steven-clifford","kind":"person","name":"Steven Clifford","aka":[],"tldr":"Medulloblastoma biologist whose molecular subgrouping work underpins risk-adapted treatment of childhood brain tumours; directs Newcastle University's cancer centre.","summary":"Steven Clifford is Director of the Newcastle University Centre for Cancer and Chair of Molecular Paediatric Oncology. His research has defined molecular subgroups and prognostic biomarkers of medulloblastoma, the most common malignant childhood brain tumour, informing risk stratification in European SIOP trials and clinical guidelines. The centre works alongside the Northern Centre for Cancer Care at Newcastle Hospitals NHS Foundation Trust.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.ncl.ac.uk/cancer/about-us/leadership-team/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Clifford+SC%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","paediatric oncology","neuro-oncology"],"related":[],"cancers":["medulloblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["newcastle-cancer-centre"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chair of Molecular Paediatric Oncology and Director, Newcastle University Centre for Cancer","institutionId":"newcastle-cancer-centre","specialisms":["Medulloblastoma","Paediatric neuro-oncology","Molecular classification","Biomarkers"],"profiles":[{"label":"Institution profile","url":"https://www.ncl.ac.uk/cancer/about-us/leadership-team/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Clifford+SC%5BAuthor%5D"}],"papers":[{"title":"Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study","journal":"Lancet Oncology","year":2017,"url":"https://doi.org/10.1016/S1470-2045(17)30243-7","doi":"10.1016/S1470-2045(17)30243-7"},{"title":"EANO-EURACAN clinical practice guideline for diagnosis, treatment, and follow-up of post-pubertal and adult patients with medulloblastoma","journal":"Lancet Oncology","year":2019,"url":"https://doi.org/10.1016/S1470-2045(19)30669-2","doi":"10.1016/S1470-2045(19)30669-2"},{"title":"Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial","journal":"Lancet Oncology","year":2018,"url":"https://doi.org/10.1016/S1470-2045(18)30532-1","doi":"10.1016/S1470-2045(18)30532-1"}]},{"id":"steven-artandi","kind":"person","name":"Steven E. Artandi","aka":[],"tldr":"Steven Artandi is a telomerase biologist who directs Stanford's cancer institute.","summary":"Steven Artandi is Director of the Stanford Cancer Institute, a post he has held since 2019. A physician-scientist specialising in telomere biology and cancer stem cells, his laboratory studies telomerase regulation, telomere dysfunction and stem cells in cancer. His papers include a Carcinogenesis review of telomeres and telomerase in cancer and a Nature Reviews Molecular Cell Biology review of the regulation of human telomerase in homeostasis and disease. His record links his work to CRISPR functional genomics alongside his cancer centre leadership.","asOf":"2026-09-08","links":[{"label":"Stanford profile","url":"https://profiles.stanford.edu/search?q=Steven%20E.%20Artandi"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Artandi%20SE%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Steven%20E.%20Artandi"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["crispr-screens"],"targets":[],"drugs":[],"companies":[],"institutions":["stanford"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["carcinogenesis"],"dependsOn":[],"notes":[],"role":"Director, Stanford Cancer Institute","institutionId":"stanford","specialisms":["Telomere biology","Cancer stem cells","Cancer center leadership"],"profiles":[{"label":"Stanford profile","url":"https://profiles.stanford.edu/search?q=Steven%20E.%20Artandi"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Artandi%20SE%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Steven%20E.%20Artandi"}],"papers":[{"title":"Telomeres and telomerase in cancer","journal":"Carcinogenesis","year":2010,"url":"https://doi.org/10.1093/carcin/bgp268","doi":"10.1093/carcin/bgp268"},{"title":"Regulation of human telomerase in homeostasis and disease","journal":"Nature Reviews Molecular Cell Biology","year":2020,"url":"https://doi.org/10.1038/s41580-020-0234-z","doi":"10.1038/s41580-020-0234-z"}]},{"id":"steven-k-libutti","kind":"person","name":"Steven K. Libutti","aka":[],"tldr":"Surgeon who directs Rutgers Cancer Institute of New Jersey, the state's NCI-designated comprehensive cancer centre.","summary":"Steven K. Libutti, MD, FACS, is Director of Rutgers Cancer Institute of New Jersey, which holds National Cancer Institute designation as a Comprehensive Cancer Center. He is a Fellow of the American College of Surgeons and runs the Libutti Laboratory within the institute's resident faculty research programme. The institute's website lists him at the head of its leadership and publishes a message from the Director under his name.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Steven_Libutti","links":[{"label":"Source: Rutgers Cancer Institute leadership profile","url":"https://www.cinj.org/about-cinj/steven-k-libutti-md-facs"},{"label":"Rutgers Cancer Institute home page naming the Director","url":"https://www.cinj.org/"}],"tags":["leadership","clinician-scientist","comprehensive-cancer-centre"],"related":[],"cancers":["neuroendocrine"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["rutgers-cinj"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Rutgers Cancer Institute of New Jersey","institutionId":"rutgers-cinj","specialisms":["Surgical oncology","Endocrine and neuroendocrine tumours","Cancer centre leadership"],"profiles":[{"label":"Rutgers Cancer Institute profile","url":"https://www.cinj.org/about-cinj/steven-k-libutti-md-facs"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Libutti+SK%5BAuthor%5D"}],"papers":[{"title":"Management of Other Gastric and Duodenal Neuroendocrine Tumors","journal":"Surgical Oncology Clinics of North America","year":2020,"doi":"10.1016/j.soc.2019.11.009"},{"title":"B7 immune-checkpoints as targets for the treatment of neuroendocrine tumors","journal":"Endocrine-Related Cancer","year":2021,"doi":"10.1530/erc-20-0337"},{"title":"Association of VHL Genotype With Pancreatic Neuroendocrine Tumor Phenotype in Patients With von Hippel–Lindau Disease","journal":"JAMA Oncology","year":2018,"doi":"10.1001/jamaoncol.2017.3428"}]},{"id":"steven-le-gouill","kind":"person","name":"Steven Le Gouill","aka":[],"tldr":"Steven Le Gouill is a lymphoma specialist who leads the Institut Curie hospitals.","summary":"Steven Le Gouill is Director of the Institut Curie Hospital Group in Paris and a haematologist. His specialisms are lymphoma, mantle cell lymphoma and hospital leadership. He is a lymphoma trialist known for mantle cell lymphoma studies with the LYSA group. His papers include the long-term follow-up of rituximab maintenance in young patients with mantle cell lymphoma in the LYMA trial, the final results of a phase II study of acalabrutinib monotherapy in relapsed or refractory mantle cell lymphoma, and a Blood comparison of obinutuzumab and rituximab for transplant-eligible patients with mantle cell lymphoma. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Le%20Gouill%20S%5BAuthor%5D%20mantle%20cell%20lymphoma"}],"tags":[],"related":[],"cancers":["dlbcl"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["institut-curie"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["haematologica"],"dependsOn":[],"notes":[],"role":"Director, Institut Curie Hospital Group; haematologist","institutionId":"institut-curie","specialisms":["Lymphoma","Mantle cell lymphoma","Hospital leadership"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Le%20Gouill%20S%5BAuthor%5D%20mantle%20cell%20lymphoma"}],"papers":[{"title":"Long-Term Follow-Up of Rituximab Maintenance in Young Patients With Mantle-Cell Lymphoma Included in the LYMA Trial: A LYSA Study","journal":"Journal of Clinical Oncology","year":2024,"doi":"10.1200/jco.23.01586"},{"title":"Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors","journal":"Haematologica","year":2023,"doi":"10.3324/haematol.2022.282469"},{"title":"Obinutuzumab vs rituximab for transplant-eligible patients with mantle cell lymphoma","journal":"Blood","year":2024,"doi":"10.1182/blood.2024023944"}],"orcid":"0000-0001-9840-2128"},{"id":"steven-horwitz","kind":"person","name":"Steven M. Horwitz","aka":[],"tldr":"Led ECHELON-2, the first trial to improve survival in peripheral T-cell lymphoma, using brentuximab vedotin.","summary":"Steven Horwitz was principal investigator of ECHELON-2, which showed brentuximab vedotin plus CHP improves progression-free and overall survival compared with CHOP in CD30-positive peripheral T-cell lymphoma, the first randomised survival benefit in the disease. He has led trials of pralatrexate, romidepsin, duvelisib and other agents in T-cell lymphomas and leads the T-cell lymphoma programme at MSKCC.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Horwitz%20SM%5BAuthor%5D%20T-cell%20lymphoma"}],"tags":["lymphoma","t-cell","adc"],"related":[],"cancers":["peripheral-t-cell-lymphoma"],"sections":[],"technologies":["adc"],"targets":[],"drugs":["brentuximab-vedotin"],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Attending Physician, Lymphoma Service, Memorial Sloan Kettering Cancer Center","institutionId":"mskcc","specialisms":["Peripheral T-cell lymphoma","Cutaneous T-cell lymphoma","Antibody-drug conjugates","Novel agents"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Horwitz%20SM%5BAuthor%5D%20T-cell%20lymphoma"}],"papers":[{"title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","journal":"Lancet","year":2019,"doi":"10.1016/S0140-6736(18)32984-2"},{"title":"The ECHELON-2 trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma","journal":"Annals of Oncology","year":2022,"doi":"10.1016/j.annonc.2021.12.002"}],"orcid":"0000-0002-6399-2006"},{"id":"steven-treon","kind":"person","name":"Steven P. Treon","aka":[],"tldr":"Discovered the MYD88 mutation that defines Waldenström macroglobulinaemia and led the trial that made ibrutinib its first approved drug.","summary":"Steven Treon led the whole-genome sequencing that found the MYD88 L265P mutation in more than 90% of Waldenström macroglobulinaemia, a diagnostic marker and therapeutic target, and then the pivotal trial of ibrutinib that produced the disease's first FDA approval. He identified CXCR4 mutations as a resistance mechanism and directs the world's largest Waldenström research centre at Dana-Farber.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Treon%20SP%5BAuthor%5D%20Waldenstrom"}],"tags":["lymphoma","waldenstrom","genomics"],"related":[],"cancers":["waldenstrom"],"sections":[],"technologies":["kinase-inhibitors","wes-wgs"],"targets":[],"drugs":[],"companies":[],"institutions":["dana-farber"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute","institutionId":"dana-farber","specialisms":["Waldenström macroglobulinaemia","MYD88 and CXCR4 genomics","BTK inhibitors","Rare lymphomas"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Treon%20SP%5BAuthor%5D%20Waldenstrom"}],"papers":[{"title":"MYD88 L265P somatic mutation in Waldenström's macroglobulinemia","journal":"NEJM","year":2012,"doi":"10.1056/NEJMoa1200710"},{"title":"Ibrutinib in previously treated Waldenström's macroglobulinemia","journal":"NEJM","year":2015,"doi":"10.1056/NEJMoa1501548"}],"orcid":"0000-0001-6393-6154"},{"id":"steven-rosen","kind":"person","name":"Steven T. Rosen","aka":[],"tldr":"Steven Rosen is a lymphoma specialist who directs City of Hope's research enterprise.","summary":"Steven Rosen is Provost and Chief Scientific Officer of City of Hope and Director of its Beckman Research Institute, having previously directed Northwestern's Lurie Cancer Center for 25 years. A haematologist-oncologist specialising in lymphoma and translational science, he leads Beckman Research Institute and City of Hope's comprehensive cancer centre designation. His papers include a Blood Reviews article on primary cutaneous lymphomas and their treatment options and a Blood phase II trial of 2-chlorodeoxyadenosine for cutaneous T-cell lymphoma. His work links lymphoma research, including diffuse large B-cell lymphoma, to cancer research leadership.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Steven_T._Rosen","links":[{"label":"City of Hope research faculty","url":"https://www.cityofhope.org/research/find-a-researcher"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rosen%20ST%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Steven%20T.%20Rosen"}],"tags":[],"related":[],"cancers":["dlbcl"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["city-of-hope"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Provost and Chief Scientific Officer; Director, Beckman Research Institute, City of Hope","institutionId":"city-of-hope","specialisms":["Lymphoma","Cancer research leadership","Translational science"],"profiles":[{"label":"City of Hope research faculty","url":"https://www.cityofhope.org/research/find-a-researcher"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rosen%20ST%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Steven%20T.%20Rosen"}],"papers":[{"title":"Primary cutaneous lymphomas: a review with current treatment options","journal":"Blood Reviews","year":2003,"url":"https://doi.org/10.1016/s0268-960x(03)00004-3","doi":"10.1016/s0268-960x(03)00004-3"},{"title":"Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma","journal":"Blood","year":1996}],"orcid":"0000-0002-8818-7724"},{"id":"gupta-sudeep","kind":"person","name":"Sudeep Gupta","aka":[],"tldr":"Sudeep Gupta leads India's largest cancer centre and its programme of pragmatic, affordable trials.","summary":"Sudeep Gupta is Director of the Tata Memorial Centre in Mumbai, India's largest cancer centre, and Professor of Medical Oncology. A breast and gynaecologic medical oncologist, he leads the centre's programme of pragmatic, affordable trials, randomised studies designed for resource-limited settings that reach tens of thousands of new patients a year. His publications include the randomised trial of locoregional treatment of the primary tumour in metastatic breast cancer and the trial of peritumoral infiltration of local anaesthetic before surgery in early breast cancer. His interests span HR-positive, triple-negative and ovarian cancer, clinical trials and global oncology.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Sudeep_Gupta","links":[{"label":"Tata Memorial Centre","url":"https://tmc.gov.in"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gupta%20S%5BAuthor%5D%20Tata%20Memorial%20breast%20cancer"}],"tags":[],"related":[],"cancers":["breast-hr-positive","tnbc","ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["tata-memorial"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Tata Memorial Centre; Professor of Medical Oncology","institutionId":"tata-memorial","specialisms":["Breast cancer","Gynaecologic oncology","Clinical trials","Global oncology"],"profiles":[{"label":"Tata Memorial Centre","url":"https://tmc.gov.in"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gupta%20S%5BAuthor%5D%20Tata%20Memorial%20breast%20cancer"}],"papers":[{"title":"Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial","journal":"The Lancet Oncology","year":2015,"doi":"10.1016/s1470-2045(15)00135-7"},{"title":"Effect of Peritumoral Infiltration of Local Anesthetic Before Surgery on Survival in Early Breast Cancer","journal":"Journal of Clinical Oncology","year":2023,"doi":"10.1200/jco.22.01966"}],"orcid":"0000-0002-6742-6378"},{"id":"sulaiman-shahabuddin","kind":"person","name":"Sulaiman Shahabuddin","aka":[],"tldr":"Sulaiman Shahabuddin represents The Aga Khan Hospital, Dar es Salaam in the Organisation of European Cancer Institutes, which lists the centre among its members in Tanzania.","summary":"Sulaiman Shahabuddin is listed by the Organisation of European Cancer Institutes (OECI) as the representative of The Aga Khan Hospital, Dar es Salaam, its associate member in Tanzania. OnCo records the name from the OECI membership list so that the centre's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the institution's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"The Aga Khan Hospital, Dar es Salaam website","url":"https://www.akdn.org/our-agencies/aga-khan-health-services"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["aga-khan-hospital-dar-es-salaam"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of The Aga Khan Hospital, Dar es Salaam to the Organisation of European Cancer Institutes","institutionId":"aga-khan-hospital-dar-es-salaam","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"The Aga Khan Hospital, Dar es Salaam website","url":"https://www.akdn.org/our-agencies/aga-khan-health-services"}],"papers":[{"title":"Surgical removal of an embolised patent ductus arteriosus amplatzer occluding device in a 4-year-old girl","journal":"Interact Cardiovasc Thorac Surg","year":2007,"url":"https://doi.org/10.1510/icvts.2007.152298","doi":"10.1510/icvts.2007.152298","note":"Europe PMC author record matched by affiliation"},{"title":"Risk stratification analysis of operative mortality in isolated coronary artery bypass graft patients in Pakistan: comparison between additive and logistic EuroSCORE models","journal":"Interact Cardiovasc Thorac Surg","year":2011,"url":"https://doi.org/10.1510/icvts.2011.266890","doi":"10.1510/icvts.2011.266890","note":"Europe PMC author record matched by affiliation"},{"title":"Tuberculous ascending aortic pseudoaneurysm","journal":"Interact Cardiovasc Thorac Surg","year":2013,"url":"https://doi.org/10.1093/icvts/ivt271","doi":"10.1093/icvts/ivt271","note":"Europe PMC author record matched by affiliation"}]},{"id":"sultan-mohamed-alkaram","kind":"person","name":"Sultan Mohamed Alkaram","aka":[],"tldr":"Chief executive for the Al Ain region who leads Tawam Hospital, the main national cancer treatment centre in the United Arab Emirates.","summary":"Dr Sultan Mohamed Alkaram is Chief Executive Officer for the Al Ain Region and signs the CEO message on the Tawam Hospital website. Tawam Hospital, part of the SEHA network, has served the community for four decades and describes a focused commitment to specialised care in women's and children's health and cancer treatment. Its oncology centre is the main national cancer treatment centre and a regional referral centre.","asOf":"2026-09-10","links":[{"label":"Source: Tawam Hospital homepage, Message from the CEO","url":"https://tawam.seha.ae/"}],"tags":["leadership","hospital-management","uae"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["tawam-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive Officer, Al Ain Region (Tawam Hospital)","institutionId":"tawam-hospital","specialisms":["Hospital leadership","Regional health system management","Cancer services"],"profiles":[{"label":"Tawam Hospital (Message from the CEO)","url":"https://tawam.seha.ae/"}],"papers":[]},{"id":"sumanta-pal","kind":"person","name":"Sumanta K. Pal","aka":[],"tldr":"Led SWOG 1500, the first randomised trial to set a standard for papillary kidney cancer, and studies of the microbiome in RCC immunotherapy.","summary":"Sumanta Pal was principal investigator of SWOG PAPMET (S1500), which showed cabozantinib outperforms sunitinib in metastatic papillary renal cell carcinoma, the first practice-changing randomised trial in a non-clear-cell histology, and a lead investigator of COSMIC-313 and CONTACT-03. He led the randomised trial of the live bacterial product CBM588 with immunotherapy. He co-directs the kidney cancer programme at City of Hope.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Pal%20SK%5BAuthor%5D%20renal%20cell"}],"tags":["rcc","swog","microbiome"],"related":[],"cancers":["rcc"],"sections":[],"technologies":["checkpoint-inhibitor","kinase-inhibitors"],"targets":[],"drugs":["nivolumab","ipilimumab","atezolizumab"],"companies":[],"institutions":["city-of-hope"],"pathways":[],"terms":[],"trials":["cosmic-313","contact-03"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor and Co-Director, Kidney Cancer Program, City of Hope","institutionId":"city-of-hope","specialisms":["Renal cell carcinoma","Non-clear-cell histologies","Microbiome and immunotherapy","Cooperative-group trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Pal%20SK%5BAuthor%5D%20renal%20cell"}],"papers":[{"title":"A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma (SWOG 1500)","journal":"Lancet","year":2021,"doi":"10.1016/S0140-6736(21)00152-5"},{"title":"Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03)","journal":"Lancet","year":2023,"doi":"10.1016/S0140-6736(23)00922-4"}]},{"id":"sumit-gupta","kind":"person","name":"Sumit Gupta","aka":[],"tldr":"Led COG AALL1731, which showed adding blinatumomab to chemotherapy improves survival for children with standard-risk leukaemia.","summary":"Sumit Gupta was study chair of Children's Oncology Group AALL1731, the randomised trial showing that adding the CD19 bispecific blinatumomab to chemotherapy dramatically improves disease-free survival in children with newly diagnosed standard-risk B-cell acute lymphoblastic leukaemia, the largest advance in front-line childhood ALL in decades. He also studies disparities and outcomes in paediatric cancer at SickKids.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gupta%20S%5BAuthor%5D%20blinatumomab%20AALL1731"}],"tags":["paediatric","all","immunotherapy"],"related":[],"cancers":["all-leukemia"],"sections":[],"technologies":["t-cell-engager"],"targets":["cd19","cd3"],"drugs":["blinatumomab"],"companies":[],"institutions":["sickkids"],"pathways":[],"terms":[],"trials":["aall1731"],"people":[],"bottlenecks":[],"keyPapers":["paper-aall1731-blinatumomab-children-nejm-2025"],"journals":["cancer-wiley"],"dependsOn":[],"notes":[],"role":"Staff Oncologist and Senior Scientist, The Hospital for Sick Children (SickKids), Toronto","institutionId":"sickkids","specialisms":["Paediatric acute lymphoblastic leukaemia","Immunotherapy","Health outcomes research","Cooperative-group trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gupta%20S%5BAuthor%5D%20blinatumomab%20AALL1731"}],"papers":[{"title":"Blinatumomab in standard-risk B-cell acute lymphoblastic leukemia in children (AALL1731)","journal":"NEJM","year":2025},{"title":"Pediatric cancer outcomes and socioeconomic status: population-based studies","journal":"Cancer","year":2016},{"title":"Children's Oncology Group AALL1731: blinatumomab added to chemotherapy for children with standard-risk B-cell ALL","journal":"New England Journal of Medicine","year":2025,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=AALL1731%20blinatumomab%20standard-risk%20B-ALL%20children%20Gupta%20NEJM%202025"}]},{"id":"rha-sun-young","kind":"person","name":"Sun Young Rha","aka":[],"tldr":"A gastric cancer trialist who led Korean arms of first-line immunotherapy and Claudin 18.2 studies.","summary":"Sun Young Rha is Professor of Medical Oncology at Severance Hospital, Yonsei University, in Seoul, specialising in gastric cancer. She leads gastric cancer research at Yonsei Cancer Center and led the Korean arms of first-line immunotherapy and Claudin 18.2 studies, with principal or co-investigator roles in KEYNOTE-859 with pembrolizumab, in SPOTLIGHT and GLOW with zolbetuximab, and in HER2-directed trials. Her publications include the KEYNOTE-859 trial of pembrolizumab plus chemotherapy for HER2-negative advanced gastric cancer. Her interests are gastric cancer, immunotherapy, HER2 and clinical trials.","asOf":"2026-09-08","links":[{"label":"Yonsei Cancer Center","url":"https://sev.severance.healthcare"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rha%20SY%5BAuthor%5D%20Yonsei%20gastric"}],"tags":[],"related":[],"cancers":["gastric"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab","zolbetuximab"],"companies":[],"institutions":["severance"],"pathways":[],"terms":[],"trials":["keynote-859","spotlight-glow"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology; gastric cancer","institutionId":"severance","specialisms":["Gastric cancer","Immunotherapy","HER2","Clinical trials"],"profiles":[{"label":"Yonsei Cancer Center","url":"https://sev.severance.healthcare"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rha%20SY%5BAuthor%5D%20Yonsei%20gastric"}],"papers":[{"title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859)","journal":"Lancet Oncology","year":2023,"doi":"10.1016/S1470-2045(23)00515-6"},{"title":"CLEAR: lenvatinib plus pembrolizumab versus sunitinib as first treatment for advanced kidney cancer","journal":"New England Journal of Medicine","year":2021,"url":"https://doi.org/10.1056/NEJMoa2035716","doi":"10.1056/NEJMoa2035716"}]},{"id":"sundar-jagannath","kind":"person","name":"Sundar Jagannath","aka":[],"tldr":"Veteran myeloma trialist who helped bring proteasome inhibitors and bispecifics to patients.","summary":"Sundar Jagannath is Director of the Center of Excellence for Multiple Myeloma at The Mount Sinai Hospital and Tisch Cancer Institute. He is a veteran myeloma trialist who helped bring proteasome inhibitors and bispecific antibodies to patients, serving as principal investigator across bortezomib, carfilzomib and teclistamab-era studies. His selected paper reports bortezomib alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. He directs Mount Sinai's myeloma centre and continues to work on novel agents and bispecific antibodies.","asOf":"2026-09-08","links":[{"label":"Mount Sinai profile","url":"https://profiles.mountsinai.org/sundar-jagannath"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Jagannath%20S%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":["bortezomib","carfilzomib","teclistamab"],"companies":[],"institutions":["mount-sinai"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Center of Excellence for Multiple Myeloma","institutionId":"mount-sinai","specialisms":["Multiple myeloma","Novel agents","Bispecific antibodies"],"profiles":[{"label":"Mount Sinai profile","url":"https://profiles.mountsinai.org/sundar-jagannath"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Jagannath%20S%5BAuthor%5D"}],"papers":[{"title":"Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma","journal":"British Journal of Haematology","year":2005}]},{"id":"kim-sung-bae","kind":"person","name":"Sung-Bae Kim","aka":[],"tldr":"Sung-Bae Kim is a leading Korean breast oncologist on the steering committees of the trastuzumab emtansine and deruxtecan trials.","summary":"Sung-Bae Kim is Professor of Medical Oncology at Asan Medical Center in Seoul, specialising in breast cancer. He is a leading Korean breast oncologist who sits on the steering committees of the trastuzumab emtansine and trastuzumab deruxtecan trials, and has been an investigator on many pivotal HER2-positive and triple-negative breast cancer studies, including EMILIA, the DESTINY-Breast trials and immunotherapy combinations. His publications include the DESTINY-Breast03 trial comparing trastuzumab deruxtecan with trastuzumab emtansine in HER2-positive metastatic breast cancer. He co-leads Korean breast cancer research networks, with interests in HER2-positive disease and antibody-drug conjugates.","asOf":"2026-09-08","links":[{"label":"Asan Medical Center","url":"https://eng.amc.seoul.kr"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kim%20SB%5BAuthor%5D%20Asan%20Medical%20Center%20breast%20cancer"}],"tags":[],"related":[],"cancers":["breast-her2-positive","tnbc"],"sections":[],"technologies":[],"targets":["her2"],"drugs":["trastuzumab-deruxtecan","trastuzumab-emtansine"],"companies":[],"institutions":["asan-medical-center"],"pathways":[],"terms":[],"trials":["destiny-breast03"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology; breast cancer","institutionId":"asan-medical-center","specialisms":["Breast cancer","HER2-positive disease","Triple-negative breast cancer","Antibody-drug conjugates"],"profiles":[{"label":"Asan Medical Center","url":"https://eng.amc.seoul.kr"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kim%20SB%5BAuthor%5D%20Asan%20Medical%20Center%20breast%20cancer"}],"papers":[{"title":"Trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive metastatic breast cancer (DESTINY-Breast03)","journal":"NEJM","year":2022,"doi":"10.1056/NEJMoa2115022"},{"title":"DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group","journal":"New England Journal of Medicine","year":2022,"url":"https://doi.org/10.1056/NEJMoa2203690","doi":"10.1056/NEJMoa2203690"}]},{"id":"lee-sung-gyu","kind":"person","name":"Sung-Gyu Lee","aka":[],"tldr":"Built the world's highest-volume living-donor liver transplant programme, a cornerstone of liver cancer care in Asia.","summary":"Sung-Gyu Lee is Professor of Surgery at Asan Medical Center in Seoul and leads its liver transplantation programme. He pioneered dual-graft and right-lobe living-donor liver transplantation, building the world's highest-volume living-donor programme, which treats a large share of Korean hepatocellular carcinoma within transplant criteria and is a cornerstone of liver cancer care in Asia. His publications include a description of dual-graft adult living donor liver transplantation as a procedure for expanding the live donor pool. His interests are living-donor liver transplantation, hepatocellular carcinoma surgery and hepatobiliary surgery.","asOf":"2026-09-08","links":[{"label":"Asan Medical Center","url":"https://eng.amc.seoul.kr"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lee%20SG%5BAuthor%5D%20Asan%20living%20donor%20liver%20transplantation"}],"tags":[],"related":[],"cancers":["hcc"],"sections":[],"technologies":["liver-transplant-oncology"],"targets":[],"drugs":[],"companies":[],"institutions":["asan-medical-center"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Surgery; Asan liver transplantation programme","institutionId":"asan-medical-center","specialisms":["Living-donor liver transplantation","Hepatocellular carcinoma surgery","Hepatobiliary surgery"],"profiles":[{"label":"Asan Medical Center","url":"https://eng.amc.seoul.kr"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lee%20SG%5BAuthor%5D%20Asan%20living%20donor%20liver%20transplantation"}],"papers":[{"title":"Dual-graft adult living donor liver transplantation: an innovative surgical procedure for live liver donor pool expansion","journal":"Annals of Surgery","year":2017,"doi":"10.1097/SLA.0000000000001776"}],"orcid":"0000-0001-9161-3491"},{"id":"sunil-kumar-barnwal","kind":"person","name":"Sunil Kumar Barnwal","aka":[],"tldr":"Civil servant who leads the National Health Authority, the agency that runs India's Ayushman Bharat PM-JAY public health insurance scheme.","summary":"Sunil Kumar Barnwal leads the National Health Authority (NHA) as its Chief Executive Officer. The NHA is the Government of India agency responsible for implementing Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (PM-JAY), the publicly funded health assurance scheme that covers hospital treatment, including cancer care, for eligible low-income families. The English Wikipedia article on the NHA lists him as the incumbent CEO; the NHA website itself could not be read for this record.","asOf":"2026-09-10","links":[{"label":"Source: Wikipedia article naming the CEO","url":"https://en.wikipedia.org/wiki/National_Health_Authority"}],"tags":["leadership","government"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["nha-pmjay"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive Officer, National Health Authority (Ayushman Bharat PM-JAY)","institutionId":"nha-pmjay","specialisms":["Public administration","Health insurance and financing","Digital health"],"profiles":[{"label":"Wikipedia article on the National Health Authority","url":"https://en.wikipedia.org/wiki/National_Health_Authority"}],"papers":[]},{"id":"sunil-lakhani","kind":"person","name":"Sunil Lakhani","aka":[],"tldr":"Brisbane breast pathologist who chairs the board of Breast Cancer Trials, the Australia and New Zealand breast cancer clinical trials group.","summary":"Sunil Lakhani has chaired the Board of Breast Cancer Trials, the Australia and New Zealand cooperative trials group, since September 2021. He is a professor of pathology at the University of Queensland and Senior Staff Specialist at Pathology Queensland. His research addresses the molecular pathology and classification of breast cancer, and he has contributed to the WHO classification of breast tumours.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.breastcancertrials.org.au/our-people/board-of-directors/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lakhani+SR%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","breast cancer","pathology"],"related":[],"cancers":["breast-hr-positive","breast-her2-positive","tnbc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["breast-cancer-trials"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chair of the Board","institutionId":"breast-cancer-trials","specialisms":["Breast pathology","Breast cancer","Molecular pathology"],"profiles":[{"label":"Institution profile","url":"https://www.breastcancertrials.org.au/our-people/board-of-directors/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lakhani+SR%5BAuthor%5D"}],"papers":[{"title":"Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update","journal":"Journal of Clinical Oncology","year":2020,"doi":"10.1200/jco.19.02309"},{"title":"Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study","journal":"The Lancet Oncology","year":2018,"doi":"10.1016/s1470-2045(17)30891-4"},{"title":"Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth","journal":"Nature","year":2015,"doi":"10.1038/nature15376"}],"orcid":"0000-0003-4067-2760"},{"id":"supriya-mohile","kind":"person","name":"Supriya G. Mohile","aka":[],"tldr":"Led GAP70+, which showed a geriatric assessment cuts serious chemotherapy toxicity in older patients.","summary":"Supriya Mohile was principal investigator of GAP70+, the cluster-randomised trial showing that giving oncologists a geriatric assessment with management recommendations reduces grade 3-5 toxicity in older adults with advanced cancer without compromising survival, and led the ASCO guideline recommending geriatric assessment for all patients over 65 receiving chemotherapy. She directs geriatric oncology research at Wilmot.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mohile%20SG%5BAuthor%5D%20geriatric%20assessment"}],"tags":["supportive-care","geriatric-oncology","toxicity"],"related":[],"cancers":[],"sections":[],"technologies":["geriatric-assessment"],"targets":[],"drugs":[],"companies":[],"institutions":["wilmot"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-gap70-geriatric-assessment-lancet-2021"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medicine and Surgery, Wilmot Cancer Institute, University of Rochester","institutionId":"wilmot","specialisms":["Geriatric oncology","Geriatric assessment","Older adults in trials","Supportive care"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mohile%20SG%5BAuthor%5D%20geriatric%20assessment"}],"papers":[{"title":"Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study","journal":"Lancet","year":2021,"doi":"10.1016/S0140-6736(21)01789-X"},{"title":"Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology","journal":"JCO","year":2018,"doi":"10.1200/JCO.2018.78.8687"}],"orcid":"0000-0003-0867-327X"},{"id":"shastri-surendra","kind":"person","name":"Surendra Shastri","aka":[],"tldr":"Led the Mumbai trial showing that visual inspection with acetic acid by health workers cuts cervical cancer deaths.","summary":"Surendra Shastri is a preventive oncologist and former Head of Preventive Oncology at Tata Memorial Hospital, part of the Tata Memorial Centre in Mumbai. He ran the cluster-randomised trial of visual inspection with acetic acid screening delivered by primary health workers in Mumbai slums, which showed that this approach cuts cervical cancer deaths and informed screening policy across low-resource settings. His publications include the Mumbai randomised controlled study of VIA screening by primary health workers. His interests span cervical, breast and oral cancer screening, HPV testing and self-sampling, and community trials.","asOf":"2026-09-08","links":[{"label":"Tata Memorial Centre","url":"https://tmc.gov.in"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Shastri%20SS%5BAuthor%5D%20visual%20inspection%20acetic%20acid%20cervical"}],"tags":[],"related":[],"cancers":["cervical"],"sections":[],"technologies":["hpv-testing","colposcopy-excision"],"targets":[],"drugs":[],"companies":[],"institutions":["tata-memorial"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Preventive oncologist; former Head, Preventive Oncology, Tata Memorial Hospital","institutionId":"tata-memorial","specialisms":["Cervical cancer screening","Visual inspection with acetic acid","Breast and oral cancer screening","Community trials"],"profiles":[{"label":"Tata Memorial Centre","url":"https://tmc.gov.in"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Shastri%20SS%5BAuthor%5D%20visual%20inspection%20acetic%20acid%20cervical"}],"papers":[{"title":"Effect of VIA screening by primary health workers: randomized controlled study in Mumbai, India","journal":"Journal of the National Cancer Institute","year":2014,"doi":"10.1093/jnci/dju009"},{"title":"HPV screening for cervical cancer in rural India (Osmanabad)","journal":"New England Journal of Medicine","year":2009,"url":"https://doi.org/10.1056/NEJMoa0808516","doi":"10.1056/NEJMoa0808516"}]},{"id":"suresh-ramalingam","kind":"person","name":"Suresh S. Ramalingam","aka":[],"tldr":"Lung cancer medical oncologist who leads Winship Cancer Institute of Emory University and led the FLAURA trial of osimertinib.","summary":"Suresh S. Ramalingam is Executive Director of Winship Cancer Institute of Emory University, Georgia's NCI-designated comprehensive cancer centre. A thoracic medical oncologist, he was a principal investigator of the FLAURA trial establishing osimertinib as first-line therapy for EGFR-mutated non-small cell lung cancer, and has led numerous national lung cancer trials through ECOG-ACRIN.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ramalingam+SS%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","lung cancer","targeted therapy"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["emory-winship"],"pathways":[],"terms":[],"trials":["flaura2"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Executive Director","institutionId":"emory-winship","specialisms":["Lung cancer","Thoracic medical oncology","Targeted therapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ramalingam+SS%5BAuthor%5D"}],"papers":[{"title":"Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC","journal":"New England Journal of Medicine","year":2020,"url":"https://doi.org/10.1056/NEJMoa1913662","doi":"10.1056/NEJMoa1913662"}],"orcid":"0000-0002-0757-3106"},{"id":"susan-msadabwe","kind":"person","name":"Susan C. Msadabwe","aka":[],"tldr":"Physician who runs the Cancer Diseases Hospital in Lusaka, Zambia's national cancer treatment hospital, as its Senior Medical Superintendent.","summary":"Dr Susan C. Msadabwe is Senior Medical Superintendent of the Cancer Diseases Hospital (CDH) in Lusaka, the Zambian public cancer hospital on the University Teaching Hospital campus at Nationalist Road. The hospital's website presents her welcome message in its 'Who We Are' section, describing a team committed to patient care, research and wellness initiatives and a customer service charter for patients. The website gives no further biographical detail.","asOf":"2026-09-10","links":[{"label":"Source: Cancer Diseases Hospital homepage naming the Senior Medical Superintendent","url":"https://www.cdh.gov.zm/"}],"tags":["leadership","hospital-management","clinician-scientist"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cancer-diseases-hospital-lusaka"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Senior Medical Superintendent, Cancer Diseases Hospital, Lusaka","institutionId":"cancer-diseases-hospital-lusaka","specialisms":["Oncology","Hospital management","Cancer care in Zambia"],"profiles":[{"label":"Cancer Diseases Hospital website","url":"https://www.cdh.gov.zm/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Msadabwe+S%5BAuthor%5D"}],"papers":[{"title":"Defining national research priorities for prostate cancer in Zambia: using the Delphi process for comprehensive cancer policy setting in sub-Saharan Africa","journal":"BMJ Oncology","year":2024,"doi":"10.1136/bmjonc-2023-000172"},{"title":"Delays in seeking, reaching and access to quality cancer care in sub-Saharan Africa: a systematic review","journal":"BMJ Open","year":2023,"doi":"10.1136/bmjopen-2022-067715"}]},{"id":"susan-clark","kind":"person","name":"Susan Clark","aka":[],"tldr":"Pioneer of DNA methylation analysis whose Garvan laboratory studies how epigenetic changes drive prostate and breast cancer.","summary":"Susan Clark heads the Cancer Epigenetics Laboratory at the Garvan Institute of Medical Research in Sydney. She developed the bisulphite sequencing method that made genome-wide DNA methylation mapping possible, and her group investigates epigenome remodelling in prostate and breast cancer and its use in biomarkers. She is a Fellow of the Australian Academy of Science.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Clark+SJ%5BAuthor%5D+methylation"}],"tags":["clinician-scientist","epigenetics","prostate cancer","breast cancer"],"related":[],"cancers":["prostate","breast-hr-positive"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["garvan-institute"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Head of the Cancer Epigenetics Laboratory","institutionId":"garvan-institute","specialisms":["Cancer epigenetics","DNA methylation","Prostate and breast cancer"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Clark+SJ%5BAuthor%5D+methylation"}],"papers":[{"title":"DNA methylation of oestrogen-regulated enhancers defines endocrine sensitivity in breast cancer","journal":"Nature Communications","year":2015,"doi":"10.1038/ncomms8758"},{"title":"Methylome sequencing in triple-negative breast cancer reveals distinct methylation clusters with prognostic value","journal":"Nature Communications","year":2015,"doi":"10.1038/ncomms6899"},{"title":"Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer","journal":"Nature Communications","year":2020,"doi":"10.1038/s41467-019-14098-x"}],"orcid":"0000-0001-5925-5030"},{"id":"susan-furth","kind":"person","name":"Susan Furth","aka":[],"tldr":"Paediatric nephrologist and Chief Scientific Officer of Children's Hospital of Philadelphia, overseeing its research institute including paediatric cancer research.","summary":"Susan Furth is Chief Scientific Officer of Children's Hospital of Philadelphia and leads the CHOP Research Institute. A paediatric nephrologist and clinical epidemiologist, she has directed large cohort studies of chronic kidney disease in children. In her executive role she oversees CHOP's research portfolio, which includes major programmes in paediatric oncology and cellular immunotherapy.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.chop.edu/about-us/executive-leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Furth+SL%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","paediatrics"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["chop"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Scientific Officer","institutionId":"chop","specialisms":["Paediatric research leadership","Paediatric nephrology","Clinical epidemiology"],"profiles":[{"label":"Institution profile","url":"https://www.chop.edu/about-us/executive-leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Furth+SL%5BAuthor%5D"}],"papers":[{"title":"Improved equations estimating GFR in children with chronic kidney disease using an immunonephelometric determination of cystatin C","journal":"Kidney International","year":2012,"url":"https://doi.org/10.1038/ki.2012.169","doi":"10.1038/ki.2012.169","note":"Europe PMC author record matched by affiliation"},{"title":"Age- and sex-dependent clinical equations to estimate glomerular filtration rates in children and young adults with chronic kidney disease","journal":"Kidney International","year":2021,"url":"https://doi.org/10.1016/j.kint.2020.10.047","doi":"10.1016/j.kint.2020.10.047","note":"Europe PMC author record matched by affiliation"},{"title":"Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease","journal":"Kidney International","year":2021,"url":"https://doi.org/10.1016/j.kint.2020.10.026","doi":"10.1016/j.kint.2020.10.026","note":"Europe PMC author record matched by affiliation"}]},{"id":"susan-cohn","kind":"person","name":"Susan L. Cohn","aka":[],"tldr":"Neuroblastoma expert who built the international risk classification used to guide treatment.","summary":"Susan Cohn is Professor of Pediatrics at the University of Chicago and a neuroblastoma leader within the Children's Oncology Group (COG). A paediatric oncologist specialising in neuroblastoma and risk stratification, she chaired the International Neuroblastoma Risk Group task force that produced the INRG classification, the international risk classification used to guide treatment, and has long led the COG neuroblastoma committee. Her papers include the Journal of Clinical Oncology report of the INRG classification system from the task force and the Children's Oncology Group's 2013 blueprint for neuroblastoma research in Pediatric Blood & Cancer. Her work underpins how paediatric neuroblastoma is classified and treated.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Susan_L._Cohn","links":[{"label":"Children's Oncology Group","url":"https://childrensoncologygroup.org"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cohn%20SL%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Susan%20L.%20Cohn"}],"tags":[],"related":[],"cancers":["neuroblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["childrens-oncology-group"],"institutions":[],"pathways":[],"terms":["inrg-staging","mycn-amplification"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["pediatric-blood-and-cancer"],"dependsOn":[],"notes":[],"role":"Professor of Pediatrics, University of Chicago; Children's Oncology Group neuroblastoma leader","institutionId":"childrens-oncology-group","specialisms":["Neuroblastoma","Risk stratification","Paediatric oncology"],"profiles":[{"label":"Children's Oncology Group","url":"https://childrensoncologygroup.org"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cohn%20SL%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Susan%20L.%20Cohn"}],"papers":[{"title":"The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report","journal":"Journal of Clinical Oncology","year":2009,"url":"https://doi.org/10.1200/JCO.2008.16.6785","doi":"10.1200/JCO.2008.16.6785"},{"title":"Children's Oncology Group's 2013 blueprint for research: neuroblastoma","journal":"Pediatric Blood & Cancer","year":2013,"url":"https://doi.org/10.1002/pbc.24433","doi":"10.1002/pbc.24433"}],"orcid":"0000-0001-5749-7650"},{"id":"susan-love","kind":"person","name":"Susan Love","aka":[],"tldr":"Her Breast Book gave women the information to question their surgeons; she co-founded the National Breast Cancer Coalition and in 2008 recruited hundreds of thousands of women into research through the Army of Women.","summary":"Susan Love (1948-2023) was one of the first women to become a breast surgeon in the United States, at Beth Israel and later as director of the UCLA Breast Center. Dr. Susan Love's Breast Book (1990), now in its seventh edition, became the reference that let patients understand their options and question the reflex to mastectomy. In 1991 she co-founded the National Breast Cancer Coalition with Fran Visco. Through the Dr. Susan Love Research Foundation she pursued the causes and prevention of breast cancer, and in 2008 launched the Army of Women, later Love Research Army, which enrolled more than 380,000 volunteers willing to be contacted for studies, cutting recruitment times for researchers. She was treated for acute myeloid leukaemia in 2012 and wrote about being a patient. She died in July 2023.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Susan_Love","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Susan_Love"},{"label":"National Breast Cancer Coalition","url":"https://www.stopbreastcancer.org/"}],"tags":["hero","advocate","pioneer","patient"],"related":[],"cancers":["aml"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ucla-jonsson"],"pathways":[],"terms":[],"trials":[],"people":["fran-visco"],"bottlenecks":["b-trial-enrolment","b-patient-voice"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Breast surgeon, author and founder of the Army of Women","specialisms":["Breast surgery","Breast cancer prevention","Patient education","Research participation"],"profiles":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Susan_Love"},{"label":"National Breast Cancer Coalition","url":"https://www.stopbreastcancer.org/"}],"papers":[{"title":"Breast-duct endoscopy to study stages of cancerous breast disease","journal":"The Lancet","year":1996,"doi":"10.1016/s0140-6736(96)04145-1"},{"title":"Anatomy of the nipple and breast ducts revisited","journal":"Cancer","year":2004,"doi":"10.1002/cncr.20559"},{"title":"Palpable Breast Lump Triage by Minimally Trained Operators in Mexico Using Computer-Assisted Diagnosis and Low-Cost Ultrasound","journal":"Journal of Global Oncology","year":2018,"doi":"10.1200/jgo.17.00222"}]},{"id":"susan-domchek","kind":"person","name":"Susan M. Domchek","aka":[],"tldr":"Leads the world's first centre dedicated to BRCA-related cancers and the trials of PARP inhibitors plus immunotherapy.","summary":"Susan M. Domchek is Executive Director of the Basser Center for BRCA at the Abramson Cancer Center, University of Pennsylvania. She leads the world's first centre dedicated to BRCA-related cancers and is known for trials combining PARP inhibitors with immunotherapy, including MEDIOLA with olaparib plus durvalumab, and for analyses of PARP-inhibitor resistance and reversion in germline BRCA carriers. Her selected paper reports the MEDIOLA study of olaparib and durvalumab in germline BRCA-mutated metastatic breast cancer. Her work spans hereditary breast, ovarian and pancreatic cancer and germline testing.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Susan_Domchek","links":[{"label":"Basser Center","url":"https://www.basser.org"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Domchek%20SM%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["tnbc","breast-hr-positive","ovarian","pancreatic"],"sections":[],"technologies":["germline-testing"],"targets":["brca","parp"],"drugs":["olaparib"],"companies":[],"institutions":["penn-abramson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Executive Director, Basser Center for BRCA","institutionId":"penn-abramson","specialisms":["BRCA1/2","Hereditary cancer","PARP inhibitors"],"profiles":[{"label":"Basser Center","url":"https://www.basser.org"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Domchek%20SM%5BAuthor%5D"}],"papers":[{"title":"Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA)","journal":"Lancet Oncology","year":2020,"url":"https://doi.org/10.1016/S1470-2045(20)30324-7","doi":"10.1016/S1470-2045(20)30324-7"},{"title":"OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer","journal":"New England Journal of Medicine","year":2021,"url":"https://doi.org/10.1056/NEJMoa2105215","doi":"10.1056/NEJMoa2105215"},{"title":"PROSE consortium: preventive surgery lowers cancer and death in BRCA1 and BRCA2 carriers","journal":"JAMA","year":2010,"url":"https://doi.org/10.1001/jama.2010.1237","doi":"10.1001/jama.2010.1237"}],"orcid":"0000-0002-5914-7272"},{"id":"susana-banerjee","kind":"person","name":"Susana Banerjee","aka":[],"tldr":"London gynaecological oncologist who led RAMP 201, the trial that established the avutometinib and defactinib combination for recurrent KRAS-mutant low-grade serous ovarian cancer.","summary":"Susana Banerjee is a consultant medical oncologist at The Royal Marsden and research lead for its gynaecology unit. She was first author of the 2025 Journal of Clinical Oncology report of RAMP 201, the phase 2 trial in which the RAF/MEK clamp avutometinib plus the FAK inhibitor defactinib produced responses in recurrent low-grade serous ovarian cancer, particularly KRAS-mutant disease, the basis of the combination's accelerated approval. She has led ESMO's gynaecological cancer guidelines and trials of PARP inhibitors.","asOf":"2026-09-18","wikipedia":"https://en.wikipedia.org/wiki/Susana_Banerjee","links":[],"tags":["ovarian","gynaecological","targeted-therapy","trialist"],"related":[],"cancers":["low-grade-serous-ovarian-cancer","ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["royal-marsden"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-ramp-201-avutometinib-defactinib-lgsoc-jco-2025"],"journals":[],"dependsOn":[],"notes":[],"role":"Consultant medical oncologist, The Royal Marsden and The Institute of Cancer Research","institutionId":"royal-marsden","specialisms":["Ovarian cancer","Low-grade serous ovarian cancer","Rare gynaecological cancers"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Banerjee%5BAuthor%5D"}],"papers":[{"title":"RAMP 201: avutometinib with or without defactinib in recurrent low-grade serous ovarian cancer","journal":"Journal of Clinical Oncology","year":2025,"url":"https://doi.org/10.1200/JCO-25-00112","doi":"10.1200/JCO-25-00112"}],"orcid":"0000-0002-8840-7934"},{"id":"susana-blanco","kind":"person","name":"Susana Blanco","aka":[],"tldr":"Physician who heads Argentina's Dirección Nacional del Cáncer, the national cancer body within the Ministry of Health that succeeded the Instituto Nacional del Cáncer.","summary":"Dra. Susana Blanco holds the Dirección Nacional of the Dirección Nacional del Cáncer (DNC), the body within Argentina's Ministerio de Salud that designs and implements public policy for cancer prevention and control and carries the functions of the Instituto Nacional del Cáncer. The ministry's team page lists her at the head of a structure that includes Dr Federico Cisneros for prevention, diagnosis and treatment and Dra. Graciela Abriata for cancer information systems and the SIVER-Ca surveillance system, together with national programmes for breast, cervical, colorectal and familial cancer, childhood cancer and palliative care. The page gives no appointment date.","asOf":"2026-09-10","links":[{"label":"Source: Argentina Ministry of Health, Instituto Nacional del Cáncer team page","url":"https://www.argentina.gob.ar/salud/inc/institucional/equipo-de-trabajo"}],"tags":["leadership","government"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["inc-argentina"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Directora Nacional, Dirección Nacional del Cáncer (Instituto Nacional del Cáncer), Ministerio de Salud de Argentina","institutionId":"inc-argentina","specialisms":["Cancer control policy","Public health"],"profiles":[{"label":"Ministerio de Salud, INC team page","url":"https://www.argentina.gob.ar/salud/inc/institucional/equipo-de-trabajo"}],"papers":[]},{"id":"susana-puig","kind":"person","name":"Susana Puig","aka":[],"tldr":"Dermatologist and melanoma researcher who directs IDIBAPS, the research institute of Hospital Clínic de Barcelona.","summary":"Susana Puig is Director of the August Pi i Sunyer Biomedical Research Institute (IDIBAPS), the research arm of Hospital Clínic de Barcelona and the University of Barcelona. She is a dermatologist whose research addresses melanoma susceptibility, early detection with dermoscopy and imaging, and skin cancer genetics. She leads a large multidisciplinary research institute spanning oncology, neuroscience and other areas.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.clinicbarcelona.org/en/idibaps/about-us/scientific-organizational-structure"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Puig+S%5BAuthor%5D+melanoma"}],"tags":["leadership","clinician-scientist","melanoma"],"related":[],"cancers":["melanoma","basal-cell-carcinoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["hospital-clinic-barcelona"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, IDIBAPS","institutionId":"hospital-clinic-barcelona","specialisms":["Melanoma","Dermato-oncology","Cancer genetics"],"profiles":[{"label":"Institution profile","url":"https://www.clinicbarcelona.org/en/idibaps/about-us/scientific-organizational-structure"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Puig+S%5BAuthor%5D+melanoma"}],"papers":[{"title":"Role of the CDKN2A Locus in Patients With Multiple Primary Melanomas","journal":"Journal of Clinical Oncology","year":2005,"doi":"10.1200/jco.2005.08.034"},{"title":"Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial","journal":"The Lancet Oncology","year":2017,"doi":"10.1016/s1470-2045(17)30072-4"},{"title":"Update in genetic susceptibility in melanoma","journal":"Ann Transl Med","year":2015,"doi":"10.3978/j.issn.2305-5839.2015.08.11"}],"orcid":"0000-0003-1337-9745"},{"id":"suzanne-topalian","kind":"person","name":"Suzanne L. Topalian","aka":[],"tldr":"Suzanne Topalian led the first nivolumab trials showing PD-1 blockade works across several cancers.","summary":"Suzanne L. Topalian is the Bloomberg~Kimmel Professor of Cancer Immunotherapy and Associate Director of the Bloomberg~Kimmel Institute at Johns Hopkins Hospital and the Sidney Kimmel Comprehensive Cancer Center. She is known for leading the first nivolumab trials showing that PD-1 blockade works across several cancers, as first author of the 2012 study establishing activity in melanoma, lung and kidney cancer. Her selected paper reports the safety, activity and immune correlates of anti-PD-1 antibody in cancer. She pioneered neoadjuvant immunotherapy as a scientific platform and continues to work on immune checkpoint inhibitors.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Suzanne_L._Topalian","links":[{"label":"Hopkins profile","url":"https://www.hopkinsmedicine.org/profiles/details/suzanne-topalian"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Topalian%20SL%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["melanoma","nsclc","rcc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["pd1"],"drugs":["nivolumab"],"companies":[],"institutions":["johns-hopkins"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Bloomberg~Kimmel Professor of Cancer Immunotherapy; Associate Director, Bloomberg~Kimmel Institute","institutionId":"johns-hopkins","specialisms":["PD-1 blockade","Melanoma","Neoadjuvant immunotherapy"],"profiles":[{"label":"Hopkins profile","url":"https://www.hopkinsmedicine.org/profiles/details/suzanne-topalian"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Topalian%20SL%5BAuthor%5D"}],"papers":[{"title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","journal":"New England Journal of Medicine","year":2012,"url":"https://doi.org/10.1056/NEJMoa1200690","doi":"10.1056/NEJMoa1200690"}]},{"id":"suzette-delaloge","kind":"person","name":"Suzette Delaloge","aka":[],"tldr":"Breast medical oncologist from Gustave Roussy who chairs the board of France's Institut National du Cancer.","summary":"Suzette Delaloge is Chair (Présidente) of the Board of Directors of the Institut National du Cancer (INCa), the French national cancer agency, appointed in 2026. A medical oncologist at Gustave Roussy, she has led major breast cancer research including the MyPeBS trial of risk-based breast screening and Gustave Roussy's cancer prevention programme.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.cancer.fr/l-institut-national-du-cancer/notre-organisation/instances/conseil-d-administration"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Delaloge+S%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","breast cancer","cancer policy"],"related":[],"cancers":["breast-hr-positive","breast-her2-positive","tnbc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["inca"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chair of the Board of Directors","institutionId":"inca","specialisms":["Breast cancer","Medical oncology","Cancer prevention and personalised screening"],"profiles":[{"label":"Institution profile","url":"https://www.cancer.fr/l-institut-national-du-cancer/notre-organisation/instances/conseil-d-administration"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Delaloge+S%5BAuthor%5D"}],"papers":[{"title":"Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial☆","journal":"Annals of Oncology","year":2020,"doi":"10.1016/j.annonc.2020.06.020"},{"title":"OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer","journal":"Annals of Oncology","year":2019,"doi":"10.1093/annonc/mdz012"},{"title":"Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation","journal":"New England Journal of Medicine","year":2017,"doi":"10.1056/nejmoa1706450"}]},{"id":"sylvie-bonvalot","kind":"person","name":"Sylvie Bonvalot","aka":[],"tldr":"Paris surgeon who championed compartmental resection for retroperitoneal sarcoma and led STRASS, the trial that showed preoperative radiotherapy does not improve abdominal recurrence-free survival overall.","summary":"Sylvie Bonvalot is a sarcoma surgeon at Institut Curie in Paris. She was first author of the 2009 Journal of Clinical Oncology study showing that systematic en bloc resection of adjacent organs reduced local recurrence in primary retroperitoneal sarcoma, and of the 2020 Lancet Oncology report of the EORTC STRASS trial, in which preoperative radiotherapy did not significantly improve abdominal recurrence-free survival compared with surgery alone, though a possible benefit in liposarcoma remains under study.","asOf":"2026-09-18","links":[],"tags":["sarcoma","surgery","trialist"],"related":[],"cancers":["retroperitoneal-sarcoma","liposarcoma","sarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["institut-curie"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-strass-lancet-oncol-2020","paper-bonvalot-retroperitoneal-sarcoma-compartmental-jco-2009"],"journals":[],"dependsOn":[],"notes":[],"role":"Surgical oncologist, Institut Curie, Paris","institutionId":"institut-curie","specialisms":["Retroperitoneal sarcoma","Sarcoma surgery","Preoperative radiotherapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bonvalot%5BAuthor%5D"}],"papers":[{"title":"Primary retroperitoneal sarcomas: a multivariate analysis of surgical factors associated with local control","journal":"Journal of Clinical Oncology","year":2009,"url":"https://doi.org/10.1200/JCO.2008.18.0802","doi":"10.1200/JCO.2008.18.0802"},{"title":"STRASS (EORTC 62092): preoperative radiotherapy plus surgery versus surgery alone for primary retroperitoneal sarcoma","journal":"The Lancet Oncology","year":2020,"url":"https://doi.org/10.1016/S1470-2045(20)30446-0","doi":"10.1016/S1470-2045(20)30446-0"}]},{"id":"t-naveen","kind":"person","name":"T. Naveen","aka":[],"tldr":"Director of Kidwai Memorial Institute of Oncology, the Karnataka state government's regional cancer centre in Bengaluru.","summary":"T. Naveen (Dr T Naveen) is Director of the Kidwai Memorial Institute of Oncology (KMIO), the state-run regional cancer centre in Bengaluru, Karnataka. An October 2025 Medical Dialogues report on plans to add 450 beds to the institute names him as KMIO director, noting that Karnataka's medical education minister Sharan Prakash Patil directed him to release full salaries to nurses who had been on maternity leave. The institute's own website could not be reached, so no appointment date or biographical detail is given.","asOf":"2026-09-10","links":[{"label":"Source: Medical Dialogues report on the 450-bed expansion naming the Director (October 2025)","url":"https://medicaldialogues.in/news/health/hospital-diagnostics/kidwai-memorial-institute-of-oncology-plans-450-bed-expansion-156647"}],"tags":["leadership","hospital-management","government"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["kidwai-memorial-institute-of-oncology"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["oral-oncology","indian-journal-of-cancer","journal-of-cancer-research-and-therapeutics"],"dependsOn":[],"notes":[],"role":"Director, Kidwai Memorial Institute of Oncology, Bengaluru","institutionId":"kidwai-memorial-institute-of-oncology","specialisms":["Oncology","Cancer hospital management"],"profiles":[{"label":"Medical Dialogues report naming the KMIO director (October 2025)","url":"https://medicaldialogues.in/news/health/hospital-diagnostics/kidwai-memorial-institute-of-oncology-plans-450-bed-expansion-156647"}],"papers":[{"title":"Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: A randomized, open-label, phase IIb, 5-year study in Indian patients","journal":"Oral Oncology","year":2014,"doi":"10.1016/j.oraloncology.2013.11.008"},{"title":"Cell-free circulating tumor DNA in patients with high-grade glioma as diagnostic biomarker – A guide to future directive","journal":"Indian Journal of Cancer","year":2019,"doi":"10.4103/ijc.ijc_551_17"},{"title":"Prostate permanent implant brachytherapy with BARC I-125 Ocu-Prosta seeds","journal":"Journal of Cancer Research and Therapeutics","year":2021,"doi":"10.4103/jcrt.jcrt_424_20"}]},{"id":"kim-tae-won","kind":"person","name":"Tae Won Kim","aka":[],"tldr":"Tae Won Kim is Korea's leading colorectal cancer trialist, an investigator on the fruquintinib, trifluridine/tipiracil, and anti-EGFR studies used worldwide.","summary":"Tae Won Kim is Professor of Medical Oncology at Asan Medical Center in Seoul, where he leads colorectal oncology. He is Korea's leading colorectal cancer trialist, serving on the steering committees of global metastatic colorectal cancer trials including FRESCO-2 with fruquintinib and SUNLIGHT with trifluridine/tipiracil, and on Asian anti-EGFR and KRAS studies. His publications include the FRESCO-2 trial of fruquintinib against placebo in refractory metastatic colorectal cancer. His interests are colorectal cancer, targeted therapy and clinical trials.","asOf":"2026-09-08","links":[{"label":"Asan Medical Center","url":"https://eng.amc.seoul.kr"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kim%20TW%5BAuthor%5D%20Asan%20colorectal"}],"tags":[],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":["fruquintinib","trifluridine-tipiracil"],"companies":[],"institutions":["asan-medical-center"],"pathways":[],"terms":[],"trials":["fresco-2","sunlight"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology; colorectal cancer","institutionId":"asan-medical-center","specialisms":["Colorectal cancer","Targeted therapy","Clinical trials"],"profiles":[{"label":"Asan Medical Center","url":"https://eng.amc.seoul.kr"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kim%20TW%5BAuthor%5D%20Asan%20colorectal"}],"papers":[{"title":"Fruquintinib versus placebo in refractory metastatic colorectal cancer (FRESCO-2)","journal":"Lancet","year":2023,"doi":"10.1016/S0140-6736(23)00772-9"},{"title":"BREAKWATER: encorafenib plus cetuximab with chemotherapy as first treatment for BRAF V600E-mutated colorectal cancer","journal":"New England Journal of Medicine","year":2025,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BREAKWATER+encorafenib+cetuximab+mFOLFOX6+colorectal"},{"title":"CodeBreaK 300: sotorasib plus panitumumab in chemotherapy-refractory KRAS G12C colorectal cancer","journal":"New England Journal of Medicine","year":2023,"url":"https://doi.org/10.1056/NEJMoa2308795","doi":"10.1056/NEJMoa2308795"},{"title":"KEYNOTE-177: pembrolizumab instead of chemotherapy as first treatment for mismatch-repair-deficient metastatic colorectal cancer","journal":"New England Journal of Medicine","year":2020,"url":"https://doi.org/10.1056/NEJMoa2017699","doi":"10.1056/NEJMoa2017699"}]},{"id":"kim-tae-you","kind":"person","name":"Tae-You Kim","aka":[],"tldr":"A GI oncologist and genomics researcher who leads precision oncology and colorectal cancer trials at Seoul National University.","summary":"Tae-You Kim is Professor of Internal Medicine at Seoul National University Hospital, working in gastrointestinal oncology and cancer genomics. His group studies the genomic and epigenetic landscape of colorectal and gastric cancer and runs biomarker-driven trials using comprehensive genomic profiling, contributing to the Korean precision oncology programme and to global colorectal studies. His publications include a single-centre phase 2 study of gemcitabine and cisplatin plus durvalumab, with or without tremelimumab, in chemotherapy-naive advanced biliary tract cancer. His interests are colorectal cancer, gastric cancer, cancer genomics and precision oncology.","asOf":"2026-09-08","links":[{"label":"Seoul National University Hospital","url":"https://www.snuh.org"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kim%20TY%5BAuthor%5D%20Seoul%20National%20University%20colorectal"}],"tags":[],"related":[],"cancers":["colorectal","gastric"],"sections":[],"technologies":["cgp"],"targets":[],"drugs":[],"companies":[],"institutions":["snuh"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Internal Medicine; gastrointestinal oncology and cancer genomics","institutionId":"snuh","specialisms":["Colorectal cancer","Gastric cancer","Cancer genomics","Precision oncology"],"profiles":[{"label":"Seoul National University Hospital","url":"https://www.snuh.org"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kim%20TY%5BAuthor%5D%20Seoul%20National%20University%20colorectal"}],"papers":[{"title":"Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study","journal":"The Lancet Gastroenterology & Hepatology","year":2022,"doi":"10.1016/s2468-1253(22)00043-7"},{"title":"IMbrave150: atezolizumab plus bevacizumab replaces sorafenib as first treatment for advanced liver cancer","journal":"New England Journal of Medicine","year":2020,"url":"https://doi.org/10.1056/NEJMoa1915745","doi":"10.1056/NEJMoa1915745"}]},{"id":"tak-mak","kind":"person","name":"Tak W. Mak","aka":[],"tldr":"Cloned the T-cell receptor and co-discovered CTLA-4's brake function, foundations of modern immunotherapy.","summary":"Tak W. Mak is a Senior Scientist at the Princess Margaret Cancer Centre and University Professor at the University of Toronto. He is an immunologist known for cloning the human T-cell receptor beta chain in 1984 and for generating the CTLA-4 knockout mouse that revealed the molecule's inhibitory role, foundations of modern immunotherapy. His selected paper reports lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. He now studies cancer metabolism and IDH mutations alongside his continuing interest in immune checkpoints.","asOf":"2026-09-08","links":[{"label":"UHN profile","url":"https://www.uhnresearch.ca/researcher/tak-w-mak"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mak%20TW%5BAuthor%5D"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["ctla4","idh"],"drugs":[],"companies":[],"institutions":["princess-margaret"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Senior Scientist, Princess Margaret Cancer Centre; University Professor, University of Toronto","institutionId":"princess-margaret","specialisms":["T-cell receptor","Immunology","Cancer metabolism","IDH"],"profiles":[{"label":"UHN profile","url":"https://www.uhnresearch.ca/researcher/tak-w-mak"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mak%20TW%5BAuthor%5D"}],"papers":[{"title":"Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4","journal":"Science","year":1995,"url":"https://doi.org/10.1126/science.270.5238.985","doi":"10.1126/science.270.5238.985"}],"orcid":"0000-0002-0459-4112"},{"id":"takashi-kamei","kind":"person","name":"Takashi Kamei","aka":[],"tldr":"Director of Tohoku University Hospital, the leading university hospital and cancer genomic medicine hub for the Tohoku region of Japan.","summary":"Takashi Kamei is Hospital Director of Tohoku University Hospital in Sendai, the only Designated Special Functioning Hospital in Miyagi Prefecture and a Clinical Research Core Hospital and Designated Core Hospital for Cancer Genomic Medicine for the Tohoku region. In his director's message he frames the hospital's mission as providing the best possible treatment while empathising with patients, and commits it to advanced care, training healthcare professionals and innovative treatments for communities across Tohoku. The hospital traces its history to 1915.","asOf":"2026-09-10","links":[{"label":"Source: Tohoku University Hospital, Message from the Director","url":"https://www.hosp.tohoku.ac.jp/en/outline/002.php"}],"tags":["leadership","hospital-management","japan"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["tohoku-university-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["annals-of-surgical-oncology"],"dependsOn":[],"notes":[],"role":"Hospital Director, Tohoku University Hospital","institutionId":"tohoku-university-hospital","specialisms":["Hospital leadership","Academic medicine","Regional cancer care"],"profiles":[{"label":"Message from the Director","url":"https://www.hosp.tohoku.ac.jp/en/outline/002.php"}],"papers":[{"title":"The Influence of the Perioperative Nutritional Status on the Survival Outcomes for Esophageal Cancer Patients with Neoadjuvant Chemotherapy","journal":"Annals of Surgical Oncology","year":2019,"doi":"10.1245/s10434-019-07742-9"},{"title":"Immune microenvironment in Barrett’s esophagus adjacent to esophageal adenocarcinoma: possible influence of adjacent mucosa on cancer development and progression","journal":"Virchows Archiv","year":2020,"doi":"10.1007/s00428-020-02854-0"},{"title":"Professional Oral Care Reduces Carcinogenic Acetaldehyde Levels in Mouth Air of Perioperative Esophageal Cancer Patients: A Prospective Comparative Study","journal":"The Tohoku Journal of Experimental Medicine","year":2019,"doi":"10.1620/tjem.249.75"}]},{"id":"kohno-takashi","kind":"person","name":"Takashi Kohno","aka":[],"tldr":"Genomics leader behind LC-SCRUM-Japan, the nationwide screening network that finds rare lung cancer drivers for trials.","summary":"Takashi Kohno is Chief of the Division of Genome Biology at the National Cancer Center Research Institute in Tokyo. His laboratory discovered and characterised fusion oncogenes in lung adenocarcinoma, including RET fusions, and he helped build the SCRUM-Japan genomic screening network, including LC-SCRUM-Japan, which finds rare lung cancer drivers and feeds patients into targeted-therapy trials. His publications include the discovery of KIF5B-RET fusions in lung adenocarcinoma. His interests are cancer genomics, lung cancer fusions and genomic screening networks using comprehensive genomic profiling and RNA sequencing.","asOf":"2026-09-08","links":[{"label":"National Cancer Center Research Institute","url":"https://www.ncc.go.jp/en/ri/index.html"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kohno%20T%5BAuthor%5D%20National%20Cancer%20Center%20RET%20fusion"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["cgp","rna-seq"],"targets":["ret"],"drugs":[],"companies":[],"institutions":["ncc-japan"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief, Division of Genome Biology, National Cancer Center Research Institute","institutionId":"ncc-japan","specialisms":["Cancer genomics","Lung cancer fusions","Genomic screening networks"],"profiles":[{"label":"National Cancer Center Research Institute","url":"https://www.ncc.go.jp/en/ri/index.html"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kohno%20T%5BAuthor%5D%20National%20Cancer%20Center%20RET%20fusion"}],"papers":[{"title":"KIF5B-RET fusions in lung adenocarcinoma","journal":"Nature Medicine","year":2012,"doi":"10.1038/nm.2644"}]},{"id":"ueno-takayuki","kind":"person","name":"Takayuki Ueno","aka":[],"tldr":"Takayuki Ueno is a breast surgeon whose translational work links tumour biology to neoadjuvant response.","summary":"Takayuki Ueno is a breast surgical oncologist at the Cancer Institute Hospital of JFCR in Tokyo. He combines surgical practice with translational research on immune and genomic predictors of response to neoadjuvant therapy, linking tumour biology to how breast cancers respond before surgery. His publications include a review of biomarkers of neoadjuvant and adjuvant endocrine therapy for ER-positive, HER2-negative breast cancer, a study of neoadjuvant palbociclib in operable hormone receptor-positive breast cancer, and a review of local management after neoadjuvant treatment. His interests are breast surgery, neoadjuvant therapy and translational research.","asOf":"2026-09-08","links":[{"label":"Cancer Institute Hospital of JFCR","url":"https://www.jfcr.or.jp/english/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ueno%20T%5BAuthor%5D%20breast%20Cancer%20Institute%20Hospital%20JFCR"}],"tags":[],"related":[],"cancers":["breast-hr-positive","tnbc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["jfcr"],"pathways":[],"terms":["pcr"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["chinese-clinical-oncology","endocrine-related-cancer"],"dependsOn":[],"notes":[],"role":"Breast surgical oncologist, Cancer Institute Hospital of JFCR","institutionId":"jfcr","specialisms":["Breast surgery","Neoadjuvant therapy","Translational research"],"profiles":[{"label":"Cancer Institute Hospital of JFCR","url":"https://www.jfcr.or.jp/english/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ueno%20T%5BAuthor%5D%20breast%20Cancer%20Institute%20Hospital%20JFCR"}],"papers":[{"title":"Biomarkers of neoadjuvant/adjuvant endocrine therapy for ER-positive/HER2-negative breast cancer","journal":"Chinese Clinical Oncology","year":2020,"doi":"10.21037/cco-20-165"},{"title":"Neoadjuvant palbociclib in women with operable, hormone receptor-positive breast cancer","journal":"Endocrine-Related Cancer","year":2025,"doi":"10.1530/erc-24-0353"},{"title":"Local management after neoadjuvant treatment for breast cancer","journal":"Chinese Clinical Oncology","year":2020,"doi":"10.21037/cco-20-164"}],"orcid":"0000-0002-9080-9377"},{"id":"yoshino-takayuki","kind":"person","name":"Takayuki Yoshino","aka":["takayuki-yoshino"],"tldr":"Leads CIRCULATE-Japan, the largest ctDNA-guided adjuvant programme in colorectal cancer, and the PARADIGM and SCRUM-Japan GI efforts.","summary":"Takayuki Yoshino is Chief of the Department of Gastroenterology and Gastrointestinal Oncology at the National Cancer Center Hospital East in Japan. He leads CIRCULATE-Japan, the largest circulating tumour DNA-guided adjuvant programme in colorectal cancer, comprising the GALAXY, VEGA and ALTAIR studies, as well as the PARADIGM trial of first-line panitumumab and the gastrointestinal arm of SCRUM-Japan. His publications include the GALAXY analysis of molecular residual disease and the efficacy of adjuvant chemotherapy in colorectal cancer, and the PARADIGM comparison of panitumumab and bevacizumab added to first-line chemotherapy in left-sided RAS wild-type metastatic disease. He is one of the most influential figures in colorectal cancer research. He is President of the Japanese Society of Medical Oncology and Professor at Keio University School of Medicine, and has driven large genomic screening platforms for gastrointestinal cancers in Japan and the Asia-Pacific region.","asOf":"2026-09-08","links":[{"label":"National Cancer Center Hospital East","url":"https://www.ncc.go.jp/en/ncce/index.html"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Yoshino%20T%5BAuthor%5D%20National%20Cancer%20Center%20Hospital%20East%20colorectal"},{"label":"JSMO directors","url":"https://www.jsmo.or.jp/eng/about/directors/"}],"tags":["leadership","clinician-scientist","colorectal cancer","precision oncology"],"related":[],"cancers":["colorectal","gastric"],"sections":[],"technologies":["mrd-testing","liquid-biopsy"],"targets":[],"drugs":["panitumumab"],"companies":[],"institutions":["ncc-japan","jsmo"],"pathways":[],"terms":[],"trials":["circulate-japan","paradigm"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief, Department of Gastroenterology and GI Oncology, National Cancer Center Hospital East; President, Japanese Society of Medical Oncology","institutionId":"ncc-japan","specialisms":["Colorectal cancer","ctDNA and molecular residual disease","Precision oncology","Clinical trials"],"profiles":[{"label":"National Cancer Center Hospital East","url":"https://www.ncc.go.jp/en/ncce/index.html"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Yoshino%20T%5BAuthor%5D%20National%20Cancer%20Center%20Hospital%20East%20colorectal"},{"label":"JSMO directors","url":"https://www.jsmo.or.jp/eng/about/directors/"}],"papers":[{"title":"Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer (GALAXY)","journal":"Nature Medicine","year":2023,"doi":"10.1038/s41591-022-02115-4"},{"title":"Panitumumab vs bevacizumab added to standard first-line chemotherapy in left-sided RAS wild-type metastatic colorectal cancer (PARADIGM)","journal":"JAMA","year":2023,"doi":"10.1001/jama.2023.4428"},{"title":"BREAKWATER: encorafenib plus cetuximab with chemotherapy as first treatment for BRAF V600E-mutated colorectal cancer","journal":"New England Journal of Medicine","year":2025,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BREAKWATER+encorafenib+cetuximab+mFOLFOX6+colorectal"},{"title":"KEYNOTE-177: pembrolizumab instead of chemotherapy as first treatment for mismatch-repair-deficient metastatic colorectal cancer","journal":"New England Journal of Medicine","year":2020,"url":"https://doi.org/10.1056/NEJMoa2017699","doi":"10.1056/NEJMoa2017699"}]},{"id":"sano-takeshi","kind":"person","name":"Takeshi Sano","aka":[],"tldr":"Takeshi Sano is one of the world's authorities on gastric cancer surgery and the Japanese staging and treatment guidelines.","summary":"Takeshi Sano is a gastric surgeon and former Director of the Cancer Institute Hospital of JFCR in Tokyo. He is one of the world's authorities on gastric cancer surgery, including D2 lymphadenectomy, and on the Japanese staging and treatment guidelines. He led gastric surgery and hospital leadership at the Cancer Institute Hospital, chaired the Japanese gastric cancer treatment guideline committees and contributed to international TNM staging revisions. His publications include the fifth edition of the Japanese gastric cancer treatment guidelines, and his interests include minimally invasive surgery and staging systems.","asOf":"2026-09-08","links":[{"label":"Cancer Institute Hospital of JFCR","url":"https://www.jfcr.or.jp/english/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sano%20T%5BAuthor%5D%20gastric%20cancer%20surgery%20Cancer%20Institute%20Hospital"}],"tags":[],"related":[],"cancers":["gastric"],"sections":[],"technologies":["robotic-surgery"],"targets":[],"drugs":[],"companies":[],"institutions":["jfcr"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["gastric-cancer"],"dependsOn":[],"notes":[],"role":"Gastric surgeon; former Director, Cancer Institute Hospital of JFCR","institutionId":"jfcr","specialisms":["Gastric cancer surgery","D2 lymphadenectomy","Staging systems"],"profiles":[{"label":"Cancer Institute Hospital of JFCR","url":"https://www.jfcr.or.jp/english/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sano%20T%5BAuthor%5D%20gastric%20cancer%20surgery%20Cancer%20Institute%20Hospital"}],"papers":[{"title":"Japanese gastric cancer treatment guidelines 2018 (5th edition)","journal":"Gastric Cancer","year":2021,"doi":"10.1007/s10120-020-01042-y"}]},{"id":"talia-golan","kind":"person","name":"Talia Golan","aka":[],"tldr":"Led POLO, the first biomarker-driven trial in pancreatic cancer, which brought olaparib to BRCA carriers.","summary":"Talia Golan was principal investigator and first author of POLO, which showed maintenance olaparib nearly doubles progression-free survival in germline BRCA-mutant metastatic pancreatic cancer after platinum chemotherapy, the first targeted therapy approval in the disease. She directs the pancreatic cancer centre at Sheba and works on organoid-guided therapy and DNA damage response combinations.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Golan%20T%5BAuthor%5D%20pancreatic%20olaparib"}],"tags":["pancreatic","parp","brca"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":["parp-inhibitor","organoids"],"targets":["parp","brca"],"drugs":["olaparib"],"companies":[],"institutions":["sheba"],"pathways":[],"terms":[],"trials":["polo"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Pancreatic Cancer Center, Sheba Medical Center","institutionId":"sheba","specialisms":["Pancreatic cancer","BRCA-associated cancer","PARP inhibitors","Precision oncology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Golan%20T%5BAuthor%5D%20pancreatic%20olaparib"}],"papers":[{"title":"Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer (POLO)","journal":"NEJM","year":2019,"doi":"10.1056/NEJMoa1903387"},{"title":"Overall survival from the phase 3 POLO trial: maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer","journal":"JCO","year":2021,"doi":"10.1200/JCO.21.01604"}]},{"id":"tammy-kang","kind":"person","name":"Tammy Kang","aka":[],"tldr":"Paediatric oncologist and palliative care physician serving as Interim Director of Texas Children's Cancer and Hematology Center.","summary":"Tammy Kang, MD, is Interim Director of Texas Children's Cancer and Hematology Center in Houston, one of the largest paediatric cancer and blood disorders programmes in the United States and affiliated with Baylor College of Medicine. Her background is in paediatric oncology and paediatric palliative care, with research on symptom management and quality of care for children with cancer. Her role is listed on the center's leadership page.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.texaschildrens.org/departments/cancer-and-hematology-center/our-leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kang+TI%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","paediatric oncology"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["texas-childrens"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["pediatric-blood-and-cancer"],"dependsOn":[],"notes":[],"role":"Interim Director","institutionId":"texas-childrens","specialisms":["Paediatric oncology","Paediatric palliative care","Quality of care"],"profiles":[{"label":"Institution profile","url":"https://www.texaschildrens.org/departments/cancer-and-hematology-center/our-leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kang+TI%5BAuthor%5D"}],"papers":[{"title":"Care experiences that foster trust between parents and physicians of children with cancer","journal":"Pediatric Blood & Cancer","year":2020,"doi":"10.1002/pbc.28399"},{"title":"Attempting to Define Clinical Productivity Metrics among Pediatric Palliative Care Services at Academic Children's Hospitals","journal":"Journal of Palliative Medicine","year":2020,"doi":"10.1089/jpm.2019.0164"},{"title":"Goals of Care Among Parents of Children Receiving Palliative Care","journal":"JAMA Pediatrics","year":2023,"doi":"10.1001/jamapediatrics.2023.1602"}]},{"id":"tammy-quigley","kind":"person","name":"Tammy Quigley","aka":[],"tldr":"Hospital executive who leads the cancer programme at London Health Sciences Centre, home of the Verspeeten Family Cancer Centre, and the South West Regional Cancer Program in Ontario.","summary":"Tammy Quigley is Vice President of Cancer, Renal, Mental Health and Patient Flow at London Health Sciences Centre (LHSC) in London, Ontario, and Regional Vice President for the South West Regional Cancer Program. LHSC's executive leadership page lists her in these roles; the Verspeeten Family Cancer Centre is LHSC's regional cancer centre for south western Ontario. The same page records that David Musyj currently serves as Supervisor of LHSC.","asOf":"2026-09-10","links":[{"label":"Source: LHSC executive leadership team page","url":"https://www.lhsc.on.ca/about-lhsc/executive-leadership-team"}],"tags":["leadership","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["lhsc-verspeeten"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Vice President, Cancer, Renal, Mental Health and Patient Flow, London Health Sciences Centre; Regional Vice President, South West Regional Cancer Program","institutionId":"lhsc-verspeeten","specialisms":["Cancer programme leadership","Hospital operations","Regional cancer services"],"profiles":[{"label":"LHSC executive leadership team","url":"https://www.lhsc.on.ca/about-lhsc/executive-leadership-team"}],"papers":[]},{"id":"tan-weihong","kind":"person","name":"Tan Weihong","aka":[],"tldr":"Chinese Academy of Sciences academician who is President of Zhejiang Cancer Hospital in Hangzhou and director of the CAS Hangzhou Institute of Medicine.","summary":"Tan Weihong (谭蔚泓) is President (院长) of Zhejiang Cancer Hospital, a tertiary specialist cancer hospital in Hangzhou designated a national regional cancer medical centre. The hospital's leadership listing names him as president alongside Party Secretary Cheng Xiangdong, and a hospital news item records that on 22 June 2025 the hospital was formally designated the affiliated cancer hospital of the Hangzhou Institute of Medicine of the Chinese Academy of Sciences, describing Tan as a CAS academician and director of that institute. The hospital's website moved from zjcc.org.cn to zchospital.com and was unreachable when checked, so its pages are cited from archived copies of January 2026.","asOf":"2026-09-10","links":[{"label":"Source: Zhejiang Cancer Hospital leadership listing (archived copy, January 2026)","url":"https://web.archive.org/web/20260118064043/https://www.zchospital.com/cn/survey"},{"label":"Source: Zhejiang Cancer Hospital homepage with June 2025 news naming the president (archived copy)","url":"https://web.archive.org/web/20260118080219/https://www.zchospital.com/cn/index"}],"tags":["leadership","clinician-scientist","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["zhejiang-cancer-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President (院长) of Zhejiang Cancer Hospital","institutionId":"zhejiang-cancer-hospital","specialisms":["Chemical biology","Molecular medicine","Hospital and institute leadership"],"profiles":[{"label":"Zhejiang Cancer Hospital overview and leadership (Chinese)","url":"https://www.zchospital.com/cn/survey"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tan+W%5BAuthor%5D+AND+Hangzhou+Institute+of+Medicine"}],"papers":[{"title":"Aptasensor with Expanded Nucleotide Using DNA Nanotetrahedra for Electrochemical Detection of Cancerous Exosomes","journal":"ACS Nano","year":2017,"doi":"10.1021/acsnano.7b00373"},{"title":"A Smart Photosensitizer–Manganese Dioxide Nanosystem for Enhanced Photodynamic Therapy by Reducing Glutathione Levels in Cancer Cells","journal":"Angewandte Chemie International Edition","year":2016,"doi":"10.1002/anie.201510748"},{"title":"Low-cost thermophoretic profiling of extracellular-vesicle surface proteins for the early detection and classification of cancers","journal":"Nature Biomedical Engineering","year":2019,"doi":"10.1038/s41551-018-0343-6"}]},{"id":"tanios-bekaii-saab","kind":"person","name":"Tanios Bekaii-Saab","aka":[],"tldr":"GI oncologist behind trials of KRAS, HER2, and FGFR-directed therapy in colorectal and bile duct cancer.","summary":"Tanios Bekaii-Saab is Professor of Medicine and Leader of the GI Cancer Program at Mayo Clinic Arizona, part of the Mayo Clinic Comprehensive Cancer Center. A medical oncologist specialising in colorectal and biliary cancer, he leads gastrointestinal cancer research in Arizona and has been an investigator on ANCHOR CRC, MOUNTAINEER and FGFR2 inhibitor trials in cholangiocarcinoma. His papers include the New England Journal of Medicine report of adagrasib with or without cetuximab in colorectal cancer with mutated KRAS G12C and the ReDOS phase 2 study of regorafenib dose-optimisation in refractory metastatic colorectal cancer. A frequent voice on colorectal cancer treatment sequencing, his work spans KRAS, HER2 and FGFR2 in colorectal, biliary tract and pancreatic cancer.","asOf":"2026-09-08","links":[{"label":"Mayo Clinic research faculty","url":"https://www.mayo.edu/research/faculty"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bekaii-Saab%20T%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Tanios%20Bekaii-Saab"}],"tags":[],"related":[],"cancers":["colorectal","cholangiocarcinoma","pancreatic"],"sections":[],"technologies":[],"targets":["kras","her2","fgfr2"],"drugs":[],"companies":[],"institutions":["mayo-clinic","mayo-clinic-arizona"],"pathways":[],"terms":[],"trials":["mountaineer"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medicine; Leader, GI Cancer Program, Mayo Clinic Arizona","institutionId":"mayo-clinic","specialisms":["Gastrointestinal oncology","Colorectal cancer","Biliary cancer"],"profiles":[{"label":"Mayo Clinic research faculty","url":"https://www.mayo.edu/research/faculty"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bekaii-Saab%20T%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Tanios%20Bekaii-Saab"}],"papers":[{"title":"Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C","journal":"New England Journal of Medicine","year":2023,"url":"https://doi.org/10.1056/nejmoa2212419","doi":"10.1056/nejmoa2212419"},{"title":"Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study","journal":"Lancet Oncology","year":2019,"url":"https://doi.org/10.1016/S1470-2045(19)30272-4","doi":"10.1016/S1470-2045(19)30272-4"},{"title":"NAPOLI-3: NALIRIFOX versus gemcitabine plus nab-paclitaxel as first treatment for metastatic pancreatic cancer","journal":"The Lancet","year":2023,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NAPOLI-3+NALIRIFOX+Wainberg+Lancet"}],"orcid":"0000-0001-7721-1699"},{"id":"tao-cheng","kind":"person","name":"Tao Cheng","aka":[],"tldr":"Academician of the Chinese Academy of Engineering who heads the Institute of Hematology and Blood Diseases Hospital in Tianjin, China's largest national research hospital for haematology.","summary":"Tao Cheng (程涛) is President and Institute Director (所院长) of the Institute of Hematology and Blood Diseases Hospital of the Chinese Academy of Medical Sciences (IHCAMS) in Tianjin, and an Academician of the Chinese Academy of Engineering. The hospital's leadership page lists him alongside Party Secretary and Vice President Chang Zikui (常子奎) and vice presidents including Zhang Lei, Wang Jinyu, Shi Jun, Shi Lihong and Jiang Erlie. IHCAMS, founded in 1957, describes itself as China's largest national research hospital in haematology, a Grade A tertiary specialist hospital under the National Health Commission with 1,540 beds across 14 clinical centres, more than 260,000 patient visits in 2024, and the base for the National Key Laboratory of Blood Science and the National Clinical Research Center for Blood Diseases.","asOf":"2026-09-10","links":[{"label":"Source: IHCAMS leadership team listing (Chinese)","url":"https://www.chinablood.com.cn/jyb/hospitals.html"},{"label":"Source: IHCAMS English introduction","url":"https://www.chinablood.com.cn/en/IHCAMS.html"}],"tags":["leadership","hospital-management","research-institute"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cams-hematology"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["blood"],"dependsOn":[],"notes":[],"role":"President (所院长), Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences","institutionId":"cams-hematology","specialisms":["Haematology","Blood diseases research","Hospital management"],"profiles":[{"label":"Hospital overview and leadership team (Chinese)","url":"https://www.chinablood.com.cn/jyb/hospitals.html"},{"label":"IHCAMS research team page (English)","url":"https://www.chinablood.com.cn/en/science/team.html"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cheng+T%5BAuthor%5D+AND+Tianjin+hematology"}],"papers":[{"title":"Leukemic marrow infiltration reveals a novel role for Egr3 as a potent inhibitor of normal hematopoietic stem cell proliferation","journal":"Blood","year":2015,"doi":"10.1182/blood-2015-01-623645"}],"orcid":"0000-0002-5925-2769"},{"id":"taofeek-owonikoko","kind":"person","name":"Taofeek K. Owonikoko","aka":[],"tldr":"Medical oncologist who is Executive Director of the NCI-designated Greenebaum Comprehensive Cancer Center at the University of Maryland in Baltimore.","summary":"Taofeek K. Owonikoko, MD, PhD, is Executive Director of the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC), a National Cancer Institute-designated comprehensive cancer centre in Baltimore. He holds the Kevin J. Cullen, MD, Distinguished Professorship of Oncology and is Senior Associate Dean of Cancer Programs at the University of Maryland School of Medicine and Associate Vice President of Cancer Programs at the University of Maryland, Baltimore. In his director's welcome he describes a centre with more than 58,000 unique outpatient visits in 2023 that integrates innovative therapies and individualised care with research and education.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Taofeek_Owonikoko","links":[{"label":"Source: UMGCCC Director's Welcome page","url":"https://www.umms.org/umgccc/about/director-welcome"}],"tags":["leadership","clinician-scientist","comprehensive-cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["maryland-greenebaum"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["cancer-wiley","nejm","future-oncology"],"dependsOn":[],"notes":[],"role":"Executive Director, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center","institutionId":"maryland-greenebaum","specialisms":["Medical oncology","Thoracic oncology","Cancer centre leadership"],"profiles":[{"label":"UMGCCC Director's Welcome","url":"https://www.umms.org/umgccc/about/director-welcome"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Owonikoko+TK%5BAuthor%5D"}],"papers":[{"title":"Practical management of adverse events in patients receiving tarlatamab, a delta‐like ligand 3–targeted bispecific T‐cell engager immunotherapy, for previously treated small cell lung cancer","journal":"Cancer","year":2025,"doi":"10.1002/cncr.35738"},{"title":"Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy","journal":"New England Journal of Medicine","year":2025,"doi":"10.1056/nejmoa2502099"},{"title":"IDeate-Lung02: a Phase 3 study of second-line ifinatamab deruxtecan in patients with relapsed small cell lung cancer","journal":"Future Oncology","year":2025,"doi":"10.1080/14796694.2025.2565995"}]},{"id":"tari-king","kind":"person","name":"Tari A. King","aka":[],"tldr":"Breast surgical oncologist at Winship Cancer Institute and President-Elect of the Society of Surgical Oncology, known for research on lobular breast cancer and surgical de-escalation.","summary":"Tari King is President-Elect of the Society of Surgical Oncology and a breast surgical oncologist at the Winship Cancer Institute of Emory University in Atlanta. Her research addresses invasive lobular carcinoma, ductal carcinoma in situ and the safe de-escalation of breast and axillary surgery. She has led national cooperative group studies in breast surgical oncology.","asOf":"2026-09-10","links":[{"label":"Society page","url":"https://www.surgonc.org/about-sso/leadership/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=King+TA%5BAuthor%5D+breast"}],"tags":["leadership","clinician-scientist","surgical oncology","breast cancer"],"related":[],"cancers":["breast-hr-positive","breast-her2-positive"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["sso"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President-Elect","institutionId":"sso","specialisms":["Breast surgical oncology","Breast cancer","Lobular carcinoma"],"profiles":[{"label":"Society page","url":"https://www.surgonc.org/about-sso/leadership/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=King+TA%5BAuthor%5D+breast"}],"papers":[{"title":"Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy","journal":"Nature Reviews Clinical Oncology","year":2015,"doi":"10.1038/nrclinonc.2015.63"},{"title":"Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab","journal":"Cancer Discovery","year":2021,"doi":"10.1158/2159-8290.cd-20-1557"},{"title":"In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer","journal":"Nature Genetics","year":2015,"doi":"10.1038/ng.3391"}]},{"id":"tariq-enver","kind":"person","name":"Tariq Enver","aka":[],"tldr":"Scientist who directs the Cancer Research UK City of London Centre, the multi-institution London hub for cancer biotherapeutics research.","summary":"Tariq Enver is Director of the Cancer Research UK City of London Centre, which Cancer Research UK lists among its research centres with King's College London, University College London, Barts Cancer Institute and The Francis Crick Institute as partner institutions. The centre describes itself as a world class hub for cancer biotherapeutics that brings together cancer researchers from across Barts/QMUL, KCL, UCL and the Crick, with adult and paediatric faculty, shared infrastructure cores and a training programme. It also hosts the CRUK RadNet City of London radiation research network.","asOf":"2026-09-10","links":[{"label":"Source: Cancer Research UK research centres page listing the centre Director","url":"https://www.cancerresearchuk.org/funding-for-researchers/our-research-infrastructure/our-centres"}],"tags":["leadership","clinician-scientist","research-institute"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cruk","francis-crick"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Cancer Research UK City of London Centre","institutionId":"cruk-city-of-london-centre","specialisms":["Cancer biotherapeutics","Stem cell and leukaemia biology","Research centre leadership"],"profiles":[{"label":"Cancer Research UK: our centres (names the Director)","url":"https://www.cancerresearchuk.org/funding-for-researchers/our-research-infrastructure/our-centres"},{"label":"CRUK City of London Centre website","url":"https://www.colcc.ac.uk/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Enver+T%5BAuthor%5D"}],"papers":[{"title":"Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition","journal":"Cell","year":2021,"doi":"10.1016/j.cell.2021.01.002"},{"title":"Regulome analysis in B-acute lymphoblastic leukemia exposes Core Binding Factor addiction as a therapeutic vulnerability","journal":"Nature Communications","year":2022,"doi":"10.1038/s41467-022-34653-3"},{"title":"Genetic variegation of clonal architecture and propagating cells in leukaemia","journal":"Nature","year":2010,"doi":"10.1038/nature09650"}],"orcid":"0000-0002-0866-6443"},{"id":"tarmo-bakler","kind":"person","name":"Tarmo Bakler","aka":[],"tldr":"Tarmo Bakler represents East Tallinn Central Hospital in the Organisation of European Cancer Institutes, which lists the centre among its members in Estonia.","summary":"Tarmo Bakler is listed by the Organisation of European Cancer Institutes (OECI) as the representative of East Tallinn Central Hospital, its member in Estonia. East Tallinn Central Hospital is a Tallinn hospital providing cancer care and a full member of the Organisation of European Cancer Institutes. OnCo records the name from the OECI membership list so that the centre's page has a named contact point; the person's exact title, appointment date and biography are not yet recorded and should be checked on the institution's own pages before being relied on.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"East Tallinn Central Hospital website","url":"https://www.itk.ee/en"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["east-tallinn-central-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of East Tallinn Central Hospital to the Organisation of European Cancer Institutes","institutionId":"east-tallinn-central-hospital","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"East Tallinn Central Hospital website","url":"https://www.itk.ee/en"}],"papers":[]},{"id":"tasuku-honjo","kind":"person","name":"Tasuku Honjo","aka":[],"tldr":"He discovered the PD-1 molecule on T cells in 1992 and showed it acts as a brake on immune attack. Blocking it produced nivolumab and pembrolizumab, now used across dozens of cancers; Nobel Prize 2018.","summary":"Tasuku Honjo, at Kyoto University, identified programmed cell death protein 1 (PD-1) in 1992 as a gene switched on in dying T cells and, over the following decade, showed with knockout mice that it restrains immune responses and that its blockade lets T cells attack tumours. He worked with Ono Pharmaceutical, later joined by Medarex and Bristol-Myers Squibb, to develop an antibody against it; nivolumab was approved in Japan in July 2014 for melanoma and in the United States in December 2014, and with pembrolizumab established PD-1 blockade as the most widely used cancer immunotherapy, in lung, kidney, bladder, head and neck, Hodgkin lymphoma and many other cancers. He shared the 2018 Nobel Prize in Physiology or Medicine with James Allison for the discovery of cancer therapy by inhibition of negative immune regulation, and his earlier work identified activation-induced cytidine deaminase, central to antibody class switching.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Tasuku_Honjo","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Tasuku_Honjo"},{"label":"Nobel Prize biography","url":"https://www.nobelprize.org/prizes/medicine/2018/honjo/facts/"}],"tags":["hero","pioneer"],"related":[],"cancers":["melanoma","nsclc"],"sections":["immunotherapy"],"technologies":["checkpoint-inhibitor"],"targets":["pd1","pdl1"],"drugs":["nivolumab","pembrolizumab"],"companies":[],"institutions":["kyoto-university-hospital"],"pathways":[],"terms":[],"trials":[],"people":["james-allison"],"bottlenecks":["b-immunotherapy-response"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Immunologist who discovered PD-1 and opened the way to anti-PD-1 therapy","institutionId":"kyoto-university-hospital","specialisms":["Immunology","PD-1","Checkpoint immunotherapy"],"profiles":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Tasuku_Honjo"},{"label":"Nobel Prize biography","url":"https://www.nobelprize.org/prizes/medicine/2018/honjo/facts/"}],"papers":[{"title":"PPAR-Induced Fatty Acid Oxidation in T Cells Increases the Number of Tumor-Reactive CD8+ T Cells and Facilitates Anti–PD-1 Therapy","journal":"Cancer Immunology Research","year":2018,"doi":"10.1158/2326-6066.cir-18-0095"},{"title":"Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer","journal":"Journal of Clinical Oncology","year":2015,"doi":"10.1200/jco.2015.62.3397"},{"title":"Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity","journal":"Proceedings of the National Academy of Sciences","year":2017,"doi":"10.1073/pnas.1620433114"}]},{"id":"tatsuya-ohno","kind":"person","name":"Tatsuya Ohno","aka":[],"tldr":"Carbon-ion radiotherapy specialist who directs the Gunma University Heavy Ion Medical Center, Japan's first university-based carbon-ion cancer treatment facility.","summary":"Tatsuya Ohno is Director of the Gunma University Heavy Ion Medical Center in Maebashi, which began heavy-ion (carbon-ion) cancer treatment in 2010 as the first university-based facility of its kind in Japan. In his director's greeting he describes the advantages of heavy-ion therapy over conventional X-ray treatment in dose concentration and biological effectiveness, with courses typically completed within one to four weeks, and the centre's roles in training specialists and promoting international collaboration. He has published extensively on carbon-ion radiotherapy from the Gunma facility.","asOf":"2026-09-10","links":[{"label":"Source: GHMC director's greeting","url":"https://heavy-ion.showa.gunma-u.ac.jp/page.php?id=15"}],"tags":["leadership","clinician-scientist","radiotherapy","particle-therapy"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["gunma-heavy-ion-medical-center"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["cancers-mdpi"],"dependsOn":[],"notes":[],"role":"Director of the Gunma University Heavy Ion Medical Center","institutionId":"gunma-heavy-ion-medical-center","specialisms":["Carbon-ion radiotherapy","Radiation oncology","Particle therapy"],"profiles":[{"label":"Institution profile","url":"https://heavy-ion.showa.gunma-u.ac.jp/page.php?id=15"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ohno+T%5BAuthor%5D+carbon+ion+Gunma"}],"papers":[{"title":"Carbon Ion Radiotherapy at the Gunma University Heavy Ion Medical Center: New Facility Set-up","journal":"Cancers","year":2011,"doi":"10.3390/cancers3044046"},{"title":"Particle radiotherapy with carbon ion beams","journal":"EPMA Journal","year":2013,"doi":"10.1186/1878-5085-4-9"},{"title":"Efficacy and Safety of 4 Fractions of Carbon-Ion Radiation Therapy for Hepatocellular Carcinoma: A Prospective Study","journal":"Liver Cancer","year":2021,"doi":"10.1159/000520277"}],"orcid":"0000-0002-6703-3144"},{"id":"ted-williams","kind":"person","name":"Ted Williams","aka":[],"tldr":"From the 1940s until his last clinic visit in 1999 the greatest hitter in baseball raised money for Dana-Farber's Jimmy Fund and visited children on the wards on condition that no one wrote about it.","summary":"Ted Williams (1918-2002), the Boston Red Sox left fielder and last player to bat .400 in a season, attached himself to the Jimmy Fund soon after its 1948 founding and stayed with it for the rest of his life. The Jimmy Fund's own pages record his decades as its public champion, his insistence that his bedside visits to children with cancer go unreported, and his last visit to the clinic in July 1999. The Red Sox partnership he embodied, which began formally in 1953, has raised more than $172 million for Dana-Farber Cancer Institute according to the Jimmy Fund, and the WEEI/NESN Radio-Telethon started in his memory has raised more than $74 million since 2002. When the Fund began, nearly all children with cancer died; by his last visit, more than three in four survived.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Ted_Williams","links":[{"label":"Jimmy Fund: Ted Williams","url":"https://www.jimmyfund.org/about-us/boston-red-sox/ted-williams/"},{"label":"Jimmy Fund: history of the Red Sox partnership","url":"https://www.jimmyfund.org/about/partnerships/boston-red-sox/history-of-partnership"}],"tags":["public-figure","donor"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["jimmy-fund","dana-farber"],"pathways":[],"terms":[],"trials":[],"people":["einar-gustafson","sidney-farber"],"bottlenecks":["b-funding-allocation","b-rare-cancers"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Boston Red Sox star who was the Jimmy Fund's public champion for half a century","specialisms":["Cancer fundraising","Paediatric cancer","Sport and philanthropy"],"profiles":[],"papers":[]},{"id":"tedros-adhanom-ghebreyesus","kind":"person","name":"Tedros Adhanom Ghebreyesus","aka":[],"tldr":"Director-General of the World Health Organization, under whom WHO's global cancer initiatives are run.","summary":"Tedros Adhanom Ghebreyesus is Director-General of the World Health Organization. He leads the agency responsible for global health norms and programmes, including WHO's cancer control work such as the Global Initiative for Childhood Cancer, the Global Breast Cancer Initiative and the cervical cancer elimination strategy. He previously served as Ethiopia's Minister of Health and Minister of Foreign Affairs.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.who.int/director-general"}],"tags":["leadership","global health","cancer control"],"related":[],"cancers":["cervical"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["who"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director-General","institutionId":"who","specialisms":["Global health","Health policy","Noncommunicable disease control"],"profiles":[{"label":"Institution profile","url":"https://www.who.int/director-general"}],"papers":[{"title":"The Global Platform for Access to Childhood Cancer Medicines: addressing inequities in childhood cancer care","journal":"The Lancet Oncology","year":2025,"doi":"10.1016/s1470-2045(25)00146-9"}]},{"id":"teresa-cotta-dias","kind":"person","name":"Teresa Cotta-Dias","aka":[],"tldr":"Secretary-General responsible for the Champalimaud Clinical Centre, the Foundation's cancer-focused clinical arm.","summary":"Teresa Cotta-Dias is Secretary-General for the Champalimaud Clinical Centre at the Champalimaud Foundation in Lisbon. She oversees management of the clinical centre, which delivers multidisciplinary cancer care and hosts clinical research programmes including the Botton-Champalimaud Pancreatic Cancer Centre.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://fchampalimaud.org/champalimaud-foundation/team"}],"tags":["leadership","hospital management"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["champalimaud"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Secretary-General for the Champalimaud Clinical Centre","institutionId":"champalimaud","specialisms":["Clinical centre management","Cancer care delivery"],"profiles":[{"label":"Institution profile","url":"https://fchampalimaud.org/champalimaud-foundation/team"}],"papers":[]},{"id":"terry-fox","kind":"person","name":"Terry Fox","aka":[],"tldr":"After losing a leg to bone cancer at 18, he set out in 1980 to run across Canada for cancer research. He covered 5,373 km before the disease returned; the run he started has raised over C$850 million.","summary":"Terry Fox (1958-1981) was diagnosed with osteosarcoma in 1977 and had his right leg amputated above the knee. Moved by the children he met on the cancer ward, he began the Marathon of Hope on 12 April 1980 at St John's, Newfoundland, running close to a marathon a day on a prosthetic leg. He was forced to stop on 1 September 1980 outside Thunder Bay, Ontario, after 143 days and 5,373 km, when the cancer was found in his lungs. He died on 28 June 1981 at 22. The annual Terry Fox Run, held in Canada and dozens of countries, and the Terry Fox Foundation and Research Institute have since raised more than C$850 million for cancer research, and his name is one of the most recognised in Canadian public life.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Terry_Fox","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Terry_Fox"},{"label":"Terry Fox Foundation","url":"https://terryfox.org/"}],"tags":["hero","patient"],"related":[],"cancers":["osteosarcoma","sarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["terry-fox-foundation"],"pathways":[],"terms":["aya-oncology"],"trials":[],"people":[],"bottlenecks":["b-funding-allocation","b-rare-cancers"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Patient whose Marathon of Hope built Canada's largest cancer research fundraiser","specialisms":["Osteosarcoma","Cancer fundraising","Adolescent and young adult cancer"],"profiles":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Terry_Fox"},{"label":"Terry Fox Foundation","url":"https://terryfox.org/"}],"papers":[]},{"id":"theodore-levin","kind":"person","name":"Theodore R. Levin","aka":[],"tldr":"Gastroenterologist who leads cancer research at Kaiser Permanente's Division of Research and is a leading figure in colorectal cancer screening.","summary":"Theodore R. Levin is Associate Director for Cancer research at the Kaiser Permanente Division of Research and a practising gastroenterologist. His work has evaluated organised colorectal cancer screening programmes, faecal immunochemical testing and colonoscopy quality in a large integrated health system, informing US screening guidelines.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://divisionofresearch.kaiserpermanente.org/our-team/leadership-team/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Levin+TR%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","colorectal cancer","screening"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["kaiser-permanente-research"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Associate Director, Cancer","institutionId":"kaiser-permanente-research","specialisms":["Colorectal cancer screening","Gastroenterology","Cancer epidemiology"],"profiles":[{"label":"Institution profile","url":"https://divisionofresearch.kaiserpermanente.org/our-team/leadership-team/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Levin+TR%5BAuthor%5D"}],"papers":[{"title":"Current and future colorectal cancer screening strategies","journal":"Nature Reviews Gastroenterology & Hepatology","year":2022,"doi":"10.1038/s41575-022-00612-y"},{"title":"Impact of the COVID-19 Pandemic on Fecal Immunochemical Testing, Colonoscopy Services, and Colorectal Neoplasia Detection in a Large United States Community-based Population","journal":"Gastroenterology","year":2022,"doi":"10.1053/j.gastro.2022.05.014"},{"title":"Variation in Adenoma Detection Rate and the Lifetime Benefits and Cost of Colorectal Cancer Screening","journal":"JAMA","year":2015,"doi":"10.1001/jama.2015.6251"}],"orcid":"0000-0002-0842-2377"},{"id":"theodore-hong","kind":"person","name":"Theodore S. Hong","aka":[],"tldr":"Showed how radiation, including proton therapy, can be used in liver and pancreatic cancers previously considered unsuitable.","summary":"Theodore S. Hong is Director of Gastrointestinal Radiation Oncology at Massachusetts General Hospital Cancer Center. He is a radiation oncologist known for showing how radiation, including proton therapy, can be used in liver and pancreatic cancers previously considered unsuitable for it. His selected paper reports a multi-institutional phase 2 study of high-dose hypofractionated proton beam therapy in localised, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma. He leads proton and stereotactic radiotherapy studies in hepatobiliary and pancreatic cancers and neoadjuvant chemoradiation combinations, including losartan-based stromal modulation.","asOf":"2026-09-08","links":[{"label":"MGH profile","url":"https://www.massgeneral.org/doctors/17557/theodore-hong"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hong%20TS%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["hcc","cholangiocarcinoma","pancreatic"],"sections":[],"technologies":["proton-therapy","sbrt"],"targets":[],"drugs":[],"companies":[],"institutions":["mgh"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Gastrointestinal Radiation Oncology","institutionId":"mgh","specialisms":["Proton therapy","Liver and pancreatic cancer radiation","Total neoadjuvant therapy"],"profiles":[{"label":"MGH profile","url":"https://www.massgeneral.org/doctors/17557/theodore-hong"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hong%20TS%5BAuthor%5D"}],"papers":[{"title":"Multi-institutional phase II study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma","journal":"Journal of Clinical Oncology","year":2016,"url":"https://doi.org/10.1200/JCO.2015.64.2710","doi":"10.1200/JCO.2015.64.2710"}],"orcid":"0000-0001-8481-6581"},{"id":"theodore-lawrence","kind":"person","name":"Theodore S. Lawrence","aka":[],"tldr":"Radiation oncologist who developed adaptive liver radiotherapy and radiosensitising drug combinations.","summary":"Theodore S. Lawrence is the Isadore Lampe Professor of Radiation Oncology at the University of Michigan Rogel Cancer Center. He is a radiation oncologist known for developing individualised adaptive radiotherapy for liver tumours and radiosensitising drug combinations that target the DNA damage response. His selected paper reports individualised adaptive stereotactic body radiotherapy for liver cancer. A former chair of radiation oncology at Michigan, he continues to work on stereotactic and image-guided radiotherapy in hepatocellular and pancreatic cancer.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Theodore_Lawrence","links":[{"label":"Michigan profile","url":"https://www.rogelcancercenter.org/theodore-s-lawrence-md-phd"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lawrence%20TS%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["hcc","pancreatic"],"sections":[],"technologies":["sbrt","imrt-igrt"],"targets":[],"drugs":[],"companies":[],"institutions":["michigan-rogel"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Isadore Lampe Professor of Radiation Oncology","institutionId":"michigan-rogel","specialisms":["Radiation oncology","Radiosensitisers","Liver and pancreatic radiation"],"profiles":[{"label":"Michigan profile","url":"https://www.rogelcancercenter.org/theodore-s-lawrence-md-phd"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lawrence%20TS%5BAuthor%5D"}],"papers":[{"title":"Individualized adaptive stereotactic body radiotherapy for liver cancer","journal":"Journal of Clinical Oncology","year":2016}],"orcid":"0000-0002-4186-8821"},{"id":"thierry-andre","kind":"person","name":"Thierry André","aka":[],"tldr":"Led MOSAIC, which made FOLFOX the adjuvant standard, and KEYNOTE-177, which made pembrolizumab first-line for MSI-high colon cancer.","summary":"Thierry André (Hôpital Saint-Antoine, Paris) was principal investigator of MOSAIC, the trial that established oxaliplatin-based adjuvant chemotherapy for stage III colon cancer, and two decades later of KEYNOTE-177, which showed pembrolizumab doubles progression-free survival versus chemotherapy in MSI-high metastatic colorectal cancer. He also led CheckMate 8HW (nivolumab plus ipilimumab) and the IDEA collaboration on three versus six months of adjuvant therapy. He remains a leading GERCOR investigator.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Andre%20T%5BAuthor%5D%20colorectal%20pembrolizumab%20OR%20MOSAIC"}],"tags":["colorectal","immunotherapy","adjuvant"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy"],"targets":["pd1","ctla4"],"drugs":["pembrolizumab","nivolumab","ipilimumab"],"companies":[],"institutions":["iuc-aphp-sorbonne"],"pathways":[],"terms":[],"trials":["keynote-177","checkmate-8hw"],"people":[],"bottlenecks":[],"keyPapers":["paper-keynote-177-nejm-2020"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology, Sorbonne University; Head of Medical Oncology, Hôpital Saint-Antoine, Paris","institutionId":"iuc-aphp-sorbonne","specialisms":["Colorectal cancer","Adjuvant chemotherapy","MSI-high immunotherapy","Cooperative-group trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Andre%20T%5BAuthor%5D%20colorectal%20pembrolizumab%20OR%20MOSAIC"}],"papers":[{"title":"Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer (MOSAIC)","journal":"NEJM","year":2004,"doi":"10.1056/NEJMoa032709"},{"title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer (KEYNOTE-177)","journal":"NEJM","year":2020,"doi":"10.1056/NEJMoa2017699"},{"title":"Nivolumab plus ipilimumab in microsatellite-instability-high metastatic colorectal cancer (CheckMate 8HW)","journal":"NEJM","year":2024,"doi":"10.1056/NEJMoa2402141"}]},{"id":"thierry-conroy","kind":"person","name":"Thierry Conroy","aka":[],"tldr":"Led the FOLFIRINOX trials that gave pancreatic cancer its most active chemotherapy in both metastatic and adjuvant settings.","summary":"Thierry Conroy (Nancy, France) was principal investigator of PRODIGE 4/ACCORD 11, which showed FOLFIRINOX nearly doubles survival versus gemcitabine in metastatic pancreatic cancer, and of PRODIGE 24, which showed modified FOLFIRINOX after resection extends median survival to more than four years. These two trials define modern pancreatic cancer chemotherapy. He continues to lead PRODIGE GI trials.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Conroy%20T%5BAuthor%5D%20FOLFIRINOX"}],"tags":["pancreatic","chemotherapy","trialist"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":[],"companies":[],"institutions":["institut-de-cancerologie-de-lorraine"],"pathways":[],"terms":[],"trials":["prodige-24"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Medical Oncologist, Institut de Cancérologie de Lorraine; Professor, University of Lorraine","institutionId":"institut-de-cancerologie-de-lorraine","specialisms":["Pancreatic cancer","Chemotherapy regimens","Adjuvant therapy","Oesophageal cancer"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Conroy%20T%5BAuthor%5D%20FOLFIRINOX"}],"papers":[{"title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer (PRODIGE 4/ACCORD 11)","journal":"NEJM","year":2011,"doi":"10.1056/NEJMoa1011923"},{"title":"FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer (PRODIGE 24)","journal":"NEJM","year":2018,"doi":"10.1056/NEJMoa1809775"}],"orcid":"0000-0001-7548-284X"},{"id":"thierry-facon","kind":"person","name":"Thierry Facon","aka":[],"tldr":"Led MAIA, which made daratumumab-lenalidomide-dexamethasone the standard for older patients with myeloma.","summary":"Thierry Facon (Lille) was principal investigator of MAIA, the trial showing daratumumab plus lenalidomide-dexamethasone dramatically improves progression-free and overall survival in transplant-ineligible newly diagnosed myeloma, with median survival now beyond seven years, and of FIRST, which established continuous lenalidomide-dexamethasone in this population. He led the IFM frailty score work and co-leads the IMROZ isatuximab trial.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Facon%20T%5BAuthor%5D%20myeloma%20daratumumab%20MAIA"}],"tags":["myeloma","older-patients","trialist"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":["monoclonal-antibody"],"targets":["cd38"],"drugs":[],"companies":[],"institutions":["chu-lille"],"pathways":[],"terms":[],"trials":["imroz"],"people":[],"bottlenecks":[],"keyPapers":["paper-maia-daratumumab-rd-nejm-2019"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Hematology, Lille University Hospital (CHU Lille)","institutionId":"chu-lille","specialisms":["Multiple myeloma","Older and transplant-ineligible patients","Daratumumab","Frailty"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Facon%20T%5BAuthor%5D%20myeloma%20daratumumab%20MAIA"}],"papers":[{"title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma (MAIA)","journal":"NEJM","year":2019,"doi":"10.1056/NEJMoa1817249"},{"title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma (FIRST)","journal":"NEJM","year":2014,"doi":"10.1056/NEJMoa1402551"}]},{"id":"thomas-hope","kind":"person","name":"Thomas A. Hope","aka":[],"tldr":"Nuclear medicine physician who led the trials that got PSMA PET approved in the United States.","summary":"Thomas Hope is Professor of Radiology and Chief of Nuclear Medicine at UCSF, within the UCSF Helen Diller Family Comprehensive Cancer Center. A nuclear medicine physician specialising in PSMA PET and theranostics, his prospective studies of 68Ga-PSMA-11 PET at UCSF and UCLA supported the first FDA approval of PSMA PET in the United States in 2020. His papers include a JAMA Oncology multicentre prospective phase 3 imaging trial of the diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis before radical prostatectomy and a JAMA Oncology prospective single-arm trial assessing its accuracy in localising recurrent prostate cancer. He leads theranostics research and PSMA radioligand dosimetry work in prostate cancer.","asOf":"2026-09-08","links":[{"label":"UCSF profile","url":"https://profiles.ucsf.edu/search/?searchtype=people&searchfor=Thomas%20A.%20Hope"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hope%20TA%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Thomas%20A.%20Hope"}],"tags":[],"related":[],"cancers":["prostate"],"sections":[],"technologies":["psma-pet","radioligand-therapy","pet"],"targets":["psma"],"drugs":[],"companies":[],"institutions":["ucsf"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Radiology; Chief of Nuclear Medicine, UCSF","institutionId":"ucsf","specialisms":["Nuclear medicine","PSMA PET","Theranostics"],"profiles":[{"label":"UCSF profile","url":"https://profiles.ucsf.edu/search/?searchtype=people&searchfor=Thomas%20A.%20Hope"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hope%20TA%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Thomas%20A.%20Hope"}],"papers":[{"title":"Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial","journal":"JAMA Oncology","year":2021,"url":"https://doi.org/10.1001/jamaoncol.2021.3771","doi":"10.1001/jamaoncol.2021.3771"},{"title":"Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial","journal":"JAMA Oncology","year":2019,"url":"https://doi.org/10.1001/jamaoncol.2019.0096","doi":"10.1001/jamaoncol.2019.0096"}]},{"id":"thomas-bachelot","kind":"person","name":"Thomas Bachelot","aka":[],"tldr":"Breast oncologist who led UNICANCER trials on brain metastases and hormone therapy resistance.","summary":"Thomas Bachelot is Head of Medical Oncology at Centre Léon Bérard in Lyon, part of the UNICANCER network. His specialisms are breast cancer, brain metastases and endocrine therapy. He led LANDSCAPE, the trial of lapatinib with capecitabine for brain metastases, and the TAMRAD and PADA-1 collaborations within UNICANCER's breast group. His papers include the GINECO randomised phase II trial of everolimus combined with tamoxifen in hormone receptor-positive metastatic breast cancer after aromatase inhibitors, the BELLE-3 phase 3 trial of buparlisib plus fulvestrant after mTOR inhibition, and the PANACEA trial of pembrolizumab plus trastuzumab in trastuzumab-resistant HER2-positive breast cancer. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bachelot%20T%5BAuthor%5D%20breast"}],"tags":[],"related":[],"cancers":["breast-hr-positive","breast-her2-positive"],"sections":[],"technologies":[],"targets":[],"drugs":["lapatinib"],"companies":["unicancer"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Head of Medical Oncology, Centre Léon Bérard, Lyon","institutionId":"unicancer","specialisms":["Breast cancer","Brain metastases","Endocrine therapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bachelot%20T%5BAuthor%5D%20breast"}],"papers":[{"title":"Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study","journal":"Journal of Clinical Oncology","year":2012,"doi":"10.1200/jco.2011.39.0708"},{"title":"Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial","journal":"The Lancet Oncology","year":2018,"doi":"10.1016/s1470-2045(17)30688-5"},{"title":"Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial","journal":"The Lancet Oncology","year":2019,"doi":"10.1016/s1470-2045(18)30812-x"}],"orcid":"0000-0002-0866-9484"},{"id":"thomas-balle-kristensen","kind":"person","name":"Thomas Balle Kristensen","aka":[],"tldr":"Chief Executive Officer of Aarhus University Hospital, Denmark's largest hospital and a major cancer treatment centre.","summary":"Thomas Balle Kristensen is Chief Executive Officer of Aarhus University Hospital, leading the executive management team responsible for running the hospital and its treatment and care. The hospital is Denmark's largest and hosts the Danish Centre for Particle Therapy and a large oncology department.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.en.auh.dk/About-the-Hospital/executive-management/"}],"tags":["leadership","hospital management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["aarhus-university-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive Officer","institutionId":"aarhus-university-hospital","specialisms":["Hospital management","Health services"],"profiles":[{"label":"Institution profile","url":"https://www.en.auh.dk/About-the-Hospital/executive-management/"}],"papers":[]},{"id":"thomas-gajewski","kind":"person","name":"Thomas F. Gajewski","aka":[],"tldr":"Defined the T-cell-inflamed tumour, discovered STING's role in anti-tumour immunity and showed gut bacteria shape immunotherapy response.","summary":"Thomas Gajewski defined the T-cell-inflamed versus non-inflamed tumour microenvironment phenotype that predicts checkpoint inhibitor response, showed that the STING pathway is required for innate immune sensing of tumours, and led the 2015 Science paper showing commensal Bifidobacterium enhances anti-PD-L1 efficacy, one of the founding results of microbiome immuno-oncology. He leads immunotherapy research at the University of Chicago.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gajewski%20TF%5BAuthor%5D%20tumor%20immunity"}],"tags":["immunotherapy","microbiome","sting"],"related":[],"cancers":[],"sections":[],"technologies":["checkpoint-inhibitor","sting-agonist"],"targets":[],"drugs":[],"companies":[],"institutions":["uchicago-cancer"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"AbbVie Foundation Professor of Cancer Immunotherapy, University of Chicago","institutionId":"uchicago-cancer","specialisms":["Tumour immunology","STING pathway","Microbiome and immunotherapy","T-cell-inflamed tumours"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gajewski%20TF%5BAuthor%5D%20tumor%20immunity"}],"papers":[{"title":"Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy","journal":"Science","year":2015,"doi":"10.1126/science.aac4255"},{"title":"STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors","journal":"Immunity","year":2014,"doi":"10.1016/j.immuni.2014.10.017"}]},{"id":"thomas-helleday","kind":"person","name":"Thomas Helleday","aka":[],"tldr":"Co-discovered that PARP inhibitors kill BRCA-deficient cells, the synthetic lethality behind olaparib and its successors.","summary":"Thomas Helleday's laboratory published, back-to-back with Alan Ashworth's, the 2005 Nature paper showing that BRCA2-deficient cells are exquisitely sensitive to PARP inhibition, the discovery that led to olaparib, niraparib, rucaparib and talazoparib and established synthetic lethality as a drug-discovery strategy. He later developed the MTH1 inhibitor concept and continues to work on DNA repair targets.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Helleday%20T%5BAuthor%5D%20PARP%20synthetic%20lethality"}],"tags":["parp","synthetic-lethality","discovery"],"related":[],"cancers":[],"sections":[],"technologies":["parp-inhibitor","synthetic-lethality-approaches"],"targets":["parp","brca"],"drugs":["olaparib"],"companies":[],"institutions":["karolinska"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["molecular-oncology"],"dependsOn":[],"notes":[],"role":"Professor of Chemical Biology, Karolinska Institutet; Professor, University of Sheffield","institutionId":"karolinska","specialisms":["DNA damage response","Synthetic lethality","PARP inhibitors","Drug discovery"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Helleday%20T%5BAuthor%5D%20PARP%20synthetic%20lethality"}],"papers":[{"title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","journal":"Nature","year":2005,"doi":"10.1038/nature03443"},{"title":"The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings","journal":"Molecular Oncology","year":2011,"doi":"10.1016/j.molonc.2011.07.001"}],"orcid":"0000-0002-7384-092X"},{"id":"thomas-herzog","kind":"person","name":"Thomas Herzog","aka":[],"tldr":"Cincinnati gynecologic oncologist who has led the GOG Foundation as President since July 2023.","summary":"Thomas Herzog took office as President of The GOG Foundation, Inc. on 20 July 2023. He is Deputy Director of the University of Cincinnati Cancer Center and the Paul and Carolyn Flory Professor in the Department of Obstetrics and Gynecology. His research focuses on ovarian and other gynecologic cancers and on the design of cooperative-group and industry-partnered clinical trials.","asOf":"2026-09-10","links":[{"label":"Society page","url":"https://www.gog.org/about/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Herzog+TJ%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","gynecologic oncology","ovarian cancer"],"related":[],"cancers":["ovarian","endometrial","cervical"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["gog-foundation"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["international-journal-of-gynecological-cancer"],"dependsOn":[],"notes":[],"role":"President","institutionId":"gog-foundation","specialisms":["Gynecologic oncology","Ovarian cancer","Clinical trials"],"profiles":[{"label":"Society page","url":"https://www.gog.org/about/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Herzog+TJ%5BAuthor%5D"}],"papers":[{"title":"Long-Term Survival Advantage and Prognostic Factors Associated With Intraperitoneal Chemotherapy Treatment in Advanced Ovarian Cancer: A Gynecologic Oncology Group Study","journal":"Journal of Clinical Oncology","year":2015,"doi":"10.1200/jco.2014.55.9898"},{"title":"An open-label randomized active-controlled phase II clinical study to assess the efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer (PROFECTA-II/GOG-3044)","journal":"Gynecologic Oncology","year":2025,"doi":"10.1016/j.ygyno.2025.03.001"},{"title":"Joint GOG-Foundation (GOG) and European Network of Gynaecological Oncological Trial Groups (ENGOT) clinical trials guidance for operations with industry partners","journal":"International Journal of Gynecological Cancer","year":2026,"doi":"10.1016/j.ijgc.2026.104753"}],"orcid":"0000-0002-4584-8908"},{"id":"thomas-fuchs","kind":"person","name":"Thomas J. Fuchs","aka":[],"tldr":"Trained the first clinical-grade AI on tens of thousands of slides, leading to the first FDA-authorised AI pathology product.","summary":"Thomas Fuchs led the MSKCC work that trained a deep-learning system on 44,000 whole-slide images using only slide-level labels and showed it could triage prostate, skin and breast biopsies at clinical accuracy, the foundation for Paige Prostate, the first FDA-authorised AI in pathology. He co-founded Paige and now leads AI and human health at Mount Sinai, focusing on foundation models for medicine.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fuchs%20TJ%5BAuthor%5D%20computational%20pathology"}],"tags":["ai","pathology","digital-pathology"],"related":[],"cancers":["prostate"],"sections":[],"technologies":["digital-pathology-ai","pathology-foundation-model"],"targets":[],"drugs":[],"companies":[],"institutions":["mount-sinai"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Dean of Artificial Intelligence and Human Health, Icahn School of Medicine at Mount Sinai; Co-founder, Paige","institutionId":"mount-sinai","specialisms":["Computational pathology","Clinical-grade AI","Machine learning at scale","Digital pathology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fuchs%20TJ%5BAuthor%5D%20computational%20pathology"}],"papers":[{"title":"Clinical-grade computational pathology using weakly supervised deep learning on whole slide images","journal":"Nature Medicine","year":2019,"doi":"10.1038/s41591-019-0508-1"},{"title":"Computational pathology: challenges and promises for tissue analysis","journal":"Computerized Medical Imaging and Graphics","year":2011,"doi":"10.1016/j.compmedimag.2011.02.006"}]},{"id":"thomas-george","kind":"person","name":"Thomas J. George","aka":[],"tldr":"Oncologist (FACP, FASCO) who is Interim Director of the UF Health Cancer Institute in Gainesville, Florida's only NCI-designated cancer centre based at a public university.","summary":"Thomas J. George, MD, FACP, FASCO, is Interim Director of the UF Health Cancer Institute, the University of Florida's cancer centre in Gainesville, and writes the director's welcome on its website. The institute became the 72nd NCI-designated cancer centre in June 2023 and is the only one based at a public university in Florida. It serves a 26-county area of north central Florida, has more than 350 researcher, clinician and educator members across the University of Florida and UF Health, and its clinical services include proton therapy, stem cell transplantation and immunotherapy. The leadership page did not give an appointment date.","asOf":"2026-09-10","links":[{"label":"Source: UF Health Cancer Institute leadership page","url":"https://cancer.ufl.edu/about/leadership/"}],"tags":["leadership","clinician-scientist","comprehensive-cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":["proton-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":["uf-health-cancer-center"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Interim Director, UF Health Cancer Institute (University of Florida Health Cancer Center)","institutionId":"uf-health-cancer-center","specialisms":["Oncology","Academic cancer centre leadership"],"profiles":[{"label":"UF Health Cancer Institute leadership page","url":"https://cancer.ufl.edu/about/leadership/"},{"label":"Interim director's welcome","url":"https://cancer.ufl.edu/about/welcome-overview/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=George+TJ%5BAuthor%5D+AND+Florida"}],"papers":[{"title":"Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer","journal":"JAMA Oncology","year":2021,"doi":"10.1001/jamaoncol.2021.1683"},{"title":"Prospective Correlation of Magnetic Resonance Tumor Regression Grade With Pathologic Outcomes in Total Neoadjuvant Therapy for Rectal Adenocarcinoma","journal":"Journal of Clinical Oncology","year":2023,"doi":"10.1200/jco.22.02525"},{"title":"Neoadjuvant Rectal (NAR) Score: a New Surrogate Endpoint in Rectal Cancer Clinical Trials","journal":"Current Colorectal Cancer Reports","year":2015,"doi":"10.1007/s11888-015-0285-2"}]},{"id":"thomas-lynch","kind":"person","name":"Thomas J. Lynch Jr.","aka":[],"tldr":"Thomas Lynch is a lung cancer oncologist who co-discovered EGFR mutations and now leads Fred Hutch.","summary":"Thomas Lynch Jr. is President and Director of Fred Hutchinson Cancer Center, a role he has held since 2020, having previously led Yale Cancer Center and Massachusetts General Hospital's cancer centre. A thoracic oncologist specialising in lung cancer and targeted therapy, his 2004 New England Journal of Medicine paper identified EGFR mutations as the reason some lung cancers respond to gefitinib. His papers include that report of activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib and the BMS099 phase III trial of cetuximab with first-line taxane and carboplatin chemotherapy in advanced non-small-cell lung cancer. His work links EGFR and small-molecule kinase inhibitors to cancer centre leadership.","asOf":"2026-09-08","links":[{"label":"Fred Hutch faculty directory","url":"https://www.fredhutch.org/en/faculty-lab-directory.html?q=Thomas%20J.%20Lynch%20Jr."},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lynch%20TJ%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Thomas%20J.%20Lynch%20Jr."}],"tags":[],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["kinase-inhibitors"],"targets":["egfr"],"drugs":[],"companies":[],"institutions":["fred-hutch"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President and Director, Fred Hutchinson Cancer Center","institutionId":"fred-hutch","specialisms":["Lung cancer","Targeted therapy","Cancer center leadership"],"profiles":[{"label":"Fred Hutch faculty directory","url":"https://www.fredhutch.org/en/faculty-lab-directory.html?q=Thomas%20J.%20Lynch%20Jr."},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lynch%20TJ%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Thomas%20J.%20Lynch%20Jr."}],"papers":[{"title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","journal":"New England Journal of Medicine","year":2004,"url":"https://doi.org/10.1056/NEJMoa040938","doi":"10.1056/NEJMoa040938"},{"title":"Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099","journal":"Journal of Clinical Oncology","year":2010,"url":"https://doi.org/10.1200/JCO.2009.21.9618","doi":"10.1200/JCO.2009.21.9618"}],"orcid":"0009-0000-9455-3367"},{"id":"thomas-kaiser","kind":"person","name":"Thomas Kaiser","aka":[],"tldr":"Physician who directs IQWiG, the German institute that produces the benefit assessments underpinning cancer drug pricing and coverage decisions.","summary":"Dr. med. Thomas Kaiser is Director of the Institute for Quality and Efficiency in Health Care (IQWiG) in Cologne. He previously headed IQWiG's Drug Assessment department and has been a central figure in Germany's early benefit assessment (AMNOG) process for new medicines, including oncology drugs. He publishes on evidence standards, surrogate endpoints and health technology assessment methodology.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.iqwig.de/ueber-uns/struktur-des-instituts/institutsleitung/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kaiser+T%5BAuthor%5D+IQWiG"}],"tags":["leadership","health technology assessment","regulation"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["g-ba-iqwig"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director (Institutsleiter), IQWiG","institutionId":"g-ba-iqwig","specialisms":["Health technology assessment","Evidence-based medicine","Drug benefit assessment"],"profiles":[{"label":"Institution profile","url":"https://www.iqwig.de/ueber-uns/struktur-des-instituts/institutsleitung/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kaiser+T%5BAuthor%5D+IQWiG"}],"papers":[{"title":"Weiterentwicklung und Vernetzung der onkologischen Versorgungsstrukturen, der Qualitätssicherung und der Forschung","journal":"Das Gesundheitswesen","year":2022,"doi":"10.1055/a-1926-6818"}],"orcid":"0000-0003-0795-538X"},{"id":"thomas-kindler","kind":"person","name":"Thomas Kindler","aka":[],"tldr":"Haematologist-oncologist who directs the University Cancer Center Mainz at Universitätsmedizin Mainz.","summary":"Thomas Kindler is the director of the University Cancer Center Mainz (UCT Mainz) at Universitätsmedizin Mainz, where he speaks for the UCT team on the centre's public pages. A professor of haematology and medical oncology, his research addresses acute myeloid leukaemia and the molecular mechanisms and targeted treatment of haematological malignancies.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.unimedizin-mainz.de/uct"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kindler+T%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","leukaemia","haematology"],"related":[],"cancers":["aml"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["uct-mainz"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director","institutionId":"uct-mainz","specialisms":["Haematology","Acute leukaemia","Medical oncology"],"profiles":[{"label":"Institution profile","url":"https://www.unimedizin-mainz.de/uct"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kindler+T%5BAuthor%5D"}],"papers":[{"title":"Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML)","journal":"Blood","year":2005,"doi":"10.1182/blood-2004-02-0660"},{"title":"SIRT1 prevents genotoxic stress-induced p53 activation in acute myeloid leukemia","journal":"Blood","year":2014,"doi":"10.1182/blood-2013-11-538819"},{"title":"Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group","journal":"Blood","year":2019,"doi":"10.1182/blood.2019001425"}]},{"id":"thomas-loughran","kind":"person","name":"Thomas P. Loughran Jr.","aka":[],"tldr":"Director who leads the UVA Comprehensive Cancer Center in Charlottesville, Virginia's first NCI-designated comprehensive cancer centre.","summary":"Thomas P. Loughran Jr. leads the UVA Comprehensive Cancer Center at the University of Virginia, which UVA Health describes as Virginia's first National Cancer Institute comprehensive cancer centre. According to the centre's Wikipedia article he became director in 2013, succeeding Michael J. Weber, who stepped down after twelve years; the article, last updated in August 2026, lists no successor. The UVA websites fetched for this record did not display a leadership page, so the role is recorded here from Wikipedia and should be re-checked.","asOf":"2026-09-10","links":[{"label":"Source: Wikipedia article on UVA Cancer Center naming the director","url":"https://en.wikipedia.org/wiki/University_of_Virginia_Cancer_Center"}],"tags":["leadership","clinician-scientist","comprehensive-cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["uva-cancer-center"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["blood","leukemia","the-oncologist"],"dependsOn":[],"notes":[],"role":"Director, UVA Comprehensive Cancer Center","institutionId":"uva-cancer-center","specialisms":["Cancer centre leadership","Academic medicine"],"profiles":[{"label":"Wikipedia: University of Virginia Cancer Center","url":"https://en.wikipedia.org/wiki/University_of_Virginia_Cancer_Center"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Loughran+TP%5BAuthor%5D"}],"papers":[{"title":"LGL leukemia: from pathogenesis to treatment","journal":"Blood","year":2017,"doi":"10.1182/blood-2016-08-692590"},{"title":"Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998)","journal":"Leukemia","year":2014,"doi":"10.1038/leu.2014.298"},{"title":"Large Granular Lymphocyte Leukemia","journal":"The Oncologist","year":2006,"doi":"10.1634/theoncologist.11-3-263"}]},{"id":"thomas-powles","kind":"person","name":"Thomas Powles","aka":[],"tldr":"Led EV-302, NIAGARA and IMvigor011, the trials that transformed bladder cancer from chemotherapy-only to ADC, immunotherapy and ctDNA-guided care.","summary":"Thomas Powles was principal investigator of EV-302, which showed enfortumab vedotin plus pembrolizumab nearly doubles survival versus chemotherapy in first-line advanced urothelial cancer, of NIAGARA (perioperative durvalumab), of JAVELIN Bladder 100 (avelumab maintenance) and of IMvigor011, the first trial to show ctDNA can select who benefits from adjuvant immunotherapy. He also led KEYNOTE-426 and CLEAR analyses in kidney cancer. He is among the most cited investigators in GU oncology.","asOf":"2026-09-10","links":[{"label":"Barts Cancer Institute","url":"https://www.bartscancer.london/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Powles%20T%5BAuthor%5D%20urothelial"}],"tags":["urothelial","adc","ctdna","trialist"],"related":[],"cancers":["urothelial","rcc"],"sections":[],"technologies":["adc","checkpoint-inhibitor","mrd-testing"],"targets":["nectin4","pd1","pdl1"],"drugs":["enfortumab-vedotin","pembrolizumab","durvalumab","atezolizumab","signatera"],"companies":[],"institutions":["barts-cancer-institute"],"pathways":[],"terms":[],"trials":["ev-302","niagara","javelin-bladder-100","imvigor011","keynote-426"],"people":[],"bottlenecks":[],"keyPapers":["paper-ev-302-nejm-2024","paper-niagara-nejm-2024","paper-imvigor011-nejm-2025"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Genitourinary Oncology and Director, Barts Cancer Centre, Queen Mary University of London","institutionId":"barts-cancer-institute","specialisms":["Urothelial cancer","Renal cell carcinoma","Antibody-drug conjugates","Immunotherapy","Circulating tumour DNA"],"profiles":[{"label":"Barts Cancer Institute","url":"https://www.bartscancer.london/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Powles%20T%5BAuthor%5D%20urothelial"}],"papers":[{"title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer (EV-302)","journal":"NEJM","year":2024,"doi":"10.1056/NEJMoa2312117"},{"title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer (NIAGARA)","journal":"NEJM","year":2024,"doi":"10.1056/NEJMoa2408154"},{"title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma (JAVELIN Bladder 100)","journal":"NEJM","year":2020,"doi":"10.1056/NEJMoa2002788"},{"title":"ctDNA guiding adjuvant immunotherapy in urothelial carcinoma","journal":"Nature","year":2021,"doi":"10.1038/s41586-021-03642-9"},{"title":"IMvigor011: using a blood test for leftover cancer to decide who gets immunotherapy after bladder surgery","journal":"New England Journal of Medicine","year":2025,"url":"https://clinicaltrials.gov/study/NCT04660344"}],"orcid":"0000-0001-7760-4724"},{"id":"thomas-marron","kind":"person","name":"Thomas U. Marron","aka":[],"tldr":"Showed that neoadjuvant immunotherapy can produce major pathologic responses in liver cancer.","summary":"Thomas U. Marron is Director of the Early Phase Trials Unit at The Mount Sinai Hospital and Tisch Cancer Institute. He is known for showing that neoadjuvant immunotherapy can produce major pathological responses in liver cancer, leading perioperative cemiplimab studies in hepatocellular carcinoma. His selected paper reports a single-arm phase 2 trial of neoadjuvant cemiplimab for resectable hepatocellular carcinoma. He runs Mount Sinai's early-phase unit and leads window-of-opportunity trials.","asOf":"2026-09-08","links":[{"label":"Mount Sinai profile","url":"https://profiles.mountsinai.org/thomas-u-marron"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Marron%20TU%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["hcc"],"sections":[],"technologies":[],"targets":[],"drugs":["cemiplimab"],"companies":[],"institutions":["mount-sinai"],"pathways":[],"terms":["neoadjuvant-adjuvant"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Early Phase Trials Unit","institutionId":"mount-sinai","specialisms":["Neoadjuvant immunotherapy","Liver cancer","Phase 1 trials"],"profiles":[{"label":"Mount Sinai profile","url":"https://profiles.mountsinai.org/thomas-u-marron"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Marron%20TU%5BAuthor%5D"}],"papers":[{"title":"Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial","journal":"Lancet Gastroenterology & Hepatology","year":2022,"url":"https://doi.org/10.1016/S2468-1253(21)00385-X","doi":"10.1016/S2468-1253(21)00385-X"}]},{"id":"tim-maughan","kind":"person","name":"Tim Maughan","aka":[],"tldr":"The oncologist who led COIN, which showed that adding cetuximab to first-line chemotherapy did not extend life even in RAS wild-type bowel cancer, and who ran the UK's molecularly stratified platform trial.","summary":"Tim Maughan was appointed Professor of Clinical Oncology and clinical director of the Oxford Institute for Radiation Oncology in the University of Oxford's Department of Oncology in 2011, and before that was an NHS consultant clinical oncologist in Cardiff, becoming Professor of Cancer Studies in 2007. He was first author of MRC COIN, which found no overall survival gain from adding cetuximab to oxaliplatin-based first-line chemotherapy even in KRAS wild-type disease, and is the senior author of the account of ten years of running FOCUS4, the adaptive platform trial that split metastatic colorectal cancer by molecular group and whose FOCUS4-N arm legitimised chemotherapy breaks.","asOf":"2026-09-24","links":[{"label":"University of Oxford staff page","url":"https://www.oncology.ox.ac.uk/team/tim-maughan"}],"tags":["colorectal","trialist","uk"],"related":["matt-seymour","rachel-kerr"],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":["kras","braf"],"drugs":["cetuximab","folfox","capecitabine"],"companies":[],"institutions":["oxford-cancer","velindre-cardiff"],"pathways":[],"terms":[],"trials":["coin","focus4"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Emeritus Professor of Clinical Oncology, University of Oxford","institutionId":"oxford-cancer","specialisms":["Advanced colorectal cancer","Molecularly stratified platform trials","Radiation oncology"],"profiles":[{"label":"University of Oxford staff page","url":"https://www.oncology.ox.ac.uk/team/tim-maughan"}],"papers":[{"title":"Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial","journal":"Lancet","year":2011,"doi":"10.1016/S0140-6736(11)60613-2"},{"title":"Experiences of running a stratified medicine adaptive platform trial: challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer","journal":"Clinical Trials","year":2022,"doi":"10.1177/17407745211069879"}]},{"id":"tim-somervaille","kind":"person","name":"Tim Somervaille","aka":[],"tldr":"Haematologist and Senior Group Leader at CRUK Manchester Institute studying the transcriptional drivers of acute myeloid leukaemia.","summary":"Tim Somervaille is a Senior Group Leader at the Cancer Research UK Manchester Institute, where his Leukaemia Biology laboratory investigates transcription factors and epigenetic regulators that sustain acute myeloid leukaemia. He is also a consultant haematologist at The Christie NHS Foundation Trust. His group has identified FOXC1 derepression as a recurrent feature in AML and explored EP300/CBP bromodomain inhibition as a therapeutic strategy.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.cruk.manchester.ac.uk/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Somervaille+TC%5BAuthor%5D"}],"tags":["clinician-scientist","leukaemia","haematology"],"related":[],"cancers":["aml"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cruk-manchester-institute"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Senior Group Leader","institutionId":"cruk-manchester-institute","specialisms":["Acute myeloid leukaemia","Leukaemia biology","Haematology"],"profiles":[{"label":"Institution profile","url":"https://www.cruk.manchester.ac.uk/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Somervaille+TC%5BAuthor%5D"}],"papers":[{"title":"Frequent Derepression of the Mesenchymal Transcription Factor Gene FOXC1 in Acute Myeloid Leukemia","journal":"Cancer Cell","year":2015,"url":"https://doi.org/10.1016/j.ccell.2015.07.017","doi":"10.1016/j.ccell.2015.07.017"},{"title":"Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies","journal":"Cancer Cell","year":2023,"url":"https://doi.org/10.1016/j.ccell.2023.11.001","doi":"10.1016/j.ccell.2023.11.001"}],"orcid":"0000-0002-9188-4379"},{"id":"timothy-chan","kind":"person","name":"Timothy A. Chan","aka":[],"tldr":"Timothy Chan showed that tumour mutational burden predicts who benefits from checkpoint inhibitors.","summary":"Timothy A. Chan is Director of the Global Center for Immunotherapy and Chair of the Center for Immunotherapy and Precision Immuno-Oncology at Cleveland Clinic Taussig Cancer Institute. He is a physician-scientist known for showing that tumour mutational burden predicts who benefits from checkpoint inhibitors, through genomic studies in 2014 and 2015 that linked mutational load and neoantigens to response to CTLA-4 and PD-1 blockade. His selected papers report the genetic basis for clinical response to CTLA-4 blockade in melanoma and the mutational landscape determining sensitivity to PD-1 blockade in lung cancer. He also showed that HLA diversity shapes immunotherapy benefit and continues to work in immunogenomics.","asOf":"2026-09-08","links":[{"label":"Cleveland Clinic profile","url":"https://www.lerner.ccf.org/immunotherapy/chan/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chan%20TA%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["melanoma","nsclc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":[],"companies":[],"institutions":["cleveland-clinic"],"pathways":[],"terms":["tmb","neoantigen"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Global Center for Immunotherapy; Chair, Center for Immunotherapy and Precision Immuno-Oncology","institutionId":"cleveland-clinic","specialisms":["Immunogenomics","Tumour mutational burden","HLA and immunotherapy response"],"profiles":[{"label":"Cleveland Clinic profile","url":"https://www.lerner.ccf.org/immunotherapy/chan/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chan%20TA%5BAuthor%5D"}],"papers":[{"title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","journal":"New England Journal of Medicine","year":2014,"url":"https://doi.org/10.1056/NEJMoa1406498","doi":"10.1056/NEJMoa1406498"},{"title":"Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","journal":"Science","year":2015,"url":"https://doi.org/10.1126/science.aaa1348","doi":"10.1126/science.aaa1348"}],"orcid":"0000-0002-9265-0283"},{"id":"timothy-cloughesy","kind":"person","name":"Timothy F. Cloughesy","aka":[],"tldr":"Neuro-oncologist whose neoadjuvant PD-1 trial showed immunotherapy before surgery can activate immune responses in glioblastoma.","summary":"Timothy Cloughesy led the randomised pilot trial showing neoadjuvant pembrolizumab before surgery for recurrent glioblastoma enhances intratumoural T-cell responses and was associated with longer survival than adjuvant-only dosing, a template for window-of-opportunity trials in brain tumours. He co-led the vocimagene (Toca 511) and GBM AGILE platform trial efforts and directs neuro-oncology at UCLA.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cloughesy%20TF%5BAuthor%5D%20glioblastoma"}],"tags":["glioma","immunotherapy","neoadjuvant"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["pd1"],"drugs":["pembrolizumab"],"companies":[],"institutions":["ucla-jonsson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, UCLA Neuro-Oncology Program","institutionId":"ucla-jonsson","specialisms":["Glioblastoma","Neoadjuvant immunotherapy","Targeted therapy","Clinical trial design"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cloughesy%20TF%5BAuthor%5D%20glioblastoma"}],"papers":[{"title":"Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma","journal":"Nature Medicine","year":2019,"doi":"10.1038/s41591-018-0337-7"},{"title":"Glioblastoma: from molecular pathology to targeted treatment","journal":"Annual Review of Pathology","year":2014,"doi":"10.1146/annurev-pathol-011110-130324"}]},{"id":"timothy-eberlein","kind":"person","name":"Timothy J. Eberlein","aka":[],"tldr":"Surgeon who has led Siteman since its founding and built it into a top NCI comprehensive centre.","summary":"Timothy J. Eberlein is Director of the Siteman Cancer Center at Washington University and the Spencer T. and Ann W. Olin Distinguished Professor. He is a surgical oncologist and tumour immunologist who has led Siteman since its founding and built it into a top NCI comprehensive cancer centre, having also served as long-time chair of surgery at WashU. His selected paper discusses tumour-infiltrating lymphocytes as a therapeutic strategy. His clinical and research interests span breast cancer surgery and tumour immunology.","asOf":"2026-09-08","links":[{"label":"Siteman Cancer Center","url":"https://siteman.washu.edu"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Eberlein%20TJ%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["tnbc","breast-hr-positive"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["wustl-siteman"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Siteman Cancer Center; Spencer T. and Ann W. Olin Distinguished Professor","institutionId":"wustl-siteman","specialisms":["Surgical oncology","Breast cancer","Tumour immunology"],"profiles":[{"label":"Siteman Cancer Center","url":"https://siteman.washu.edu"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Eberlein%20TJ%5BAuthor%5D"}],"papers":[{"title":"Tumor-infiltrating lymphocytes as a therapeutic strategy","journal":"Journal of Clinical Oncology","year":1990}]},{"id":"timothy-ley","kind":"person","name":"Timothy J. Ley","aka":[],"tldr":"Timothy Ley led the first whole-genome sequencing of a cancer, an AML genome, in 2008.","summary":"Timothy J. Ley is the Lewis T. and Rosalind B. Apple Professor of Oncology at Siteman Cancer Center, Washington University. He is a haematologist-scientist who led the first whole-genome sequencing of a cancer, an acute myeloid leukaemia genome, in 2008, and went on to discover recurrent DNMT3A and IDH mutations in AML and to define clonal evolution at relapse. His selected papers report DNA sequencing of a cytogenetically normal AML genome and DNMT3A mutations in AML. He continues to work on AML genomics and clonal evolution.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ley%20TJ%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["aml"],"sections":[],"technologies":["wes-wgs"],"targets":["idh","npm1"],"drugs":[],"companies":[],"institutions":["wustl-siteman"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Lewis T. and Rosalind B. Apple Professor of Oncology","institutionId":"wustl-siteman","specialisms":["AML genomics","Clonal evolution","DNMT3A"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ley%20TJ%5BAuthor%5D"}],"papers":[{"title":"DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome","journal":"Nature","year":2008,"url":"https://doi.org/10.1038/nature07485","doi":"10.1038/nature07485"},{"title":"DNMT3A mutations in acute myeloid leukemia","journal":"New England Journal of Medicine","year":2010,"url":"https://doi.org/10.1056/NEJMoa1005143","doi":"10.1056/NEJMoa1005143"}]},{"id":"timothy-whelan","kind":"person","name":"Timothy J. Whelan","aka":[],"tldr":"Led the Canadian trials that established three-week breast radiotherapy and defined when nodal radiotherapy helps.","summary":"Timothy Whelan led the Ontario hypofractionation trial showing 16 fractions over three weeks matches 25 fractions for breast conservation, which with the UK START trials moved the world to shorter schedules, and MA.20, which showed regional nodal irradiation reduces recurrence in node-positive disease. He led the LUMINA study showing radiotherapy can be omitted in low-risk luminal A breast cancer and chairs the CCTG breast site.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Whelan%20TJ%5BAuthor%5D%20breast%20radiotherapy"}],"tags":["radiotherapy","breast","canada"],"related":[],"cancers":["breast-hr-positive"],"sections":[],"technologies":["imrt-igrt"],"targets":[],"drugs":[],"companies":[],"institutions":["juravinski"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Oncology, McMaster University; Radiation Oncologist, Juravinski Cancer Centre","institutionId":"juravinski","specialisms":["Breast radiotherapy","Hypofractionation","Regional nodal irradiation","Radiotherapy omission"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Whelan%20TJ%5BAuthor%5D%20breast%20radiotherapy"}],"papers":[{"title":"Long-term results of hypofractionated radiation therapy for breast cancer","journal":"NEJM","year":2010,"doi":"10.1056/NEJMoa0906260"},{"title":"Regional nodal irradiation in early-stage breast cancer (MA.20)","journal":"NEJM","year":2015,"doi":"10.1056/NEJMoa1415340"},{"title":"Omitting radiotherapy after breast-conserving surgery in luminal A breast cancer (LUMINA)","journal":"NEJM","year":2023,"doi":"10.1056/NEJMoa2302344"}]},{"id":"timothy-hughes","kind":"person","name":"Timothy P. Hughes","aka":[],"tldr":"Defined molecular response monitoring in CML and showed that many patients can safely stop imatinib.","summary":"Timothy Hughes led the molecular monitoring analyses of the IRIS trial that established BCR-ABL1 quantitative PCR and the International Scale as the way to track chronic myeloid leukaemia, and co-led ENESTnd (nilotinib) and the studies of treatment-free remission showing about half of patients in deep molecular response can stop tyrosine kinase inhibitors. He has chaired the International CML Foundation.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hughes%20TP%5BAuthor%5D%20chronic%20myeloid%20leukemia"}],"tags":["cml","molecular-monitoring","australia"],"related":[],"cancers":["cml"],"sections":[],"technologies":["mrd-testing","kinase-inhibitors"],"targets":[],"drugs":["imatinib"],"companies":[],"institutions":["royal-adelaide-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-iris-imatinib-nejm-2003"],"journals":[],"dependsOn":[],"notes":[],"role":"Consultant Haematologist, Royal Adelaide Hospital; Cancer Theme Leader, South Australian Health and Medical Research Institute","institutionId":"royal-adelaide-hospital","specialisms":["Chronic myeloid leukaemia","Molecular monitoring","Treatment-free remission","Tyrosine kinase inhibitors"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hughes%20TP%5BAuthor%5D%20chronic%20myeloid%20leukemia"}],"papers":[{"title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia (IRIS)","journal":"NEJM","year":2003,"doi":"10.1056/NEJMoa030513"},{"title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia (ENESTnd)","journal":"NEJM","year":2010,"doi":"10.1056/NEJMoa0912614"},{"title":"IRIS: imatinib versus interferon plus cytarabine as first treatment for chronic myeloid leukaemia","journal":"New England Journal of Medicine","year":2003,"url":"https://doi.org/10.1056/NEJMoa022457","doi":"10.1056/NEJMoa022457"}]},{"id":"timothy-robinson","kind":"person","name":"Timothy Robinson","aka":[],"tldr":"Chief Executive of Nationwide Children's Hospital in Columbus, Ohio, a large paediatric health system with a major childhood cancer programme.","summary":"Timothy Robinson is Chief Executive Officer of Nationwide Children's Hospital in Columbus, Ohio, a paediatric health system that includes the Abigail Wexner Research Institute and the Nationwide Children's Hospital Foundation. He became CEO on 1 July 2019 after serving as executive vice president and chief financial officer. The hospital describes his financial leadership as central to its growth into a preeminent paediatric health care system.","asOf":"2026-09-10","links":[{"label":"Source: Nationwide Children's executive leadership page","url":"https://www.nationwidechildrens.org/about-us/who-we-are/leadership"}],"tags":["leadership","paediatric","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["nationwide-childrens"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive Officer, Nationwide Children's Hospital","institutionId":"nationwide-childrens","specialisms":["Hospital management","Paediatric health systems","Finance"],"profiles":[{"label":"Nationwide Children's leadership page","url":"https://www.nationwidechildrens.org/about-us/who-we-are/leadership"}],"papers":[]},{"id":"timur-atsuren","kind":"person","name":"Timur Atsüren","aka":[],"tldr":"General manager who runs Anadolu Medical Center, the foundation-owned hospital near Istanbul that is part of the Anadolu Group and known for its oncology services.","summary":"Timur Atsüren is Genel Müdür (General Manager) of Anadolu Sağlık Merkezi, the Anadolu Medical Center in Gebze near Istanbul. The hospital's management team page lists him at the head of the executive team, alongside Medical Services Director Prof. Dr. Kenan Keklikçi and directors for international services, nursing, information systems, finance and human resources. The hospital describes itself as a foundation enterprise established under Turkey's Foundations Law and part of the Anadolu Group, with a board chaired by Kamilhan Süleyman Yazıcı.","asOf":"2026-09-10","links":[{"label":"Source: Anadolu Sağlık Merkezi 'Yönetim Ekibimiz' page","url":"https://www.anadolusaglik.org/kurumsal/yonetim-ekibimiz"}],"tags":["leadership","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["anadolu-medical-center"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Genel Müdür (General Manager), Anadolu Sağlık Merkezi (Anadolu Medical Center)","institutionId":"anadolu-medical-center","specialisms":["Hospital management","Private healthcare"],"profiles":[{"label":"Anadolu Medical Center management team (Turkish)","url":"https://www.anadolusaglik.org/kurumsal/yonetim-ekibimiz"}],"papers":[]},{"id":"tina-cascone","kind":"person","name":"Tina Cascone","aka":[],"tldr":"Led CheckMate 77T, one of the perioperative immunotherapy trials that changed how operable lung cancer is treated.","summary":"Tina Cascone was principal investigator of CheckMate 77T, which showed neoadjuvant nivolumab plus chemotherapy followed by adjuvant nivolumab improves event-free survival in resectable NSCLC, and led the NEOSTAR window trials that defined pathological response endpoints. Her laboratory studies the immune correlates of response to neoadjuvant therapy.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cascone%20T%5BAuthor%5D%20neoadjuvant%20nivolumab"}],"tags":["lung","neoadjuvant","immunotherapy"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["pd1"],"drugs":["nivolumab","ipilimumab"],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":["checkmate-816","keynote-671"],"people":[],"bottlenecks":[],"keyPapers":["paper-checkmate-816-nejm-2022"],"journals":[],"dependsOn":[],"notes":[],"role":"Associate Professor of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center","institutionId":"md-anderson","specialisms":["Neoadjuvant immunotherapy","Perioperative NSCLC therapy","Translational immunology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cascone%20T%5BAuthor%5D%20neoadjuvant%20nivolumab"}],"papers":[{"title":"Perioperative nivolumab in resectable lung cancer (CheckMate 77T)","journal":"NEJM","year":2024,"doi":"10.1056/NEJMoa2311926"},{"title":"Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial","journal":"Nature Medicine","year":2021,"doi":"10.1038/s41591-020-01224-2"},{"title":"CheckMate 816: three cycles of nivolumab plus chemotherapy before lung cancer surgery","journal":"New England Journal of Medicine","year":2022,"url":"https://doi.org/10.1056/NEJMoa2202170","doi":"10.1056/NEJMoa2202170"}]},{"id":"tobias-janowitz","kind":"person","name":"Tobias Janowitz","aka":[],"tldr":"Studies how cancer wastes the whole body and how to stop it, one of the field's neglected problems.","summary":"Tobias Janowitz is Associate Professor at the Cold Spring Harbor Laboratory Cancer Center and a Medical Oncologist at Northwell Health. He is a physician-scientist who studies how cancer wastes the whole body, one of the field's neglected problems, dissecting the hepatic and neuroendocrine responses to tumours that drive cachexia. His selected paper reviews the mediators, signalling and metabolic pathways of cancer cachexia. His laboratory now works on metabolic interventions to preserve function during cancer, with a focus on pancreatic cancer.","asOf":"2026-09-08","links":[{"label":"CSHL profile","url":"https://www.cshl.edu/research/faculty-staff/tobias-janowitz/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Janowitz%20T%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["pancreatic"],"sections":["supportive-care"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cold-spring-harbor"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Associate Professor, CSHL Cancer Center; Medical Oncologist, Northwell Health","institutionId":"cold-spring-harbor","specialisms":["Cancer cachexia","Whole-body physiology of cancer","Pancreatic cancer"],"profiles":[{"label":"CSHL profile","url":"https://www.cshl.edu/research/faculty-staff/tobias-janowitz/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Janowitz%20T%5BAuthor%5D"}],"papers":[{"title":"Cancer cachexia: mediators, signaling, and metabolic pathways","journal":"Cell Metabolism","year":2012,"url":"https://doi.org/10.1016/j.cmet.2012.06.011","doi":"10.1016/j.cmet.2012.06.011"}],"orcid":"0000-0002-7820-3727"},{"id":"todd-golub","kind":"person","name":"Todd R. Golub","aka":[],"tldr":"Showed that gene expression could classify cancers, then built the Broad into the engine of cancer genomics.","summary":"Todd R. Golub is Director of the Broad Institute of MIT and Harvard and Charles A. Dana Investigator at Dana-Farber. He is known for showing that gene expression could classify cancers, with a 1999 leukaemia classification paper that launched expression-based cancer taxonomy, and for building the Broad into the engine of cancer genomics as founding director of its cancer programme. His selected papers report the molecular classification of cancer by gene expression monitoring and the discovery of anticancer potential in non-oncology drugs through systematic viability profiling. His laboratory created the PRISM pooled cell-line screening platform behind DepMap, and he has been Broad director since 2020.","asOf":"2026-09-08","links":[{"label":"Broad bio","url":"https://www.broadinstitute.org/bios/todd-r-golub"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Golub%20TR%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["aml","all-leukemia"],"sections":[],"technologies":["crispr-screens","rna-seq"],"targets":[],"drugs":[],"companies":[],"institutions":["broad-institute"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nature-cancer"],"dependsOn":[],"notes":[],"role":"Director, Broad Institute; Charles A. Dana Investigator, Dana-Farber","institutionId":"broad-institute","specialisms":["Cancer genomics","Functional genomics","PRISM drug screening","Paediatric leukaemia"],"profiles":[{"label":"Broad bio","url":"https://www.broadinstitute.org/bios/todd-r-golub"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Golub%20TR%5BAuthor%5D"}],"papers":[{"title":"Molecular classification of cancer: class discovery and class prediction by gene expression monitoring","journal":"Science","year":1999,"url":"https://doi.org/10.1126/science.286.5439.531","doi":"10.1126/science.286.5439.531"},{"title":"Discovering the anticancer potential of non-oncology drugs by systematic viability profiling","journal":"Nature Cancer","year":2020,"url":"https://doi.org/10.1038/s43018-019-0018-6","doi":"10.1038/s43018-019-0018-6"}]},{"id":"tomas-jovaisa","kind":"person","name":"Tomas Jovaiša","aka":[],"tldr":"Tomas Jovaiša represents Vilnius University Hospital Santaros Klinikos in the Organisation of European Cancer Institutes, which lists the centre among its members in Lithuania.","summary":"Tomas Jovaiša is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Vilnius University Hospital Santaros Klinikos, its member in Lithuania. Santaros Klinikos is the teaching hospital of Vilnius University's Faculty of Medicine and a full member of the Organisation of European Cancer Institutes. OnCo records the name from the OECI membership list so that the centre's page has a named contact point; the person's exact title, appointment date and biography are not yet recorded and should be checked on the institution's own pages before being relied on.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Vilnius University Hospital Santaros Klinikos website","url":"https://www.santa.lt/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["santaros-klinikos"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Vilnius University Hospital Santaros Klinikos to the Organisation of European Cancer Institutes","institutionId":"santaros-klinikos","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Vilnius University Hospital Santaros Klinikos website","url":"https://www.santa.lt/"}],"papers":[{"title":"A Core Outcome Set for Adult General ICU Patients","journal":"Crit Care Med","year":2025,"url":"https://doi.org/10.1097/ccm.0000000000006556","doi":"10.1097/ccm.0000000000006556","note":"Europe PMC author record matched by affiliation"},{"title":"Long-term quality of life in patients treated with extracorporeal membrane oxygenation for postcardiotomy cardiogenic shock","journal":"Perfusion","year":2019,"url":"https://doi.org/10.1177/0267659118815291","doi":"10.1177/0267659118815291","note":"Europe PMC author record matched by affiliation"}],"orcid":"0000-0002-0229-5100"},{"id":"tomas-kazda","kind":"person","name":"Tomáš Kazda","aka":[],"tldr":"Radiation oncologist directing science and research at Masaryk Memorial Cancer Institute, with a research focus on brain tumours and brain metastases.","summary":"Doc. Tomáš Kazda is Director for Science & Research at the Masaryk Memorial Cancer Institute in Brno and a radiation oncologist. His published work centres on neuro-oncology, including radiotherapy for glioma and brain metastases. He coordinates the institute's research portfolio and clinical trial activity.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.mou.cz/en/management/t1644"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kazda+T%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","radiotherapy","neuro-oncology"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["mou-brno"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["radiation-oncology","radiology-and-oncology"],"dependsOn":[],"notes":[],"role":"Director for Science & Research","institutionId":"mou-brno","specialisms":["Radiation oncology","Neuro-oncology","Brain metastases"],"profiles":[{"label":"Institution profile","url":"https://www.mou.cz/en/management/t1644"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kazda+T%5BAuthor%5D"}],"papers":[{"title":"Why and how to spare the hippocampus during brain radiotherapy: the developing role of hippocampal avoidance in cranial radiotherapy","journal":"Radiation Oncology","year":2014,"doi":"10.1186/1748-717x-9-139"},{"title":"Radiotherapy of glioblastoma 15 years after the landmark Stupp’s trial: more controversies than standards?","journal":"Radiology and Oncology","year":2018,"doi":"10.2478/raon-2018-0023"},{"title":"Advanced MRI increases the diagnostic accuracy of recurrent glioblastoma: Single institution thresholds and validation of MR spectroscopy and diffusion weighted MR imaging","journal":"NeuroImage: Clinical","year":2016,"doi":"10.1016/j.nicl.2016.02.016"}],"orcid":"0000-0001-7288-8975"},{"id":"tomasz-maciejewski","kind":"person","name":"Tomasz Maciejewski","aka":[],"tldr":"Tomasz Maciejewski represents Institute of Mother and Child, Warsaw in the Organisation of European Cancer Institutes, which lists the organisation among its members in Poland.","summary":"Tomasz Maciejewski is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Institute of Mother and Child, Warsaw, its full member in Poland. OnCo records the name from the OECI membership list so that the organisation's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the organisation's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Institute of Mother and Child, Warsaw website","url":"https://imid.med.pl/pl/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["institute-of-mother-and-child"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Institute of Mother and Child, Warsaw to the Organisation of European Cancer Institutes","institutionId":"institute-of-mother-and-child","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Institute of Mother and Child, Warsaw website","url":"https://imid.med.pl/pl/"}],"papers":[{"title":"Insight into the Key Points of Preeclampsia Pathophysiology: Uterine Artery Remodeling and the Role of MicroRNAs","journal":"Int J Mol Sci","year":2021,"url":"https://doi.org/10.3390/ijms22063132","doi":"10.3390/ijms22063132","note":"Europe PMC author record matched by affiliation"},{"title":"Non-obstetric complications in preeclampsia","journal":"Prz Menopauzalny","year":2019,"url":"https://doi.org/10.5114/pm.2019.85785","doi":"10.5114/pm.2019.85785","note":"Europe PMC author record matched by affiliation"},{"title":"Sentinel lymph node mapping using indocyanine green in patients with uterine and cervical neoplasms: restrictions of the method","journal":"Arch Gynecol Obstet","year":2019,"url":"https://doi.org/10.1007/s00404-019-05063-6","doi":"10.1007/s00404-019-05063-6","note":"Europe PMC author record matched by affiliation"}],"orcid":"0000-0003-3761-1924"},{"id":"tomi-p-makela","kind":"person","name":"Tomi P. Mäkelä","aka":[],"tldr":"Tomi P. Mäkelä represents Finnish Cancer Center (FICAN) in the Organisation of European Cancer Institutes, which lists the organisation among its full members in Finland.","summary":"Tomi P. Mäkelä is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Finnish Cancer Center (FICAN), its full member in Finland. OnCo records the name from the OECI membership list so that the organisation's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the organisation's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Finnish Cancer Center (FICAN) website","url":"https://www.fican.fi"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["fican"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Finnish Cancer Center (FICAN) to the Organisation of European Cancer Institutes","institutionId":"fican","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Finnish Cancer Center (FICAN) website","url":"https://www.fican.fi"}],"papers":[{"title":"Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade","journal":"J Biol","year":2003,"url":"https://doi.org/10.1186/1475-4924-2-28","doi":"10.1186/1475-4924-2-28","note":"Europe PMC author record matched by affiliation"}]},{"id":"tomoki-todo","kind":"person","name":"Tomoki Todo","aka":[],"tldr":"Tomoki Todo built the triple-mutated herpes virus that became the first oncolytic virus approved in Japan, and ran the trial in recurrent glioblastoma behind that approval.","summary":"Tomoki Todo is a professor at the Institute of Medical Science of The University of Tokyo, in the Division of Innovative Cancer Therapy and the Department of Surgical Neuro-Oncology. He developed G47 delta, a triple-mutated third-generation oncolytic herpes simplex virus type 1.\n\nHis investigator-initiated single-arm phase 2 trial gave G47 delta repeatedly into the tumour in 19 adults with residual or recurrent supratentorial glioblastoma after radiotherapy and temozolomide. One-year survival after starting treatment was 84.2 per cent, the prespecified endpoint was met and the trial stopped early. Imaging showed a characteristic pattern of the lesion enlarging while contrast enhancement cleared after each dose, so conventional response criteria recorded almost every patient as stable disease, and biopsies showed rising CD4-positive and CD8-positive lymphocyte infiltration with persistently low regulatory T cells. The result led to the approval of G47 delta in Japan, the first oncolytic virus product approved there.","asOf":"2026-09-25","links":[{"label":"ORCID","url":"https://orcid.org/0000-0003-0523-8010"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Todo%20T%5BAuthor%5D%20oncolytic"},{"label":"Institute of Medical Science, The University of Tokyo","url":"https://www.ims.u-tokyo.ac.jp/imsut/en/"}],"tags":["oncolytic-virus","neuro-oncology","japan"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":["oncolytic-virus"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-todo-g47delta-glioblastoma-natmed-2022"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor, Division of Innovative Cancer Therapy, Advanced Clinical Research Center, and Department of Surgical Neuro-Oncology, Institute of Medical Science, The University of Tokyo","specialisms":["Oncolytic herpes simplex virus","Neuro-oncology","Glioblastoma","Investigator-initiated trials"],"profiles":[{"label":"ORCID","url":"https://orcid.org/0000-0003-0523-8010"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Todo%20T%5BAuthor%5D%20oncolytic"},{"label":"Institute of Medical Science, The University of Tokyo","url":"https://www.ims.u-tokyo.ac.jp/imsut/en/"}],"papers":[{"title":"Intratumoral oncolytic herpes virus G47 delta for residual or recurrent glioblastoma: a phase 2 trial","journal":"Nature Medicine","year":2022,"doi":"10.1038/s41591-022-01897-x"}],"orcid":"0000-0003-0523-8010"},{"id":"ton-schumacher","kind":"person","name":"Ton Schumacher","aka":[],"tldr":"Immunologist who showed T cells recognise cancer neoantigens, the basis for personalised vaccines and TCR therapies.","summary":"Ton Schumacher is Senior Group Leader at the Netherlands Cancer Institute (NKI-AvL) and Professor at Leiden University. His specialisms are T-cell immunology, neoantigens and TCR discovery. His work demonstrated neoantigen-specific T-cell responses in melanoma patients, showing that T cells recognise cancer neoantigens, and he developed technologies for TCR discovery. His Science review on neoantigens in cancer immunotherapy set out the basis for personalised neoantigen vaccines and TCR-T cell therapies. He co-founded Neogene Therapeutics, and his publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schumacher%20TN%5BAuthor%5D%20neoantigen"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["tcr-t","neoantigen-mrna-vaccine"],"targets":[],"drugs":[],"companies":[],"institutions":["nki"],"pathways":[],"terms":["neoantigen"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Senior Group Leader, Netherlands Cancer Institute; Professor, Leiden University","institutionId":"nki","specialisms":["T-cell immunology","Neoantigens","TCR discovery"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Schumacher%20TN%5BAuthor%5D%20neoantigen"}],"papers":[{"title":"Neoantigens in cancer immunotherapy","journal":"Science","year":2015,"doi":"10.1126/science.aaa4971"},{"title":"NICHE-2: a month of nivolumab and ipilimumab before surgery clears mismatch-repair-deficient colon cancer in most patients","journal":"New England Journal of Medicine","year":2024,"url":"https://doi.org/10.1056/NEJMoa2400634","doi":"10.1056/NEJMoa2400634"},{"title":"NICHE-2: a single dose of ipilimumab and two of nivolumab before surgery clears dMMR colon cancer in most patients","journal":"New England Journal of Medicine","year":2024,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NICHE-2%20neoadjuvant%20nivolumab%20ipilimumab%20dMMR%20colon%20cancer%20Chalabi%20NEJM%202024"},{"title":"Rohaas 2022: the first randomised trial of TIL therapy, against ipilimumab, in advanced melanoma","journal":"New England Journal of Medicine","year":2022,"url":"https://doi.org/10.1056/NEJMoa2210233","doi":"10.1056/NEJMoa2210233"}],"orcid":"0000-0003-0517-8804"},{"id":"toni-choueiri","kind":"person","name":"Toni K. Choueiri","aka":[],"tldr":"Leads kidney cancer research worldwide, including the adjuvant pembrolizumab and belzutifan trials.","summary":"Toni K. Choueiri is Director of the Lank Center for Genitourinary Oncology at Dana-Farber Brigham Cancer Center. He leads kidney cancer research worldwide, serving as principal investigator on CheckMate 9ER, the KEYNOTE-564 trial of adjuvant pembrolizumab and the LITESPARK studies of the HIF-2 alpha inhibitor belzutifan. His selected papers report adjuvant pembrolizumab after nephrectomy in renal cell carcinoma and belzutifan versus everolimus for advanced renal cell carcinoma. He continues to work on immunotherapy combinations, cabozantinib and HIF-2 alpha inhibition in kidney cancer.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Toni_Choueiri","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Choueiri%20TK%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["rcc"],"sections":[],"technologies":[],"targets":["hif2a","pd1"],"drugs":["pembrolizumab","belzutifan","cabozantinib"],"companies":[],"institutions":["dana-farber"],"pathways":[],"terms":[],"trials":["keynote-564","litespark-005","checkmate-9er"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Lank Center for Genitourinary Oncology","institutionId":"dana-farber","specialisms":["Kidney cancer","Immunotherapy combinations","HIF-2α"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Choueiri%20TK%5BAuthor%5D"}],"papers":[{"title":"Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma","journal":"New England Journal of Medicine","year":2021,"url":"https://doi.org/10.1056/NEJMoa2106391","doi":"10.1056/NEJMoa2106391"},{"title":"Belzutifan versus everolimus for advanced renal-cell carcinoma","journal":"New England Journal of Medicine","year":2024,"url":"https://doi.org/10.1056/NEJMoa2313906","doi":"10.1056/NEJMoa2313906"},{"title":"CLEAR: lenvatinib plus pembrolizumab versus sunitinib as first treatment for advanced kidney cancer","journal":"New England Journal of Medicine","year":2021,"url":"https://doi.org/10.1056/NEJMoa2035716","doi":"10.1056/NEJMoa2035716"}],"orcid":"0000-0002-9201-3217"},{"id":"toni-vekov","kind":"person","name":"Toni Vekov","aka":[],"tldr":"Toni Vekov represents Heart and Brain Hospital, Pleven in the Organisation of European Cancer Institutes, which lists the organisation among its members in Bulgaria.","summary":"Toni Vekov is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Heart and Brain Hospital, Pleven, its full member in Bulgaria. OnCo records the name from the OECI membership list so that the organisation's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the organisation's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Heart and Brain Hospital, Pleven website","url":"https://cardiacinstitute.bg/en/hospitals-and-centers/heart-and-brain-center-of-excellence-pleven/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["heart-and-brain-pleven"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Heart and Brain Hospital, Pleven to the Organisation of European Cancer Institutes","institutionId":"heart-and-brain-pleven","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Heart and Brain Hospital, Pleven website","url":"https://cardiacinstitute.bg/en/hospitals-and-centers/heart-and-brain-center-of-excellence-pleven/"}],"papers":[{"title":"Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2","journal":"Biomed Pharmacother","year":2020,"url":"https://doi.org/10.1016/j.biopha.2020.110668","doi":"10.1016/j.biopha.2020.110668","note":"Europe PMC author record matched by affiliation"},{"title":"Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis","journal":"Diabetes Ther","year":2017,"url":"https://doi.org/10.1007/s13300-017-0273-4","doi":"10.1007/s13300-017-0273-4","note":"Europe PMC author record matched by affiliation"},{"title":"Effects of pioglitazone therapy on blood parameters, weight and BMI: a meta-analysis","journal":"Diabetol Metab Syndr","year":2017,"url":"https://doi.org/10.1186/s13098-017-0290-5","doi":"10.1186/s13098-017-0290-5","note":"Europe PMC author record matched by affiliation"}]},{"id":"tony-mok","kind":"person","name":"Tony S. K. Mok","aka":[],"tldr":"Lung cancer pioneer whose IPASS trial established EGFR-targeted therapy as first-line treatment; chairs Clinical Oncology at CUHK.","summary":"Tony Mok is Chairman of the Department of Clinical Oncology and Li Shu Fan Professor of Clinical Oncology at The Chinese University of Hong Kong, practising at Prince of Wales Hospital. He led the IPASS trial, which showed that EGFR mutation status predicts benefit from gefitinib over chemotherapy, a landmark in the shift to biomarker-driven lung cancer treatment, and has led numerous subsequent global trials of targeted therapy and immunotherapy in lung cancer.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.clo.cuhk.edu.hk/staff/university-staff/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mok+TS%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","lung cancer","precision oncology"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["prince-of-wales-hospital-cuhk"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chairman, Department of Clinical Oncology; Li Shu Fan Professor of Clinical Oncology","institutionId":"prince-of-wales-hospital-cuhk","specialisms":["Lung cancer","EGFR-targeted therapy","Precision oncology","Clinical trials"],"profiles":[{"label":"Institution profile","url":"https://www.clo.cuhk.edu.hk/staff/university-staff/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mok+TS%5BAuthor%5D"}],"papers":[{"title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","journal":"New England Journal of Medicine","year":2009,"url":"https://doi.org/10.1056/NEJMoa0810699","doi":"10.1056/NEJMoa0810699"}]},{"id":"doi-toshihiko","kind":"person","name":"Toshihiko Doi","aka":["toshihiko-doi"],"tldr":"Led the first-in-human study of trastuzumab deruxtecan and runs one of Asia's most productive phase 1 units.","summary":"Toshihiko Doi is Director of the Department of Experimental Therapeutics at the National Cancer Center Hospital East in Japan. He runs one of Asia's most productive phase 1 units and led the first-in-human study of DS-8201, the Daiichi Sankyo antibody-drug conjugate now known as trastuzumab deruxtecan, along with numerous other first-in-class studies in solid tumours. His publications include the phase 1 dose-escalation study of trastuzumab deruxtecan in patients with advanced breast and gastric or gastro-oesophageal tumours. His interests are phase 1 trials, drug development, gastrointestinal oncology and antibody-drug conjugates. He also directs National Cancer Center Hospital East in Kashiwa, one of the main sites for first-in-human oncology trials in Japan, and led pivotal work on trastuzumab deruxtecan and trifluridine/tipiracil in gastric cancer.","asOf":"2026-09-08","links":[{"label":"National Cancer Center Hospital East","url":"https://www.ncc.go.jp/en/ncce/index.html"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Doi%20T%5BAuthor%5D%20National%20Cancer%20Center%20Hospital%20East%20phase%201"},{"label":"Hospital director greeting","url":"https://www.ncc.go.jp/en/ncce/about/greeting/index.html"}],"tags":["leadership","clinician-scientist","gastric cancer","drug development"],"related":[],"cancers":["gastric","esophageal"],"sections":[],"technologies":["adc"],"targets":[],"drugs":["trastuzumab-deruxtecan"],"companies":["daiichi-sankyo"],"institutions":["ncc-japan","ncc-hospital-east"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Department of Experimental Therapeutics, National Cancer Center Hospital East","institutionId":"ncc-japan","specialisms":["Phase 1 trials","Drug development","Gastrointestinal oncology","Antibody-drug conjugates","Gastric cancer"],"profiles":[{"label":"National Cancer Center Hospital East","url":"https://www.ncc.go.jp/en/ncce/index.html"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Doi%20T%5BAuthor%5D%20National%20Cancer%20Center%20Hospital%20East%20phase%201"},{"label":"Hospital director greeting","url":"https://www.ncc.go.jp/en/ncce/about/greeting/index.html"}],"papers":[{"title":"Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study","journal":"Lancet Oncology","year":2017,"doi":"10.1016/S1470-2045(17)30604-6"},{"title":"Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial","journal":"Lancet Oncology","year":2018,"doi":"10.1016/S1470-2045(18)30739-3"},{"title":"Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study","journal":"Lancet Oncology","year":2019,"doi":"10.1016/S1470-2045(19)30088-9"}]},{"id":"tracey-fitzpatrick","kind":"person","name":"Tracey Fitzpatrick","aka":[],"tldr":"Tracey Fitzpatrick represents Mater Misericordiae University Hospital in the Organisation of European Cancer Institutes, which lists the centre among its members in Ireland.","summary":"Tracey Fitzpatrick is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Mater Misericordiae University Hospital, its full member in Ireland. OnCo records the name from the OECI membership list so that the centre's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the institution's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Mater Misericordiae University Hospital website","url":"https://www.mater.ie"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["mater-misericordiae"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Mater Misericordiae University Hospital to the Organisation of European Cancer Institutes","institutionId":"mater-misericordiae","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Mater Misericordiae University Hospital website","url":"https://www.mater.ie"}],"papers":[]},{"id":"trevor-pugh","kind":"person","name":"Trevor J. Pugh","aka":[],"tldr":"Genomicist who applies cell-free DNA and single-cell sequencing to track cancer and immunotherapy response.","summary":"Trevor J. Pugh is a Senior Scientist at the Princess Margaret Cancer Centre and Director of Genomics at the Ontario Institute for Cancer Research. He is a genomicist who applies cell-free DNA and single-cell sequencing to track cancer and immunotherapy response, leading translational genomics programmes on cfDNA methylation, immune repertoire sequencing and clinical trial genomics. His selected paper reports the genetic landscape of high-risk neuroblastoma. He continues to work on liquid biopsy and single-cell and spatial profiling.","asOf":"2026-09-08","links":[{"label":"UHN profile","url":"https://www.uhnresearch.ca/researcher/trevor-j-pugh"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Pugh%20TJ%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["neuroblastoma"],"sections":[],"technologies":["liquid-biopsy","single-cell-spatial"],"targets":[],"drugs":[],"companies":[],"institutions":["princess-margaret"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Senior Scientist, Princess Margaret; Director of Genomics, Ontario Institute for Cancer Research","institutionId":"princess-margaret","specialisms":["Cancer genomics","ctDNA","Single-cell sequencing"],"profiles":[{"label":"UHN profile","url":"https://www.uhnresearch.ca/researcher/trevor-j-pugh"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Pugh%20TJ%5BAuthor%5D"}],"papers":[{"title":"The genetic landscape of high-risk neuroblastoma","journal":"Nature Genetics","year":2013,"url":"https://doi.org/10.1038/ng.2529","doi":"10.1038/ng.2529"}],"orcid":"0000-0002-8073-5888"},{"id":"trevor-mundel","kind":"person","name":"Trevor Mundel","aka":[],"tldr":"Physician-scientist who leads the Gates Foundation's Global Health division, including its vaccine and product development work.","summary":"Trevor Mundel is President of Global Health at the Gates Foundation, overseeing research and development of vaccines, drugs and diagnostics for diseases affecting low- and middle-income countries, including HPV vaccine access relevant to cervical cancer prevention. A former head of global development at Novartis, he trained as a physician and mathematician.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.gatesfoundation.org/about/leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mundel+T%5BAuthor%5D"}],"tags":["leadership","global health","vaccines"],"related":[],"cancers":["cervical"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["gates-foundation"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President, Global Health","institutionId":"gates-foundation","specialisms":["Global health","Drug and vaccine development","Infectious disease"],"profiles":[{"label":"Institution profile","url":"https://www.gatesfoundation.org/about/leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mundel+T%5BAuthor%5D"}],"papers":[{"title":"CEPI-a new global R&D organisation for epidemic preparedness and response","journal":"Lancet","year":2017,"url":"https://doi.org/10.1016/s0140-6736(17)30131-9","doi":"10.1016/s0140-6736(17)30131-9","note":"Europe PMC author record matched by affiliation"},{"title":"Precisely Tracking Childhood Death","journal":"Am J Trop Med Hyg","year":2017,"url":"https://doi.org/10.4269/ajtmh.16-0302","doi":"10.4269/ajtmh.16-0302","note":"Europe PMC author record matched by affiliation"},{"title":"Providing incentives to share data early in health emergencies: the role of journal editors","journal":"Lancet","year":2015,"url":"https://doi.org/10.1016/s0140-6736(15)00758-8","doi":"10.1016/s0140-6736(15)00758-8","note":"Europe PMC author record matched by affiliation"}]},{"id":"ugur-sahin","kind":"person","name":"Uğur Şahin","aka":[],"tldr":"Immunologist who built individualised mRNA neoantigen vaccines for cancer, the platform later used for COVID-19.","summary":"Uğur Şahin led the 2017 Nature trial showing individualised mRNA vaccines encoding each patient's mutations induce T-cell responses in melanoma, the proof of concept for personalised cancer vaccines now in phase 2 and 3 trials with autogene cevumeran in pancreatic and colorectal cancer. He co-founded BioNTech with Özlem Türeci and continues academic work in Mainz on mRNA, CAR-T and bispecific therapies.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/U%C4%9Fur_%C5%9Eahin","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sahin%20U%5BAuthor%5D%20mRNA%20vaccine%20neoantigen"}],"tags":["vaccine","mrna","immunotherapy"],"related":[],"cancers":["melanoma","pancreatic"],"sections":[],"technologies":["neoantigen-mrna-vaccine"],"targets":[],"drugs":["autogene-cevumeran"],"companies":[],"institutions":["uct-mainz"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-rojas-mrna-neoantigen-vaccine-pancreatic-nature-2023"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Translational Oncology, University Medical Center Mainz; Co-founder and CEO, BioNTech","institutionId":"uct-mainz","specialisms":["mRNA cancer vaccines","Neoantigen immunotherapy","Translational oncology","Individualised therapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sahin%20U%5BAuthor%5D%20mRNA%20vaccine%20neoantigen"}],"papers":[{"title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","journal":"Nature","year":2017,"doi":"10.1038/nature23003"},{"title":"An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma","journal":"Nature","year":2020,"doi":"10.1038/s41586-020-2537-9"},{"title":"Rojas 2023: a personalised mRNA vaccine trained T cells against each patient's pancreatic cancer, and those who responded stayed cancer-free longer","journal":"Nature","year":2023,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Personalized%20RNA%20neoantigen%20vaccines%20stimulate%20T%20cells%20in%20pancreatic%20cancer%20Rojas%20Nature%202023"}],"orcid":"0000-0003-0363-1564"},{"id":"ulrich-steidl","kind":"person","name":"Ulrich G. Steidl","aka":[],"tldr":"Physician-scientist who directs the Montefiore Einstein Comprehensive Cancer Center, the NCI-designated cancer centre serving the Bronx and surrounding New York communities.","summary":"Ulrich G. Steidl, MD, PhD, is Director of the Montefiore Einstein Comprehensive Cancer Center, the joint cancer centre of Montefiore Health System and Albert Einstein College of Medicine in the Bronx, New York. The centre's team page lists him at the head of a leadership group that includes Deputy Director Amit K. Verma, Deputy Director for Administration Lauren E. Hackett, Deputy Director for Community Outreach and Engagement Alyson B. Moadel-Robblee, and associate directors Julio A. Aguirre-Ghiso (basic science), Balazs Halmos (clinical science), Marina Konopleva (translational science), Shalom Kalnicki (clinical affairs) and Brendon M. Stiles (surgical oncology). The page gives no appointment date.","asOf":"2026-09-10","links":[{"label":"Source: Montefiore Einstein Comprehensive Cancer Center team page","url":"https://montefioreeinstein.org/cancer/about/team"}],"tags":["leadership","clinician-scientist","comprehensive-cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["montefiore-einstein"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nature-medicine","science-translational-medicine"],"dependsOn":[],"notes":[],"role":"Director, Montefiore Einstein Comprehensive Cancer Center","institutionId":"montefiore-einstein","specialisms":["Haematological malignancies","Stem cell biology","Cancer centre leadership"],"profiles":[{"label":"Montefiore Einstein cancer centre team page","url":"https://montefioreeinstein.org/cancer/about/team"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Steidl+U%5BAuthor%5D"}],"papers":[{"title":"Myelodysplastic syndrome progression to acute myeloid leukemia at the stem cell level","journal":"Nature Medicine","year":2018,"doi":"10.1038/s41591-018-0267-4"},{"title":"Minimal PU.1 reduction induces a preleukemic state and promotes development of acute myeloid leukemia","journal":"Nature Medicine","year":2015,"doi":"10.1038/nm.3936"},{"title":"Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia","journal":"Science Translational Medicine","year":2018,"doi":"10.1126/scitranslmed.aao3003"}]},{"id":"ulrich-keilholz","kind":"person","name":"Ulrich Keilholz","aka":[],"tldr":"Ulrich Keilholz is a medical oncologist who directs the Charité Comprehensive Cancer Center.","summary":"Ulrich Keilholz is Director of the Charité Comprehensive Cancer Center at Charité Universitätsmedizin Berlin, with long-standing links to the EORTC. A medical oncologist, his specialisms are melanoma, head and neck cancer, immunotherapy and cancer centre leadership. He has a long record in melanoma and head and neck squamous cell carcinoma immunotherapy trials with EORTC. His papers include the ESMO consensus conference recommendations on the management of metastatic melanoma and of locoregional melanoma, and the ESMO Clinical Practice Guidelines on cutaneous melanoma, all in Annals of Oncology. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Keilholz%20U%5BAuthor%5D%20melanoma"}],"tags":[],"related":[],"cancers":["melanoma","head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["curie-nki-eortc"],"institutions":["charite"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Charité Comprehensive Cancer Center","institutionId":"charite","specialisms":["Melanoma","Head and neck cancer","Immunotherapy","Cancer centre leadership"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Keilholz%20U%5BAuthor%5D%20melanoma"}],"papers":[{"title":"ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee","journal":"Annals of Oncology","year":2020,"doi":"10.1016/j.annonc.2020.07.004"},{"title":"ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee","journal":"Annals of Oncology","year":2020,"doi":"10.1016/j.annonc.2020.07.005"},{"title":"Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","journal":"Annals of Oncology","year":2019,"doi":"10.1093/annonc/mdz411"}],"orcid":"0000-0001-6773-9406"},{"id":"ursula-matulonis","kind":"person","name":"Ursula A. Matulonis","aka":[],"tldr":"Ursula Matulonis led the MIRASOL trial that gave ovarian cancer its first ADC with a survival benefit.","summary":"Ursula A. Matulonis is Chief of the Division of Gynecologic Oncology at Dana-Farber Brigham Cancer Center. She is a gynaecologic oncologist known for leading the MIRASOL trial of mirvetuximab soravtansine, which gave ovarian cancer its first antibody-drug conjugate, as well as trials of PARP inhibitors and bevacizumab combinations. Her selected paper reports mirvetuximab soravtansine in folate receptor alpha-positive, platinum-resistant ovarian cancer. She continues to lead trials of PARP inhibitors such as olaparib and of ADCs in ovarian cancer.","asOf":"2026-09-08","links":[{"label":"Dana-Farber profile","url":"https://www.dana-farber.org/find-a-doctor/ursula-a-matulonis"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Matulonis%20UA%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":["folr1","parp"],"drugs":["mirvetuximab-soravtansine","olaparib"],"companies":[],"institutions":["dana-farber"],"pathways":[],"terms":[],"trials":["mirasol"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief, Division of Gynecologic Oncology","institutionId":"dana-farber","specialisms":["Ovarian cancer","PARP inhibitors","Antibody-drug conjugates"],"profiles":[{"label":"Dana-Farber profile","url":"https://www.dana-farber.org/find-a-doctor/ursula-a-matulonis"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Matulonis%20UA%5BAuthor%5D"}],"papers":[{"title":"Mirvetuximab soravtansine in FRα-positive, platinum-resistant ovarian cancer","journal":"New England Journal of Medicine","year":2023,"url":"https://doi.org/10.1056/NEJMoa2309169","doi":"10.1056/NEJMoa2309169"}]},{"id":"usha-menon","kind":"person","name":"Usha Menon","aka":[],"tldr":"Led UKCTOCS, the 200,000-woman trial that found ovarian cancer screening does not save lives despite detecting cancers earlier.","summary":"Usha Menon was co-principal investigator of UKCTOCS, the largest cancer screening trial ever run, whose 2021 final report showed neither annual CA125-based multimodal screening nor ultrasound reduced ovarian cancer mortality despite a stage shift, a landmark negative result for early detection. She developed the Risk of Ovarian Cancer Algorithm and continues to lead early detection and biobank research at UCL.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Menon%20U%5BAuthor%5D%20UKCTOCS"}],"tags":["screening","ovarian","early-detection"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":["ultrasound"],"targets":[],"drugs":[],"companies":[],"institutions":["uclh"],"pathways":[],"terms":[],"trials":["ukctocs"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Gynaecological Cancer, MRC Clinical Trials Unit at UCL","institutionId":"uclh","specialisms":["Ovarian cancer screening","Population trials","Risk algorithms","Early detection"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Menon%20U%5BAuthor%5D%20UKCTOCS"}],"papers":[{"title":"Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)","journal":"Lancet","year":2021,"doi":"10.1016/S0140-6736(21)00731-5"},{"title":"Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial","journal":"Lancet","year":2016,"doi":"10.1016/S0140-6736(15)01224-6"}],"orcid":"0000-0003-3708-1732"},{"id":"uta-dirksen","kind":"person","name":"Uta Dirksen","aka":[],"tldr":"Paediatric oncologist from University Hospital Essen who presides over SIOP Europe and has led international Ewing sarcoma trials.","summary":"Uta Dirksen is President of SIOP Europe, the European Society for Paediatric Oncology, and a paediatric oncologist at University Hospital Essen, Germany. She has coordinated cooperative bone sarcoma trials including the Ewing 2008 and iEuroEwing studies, and works on adolescent and young adult cancer care and European paediatric oncology policy.","asOf":"2026-09-10","links":[{"label":"Society page","url":"https://siope.eu/about-siope/board/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dirksen+U%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","paediatric oncology","sarcoma"],"related":[],"cancers":["ewing-sarcoma","osteosarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["siop-europe"],"pathways":[],"terms":[],"trials":["euro-ewing-2012"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President","institutionId":"siop-europe","specialisms":["Paediatric oncology","Ewing sarcoma","Bone sarcoma trials"],"profiles":[{"label":"Society page","url":"https://siope.eu/about-siope/board/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dirksen+U%5BAuthor%5D"}],"papers":[{"title":"High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008","journal":"Journal of Clinical Oncology","year":2019,"doi":"10.1200/jco.19.00915"},{"title":"Rhabdomyosarcoma, Ewing Sarcoma, and Other Round Cell Sarcomas","journal":"Journal of Clinical Oncology","year":2018,"doi":"10.1200/jco.2017.74.7402"},{"title":"Cyclophosphamide Compared With Ifosfamide in Consolidation Treatment of Standard-Risk Ewing Sarcoma: Results of the Randomized Noninferiority Euro-EWING99-R1 Trial","journal":"Journal of Clinical Oncology","year":2014,"doi":"10.1200/jco.2013.54.4833"}]},{"id":"uwe-haberkorn","kind":"person","name":"Uwe Haberkorn","aka":[],"tldr":"Nuclear medicine physician whose group invented FAPI PET tracers and pioneered PSMA and FAP radioligand therapy.","summary":"Uwe Haberkorn is Head of Nuclear Medicine at Heidelberg University Hospital and the German Cancer Research Center (DKFZ). His specialisms are nuclear medicine, FAP-targeted radiopharmaceuticals and theranostics, with a focus on the FAP and PSMA targets. His Heidelberg group invented the quinoline-based FAP inhibitor (FAPI) tracers, and his Journal of Nuclear Medicine paper reported 68Ga-FAPI PET/CT tracer uptake across 28 different kinds of cancer. The group also led early PSMA-617 and FAP-targeted radioligand therapy in humans, and his record links him to FAP-2286 and lutetium-177 vipivotide tetraxetan. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Haberkorn%20U%5BAuthor%5D%20FAPI"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["fapi-pet","radioligand-therapy","psma-pet"],"targets":["fap","psma"],"drugs":["fap-2286","pluvicto"],"companies":[],"institutions":["heidelberg-nct","dkfz"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["journal-of-nuclear-medicine"],"dependsOn":[],"notes":[],"role":"Head of Nuclear Medicine, Heidelberg University Hospital and DKFZ","institutionId":"heidelberg-nct","specialisms":["Nuclear medicine","FAP-targeted radiopharmaceuticals","Theranostics"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Haberkorn%20U%5BAuthor%5D%20FAPI"}],"papers":[{"title":"68Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer","journal":"Journal of Nuclear Medicine","year":2019,"doi":"10.2967/jnumed.119.227967"}]},{"id":"uwe-oelfke","kind":"person","name":"Uwe Oelfke","aka":[],"tldr":"Uwe Oelfke is the radiotherapy physicist behind the Marsden's pioneering MR-linac programme.","summary":"Uwe Oelfke is Head of the Joint Department of Physics at The Institute of Cancer Research and The Royal Marsden. His specialisms are radiotherapy physics, MR-guided radiotherapy and adaptive radiotherapy. He is the physicist behind the Marsden's pioneering MR-linac programme, and his department delivered some of the first MR-linac treatments while developing adaptive and biology-guided radiotherapy. His Clinical Oncology paper described magnetic resonance guided radiotherapy with the MR-Linac. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Oelfke%20U%5BAuthor%5D%20MR-linac"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["mr-linac","imrt-igrt"],"targets":[],"drugs":[],"companies":[],"institutions":["royal-marsden","icr-london"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["clinical-oncology-rcr"],"dependsOn":[],"notes":[],"role":"Head of Joint Department of Physics, ICR and Royal Marsden","institutionId":"royal-marsden","specialisms":["Radiotherapy physics","MR-guided radiotherapy","Adaptive radiotherapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Oelfke%20U%5BAuthor%5D%20MR-linac"}],"papers":[{"title":"Magnetic resonance guided radiotherapy: the MR-Linac","journal":"Clinical Oncology","year":2018}]},{"id":"uwe-platzbecker","kind":"person","name":"Uwe Platzbecker","aka":[],"tldr":"Led MEDALIST and COMMANDS, which made luspatercept a first-line treatment for anaemia in lower-risk MDS.","summary":"Uwe Platzbecker (Leipzig) was a principal investigator of MEDALIST and led COMMANDS, the trials establishing luspatercept for transfusion-dependent anaemia in lower-risk myelodysplastic syndromes, first after and then instead of erythropoiesis-stimulating agents. He coordinates the German MDS Study Group and the European MDS registry and has led trials of hypomethylating agent combinations in higher-risk disease.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Platzbecker%20U%5BAuthor%5D%20luspatercept%20MDS"}],"tags":["mds","anaemia","trialist"],"related":[],"cancers":["mds","aml"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["university-hospital-leipzig"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-commands-luspatercept-mds-lancet-2023"],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Department of Hematology, Cellular Therapy and Hemostaseology, University Hospital Leipzig","institutionId":"university-hospital-leipzig","specialisms":["Myelodysplastic syndromes","Anaemia therapeutics","Acute myeloid leukaemia","Cooperative-group trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Platzbecker%20U%5BAuthor%5D%20luspatercept%20MDS"}],"papers":[{"title":"Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS)","journal":"Lancet","year":2023,"doi":"10.1016/S0140-6736(23)00874-7"},{"title":"Luspatercept in patients with lower-risk myelodysplastic syndromes (MEDALIST)","journal":"NEJM","year":2020,"doi":"10.1056/NEJMoa1908892"},{"title":"COMMANDS: luspatercept versus epoetin alfa as first treatment for anaemia in lower-risk MDS needing transfusions","journal":"The Lancet","year":2023,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=COMMANDS%20luspatercept%20epoetin%20alfa%20lower-risk%20MDS%20Platzbecker%20Lancet%202023"}]},{"id":"shanta-v","kind":"person","name":"V. Shanta","aka":[],"tldr":"The doctor who spent 66 years building Chennai's Cancer Institute into a hospital where most patients are treated free, and who set up India's first population cancer registry and paediatric oncology unit.","summary":"Viswanathan Shanta (11 March 1927 to 19 January 2021) joined the Cancer Institute (WIA) in Adyar, Chennai, in 1955 and lived on its campus until her death, serving as Director from 1980 to 1997 and then Chairman. Under her leadership the Institute grew from a small charitable hospital into a comprehensive cancer centre offering free or subsidised care to about 60% of its roughly 100,000 annual patients, opened India's first paediatric oncology unit, established the Madras Metropolitan Tumour Registry, and led Indian trials in cervical and oral cancer screening. She received the Ramon Magsaysay Award (2005) and the Padma Shri (1986), Padma Bhushan (2006) and Padma Vibhushan (2016).","status":"historic","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/V._Shanta","links":[{"label":"Cancer Institute (WIA)","url":"https://www.cancerinstitutewia.in"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Shanta%20V%5BAuthor%5D%20Cancer%20Institute%20Adyar"}],"tags":[],"related":[],"cancers":["cervical","all-leukemia","head-and-neck"],"sections":[],"technologies":["cancer-registries-surveillance","global-oncology-access"],"targets":[],"drugs":[],"companies":[],"institutions":["cancer-institute-adyar"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["pediatric-hematology-and-oncology"],"dependsOn":[],"notes":[],"role":"Chairman and former Director, Cancer Institute (WIA), Adyar (1927-2021)","institutionId":"cancer-institute-adyar","specialisms":["Medical oncology","Paediatric oncology","Cancer registries","Charitable cancer care"],"profiles":[{"label":"Cancer Institute (WIA)","url":"https://www.cancerinstitutewia.in"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Shanta%20V%5BAuthor%5D%20Cancer%20Institute%20Adyar"}],"papers":[{"title":"Retrospective Analysis of Locally Advanced Noninflammatory Breast Cancer From Chennai, South India, 1990–1999","journal":"International Journal of Radiation Oncology*Biology*Physics","year":2008,"doi":"10.1016/j.ijrobp.2007.05.050"},{"title":"Cancer registration in Madras Metropolitan Tumour Registry, India","journal":"European Journal of Cancer","year":1994,"doi":"10.1016/0959-8049(94)90126-0"},{"title":"Prognostic Variables and Survival in Pediatric Acute Lymphoblastic Leukemias: Cancer Institute Experience","journal":"Pediatric Hematology and Oncology","year":1996,"doi":"10.3109/08880019609030819"}]},{"id":"vadims-beluns","kind":"person","name":"Vadims Beļuns","aka":[],"tldr":"Chair of the management board of Riga East University Hospital, Latvia's largest hospital and home of the Oncology Centre of Latvia.","summary":"Vadims Beļuns is Chair of the Board (valdes priekšsēdētājs) of SIA Rīgas Austrumu klīniskā universitātes slimnīca (Riga East University Hospital), the largest hospital in Latvia, whose sites include the Oncology Centre of Latvia. The hospital's board page lists him alongside board members Kaspars Plūme and Ineta Derjabo and describes his focus as achieving the hospital's strategic objectives under its 'Future Hospital' vision across clinical care, education and research. The Latvian Wikipedia article on the hospital gives his term of office as 2026 to 2031.","asOf":"2026-09-10","links":[{"label":"Source: Riga East University Hospital board (valde) page","url":"https://aslimnica.lv/par-mums/valde/"},{"label":"Wikipedia (Latvian) article on the hospital","url":"https://lv.wikipedia.org/wiki/Rīgas_Austrumu_klīniskā_universitātes_slimnīca"}],"tags":["leadership","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["riga-east-university-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chair of the Board (valdes priekšsēdētājs), Riga East University Hospital","institutionId":"riga-east-university-hospital","specialisms":["Hospital management","Health system strategy"],"profiles":[{"label":"Riga East University Hospital board page","url":"https://aslimnica.lv/par-mums/valde/"}],"papers":[]},{"id":"valdas-peceliunas","kind":"person","name":"Valdas Pečeliūnas","aka":[],"tldr":"Director who leads the National Cancer Institute in Vilnius, Lithuania's national specialist cancer treatment and research institute.","summary":"Valdas Pečeliūnas leads the National Cancer Institute (Nacionalinis vėžio institutas, NVI) in Vilnius as its Director. The institute is a non-profit public legal entity that combines specialist cancer treatment with cancer research, and its scientific work is overseen by an eleven-member Scientific Council elected for five-year terms. The Lithuanian Wikipedia article on the institute names him as the current director; the institute's own website describes its structure and administration without publishing leadership names.","asOf":"2026-09-10","links":[{"label":"Source: Lithuanian Wikipedia article naming the director","url":"https://lt.wikipedia.org/wiki/Nacionalinis_vėžio_institutas"},{"label":"Institute about page","url":"https://nvi.lt/apie-mus/"}],"tags":["leadership","research-institute","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["nci-vilnius"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["lancet-haematology"],"dependsOn":[],"notes":[],"role":"Director, National Cancer Institute (Nacionalinis vėžio institutas), Vilnius","institutionId":"nci-vilnius","specialisms":["Oncology","Cancer institute management","Cancer research"],"profiles":[{"label":"Wikipedia (Lithuanian) article on the institute","url":"https://lt.wikipedia.org/wiki/Nacionalinis_vėžio_institutas"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Peceliunas+V%5BAuthor%5D"}],"papers":[{"title":"Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study","journal":"The Lancet Haematology","year":2021,"doi":"10.1016/s2352-3026(21)00169-1"},{"title":"Adhesion molecule immunophenotype of bone marrow multiple myeloma plasma cells impacts the presence of malignant circulating plasma cells in peripheral blood","journal":"International Journal of Laboratory Hematology","year":2020,"doi":"10.1111/ijlh.13387"},{"title":"Time from Symptom Onset to Diagnosis and Treatment among Haematological Malignancies: Influencing Factors and Associated Negative Outcomes","journal":"Medicina","year":2019,"doi":"10.3390/medicina55060238"}]},{"id":"valerie-rusch","kind":"person","name":"Valerie W. Rusch","aka":[],"tldr":"Thoracic surgeon who led the IASLC staging projects that define how lung cancer and mesothelioma are staged.","summary":"Valerie Rusch chaired the IASLC lymph node map and staging committees whose work underpins the seventh, eighth and ninth editions of the TNM classification for lung cancer and mesothelioma, and led surgical studies in mesothelioma and the surgical arm of the CheckMate 816 and other neoadjuvant trials. She was the first woman president of the American Association for Thoracic Surgery.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rusch%20VW%5BAuthor%5D%20lung%20cancer%20staging"}],"tags":["surgery","thoracic","staging"],"related":[],"cancers":["nsclc","mesothelioma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":["checkmate-816"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["journal-of-thoracic-oncology"],"dependsOn":[],"notes":[],"role":"Attending Thoracic Surgeon and Miner Family Chair in Intrathoracic Cancers, Memorial Sloan Kettering Cancer Center","institutionId":"mskcc","specialisms":["Thoracic surgery","Lung cancer staging","Mesothelioma surgery","Surgical trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rusch%20VW%5BAuthor%5D%20lung%20cancer%20staging"}],"papers":[{"title":"The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer","journal":"Journal of Thoracic Oncology","year":2009,"doi":"10.1097/JTO.0b013e3181a0d82e"},{"title":"Initial analysis of the International Association for the Study of Lung Cancer mesothelioma database","journal":"Journal of Thoracic Oncology","year":2012,"doi":"10.1097/JTO.0b013e3182641c0b"}],"orcid":"0000-0003-2345-6900"},{"id":"valery-lemmens","kind":"person","name":"Valery Lemmens","aka":[],"tldr":"Cancer epidemiologist and professor who became Director of OncoZON, the oncology network of ten hospitals in the south-east Netherlands, in August 2026.","summary":"Valery Lemmens is Director of OncoZON, the regional oncology network of ten affiliated healthcare institutions in the south-east Netherlands that coordinates shared care pathways, expert teams and knowledge exchange for cancer care. He took up the post on 1 August 2026, succeeding René van der Hulst, who had led the network for three years. An epidemiologist, he has held a professorship in region-integrated cancer care at Maastricht University since 2024, spent more than 20 years with the Netherlands Comprehensive Cancer Organisation (IKNL), including as a board member from 2019 and later as medical adviser, and previously held board positions at Maastro and a professorship in cancer surveillance at Erasmus MC. Board chair Helen Mertens, CEO of Maastricht UMC+, announced the appointment.","asOf":"2026-09-10","links":[{"label":"Source: OncoZON news item announcing the appointment (August 2026)","url":"https://www.oncozon.nl/prof-dr-valery-lemmens-benoemd-tot-directeur-van-oncozon/"}],"tags":["leadership","clinician-scientist","comprehensive-cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["erasmus-mc"],"pathways":[],"terms":[],"trials":[],"people":["helen-mertens"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, OncoZON (regional oncology network, south-east Netherlands)","institutionId":"oncozon","specialisms":["Cancer epidemiology","Cancer registries and surveillance","Regional cancer networks"],"profiles":[{"label":"OncoZON appointment announcement","url":"https://www.oncozon.nl/prof-dr-valery-lemmens-benoemd-tot-directeur-van-oncozon/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lemmens+VE%5BAuthor%5D"}],"papers":[{"title":"Patterns of metachronous metastases after curative treatment of colorectal cancer","journal":"Cancer Epidemiology","year":2014,"doi":"10.1016/j.canep.2014.04.004"},{"title":"Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: A population‐based study","journal":"International Journal of Cancer","year":2010,"doi":"10.1002/ijc.25596"}]},{"id":"noronha-vanita","kind":"person","name":"Vanita Noronha","aka":[],"tldr":"A medical oncologist who co-leads Tata Memorial's lung cancer trials and built India's geriatric oncology programme.","summary":"Vanita Noronha is Professor of Medical Oncology at Tata Memorial Hospital, part of the Tata Memorial Centre in Mumbai, working in geriatric oncology and lung cancer. She co-leads the hospital's lung cancer trials and co-led the trial of gefitinib with or without pemetrexed and carboplatin chemotherapy in EGFR-mutant lung cancer. She also built India's geriatric oncology programme, establishing a geriatric oncology clinic and research programme based on geriatric assessment. Her interests are lung cancer, geriatric oncology, head and neck cancer and clinical trials.","asOf":"2026-09-08","links":[{"label":"Tata Memorial Centre","url":"https://tmc.gov.in"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Noronha%20V%5BAuthor%5D%20Tata%20Memorial%20lung"}],"tags":[],"related":[],"cancers":["nsclc","head-and-neck"],"sections":[],"technologies":["geriatric-assessment"],"targets":[],"drugs":[],"companies":[],"institutions":["tata-memorial"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology, Tata Memorial Hospital; geriatric oncology and lung cancer","institutionId":"tata-memorial","specialisms":["Lung cancer","Geriatric oncology","Head and neck cancer","Clinical trials"],"profiles":[{"label":"Tata Memorial Centre","url":"https://tmc.gov.in"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Noronha%20V%5BAuthor%5D%20Tata%20Memorial%20lung"}],"papers":[{"title":"Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-mutated lung cancer","journal":"Journal of Clinical Oncology","year":2020,"doi":"10.1200/JCO.19.01154"},{"title":"Low-dose immunotherapy in head and neck cancer: a randomised study (Tata Memorial)","journal":"Journal of Clinical Oncology","year":2023,"url":"https://doi.org/10.1200/JCO.22.01015","doi":"10.1200/JCO.22.01015"}]},{"id":"vasanta-nanduri","kind":"person","name":"Vasanta Nanduri","aka":[],"tldr":"Clinician at Watford General Hospital who is President of the Histiocyte Society, the international research society for histiocytic disorders, for the 2025 to 2028 term.","summary":"Vasanta Nanduri, of Watford General Hospital in the United Kingdom, is President of the Histiocyte Society for the 2025 to 2028 term. The society's executive board page lists her alongside past president Kim Nichols of St. Jude Children's Research Hospital, treasurer Scott Baker of Fred Hutchinson Cancer Center, secretary Caroline Hutter of St. Anna Kinderspital in Vienna, and members at large Oussama Abla and Astrid van Halteren. The Histiocyte Society is an international society of physicians and scientists working on histiocytic disorders.","asOf":"2026-09-10","links":[{"label":"Source: Histiocyte Society executive board page","url":"https://histiocytesociety.org/executive-board/"}],"tags":["leadership","professional-society","clinician-scientist"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["histiocyte-society"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["jco","european-journal-of-cancer","pediatric-blood-and-cancer"],"dependsOn":[],"notes":[],"role":"President, Histiocyte Society","institutionId":"histiocyte-society","specialisms":["Histiocytic disorders","Clinical research collaboration"],"profiles":[{"label":"Histiocyte Society executive board","url":"https://histiocytesociety.org/executive-board/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Nanduri+V%5BAuthor%5D"}],"papers":[{"title":"Cognitive Outcome of Long-Term Survivors of Multisystem Langerhans Cell Histiocytosis: A Single-Institution, Cross-Sectional Study","journal":"Journal of Clinical Oncology","year":2003,"doi":"10.1200/jco.2003.05.048"},{"title":"Long term morbidity and health related quality of life after multi-system Langerhans cell histiocytosis","journal":"European Journal of Cancer","year":2006,"doi":"10.1016/j.ejca.2006.05.031"},{"title":"High incidence of hearing loss in long‐term survivors of multisystem Langerhans cell histiocytosis","journal":"Pediatric Blood & Cancer","year":2009,"doi":"10.1002/pbc.22186"}]},{"id":"vasyl-f-chekhun","kind":"person","name":"Vasyl F. Chekhun","aka":[],"tldr":"Vasyl F. Chekhun represents R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology in the Organisation of European Cancer Institutes, which lists the centre among its members in Ukraine.","summary":"Vasyl F. Chekhun is listed by the Organisation of European Cancer Institutes (OECI) as the representative of R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, its associate member in Ukraine. OnCo records the name from the OECI membership list so that the centre's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the institution's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology website","url":"https://www.iepor.site"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["kavetsky-institute-kyiv"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology to the Organisation of European Cancer Institutes","institutionId":"kavetsky-institute-kyiv","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology website","url":"https://www.iepor.site"}],"papers":[{"title":"Iron metabolism disturbances in the MCF-7 human breast cancer cells with acquired resistance to doxorubicin and cisplatin","journal":"Int J Oncol","year":2013,"url":"https://doi.org/10.3892/ijo.2013.2063","doi":"10.3892/ijo.2013.2063","note":"Europe PMC author record matched by affiliation"},{"title":"Role of DNA hypomethylation in the development of the resistance to doxorubicin in human MCF-7 breast adenocarcinoma cells","journal":"Cancer Lett","year":2006,"url":"https://doi.org/10.1016/j.canlet.2005.01.038","doi":"10.1016/j.canlet.2005.01.038","note":"Europe PMC author record matched by affiliation"}],"orcid":"0000-0003-1024-3703"},{"id":"vicente-borrero","kind":"person","name":"Vicente Borrero","aka":[],"tldr":"Hospital leader who has run Fundación Valle del Lili in Cali, Colombia, as Director General for three decades.","summary":"Vicente Borrero is Director General of Fundación Valle del Lili, a non profit hospital and medical foundation in Cali, Colombia, that also runs education and research programmes. In February 2026 the foundation paid tribute to him for 30 years of managing the institution, and it also reported his recognition as businessman of the year for Colombia's Pacific zone, an interview in which he said the humanitarian response of his medical staff during the pandemic had been more gratifying than any economic result. The foundation's website names Marcela Granados as Subdirectora General.","asOf":"2026-09-10","links":[{"label":"Source: Fundación Valle del Lili article naming the Director General","url":"https://valledellili.org/homenaje-al-dr-vicente-borrero-director-general-de-la-fundacion-valle-del-lili-por-sus-30-anos-de-gestion-de-la-institucion/"}],"tags":["leadership","hospital-management","philanthropy"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["fundacion-valle-del-lili"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director General, Fundación Valle del Lili","institutionId":"fundacion-valle-del-lili","specialisms":["Hospital management","Healthcare leadership"],"profiles":[{"label":"Fundación Valle del Lili tribute article (February 2026)","url":"https://valledellili.org/homenaje-al-dr-vicente-borrero-director-general-de-la-fundacion-valle-del-lili-por-sus-30-anos-de-gestion-de-la-institucion/"}],"papers":[]},{"id":"vicky-makker","kind":"person","name":"Vicky Makker","aka":[],"tldr":"New York oncologist who led KEYNOTE-775, the trial that established lenvatinib plus pembrolizumab for advanced endometrial cancer after chemotherapy.","summary":"Vicky Makker is a gynaecologic medical oncologist at Memorial Sloan Kettering Cancer Center. She led the phase 2 study and was first author of the 2022 New England Journal of Medicine report of KEYNOTE-775, the phase 3 trial in which lenvatinib plus pembrolizumab improved progression-free and overall survival compared with chemotherapy in advanced endometrial cancer after platinum-based therapy, including mismatch repair-proficient tumours.","asOf":"2026-09-18","links":[],"tags":["endometrial","gynaecological","immunotherapy","trialist"],"related":[],"cancers":["advanced-recurrent-endometrial-cancer","endometrial"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-keynote-775-nejm-2022"],"journals":[],"dependsOn":[],"notes":[],"role":"Gynaecologic medical oncologist, Memorial Sloan Kettering Cancer Center","institutionId":"mskcc","specialisms":["Endometrial cancer","Immunotherapy combinations","Targeted therapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Makker%5BAuthor%5D"}],"papers":[{"title":"KEYNOTE-775: lenvatinib plus pembrolizumab versus chemotherapy for previously treated advanced endometrial cancer","journal":"New England Journal of Medicine","year":2022,"url":"https://doi.org/10.1056/NEJMoa2108330","doi":"10.1056/NEJMoa2108330"}]},{"id":"victor-hugo-borja-aburto","kind":"person","name":"Víctor Hugo Borja Aburto","aka":[],"tldr":"Epidemiologist who heads COFEPRIS, Mexico's federal regulator for medicines, medical devices and other health risks.","summary":"Dr Víctor Hugo Borja Aburto is Comisionado Federal of the Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS), Mexico's health regulatory agency; Spanish Wikipedia lists his term as beginning in 2026. He trained in medicine at the Universidad Autónoma Metropolitana-Xochimilco, holds master's degrees in public health and epidemiological sciences from the Instituto Nacional de Salud Pública and a doctorate in epidemiology from the University of North Carolina at Chapel Hill. His earlier career included directing the Centro Nacional de Salud Ambiental, research at CINVESTAV-IPN and leadership roles in epidemiological surveillance and primary care at IMSS.","asOf":"2026-09-10","links":[{"label":"Source: COFEPRIS commissioner profile","url":"https://www.gob.mx/cofepris/estructuras/dr-victor-hugo-borja-aburto"}],"tags":["leadership","clinician-scientist","regulator"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cofepris"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Comisionado Federal para la Protección contra Riesgos Sanitarios (2026-)","institutionId":"cofepris","specialisms":["Epidemiology","Public health","Health regulation","Environmental health"],"profiles":[{"label":"Institution profile","url":"https://www.gob.mx/cofepris/estructuras/dr-victor-hugo-borja-aburto"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Borja-Aburto+VH%5BAuthor%5D"}],"papers":[{"title":"Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data","journal":"Lancet Respir Med","year":2014,"url":"https://doi.org/10.1016/s2213-2600(14)70041-4","doi":"10.1016/s2213-2600(14)70041-4","note":"Europe PMC author record matched by affiliation"},{"title":"Infection and death from influenza A H1N1 virus in Mexico: a retrospective analysis","journal":"Lancet","year":2009,"url":"https://doi.org/10.1016/s0140-6736(09)61638-x","doi":"10.1016/s0140-6736(09)61638-x","note":"Europe PMC author record matched by affiliation"},{"title":"Vulnerability to heat-related mortality in Latin America: a case-crossover study in Sao Paulo, Brazil, Santiago, Chile and Mexico City, Mexico","journal":"Int J Epidemiol","year":2008,"url":"https://doi.org/10.1093/ije/dyn094","doi":"10.1093/ije/dyn094","note":"Europe PMC author record matched by affiliation"}]},{"id":"victor-piana-de-andrade","kind":"person","name":"Victor Piana de Andrade","aka":[],"tldr":"Chief executive of A.C.Camargo Cancer Center in Sao Paulo, one of Latin America's leading cancer hospitals, which he has directed since 2021.","summary":"Victor Piana de Andrade is CEO of A.C.Camargo Cancer Center, the Sao Paulo cancer hospital run by the Fundacao Antonio Prudente that combines care, teaching and research. The trade publication Medicina S/A reported his appointment as diretor-geral of the institution in June 2021, and a Medicina S/A article of May 2026 on a leadership programme run with Toronto's Princess Margaret Cancer Centre again quotes him as CEO of A.C.Camargo, stressing that cancer centres work in networks to learn faster from one another. The same article names Jose Humberto Fregnani as the centre's Director of Teaching, Research and Innovation. The hospital's own governance page could not be fetched (access blocked), so this record relies on dated press coverage.","asOf":"2026-09-10","links":[{"label":"Source: Medicina S/A article quoting him as CEO of A.C.Camargo (May 2026)","url":"https://medicinasa.com.br/programa-princess-margaret/"},{"label":"Source: Medicina S/A appointment news (June 2021)","url":"https://medicinasa.com.br/victor-piana-de-andrade/"}],"tags":["leadership","hospital-management","comprehensive-cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ac-camargo"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["cancer-cytopathology","nature-medicine"],"dependsOn":[],"notes":[],"role":"CEO (Diretor-Geral) of A.C.Camargo Cancer Center","institutionId":"ac-camargo","specialisms":["Cancer centre management","Oncology services","Value-based care"],"profiles":[{"label":"Medicina S/A: appointment as diretor-geral (June 2021)","url":"https://medicinasa.com.br/victor-piana-de-andrade/"}],"papers":[{"title":"Infections with multiple high‐risk HPV types are associated with high‐grade and persistent low‐grade intraepithelial lesions of the cervix","journal":"Cancer Cytopathology","year":2016,"doi":"10.1002/cncy.21789"},{"title":"Priorities for cancer research in low- and middle-income countries: a global perspective","journal":"Nature Medicine","year":2022,"doi":"10.1038/s41591-022-01738-x"},{"title":"NLRP3 inflammasome-mediated cytokine production and pyroptosis cell death in breast cancer","journal":"Journal of Biomedical Science","year":2021,"doi":"10.1186/s12929-021-00724-8"}]},{"id":"vigdis-hallgrimsdottir","kind":"person","name":"Vigdís Hallgrímsdóttir","aka":[],"tldr":"Vigdís Hallgrímsdóttir represents Landspítali, the National University Hospital of Iceland in the Organisation of European Cancer Institutes, which lists the centre among its members in Iceland.","summary":"Vigdís Hallgrímsdóttir is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Landspítali, the National University Hospital of Iceland, its member in Iceland. Landspítali is Iceland's national university hospital and the country's cancer centre, and a full member of the Organisation of European Cancer Institutes. OnCo records the name from the OECI membership list so that the centre's page has a named contact point; the person's exact title, appointment date and biography are not yet recorded and should be checked on the institution's own pages before being relied on.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Landspítali, the National University Hospital of Iceland website","url":"https://www.landspitali.is/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["landspitali"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Landspítali, the National University Hospital of Iceland to the Organisation of European Cancer Institutes","institutionId":"landspitali","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Landspítali, the National University Hospital of Iceland website","url":"https://www.landspitali.is/"}],"papers":[]},{"id":"patil-vijay","kind":"person","name":"Vijay Patil","aka":[],"tldr":"Showed that very low-dose nivolumab added to cheap chemotherapy improves survival in head and neck cancer, a landmark for affordable immunotherapy.","summary":"Vijay Patil is Professor of Medical Oncology at Tata Memorial Hospital, part of the Tata Memorial Centre in Mumbai, specialising in head and neck oncology. He led the randomised trial of low-dose nivolumab added to triple metronomic chemotherapy in advanced head and neck cancer, which showed that very low-dose immunotherapy combined with cheap chemotherapy improves outcomes at a fraction of the cost of standard dosing, a landmark for affordable immunotherapy. His publications include the randomised study of low-dose immunotherapy in head and neck cancer. His interests are low-dose immunotherapy, metronomic chemotherapy and pragmatic trials.","asOf":"2026-09-08","links":[{"label":"Tata Memorial Centre","url":"https://tmc.gov.in"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Patil%20VM%5BAuthor%5D%20low-dose%20nivolumab%20head%20and%20neck"}],"tags":[],"related":[],"cancers":["head-and-neck"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["nivolumab"],"companies":[],"institutions":["tata-memorial"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology, Tata Memorial Hospital; head and neck oncology","institutionId":"tata-memorial","specialisms":["Head and neck cancer","Low-dose immunotherapy","Metronomic chemotherapy","Pragmatic trials"],"profiles":[{"label":"Tata Memorial Centre","url":"https://tmc.gov.in"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Patil%20VM%5BAuthor%5D%20low-dose%20nivolumab%20head%20and%20neck"}],"papers":[{"title":"Low-dose immunotherapy in head and neck cancer: a randomized study","journal":"Journal of Clinical Oncology","year":2023,"doi":"10.1200/JCO.22.01015"}]},{"id":"viktor-adalsteinsson","kind":"person","name":"Viktor A. Adalsteinsson","aka":[],"tldr":"Engineer who showed low-pass sequencing of blood can replace tumour biopsies and built ultra-sensitive MRD tests.","summary":"Viktor Adalsteinsson led the work showing that ultra-low-pass whole-genome sequencing of cell-free DNA can screen for tumour fraction and that whole-exome sequencing of plasma faithfully reproduces the tumour's mutations, enabling biopsy-free genomic profiling. His group developed MAESTRO and other methods to detect residual disease at parts-per-million sensitivity, and he directs cancer diagnostics at the Broad Institute.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Adalsteinsson%20VA%5BAuthor%5D%20cell-free%20DNA"}],"tags":["ctdna","mrd","diagnostics"],"related":[],"cancers":[],"sections":[],"technologies":["liquid-biopsy","mrd-testing"],"targets":[],"drugs":[],"companies":[],"institutions":["broad-institute"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nature-communications"],"dependsOn":[],"notes":[],"role":"Director, Gerstner Center for Cancer Diagnostics, Broad Institute of MIT and Harvard","institutionId":"broad-institute","specialisms":["Liquid biopsy technology","Minimal residual disease detection","Cancer genomics","Diagnostics engineering"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Adalsteinsson%20VA%5BAuthor%5D%20cell-free%20DNA"}],"papers":[{"title":"Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors","journal":"Nature Communications","year":2017,"doi":"10.1038/s41467-017-00965-y"},{"title":"MRD detection in a variety of cancers at unprecedented sensitivity with MAESTRO (minor allele enriched sequencing through recognition oligonucleotides)","journal":"Nature Communications","year":2022}],"orcid":"0000-0003-4555-2485"},{"id":"vincent-tuohy","kind":"person","name":"Vincent K. Tuohy","aka":[],"tldr":"Vincent Tuohy invented a preventive vaccine against triple-negative breast cancer, now in early human trials.","summary":"Vincent K. Tuohy holds the Mort and Iris November Distinguished Chair in Innovative Breast Cancer Research at the Lerner Research Institute, Cleveland Clinic Taussig Cancer Institute. He is an immunologist who invented a preventive vaccine against triple-negative breast cancer targeting alpha-lactalbumin, a protein expressed in the tumour but not in healthy non-lactating tissue. His selected paper describes targeted vaccination against human alpha-lactalbumin for immunotherapy and primary immunoprevention of triple-negative breast cancer. The vaccine entered phase 1 trials in 2021 with a prevention cohort in BRCA carriers.","asOf":"2026-09-08","links":[{"label":"Cleveland Clinic profile","url":"https://www.lerner.ccf.org/inflammation-immunity/tuohy/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tuohy%20VK%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["tnbc"],"sections":[],"technologies":["shared-antigen-vaccine","chemoprevention"],"targets":[],"drugs":[],"companies":[],"institutions":["cleveland-clinic"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Mort and Iris November Distinguished Chair in Innovative Breast Cancer Research, Lerner Research Institute","institutionId":"cleveland-clinic","specialisms":["Preventive cancer vaccines","Alpha-lactalbumin","Triple-negative breast cancer"],"profiles":[{"label":"Cleveland Clinic profile","url":"https://www.lerner.ccf.org/inflammation-immunity/tuohy/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tuohy%20VK%5BAuthor%5D"}],"papers":[{"title":"Targeted vaccination against human α-lactalbumin for immunotherapy and primary immunoprevention of triple negative breast cancer","journal":"Cancers","year":2016,"url":"https://doi.org/10.3390/cancers8060056","doi":"10.3390/cancers8060056"}]},{"id":"vincenza-trivigno","kind":"person","name":"Vincenza Trivigno","aka":[],"tldr":"Executive Director of Swissmedic, the Swiss agency that authorises and supervises medicines and medical devices, including new cancer therapies.","summary":"Vincenza Trivigno, lic. rer. pol., is Executive Director of Swissmedic, the Swiss Agency for Therapeutic Products responsible for authorising and monitoring medicinal products and medical devices in Switzerland. She heads the Management Board, the agency's executive body responsible for operations, whose members include Deputy Executive Director Philippe Girard (medicinal product licences and surveillance) and Eveline Trachsel (medicinal product authorisation and vigilance).","asOf":"2026-09-10","links":[{"label":"Source: Swissmedic Management Board page","url":"https://www.swissmedic.ch/swissmedic/en/home/about-us/organisation/management-board.html"}],"tags":["leadership","regulator","drug-regulation"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["swissmedic"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Executive Director of Swissmedic","institutionId":"swissmedic","specialisms":["Medicines regulation","Public administration","Agency leadership"],"profiles":[{"label":"Swissmedic Management Board","url":"https://www.swissmedic.ch/swissmedic/en/home/about-us/organisation/management-board.html"}],"papers":[]},{"id":"vincenzo-valentini","kind":"person","name":"Vincenzo Valentini","aka":[],"tldr":"Vincenzo Valentini is a radiation oncologist known for rectal cancer chemoradiation and outcome modelling.","summary":"Vincenzo Valentini is Professor of Radiation Oncology at the Università Cattolica and Policlinico Universitario A. Gemelli in Rome. His specialisms are radiation oncology, rectal cancer and predictive modelling, using modern image-guided external beam techniques. He led radiation oncology at Gemelli and contributed nomograms and trials in rectal cancer chemoradiotherapy. His papers include the second European Rectal Cancer Consensus Conference (EURECA-CC2) on multidisciplinary rectal cancer management, a pooled analysis of randomised trials on the timing needed to achieve the highest rate of pathological complete response after preoperative radiochemotherapy, and a review of online adaptive MR-guided radiotherapy for pancreatic cancer. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Valentini%20V%5BAuthor%5D%20rectal"}],"tags":[],"related":[],"cancers":["colorectal"],"sections":[],"technologies":["imrt-igrt"],"targets":[],"drugs":[],"companies":[],"institutions":["gemelli"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["radiation-oncology"],"dependsOn":[],"notes":[],"role":"Professor of Radiation Oncology, Università Cattolica; Gemelli","institutionId":"gemelli","specialisms":["Radiation oncology","Rectal cancer","Predictive modelling"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Valentini%20V%5BAuthor%5D%20rectal"}],"papers":[{"title":"Multidisciplinary Rectal Cancer Management: 2nd European Rectal Cancer Consensus Conference (EURECA-CC2)","journal":"Radiotherapy and Oncology","year":2009,"doi":"10.1016/j.radonc.2009.06.027"},{"title":"Timing to achieve the highest rate of pCR after preoperative radiochemotherapy in rectal cancer: a pooled analysis of 3085 patients from 7 randomized trials","journal":"Radiotherapy and Oncology","year":2021,"doi":"10.1016/j.radonc.2020.09.026"},{"title":"Online adaptive magnetic resonance guided radiotherapy for pancreatic cancer: state of the art, pearls and pitfalls","journal":"Radiation Oncology","year":2019,"doi":"10.1186/s13014-019-1275-3"}],"orcid":"0000-0003-4637-6487"},{"id":"vinod-balachandran","kind":"person","name":"Vinod P. Balachandran","aka":[],"tldr":"Surgeon-scientist whose personalised mRNA vaccine trial showed pancreatic cancer can provoke lasting T-cell immunity.","summary":"Vinod Balachandran led the phase 1 trial of the individualised mRNA neoantigen vaccine autogene cevumeran after pancreatic cancer surgery, showing that half of patients mounted durable neoantigen-specific T cells and that responders had markedly longer recurrence-free survival. His earlier Nature paper showed long-term pancreatic cancer survivors have high-quality neoantigens. He leads the phase 2 IMCODE003 trial.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Vinod_P._Balachandran","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Balachandran%20VP%5BAuthor%5D%20pancreatic%20vaccine"}],"tags":["pancreatic","vaccine","immunotherapy"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":["neoantigen-mrna-vaccine"],"targets":[],"drugs":["autogene-cevumeran"],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-rojas-mrna-neoantigen-vaccine-pancreatic-nature-2023"],"journals":[],"dependsOn":[],"notes":[],"role":"Surgical Oncologist and Member, Immuno-Oncology Service, Memorial Sloan Kettering Cancer Center","institutionId":"mskcc","specialisms":["Pancreatic cancer","Neoantigen vaccines","Tumour immunology","Hepatopancreatobiliary surgery"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Balachandran%20VP%5BAuthor%5D%20pancreatic%20vaccine"}],"papers":[{"title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","journal":"Nature","year":2023,"doi":"10.1038/s41586-023-06063-w"},{"title":"Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer","journal":"Nature","year":2017,"doi":"10.1038/nature24462"},{"title":"Rojas 2023: a personalised mRNA vaccine trained T cells against each patient's pancreatic cancer, and those who responded stayed cancer-free longer","journal":"Nature","year":2023,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Personalized%20RNA%20neoantigen%20vaccines%20stimulate%20T%20cells%20in%20pancreatic%20cancer%20Rojas%20Nature%202023"}],"orcid":"0000-0002-2956-223X"},{"id":"raina-vinod","kind":"person","name":"Vinod Raina","aka":[],"tldr":"A medical oncologist who led the cancer hospital at AIIMS Delhi for many years, trained a large share of India's medical oncologists and helped write the country's early cancer treatment standards.","summary":"Vinod Raina headed the Department of Medical Oncology at the Dr B.R. Ambedkar Institute Rotary Cancer Hospital, AIIMS New Delhi, before joining Fortis Memorial Research Institute in Gurugram as head of medical oncology and haematology. His publications cover breast cancer, lymphoma, supportive care and the epidemiology and treatment patterns of cancer in north India, and he has been a leading voice in Indian oncology societies and guideline efforts.","asOf":"2026-09-10","links":[{"label":"Fortis Healthcare","url":"https://www.fortishealthcare.com"},{"label":"AIIMS New Delhi","url":"https://www.aiims.edu"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Raina%20V%5BAuthor%5D%20AIIMS%20medical%20oncology"}],"tags":[],"related":[],"cancers":["breast-hr-positive","dlbcl","hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["aiims-delhi"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["indian-journal-of-cancer"],"dependsOn":[],"notes":[],"role":"Executive Director, Medical Oncology and Haematology, Fortis Memorial Research Institute, Gurugram; former Head of Medical Oncology, AIIMS New Delhi","specialisms":["Medical oncology","Breast cancer","Lymphoma and haematological malignancies","Oncology training"],"profiles":[{"label":"Fortis Healthcare","url":"https://www.fortishealthcare.com"},{"label":"AIIMS New Delhi","url":"https://www.aiims.edu"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Raina%20V%5BAuthor%5D%20AIIMS%20medical%20oncology"}],"papers":[{"title":"Clinical features and prognostic factors of early breast cancer at a major cancer center in North India","journal":"Indian Journal of Cancer","year":2005,"doi":"10.4103/0019-509x.15099"},{"title":"Complete Response From Thalidomide in Angiosarcoma After Treatment of Breast Cancer","journal":"Journal of Clinical Oncology","year":2007,"doi":"10.1200/jco.2006.09.7261"},{"title":"Non-Hodgkins lymphoma with lactic acidosis at presentation: A case report of a rare oncologic emergency","journal":"Indian Journal of Medical and Paediatric Oncology","year":2014,"doi":"10.4103/0971-5851.133728"}]},{"id":"virginia-pappas","kind":"person","name":"Virginia Pappas","aka":[],"tldr":"Long-serving CEO of the Society of Nuclear Medicine and Molecular Imaging.","summary":"Virginia Pappas is Chief Executive Officer of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the principal US professional society for nuclear medicine physicians, scientists and technologists. She leads the society's staff and operations, supporting its scientific meetings, journals and advocacy for molecular imaging and radiopharmaceutical therapy in oncology.","asOf":"2026-09-10","links":[{"label":"Society page","url":"https://www.snmmi.org/"}],"tags":["leadership","nuclear medicine"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["snmmi"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive Officer","institutionId":"snmmi","specialisms":["Association management","Nuclear medicine advocacy"],"profiles":[{"label":"Society page","url":"https://www.snmmi.org/"}],"papers":[]},{"id":"virginia-sun","kind":"person","name":"Virginia Sun","aka":[],"tldr":"Virginia Sun is a nurse scientist who leads SWOG's supportive care and survivorship research.","summary":"Virginia Sun is Professor of Population Sciences and Surgery at City of Hope and SWOG Executive Officer for Palliative Care and Survivorship. A nurse scientist specialising in survivorship, palliative care and symptom science, she studies symptom management, caregiver support and survivorship after cancer surgery. Her papers include a Cancer report on the effectiveness of an interdisciplinary palliative care intervention for family caregivers in lung cancer and an Oncology Nursing Forum study of symptom concerns and quality of life in hepatobiliary cancers. She leads supportive care and survivorship research within the SWOG Cancer Research Network, with links to exercise and lifestyle oncology and geriatric assessment.","asOf":"2026-09-08","links":[{"label":"City of Hope research faculty","url":"https://www.cityofhope.org/research/find-a-researcher"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sun%20V%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Virginia%20Sun"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["exercise-oncology","geriatric-assessment"],"targets":[],"drugs":[],"companies":["swog"],"institutions":["city-of-hope"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["cancer-wiley","oncology-nursing-forum"],"dependsOn":[],"notes":[],"role":"Professor, Population Sciences and Surgery, City of Hope; SWOG Executive Officer, Palliative Care and Survivorship","institutionId":"city-of-hope","specialisms":["Survivorship","Palliative care","Symptom science"],"profiles":[{"label":"City of Hope research faculty","url":"https://www.cityofhope.org/research/find-a-researcher"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sun%20V%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Virginia%20Sun"}],"papers":[{"title":"Effectiveness of an interdisciplinary palliative care intervention for family caregivers in lung cancer","journal":"Cancer","year":2015,"url":"https://doi.org/10.1002/cncr.29567","doi":"10.1002/cncr.29567"},{"title":"Symptom concerns and quality of life in hepatobiliary cancers","journal":"Oncology Nursing Forum","year":2008,"url":"https://doi.org/10.1188/08.ONF.E45-E52","doi":"10.1188/08.ONF.E45-E52"}],"orcid":"0000-0003-3129-4235"},{"id":"vivek-lal","kind":"person","name":"Vivek Lal","aka":[],"tldr":"Neurologist who directs PGIMER Chandigarh, one of India's leading public tertiary-care and research institutes with a large oncology service.","summary":"Prof. Vivek Lal is Director of the Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, according to public records. He is a neurologist with a research interest in neuro-ophthalmology and headache disorders. PGIMER is a national institute of importance whose departments of radiotherapy, medical oncology and haematology serve northern India.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lal+V%5BAuthor%5D+PGIMER"}],"tags":["leadership","neurology"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["pgimer-chandigarh"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director","institutionId":"pgimer-chandigarh","specialisms":["Neurology","Neuro-ophthalmology","Academic medicine leadership"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lal+V%5BAuthor%5D+PGIMER"}],"papers":[{"title":"Nuclear third nerve palsy as a presenting manifestation of breast carcinoma","journal":"Neurology India","year":2017,"doi":"10.4103/neuroindia.ni_1349_15"},{"title":"Anti- RI antibody associated progressive supranuclear palsy like presentation in a patient with breast carcinoma","journal":"Journal of Neuroimmunology","year":2020,"doi":"10.1016/j.jneuroim.2020.577345"},{"title":"Clinical Characteristics of Primary Vitreoretinal Lymphoma in an Indian Population","journal":"Ocular Immunology and Inflammation","year":2016,"doi":"10.3109/09273948.2016.1139731"}]},{"id":"vivek-subbiah","kind":"person","name":"Vivek Subbiah","aka":[],"tldr":"Early-phase trialist who led the study showing dabrafenib and trametinib work in BRAF-mutant anaplastic thyroid cancer, the first approved treatment for that disease, and many of the RET inhibitor trials.","summary":"Vivek Subbiah ran early-phase trials at MD Anderson Cancer Center before becoming chief of early-phase drug development at Sarah Cannon Research Institute in 2023. He was first author of the 2018 Journal of Clinical Oncology report of the ROAR basket trial cohort in which dabrafenib plus trametinib produced responses in most patients with BRAF V600E-mutant anaplastic thyroid cancer, the basis of the first approval for the disease, and a lead investigator of the LIBRETTO and ARROW trials of selective RET inhibitors.","asOf":"2026-09-18","links":[],"tags":["thyroid","targeted-therapy","early-phase","trialist"],"related":[],"cancers":["anaplastic-thyroid-cancer","thyroid","medullary-thyroid-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-subbiah-dabrafenib-trametinib-atc-jco-2018"],"journals":[],"dependsOn":[],"notes":[],"role":"Medical oncologist and Chief of Early-Phase Drug Development, Sarah Cannon Research Institute","specialisms":["Early-phase trials","Tumour-agnostic targeted therapy","RET and BRAF inhibitors"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Subbiah%5BAuthor%5D"}],"papers":[{"title":"Dabrafenib and trametinib in BRAF V600E-mutant anaplastic thyroid cancer (ROAR)","journal":"Journal of Clinical Oncology","year":2018,"url":"https://doi.org/10.1200/JCO.2017.73.6785","doi":"10.1200/JCO.2017.73.6785"}]},{"id":"volker-heinemann","kind":"person","name":"Volker Heinemann","aka":[],"tldr":"Gastrointestinal oncologist who led FIRE-3, a key trial of cetuximab versus bevacizumab in colorectal cancer.","summary":"Volker Heinemann is Director of the Comprehensive Cancer Center Munich at LMU Klinikum München and Professor of Medical Oncology. His specialisms are colorectal cancer, pancreatic ductal adenocarcinoma and anti-EGFR therapy. He led FIRE-3, the Lancet Oncology trial of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for metastatic colorectal cancer, a key comparison that shaped the use of anti-EGFR therapy according to tumour sidedness. His record links him to the CRYSTAL and FIRE-3 trials, and his publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Heinemann%20V%5BAuthor%5D%20FIRE-3"}],"tags":[],"related":[],"cancers":["colorectal","pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":["cetuximab","bevacizumab"],"companies":[],"institutions":["lmu-munich"],"pathways":[],"terms":[],"trials":["crystal-fire3"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Comprehensive Cancer Center Munich (LMU); Professor of Medical Oncology","institutionId":"lmu-munich","specialisms":["Colorectal cancer","Pancreatic cancer","Anti-EGFR therapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Heinemann%20V%5BAuthor%5D%20FIRE-3"}],"papers":[{"title":"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3)","journal":"Lancet Oncology","year":2014,"doi":"10.1016/S1470-2045(14)70330-4"}]},{"id":"walter-winchell","kind":"person","name":"Walter Winchell","aka":[],"tldr":"When his friend Damon Runyon died of throat cancer in 1946 he asked his radio audience for a penny, a nickel, a dime or a dollar; the fund he started has invested over $490 million and backed more than 4,000 scientists.","summary":"Walter Winchell (1897-1972), the most widely heard gossip columnist and broadcaster in America, lost his friend the sportswriter Damon Runyon to throat cancer in 1946. The Foundation's history records his appeal: 'Won't you send me a penny, a nickel, a dime, or a dollar? All of your money will go directly to the cancer fighters, in Damon Runyon's name.' He established the Damon Runyon Cancer Memorial Fund and led its fundraising with Marlene Dietrich, Bob Hope, Milton Berle, Marilyn Monroe and Joe DiMaggio until his own death from cancer in 1972. The Damon Runyon Cancer Research Foundation states that since its founding it has invested over $490 million and funded over 4,000 scientists, chosen early in their careers for high-risk, high-reward work; its alumni include many of the field's leaders and Nobel laureates.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Walter_Winchell","links":[{"label":"Damon Runyon Cancer Research Foundation: our history","url":"https://www.damonrunyon.org/our-strategy/our-history"}],"tags":["public-figure","donor"],"related":[],"cancers":["head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["damon-runyon"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-funding-allocation","b-workforce"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Broadcaster whose 1946 radio appeal founded the Damon Runyon Cancer Research Foundation","specialisms":["Cancer research fundraising","Early-career scientist funding"],"profiles":[],"papers":[]},{"id":"wang-ying","kind":"person","name":"Wang Ying","aka":[],"tldr":"Radiation oncologist who is President of Chongqing University Cancer Hospital, the tertiary cancer hospital and regional cancer centre for Chongqing.","summary":"Wang Ying (王颖) is President (院长) and Deputy Party Secretary of Chongqing University Cancer Hospital, also known as Chongqing Cancer Hospital, Chongqing Cancer Institute and Chongqing Cancer Center, a national regional cancer medical centre. The hospital's leadership page describes her as a doctor of medicine, doctoral supervisor, chief physician and second-level professor in oncology and radiation oncology, born in November 1970, who holds a State Council special government allowance and is a Chongqing academic and technical leader. Her academic posts include vice chair of the Chinese Medical Association's radiation oncology branch, chair of the Chongqing Medical Association oncology branch and vice president of the Chongqing Anti-Cancer Association. She is responsible for the hospital's overall administration, including medical care, research, teaching and construction, and works alongside Party Secretary Wu Yongzhong.","asOf":"2026-09-10","links":[{"label":"Source: Chongqing University Cancer Hospital leadership page","url":"https://www.cqch.cn/intos_yylds/"}],"tags":["leadership","clinician-scientist","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["chongqing-university-cancer-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["oncology-reports"],"dependsOn":[],"notes":[],"role":"President (院长) and Deputy Party Secretary, Chongqing University Cancer Hospital","institutionId":"chongqing-university-cancer-hospital","specialisms":["Radiation oncology","Oncology","Hospital management"],"profiles":[{"label":"Hospital leadership page (Chinese)","url":"https://www.cqch.cn/intos_yylds/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wang+Y%5BAuthor%5D+AND+Chongqing+University+Cancer+Hospital"}],"papers":[{"title":"2-Methoxyestradiol inhibits the proliferation and migration and reduces the radioresistance of nasopharyngeal carcinoma CNE-2 stem cells via NF-κB/HIF-1 signaling pathway inactivation and EMT reversal","journal":"Oncology Reports","year":2016,"doi":"10.3892/or.2016.5319"}]},{"id":"waseem-qasim","kind":"person","name":"Waseem Qasim","aka":[],"tldr":"Delivered the first gene-edited off-the-shelf CAR-T cells to infants with leukaemia and the first base-edited CAR-T therapy.","summary":"Waseem Qasim led the compassionate use and then trials of UCART19, TALEN-edited universal donor CAR T cells, in infants and children with refractory ALL, the first clinical use of gene-edited allogeneic CAR-T. In 2023 his team reported the first patient treated with base-edited CAR7 T cells for T-cell ALL, a disease where autologous CAR-T is impractical. He leads cell and gene therapy at Great Ormond Street.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Qasim%20W%5BAuthor%5D%20CAR%20T%20gene-edited"}],"tags":["cell-therapy","gene-editing","paediatric"],"related":[],"cancers":["all-leukemia"],"sections":[],"technologies":["allogeneic-cell-therapy","car-t","crispr-screens"],"targets":["cd19"],"drugs":[],"companies":[],"institutions":["great-ormond-street"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-ucart19-allogeneic-car-t-lancet-2020"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Cell and Gene Therapy, UCL Great Ormond Street Institute of Child Health","institutionId":"great-ormond-street","specialisms":["Gene-edited cell therapy","Allogeneic CAR T cells","Base editing","Paediatric leukaemia"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Qasim%20W%5BAuthor%5D%20CAR%20T%20gene-edited"}],"papers":[{"title":"Genome-edited allogeneic donor 'universal' anti-CD19 CAR T cells in paediatric and adult B-cell acute lymphoblastic leukaemia (UCART19)","journal":"Lancet","year":2020,"doi":"10.1016/S0140-6736(20)32334-5"},{"title":"Base-edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia","journal":"NEJM","year":2023,"doi":"10.1056/NEJMoa2300709"},{"title":"UCART19: the first gene-edited, donor-derived CAR-T cells in children and adults with relapsed B-cell ALL","journal":"The Lancet","year":2020,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=UCART19%20genome-edited%20donor-derived%20allogeneic%20anti-CD19%20CAR%20T%20Benjamin%20Lancet%202020"}],"orcid":"0000-0001-8353-4494"},{"id":"wasiu-lanre-adeyemo","kind":"person","name":"Wasiu Lanre Adeyemo","aka":[],"tldr":"Oral and maxillofacial surgeon who serves as Chief Medical Director of Lagos University Teaching Hospital, Nigeria's largest tertiary hospital.","summary":"Wasiu Lanre Adeyemo is Chief Medical Director of Lagos University Teaching Hospital (LUTH) and a professor of oral and maxillofacial surgery at the University of Lagos. LUTH hosts one of Nigeria's principal cancer treatment centres, including radiotherapy services, and Adeyemo has led the hospital since 2023. His research covers craniofacial surgery, orofacial clefts and oral disease in West Africa.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Adeyemo+WL%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","head and neck cancer","global oncology"],"related":[],"cancers":["head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["luth-lagos"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Medical Director","institutionId":"luth-lagos","specialisms":["Oral and maxillofacial surgery","Hospital leadership","Head and neck surgery"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Adeyemo+WL%5BAuthor%5D"}],"papers":[{"title":"A prospective epidemiological study on odontogenic tumours in a black African population, with emphasis on the relative frequency of ameloblastoma","journal":"International Journal of Oral and Maxillofacial Surgery","year":2015,"doi":"10.1016/j.ijom.2015.03.018"},{"title":"Current evidence on the burden of head and neck cancers in Nigeria","journal":"Head & Neck Oncology","year":2009,"doi":"10.1186/1758-3284-1-14"}],"orcid":"0000-0002-0257-7853"},{"id":"wayne-roberts","kind":"person","name":"Wayne Roberts","aka":[],"tldr":"Public administrator who leads the Cancer Prevention and Research Institute of Texas, the state agency that funds cancer research and prevention across Texas.","summary":"Wayne Roberts is Chief Executive Officer of the Cancer Prevention and Research Institute of Texas (CPRIT), the Texas state agency created by voters to fund cancer research, product development and prevention programmes. Wikipedia lists him as the agency's chief executive and notes that in July 2018 the Texas State Agency Business Administrators' Association named him its Administrator of the Year. The CPRIT website could not be fetched directly, so this record relies on the agency's Wikipedia article.","asOf":"2026-09-10","links":[{"label":"Source: Wikipedia article on CPRIT (infobox names the CEO)","url":"https://en.wikipedia.org/wiki/Cancer_Prevention_and_Research_Institute_of_Texas"}],"tags":["leadership","government","philanthropy"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cprit"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive Officer, Cancer Prevention and Research Institute of Texas (CPRIT)","institutionId":"cprit","specialisms":["Public administration","Research funding","Cancer prevention policy"],"profiles":[{"label":"Wikipedia: Cancer Prevention and Research Institute of Texas","url":"https://en.wikipedia.org/wiki/Cancer_Prevention_and_Research_Institute_of_Texas"}],"papers":[]},{"id":"su-weiguo","kind":"person","name":"Weiguo Su","aka":["苏慰国"],"tldr":"Weiguo Su led the Shanghai chemistry that produced fruquintinib, savolitinib and surufatinib, three Chinese-discovered cancer pills approved at home and, for fruquintinib, in the US.","summary":"A former Pfizer chemist who joined Hutchmed in 2005 as head of research and became CEO in 2022; his team designed fruquintinib (FDA approval 2023 via Takeda), the selective MET inhibitor savolitinib (partnered with AstraZeneca) and surufatinib, the first Chinese-discovered small molecules to reach global markets.","asOf":"2026-09-10","links":[{"label":"Hutchmed","url":"https://www.hutch-med.com/"}],"tags":["china"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["fruquintinib","savolitinib"],"companies":["hutchmed"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"CEO and Chief Scientific Officer, Hutchmed","specialisms":["Kinase inhibitor discovery","Medicinal chemistry"],"profiles":[{"label":"Hutchmed","url":"https://www.hutch-med.com/"}],"papers":[{"title":"Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer","journal":"JAMA","year":2018,"doi":"10.1001/jama.2018.7855"},{"title":"Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study","journal":"The Lancet Respiratory Medicine","year":2021,"doi":"10.1016/s2213-2600(21)00084-9"},{"title":"Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study","journal":"The Lancet Oncology","year":2020,"doi":"10.1016/s1470-2045(20)30496-4"}]},{"id":"li-weimin","kind":"person","name":"Weimin Li","aka":[],"tldr":"Leads one of the world's largest hospitals and its lung cancer screening and AI programmes.","summary":"Weimin Li is President of West China Hospital, Sichuan University, and Professor of Respiratory Medicine. He leads one of the world's largest hospitals and its lung cancer screening and artificial intelligence programmes. As a respiratory physician he has led lung cancer early-detection research, including large low-dose CT screening cohorts and AI-based assessment of lung nodules. His interests are lung cancer early detection, respiratory medicine, AI in imaging and hospital leadership.","asOf":"2026-09-08","links":[{"label":"West China Hospital","url":"https://www.wchscu.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Li%20W%5BAuthor%5D%20West%20China%20Hospital%20lung%20cancer%20screening"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["low-dose-ct-screening","radiology-ai-screening"],"targets":[],"drugs":[],"companies":[],"institutions":["west-china"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President, West China Hospital; Professor of Respiratory Medicine","institutionId":"west-china","specialisms":["Lung cancer early detection","Respiratory medicine","AI in imaging","Hospital leadership"],"profiles":[{"label":"West China Hospital","url":"https://www.wchscu.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Li%20W%5BAuthor%5D%20West%20China%20Hospital%20lung%20cancer%20screening"}],"papers":[{"title":"High-throughput sequencing reveals distinct genetic features and clinical implications of NSCLC with de novo and acquired EGFR T790M mutation","journal":"Lung Cancer","year":2018,"doi":"10.1016/j.lungcan.2018.08.014"},{"title":"NGS and FISH for MET amplification detection in EGFR TKI resistant non-small cell lung cancer (NSCLC) patients: A prospective, multicenter study in China","journal":"Lung Cancer","year":2024,"doi":"10.1016/j.lungcan.2024.107897"},{"title":"Non-Invasive Measurement Using Deep Learning Algorithm Based on Multi-Source Features Fusion to Predict PD-L1 Expression and Survival in NSCLC","journal":"Frontiers in Immunology","year":2022,"doi":"10.3389/fimmu.2022.828560"}]},{"id":"weiping-zou","kind":"person","name":"Weiping Zou","aka":[],"tldr":"Immunologist who showed PD-L1 on tumours suppresses T cells and linked interferon to ferroptosis.","summary":"Weiping Zou is the Charles B. de Nancrede Professor of Surgery, Immunology, Biology and Pathology and Director of the Center of Excellence for Cancer Immunology and Immunotherapy at the University of Michigan Rogel Cancer Center. He is an immunologist known for showing that PD-L1 on tumours suppresses T cells, defining immunosuppressive mechanisms in the tumour microenvironment including B7-H1/PD-L1 and myeloid suppression. His selected paper shows that CD8-positive T cells regulate tumour ferroptosis during cancer immunotherapy. He continues to study PD-L1 biology and the link between interferon, ferroptosis and immunity.","asOf":"2026-09-08","links":[{"label":"Michigan profile","url":"https://www.rogelcancercenter.org/weiping-zou-md-phd"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Zou%20W%5BAuthor%5D"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["pdl1"],"drugs":[],"companies":[],"institutions":["michigan-rogel"],"pathways":["pd1-checkpoint"],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Charles B. de Nancrede Professor of Surgery, Immunology, Biology and Pathology; Director, Center of Excellence for Cancer Immunology and Immunotherapy","institutionId":"michigan-rogel","specialisms":["Tumour immunology","PD-L1 biology","Ferroptosis and immunity"],"profiles":[{"label":"Michigan profile","url":"https://www.rogelcancercenter.org/weiping-zou-md-phd"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Zou%20W%5BAuthor%5D"}],"papers":[{"title":"CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy","journal":"Nature","year":2019,"url":"https://doi.org/10.1038/s41586-019-1170-y","doi":"10.1038/s41586-019-1170-y"}],"orcid":"0000-0001-7952-3549"},{"id":"wen-zhao-zhong","kind":"person","name":"Wen-Zhao Zhong","aka":[],"tldr":"Thoracic surgeon-scientist and hospital Vice President who led the ADJUVANT/CTONG1104 trial establishing adjuvant EGFR-TKI therapy in resected lung cancer.","summary":"Wen-Zhao Zhong is Vice President of Guangdong Provincial People's Hospital and a thoracic surgical oncologist at the Guangdong Lung Cancer Institute. He was first author of the ADJUVANT/CTONG1104 phase 3 trial, which compared adjuvant gefitinib with chemotherapy in resected EGFR-mutant non-small-cell lung cancer, and has published extensively on perioperative targeted therapy through the Chinese Thoracic Oncology Group.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.gdghospital.org.cn/thecurrentleader/list.html"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Zhong+WZ%5BAuthor%5D"}],"tags":["clinician-scientist","leadership","lung cancer","thoracic surgery"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["guangdong-provincial-peoples-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Vice President and Party Standing Committee Member","institutionId":"guangdong-provincial-peoples-hospital","specialisms":["Thoracic surgery","Lung cancer","EGFR-mutant NSCLC","Clinical trials"],"profiles":[{"label":"Institution profile","url":"https://www.gdghospital.org.cn/thecurrentleader/list.html"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Zhong+WZ%5BAuthor%5D"}],"papers":[{"title":"Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study","journal":"Lancet Oncology","year":2018,"url":"https://doi.org/10.1016/S1470-2045(17)30729-5","doi":"10.1016/S1470-2045(17)30729-5"},{"title":"Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial","journal":"Journal of Clinical Oncology","year":2021,"url":"https://doi.org/10.1200/JCO.20.01820","doi":"10.1200/JCO.20.01820"}]},{"id":"parulekar-wendy","kind":"person","name":"Wendy Parulekar","aka":[],"tldr":"Senior investigator behind CCTG's breast cancer trials, including the MA.17 and MA.32 studies of extended endocrine therapy and metformin.","summary":"Wendy Parulekar is Senior Investigator at the Canadian Cancer Trials Group and Professor of Oncology at Queen's University. She is the senior investigator behind the group's breast cancer trials, having led or co-led MA.17R, which tested extended adjuvant letrozole, and MA.32, which tested metformin, and she oversees the group's trial operations. Her publications include the MA.17R trial of extending aromatase-inhibitor adjuvant therapy to ten years. Her interests are breast cancer, clinical trial conduct and endocrine therapy.","asOf":"2026-09-08","links":[{"label":"Canadian Cancer Trials Group","url":"https://www.ctg.queensu.ca"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Parulekar%20WR%5BAuthor%5D%20Canadian%20Cancer%20Trials%20Group%20breast"}],"tags":[],"related":[],"cancers":["breast-hr-positive"],"sections":[],"technologies":["endocrine-therapy"],"targets":[],"drugs":["letrozole"],"companies":["cctg"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Senior Investigator, Canadian Cancer Trials Group; Professor of Oncology, Queen's University","institutionId":"cctg","specialisms":["Breast cancer","Clinical trial conduct","Endocrine therapy"],"profiles":[{"label":"Canadian Cancer Trials Group","url":"https://www.ctg.queensu.ca"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Parulekar%20WR%5BAuthor%5D%20Canadian%20Cancer%20Trials%20Group%20breast"}],"papers":[{"title":"Extending aromatase-inhibitor adjuvant therapy to 10 years (MA.17R)","journal":"NEJM","year":2016,"doi":"10.1056/NEJMoa1604700"}]},{"id":"fang-wenfeng","kind":"person","name":"Wenfeng Fang","aka":[],"tldr":"Wenfeng Fang is a lung cancer oncologist at the centre of China's PD-1 and bispecific antibody trials, including ivonescimab in EGFR-mutant disease.","summary":"Wenfeng Fang is Professor of Medical Oncology at Sun Yat-sen University Cancer Center in Guangzhou. He is a lung cancer oncologist at the centre of China's PD-1 and bispecific antibody trials, having led or co-led studies of camrelizumab, of the Akeso PD-1 and VEGF bispecific ivonescimab in HARMONi-A, and of other immunotherapies in non-small-cell lung cancer and nasopharyngeal carcinoma. His publications include the HARMONi-A phase 3 trial of ivonescimab plus chemotherapy in EGFR-mutant lung cancer after progression on an EGFR tyrosine kinase inhibitor. His interests are lung cancer, immunotherapy, nasopharyngeal carcinoma and bispecific antibodies.","asOf":"2026-09-08","links":[{"label":"Sun Yat-sen University Cancer Center","url":"https://www.sysucc.org.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fang%20W%5BAuthor%5D%20Sun%20Yat-sen%20ivonescimab"}],"tags":[],"related":[],"cancers":["nsclc","head-and-neck"],"sections":[],"technologies":[],"targets":["pd1","vegf"],"drugs":["ivonescimab","camrelizumab"],"companies":["akeso"],"institutions":["sysucc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology, Sun Yat-sen University Cancer Center","institutionId":"sysucc","specialisms":["Lung cancer","Immunotherapy","Nasopharyngeal carcinoma","Bispecific antibodies"],"profiles":[{"label":"Sun Yat-sen University Cancer Center","url":"https://www.sysucc.org.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fang%20W%5BAuthor%5D%20Sun%20Yat-sen%20ivonescimab"}],"papers":[{"title":"Ivonescimab plus chemotherapy in NSCLC with EGFR variant after EGFR-TKI: the HARMONi-A phase 3 randomized clinical trial","journal":"JAMA","year":2024,"doi":"10.1001/jama.2024.10613"}]},{"id":"wensheng-liu","kind":"person","name":"Wensheng Liu","aka":[],"tldr":"Wensheng Liu represents Jinshazhou Hospital of Guangzhou University of Chinese Medicine in the Organisation of European Cancer Institutes, which lists the organisation among its members in China.","summary":"Wensheng Liu is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Jinshazhou Hospital of Guangzhou University of Chinese Medicine, its associate member in China. OnCo records the name from the OECI membership list so that the organisation's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the organisation's website.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Jinshazhou Hospital of Guangzhou University of Chinese Medicine website","url":"https://www.jsz120.com/szll_gjzlylzx.html"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["jinshazhou-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Jinshazhou Hospital of Guangzhou University of Chinese Medicine to the Organisation of European Cancer Institutes","institutionId":"jinshazhou-hospital","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Jinshazhou Hospital of Guangzhou University of Chinese Medicine website","url":"https://www.jsz120.com/szll_gjzlylzx.html"}],"papers":[]},{"id":"willemien-van-driel","kind":"person","name":"Willemien J. van Driel","aka":[],"tldr":"Led OVHIPEC-1, the trial that showed heated intraperitoneal chemotherapy at surgery extends survival in ovarian cancer.","summary":"Willemien van Driel was principal investigator of OVHIPEC-1, the Dutch randomised trial showing that adding hyperthermic intraperitoneal cisplatin to interval cytoreductive surgery improves recurrence-free and overall survival in stage III ovarian cancer, the first level-one evidence for HIPEC in the disease. She leads OVHIPEC-2 in the primary surgery setting.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=van%20Driel%20WJ%5BAuthor%5D%20HIPEC%20ovarian"}],"tags":["ovarian","surgery","hipec"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":["hipec"],"targets":[],"drugs":[],"companies":[],"institutions":["nki"],"pathways":[],"terms":[],"trials":["ovhipec-1"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Gynaecologic Oncologist, Netherlands Cancer Institute","institutionId":"nki","specialisms":["Ovarian cancer surgery","HIPEC","Interval cytoreduction"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=van%20Driel%20WJ%5BAuthor%5D%20HIPEC%20ovarian"}],"papers":[{"title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer (OVHIPEC-1)","journal":"NEJM","year":2018,"doi":"10.1056/NEJMoa1708618"},{"title":"Overall survival after hyperthermic intraperitoneal chemotherapy for ovarian cancer: 10-year follow-up of OVHIPEC-1","journal":"Lancet Oncology","year":2023}],"orcid":"0000-0003-2246-1994"},{"id":"william-tap","kind":"person","name":"William D. Tap","aka":[],"tldr":"Sarcoma oncologist who led ANNOUNCE and the pexidartinib trial that produced the first drug for tenosynovial giant cell tumour.","summary":"William Tap led ANNOUNCE, the phase 3 trial that found olaratumab did not improve survival in soft-tissue sarcoma despite a striking phase 2 result, a widely cited cautionary tale for accelerated approval, and ENLIVEN, which won pexidartinib approval for tenosynovial giant cell tumour. He chairs the Alliance sarcoma committee and leads sarcoma medical oncology at MSKCC.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tap%20WD%5BAuthor%5D%20sarcoma"}],"tags":["sarcoma","trialist"],"related":[],"cancers":["sarcoma"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":[],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":["announce"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief, Sarcoma Medical Oncology Service, Memorial Sloan Kettering Cancer Center","institutionId":"mskcc","specialisms":["Soft-tissue sarcoma","Tenosynovial giant cell tumour","Kinase inhibitors","Trial design"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tap%20WD%5BAuthor%5D%20sarcoma"}],"papers":[{"title":"Effect of doxorubicin plus olaratumab vs doxorubicin plus placebo on survival in patients with advanced soft tissue sarcomas (ANNOUNCE)","journal":"JAMA","year":2020,"doi":"10.1001/jama.2020.1707"},{"title":"Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN)","journal":"Lancet","year":2019,"doi":"10.1016/S0140-6736(19)30764-0"}]},{"id":"william-kaelin","kind":"person","name":"William G. Kaelin Jr.","aka":[],"tldr":"William Kaelin is the Nobel laureate whose work on VHL and HIF-2α led directly to belzutifan.","summary":"William G. Kaelin Jr. is the Sidney Farber Professor of Medicine and an HHMI Investigator at Dana-Farber Brigham Cancer Center. He is the Nobel laureate who shared the 2019 Nobel Prize in Physiology or Medicine for discovering how cells sense oxygen, through work on the VHL tumour suppressor and hypoxia-inducible factor. His selected paper shows that HIF alpha is targeted for VHL-mediated destruction by proline hydroxylation. His VHL and HIF work defined the target for HIF-2 alpha inhibitors such as belzutifan, now approved in kidney cancer.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kaelin%20WG%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["rcc"],"sections":[],"technologies":[],"targets":["hif2a"],"drugs":["belzutifan"],"companies":[],"institutions":["dana-farber"],"pathways":["hif-vhl"],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Sidney Farber Professor of Medicine; HHMI Investigator","institutionId":"dana-farber","specialisms":["VHL and HIF biology","Kidney cancer","Oxygen sensing"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kaelin%20WG%5BAuthor%5D"}],"papers":[{"title":"HIFα targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing","journal":"Science","year":2001,"url":"https://doi.org/10.1126/science.1059817","doi":"10.1126/science.1059817"}],"orcid":"0000-0002-0574-4856"},{"id":"william-nelson","kind":"person","name":"William G. Nelson","aka":["william-g-nelson"],"tldr":"William Nelson is the long-time director of the Johns Hopkins cancer centre and a prostate cancer epigenetics researcher.","summary":"William G. Nelson is Director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital. He is the long-time director of the Johns Hopkins cancer centre and a prostate cancer researcher whose work addresses epigenetic changes, including GSTP1 methylation, and inflammation in prostate carcinogenesis. He chairs the Scientific Advisory Committee of Stand Up To Cancer, which selects and oversees the charity's funded research teams. He continues to combine leadership of the Kimmel Cancer Center with research on prostate cancer epigenetics and prevention.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/William_G._Nelson","links":[{"label":"Kimmel Cancer Center","url":"https://www.hopkinsmedicine.org/kimmel-cancer-center"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Nelson%20WG%5BAuthor%5D"},{"label":"Stand Up To Cancer leadership","url":"https://standuptocancer.org/about-us/leadership/"}],"tags":["leadership","clinician-scientist","prostate cancer"],"related":[],"cancers":["prostate"],"sections":[],"technologies":["epigenetic-drugs"],"targets":[],"drugs":[],"companies":[],"institutions":["johns-hopkins","stand-up-to-cancer"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Sidney Kimmel Comprehensive Cancer Center","institutionId":"johns-hopkins","specialisms":["Prostate cancer","Epigenetics","Cancer prevention","Medical oncology"],"profiles":[{"label":"Kimmel Cancer Center","url":"https://www.hopkinsmedicine.org/kimmel-cancer-center"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Nelson%20WG%5BAuthor%5D"},{"label":"Stand Up To Cancer leadership","url":"https://standuptocancer.org/about-us/leadership/"}],"papers":[{"title":"Prostate Cancer","journal":"New England Journal of Medicine","year":2003,"url":"https://doi.org/10.1056/nejmra021562","doi":"10.1056/nejmra021562"},{"title":"Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer","journal":"Nature Medicine","year":2009,"url":"https://doi.org/10.1038/nm.1944","doi":"10.1038/nm.1944"},{"title":"DNA Strand Breaks: the DNA Template Alterations That Trigger p53-Dependent DNA Damage Response Pathways","journal":"Molecular and Cellular Biology","year":1994,"url":"https://doi.org/10.1128/mcb.14.3.1815-1823.1994","doi":"10.1128/mcb.14.3.1815-1823.1994"}]},{"id":"william-wierda","kind":"person","name":"William G. Wierda","aka":[],"tldr":"Led CAPTIVATE, which established fixed-duration ibrutinib plus venetoclax as a first-line option for CLL.","summary":"William Wierda was principal investigator of CAPTIVATE, the trial showing fixed-duration ibrutinib plus venetoclax produces high rates of undetectable MRD and durable remissions in untreated CLL and led to its approval in Europe, and led the MRD-guided cohort of that study. He chairs the NCCN CLL guidelines panel and helped develop the MD Anderson prognostic nomogram for CLL.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wierda%20WG%5BAuthor%5D%20chronic%20lymphocytic%20leukemia"}],"tags":["cll","fixed-duration","guidelines"],"related":[],"cancers":["cll"],"sections":[],"technologies":["mrd-testing","kinase-inhibitors"],"targets":["bcl2"],"drugs":["venetoclax"],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":["captivate"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor and Section Chief of CLL, Department of Leukemia, MD Anderson Cancer Center","institutionId":"md-anderson","specialisms":["Chronic lymphocytic leukaemia","Fixed-duration targeted therapy","MRD-guided treatment","Guidelines"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wierda%20WG%5BAuthor%5D%20chronic%20lymphocytic%20leukemia"}],"papers":[{"title":"Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE study","journal":"JCO","year":2021,"doi":"10.1200/JCO.21.00807"},{"title":"Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort","journal":"Blood","year":2022,"doi":"10.1182/blood.2021014488"}],"orcid":"0000-0002-7357-270X"},{"id":"winette-van-der-graaf","kind":"person","name":"Winette T. A. van der Graaf","aka":[],"tldr":"Led PALETTE, the trial that made pazopanib the first targeted drug for soft-tissue sarcoma.","summary":"Winette van der Graaf was principal investigator of PALETTE, the EORTC trial showing pazopanib improves progression-free survival in pretreated non-adipocytic soft-tissue sarcoma, leading to its approval as the first targeted therapy in the disease. She chaired the EORTC Soft Tissue and Bone Sarcoma Group and leads adolescent and young adult cancer research in the Netherlands.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=van%20der%20Graaf%20WT%5BAuthor%5D%20sarcoma%20pazopanib"}],"tags":["sarcoma","eortc","aya"],"related":[],"cancers":["sarcoma"],"sections":[],"technologies":["kinase-inhibitors","antiangiogenic"],"targets":["vegf"],"drugs":[],"companies":[],"institutions":["nki","erasmus-mc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["esmo-open"],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology, Netherlands Cancer Institute and Erasmus MC","institutionId":"nki","specialisms":["Soft-tissue sarcoma","Adolescent and young adult oncology","Targeted therapy","EORTC trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=van%20der%20Graaf%20WT%5BAuthor%5D%20sarcoma%20pazopanib"}],"papers":[{"title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE)","journal":"Lancet","year":2012,"doi":"10.1016/S0140-6736(12)60651-5"},{"title":"Adolescents and young adults (AYA) with cancer: a position paper from the AYA Working Group of the European Society for Medical Oncology (ESMO) and the European Society for Paediatric Oncology (SIOPE)","journal":"ESMO Open","year":2021,"doi":"10.1016/j.esmoop.2021.100096"}],"orcid":"0000-0001-7549-3338"},{"id":"wolfgang-weber","kind":"person","name":"Wolfgang A. Weber","aka":[],"tldr":"Nuclear medicine physician who established PET response criteria and leads Munich's radiopharmaceutical development pipeline.","summary":"Wolfgang Weber led the early studies showing FDG-PET response after one cycle of chemotherapy predicts outcome in lung and gastro-oesophageal cancer and helped define PERCIST response criteria. He directs nuclear medicine at TUM, where PSMA ligands and FAP inhibitors were developed, and has been president of the Society of Nuclear Medicine and Molecular Imaging. His current focus is trial design for theranostics.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Weber%20WA%5BAuthor%5D%20PET"}],"tags":["nuclear-medicine","imaging","theranostics"],"related":[],"cancers":[],"sections":[],"technologies":["pet","fdg-pet","radioligand-therapy","fapi-pet"],"targets":[],"drugs":[],"companies":[],"institutions":["tum-munich","snmmi"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chair of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich","institutionId":"tum-munich","specialisms":["Molecular imaging","PET response assessment","Theranostics","Radiopharmaceutical development"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Weber%20WA%5BAuthor%5D%20PET"}],"papers":[{"title":"Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use","journal":"JCO","year":2003,"doi":"10.1200/JCO.2003.06.120"},{"title":"Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging","journal":"JCO","year":2001,"doi":"10.1200/JCO.2001.19.12.3058"}],"orcid":"0000-0002-7854-4345"},{"id":"kang-won-ki","kind":"person","name":"Won Ki Kang","aka":[],"tldr":"A senior gastric cancer oncologist whose adjuvant and perioperative trials in Korea helped define post-gastrectomy chemotherapy.","summary":"Won Ki Kang is Professor of Medical Oncology at Samsung Medical Center in Seoul, specialising in gastrointestinal oncology. A senior gastric cancer oncologist, he has led Korean multicentre trials including the ARTIST studies of adjuvant chemoradiation, which helped define chemotherapy after gastrectomy, and has been an investigator on first-line immunotherapy trials such as CheckMate 649 and on HER2 trials. His publications include the ARTIST phase 3 trial of adjuvant capecitabine and cisplatin with or without radiotherapy in D2-resected gastric cancer. His interests are gastric cancer, adjuvant chemotherapy and clinical trials.","asOf":"2026-09-08","links":[{"label":"Samsung Medical Center","url":"https://www.samsunghospital.com/gb/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kang%20WK%5BAuthor%5D%20gastric%20cancer%20Samsung"}],"tags":[],"related":[],"cancers":["gastric"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["samsung-medical-center"],"pathways":[],"terms":[],"trials":["checkmate-649"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology; gastrointestinal oncology","institutionId":"samsung-medical-center","specialisms":["Gastric cancer","Adjuvant chemotherapy","Clinical trials"],"profiles":[{"label":"Samsung Medical Center","url":"https://www.samsunghospital.com/gb/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kang%20WK%5BAuthor%5D%20gastric%20cancer%20Samsung"}],"papers":[{"title":"Phase III trial of adjuvant capecitabine/cisplatin with or without radiotherapy in D2-resected gastric cancer (ARTIST)","journal":"Journal of Clinical Oncology","year":2012,"doi":"10.1200/JCO.2011.39.1953"}],"orcid":"0000-0002-7194-2404"},{"id":"park-woong-yang","kind":"person","name":"Woong-Yang Park","aka":[],"tldr":"Built the genome institute behind Samsung Medical Center's precision oncology programme and its single-cell studies of tumours.","summary":"Woong-Yang Park is Director of the Samsung Genome Institute and Professor of Molecular Cell Biology at Samsung Medical Center in Seoul. He built the genome institute behind the hospital's precision oncology programme, which runs clinical sequencing and produces single-cell and spatial studies of lung, breast and gastric tumours that underpin its precision oncology trials. His publications include a single-cell RNA sequencing study demonstrating the molecular and cellular reprogramming of metastatic lung adenocarcinoma. His interests are cancer genomics, single-cell sequencing and precision oncology platforms.","asOf":"2026-09-08","links":[{"label":"Samsung Genome Institute","url":"https://www.samsunghospital.com/gb/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Park%20WY%5BAuthor%5D%20Samsung%20Genome%20Institute"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["single-cell-spatial","cgp"],"targets":[],"drugs":[],"companies":[],"institutions":["samsung-medical-center"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nature-communications"],"dependsOn":[],"notes":[],"role":"Director, Samsung Genome Institute; Professor of Molecular Cell Biology","institutionId":"samsung-medical-center","specialisms":["Cancer genomics","Single-cell sequencing","Precision oncology platforms"],"profiles":[{"label":"Samsung Genome Institute","url":"https://www.samsunghospital.com/gb/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Park%20WY%5BAuthor%5D%20Samsung%20Genome%20Institute"}],"papers":[{"title":"Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma","journal":"Nature Communications","year":2020,"doi":"10.1038/s41467-020-16164-1"}],"orcid":"0000-0003-4234-0380"},{"id":"wouter-de-laat","kind":"person","name":"Wouter de Laat","aka":[],"tldr":"Genome biologist who chairs UMC Utrecht's Strategic Program Cancer, the umbrella for more than 800 cancer researchers in Utrecht.","summary":"Wouter de Laat is Chair of the Strategic Program Cancer at UMC Utrecht, which coordinates cancer research across the UMC Utrecht Cancer Center and the Hubrecht Institute. He is a professor of biomedical genomics whose laboratory pioneered chromosome conformation capture (4C) methods to study three-dimensional genome organisation. His work links chromatin structure to gene regulation and disease.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://research.umcutrecht.nl/strategic-programs/cancer/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=de+Laat+W%5BAuthor%5D"}],"tags":["leadership","basic science","cancer genomics"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["umc-utrecht"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["cell","cancer-cell","nature-communications"],"dependsOn":[],"notes":[],"role":"Chair, Strategic Program Cancer","institutionId":"umc-utrecht","specialisms":["Genome organisation","Chromatin biology","Cancer genomics"],"profiles":[{"label":"Institution profile","url":"https://research.umcutrecht.nl/strategic-programs/cancer/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=de+Laat+W%5BAuthor%5D"}],"papers":[{"title":"A Single Oncogenic Enhancer Rearrangement Causes Concomitant EVI1 and GATA2 Deregulation in Leukemia","journal":"Cell","year":2014,"doi":"10.1016/j.cell.2014.02.019"},{"title":"Integrated Transcript and Genome Analyses Reveal NKX2-1 and MEF2C as Potential Oncogenes in T Cell Acute Lymphoblastic Leukemia","journal":"Cancer Cell","year":2011,"doi":"10.1016/j.ccr.2011.02.008"},{"title":"Genome-wide profiling of p53-regulated enhancer RNAs uncovers a subset of enhancers controlled by a lncRNA","journal":"Nature Communications","year":2015,"doi":"10.1038/ncomms7520"}],"orcid":"0000-0002-6393-595X"},{"id":"wyndham-wilson","kind":"person","name":"Wyndham H. Wilson","aka":[],"tldr":"Developed dose-adjusted EPOCH-R, the regimen that cures primary mediastinal B-cell lymphoma without radiotherapy.","summary":"Wyndham Wilson developed the infusional dose-adjusted EPOCH regimen and showed that DA-EPOCH-R cures primary mediastinal B-cell lymphoma in more than 90% of patients without radiotherapy, and led the NCI studies of ibrutinib in ABC-subtype DLBCL that linked molecular subtype to treatment response. He co-led the Alliance/CALGB 50303 trial comparing DA-EPOCH-R with R-CHOP and studies of Burkitt lymphoma with reduced-intensity therapy.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wilson%20WH%5BAuthor%5D%20lymphoma%20EPOCH"}],"tags":["lymphoma","nci","chemotherapy"],"related":[],"cancers":["dlbcl"],"sections":[],"technologies":[],"targets":["cd20"],"drugs":[],"companies":[],"institutions":["nci-ccr","nci"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Senior Investigator and Head, Lymphoma Therapeutics Section, National Cancer Institute Center for Cancer Research","institutionId":"nci-ccr","specialisms":["Aggressive lymphoma","Dose-adjusted EPOCH","Primary mediastinal lymphoma","Molecular subtypes"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wilson%20WH%5BAuthor%5D%20lymphoma%20EPOCH"}],"papers":[{"title":"Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma","journal":"NEJM","year":2013,"doi":"10.1056/NEJMoa1214561"},{"title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","journal":"Nature Medicine","year":2015,"doi":"10.1038/nm.3884"}]},{"id":"xavier-pivot","kind":"person","name":"Xavier Pivot","aka":[],"tldr":"Xavier Pivot represents Institut Strauss in the Organisation of European Cancer Institutes, which lists the organisation among its members in France.","summary":"Xavier Pivot is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Institut Strauss, its full member in France. OnCo records the name from the OECI membership list so that the organisation's page names its contact within Europe's cancer-centre network; the person's clinical or management role is not stated by the list and should be checked at the organisation's website.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Xavier_Pivot","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Institut Strauss website","url":"https://www.institut-strauss.fr/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["institut-strauss"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Institut Strauss to the Organisation of European Cancer Institutes","institutionId":"institut-strauss","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Institut Strauss website","url":"https://www.institut-strauss.fr/"}],"papers":[{"title":"The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial","journal":"JAMA Oncol","year":2020,"url":"https://doi.org/10.1001/jamaoncol.2019.4782","doi":"10.1001/jamaoncol.2019.4782","note":"Europe PMC author record matched by affiliation"},{"title":"Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3","journal":"Ann Oncol","year":2024,"url":"https://doi.org/10.1016/j.annonc.2024.04.013","doi":"10.1016/j.annonc.2024.04.013","note":"Europe PMC author record matched by affiliation"},{"title":"6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial","journal":"Lancet","year":2019,"url":"https://doi.org/10.1016/s0140-6736(19)30653-1","doi":"10.1016/s0140-6736(19)30653-1","note":"Europe PMC author record matched by affiliation"}],"orcid":"0000-0003-3689-5013"},{"id":"xia-jiahong","kind":"person","name":"Xia Jiahong","aka":[],"tldr":"President of Wuhan Union Hospital, the large university hospital of Tongji Medical College that includes a national regional medical centre.","summary":"Xia Jiahong (夏家红) is President (院长) of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, in Wuhan, and Dean of the university's First Clinical College. The hospital's English governance page lists him as President and as a Vice Chair of the Hospital Committee under Party Secretary Zhang Yu, with vice presidents Huang Kai, Ji Xiangnian, Jin Yang and Zhang Jinxiang. The Chinese organisation page states that he presides over the hospital's overall administration and is responsible for research and audit, overseeing the President's Office and the audit office. Union Hospital operates several campuses including the Chegu, Jinyinhu and orthopaedic sites.","asOf":"2026-09-10","links":[{"label":"Source: Union Hospital governance and structure page (English)","url":"https://www.whuh.com/en/About_Us1/Governance___Structure.htm"},{"label":"Source: Union Hospital organisation page (Chinese)","url":"https://www.whuh.com/HospitalOverview/organization.htm"}],"tags":["leadership","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["union-hospital-wuhan"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President (院长) of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","institutionId":"union-hospital-wuhan","specialisms":["Hospital management","Academic medicine","Research administration"],"profiles":[{"label":"Union Hospital governance and structure (English)","url":"https://www.whuh.com/en/About_Us1/Governance___Structure.htm"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Xia+J%5BAuthor%5D+AND+Union+Hospital+AND+Wuhan"}],"papers":[{"title":"Amphiregulin Confers Regulatory T Cell Suppressive Function and Tumor Invasion via the EGFR/GSK-3β/Foxp3 Axis","journal":"Journal of Biological Chemistry","year":2016,"doi":"10.1074/jbc.m116.717892"}]},{"id":"xiang-hua","kind":"person","name":"Xiang Hua","aka":[],"tldr":"Hospital president who leads Hunan Cancer Hospital, the provincial cancer hospital of Hunan and the affiliated cancer hospital of Central South University's Xiangya School of Medicine.","summary":"Xiang Hua (向华) is President (院长) of Hunan Cancer Hospital (湖南省肿瘤医院), the provincial cancer hospital of Hunan, which Chinese-language Wikipedia lists as the affiliated cancer hospital of Central South University's Xiangya School of Medicine. In an interview published by Xinhua on 19 August 2025 for China's Doctors' Day he described the hospital's 'three technologies, three guarantees' (三化三保) approach, which pairs minimally invasive, endoscopic and interventional treatment with commitments to efficacy, organ and function preservation and patient comfort, and its multidisciplinary team management of cancer patients from diagnosis through follow-up. He said doctoral graduates account for close to 40 percent at the hospital and outlined five-year talent and research plans aimed at younger doctors. The hospital's own website could not be reached for this check, so the role was confirmed from the Xinhua interview.","asOf":"2026-09-10","links":[{"label":"Source: Xinhua 'Dialogue on Healthy China' interview naming him President of Hunan Cancer Hospital (August 2025)","url":"https://www.news.cn/digital/20250819/687dbd6108a141b7951f20ca6c64e4a8/c.html"}],"tags":["leadership","clinician-scientist","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["hunan-cancer-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President (院长), Hunan Cancer Hospital","institutionId":"hunan-cancer-hospital","specialisms":["Oncology","Hospital management","Public hospital reform"],"profiles":[{"label":"Xinhua interview (Chinese)","url":"https://www.news.cn/digital/20250819/687dbd6108a141b7951f20ca6c64e4a8/c.html"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Xiang+H%5BAuthor%5D+AND+Hunan+Cancer+Hospital"}],"papers":[]},{"id":"xiao-haipeng","kind":"person","name":"Xiao Haipeng","aka":[],"tldr":"Hospital president who leads the First Affiliated Hospital of Sun Yat-sen University in Guangzhou, one of the largest university teaching hospitals in southern China.","summary":"Xiao Haipeng is President of The First Affiliated Hospital, Sun Yat-sen University (中山大学附属第一医院) in Guangzhou. The hospital's English leadership page lists him as President alongside Party Committee Secretary Luo Teng and vice presidents Zeng Jinsheng, Kuang Ming, Wang Zilian, Yin Xiaoyu, Zhu Qingtang and Chen Wei. The page gives no appointment date or biographical detail.","asOf":"2026-09-10","links":[{"label":"Source: First Affiliated Hospital leadership page","url":"https://www.fahsysu.org.cn/en/basic/32843"}],"tags":["leadership","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["sysu-first-affiliated-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President, The First Affiliated Hospital, Sun Yat-sen University","institutionId":"sysu-first-affiliated-hospital","specialisms":["Hospital management","Academic medicine"],"profiles":[{"label":"Hospital leadership page (English)","url":"https://www.fahsysu.org.cn/en/basic/32843"}],"papers":[{"title":"Review of Factors Related to the Thyroid Cancer Epidemic","journal":"International Journal of Endocrinology","year":2017,"doi":"10.1155/2017/5308635"}]},{"id":"huang-xiaojun","kind":"person","name":"Xiaojun Huang","aka":["Huang Xiao-Jun","黄晓军"],"tldr":"Xiaojun Huang built the Beijing Protocol for stem cell transplants from half-matched family donors, which means almost every Chinese leukaemia patient can now find a donor.","summary":"Huang's group developed haploidentical transplantation without in vitro T-cell depletion using G-CSF-primed grafts and anti-thymocyte globulin (Bone Marrow Transplantation 2006), now the most common transplant type in China and increasingly used worldwide; his centre performs more haploidentical transplants than any other. Later work covers relapse prevention, GVHD and CAR-T bridging to transplant. Academician of the Chinese Academy of Engineering.","asOf":"2026-09-10","links":[{"label":"Peking University People's Hospital","url":"https://www.pkuph.cn/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Huang%20XJ%5BAuthor%5D%20haploidentical%20Peking%20University"}],"tags":["china"],"related":[],"cancers":["aml","all-leukemia"],"sections":[],"technologies":["allogeneic-cell-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":["pku-peoples-hospital"],"pathways":[],"terms":["allogeneic-transplant","gvhd"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Peking University Institute of Hematology; Peking University People's Hospital","institutionId":"pku-peoples-hospital","specialisms":["Haematopoietic stem cell transplantation","Haploidentical transplantation","Acute leukaemia","Graft-versus-host disease"],"profiles":[{"label":"Peking University People's Hospital","url":"https://www.pkuph.cn/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Huang%20XJ%5BAuthor%5D%20haploidentical%20Peking%20University"}],"papers":[{"title":"Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies","journal":"Bone Marrow Transplantation","year":2006,"doi":"10.1038/sj.bmt.1705445"}]},{"id":"hu-xichun","kind":"person","name":"Xichun Hu","aka":[],"tldr":"A breast medical oncologist who has led Chinese trials of chemotherapy, CDK4/6 inhibitors, and ADCs in advanced breast cancer.","summary":"Xichun Hu is Professor of Medical Oncology and Chief of the Department of Breast and Urologic Medical Oncology at Fudan University Shanghai Cancer Center. He has led Chinese trials of chemotherapy, CDK4/6 inhibitors and antibody-drug conjugates in advanced breast cancer, serving as principal investigator on studies of platinum-based chemotherapy in triple-negative disease, dalpiciclib, and new conjugates including sacituzumab tirumotecan and trastuzumab rezetecan. His publications include the CBCSG006 trial comparing cisplatin plus gemcitabine with paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer. His interests are breast cancer, chemotherapy, antibody-drug conjugates and clinical trials.","asOf":"2026-09-08","links":[{"label":"Fudan University Shanghai Cancer Center","url":"https://www.shca.org.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hu%20X%5BAuthor%5D%20Fudan%20breast%20cancer"}],"tags":[],"related":[],"cancers":["tnbc","breast-hr-positive"],"sections":[],"technologies":["platinum"],"targets":[],"drugs":["sacituzumab-tirumotecan","trastuzumab-rezetecan"],"companies":[],"institutions":["fuscc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology; Chief, Department of Breast and Urologic Medical Oncology, Fudan University Shanghai Cancer Center","institutionId":"fuscc","specialisms":["Breast cancer","Chemotherapy","Antibody-drug conjugates","Clinical trials"],"profiles":[{"label":"Fudan University Shanghai Cancer Center","url":"https://www.shca.org.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hu%20X%5BAuthor%5D%20Fudan%20breast%20cancer"}],"papers":[{"title":"Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006)","journal":"Lancet Oncology","year":2015,"doi":"10.1016/S1470-2045(15)70064-1"},{"title":"DESTINY-Breast06: trastuzumab deruxtecan before any chemotherapy in hormone-receptor-positive, HER2-low or ultralow breast cancer","journal":"New England Journal of Medicine","year":2024,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DESTINY-Breast06+trastuzumab+deruxtecan+HER2-low+chemotherapy-naive"}]},{"id":"yacine-merrouche","kind":"person","name":"Yacine Merrouche","aka":[],"tldr":"Yacine Merrouche represents Institut Godinot in the Organisation of European Cancer Institutes, which lists the centre among its members in France.","summary":"Yacine Merrouche is listed by the Organisation of European Cancer Institutes (OECI) as the representative of Institut Godinot, its member in France. Institut Godinot is the Unicancer comprehensive cancer centre for the Reims region of north-eastern France and a full member of the Organisation of European Cancer Institutes. OnCo records the name from the OECI membership list so that the centre's page has a named contact point; the person's exact title, appointment date and biography are not yet recorded and should be checked on the institution's own pages before being relied on.","asOf":"2026-09-10","links":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Institut Godinot website","url":"https://www.institutgodinot.fr/fr/"}],"tags":["oeci-representative","leader"],"related":["oeci"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["institut-godinot"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Representative of Institut Godinot to the Organisation of European Cancer Institutes","institutionId":"institut-godinot","specialisms":["Cancer centre representation (OECI)"],"profiles":[{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Institut Godinot website","url":"https://www.institutgodinot.fr/fr/"}],"papers":[{"title":"Targeting the Tumor Microenvironment: The Protumor Effects of IL-17 Related to Cancer Type","journal":"Int J Mol Sci","year":2016,"url":"https://doi.org/10.3390/ijms17091433","doi":"10.3390/ijms17091433","note":"Europe PMC author record matched by affiliation"},{"title":"Delayed care for patients with newly diagnosed cancer due to COVID-19 and estimated impact on cancer mortality in France","journal":"ESMO Open","year":2021,"url":"https://doi.org/10.1016/j.esmoop.2021.100134","doi":"10.1016/j.esmoop.2021.100134","note":"Europe PMC author record matched by affiliation"},{"title":"IL-17A and its homologs IL-25/IL-17E recruit the c-RAF/S6 kinase pathway and the generation of pro-oncogenic LMW-E in breast cancer cells","journal":"Sci Rep","year":2015,"url":"https://doi.org/10.1038/srep11874","doi":"10.1038/srep11874","note":"Europe PMC author record matched by affiliation"}]},{"id":"yael-mosse","kind":"person","name":"Yael P. Mossé","aka":[],"tldr":"Discovered ALK mutations in neuroblastoma and led the trials bringing crizotinib and lorlatinib to children.","summary":"Yael Mossé was first author of the 2008 discovery of ALK mutations in neuroblastoma and has led the clinical translation of ALK inhibition in children through the Children's Oncology Group and NANT consortium, including the phase 1 trials of crizotinib and lorlatinib and the addition of lorlatinib to front-line high-risk neuroblastoma therapy in COG ANBL1531. She leads the developmental therapeutics programme at CHOP.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mosse%20YP%5BAuthor%5D%20neuroblastoma%20ALK"}],"tags":["paediatric","neuroblastoma","alk"],"related":[],"cancers":["neuroblastoma"],"sections":[],"technologies":["kinase-inhibitors"],"targets":["alk"],"drugs":["lorlatinib"],"companies":[],"institutions":["chop"],"pathways":[],"terms":[],"trials":["anbl1531"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Pediatrics and Patricia Brophy Endowed Chair in Neuroblastoma Research, Children's Hospital of Philadelphia","institutionId":"chop","specialisms":["Neuroblastoma","ALK-targeted therapy","Paediatric drug development","Precision oncology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mosse%20YP%5BAuthor%5D%20neuroblastoma%20ALK"}],"papers":[{"title":"Identification of ALK as a major familial neuroblastoma predisposition gene","journal":"Nature","year":2008,"doi":"10.1038/nature07261"},{"title":"Lorlatinib for ALK-driven relapsed or refractory neuroblastoma (NANT 2015-02)","journal":"Nature Medicine","year":2023,"doi":"10.1038/s41591-023-02297-5"}]},{"id":"yakubu-seidu-adam","kind":"person","name":"Yakubu Seidu Adam","aka":[],"tldr":"Consultant eye surgeon who has been Chief Executive of Korle Bu Teaching Hospital, Ghana's largest referral hospital, since May 2025.","summary":"Yakubu Seidu Adam is Chief Executive Officer of Korle Bu Teaching Hospital in Accra, Ghana's premier tertiary teaching hospital and national referral centre, with around 2,000 beds and services including oncology. A consultant eye surgeon with expertise in glaucoma, cataract and refractive surgery, he joined Korle Bu in 2003 and from 2017 headed its Lions International Eye Centre; he is a Fellow of the Ghana College of Surgeons. His appointment as Chief Executive took effect on 6 May 2025, succeeding Opoku Ware Ampomah, and he continued in the role in 2026.","asOf":"2026-09-10","links":[{"label":"Source: MyJoyOnline report of appointment, May 2025","url":"https://www.myjoyonline.com/dr-yakubu-seidu-adam-appointed-as-new-korle-bu-teaching-hospital-ceo/"}],"tags":["leadership","clinician-scientist","ophthalmology"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["korle-bu-teaching-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive Officer of Korle Bu Teaching Hospital","institutionId":"korle-bu-teaching-hospital","specialisms":["Ophthalmology","Glaucoma and cataract surgery","Hospital leadership"],"profiles":[{"label":"Appointment report, MyJoyOnline","url":"https://www.myjoyonline.com/dr-yakubu-seidu-adam-appointed-as-new-korle-bu-teaching-hospital-ceo/"}],"papers":[],"orcid":"0009-0002-8666-9831"},{"id":"yardena-samuels","kind":"person","name":"Yardena Samuels","aka":[],"tldr":"She found that PIK3CA is one of the most frequently mutated genes in human cancer, then spent the next twenty years working out which of a melanoma's mutations the immune system can actually see.","summary":"Yardena Samuels was first author, working in Bert Vogelstein and Victor Velculescu's group at Johns Hopkins before she moved to the National Cancer Institute and then to Weizmann, of the 2004 Science paper that found high-frequency mutations of PIK3CA in human cancers, the work behind the PI3K-alpha inhibitors alpelisib and inavolisib and behind the E542K, E545K and H1047R hotspots that OnCo records on the PIK3CA page. Her laboratory at the Weizmann Institute now works on melanoma genomics and on the immunopeptidome: which mutated and non-canonical peptides a tumour actually displays on its MHC molecules, how intratumour heterogeneity across genetic, transcriptional and immunopeptidomic layers limits immunotherapy, and how translational recoding creates antigens that were never in the genome. That work sits directly under the neoantigen vaccine and adoptive cell therapy programmes at Sheba and elsewhere in Israel.","asOf":"2026-09-25","links":[{"label":"Samuels laboratory, Weizmann Institute","url":"https://www.weizmann.ac.il/molgen/Samuels/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Samuels%20Y%5BAuthor%5D%20melanoma%20Weizmann"}],"tags":["scientist","genomics","immunology"],"related":[],"cancers":["melanoma"],"sections":["immunotherapy","drug-discovery"],"technologies":["neoantigen-mrna-vaccine","til-therapy"],"targets":["pik3ca"],"drugs":[],"companies":[],"institutions":["weizmann"],"pathways":[],"terms":["neoantigen"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor, Department of Molecular Cell Biology, Weizmann Institute of Science","institutionId":"weizmann","specialisms":["Melanoma genomics","Neoantigens and immunopeptidomics","Cancer gene discovery","Intratumour heterogeneity"],"profiles":[{"label":"Samuels laboratory, Weizmann Institute","url":"https://www.weizmann.ac.il/molgen/Samuels/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Samuels%20Y%5BAuthor%5D%20melanoma%20Weizmann"}],"papers":[{"title":"High frequency of mutations of the PIK3CA gene in human cancers","journal":"Science","year":2004,"doi":"10.1126/science.1096502"},{"title":"Mapping intratumor heterogeneity across layers for advancing immunotherapy","journal":"Cell","year":2026,"doi":"10.1016/j.cell.2026.03.025"},{"title":"Translational recoding in tumors","journal":"Cold Spring Harbor Perspectives in Biology","year":2026,"doi":"10.1101/cshperspect.a041869"}]},{"id":"yasmine-belkaid","kind":"person","name":"Yasmine Belkaid","aka":[],"tldr":"Immunologist who leads the Institut Pasteur in Paris, having taken up its presidency in January 2024 after a long career at the US National Institutes of Health.","summary":"Yasmine Belkaid is President of the Institut Pasteur, the Paris-based private non-profit foundation for biomedical research, education and public health. She was appointed on 29 March 2023 and began a six-year term in January 2024. Her research addresses interactions between hosts and microbes, in particular how the microbiota shapes immunity and inflammation. She previously headed the Mucosal Immunology Unit and directed the Microbiome programme at the US National Institute of Allergy and Infectious Diseases, and held an adjunct professorship at the University of Pennsylvania.","asOf":"2026-09-10","links":[{"label":"Source: Wikipedia, Pasteur Institute (director-general listing)","url":"https://en.wikipedia.org/wiki/Pasteur_Institute"}],"tags":["leadership","clinician-scientist","immunology"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["institut-pasteur"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["science"],"dependsOn":[],"notes":[],"role":"President (Director General) of the Institut Pasteur","institutionId":"institut-pasteur","specialisms":["Immunology","Microbiome and host-microbe interactions","Mucosal immunology"],"profiles":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Yasmine_Belkaid"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Belkaid+Y%5BAuthor%5D"}],"papers":[{"title":"How microbiota improve immunotherapy","journal":"Science","year":2021,"doi":"10.1126/science.abl3656"}]},{"id":"yasuharu-nakashima","kind":"person","name":"Yasuharu Nakashima","aka":[],"tldr":"Orthopaedic surgeon who became Director of Kyushu University Hospital in Fukuoka in April 2026 after eight years as a vice director.","summary":"Yasuharu Nakashima (中島康晴) is Hospital Director of Kyushu University Hospital in Fukuoka, the university's principal teaching hospital, according to the hospital's leadership list dated 1 April 2026. He is Professor and Chairman of the Department of Orthopaedic Surgery at Kyushu University, a post he has held since 2016, with clinical interests in hip surgery, total hip arthroplasty, rheumatoid arthritis and paediatric orthopaedics. In his director's greeting he notes that he served as a vice director from 2018, including through the COVID-19 pandemic, before taking the top post.","asOf":"2026-09-10","links":[{"label":"Source: Kyushu University Hospital leadership list, 1 April 2026","url":"https://www.hosp.kyushu-u.ac.jp/uploads/file/articles/16324.pdf"}],"tags":["leadership","clinician-scientist","orthopaedics"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["kyushu-university-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Hospital Director (病院長) of Kyushu University Hospital","institutionId":"kyushu-university-hospital","specialisms":["Orthopaedic surgery","Hip surgery","Hospital management"],"profiles":[{"label":"Director's greeting (Japanese)","url":"https://www.hosp.kyushu-u.ac.jp/info/aisatsu_20260401/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Nakashima+Y%5BAuthor%5D+AND+Kyushu+orthopaedic"}],"papers":[{"title":"Development of a clinical prediction score for perioperative complications following metastatic spinal surgery (PERCOM) score","journal":"Heliyon","year":2024,"doi":"10.1016/j.heliyon.2024.e25180"},{"title":"Tumor-induced osteomalacia caused by a massive phosphaturic mesenchymal tumor of the acetabulum: A case report","journal":"Modern Rheumatology","year":2016,"doi":"10.3109/14397595.2016.1173322"}]},{"id":"yasuhiro-fujiwara","kind":"person","name":"Yasuhiro Fujiwara","aka":[],"tldr":"Medical oncologist who heads Japan's Pharmaceuticals and Medical Devices Agency, the national drug and device regulator.","summary":"Yasuhiro Fujiwara, MD, PhD, is Chief Executive of the Pharmaceuticals and Medical Devices Agency (PMDA), Japan's regulatory authority for drugs and medical devices. A medical oncologist formerly at the National Cancer Center Japan, he brings a cancer drug development background to regulatory review and international regulatory harmonisation.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.pmda.go.jp/english/about-pmda/outline/0004.html"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fujiwara+Y%5BAuthor%5D+regulatory"}],"tags":["leadership","regulation","drug development"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["pmda"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["the-oncologist"],"dependsOn":[],"notes":[],"role":"Chief Executive","institutionId":"pmda","specialisms":["Drug regulation","Medical oncology","Regulatory science"],"profiles":[{"label":"Institution profile","url":"https://www.pmda.go.jp/english/about-pmda/outline/0004.html"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fujiwara+Y%5BAuthor%5D+regulatory"}],"papers":[{"title":"Regulatory and operational challenges in conducting Asian International Academic Trial for expanding the indications of cancer drugs","journal":"Clinical and Translational Science","year":2021,"doi":"10.1111/cts.12965"},{"title":"Clinical Utility of Circulating Tumor DNA in Advanced Rare Cancers","journal":"Frontiers in Oncology","year":2021,"doi":"10.3389/fonc.2021.732525"},{"title":"Regulatory Issues: PMDA – Review of Sakigake Designation Products: Oncolytic Virus Therapy with Delytact Injection (Teserpaturev) for Malignant Glioma","journal":"The Oncologist","year":2023,"doi":"10.1093/oncolo/oyad041"}],"orcid":"0000-0002-1229-5446"},{"id":"yasumasa-niwa","kind":"person","name":"Yasumasa Niwa","aka":[],"tldr":"Physician who leads Aichi Cancer Center Hospital, the 500-bed prefectural cancer hospital in Nagoya, Japan, as its hospital director.","summary":"Yasumasa Niwa (丹羽康正) is listed as Hospital Director (病院長) of Aichi Cancer Center Hospital, the prefectural cancer hospital of Aichi Prefecture in Chikusa, Nagoya. The hospital opened in December 1964, has 500 general beds and offers internal medicine, surgery, orthopaedics, neurosurgery, dermatology, urology, gynaecology, ophthalmology, otolaryngology, radiology, anaesthesiology and dentistry. The centre's own website could not be reached, so this record relies on the Japanese Wikipedia article and gives no start date.","asOf":"2026-09-10","links":[{"label":"Source: Japanese Wikipedia article on Aichi Cancer Center","url":"https://ja.wikipedia.org/wiki/%E6%84%9B%E7%9F%A5%E7%9C%8C%E3%81%8C%E3%82%93%E3%82%BB%E3%83%B3%E3%82%BF%E3%83%BC"}],"tags":["leadership","clinician-scientist","hospital"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["aichi-cancer-center"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["annals-of-oncology"],"dependsOn":[],"notes":[],"role":"Hospital Director, Aichi Cancer Center Hospital","institutionId":"aichi-cancer-center","specialisms":["Cancer hospital leadership","Oncology","Hospital management"],"profiles":[{"label":"Wikipedia (Japanese)","url":"https://ja.wikipedia.org/wiki/%E6%84%9B%E7%9F%A5%E7%9C%8C%E3%81%8C%E3%82%93%E3%82%BB%E3%83%B3%E3%82%BF%E3%83%BC"}],"papers":[{"title":"Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer","journal":"Annals of Oncology","year":2015,"doi":"10.1093/annonc/mdu472"},{"title":"Diagnostic ability of artificial intelligence using deep learning analysis of cyst fluid in differentiating malignant from benign pancreatic cystic lesions","journal":"Scientific Reports","year":2019,"doi":"10.1038/s41598-019-43314-3"},{"title":"Usefulness of Deep Learning Analysis for the Diagnosis of Malignancy in Intraductal Papillary Mucinous Neoplasms of the Pancreas","journal":"Clinical and Translational Gastroenterology","year":2019,"doi":"10.14309/ctg.0000000000000045"}]},{"id":"yasuyuki-nasuhara","kind":"person","name":"Yasuyuki Nasuhara","aka":[],"tldr":"Hospital director who has led Hokkaido University Hospital, a large university teaching hospital in Sapporo, since April 2025.","summary":"Yasuyuki Nasuhara (南須原 康行) is Director of Hokkaido University Hospital, the university teaching hospital of Hokkaido University in Sapporo with about 967 beds. He was appointed Director on 1 April 2025. In his director's message he sets out four priorities for the hospital: patient safety, professional development, advanced medical innovation and contribution to regional healthcare across Hokkaido. The hospital marked its centenary in 2021.","asOf":"2026-09-10","links":[{"label":"Source: Hokkaido University Hospital director's page","url":"https://www.huhp.hokudai.ac.jp/director/"}],"tags":["leadership","clinician-scientist","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["hokkaido-university-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director of Hokkaido University Hospital","institutionId":"hokkaido-university-hospital","specialisms":["Hospital management","Academic medicine","Regional healthcare"],"profiles":[{"label":"Director's message (Japanese)","url":"https://www.huhp.hokudai.ac.jp/director/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Nasuhara+Y%5BAuthor%5D"}],"papers":[{"title":"Airflow limitation and airway dimensions in chronic obstructive pulmonary disease","journal":"American Journal of Respiratory and Critical Care Medicine","year":2006,"url":"https://doi.org/10.1164/rccm.200601-037oc","doi":"10.1164/rccm.200601-037oc","note":"Europe PMC author record matched by affiliation"},{"title":"Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease","journal":"American Journal of Respiratory and Critical Care Medicine","year":2012,"url":"https://doi.org/10.1164/rccm.201106-0992oc","doi":"10.1164/rccm.201106-0992oc","note":"Europe PMC author record matched by affiliation"},{"title":"Down-regulated NF-E2-related factor 2 in pulmonary macrophages of aged smokers and patients with chronic obstructive pulmonary disease","journal":"American Journal of Respiratory Cell and Molecular Biology","year":2008,"url":"https://doi.org/10.1165/rcmb.2007-0424oc","doi":"10.1165/rcmb.2007-0424oc","note":"Europe PMC author record matched by affiliation"}]},{"id":"yechezkel-barenholz","kind":"person","name":"Yechezkel Barenholz","aka":[],"tldr":"Invented the chemistry that made Doxil work, the first nanomedicine any regulator approved, which is still a standard treatment for relapsed ovarian cancer three decades later.","summary":"Yechezkel Barenholz's Laboratory of Membrane and Liposome Research at the Hebrew University-Hadassah Medical School devised the pegylated liposomal formulation of doxorubicin approved by the FDA in 1995 as Doxil, the first nano-drug approved anywhere. His own account in Journal of Controlled Release identifies three unrelated principles that had to work together: a polyethylene-glycol coat that keeps the liposome in circulation and away from the reticuloendothelial system, high and stable remote loading of doxorubicin driven by a transmembrane ammonium sulfate gradient that also allows release at the tumour, and a lipid bilayer held in a liquid-ordered phase by a high-melting phosphatidylcholine with cholesterol. The clinical effect is that hand-foot syndrome and mucositis replace the hair loss and heart damage of free doxorubicin. Barenholz's laboratory still publishes on liposome and PEGylation chemistry.","asOf":"2026-09-25","links":[{"label":"Laboratory of Membrane and Liposome Research, Hebrew University","url":"https://medicine.ekmd.huji.ac.il/en/research/yechezkelb/Pages/default.aspx"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Barenholz%20Y%5BAuthor%5D%20liposome"}],"tags":["scientist","drug-delivery"],"related":[],"cancers":["ovarian","kaposi-sarcoma"],"sections":["drug-discovery","chemotherapy"],"technologies":[],"targets":[],"drugs":["pegylated-liposomal-doxorubicin","doxorubicin"],"companies":[],"institutions":["hebrew-university-of-jerusalem","hadassah"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor, Laboratory of Membrane and Liposome Research, Hebrew University-Hadassah Medical School","institutionId":"hebrew-university-of-jerusalem","specialisms":["Liposome science","Nanomedicine","Drug delivery","PEGylation"],"profiles":[{"label":"Laboratory of Membrane and Liposome Research, Hebrew University","url":"https://medicine.ekmd.huji.ac.il/en/research/yechezkelb/Pages/default.aspx"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Barenholz%20Y%5BAuthor%5D%20liposome"}],"papers":[{"title":"Doxil, the first FDA-approved nano-drug: lessons learned","journal":"Journal of Controlled Release","year":2012,"doi":"10.1016/j.jconrel.2012.03.020"},{"title":"PEGylation technology: addressing concerns, moving forward","year":2025,"note":"Hebrew University-Hadassah Medical School; indexed on Europe PMC"}]},{"id":"yelena-janjigian","kind":"person","name":"Yelena Y. Janjigian","aka":[],"tldr":"Led CheckMate 649, which made immunotherapy plus chemotherapy the first-line standard for gastric cancer, and the pembrolizumab-trastuzumab combination in HER2-positive disease.","summary":"Yelena Y. Janjigian is Chief of the Gastrointestinal Oncology Service at Memorial Sloan Kettering Cancer Center. She is a gastrointestinal oncologist known for leading CheckMate 649, which made nivolumab plus chemotherapy the first-line standard for gastric cancer, and KEYNOTE-811, which established pembrolizumab with trastuzumab in HER2-positive disease. Her selected papers report first-line nivolumab plus chemotherapy in advanced gastric, gastro-oesophageal junction and oesophageal adenocarcinoma, and the KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Her research programme focuses on HER2 and immune biomarkers in gastro-oesophageal cancer.","asOf":"2026-09-08","links":[{"label":"MSK profile","url":"https://www.mskcc.org/cancer-care/doctors/yelena-janjigian"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Janjigian%20YY%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["gastric","esophageal"],"sections":[],"technologies":[],"targets":["pd1","her2"],"drugs":["nivolumab","pembrolizumab","trastuzumab"],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":["checkmate-649"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief, Gastrointestinal Oncology Service","institutionId":"mskcc","specialisms":["Gastric and oesophageal cancer","HER2-positive GI cancer","Immunotherapy"],"profiles":[{"label":"MSK profile","url":"https://www.mskcc.org/cancer-care/doctors/yelena-janjigian"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Janjigian%20YY%5BAuthor%5D"}],"papers":[{"title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649)","journal":"Lancet","year":2021,"url":"https://doi.org/10.1016/S0140-6736(21)00797-2","doi":"10.1016/S0140-6736(21)00797-2"},{"title":"The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer","journal":"Nature","year":2021,"url":"https://doi.org/10.1038/s41586-021-04161-3","doi":"10.1038/s41586-021-04161-3"},{"title":"CheckMate 649: nivolumab plus chemotherapy as first treatment for advanced gastric, gastro-oesophageal junction and oesophageal adenocarcinoma","journal":"The Lancet","year":2021,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CheckMate+649+nivolumab+chemotherapy+gastric+Janjigian+Lancet+2021"},{"title":"KEYNOTE-811: pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma","journal":"The Lancet","year":2023,"url":"https://doi.org/10.1016/S0140-6736(23)02033-0","doi":"10.1016/S0140-6736(23)02033-0"}]},{"id":"park-yeon-hee","kind":"person","name":"Yeon Hee Park","aka":[],"tldr":"Leads breast medical oncology at Samsung Medical Center and has driven Korean participation in the HER2 and CDK4/6 trials that changed practice.","summary":"Yeon Hee Park is Professor of Medical Oncology at Samsung Medical Center in Seoul, where she leads the breast cancer programme. She has driven Korean participation in the HER2 and CDK4/6 trials that changed practice, contributing to the trastuzumab deruxtecan, palbociclib and ribociclib programmes and to Korean genomic cohorts of young-onset breast cancer. Her publications include the Young-PEARL trial of palbociclib plus exemestane with a GnRH agonist against capecitabine in premenopausal women with hormone receptor-positive metastatic breast cancer. Her interests are HER2-positive disease, young-onset breast cancer and endocrine therapy.","asOf":"2026-09-08","links":[{"label":"Samsung Medical Center","url":"https://www.samsunghospital.com/gb/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Park%20YH%5BAuthor%5D%20Samsung%20Medical%20Center%20breast"}],"tags":[],"related":[],"cancers":["breast-hr-positive","breast-her2-positive"],"sections":[],"technologies":[],"targets":["her2","cdk4-6"],"drugs":["palbociclib","trastuzumab-deruxtecan"],"companies":[],"institutions":["samsung-medical-center"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology; breast cancer programme","institutionId":"samsung-medical-center","specialisms":["Breast cancer","HER2-positive disease","Young-onset breast cancer","Endocrine therapy"],"profiles":[{"label":"Samsung Medical Center","url":"https://www.samsunghospital.com/gb/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Park%20YH%5BAuthor%5D%20Samsung%20Medical%20Center%20breast"}],"papers":[{"title":"Palbociclib plus exemestane with GnRH agonist versus capecitabine in premenopausal HR+ metastatic breast cancer (Young-PEARL)","journal":"Lancet Oncology","year":2019,"doi":"10.1016/S1470-2045(19)30565-0"},{"title":"DESTINY-Breast03: trastuzumab deruxtecan beats T-DM1 as second-line treatment of HER2-positive metastatic breast cancer","journal":"New England Journal of Medicine","year":2022,"url":"https://doi.org/10.1056/NEJMoa2115022","doi":"10.1056/NEJMoa2115022"},{"title":"DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group","journal":"New England Journal of Medicine","year":2022,"url":"https://doi.org/10.1056/NEJMoa2203690","doi":"10.1056/NEJMoa2203690"},{"title":"KEYNOTE-522: adding pembrolizumab before and after surgery in early triple-negative breast cancer","journal":"New England Journal of Medicine","year":2022,"url":"https://doi.org/10.1056/NEJMoa2112651","doi":"10.1056/NEJMoa2112651"}]},{"id":"wu-yi-long","kind":"person","name":"Yi-Long Wu","aka":[],"tldr":"Co-led ADAURA and IPASS, the trials that made EGFR-targeted pills standard before and after surgery.","summary":"Yi-Long Wu is Professor at the Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, and a leader of the Chinese Thoracic Oncology Group. He is among the most cited lung cancer trialists in the world, co-principal investigator of ADAURA, which tested adjuvant osimertinib in resected EGFR-mutated non-small-cell lung cancer, and a leader of IPASS and ADJUVANT-CTONG, the trials that made EGFR-targeted pills standard before and after surgery. His publications include the ADAURA report on osimertinib in resected EGFR-mutated lung cancer. His interests are EGFR-mutant disease, adjuvant targeted therapy and clinical trials.","asOf":"2026-09-08","links":[{"label":"Guangdong Lung Cancer Institute","url":"https://www.gdghospital.org.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wu%20YL%5BAuthor%5D%20Guangdong%20Lung%20Cancer%20Institute%20osimertinib"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":["egfr"],"drugs":["osimertinib"],"companies":["ctong"],"institutions":["guangdong-provincial-peoples-hospital"],"pathways":[],"terms":[],"trials":["adaura"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital","institutionId":"guangdong-provincial-peoples-hospital","specialisms":["Lung cancer","EGFR-mutant NSCLC","Adjuvant targeted therapy","Clinical trials"],"profiles":[{"label":"Guangdong Lung Cancer Institute","url":"https://www.gdghospital.org.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wu%20YL%5BAuthor%5D%20Guangdong%20Lung%20Cancer%20Institute%20osimertinib"}],"papers":[{"title":"Osimertinib in resected EGFR-mutated non-small-cell lung cancer (ADAURA)","journal":"NEJM","year":2020,"doi":"10.1056/NEJMoa2027071"}]},{"id":"jiang-yi-zhou","kind":"person","name":"Yi-Zhou Jiang","aka":[],"tldr":"Co-architect of the Fudan TNBC subtypes and the metabolic and immune atlases that guide subtype-specific treatment.","summary":"Yi-Zhou Jiang is Professor of Breast Surgery at Fudan University Shanghai Cancer Center. He is co-architect of the Fudan subtypes of triple-negative breast cancer and led the multi-omic characterisation of Chinese triple-negative breast cancers, including the metabolomic and immune atlases that guide subtype-specific treatment. His publications include the genomic and transcriptomic landscape of triple-negative breast cancers and the treatment strategies it suggests. He co-leads the FUTURE trial series with Zhi-Ming Shao, with interests in multi-omics, metabolomics, proteomics and precision oncology.","asOf":"2026-09-08","links":[{"label":"Fudan University Shanghai Cancer Center","url":"https://www.shca.org.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Jiang%20YZ%5BAuthor%5D%20triple-negative%20breast%20cancer%20Fudan"}],"tags":[],"related":[],"cancers":["tnbc"],"sections":[],"technologies":["proteomics","rna-seq"],"targets":[],"drugs":[],"companies":[],"institutions":["fuscc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Breast Surgery, Fudan University Shanghai Cancer Center","institutionId":"fuscc","specialisms":["Triple-negative breast cancer","Multi-omics","Metabolomics","Precision oncology"],"profiles":[{"label":"Fudan University Shanghai Cancer Center","url":"https://www.shca.org.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Jiang%20YZ%5BAuthor%5D%20triple-negative%20breast%20cancer%20Fudan"}],"papers":[{"title":"Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies","journal":"Cancer Cell","year":2019,"doi":"10.1016/j.ccell.2019.02.001"}]},{"id":"cheng-ying","kind":"person","name":"Ying Cheng","aka":["程颖"],"tldr":"Ying Cheng has led most of the Chinese small cell lung cancer immunotherapy trials, including ASTRUM-005 and CAPSTONE-1.","summary":"Principal investigator of ASTRUM-005 (serplulimab plus chemotherapy, JAMA 2022), CAPSTONE-1 (adebrelimab plus chemotherapy, Lancet Oncology 2022) and the benmelstobart plus anlotinib trial in extensive-stage SCLC, as well as Chinese cohorts of global lung cancer studies; chairs CSCO's small cell lung cancer committee.","asOf":"2026-09-10","links":[{"label":"Jilin Cancer Hospital","url":"https://www.jlszlyy.com/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cheng%20Y%5BAuthor%5D%20small%20cell%20lung%20cancer%20Jilin%20Cancer%20Hospital"}],"tags":["china"],"related":[],"cancers":["sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["serplulimab","adebrelimab","anlotinib"],"companies":[],"institutions":["jilin-cancer-hospital"],"pathways":[],"terms":[],"trials":["astrum-005","capstone-1"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor and President, Jilin Cancer Hospital, Changchun","institutionId":"jilin-cancer-hospital","specialisms":["Small cell lung cancer","Thoracic oncology","Immunotherapy trials"],"profiles":[{"label":"Jilin Cancer Hospital","url":"https://www.jlszlyy.com/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cheng%20Y%5BAuthor%5D%20small%20cell%20lung%20cancer%20Jilin%20Cancer%20Hospital"}],"papers":[{"title":"Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: the ASTRUM-005 randomized clinical trial","journal":"JAMA","year":2022,"doi":"10.1001/jama.2022.16464"}]},{"id":"yitshak-kreiss","kind":"person","name":"Yitshak Kreiss","aka":[],"tldr":"Director General of Sheba Medical Center since 2016, leading Israel's largest hospital and its cancer centre.","summary":"Yitshak Kreiss has been Director General of Sheba Medical Center at Tel Hashomer since 15 August 2016. A physician and former Surgeon General of the Israel Defense Forces, he has driven Sheba's innovation agenda and international collaborations. Sheba houses one of Israel's largest cancer treatment and research centres under his leadership.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.shebaonline.org/"}],"tags":["leadership","hospital management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["sheba"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director General","institutionId":"sheba","specialisms":["Hospital management","Health innovation","Disaster medicine"],"profiles":[{"label":"Institution profile","url":"https://www.shebaonline.org/"}],"papers":[{"title":"The Founder Mutations in the BRCA1 , BRCA2 , and ATM Genes in Moroccan Jewish Women with Breast Cancer","journal":"Genetic Testing","year":2000,"doi":"10.1089/109065700750065171"},{"title":"Hypertension in adolescence is not an independent risk factor for renal cancer: A cohort study of 918,965 males","journal":"Journal of the American Society of Hypertension","year":2013,"doi":"10.1016/j.jash.2013.04.003"}]},{"id":"yongyut-sirivatanauksorn","kind":"person","name":"Yongyut Sirivatanauksorn","aka":[],"tldr":"Physician who directs Siriraj Hospital, Thailand's oldest and largest hospital and the teaching hospital of Mahidol University's Faculty of Medicine Siriraj Hospital.","summary":"Professor Yongyut Sirivatanauksorn is Director of Siriraj Hospital, Thailand's oldest and largest hospital and the teaching hospital of the Faculty of Medicine Siriraj Hospital, Mahidol University, in Bangkok. He serves on the faculty's administrative team under Dean Professor Apichat Asavamongkolkul. A surgeon by background, his research on liver and bile duct cancers includes a comparison of staging systems for hepatocellular carcinoma, the differential expression of sprouty genes in hepatocellular carcinoma, and how the microRNA-15a-PAI-2 axis in cholangiocarcinoma-associated fibroblasts promotes migration of cancer cells. He combines hospital leadership with surgery and academic medicine.","asOf":"2026-09-10","links":[{"label":"Source: Siriraj administrative team page","url":"https://www2.si.mahidol.ac.th/en/administration/administrative-team/"}],"tags":["leadership","clinician-scientist","university-hospital"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["siriraj-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["journal-of-surgical-oncology","molecular-cancer"],"dependsOn":[],"notes":[],"role":"Director of Siriraj Hospital","institutionId":"siriraj-hospital","specialisms":["Hospital leadership","Surgery","Academic medicine"],"profiles":[{"label":"Siriraj administrative team","url":"https://www2.si.mahidol.ac.th/en/administration/administrative-team/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sirivatanauksorn+Y%5BAuthor%5D"}],"papers":[{"title":"Comparison of Staging Systems of Hepatocellular Carcinoma","journal":"HPB Surgery","year":2011,"doi":"10.1155/2011/818217"},{"title":"Differential expression of sprouty genes in hepatocellular carcinoma","journal":"Journal of Surgical Oncology","year":2012,"doi":"10.1002/jso.22095"},{"title":"The microRNA-15a-PAI-2 axis in cholangiocarcinoma-associated fibroblasts promotes migration of cancer cells","journal":"Molecular Cancer","year":2018,"doi":"10.1186/s12943-018-0760-x"}]},{"id":"yoon-seung-kew","kind":"person","name":"Yoon Seung-kew","aka":[],"tldr":"President of Seoul St. Mary's Hospital, the flagship 1,374-bed hospital of the Catholic University of Korea, which he is steering towards personalised, patient-centred care in cancer and other major diseases.","summary":"Yoon Seung-kew is President of Seoul St. Mary's Hospital, the flagship hospital of the Catholic Medical Center of the Catholic University of Korea and the largest single-building hospital in Korea with 1,374 beds. In his presidential greeting he commits the hospital to personalised medicine and patient-centred care, to tackling cancer, heart disease, brain disease and rare conditions, and to charity care grounded in Catholic medical ethics.","asOf":"2026-09-10","links":[{"label":"Source: Seoul St. Mary's Hospital president's greeting","url":"https://www.cmcseoul.or.kr/en.aboutus.greeting.sp"}],"tags":["leadership","university-hospital"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["seoul-st-marys-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["jitc"],"dependsOn":[],"notes":[],"role":"President of Seoul St. Mary's Hospital","institutionId":"seoul-st-marys-hospital","specialisms":["Hospital leadership","Academic medicine","Catholic healthcare"],"profiles":[{"label":"President's greeting","url":"https://www.cmcseoul.or.kr/en.aboutus.greeting.sp"}],"papers":[{"title":"Inflammatory cytokines and change of Th1/Th2 balance as prognostic indicators for hepatocellular carcinoma in patients treated with transarterial chemoembolization","journal":"Scientific Reports","year":2019,"doi":"10.1038/s41598-019-40078-8"},{"title":"EpCAM-high liver cancer stem cells resist natural killer cell–mediated cytotoxicity by upregulating CEACAM1","journal":"Journal for ImmunoTherapy of Cancer","year":2020,"doi":"10.1136/jitc-2019-000301"},{"title":"Obesity and the risk of primary liver cancer: A systematic review and meta-analysis","journal":"Clinical and Molecular Hepatology","year":2021,"doi":"10.3350/cmh.2020.0176"}]},{"id":"kang-yoon-koo","kind":"person","name":"Yoon-Koo Kang","aka":[],"tldr":"Led the ATTRACTION-2 nivolumab trial and the SPOTLIGHT zolbetuximab trial, two of the defining gastric cancer studies of the decade.","summary":"Yoon-Koo Kang is Professor of Medical Oncology at Asan Medical Center in Seoul, specialising in gastric cancer and gastrointestinal stromal tumours. He led ATTRACTION-2, which established the PD-1 antibody nivolumab in late-line gastric cancer in Asia, and SPOTLIGHT, which established zolbetuximab as the first Claudin 18.2-directed therapy, two of the defining gastric cancer studies of the decade. His publications include the ATTRACTION-2 trial of nivolumab in heavily pretreated gastric or gastro-oesophageal junction cancer and the SPOTLIGHT trial of zolbetuximab plus mFOLFOX6 in Claudin 18.2-positive disease. He also led imatinib and other KIT-directed GIST studies.","asOf":"2026-09-08","links":[{"label":"Asan Medical Center","url":"https://eng.amc.seoul.kr"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kang%20YK%5BAuthor%5D%20Asan%20gastric"}],"tags":[],"related":[],"cancers":["gastric","sarcoma"],"sections":[],"technologies":[],"targets":["cldn18-2","pd1","kit"],"drugs":["zolbetuximab","nivolumab","imatinib"],"companies":[],"institutions":["asan-medical-center"],"pathways":[],"terms":[],"trials":["spotlight-glow"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology; gastric cancer and GIST","institutionId":"asan-medical-center","specialisms":["Gastric cancer","Gastrointestinal stromal tumour","Immunotherapy","Claudin 18.2"],"profiles":[{"label":"Asan Medical Center","url":"https://eng.amc.seoul.kr"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kang%20YK%5BAuthor%5D%20Asan%20gastric"}],"papers":[{"title":"Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to two or more previous chemotherapy regimens (ATTRACTION-2)","journal":"Lancet","year":2017,"doi":"10.1016/S0140-6736(17)31827-5"},{"title":"Zolbetuximab plus mFOLFOX6 in CLDN18.2-positive, HER2-negative gastric or GEJ adenocarcinoma (SPOTLIGHT)","journal":"Lancet","year":2023,"doi":"10.1016/S0140-6736(23)00620-7"},{"title":"SPOTLIGHT: zolbetuximab, the first Claudin 18.2 antibody, added to chemotherapy in gastric cancer","journal":"The Lancet","year":2023,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=SPOTLIGHT+zolbetuximab+mFOLFOX6+Shitara+Lancet"}],"orcid":"0000-0003-0783-6583"},{"id":"yoram-weiss","kind":"person","name":"Yoram G. Weiss","aka":[],"tldr":"Director General of Hadassah Medical Center in Jerusalem since 2021.","summary":"Yoram G. Weiss is Director General of Hadassah Medical Center in Jerusalem, having taken over after the resignation of his predecessor in July 2021. An anaesthesiologist and intensive care physician by background, he leads Hadassah's two campuses, which include the Sharett Institute of Oncology and extensive translational research activities.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.hadassah.org.il/en/"}],"tags":["leadership","hospital management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["hadassah"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nejm","jci"],"dependsOn":[],"notes":[],"role":"Director General","institutionId":"hadassah","specialisms":["Hospital management","Anaesthesiology and critical care"],"profiles":[{"label":"Institution profile","url":"https://www.hadassah.org.il/en/"}],"papers":[{"title":"Hydrocortisone therapy for patients with septic shock","journal":"New England Journal of Medicine","year":2008,"url":"https://doi.org/10.1056/nejmoa071366","doi":"10.1056/nejmoa071366","note":"Europe PMC author record matched by affiliation"},{"title":"Genome-wide association study of survival from sepsis due to pneumonia: an observational cohort study","journal":"The Lancet Respiratory Medicine","year":2015,"url":"https://doi.org/10.1016/s2213-2600(14)70290-5","doi":"10.1016/s2213-2600(14)70290-5","note":"Europe PMC author record matched by affiliation"},{"title":"Adenoviral transfer of HSP-70 into pulmonary epithelium ameliorates experimental acute respiratory distress syndrome","journal":"Journal of Clinical Investigation","year":2002,"url":"https://doi.org/10.1172/jci15888","doi":"10.1172/jci15888","note":"Europe PMC author record matched by affiliation"}]},{"id":"yosef-yarden","kind":"person","name":"Yosef Yarden","aka":[],"tldr":"One of the people who worked out what the HER family of receptors does and how antibodies against them behave, including why combining two antibodies against the same receptor works better than either alone.","summary":"Yosef Yarden's laboratory at the Weizmann Institute has spent four decades on the ErbB/HER receptor family: how EGFR and HER2 dimerise and signal, how the cell shuts them down, and how tumours escape drugs aimed at them. With Michael Sela he published a long series showing that pairs of antibodies against distinct epitopes of the same receptor outperform either alone, by driving receptor endocytosis and ubiquitination, including the 2009 PNAS paper on persistent elimination of HER2-overexpressing tumours. That is mechanistic evidence convergent with the clinical pairing of trastuzumab and pertuzumab, not a documented causal path to it, and this record does not claim more. His recent reviews trace how resistance to EGFR inhibitors in lung cancer emerges and how it might be pre-empted, and he also publishes on endocrine resistance in breast cancer and androgen-receptor resistance in prostate cancer.","asOf":"2026-09-25","links":[{"label":"Yarden laboratory, Weizmann Institute","url":"https://www.weizmann.ac.il/Biological_Regulation/Yarden/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Yarden%20Y%5BAuthor%5D%20Weizmann%20EGFR"}],"tags":["scientist","cancer-biology"],"related":[],"cancers":["breast-her2-positive","nsclc"],"sections":["targeted-therapy","drug-discovery"],"technologies":["monoclonal-antibody"],"targets":["egfr","her2"],"drugs":[],"companies":[],"institutions":["weizmann"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor, Department of Immunology and Regenerative Biology, Weizmann Institute of Science","institutionId":"weizmann","specialisms":["ErbB/HER receptor signalling","EGFR biology","Antibody combinations","Resistance to targeted therapy"],"profiles":[{"label":"Yarden laboratory, Weizmann Institute","url":"https://www.weizmann.ac.il/Biological_Regulation/Yarden/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Yarden%20Y%5BAuthor%5D%20Weizmann%20EGFR"}],"papers":[{"title":"Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis","journal":"Proceedings of the National Academy of Sciences","year":2009,"doi":"10.1073/pnas.0812059106","note":"Ben-Kasus T, Schechter B, Lavi S, Yarden Y, Sela M."},{"title":"Targeting EGFR in lung cancer: lessons in signal transduction and treatment-induced mechanisms of resistance","year":2026,"note":"Weizmann Institute of Science affiliation; indexed on Europe PMC"},{"title":"TMPRSS2-ERG confers resistance of prostate cancer to antiandrogens","year":2026,"note":"Weizmann Institute of Science affiliation; indexed on Europe PMC"}]},{"id":"lu-you","kind":"person","name":"You Lu","aka":[],"tldr":"Ran the first clinical trial of CRISPR-edited T cells in humans, in patients with lung cancer.","summary":"You Lu is Professor of Thoracic Oncology at West China Hospital, Sichuan University, where he leads thoracic oncology. He ran the first clinical trial of CRISPR-edited T cells in humans, a first-in-human study of PD-1-edited T cells in patients with lung cancer, alongside research in lung cancer radiotherapy and immunotherapy. His publications include the report on the safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer. His interests are lung cancer, radiation oncology, CRISPR-edited and engineered T cells, and immunotherapy.","asOf":"2026-09-08","links":[{"label":"West China Hospital","url":"https://www.wchscu.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lu%20Y%5BAuthor%5D%20West%20China%20CRISPR%20PD-1%20T%20cells"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["car-t","tcr-t","crispr-screens"],"targets":["pd1"],"drugs":[],"companies":[],"institutions":["west-china"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Thoracic Oncology, West China Hospital, Sichuan University","institutionId":"west-china","specialisms":["Lung cancer","Radiation oncology","CRISPR-edited T cells","Immunotherapy"],"profiles":[{"label":"West China Hospital","url":"https://www.wchscu.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lu%20Y%5BAuthor%5D%20West%20China%20CRISPR%20PD-1%20T%20cells"}],"papers":[{"title":"Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer","journal":"Nature Medicine","year":2020,"doi":"10.1038/s41591-020-0840-5"}],"orcid":"0000-0001-5761-3121"},{"id":"youn-kim","kind":"person","name":"Youn H. Kim","aka":[],"tldr":"Stanford dermatologist who led MAVORIC, the trial that established mogamulizumab for mycosis fungoides and Sézary syndrome after earlier treatment.","summary":"Youn Kim directs the cutaneous lymphoma programme at Stanford. She was first author of the 2018 Lancet Oncology report of MAVORIC, the phase 3 trial in which the anti-CCR4 antibody mogamulizumab improved progression-free survival compared with vorinostat in previously treated mycosis fungoides and Sézary syndrome, the basis for its approval. She has led many trials of new agents in cutaneous T-cell lymphoma and helped define its staging and response criteria.","asOf":"2026-09-18","links":[],"tags":["lymphoma","dermatology","trialist"],"related":[],"cancers":["cutaneous-t-cell-lymphoma","peripheral-t-cell-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["stanford"],"pathways":[],"terms":[],"trials":["mavoric"],"people":[],"bottlenecks":[],"keyPapers":["paper-mavoric-mogamulizumab-lancet-oncol-2018"],"journals":[],"dependsOn":[],"notes":[],"role":"Dermatologist and Director of the Multidisciplinary Cutaneous Lymphoma Program, Stanford","institutionId":"stanford","specialisms":["Cutaneous T-cell lymphoma","Mycosis fungoides and Sézary syndrome","Novel therapies"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kim%5BAuthor%5D"}],"papers":[{"title":"MAVORIC: mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma","journal":"The Lancet Oncology","year":2018,"url":"https://doi.org/10.1016/S1470-2045(18)30379-6","doi":"10.1016/S1470-2045(18)30379-6"}],"orcid":"0000-0003-2686-5873"},{"id":"yu-jinming","kind":"person","name":"Yu Jinming","aka":[],"tldr":"Academician of the Chinese Academy of Engineering who is President of Shandong Cancer Hospital and Institute, the provincial cancer hospital in Jinan.","summary":"Yu Jinming (于金明) is President (院长) of Shandong Cancer Hospital and Institute, also known as the Affiliated Cancer Hospital of Shandong First Medical University, the provincial specialist cancer hospital in Jinan. The hospital's leadership page lists him first in the leadership team as an academician of the Chinese Academy of Engineering and President, alongside Party Secretary Lu Youhua and vice presidents Xing Ligang, Liu Yuguo and Meng Xue. Search summaries describe him as a radiation oncology specialist.","asOf":"2026-09-10","links":[{"label":"Source: Shandong Cancer Hospital leadership team page","url":"http://www.sd-cancer.com/into_staff/"}],"tags":["leadership","clinician-scientist","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["shandong-cancer-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["journal-of-hematology-and-oncology","cancer-treatment-reviews","journal-of-experimental-and-clinical-cancer-research"],"dependsOn":[],"notes":[],"role":"President (院长), Shandong Cancer Hospital and Institute","institutionId":"shandong-cancer-hospital","specialisms":["Radiation oncology","Hospital management","Cancer research"],"profiles":[{"label":"Hospital leadership team page (Chinese)","url":"http://www.sd-cancer.com/into_staff/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Yu+J%5BAuthor%5D+AND+Shandong+Cancer+Hospital"}],"papers":[{"title":"Abscopal effect of radiotherapy combined with immune checkpoint inhibitors","journal":"Journal of Hematology & Oncology","year":2018,"doi":"10.1186/s13045-018-0647-8"},{"title":"Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy","journal":"Cancer Treatment Reviews","year":2015,"doi":"10.1016/j.ctrv.2015.11.001"},{"title":"Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma","journal":"Journal of Experimental & Clinical Cancer Research","year":2019,"doi":"10.1186/s13046-019-1085-3"}]},{"id":"shi-yuankai","kind":"person","name":"Yuankai Shi","aka":[],"tldr":"A medical oncologist who has led many of China's registrational trials of domestically developed targeted agents and antibodies.","summary":"Yuankai Shi is Professor of Medical Oncology at the Cancer Hospital of the Chinese Academy of Medical Sciences in Beijing. He has led many of China's registrational trials of domestically developed targeted agents and antibodies, serving as principal investigator for phase 3 trials of EGFR inhibitors, PD-1 antibodies and lymphoma therapies. His publications include the pivotal phase 2 study of chidamide in relapsed or refractory peripheral T-cell lymphoma, the ICOGEN non-inferiority trial of icotinib against gefitinib in previously treated lung cancer, and the PIONEER molecular epidemiology study of EGFR mutations in Asian patients with lung adenocarcinoma. He leads the hospital's clinical pharmacology and drug development programme.","asOf":"2026-09-08","links":[{"label":"Cancer Hospital, CAMS","url":"https://www.cicams.ac.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Shi%20Y%5BAuthor%5D%20Chinese%20Academy%20of%20Medical%20Sciences%20lung%20cancer"}],"tags":[],"related":[],"cancers":["nsclc","dlbcl"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cams-cancer-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology; Cancer Hospital, Chinese Academy of Medical Sciences","institutionId":"cams-cancer-hospital","specialisms":["Lung cancer","Lymphoma","Drug development","Clinical trials"],"profiles":[{"label":"Cancer Hospital, CAMS","url":"https://www.cicams.ac.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Shi%20Y%5BAuthor%5D%20Chinese%20Academy%20of%20Medical%20Sciences%20lung%20cancer"}],"papers":[{"title":"Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma","journal":"Annals of Oncology","year":2015,"doi":"10.1093/annonc/mdv237"},{"title":"Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial","journal":"The Lancet Oncology","year":2013,"doi":"10.1016/s1470-2045(13)70355-3"},{"title":"A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)","journal":"Journal of Thoracic Oncology","year":2014,"doi":"10.1097/jto.0000000000000033"}]},{"id":"yuichiro-doki","kind":"person","name":"Yuichiro Doki","aka":[],"tldr":"Japanese surgeon who was lead author of CheckMate 648, which established nivolumab-based first-line treatment for advanced oesophageal squamous-cell carcinoma.","summary":"Yuichiro Doki is professor of gastroenterological surgery at Osaka University. He was first author of the 2022 New England Journal of Medicine report of CheckMate 648, which showed that nivolumab plus chemotherapy and nivolumab plus ipilimumab both lengthened survival compared with chemotherapy alone in untreated advanced oesophageal squamous-cell carcinoma. He has led Japanese surgical and perioperative trials in oesophageal cancer.","asOf":"2026-09-18","links":[],"tags":["oesophageal","surgery","trialist"],"related":[],"cancers":["oesophageal-squamous-cell-carcinoma","esophageal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["osaka-university"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-checkmate-648-nejm-2022"],"journals":[],"dependsOn":[],"notes":[],"role":"Gastrointestinal surgeon, Osaka University","institutionId":"osaka-university","specialisms":["Oesophageal squamous-cell carcinoma","Gastrointestinal surgery","Immunotherapy trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Doki%5BAuthor%5D"}],"papers":[{"title":"CheckMate 648: nivolumab combination therapy in advanced oesophageal squamous cell carcinoma","journal":"New England Journal of Medicine","year":2022,"url":"https://doi.org/10.1056/NEJMoa2111380","doi":"10.1056/NEJMoa2111380"}]},{"id":"ohe-yuichiro","kind":"person","name":"Yuichiro Ohe","aka":[],"tldr":"Thoracic oncologist who leads NCC Hospital in Tokyo and has been a Japanese principal investigator on a generation of lung cancer trials.","summary":"Yuichiro Ohe is Director of the National Cancer Center Hospital in Tokyo and a thoracic oncologist. He has been a Japanese principal investigator on a generation of lung cancer trials, leading Japanese participation in EGFR, ALK and immunotherapy studies in non-small-cell and small-cell lung cancer. His publications include the FLAURA trial of osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. He directs the hospital while continuing work on lung cancer chemotherapy, targeted therapy and clinical trials.","asOf":"2026-09-08","links":[{"label":"National Cancer Center Hospital","url":"https://www.ncc.go.jp/en/ncch/index.html"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ohe%20Y%5BAuthor%5D%20National%20Cancer%20Center%20lung"}],"tags":[],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["osimertinib"],"companies":[],"institutions":["ncc-japan"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, National Cancer Center Hospital; thoracic oncology","institutionId":"ncc-japan","specialisms":["Lung cancer","Chemotherapy","Targeted therapy","Clinical trials"],"profiles":[{"label":"National Cancer Center Hospital","url":"https://www.ncc.go.jp/en/ncch/index.html"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ohe%20Y%5BAuthor%5D%20National%20Cancer%20Center%20lung"}],"papers":[{"title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer (FLAURA)","journal":"NEJM","year":2018,"doi":"10.1056/NEJMoa1713137"}]},{"id":"kitagawa-yuko","kind":"person","name":"Yuko Kitagawa","aka":[],"tldr":"Yuko Kitagawa is a leading oesophageal surgeon in the JCOG network, whose trials define perioperative treatment for oesophageal cancer in Japan.","summary":"Yuko Kitagawa is Professor of Surgery at Keio University, an oesophageal surgeon and a leader of the oesophageal group within the Japan Clinical Oncology Group. His JCOG trials define perioperative treatment for oesophageal cancer in Japan, including JCOG1109, known as NExT, which established triplet neoadjuvant chemotherapy for locally advanced oesophageal squamous cell carcinoma. His publications include the NExT comparison of neoadjuvant cisplatin plus 5-FU, docetaxel plus cisplatin plus 5-FU, and chemoradiotherapy, a Japanese counterpart to the CROSS approach. His interests are oesophageal cancer surgery, perioperative therapy and sentinel node navigation.","asOf":"2026-09-08","links":[{"label":"JCOG","url":"https://jcog.jp/en/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kitagawa%20Y%5BAuthor%5D%20esophageal%20JCOG"}],"tags":[],"related":[],"cancers":["esophageal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["jcog"],"institutions":[],"pathways":[],"terms":[],"trials":["cross"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Surgery, Keio University; oesophageal surgery; JCOG oesophageal group leadership","institutionId":"jcog","specialisms":["Oesophageal cancer surgery","Perioperative therapy","Sentinel node navigation"],"profiles":[{"label":"JCOG","url":"https://jcog.jp/en/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kitagawa%20Y%5BAuthor%5D%20esophageal%20JCOG"}],"papers":[{"title":"Neoadjuvant chemotherapy with cisplatin plus 5-FU vs docetaxel, cisplatin, and 5-FU vs chemoradiotherapy for oesophageal squamous cell carcinoma (JCOG1109 NExT)","journal":"Lancet","year":2024,"doi":"10.1016/S0140-6736(24)00745-1"}]},{"id":"yuman-fong","kind":"person","name":"Yuman Fong","aka":[],"tldr":"Liver surgeon who defined who benefits from resecting colorectal liver metastases and pioneered oncolytic virus therapy.","summary":"Yuman Fong developed the Clinical Risk Score for colorectal liver metastases that guides selection for hepatectomy and established that liver resection can cure a substantial fraction of patients with metastatic colorectal cancer, and pioneered the use of engineered herpes and vaccinia viruses as oncolytic and imaging agents. He chairs surgery at City of Hope after leading hepatobiliary surgery at MSKCC.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Yuman_Fong","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fong%20Y%5BAuthor%5D%20hepatic%20metastases"}],"tags":["surgery","liver","oncolytic-virus"],"related":[],"cancers":["colorectal","hcc"],"sections":[],"technologies":["oncolytic-virus","robotic-surgery"],"targets":[],"drugs":[],"companies":[],"institutions":["city-of-hope"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chair, Department of Surgery, City of Hope","institutionId":"city-of-hope","specialisms":["Hepatobiliary surgery","Liver metastases","Oncolytic viruses","Surgical innovation"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fong%20Y%5BAuthor%5D%20hepatic%20metastases"}],"papers":[{"title":"Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases","journal":"Annals of Surgery","year":1999,"doi":"10.1097/00000658-199909000-00004"},{"title":"Actual 10-year survival after resection of colorectal liver metastases defines cure","journal":"JCO","year":2007,"doi":"10.1200/JCO.2007.11.0833"}],"orcid":"0000-0002-8934-9959"},{"id":"yung-s-lie","kind":"person","name":"Yung S. Lie","aka":[],"tldr":"Scientist who leads the Damon Runyon Cancer Research Foundation, a US funder of high-risk, high-reward research by young cancer investigators.","summary":"Yung S. Lie, PhD, is President and Chief Executive Officer of the Damon Runyon Cancer Research Foundation in New York. The foundation funds young investigators pursuing high-risk, high-reward research across all cancer types, selecting them through panels of distinguished scientists. She is listed at the head of the foundation's leadership and staff pages.","asOf":"2026-09-10","links":[{"label":"Source: Damon Runyon leadership page","url":"https://www.damonrunyon.org/our-strategy/our-leadership"}],"tags":["leadership","funder"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["damon-runyon"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President and Chief Executive Officer of the Damon Runyon Cancer Research Foundation","institutionId":"damon-runyon","specialisms":["Research funding","Early-career scientist support","Cancer research strategy"],"profiles":[{"label":"Institution leadership page","url":"https://www.damonrunyon.org/our-strategy/our-leadership"}],"papers":[]},{"id":"bang-yung-jue","kind":"person","name":"Yung-Jue Bang","aka":[],"tldr":"Principal investigator of ToGA, the trial that made trastuzumab standard in HER2-positive gastric cancer, and a founder of Korean phase 1 oncology.","summary":"Yung-Jue Bang is Professor Emeritus of Internal Medicine at the Seoul National University Cancer Research Institute and Seoul National University Hospital. He was principal investigator of ToGA, the trial that made trastuzumab standard in HER2-positive advanced gastric cancer, and a founder of Korean phase 1 oncology, leading a long series of first-in-human and phase 1 studies including early testing of PD-1 antibodies and PARP inhibitors in gastric cancer. His publications include the ToGA trial of trastuzumab with chemotherapy against chemotherapy alone in HER2-positive gastric or gastro-oesophageal junction cancer. He mentored much of Korea's medical oncology leadership.","asOf":"2026-09-08","links":[{"label":"Seoul National University Hospital","url":"https://www.snuh.org"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bang%20YJ%5BAuthor%5D%20gastric%20cancer%20Seoul%20National%20University"}],"tags":[],"related":[],"cancers":["gastric"],"sections":[],"technologies":[],"targets":["her2","pd1"],"drugs":["trastuzumab"],"companies":[],"institutions":["snuh"],"pathways":[],"terms":[],"trials":["toga"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor Emeritus of Internal Medicine; Seoul National University Cancer Research Institute","institutionId":"snuh","specialisms":["Gastric cancer","HER2","Early-phase drug development","Immunotherapy"],"profiles":[{"label":"Seoul National University Hospital","url":"https://www.snuh.org"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bang%20YJ%5BAuthor%5D%20gastric%20cancer%20Seoul%20National%20University"}],"papers":[{"title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA)","journal":"Lancet","year":2010,"doi":"10.1016/S0140-6736(10)61121-X"},{"title":"SPOTLIGHT: zolbetuximab, the first Claudin 18.2 antibody, added to chemotherapy in gastric cancer","journal":"The Lancet","year":2023,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=SPOTLIGHT+zolbetuximab+mFOLFOX6+Shitara+Lancet"}],"orcid":"0000-0001-6000-4597"},{"id":"yuqin-song","kind":"person","name":"Yuqin Song","aka":[],"tldr":"Lymphoma specialist and Vice President of Peking University Cancer Hospital.","summary":"Yuqin Song is Vice President of Peking University Cancer Hospital and a senior clinician in its lymphoma department. Her research focuses on B-cell lymphomas and the clinical development of targeted and immune therapies for Chinese patients. She has contributed to multiple multicentre trials of novel agents in relapsed or refractory lymphoma.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.bjcancer.org/Html/News/Columns/1/Index.html"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Song+YQ%5BAuthor%5D+lymphoma"}],"tags":["leadership","clinician-scientist","lymphoma"],"related":[],"cancers":["dlbcl","follicular-lymphoma","mantle-cell-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["pku-cancer-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Vice President","institutionId":"pku-cancer-hospital","specialisms":["Lymphoma","Haematologic oncology","Novel agents in B-cell malignancies"],"profiles":[{"label":"Institution profile","url":"https://www.bjcancer.org/Html/News/Columns/1/Index.html"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Song+YQ%5BAuthor%5D+lymphoma"}],"papers":[{"title":"Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study","journal":"Blood","year":2022,"doi":"10.1182/blood.2021014162"},{"title":"Treatment of Patients with Relapsed or Refractory Mantle–Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase","journal":"Clinical Cancer Research","year":2020,"doi":"10.1158/1078-0432.ccr-19-3703"},{"title":"Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study","journal":"Leukemia","year":2019,"doi":"10.1038/s41375-019-0545-2"}],"orcid":"0000-0001-5451-6481"},{"id":"wei-yuquan","kind":"person","name":"Yuquan Wei","aka":[],"tldr":"Built China's flagship biotherapy laboratory, a source of cancer vaccines, gene therapies, and biologics.","summary":"Yuquan Wei is Professor and Director of the State Key Laboratory of Biotherapy at West China Hospital, Sichuan University. He founded the laboratory, China's flagship biotherapy institute and one of its largest translational cancer research centres, which has produced cancer vaccines, gene therapies and biologics, and he was president of Sichuan University. His publications include reviews of cancer vaccine platforms and progress, of mRNA vaccines as a therapeutic strategy, and of the CCL2-CCR2 signalling axis in cancer and its therapeutic targeting. His interests are cancer biotherapy, gene therapy, off-the-shelf and personalised neoantigen vaccines, and translational research.","asOf":"2026-09-08","links":[{"label":"West China Hospital","url":"https://www.wchscu.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wei%20YQ%5BAuthor%5D%20State%20Key%20Laboratory%20of%20Biotherapy"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["shared-antigen-vaccine","neoantigen-mrna-vaccine"],"targets":[],"drugs":[],"companies":[],"institutions":["west-china"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["journal-of-hematology-and-oncology","molecular-cancer"],"dependsOn":[],"notes":[],"role":"Professor; Director, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University","institutionId":"west-china","specialisms":["Cancer biotherapy","Gene therapy","Vaccines","Translational research"],"profiles":[{"label":"West China Hospital","url":"https://www.wchscu.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wei%20YQ%5BAuthor%5D%20State%20Key%20Laboratory%20of%20Biotherapy"}],"papers":[{"title":"Cancer vaccines as promising immuno-therapeutics: platforms and current progress","journal":"Journal of Hematology & Oncology","year":2022,"doi":"10.1186/s13045-022-01247-x"},{"title":"Role of the CCL2‐CCR2 signalling axis in cancer: Mechanisms and therapeutic targeting","journal":"Cell Proliferation","year":2021,"doi":"10.1111/cpr.13115"},{"title":"mRNA vaccine: a potential therapeutic strategy","journal":"Molecular Cancer","year":2021,"doi":"10.1186/s12943-021-01311-z"}]},{"id":"zelig-eshhar","kind":"person","name":"Zelig Eshhar","aka":[],"tldr":"The immunologist who, in 1989, first gave a T cell an antibody's aim. Every CAR-T product on the market descends from that experiment.","summary":"Zelig Eshhar's laboratory at the Weizmann Institute of Science built the first chimeric antigen receptor. In Gross, Waks and Eshhar's 1989 paper in the Proceedings of the National Academy of Sciences, the variable domains of an antibody against trinitrophenyl were spliced onto the constant domains of the T-cell receptor alpha and beta chains and expressed in a cytotoxic T-cell hybridoma. The transfected cells killed and made interleukin-2 in response to the hapten without needing the major histocompatibility complex to present it, across strain and species barriers, and responded to immobilised conjugates, bypassing antigen processing altogether. Eshhar called the construct a \"T-body\", and his group's 1993 single-chain variable fragment design is the format every modern CAR uses. Every approved CAR-T product, from tisagenlecleucel to the BCMA products in myeloma, descends from it, with costimulatory domains added later by Michel Sadelain, Carl June and Dario Campana.\n\nPriority is genuinely contested and this record says so. Kuwana and colleagues in Japan built an antibody-variable and T-cell-receptor-constant chimera in 1987, two years earlier, and showed antigen-triggered calcium signalling; what the 1989 Weizmann paper added was redirected killing and cytokine secretion independent of the major histocompatibility complex. Which counts as the first chimeric antigen receptor depends on whether you require function. Eshhar later published repeatedly with Steven Rosenberg's group at the National Cancer Institute, including the first-in-human CAR trial from that collaboration, in ovarian cancer, which was negative; he continued on dual-specificity CARs and on CAR dosing and safety, and his recent papers carry a Tel Aviv Sourasky Medical Center affiliation.","asOf":"2026-09-25","links":[{"label":"Weizmann Institute of Science","url":"https://www.weizmann.ac.il"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Eshhar%20Z%5BAuthor%5D%20chimeric"}],"tags":["clinician-scientist","immunology","cell-therapy"],"related":[],"cancers":["all-leukemia","dlbcl","multiple-myeloma"],"sections":["cell-therapy","immunotherapy"],"technologies":["car-t"],"targets":["cd19"],"drugs":[],"companies":[],"institutions":["weizmann","tel-aviv-university","tel-aviv-sourasky"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-manufacturing-cell-therapy"],"keyPapers":["paper-gross-eshhar-chimeric-receptor-pnas-1989"],"journals":[],"dependsOn":[],"notes":[],"role":"Immunologist; professor emeritus, Weizmann Institute of Science, latterly Immunology Laboratory, Tel Aviv Sourasky Medical Center","institutionId":"weizmann","specialisms":["Cancer immunology","Chimeric antigen receptors","Adoptive cell therapy","T-cell engineering"],"profiles":[{"label":"Weizmann Institute of Science","url":"https://www.weizmann.ac.il"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Eshhar%20Z%5BAuthor%5D%20chimeric"}],"papers":[{"title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","journal":"Proceedings of the National Academy of Sciences","year":1989,"doi":"10.1073/pnas.86.24.10024","note":"Gross G, Waks T, Eshhar Z. The first chimeric antigen receptor."},{"title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","journal":"Proceedings of the National Academy of Sciences","year":1993,"doi":"10.1073/pnas.90.2.720","note":"Eshhar Z, Waks T, Gross G, Schindler DG. The single-chain design modern CARs use."},{"title":"Therapeutic potential of T cell chimeric antigen receptors (CARs) in cancer treatment: counteracting off-tumor toxicities for safe CAR T cell therapy","journal":"Annual Review of Pharmacology and Toxicology","year":2016,"doi":"10.1146/annurev-pharmtox-010814-124844"},{"title":"Treatment of multiple myeloma using chimeric antigen receptor T cells with dual specificity","journal":"Cancer Immunology Research","year":2020,"doi":"10.1158/2326-6066.cir-20-0118"}]},{"id":"zev-wainberg","kind":"person","name":"Zev A. Wainberg","aka":[],"tldr":"Led NAPOLI 3, the trial that made NALIRIFOX a first-line option for metastatic pancreatic cancer.","summary":"Zev Wainberg was principal investigator of NAPOLI 3, which showed NALIRIFOX (liposomal irinotecan, oxaliplatin, fluorouracil) improves survival over gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer, and has led FGFR2b (bemarituzumab) and claudin 18.2 trials in gastric cancer. He co-directs GI oncology at UCLA and runs early-phase GI trials.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wainberg%20ZA%5BAuthor%5D%20pancreatic%20NAPOLI"}],"tags":["pancreatic","gastric","trialist"],"related":[],"cancers":["pancreatic","gastric"],"sections":[],"technologies":[],"targets":["cldn18-2","fgfr2"],"drugs":[],"companies":[],"institutions":["ucla-jonsson"],"pathways":[],"terms":[],"trials":["napoli-3","fortitude-101"],"people":[],"bottlenecks":[],"keyPapers":["paper-napoli-3-lancet-2023"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medicine and Co-Director, GI Oncology Program, UCLA Jonsson Comprehensive Cancer Center","institutionId":"ucla-jonsson","specialisms":["Pancreatic cancer","Gastro-oesophageal cancer","Early drug development","Targeted therapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wainberg%20ZA%5BAuthor%5D%20pancreatic%20NAPOLI"}],"papers":[{"title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3)","journal":"Lancet","year":2023,"doi":"10.1016/S0140-6736(23)01366-1"},{"title":"Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT)","journal":"Lancet Oncology","year":2022,"doi":"10.1016/S1470-2045(22)00603-9"},{"title":"NAPOLI-3: NALIRIFOX versus gemcitabine plus nab-paclitaxel as first treatment for metastatic pancreatic cancer","journal":"The Lancet","year":2023,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NAPOLI-3+NALIRIFOX+Wainberg+Lancet"}]},{"id":"zhang-jiangong","kind":"person","name":"Zhang Jiangong","aka":[],"tldr":"Hospital president who leads Henan Cancer Hospital in Zhengzhou, the provincial specialist cancer hospital for Henan province.","summary":"Zhang Jiangong (张建功) is President of Henan Cancer Hospital (河南省肿瘤医院) in Zhengzhou, the provincial specialist cancer hospital for Henan province. The Chinese Wikipedia article on the hospital lists him in the president field of its infobox, and that article is the source this record was checked against. The hospital's own website could not be reached when checked, so no appointment date or biography is given here. His role combines oncology with hospital management.","asOf":"2026-09-10","links":[{"label":"Source: Chinese Wikipedia article on Henan Cancer Hospital (president field)","url":"https://zh.wikipedia.org/wiki/河南省肿瘤医院"}],"tags":["leadership","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["henan-cancer-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President (院长), Henan Cancer Hospital","institutionId":"henan-cancer-hospital","specialisms":["Oncology","Hospital management"],"profiles":[{"label":"Wikipedia (Chinese) article on Henan Cancer Hospital","url":"https://zh.wikipedia.org/wiki/河南省肿瘤医院"}],"papers":[]},{"id":"zhang-shuyang","kind":"person","name":"Zhang Shuyang","aka":[],"tldr":"Physician who leads Peking Union Medical College Hospital, the flagship academic hospital of the Chinese Academy of Medical Sciences in Beijing.","summary":"Zhang Shuyang (张抒扬) leads Peking Union Medical College Hospital (PUMCH) in Beijing as its President. PUMCH, founded in 1921 and affiliated to Peking Union Medical College and the Chinese Academy of Medical Sciences, is a Class A tertiary comprehensive hospital designated by the National Health Commission as a national guiding centre for complex disorders and a demonstration centre for medical education. The Chinese Wikipedia article on the hospital names Zhang Shuyang as President; the hospital's own website did not return a readable leadership page for this record.","asOf":"2026-09-10","links":[{"label":"Source: Chinese Wikipedia article naming the President","url":"https://zh.wikipedia.org/wiki/北京协和医院"},{"label":"PUMCH about page (English)","url":"https://www.pumch.cn/en/new_about.html"}],"tags":["leadership","hospital-management","clinician-scientist"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["pumch"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President (院长), Peking Union Medical College Hospital, Beijing","institutionId":"pumch","specialisms":["Cardiology","Hospital management","Academic medicine"],"profiles":[{"label":"Wikipedia (Chinese) article on PUMCH","url":"https://zh.wikipedia.org/wiki/北京协和医院"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Zhang+S%5BAuthor%5D+AND+Peking+Union+Medical+College+Hospital"}],"papers":[]},{"id":"shao-zhi-ming","kind":"person","name":"Zhi-Ming Shao","aka":[],"tldr":"Leads the world's highest-volume breast cancer surgical unit and the FUTURE trial that treats triple-negative breast cancer by molecular subtype.","summary":"Zhi-Ming Shao is Professor of Breast Surgery and Director of the Department of Breast Surgery at Fudan University Shanghai Cancer Center, the world's highest-volume breast cancer surgical unit. His group defined the Fudan classification of triple-negative breast cancer into four molecular subtypes using genomic profiling and RNA sequencing, and tested subtype-directed therapy in the FUTURE umbrella trial, which produced response rates far above conventional chemotherapy in refractory disease. His publications include the molecular subtyping and genomic profiling study that exposed precision therapy strategies in triple-negative breast cancer, and the FUTURE phase 2 umbrella trial in heavily pretreated metastatic disease. His interests are subtyping, precision oncology and umbrella trials.","asOf":"2026-09-08","links":[{"label":"Fudan University Shanghai Cancer Center","url":"https://www.shca.org.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Shao%20ZM%5BAuthor%5D%20triple-negative%20breast%20cancer%20Fudan"}],"tags":[],"related":[],"cancers":["tnbc"],"sections":[],"technologies":["cgp","rna-seq"],"targets":[],"drugs":[],"companies":[],"institutions":["fuscc"],"pathways":[],"terms":["basket-umbrella-platform"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Breast Surgery; Director, Department of Breast Surgery, Fudan University Shanghai Cancer Center","institutionId":"fuscc","specialisms":["Breast cancer surgery","Triple-negative breast cancer subtyping","Precision oncology","Umbrella trials"],"profiles":[{"label":"Fudan University Shanghai Cancer Center","url":"https://www.shca.org.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Shao%20ZM%5BAuthor%5D%20triple-negative%20breast%20cancer%20Fudan"}],"papers":[{"title":"Molecular subtyping and genomic profiling expose precision therapy strategies in triple-negative breast cancer","journal":"Cancer Cell","year":2019,"doi":"10.1016/j.ccell.2019.02.001"},{"title":"Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: the FUTURE phase II umbrella clinical trial","journal":"Cell Research","year":2023,"doi":"10.1038/s41422-023-00795-2"},{"title":"KATHERINE: switching to T-DM1 when HER2-positive breast cancer survives pre-surgery treatment","journal":"New England Journal of Medicine","year":2019,"url":"https://doi.org/10.1056/NEJMoa1814017","doi":"10.1056/NEJMoa1814017"},{"title":"monarchE: two years of abemaciclib after surgery in high-risk, hormone-receptor-positive early breast cancer","journal":"Journal of Clinical Oncology","year":2020,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=monarchE+abemaciclib+adjuvant+Johnston+2020"},{"title":"OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer","journal":"New England Journal of Medicine","year":2021,"url":"https://doi.org/10.1056/NEJMoa2105215","doi":"10.1056/NEJMoa2105215"}],"orcid":"0000-0002-4503-148X"},{"id":"chen-zhu","kind":"person","name":"Zhu Chen","aka":["陈竺"],"tldr":"Zhu Chen, a leukaemia scientist who became China's health minister, co-developed the retinoic acid plus arsenic treatment that cures most acute promyelocytic leukaemia and then reformed the health system that pays for it.","summary":"At the Shanghai Institute of Hematology, Chen's laboratory showed that arsenic trioxide degrades the PML-RARA oncoprotein and, with Saijuan Chen, established ATRA plus arsenic as frontline APL therapy (PNAS 2004), a synthesis of a Chinese traditional remedy with molecular oncology. As Minister of Health he oversaw the 2009 health reform that extended basic insurance to almost the whole population, the foundation of today's NRDL negotiations. Academician of the Chinese Academy of Sciences and foreign associate of the US National Academy of Sciences.","asOf":"2026-09-10","links":[{"label":"Ruijin Hospital","url":"https://www.rjh.com.cn/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chen%20Z%5BAuthor%5D%20arsenic%20trioxide%20PML-RARA"}],"tags":["china"],"related":["nhsa"],"cancers":["aml"],"sections":[],"technologies":[],"targets":[],"drugs":["tretinoin-atra","arsenic-trioxide"],"companies":[],"institutions":["ruijin-hospital"],"pathways":[],"terms":[],"trials":[],"people":["chen-saijuan"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor, Shanghai Institute of Hematology, Ruijin Hospital; former Minister of Health of China (2007 to 2013)","institutionId":"ruijin-hospital","specialisms":["Acute promyelocytic leukaemia","Molecular haematology","Health policy"],"profiles":[{"label":"Ruijin Hospital","url":"https://www.rjh.com.cn/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chen%20Z%5BAuthor%5D%20arsenic%20trioxide%20PML-RARA"}],"papers":[{"title":"All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia","journal":"PNAS","year":2004,"doi":"10.1073/pnas.0400053101"}]},{"id":"ziyu-li","kind":"person","name":"Ziyu Li","aka":[],"tldr":"Gastric cancer surgeon who serves as President of Peking University Cancer Hospital.","summary":"Ziyu Li is President of Peking University Cancer Hospital (Beijing Cancer Hospital), one of China's largest specialist cancer hospitals. He is a gastrointestinal surgeon whose research addresses surgical and perioperative management of gastric cancer, including laparoscopic approaches and multimodal treatment. As hospital president he oversees clinical services, research and training across the institution.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.bjcancer.org/Html/News/Columns/1/Index.html"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Li+ZY%5BAuthor%5D+gastric"}],"tags":["leadership","clinician-scientist","gastric cancer","surgical oncology"],"related":[],"cancers":["gastric"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["pku-cancer-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"President and Deputy Party Secretary","institutionId":"pku-cancer-hospital","specialisms":["Gastric cancer surgery","Gastrointestinal surgical oncology","Minimally invasive surgery"],"profiles":[{"label":"Institution profile","url":"https://www.bjcancer.org/Html/News/Columns/1/Index.html"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Li+ZY%5BAuthor%5D+gastric"}],"papers":[{"title":"Development and validation of an individualized nomogram to identify occult peritoneal metastasis in patients with advanced gastric cancer","journal":"Annals of Oncology","year":2019,"doi":"10.1093/annonc/mdz001"},{"title":"Laparoscopic vs Open Distal Gastrectomy for Locally Advanced Gastric Cancer","journal":"JAMA Surgery","year":2022,"doi":"10.1001/jamasurg.2021.5104"},{"title":"Effects of Helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized intervention trial","journal":"BMJ","year":2019,"doi":"10.1136/bmj.l5016"}]},{"id":"zlata-stiblar-kisic","kind":"person","name":"Zlata Štiblar Kisić","aka":[],"tldr":"Director of the Institute of Oncology Ljubljana, Slovenia's national comprehensive cancer centre.","summary":"Zlata Štiblar Kisić is Director (Direktorica) of the Institute of Oncology Ljubljana, Slovenia's national comprehensive cancer centre, which provides cancer treatment, research and education for the country. A lawyer by training, with expertise in hospital management and health law, she leads the institute's general management alongside the Medical Director. Her responsibilities cover the administration of the national centre rather than clinical practice. The institution profile is the public record of her appointment.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.onko-i.si/o-nas/sektorji-in-oddelki/vodstvo"}],"tags":["leadership","hospital management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["onkoloski-institut-ljubljana"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director (Direktorica)","institutionId":"onkoloski-institut-ljubljana","specialisms":["Hospital management","Health law"],"profiles":[{"label":"Institution profile","url":"https://www.onko-i.si/o-nas/sektorji-in-oddelki/vodstvo"}],"papers":[]},{"id":"zoe-robledo","kind":"person","name":"Zoé Robledo","aka":[],"tldr":"Mexican public official who has been Director General of IMSS, the social security institute that runs the Hospital de Oncología at Centro Médico Nacional Siglo XXI, since May 2019.","summary":"Zoé Robledo is Director General of the Instituto Mexicano del Seguro Social (IMSS), Mexico's social security institute, which operates the Hospital de Oncología of the Centro Médico Nacional Siglo XXI in Mexico City as one of its high-speciality units. According to Spanish Wikipedia he has held the post since 22 May 2019, appointed under President Andrés Manuel López Obrador, and on 25 July 2024 the then president-elect Claudia Sheinbaum confirmed that he would remain Director General of IMSS in her cabinet. IMSS's own website and press room did not name the current director of the Hospital de Oncología, so the institute's Director General is recorded here as the parent-body head.","asOf":"2026-09-10","links":[{"label":"Source: Spanish Wikipedia article on Zoé Robledo (IMSS Director General since 2019)","url":"https://es.wikipedia.org/wiki/Zo%C3%A9_Robledo"}],"tags":["leadership","government"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["imss-oncologia-siglo-xxi"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director General of the Instituto Mexicano del Seguro Social (IMSS), parent body of the Hospital de Oncología, Centro Médico Nacional Siglo XXI","institutionId":"imss-oncologia-siglo-xxi","specialisms":["Public administration","Social security","Health system management"],"profiles":[{"label":"Wikipedia (Spanish)","url":"https://es.wikipedia.org/wiki/Zo%C3%A9_Robledo"}],"papers":[]},{"id":"li-zonghai","kind":"person","name":"Zonghai Li","aka":["李宗海"],"tldr":"Zonghai Li moved CAR-T therapy from blood cancers into stomach cancer, founding CARsgen and developing satri-cel, the first CAR-T approved for a solid tumour.","summary":"At the Shanghai Cancer Institute Li developed GPC3-directed CAR-T for liver cancer and the Claudin 18.2 CAR-T CT041, whose phase 1 results (Nature Medicine 2022) and randomised phase 2 trial in gastric cancer led to NMPA approval as satricabtagene autoleucel in 2025; CARsgen's fully human BCMA CAR-T zevorcabtagene autoleucel was approved in 2024. He founded CARsgen in 2014 and listed it in Hong Kong in 2021.","asOf":"2026-09-10","links":[{"label":"CARsgen Therapeutics","url":"https://www.carsgen.com/en/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Li%20Z%5BAuthor%5D%20claudin18.2%20CAR-T%20gastric"}],"tags":["china"],"related":[],"cancers":["gastric","hcc","multiple-myeloma"],"sections":[],"technologies":["car-t"],"targets":["cldn18-2","gpc3","bcma"],"drugs":["satricabtagene-autoleucel","zevorcabtagene-autoleucel"],"companies":["carsgen"],"institutions":["renji-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Founder, Chairman and CEO, CARsgen Therapeutics; Professor, Shanghai Cancer Institute, Renji Hospital","institutionId":"renji-hospital","specialisms":["CAR-T for solid tumours","Claudin 18.2","GPC3","Antibody engineering"],"profiles":[{"label":"CARsgen Therapeutics","url":"https://www.carsgen.com/en/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Li%20Z%5BAuthor%5D%20claudin18.2%20CAR-T%20gastric"}],"papers":[{"title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results","journal":"Nature Medicine","year":2022,"doi":"10.1038/s41591-022-01800-8"}],"orcid":"0000-0003-2448-3636"}]